WARNING:absl:No GPU/TPU found, falling back to CPU. (Set TF_CPP_MIN_LOG_LEVEL=0 and rerun for more info.)
loading shards for part 0
read from checkpoint
< (8, 4096) to (4096,)
> transformer.wte.bias torch.Size([4096])
< (8, 6300, 4096) to (1, 50400, 4096)
> transformer.wte.weight torch.Size([4096, 50400])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.0.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.0.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.0.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.0.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.0.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.0.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.0.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.0.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.0.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.0.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.1.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.1.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.1.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.1.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.1.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.1.mlp.c_fc.weight torch.Size([16384, 4096])
loading shards for part 1
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.1.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.1.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.1.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.1.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.10.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.10.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.10.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.10.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.10.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.10.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.10.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.10.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.10.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.10.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.11.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.11.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.11.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.11.attn.attention.out_proj.weight torch.Size([4096, 4096])
loading shards for part 2
read from checkpoint
< (8, 2048) to (1, 16384)
> transformer.h.11.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.11.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.11.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.11.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.11.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.11.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.12.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.12.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.12.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.12.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.12.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.12.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.12.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.12.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.12.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.12.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.13.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.13.attn.attention.v_proj.weight torch.Size([4096, 4096])
loading shards for part 3
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.13.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.13.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.13.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.13.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.13.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.13.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.13.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.13.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.14.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.14.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.14.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.14.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.14.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.14.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.14.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.14.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.14.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.14.ln_1.weight torch.Size([4096])
loading shards for part 4
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.15.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.15.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.15.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.15.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.15.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.15.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.15.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.15.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.15.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.15.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.16.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.16.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.16.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.16.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.16.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.16.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.16.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.16.mlp.c_proj.weight torch.Size([4096, 16384])
loading shards for part 5
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.16.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.16.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.17.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.17.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.17.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.17.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.17.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.17.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.17.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.17.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.17.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.17.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.18.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.18.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.18.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.18.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.18.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.18.mlp.c_fc.weight torch.Size([16384, 4096])
loading shards for part 6
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.18.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.18.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.18.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.18.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.19.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.19.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.19.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.19.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.19.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.19.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.19.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.19.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.19.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.19.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.2.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.2.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.2.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.2.attn.attention.out_proj.weight torch.Size([4096, 4096])
loading shards for part 7
read from checkpoint
< (8, 2048) to (1, 16384)
> transformer.h.2.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.2.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.2.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.2.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.2.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.2.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.20.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.20.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.20.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.20.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.20.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.20.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.20.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.20.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.20.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.20.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.21.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.21.attn.attention.v_proj.weight torch.Size([4096, 4096])
loading shards for part 8
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.21.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.21.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.21.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.21.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.21.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.21.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.21.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.21.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.22.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.22.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.22.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.22.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.22.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.22.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.22.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.22.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.22.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.22.ln_1.weight torch.Size([4096])
loading shards for part 9
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.23.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.23.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.23.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.23.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.23.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.23.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.23.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.23.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.23.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.23.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.24.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.24.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.24.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.24.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.24.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.24.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.24.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.24.mlp.c_proj.weight torch.Size([4096, 16384])
loading shards for part 10
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.24.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.24.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.25.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.25.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.25.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.25.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.25.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.25.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.25.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.25.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.25.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.25.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.26.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.26.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.26.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.26.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.26.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.26.mlp.c_fc.weight torch.Size([16384, 4096])
loading shards for part 11
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.26.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.26.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.26.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.26.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.27.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.27.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.27.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.27.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.27.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.27.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.27.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.27.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.27.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.27.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.3.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.3.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.3.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.3.attn.attention.out_proj.weight torch.Size([4096, 4096])
loading shards for part 12
read from checkpoint
< (8, 2048) to (1, 16384)
> transformer.h.3.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.3.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.3.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.3.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.3.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.3.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.4.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.4.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.4.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.4.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.4.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.4.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.4.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.4.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.4.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.4.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.5.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.5.attn.attention.v_proj.weight torch.Size([4096, 4096])
loading shards for part 13
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.5.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.5.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.5.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.5.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.5.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.5.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.5.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.5.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.6.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.6.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.6.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.6.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.6.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.6.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.6.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.6.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.6.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.6.ln_1.weight torch.Size([4096])
loading shards for part 14
read from checkpoint
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.7.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.7.attn.attention.v_proj.weight torch.Size([4096, 4096])
/raid/stevens/INHIBIT/convert-n-run-query-loop.py:172: DeprecationWarning: Using or importing the ABCs from 'collections' instead of from 'collections.abc' is deprecated since Python 3.3, and in 3.10 it will stop working
  class Checkpoint(collections.MutableMapping):
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.7.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.7.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.7.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.7.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.7.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.7.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.7.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.7.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.8.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.8.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.8.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.8.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.8.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.8.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.8.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.8.mlp.c_proj.weight torch.Size([4096, 16384])
loading shards for part 15
read from checkpoint
< (8, 4096) to (4096,)
> transformer.h.8.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.8.ln_1.weight torch.Size([4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.9.attn.attention.q_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.9.attn.attention.v_proj.weight torch.Size([4096, 4096])
< (8, 4096, 512) to (1, 4096, 4096)
> transformer.h.9.attn.attention.k_proj.weight torch.Size([4096, 4096])
< (8, 512, 4096) to (1, 4096, 4096)
> transformer.h.9.attn.attention.out_proj.weight torch.Size([4096, 4096])
< (8, 2048) to (1, 16384)
> transformer.h.9.mlp.c_fc.bias torch.Size([16384])
< (8, 4096, 2048) to (1, 4096, 16384)
> transformer.h.9.mlp.c_fc.weight torch.Size([16384, 4096])
< (8, 4096) to (4096,)
> transformer.h.9.mlp.c_proj.bias torch.Size([4096])
< (8, 2048, 4096) to (1, 16384, 4096)
> transformer.h.9.mlp.c_proj.weight torch.Size([4096, 16384])
< (8, 4096) to (4096,)
> transformer.h.9.ln_1.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.h.9.ln_1.weight torch.Size([4096])
< (8, 6300) to (1, 50400)
> lm_head.bias torch.Size([50400])
< (8, 4096, 6300) to (1, 4096, 50400)
> lm_head.weight torch.Size([50400, 4096])
< (8, 4096) to (4096,)
> transformer.ln_f.bias torch.Size([4096])
< (8, 4096) to (4096,)
> transformer.ln_f.weight torch.Size([4096])
left over: [array([383502., 383502., 383502., 383502., 383502., 383502., 383502., 383502.], dtype=float32)]
saving
done
load
ok
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  10-Hydroxycamptothecinis a drug that inhibits
 
Response: 10-Hydroxycamptothecinis a drug that inhibits telomerase

10-Hydroxycamptothecinis a drug that inhibits telomerase

10-Hydroxycamptothecinis, a new inhibitor of human telomerase, has been synthesized and its structure determined. The compound potently inhibits telomerase activity with IC50 of 0.3 nM.10-Hydroxycamptothecinis is a water-soluble camptothecin derivative, which is not as toxic as the parent compound camptothecin.10-Hydroxycamptothecinis is more active against human than mouse telomerase and more active against telomerase in the presence of a G-quadruplex structure than against the same enzyme in the presence of a duplex DNA. The compound also inhibits telomerase activity in the presence of telomerase components, suggesting that the compound acts at the active site of the enzyme.10
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  1,2-Propanediolis a drug that inhibits
 
Response: 1,2-Propanediolis a drug that inhibits lactate production by tumor cells, thereby suppressing their growth. This drug was first discovered in 1988 and later became a drug for cancer therapy. In addition, 1,2-propanediol is also used in cosmetics and foods. In the present study, we cloned the 1,2-propanediol oxidoreductase gene (ProDH) from Escherichia coli. The cloned ProDH gene consisted of a 7.8-kb open reading frame, and the predicted amino acid sequence contained three domains: a NADPH-binding domain, a NAD-binding domain, and a flavin-binding domain. We expressed the ProDH gene in E. coli, and purified the enzyme using Ni-NTA affinity chromatography. The ProDH enzyme showed high substrate specificity and catalyzed the conversion of 1,2-propanediol to acetoin. This enzyme was composed of FAD, FM
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  14028-44-5is a drug that inhibits
 
Response: 14028-44-5is a drug that inhibits the action of dipeptidyl peptidase IV, which is an enzyme that removes dipeptides from the N-terminal side of a peptide chain. The peptide chains are attached to the nitrogen atom of the amino acid L-alanine, and the removal of dipeptides from the N-terminal side of the peptide chain prevents the peptide from being degraded.
Dipeptidyl peptidase IV (DPP-IV) is an enzyme that cleaves N-terminal dipeptides from a polypeptide. It is widely distributed in the tissues of the human body, and is known to be present in the blood, plasma, and serum.
The degradation of peptides by DPP-IV is an important process in the regulation of various peptide hormones, such as GLP-1, GLP-2, and GIP, and is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  17-Beta-Estradiol-3,17-Dipropionateis a drug that inhibits
 
Response: 17-Beta-Estradiol-3,17-Dipropionateis a drug that inhibits the activity of the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. Inhibitors of aromatase are being developed as an alternative to the currently available non-steroidal anti-estrogens for the treatment of hormone-dependent breast cancer. The objective of this study was to compare the efficacy of aromatase inhibitors with that of tamoxifen as first-line treatment for postmenopausal women with hormone receptor-positive breast cancer. We searched the Cochrane Breast Cancer Group's Specialised Register (September 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 9), MEDLINE (Ovid, 1946 to August 2013), EMBASE (Ovid, 1980 to August 2013), CINAHL (EBSCO, 1982 to August 2013), PsycINFO (Ovid, 1806 to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  17-Hydroxyprogesteroneis a drug that inhibits
 
Response: 17-Hydroxyprogesteroneis a drug that inhibits the secretion of gonadotropins by the anterior pituitary gland. This drug is a progestational hormone and is used for the treatment of hormonally active uterine leiomyomas and endometriosis. It is used to treat gynecomastia, precocious puberty, male hypogonadism, and in some countries to induce abortions. It is also used for the treatment of breast cancer in postmenopausal women and in men with advanced prostatic cancer.

Chemistry

The chemical name for 17-hydroxyprogesterone is 17α-hydroxy-4,6-pregnadien-3-one. The chemical formula for 17-hydroxyprogesterone is C27H44O3. The molecular weight of 17-hydroxyprogesterone is 466.7 g/mol. 17-Hydroxyprogesterone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  1-Hexadecanolis a drug that inhibits
 
Response: 1-Hexadecanolis a drug that inhibits steroid synthesis in the adrenal gland, can be used to treat Cushing's disease, a disease in which too much cortisol is produced. The disease is characterized by too much hair growth, high blood pressure, muscle weakness, and loss of muscle and bone density.

2-Hexyl-5-methyl-2,4-imidazolidinedione A drug that inhibits steroid synthesis in the adrenal gland, can be used to treat Cushing's disease, a disease in which too much cortisol is produced. The disease is characterized by too much hair growth, high blood pressure, muscle weakness, and loss of muscle and bone density.

2-Isobutyl-5-methyl-2,4-imidazolidinedione A drug that inhibits steroid synthesis in the adrenal gland, can be used to treat Cushing's disease, a disease in which too much cortisol is produced. The disease
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  1-Indanoneis a drug that inhibits
 
Response: 1-Indanoneis a drug that inhibits cytochrome P450 2E1, and may thus be useful in treating a variety of conditions including ischemic heart disease, obesity, and liver disease.

Ischemic heart disease (IHD) is the leading cause of death in industrialized nations and has been estimated to cause approximately 12 million deaths per year worldwide.1IHD is a disorder characterized by an imbalance between myocardial oxygen supply and demand. The main clinical manifestation of IHD is angina pectoris. However, the condition can progress to myocardial infarction, in which a portion of the heart muscle is deprived of blood flow, and ischemia, in which the entire heart is deprived of blood flow. Ischemia is usually caused by a reduction in the flow of oxygenated blood to the heart muscle due to reduced coronary blood flow, which may be the result of atherosclerotic disease or spasm of the coronary arteries
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2,4-dichlorobenzylis a drug that inhibits
 
Response: 2,4-dichlorobenzylis a drug that inhibits glycogen phosphorylase, an enzyme that is essential for the metabolism of glycogen.

Synthesis

Synthesis from phloroglucinol 
Phloroglucinol can be converted into the corresponding dibromide. The dibromide is reacted with triphenylphosphine in acetonitrile to give the phosphonium salt. The aryl halide is then added to give the benzylated product.

See also
 Phloroglucinol ethers

References

External links
 Glycogen Phosphorylase

Category:Benzoic acids
Category:Benzyl compounds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Amino-6-methylheptanis a drug that inhibits
 
Response: 2-Amino-6-methylheptanis a drug that inhibits prolactin release in vitro. It is an analog of nipecotic acid and an analog of valproic acid.

References

Category:Tetrahydrofurans
Category:Sulfonamides
Category:Amines
Category:Anticonvulsants
Category:Drugs acting on the nervous system
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Aminoethanethiolis a drug that inhibits
 
Response: 2-Aminoethanethiolis a drug that inhibits thyroid peroxidase, the key enzyme involved in thyroid hormone synthesis, thus lowering serum T3 and T4 levels. The reduction in thyroid hormone is accompanied by a reduction in TSH. In the setting of thyroid hormone reduction, which may lead to clinical hypothyroidism, thyroid peroxidase inhibition may prevent the development of hypothyroidism.

**What is the mechanism of action of Iodine-131?**

Iodine-131 is a low-energy beta emitter and is taken up by the thyroid follicles, which results in cell death and the release of thyroglobulin. This thyroglobulin is then processed and incorporated into thyroid hormone, resulting in the reduction of serum T3 and T4 levels. The reduction of thyroid hormone is accompanied by a reduction in TSH. In the setting of thyroid hormone reduction, which may lead to clinical hyp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Aminoethylis a drug that inhibits
 
Response: 2-Aminoethylis a drug that inhibits protein phosphatase 2A. The authors reported a modest inhibition of ABL kinase activity, consistent with their findings that BCR-ABL/PP2A-AII complex was highly unstable.

More recently, we have performed a mass spectrometry-based phosphoproteomics screen to determine the sites of BCR-ABL-mediated phosphorylation in K562 cells ([@bib7]). We focused on sites of phosphorylation that have not been described previously, and identified phosphorylation of many proteins in a cell-free kinase assay using recombinant ABL kinase. Interestingly, phosphorylation of many proteins was inhibited by phosphatase 2A-AII, and a significant fraction of these proteins were identified as substrates for BCR-ABL in a previous report ([@bib3]).

In our study, we identified ∼300 unique proteins that are phosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Methoxyestradiolis a drug that inhibits
 
Response: 2-Methoxyestradiolis a drug that inhibits the proliferation of cancer cells, and has been shown to inhibit tumor growth in a xenograft mouse model. However, it is rapidly metabolized to a sulfate and glucuronide conjugate. Thus, a high dose of 2-methoxyestradiol is needed to achieve an anti-proliferative effect in vivo.

The first synthesis of 2-methoxyestradiol was published in 1991 by Chu and Ben-Sasson [3]. However, the synthesis is limited to 10 milligrams of product per reaction.

The patent application [4] describes the synthesis of 2-methoxyestradiol from 2-hydroxyestradiol. The key step is the reaction of 2-hydroxyestradiol with methoxylamine in the presence of pyridine to produce a mixture of 3- and 4-methoxyestradiol.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Methylhexanoicis a drug that inhibits
 
Response: 2-Methylhexanoicis a drug that inhibits or blocks the activity of an enzyme, called acetyl-CoA carboxylase.

The effect of the drug on the body depends on the amount taken.

Adverse Effects

Nausea, headache, stomach upset, diarrhea, rash, dry mouth, blurred vision, confusion, light-headedness, fatigue, drowsiness, and constipation may occur.

Dosage

The dose of methylcobalamin should be individualized for each patient. The initial dose should be 50 mcg three times a day.

If the initial dose is tolerated, the dose can be increased to 100 mcg three times a day.

The dosage can be increased to 200 mcg three times a day.

The dosage can be increased to 400 mcg three times a day.

The dosage can be increased to 600 mcg three times a day.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Naphtholis a drug that inhibits
 
Response: 2-Naphtholis a drug that inhibits the growth of tumors by blocking DNA synthesis, but has very little effect on the growth of normal tissues.

2-Amino-1-butylimidazole (2-AB) is a synthetic chemical that is a major component of many commercial wood preservatives. It has been found that 2-AB has a carcinogenic effect in animals and can cause chromosome damage in cultured mammalian cells. However, little is known about the effect of 2-AB on human cells. The objective of this study was to determine whether 2-AB is toxic to human cells. The study was conducted in a series of tests. First, an Ames test was used to evaluate the mutagenicity of 2-AB. In the second part of the study, the cytotoxicity of 2-AB was determined in the cultures of various human cell lines. The results of the study indicate that 2-AB is a very weak mutagen and that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  2-Thiouracilis a drug that inhibits
 
Response: 2-Thiouracilis a drug that inhibits the activity of thyrosyl-tRNA synthetase. This enzyme catalyzes the formation of thiophosphoryl-AMP, a reaction essential for the activity of aminoacyl-tRNA synthetases. Thiouracil also inhibits DNA replication and, in some cases, cell division. In the present study, the effect of this drug on the interaction of herpes simplex virus (HSV) type 1 (strain KOS) with its host cells was examined. Viral DNA synthesis was inhibited at low concentrations of the drug (10(-5) M). When virus was pre-incubated with thiouracil for 1 hr, no effect was observed on the subsequent adsorption of the virus to host cells. However, at concentrations higher than 10(-4) M, the drug markedly inhibited the adsorption of virus to the cells. Furthermore, when the drug was added to the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  3469-LCZ696is a drug that inhibits
 
Response: 3469-LCZ696is a drug that inhibits TRPM8 channels. The TRPM8 channel has a large current (up to several milliampers) when activated by cooling temperatures (23-26°C).

This drug is in phase II clinical trials for the treatment of various pain conditions including painful diabetic neuropathy and cluster headache.

A large body of preclinical evidence suggests that activation of the TRPM8 channel may have a role in the analgesia induced by low-level laser therapy (LLLT) and cold stimuli.

The activation of TRPM8 channels by cooling is associated with analgesia, and the lack of TRPM8 activation is associated with pain hypersensitivity.

Preclinical evidence indicates that the TRPM8 channel may be a target for analgesic drug development.

NPS 2377 is a potent TRPM8 agonist.

The TRPM8 agonist NPS 2377 has a low toxicity profile in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  3,4-Diaminopyridineis a drug that inhibits
 
Response: 3,4-Diaminopyridineis a drug that inhibits the voltage-gated sodium channels. It has been used for treating a variety of neuropathic disorders. Here, we report a case of a patient with idiopathic spinal cord injury, which was successfully treated with 3,4-diaminopyridine. A 24-year-old man was admitted to our hospital with a 4-year history of paraplegia, sensory disturbances and urinary incontinence. The initial neurological examination showed paraplegia and sensory disturbances below the Th6 level. He had a past history of traumatic spinal cord injury. MRI revealed the presence of a spinal cord tumor extending from the Th11 to the Th12 level. The tumor was partially resected, and histopathological examination revealed a high-grade glioma. The patient's neurological status improved with 3,4-diaminopyridine, and his urinary incontinence was resolved. There are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Aminoantipyrineis a drug that inhibits
 
Response: 4-Aminoantipyrineis a drug that inhibits oxidative deamination of the neurotransmitter noradrenaline.

4-Aminoantipyrine, also known as 4-aminoantipyrine, 4-aminoantipyrine sodium salt, antipyrine sodium salt, and sodium antipyrine, is a colorless solid chemical compound with the chemical formula C10H10N2O2S. It is a member of the class of chemical compounds called pyridines.

The chemical is widely used in industry and in medicine, and it is an important intermediate in the manufacture of many pharmaceuticals.

4-Aminoantipyrine is a non-specific monoamine oxidase inhibitor, which means it inhibits both the A and B forms of the enzyme.

The chemical has been used as an analgesic, antipyretic, and antiphlogistic, and it has been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Aminobenzoicis a drug that inhibits
 
Response: 4-Aminobenzoicis a drug that inhibits the enzyme acyl CoA-cholesterol acyl transferase (ACAT), an enzyme that catalyzes the transfer of an acyl group from the sn-2 position of a fatty acyl CoA to the 3-hydroxyl group of cholesterol, thereby producing a molecule with a longer-chain fatty acyl group and a 3-OH group on cholesterol. It was first synthesized in 1959 by the Pfizer Company. ACAT inhibitors have been used as hypolipidemic drugs and have been reported to have anti-inflammatory, anti-atherosclerotic and anti-thrombotic properties.
U.S. Pat. No. 4,263,334 describes ACAT inhibitors having the following general formula: ##STR1## wherein R.sup.1 is hydrogen or hydroxy, and R.sup.2 is methyl, ethyl, methoxy, ethoxy, or phenyl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-AMINOHIPPURICis a drug that inhibits
 
Response: 4-AMINOHIPPURICis a drug that inhibits tryptophan metabolism, the enzyme tryptophan hydroxylase (TPH). It was developed to treat depression. 4-AMINOHIPPURIC is a potent and selective inhibitor of TPH, the enzyme that converts tryptophan to serotonin. Inhibition of this enzyme reduces the levels of serotonin, a neurotransmitter that is involved in mood regulation.

Like other antidepressants, 4-AMINOHIPPURIC is thought to increase the levels of serotonin in the brain, a theory supported by animal studies. However, some of the side effects of 4-AMINOHIPPURIC, including insomnia, nausea, headache, and agitation, have been attributed to the drug's ability to reduce serotonin levels.4-AMINOHIPPURIC is not currently approved for use in the United States.

Sertraline (ZOLOFT) is an antidepressant that is struct
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Hydroxytamoxifenis a drug that inhibits
 
Response: 4-Hydroxytamoxifenis a drug that inhibits the growth of breast cancer cells. It has a steroidal structure that consists of a triphenylethylene nucleus and an oxirane ring. It has a binding affinity for estrogen receptors and competitively inhibits estradiol-binding sites. The anticancer activity of 4-hydroxytamoxifen has been studied in vivo and in vitro.

Methods
=======

**Materials**

4-Hydroxytamoxifen was purchased from Sigma-Aldrich. Cell culture media and reagents were purchased from Gibco, Thermo Fisher Scientific, Inc.

**Cell lines**

MCF-7 (human breast adenocarcinoma), MCF-10A (human breast epithelial), T47D (human breast adenocarcinoma), MCF-7/HER2 (breast adenocarcinoma with overe
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Methyl-2-pentanoneis a drug that inhibits
 
Response: 4-Methyl-2-pentanoneis a drug that inhibits myelin formation and induces demyelination in the central nervous system (CNS). The effects of 3-methyl-2-pentanone on the expression of myelin proteins and the differentiation of oligodendrocytes were studied in cultured CNS glial cells. 3-Methyl-2-pentanone significantly decreased the levels of myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) mRNAs and protein, as well as the number of MBP-positive cells in the cultures. The myelin-related genes were not affected by 3-methyl-2-pentanone. Treatment of oligodendrocytes with 3-methyl-2-pentanone reduced the number of cells that expressed O4, a differentiation marker of oligodendrocytes, in a dose-dependent manner. These results indicate that 3-methyl-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Methylumbelliferoneis a drug that inhibits
 
Response: 4-Methylumbelliferoneis a drug that inhibits hepatic glucuronidation.

The free-drug concentration (C(f)) was calculated by dividing the free concentration (C(f)) by the unbound fraction (fu) of the metabolite.

The area under the concentration-time curve (AUC) was calculated using the linear trapezoidal method, and the maximum concentration (C(max)) was obtained from the observed concentration at the last measured time point. The clearance (CL/F) was calculated by dividing the dose by the AUC, and the apparent volume of distribution at steady-state (V(ss)/F) was calculated by dividing the dose by the AUC and C(max).

The relative bioavailability (F) was calculated as the ratio of the AUC and C(max) of the test drug to the AUC and C(max) of the reference drug, using the formula F=AUC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4-Nitrophenolis a drug that inhibits
 
Response: 4-Nitrophenolis a drug that inhibits the enzyme nitrotyrosine reductase, which converts the nitroso-protein product of nitrosative stress to the aminonitrophenol product.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4SC-201(resminostat,BYK408740)is a drug that inhibits
 
Response: 4SC-201(resminostat,BYK408740)is a drug that inhibits both class I and class II HDACs and also inhibits class III HDACs. It has been shown to be active in vivo in a dose-dependent manner. In cell culture, it inhibits cell proliferation, induces cell cycle arrest, and promotes apoptosis. In vivo, it causes significant reductions in tumor size in a number of xenograft models. The effect on normal cells is much less than on cancer cells, suggesting that it is selectively cytotoxic to cancer cells. In cell culture, it inhibits the growth of human breast, prostate, and cervical cancer cells and of colon, lung, and ovarian cancer cells. It also inhibits the growth of breast and prostate cancer cells that have become resistant to chemotherapy. It also inhibits the growth of primary human leukemia cells and induces apoptosis. It is an effective agent against human prostate cancer xenografts. It is active against human colon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  4SC-202is a drug that inhibits
 
Response: 4SC-202is a drug that inhibits HIV-1 and HIV-2 replication.

4SC-202 is an HIV-1 inhibitor, which is being developed by Seragon Pharmaceuticals. It is a capsid inhibitor that targets the assembly of the virus. This is done by interfering with the interaction between capsid protein and the viral RNA. 4SC-202 works by binding to the CA protein, preventing the nucleation of capsid proteins. It then blocks the assembly of the capsid proteins into the viral core.

HIV is a virus that infects and destroys human immune cells, resulting in immune system dysfunction. This virus causes acquired immunodeficiency syndrome (AIDS), which is a fatal disease. HIV can also infect the brain, causing a brain infection called HIV encephalitis. In addition to the destruction of immune cells, HIV also damages the brain cells. HIV causes the loss of brain cells in the parts of the brain that control the memory and emotions
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  5-Aminolevulinicis a drug that inhibits
 
Response: 5-Aminolevulinicis a drug that inhibits heme synthesis. We show that this drug is an efficient photosensitizer for the photodynamic therapy of malignant gliomas. This therapy has the advantage of being localized in the tumor and does not affect the surrounding normal brain. The combination of photodynamic therapy and a cytotoxic agent (BCNU) could be a very promising approach for the treatment of malignant gliomas.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  5-HTPis a drug that inhibits
 
Response: 5-HTPis a drug that inhibits the conversion of the amino acid, L-tryptophan, to serotonin (5-HT). Serotonin is a neurotransmitter and 5-HTP can be converted into serotonin by the enzyme, tryptophan hydroxylase. The aim of this review is to provide a brief overview of the role of serotonin in the brain and peripheral organs. The mechanism of action of 5-HTP in various peripheral organs and its use in the treatment of various neurological disorders is also discussed.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  5-Methoxytryptamineis a drug that inhibits
 
Response: 5-Methoxytryptamineis a drug that inhibits the enzyme tryptophan hydroxylase, and hence reduces the synthesis of serotonin in the brain. It has been used in the treatment of depression, and as an adjunct to antidepressants. It is also used to treat attention deficit hyperactivity disorder. In India, it is commonly used as a dietary supplement for weight loss, and to reduce anxiety.

It has the chemical formula C11H14N2O, and a molecular weight of 206.26 g/mol. It is a white or off-white powder, which is insoluble in water. The structure of the drug is shown in the figure below.

Figure 1: Structure of 5-Methoxytryptamine

5-Methoxytryptamine is an analogue of tryptophan. This means that it has similar chemical structure and chemical properties to tryptophan. This drug has been patented in many countries.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  6-Mercaptopurineis a drug that inhibits
 
Response: 6-Mercaptopurineis a drug that inhibits the enzyme dihydrofolate reductase. It is used in the treatment of leukemias, lymphomas, and some solid tumors. A unique side effect of this drug is that it can cause a severe skin rash. The most common side effect is the acute rash that occurs in approximately 30% of patients receiving the drug. We describe a patient with erythema multiforme, as well as the acute, painful, severe, extensive, and symmetrical skin eruption that developed after a 6-mercaptopurine dose. This side effect has not been reported previously.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  726169-73-9is a drug that inhibits
 
Response: 726169-73-9is a drug that inhibits the expression of the β-catenin protein.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  7-Aminocephalosporanicis a drug that inhibits
 
Response: 7-Aminocephalosporanicis a drug that inhibits cell wall biosynthesis. It is active against gram-negative organisms and is an alternative to cephalosporins in the treatment of community-acquired pneumonia, complicated intra-abdominal infections, and uncomplicated skin and skin structure infections.

7-Aminocephalosporanic acid, the antibiotic, is produced from 7-aminodesacetoxycephalosporanic acid by the enzyme cephalosporin acylase, a soluble enzyme that has been purified from several species of bacteria.

The 7-aminodesacetoxycephalosporanic acid is produced by bacterial strains of the genus Bacillus. These organisms have a 7-aminocephalosporanic acid-7-aminodesacetoxycephalosporanic acid acylase, which catalyzes the hydrolysis of 7-aminodesacetoxycephalosporanic acid. The acylase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  8-Hydroxyquinolineis a drug that inhibits
 
Response: 8-Hydroxyquinolineis a drug that inhibits mitochondrial DNA (mtDNA) topoisomerase-2 (mtTop2) and has demonstrated antitumor activity. Here, we have used a yeast-based assay to evaluate the ability of 8-hydroxyquinoline derivatives to stabilize mtDNA in vivo. A specific mtDNA instability was induced in Saccharomyces cerevisiae strains expressing either the wild-type or the E202Q mutant form of human mtTop2, which is defective in the catalytic activity of the enzyme. The presence of 8-hydroxyquinoline derivatives in the growth medium significantly decreased the spontaneous mtDNA instability in a dose-dependent manner, restoring the growth rate of the mtTop2-deficient yeast cells. The induction of mtDNA instability by a mutant form of mtTop2 was not inhibited by 8-hydroxyquinoline derivatives. These data indicate that 8-hydroxyquinoline derivatives can stabilize mtDNA in vivo and are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Abacaviris a drug that inhibits
 
Response: Abacaviris a drug that inhibits a key enzyme in cholesterol synthesis, has been shown to be effective in the treatment of familial hypercholesterolemia (FH). To assess the safety of treatment with abacavir in patients with heterozygous FH, and to assess the relationship between the LDL cholesterol (LDL-C) response to treatment and the extent of atherosclerosis in FH patients. Two double-blind, randomized, placebo-controlled trials were conducted. In the first trial, 6 FH patients with LDL-C levels >300 mg/dL (4.4 mmol/L) received 600 mg of abacavir daily for 8 weeks, followed by a 4-week placebo washout period. In the second trial, 9 FH patients with LDL-C levels >200 mg/dL (5.7 mmol/L) received 600 mg of abacavir daily for 6 weeks. In both trials, LDL-C levels were measured at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Abametapiris a drug that inhibits
 
Response: Abametapiris a drug that inhibits the enzyme aldehyde dehydrogenase and is used in the treatment of breast cancer and other diseases. This enzyme metabolizes the aldehydes that form during metabolism of alcohol.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABC294640is a drug that inhibits
 
Response: ABC294640is a drug that inhibits FKBP51, which regulates many steroid receptors, including AR. This drug was recently shown to be effective in patients with prostate cancer that has developed resistance to castration.[@b2-ott-9-3603] To our knowledge, this is the first case report to demonstrate a therapeutic effect of the combination of TAD and abiraterone in patients with prostate cancer who have failed to respond to ADT and abiraterone monotherapy.

In this case, the patient was initially treated with TAD and ADT, and although the PSA level dropped, the patient did not respond to this treatment. The progression of the disease was confirmed on follow-up computed tomography scans. In a previous study, ADT alone did not lead to a PSA response in patients with CRPC.[@b3-ott-9-3603] The patient was subsequently treated with the combination of TAD and abir
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABELCETis a drug that inhibits
 
Response: ABELCETis a drug that inhibits the activity of CETP, a protein that is responsible for removing cholesterol from HDL. When an HIV-infected patient takes a combination of an anti-retroviral drug (i.e. abacavir, didanosine, lamivudine, stavudine, or zidovudine) and a CETP inhibitor, the virus becomes less likely to build up in the patient’s cells.

A. CETP Inhibitors

There are currently two classes of CETP inhibitors in development: a monoclonal antibody and a synthetic molecule.

1. Monoclonal Antibodies

CETP is a plasma protein that has a number of functions, including removing cholesterol from HDL. Researchers have found that CETP is also present on the surface of cells in the body, where it is involved in the absorption of dietary cholesterol. Inhibition of CETP is a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABILIFYis a drug that inhibits
 
Response: ABILIFYis a drug that inhibits the action of an enzyme called acetylcholinesterase. This enzyme is found in the nervous system. Abilify is used to treat certain mental illnesses. Abilify is in a class of drugs called atypical antipsychotics.

Abilify is used to treat symptoms of schizophrenia. It is used to treat symptoms of bipolar disorder. It may be used to treat symptoms of anxiety, irritability, and aggression in children and adolescents. It may be used to treat symptoms of depression in adults. It may be used to treat agitation and psychosis in people with Alzheimer’s disease.

ABILIFY is used to treat the symptoms of certain mental illnesses.

HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Abirateroneis a drug that inhibits
 
Response: Abirateroneis a drug that inhibits the enzyme CYP17 and can thus reduce the production of androgens. It is given as a combination of abiraterone and prednisone.

The current indications for the use of abiraterone are in the treatment of prostate cancer.

Abiraterone can be given as a single agent, or in combination with prednisone.

It has a long-term safety record and can be given without the need for chemotherapy.

Abiraterone is a new treatment for advanced prostate cancer and may be used in combination with prednisone.

Abiraterone can be given to men with advanced prostate cancer as a single agent or in combination with prednisone.

It is not yet known whether abiraterone is effective in men with earlier stage prostate cancer.

A recent trial found that abiraterone plus prednisone did not improve overall survival in men with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Abitrexateis a drug that inhibits
 
Response: Abitrexateis a drug that inhibits the enzyme dihydrofolate reductase (DHFR). This enzyme is responsible for catalyzing the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). DHF is the normal precursor of tetrahydrofolate (THF) which is required to synthesize new purines and thymidylate for DNA synthesis and repair. Abitrexate acts as an antimetabolite, meaning that it competes with DHF for binding to DHFR, thereby inhibiting the enzyme's activity. As a result, tetrahydrofolate (THF) is unable to bind to the enzyme, which is the normal process in which it is converted to dihydrofolate (DHF). The process of the conversion of THF to DHF is essential for cell division and cell growth.
Abitrexate is an anti-neoplastic drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Abscisicis a drug that inhibits
 
Response: Abscisicis a drug that inhibits the action of abscisic acid on plant seeds.

Abscisic acid is a phytohormone that is present in all land plants. It plays a role in the development of seeds and germination of plants. It is also an important hormone in plants' response to stress.

Abscisic acid is also known as the'stress hormone' because it is released during stress and its levels are increased during periods of stress.

Abscisic acid is used in medicine to treat the symptoms of stress and is the active ingredient in prescription medication such as Effexor and Abilify.

What is Abscisic Acid?

Abscisic acid is a naturally occurring plant hormone that is released by seeds to prepare them for germination.

Abscisic acid is a type of phytohormone that is important for seed development. It is also important
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABT-199is a drug that inhibits
 
Response: ABT-199is a drug that inhibits the proliferation of B cells, specifically those that have received the B-cell receptor (BCR) signal, and that have failed to mature into plasma cells. This treatment would allow the immune system to target the disease, rather than the cancer itself. In addition, as it works on B cells, it would not affect normal plasma cells that produce healthy antibodies.

In a recent paper in the journal Cell, researchers from the University of Pennsylvania in Philadelphia explain that the drug is effective against chronic lymphocytic leukaemia (CLL) in mice. The study demonstrates that the drug is effective in treating the disease in the early stages, before the cancer has become aggressive and harder to treat.

“I think that we’ve found a treatment that’s very effective in the earliest stages of the disease,” says Dr Kevin Liu, a researcher at Penn’s Abramson Cancer Center and first author of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABT-492(Delafloxacin)is a drug that inhibits
 
Response: ABT-492(Delafloxacin)is a drug that inhibits the bacterial topoisomerase IV. It is administered as a single daily dose. The efficacy and safety of ABT-492(Delafloxacin) has been evaluated in patients with moderate to severe acute bacterial exacerbation of chronic bronchitis (AECB).

ABT-492(Delafloxacin) was effective and well tolerated in the treatment of AECB. In patients with AECB, ABT-492(Delafloxacin) was superior to placebo and non-inferior to levofloxacin.

About ABT-492(Delafloxacin)

ABT-492(Delafloxacin) is an oral, single-dose, investigational drug. It is administered as a single daily dose.

ABT-492(Delafloxac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  abt-751is a drug that inhibits
 
Response: abt-751is a drug that inhibits the action of TGF-β1 in many cell types, including those of the heart, and thereby promotes ventricular repair after myocardial infarction. We assessed the effects of ABT-751 on the growth of cultured cardiac myofibroblasts. ABT-751 caused a dose-dependent inhibition of TGF-β1-induced expression of α-SMA, Col I, Col III, fibronectin, and pSMAD3 in myofibroblasts. The inhibitory effect of ABT-751 was detectable at doses as low as 1 nM and reached maximum inhibition at doses of 10 nM. The maximal inhibitory effect of ABT-751 was observed after 48 hours of incubation. ABT-751 had no effect on TGF-β1-induced expression of α-SMA in neonatal rat cardiac myofibroblasts, and ABT-751
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABT-888(Veliparib)is a drug that inhibits
 
Response: ABT-888(Veliparib)is a drug that inhibits the enzyme PARP1. It is used to treat some cancers that have a defect in the BRCA1 and BRCA2 genes.

**How does it work?**

In healthy cells, PARP1 repairs damaged DNA. In cancer cells, the DNA is damaged and PARP1 becomes active. This causes a buildup of DNA damage and eventually the cancer cell dies.

**What does the evidence show?**

Clinical trials of PARP inhibitors in ovarian cancer have shown that they are effective in treating this disease. They have been found to be more effective than chemotherapy.

The phase III clinical trial for PARP inhibitors (OlympiA) in ovarian cancer was carried out in women who had a germline mutation in BRCA1 or BRCA2. The drug was given for 6 months.

Ovarian cancer is one of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ABX-1431is a drug that inhibits
 
Response: ABX-1431is a drug that inhibits cyclin-dependent kinase 2 (CDK2) and thus prevents the transition from G1 to S phase of the cell cycle. The drug has been shown to have antitumor activity in preclinical models, and the results of a phase I clinical trial suggested that the drug was well tolerated in humans. However, because of a loss of efficacy in one patient, the phase II trial was terminated prematurely. The results of the current study suggest that there is a need for further studies to investigate the potential benefits of ABX-1431 in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

The authors evaluated the efficacy and safety of ABX-1431 in patients with advanced or metastatic NSCLC who had been previously treated with platinum-based chemotherapy. Patients received the drug at doses of 50 mg/m(2) and 100 mg/m(2) as a 1-hour
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AC220is a drug that inhibits
 
Response: AC220is a drug that inhibits the kinase activity of Pim-1 kinase, a critical effector of the survival pathways induced by growth factor signaling \[[@B49-ijms-19-00139]\]. The Pim-1 kinase, also known as oncogene Pim-1, is an oncogene that promotes cell cycle progression and growth by inactivating the tumor suppressor protein p27. A Pim-1 kinase inhibitor (AC220) has been developed and has been shown to inhibit Pim-1 kinase and suppress cell growth \[[@B49-ijms-19-00139]\]. The use of AC220 in the treatment of prostate cancer has been studied and shows promise in preclinical and clinical studies.

### 2.3.2. Sorafenib {#sec2dot3dot2-ijms-19-00139}

Sorafenib is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acalabrutinibis a drug that inhibits
 
Response: Acalabrutinibis a drug that inhibits the tyrosine kinase activity of Bruton\'s tyrosine kinase (BTK). Inhibition of BTK reduces B-cell and plasma cell survival, growth, and cytokine production, and induces apoptosis.[@bib1] Acalabrutinib is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) and is being evaluated in a variety of other B-cell malignancies.

B-cell non-Hodgkin lymphoma (B-NHL) is a heterogeneous group of lymphoid malignancies that can be classified into distinct categories, including B-cell follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), MCL, and Burkitt lymphoma (BL). Although acalabrutinib is approved for treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acarboseis a drug that inhibits
 
Response: Acarboseis a drug that inhibits the digestion of the carbohydrates and hence slows down the absorption of glucose in the body. This drug is used in type 2 diabetes mellitus (DM) and has also been found to be beneficial in patients with non-alcoholic fatty liver disease (NAFLD).\[[@ref1]\] In a study conducted in children with type 2 DM, a combination of acarbose and insulin was found to be effective in reducing glycated hemoglobin (HbA1c) levels and improving fasting blood glucose (FBG) levels.\[[@ref2]\]

Acarbose is a competitive inhibitor of α-glucosidase, the enzyme responsible for the digestion of carbohydrates. It is used as a monotherapy or in combination with other oral antidiabetic drugs (OADs).\[[@ref3]\] The efficacy of acarbose in the management of type 2 DM is well established.\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACCOLATEis a drug that inhibits
 
Response: ACCOLATEis a drug that inhibits the formation of hyaluronic acid (HA), a major component of the extracellular matrix. It is a common ingredient in fillers. It was approved by the FDA in December 2013 for the treatment of nasolabial folds, nasojugal folds, perioral lines, and periorbital lines. It is also approved for use in adults in the treatment of mild to moderate nasolabial folds, mild to moderate nasojugal folds, moderate to severe nasolabial folds, moderate to severe nasojugal folds, and moderate to severe perioral lines and periorbital lines. Acai is a berry from the acai palm tree, which is native to the Amazon basin in South America. It is cultivated and consumed as a fruit in Brazil and in other parts of South America. The berry has a gelatinous texture, red color, and is typically eaten raw or is added to smoothies
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  acebutololis a drug that inhibits
 
Response: acebutololis a drug that inhibits the immune system and was prescribed to a woman who was pregnant with triplets. The pregnancy progressed normally and was considered a success. But the three babies were stillborn and the mother died of an infection.

Advertisement

Advertisement

The CDC says that, between 2004 and 2013, it received nearly two dozen reports of adverse pregnancy outcomes linked to the use of the drug, and another 22 reports of adverse birth outcomes associated with use of fluoroquinolone antibiotics in general.

The CDC warns pregnant women to avoid fluoroquinolones and encourages them to take other, less risky medications, such as those used to treat infections of the urinary tract or the respiratory system.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aceclidineis a drug that inhibits
 
Response: Aceclidineis a drug that inhibits the voltage-gated sodium channel and is widely used in the treatment of epilepsy. There are limited studies on the pharmacokinetics of aceclidine. The aim of this study was to establish a validated method for the determination of aceclidine in human plasma and urine by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). This method was successfully applied to a pharmacokinetic study of aceclidine after intravenous administration to healthy male volunteers. The results indicated that aceclidine was rapidly eliminated with a half-life of approximately 1.27 h. No accumulation of aceclidine was observed after repeated administration. The developed method was fully validated and proved to be reliable and accurate for the determination of aceclidine in human plasma and urine.

1. Introduction

Aceclidine is a drug that inhibits the voltage-gated sodium channel and is widely used in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aceglutamideis a drug that inhibits
 
Response: Aceglutamideis a drug that inhibits cystine-glutamate antiporter, which is a membrane transporter that exports cystine from the cells into the extracellular space. Glutamate is produced from the hydrolysis of cystine by the action of xc-cystine aminopeptidase. In the absence of the cystine-glutamate antiporter, extracellular glutamate is accumulated in the cells.

In recent years, glutamate is known to be an important neurotransmitter in the central nervous system, and has been implicated in many diseases including epilepsy, neuropathic pain, and Parkinson's disease. However, it has been difficult to evaluate the pharmacological activity of glutamate in the central nervous system. This is because glutamate in the central nervous system is mainly transported by the excitatory amino acid transporters (EAATs), and the transport activity of EAATs is saturated by extracellular glutamate. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acemetacinis a drug that inhibits
 
Response: Acemetacinis a drug that inhibits the activity of histone deacetylases, thereby causing the acetylation of histones. This in turn prevents the binding of the repressor protein to DNA, leading to the transcription of genes in the cell.

Adalimumab - an antibody against tumour necrosis factor.

Acyclovir - an antiviral agent used in the treatment of herpes simplex virus and varicella zoster virus infections.

AED - anti-epileptic drug.

AEDs - anti-epileptic drugs.

Afatinib - an irreversible ErbB family blocker that is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer.

Agents acting on the renin-angiotensin system (RAS) - a system of hormones that regulate blood pressure, fluid and electrolyte balance and other functions of the body.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACEONis a drug that inhibits
 
Response: ACEONis a drug that inhibits the enzyme renin and lowers blood pressure. It is also used to treat certain types of kidney disease.

ACRONYMmPTHrP is a hormone that is secreted by the kidney and stimulates bone formation.

ACRONYMOMRU is a drug that is used to treat bone cancer.

ACRONYMOTARGIN is a drug that treats arthritis.

ACRONYMPAT is a drug that is used to treat blood clots.

ACRONYMPATAMINE is a drug that treats anxiety.

ACRONYMPHENAZONE is a drug that is used to treat mental disorders.

ACRONYMPIPETIDINE is a drug that treats diarrhea.

ACRONYMPROMA is a drug that treats psoriasis.

ACRONYMPROPION is a drug that treats depression.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acesulfameis a drug that inhibits
 
Response: Acesulfameis a drug that inhibits the enzyme acesulfame K, an artificial sweetener that acts as a substrate for the enzyme. Inhibition of the enzyme may also have potential therapeutic uses.

Acesulfame K is the name of the compound and its structure is

Chemical name

C12H20O6S

CAS No.

120535-29-8

Synonyms

Acesulfame

BAS No.

4138-82-8

PubChem CID

25820

Inhibition of the enzyme acesulfame K, an artificial sweetener that acts as a substrate for the enzyme. Inhibition of the enzyme may also have potential therapeutic uses.

Acesulfame K is the name of the compound and its structure is

Chemical name

C12H20O6S

CAS No.

12
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACETADOTEis a drug that inhibits
 
Response: ACETADOTEis a drug that inhibits the development of atherosclerosis by inhibiting the activation of NF-kappaB and decreasing TNF-alpha and IL-1beta expression. In this study, we investigated the effect of acetylsalicylic acid (ASA) in combination with a high-fat diet on the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. ApoE-/- mice were fed a high-fat diet with or without 0.05% (w/w) ASA for 16 weeks. After the treatment, the blood pressure, plasma levels of lipids and cholesterol, and the body weight of the ASA-treated mice were significantly lower than those of the untreated mice. However, the atherosclerotic lesions in the aorta and coronary arteries of the ASA-treated mice were larger than those of the untreated mice. ASA significantly decreased the plasma levels of TNF-alpha and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acetanilideis a drug that inhibits
 
Response: Acetanilideis a drug that inhibits acetylcholinesterase (AChE). The enzyme acetylcholinesterase (AChE) plays an important role in the neurotransmission of the cholinergic system. In the brain, AChE is found in high concentrations in the synaptic cleft and is responsible for the breakdown of acetylcholine, a neurotransmitter that is released at the synapse. Acetylcholinesterase (AChE) is the major enzyme involved in cholinergic neurotransmission. Acetylcholinesterase (AChE) is the major enzyme involved in cholinergic neurotransmission. The therapeutic effect of the cholinergic drugs is mediated by their inhibitory action on the enzyme acetylcholinesterase (AChE). The inhibitory action of acetylcholinesterase (AChE) inhibitors is used to improve cognitive functions, enhance memory and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acetazolamideis a drug that inhibits
 
Response: Acetazolamideis a drug that inhibits carbonic anhydrase (CA). It is used in the treatment of glaucoma and as a diuretic.

Mechanism of action

CA converts carbon dioxide into a soluble ionic form and H+ into a non-ionic form. Thus CA converts a gas (carbon dioxide) into a liquid (bicarbonate) and an acid (H+) into a non-ionized form. It is an effective antiglaucoma agent by inhibiting aqueous humor secretion.

Uses

Inhibition of carbonic anhydrase causes a number of side effects.

Adverse effects

Adverse effects of acetazolamide are

High fever

Seizures

Dizziness

Visual disturbance

Allergic reactions

Nausea

Diarrhea

Dry mouth

Mild to moderate headache

Photos
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acetylcholineis a drug that inhibits
 
Response: Acetylcholineis a drug that inhibits the movement of the muscle. It is used to treat respiratory disorders. Acetylcholine is also known as ACh.

A Choline bitartrate can be used as an expectorant and to reduce inflammation. It is also used in combination with other drugs to treat neurological disorders, such as Parkinson’s disease. It is also used in combination with other drugs to treat sleep disorders, such as insomnia and narcolepsy. It is used in combination with other drugs to treat gastrointestinal disorders, such as ulcer and esophagitis. It is used in combination with other drugs to treat neurological disorders, such as Parkinson’s disease. It is used in combination with other drugs to treat memory disorders, such as Alzheimer’s disease. It is used in combination with other drugs to treat skin disorders, such as acne. It is used in combination with other drugs to treat liver disorders, such as j
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acetylleucineis a drug that inhibits
 
Response: Acetylleucineis a drug that inhibits prolyl endopeptidase, a serine endopeptidase involved in the maturation of neuropeptides such as substance P and somatostatin. Acetylleucine has been shown to have anti-nociceptive effects in a number of animal models of pain, but its efficacy and safety in humans have not been established. The purpose of this study was to determine the safety, tolerability, and efficacy of oral acetylleucine in patients with pain associated with chronic musculoskeletal conditions. Patients were randomly assigned to receive oral acetylleucine or placebo in a double-blind fashion. Acetylleucine was administered at the dosage of 150 mg twice daily for 6 weeks. Primary efficacy measures were the percentage of patients who had a 30% or greater decrease in pain intensity at week 6, and the percentage of patients who had a 50% or greater
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACHES-N-PAINis a drug that inhibits
 
Response: ACHES-N-PAINis a drug that inhibits substance P, which is an active agent in the pain system. In many people, it has been shown to reduce the pain of dental procedures. It may be used as a short-term painkiller, for example for a broken arm or leg, but is not generally used for chronic pain. It is available in the UK as a nasal spray or an oral tablet.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACILACis a drug that inhibits
 
Response: ACILACis a drug that inhibits the enzyme telomerase, which is required for the growth of cancer cells.

What are the side effects of ACILAC?

Side effects of ACILAC include nausea, vomiting, diarrhea, and abdominal pain.

What are the precautions before taking ACILAC?

ACILAC is only available by prescription. Do not take it if you are allergic to any of its ingredients. Before taking ACILAC, tell your doctor if you have an infection or are taking any other medicines.

What are the uses of ACILAC?

ACILAC is used to treat certain types of cancer. It is not known if ACILAC is safe and effective in children.

What are the dosage instructions?

The recommended dose of ACILAC is two capsules per day for a period of 6 weeks.

What are the dosage forms of ACILAC?

ACILAC is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acipimoxis a drug that inhibits
 
Response: Acipimoxis a drug that inhibits intestinal absorption of cholesterol and fats.

It is indicated in patients with hypercholesterolemia and hypertriglyceridemia.

The product contains acipimox, a hypolipidemic drug that inhibits intestinal absorption of cholesterol and triglycerides.

It is a white or nearly white, tasteless, odorless powder, with an effective daily dose of 150 to 250 mg, preferably in the form of oral solution.

Acipimox is marketed in the United States under the trade name “Vascepa”.

Acipimox is used in the treatment of hyperlipidemia.

It belongs to the group of hypolipidemic drugs that are known as statins.

In addition to acipimox, there are other hypolipidemic drugs that belong to the group of statins.

The main difference between acipim
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acitretinis a drug that inhibits
 
Response: Acitretinis a drug that inhibits the contraction of the muscles of the uterus, which are responsible for contractions of the uterus. The most commonly used drug is Terbutaline.

Aromatase inhibitor A drug that inhibits the production of estrogen by the ovaries.

Progestogen Progesterone is a female sex hormone that is synthesized in the ovaries and the placenta. Progesterone is the main female hormone in pregnancy.

Progestogen Progesterone is a female sex hormone that is synthesized in the ovaries and the placenta. Progesterone is the main female hormone in pregnancy.

Progestogen Progesterone is a female sex hormone that is synthesized in the ovaries and the placenta. Progesterone is the main female hormone in pregnancy.

Progestogen Progesterone is a female sex hormone that is synthesized in the ovaries and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aclidiniumis a drug that inhibits
 
Response: Aclidiniumis a drug that inhibits bronchoconstriction by blocking muscarinic receptors (muscarinic receptors). It is indicated for the treatment of chronic obstructive pulmonary disease (COPD) in adults. It is not known whether this drug is safe and effective in children.

Other Names

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclidiniumbromide

Aclid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acrivastineis a drug that inhibits
 
Response: Acrivastineis a drug that inhibits mast cell activation and is used for treatment of allergy, arthritis, chronic idiopathic urticaria and pruritus.[@b1-asm-3-288]--[@b3-asm-3-288] It has a relatively long elimination half-life (about 12 hours) and is primarily metabolized in the liver by N-acetylation, glucuronidation and sulfation.[@b4-asm-3-288] The recommended dose of the drug is 4 mg/kg twice daily for adults and 2 mg/kg twice daily for children. We present the case of a 13-year-old girl with severe, refractory pruritus associated with severe urticaria and wheezing. After a short course of systemic corticosteroids and antihistamines, the patient's pruritus and urticaria completely resolved. We discuss the etiology of her condition and review the literature
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACTIGALLis a drug that inhibits
 
Response: ACTIGALLis a drug that inhibits both the histamine H~1~ and H~2~ receptors. Its safety and tolerability have been assessed in clinical trials in patients with allergic rhinitis and in those with acute bronchial asthma. It is also being used to relieve pruritus in patients with atopic dermatitis. The aim of this review is to describe the pharmacology, clinical use, and adverse effects of ACTIGALL.

ACTIGALL (Viramune) is a drug that was developed in the late 1970s and early 1980s as a histamine H~1~ receptor antagonist. The histamine H~1~ receptor is found on both the central and peripheral nervous systems. It has a role in the regulation of neuronal excitability and, as a consequence, affects the sensory, motor, and autonomic functions of the brain and the central and peripheral nervous systems. The histamine H~1~ receptor is also found on cells of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACTIN-Nis a drug that inhibits
 
Response: ACTIN-Nis a drug that inhibits cell proliferation and induces apoptosis. The effect of ACTIN-Nis on CLL cells was evaluated using cell viability, cell cycle, apoptosis, and migration assays. An apoptosis assay showed that ACTIN-Nis caused apoptosis of CLL cells, with the level of apoptosis positively correlated with the concentration of ACTIN-Nis. Cell cycle analysis showed that ACTIN-Nis caused cell cycle arrest at the G2/M phase. A migration assay showed that ACTIN-Nis significantly inhibited the migration of CLL cells. In conclusion, ACTIN-Nis induces apoptosis of CLL cells and inhibits their migration. ACTIN-Nis may be a potential therapeutic agent for the treatment of CLL.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACTRONis a drug that inhibits
 
Response: ACTRONis a drug that inhibits the Rho-associated protein kinase (ROCK) which is a serine/threonine kinase that belongs to the AGC kinase family. It is one of the key effectors of Rho GTPase, and it phosphorylates the myosin-binding subunit of myosin phosphatase. The drug is used for the treatment of cancer and various neurological disorders. The product of the gene *ACTR2* encodes for the human ROCK1.

There are two different forms of ACTR2: a full-length, G-protein-coupled receptor (GPCR) type of ACTR2, which is found on the cell membrane, and a short form of the protein, which is localized in the nucleus and is considered to be a pseudogene.

ACTR2 is highly expressed in the central nervous system (CNS), heart, liver, skeletal muscle
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACY-1215is a drug that inhibits
 
Response: ACY-1215is a drug that inhibits a protein called poly-ADP-ribose polymerase (PARP), which is involved in the repair of DNA damage. The main indication for the use of this drug is to reduce the incidence of the side effects of radiation and chemotherapy in cancer patients. PARP inhibitors work by interfering with the repair of damaged DNA. By blocking this repair mechanism, the drug causes DNA damage that leads to the death of cancer cells. In the development of an ideal PARP inhibitor, a number of features are being considered. In this context, the ADME-Tox data for CYP3A4 and P-gp in vitro (primary human hepatocytes) is important. This is because the metabolism and efflux of a drug through CYP3A4 and P-gp are the two key factors determining its bioavailability and hence its exposure. We have evaluated the potential to use a human liver microsomal (HLM) system to predict the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Acycloviris a drug that inhibits
 
Response: Acycloviris a drug that inhibits the virus responsible for Cystic Fibrosis. Also a class of antibiotics that is used to treat people with infections of the intestines, bladder and lungs.

acyclovir, also called acyclovir valtrex, zovirax, valtrex (f) Brand name for acyclovir. Brand name for acyclovir valtrex. Read warnings. Read more. Brand name for acyclovir. Brand name for acyclovir valtrex. Acyclovir is an antiviral medication used to treat cold sores, genital herpes and shingles.

Nelfinavir is an antiretroviral medication used to treat HIV.

AIDS, or acquired immunodeficiency syndrome, is a syndrome caused by the human immunodeficiency virus (HIV) that is marked by a progressive destruction of the body's immune system.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ADALATis a drug that inhibits
 
Response: ADALATis a drug that inhibits the activity of the enzyme acetyl-CoA-ligase (ACL). By inhibiting ACL, it leads to the accumulation of acetyl-CoA, and subsequently to the activation of the hypoxia-inducible factor 1 alpha (HIF-1α) transcription factor. HIF-1α is the key regulator of the hypoxic response, and therefore its activation induces the expression of many genes involved in the cellular response to hypoxia. It has been reported that ADALAT can induce tumour cell death in different tumour types. It can also inhibit tumour growth and angiogenesis. ADALAT has been evaluated in Phase I and Phase II clinical trials for the treatment of cancer. The clinical development of ADALAT was discontinued in 2005 because of the lack of antitumour activity. In this review, we discuss the current state of ADALAT as an anticancer agent.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adapaleneis a drug that inhibits
 
Response: Adapaleneis a drug that inhibits a key enzyme in the body’s production of skin cells. It is used to treat acne.

Tretinoin (Tretin) is a drug that works by decreasing inflammation in the skin. It is used to treat acne.

Clindamycin (Clinda) is a drug that treats bacterial infections of the skin and mouth.

Isotretinoin (Aquasol) is a drug that decreases inflammation in the skin. It is used to treat severe acne.

Accutane (Isotretinoin) is a drug that decreases inflammation in the skin. It is used to treat severe acne.

Accutane (Isotretinoin) is a drug that decreases inflammation in the skin. It is used to treat severe acne.

Reverse Tretinoin (Tretin-R) is a drug that works by decreasing inflammation in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adavivintis a drug that inhibits
 
Response: Adavivintis a drug that inhibits the adenosine receptor. It is currently in phase II trials in Europe for the treatment of cancer.

The drugs of this class are of great interest because they inhibit adenosine receptors (ARs), which are present on the surface of most cells, and thus have the potential to be broadly effective in the treatment of a number of disorders. ARs are part of the family of purinergic receptors, and act as chemoreceptors that mediate responses to adenosine and other purines. They are divided into four subtypes, A1, A2A, A2B, and A3. The effects of ARs are mediated by a family of G-protein coupled receptors, of which there are four subtypes, A1, A2A, A2B, and A3.

In addition to its potential utility in the treatment of cancer, ADV has been shown to inhibit several other conditions
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adenineis a drug that inhibits
 
Response: Adenineis a drug that inhibits the enzyme adenosine deaminase, which is involved in the degradation of adenosine in the body. It is used in the treatment of leukemias, lymphomas, and metastatic solid tumors. The most common side effects of this drug include diarrhea, nausea, and vomiting.

To help treat acute myelogenous leukemia (AML), scientists at the University of Texas MD Anderson Cancer Center in Houston created a new form of the drug, CSA, which has better bioavailability and lower toxicity than its predecessor, 6-mercaptopurine.1

"We had a chance to re-engineer a drug that was already FDA approved and that we could test in a clinical trial," said senior author Rebecca McKinney, PhD, professor of medicine at MD Anderson. "The real payoff is that we were able to re-engineer a drug that's already in use, and we were able to bring it
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adenosineis a drug that inhibits
 
Response: Adenosineis a drug that inhibits immune cell function. It is a potent immunosuppressant that inhibits the proliferation of both lymphocytes and monocytes.

A non-selective adenosine antagonist such as theophylline has been shown to be effective in the treatment of asthma. However, because of its side effects, this drug is no longer recommended for the treatment of asthma.

Chemistry

Adenosine is a purine nucleoside. It is related to inosine and guanosine, which are found in the nucleic acids of the cell.

Mechanism of action

Adenosine is a purine nucleoside that is a key mediator of the body's response to injury. It is a natural anti-inflammatory compound that is produced in large amounts in response to tissue damage. Adenosine exerts its effects by binding to specific cell surface receptors. The adenosine A2A receptor is the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ADENOSINEis a drug that inhibits
 
Response: ADENOSINEis a drug that inhibits the production of melanin. It works by interfering with the production of tyrosinase. Tyrosinase is an enzyme that is responsible for the formation of melanin in the skin. Tyrosinase is also responsible for the formation of melanin in the eye.

How is adenine produced?

The precursor of adenine is AMP. AMP is made by a process called adenylation. Adenylation involves the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). The reaction is catalyzed by an enzyme called adenylate kinase. The first step of the reaction involves the conversion of ATP to ADP. The conversion of ADP to AMP is catalyzed by AMP deaminase.

Why is adenine used in the treatment of hyperpigmentation?

It is used in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adrenaloneis a drug that inhibits
 
Response: Adrenaloneis a drug that inhibits the enzyme 11-beta-hydroxysteroid dehydrogenase (11β-HSD) type 2. The enzyme 11β-HSD converts inactive cortisone to active cortisol. Adrenaloneis is useful for the treatment of Cushing's disease and hypoadrenalism in children.

Adrenaloneis a drug that inhibits the enzyme 11-beta-hydroxysteroid dehydrogenase (11β-HSD) type 2. The enzyme 11β-HSD converts inactive cortisone to active cortisol. Adrenaloneis is useful for the treatment of Cushing's disease and hypoadrenalism in children.

Lithium therapy is associated with the development of an acute syndrome characterized by fever, headache, nausea, vomiting, diarrhea, abdominal pain, and confusion. This syndrome has been called hyperthermic syndrome. It may be the result of a reaction to lithium itself, an infection, or an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adriamycinis a drug that inhibits
 
Response: Adriamycinis a drug that inhibits protein synthesis in a number of species.\[[@ref1]\] It is used in combination with other drugs to treat gram-positive infections.

Adriamycin is used in combination with other drugs to treat gram-positive infections. It has been shown that the combination of an antibiotic with an anthelmintic is synergistic against many parasites.\[[@ref2]\] In some cases, it has been shown that the combination of a drug with an anthelmintic is antagonistic.\[[@ref3]\]

Aims and objectives {#sec2-1}
===================

To evaluate the *in vitro* interaction between a fixed dose of adriamycin and anthelmintic drugs in human blood.

Materials and Methods {#sec1-1}
=====================

Study design {#sec2-2}
------------

An
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Adrucilis a drug that inhibits
 
Response: Adrucilis a drug that inhibits the production of uric acid in the body. It works by decreasing the amount of enzymes that are required to create uric acid in the body. It can be used in patients with gout, hyperuricemia, or those who are at risk of gout. Adrucilis is not approved by the FDA for the treatment of gout.

Adrucilis is an injectable medication that contains uricase, an enzyme that helps to break down uric acid in the body. Adrucilis is administered once every three weeks.

This medication may cause side effects, including nausea, diarrhea, and an increased number of side effects such as swelling, rash, or itching. It may also cause severe side effects, including kidney damage, allergic reaction, or liver damage.

The recommended dose of Adrucilis is 10 units/kg. The dose should be adjusted based on the individual's weight.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AESCULINis a drug that inhibits
 
Response: AESCULINis a drug that inhibits the action of cytochrome P450 2C9 (CYP2C9) and is commonly used to lower the concentration of warfarin. In clinical practice, the drug is generally administered with food. The present study was conducted to determine the effects of food on the pharmacokinetics of esculin and to investigate the absorption mechanism. In the food-effect study, nine healthy male subjects received esculin with a meal (350 mg) or without a meal (350 mg). In the absorption study, the oral bioavailability of esculin was determined after single and multiple doses of esculin with or without food. In the food-effect study, the area under the concentration-time curve (AUC) of esculin after esculin intake with food was significantly lower than that after esculin intake without food (1,334.3 ± 642.7 versus 1,993.5 ± 9
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Afatinibis a drug that inhibits
 
Response: Afatinibis a drug that inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, which is a receptor for epidermal growth factor (EGF) and plays an important role in the pathogenesis of various malignancies, including non-small cell lung cancer (NSCLC). It has been demonstrated that the response rate to afatinib is high in patients with EGFR-mutated NSCLC.[@R1]--[@R3] Afatinib is also approved for first-line treatment of patients with metastatic HER2-positive breast cancer.[@R4] The most common adverse events (AEs) of afatinib are rash, diarrhea, and fatigue.[@R5] Although these AEs are generally manageable, the incidence of interstitial lung disease (ILD) with afatinib is higher than that with other drugs.[@R6]--[@R9] The exact pathogenesis of ILD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AG-120is a drug that inhibits
 
Response: AG-120is a drug that inhibits the expression of C/EBP-homologous protein (CHOP) and also increases the expression of anti-apoptotic Bcl-2 and Bcl-xL. The aim of this study was to investigate the effects of AG-120 on the survival of patients with ovarian cancer. Patients with ovarian cancer who had received a total of 12 courses of platinum-based chemotherapy were enrolled. A total of 6 patients received AG-120 treatment (AG-120 group) and 6 patients received placebo treatment (placebo group). The progression-free survival was 7.2 months in the AG-120 group and 2.9 months in the placebo group (p = 0.05). The overall survival was 11.5 months in the AG-120 group and 5.8 months in the placebo group (p = 0.07). The clinical benefits of AG-120 were observed in the AG-120 group. The possible mechanisms of the benefits
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AG-221is a drug that inhibits
 
Response: AG-221is a drug that inhibits the activity of Wnt/β-catenin pathway in human breast cancer. The present study was designed to evaluate the anti-cancer effect of AG-221 on TNBC in vitro and in vivo. The results indicated that AG-221 inhibited the proliferation of TNBC cell lines and arrested cells at G2/M phase. In vivo xenograft mouse model indicated that AG-221 could suppress tumor growth of TNBC. The expression of E-cadherin was increased and that of N-cadherin and β-catenin were decreased in AG-221-treated TNBC cells. The effect of AG-221 on the expression of E-cadherin and N-cadherin was confirmed by Western blot. In addition, AG-221 could induce apoptosis of TNBC cells. Furthermore, AG-221 inhibited tumor growth of TNBC cells by activating caspase-3 and caspase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AGENERASEis a drug that inhibits
 
Response: AGENERASEis a drug that inhibits an enzyme that helps the body to process the form of vitamin K, which is used in the treatment of blood disorders and bone health.

It is used to treat and prevent bleeding due to vitamin K deficiency in people who have haemophilia or liver disease. It is also used to prevent blood clots in people with risk factors for them, such as recent surgery or an injury, and to prevent deep vein thrombosis and pulmonary embolism in people who have had a major operation.

It is also used to treat children who have had blood or platelet transfusions to prevent the development of the haemorrhagic disease of the newborn.

It is also used in people who have had certain medicines that affect the liver, such as anticoagulants.

Vitamin K has a similar role to that of vitamin A, as it helps to prevent the build-up of calcium and phosphate in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Agomelatineis a drug that inhibits
 
Response: Agomelatineis a drug that inhibits both serotonin and histamine. The combination of the serotonin and histamine inhibitory effects results in a novel therapeutic approach. Agomelatine was originally developed for the treatment of depression and anxiety, but has been approved for the treatment of major depression in some countries. Its side-effects are well-known and include nausea, weight gain, insomnia, headache and increased appetite.

Introduction {#Sec1}
============

Aromatase inhibitors are the first-line treatment for estrogen-receptor-positive early breast cancer, especially in premenopausal women, in whom they reduce recurrence and mortality. However, the anti-tumour effects of aromatase inhibitors may be limited in some patients. The endocrine therapy for patients with breast cancer is often accompanied by serious side-effects, such as joint pain, hot flushes, and weight gain.

In women with breast cancer, aromatase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ala-Glnis a drug that inhibits
 
Response: Ala-Glnis a drug that inhibits the transport of amino acids into the brain, is widely used in Europe and is marketed in the US as L-thyroxine. Its use in children is controversial. We report on a patient with pseudo-obstruction and central hypothyroidism, whose treatment with Ala-Glnis resulted in rapid clinical improvement and normalization of thyroid hormone levels. This report illustrates the usefulness of Ala-Glnis in children.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alanineis a drug that inhibits
 
Response: Alanineis a drug that inhibits platelet-derived growth factor (PDGF) signaling. The effect of alanine on corneal neovascularization was investigated. Adult male Sprague-Dawley rats received a subconjunctival injection of PDGF-BB. An area of corneal neovascularization was surgically excised and replaced with a filter paper disk that had been soaked in a solution of alanine (2 mg/ml) or PBS. Rats were examined by slit-lamp biomicroscopy and angiography at various time points. The animals were then euthanized and the corneas were processed for histological examination. The results of these experiments show that alanine has a significant inhibitory effect on PDGF-induced corneal neovascularization. The data indicate that alanine may be a useful adjunct to laser therapy and other anti-neovascular therapies for the treatment of corneal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alarelinis a drug that inhibits
 
Response: Alarelinis a drug that inhibits the release of growth hormone. It was first marketed in 1981. Alarelinis the active ingredient in Alarelin (trade name Somatuline).

It is used to treat growth hormone deficiency in children, children with Turner's syndrome, idiopathic short stature and children with certain forms of dwarfism.

Alarelinis a long-acting somatostatin analogue. It is administered as a subcutaneous injection (as an oil-in-water emulsion) every four weeks. It works by inhibiting the release of growth hormone from the pituitary gland.

Alarelinis used in the treatment of growth hormone deficiency. It is given once a month by injection into the subcutaneous tissue of the thigh. It works by inhibiting the release of growth hormone from the pituitary gland. It is used in children and adults who have low levels of growth hormone and have a short stature
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Albendazoleis a drug that inhibits
 
Response: Albendazoleis a drug that inhibits the activity of a worm that causes trichinellosis, which is also known as trichinosis. This worm resides in the intestinal tract of an animal that is eaten by people.

People who are infected with this worm can develop a fever and severe abdominal cramps. It can also be fatal if untreated. People who eat meat that has been contaminated with the worm can develop trichinellosis.

Some people who have the drug albendazole for other conditions may be more susceptible to developing trichinellosis. People who are taking albendazole are more likely to develop trichinellosis if they are infected with the worm.

Albendazole is available in tablets, liquid, and syrup. It is usually taken twice a day.

The best time to take albendazole is when you first develop symptoms of trichinellosis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALBENZAis a drug that inhibits
 
Response: ALBENZAis a drug that inhibits the rate of acetylcholine esterase in the brain, increasing the concentration of acetylcholine in the synaptic cleft. It is indicated for the treatment of generalized myasthenia gravis (MG), neuromuscular junction disorders, and various muscle spasms. Albensin is also used in the treatment of anxiety and insomnia.

**How it works:** Acetylcholine is the neurotransmitter responsible for transmitting messages from one nerve cell to another, from one muscle to another, and from the brain to other parts of the body. Acetylcholine is the chemical that is released when you swallow or when you breathe in, causing your diaphragm to contract. The acetylcholine is carried in the synapse by the acetylcholine receptors, which are proteins that span the gap between the nerve cell and the muscle cell. The acetylcholine receptors open when the neurotrans
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALDOCLOR-250is a drug that inhibits
 
Response: ALDOCLOR-250is a drug that inhibits the production of leukotrienes. It has been used to treat mild-to-moderate asthma, but was removed from the market in 2001 because of safety concerns. In July 2002, the FDA advised that it would re-examine ALDOCLOR-250 for the treatment of asthma and approved the product for that indication. In this study, the safety and efficacy of ALDOCLOR-250 were evaluated in a randomized, double-blind, placebo-controlled, crossover study of 60 subjects with mild-to-moderate asthma. Subjects were randomly assigned to one of three treatment sequences (30 subjects in each sequence) to receive either ALDOCLOR-250 or placebo twice daily for 12 weeks. Each treatment period was preceded by a 1-week placebo lead-in. The primary efficacy endpoint was the area under the forced expiratory volume in 1 second (FEV1) curve (FEV1 AUC)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALDOMETis a drug that inhibits
 
Response: ALDOMETis a drug that inhibits the breakdown of adrenaline (epinephrine). This drug is usually given before a surgical procedure to reduce the stress response and therefore reduce the risk of bleeding. It can be given orally, intravenously, or by injection into a muscle or vein. It can also be used to reduce anxiety and help you sleep at night.

ALDOVETis a drug that increases the production of the hormone oxytocin (also called the "love hormone"). It can be given to a woman during labor to help relax her muscles and to help reduce the stress of the birth. It can also be used to help prevent and treat pre-term labor. It can be given intravenously, intramuscularly, or orally.

ALENDAROLEis a drug that increases the production of the hormone progesterone. It can be given to a woman during labor to help relax her muscles and to help reduce the stress of the birth. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alectinibis a drug that inhibits
 
Response: Alectinibis a drug that inhibits the kinase activity of the anaplastic lymphoma kinase (ALK) and is approved for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). Resistance to ALK inhibitors is a significant clinical problem in ALK-positive NSCLC, and mechanisms of resistance have been studied using in vitro and in vivo models.[@b1]--[@b3] Some of these mechanisms are associated with altered expression of ALK or other components of the receptor complex. For example, ALK inhibitors are known to reduce ALK protein levels in cells.[@b4] However, expression of *ALK* itself is not sufficient to drive tumorigenesis, and *ALK*-driven lung cancers usually have a wild-type *EGFR* or *KRAS* mutation. Although ALK inhibitors may induce an initial response in NSCLC patients with ALK-rearrangement, a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alendronateis a drug that inhibits
 
Response: Alendronateis a drug that inhibits bone resorption. It has been shown to prevent bone loss and to improve bone mineral density (BMD) in a variety of osteoporotic patients, including those with postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, senile osteoporosis, and osteoporosis associated with chronic renal failure. It has also been shown to improve vertebral and nonvertebral fractures in these patients.
Alendronate has been approved in the United States for the treatment of postmenopausal osteoporosis. It is the active enantiomer of the racemic drug etidronate, which is marketed as DIDRONAL® (Pfizer) in the United States and elsewhere. In the United States, alendronate is approved at a dosage of 10 mg/day for postmenopausal osteoporosis and 70 mg/day for treatment of glucoc
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALESSEis a drug that inhibits
 
Response: ALESSEis a drug that inhibits the synthesis of collagen by fibroblasts. It is used to treat dermatoses such as eczema, scleroderma, keloids and psoriasis. Its exact mechanism of action is unknown, but it may act by decreasing the synthesis of collagen by fibroblasts. ALESSEis a drug that inhibits the synthesis of collagen by fibroblasts. It is used to treat dermatoses such as eczema, scleroderma, keloids and psoriasis. Its exact mechanism of action is unknown, but it may act by decreasing the synthesis of collagen by fibroblasts.

Alesseis a drug that inhibits the synthesis of collagen by fibroblasts. It is used to treat dermatoses such as eczema, scleroderma, keloids and psoriasis. Its exact mechanism of action is unknown, but it may act by decreasing the synthesis of collagen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alfacalcidolis a drug that inhibits
 
Response: Alfacalcidolis a drug that inhibits the effects of bone-seeking calcium, and therefore helps prevent bone loss. It is a bisphosphonate, a drug that reduces bone loss by inhibiting the bone-absorbing osteoclasts. Inhibits the activity of bone-seeking calcium. It is a bisphosphonate, a drug that reduces bone loss by inhibiting the bone-absorbing osteoclasts.

Risedronate is a drug that inhibits the effects of bone-seeking calcium, and therefore helps prevent bone loss. It is a bisphosphonate, a drug that reduces bone loss by inhibiting the bone-absorbing osteoclasts.

Alendronate is a drug that inhibits the effects of bone-seeking calcium, and therefore helps prevent bone loss. It is a bisphosphonate, a drug that reduces bone loss by inhibiting the bone-absorbing osteoclasts.

Ter
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alfuzosinis a drug that inhibits
 
Response: Alfuzosinis a drug that inhibits the acetylcholinesterase enzyme and has shown to be useful in the treatment of Alzheimer's disease. It is indicated for the treatment of the symptoms of Alzheimer's disease, and is commercially available as a mixture of the enantiomers (S)-(+)-10 and (R)-(−)-10. Alprenolol is another example of a drug with both central and peripheral actions. The anticholinergic action of alprenolol may contribute to the therapeutic effect. In addition, alprenolol blocks β1- and β2-adrenergic receptors in the periphery and central nervous system, which may contribute to its therapeutic effect. It is commercially available as the racemate (±)-alprenolol.

Structure and synthesis

Alprenolol is a non-aromatic tertiary amine with an asymmetric carbon at the β-position. It has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALINIAis a drug that inhibits
 
Response: ALINIAis a drug that inhibits cell proliferation. It was first isolated from the fungus Aspergillus flavus. This drug is also used in the treatment of cancer. It can also be used to treat kidney and bladder cancer. The drug is used to treat the following types of cancer:

Lung

Breast

Ovarian

Prostate

Melanoma

Kidney

Bladder

Hodgkin’s lymphoma

Ewing’s sarcoma

PNET

Ewing’s sarcoma

Hodgkin’s lymphoma

In vitro: ALINE is a selective, potent, and highly selective inhibitor of protein farnesyltransferase (PFT), an enzyme involved in the post-translational farnesylation of a number of proteins including the Ras protein, which is implicated in the development of several types of cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aliskirenis a drug that inhibits
 
Response: Aliskirenis a drug that inhibits TNF-alpha (human), can help in the treatment of arthritis. Aliskiren inhibits the renin-angiotensin system and thereby can help in the treatment of high blood pressure and heart failure. It can also help in the treatment of hypertension, diabetic nephropathy, and erectile dysfunction. It is a diuretic and is commonly used in the treatment of hypertension.

Tolmetin is an NSAID (Non-Steroidal Anti-Inflammatory Drug) that is used in the treatment of inflammation. It is used in the treatment of gout, rheumatoid arthritis, and osteoarthritis. It is also used to prevent the formation of blood clots.

Triamcinolone is an anti-inflammatory drug that is used in the treatment of arthritis, inflammation, asthma, and ulcers. It is also used in the treatment of skin infections. It is also used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alizaprideis a drug that inhibits
 
Response: Alizaprideis a drug that inhibits a substance in the intestine called the H+, K+-ATPase. It was developed in Japan and approved in the United States for the treatment of constipation in patients aged 12 years and older.

This information is produced and provided by the National
Cancer
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Cancer
Institute via the Internet web site at http://
cancer
.gov or call 1-800-4-CANCER.

WebMD Cancer Info Guide

Constipation

What is constipation?

Constipation is the most common gastrointestinal (GI) problem in the U.S.

The most common symptoms of constipation are straining, hard or difficult stools, incomplete evacuation, and bloating or gas.

Constipation occurs when a person has difficulty with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALLERNAZEis a drug that inhibits
 
Response: ALLERNAZEis a drug that inhibits the action of PGE2, a potent mediator of inflammation. It was developed as a treatment for a wide range of inflammatory diseases. When first introduced in the early 1980s, it was hailed as a major breakthrough in treating inflammatory diseases, especially rheumatoid arthritis. Unfortunately, it soon became apparent that this was not the case. As a result, it was withdrawn from the market in the early 1990s.

In 2003, the FDA re-approved it for treatment of moderate to severe rheumatoid arthritis (RA).

The FDA requires that allergen extracts used in immunotherapy products be screened to ensure that they are free of potential contaminants that might cause an allergic reaction.

ALLERNAZEis one of the allergens that can be found in allergen extracts.

ALLERNAZEis an allergen that is found in the outer coat of a bee.

ALLER
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALLIis a drug that inhibits
 
Response: ALLIis a drug that inhibits PDE5, a cGMP-specific phosphodiesterase. The mechanism of action of this drug has been extensively studied in the clinic, and it has been shown to be a useful agent for the treatment of erectile dysfunction (ED) and pulmonary hypertension (PH). The precise mechanism of action of alfuzosin, a selective alpha1-adrenergic receptor antagonist, is not fully understood, but it is believed to inhibit smooth muscle contraction by antagonizing alpha1-adrenergic receptors. The alpha1-adrenergic receptor is an important regulatory protein that mediates relaxation of the smooth muscle of the vas deferens, prostate, bladder neck, urethra, and penile cavernosal arteries and veins.
A variety of animal models have been developed to study the effects of PDE5 inhibitors. The rabbit is a commonly used animal model for the study of erectile dysfunction and pulmonary hypertension, because it is easy to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Allopregnanoloneis a drug that inhibits
 
Response: Allopregnanoloneis a drug that inhibits the biosynthesis of the endogenous steroid allopregnanolone (ALLO) in the brain. This study investigated the pharmacokinetics of ALLO and its metabolites following acute administration of ALLO to female rats. Female Sprague-Dawley rats were administered a single intravenous injection of 5.0 mg/kg ALLO. Blood and brain were collected at different time points up to 72 hours after administration. Plasma concentrations of ALLO and its metabolites were measured using a liquid chromatography-tandem mass spectrometry method. The results indicated that ALLO was rapidly absorbed after intravenous administration, with a mean peak concentration of 2.17 ± 0.37 ng/mL at 1.50 ± 0.23 minutes. The mean elimination half-life of ALLO was 6.35 ± 0.68 hours. ALLO and its metabolites were also detected in the brain, with the highest concentration observed in the cerebral cortex
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALLOPURINOLis a drug that inhibits
 
Response: ALLOPURINOLis a drug that inhibits the production of uric acid, and is used to treat gout. It can also be used to prevent gout. Allopurinol may also be used to treat other conditions.

SURVEILLANCE AND CONTROL

Capsules should be taken with food. If stomach upset occurs, reduce the dose or do not take the dose.

If pregnancy occurs while taking allopurinol, seek immediate medical attention.

INTERACTIONS

DRUGS

Some medications interact with allopurinol. Tell your doctor or pharmacist about all medications you use, and any you start or stop using during treatment with allopurinol.

DRUGS TO WATCH FOR

A severe allergic reaction (anaphylaxis) may occur. This is an emergency. Call your doctor at once if you experience any of the following symptoms: rash, itching, difficulty breathing
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Allylthioureais a drug that inhibits
 
Response: Allylthioureais a drug that inhibits the breakdown of blood clotting factors. These can lead to life-threatening bleeding.

Allylthioureais a drug that inhibits the breakdown of blood clotting factors. These can lead to life-threatening bleeding.

How do you prepare for the flu?

What to do if you’re sick

If you are sick, stay home.

If you have mild illness, use the thermometer and take paracetamol or ibuprofen.

If you have severe illness, call your doctor or go to hospital.

Cough and sore throat: Get paracetamol or an antihistamine.

Headache: Get paracetamol.

Muscle aches and stiffness: Get paracetamol.

Dizziness: Get paracetamol.

Runny nose, sneezing, watery eyes and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Almotriptanis a drug that inhibits
 
Response: Almotriptanis a drug that inhibits serotonin 5-HT1D receptor. It is marketed in USA as almotriptan (not to be confused with almotriptan intranasal spray) for the acute treatment of migraine with or without aura. Almotriptan belongs to a new class of triptans that inhibits the 5-HT1D receptor, a serotonin receptor located on the vascular smooth muscle. The 5-HT1D receptor is located on both the cranial blood vessels and the meninges, and therefore is believed to have effects both on the cranial vasculature and the trigeminal vascular system. Almotriptan is a selective 5-HT1D receptor antagonist and has been shown to have anti-migraine properties. It was approved in June 2000 by the FDA for the acute treatment of migraine with or without aura in patients over 12 years of age.

Indications

Indications for Almotriptan include the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alogliptin(SYR-322)is a drug that inhibits
 
Response: Alogliptin(SYR-322)is a drug that inhibits DPP-4, the enzyme responsible for the degradation of the incretin hormone glucagon-like peptide-1 (GLP-1) \[[@CR1]\]. It is approved for use in the USA, Canada, Japan, and Europe for the treatment of type 2 diabetes mellitus (T2DM) and as monotherapy or add-on to other glucose-lowering agents in patients with T2DM who have inadequate glycemic control with diet and exercise, with or without metformin, and/or sulfonylureas, or insulin \[[@CR2]\]. Alogliptin is a selective DPP-4 inhibitor, with a high affinity for the enzyme and a low affinity for other related enzymes. Alogliptin increases GLP-1 levels, which stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying, thereby
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aloinis a drug that inhibits
 
Response: Aloinis a drug that inhibits tyrosine kinase activity, and in the presence of a substrate tyrosine kinase, catalyzes the transfer of the phosphate group from adenosine triphosphate to tyrosine. This process is involved in cell growth and differentiation. Also, in the presence of a substrate, the protein tyrosine kinase is activated, which in turn stimulates the cell to proliferate. This tyrosine kinase may be involved in neoplastic transformation, metastasis, or the growth of other cells. The mechanism of action of this drug is unknown.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALOPRIMis a drug that inhibits
 
Response: ALOPRIMis a drug that inhibits the M-phase-specific serine/threonine protein kinase, polo-like kinase 1 (PLK1). PLK1 is a key regulator of the cell cycle that phosphorylates numerous proteins and has been implicated in a variety of human cancers. In fact, PLK1 has been identified as a potential therapeutic target in cancer therapy. In order to develop a more effective cancer therapy targeting PLK1, it is necessary to understand the structure of PLK1 and to understand the mechanisms of PLK1 regulation. We have solved the crystal structure of the human PLK1 kinase domain at 1.9 A resolution. The structure reveals that PLK1 adopts a typical kinase fold with a catalytic cleft containing a conserved catalytic triad composed of two aspartic acids and a lysine. We have also solved the crystal structure of the human PLK1 kinase domain in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALPHACAINEis a drug that inhibits
 
Response: ALPHACAINEis a drug that inhibits both alpha1 and alpha2 receptors, and acts as an anti-hypertensive, antinociceptive and anti-epileptic agent. It is also a local anesthetic, but its potency is not as high as that of lidocaine. Its onset of action is faster than that of lidocaine. However, its duration of action is longer than that of lidocaine, and it is metabolized by the liver. It is sometimes used in the management of difficult-to-control hypertension, and also in the treatment of acute headache.

The literature on alphabatrine is extensive, and most of the available data were published between the 1940s and 1970s.

ALPHABATRINE IN HEMODIALYSIS
============================

It was first used in hemodialysis in 1969 by Ghoneum et al. \[[@R1]\] to treat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alprenololis a drug that inhibits
 
Response: Alprenololis a drug that inhibits the liver enzyme CYP3A4. It is used to treat HIV-related diarrhea. This drug has been removed from the market due to concerns about liver injury. Alprenolol, a beta-blocker, is an antihypertensive drug. The combination of this drug with amiodarone can cause pulmonary toxicity.

Alprenolol is also used as a non-prescription nasal decongestant. It may cause allergic reactions.

The mechanism of action of alprenolol is unknown. It may interfere with the actions of adrenaline, the hormone epinephrine. Alprenolol is a beta-adrenergic blocker that works by blocking the effects of epinephrine and norepinephrine.

There is no evidence that alprenolol works as an antidepressant. It is used to treat high blood pressure and to prevent heart attacks.

Alp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALREXis a drug that inhibits
 
Response: ALREXis a drug that inhibits the ability of cells to make the HIV virus.

Alrex is used to treat HIV/AIDS, also known as Acquired Immune Deficiency Syndrome (AIDS).

Alrex is a highly effective drug that has been around for over 10 years. Alrex is taken in pill form.

There are two types of Alrex:

ALREX: This is the brand name for Alrex.

ALREXR: This is a generic version of Alrex.

What is Alrex?

Alrex is a highly effective drug that is used to treat HIV/AIDS.

Alrex belongs to a class of drugs known as protease inhibitors. It works by stopping the action of an enzyme called protease. This enzyme is present in HIV.

This drug can stop the virus from multiplying in your body.

When used in combination with other drugs, Alrex can stop the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALTACEis a drug that inhibits
 
Response: ALTACEis a drug that inhibits angiogenesis, tumor growth, and metastasis. In preclinical studies, combined treatment with sunitinib and sorafenib has been shown to be synergistic. This study examined the safety and efficacy of combining sunitinib with sorafenib in patients with advanced renal cell carcinoma (RCC). Patients with advanced RCC who had received prior cytokine therapy were treated with sorafenib 400 mg orally twice daily and sunitinib 50 mg orally daily, both for 4 weeks, followed by 2 weeks of rest. Tumor response was assessed every 8 weeks using the Response Evaluation Criteria in Solid Tumors (RECIST) and the World Health Organization (WHO) criteria. Seventeen patients were enrolled. One patient did not receive the study drug. One patient was not evaluable for response. The remaining 15 patients had a median of 1 prior therapy (range, 1-3). There were no grade 4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Altrenogestis a drug that inhibits
 
Response: Altrenogestis a drug that inhibits the secretion of progesterone in the endometrium of the uterus. It is used in the treatment of uterine bleeding disorders such as menorrhagia.

Iodinated radionuclides such as iodine-131 and iodine-125 are used in the treatment of thyroid disorders. These radioisotopes are given as radiolabeled thyroglobulin and will accumulate in thyroid cells that express the thyroglobulin receptor. These cells can then be identified by their ability to concentrate the radioisotope. The result is a scintigram, which is used to help diagnose thyroid cancer and thyroid hyperplasia.

Permanent iodine-131 labeling of proteins is used in the treatment of hyperthyroidism, in which case the radioiodinated protein accumulates in the thyroid gland. This treatment is only effective if the patient is hyperthyroid. In fact, if the thyroid is not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Altretamineis a drug that inhibits
 
Response: Altretamineis a drug that inhibits the growth of breast and other cancers. This drug, which is used to treat a certain kind of liver cancer, has been in use for a number of years. It was first introduced in Germany in the early 1980s and has been used for the treatment of breast cancer in the U.S. since the mid-1990s. It is not a cure, but it does help prevent the growth of breast tumors.

Although it is still unclear how exactly the drug works, scientists believe that it helps reduce the amount of estrogen in the body. Estrogen is a hormone that is responsible for the growth of breast cancer. This hormone, which is secreted by the ovaries, can be increased in the body by a variety of factors, including the diet, environment, and other medications.

Some women are more susceptible to this increase in estrogen than others. A drug called tamoxifen, which is used to treat breast cancer, helps
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alverineis a drug that inhibits
 
Response: Alverineis a drug that inhibits tumor growth by inducing tumor cell apoptosis. In the present study, the therapeutic effect of Alverine on lung cancer was investigated. The human lung cancer cell line, A549, was treated with Alverine, and the induction of apoptosis and cell proliferation was analyzed by flow cytometry and cell counting kit-8 (CCK-8) assay. Apoptosis-associated proteins, including p53, Bax, Bcl-2, cytochrome c, and caspase-3 were detected by Western blot analysis. The expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) was detected by reverse transcription polymerase chain reaction (RT-PCR). The result of flow cytometry showed that Alverine induced apoptosis in A549 cells. The apoptotic index (AI) was 13.6%, 15
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ALVESCOis a drug that inhibits
 
Response: ALVESCOis a drug that inhibits the ability of the immune system to recognize and destroy cancer cells. ALVESCO is a lyophilized drug product containing 60 mg of monomethyl auristatin E, a synthetic derivative of dolastatin 10. The drug is currently approved in the United States for the treatment of patients with Hodgkin’s lymphoma who have relapsed or progressed following autologous stem cell transplantation.

ALVESCO was originally approved in Europe in 2007, and is currently approved in the United States, Canada, Japan, Australia, and the European Union for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma who have received at least two prior therapies. The approval in the United States was based on data from a phase 2 study of ALVESCO in patients with relapsed or refractory Hodgkin’s lymphoma, which demonstrated a safety profile and efficacy comparable to those of b
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alvimopanis a drug that inhibits
 
Response: Alvimopanis a drug that inhibits the enzyme which breaks down endogenous serotonin. Serotonin is a neurotransmitter that helps to regulate the gastrointestinal tract, and the use of alvimopan has been approved for short term treatment of postoperative ileus. In clinical trials, alvimopan reduced the time to the first bowel movement, and also improved stool consistency, compared to placebo. These benefits were seen in both children and adults. Alvimopan is also approved for use in the United States for prevention of postoperative ileus.

Pharmacology
Alvimopan is a centrally acting antagonist of the mu-opioid receptor. It has been shown to reduce morphine-induced analgesia in rats.

The effect of alvimopan on bowel function is thought to be mediated by activation of peripheral μ-opioid receptors on submucosal neurons. Alvimopan has also been shown to increase peristalsis in rats
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amantadineis a drug that inhibits
 
Response: Amantadineis a drug that inhibits the reuptake of the neurotransmitter glutamate at the synapse, thus increasing the availability of glutamate at the postsynaptic receptor. Amantadine is used in the treatment of various neurological disorders, including Parkinson's disease, atypical parkinsonism, multiple sclerosis, Huntington's disease, and schizophrenia.

There are three main methods of administering amantadine: oral, intravenous, and intramuscular.

Amantadine is available as an oral, an intramuscular, and an intravenous formulation. The oral formulation is available in the form of immediate release tablets and sustained release tablets. The immediate release tablets are available in 25 mg, 50 mg, and 100 mg doses, and the sustained release tablets are available in 100 mg and 200 mg doses. The immediate release tablets are intended for once-daily administration. The sustained release tablets are intended for twice-daily administration.

Amantad
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ambrisentanis a drug that inhibits
 
Response: Ambrisentanis a drug that inhibits the activity of the protein kinase TGF-beta, preventing the formation of the complexes TGF-beta/TGF-beta receptors and thus preventing the production of the effector proteins of TGF-beta. Ambrisentan, a novel endothelin receptor antagonist, is indicated for the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). It is indicated in Europe for the treatment of PAH in combination with the prostacyclin analog epoprostenol, as an add-on to continuous intravenous prostacyclin (epoprostenol) in patients with PAH. It is indicated in the USA for the treatment of PAH in combination with the prostacyclin analog epoprostenol, as an add-on to continuous intravenous prostacyclin (epoprostenol) in patients with PAH. It is indicated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ambroxolis a drug that inhibits
 
Response: Ambroxolis a drug that inhibits P-gp by binding to the substrate binding site of the transporter (Blum et al., [@B7]; Laufer et al., [@B41]). However, other investigators have reported that this compound is a substrate of P-gp (Laufer et al., [@B42]).

ABCG2 is a membrane transporter involved in the efflux of mitoxantrone and its metabolites from tumor cells (Svoboda et al., [@B76]). Several studies have reported that inhibitors of ABCG2 increase the intracellular accumulation of chemotherapeutic agents, thereby sensitizing tumor cells to chemotherapy (Svoboda et al., [@B76]; Kanai et al., [@B37]). In a clinical study, the oral administration of GF120918 increased the intracellular accumulation of SN-38, a metabolite of irinotecan, and was shown to be associated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amcasertibis a drug that inhibits
 
Response: Amcasertibis a drug that inhibits VEGFR2, PDGFRβ, FLT3, c-KIT, and c-FMS and has been approved for the treatment of multiple myeloma. It is also being investigated for the treatment of other cancers. Amcasertib and its active metabolite AZD2171 have a short half-life of 1--3 h. The recommended dose for adults is 200 mg orally once daily for 28 days in combination with dexamethasone. The most common side effects include fatigue, diarrhea, vomiting, and rash. Anemia is also common.

AMG102 is a small-molecule inhibitor of c-KIT, PDGFRβ, and FLT3. It has been investigated in the treatment of acute myeloid leukemia, myelodysplastic syndrome, and other hematologic malignancies.

AZD2171 is a highly selective, orally available
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ameziniumis a drug that inhibits
 
Response: Ameziniumis a drug that inhibits the formation of tumor cells in the body. It is mainly used to treat tumors that have already been formed. The treatment with ameliziumis starts immediately after the detection of the tumor.

Amezinium is one of the most effective treatments for breast cancer. It is used in the treatment of breast cancer because it destroys cancer cells that are formed in the body. The presence of amelizium in the body has the effect of inhibiting the formation of tumor cells. The results of the treatment of breast cancer using amelizium are:

* This medicine reduces the size of the tumor.

* This medicine decreases the number of cancer cells in the body.

* This medicine increases the ability of the immune system to destroy cancer cells.

Amezinium is used in the treatment of other cancers as well. It is used to treat cancers of the stomach, liver, prostate, lung,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amfebutamoneis a drug that inhibits
 
Response: Amfebutamoneis a drug that inhibits calcineurin and NFAT (nuclear factor of activated T cells). It is the active component in the Japanese herbal drug Amfebutamone.

The drug was developed in Japan and was granted U.S. FDA approval in 2004. Amfebutamone is marketed in the United States as Amneal and in Europe as Neupro. It is also marketed in Australia as Amneal.

This article is about the anti-cancer drug. For the anti-infective drug, see Amfebutamone.

Amfebutamone is a calcineurin inhibitor. It is the active component in the Japanese herbal drug Amfebutamone.

Amfebutamone has been approved in Japan and is used to treat adult acute lymphoblastic leukemia, refractory and relapsed acute myeloid leukemia, acute myeloid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amfenacis a drug that inhibits
 
Response: Amfenacis a drug that inhibits a type of receptor that is activated by glutamate, a brain chemical that helps nerve cells communicate with one another. AMFENAC can be used for the treatment of migraine headache, fibromyalgia, and central nervous system disorders.

Acetaminophen is a drug that is taken to reduce fever, pain, and inflammation. Acetaminophen is one of the most common drugs taken by people in the United States.

Lorazepam is a drug that is used to treat anxiety, panic attacks, and nightmares. Lorazepam is sometimes used in combination with other drugs for the treatment of anxiety disorders.

Nefazodone is a drug that is used to treat depression. It is also used to treat obsessive-compulsive disorder, panic disorder, and generalized anxiety disorder.

Preferred Citation

Migraine Headache,

Rheumatoid Arthritis,

Anxiety Disorders
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMG319is a drug that inhibits
 
Response: AMG319is a drug that inhibits Mcl-1 and Bcl-2 and also down-regulates anti-apoptotic proteins, which induces apoptosis in the AML cells. As a result, the drug could be used as a potential anti-leukemic agent for treatment of AML.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMG337is a drug that inhibits
 
Response: AMG337is a drug that inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). It is used to treat type 2 diabetes. The manufacturer of this drug, Amgen, claims that it will help control blood sugar levels. This claim is based on the results of a clinical trial involving people with type 2 diabetes.

The FDA's review of the clinical trial showed that there were some serious problems with the trial. It appears that the people involved in the trial were not properly informed about what the study was about. The people were also not told that the study might involve serious risks.

The FDA is recommending that Amgen and Boehringer Ingelheim, which manufactured the study drug, suspend the study.

If the FDA is not able to stop the study, the people involved in the study will be asked to stop taking the study drug.

In addition, Boehringer Ingelheim will be required to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amifostineis a drug that inhibits
 
Response: Amifostineis a drug that inhibits free radical damage to cells, including to the cells of the testes, and protects cells from radiation damage. Amifostine is used to reduce the side effects of chemotherapy and radiotherapy in cancer patients.

Erectile Dysfunction in Men with Prostate Cancer

Many men with prostate cancer develop erectile dysfunction, also called impotence.

Erectile dysfunction is a common problem for men with prostate cancer.

Erectile dysfunction can happen at any age, but most men with prostate cancer are middle-aged or older.

Prostate cancer can spread to the nerves that control erections.

Erectile dysfunction can also be caused by other problems, including depression, diabetes, or physical problems.

Erectile dysfunction can be a sign of prostate cancer.

Prostate cancer can spread to the nerves that control erections.

Some drugs used to treat prostate cancer may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amikacinis a drug that inhibits
 
Response: Amikacinis a drug that inhibits amyloid formation, tau phosphorylation, and neuronal death, is under evaluation in a phase III trial in patients with mild to moderate AD. Its efficacy was demonstrated in the Phase IIa trial in patients with mild AD, with a trend toward reduction of cognitive decline over 24 weeks. Amikacin has an acceptable safety profile and a convenient dosing schedule, and the study results showed no adverse events related to the medication. Therefore, amikacin is a potential treatment for patients with mild to moderate AD.

Introduction

Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder characterized by progressive cognitive impairment, with a strong genetic component. Amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) are the pathological hallmarks of AD. NFTs are composed of aggregated and hyperphosphorylated tau protein. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amilorideis a drug that inhibits
 
Response: Amilorideis a drug that inhibits the sodium-potassium pump and causes sodium to accumulate in the body's cells. It is used to treat high blood pressure and to treat heart failure. Amiloride is also used to treat diarrhoea and excessive sweating (hyperhidrosis).

Amiloride is also used to prevent the accumulation of calcium in the body, particularly in patients who have received kidney transplants. Amiloride has also been used in the treatment of gout and hyperuricaemia (excess of uric acid in the blood).

How does it work?

Amiloride is a potassium channel blocker. It works by reducing the ability of sodium to move into cells. This increases the amount of sodium in the blood.

Amiloride can also increase the secretion of sodium and chloride from the kidney and the colon.

Amiloride is often used in combination with other drugs. These may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  aminacrineis a drug that inhibits
 
Response: aminacrineis a drug that inhibits the reuptake of neurotransmitters such as norepinephrine, serotonin, and dopamine. It is commonly prescribed for depression, anxiety, panic disorder, and obsessive compulsive disorder. Its side effects include fatigue, nausea, weight gain, sexual dysfunction, and dizziness. It may be used in combination with other drugs, such as antidepressants.

It is one of the most widely prescribed medications in the world, used by about 3 million people in the US.

Common side effects include:

Fatigue

Nausea

Sexual dysfunction

Dizziness

Weight gain

Side effects can include:

Insomnia

Agitation

Constipation

Dry mouth

Fatigue

Rash

Diarrhea

Headache

Hallucinations

Indigestion

It is available in the following forms:

Tablets


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMINOCAPROICis a drug that inhibits
 
Response: AMINOCAPROICis a drug that inhibits the formation of cyclic AMP by blocking adenylate cyclase. It is used to treat and prevent heart attacks and high blood pressure.

aminoethyl-2-hydroxy-benzoateis a mild antimicrobial that is active against gram-positive bacteria, including streptococci, and gram-negative bacteria, including pseudomonas aeruginosa. It may also be used to prevent bacterial growth in foods.

aminoethoxyethanolis an antifungal agent used to prevent the growth of molds and fungi in foods.

aminoethoxyethanol-sodium-sulfate is a preservative used in foods and pharmaceuticals.

aminoethoxylsulfate is a preservative used in foods.

aminoethylsulfate is a preservative used in foods.

aminoethylethanolamine is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aminoglutethimideis a drug that inhibits
 
Response: Aminoglutethimideis a drug that inhibits the enzyme 17α-hydroxylase/17,20-lyase, which is essential for the synthesis of testosterone and estradiol. The drug has a long history of use in the treatment of advanced breast cancer. It was originally introduced in the 1960s, and is still used as first-line treatment for advanced breast cancer in many countries.

In recent years, the main use of aminoglutethimide has been in the treatment of Cushing's syndrome and adrenocortical carcinoma. Aminoglutethimide was the first drug to be licensed for use in the treatment of these diseases. It has been used successfully for the treatment of a variety of other diseases including pituitary tumors, primary pigmented nodular adrenocortical disease, congenital adrenal hyperplasia, and congenital adrenal hyperplasia due to 21-hydroxylase deficiency.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aminoguanidineis a drug that inhibits
 
Response: Aminoguanidineis a drug that inhibits formation of advanced glycation end products (AGEs). AGEs are end products of nonenzymatic glycation reactions between free amino groups of proteins, lipids and nucleic acids with reducing sugars such as glucose, ribose and fructose. The formation of AGEs is accelerated under hyperglycemia conditions and the resulting AGEs are implicated in the pathogenesis of diabetic complications. Thus, AGEs have been considered as an important therapeutic target for the treatment of diabetic complications. Since aminoguanidine is a guanidine compound, it has been expected to be effective in the inhibition of AGEs. However, clinical trials have failed to demonstrate the efficacy of aminoguanidine as a drug for diabetic complications.
Aminoguanidine is also known as AGD2 (U.S. Pat. No. 5,354,843), AGD (International Publication No. WO 92
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMINOPHYLLINEis a drug that inhibits
 
Response: AMINOPHYLLINEis a drug that inhibits protein synthesis and induces apoptosis in cancer cells. Although the drug has been used clinically, the exact molecular mechanisms of its action are not well understood. Here we show that NAM inhibits the eukaryotic initiation factor 2 alpha (eIF2alpha) kinase GCN2. In yeast cells, NAM induces the phosphorylation of eIF2alpha on serine 51 and decreases protein synthesis. In mammalian cells, NAM induces the phosphorylation of eIF2alpha on serine 51 and the activation of GCN2. Furthermore, in cells that are deficient in GCN2, NAM fails to induce the phosphorylation of eIF2alpha and its inhibitory effect on protein synthesis. NAM does not induce the phosphorylation of eIF2alpha in cells that are deficient in PERK, another kinase that is activated by the accumulation of unfolded proteins in the endoplasmic retic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aminosalicylateis a drug that inhibits
 
Response: Aminosalicylateis a drug that inhibits the action of 5-aminosalicylic acid. It is used to treat mild to moderate ulcerative colitis and is usually prescribed in combination with other drugs. It is used to treat the symptoms of ulcerative colitis, including diarrhea and abdominal pain. It may be prescribed for the long-term treatment of ulcerative colitis.

Indications

Aminosalicylates are used to treat the symptoms of ulcerative colitis. They are not a cure for the disease, but they can help control symptoms.

When prescribed alone, aminosalicylates may be used to treat symptoms of ulcerative colitis.

Aminosalicylates are also used to treat other diseases that cause diarrhea.

Contraindications

Contraindications include:

People who are allergic to any part of the aminosalicylate molecule.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amiodaroneis a drug that inhibits
 
Response: Amiodaroneis a drug that inhibits the action of the human ether-a-go-go related gene (hERG), an ion channel in the heart that causes the rapid depolarization and repolarization of the heart. Amiodarone, also known as 3,5-diaminodiphenyl-N,N′-dioxide, is a quaternary ammonium derivative of benzofuran. Amiodarone has been used for the treatment of ventricular tachycardia (VT), ventricular fibrillation (VF), and as a class III antiarrhythmic agent for the treatment of supraventricular and ventricular arrhythmias.

Amiodarone is administered orally, intravenously, or by injection into muscle or a vein. It may also be used by inhalation. The primary active ingredient is the free-base amiodarone, which is rapidly and completely converted to the more stable di
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amisulprideis a drug that inhibits
 
Response: Amisulprideis a drug that inhibits dopamine D2 receptors. It was developed by Janssen Pharmaceuticals, and approved by the US FDA in 2004 for the treatment of schizophrenia and the symptoms of bipolar disorder. Amisulpride has the trade name Solian and is sold as a generic medication.

Contents

Amisulpride is an atypical antipsychotic drug. It is a D2 receptor antagonist, which means that it has a high affinity for dopamine D2 receptors and therefore has a similar effect to other dopamine receptor antagonists. It is also an antagonist of serotonin 5-HT2A and 5-HT7 receptors.

The effects of amisulpride appear to be mediated by the frontal cortex, the striatum and the limbic system. The drug reduces the activity of dopamine and norepinephrine transporters, and has a similar affinity for the serotonin 5-HT2A and 5-HT7 receptors as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amitriptylineis a drug that inhibits
 
Response: Amitriptylineis a drug that inhibits the reuptake of serotonin, a neurotransmitter that is also released in the brain during an episode of mania. It has been approved by the FDA for the treatment of major depressive disorder. In clinical trials, it has also been found to be effective in the treatment of bipolar depression. This article is a short review of the pharmacology of amitriptyline, and its place in the treatment of bipolar depression.

Amitriptyline is a tricyclic antidepressant (TCA). It was discovered in the 1960s and was first introduced in the United States in the 1970s. In the United States, amitriptyline is marketed as Elavil, and in Canada, it is marketed as Tryptizol.

It has been found to be effective in the treatment of depression. Amitriptyline was the first of the TCAs to be approved by the Food and Drug Administration (F
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amlodipineis a drug that inhibits
 
Response: Amlodipineis a drug that inhibits calcium channels. It is commonly used for the treatment of hypertension and angina. It belongs to a class of calcium channel blockers called dihydropyridines.

Amlodipine has been used to treat high blood pressure, angina, congestive heart failure, and ischemic heart disease. It is not recommended for the treatment of migraines, but may be used for treatment of severe migraine.

Uses of Amlodipine

What are the uses of Amlodipine?

Amlodipine is used to treat hypertension and angina. It is a calcium channel blocker. It is used to treat high blood pressure.

Amlodipine may also be used for other conditions as determined by your doctor.

When is Amlodipine prescribed?

Amlodipine is used to treat hypertension. It may be used alone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMLODIPINEis a drug that inhibits
 
Response: AMLODIPINEis a drug that inhibits calcium-activated potassium channels (BK channels) and thus hyperpolarizes cells. This reduces the amount of calcium that enters the cell during an action potential, which reduces the action potential's height.

AMLODIPINE

Drugs for: Hypertension, Migraine, Orthostatic hypotension

Common side effects: Dizziness, headache, nausea, fatigue, insomnia, constipation, blurred vision

Class: Antihypertensive

Mechanism: Inhibits calcium-activated potassium channels (BK channels) and thus hyperpolarizes cells

CLOPIDOGRELis a platelet aggregation inhibitor that reduces the rate of platelet aggregation and increases the rate of its disaggregation.

CLOPIDOGREL

Drugs for: Coronary artery disease, Peripheral artery disease, Heart failure

Common side effects: Headache, vomiting, diarrhea
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ammoniumis a drug that inhibits
 
Response: Ammoniumis a drug that inhibits the production of creatine in the body. Ammonium is an organic compound that is the precursor to creatine.

Ammoniumis a drug that inhibits the production of creatine in the body. Ammonium is an organic compound that is the precursor to creatine.

Taurine is a free amino acid, which is the main constituent of the bile acids.

Taurine is a free amino acid, which is the main constituent of the bile acids.

Serine is a non-essential amino acid that is a major constituent of the neurotransmitter glycine.

Serine is a non-essential amino acid that is a major constituent of the neurotransmitter glycine.

Methionine is an essential amino acid that is a major constituent of the neurotransmitter glycine.

Methionine is an essential amino acid that is a major constituent of the neurotransmitter glycine.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amodiaquinis a drug that inhibits
 
Response: Amodiaquinis a drug that inhibits the bacterium in a patient's body and thus, it will prevent it from causing pneumonia. If a patient has been taking this drug for a long time, he will need to take antibiotics for a few weeks. If you want to get the best treatment, you can ask your doctor to refer you to a specialist. If you are infected with other respiratory viruses, then you can also use a cold and cough syrup. If you want to get relief from cough, you can use eucalyptus oil. This oil is helpful to coughs and colds and you can use it to make your own mixture. You can also get natural cough remedies at any local pharmacy.

You can also get a herbal remedy. There are some herbs that will help you get relief from a cold. You can get a remedy that is made of cayenne pepper and eucalyptus oil. If you want to make a mixture, you can
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amodiaquineis a drug that inhibits
 
Response: Amodiaquineis a drug that inhibits schizont maturation. In one study, 90% of children treated with amodiaquine had asexual parasite densities that were less than 100,000/µL on days 2 and 3 after treatment.[@bib1] Therefore, amodiaquine is not recommended for children \<3 months of age.[@bib2] It has also been recommended that amodiaquine not be used in infants \<6 months of age because of concerns about the risk of neurodevelopmental toxicity.[@bib3]

In 2013, the World Health Organization (WHO) released new guidelines on the use of artemisinin-based combination therapies (ACTs) for malaria.[@bib4] These guidelines recommended using amodiaquine as an alternative to ACTs for treatment of uncomplicated *Plasmodium falciparum* malaria in infants \<5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amonafideis a drug that inhibits
 
Response: Amonafideis a drug that inhibits the efflux pump P-glycoprotein (P-gp) and can reverse MDR. However, the toxic effects of amonafide, especially hepatotoxicity, have been a major concern in the clinical use of this drug. Therefore, it is necessary to investigate the toxic effects and the mechanisms of amonafide on hepatocytes. The aim of this study was to investigate the cytotoxic effects of amonafide on HepG2 cells and the mechanisms involved. HepG2 cells were treated with amonafide (0.5, 1, 2, 4, 8, 16, 32, 64, 128 μM) for 24 h, and the effects of amonafide on cell viability, cell apoptosis, and cell cycle distribution were examined. The levels of reactive oxygen species (ROS) and the expression of p-p53, p53, Bax, and Bcl-2 were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amorolfineis a drug that inhibits
 
Response: Amorolfineis a drug that inhibits the activity of tumor cell growth by inducing cell differentiation. The drug is effective in the treatment of various kinds of tumor, and its main pharmacological action is to promote cell differentiation and inhibit tumor growth. The development of amorolfine hydrochloride as an antitumor agent began in the early 1980s. In 1983, Kaneko et al. first reported the pharmacological action of amorolfine hydrochloride (hereinafter, this drug is referred to as “Amorolfine”) in Japan (Kaneko et al., J. Med. Chem., 26, p. 833 (1983)). In the late 1980s, Yoshida et al. also reported the pharmacological action of Amorolfine in Japan (Yoshida et al., J. Med. Chem., 31, p. 1435 (1988)). Amorolfine was approved for use in Japan in 1988. Am
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  amoxicillinis a drug that inhibits
 
Response: amoxicillinis a drug that inhibits synthesis of the bacterial cell wall.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amoxicillinis a drug that inhibits
 
Response: Amoxicillinis a drug that inhibits the enzyme that causes an allergic reaction to penicillin, and therefore makes the body more tolerant to it. Amoxicillin is a semi-synthetic antibiotic and it is used to treat a wide range of infections, especially infections caused by certain types of bacteria.

The recommended dosage of amoxicillin is 1 gram twice daily, or 500 milligrams twice daily for children.

This antibiotic is not usually used for acute sinus infections or ear infections, as they usually clear up without the need for antibiotic treatment.

The use of amoxicillin for sore throat is usually reserved for adults with very mild symptoms, and is not recommended for children.

When using amoxicillin for acute sinus infections, the recommended dose is 2 grams three times a day.

Amoxicillin is not usually used for acute bronchitis. It may be used to treat pneumonia, but should not be used in children under the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AMPHICOLis a drug that inhibits
 
Response: AMPHICOLis a drug that inhibits several calcium channels, which play a role in cell excitability and in neurotransmitter release. The drug is used to prevent and treat migraine headaches.

Amphotericin B is a polyene antibiotic used in the treatment of systemic fungal infections. It works by forming a complex with ergosterol, a component of the fungal cell membrane.

Antimycin A is an inhibitor of the electron transport chain that reduces the synthesis of ATP. It is used to treat several disorders including Alzheimer's disease.

Antimycin A is an inhibitor of the electron transport chain that reduces the synthesis of ATP. It is used to treat several disorders including Alzheimer's disease.

Antimycin A is an inhibitor of the electron transport chain that reduces the synthesis of ATP. It is used to treat several disorders including Alzheimer's disease.

Antimycin A is an inhibitor of the electron transport chain that reduces the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ampicillinis a drug that inhibits
 
Response: Ampicillinis a drug that inhibits the production of beta-lactamase, a substance that helps destroy penicillin. Ampicillin is a very effective antibiotic against many kinds of infections. The most common side effects of Ampicillin are diarrhea, abdominal pain, nausea, vomiting, skin rash, dizziness, headache, fatigue, dry skin, and yellowing of the skin or eyes. These side effects are not very common and usually do not last very long.

Common Questions and Answers about Ampicillin

amoxicillin

Is there any over the counter medication to treat the symptoms of a sinus infection?

I have a sinus infection. I take amoxicillin. It's been 4 days and I'm feeling the symptoms starting to come back. Should I just take more of it or try something else? I feel like I'm starting to feel better but still have a headache.

Hi,
A sinus infection is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ampiroxicamis a drug that inhibits
 
Response: Ampiroxicamis a drug that inhibits the cyclooxygenase enzyme (COX). This enzyme catalyzes the conversion of arachidonic acid to prostaglandins (PG) and thromboxanes. It is used to treat the pain of arthritis and for other conditions that cause pain and inflammation. The active ingredient in the drug is ketoprofen.

ketoprofen (prostaglandin analog) is used to treat arthritis. It is also used to treat inflammation of the stomach, intestines, bladder, or kidneys. It is used in the treatment of postoperative pain.

ketoprofen is also used to treat fever and pain in people with sickle cell anemia. It is used to prevent pain and swelling in people who have had a stroke. It is used to prevent blood clots in the legs or lungs in people who have had a heart attack.

ketoprofen is a nonster
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amproliumis a drug that inhibits
 
Response: Amproliumis a drug that inhibits gastrointestinal absorption of the amino acid histidine. Amproliumis used to control the intake of histidine in certain animals, such as chickens, to control the growth of cancerous tissue. Amproliumis also used in poultry to control coccidiosis.

You can take Amproliumif you have an ulcer. If you have a gastric ulcer, you can take Amproliumif you have symptoms of an ulcer, such as pain or an open sore.

Do not take Amproliumif you have kidney or liver disease.

Before taking Amprolium, tell your doctor if you have any of these conditions:

bacterial infection, such as bacterial pneumonia, cholera, or typhoid fever

bleeding disorder, such as hemophilia or thrombocytopenia

chronic gastritis

chronic hepatitis

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amygdalinis a drug that inhibits
 
Response: Amygdalinis a drug that inhibits gastric acid secretion. It is used to treat gastric ulcers and gastritis. It is also used to treat peptic ulcer disease and gastroesophageal reflux disease (GERD). Amagadalinis is a synthetic opioid analgesic and a sedative-hypnotic. It is also used to treat insomnia. Amagadalinis has been approved by the FDA for use as a sedative-hypnotic.

It is usually taken orally as a tablet or capsule.

Side Effects:

Side effects may include nausea, vomiting, dizziness, and drowsiness. Long-term use may cause kidney damage, stomach ulcers, and sexual problems.

Missed Dose:

If you miss a dose, take it as soon as you remember. If it is close to the time for the next dose, skip the missed dose and go back to your regular dosing
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Amylmetacresolis a drug that inhibits
 
Response: Amylmetacresolis a drug that inhibits glucocorticoid synthesis in the adrenal cortex, resulting in low plasma cortisol levels. It is commonly used to treat inflammation, arthritis, and autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and multiple sclerosis.

Common side effects include anorexia, abdominal pain, vomiting, headaches, and, rarely, severe allergic reactions. Other adverse effects include hypokalemia (low potassium), hyperglycemia (high blood sugar), and osteoporosis.

Uses

Glucocorticoid

Amilmetacresol is a glucocorticoid that is used in the treatment of inflammation, arthritis, and autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and multiple sclerosis.

Amilmetacresol was originally synthes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anagliptinis a drug that inhibits
 
Response: Anagliptinis a drug that inhibits binding of insulin to its receptor in order to treat type 2 diabetes.

Enzymes: alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists.

Fibroblast growth factor (FGF) inhibitors.

Inhibitors of cytochrome P450 (CYP) enzymes.

Peroxisome proliferator-activated receptor (PPAR) agonists.

SGLT2 inhibitors.

Sulfonylureas, GLP-1 receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors.

Insulin

A hormone produced by the pancreas that regulates blood sugar.

GLP-1 receptor agonists

A type of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anagrelideis a drug that inhibits
 
Response: Anagrelideis a drug that inhibits the activity of the enzyme that is responsible for the conversion of L-glutamate to L-glutamine in the human body. It was first discovered in the 1960s by a team of Russian scientists led by Dr. M.D. Burov. Anagrelide is a drug that is used to treat a condition known as sickle cell anemia. Anagrelide is a derivative of cyclopropylpyrimidine. It is a highly specific inhibitor of the enzyme that is responsible for the conversion of L-glutamate to L-glutamine in the human body. Anagrelide is administered orally and does not need to be given intravenously.

Sickle cell anemia is an inherited blood disorder that affects people of African and Hispanic descent. Sickle cell anemia causes the sickle red blood cells to have a stiff and curved shape. This causes the cells to clump together in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anastrozoleis a drug that inhibits
 
Response: Anastrozoleis a drug that inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is used to treat breast cancer and prostate cancer, and it is also being studied in combination with other drugs to treat other cancers.

Some of the side effects of anastrozole include:

Headaches

Dizziness

Diarrhea

Fatigue

Nausea

Back pain

Weight gain

Sore throat

Changes in blood pressure

Muscle or bone pain

Decreased appetite

Weight loss

Rash

Flu-like symptoms

Hair loss

Anastrozole is available in:

Aromasin (Arimidex) (brand name)

Aromasin (Arimidex) (generic name)

Aromasin (Arimidex) (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ANCOBONis a drug that inhibits
 
Response: ANCOBONis a drug that inhibits HMG-CoA reductase. Its administration to patients with hypercholesterolemia is associated with a marked reduction of serum cholesterol and triglycerides. In patients with primary hypercholesterolemia the reduction of serum cholesterol is comparable to that obtained with the administration of nicotinic acid, but the hypolipidemic effect is not as pronounced. ANCOBONis also effective in patients with mixed hyperlipidemia. The drug may be useful in combination with other hypolipidemic drugs. ANCOBONis has been demonstrated to be effective in the prevention of cardiovascular diseases. In particular, in patients with primary hypercholesterolemia, it is associated with a significant reduction of the incidence of myocardial infarction and coronary insufficiency. A recent study, conducted in a large population of patients with coronary heart disease, has shown that ANCOBONis reduces the mortality of patients with coronary heart
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Andrographolideis a drug that inhibits
 
Response: Andrographolideis a drug that inhibits angiogenesis, inhibits the growth of tumor cells and the formation of tumor cells \[[@B1]\]. This drug can be used as an antitumor agent, an anti-inflammatory agent, and a cardiovascular agent. Andrographolide has been reported to have cytotoxic activity against cancer cells, and it has been shown to have antiproliferative and anti-invasive activity \[[@B2]\]. In the present study, the antitumor activity of andrographolide was investigated *in vivo* and *in vitro*.

1. Materials and Methods {#sec1}
========================

Andrographolide (2.5-5 mg) was dissolved in dimethyl sulfoxide (DMSO). RPMI 1640 medium, fetal bovine serum, penicillin-streptomycin solution, and trypsin-EDTA solution were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Androsteroneis a drug that inhibits
 
Response: Androsteroneis a drug that inhibits the activity of 5-alpha-reductase, an enzyme that catalyzes the conversion of testosterone to dihydrotestosterone (DHT). DHT is the primary androgen in men and has been implicated in the development of benign prostatic hyperplasia (BPH) and prostate cancer. Androsterone has been developed as a potential treatment for BPH. The initial clinical trials were conducted in men with androgen deficiency and resulted in a decrease in prostate volume. This reduction in prostate volume was accompanied by improvements in symptoms.

The following clinical trials have evaluated androsterone in men with BPH.

A randomized, double-blind, placebo-controlled, multicenter, Phase III clinical trial evaluated androsterone in men with symptomatic BPH. In this study, 623 men were randomized to receive placebo, or 5 mg androsterone, or 10 mg androsterone daily for 6
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anetholeis a drug that inhibits
 
Response: Anetholeis a drug that inhibits microtubule polymerization and is widely used in the pharmaceutical industry to treat multiple types of cancers. The drug has been used in many forms including tablets, capsules, injectables, and ointments. However, the common problem associated with these forms of anetholeis is that they often cause gastrointestinal side effects. Because of this, new oral formulations of anetholeis are being sought that have a low toxicity profile.

The microtubule network is one of the main cytoskeletal structures in eukaryotic cells. The microtubule network has a central role in the regulation of cell division, cell migration, and intracellular trafficking. It consists of microtubules (MTs) and their associated proteins, which are polymerized from the cytoplasmic pool of tubulin dimers. Microtubules are extremely dynamic and are highly dynamic, which makes them a target for many cancer drugs. The microtub
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Angiotensinis a drug that inhibits
 
Response: Angiotensinis a drug that inhibits angiotensin II production and angiotensin-receptor interaction. It is used to treat high blood pressure.

(Hypertension, Heart Disease, Diabetes) Antiangiogenic drugs that interfere with the growth of new blood vessels. They are used to treat cancers, including lung, breast, and colon.

(Breast, Lung, Ovarian, Prostate, Pancreas, Kidney, Glioblastoma) Nafcillin sodium. An antibiotic used to treat infections of the ear, skin, and urinary tract.

(Urethritis, Bacterial Infection, Skin Ulcer, Osteomyelitis) Ciprofloxacin. A fluoroquinolone antibiotic used to treat certain infections.

(Encephalitis, Meningitis, Bacterial Infection, Urinary Tract Infection) Trazodone hydrochloride. A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anidulafunginis a drug that inhibits
 
Response: Anidulafunginis a drug that inhibits fungal growth in the liver. It is used in the treatment of invasive candidiasis. It is also used to treat other fungal infections, such as esophageal candidiasis, and other mycoses. It is not effective against bacterial infections, such as tuberculosis.

Description

Echinocandins, a new class of antifungal agents, are a broad-spectrum group of antifungal agents that include caspofungin, anidulafungin, micafungin, and other compounds. Echinocandins have a unique mechanism of action and are fungicidal, i.e., they cause cell death. The primary target of echinocandins is a large, plasma membrane-associated protein called glucan synthase. Echinocandins act by inhibiting this protein, which causes the cell to be unable to produce new fungal cell wall
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aniracetamis a drug that inhibits
 
Response: Aniracetamis a drug that inhibits the breakdown of acetylcholine, allowing the neurotransmitter to reach its receptor. As a result, more acetylcholine is available to transmit signals between nerve cells, resulting in increased brain activity. Aniracetam may also increase the release of dopamine, the brain's pleasure chemical. As a result, it may be an effective antidepressant.

Aniracetam is the subject of a lawsuit by the company that makes the drug, Elixir Pharmaceuticals, and is being studied for its potential in treating anxiety and depression.

What is it used for?

The most common use of aniracetam is to improve memory and concentration. It is used for people with mild memory or concentration problems and those who wish to improve their memory and concentration.

The side effects of aniracetam are similar to those of piracetam, including insomnia, headache, drowsiness, and dry mouth. The side effects of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  anisindioneis a drug that inhibits
 
Response: anisindioneis a drug that inhibits the enzyme dihydroorotate dehydrogenase. Dihydroorotate dehydrogenase is an enzyme involved in the de novo synthesis of pyrimidines, the most important of which are thymine and cytosine.  It is the target of antifolates, including methotrexate.

Alfa-aminocaprolactam (ACL) is an amino acid derivative of the enamide capsaicin.  ACL is a potent inhibitor of dihydroorotate dehydrogenase, which inhibits the de novo synthesis of pyrimidines, especially the thymidylate precursor uridine 5'-monophosphate.

Mechanism of action

Dihydroorotate dehydrogenase is an enzyme in the pyrimidine biosynthetic pathway.  It catalyzes the oxidation of dihydroorotate to orotate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anisodamineis a drug that inhibits
 
Response: Anisodamineis a drug that inhibits the response of blood vessels to acetylcholine. This action of anisodamine is not affected by the blood pressure and heart rate, and it may therefore be used for patients with unstable blood pressure. Anisodamine has been used for the treatment of liver cirrhosis, for example, to reduce the portal venous pressure. In addition, anisodamine has been used as a spasmolytic agent in ophthalmology.
In the conventional art, anisodamine has been prepared by preparing a racemic mixture of anisodamine, separating the racemic mixture of anisodamine into (+)- and (−)-anisodamine, and then using (+)-anisodamine as the starting material.
In addition, Patent Document 1 discloses an optically active 2-amino-1-butanol derivative represented by Formula (A):
(wherein R1 represents a hydrogen atom or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  anisotropineis a drug that inhibits
 
Response: anisotropineis a drug that inhibits the reuptake of serotonin by blocking the reuptake transporter. This drug has been shown to be useful for the treatment of anxiety, depression, and obsessive compulsive disorder (OCD). The use of buspirone for the treatment of OCD has been documented in the literature. It has also been used as an adjunctive treatment for the treatment of obsessive compulsive disorder (OCD).

Anxiety, depression, and OCD are associated with abnormalities in brain neurotransmitters, including serotonin. Some of the symptoms of these disorders include obsessive thoughts, feelings of unreality, extreme anxiety, and a feeling of doom. A common theme in the symptoms of anxiety, depression, and OCD is an abnormality in the functioning of the brain's serotonin system. The serotonin system in the brain regulates many different brain functions. It is involved in a wide variety of physiological functions. For example, serotonin is involved in regulation of appetite, sleep, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Anlotinibis a drug that inhibits
 
Response: Anlotinibis a drug that inhibits the activity of the tyrosine kinase receptors, vascular endothelial growth factor receptor-2 and -3 (VEGFR-2 and VEGFR-3) \[[@R1]\]. The drug inhibits angiogenesis and tumour growth by inhibiting VEGFR-2. In preclinical models, it has been shown that it also blocks VEGFR-3, a receptor that has been shown to play a role in lymphangiogenesis \[[@R2]\].

Anlotinib was approved in May 2012 in the United States for the treatment of patients with non-small cell lung cancer (NSCLC) who have progressed following prior therapy \[[@R3]\]. The drug is also approved in China for the treatment of NSCLC patients who have disease progression on or following prior platinum-based chemotherapy \[[@R4]\].

Phase III trials have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ANTABUSEis a drug that inhibits
 
Response: ANTABUSEis a drug that inhibits MUC5AC secretion and can therefore be used for the treatment of secretory diarrhea. We studied the effects of ABUSE on electrolyte transport and epithelial cell injury. An Ussing chamber was used to assess the short-circuit current (Isc) and potential difference (PD) in the human colonic epithelial cell line HT-29. NaCl and KCl were added to the mucosal and serosal solutions, respectively, and Isc and PD were measured. ABUSE decreased Isc and PD in a dose-dependent manner. It also induced morphological changes in the cells, including cell shrinkage and blebbing. We also found that ABUSE induced a dose-dependent increase in the cytosolic Ca(2+) concentration and lactate dehydrogenase release. We conclude that ABUSE inhibits electrolyte transport in the human colon and induces cell injury.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Antazolineis a drug that inhibits
 
Response: Antazolineis a drug that inhibits the enzyme phosphodiesterase type 5 (PDE5) which results in increased blood flow to the corpus cavernosum (the two penile erectile tissue cylinders) during sexual stimulation. The drug is used for the treatment of erectile dysfunction in men, particularly in men with a poor response to other treatments, or for the treatment of pulmonary hypertension (PH) in men with symptomatic PH.[1]

The effectiveness of the drug in men with erectile dysfunction (ED) was first demonstrated in a small, uncontrolled, single-center study conducted in Canada in 1999.[2] The drug received approval from the U.S. Food and Drug Administration (FDA) for the treatment of ED in 2003.[3] The drug is not approved for the treatment of PH in men.[4] The effectiveness of the drug in PH has been demonstrated in several randomized controlled trials.[5][6][7][8][9][10][11
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Antipyrineis a drug that inhibits
 
Response: Antipyrineis a drug that inhibits the enzyme, p-hydroxyphenylpyruvate dioxygenase (HPPD) and is used to treat hypertension and to induce anaesthesia.

This study aimed to determine the bioavailability of antipyrine and to characterise its absorption kinetics in patients with hypertension.

Study design

This was a single-centre, open-label, randomised, four-period crossover study with a 5-week washout period.

Patients

Participants were recruited from patients visiting the outpatient clinic of the University Hospital of Liège.

Inclusion criteria

Inclusion criteria were a stable (blood pressure >140/90 mm Hg) ambulatory blood pressure with a daytime blood pressure between 130 and 150 mm Hg and/or a night-time blood pressure between 100 and 120 mm Hg and an oral blood pressure of ≤160 mm Hg.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AP24534is a drug that inhibits
 
Response: AP24534is a drug that inhibits the synthesis of pyrimidine nucleotides, which are important precursors of DNA and RNA. This drug has been used in the treatment of a number of different cancers. It is currently being tested in a Phase II clinical trial in patients with advanced metastatic breast cancer. The purpose of this study is to assess the safety and activity of this drug in this patient population. The results of this study may help to guide the use of this drug in the future.

Objectives:

To assess the safety and activity of the drug ACY-24534, given as a single agent, in patients with advanced breast cancer.

Study Design:

This is a Phase II, single-agent, open-label, multicenter, dose-escalation study. Patients with advanced breast cancer will be enrolled into one of two cohorts: Cohort 1: Patients will receive ACY-24534 as a single agent, and Coh
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apatinibis a drug that inhibits
 
Response: Apatinibis a drug that inhibits angiogenesis and has been approved in China for the treatment of advanced gastric cancer (GC) ([@bib15]; [@bib3]). The efficacy of apatinib is well demonstrated in GC patients with *HER2* gene amplification ([@bib12]; [@bib21]; [@bib24]; [@bib25]; [@bib14]). However, there is limited information on the efficacy of apatinib in patients with *HER2*-negative GC (HNGC) who have a high risk of recurrence.

Clinical data from the Shanghai cohort demonstrated that patients with *HER2*-negative GC had a significantly higher recurrence rate than patients with *HER2*-positive GC, and patients with a low tumour burden had a significantly better prognosis than those with a high tumour burden ([@bib10]). In addition, a study on the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apigeninis a drug that inhibits
 
Response: Apigeninis a drug that inhibits phosphatidylinositol-specific phospholipase C. It is a weak inhibitor of phosphatidylcholine-specific phospholipase C, but it is a potent inhibitor of phosphatidylinositol-specific phospholipase C. It inhibits the growth of a variety of cancer cell lines in vitro. Apigenin is a member of the flavonoid family of natural products.

Metastatic melanoma is a highly aggressive form of skin cancer that carries a poor prognosis. The main treatment for metastatic melanoma is chemotherapy. Chemotherapeutic drugs used to treat melanoma are often poorly tolerated and have a high incidence of toxicity. In addition, these drugs have been shown to be ineffective at halting the progression of melanoma. Inhibition of phosphatidylinositol-specific phospholipase C (PI-PLC) has been shown to be a promising new approach
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apixabanis a drug that inhibits
 
Response: Apixabanis a drug that inhibits factor Xa, a serine protease that plays a key role in the coagulation cascade by converting prothrombin to thrombin. Apixaban is a member of a new class of anticoagulants called factor Xa inhibitors, or direct factor Xa inhibitors, which have the advantage of a rapid onset of anticoagulation, which is not associated with the need for monitoring or dose adjustments.

This article is part of a series on thrombosis. Other articles in this series are:

Thrombosis is a common cause of morbidity and mortality. Although anticoagulation is effective in preventing thrombotic events, adverse effects are a concern. Apixaban is a new, highly selective factor Xa inhibitor that has been developed to address these concerns. In addition to its anticoagulant activity, apixaban has a potent anti-inflammatory effect. This article
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  APR-246is a drug that inhibits
 
Response: APR-246is a drug that inhibits nuclear factor-kappaB (NF-kappaB) activation by inhibiting IKK. Here, we investigated the effects of APR-246 on endothelial function and endothelial progenitor cells (EPCs). First, we examined the effects of APR-246 on vascular endothelial cells in vitro. The treatment of human umbilical vein endothelial cells (HUVECs) with APR-246 inhibited the activation of NF-kappaB induced by tumor necrosis factor-alpha (TNF-alpha) or oxidized low-density lipoprotein (oxLDL) in a concentration-dependent manner. The treatment of HUVECs with APR-246 significantly reduced the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) induced by TNF-alpha or oxLDL. In addition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apraclonidineis a drug that inhibits
 
Response: Apraclonidineis a drug that inhibits the formation of the ciliary epithelium in the eyes of animals and man. The side effects of apraclonidine are generally mild and transient, with the most common being an unpleasant sensation of burning or stinging.

Apraclonidine is marketed as:

Apraclonidine hydrochloride

Apraclonidine hydrochloride is an ophthalmic anti-glaucoma drug, used for the treatment of ocular hypertension and primary open-angle glaucoma (POAG). It works by decreasing aqueous humor production and increasing uveoscleral outflow. Apraclonidine is a derivative of 2-amino-3-methyl-1,4-naphthoquinone, a molecule found in the Japanese horsetail plant, Scrophularia ningpoensis.

Apraclonidine has been used for many years, and it is generally
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apramycinis a drug that inhibits
 
Response: Apramycinis a drug that inhibits ribonucleotide reductase (RR), and causes cell death in both normal and cancer cells. We show that: (i) a number of species-specific daunorubicin derivatives (ApD) can be prepared from the dimeric natural product Apramycin A2; (ii) ApD exhibit potent antitumor activity against several human and mouse cancer cell lines, including P388 leukemia, A549 lung carcinoma, and HT29 colon carcinoma; (iii) ApD selectively kill tumor cells with elevated expression of RR; (iv) ApD show little cytotoxicity against cells with wild-type RR; (v) ApD also inhibit RR in cultured human primary fibroblasts and bone marrow cells.

Ribonucleotide reductase (RR) catalyzes the rate-limiting step in de novo DNA synthesis. Inhibitors of RR can kill rapidly dividing cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apremilastis a drug that inhibits
 
Response: Apremilastis a drug that inhibits phosphodiesterase 4 (PDE4), the enzyme that degrades cAMP. It has been used for treating patients with psoriasis and other inflammatory diseases \[[@b1-amjcaserep-21-e919289]\]. It has been shown to be effective in patients with psoriasis who have had an inadequate response to previous treatment \[[@b2-amjcaserep-21-e919289]\]. PDE4 inhibitors can cause headache, nausea, diarrhea, and myalgia \[[@b3-amjcaserep-21-e919289]\]. They are also known to cause visual disturbances, including blurred vision, dizziness, and headaches \[[@b4-amjcaserep-21-e919289]\].

Cases of PDE4 inhibitor-induced hyperpigmentation of the skin are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aprepitantis a drug that inhibits
 
Response: Aprepitantis a drug that inhibits
or reverses Alzheimer's Disease and other
neurodegenerative disorders is a ketone body.
Ketone bodies are metabolites that are produced
from the liver by the body.
The brain does not have the ability to make
ketone bodies on its own.
Therefore, the body produces ketone bodies
from the breakdown of fats and carbohydrates
that the brain cannot use.
When ketone bodies are made in large amounts,
the brain has a much lower requirement for
glucose.
This means that the brain will not need to
consume as much glucose, and this will result
in a lower level of glucose in the brain.
As the brain's glucose supply is lowered,
it is less able to produce the neurotransmitter
glutamate.
With lower glutamate levels, neurons will
be less likely to fire and the brain will
be less likely to transmit messages from
one
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  APRISOis a drug that inhibits
 
Response: APRISOis a drug that inhibits AP-1 and AP-2, two transcription factors that play a key role in the regulation of the gene expression involved in the development of prostate cancer (PCa) and its progression. In this study, we evaluated the efficacy of APRISO against the progression of PCa in a murine model. We observed that APRISO delayed the development of the prostate tumor and the appearance of distant metastases in a model of castration-resistant prostate cancer (CRPC). Interestingly, the administration of APRISO reduced the tumor burden in an orthotopic model of PCa. In addition, APRISO reduced the cell proliferation and the levels of expression of c-fos and cyclin D1 in vitro and in vivo. Finally, we found that the administration of APRISO reduced the expression of growth factors (FGF2 and VEGF) and the activation of the Akt and ERK signaling pathways in PCa cells. These results demonstrate that APR
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Apronalis a drug that inhibits
 
Response: Apronalis a drug that inhibits TNF-α, a cytokine that stimulates the inflammatory process. It was approved in January 2004 for the treatment of rheumatoid arthritis. This report summarizes the clinical trials of apremilast in patients with rheumatoid arthritis. The clinical trials are listed in Table 1. In these trials, the drug was well tolerated and generally safe and well-tolerated.

Apremilast is not an anti-inflammatory drug, and it does not interfere with the immune system. It is a phosphodiesterase-4 (PDE-4) inhibitor. This enzyme is found in cells throughout the body, and it helps cells regulate themselves by releasing certain substances.

The substance apremilast inhibits the enzyme PDE-4, and this blocks the production of inflammatory substances in the body.

What are the most important points?

In this study, the authors reported that apremilast was generally
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aprotininis a drug that inhibits
 
Response: Aprotininis a drug that inhibits the action of the protease trypsin (S. Ramon et al., J. Biol. Chem. 257, p. 4138-4143 (1982)).
The inhibition of proteases is a useful method of controlling the development of metastatic tumors (H. Liotta, Semin. Oncol. 8, p. 461-469 (1981)).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Arabicis a drug that inhibits
 
Response: Arabicis a drug that inhibits the
production of melanin, which is a brown
color that gives you your tan. And we all
want a tan. But it also has a side effect.
And it's that it also reduces the amount
of vitamin D that your body produces.
That's how we know it works. So you take
it and you don't produce melanin and you
don't get a tan. So the effect is it
produces the skin, it doesn't tan you.
That's not a good thing. So that's the
science behind it.
And then there's this guy.
What does this say?
Sri Lanka is the second most tanned
country in the world. And it's where I
come from.
So it's a good country for the tan.
And what's it says?
That you can take a pill that will
lower your levels of melanin, but
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Arbidolis a drug that inhibits
 
Response: Arbidolis a drug that inhibits the synthesis of LPS. The study was performed in the same period as the study of Bannai et al. (2005) and aimed to demonstrate that TAA had the same effect on gram-negative bacteria, both in vivo and in vitro. The results of this study were reported in 2005.

Conclusion
==========

Our results demonstrate that TAA can significantly inhibit the growth of gram-negative bacteria and that this effect can be demonstrated both in vivo and in vitro. In conclusion, we can conclude that TAA is a useful and effective drug against gram-negative bacteria.

Acknowledgements
================

The authors would like to thank Dr. Naoki Kikuchi (Department of Pediatrics, Chiba University) for his valuable advice on this project.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Arbutinis a drug that inhibits
 
Response: Arbutinis a drug that inhibits fatty acid synthase (FASN) activity. In addition, this drug causes the downregulation of fatty acid synthesis and an increase in fatty acid oxidation in cancer cells \[[@B40-molecules-21-01088]\]. Anacetrapib is an acetyl-CoA carboxylase (ACC) inhibitor, and in vitro studies have shown that this drug can inhibit the growth of cancer cells and reduce the incidence of cancers \[[@B41-molecules-21-01088]\]. AZD1208 is a selective and potent dual inhibitor of diacylglycerol acyltransferase-1 (DGAT-1) and DGAT-2. In vitro studies have shown that this drug can inhibit the growth of cancer cells and reduce the incidence of cancers \[[@B42-molecules-21-01088]\].

2.3. Mechanism
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARC029(Nilvadipine)is a drug that inhibits
 
Response: ARC029(Nilvadipine)is a drug that inhibits the smooth muscle calcium channels.

CHF_ACH034(Paroxetine)is a SSRI. It is a potent and selective inhibitor of serotonin reuptake and acts by blocking serotonin reuptake from the synapse.

CHF_ACH035(Pimozide)is an antipsychotic agent.

CHF_ACH036(Pimobendan)is a cardiotonic agent. It has a positive inotropic action.

CHF_ACH037(Pindolol)is a beta-adrenergic blocker. It has some actions which are not typical of beta-blockers.

CHF_ACH038(Pitavastatin)is a lipid-lowering agent.

CHF_ACH039(Plazomicin)is an aminoglycoside.

CHF_
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Arecolineis a drug that inhibits
 
Response: Arecolineis a drug that inhibits calcium transport across the epithelial membrane of the small intestine and promotes the secretion of gastric acid, decreasing gastric pH. This decreases gastric pH, which in turn prevents bacterial overgrowth, decreases the production of ammonia, decreases ammonia absorption and increases the production of urea in the blood.

Arecoline may also be a medicine for the treatment of overactive bladder and interstitial cystitis.

It may also be used to treat other conditions as determined by your doctor.

For how long should I use Arecoline?

Use Arecoline for as long as your doctor tells you to. Your doctor may prescribe Arecoline for a specific time or for as long as needed to achieve the desired results. The dose of Arecoline will depend on your medical condition or how long you have been using Arecoline.

Are there any side effects of Arecoline?

Like all medicines,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Argatrobanis a drug that inhibits
 
Response: Argatrobanis a drug that inhibits the conversion of fibrinogen to fibrin by inhibiting the binding of thrombin to fibrinogen. The pharmacokinetics of argatroban in healthy subjects was investigated. Subjects were given a single oral dose of 100 mg argatroban. Blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after dosing. The mean time to reach maximum plasma concentration was 0.25 hour. The mean maximum plasma concentration was 3.96 mcg/mL. The mean plasma clearance was 0.20 L/hr/kg. The mean half-life was 2.02 hours. The mean volume of distribution was 0.59 L/kg. In the safety population, 1 subject had an elevated aminotransferase value on the day of dosing. No other drug-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aristolochicis a drug that inhibits
 
Response: Aristolochicis a drug that inhibits the enzyme COX-2, preventing the conversion of arachidonic acid to prostaglandin-2. This results in reduced blood clotting, and therefore reduced bleeding in the gastrointestinal tract, as well as reduced inflammation.

Since it was first isolated in 1970, Aristolochic Acid has been used as a natural remedy for gout, rheumatism, arthritis, as well as certain skin conditions.

In Europe, it has been widely used to treat warts, a condition in which the skin becomes inflamed. In fact, in the early 1980s, the FDA issued a warning to physicians not to use Aristolochic Acid to treat warts.

Aristolochic Acid has been used to treat cancers of the breast, cervix, and prostate, and in combination with other anti-cancer drugs, has been used to treat ovarian cancer.

While there is some evidence
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARN-509is a drug that inhibits
 
Response: ARN-509is a drug that inhibits TLR-7, a protein found in the intracellular compartment of monocytes, macrophages, and dendritic cells. In a randomized, double-blind, multicenter trial of 52 patients with chronic hepatitis C, the addition of the TLR-7 inhibitor to interferon and ribavirin resulted in a higher sustained virologic response rate than with interferon and ribavirin alone (53% vs 33%, P =.04). In a separate randomized, double-blind, multicenter trial, 48 patients with chronic hepatitis C were randomized to receive either peg-interferon alfa-2b, ribavirin, or the combination of both. In addition, one-half of the patients in each arm received either the TLR-7 inhibitor (SAR-105326) or placebo. After 24 weeks of therapy, the sustained virologic response rate was 67% in the combination arm
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARQis a drug that inhibits
 
Response: ARQis a drug that inhibits the inducible form of nitric oxide synthase (iNOS). It has been shown to be effective in the treatment of septic shock, in part because it decreases nitric oxide (NO) levels, which are known to be elevated in this condition \[[@B25]\]. The reduction in NO levels is due to the inhibition of iNOS expression and activity by ARQ \[[@B25]\]. In addition, the treatment with ARQ decreases proinflammatory cytokine levels \[[@B26]\].

In a study in rats, cecal ligation and puncture (CLP) was performed, and the rats were treated with a bolus dose of 10 mg/kg of ARQ at the time of surgery or with 5 mg/kg every 8 hours for 72 hours. In the group treated with ARQ, there was a significant decrease in serum levels of IL-1β and IL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Arranonis a drug that inhibits
 
Response: Arranonis a drug that inhibits the activity of Rho kinase, which is an enzyme that is implicated in the development of atherosclerosis.

Rho kinase has also been implicated in the formation of atherosclerotic plaques in arteries.

Arranonis has been shown to improve the function of blood vessels and to reduce blood pressure in animals.

In a double-blind, placebo-controlled, dose-ranging trial, Arranonis reduced the rate of recurrent heart attacks in patients with previous heart attacks.

Arranonis has also been shown to reduce the progression of atherosclerosis in the aorta of animals.

Arranonis has been shown to reduce the rate of angina in patients with coronary heart disease.

Mechanism of action

Arranonis inhibits the activity of Rho kinase, an enzyme that is implicated in the development of atherosclerosis.

Arranonis also has other actions that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARRY-380is a drug that inhibits
 
Response: ARRY-380is a drug that inhibits multiple isoforms of phosphodiesterase (PDE) enzymes, thereby increasing intracellular cAMP levels. The role of cAMP in the regulation of glucocorticoid action is well established. The PDE4 isoform is the major PDE that hydrolyses cAMP, and inhibitors of this enzyme are currently in development for the treatment of inflammatory and allergic diseases.

ARRY-380, a potent and selective PDE4 inhibitor, is currently in development for the treatment of inflammatory and allergic diseases.

Pharmacokinetic (PK) data have been reported for ARRY-380 following single-dose oral administration to healthy volunteers (n = 20). After single-dose administration of ARRY-380 (5 mg) to healthy volunteers, maximum plasma concentration (Cmax) of ARRY-380 was 1.05 μg/mL, and the time to reach maximum plasma concentration (tmax) was 3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Artemetheris a drug that inhibits
 
Response: Artemetheris a drug that inhibits the metabolism of pyrimethamine. It is administered as a single dose, and its mechanism of action is thought to be inhibition of dihydrofolate reductase, the enzyme that converts dihydropteroate to tetrahydrofolate, the cofactor required for thymidylate synthesis. In vitro and in vivo data show that artemether has a greater inhibitory effect on dihydrofolate reductase than pyrimethamine. It is also active against many other protozoal infections and, because of its longer half-life, is the drug of choice for treating malaria in pregnant women. Artemether is given in a dosage of 20 mg/kg.

INVESTIGATIONS

Artemether is primarily metabolized by hepatic P450-mediated oxidation to dihydroartemisinin, which is further metabolized to the primary active metabolite art
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Artemisininis a drug that inhibits
 
Response: Artemisininis a drug that inhibits parasite growth in liver stage of malaria by inhibiting the activity of the enzyme dihydroorotate dehydrogenase. It is also active against the sexually transmitted disease chlamydia, which infects the genital tract. Artemisinin is also a good antioxidant. The active component of the drug is the sesquiterpene lactone artemisinin.

Artemisinin has a structure of a lactone ring with a side chain attached. It is synthesized in the leaves of the sweet wormwood plant. The drug is extracted from the leaves of the sweet wormwood plant, Artemisia annua. The plant has been used in traditional medicine for a long time. Artemisinin was discovered in 1972 by Chinese scientists. The drug is now being developed for treatment of malaria. The World Health Organization has established a target of treating at least 40% of malaria cases with artemisinin drugs. The drug has been used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Artesunateis a drug that inhibits
 
Response: Artesunateis a drug that inhibits the enzyme, chorismate synthase, which is involved in the biosynthesis of the aromatic amino acids, phenylalanine and tyrosine. Chorismate synthase is the fourth enzyme in the shikimate pathway and is also known as shikimate-5-dehydrogenase. This enzyme converts chorismate into 4-aminobenzoate, which is the starting material for the biosynthesis of the aromatic amino acids. The antimalarial activity of this compound was discovered in the 1940s, and it was developed into a clinically useful drug.

The development of artesunate began in 1955 when a team of scientists at the Walter Reed Army Institute of Research discovered that the fungus, *Trichophyton rubrum*, was sensitive to the drug. This organism has been isolated from many species of people and animals, including horses and dogs. *T. rubrum* is a fungus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARTHROTECis a drug that inhibits
 
Response: ARTHROTECis a drug that inhibits several enzymes that are implicated in the development of chronic obstructive pulmonary disease (COPD). It has a wide therapeutic index, and is currently used to treat COPD in the United States.

Introduction {#Sec1}
============

Drug development is an expensive and time-consuming process, and the attrition rate for new drug development is approximately 50% \[[@CR1]\]. The current strategy for increasing the efficiency of drug development is to reduce the number of molecules tested in the discovery phase. In the first phase of drug discovery, a large number of molecules are synthesized and screened in vitro, and only those that are found to be active are progressed to the second phase of drug discovery, which is usually animal studies and clinical trials. The high attrition rate in the discovery phase is due to the fact that only a small fraction of molecules are active in vivo.

The majority of compounds that are tested in vitro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Articaineis a drug that inhibits
 
Response: Articaineis a drug that inhibits the release of inflammatory mediators. It is usually applied as an adjunct to other medications. Although the majority of clinical studies have been done with bupivacaine, the efficacy of articaine is similar to that of lidocaine, and is also available as a spray, a lozenge, and a suppository.

A review of the published literature on the use of articaine in dentistry was conducted using the PubMed database. A total of 24 articles were found to be relevant to the topic.

The most commonly reported adverse events associated with articaine are transient mild to moderate local anesthetic toxicity, nausea, vomiting, dizziness, and, rarely, respiratory depression, palpitations, and cardiac arrhythmias.

Articaine has a wide margin of safety, and no reports of serious toxicity have been found in the literature.

Articaine, a member of the ester group of local an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AS101is a drug that inhibits
 
Response: AS101is a drug that inhibits p110δ (PIK3CD) and prevents it from phosphorylating Akt and thus inhibits the PI3K/Akt pathway \[[@CR24]\]. It is currently being investigated in the clinic for the treatment of relapsed/refractory acute lymphoblastic leukaemia \[[@CR25]\].

Results {#Sec2}
=======

Efficacy of LY303511 and BKM120 in MCL cell lines {#Sec3}
-------------------------------------------------

The phosphoinositide 3-kinase (PI3K) pathway is constitutively active in MCL cells \[[@CR26]\]. LY303511, a potent and selective inhibitor of p110δ \[[@CR27]\], inhibits the growth of MCL cell lines \[[@CR28]\]. To test whether BKM120
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Asciminib(ABL001)is a drug that inhibits
 
Response: Asciminib(ABL001)is a drug that inhibits T315I-mutated BCR-ABL tyrosine kinase. It is a second-generation TKI and has an activity against most of the BCR-ABL TKIs currently available. As a result of the wide activity spectrum, asciminib is useful in the treatment of patients with chronic myeloid leukemia (CML) resistant to first-line therapy or with suboptimal response to imatinib. In phase 1/2 studies, it has shown a favorable safety profile and high overall response rate (ORR) in CML patients. In the phase 3 study of 537 imatinib-resistant/intolerant CML patients, the ORR was 93.3% and the complete cytogenetic response (CCyR) rate was 87.6%. The most common adverse events (AEs) were fatigue (37.9%), diarrhea (33
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ascomycinis a drug that inhibits
 
Response: Ascomycinis a drug that inhibits fungal DNA replication by blocking a single-stranded DNA-binding protein.
We have isolated a potent, specific, and nontoxic inhibitor of fungal DNA replication. It is a 2,6-disubstituted purine, with a methyl group on the 2-position of the purine ring. The compound, named ascomycin, inhibits the DNA replication of the broad-host-range mycobacteriophage phiX174 DNA polymerase and also of the filamentous fungus Neurospora crassa. This inhibition is completely reversible and occurs at concentrations less than those required for DNA polymerase alpha inhibition. Ascomycin appears to inhibit the fungal DNA replication by binding to a single-stranded DNA-binding protein, as indicated by competition experiments with the bacterial single-stranded DNA-binding protein SSB and the fungal DNA polymerase beta. These results suggest that ascom
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ascorbicis a drug that inhibits
 
Response: Ascorbicis a drug that inhibits tyrosine kinase activity, blocks B-cell differentiation, and causes loss of proliferative response to IL-2.
The effects of all-trans-retinoic acid (ATRA) and ara-A (Ascorbicis a) on the activity of tyrosine kinase and on the growth of the immunoglobulin (Ig) M-B lymphoblastoid cell line (LCL) WEHI-231 were studied. ATRA and ara-A inhibited tyrosine kinase activity in WEHI-231 cells. Ara-A was a more potent inhibitor of tyrosine kinase activity than ATRA. The concentration of ara-A needed to inhibit tyrosine kinase activity by 50% was about 0.3 microM. Ara-A did not inhibit tyrosine kinase activity in other B cell lines, such as Ramos and JEKO-1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Asenapineis a drug that inhibits
 
Response: Asenapineis a drug that inhibits serotonin reuptake, increasing the levels of serotonin in the synapse. It was approved by the US Food and Drug Administration (FDA) in June 2006. Asenapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder (Manic or Mixed Episode of Bipolar I Disorder). The manufacturer has approved the following doses: asenapine 1mg, 2mg, 3mg, 4mg, 5mg, and 10mg.

The 1mg dose is available in 2mg and 5mg tablets.

2mg tablets are identical to the 1mg dose, except for the appearance of a different colored cap.

5mg tablets are identical to the 2mg dose, except for the appearance of a different colored cap.

Tablets can be crushed and mixed with food. The tablet should be swallowed whole. Do not break, crush, dissolve, or divide the tablets.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ASP015Kis a drug that inhibits
 
Response: ASP015Kis a drug that inhibits the growth of multiple myeloma cells by inhibiting the activation of STAT3. This effect has been shown to be more pronounced in cells with an activated JAK2 pathway, which is frequently seen in patients with myeloma.

1. Introduction {#sec1-molecules-21-01088}
===============

Myeloma is a neoplastic disorder of plasma cells. It is a disease of the bone marrow characterized by a monoclonal expansion of malignant plasma cells that results in increased production of monoclonal immunoglobulin, which then accumulates in the blood and causes a myeloma-related bone disorder. This disease is a highly heterogeneous malignancy. It is typically diagnosed when patients present with the presence of the paraprotein in their blood, although patients with asymptomatic paraproteinemia or monoclonal gammopathy of undetermined significance are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Aspartameis a drug that inhibits
 
Response: Aspartameis a drug that inhibits or prevents the reabsorption of nutrients from the small intestine. It is an excitatory amino acid, which is the basic substance of the brain, nerves, and muscles.

What is aspartame?

It is the excitatory amino acid, which is the basic substance of the brain, nerves, and muscles.

How does aspartame affect the body?

Aspartame is a drug that inhibits or prevents the reabsorption of nutrients from the small intestine. It is an excitatory amino acid, which is the basic substance of the brain, nerves, and muscles.

What are the side effects of aspartame?

Aspartame is a drug that inhibits or prevents the reabsorption of nutrients from the small intestine. It is an excitatory amino acid, which is the basic substance of the brain, nerves, and muscles.

What are the side effects of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  aspirinis a drug that inhibits
 
Response: aspirinis a drug that inhibits pro-inflammatory cytokine production and reduces the incidence of pneumonia, and of ulcerative colitis, a disease of the colon. The use of 5-ASA has become widespread, with 1.5 billion doses used in the United States in 1998.

The mechanism of action of 5-ASA has not been completely elucidated, but its major activity seems to be due to the binding of the drug to sulfhydryl groups of mucin, the main component of mucus, which leads to the inhibition of mucus secretion and the subsequent decrease of inflammation. This mechanism is supported by the fact that the amount of mucus in the feces increases following 5-ASA administration.

The clinical effect of 5-ASA has been studied in various diseases, but most studies have been performed in inflammatory bowel disease, in particular, ulcerative colitis. In ulcerative colitis, 5-ASA has been shown to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AT101is a drug that inhibits
 
Response: AT101is a drug that inhibits HDAC6 activity. It was recently identified as a promising anti-cancer agent in the field of hematological malignancies, particularly in lymphoma. It was also demonstrated that HDAC6 inhibitor Vorinostat (SAHA) enhances the efficacy of current treatments for certain types of leukemia.^[@bib20]^ However, the exact mechanisms of how HDAC6 inhibitors exert their anti-tumor activity remain unclear. To date, it is not known whether HDAC6 inhibition can modulate the function of the microtubule-associated protein 1A/1B light chain 3 (LC3).

To explore the underlying mechanism of action of HDAC6 inhibitor, we investigated whether HDAC6 inhibitor exerts its effect on anti-cancer efficacy by modulating the level of LC3-II, which is associated with the autophagic process. Our data indicated that HDAC6 inhibition resulted in increased LC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AT13387is a drug that inhibits
 
Response: AT13387is a drug that inhibits a receptor tyrosine kinase, HER2, which is over-expressed in approximately 20-30% of breast cancer. The drug, which is given intravenously, has shown promising results in clinical trials, with clinical benefit seen in the first-line and second-line settings.

I was given the opportunity to speak to Dr. Nabi at the European Society for Medical Oncology (ESMO) congress in Barcelona in February 2015.

What is it that makes this drug so interesting?

This is a drug that is given intravenously and can be given on a weekly basis or every three weeks. It’s also given in combination with other drugs, so you can be given three or four drugs in a cycle. This means that it’s easier to administer the drug and also means that the toxicity profile is less severe.

It has shown good efficacy in first-line treatment, in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AT-406is a drug that inhibits
 
Response: AT-406is a drug that inhibits the binding of 5-hydroxytryptamine (5-HT) to 5-HT receptors and acts as an antagonist for the 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 subtypes.

References

Category:Piperidines
Category:5-HT1A antagonists
Category:5-HT2 antagonists
Category:5-HT3 antagonists
Category:5-HT6 antagonists
Category:5-HT7 antagonists
Category:Antidepressants
Category:Chloroarenes
Category:CNS stimulants
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AT7519is a drug that inhibits
 
Response: AT7519is a drug that inhibits farnesylation, which is necessary for the maturation of Ras proteins. Although the in vivo role of this enzyme is still not completely understood, a few studies have suggested that it may play a role in the regulation of cell proliferation, differentiation, and apoptosis.

To date, several Ras inhibitors have been developed, including farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors. Farnesyltransferase inhibitors are of two types: the first are derived from the natural substrate geranylgeranyl pyrophosphate (GGPP), and the second are derived from farnesyl pyrophosphate (FPP). The inhibitors of farnesyltransferase derived from GGPP are initially called “farnesyltransferase inhibitors”. On the other hand, those derived from FPP are called “geranylgeranyltransferase inhibitors”.

Although the specificity of the farnesyltransfer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ATACANDis a drug that inhibits
 
Response: ATACANDis a drug that inhibits histone deacetylase (HDAC) activity. This is the first agent to be developed specifically for use in cancer therapy, but the underlying mechanism of action of the drug remains controversial. We recently reported that ATACANDis a non-competitive inhibitor of the enzymatic activity of HDAC1, HDAC2, and HDAC3 in vitro. Furthermore, ATACANDis a potent anticancer agent that induces apoptosis and autophagy in various human cancer cell lines. This study is aimed at further elucidating the mechanism of action of ATACANDis in cancer therapy. The anticancer effects of ATACANDis in various cancer cell lines were examined in vitro. ATACANDis also was evaluated in vivo using a xenograft model. Apoptosis induction and inhibition of autophagy by ATACANDis were examined in human cancer cells in vitro. In vivo anticancer activity of ATACANDis was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atazanaviris a drug that inhibits
 
Response: Atazanaviris a drug that inhibits virus replication. Allografts of immunosuppressed animals are effective at inhibiting virus replication in the recipient.

A cell-mediated immune response is the mechanism responsible for eliminating virus-infected cells. When this response is inadequate, the virus will continue to replicate in the host and may be lethal.

Cell-mediated immunity. This is mediated by CD4+ T cells that interact with antigen presenting cells. It is initiated by recognition of viral antigens on the cell surface of infected cells by receptors on the surface of CD4+ T cells.

Cell-mediated immunity. This is mediated by CD8+ T cells that interact with antigen presenting cells. It is initiated by recognition of viral antigens on the cell surface of infected cells by receptors on the surface of CD8+ T cells.

CD8+ cytotoxic T lymphocytes (CTLs). CD8+ T cells have the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atomoxetineis a drug that inhibits
 
Response: Atomoxetineis a drug that inhibits the reuptake of serotonin in the brain. It is used to treat depression, ADHD and OCD. This drug can be prescribed to adults, teenagers and children. The most common side effects of this drug include nausea, headaches, dizziness, loss of appetite, dry mouth and anxiety. Atomoxetine can be used to treat symptoms of depression in children and adolescents.

Description

The antidepressant atomoxetine (Atomoxetine, Strattera) is a drug that inhibits the reuptake of serotonin in the brain. It is used to treat depression, ADHD and OCD. This drug can be prescribed to adults, teenagers and children. The most common side effects of this drug include nausea, headaches, dizziness, loss of appetite, dry mouth and anxiety. Atomoxetine can be used to treat symptoms of depression in children and adolescents.

Common side effects

Nausea

Head
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  atorvastatinis a drug that inhibits
 
Response: atorvastatinis a drug that inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis. Atorvastatin lowers LDL-cholesterol (LDL-C) and triglycerides, and increases HDL-cholesterol (HDL-C). Atorvastatin is indicated for primary and secondary prevention of cardiovascular disease (CVD). The reduction of CVD by statins, and particularly by atorvastatin, is clearly demonstrated by randomized controlled trials (RCTs) and meta-analyses. The most recent Cochrane meta-analysis of RCTs of atorvastatin (n=4,946) versus placebo or other statins (n=3,270) in primary prevention of CVD (myocardial infarction (MI), stroke, and death) reported a significant 21% reduction in major cardiovascular events (MACE; MI, stroke, and death) with atorv
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atorvastatinis a drug that inhibits
 
Response: Atorvastatinis a drug that inhibits HMG-CoA reductase. It is used for the treatment of hypercholesterolemia, primary and secondary prevention of cardiovascular events and atherosclerosis. It is also used for treatment of dyslipidemia in patients with type 2 diabetes mellitus.\[[@ref1]\] Atorvastatin is a hydrophobic drug, with poor water solubility and low bioavailability. The drug is administered orally, at a dose of 10--80 mg/day.\[[@ref2]\] Its major side effects include diarrhea, myalgia, hepatotoxicity, rhabdomyolysis, hepatic dysfunction, myopathy, hyperlipidemia, anemia, headache, backache, pruritus, dizziness, insomnia, insomnia, constipation, nausea, abdominal pain, vomiting, dry mouth, and asthenia.\[[@ref3][@ref4]
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atosibanis a drug that inhibits
 
Response: Atosibanis a drug that inhibits contractions of the uterine muscle. It is used in the treatment of preterm labour and uterine contractions associated with dysfunctional labour. It works by blocking the effect of oxytocin. This drug is taken orally.

Dosage

The dosage of atosiban depends on the weight of the mother. The recommended dose is 40 mcg per kg body weight.

Side Effects

The side effects of atosiban are few. It causes the mother to have increased bleeding and there may be some nausea and vomiting. The baby may be born early and weigh less than normal.

Contraindications

This drug is contraindicated in women who are allergic to atosiban or to any of its components.

Drug Interactions

The effect of atosiban is antagonized by progesterone. Hence, it should not be used in combination with progesterone. The effect of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  atovaquoneis a drug that inhibits
 
Response: atovaquoneis a drug that inhibits the enzyme, dihydrofolate reductase, which is required for the synthesis of the folate cofactors tetrahydrofolate and dihydrofolate. Folate is essential for the metabolism of purines and pyrimidines, which are required for DNA synthesis and cell division.

Sodium/proton exchangers (Na+/H+ antiporters) mediate the electroneutral exchange of Na+ for H+ across the plasma membrane. They are found in many organisms, including bacteria, yeast, and animals, and are of major importance in maintaining cellular homeostasis. A membrane protein, which catalyzes the exchange of Na+ for H+ on the luminal side of the plasma membrane, is termed a Na+/H+ antiporter or a Na+/proton antiporter. These antiporters are also termed H+-ATPases, and are responsible for acidifying
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ATPis a drug that inhibits
 
Response: ATPis a drug that inhibits the catalytic activity of P2X7 receptors (Murata et al., [@B31]). The concentration of ATP used was 10 μM. This concentration of ATP is the highest concentration of ATP that has been used in previous experiments. In our experiments, a high concentration of ATP may have inhibited the development of synaptic plasticity in the LTP model (Chen et al., [@B8]).

In the present study, the rats were divided into four groups: the sham group (n = 8), the control group (n = 8), the MPTP group (n = 8), and the MPTP + P2X7R antagonist group (n = 8). The behavior and locomotor activity of the rats were measured using the open-field test. The time spent in the center of the open field was significantly shorter in the MPTP group than in the control group. In the MPTP + P2X7R antagonist
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atracuriumis a drug that inhibits
 
Response: Atracuriumis a drug that inhibits neuromuscular transmission by binding to the muscle ACh receptor (M-AChR). It is widely used in the operating room, but has a relatively long onset time of action. The elimination half-life of atracurium is around 40 min. It is not eliminated by the kidneys, but is metabolized in the liver. Atracurium is metabolized to the inactive metabolites, laudanosine and laudanosyl-5-acetylamino-2-methyl-4-trifluoromethylpyridine (AMTPF). A major metabolite of atracurium, laudanosine, is eliminated by the kidneys and is renally excreted. A major metabolite of atracurium, laudanosyl-5-acetylamino-2-methyl-4-trifluoromethylpyridine (AMTPF), is eliminated by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ATRALINis a drug that inhibits
 
Response: ATRALINis a drug that inhibits acetylcholinesterase, which has been used in the treatment of Alzheimer's disease. Recently, atrial natriuretic peptide (ANP) has been shown to be involved in norepinephrine (NE) clearance in brain. Therefore, we investigated whether ATRILIN has an effect on the in vitro NE uptake by synaptosomes. We found that ATRILIN inhibits the uptake of NE in a dose-dependent manner. This effect is due to a decrease in the Km for the uptake of NE. Furthermore, ATRILIN is able to increase the Km of the NE uptake, suggesting that it is an allosteric effector. In addition, we found that ATRILIN decreases the uptake of 3H-noradrenaline in a dose-dependent manner, which is due to a decrease in the Km. In addition, ATRILIN is able to increase the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Atropineis a drug that inhibits
 
Response: Atropineis a drug that inhibits the activity of the enzyme acetylcholinesterase. The drug can be used to reverse the effects of nerve gas, such as sarin, on the human body. It is also used to reverse the effects of botulinum toxin on the human body.

Amphetamines are a group of stimulants that can cause feelings of increased energy and alertness. They can also increase blood pressure, heart rate, and body temperature. Some amines can be addictive. Amphetamines can also increase body temperature and blood pressure.

Amiodarone is a drug that can be used to treat certain heart conditions. It can also be used to prevent and control heart rhythm problems. It is also used to treat heart problems in children.

Amphotericin B is a drug that can be used to treat fungal infections. It can also be used to treat cryptococcal meningitis.

Amphoteric
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ATROVENTis a drug that inhibits
 
Response: ATROVENTis a drug that inhibits mTOR and has been tested in clinical trials for a number of cancers including HCC \[[@B56-ijms-18-01991]\]. In a study using primary liver cancer cell lines, Dasatinib (a multikinase inhibitor) decreased the viability of liver cancer cells by inhibiting mTOR signaling \[[@B57-ijms-18-01991]\]. Rapamycin, another mTOR inhibitor, has also been shown to inhibit cell proliferation and induce apoptosis in HCC cells \[[@B58-ijms-18-01991]\]. Additionally, another study using a mouse model of HCC found that treatment with Rapamycin inhibited tumor growth and prolonged the survival of tumor-bearing mice \[[@B59-ijms-18-01991]\].

3.4. PI3K/Akt/mTOR Pathway
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Auranofinis a drug that inhibits
 
Response: Auranofinis a drug that inhibits the activity of the enzyme that controls the balance of oxygen in the body and, if the concentration is not regulated, can cause damage to the blood vessels, the brain and other organs. This is an important reason why these drugs are not usually used for extended periods.

Is not necessary to take the drug when the use of the new drug called Arsenofin, which acts as a medication to treat chronic heart failure, but to do so the patient must have severe symptoms, as stated in the recommendations of the American College of Cardiology.

The manufacturer of the drug says that the therapy is not recommended in the treatment of heart failure because it does not have a clear benefit. It is only recommended in patients with severe symptoms of the disease and with advanced disease, that is, when the heart is not functioning.

But doctors who prescribe the drug are doing so on the basis of the manufacturer’s own study, in which patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AV-951is a drug that inhibits
 
Response: AV-951is a drug that inhibits the enzyme protein kinase C (PKC). It has been used in the treatment of restenosis after balloon angioplasty. It is also used for preventing the effects of graft rejection after transplantation.

Although it is an FDA approved drug, it is not currently approved in the United States for any specific use.

Contents

Aminocaproic acid is a medication that inhibits the enzyme protein kinase C (PKC). It is used in the treatment of restenosis after balloon angioplasty and for preventing the effects of graft rejection after transplantation.

Aminocaproic acid is an antiplatelet agent and can be used in the prevention of blood clots and the treatment of certain blood clots, such as those in the veins of the legs. It is also used to prevent or treat blood clots in the lungs.

The effects of aminocapro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AVAGEis a drug that inhibits
 
Response: AVAGEis a drug that inhibits the enzyme vascular endothelial growth factor receptor (VEGFR). It has been approved for the treatment of a variety of solid tumours, and is also being studied in other diseases such as diabetic macular oedema. This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of avastin in healthy volunteers and patients with solid tumours. A total of 30 healthy volunteers and 80 patients with solid tumours were randomised to receive one of three dose regimens of avastin (10 mg/kg, 15 mg/kg, or 20 mg/kg) or placebo. Blood samples were taken to determine the pharmacokinetics of avastin. Patients were monitored for adverse events, and were assessed for the pharmacodynamic effects of avastin on circulating angiogenic factors. The pharmacokinetics of avastin in healthy volunteers were linear over the dose range tested. Avastin had a moderate to weak effect on circulating
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Avanafilis a drug that inhibits
 
Response: Avanafilis a drug that inhibits the action of an enzyme that prevents cGMP from breaking down. It is also known as vardenafil. It is used to treat erectile dysfunction.

How does Avanafil work?

Avanafil belongs to a group of drugs known as phosphodiesterase type 5 inhibitors (PDE5-Is). This group of drugs works by inhibiting an enzyme that breaks down the chemical cGMP. When this chemical cGMP breaks down, the cells in the penis become relaxed, which allows blood to flow into the penis. This causes an erection. Avanafil works by inhibiting the action of the enzyme that breaks down cGMP.

Avanafil is a drug that has been developed for the treatment of erectile dysfunction. Avanafil works by inhibiting the action of an enzyme called phosphodiesterase type 5. This enzyme is responsible for breaking down the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Avatrombopagis a drug that inhibits
 
Response: Avatrombopagis a drug that inhibits the receptor for thrombopoietin.

The structure of Avatrombopag is shown in the image above.

It was approved by the FDA in June 2012.

There are no drugs in the United States that stimulate the thrombopoietin receptor.

Thrombopoietin, also known as megakaryocyte growth and development factor, is a cytokine that stimulates the production of platelets.

It is produced in the liver and spleen and is the main regulator of megakaryopoiesis, the production of platelets in the bone marrow.

It also acts on megakaryocytes and megakaryocytic precursors, including megakaryoblasts, megakaryocyte-erythrocyte precursors, and platelet precursors, and stimulates megakaryocyte maturation and plate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AVCis a drug that inhibits
 
Response: AVCis a drug that inhibits angiogenesis in various cancers. In the present study, we investigated the effects of AVC on proliferation and migration of A549 cells and explored the potential mechanisms. We found that AVC inhibited proliferation and migration of A549 cells in a dose-dependent manner. AVC decreased the levels of phosphorylated ERK and AKT. AVC down-regulated the expression of cyclin D1, CDK2, MMP-2 and MMP-9. AVC also suppressed the expression of phosphorylated ERK and AKT. In addition, AVC reduced the protein expression of VEGF. These results indicated that AVC could suppress proliferation and migration of A549 cells by inhibiting the expression of VEGF and its downstream signaling pathways, and the mechanism of AVC might be related to down-regulating the expression of cyclin D1, CDK2, MMP-2 and MMP-9.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Avitinibis a drug that inhibits
 
Response: Avitinibis a drug that inhibits VEGF receptor 2 (VEGFR2), which is a tyrosine kinase that is responsible for the activation of VEGF. VEGF receptors are the main target of anti-angiogenic agents and are therefore important in cancer. This drug can also inhibit c-kit, which is a tyrosine kinase that is involved in cell growth.

Avitinib is a first-in-class small molecule inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2) that has been shown to inhibit angiogenesis and tumor growth in a wide variety of preclinical models, including in human cancer.

Important Information

Avitinib is a first-in-class small molecule inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2) that has been shown to inhibit angiogenesis and tumor growth in a wide variety of preclinical models, including in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AVL-292is a drug that inhibits
 
Response: AVL-292is a drug that inhibits the activity of Vascular Endothelial Growth Factor (VEGF) and Receptor (VEGFR).

The key elements of this drug are its high potency in inhibiting the growth of angiogenic endothelial cells (Vasculogenesis) and its ability to inhibit the formation of new blood vessels (Angiogenesis). The inhibition of the growth of these cells results in reduced vascularization and decreased tumor size.

Avastin is used to treat breast cancer and other types of cancer.

It is also used to treat other conditions that cause or are associated with excessive or abnormal blood vessel growth (angiogenesis) including, but not limited to, macular degeneration, retinopathy, diabetic retinopathy, diabetic macular edema, neovascular glaucoma, age-related macular degeneration, and rheumatoid arthritis.

Avastin is also used to treat eye
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZACTAMis a drug that inhibits
 
Response: AZACTAMis a drug that inhibits cytochrome P450 3A4, the enzyme responsible for the metabolism of many of the most commonly prescribed drugs. It can lead to increased blood levels of digoxin and other drugs that are metabolized by the same enzyme. It may also affect the metabolism of other drugs that are not metabolized by cytochrome P450 3A4.

ACTAM is a misnomer. It does not contain any of the azoles. Rather, it is a drug with a broad spectrum of antibacterial activity. This includes resistance to penicillins and cephalosporins.

It was initially marketed as an antibiotic. This was the case in the early 1960s. However, this led to confusion, and ACTAM was changed to a diuretic. The drug is still available under this trade name in the US, but the brand name in most other countries is a diuretic.

The manufacturer of ACT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azaperoneis a drug that inhibits
 
Response: Azaperoneis a drug that inhibits the binding of the excitatory neurotransmitter, glutamate, to its receptors, NMDA and AMPA. It is not a neuroleptic, it is therefore non-sedating, but can be sedating in higher doses.

Classification

Alpha2

Alpha2-agonists

Diazepam

Dosage

Oral

Alpha2

0.3–0.5 mg/kg/day

0.3–0.5 mg/kg/day

Sublingual

0.1–0.3 mg/kg/day

0.1–0.3 mg/kg/day

Intranasal

0.1–0.3 mg/kg/day

0.1–0.3 mg/kg/day

Sublingual

0.5–1.0 mg/kg/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azasetronis a drug that inhibits
 
Response: Azasetronis a drug that inhibits the enzyme DDAH, thereby increasing NO production and causing vasodilation and natriuresis. DDAH is expressed in the endothelium of the aorta, carotid, and renal arteries, and the inhibition of DDAH results in vasodilation and a decrease in systemic vascular resistance, which is accompanied by a fall in blood pressure and an increase in renal blood flow.[@b2-jmdh-11-233]--[@b4-jmdh-11-233] Thus, the treatment with azasetronis was expected to lower blood pressure and increase blood flow in the cerebral vessels.

However, several clinical studies have failed to show a significant effect of azasetronis on the blood pressure or blood flow in the cerebral vessels.[@b5-jmdh-11-233],[@b6-jmdh-11-233] This may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azatadineis a drug that inhibits
 
Response: Azatadineis a drug that inhibits histamine H1 receptors. It has been used to treat allergic rhinitis and other symptoms. It is a prodrug that is rapidly converted into its active form, which is then excreted in the urine. It can be administered either orally or intravenously.

H1 receptor antagonists, also called antihistamines, are a class of drugs that are used to treat allergies, asthma, and motion sickness. They work by inhibiting the action of histamine, a chemical released by the body during an allergic reaction.

The first histamine H1 receptor antagonist to be developed was chlorpheniramine. It was discovered in the early 1950s, but was not approved for medical use until 1976.

This is a short overview of the general use of the drug.

Allergies

Allergies are caused by the immune system’s overreaction to an antigen (an allergen).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD1981is a drug that inhibits
 
Response: AZD1981is a drug that inhibits the farnesyltransferase enzyme (FTase), a protein that is required for the post-translational addition of a "farnesyl" lipid to proteins, which is important for the normal function of the cell. It is used to treat patients with Ras-related diseases such as, cancer.

[^1]: See [Table 2](#tbl2){ref-type="table"} for an explanation of each phase.

[^2]: In Phase 1, a Phase I trial was conducted to determine the safety and tolerability of single ascending doses of AZD1981 administered as a bolus IV infusion over 10 minutes in combination with oral administration of a fixed-dose AZD5438 tablet. In this phase, 3 cohorts of 4--8 subjects were enrolled. Cohorts received either: (i) AZD1981 (single IV infusion of 20, 30, 40, or 50 mg/m^2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD2281is a drug that inhibits
 
Response: AZD2281is a drug that inhibits phosphodiesterase 4 (PDE4), which is a key enzyme in the intracellular signalling pathway that leads to the production of inflammatory mediators. It has been suggested that PDE4 inhibitors may have therapeutic potential in the treatment of a number of inflammatory diseases. These include chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, and Crohn's disease.

However, there are also data that suggest that PDE4 inhibitors may be detrimental to patients with COPD.

AZD2281 is a new chemical entity that has been developed by AstraZeneca and is currently in development for the treatment of COPD.

The efficacy of AZD2281 was evaluated in a series of preclinical studies. These included a number of models of COPD in guinea pigs, and a model of allergic airway inflammation in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD3293is a drug that inhibits
 
Response: AZD3293is a drug that inhibits the activity of PI3K and mTOR, a protein kinase in the PI3K pathway that regulates cell growth and metabolism. The drug was originally designed to treat patients with certain types of cancer but has been shown to have a broader range of activities. AZD3293 has been found to be effective in treating several forms of cancer including renal cell carcinoma, pancreatic cancer, and glioblastoma. It has been shown to work in combination with a number of different anticancer agents including mTOR inhibitors, angiogenesis inhibitors, and EGFR inhibitors.

NCT02012296 is a study that is studying the safety and efficacy of AZD3293 in patients with metastatic breast cancer. The study is being conducted at 18 sites in the United States and Canada. Patients will be randomized to receive either AZD3293 or a placebo.

The safety and tolerability of AZD3293 is being
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD3759is a drug that inhibits
 
Response: AZD3759is a drug that inhibits liver enzymes, preventing the breakdown of the thyroid hormone thyroxine.

The thyroid gland produces thyroid hormones that control the rate at which your body uses energy.

Thyroid hormone production can be disrupted by medications or by food that causes liver damage.

Thyroid hormone replacement therapy is required for some people with thyroid conditions, including Hashimoto’s thyroiditis.

A variety of other drugs that interfere with liver enzymes may be prescribed to treat liver disease or as part of other therapies.

Taking Azithromycin with the thyroid drug T4 is a common drug interaction.

Azithromycin may increase your risk of developing serious liver problems.

Azithromycin has a narrow therapeutic index, meaning that the amount of the drug needed to treat an infection may vary greatly among different patients.

A higher than recommended dose of Azithromycin may lead to an overdose.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD4547is a drug that inhibits
 
Response: AZD4547is a drug that inhibits CYP2C8. This drug is prescribed to treat cardiovascular diseases and is known to cause many adverse effects such as nausea, diarrhoea, rash and fatigue. However, its side effects are usually dose-dependent and serious. Therefore, it is important to develop an approach to accurately identify the patients who are likely to experience such side effects at the lowest possible doses.

The main purpose of this study was to identify CYP2C8 genotype-phenotype associations in Japanese patients. The CYP2C8 genotype and phenotype were determined using the real-time PCR method and the clinical response to AZD4547, respectively. Our results showed that the CYP2C8*3 allele was associated with a higher incidence of diarrhea in Japanese patients, and that the genotype was also significantly associated with the AZD4547 dose at which the diarrhea occurred.

This study used a real-time PCR method to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD-5069is a drug that inhibits
 
Response: AZD-5069is a drug that inhibits the proteasome. It is under investigation for the treatment of multiple myeloma.

See also 
 Chloroquine

References 

Category:Pyridines
Category:Experimental cancer drugs
Category:Quinolines
Category:Chloroarenes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD5363is a drug that inhibits
 
Response: AZD5363is a drug that inhibits VEGFR2/3, FGFR1, PDGFRα/β, FLT3, c-Kit and RET. The drug is currently in phase II trials for the treatment of multiple solid tumours and haematological malignancies.^[@bib1],\ [@bib2]^

We have previously shown that ZD6474 (in the absence of doxorubicin) is an effective inhibitor of leukaemia cell survival, growth and proliferation.^[@bib3],\ [@bib4]^ The drug also inhibits the survival of leukaemia cells that are resistant to chemotherapy.^[@bib5]^ In the present study, we show that ZD6474 inhibits the survival and growth of multiple solid tumour cells, including colon cancer cells that are resistant to chemotherapy.

The drug was obtained from Novartis (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  azd6244is a drug that inhibits
 
Response: azd6244is a drug that inhibits sirtuin1, which may have beneficial effects in neurodegenerative diseases, including AD. However, little is known about the potential adverse effects of AZD6244 in the brain. Here, we show that chronic treatment with AZD6244 induces microglial activation and amyloid plaque-associated astrocytosis in the brains of mice. Microglial activation was also observed in the brains of Tg2576 transgenic mice, an animal model of AD, after AZD6244 treatment. Moreover, the level of pro-inflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor-α, was significantly increased in the brain of AZD6244-treated mice. We also found that AZD6244 significantly increased the levels of soluble amyloid precursor protein, amyloid-β (Aβ)40 and Aβ42, which are major Aβ species
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD6738is a drug that inhibits
 
Response: AZD6738is a drug that inhibits ATAD2, a subunit of the Mi-2/NuRD complex. It is currently in clinical trials for use in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Overexpression of ATAD2 is associated with poor prognosis in AML, and the drug is thought to be particularly useful in patients with this type of leukemia.[1]

This drug is not approved for any use in any country.

The chemical name for AZD6738 is N-(2-{3-hydroxy-4-[4-(3-methyl-1,2,4-triazol-1-yl)phenoxy]phenyl}acetyl)glycine, and the chemical formula is C17H17N3O3.

AZD6738 was developed by AstraZeneca and is marketed by Zen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD7648is a drug that inhibits
 
Response: AZD7648is a drug that inhibits Src tyrosine kinase and that is being developed for the treatment of non-small cell lung cancer. This study was designed to determine the potential use of imaging in the early identification of patients who may respond to treatment with AZD7648.

Methods
=======

Patients were treated with AZD7648 in an open-label, non-randomized study. After 24 hours, imaging studies were performed with the investigational drug (IV) and a matched placebo. Dose escalation was possible. The final dose was 100 mg IV. Primary endpoints were changes in the size of tumor lesions.

Results
=======

Thirty-two patients were enrolled and treated. The final dose was 100 mg IV. One patient had a partial response, 11 had stable disease, and 20 had progressive disease. The best overall response was stable disease. Overall, the changes in tumor size from baseline were not statistically significant
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD8186is a drug that inhibits
 
Response: AZD8186is a drug that inhibits the cyclin-dependent kinase CDK9 (Cdk9), a subunit of the positive transcription elongation factor b (P-TEFb). P-TEFb phosphorylates serine 2 (Ser2) of the C-terminal domain of the RNA polymerase II (Pol II) C-terminal domain (CTD), a process that promotes Pol II recruitment to the promoter and elongation of the transcript.^[@bib1]^ CDK9 has emerged as a potential therapeutic target in a variety of diseases, including viral infection,^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ neurodegenerative diseases^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD8931is a drug that inhibits
 
Response: AZD8931is a drug that inhibits the kinase activity of FGFR3. FGFR3 is a receptor tyrosine kinase and its activation is involved in the progression of lung cancer. AZD8931 is a selective inhibitor of FGFR3, and can be used to treat lung cancer. The purpose of this study was to evaluate the anti-tumor activity of AZD8931.

In the study, AZD8931 was used to treat H460, A549, H1299, and H1975 cell lines. The effects of AZD8931 on the proliferation of H460, A549, H1299, and H1975 cells were detected by CCK8 assays. The anti-proliferation activity of AZD8931 in H460, A549, H1299, and H1975 cells was dose-dependent. The anti-proliferation effect of AZD8931 on H460, A549, H
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZD9668is a drug that inhibits
 
Response: AZD9668is a drug that inhibits the growth of colon cancer cells and induces apoptosis, and also has antitumor activity in other types of cancer, such as breast, lung, gastric, ovarian, and cervical cancer \[[@B38-ijms-17-00817],[@B39-ijms-17-00817]\].

In our study, the human colon cancer cell line HCT116 was used to investigate the effects of UDCA and AZD9668 on the cell viability and cell cycle distribution. The results showed that UDCA and AZD9668 could decrease the cell viability and induce G1/S cell cycle arrest.

Apoptosis is a genetically controlled process of cell death, and plays a crucial role in regulating normal development and homeostasis of the body \[[@B40-ijms-17-00817]\]. In the present study, UDCA and AZD9668 treatment significantly induced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azelastineis a drug that inhibits
 
Response: Azelastineis a drug that inhibits phospholipase A2 (PLA2), the enzyme that releases arachidonic acid from the membrane. It is marketed as azelastine hydrochloride in the form of tablets, aerosol, and nasal spray. It is used to treat allergic rhinitis, chronic urticaria, and acute asthma. The use of azelastine in the treatment of these diseases has been approved by the U.S. Food and Drug Administration (FDA). It is the most widely prescribed antihistamine for the treatment of allergic rhinitis in the United States.

1.1 Objective

The objective of this study was to evaluate the effects of azelastine on global activity of PLA2 and its effect on the inhibition of histamine release.

1.2 Design

Azelastine hydrochloride was selected for the evaluation of its effect on PLA2. The inhibition of PLA2 by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azeliragonis a drug that inhibits
 
Response: Azeliragonis a drug that inhibits S-adenosylhomocysteine hydrolase, an enzyme that recycles methyl groups in the cells. The product of the enzyme's activity is S-adenosylhomocysteine, which can be recycled to form methionine, a component of hemoglobin and other proteins. Azeliragonis was developed by L-Azacytidine (Zelzar) Pharmaceuticals. Zelzar has filed for a BLA for a formulation of azeliragonis in oral solution and tablets.

Efficacy and Safety

Zelzar's BLA is for a formulation of azeliragonis in oral solution and tablets. Zelzar's formulation is indicated for the treatment of moderate to severe anemia in patients with chronic kidney disease (CKD) who are receiving dialysis. In clinical trials, the oral solution of azeliragonis at doses of 1 to 4 mg/kg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azelnidipineis a drug that inhibits
 
Response: Azelnidipineis a drug that inhibits the calcium channel in the vascular smooth muscle cells and thus reduces blood pressure.\[[@ref1]\] The recommended dose is 4 mg once daily in the morning. Azelnidipine has a long half-life and is eliminated mainly through metabolism. Its metabolites, (N)-desmethylazelnidipine and (E)-desmethylazelnidipine, have a longer half-life and are also eliminated mainly through metabolism.\[[@ref2]\] A drug-drug interaction study conducted in healthy volunteers showed that azelnidipine significantly increased the plasma concentrations of nifedipine, a calcium channel blocker, and digoxin, a potent CYP3A4 inhibitor.\[[@ref3]\] A subsequent study confirmed that the increase in plasma concentrations of nifedipine and digoxin was due to inhibition of CYP3A4.\[[@ref
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azilsartanis a drug that inhibits
 
Response: Azilsartanis a drug that inhibits the angiotensin II receptor AT1 and its metabolites. In Japan, a phase III clinical trial was conducted for chronic heart failure patients, which showed that the drug was superior to other antihypertensive drugs in terms of both blood pressure and left ventricular function. The drug was approved for the treatment of chronic heart failure in September 2004. However, a large phase III clinical trial for the treatment of diabetic nephropathy showed that the drug had a beneficial effect on proteinuria and blood pressure, but did not show a significant effect on renal function. It was also reported that there was no significant difference in the occurrence of stroke and other cardiovascular events between the drug and other antihypertensive drugs. This drug is expected to be used for the treatment of patients with diabetic nephropathy. In addition, it has been reported that the drug is effective for patients with chronic heart failure who are resistant to ACE inhibitor therapy.

2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azithromycinis a drug that inhibits
 
Response: Azithromycinis a drug that inhibits melanin synthesis in mammals.
A substance that inhibits melanin synthesis in mammals has been isolated from the culture broth of a strain of Penicillium islandicum (Bats. & Fell) Thom (Hib. Mycol. 2: 247, 1968). The substance has the following formula: ##STR2## wherein R.sub.1 is H, Cl, Br, or OH; R.sub.2 is H, CH.sub.3, or OH; and R.sub.3 is H, CH.sub.3, or OH. The substance is referred to herein as "compound A."
Compound A has been shown to be effective in vivo against guinea pigs infected with Brugia malayi (see, generally, J. Antibiotics, 30: 735, 1977). However, compound A is not commercially available.
The present invention provides a method for inhibiting the synthesis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azlocillinis a drug that inhibits
 
Response: Azlocillinis a drug that inhibits the production of tumor-promoting inflammatory cytokines. A natural compound, this medication is used to treat the symptoms of asthma, inflammatory bowel disease, and other conditions. Azlocillin may also be used to prevent bacterial infection in premature babies.

USES

Treatment of acute bacterial infections, including pneumonia.

IMPORTANT SAFETY INFORMATION

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any signs of a serious allergic reaction, including rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

What is the most important information I should know about AZLOCILLIN?

Do not use AZLOCILLIN if you are allergic to any other medicines that contain the drug fosfomycin or other penicillins.

AZLOCILLIN can cause low blood
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Azodicarbonamideis a drug that inhibits
 
Response: Azodicarbonamideis a drug that inhibits platelet aggregation and increases the bleeding time. It is a heterocyclic compound with the formula NH2C(O)CH2NH2. It is used as a synthetic resin for making chewing gum, and in various food and pharmaceutical products.

Uses

Azodicarbonamide is used in chewing gum and confectionary to prevent sticking.

Azodicarbonamide is also used in the manufacturing of polyurethane foams, flexible foams, elastomers, coatings, films, sealants, adhesives, as a foam stabilizer, and as a cross-linking agent.

It is also used as a polymerization initiator, and in coatings, paints, adhesives, binders, and sealants.

It is used as a plasticizer in pharmaceuticals and food products, and is an additive to polymers and in the manufacture of rubber, el
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  AZOLIDis a drug that inhibits
 
Response: AZOLIDis a drug that inhibits P-glycoprotein (P-gp) and also induces the expression of P-gp in cells. This drug can inhibit the function of P-gp and then increase the absorption of other drugs and P-gp substrates. As a result, it can decrease the concentration of drugs and P-gp substrates in the blood, leading to their side effects.

In this paper, we analyzed the correlation between drug-induced P-gp expression and the drug's therapeutic index. The study provides a basis for determining whether a drug is suitable for combination therapy.

2. Materials and Methods {#sec2-ijms-21-03987}
========================

2.1. Data Collection {#sec2dot1-ijms-21-03987}
--------------------

Data from PubChem, DrugBank, and PharmGKB were collected to obtain all P-gp inhibitors and substrates in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bacitracinis a drug that inhibits
 
Response: Bacitracinis a drug that inhibits the bacterial uptake of nutrients from the environment. Because the bacteria are deprived of nutrients, they die. Bacitracin is one of the few drugs that can treat antibiotic-resistant infections. However, the use of bacitracin is limited because it is not available in a sterile form. It is available in powder form and is added to the feed.

Bacitracin was first introduced in the 1950s. It was not considered an effective drug because it did not completely stop the growth of bacteria in the intestinal tract. The only way to use bacitracin was to add it to the feed, which is not a practical solution. A drug that can be given in a sterile form is needed.

In recent years, a number of bacteria have become resistant to antibiotics. To overcome this problem, scientists have developed drugs that are used to inhibit the growth of bacteria. This class of drugs is called bacteri
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BAF312is a drug that inhibits
 
Response: BAF312is a drug that inhibits IKK-β and is currently being evaluated in phase II clinical trials for the treatment of chronic lymphocytic leukemia (CLL). Here we investigated the impact of IKK-β inhibition on the immune response to leukemia and lymphoma in vitro and in vivo. We found that BAF312 decreased proliferation of CLL cells and impeded leukemia cell adhesion to lymph node cells and VCAM-1, E-selectin, and ICAM-1 on endothelial cells. Furthermore, BAF312 reduced CLL cell homing to the bone marrow, as well as homing of leukemia cells to the spleen and liver. BAF312 also inhibited the adhesion of lymphoma cells to endothelial cells and their homing to lymph nodes. These effects were partially dependent on IKK-β. Our data demonstrate that IKK-β is an important regulator of the adhesion of leukemia and lymphoma cells to vascular cells, as well as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Baicaleinis a drug that inhibits
 
Response: Baicaleinis a drug that inhibits the growth of lung cancer.

The scientists looked at the activity of a single cell type, the lung cancer cell line A549. The scientists then found that they could control the size of the tumour by turning on and off a gene that is active in the cell. They also found that the size of the tumour can be reduced by changing the temperature of the cells.

The team of scientists, led by Professor Bert Vogelstein from Johns Hopkins University School of Medicine in Baltimore, Maryland, said that it is a step forward in the treatment of lung cancer. They said that the drug may be available in a few years.

If you want to find out more about lung cancer, visit our Lung Cancer page.

There is no one size fits all approach to lung cancer treatment, which is why each patient’s treatment plan is tailored to their needs.

Lung cancer is one of the most common cancers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Baicalinis a drug that inhibits
 
Response: Baicalinis a drug that inhibits angiogenesis, suppresses tumor growth and improves the quality of life in patients with cancer. We investigated the anti-angiogenic and anti-tumor effects of baicalin in tumor-bearing mice. The anti-angiogenic effect of baicalin was evaluated in vivo using the chick chorioallantoic membrane (CAM) assay and in vitro using human umbilical vein endothelial cells (HUVECs). The anti-tumor effect of baicalin was evaluated in vivo using a B16 melanoma-bearing mouse model and in vitro using a B16 melanoma cell line. Baicalin inhibited the CAM angiogenesis induced by VEGF and HUVECs tube formation. The treatment of B16 melanoma-bearing mice with baicalin reduced the tumor volume and the number of metastatic nodules in the lung and liver. In addition, baicalin suppressed the VEGF
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Balofloxacinis a drug that inhibits
 
Response: Balofloxacinis a drug that inhibits the growth of Microsporum canis.
Microsporum canis is a dermatophyte which is pathogenic to humans. It is the etiological agent of tinea capitis and tinea corporis. The development of an effective treatment against M. canis is of high priority. Balofloxacin is a new fluoroquinolone drug. Its chemical structure is similar to other fluoroquinolones, but it has some advantages. The present study was designed to evaluate the in vitro and in vivo antifungal activity of balofloxacin. Minimum inhibitory concentration (MIC) of balofloxacin was determined by the broth microdilution method and the fungicidal activity was evaluated by the fluconazole assay. Balofloxacin had good in vitro activity against M. canis and the inhibitory effect was dose-dependent. The MIC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Baloxaviris a drug that inhibits
 
Response: Baloxaviris a drug that inhibits the replication of the virus

Vaccines against yellow fever are made from a live, weakened virus. In a yellow fever vaccine, the yellow fever virus replicates in the human body, causing the immune system to make antibodies against it. The immune system recognizes the virus as foreign and kills it, preventing the virus from infecting other people.

There are no vaccines against the other flaviviruses. A vaccine is a very risky thing to make, because the live virus could re-infect the person who has received it. This is the risk of live, weakened virus vaccines, and the risk is so high that these vaccines are not used for people who have never been vaccinated against yellow fever or who have not been vaccinated in a long time.

Live, weakened virus vaccines have been used for more than 100 years. They are very safe and effective. The problem is that they can cause very serious and even deadly complications in some people
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bambuterolis a drug that inhibits
 
Response: Bambuterolis a drug that inhibits the growth of cancer cells in human tumors.

Bambuterol has been reported to have some effects in improving sleep disorders and its toxicity is very low.

4.5. Calcium Channel Blockers

There are three types of calcium channels, namely, L-type, T-type and N-type. In general, the N-type channel is found in the sympathetic nerves and the T-type channel is found in the peripheral and central nervous system.

Calcium channel blockers have been used for treating neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and stroke.

Calcium channel blockers have been shown to have potential to be used for treating gastrointestinal diseases such as diarrhea, constipation, chronic constipation, gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS).

In addition, calcium channel blockers have been reported
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Baricitinibis a drug that inhibits
 
Response: Baricitinibis a drug that inhibits the Janus kinase 1 and 2 (JAK1 and JAK2), which is used to treat rheumatoid arthritis (RA) and other autoimmune diseases. It is administered orally once a day. It is also known as tofacitinib, a generic name.

The American College of Rheumatology and the European League Against Rheumatism have issued recommendations on the use of tofacitinib for the treatment of RA. The recommendations, which are published in the Rheumatology (2013; 52[Suppl. 1]) and the Journal of Rheumatology (2013; 50[Suppl. 1]) respectively, state that tofacitinib is effective in improving symptoms, physical function and quality of life in patients with RA who have an inadequate response to conventional DMARDs (disease-modifying anti-rheumatic drugs).

One of the key findings
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BAYis a drug that inhibits
 
Response: BAYis a drug that inhibits the action of the hormone, thyroid-stimulating hormone (TSH).

**BAYW:** abbreviation for _Baylis-Haber-Weiss_ reaction.

**b-carotene:** the yellow pigment that makes carrots, pumpkins, and winter squash yellow.

**b.c. (biphasic control):** _see_ Control.

**B cell:** a lymphocyte that has a round nucleus and is found in the thymus, bone marrow, and lymph nodes.

**B cell lymphoma:** _see_ Burkitt's lymphoma.

**BCG:** abbreviation for _Bacillus Calmette-Guérin_ (or _Mycobacterium bovis_ ), a widely used tuberculosis vaccine.

**BCG vaccination:** _see_ Tuberculosis.

**B cell:
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BAY57-1293is a drug that inhibits
 
Response: BAY57-1293is a drug that inhibits LPA-induced cell migration and invasion in the human breast cancer cell line MCF-7, as well as in the mouse model of breast cancer. It is one of the first synthetic LPA analogs to be used as an antitumor agent.

LPA signaling is a critical regulator of breast cancer metastasis and has been linked to the progression of many cancers, including breast cancer.[@b1-ott-12-991],[@b2-ott-12-991] Recently, it was demonstrated that LPA signaling plays a crucial role in the process of breast cancer metastasis, especially in bone metastasis. LPA is an important factor in the regulation of the tumor microenvironment, which is associated with tumor progression, including tumor growth, migration, and invasion.[@b3-ott-12-991]

In breast cancer, the role of LPA signaling in cancer progression is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bazedoxifeneis a drug that inhibits
 
Response: Bazedoxifeneis a drug that inhibits the effects of estrogens on the body. Bazedoxifene has no effect on sex hormones such as estrogen or progesterone, and so has no effect on the development of the reproductive organs.

The side effects of bazedoxifene include abnormal menstrual bleeding, and breast pain or tenderness.

The drug bazedoxifene is taken by mouth, and has been used to treat women with an early stage of breast cancer.

Bazedoxifene is also known as bazedoxifene disodium, and bazedoxifene hydrochloride.

Bazedoxifene has been used to treat women with breast cancer, as well as women with osteoporosis.

Bazedoxifene is taken by mouth, and has been used to treat women with an early stage of breast cancer.

Bazedoxifene is also known as bazedox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BBI608(Napabucasinis a drug that inhibits
 
Response: BBI608(Napabucasinis a drug that inhibits angiogenesis in cancer). Also included in the present study is a relatively new anti-angiogenic agent, ABT-199 (Sutent). This drug is currently being tested in combination with BBI608 in several trials in lung cancer, melanoma, and pancreatic cancer. It is an orally active inhibitor of the BCL2 family protein BCL2L1 (BCL2-like 1) and has been shown to be efficacious in xenograft models of various cancers \[[@CR50]\].

Drugs that interfere with the EGFR pathway, such as the anti-EGFR antibodies cetuximab and panitumumab, and small molecule EGFR tyrosine kinase inhibitors such as erlotinib and gefitinib, have been extensively studied in lung cancer. The efficacy of these agents in combination with cytotoxic chemotherapy has been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Beclomethasoneis a drug that inhibits
 
Response: Beclomethasoneis a drug that inhibits inflammation by binding to glucocorticoid receptors in the cells. It is used for treating asthma, rheumatoid arthritis, lupus, and other inflammatory conditions. It can also be used to prevent acute graft-versus-host disease. It is available as the metered-dose inhaler (MDI) and the aerosol inhaler (AI).

Tablets, Oral Sprays, Injectable, and Nasal Spray

Generic Name: Beclomethasone

Brand Name:

Dipropionate, Nasal, Solu-Medrol, Solu-Tab, Vancocin, Vancocin XR

What is Beclomethasone?

Beclomethasone dipropionate is a corticosteroid. It is used to treat allergic rhinitis and asthma.

It is available as the metered
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Belotecanis a drug that inhibits
 
Response: Belotecanis a drug that inhibits cell division in cancer cells by blocking their ability to divide. It is approved for use in cancer treatment in some countries, but is still under development in others. Belotecanis is in a class of drugs called topoisomerase inhibitors.

How does belotecanis work?

Belotecanis works by interfering with a protein called topoisomerase. Topoisomerase controls the way DNA is twisted and twisted around other DNA and other proteins in a cell. Belotecanis works by blocking the action of topoisomerase, which in turn stops the cell from dividing.

Belotecanis also affects another protein called tubulin. Tubulin is a protein that helps the cell to form a part of the cell wall called the microtubule. Belotecanis can interfere with the microtubule, which stops the cell from dividing.

What is the mechanism
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bemegrideis a drug that inhibits
 
Response: Bemegrideis a drug that inhibits Nogo receptor 1, a protein that has been linked to the inhibition of neurogenesis.

To test the potential of bemegrideis to improve cognitive function in aged rodents, the team led by Dr. Hua Du of University of Texas Health Science Center San Antonio and her colleagues gave bemegrideis to young and aged rats.

The researchers administered bemegrideis (or placebo) to aged rats for three weeks and then assessed the rats’ cognitive function.

They found that the bemegrideis group performed better on a test that measures learning and memory.

The researchers also found that bemegrideis treatment reduced the levels of Nogo receptor 1 protein in the brains of the aged rats.

The study was published in the Journal of Alzheimer’s Disease.

About 9% of the world’s population is 65 years old or older. This number
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benazeprilis a drug that inhibits
 
Response: Benazeprilis a drug that inhibits angiotensin-converting enzyme (ACE). It is used to treat high blood pressure, heart failure, and diabetic kidney disease.

Name: Benazepril

Generic Name: enalapril

Active Ingredient: enalapril

Mechanism of Action: Benazepril blocks the conversion of angiotensin I to angiotensin II, an octapeptide that increases blood pressure by causing vasoconstriction. Angiotensin II also causes sodium and water retention and stimulates the secretion of aldosterone, a hormone that causes the kidneys to reabsorb sodium and retain water. Benazepril inhibits the conversion of angiotensin I to angiotensin II, which causes vasodilation and diuresis.

Package: 20 mg/tablet

Effectiveness: 100%

Duration: 1-12 months

P
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bendamustineis a drug that inhibits
 
Response: Bendamustineis a drug that inhibits the enzyme topoisomerase II and induces DNA damage. It is indicated in the treatment of chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and Hodgkin's lymphoma (HL). It is administered intravenously.

**Therapeutic Effect:**

Induces apoptosis in leukemia cells.

#####  PHARMACOKINETICS

Rapidly, well absorbed after IV administration. Peak plasma concentration occurs in 2–4 hrs. Protein binding: 97%. Widely distributed to tissues. Metabolized in liver. Excreted in urine (80%), feces (5%). Not removed by hemodialysis. **Half-life:** 3–4 hrs.

#####    ​LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** May cause fetal harm. Unknown if distributed in breast milk
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bendazacis a drug that inhibits
 
Response: Bendazacis a drug that inhibits the enzyme 11-β-hydroxysteroid dehydrogenase type 1 (11-β-HSD1). It is used for the treatment of diabetes and some forms of cancer ([@B1]). In addition, it is used in the treatment of inflammatory diseases such as rheumatoid arthritis, asthma, and Crohn\'s disease ([@B2]). The drug was originally approved in 1999 for the treatment of type 2 diabetes. It has been used off-label in patients with type 1 diabetes ([@B3]). However, its mechanism of action and effectiveness in type 1 diabetes is not well understood.

The 11-β-HSD1 enzyme catalyzes the conversion of inactive cortisone to active cortisol ([@B4]). It is expressed in many tissues, but highest levels are found in the liver, adipose tissue, and kidney ([@B5]). In the liver, 11-β-HSD1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  bendroflumethiazideis a drug that inhibits
 
Response: bendroflumethiazideis a drug that inhibits the sodium-chloride reabsorption in the thick ascending limb of Henle's loop. This leads to a decrease in plasma concentration of sodium, water, and potassium, and to an increase in the concentration of chloride and bicarbonate.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BENEMIDis a drug that inhibits
 
Response: BENEMIDis a drug that inhibits the enzyme phosphodiesterase type 5 (PDE5) in the penis and decreases blood flow to the penis, thereby preventing erection. Common side effects include headache, flushing, chest pain, nausea, and diarrhea.

BENICILLINDrugs used to treat urinary tract infections. The active ingredient is the chemical antibiotic ampicillin.

BENZAMYCINDrugs used to treat bacterial infections. The active ingredient is the chemical antibiotic benzoic acid.

BENZOTAMINEDrugs used to treat bacterial infections. The active ingredient is the chemical antibiotic benzotamin.

BEPIRBUTOINAOral drug used to treat overactive bladder. The active ingredient is the chemical bisphenol A.

BERBERINEAn antidepressant. The active ingredient is the chemical alkaloid berberine.

BERBERINE HYDROCHLOR
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bengeninis a drug that inhibits
 
Response: Bengeninis a drug that inhibits GSK-3 and causes upregulation of protein synthesis and protein synthesis-related signaling pathways \[[@B56-ijms-20-01459]\]. Moreover, activation of mTOR signaling pathways by inhibition of GSK-3 in the brain enhances long-term memory \[[@B57-ijms-20-01459]\].

Bromocriptine (Br-2-C-P) is a D2 agonist that stimulates the synthesis and release of DA. In the frontal cortex, Br-2-C-P induces phosphorylation of Akt and GSK-3β \[[@B58-ijms-20-01459]\]. Br-2-C-P also activates mTOR, which in turn enhances protein synthesis, and enhances protein synthesis-related signaling pathways \[[@B59-ijms-20-01459]\]. Moreover, in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BENICARis a drug that inhibits
 
Response: BENICARis a drug that inhibits the enzyme that converts the folic acid in food into a form that the body can use. This prevents the folic acid from being absorbed into the body. Therefore, B-complex vitamins cannot be used for food, as this process has already taken place. B-complex vitamins are given orally, usually in tablet form.

#####  ♦ CLASSIFICATION

**PHARMACOTHERAPEUTIC:** Antioxidant. **CLINICAL:** Anticonvulsant.

#####  USES

Prevention of neural tube defects in women of childbearing age. Treatment of the symptom complex of phenytoin toxicity.

#####  PRECAUTIONS

**Contraindications:** Hypersensitivity to phenytoin. **Cautions:** Renal impairment, elderly, history of hepatic disease.

#####  ACTION

Prevents
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benidipineis a drug that inhibits
 
Response: Benidipineis a drug that inhibits the entry of calcium into vascular smooth muscle cells and relaxes vascular smooth muscle. It is used to treat hypertension and angina pectoris. Benidipineis a drug that inhibits the entry of calcium into vascular smooth muscle cells and relaxes vascular smooth muscle. It is used to treat hypertension and angina pectoris.

Benidipine is a calcium antagonist. It works by blocking calcium entry into vascular smooth muscle cells. This action reduces the ability of these cells to contract. Benidipine reduces blood pressure by causing the heart to beat more slowly, thus reducing the amount of blood ejected into the peripheral circulation.

Benidipine is a calcium antagonist. It works by blocking calcium entry into vascular smooth muscle cells. This action reduces the ability of these cells to contract. Benidipine reduces blood pressure by causing the heart to beat more slowly, thus reducing the amount of blood ejected into the peripheral circulation.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BENOQUINis a drug that inhibits
 
Response: BENOQUINis a drug that inhibits the enzyme that metabolizes dopamine. It is the main active ingredient in several antipsychotic drugs (also known as neuroleptics).

The drug is used in the treatment of schizophrenia and mania associated with bipolar disorder. It is also used in the treatment of major depressive disorder (MDD) in combination with an antidepressant.

BENOQUIN has a similar effect to haloperidol (HALO), but it is generally less sedating. It is not associated with the same risk of extrapyramidal symptoms (EPS).

In clinical practice, the following table compares the side effects of BENOQUIN and HALO:

Side effect

BENOQUIN

HALO

Abnormal movements

3%

2%

Akathisia

11%

2%

Anorexia

3%

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benserazideis a drug that inhibits
 
Response: Benserazideis a drug that inhibits the enzyme catechol-O-methyltransferase. This enzyme inactivates the catecholamines, which include norepinephrine and epinephrine. Benserazide increases the levels of the catecholamines in the body. It is also used to treat people with Parkinson’s disease.

Benserazide is also used for other conditions as determined by your doctor.

Benserazide may be available under multiple brand names.

Benserazide is typically taken by mouth.

It is usually taken once a day.

Your doctor may need to gradually increase the dose of benserazide.

Side effects may include:

nausea

vomiting

heartburn

constipation

sleepiness

numbness

loss of appetite

headache

If you notice any other effects, check with your
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bentamapimodis a drug that inhibits
 
Response: Bentamapimodis a drug that inhibits activation of the NLRP3 inflammasome, an immune-regulatory protein complex that promotes the maturation of pro-inflammatory cytokines IL-1β and IL-18. By blocking the inflammasome, it can block the release of inflammatory cytokines. It is an oral treatment for ulcerative colitis (UC) that is given once a day.

It was originally developed by Roche and is marketed by Vifor Pharma in Europe and by Almirall in the United States.

Adverse effects 
The adverse effect profile of bentamapimod is similar to that of other anti-TNF therapies. In the phase 3 trial for ulcerative colitis, the most commonly reported adverse events were headache, upper respiratory tract infection, diarrhoea, abdominal pain, nausea, fatigue, arthralgia, and back pain.

Contraindications 

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  bentiromideis a drug that inhibits
 
Response: bentiromideis a drug that inhibits inositol monophosphate (IP1) accumulation, and therefore inhibits IP3-mediated Ca2+ release. In order to evaluate the effects of theophylline on calcium mobilization, the authors used cultured astrocytes from Wistar rats. The results showed that theophylline is able to induce a significant increase in [Ca2+]i when added to the culture medium. The effect was not mediated by cyclic AMP, since theophylline did not change the cyclic AMP levels in the culture medium. This action of theophylline was inhibited by cyclic AMP-dependent protein kinase inhibitors, such as KT-5720 and H-8. The effect of theophylline was not due to a specific inhibition of IP3-mediated Ca2+ release, since the drug did not alter the increase in [Ca2+]i induced by the agonist of IP3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzamidineis a drug that inhibits
 
Response: Benzamidineis a drug that inhibits AChE. In fact, the main indication of this drug is to treat the symptoms of AD. This drug was developed and patented in 1949 by Hoechst, a German pharmaceutical company, and it was approved by the US Food and Drug Administration (FDA) in 1966. Benomyl is a derivative of benzamidine, and it is still in use.

Benzamidine is a heterocyclic compound, and it has the general formula (1) as shown in [Figure 1](#F1){ref-type="fig"}. It is an aromatic heterocyclic compound that is used as an enzyme inhibitor. This drug is used in the treatment of AD, and it is also used in the treatment of Parkinson\'s disease and other diseases.

![Structure of benzamidine](JPBS-7-522-g001){#F1}

Benzamidine can be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzathineis a drug that inhibits
 
Response: Benzathineis a drug that inhibits cell division by blocking a key step in mitosis.

A novel, fast-acting, and short-term treatment for patients with multiple myeloma who have failed conventional chemotherapy and who are ineligible for stem cell transplantation.

Zoledronic acid is a bone-targeted agent.

Ketoconazole is an imidazole derivative used to treat fungal infections.

Etoposide is a synthetic derivative of podophyllotoxin.

Trastuzumab is a humanized monoclonal antibody that binds to the HER2 receptor and prevents it from signaling in cancer cells.

Ondansetron is a serotonin receptor antagonist.

Irinotecan is a water-soluble analog of camptothecin.

Carboplatin is a platinum compound.

Dexamethasone is a corticosteroid.

B
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzbromaroneis a drug that inhibits
 
Response: Benzbromaroneis a drug that inhibits 11-beta-hydroxysteroid dehydrogenase (11-HSD) activity. Inhibiting 11-HSD activity increases cortisone (a glucocorticoid) levels, which can reduce inflammation. It is also used in the treatment of non-alcoholic steatohepatitis (NASH).

Albiflorin is an iridoid glycoside. It is derived from the dried root of Pueraria lobata, and has a variety of pharmacological properties, including hepatoprotective and anti-inflammatory effects. It has been shown to inhibit hepatic stellate cell (HSC) activation and the production of collagen in vitro and in animal models.

Tetrandrine is a bisbenzylisoquinoline alkaloid isolated from the root of Stephania tetrandra. It is used to treat patients with chronic hepatitis B.

Sily
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzethoniumis a drug that inhibits
 
Response: Benzethoniumis a drug that inhibits the action of acetylcholinesterase, a naturally occurring enzyme that is responsible for the breakdown of acetylcholine. By inhibiting the breakdown of acetylcholine, benethoniumcan help to prevent muscle contractions. This is done by increasing the amount of acetylcholine in the body, which helps to increase the amount of neurotransmitters that are available to the nerves in the body. Benethoniumcan be used to treat muscle spasms, cramps, and spasticity.

This medication is available only with your doctor's prescription.

You should not use this medication if you are allergic to benethonium, or if you have had a severe allergic reaction to it.

This medication may have side effects. Tell your doctor if you have any unusual or bothersome symptoms that you want to know about.

There may be other drugs that can be used to treat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzocaineis a drug that inhibits
 
Response: Benzocaineis a drug that inhibits the enzyme, phosphodiesterase. It was first introduced in the late 1960s and is still in use today. It is used as a topical anesthetic for minor procedures such as shots and dental work.

B

Barbiturate. Barbiturates are drugs that cause a state of drowsiness. They are sedatives and have been used for years in veterinary medicine. Barbiturates work by acting on the brain to inhibit the activity of the central nervous system. The primary function of the brain is to control the body's activities. The body controls most of its functions by sending nerve impulses to the brain.

Barbiturate Poisoning

In humans, barbiturates are usually prescribed to treat anxiety and insomnia. However, if a person takes a barbiturate in an attempt to commit suicide, he or she will experience drowsiness, nausea, and an increase in blood pressure and pulse. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzoicis a drug that inhibits
 
Response: Benzoicis a drug that inhibits some cytochrome P450 isozymes. It is used in the treatment of benign prostatic hypertrophy and hormone-sensitive breast cancer.

NON-Hormonal contraception

Levonorgestrel, an oral contraceptive, is also used to treat breast cancer.

Aromatase inhibitors

The drug Arimidex is an aromatase inhibitor that blocks the conversion of androgens to estrogens in breast cancer cells. It is used in postmenopausal women with advanced disease.

Mastectomy

The drug Neoadjuvant is used after a mastectomy. It is an anticancer agent used to shrink the tumor before surgery. It may also be used to treat metastatic disease.

Oral contraceptives

Oral contraceptives are used to treat breast cancer in premenopausal women.

Tamoxifen

Tamoxifen is used to treat breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzonatateis a drug that inhibits
 
Response: Benzonatateis a drug that inhibits the activity of monoamine oxidase A (MAO-A) \[[@r3]\]. It is widely used for the treatment of neurological diseases, such as depression and anxiety disorders \[[@r4]\]. In the United States, benzonatate is used as a veterinary drug. However, benzonatate is not approved for use in cats in Japan.

The enzyme MAO-A, which is located in the outer membrane of mitochondria, metabolizes neurotransmitters such as serotonin and dopamine \[[@r1]\]. Inhibition of MAO-A is therefore expected to have a therapeutic effect on neurological diseases \[[@r4]\]. However, benzonatate inhibits not only MAO-A but also MAO-B \[[@r2]\]. Therefore, benzonatate has a number of side effects, such as sedation, drowsiness
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  benzthiazideis a drug that inhibits
 
Response: benzthiazideis a drug that inhibits sodium reabsorption in the kidney, leading to natriuresis and diuresis. It is used in the treatment of hypertension, heart failure, edema, and renal disease.

INDICATIONS: It is prescribed for the treatment of hypertension and edema.

CONTRAINDICATIONS: Anuria, hypersensitivity to sulfonamides, or known hypersensitivity to other sulfonamides prohibits its use.

WARNINGS: It should be used with caution in patients with severe heart failure and severe hypertension. Drowsiness, nausea, and headache may occur.

ADVERSE EFFECTS: Among the more serious adverse effects are azoospermia, increased risk of hepatic failure, hypokalemia, hyperuricemia, agranulocytosis, and neutropenia.

####  Triamcinolone Acetonide

tr **a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benztropineis a drug that inhibits
 
Response: Benztropineis a drug that inhibits the dopamine transporter. It was developed as a potential treatment for schizophrenia, but it is now used to treat other disorders. The drug is also called a tertiary amine and it is a phenyltropane. It is sometimes used in combination with other drugs.

Side Effects

There are many different types of side effects. The following is a list of the most common side effects:

Diarrhea

Constipation

Abdominal pain

Headache

Nausea

Vomiting

Sedation

Psychosis

Anxiety

Dizziness

Fatigue

Muscle weakness

Cough

Dry mouth

Sexual dysfunction

Depression

Urinary retention

Difficulty urinating

Drowsiness

Fatigue

Impotence

Dizziness

Fatigue

Impot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzydamineis a drug that inhibits
 
Response: Benzydamineis a drug that inhibits the production of prolactin in the pituitary gland. It has been used to treat urinary tract infections, as a treatment for allergic reactions and to treat non-infectious vaginal candidiasis.

It is also used to treat genital herpes infections.

The drug is sometimes used to treat the sexual side effects of other medications, such as birth control pills.

Prolactin is a hormone produced by the pituitary gland that stimulates lactation in female animals and milk production in humans.

In humans, prolactin is responsible for the production of breast milk. It also stimulates the growth of breast tissue.

The production of prolactin is inhibited by bromocriptine and other drugs.

In people who are experiencing painful sexual intercourse, bromocriptine can be used to reduce the amount of prolactin that is produced.

It can also be used to treat other symptoms
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Benzylpenicillinis a drug that inhibits
 
Response: Benzylpenicillinis a drug that inhibits the action of bacteria that cause urinary tract infections (UTIs). It is most often prescribed to women after childbirth to prevent UTIs.

Moxifloxacin, also called Floxin, is a prescription medicine used to treat bacterial infections, such as sinusitis, ear infections, strep throat, UTIs, and pneumonia.

Ampicillin is a prescription antibiotic used to treat infections caused by bacteria, such as sinusitis, ear infections, strep throat, UTIs, and pneumonia.

Fluoroquinolones are a class of antibiotics that have an effect on bacteria by interfering with the ability of the bacteria to make a protein that helps them reproduce. They are most commonly used to treat bacterial infections, such as sinusitis, ear infections, strep throat, UTIs, and pneumonia.

Amoxicillin is a prescription antibiotic used to treat bacterial infections, such as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  bepheniumis a drug that inhibits
 
Response: bepheniumis a drug that inhibits the enzyme phenylalanine hydroxylase. It is used to treat children with phenylketonuria.

bepheniumis an investigational drug. It is under development for the treatment of phenylketonuria. It may also be useful for other conditions as yet undetermined. Bephenium has not yet been approved by the U.S. Food and Drug Administration (FDA).

CASRN [Molecule]

A chemical compound, bephenium, that is under investigation as a potential treatment for phenylketonuria.

c.160[CASRN: 1453-46-9]

bephenium,

bephenium(I) is a drug that inhibits the enzyme phenylalanine hydroxylase. It is used to treat children with phenylketonuria.

bepheniumis an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bepotastineis a drug that inhibits
 
Response: Bepotastineis a drug that inhibits histamine H1 receptor, and is used for allergic rhinitis and pruritus. Bepotastine has a unique chemical structure, which differs from those of other antihistamines, and is expected to have an improved safety profile. We performed a phase I study to evaluate the pharmacokinetics, safety, and tolerability of bepotastine in healthy male volunteers. The doses studied were 10, 30, and 100 mg. In addition, the pharmacokinetics of bepotastine and its active metabolite (M1) were evaluated in the fasting state and after a standard breakfast. The pharmacokinetic parameters were estimated by noncompartmental analysis. All of the treatments were well tolerated, and no serious adverse events were observed. The 90% confidence intervals for the Cmax and AUC0-infinity of bepotastine and M1 after administration of 10 mg were within the standard ranges. The pharmac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bepridilis a drug that inhibits
 
Response: Bepridilis a drug that inhibits K^+^ channels and is a precursor of the new K^+^ channel activator (+)-2-(3-methyl-2-oxo-1,2-dihydroquinazolin-6-yl)-N-phenylacetamide (MK-196). It has been demonstrated that bepridil has a beneficial effect on heart failure \[[@B1]\].

Sodium-dependent calcium transport is inhibited by bepridil in the myocardium \[[@B2]\]. Bepridil inhibits the influx of Ca^2+^ through L-type Ca^2+^ channels in the plasma membrane of cardiac myocytes \[[@B3]\]. In addition, bepridil increases the refractory period of the cardiac action potential \[[@B4]\].

The antiarrhythmic activity of bepridil is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Berberineis a drug that inhibits
 
Response: Berberineis a drug that inhibits Na^+^/K^+^-ATPase in the plasma membrane of cancer cells, thereby inducing apoptosis \[[@B12-ijms-21-03987],[@B13-ijms-21-03987]\]. This drug has been used in China for the treatment of hyperlipidemia and metabolic syndrome, and it has been approved by the Food and Drug Administration (FDA) in the United States for the treatment of type 2 diabetes mellitus \[[@B12-ijms-21-03987],[@B13-ijms-21-03987]\]. Berberine was also shown to induce apoptosis in human cancer cells, including those of the breast, colon, liver, and pancreas \[[@B12-ijms-21-03987],[@B13-ijms-21-03987]\].

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bergaptenis a drug that inhibits
 
Response: Bergaptenis a drug that inhibits the production of cholesterol in the body. It is used in treating atherosclerosis, peripheral vascular disease, and in decreasing the risk of stroke. It can also be used in combination with other drugs to treat high cholesterol.

It is a member of the spirostanol saponin family and is found in a variety of plants including the aloe and the ginseng.

The active ingredients of the drug are the saponins and sapogenins. They are very similar to cholesterol and bind to the same receptor in the liver. This results in the inhibition of the production of cholesterol.

The drug was developed by Pfizer and has been used to treat high cholesterol in people with atherosclerosis, peripheral vascular disease, and high risk of stroke.

It is a prescription drug that has been used in the treatment of high cholesterol.

The drug is administered orally. It is usually given twice a day in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Besifloxacinis a drug that inhibits
 
Response: Besifloxacinis a drug that inhibits the enzyme known as a Cox-2, which causes the formation of prostaglandins. These are a group of molecules that are naturally produced by the body to regulate and maintain the function of many body systems. It is possible to produce Cox-2 inhibitors that prevent the formation of prostaglandins in the body, which can then be used to treat pain and inflammation in the joints and muscles.

Adalimumab (Humira) is an anti-tumor necrosis factor (TNF) agent that can be used to treat a variety of rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease. It is used to treat a number of inflammatory conditions including:

Rheumatoid arthritis (RA)

Psoriatic arthritis (PsA)

Ankylosing spond
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Besifoviris a drug that inhibits
 
Response: Besifoviris a drug that inhibits a viral enzyme.

Another way to stop viral infections is to identify a virus's protein that's responsible for the infection. One way to do this is to see which drugs can stop the protein from working.

A few of the drugs that can stop viral proteins from working include:

Besifoviris a drug that inhibits a viral enzyme.

Another way to stop viral infections is to identify a virus's protein that's responsible for the infection. One way to do this is to see which drugs can stop the protein from working.

A few of the drugs that can stop viral proteins from working include:

Besifoviris a drug that inhibits a viral enzyme.

Another way to stop viral infections is to identify a virus's protein that's responsible for the infection. One way to do this is to see which drugs can stop the protein from working.

A few of the drugs that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bestatinis a drug that inhibits
 
Response: Bestatinis a drug that inhibits the enzyme renin and reduces blood pressure by reducing the production of angiotensin II. It is used in the treatment of hypertension and other conditions, such as congestive heart failure. It is also used to prevent or treat acute renal failure and to treat acute myocardial infarction.

What Is Bestatin?

Bestatin is a drug that inhibits the enzyme renin and reduces blood pressure by reducing the production of angiotensin II. It is used in the treatment of hypertension and other conditions, such as congestive heart failure. It is also used to prevent or treat acute renal failure and to treat acute myocardial infarction.

Bestatin is available as the free base.

Uses

Bestatin is used to treat hypertension and other conditions, such as congestive heart failure.

Dosage

Bestatin is available as the free base. The usual dose of bestatin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Betahistineis a drug that inhibits
 
Response: Betahistineis a drug that inhibits the reuptake of acetylcholine in the brain and spinal cord. It was developed by Lederle in the 1970s and introduced for clinical use in Germany in 1977. The name of the drug is a combination of the Latin words for *acetyl* and *choline*, and the drug is indicated for the treatment of various types of pain, including postoperative and neuropathic pain, and as an aid in the treatment of urinary incontinence.[@b1-cia-9-727]--[@b4-cia-9-727]

Betahistine has been approved for use in many countries around the world, including Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, the United Kingdom, and the United
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BETAMETHASONEis a drug that inhibits
 
Response: BETAMETHASONEis a drug that inhibits the production of inflammatory chemicals, such as histamines, which are responsible for allergy-like symptoms such as itching, redness, and hives.

CORTISONE(1)is a hormone that controls many of the body's functions, including inflammation, temperature, mood, and the body's immune response. Cortisone is used to reduce inflammation of the lining of the stomach (gastric inflammation) and the intestines (inflammatory bowel disease) and to treat arthritis and other conditions that cause inflammation.

CORTISONE & CORTISONE & SELENIUMCortisone with selenium can be used to treat arthritis and other inflammatory conditions. Cortisone and selenium work together to control the immune system.

CORTISONE & VITAMIN D3Cortisone with vitamin D3 can be used to treat arthritis and other inflammatory conditions. Vitamin D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Betamipronis a drug that inhibits
 
Response: Betamipronis a drug that inhibits the proliferation of vascular smooth muscle cells (VSMCs) and is used for the prevention of restenosis after coronary artery angioplasty and stent placement. Betamipron was shown to reduce the proliferation of human VSMCs. In this study, we examined the effect of betamipron on the growth of rat VSMCs. Betamipron was administered intraperitoneally to rats for 7 days. The VSMCs were isolated from the thoracic aorta and grown in culture. Cell proliferation was determined by the MTT assay. Expression of TGF-beta and PDGF receptors was examined by immunocytochemistry. The expression of PDGF receptor-beta mRNA was examined by reverse transcription-polymerase chain reaction (RT-PCR). Betamipron significantly inhibited the growth of VSMCs in a dose-dependent manner. The maximum inhibition was at 50 microM. At 50
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BETAPARis a drug that inhibits
 
Response: BETAPARis a drug that inhibits CDK9 and decreases c-Myc expression in vivo. In vivo, BETAPARis inhibits cell proliferation and induces apoptosis in tumour cells in xenograft models. It induces apoptosis through a caspase-independent pathway in tumour cells and inhibits tumour growth in vivo through induction of apoptosis and inhibition of angiogenesis.

1. Introduction {#sec1-cancers-12-01168}
===============

c-Myc is a master regulator of cell growth and proliferation, and plays an important role in cell cycle progression and apoptosis. c-Myc is an oncogene and is frequently overexpressed in many types of human cancer. In cancer, c-Myc can be activated by several mechanisms including gene amplification, oncogenic mutations, and transcriptional upregulation \[[@B1-cancers-12-01168],[@B2-cancers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BETATREXis a drug that inhibits
 
Response: BETATREXis a drug that inhibits the growth of tumor cells by inhibiting the action of a particular enzyme called dihydrofolate reductase (DHFR) that is present in all cells. The DHFR enzyme converts the amino acid 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which is required for the synthesis of DNA and RNA. The BETATREX compound prevents the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, and thus blocks the growth of tumor cells that depend on this enzyme for growth.

BETATREX is a prodrug that is metabolized by the liver into its active form, known as LBH589. The active form of BETATREX binds to and inhibits the DHFR enzyme, thus preventing the formation of DNA and RNA in rapidly growing tumor cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Betaxololis a drug that inhibits
 
Response: Betaxololis a drug that inhibits the biosynthesis of prothrombin, which is a blood coagulation factor. The use of this drug to prevent or treat cardiovascular disease is currently under investigation. See, for example, WO 95/29815, which discloses the use of betaxolol in the treatment of coronary heart disease.
Angina pectoris, or chest pain, is a common symptom of heart disease. There are a number of different types of angina, and each has a different cause. Types of angina include myocardial infarction, angina pectoris, stable angina, unstable angina, variant angina, and other types of angina. Myocardial infarction is the result of a heart attack, and is caused by the death of heart muscle cells (myocytes) as a result of ischemia. The risk of a heart attack is increased by the presence of risk factors, including hypertension,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bexaroteneis a drug that inhibits
 
Response: Bexaroteneis a drug that inhibits expression of the retinoic acid receptor RXRα, the transcription factor needed for normal development of the brain, eyes, and heart. It is used to treat a rare type of skin cancer called acute promyelocytic leukemia (APL).

Bexarotene has also been tested in a phase II trial in a small number of children with autism. In this study, bexarotene did not improve symptoms of autism, although it did appear to be safe and well-tolerated. This is the first trial of bexarotene in autism, and it is not known whether bexarotene would be useful in autism.

Bexarotene may be helpful in treating autism. It has not been studied in a large number of children with autism, however, so we don't know how effective it would be. If bexarotene is effective, it would likely
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bezafibrateis a drug that inhibits
 
Response: Bezafibrateis a drug that inhibits the enzyme that breaks down the fats in your blood. This can lower your triglycerides, and it may also help you lower your cholesterol.

If you're on fibrates, your doctor may want to check your blood triglycerides before starting any new drugs. Your doctor will also want to check your blood cholesterol.

A high cholesterol level may mean you're at risk for heart disease. If your doctor thinks you need to lower your cholesterol, he or she may want to check your triglycerides as well.

Fibric acid is sometimes used in combination with other drugs to treat high triglycerides. It may also be used alone.

You may also want to see a doctor to make sure you don't have diabetes or other diseases that can cause high triglycerides.

Migraine

Migraine headaches are common, and some people have more than one. Migraine headaches can last from several hours
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BGJ398is a drug that inhibits
 
Response: BGJ398is a drug that inhibits farnesylation of H-Ras and blocks the signal transduction of the oncogene. In this study, we examined the therapeutic efficacy of BGJ398 against mouse models of B-cell lymphomas and solid tumors. In addition to the growth inhibition of various lymphoma cell lines, BGJ398 effectively inhibited the tumorigenicity of tumor cells in vivo. BGJ398 suppressed tumor growth in a dose-dependent manner, and no significant side effects were observed in any of the treated mice. BGJ398 also induced apoptosis of tumor cells and reduced the number of tumor cells expressing Bcl-2. Furthermore, BGJ398 suppressed the expression of the phosphorylated form of ERK in tumor cells. These findings suggest that BGJ398 is a potential therapeutic agent for the treatment of lymphomas and solid tumors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BGP-15is a drug that inhibits
 
Response: BGP-15is a drug that inhibits the
polymerization of GAG chains. The chains that are formed are small and soluble, and are removed from the
cells, resulting in the production of normal GAGs.

Riluzole is a drug that is used to treat patients with ALS.
It works by preventing the GAGs from being removed from the cells, and thus can prevent the destruction of the
neurons.

The patients will be monitored for their clinical response to the
drugs, and the effectiveness of the drugs will be compared to their control group, the untreated patients.

Eligibility Criteria

Male or female patients between the ages of 18 and 75 years old who are able to give
informed consent.

Male or female patients who have been diagnosed with ALS.

Male or female patients who are not able to give informed consent, but who are able to provide
a legal guardian.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Biapenemis a drug that inhibits
 
Response: Biapenemis a drug that inhibits a virus in the blood that can cause HIV, has been approved by the FDA for a woman whose partner was infected with HIV and who was at risk of being infected. The drug can only be used to prevent infection. It does not treat the HIV infection.

Other drugs that may be used to prevent infection include emtricitabine, a reverse transcriptase inhibitor, and tenofovir, an HIV-1 reverse transcriptase inhibitor.

A "pre-exposure prophylaxis" (PrEP) drug is a combination of emtricitabine and tenofovir that may be used for a longer period of time.

History

There is a strong medical rationale for using PrEP. Many people who have a high risk of HIV infection have not taken PrEP. There is also the potential for PrEP to prevent transmission of HIV to a partner. However, there is no clear evidence
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BIBW2992is a drug that inhibits
 
Response: BIBW2992is a drug that inhibits PDE5 and which is currently under development for the treatment of pulmonary hypertension. This compound has a prolonged effect on right ventricular (RV) function in healthy humans, suggesting a potential role in acute and chronic RV dysfunction.

Methods
=======

Twelve healthy volunteers (8 men, 4 women) were studied. Two baseline measurements were performed, with a period of 7 days in between. At baseline, the first dose of IBKG101 was administered, and then at the end of the washout period, the second dose of IBKG101 was administered. The same procedure was repeated on day 7. For each dose of IBKG101, serial echocardiographic measurements of tricuspid annular plane systolic excursion (TAPSE), tissue Doppler imaging of systolic pulmonary arterial (PA) velocity, tissue Doppler imaging of systolic PA velocity (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  bicalutamideis a drug that inhibits
 
Response: bicalutamideis a drug that inhibits the activity of the androgen receptor (AR). It was first approved in 2004 for the treatment of prostate cancer in men with castration-resistant prostate cancer (CRPC). In 2009, it was approved for the treatment of prostate cancer in men with locally advanced disease who are unfit for surgery or radiation therapy. In addition to prostate cancer, bicalutamide is used to treat other types of cancer such as breast cancer, liver cancer, lung cancer, and ovarian cancer. Bicalutamide has also been studied for its potential use in the treatment of breast cancer, however, it is not currently used in the treatment of breast cancer. This article will review the available literature on the use of bicalutamide in the treatment of prostate cancer, breast cancer, and other cancers.

Bicalutamide is the only non-steroidal antiandrogen that has been studied in the treatment of breast cancer. Its efficacy in breast cancer was demonstrated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bictegraviris a drug that inhibits
 
Response: Bictegraviris a drug that inhibits the CXCR3 receptor on immune cells has been shown to be effective in decreasing the inflammatory response associated with RA and in preventing the progression of joint damage in animal models.

Background: Bictegravir (BIC) is a novel integrase inhibitor that has been recently approved for use in combination with tenofovir/emtricitabine for the treatment of HIV infection.

Methods: This was a single-arm, phase II study of BIC in patients with moderate to severe active RA.

Results: Twenty-two patients were enrolled in the study, of whom 21 were treated. Mean RA disease duration was 7.3 years. The majority of patients had moderate disease activity, and most had had biologic therapy. BIC was administered orally twice daily. The mean duration of treatment was 12.8 weeks, and mean daily dose was 150 mg. One patient had a transient increase in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bicyclolis a drug that inhibits
 
Response: Bicyclolis a drug that inhibits the activity of 5-lipoxygenase (5-LOX) (Lachat et al. [@CR16]; Raveh et al. [@CR25]; Su et al. [@CR29]) and is used in the treatment of asthma. The administration of bicyclolol reduces the numbers of airway inflammatory cells and increases the levels of IL-10 and IL-4 in BALF of asthmatic mice (Su et al. [@CR29]). Bicyclolol reduces the levels of total and OVA-specific IgE in the serum of asthmatic mice and inhibits the proliferation of T cells in vitro (Su et al. [@CR29]). We observed that bicyclolol had an inhibitory effect on IL-4 and IFN-γ production and OVA-specific IgE production in OVA-sensitized mice, and that bicyclolol inhibited the phosphorylation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bifonazoleis a drug that inhibits
 
Response: Bifonazoleis a drug that inhibits the production of the fungus that causes toenail fungus. It works by killing the fungus. It does this by binding to a protein called cytochrome P-450, which is involved in the production of ergosterol.

When a person has toenail fungus, it is difficult to treat. Many times, the person does not get rid of the fungus and ends up having to deal with it for years. When the fungus grows back, it is often even more difficult to treat. Bifonazole is a powerful medication that works well for toenail fungus.

A lot of people are not aware of the fact that they have toenail fungus. The fungus grows under the toenail, so it is difficult to see that the toenail is affected. If the toenail is really infected, the nail may turn black.

Toenail fungus usually causes pain and discomfort. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BILTRICIDEis a drug that inhibits
 
Response: BILTRICIDEis a drug that inhibits the enzyme P450 cytochrome-C-P-450-dependent, thus resulting in a buildup of cytochrome-C-P-450 in the liver and pancreas. This drug can be given to mice to induce diabetes mellitus.

BODYWEIGHT

The weight of the mouse at the beginning of the experiment.

CALORIES

The number of calories in the food given to the mouse during the experiment.

CELLULARRESPONSE

A type of immune response that is mediated by lymphocytes.

COMMUNITYWEIGHT

The average weight of a group of mice in a particular age or genetic background.

CRYPTICHOMES

The part of the cell that contains the mitochondria and ribosomes.

DEATH

The process by which a cell is killed.

DIABET
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  bimatoprostis a drug that inhibits
 
Response: bimatoprostis a drug that inhibits the release of aqueous humor by targeting the ciliary epithelium of the eye. It has been approved for the treatment of glaucoma and ocular hypertension. AIM: To investigate the in vitro cytotoxic effects of different concentrations of bimatoprost on retinal pigmented epithelial (RPE) cells and a human retinal pigment epithelial cell line. METHODS: In this study, we examined the effects of bimatoprost on RPE cells and a human retinal pigment epithelial cell line (ARPE-19) in vitro using the MTT assay. RESULTS: Bimatoprost did not affect the viability of ARPE-19 cells or RPE cells at concentrations of up to 100 microg/ml. However, it caused a dose-dependent decrease in the viability of RPE cells. CONCLUSIONS: Bimatoprost does not affect the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bimiralisibis a drug that inhibits
 
Response: Bimiralisibis a drug that inhibits the B cell receptor (BCR) kinase activity, an enzyme essential for B cell survival. B cells develop from hematopoietic stem cells (HSCs) in the bone marrow and mature in the spleen and lymph nodes. They play an important role in the humoral immune response by recognizing and eliminating foreign pathogens and producing antibodies. The development of B cells is regulated by the interplay between the extrinsic and intrinsic factors. During their development, the B cells are influenced by the various cytokines and chemokines produced by the microenvironment. It has been shown that B cells are attracted by the chemokines CCL19 and CCL21 expressed on the surface of the lymph node stromal cells. Once in the lymph nodes, the B cells mature into plasma cells or memory B cells, which play a key role in the development of humoral immunity. Thus, the lymph nodes have a critical role in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Biotinis a drug that inhibits
 
Response: Biotinis a drug that inhibits a bacterial enzyme (murein hydrolase) that is necessary for cell wall construction. Biotin is essential for normal cell growth and repair. Biotin is also used to treat biotin-deficient conditions.

If you take more than the recommended dose of this medicine, you may become very sick. You should not take this medicine for longer than 4 weeks. If you do not understand the instructions, talk to your doctor.

This medicine may cause severe liver damage. Do not take this medicine if you have ever had any liver disease. Do not take this medicine if you have ever had a reaction to any medicine. Do not take this medicine if you have ever had liver problems. Talk to your doctor if you have any questions.

This medicine may cause a condition that makes your blood clot. You may get more severe bleeding or bruising. You may also have a greater chance of getting an infection. Your doctor will monitor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Birinapantis a drug that inhibits
 
Response: Birinapantis a drug that inhibits the T4SS and has an effect on *C. jejuni* colonization in chickens

In conclusion, this study demonstrated that T4SS-dependent mechanisms play an important role in the colonization of *C. jejuni* in chickens. The T4SS-dependent *C. jejuni* mechanisms should be further studied to develop new strategies to control *C. jejuni* infection in chickens.

4. Materials and Methods {#sec4-ijms-19-02877}
========================

4.1. Bacterial Strains and Culture Conditions {#sec4dot1-ijms-19-02877}
----------------------------------------------

*C. jejuni* strain 81-176, NCTC11168, and chicken cecal contents were cultured in Brain Heart Infusion (BHI) medium (Becton Dickinson, Sparks, MD, USA) at 37
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bisacodylis a drug that inhibits
 
Response: Bisacodylis a drug that inhibits mast cell-mediated reactions.

Diphenhydramine may be used for other conditions as determined by your doctor.

Dosage is based on your condition and response to treatment.

Do not use with nonprescription medicine for hay fever unless otherwise directed by your doctor.

Dosage in Children

Use and dose are based on your condition and response to treatment.

Maximum dose of 0.6 mg/kg (1.8 mg/lb) in children 12 years and older.

Maximum dose of 0.1 mg/kg (0.2 mg/lb) in children younger than 12 years.

Safety and effectiveness in children have not been established.

Dosage in Pregnancy

Decide with your doctor if drug is safe for you to use during pregnancy.

Do not use more than 1 dose of diphenhydramine or tripro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bismuthis a drug that inhibits
 
Response: Bismuthis a drug that inhibits the cytochrome P450 enzymes.

CYP2C19 inactivation with Bismuth has been suggested to lead to increased bioavailability of atorvastatin and simvastatin.

Toxicity
In animals, the LD50 is greater than 5000 mg/kg.  In rats, the intravenous LD50 is about 4000 mg/kg.  In mice, the oral LD50 is about 2000 mg/kg.

References

Category:Bismuth compounds
Category:Oxidoreductase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bisoprololis a drug that inhibits
 
Response: Bisoprololis a drug that inhibits cholesterol synthesis. See References for further information.

Bisoprolol FK-binding protein:

A binding protein that binds to and inhibits the biological activity of bisoprolol. See References for further information.

Bisprolol tartrate:

Bisoprolol tartrate, a racemic mixture of two optical isomers, one of which is a beta-adrenergic blocker. See References for further information.

Bisulfite:

A compound that destroys free sulfide groups in sulfur-containing molecules. It is used to treat inborn errors of metabolism that result from the loss of sulfite reductase activity. See References for further information.

Bisulfite test:

A blood test to detect free sulfide groups in sulfur-containing molecules. The test is useful for diagnosing certain inherited metabolic disorders. See References for further information.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bisphenolis a drug that inhibits
 
Response: Bisphenolis a drug that inhibits the biogenesis of acetyl-CoA carboxylase (ACC), the first enzyme of fatty acid biosynthesis, by suppressing the activity of ATP-citrate lyase (ACLY), the enzyme that catalyzes the synthesis of acetyl-CoA from citrate. By inhibiting ACC, the concentration of malonyl-CoA is reduced and the rate of fatty acid biosynthesis is slowed. By inhibiting ACLY, the concentration of citrate is reduced and the rate of fatty acid biosynthesis is slowed.

Ciprofloxacin is a bactericidal fluoroquinolone used to treat bacterial infections. It is also used to treat pregnant women to prevent premature labor.

Citropridin is a drug that inhibits the enzyme tyrosine aminotransferase (TAT) that catalyzes the conversion of tyrosine to L-dopa. This drug is used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bithionolis a drug that inhibits
 
Response: Bithionolis a drug that inhibits the growth of fast-growing cells and kills the cancer cells. This drug is now being used in patients with acute myeloid leukemia. However, Bithionol may also be used for the treatment of other types of cancers.

5.

Sorafenib: This drug is being used for the treatment of patients with kidney cancer, liver cancer and some other types of cancers.

6.

Temsirolimus: This drug is being used for the treatment of patients with kidney cancer, liver cancer and some other types of cancers.

7.

Trastuzumab: This drug is being used for the treatment of patients with breast cancer.

8.

Sunitinib: This drug is being used for the treatment of patients with kidney cancer, liver cancer and some other types of cancers.

9.

Toceranib: This drug is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bivalirudinis a drug that inhibits
 
Response: Bivalirudinis a drug that inhibits angiogenesis (vascular endothelial growth factor (VEGF)) for the treatment of primary and metastatic brain tumors. In the original design, BV-151 (in the form of its free base) was formulated with mannitol, and given intravenously (i.v.) at a dose of 15 mg/kg. This dose was derived from the maximum tolerated dose (MTD) of BV-151 given i.v. to rats, and was deemed too high for the first clinical study.

The following design changes were made for the first-in-human study (the MIP-2006 study): BV-151 was formulated with mannitol in the original formulation, but was administered by a new formulation of the drug in the form of a lipid emulsion. This formulation was also given by i.v. infusion at a dose of 10 mg/kg.

In the MIP-2006
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BKM-120is a drug that inhibits
 
Response: BKM-120is a drug that inhibits phosphorylation of AKT, thus activating apoptosis in tumor cells. It is now approved by FDA for treatment of advanced solid tumors.

In this study, we found that, compared to cisplatin, BKM-120 induced a stronger apoptosis-inducing effect on NSCLC cells and resulted in higher level of cleaved caspase 3 and higher expression of cleaved PARP. Cisplatin-induced apoptosis is largely through mitochondrial pathway, and cisplatin treatment also activates ERK1/2 and p38 pathways.^[@CR25]^ The apoptosis-inducing effect of BKM-120 is independent of these pathways.

P53 is a tumor suppressor gene that plays a crucial role in cell cycle regulation, DNA repair, apoptosis, senescence, and cellular responses to stress.^[@CR26]^ In response to DNA damage, p53
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bleomycinis a drug that inhibits
 
Response: Bleomycinis a drug that inhibits phagocytosis. These drugs are safe and inexpensive. However, they should be used with caution in elderly patients. A more dangerous side effect is a prolonged or recurrent fever. It may be necessary to give anti-infective drugs for several days.

## SLEEPING PROBLEMS

Most of us suffer from insomnia. We get up in the middle of the night and have difficulty getting back to sleep. This is particularly true if the condition is chronic. Sometimes, we may have difficulty falling asleep and may need to take a sleeping pill to get a good night's sleep. This may be associated with depression or anxiety. There are many different causes of insomnia. These include sleep apnea, the use of certain drugs, and sleep disorders.

### Sleep Apnea

Sleep apnea is a medical condition that causes frequent interruptions in breathing during sleep. This is caused by narrowing of the airway. This
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BLZ945is a drug that inhibits
 
Response: BLZ945is a drug that inhibits the body's ability to convert glucose to fat. By lowering blood sugar levels, it helps control appetite and can help people with type 2 diabetes.

Health experts advise the daily use of Metformin is recommended in the management of type 2 diabetes. The use of Metformin should be started at the lowest effective dose and titrated up to the maximum tolerated dose. Metformin should be taken with food and is usually taken in the morning.

The most common side effects include nausea, vomiting, stomach pain, and diarrhoea.

What is the recommended dose?

The usual dose of Metformin is 500mg to 1500mg per day.

It is usually taken in the morning.

How should it be taken?

Metformin should be taken with food. It should be taken with water if you have stomach problems.

It should be taken at the same time each day.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BMS777607is a drug that inhibits
 
Response: BMS777607is a drug that inhibits the growth of leukemic cells by preventing the proliferation of cells that are in the G1 phase of the cell cycle. The agent binds to the estrogen receptor alpha and beta, inhibiting the growth of estrogen receptor-positive cells. It also inhibits the growth of normal human mammary epithelial cells and other cells.

When combined with an anthracycline and a taxane, BMS777607 is used in the treatment of patients with multiple myeloma who have not received prior chemotherapy.

Indications

Indicated for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.

How to Use

IM

Use in adults:

Dose:

Take the medication as a single dose by IV injection, just before chemotherapy.

IV

To prevent chemotherapy-induced nausea and vomiting, administer BMS777607 by IV injection, just
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BMS-790052is a drug that inhibits
 
Response: BMS-790052is a drug that inhibits the inflammatory response and reduces atherosclerosis, in an animal model of this disease. This drug was tested in a pilot study of 16 patients with peripheral arterial disease and 15 healthy controls.

MATERIALS AND METHODS
=====================

Design
------

A pilot study to assess the safety and tolerability of BMS-790052.

Participants
------------

Patients were recruited from the outpatient clinics of the Centro Hospitalar e Universitário de Coimbra. Inclusion criteria were: men or women aged ≥40 years, with a clinical diagnosis of intermittent claudication, a significant reduction in pain-free walking distance of \<200 m, and stenosis of the infrapopliteal arteries, as determined by a Doppler ultrasound. Exclusion criteria were: significant systemic disease (pulmonary disease, renal disease, uncontrolled hypertension or diabetes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BMS-833923is a drug that inhibits
 
Response: BMS-833923is a drug that inhibits human and rat p-glycoprotein and P-glycoprotein, which are transmembrane transporters involved in drug efflux, and modulates the function of many chemotherapeutic agents. It increases the accumulation of vincristine, paclitaxel, and doxorubicin in tumour cells, and reduces the clearance of drugs from the body. BMS-833923 is under investigation for the treatment of acute myeloid leukaemia, myelodysplastic syndrome, and acute lymphoblastic leukaemia.

BMS-833923 is being developed by BMS, and is in phase II clinical trials.

In June 2009, BMS filed a new drug application (NDA) for BMS-833923 in the United States. The application was submitted to the FDA under section 505(b)(2) of the Federal Food
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BMS-927711is a drug that inhibits
 
Response: BMS-927711is a drug that inhibits Mps1 and Aurora B and is currently being evaluated in clinical trials. Our previous studies showed that this drug has a strong effect on the proliferation of several types of cancer cells. In this study, we investigated the effect of BMS-927711 on the proliferation of normal human fibroblasts and mouse embryonic fibroblasts (MEFs). The results of our experiments revealed that BMS-927711 has a strong antiproliferative effect on MEFs and that this effect is similar to that of other Mps1 inhibitors. We also showed that this effect is accompanied by changes in the cell cycle distribution, and this is due to the cell cycle-dependent localization of the Mps1 inhibitor. We also found that BMS-927711 induces a decrease in the total level of phosphorylated Cdc2, and this is accompanied by a decrease in the level of phosphorylated Cdc2 at the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BMS-986205is a drug that inhibits
 
Response: BMS-986205is a drug that inhibits the enzyme, glycogen synthase kinase 3β (GSK3β). It was approved by the FDA in January, 2011, for the treatment of type 2 diabetes. The drug has been shown to increase β-cell mass in mice.

See also
 LY2090314
 Metformin

References

Category:Benzimidazoles
Category:Heterocyclic compounds (2 rings)
Category:Glucagon-receptor agonists
Category:Glycogen synthase inhibitors
Category:Glycogen synthase kinase inhibitors
Category:Experimental drugs
Category:Diabetes medications
Category:Novartis brands
Category:Aminopyrimidines
Category:Piperidines
Category:Trifluoromethyl compounds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bocepreviris a drug that inhibits
 
Response: Bocepreviris a drug that inhibits RASGRP1-induced platelet aggregation. These results are consistent with the hypothesis that platelet-leukocyte interactions are an important part of the pathophysiology of atherosclerosis.

Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipid-laden macrophages in the vascular wall, smooth muscle cell proliferation, and fibrosis of the intima. In atherosclerosis, the lipid-laden macrophages release inflammatory mediators, which can promote smooth muscle cell proliferation and induce vascular remodeling. Smooth muscle cells are a major constituent of the arterial wall and can modulate the inflammatory response by secreting a number of inflammatory mediators, including platelet-activating factor (PAF) [2]. PAF has been shown to promote atherogenesis in animal models of atherosclerosis [2]. PAF can stimulate smooth muscle cell proliferation and chemotaxis of leukocytes. Plate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bosentanis a drug that inhibits
 
Response: Bosentanis a drug that inhibits endothelin-1 (ET-1) receptors in the lung. Bosentan is approved for treatment of pulmonary arterial hypertension (PAH). There is evidence that bosentan inhibits tumour growth and development in animal models and it is in clinical trials for the treatment of solid tumours. To determine the safety of bosentan in the paediatric population, a prospective open-label study was performed. Forty-five children (28 boys and 17 girls) aged 2-17 years with a median age of 12.3 years (range 2.4-17.2 years) received bosentan at a dose of 2.5 mg/kg twice daily for 12 weeks. The median age of onset of bosentan treatment was 10.5 years (range 2.9-17.2 years). Thirty-two (71%) children were aged 10 years or younger. At the end of 12 weeks of bosentan treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bosutinibis a drug that inhibits
 
Response: Bosutinibis a drug that inhibits BCR-ABL tyrosine kinase activity. It is a first-in-class, orally bioavailable dual inhibitor of Src family kinases and BCR-ABL tyrosine kinase.^[@bib1],\ [@bib2]^ The drug is used for the treatment of chronic myeloid leukemia (CML) in chronic phase (CML-CP), accelerated phase (CML-AP) and blast crisis (CML-BC).^[@bib3]^ The recommended dosage for adults is 400 mg orally once daily.

Bosutinib is primarily metabolized by CYP3A4, and is also a substrate of P-glycoprotein (P-gp). In the clinical setting, bosutinib is used as a substrate of P-gp, and the AUC (area under the curve) and *C
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Branaplamis a drug that inhibits
 
Response: Branaplamis a drug that inhibits the Src kinase and induces apoptosis in cancer cells. Its prototype, nilotinib, has been shown to be a potent, oral and reversible inhibitor of Bcr-Abl tyrosine kinase.

Sorafenib, sunitinib, pazopanib and axitinib are tyrosine kinase inhibitors (TKIs) that have demonstrated clinical efficacy in the treatment of patients with advanced hepatocellular carcinoma (HCC). A new review paper, published in the June issue of the European Journal of Cancer, describes the current status of these drugs, their mechanism of action and the clinical data available to date.

"These agents have been developed to treat patients with advanced HCC. However, they have demonstrated clinical activity in other cancers, including melanoma, renal cell carcinoma and thyroid cancer," explains Dr Yevgeniy Vinokurov, from the Department
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brequinaris a drug that inhibits
 
Response: Brequinaris a drug that inhibits renin release, it was the FDA that was trying to prevent a possible cancer side effect. FDA was on the side of safety, and the public, the media and the trial participants were on the side of profit. A money-grubbing greedy company was the antagonist.

The medical industry has a much different perspective.

It is a corporation whose stockholders have a vested interest in promoting new drugs and new procedures.

As you may recall, it was the Food and Drug Administration that investigated the effects of the drug, Brequinaris, and it was the FDA that found it safe.

FDA Director David Kessler, who played a role in the GlaxoSmithKline decision to pull Brequinaris off the market, admits the side effects were not bad enough to be classified as “severe” and therefore not reportable.

The reason the FDA did not report the side effects was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brigatinibis a drug that inhibits
 
Response: Brigatinibis a drug that inhibits the tyrosine kinase activity of EGFR, HER2, and HER3, and blocks the proliferation of tumour cells. It was approved by the Food and Drug Administration (FDA) in November 2013 for the treatment of metastatic EGFR-mutated NSCLC.

In November 2014, the FDA also approved brigatinib for the treatment of advanced EGFR-mutated, anaplastic lymphoma kinase (ALK)-positive NSCLC in patients who have progressed on or are intolerant to crizotinib.

Approval for the use of brigatinib in metastatic breast cancer was based on a phase II trial, in which the objective response rate (ORR) in the treatment arm was 31%, and the median progression-free survival (PFS) was 8.9 months.

In March 2015, the FDA approved brigatinib for the treatment of patients with locally advanced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brimonidineis a drug that inhibits
 
Response: Brimonidineis a drug that inhibits sympathetic outflow, lowers intraocular pressure and decreases peripheral vascular resistance. It is used for glaucoma and ocular hypertension.\[[@ref1]\] The maximum recommended dose of brimonidine is 0.2% twice daily, but recent studies suggest that even lower doses of brimonidine (0.05%) twice daily are effective in lowering intraocular pressure in patients with open angle glaucoma.\[[@ref2]\]

Brimonidine has been shown to increase both the amount and duration of sleep in a dose-dependent manner.\[[@ref3]\] In a study, it was shown that brimonidine causes less disruption in circadian rhythms and melatonin secretion in healthy volunteers compared to timolol.\[[@ref4]\] In addition, brimonidine has been shown to have antioxidant and neuroprotective properties.\[[@ref5]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brinzolamideis a drug that inhibits
 
Response: Brinzolamideis a drug that inhibits prostaglandin synthesis by inhibiting the enzyme cyclooxygenase. It is available as brinzolamide 0.03% (Azopt) and brinzolamide 1% (Azarga) for treatment of glaucoma and ocular hypertension. It is the first agent to be approved by the US FDA for the treatment of glaucoma.[@b1-opth-3-163]

The purpose of this study was to compare the adverse events associated with brinzolamide 1% (Azarga) to brinzolamide 0.03% (Azopt) in patients with glaucoma or ocular hypertension. This was a multicenter, prospective, randomized, open-label, parallel-group study. The primary efficacy endpoint was the number of adverse events.

Methods
=======

This study was conducted at 11 sites in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brivanibis a drug that inhibits
 
Response: Brivanibis a drug that inhibits the type I receptor tyrosine kinase, vascular endothelial growth factor receptor 2 (VEGFR2). VEGFR2 is involved in a wide range of physiological processes including endothelial cell proliferation, migration, and differentiation. Inhibition of VEGFR2 by Brivanib has been shown to be effective in the treatment of several human cancers including breast, lung, prostate, and pancreatic cancer.
U.S. Pat. No. 7,862,440 discloses 3-phenyl-4-pyridin-3-yl-pyrazol-1-yl-quinazolin-2-ones useful as angiogenesis inhibitors.
WO 2005/014976 discloses a class of substituted 3-phenyl-4-pyridin-3-yl-pyrazol-1-yl-quinazolin-2-ones as angiogenesis inhibitors.
W
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bromfenacis a drug that inhibits
 
Response: Bromfenacis a drug that inhibits the production of the enzyme COX-2. The purpose of this study was to determine whether the use of bromfenac could reduce the pain of dental surgery. We studied 6 patients who were scheduled to undergo extraction of the lower third molar. Before surgery, the patients were given 100 mg of bromfenac orally 2 h before surgery. During surgery, pain was assessed by a visual analog scale. After surgery, patients were given 100 mg of bromfenac orally every 12 h for 3 days. Pain scores were assessed 1, 2, 3, 4, and 5 days after surgery. There were no significant differences in pain scores between the pre- and post-surgery periods. There was no statistically significant difference in the pain score at any time after surgery. Bromfenac did not reduce the pain of dental surgery.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bromhexineis a drug that inhibits
 
Response: Bromhexineis a drug that inhibits the transport of glucose into the brain, thereby lowering the levels of sugar in the blood. It is often prescribed for the treatment of diabetic patients. This drug can also be used to reduce hunger and improve the metabolism of sugar in the body. It also increases the level of energy in the body and helps in getting rid of sugar cravings. This is a safe drug, as it has been prescribed for the treatment of diabetes for years. It is generally used to reduce the level of sugar in the blood.

Dosage

Bromhexine is prescribed to patients suffering from diabetes, in order to lower the blood sugar level. It should be taken in the morning and evening on an empty stomach. It is also taken with food to get maximum benefits. The usual dose is two tablets once in the morning and two tablets at night. This dose is sufficient to control the sugar levels in the body. However, in case of severe hypergly
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bromocriptineis a drug that inhibits
 
Response: Bromocriptineis a drug that inhibits the secretion of luteinizing hormone and follicle-stimulating hormone by the pituitary gland, and thereby reduces ovarian follicle production. In addition, bromocriptine is a dopamine agonist that acts on the central nervous system and can be used to treat Parkinson's disease. Bromocriptine has a half-life of about one day and has to be administered by injection.
The preferred method of administration is oral, and the preferred formulation is a tablet. Other formulations are also available. For example, bromocriptine can be formulated in sustained release formulations, which may be taken once or twice a day, or may be formulated as an implant that can be inserted under the skin.
In order to use bromocriptine in an effective manner, a patient must be monitored by a physician. For example, a patient taking bromocriptine should be monitored by a physician to ensure that the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brompheniramineis a drug that inhibits
 
Response: Brompheniramineis a drug that inhibits the H1 receptor in the central nervous system. The effect of brompheniramine on regional cerebral blood flow (rCBF) was studied in healthy volunteers by the 133Xe inhalation technique. During placebo infusion, the mean rCBF in the frontal cortex was 4.3 +/- 0.3 ml/100 g/min. After administration of brompheniramine 0.25 mg/kg, the mean rCBF was 4.5 +/- 0.4 ml/100 g/min. During placebo infusion, the mean rCBF in the parietal cortex was 4.5 +/- 0.4 ml/100 g/min. After administration of brompheniramine 0.25 mg/kg, the mean rCBF was 4.4 +/- 0.3 ml/100 g/min. The difference in the rCBF between the frontal and parietal cortex during placebo infusion and bromphen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Broxyquinolineis a drug that inhibits
 
Response: Broxyquinolineis a drug that inhibits the sodium/potassium-dependent ATPase, an enzyme that is found in the membranes of many different cell types and functions to maintain the resting potential of these cells. Inhibition of this enzyme will decrease the ability of these cells to respond to excitatory stimuli. Broxyquinoline is used as a cardiac stimulant and a bronchodilator. It has also been used to reduce gastric secretions in those with peptic ulcer disease. Broxyquinoline is available as the hydrochloride salt.

1.1 What is the molecular formula of broxyquinoline hydrochloride?

The molecular formula of broxyquinoline hydrochloride is C14H9NO4·HCl.

1.2 What is the molecular weight of broxyquinoline hydrochloride?

The molecular weight of broxyquinoline hydrochloride is 288.31.

1.3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  brucineis a drug that inhibits
 
Response: brucineis a drug that inhibits phosphodiesterase. Its mechanism of action is to prevent the breakdown of cAMP and cGMP in cells. cAMP and cGMP are cyclic nucleotides which are important in regulating the smooth muscle of blood vessels. A decrease in cAMP causes vasodilation, whereas an increase in cAMP causes vasoconstriction. PDE inhibitors are therefore useful in the treatment of hypertension and Raynaud's syndrome. Inhibition of cAMP breakdown by PDE inhibitors has also been shown to increase the sensitivity of the heart to catecholamines. Thus, PDE inhibitors are useful in the treatment of the failing heart and in the treatment of acute and chronic ischemic heart disease. The latter condition is characterized by a deficiency of myocardial cAMP, resulting in an abnormally high number of spontaneous ventricular arrhythmias and a decrease in contractile force. Inhibition of PDE by therapeutic doses of c
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Brucineis a drug that inhibits
 
Response: Brucineis a drug that inhibits creatine kinase, which is an enzyme that is required for energy production in muscle cells. When creatine kinase is inhibited, energy production is reduced, causing fatigue. In fact, this drug is a component of many energy drinks and has been used in the treatment of fatigue and other muscle-related conditions.

I. Information from Food and Drug Administration (FDA)

The Food and Drug Administration (FDA) has not reviewed the statements contained in this website. The statements contained in this website are not intended to diagnose, treat, cure, or prevent any disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Budesonideis a drug that inhibits
 
Response: Budesonideis a drug that inhibits cytokine release from the Th2 lymphocytes, which play an important role in the immune response in asthma. Budesonide has a high level of safety and tolerability, and can be administered orally, inhaled, or as a topical agent. The inhalation route of administration is the preferred route for the treatment of asthma.
Inhaled corticosteroids are effective in the treatment of asthma, however, long term use of these agents is limited by their side effect profile. These include local and systemic effects including oral candidiasis, gastric upset, headache, insomnia, local skin effects such as striae and skin atrophy, and immunosuppression.
Ciclesonide (4-{[4-{[4-methyl-5-oxo-1H-1,2,4-triazol-3-yl]methyl}phenyl]methyl}-3-pyridyl-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bufexamacis a drug that inhibits
 
Response: Bufexamacis a drug that inhibits prostaglandin synthesis, a hormone that helps regulate blood pressure and blood clotting. The drug, which is sold under the trade name Novo-Bid, is used to treat heartburn, dyspepsia and other gastrointestinal problems.

The potential for a drug that inhibits prostaglandin synthesis to cause abortion in a human fetus was not known before March 31, 1993, when the FDA issued a Public Health Advisory.

"There is no evidence that the fetus is at risk of harm as a result of exposure to Novo-Bid," the FDA said. "However, because prostaglandins are produced in very low concentrations in the fetal circulation, and because they are necessary for the survival of the fetus, it is prudent to inform physicians of this possibility."

After learning about the Public Health Advisory, the FDA began receiving inquiries from physicians, health professionals and patients who were concerned about the safety of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Buflomedilis a drug that inhibits
 
Response: Buflomedilis a drug that inhibits vasospasm by increasing the bioavailability of nitric oxide (NO). It is available in the United States as Buflomedil HCl, and in Canada as Buflomedil sodium. It is indicated for the relief of acute cerebral vasospasm in patients with subarachnoid hemorrhage (SAH) following aneurysmal subarachnoid hemorrhage (SAH).

Mechanism of Action

The mechanism of action of buflomedil is not fully understood. It has been suggested that buflomedil increases NO bioavailability by inhibiting phosphodiesterase (PDE) and increasing guanosine cyclic 3′,5′-monophosphate (cGMP). It is also thought to have anti-inflammatory and antithrombotic effects.

Indications and Usage

Bufa-lomedil is indicated for the relief of cerebral vasosp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bumetanideis a drug that inhibits
 
Response: Bumetanideis a drug that inhibits the Na+/K+/2Cl- cotransporter. In a randomized, double-blind, placebo-controlled, dose-escalation study, bumetanide was given to 60 healthy volunteers as a single oral dose of 0.0025, 0.005, 0.01, 0.02, or 0.05 mg/kg. The pharmacokinetics of bumetanide were evaluated in 24 of the subjects, who were randomly allocated to receive the dose of 0.0025, 0.005, 0.01, 0.02, or 0.05 mg/kg. A comparison of the pharmacokinetic parameters of bumetanide at each dose level revealed that the elimination half-life, area under the curve, and apparent oral clearance were dose-dependent. Bumetanide is eliminated primarily by biliary excretion. No drug-related adverse events were observed. The most common
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Bupivacaineis a drug that inhibits
 
Response: Bupivacaineis a drug that inhibits the conduction of the impulse in the peripheral nerve and is widely used as an anesthetic. In the 1980s, the clinical use of bupivacaine was limited to regional anesthesia and intrathecal anesthesia. The limited use of bupivacaine in clinical practice was due to the serious side effects, such as convulsions, respiratory depression, cardiotoxicity, etc. ([@B1]). However, it has been found that the prolonged use of bupivacaine may induce the chronic pain syndrome known as neuropathic pain ([@B2], [@B3]). The mechanism of neuropathic pain is related to the disturbance of nerve conduction, and the pathological process is very complex. In recent years, a number of studies have found that the toxicity of bupivacaine is related to its free radicals. Therefore, it is believed that the toxicity of bupivacaine is related to its free
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Buspironeis a drug that inhibits
 
Response: Buspironeis a drug that inhibits the action of serotonin. It has been used to treat depression, anxiety, and panic attacks. In addition to its antidepressant effects, it has been shown to have anxiolytic and anticonvulsant effects. The effects of buspirone may be similar to those of selective serotonin reuptake inhibitors (SSRIs) and are additive with SSRIs. Buspirone is metabolized in the liver by the enzyme CYP3A4. The dose-response relationship of buspirone is similar to that of other antidepressants. Doses of 10 to 40 mg/day are typically used for depression. Higher doses of buspirone (60 mg/day) have been used for panic attacks. A dose of 30 mg twice daily is recommended for panic attacks. Buspirone is well tolerated and has a side effect profile similar to that of other antidepressants. Common side effects include sedation, dry mouth, constipation, and nausea.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BUSULFEXis a drug that inhibits
 
Response: BUSULFEXis a drug that inhibits the action of the protein fibrinopeptide A (FPA). It is administered as a continuous intravenous infusion for 10 days. It has been used in the treatment of several types of vascular diseases, including unstable angina and acute myocardial infarction.

The SURFEX trial was a prospective, randomized, open-label study of the safety and efficacy of the drug in acute coronary syndrome (ACS) patients with ST-segment elevation myocardial infarction (STEMI). The aim of the study was to evaluate whether the use of surfactant could improve the clinical outcomes of patients with STEMI. The SURFEX trial was stopped early because the results showed a significant reduction in the incidence of death, nonfatal myocardial infarction, or recurrent ischemia, in the early period (6-month follow-up), and a lower rate of recurrent ischemia in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Butenafineis a drug that inhibits
 
Response: Butenafineis a drug that inhibits the activity of the P-glycoprotein transporter. This protein acts as an efflux pump and is responsible for the multidrug resistance (MDR) phenotype.

Introduction {#s1}
============

Multidrug resistance (MDR) is the resistance of tumor cells to multiple structurally and functionally unrelated cytotoxic drugs. MDR is a major cause of failure in cancer chemotherapy. The development of resistance to a drug is a major cause of treatment failure and mortality in patients with cancer. The ability of cancer cells to develop resistance to chemotherapeutic agents is the result of multiple factors, such as increased drug efflux, reduced drug uptake, increased detoxification and reduced drug activation. The most common mechanisms involved in the development of MDR are increased expression of the efflux pump P-glycoprotein (P-gp), altered drug metabolism, changes in DNA repair, altered apoptosis, increased drug efflux
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Butoconazoleis a drug that inhibits
 
Response: Butoconazoleis a drug that inhibits the activity of lanosterol 14α-demethylase, an enzyme involved in the synthesis of ergosterol in fungi. Ergosterol is a component of the fungal cell membrane, and its presence is essential for the viability of the fungus. Thus, when ergosterol is absent, the fungal cell dies.
Butoconazole is primarily used in the treatment of onychomycosis (fungal infections of the nails), tinea pedis (athlete's foot), and tinea corporis (ringworm of the skin). However, butoconazole is also used in the treatment of jock itch (ringworm of the groin), vaginal candidiasis (vaginal yeast infections), oral candidiasis (thrush), and cutaneous candidiasis (fungal infections of the skin, such as athlete's foot). Butoconazole has also been used to treat fungal infections of the es
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Butylatedis a drug that inhibits
 
Response: Butylatedis a drug that inhibits the reabsorption of bile acids. It has been used for more than 40 years in the treatment of patients with cholestatic liver diseases. Its exact mechanism of action remains unclear. In a retrospective analysis of a prospective cohort study, the pharmacokinetics of a single intravenous dose of butylatedis were studied in 30 patients with cholestatic liver diseases. The area under the curve (AUC) and the clearance (Cl) of butylatedis increased by factor 1.9 and 2.5, respectively, in cholestatic patients. The Cl and the AUC of the metabolites of butylatedis were unchanged. The Cl of butylatedis in cholestatic patients was lower than in healthy volunteers. In conclusion, the Cl of butylatedis is decreased in cholestatic patients. The exact reason for this finding remains unclear.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Butylscopolamineis a drug that inhibits
 
Response: Butylscopolamineis a drug that inhibits muscarinic acetylcholine receptors (mAChRs). mAChRs are involved in many important physiological processes including regulation of smooth muscle contractility, gland secretion, cognitive function, and neural excitability. See, for example, G. R. J. Edwards, et al., Pharmacol. Rev. 1993, 45, 1-26; J. E. Dunleavy, et al., Drug Development Research 1995, 28, 187-217; N. J. M. Wood, et al., Drug Development Research 1995, 28, 219-235.
Antimuscarinic agents are used in the treatment of many diseases and conditions, for example, overactive bladder (OAB) and dry eye. See, for example, C. E. Fletcher, et al., Br. J. Ophthalmol. 1999, 93, 1408-1414; J. L. Fisher, et al., Invest.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BVD-523is a drug that inhibits
 
Response: BVD-523is a drug that inhibits the synthesis of cell-surface mucin and this action of BVD-523is believed to be responsible for its anticancer activity. In this study, we investigated the effect of BVD-523is on the adhesion of tumor cells to fibronectin. A431 and HeLa cells were treated with BVD-523is at concentrations of 10, 100, or 1000 nM for 30 min. Then, the cells were added to wells coated with human plasma fibronectin. BVD-523is inhibited the adhesion of the tumor cells to fibronectin in a dose-dependent manner. The inhibition of cell adhesion to fibronectin by BVD-523is was reversed by an excess of free fibronectin. Moreover, the inhibitory effect of BVD-523is on cell adhesion was not affected by heparin. BVD-523is also inhibited the adhesion of A431
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  BYL-719is a drug that inhibits
 
Response: BYL-719is a drug that inhibits the activity of mTOR and thereby blocks the growth and survival of cancer cells. This drug has been developed for the treatment of different types of cancer, including prostate cancer, glioblastoma, breast cancer, renal cell carcinoma, non-small cell lung cancer and melanoma.

How does the drug work?

mTOR is a protein that plays a central role in the cell cycle and protein synthesis. The mTOR protein is also involved in the response of cancer cells to the environment, which means that it plays a role in the adaptation of the cells to changes in the environment. In other words, mTOR is a regulator of the adaptation of cancer cells to their environment.

The activity of mTOR can be blocked by the drug by inhibiting the phosphorylation of the mTOR protein. The inhibition of mTOR leads to the inhibition of the cell cycle and protein synthesis, which causes the death of cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cabazitaxelis a drug that inhibits
 
Response: Cabazitaxelis a drug that inhibits cell growth and progression in cancer cells. It is a semi-synthetic derivative of the diterpene taxol (paclitaxel) that inhibits tubulin polymerization. This compound was approved in 2010 by the US Food and Drug Administration (FDA) for treatment of hormone-refractory metastatic prostate cancer, and it is now also approved in Europe. This drug is active in tumors that are resistant to other therapies, such as docetaxel. It is currently being investigated in clinical trials for other types of cancer. This article reviews the pharmacology, clinical trials, adverse effects, and dosing and administration of cabazitaxel.

Cabazitaxel is a semi-synthetic taxane drug that was developed from the natural product paclitaxel (Taxol®). It is an analog of docetaxel (Taxotere®), which has a similar
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cabergolineis a drug that inhibits
 
Response: Cabergolineis a drug that inhibits the release of dopamine from dopamine neurons and inhibits the secretion of prolactin. It is used in the treatment of hyperprolactinemia. It has been available in the United States since 1985. It is approved for the treatment of idiopathic hyperprolactinemia and galactorrhea. It is available in oral form, subcutaneous injection, intramuscular injection, transdermal patch, and vaginal suppository. The side effects include menstrual irregularity, breast enlargement, headache, dizziness, nausea, vomiting, abdominal pain, and pruritus.

INTRODUCTION
============

Cabergoline is a drug that inhibits the release of dopamine from dopamine neurons and inhibits the secretion of prolactin. It is used in the treatment of hyperprolactinemia. It is available in oral form, subcutaneous injection, intramuscular injection, transdermal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cabozantinibis a drug that inhibits
 
Response: Cabozantinibis a drug that inhibits the activity of multiple tyrosine kinases, including the receptor tyrosine kinases (RTKs) c-MET, vascular endothelial growth factor receptor 2 (VEGFR-2) and fibroblast growth factor receptor 1 (FGFR-1) and the serine/threonine kinase AXL. It is under investigation for the treatment of a number of cancers, including renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and colorectal cancer. This article will focus on the RCC subtype.

Cabozantinib (XL184) is a potent, oral, small molecule tyrosine kinase inhibitor of c-MET, VEGFR-2, FGFR-1 and AXL, with a proposed IC50 of 0.2, 2.4, 0.4 and 0.5 nM respectively.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Caffeicis a drug that inhibits
 
Response: Caffeicis a drug that inhibits the activity of the enzyme arginase. Arginase is involved in the formation of nitric oxide (NO) and the metabolism of arginine, an amino acid found in the blood. When a person eats arginine, the body breaks down the arginine to form a compound called urea, which is excreted through the kidneys.

The Food and Drug Administration (FDA) in the United States approved caffeic acid phenethyl ester (CAPE) in 2004 to treat arthritis. The Arthritis Foundation approved CAPE for treatment of rheumatoid arthritis in 2007. However, the FDA later banned the use of CAPE for this purpose in 2010. The FDA has approved caffeic acid for use as a supplement to help boost the immune system.

The American Cancer Society estimates that approximately 170,000 women in the United States will be diagnosed with breast cancer this year.

The American Cancer Society
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CAL-1011is a drug that inhibits
 
Response: CAL-1011is a drug that inhibits LPS-induced TNF-α production in human whole blood cells \[[@CR17]\]. As LPS-induced TNF-α is a key inflammatory cytokine, this study evaluated the potential of CAL-1011 to prevent and/or treat inflammatory diseases.

CAL-1011 did not show any significant cytotoxicity in human THP-1 monocytes, murine RAW 264.7 macrophages, and human primary dermal fibroblasts at the concentrations used in this study (data not shown). In addition, CAL-1011 showed no cytotoxicity in human whole blood cells at concentrations ranging from 0.5 to 10 μM, even when administered over a 4-day period (Fig. [1](#Fig1){ref-type="fig"}). Therefore, CAL-1011 showed no direct cytotoxicity at the concentrations used in this study.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Calcitriolis a drug that inhibits
 
Response: Calcitriolis a drug that inhibits the enzyme calcitriol receptor, a transcription factor that is a vitamin D receptor.

This drug can be given with vitamin D and calcium. It is available in the United States.

If you have a history of kidney stones, you may be more likely to have kidney stones again after treatment with this drug. You may need to stop using the drug before the risk of kidney stones is high.

What side effects may occur?

Call your doctor if any of these side effects occur:

Excessive sweating

Fever

Muscle weakness

Severe weakness

Symptoms of overdose may include:

Fatigue

Muscle pain

Severe weakness

Symptoms of a low blood calcium level may include:

Confusion

Dizziness

Drowsiness

Headache

Muscle weakness

Nausea

Vomiting

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  calciumis a drug that inhibits
 
Response: calciumis a drug that inhibits the action of PTH and other factors that regulate calcium levels in the body. This medication is used to treat osteoporosis, Paget's disease, hypercalcemia of malignancy, and osteolytic bone metastases.

**Side effects:** Dizziness, nausea, diarrhea, heartburn, vomiting, constipation, nervousness, anxiety, headache, dry mouth, drowsiness, fatigue, impotence, painful intercourse, irregular heartbeat, back pain, burning or tingling in hands and feet, pain in lower back and legs, pain in joints.

####  D-Phenylalanine

**dye-** **phen-** **il-** **al-** **an**

(AminoVista)

**Do not confuse D-phenylalanine with D-phenylalanine monosodium, D-phenylalanine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Camostatis a drug that inhibits
 
Response: Camostatis a drug that inhibits the expression of intercellular adhesion molecule-1 (ICAM-1) is well tolerated and effective in preventing acute ischemic stroke. The study aimed to determine the safety and efficacy of camostatis in acute ischemic stroke. A randomized, double-blind, placebo-controlled study was conducted. Patients with acute ischemic stroke were randomized to receive either intravenous camostatis (3 mg/kg) or placebo within 12 hours after symptom onset. The primary efficacy end point was the proportion of patients with an improvement of National Institutes of Health Stroke Scale (NIHSS) scores of 4 points or more at 24 hours after treatment. The secondary efficacy end points included the proportion of patients with an improvement of NIHSS scores of 4 points or more at 24 hours after treatment and the proportion of patients with a modified Rankin Scale (mRS) score of 0-2 at 90 days after treatment. A total of 150 patients were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Camptothecineis a drug that inhibits
 
Response: Camptothecineis a drug that inhibits the DNA polymerase of topoisomerase I. This drug is effective in the treatment of human breast cancer in vitro and in vivo. A clinical study has been conducted to assess the effect of camptothecin in patients with advanced cancer of the breast. This study is a randomized double-blind study, in which 30 patients were randomized into three groups: one group received 8 mg/m2 camptothecin by intravenous injection, one group received 10 mg/m2 camptothecin and one group received the placebo. The mean dose of camptothecin given was 8 mg/m2. There was a response in five patients in the 8 mg/m2 group, in three patients in the 10 mg/m2 group and in one patient in the placebo group. Toxicity was observed in all patients. The maximum toxicity was grade 3 and grade 4 neutropenia was observed in 50% of the patients.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  camylofineis a drug that inhibits
 
Response: camylofineis a drug that inhibits vascular endothelial growth factor. It is a dimethylpyridinium salt and a quaternary ammonium compound that has been used as a mitotic inhibitor. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. Camylofine is available as a generic medication. In the United States, it costs less than $1 per dose as of 2019.

References

Category:Quaternary ammonium compounds
Category:Organic sodium salts
Category:Pyridinium compounds
Category:Organic sodium salts
Category:World Health Organization essential medicines
Category:RTT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Canagliflozinis a drug that inhibits
 
Response: Canagliflozinis a drug that inhibits the enzymatic activity of the sodium/glucose co-transporter 2 (SGLT2), which is a member of the SLC5A family of solute carrier transporters. It is used in the treatment of type 2 diabetes mellitus (T2DM) and has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for this indication. In addition to its use as a treatment for T2DM, canagliflozin is being developed for other conditions, including obesity, polycystic ovary syndrome, and in the treatment of type 1 diabetes mellitus (T1DM) ([@B1],[@B2]).

Canagliflozin is primarily eliminated through the kidney ([@B3]). In addition, there is a small amount of clearance by the liver and intestine, and the bioavailability is reduced when canaglif
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Candesartanis a drug that inhibits
 
Response: Candesartanis a drug that inhibits angiotensin II (AII) receptor. It is effective in the treatment of hypertension and heart failure. The treatment with candesartan, however, may induce serious adverse reactions. In this paper, we studied the toxic effects of candesartan on C6 glioma cells and the protective effect of curcumin.

Candesartan has been approved for the treatment of hypertension and heart failure. Its therapeutic efficacy is closely related to its concentration in blood. Because of the large dose required, the treatment with candesartan can cause serious adverse reactions. It has been reported that the exposure of candesartan in vitro and in vivo may induce the toxicity of the target organ [1], [2]. In the present study, we aimed to study the toxic effects of candesartan on C6 glioma cells and to explore the protective effect of curcumin.

Materials and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  canrenoicis a drug that inhibits
 
Response: canrenoicis a drug that inhibits the enzyme that converts 5 alpha-reductase into the more potent form. Testosterone also inhibits the enzyme. It has been reported that the latter may be an important mechanism for the therapeutic effect of androgen therapy.

Dosage and administration

Injectable
It is administered intramuscularly.

References

External links
www.drugs.com
www.fda.gov

Category:Androgens and anabolic steroids
Category:Androstanes
Category:Androstanes
Category:Estranes
Category:Estradiol esters
Category:Enantiopure drugs
Category:Hepatotoxins
Category:Human drug metabolites
Category:World Anti-Doping Agency prohibited substances
Category:RTT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Capecitabineis a drug that inhibits
 
Response: Capecitabineis a drug that inhibits the action of the enzyme thymidylate synthase, thereby reducing the supply of the substrate needed to make DNA. It is also used to treat a number of other conditions, such as breast cancer, stomach cancer, and colon cancer. Capecitabine is usually given in combination with fluorouracil.

How does this drug work?

Capecitabine is an oral prodrug of 5-fluorouracil. It is broken down in the liver into 5-fluorouracil, which is then converted into the active form of the drug. This active form then blocks the production of thymidylate synthase, the enzyme that makes the precursor to DNA, which is needed for cell division.

Capecitabine may be used for other purposes. It may be used in combination with other anticancer drugs, such as 5-fluorouracil, le
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CAPEXis a drug that inhibits
 
Response: CAPEXis a drug that inhibits thymidylate synthase (TS) activity and, in combination with fluoropyrimidines, causes death in colon cancer cells. We have demonstrated that CAPE treatment can selectively sensitize TS-overexpressing colon cancer cells to 5-FU-induced cell death by increasing TS protein turnover. We found that TS-overexpressing cells were less susceptible to 5-FU than control cells. However, the CAPE-induced sensitization of TS-overexpressing cells was much more pronounced than that of control cells. In addition, the sensitization of TS-overexpressing cells to 5-FU was abolished by the overexpression of TS. Finally, we showed that CAPE increased the expression of the TS mRNA, which was mediated by a transcriptional mechanism. These results suggest that the expression of TS is one of the determinants of the sensitivity of cancer cells to CAPE-induced apoptosis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CAPITALis a drug that inhibits
 
Response: CAPITALis a drug that inhibits S-adenosylhomocysteine hydrolase (SAHH) by inhibiting the formation of S-adenosylhomocysteine (SAH). SAH is a product of methylation reactions, and is normally converted to homocysteine by the enzyme SAHH. Homocysteine is then converted to methionine by the enzyme betaine-homocysteine methyltransferase. Inhibition of SAHH results in an accumulation of SAH, which inhibits methyltransferases, including the DNA methyltransferase DNMT1, leading to DNA hypomethylation. Because of the widespread effects of DNMT1 inhibition, the drug has been shown to cause genome-wide demethylation, growth arrest, and apoptosis in cancer cells.

Tumor necrosis factor (TNF) is a cytokine that is released by the immune system in response to infection and tissue injury. TNF plays an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CAPITROLis a drug that inhibits
 
Response: CAPITROLis a drug that inhibits protein synthesis by binding to the elongation factor 2 (eEF2) on the ribosome and inhibits the activity of the GTPase domain of eEF2.

#####  USES

Used to treat acute attacks of hereditary angioedema (HAE) in adults.

#####  PRECAUTIONS

**Contraindications:** Hypersensitivity to C1-INH. **Cautions:** Hepatic/renal impairment, hypovolemia, myelosuppression, concurrent use of angiotensin-converting enzyme (ACE) inhibitors.

#####  ACTION

Inhibits conversion of angiotensin I to angiotensin II. **Therapeutic Effect:** Prevents or ameliorates HAE attacks.

#####  PHARMACOKINETICS

Rapidly absorbed after
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Capreomycinis a drug that inhibits
 
Response: Capreomycinis a drug that inhibits the growth of cancer cells in vitro and in vivo. The in vitro cytotoxicity of capreomycin is based on its activity as an intercalator of DNA and inhibition of topoisomerase II. The antitumor activity of capreomycin in murine models is based on its inhibition of DNA synthesis. However, the antitumor activity of capreomycin is also based on its activity as a mitotic inhibitor. The antitumor activity of capreomycin is likely due to the inhibition of DNA synthesis and the resulting mitotic arrest.

Intercalation

Intercalation is the binding of a ligand to a DNA molecule by wrapping the DNA around the ligand and inserting the ligand between the base pairs of the DNA. The DNA and ligand may be the same or different molecules. Intercalation of an anticancer drug into DNA inhibits replication and transcription and may induce double-str
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Captoprilis a drug that inhibits
 
Response: Captoprilis a drug that inhibits the angiotensin-converting enzyme (ACE) and therefore may inhibit the formation of angiotensin II. It is used to treat hypertension and congestive heart failure. It is a prodrug, which is converted into its active form, captopril, in the liver by carboxypeptidase-G2 (CP-G2). This review describes the pharmacokinetics and metabolism of captopril and its active metabolite, captoprilat. In addition, the effects of chronic captopril treatment on pharmacokinetics and pharmacodynamics are discussed. The development of captopril in the treatment of hypertension and congestive heart failure is described. Finally, the interactions between captopril and other drugs, such as other ACE inhibitors, digoxin, and anticoagulants, are discussed.

In humans, captopril is administered orally as a racemic mixture of its optical isomers. In
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carazololis a drug that inhibits
 
Response: Carazololis a drug that inhibits in vivo platelet aggregation and prolongs bleeding time. Because of its lack of direct anticoagulant activity, it has been proposed that carazolol's effect is due to its ability to inhibit platelet-dependent thrombin generation. The present study was designed to determine the effects of carazolol on platelet activation in whole blood in vitro. To determine the time course of platelet activation, whole blood was incubated for 0-10 min at 37 degrees C in the presence of carazolol (10(-6) M) or the solvent alone (0.1% ethanol). Platelet activation was assessed by quantifying the expression of the activation markers P-selectin, CD62P, and CD63. Carazolol was found to induce platelet activation after 2 min of incubation. This effect was dose dependent, as 10(-4) M carazolol induced platelet activation within 1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  carbacholis a drug that inhibits
 
Response: carbacholis a drug that inhibits dopamine reuptake in the brain. This is done to increase the amount of dopamine in the brain and to block the normal breakdown of dopamine, which is necessary for the breakdown of other neurotransmitters. This is an effective way to treat a number of diseases, but it has not been effective in treating patients with Parkinson's disease.

##### **MESECULA**

This term is used to refer to a combination of drugs that act on the brain and the body to improve the symptoms of Parkinson's disease. This combination of drugs includes:

• _Levodopa_, which is a drug that helps the body to make dopamine.

• _Carbidopa_, which is a drug that helps the body to metabolize levodopa.

• _Amino acid_, which is a drug that increases the availability of dopamine in the brain.

• _Anticholinergic_,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  carbadoxis a drug that inhibits
 
Response: carbadoxis a drug that inhibits fatty acid beta-oxidation. It is used to treat obesity. In fact, it is the most common drug used to treat obesity. Carbadoxis was used to treat obesity and then withdrawn because it was found to cause birth defects in babies of women who took it during pregnancy. There is a study of a compound called ciprofloxacin. Ciprofloxacin is a very potent antibiotic. It kills many bacteria. The interesting thing about it is that it also blocks fatty acid beta-oxidation. This is a very important process in the body. It is used to make energy. It is the same way that you can block the energy of ATP by blocking the energy pathway. You can block the process of making energy by blocking beta-oxidation. This was done to study the effect of blocking the process of making energy in the body. When this was done, it showed that beta-oxidation was blocked
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CARBAMAZEPINEis a drug that inhibits
 
Response: CARBAMAZEPINEis a drug that inhibits an enzyme (cyclo-oxygenase) involved in the synthesis of certain prostaglandins.

SOMATIC EMBOLISMis a disease in which there is a loss of muscle tone.

SYMPATHETIC SYSTEM is a network of nerves and tissues that control the function of various organs.

TETANUS is a disorder caused by a bacterial infection that is often acquired in early childhood.

TETANOSIS is a condition in which a child is allergic to a protein that is produced by bacteria that causes tetanus.

TOBACCO SMOKING is a habit that affects more than one in five adults in the United States.

VITAMIN B1 (thiamine) is a vitamin that helps the body produce energy.

VITAMIN B2 (riboflavin) is a vitamin that helps the body make red
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carbamyl-beta-methylcholineis a drug that inhibits
 
Response: Carbamyl-beta-methylcholineis a drug that inhibits acetylcholine-mediated transmission in the central nervous system. It is used to treat a variety of conditions including epilepsy, tremor, Parkinson's disease, anxiety, schizophrenia, and Alzheimer's disease. It is a potent, non-competitive, nicotinic receptor antagonist, with high affinity for alpha4beta2 and alpha3beta4 receptors. The purpose of this study was to determine the affinity of carbamyl-beta-methylcholine at various nicotinic receptors.

Carbamyl-beta-methylcholine has been studied as a possible antagonist of the N-methyl-D-aspartate (NMDA) receptor. It has been suggested that carbamyl-beta-methylcholine may block the NMDA receptor by competing with glycine for binding sites on the NMDA receptor complex. This study determined the affinity of carbamyl-beta-methylcholine at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carbazochromeis a drug that inhibits
 
Response: Carbazochromeis a drug that inhibits protein disulfide isomerase (PDI) by binding to its active site.^[@bib1]^ It was initially synthesized in an effort to find new anti-cancer drugs.^[@bib2]^ PDI isomerizes proteins with exposed thiol groups (such as peroxiredoxins and thioredoxins) by changing their redox state. This enzyme is overexpressed in various cancers,^[@bib3],\ [@bib4]^ and a PDI inhibitor can induce apoptosis in cancer cells by disrupting protein redox homeostasis.^[@bib5]^ Recently, carbazochrome has been shown to be a potent inhibitor of hepatitis C virus (HCV) replication.^[@bib6]^ It has been demonstrated that carbazochrome inhibits HCV replication by binding to the HCV replication complex
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carbenicillinis a drug that inhibits
 
Response: Carbenicillinis a drug that inhibits the enzyme beta-lactamase, which is the cause of the resistance to penicillins.

Bactrim (bacitracin + trimethoprim) is a combination of the two antibiotics and is available in oral, rectal, vaginal and nasal forms.

The two antibiotics have different mechanisms of action.

The combination is effective in the treatment of UTIs.

Macrolides

Macrolides are a class of antibiotics that are effective in the treatment of many infections.

They inhibit the growth of a wide variety of bacteria, including gram-positive and gram-negative bacteria, and are used in the treatment of a wide variety of bacterial infections, including:

Acute bacterial rhinosinusitis

Community-acquired pneumonia

Chronic bronchitis

Chronic gastritis

Chronic tonsillitis

Cystic fibrosis

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carbenoxoloneis a drug that inhibits
 
Response: Carbenoxoloneis a drug that inhibits aldosterone synthesis and the Na+/K+ ATPase pump. It is often used to treat the sodium and water retention associated with primary aldosteronism and also with certain forms of hypertension.

The exact mechanism of action of carbamoyl phosphate synthetase (CPS) is unknown. It is an important enzyme of the urea cycle. The enzyme catalyzes the first step in the synthesis of carbamoyl phosphate from carbamoyl aspartate and inorganic phosphate. Carbamoyl phosphate is the first intermediate in the synthesis of pyrimidine nucleotides, which are essential for DNA and RNA synthesis.

Carbamoyl phosphate synthetase is encoded by the CPS1 gene and is present in the liver and kidneys.

It was first synthesized by Ishikawa and coworkers in 1960.[1]

It is a complex enzyme with many cofactors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CARBILEVis a drug that inhibits
 
Response: CARBILEVis a drug that inhibits tumor angiogenesis. Combination therapy with carboplatin and VEGF-A or -C-blocking antibody may be an effective therapy for lung cancer.

The VEGF-A pathway plays a crucial role in tumor angiogenesis and metastasis. VEGF-A expression in lung cancer is closely related to poor prognosis and the degree of tumor differentiation, and is associated with a high rate of tumor invasion and metastasis. Therefore, VEGF-A-targeting therapy has become a promising treatment for cancer. A blocking antibody against VEGF-A (bevacizumab) has been clinically approved for lung cancer.

In addition, bevacizumab in combination with chemotherapy has been reported to be effective in patients with non-small cell lung cancer (NSCLC) with VEGF-A overexpression.

Bevacizumab has also been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carbimazoleis a drug that inhibits
 
Response: Carbimazoleis a drug that inhibits the action of the thyroid hormone thyroxine (T4) on the thyroid gland. It is also called 2-methoxy-5-isopropylphenyl-2-thiourea. It is prescribed for the treatment of hyperthyroidism.

What is the usual dose of carbimazole?

The usual dose is 30 mg/day.

How is it taken?

The usual dose is taken in the morning with or without food. It may be continued for up to 3 months.

What side effects may occur?

The most common side effects are loss of appetite, nausea, vomiting, diarrhea, rash, pruritus, and malaise.

What should be done if side effects occur?

The side effects can usually be treated with an antihistamine. If they do not improve, the dose should be reduced.

If
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carboplatinis a drug that inhibits
 
Response: Carboplatinis a drug that inhibits cell growth by alkylating DNA. Carboplatin is used to treat several types of cancer, including ovarian, lung, and head and neck cancers. Carboplatin is also used as a prophylactic measure to reduce the risk of recurrence of cancer after surgery.

A patient who has been diagnosed with cancer may be treated with carboplatin to prevent the spread of cancer cells. Carboplatin may also be used as a first-line treatment for ovarian cancer, if the cancer has not responded to other treatments. Carboplatin is also used as a second-line treatment for lung cancer.

Dosing

The dosage of carboplatin is based on the area under the concentration-time curve (AUC) and the patient's body surface area. AUC is determined by dividing the dose of carboplatin by the patient's body surface area.

Dosage is determined by the treating doctor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  carfilzomib(PR-171)is a drug that inhibits
 
Response: carfilzomib(PR-171)is a drug that inhibits the chymotrypsin-like proteasome subunit beta5 (beta5). Beta5 is the catalytic component of the chymotrypsin-like subunit of the 26S proteasome, the primary non-lysosomal protease in the cytoplasm and nucleus. It is the only proteasome subunit to be directly involved in the ubiquitin-proteasome pathway, and it is a target of immunosuppressive drugs. Carfilzomib inhibits the chymotrypsin-like activity of the proteasome, but does not inhibit the trypsin-like activity of the 20S proteasome. The proteasome is the proteolytic machinery of eukaryotic cells, responsible for the degradation of ubiquitinated proteins. Proteins targeted for degradation by the ubiquitin-proteas
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carglumicis a drug that inhibits
 
Response: Carglumicis a drug that inhibits the protein TRPV6, which is a channel that allows sodium ions to enter the cells. In the presence of this drug, the body’s sodium and potassium levels decrease, causing blood pressure to drop. In addition, this drug reduces water reabsorption, thereby reducing the level of water in the body. This may lead to a person losing water and becoming dehydrated.

If you are planning to get pregnant or are pregnant, you should not use Carglumicis. If you are breastfeeding, you should not use Carglumicis. Carglumicis may be harmful to an unborn baby or a newborn.

If you have any of these medical conditions:

kidney problems

kidney disease

heart problems

heart disease

heart failure

liver problems

liver disease

lung disease

lung cancer


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cariprazineis a drug that inhibits
 
Response: Cariprazineis a drug that inhibits the reuptake of dopamine (DA) and norepinephrine (NE) in the brain. It is approved for the treatment of schizophrenia in adults and adolescents aged 12-17 years. Cariprazine has a favorable tolerability profile, with nausea and vomiting being the most commonly reported adverse events (AEs). In this review, we provide a comprehensive review of the pharmacology, efficacy, safety, and tolerability of cariprazine, including a summary of clinical trials, safety data, and post-marketing studies.

Cariprazine is an atypical antipsychotic that was approved by the United States Food and Drug Administration in December 2013. Cariprazine is a DA and NE reuptake inhibitor. It is approved for the treatment of schizophrenia in adults and adolescents aged 12-17 years. Cariprazine has a favorable tolerability profile, with nausea and vomiting being the most commonly reported A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carmofuris a drug that inhibits
 
Response: Carmofuris a drug that inhibits TNF. Its use has been associated with significant toxicity in multiple studies.

Background

TNF is a proinflammatory cytokine produced by activated macrophages and T-cells that has a major role in the pathogenesis of rheumatoid arthritis. It is a transmembrane protein that binds to two receptors, TNFR1 and TNFR2. It is expressed in most tissues and plays a role in a variety of physiological processes.

TNF is a key mediator of the inflammatory response in rheumatoid arthritis. The production of TNF is increased in the serum of patients with rheumatoid arthritis and blocking its action results in decreased joint inflammation.

The use of TNF inhibitors in rheumatoid arthritis has been associated with a number of severe adverse effects, including infection, pancreatitis, and demyelination.

Carmofuris is a specific inhibitor of T
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Carteololis a drug that inhibits
 
Response: Carteololis a drug that inhibits fatty acid synthase. Studies show that this drug helps prevent new tumor growth. But can this drug help cure cancer?

Answer:

Fatty acid synthase (FASN) is a protein that helps the body make fatty acids. Fatty acids are used by the body to make hormones and for energy. Fatty acids are made by the body and are also found in food. Fatty acids can be either saturated or unsaturated. Saturated fatty acids have the same number of carbon atoms and hydrogen atoms. Unsaturated fatty acids have one or more double bonds. There are two types of unsaturated fatty acids, omega-3 and omega-6. Fatty acids are used in cell membranes.

Fatty acid synthase is involved in making fatty acids. Fatty acids are a type of fat that are needed by the body. Fatty acids are made by the body and are also found in food. Fatty
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CARVEDILOLis a drug that inhibits
 
Response: CARVEDILOLis a drug that inhibits the enzyme, carnitine palmitoyltransferase 1, and therefore enhances the effects of the fat-burning enzyme, uncoupling protein 2. In a small clinical trial, patients taking CARVEDILOL experienced a 20% increase in fat oxidation and had improved exercise performance during endurance training.1

Mice were also given CARVEDILOL. Those that were fed a high-fat diet gained less weight than the control mice, which is a normal response to a high-fat diet. When these mice were challenged with a high-fat diet, the CARVEDILOL-treated mice lost more weight and had improved insulin sensitivity and fatty liver.2

In humans, CARVEDILOL is given to patients who have a high risk of developing Type 2 diabetes and are on insulin. It increases the fat oxidation in the liver and muscles. The researchers have shown that CARVEDILOL is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Caryophylleneis a drug that inhibits
 
Response: Caryophylleneis a drug that inhibits the breakdown of the mitochondrial enzyme pyruvate dehydrogenase, causing buildup of the pyruvate that leads to lactic acidosis. A single dose of 400mg can cause acute lactic acidosis.

3

The anion gap is the difference between the concentration of the anions in the blood and the concentration of the anions in the serum. In anion gap acidosis, the concentration of the anions in the blood is greater than the concentration of the anions in the serum. This difference is caused by the accumulation of the anions in the blood, due to the breakdown of the cell membrane. The anions in the blood are typically the negatively charged ions, such as chloride and bicarbonate. The anions in the serum are typically positively charged ions, such as sodium and potassium.

4

Corticosteroids are anti-inflammatory drugs.

5

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Casanthranolis a drug that inhibits
 
Response: Casanthranolis a drug that inhibits the formation of the endocannabinoid, 2-AG. It may also inhibit fatty acid amide hydrolase, an enzyme that breaks down anandamide, another endocannabinoid. These drugs could help to treat certain types of anxiety.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Caspofunginis a drug that inhibits
 
Response: Caspofunginis a drug that inhibits the growth of fungi by interfering with the synthesis of the fungal cell wall, which is made of a mixture of polysaccharides and proteins. It is an echinocandin and belongs to the polyketide family of antibiotics. Caspofungin is used to treat serious fungal infections in immunocompromised patients, particularly those with a hematological malignancy. Caspofungin was approved by the FDA in 2002 and is marketed as Fungizone^®^. It is a white to off-white powder, soluble in water, and stable in solution for at least 2 months.

In 2004, the US Pharmacopeia (USP) added caspofungin as an approved drug for a specific assay, the determination of the amount of caspofungin in human serum by the enzyme multiplied immunoassay technique (EMIT). Since then, the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CATAFLAMis a drug that inhibits
 
Response: CATAFLAMis a drug that inhibits the production of a chemical called tumour necrosis factor-alpha (TNF-alpha). This chemical is important in the body's response to inflammation.

CATAFlAMis a drug that inhibits the production of a chemical called tumour necrosis factor-alpha (TNF-alpha). This chemical is important in the body's response to inflammation.

CATAMfloxacin is a broad-spectrum antibacterial drug. It is used to treat many infections.

CATAMfloxacin is a broad-spectrum antibacterial drug. It is used to treat many infections.

CATANfamicin is an antibacterial drug used to treat infections.

CATARfusidic acid is an antibacterial drug used to treat infections.

CATAMtetracycline is an antibacterial drug used to treat infections.

CATAT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Catecholis a drug that inhibits
 
Response: Catecholis a drug that inhibits catechol-O-methyltransferase (COMT), an enzyme that metabolizes dopamine and norepinephrine in the brain, was administered to two groups of subjects: healthy controls and patients with social anxiety disorder (SAD). The authors found that patients with SAD showed greater reduction in anxiety after taking the drug compared to healthy controls. These results suggest that catecholamines in the brain may play a role in the pathophysiology of SAD.

Using magnetic resonance imaging, the authors found that patients with SAD had a significantly greater decrease in the volume of the left amygdala and left thalamus after taking catecholis a drug that inhibits catechol-O-methyltransferase (COMT), an enzyme that metabolizes dopamine and norepinephrine in the brain, compared to healthy controls. This finding suggests that catecholamines in the brain may play a role in the pathophysiology of SAD.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Catharanthineis a drug that inhibits
 
Response: Catharanthineis a drug that inhibits tubulin polymerization. Its antineoplastic activity is similar to that of colchicine, but the drug has a different toxicity profile. Catharanthine was originally isolated from the South American plant Catharanthus roseus, and is currently in clinical trials.

Chemistry
Catharanthine is a natural compound that belongs to the class of indole alkaloids. It is a spiro-indol alkaloid and its molecular formula is C26H32N2O4. The core of the molecule is a C26 spiro-tetrahydroindole, which is attached to an N-methoxybenzoyl moiety. The spiro-tetrahydroindole is attached to the N-methoxybenzoyl moiety through a methylene bridge. The nitrogen atom that is bonded to the benzoyl moiety is in a p
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CAVERJECTis a drug that inhibits
 
Response: CAVERJECTis a drug that inhibits glutamate release and is useful for the treatment of hypoxic and ischemic brain damage and various neurological disorders such as migraine and epilepsy.^[@ref1]^ Glutamate is the major excitatory neurotransmitter in the central nervous system. Excitatory amino acids (EAA) such as glutamate and aspartate play a key role in the pathogenesis of many neurological disorders including stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and epilepsy.^[@ref2]^ Excitotoxicity occurs when the level of glutamate in the synaptic cleft becomes elevated above a threshold level, which results in overstimulation of postsynaptic receptors, particularly *N*-methyl-D-aspartate (NMDA) receptors.^[@ref3]^ Excitotoxicity causes irreversible damage to the brain and has been implicated in the pathogenesis of many neurodegenerative diseases such as Parkinson's
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CB-5083is a drug that inhibits
 
Response: CB-5083is a drug that inhibits the enzyme farnesyltransferase, a key enzyme in the post-translational modification of proteins. Inhibition of this enzyme prevents the attachment of a poly-isoprenoid (farnesyl) to a protein, which is required for its normal function.

Medical uses

BC-5083 is under investigation for the treatment of cancer and other diseases, such as:

Breast cancer (in combination with tamoxifen)
Colon cancer (in combination with cisplatin)
Lung cancer (in combination with gemcitabine)
Leukemia (in combination with standard chemotherapy)
Melanoma

Pharmacology

Mechanism of action

BC-5083 inhibits the enzyme farnesyltransferase, an enzyme that attaches a farnesyl group to the C-terminal cysteine of a protein. The resulting modified protein is then transported from the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CB-839is a drug that inhibits
 
Response: CB-839is a drug that inhibits VEGF receptor signaling in endothelial cells, resulting in an antiangiogenic effect. As such, it is expected to reduce the risk of recurrent stroke and improve functional outcome in patients with acute ischemic stroke. The objective of this study was to assess the safety and tolerability of a single oral dose of CB-839 in healthy subjects. This randomized, placebo-controlled, double-blind, phase 1, ascending dose study included 5 cohorts of 12 healthy subjects each. CB-839 was administered at doses of 5, 15, 25, 50, and 100 mg. Plasma samples were collected at scheduled time points for up to 48 hours post-dose. Safety assessments included monitoring of adverse events, vital signs, clinical laboratory tests, electrocardiogram, and physical examinations. CB-839 was well tolerated at all doses. The most common adverse events were headache, nausea, and fatigue. All subjects in the 5 cohorts were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CC-122is a drug that inhibits
 
Response: CC-122is a drug that inhibits the activity of one of the key proteins in the citric acid cycle, a protein called fumarate hydratase. Fumarate hydratase is an enzyme that normally breaks down fumarate to produce a compound called succinate. In some types of cancer, fumarate hydratase is mutated or not working correctly, which causes it to produce more fumarate. The increased levels of fumarate cause cancer cells to die. The CC-122 drug is designed to target and destroy cancer cells that have this mutation.

Results

The team studied the effects of CC-122 in a number of human cancer cell lines that had been genetically modified to cause them to overproduce fumarate. The CC-122 drug reduced the production of fumarate in all of these cell lines. The drug also caused cells to die and stop dividing. The team found that this drug also reduced the growth of tum
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CC-223is a drug that inhibits
 
Response: CC-223is a drug that inhibits the growth of the cell by inhibiting tubulin polymerization and prevents microtubule formation, which is necessary for the growth of the cell \[[@B36-ijerph-17-05399]\]. It is a commonly used anticancer drug that is used for the treatment of a variety of solid tumors, including breast, ovarian, and prostate cancer \[[@B37-ijerph-17-05399]\]. However, the cytotoxicity of doxorubicin is the main drawback of this drug. Therefore, we examined whether this drug can inhibit the growth of breast cancer cells in vitro and in vivo. The results of the CCK-8 assay indicated that the inhibitory effect of MCC-223 on the growth of breast cancer cells was time-dependent. MCC-223-treated cells exhibited significantly lower proliferation than untreated cells. The CCK-8 assay also indicated that MCC-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CCT245737is a drug that inhibits
 
Response: CCT245737is a drug that inhibits HIV infection by interfering with HIV entry into the host cell. It is effective against R5 and X4 HIV strains and also has potent anti-HIV activity against a broad range of HIV isolates including those resistant to other antiviral drugs.

Sanger-96 is a novel broad-spectrum anti-HIV agent with potent activity against wild-type and multi-drug resistant HIV. Sanger-96 is a novel broad-spectrum anti-HIV agent with potent activity against wild-type and multi-drug resistant HIV.

Sustiva is a drug that inhibits HIV infection by interfering with HIV entry into the host cell. It is effective against R5 and X4 HIV strains and also has potent anti-HIV activity against a broad range of HIV isolates including those resistant to other antiviral drugs.

Sustiva is a drug that inhibits HIV infection by interfering with HIV entry into the host
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CEENUis a drug that inhibits
 
Response: CEENUis a drug that inhibits the binding of TNF-alpha to its receptors, preventing the subsequent signaling cascade. It has been shown to have therapeutic effects in animal models of rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory diseases. We performed a Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of cetuximab in combination with weekly low-dose methotrexate in patients with moderate to severe plaque psoriasis. Thirty-five patients received cetuximab, starting at 250 mg/m2 and escalating in 250 mg/m2 increments up to the maximum dose of 750 mg/m2, with a weekly dose of methotrexate, 10 mg/m2. The primary outcome measure was safety. Secondary outcome measures included pharmacokinetics, biologic activity, and efficacy. Twenty-seven patients completed the study. One patient had an allergic reaction
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefazolinis a drug that inhibits
 
Response: Cefazolinis a drug that inhibits the growth of bacteria, and is used to treat bacterial infections of the skin and respiratory tract. It is also used to treat surgical site infections.

Uses

Cefazolin is used to treat bacterial infections of the skin and respiratory tract.

Cefazolin is used to treat surgical site infections.

Dosage

Cefazolin is usually given by injection. The dose of cefazolin is based on the body weight of the patient.

Cefazolin is usually given by injection. The dose of cefazolin is based on the body weight of the patient.

How to use cefazolin

Use Cefazolin as directed by your doctor or pharmacist. Do not use cefazolin for longer than recommended by your doctor.

Use Cefazolin as directed by your doctor or pharmacist. Do not use cefaz
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CEFDINIRis a drug that inhibits
 
Response: CEFDINIRis a drug that inhibits the cytochrome P450 1A2 enzyme, which is responsible for the metabolism of several commonly used medications. Its use in the United States was limited by reports of severe liver injury, but these cases were later shown to be due to the concomitant use of other medications. It is available in the United States as an oral suspension for oral administration and a topical gel for application to the skin. The gel is used to treat fungal infections of the skin and is approved for use in the United States.

INVESTIGATIONAL DRUG:

**adapalene** (Differin)

**BIOLOGICAL:**

**steroidal anti-inflammatory drug**

**CONTRACEPTIVES:**

**inhibits sperm motility, increases sperm membrane rigidity, may prevent fertilization**

#####  USES

Treatment of mild to moderate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefoperazoneis a drug that inhibits
 
Response: Cefoperazoneis a drug that inhibits bacterial cell wall synthesis by blocking the formation of peptidoglycan. It is used to treat serious infections caused by susceptible organisms. Cefoperazone is a first generation cephalosporin. It is effective against a broad spectrum of gram-positive and gram-negative organisms. The spectrum of activity of cefoperazone includes Haemophilus influenzae, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Serratia, Salmonella, Shigella, Citrobacter, Morganella, Enterobacter, Serratia, Citrobacter, Morganella, Proteus, and Pseudomonas aeruginosa. 
Cefoperazone is available as an injectable solution for infusion. It is available in 50 mg/ml and 100 mg/ml concentration.
The injectable form
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefoselisis
 
Response: Cefoselisis

Cefoselisis is a group of cephalosporins which have the general formula:

In which X is —(CH2)n— or —CH2—C(O)—, and n is an integer of 0-5.  The —CH2—C(O)— group is known as the 4-aminomethyl-3-cefoseloxacin group, which is abbreviated as a-CH2—C(O)—C(O)NH2.

Cefoselisis are synthetic broad-spectrum cephalosporins.  The first cefoselisis was discovered in the late 1970s.  It was the first of the new generation of cephalosporins and its cefoselisis designation comes from the word "cefosel" in the cephalosporin name.  The name "ce
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefotaximeis a drug that inhibits
 
Response: Cefotaximeis a drug that inhibits bacterial DNA gyrase and topoisomerase IV and is one of the most commonly used β-lactam antibiotics. It is used to treat a wide range of infections including those caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Neisseria gonorrhoeae*, *Staphylococcus aureus*, and *Escherichia coli*. It has been used in combination with other antimicrobial agents for treatment of infections caused by extended spectrum β-lactamase (ESBL)-producing organisms. These organisms are generally resistant to many other β-lactam antibiotics, and they are a major cause of nosocomial and community-acquired infections. Resistance to β-lactam antibiotics can be acquired either by acquisition of new β-lactamases or by alteration of existing β-lactamases.

The ESBLs are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefoxitinis a drug that inhibits
 
Response: Cefoxitinis a drug that inhibits the activity of the cytochrome P450 enzyme 3A4. It is an older antibiotic, first used in the 1940s, but not widely used any more. It is no longer recommended in treatment of mild to moderate cases of urinary tract infections (UTIs). It is not recommended for use in patients with serious liver disease.

**Precautions:** Cefoxitin may be associated with hypersensitivity reactions, including anaphylaxis. It is not recommended in patients with kidney or liver disease. It is not recommended in patients with intestinal infections. It is not recommended in pregnant women.

#####  ACTION

Inhibits cell wall synthesis by binding to peptidoglycan precursors. **Therapeutic Effect:** Bactericidal.

#####  PHARMACOKINETICS

Well absorbed after PO administration. Protein binding: 95%. Widely distributed. Metabol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ceftazidimeis a drug that inhibits
 
Response: ceftazidimeis a drug that inhibits a cell wall enzyme. It is used in combination with other drugs to treat certain types of infections caused by certain bacteria.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CEFTINis a drug that inhibits
 
Response: CEFTINis a drug that inhibits the action of tumor necrosis factor-alpha (TNF-alpha) in the body.

TNF-alpha is a protein that stimulates inflammation in many tissues. Cetilinib inhibits the action of TNF-alpha, which can stop the body's inflammatory response.

The immune system is responsible for fighting infections and repairing damaged tissues. Cetilinib may interfere with the body's immune system.

Cetilinib may interfere with the way the body processes blood sugar levels. People with diabetes have an increased risk of serious health problems, including heart disease, eye problems, and stroke.

This medicine may be harmful to the lungs. This can happen because the drug may increase the chances of people getting pneumonia.

Use with caution in people who have had serious heart problems.

The long-term effects of using cetilinib are not known.

Cetilin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ceftiofuris a drug that inhibits
 
Response: Ceftiofuris a drug that inhibits the action of β-lactamases. As a result, the activity of cephalosporins and penicillins is not inhibited. The use of ceftiofur in swine has been approved by the Food and Drug Administration for treatment of a wide range of diseases. The most common indication is for the treatment of neonatal pigs, particularly for those which have a higher risk of infection. Other common indications are for treatment of respiratory diseases in young pigs, treatment of infectious bronchitis in older pigs, and treatment of pigs infected with Actinobacillus pleuropneumoniae. In the past, ceftiofur has been administered to swine as a single dose of 2.2 mg/kg of body weight. However, ceftiofur is currently available as a product which includes ceftiofur crystalline free acid in the form of a lyophilized product, ceftio
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ceftizoximeis a drug that inhibits
 
Response: Ceftizoximeis a drug that inhibits beta-lactamase production. It is administered intravenously.

Indications

Ceftizoxime is used in the treatment of serious infections caused by beta-lactamase producing strains of gram-negative bacteria.

It is also used for prophylaxis of infection in patients undergoing surgery, chemotherapy, or radiation therapy, and in the prevention of infection in patients receiving immunosuppressive agents.

The recommended dose is 2 g every 8 hours.

Ceftizoxime may be administered as a single dose.

The antibiotic should be given before the start of surgery, chemotherapy, or radiation therapy.

It is given intravenously, by infusion or by continuous infusion.

Ceftizoxime is contraindicated in patients with a history of hypersensitivity to the drug or its excipients.

The drug should be used with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ceftriaxoneis a drug that inhibits
 
Response: Ceftriaxoneis a drug that inhibits the growth of gram-negative bacteria. It is used in the treatment of a variety of bacterial infections, including infections of the urinary tract, middle ear, respiratory tract, skin and soft tissues, and intra-abdominal infections. It is a cephalosporin and is available as a 1-g single-dose vial. Ceftriaxone is used for both acute and chronic infections and has a broad spectrum of activity. It is used as a single-agent therapy for community-acquired infections, including meningitis, and for infections of the respiratory tract, urinary tract, skin and soft tissues, and intra-abdominal infections.

Ceftriaxone is available in injectable form, in oral suspension form, and in oral and injectable form. The injectable form is used for treating urinary tract infections, meningitis, and intra-abdominal infections. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cefuroximeis a drug that inhibits
 
Response: Cefuroximeis a drug that inhibits the enzyme beta-lactamase. Cefuroxime is available as a suspension and a solution for intravenous infusion.

Cefuroxime is used to treat the following conditions:

Acute bacterial rhinosinusitis (sinus infection)

Bacterial infections of the urinary tract

Bacterial meningitis

Bacterial pneumonia

Bone and joint infections

Community-acquired bacterial pneumonia

Endocarditis

Tonsillitis

Tracheobronchitis

Viral infections of the respiratory tract

It may also be used to prevent the following conditions:

Prophylaxis for respiratory tract infections in patients undergoing abdominal surgery

What is the most important information I should know about cefuroxime?

You should not use cefuroxime if you have an allergy to cefuroxime, ceft
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Celecoxibis a drug that inhibits
 
Response: Celecoxibis a drug that inhibits COX-2, the inducible isoform of cyclooxygenase (COX). It is approved for the treatment of rheumatoid arthritis and other forms of osteoarthritis. It has also been investigated in the treatment of a number of other conditions, including cardiovascular disease, and cancer.

There is some evidence that it may be beneficial in treating arthritis. A systematic review of six randomised trials found it to be better than placebo, and in two of the trials better than the older NSAIDs.[@R1] [@R2] In contrast, the Cochrane review of 21 randomised controlled trials (RCTs) found that it was no better than placebo.[@R3] There were a number of reasons for this. One was that it is not a panacea. The majority of the trials involved patients with rheumatoid arthritis, and patients with osteoarthritis were not included.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CELESTONEis a drug that inhibits
 
Response: CELESTONEis a drug that inhibits or prevents cell proliferation. The efficacy of this drug depends on the dose, route of administration, and the type of cancer. The maximum tolerated dose (MTD) of CELESTONE is 20 mg/m2/day given intravenously for 5 days in a 21-day cycle.

DESCRIPTION

CELESTONE is an intravenously administered anticancer drug that is being developed by Celgene Corporation (A.G.) for the treatment of patients with advanced or refractory solid tumors. It is also being developed for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). CELESTONE inhibits cell proliferation by preventing cells from replicating DNA. CELESTONE is currently in Phase II clinical development for the treatment of patients with solid tumors, non-Hodgkin's lymphoma, and CLL.

CELESTONE has a well
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Celiprololis a drug that inhibits
 
Response: Celiprololis a drug that inhibits the action of a substance called TNF-alpha. It is given by injection into a vein.

Humira is a drug that blocks the activity of a substance called TNF-alpha. It is given by injection into a vein.

Humira is used to treat a variety of conditions that involve inflammation, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease.

A variety of skin conditions, such as psoriasis and eczema, may be treated with Humira.

A number of infections, including HIV, may be treated with Humira.

You may be given Humira by injection, in a vein (intravenously). This is usually done every 4 weeks, but the dosage may be changed to fit your needs.

A doctor may give Humira to you by injection into a vein (int
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CELLCEPTis a drug that inhibits
 
Response: CELLCEPTis a drug that inhibits cyclin-dependent kinases (CDKs) and thus blocks the transition from the G1 to the S phase of the cell cycle.^[@bib1]^ This agent has a favorable toxicity profile and is generally well tolerated, but it has not been approved for the treatment of patients with solid tumors, including those with recurrent and/or metastatic (R/M) breast cancer.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ In preclinical models, CELLCEPT has been shown to inhibit the growth of human breast cancer xenografts and to induce tumor regression, but the mechanism(s) of action has not been fully elucidated.^[@bib8]^ Here, we report a comprehensive characterization of the pharmacology of CELLCEPT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CEPHALEXINis a drug that inhibits
 
Response: CEPHALEXINis a drug that inhibits the production of a chemical messenger (cystatin C) that helps your body clean up waste. It is used to treat inflammation and can also be used to help decrease the amount of sugar in your blood after you have a kidney transplant.

I am taking Cephalanin for a few days and after the first dose I got sick with a sore throat, headache, nausea, vomiting, and some stomach pain. I think I will be fine after a few days, but if you get sick or have a reaction, tell your doctor.

I am taking Cephalanin for a few days and after the first dose I got sick with a sore throat, headache, nausea, vomiting, and some stomach pain. I think I will be fine after a few days, but if you get sick or have a reaction, tell your doctor.

Anonymous

I just received my cephalexin. I
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  cephapirinis a drug that inhibits
 
Response: cephapirinis a drug that inhibits RNA polymerase I. The drug has been approved for treatment of hepatitis C in the USA and in Europe. The drug is administered in combination with interferon alfa.

####  AZT

The antiretroviral drug zidovudine is active against HIV, but has not been found to be effective against hepatitis C.

####  INFALAVIR

The antiretroviral drug combination of indinavir, ritonavir and lamivudine is effective against HIV and hepatitis C. It is administered in combination with interferon alfa and ribavirin.

####  LAMIVUDINE

The antiretroviral drug lamivudine is active against HIV. It is used in combination with other antiretroviral drugs, including zidovudine and indinavir.

####  RIBAVIRIN


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cepharanthineis a drug that inhibits
 
Response: Cepharanthineis a drug that inhibits the activity of the enzyme cAMP-dependent protein kinase, and has been found to possess significant anti-cancer properties. Its effect on the development of experimental skin cancer has been studied in mice by using a potentiating agent, 5-bromodeoxyuridine (BrdUrd), which can be detected immunohistochemically. The aim of the present study was to investigate whether cepharanthine can prevent the development of a murine skin tumour by a similar mechanism. Mice were given topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA) to induce tumour development. When a single application of TPA was given, the incidence of papillomas and squamous cell carcinomas (SCCs) was 80% and 25%, respectively. The addition of cepharanthine (5 mg/kg) 1 day before the application
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cerdulatinibis a drug that inhibits
 
Response: Cerdulatinibis a drug that inhibits BCR-ABL tyrosine kinase. It is approved for the treatment of adult patients with chronic-phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML-CP) in the USA and EU. In the USA, it is also approved for the treatment of adult patients with CML-CP who have received prior therapy, and in the EU, it is also approved for the treatment of adult patients with CML-CP who have failed prior therapy.[@b1-mjhid-11-1-e2019045]

The efficacy of cerdulatinib in CML-CP was evaluated in two phase II studies (POLLUX and CIRCLIS). In the POLLUX study, patients received cerdulatinib at a dose of 400 mg once daily, which was selected based on the safety and efficacy data from the CIRCLIS study. A total
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CETACORTis a drug that inhibits
 
Response: CETACORTis a drug that inhibits cortisol (hydrocortisone) biosynthesis. The cortisol is a steroid hormone that stimulates several physiological processes in the body.

Drug Description

CETACORTis a drug that inhibits cortisol (hydrocortisone) biosynthesis. The cortisol is a steroid hormone that stimulates several physiological processes in the body.

Brand Name

CETACORTis a generic drug that can be used to treat many conditions. It is available as a solution to be given orally.

Dosage

The recommended dose of CETACORTis one tablet orally, twice a day.

Side Effects

Side effects of CETACORTis include:

nausea

vomiting

diarrhea

dizziness

headache

drowsiness

tremor

dry mouth

mild stomach cramps

Other Side Effects


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CETIRIZINEis a drug that inhibits
 
Response: CETIRIZINEis a drug that inhibits the function of phosphodiesterase 4 (PDE4) enzyme, thereby increasing the concentration of cyclic adenosine monophosphate (cAMP) in the brain. In the brain, cAMP mediates many functions, including memory and learning. The cAMP levels increase in response to learning. In fact, there is a direct relationship between the amount of cAMP in the brain and the ability to learn. In this way, cAMP mediates learning and memory in the brain. In addition, cAMP is also a secondary messenger in the immune system.

CETIRIZINE can cause side effects. The most common of these are headache, drowsiness, and tremor. In some patients, these side effects are severe. These side effects are more likely to occur when the drug is taken at high doses or when it is taken with alcohol. If you experience any of these side effects, call your doctor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  cetrimoniumis a drug that inhibits
 
Response: cetrimoniumis a drug that inhibits gastric acid secretion. It is available as a tablet, solution, suspension, and syrup.

▪ INDICATIONS: It is prescribed for treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and as a first-line treatment for erosive esophagitis.

▪ CONTRAINDICATIONS: Hypersensitivity to cimetidine prohibits its use. It should be used with caution in patients with peptic ulcer disease and concurrent use of anticoagulants.

▪ ADVERSE EFFECTS: Overdose can produce hypotension, bradycardia, drowsiness, dizziness, dry mouth, blurred vision, skin rash, and pruritus.

cimetidine /sē′mə-tid″nē/, a histamine H2 receptor antagonist, used in the treatment of du
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cetylpyridiniumis a drug that inhibits
 
Response: Cetylpyridiniumis a drug that inhibits the action of acetylcholine (ACh) by blocking its binding to the postsynaptic membrane receptor at the neuromuscular junction. It is used to treat myasthenia gravis, a disease that affects the muscles. Cetylpyridinium is also used in products that help the body eliminate harmful substances such as ammonia.

What are the side effects of cetylpyridinium?

Cetylpyridinium is not known to cause serious side effects. However, the side effects that have been reported in patients taking cetylpyridinium include:

When taking cetylpyridinium for an extended period of time, it may cause the following side effects:

Problems with hearing and vision.

These side effects may go away after you stop taking cetylpyridinium
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cevimelineis a drug that inhibits
 
Response: Cevimelineis a drug that inhibits melanin production in the skin. This can result in a lightening of the skin.

Cevimeline is also used for treating symptoms of irritable bowel syndrome (IBS).

Melanin is a natural skin pigment. It is found in the skin and hair of all people. Melanin protects the skin from the harmful effects of ultraviolet (UV) radiation from the sun.

However, the melanin in the skin also gives the skin a brown or black appearance.

When too much melanin is produced, it can cause the skin to darken. This is called hyperpigmentation.

It can also be caused by medications, such as psoralens and ultraviolet light therapy (PUVA), used to treat certain skin conditions.

Cevimeline belongs to a group of medications called alpha-melanocyte stimulating hormone (alpha-MSH).

It works by stopping
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CH5183284is a drug that inhibits
 
Response: CH5183284is a drug that inhibits the formation of HIV viral particles. Atovaquone is being developed by Gilead Sciences.

Dapsone 

Dapsone (4,4'-diaminodiphenyl sulfone) is an anti-inflammatory drug that has been used in the treatment of P. falciparum malaria.

Rifampin 

Rifampin (Rifadin) is an antibiotic. It was approved by the FDA in 1978. It has been used in combination with other drugs in the treatment of P. falciparum malaria.

Mefloquine 

Mefloquine (Lariam) is an anti-malarial drug. It was developed by Roche and marketed by Hoffmann-La Roche. It was the first oral anti-malarial drug. It was approved in 1987. It is effective in treatment of malaria caused by P
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CHENIXis a drug that inhibits
 
Response: CHENIXis a drug that inhibits the cyclin-dependent kinase 2 (CDK2), thereby blocking the cell cycle in the G1 phase and subsequently inducing apoptosis. It was first described as a potential treatment for cancer in 1995, but clinical trials have been hampered by toxic side effects and the fact that the agent was poorly tolerated by the patients. However, a new formulation of CHENIX (m-AMSA/CHENIX) has been developed, which overcomes the low bioavailability of the original formulation. A phase II trial showed that the new formulation of CHENIX had a better safety profile than m-AMSA, and was well tolerated by the patients. The new formulation is being tested in a number of phase II and III clinical trials for a range of malignancies. In this review, the authors discuss the preclinical and clinical development of CHENIX.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CHIBROXINis a drug that inhibits
 
Response: CHIBROXINis a drug that inhibits the activity of a certain enzyme that is found in some human cells.

Chibroxin can be used to treat stomach ulcers, stomach and duodenal ulcers, certain stomach cancers, and gastroesophageal reflux disease (GERD).

Dosage

Chibroxin is taken by mouth. The usual dose is 250 milligrams once daily.

Chibroxin Side Effects

The most common side effects include diarrhea, nausea, vomiting, abdominal pain, and headache. Chibroxin may also cause dizziness, hair loss, insomnia, rash, and fatigue. Severe side effects include bleeding in the stomach, and shortness of breath.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloramine-Tis a drug that inhibits
 
Response: Chloramine-Tis a drug that inhibits the production of interferon-gamma (IFN-gamma). Chloramine-T may be a potential anti-allergic drug for the treatment of bronchial asthma and allergic rhinitis. To investigate the influence of chloramine-T on the functions of eosinophils, the release of cytotoxic granule proteins from eosinophils was studied by flow cytometry. Chloramine-T at a concentration of 1.0 microM did not inhibit the release of eosinophil cationic protein (ECP) or eosinophil-derived neurotoxin (EDN). However, it inhibited the release of eosinophil-derived ribonuclease (EDR) at a concentration of 1.0 microM and 0.1 microM, respectively. The release of major basic protein (MBP) was also inhibited by chloramine-T
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorhexidineis a drug that inhibits
 
Response: Chlorhexidineis a drug that inhibits the growth of a variety of bacteria. It has been in use for decades and has a very good safety record. It has also been found to inhibit the growth of Candida albicans, which can cause oral thrush.

There are a number of other medications that are used to treat oral thrush. One of the most effective is nystatin. It has been shown to be effective in both treating and preventing oral thrush. It is also effective in preventing infection in those with an immune deficiency. It is not recommended in pregnant women or in those with allergies to yeast or other medications.

Echinacea is a herbal remedy that has been used for centuries to treat a variety of illnesses. It is believed to have antiviral and antibacterial properties and has been used to treat a number of different infections. It is believed to be helpful in the treatment of oral thrush.

There are a number of different herbs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloroambucilis a drug that inhibits
 
Response: Chloroambucilis a drug that inhibits tumor cell proliferation by blocking the synthesis of DNA. The drug is used in the treatment of non-Hodgkin's lymphoma, leukemia, and melanoma. It is an active agent in the treatment of small cell lung cancer. It is also used in combination with other chemotherapeutic agents to treat other solid tumors, including breast cancer, and Hodgkin's disease. Chlorambucil is administered by injection or infusion. It is given as a single agent or in combination with other drugs.

#####  PRECAUTIONS

**Contraindications:** Hypersensitivity to chlorambucil. **Cautions:** Renal impairment, GI disorders, cardiovascular disease, elderly, bone marrow depression.

#####  ACTION

Inhibits DNA synthesis by interfering with deoxyribonucleic acid polymerase, a DNA-synthesizing enzyme. **Therape
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  chlorocresolis a drug that inhibits
 
Response: chlorocresolis a drug that inhibits the binding of thyroid hormones to serum protein, and therefore enhances their concentration in serum.

Drug interactions 

Clofibrate has the potential to interact with many drugs, including warfarin, diazepam, phenytoin, carbamazepine, phenobarbital, and nifedipine. These interactions may be either inhibitory or stimulatory, and can include both decreased or increased plasma concentrations of the drug in question. This is the main reason why the drug is not recommended in patients with these conditions.

The increased concentration of phenytoin may lead to greater effects of phenytoin and, as a result, to seizures.

The increased concentration of nifedipine may lead to a lower heart rate and to less blood pressure control.

Clofibrate should not be used in patients who have used bezafibrate, ciprofloxac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorogenicis a drug that inhibits
 
Response: Chlorogenicis a drug that inhibits cholesterol synthesis, which has a lot of medical applications. It can also inhibit the activity of cancer cells. It has been found to be useful in the treatment of cancer, epilepsy, gout, hypertension, arthritis, osteoporosis, diabetes, skin diseases, viral diseases, Alzheimer's disease, psoriasis, and even liver diseases.

It has been shown to be effective in the treatment of rheumatoid arthritis. Chlorogenic acid is also used as a non-steroidal anti-inflammatory drug. It is also used in the treatment of cardiovascular diseases.

Chlorogenic acid can be used in the treatment of skin diseases. It has been found to be effective in the treatment of acne. It is also effective in the treatment of psoriasis and dermatitis.

It has been shown to be effective in the treatment of cancer. Chlorogenic acid is used in the treatment of cancers like lung, breast,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorophyllinis a drug that inhibits
 
Response: Chlorophyllinis a drug that inhibits the enzyme chlorophyllase. Chlorophyllis, or chlorophyllin, is produced by the fermentation of plants of the cabbage family. Chlorophyllin has been used as a drug for over 80 years to treat or prevent a variety of diseases.

Drug Class: Antibacterial, Antimicrobial, Antifungal, Antiprotozoal

Subclass: Nitroderivatives

Mode of Action: It is a weakly basic, nitroaromatic drug that forms a complex with free chlorophyll and inactivates it by oxidation of the porphyrin ring.

Uses: It is used to treat bacterial and fungal infections of the skin and urinary tract. It is used in combination with other antimicrobial drugs to treat urinary tract infections caused by Escherichia coli and Staphylococcus saprophyticus. It is used to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloroprocaineis a drug that inhibits
 
Response: Chloroprocaineis a drug that inhibits the propagation of action potentials in the peripheral nervous system. It is used to control pain in the peripheral nervous system and the central nervous system.

Nabumetone is a drug used to treat pain. It may be used with other drugs to treat pain. It is also used to treat inflammation. It may also be used for other purposes not listed here.

Lidocaine is a drug that inhibits the propagation of action potentials in the peripheral nervous system. It is used to control pain in the peripheral nervous system and the central nervous system.

Lidocaine is a drug that inhibits the propagation of action potentials in the peripheral nervous system. It is used to control pain in the peripheral nervous system and the central nervous system.

Lidocaine is a drug that inhibits the propagation of action potentials in the peripheral nervous system. It is used to control pain in the peripheral nervous system and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloropyramineis a drug that inhibits
 
Response: Chloropyramineis a drug that inhibits the reuptake of serotonin and norepinephrine. It is an anti-depressant, and also used as an anti-emetic, to treat gastro-intestinal disorders such as nausea and vomiting. It is available as a capsule, tablet, syrup and oral solution.

Mechanism of action

Chloropyramine has a complex mechanism of action and can produce several pharmacological effects. In humans, the antidepressant effect is thought to be related to the inhibition of the reuptake of norepinephrine and serotonin. Chloropyramine is also a weak antagonist of histamine H1 receptors. Chloropyramine has an affinity for alpha-1 adrenergic receptors. Chloropyramine inhibits MAO-A and MAO-B in vitro, but not in vivo.

Pharmacokinetics

Absorption

Chloropyramine is well absorbed following oral
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloroquineis a drug that inhibits
 
Response: Chloroquineis a drug that inhibits the conversion of heme to hemozoin. In addition to its use in the treatment of malaria, chloroquine has been shown to inhibit the growth of a variety of tumor cell lines in vitro and to be effective in the treatment of AIDS patients. The mode of action of chloroquine is thought to involve the formation of toxic free radicals and reactive oxygen species. See, for example, G. A. Nicholson et al., Cancer Res. 46: 1411-1416 (1986); A. J. Sladek et al., Biochem. Pharmacol. 35: 1067-1072 (1986); J. O. Anderson et al., Br. J. Cancer 59: 721-726 (1989); and D. W. Schafer et al., Cancer Res. 50: 2044-2049 (1990).
Cationic lipids are the cationic components of liposomes, the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chloroxylenolis a drug that inhibits
 
Response: Chloroxylenolis a drug that inhibits neutrophil infiltration into the site of inflammation and inhibits the release of the pro-inflammatory cytokines IL-1beta and TNF-alpha. It also inhibits the release of matrix metalloproteinases, the gelatinases, and collagenase-3. This drug may also be useful in the treatment of chronic obstructive pulmonary disease.

4-Oxo-8-dibenzoylmethoxy-2,3,4,5-tetrahydro-1H-1-benzazepine-2-acetic acid is a drug that acts as an inhibitor of neutrophil infiltration into the site of inflammation. It also inhibits the release of the pro-inflammatory cytokines IL-1beta and TNF-alpha. This drug may also be useful in the treatment of chronic obstructive pulmonary disease.

Chloroxylenol is a drug that inhibits neutrophil
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorphenesinis a drug that inhibits
 
Response: Chlorphenesinis a drug that inhibits phospholipase A2.

References

Category:Chloroarenes
Category:Hepatotoxins
Category:Phenols
Category:Phospholipase inhibitors
Category:Pyrazoles
Category:Pyridines
Category:Alkene derivatives
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorpheniramineis a drug that inhibits
 
Response: Chlorpheniramineis a drug that inhibits the release of histamine from mast cells. It is used to treat the symptoms of hay fever, including itching and sneezing. It is also used to treat allergies in children, and for treating allergic reactions to insect bites. Chlorpheniramine is also used to treat allergies in dogs. It may be used with other medications to treat allergies, and to treat hay fever, in children. Chlorpheniramine is available as a generic medication. There are many brand names for chlorpheniramine.

Acetaminophen(Paracetamol)is a pain reliever and fever reducer. It is used to treat mild to moderate pain, fever, and headaches. Acetaminophen is available in many different strengths. It is also available as a generic medication.

Acetylsalicylic acid (Aspirin)is a pain reliever and fever reducer. It is used to treat mild to moderate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorpromazineis a drug that inhibits
 
Response: Chlorpromazineis a drug that inhibits dopamine and serotonin reuptake. It is a typical antipsychotic drug. The typical antipsychotic drugs, such as chlorpromazine, are mainly used to treat schizophrenia. However, chlorpromazine is also used to treat many other mental disorders such as obsessive-compulsive disorder, catatonia, anxiety, and insomnia. The chemical name of chlorpromazine is 2-chloro-N-[2-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)phenyl]ethyl]acetamide. It has a molecular formula of C14H20ClN2O and a molecular weight of 284.9.

1. Chlorpromazine and its derivatives

2. History

Chlorpromazine was first discovered in 1955, and it was introduced to the market in 1960. It was first synthesized in Germany
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorpropamideis a drug that inhibits
 
Response: Chlorpropamideis a drug that inhibits insulin secretion by stimulating central nervous system dopamine receptors and inhibiting peripheral dopa-decarboxylase. Its mechanism of action is to decrease blood glucose level. In addition, chlorpropamide is used to treat type 2 diabetes mellitus.

CASE REPORT {#sec1-1}
===========

A 28-year-old woman presented with complaints of acute onset of severe headache and blurred vision, followed by nausea and vomiting. On examination, she was found to have papilledema. There was no history of trauma, fever, or seizure. The patient was a known case of type 2 diabetes mellitus and had been on oral chlorpropamide and glimepiride. There was no history of alcohol intake, use of any illicit drug, or of blood transfusion.

Hematological investigations showed anemia with hemoglobin of 7.8 g/dL and normal white blood cell count. Her serum
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorquinaldolis a drug that inhibits
 
Response: Chlorquinaldolis a drug that inhibits clathrin-mediated endocytosis. The mechanism of action is believed to be via its inhibition of clathrin-mediated endocytosis and macropinocytosis. Chlorquinaldol also inhibits cAMP phosphodiesterase.

Pharmacokinetics

Food interactions

The metabolism of chlorquinaldol is unknown.

Clinical use

Chlorquinaldol is used in the treatment of the psychiatric disorders of schizophrenia and bipolar disorder, and in the relief of chronic pain.

Chlorquinaldol has a short half-life, meaning that the drug has to be taken frequently for pain relief. The main side effects of chlorquinaldol are dizziness, confusion, sleepiness, and confusion.

History

Chlorquinaldol was first discovered by George Frederick Banting and Charles Herbert Best, while working at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlortetracyclineis a drug that inhibits
 
Response: Chlortetracyclineis a drug that inhibits the bacterial protein synthesis by blocking the peptidyl transferase reaction, which results in inhibition of the cell wall synthesis. Chlortetracycline is an anionic tetracycline derivative. The drug is a broad spectrum antibiotic, used in the treatment of bacterial infections in animals and man. Chlortetracycline is most commonly used in the treatment of the following bacterial infections in animals and man:

Acute bacterial otitis media;

Anal infections, including paratyphoid fever, fissure, fissure-in-ano, rectal abscesses and fistulas;

Aerosols and sprays;

Burns;

Cutaneous and subcutaneous abscesses and infections;

Dermatitis, including scalded skin syndrome;

Enteritis, including bacillary enteritis;

Enterotox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chlorzoxazoneis a drug that inhibits
 
Response: Chlorzoxazoneis a drug that inhibits the metabolism of the drug by the cytochrome P450 enzyme system. It is commonly used to treat patients with chronic bronchitis.

This site is intended for U.S. residents only. If you have registered, please login to continue. If you would like to know more about the products we sell, please email us at info@iherb.com. If you have any questions about the information presented on iHerb.com, please email us at info@iherb.com.

“…all the herbs, herbs and more herbs we offer on iHerb.com are the best quality you can buy. Our commitment to you is that if you order from iHerb.com and are not satisfied with your purchase, we will replace or refund your purchase price, no questions asked.”
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cholineis a drug that inhibits
 
Response: Cholineis a drug that inhibits the production of cholesterol by the liver. It's used to treat people with high cholesterol, but there are also other possible uses. It's also a vitamin, and the body needs a certain amount of choline every day.

Choline is also known as:

Choline Citrate

D-Choline

D-Choline Hydrochloride

D-Choline Salts

D-Choline Tartrate

D-Choline Tartrate Salts

D-Choline Sulphate

D-Choline Sulphate Salts

D-Choline Tartrate

D-Choline Tartrate Salts

D-Choline Sulphate

D-Choline Sulphate Salts

D-Choline Tartrate

D-Choline Tartrate Salts

D-Choline

D-Choline Hydrochloride

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chondroitinis a drug that inhibits
 
Response: Chondroitinis a drug that inhibits growth of a large number of tumor cell types in vitro, including prostate, breast, and lung. Its mechanism of action is believed to be by preventing the assembly of tubulin heterodimers into microtubules. The drug has a favorable toxicity profile and is currently being developed as a potential anticancer drug.

Chondroitin is a mucopolysaccharide that is found in the extracellular matrix and is present in cartilage, bone, and the cornea. Chondroitin sulfate is a linear polysaccharide consisting of a repeating disaccharide unit of N-acetylgalactosamine and N-acetylglucosamine. Chondroitin sulfate is found in cartilage, bone, tendon, and the cornea, and it has been implicated in several physiological processes, including growth factor binding, inflammation, and wound healing. Chondroitin sulfate also inhibits growth of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chromiumis a drug that inhibits
 
Response: Chromiumis a drug that inhibits the breakdown of cholesterol by the liver, thereby helping to lower cholesterol. It can be taken orally, as a pill or capsule. It is available as a generic drug.

Aromatase inhibitorsare a group of drugs that inhibit the action of the enzyme aromatase. They are used to treat hormone-dependent breast cancer, such as breast cancer that is caused by overactive oestrogen. Aromatase inhibitors are also used to treat breast cancer that has spread to the brain.

Calcium is an important mineral that is found in many different foods, such as milk, cheese, yoghurt, and soya beans. Calcium is also used in many medicines, including medicines used to treat high blood pressure and to treat or prevent kidney stones.

Colchicine is a drug that is used to treat gout and familial Mediterranean fever. It is also used to prevent the formation of certain types of blood cl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Chromocarbis a drug that inhibits
 
Response: Chromocarbis a drug that inhibits the activity of glycogen phosphorylase and is used to treat type II diabetes mellitus.

There are four main kinds of diabetes mellitus, Type 1, Type 2, gestational diabetes, and type 1.5, where type 1 is the most common. Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the body’s immune system attacks the insulin-producing cells in the pancreas, leading to a decrease in the amount of insulin that the pancreas produces. This causes the body to not be able to metabolize sugar in the blood, resulting in high levels of sugar in the blood. This disease can be treated by a person’s insulin, which is injected by a doctor or health care provider.

Type 2 diabetes mellitus (T2DM) is the most common type of diabetes mellitus. It occurs when the body’s ability to produce or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CIALISis
 
Response: CIALISis a non-steroidal anti-androgen that was approved by the FDA in 1999 for the treatment of erectile dysfunction (ED) and hypogonadism. In men with ED, it works by binding to androgen receptors in the penis and increasing blood flow to the penis. In men with hypogonadism, it works by blocking the production of testosterone.

SILDENAFIL CITRATE, another androgen, is a prescription drug used to treat ED. SILDENAFIL CITRATE, like CIALIS, works by binding to androgen receptors in the penis. In men with ED, SILDENAFIL CITRATE works by increasing blood flow to the penis. SILDENAFIL CITRATE is the only FDA-approved medication that is injected directly into the penis.

Although ED and hypogonadism are distinct medical conditions, the drugs used to treat them have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ciclopiroxis a drug that inhibits
 
Response: Ciclopiroxis a drug that inhibits the formation of the fungal cell wall, thereby destroying the fungus and rendering it susceptible to a number of fungicidal agents. It is used in the treatment of dermatophytosis and tinea pedis.

Ciclopirox olamine is a 1-cyclopropyl-4-[(5-chloro-2-pyridyl)amino]-5-methoxy-2-hydroxy-3-methyl-benzene-1-methan-sulfonamide.

1-cyclopropyl-4-[(5-chloro-2-pyridyl)amino]-5-methoxy-2-hydroxy-3-methyl-benzene-1-methan-sulfonamide

Ciclopirox

Ciclopirox olamine

(CAS#
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cidofoviris a drug that inhibits
 
Response: Cidofoviris a drug that inhibits DNA synthesis, allowing infected cells to repair damaged DNA before they die.

A growing number of health-care providers and laboratories are developing or implementing a fast, accurate method for the identification of C. trachomatis, the cause of the most common sexually transmitted bacterial infection in the United States. The method uses an amplification procedure to produce a diagnostic signal and is based on the fact that C. trachomatis DNA contains a highly conserved region of DNA known as the cryptic plasmid. This plasmid is present in all C. trachomatis strains and has been used as a target for DNA amplification. However, the plasmid sequence is not the same in all strains, which can result in problems when trying to use the amplification procedure to detect C. trachomatis.

C. trachomatis is most commonly identified in genital specimens and in samples of cervicovaginal secretions.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cilengitideis a drug that inhibits
 
Response: Cilengitideis a drug that inhibits the activity of the growth factor receptor α~v~β~3~. It is a tetrapeptide, G~D~VIA, consisting of a modified sequence of the amino acid D-galactose, D-valine, I-leucine, and D-aspartate ([@b37-ol-0-0-9853]). The first-generation cilengitide (Genasense^®^) was approved by the Food and Drug Administration (FDA) in September 2003 for use in combination with radiotherapy in patients with glioblastoma ([@b38-ol-0-0-9853]). The drug was first used in the clinic for patients with malignant gliomas. Cilengitide has been reported to be safe and effective in a clinical setting ([@b39-ol-0-0-9853]). Cilengit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cilnidipineis a drug that inhibits
 
Response: Cilnidipineis a drug that inhibits calcium entry in cells. It is effective in treating hypertension and preventing and treating heart attacks and strokes. It is prescribed to those with cardiovascular disease, heart failure, and high blood pressure.

It is sold as an oral drug. It is also used in eye drops.

Precautions:

Tell your doctor if you have kidney disease or high levels of calcium in your blood.

Tell your doctor if you have an allergy to cilnidipine, other calcium channel blockers, or other drugs.

Use with caution if you are taking a drug called furosemide (Lasix).

Warnings:

Use only as directed. Do not use for longer than recommended. Do not use more than 1 time per day.

Do not use if you are pregnant. Do not breastfeed while using this drug.

If you are using cilnidipine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cilostazolis a drug that inhibits
 
Response: Cilostazolis a drug that inhibits vascular smooth muscle cell proliferation and migration in vitro and in vivo, and which may be useful in the treatment of restenosis.
It has been known for many years that angiogenesis is a process by which new blood vessels are formed from pre-existing vessels. Angiogenesis is essential to a variety of normal body processes such as embryogenesis, wound healing, and menstruation. In addition, angiogenesis is involved in a number of pathological processes such as tumor growth, tumor metastasis, and retinopathy. For example, in the case of tumor growth, a tumor must continuously stimulate growth of new capillaries into the tumor. New capillaries can be formed by two processes, sprouting and intussusception. Sprouting involves the formation of new capillaries from pre-existing blood vessels. In intussusception, existing capillaries are projected into the tissue space previously occupied by the tumor. Angi
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  cimetidineis a drug that inhibits
 
Response: cimetidineis a drug that inhibits the enzyme histidine decarboxylase, the enzyme responsible for the production of histamine. Histamine is an amine that can cause itching and can cause some types of skin to get red and painful. Cimetidine is used to treat ulcers, irritable bowel syndrome, gastritis, gastric ulcers, and other conditions. Cimetidine also may be used to prevent the development of peptic ulcers.

To make a doctor's appointment or for more information, call the American Cancer Society at 1-800-227-2345.

Eligible for Medicaid

Cimetidine may be covered by Medicaid for patients with end-stage renal disease who are undergoing hemodialysis. Cimetidine may also be covered by Medicaid for patients with end-stage renal disease who are undergoing peritoneal dialysis.

Medicare

Medicare does not cover cimetidine.

Alternative
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cinacalcetis a drug that inhibits
 
Response: Cinacalcetis a drug that inhibits the receptor for calcitonin, which helps to regulate the amount of calcium in the blood. It is used to treat patients with hypercalcemia due to excess parathyroid hormone (PTH) and chronic kidney disease. It is also used to treat hypercalcemia of malignancy, osteoporosis, Paget's disease of bone, and osteitis fibrosa cystica.[2]

A few studies in rats, monkeys, and humans have suggested that it may be useful in treating hypertension.[3]

Cinacalcet was approved by the U.S. Food and Drug Administration (FDA) on August 10, 2005.[4] It was initially marketed by Amgen Inc. in the United States under the brand name Amgleva, and was later marketed by Novartis under the brand name Miasal.

In 2006, Amgen was bought
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cinchonidineis a drug that inhibits
 
Response: Cinchonidineis a drug that inhibits both cholinesterase enzymes, and therefore has a cholinergic side effect profile that is very different from that of physostigmine.

References

Category:Amines
Category:Cholinergics
Category:Iodoarenes
Category:Abandoned drugs
Category:Naphthalenesulfonamides
Category:Chloroarenes
Category:Acetate esters
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cinchonineis a drug that inhibits
 
Response: Cinchonineis a drug that inhibits the conversion of guanosine to inosine in the purine salvage pathway, which may increase levels of endogenous adenosine. It is widely used as an appetite suppressant in the management of weight loss in the obese and as a weight loss drug in the management of obesity. The drug is also used in the treatment of the symptoms of AIDS. It is available as a generic drug and is marketed under the trade name Cinchonidine in India, the United States, and elsewhere.

Introduction {#s0005}
============

Cinchonine (CIN) is a plant alkaloid with a chemical structure similar to adenosine ([Figure 1](#f0005){ref-type="fig"}). CIN is used as an appetite suppressant in the management of weight loss in the obese and as a weight loss drug in the management of obesity.[@b0005] CIN has been reported
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cinepazideis a drug that inhibits
 
Response: Cinepazideis a drug that inhibits the uptake of the catecholamine neurotransmitters, dopamine, norepinephrine and epinephrine. This drug is most often used in the treatment of cocaine withdrawal. It is usually administered orally in a dose of 0.5-1 mg/kg.

References

Category:Dopamine reuptake inhibitors
Category:Tetralins
Category:Morpholines
Category:Piperidines
Category:Chloroarenes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cinitaprideis a drug that inhibits
 
Response: Cinitaprideis a drug that inhibits an enzyme called H+/K+-ATPase, found in the stomach and intestine, and prevents the enzyme from working properly. When this enzyme isn't working properly, stomach acid is not secreted, and the stomach does not absorb food. The drug, when taken orally, blocks the action of the enzyme, and is effective in preventing symptoms of heartburn and acid indigestion.

The drug is available in immediate-release (IR) tablets, as well as extended-release (ER) tablets. The IR tablet is available in a 20 mg dose and is used to treat heartburn and acid indigestion that occur at night. The ER tablet is available in a 30 mg dose and is used to treat heartburn and acid indigestion that occur at night.

Cinitapride is a prescription drug.

Uses

Cinitapride is used to treat:


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  cinoxacinis a drug that inhibits
 
Response: cinoxacinis a drug that inhibits an enzyme that is needed for cell wall synthesis, and by the action of vancomycin, an antibiotic that binds to the cell wall, preventing cell division. The cells grow in chains, which are eventually released from the culture medium.

References

Category:Gram-positive bacteria
Category:Bacteria described in 1994
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ciprofibrateis a drug that inhibits
 
Response: Ciprofibrateis a drug that inhibits the activity of the enzyme HMG-CoA reductase, which is an enzyme involved in the synthesis of cholesterol. It also inhibits the synthesis of triglycerides and phospholipids. Ciprofibrate also lowers the level of free fatty acids in the blood. The drug can be used to treat hypertriglyceridemia, mixed hyperlipidemia, hyperlipoproteinemia, and hyperlipidemia. It is also used to treat other conditions such as hepatic steatosis and obesity.

The information presented at this site is not intended to serve as medical advice and should not be used for diagnosing or treating any disease. MTF Nutritionals, Inc. is not responsible for any third party content. You should consult a physician or other specialist for diagnosis and treatment of any medical condition and before undertaking any diet, exercise, or supplementation program.

No claims are made regarding the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cisatracuriumis a drug that inhibits
 
Response: Cisatracuriumis a drug that inhibits the transmission of nerve impulses, and it relaxes the muscles.

When you use cisatracurium, it is an intravenous injection of a muscle relaxant.

It is used for medical reasons and is used to treat muscle weakness.

This drug is also used in surgery to reduce the effects of stress, pain, and anxiety.

Cisatracurium may also be used for purposes other than those listed in this medication guide.

What is this medicine?

CISATRACURIUM (CISATRACURIUM) is a muscle relaxant that is used to relax muscles. It is used to prevent muscle spasms and contractions in people who are having surgery or who are recovering from surgery.

This medicine may also be used to prevent muscle weakness after you have had surgery.

How should I use this medicine?

Follow the directions
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Citarinostatis a drug that inhibits
 
Response: Citarinostatis a drug that inhibits androgen-mediated bone metabolism is an effective treatment for patients with prostate cancer and osteoporosis.
Androgen plays an important role in the development and progression of prostate cancer. In patients with prostate cancer, bone metastasis is the most frequent complication. Androgen ablation therapy has been the standard treatment for patients with metastatic prostate cancer. However, the effects of androgen ablation therapy on bone metabolism are not completely satisfactory. Citarinostatis is a new inhibitor of androgen-mediated bone metabolism, which is an effective drug for patients with prostate cancer and osteoporosis. It has been approved by the US Food and Drug Administration (FDA) for the treatment of osteoporosis and prostate cancer. It has been shown to reduce bone turnover and to prevent the progression of osteoporosis. This review describes the pharmacology, mechanism of action, and clinical efficacy of Citarinostatis in patients with prostate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Citricis a drug that inhibits
 
Response: Citricis a drug that inhibits muscle contraction. It is also used to treat bladder problems.

Side effects may include blurred vision, dry eyes, problems with coordination, and hearing problems. The risk of side effects may be greater for women than for men.

Citricis is not approved for use in children.

Before using citricis, tell your doctor if you are allergic to it, if you have diabetes, or if you have high blood pressure.

Do not use citricis without a doctor's approval if you are pregnant. It may cause harm to the baby.

Citricis may cause harm to an unborn baby. Talk to your doctor about the benefits and risks of using citricis during pregnancy.

Use citricis with caution in the elderly. They may be more sensitive to its side effects.

Overdose

If you think you have used too much citricis, get medical help right
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Citronellylis a drug that inhibits
 
Response: Citronellylis a drug that inhibits Nrf2 and therefore induces cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. The present study aimed to explore the apoptotic potential of citronellylis in a triple-negative breast cancer cell line. A TNBC cell line was used, MDA-MB-231, in order to study the molecular mechanisms of cell death and identify the cell death pathway involved in the cytotoxic activity of citronellylis. The results indicated that citronellylis triggered apoptosis in MDA-MB-231 cells through the mitochondrial pathway of apoptosis. Citronellylis activated the expression of the pro-apoptotic Bax protein, inhibited the expression of the anti-apoptotic Bcl-2 protein and induced the release of cytochrome c from the mitochondria. The increase in caspase-3 activity was observed after the treatment of the cells with citronellylis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CK-1827452is a drug that inhibits
 
Response: CK-1827452is a drug that inhibits pro-inflammatory mediators in microglia cells. LPS was used to activate microglia cells and to produce inflammatory mediators. Naloxone was used to inhibit opioid receptors and morphine to activate opioid receptors.

Microglia are brain resident macrophages, which are the major innate immune cells in the central nervous system (CNS). Upon activation, microglia secrete a variety of cytokines and inflammatory mediators. LPS is a major component of the outer membrane of gram-negative bacteria. LPS can activate microglia cells and promote the release of pro-inflammatory cytokines. Naloxone, a potent antagonist of opioid receptors, was used to inhibit the activation of microglia cells. Morphine, an agonist of opioid receptors, was used to activate microglia cells and promote the release of pro-inflammatory mediators.

The results showed that the levels of T
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cladribineis a drug that inhibits
 
Response: Cladribineis a drug that inhibits lymphocyte proliferation. Cladribine was originally approved by the FDA in 1983 for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. In 1997, cladribine was approved for the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in children. In the treatment of ALL, cladribine is given as a single dose or divided doses for 2-4 weeks. The drug was initially given as a single dose of 0.12-0.2 mg/kg, but is now most often given in divided doses, i.e. 0.06 mg/kg twice daily for 2-4 weeks. Cladribine is usually given as a single course of treatment.
Cladribine has been reported to have significant activity in patients with refractory or relapsed ALL and in patients with B-precursor ALL with high risk features. In addition, cladribine has been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clarithromycinis a drug that inhibits
 
Response: Clarithromycinis a drug that inhibits tumor growth. Many small molecule anticancer drugs have been identified. However, these agents have limited efficacy because of dose-limiting toxicities and acquired drug resistance. The drug resistance is due to the development of new, drug-resistant tumor cell clones. The process of acquiring resistance is a major impediment to the long-term use of existing drugs. To develop new drugs and new combinations of existing drugs, it is necessary to understand the biology of drug resistance. We have developed several in vitro and in vivo models to study the biology of drug resistance. The results of these studies have provided insights into the mechanisms of drug resistance, including mechanisms of acquired drug resistance. These mechanisms include: 1) Development of drug resistance by amplification of drug-efflux pumps; 2) Alteration of cellular drug metabolism by drug inactivation or increased metabolism of the drug; 3) Alteration of drug-target interactions by decreased drug-target binding or by alteration of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cleboprideis a drug that inhibits
 
Response: Cleboprideis a drug that inhibits the action of dopamine at the D2 receptors in the brain. It has been shown to improve constipation in children with chronic constipation. It has been used in children as young as 4 years of age.

What is it prescribed for?

This drug is prescribed for the treatment of chronic constipation in children.

What are the possible side effects?

Common side effects include headache, dizziness, nausea, dry mouth, muscle weakness, and headache.

What are the precautions?

Before using clebopride, tell your doctor if you are allergic to it, or if you have anemia, diabetes, high blood pressure, high cholesterol, heart disease, liver disease, kidney disease, or are pregnant or plan to become pregnant. Do not use it if you are breast-feeding.

Some medicines can interact with clebopride, including other medicines that affect the heart or cause dry mouth
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  clemastineis a drug that inhibits
 
Response: clemastineis a drug that inhibits the production of histamine. It is available as a nasal spray and as an oral tablet.

When you inhale or swallow a nasal spray, the medicine goes directly into your nose or mouth. When you swallow a tablet, the medicine is digested in your stomach.

Do not use nasal spray if you are allergic to cromolyn or if you have a sensitivity to latex.

Do not use this medicine if you have ever had an allergic reaction to cromolyn or if you have any kind of blood clotting disorder.

Before you use this medicine

• Store the nasal spray at room temperature away from moisture. Do not keep it in the bathroom.

• Keep the nasal spray in the refrigerator when not in use.

• Throw away unused nasal spray.

• Keep the medicine out of the reach of children.

Tell your doctor if you are allergic to any other medications, latex
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clemizoleis a drug that inhibits
 
Response: Clemizoleis a drug that inhibits the production of leukotrienes by inhibiting the enzyme 5-lipoxygenase. It is also known as zileuton, a trade name for the drug.

Zileuton is a prescription drug used to treat asthma. It works by blocking the action of leukotrienes, which are chemicals that play a role in inflammation. Zileuton has been found to be effective in improving the symptoms of asthma and preventing acute attacks in people with asthma. It is also effective in treating the symptoms of seasonal allergies, including hay fever. Zileuton may also be used to prevent or treat allergic rhinitis.

Zileuton is available only by prescription. It comes in a tablet form.

This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cleviprexis a drug that inhibits
 
Response: Cleviprexis a drug that inhibits the formation of PGE2 and PGF2 alpha by blocking the action of COX enzymes. It is used to relieve pain, fever, inflammation, swelling, and inflammation.

Cleviprex is a trade name for celecoxib (Celebrex).

It is also available under the brand name Celebrex.

How does Cleviprex work?

Cleviprex is a selective COX-2 inhibitor that selectively and reversibly inhibits the cyclooxygenase enzyme. This enzyme is involved in the formation of prostaglandins, which play a vital role in the production of pain and inflammation.

Cleviprex has been approved for use in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and in reducing the signs and symptoms of osteoarthritis of the knee in patients with moderate to severe pain.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clevudineis a drug that inhibits
 
Response: Clevudineis a drug that inhibits the activity of the enzyme telomerase, which is a normal cell component that adds to the ends of chromosomes and helps to protect them from breaking and eroding. The drug is made of a special polymer (Clevudine), that is used to make the Clevudineis a drug that inhibits the activity of the enzyme telomerase, which is a normal cell component that adds to the ends of chromosomes and helps to protect them from breaking and eroding. The drug is made of a special polymer (Clevudine), that is used to make the drug a pharmaceutical and can be used to treat cancer.



Clevudineis a drug that inhibits the activity of the enzyme telomerase, which is a normal cell component that adds to the ends of chromosomes and helps to protect them from breaking and eroding. The drug is made of a special polymer (Clevudine), that is used to make the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Climbazoleis a drug that inhibits
 
Response: Climbazoleis a drug that inhibits human skin cells from growing. Climaxin is an anti-inflammatory drug that can be taken orally to prevent the spread of inflammation in the body.

There are two types of pheromones that can be used to induce orgasm: excitatory and inhibitory. Excitatory pheromones are chemicals that stimulate the sexual desire in the human body. Excitatory pheromones have been known to work for a long time, but they are only recently being studied.

The inhibitory pheromones are those that reduce the libido in the human body. They are a more recent discovery.

Both types of pheromones work together to trigger the sexual drive in the human body. There is also a third type of pheromone that is sometimes used in order to create sexual arousal. This is a pheromone that creates a sense of smell in the human body, but
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clindamycinis a drug that inhibits
 
Response: Clindamycinis a drug that inhibits the synthesis of a protein called alpha-synuclein. It is used to treat a certain type of pneumonia and urinary tract infections. The pneumonia is usually mild and the infection can be treated with other antibiotics.

Another drug called apremilast is being used to treat rheumatoid arthritis and psoriasis.

There is also a drug called cyclosporine that is used to prevent organ rejection after transplant surgery. It is also used to treat other conditions such as psoriasis, psoriatic arthritis and refractory cutaneous lupus erythematosus.

It is used to prevent rejection of transplanted organs and is sometimes given to people with Crohn's disease and psoriasis. It is also used to treat autoimmune diseases like rheumatoid arthritis, multiple sclerosis and lupus.

It is used to prevent organ rejection after transplant surgery and to treat Crohn's
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clinofbrateis a drug that inhibits
 
Response: Clinofbrateis a drug that inhibits platelet aggregation by a combination of irreversible inhibition of platelet membrane glycoprotein IIb/IIIa and other antiplatelet activity. Clinofabates is a prodrug that is metabolized to the active form of the drug. The antiplatelet effects of clofabate have been reported in patients with thrombotic disorders including unstable angina, acute myocardial infarction, and thromboembolic stroke, and in patients with peripheral arterial occlusive disease and atherothrombotic vascular disease.

Introduction {#Sec1}
============

Clofabate (CLO, Bayhydro®, Bayer HealthCare, Germany) is a prodrug that is metabolized to the active form of the drug, clopidogrel (CLO, Plavix®, Sanofi-Aventis, France), and is indicated for the treatment of thrombotic disorders
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clobetasolis a drug that inhibits
 
Response: Clobetasolis a drug that inhibits cancer cells by blocking the production of nitric oxide (NO).

Researchers are trying to understand why different strains of bacteria make different types of NO.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and researchers at Harvard Medical School have found that one particular type of bacteria uses nitric oxide (NO) as a weapon to kill other types of bacteria.

According to NIAID researchers, the finding suggests that NO could be used to control and prevent infections caused by harmful bacteria. The researchers are also looking for ways to use the knowledge to develop new antibiotics.

The research, published in the journal Science, provides insight into the type of bacteria that cause pneumonia and sepsis.

Pneumonia and sepsis are bacterial infections that occur in the lungs and bloodstream, respectively.

“It is generally thought that different bacteria produce NO as a weapon to kill other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  clobetasoneis a drug that inhibits
 
Response: clobetasoneis a drug that inhibits the biosynthesis of cortisol. It is used to treat inflammation, itching, allergic rhinitis, and atopic dermatitis. It is also used to prevent graft-versus-host disease in patients who have received bone marrow transplants.

The concentration of clobetasone is measured in milligrams per milliliter (mg/ml).

Common side effects include skin changes, nausea, vomiting, and headache.

#####  INDICATIONS/ROUTES/DOSAGE

**◀ ALERT ▶** Topical form of clobetasone is available in 0.05% and 0.1% concentrations.

ADVERSE EFFECTS: May cause skin thinning.

#####  NURSING CONSIDERATIONS

BASELINE ASSESSMENT

Assess all topical medications for allergic reactions. Obtain baseline vital signs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clodronateis a drug that inhibits
 
Response: Clodronateis a drug that inhibits osteoclast differentiation and bone resorption. In addition, clodronate inhibits cancer cell invasion and metastasis. However, the inhibitory effect of clodronate on the progression of human prostate cancer has not been reported. The present study examined the inhibitory effect of clodronate on the progression of human prostate cancer cells in vitro and in vivo.

In the present study, we found that clodronate inhibited the progression of human prostate cancer cells in vitro and in vivo. The inhibitory effect of clodronate on the progression of prostate cancer cells was evaluated by cell viability, apoptosis, cell cycle, migration, invasion, and in vivo metastasis assays.

The in vivo effect of clodronate on the growth of human prostate cancer cells was evaluated by subcutaneous implantation of human prostate cancer cells into nude mice. The inhibitory effect of clodronate on the growth
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clofarabineis a drug that inhibits
 
Response: Clofarabineis a drug that inhibits DNA polymerase and causes DNA strand breaks. It is effective in treatment of relapsed and refractory acute lymphoblastic leukemia (ALL) and relapsed and refractory non-Hodgkin's lymphoma (NHL). Clofarabine is approved by FDA for the treatment of relapsed and refractory B-cell ALL.

Introduction

Clofarabine, a synthetic nucleoside analog, was initially developed by W.H. Carey and D.A. Witty as a treatment for Burkitt's lymphoma. The drug was found to have potent activity in a variety of solid tumors and has also been shown to have activity in hematologic malignancies, including multiple myeloma, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia. The drug is a prodrug that is converted to the active metabolite, 2-Cl-F
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clofazimineis a drug that inhibits
 
Response: Clofazimineis a drug that inhibits mycolic acid biosynthesis. The discovery of the compound, a second-line drug for the treatment of tuberculosis, was made at the NIH and at the United States Army Medical Research Institute for Infectious Diseases in the late 1980s.

Background

Clofazimine is an imidazol-dione derivative. It is a lipophilic drug with a half-life of 12 hours. Its chemical structure is similar to that of isoniazid.

Pharmacology

Clofazimine is an anti-mycobacterial agent. It is active against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium kansasii. It has activity against both intracellular and extracellular organisms. The drug is an inducer of reactive oxygen species and inhibits cell wall synthesis in mycobacteria. It inhibits the enzymatic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clofibrateis a drug that inhibits
 
Response: Clofibrateis a drug that inhibits lipogenesis in the liver. It is used to treat hyperlipidemia, an elevation of the level of cholesterol in the blood. Lipogenesis is the synthesis of fatty acids from acetyl-CoA and malonyl-CoA. This drug was discovered in 1959, but the mechanism of action was not fully understood until the early 1980's.

Clofibrate binds to the nuclear protein peroxisome proliferator-activated receptor (PPAR) which is present in the nucleus. Clofibrate changes the conformation of the PPAR-protein complex and alters its activity. It is believed that this change in the conformation of the protein leads to the inhibition of lipogenesis. The mechanism of action of clofibrate is described below.

First, the rate of fatty acid synthesis is decreased by decreasing the rate of de novo fatty acid synthesis. This is accomplished by inhibiting the conversion of acetyl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clofibricis a drug that inhibits
 
Response: Clofibricis a drug that inhibits the enzyme 5-lipoxygenase, a key enzyme in the synthesis of leukotrienes. It is indicated for the treatment of adult asthma and chronic bronchitis. It has also been reported to be useful in the treatment of allergic rhinitis and to decrease the severity of atopic dermatitis. See, e.g., New England Journal of Medicine, Vol. 336, No. 5, Nov. 20, 1997, at pages 359-364.
The primary active ingredient in clofibric acid is 5-chloro-2-methyl-3-(2,2,2-trifluoroethyl)-1,3-thiazolidine-4-carboxylic acid, also known as 2,2,2-trifluoroethyl 5-chlorothiazolidine-4-carboxylate, and in its therapeutically acceptable acid addition salt form as clof
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  clofoctolis a drug that inhibits
 
Response: clofoctolis a drug that inhibits the synthesis of eukaryotic DNA. If this approach is successful, a new generation of highly active antiviral agents will be available.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clomifeneis a drug that inhibits
 
Response: Clomifeneis a drug that inhibits ovulation. The most common side effects are headache, weight gain, breast tenderness, depression, and bloating. It is most often prescribed to treat menopausal symptoms. It also helps prevent pregnancy and treat gynecological conditions like endometriosis.

Q:What is Clomifene used for?

Clomifene is used to treat a condition called clomiphene-resistant polycystic ovary syndrome (C-PR PCOS). Clomifene works by inhibiting ovulation and increasing the production of the male hormone testosterone. It is also used to treat other conditions including endometriosis, fibroids, polycystic ovary syndrome (PCOS), and anovulation.

Q:What is Clomifene used for?

Clomifene is used to treat a condition called clomiphene-resistant polycystic ovary syndrome (C-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clomipramineis a drug that inhibits
 
Response: Clomipramineis a drug that inhibits the reuptake of serotonin and norepinephrine. It is also called a tricyclic antidepressant.

It was first developed in the 1960s and was first introduced in the US in 1965.

Clomipramine has been approved for use in treating obsessive compulsive disorder (OCD), major depressive disorder (MDD), and generalized anxiety disorder (GAD).

It is usually used as a second or third-line antidepressant in the treatment of major depression and OCD.

It is also used in the treatment of some cases of panic disorder and eating disorders.

Clomipramine has been shown to be more effective than placebo and other antidepressants in treating major depression.

Clomipramine has been shown to be more effective than placebo in treating OCD.

However, it has been associated with higher incidences of side effects than other antidepressants.

Clomip
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clonidineis a drug that inhibits
 
Response: Clonidineis a drug that inhibits sympathetic nervous system and is useful in the treatment of hypertension and Raynaud's disease. Clonidine has also been shown to decrease sexual function in the male and has a negative effect on lactation. This study evaluated the effect of clonidine on sexual function in females. Clonidine, 1 microgram/kg, was administered intramuscularly (i.m.) daily to 15 females for 2 weeks and sexual function was assessed by using a questionnaire before and after treatment. Fourteen of the 15 subjects (93%) had symptoms of hypogonadism and/or amenorrhea before treatment. No change was observed in the sexual function questionnaire after 2 weeks of treatment with clonidine. Thus, clonidine does not seem to have any effect on sexual function in females.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clopamideis a drug that inhibits
 
Response: Clopamideis a drug that inhibits sodium/potassium ATPase, so it can lower blood pressure. It's also used to treat high blood pressure, and to reduce eye pressure.

If you've had glaucoma, you may have been given this medication.

What is clopamide?

Clopamide is a prescription medicine that treats high blood pressure and reduces eye pressure. It belongs to a group of medicines called diuretics. It works by inhibiting the sodium/potassium pump, which makes sodium and potassium ions move from the inside of cells to the outside. The sodium/potassium pump also moves water into the cells. This causes the cells to swell, and the blood pressure to lower.

This medication is used to treat high blood pressure and glaucoma. It also may be used to prevent heart problems in people who have heart failure.

Common side effects include dizziness, fainting, dry mouth,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clopidogrelis a drug that inhibits
 
Response: Clopidogrelis a drug that inhibits platelet aggregation. It is used to prevent clots after percutaneous coronary intervention (PCI) or other types of coronary artery disease. It has a narrow therapeutic index. Low-dose aspirin, on the other hand, is used to prevent stroke, heart attack and other vascular events. It is recommended for use with clopidogrel to prevent platelet aggregation.

This article reviews the pharmacokinetic and pharmacodynamic characteristics of clopidogrel. It also provides information about its use in patients with clopidogrel resistance and other associated problems.

Pharmacokinetic Characteristics

Clopidogrel is a prodrug, which means it is converted into the active metabolite in the liver. This conversion is mediated by the enzyme cytochrome P450 (CYP) 2C19, and is the only metabolic pathway of clopidogrel.1

Clopid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clopidolis a drug that inhibits
 
Response: Clopidolis a drug that inhibits DPP4. It is used to treat type 2 diabetes mellitus (T2DM) and neutralizes DPP4 enzyme. This will help in the management of hyperglycemia.

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CLOPIDOL

CL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clorgylineis a drug that inhibits
 
Response: Clorgylineis a drug that inhibits the reuptake of serotonin.

Because of the rise in serotonin, the low serotonin levels in the brain, and the influence that serotonin has on mood and behavior, Clorgyline has been used in the treatment of depression.

In the study, researchers used a Clorgyline-treated mouse to see how it would affect mouse behavior.

In the study, the mice were tested on a maze. The maze had several compartments, each with its own opening, and all compartments were connected to each other.

The mice were trained to run from the beginning of the maze to the end, and they were tested by how many mistakes they made.

The mice were tested on the maze for ten minutes, and their results were recorded.

The researchers tested the mice on the maze for two weeks.

The mice were divided into two groups. One group of mice was treated with Clor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clorprenalineis a drug that inhibits
 
Response: Clorprenalineis a drug that inhibits

Clorprenalineis a drug that inhibits

the degradation of noradrenaline (norepinephrine). It is used to treat certain types of shock, especially from anaphylaxis and septic shock.

It is used in the following forms:

Clorprenaline, a tablet containing 4 mg

Clorprenaline, an injection containing 5 mg

It may also be used for purposes not listed in this medication guide.

What is Clorprenaline?

Clorprenaline is a drug that inhibits

the degradation of noradrenaline (norepinephrine). It is used to treat certain types of shock, especially from anaphylaxis and septic shock.

It is used in the following forms:

Clorprenaline, a tablet containing 4 mg

Clorprenaline, an injection containing 5 mg

It may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clorsulonis a drug that inhibits
 
Response: Clorsulonis a drug that inhibits the action of dihydrotestosterone (DHT), a hormone that is often associated with a man’s propensity to grow facial hair. Testosterone is the other main hormone in a man’s body that regulates the growth of hair and other facial characteristics.

Clomid was approved by the FDA in 1959 for the treatment of male infertility and was the first oral contraceptive for men. Clomid is often prescribed for low libido and for treatment of infertility in men.

When taken for up to three months, Clomid increases the production of testosterone and can help to stimulate a man’s sex drive.

Fluoxymesterone is a drug that is often prescribed to treat male pattern baldness and other conditions such as erectile dysfunction. It is also sometimes used to increase testosterone levels.

The effects of the drugs depend on the dose, the person taking them, and the length of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Closantelis a drug that inhibits
 
Response: Closantelis a drug that inhibits the parasite *Clonorchis sinensis* in the process of invasion of the bile duct epithelial cells. In this study, the effects of closantelis on the function of the intestine, the hepatobiliary system, and the reproductive system were investigated. In a preliminary study, closantelis (5 mg/kg/d) was administered to rats for 3 days, and the results showed that the body weight of the rats decreased by 1.6% and that the food intake decreased by 6.7%. No abnormal signs were observed in the physical examination. In the serum biochemistry, the activity of alanine aminotransferase (ALT) increased by 12.5%, the activity of aspartate aminotransferase (AST) increased by 14.1%, and the activity of alkaline phosphatase (ALP) increased by 10.8%. The contents of total protein
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cloxacillinis a drug that inhibits
 
Response: Cloxacillinis a drug that inhibits the synthesis of DNA. This is an antibiotic that can be used in combination with other antibiotics.

ciprofloxacin is a fluoroquinolone antibiotic that is used to treat a wide range of infections caused by gram-negative and gram-positive bacteria. It is often used to treat skin infections, ear infections, gonorrhea, and other infections.

Diflucan is a fluconazole-based drug that is used to treat fungal infections. It is used to treat vaginal candidiasis, esophageal candidiasis, and cryptococcal meningitis.

fluconazole is a drug that can be used to treat fungal infections. It is used to treat vaginal candidiasis, esophageal candidiasis, and cryptococcal meningitis.

Itraconazole is a drug that is used to treat fungal infections. It is used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Clozapineis a drug that inhibits
 
Response: Clozapineis a drug that inhibits the reuptake of dopamine, serotonin and norepinephrine in the brain. In other words, it can prevent the brain from being flooded with these neurotransmitters. This means that you may feel less “cranky” and “hyper”. It can also have an antidepressant effect. Clozapine can be used in the treatment of schizophrenia and schizoaffective disorder. Clozapine has been used in combination with other medications to treat people who do not respond to, or who have not tolerated, other medications.

Clozapine is a “unique” drug because it can cause a number of side effects, some of which are serious. Clozapine is also a drug that is associated with an increased risk of some types of cancer.

This page provides information about the side effects of clozapine. You can use the list of side effects to compare them with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cobicistatis a drug that inhibits
 
Response: Cobicistatis a drug that inhibits DNA polymerase, DNA topoisomerase II, and induces DNA cross-links. It is the first of a new class of antineoplastic agents, the topoisomerase inhibitors.

Therapeutic Effect

It has activity in leukemias and lymphomas. It is also used in combination with other antineoplastic agents to treat patients with breast cancer, ovarian cancer, lung cancer, and other solid tumors.

Side Effects

Myelosuppression, particularly in patients who are deficient in folate, is the most common side effect. Other common side effects include nausea, vomiting, anorexia, diarrhea, alopecia, stomatitis, fever, rash, headache, dyspnea, confusion, drowsiness, and depression. Other side effects may include thrombocytopenia, neutropenia, anemia, eosinophilia, a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Colchicineis a drug that inhibits
 
Response: Colchicineis a drug that inhibits the polymerization of tubulin, a major component of microtubules. It has been used for over 80 years to treat gout and familial Mediterranean fever. More recently, it has been used to treat familial amyloidotic polyneuropathy (FAP) \[[@B1]\], a disease that results from mutations in the transthyretin gene, and is characterized by the deposition of amyloid fibrils in peripheral nerves and viscera.

Colchicine has many off-label uses, including the treatment of other inflammatory diseases, such as Behcet\'s disease, polymyalgia rheumatica, juvenile chronic arthritis, inflammatory bowel disease, Behcet\'s disease, pericarditis, ankylosing spondylitis, Sjogren\'s syndrome, systemic lupus erythematosus, dermatomyositis, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Colistinis a drug that inhibits
 
Response: Colistinis a drug that inhibits the function of the bacterium and prevents the development of ulcers.

Cimetidine, an anti-ulcer drug that prevents stomach acid from reaching the duodenum.

cimetidine, an H2-antagonist.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers.

cimetidine, a drug that decreases gastric acid secretion and prevents the development of peptic ulcers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Combretastatinis a drug that inhibits
 
Response: Combretastatinis a drug that inhibits the enzymatic activity of tubulin, a protein that is important in the formation of microtubules, the “building blocks” of the cytoskeleton. The formation of microtubules is essential for the formation of the mitotic spindle that segregates the chromosomes during mitosis. The mitotic spindle is responsible for the proper segregation of chromosomes during cell division. In addition, the mitotic spindle is essential for the formation of the contractile apparatus, which is responsible for cell motility. Microtubules are also essential for cell migration. See, for example, S. K. Borden, Microtubules and Spindle Assembly: The Role of Tubulin and Associated Proteins, Cambridge University Press, Cambridge, UK (1993).

Cancerous cells are characterized by uncontrolled cell division and migration. Tubulin is an essential protein for cell division and migration. It is also an essential protein for the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Conivaptanis a drug that inhibits
 
Response: Conivaptanis a drug that inhibits the RAAS (renin-angiotensin-aldosterone system) by blocking the action of angiotensin II (Ang II) at the AT1 receptor. This drug has been approved by the FDA for the treatment of patients with severe heart failure (HF) who have an elevated BNP (brain natriuretic peptide) level. It is indicated in combination with standard HF therapy in patients with chronic, severe HF and an elevated BNP level (≥100 pg/mL) despite optimal medical therapy.[@b1-cia-9-565]--[@b3-cia-9-565] The recommended dose is 2.5 mg once daily for a maximum of 3 weeks. In clinical practice, some patients do not tolerate the drug and do not respond to it, and other patients are intolerant to the drug. The reasons for this are unclear, but some patients are on multiple drugs and some
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cortisoneis a drug that inhibits
 
Response: Cortisoneis a drug that inhibits the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2). This enzyme is expressed in the epithelial cells of the renal tubules. Cortisone is metabolized in the kidney, but it is not removed from the body. Inhibition of 11-beta-HSD2 prevents the metabolism of cortisone in the kidney and leads to a buildup of cortisone in the blood and tissues. Cortisone is a potent mineralocorticoid, and it has the ability to cause sodium retention and increase blood pressure. This occurs because of the effect of cortisone on the kidneys to increase the amount of sodium that is reabsorbed in the distal convoluted tubules. Cortisone is also known to cause weight gain, particularly in the abdominal region. Cortisone is used in the treatment of many diseases including rheumatoid arthritis, inflammatory bowel disease, asthma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Costunolideis a drug that inhibits
 
Response: Costunolideis a drug that inhibits the phosphorylation of Akt, and the activity of PI3K is increased, thereby leading to the apoptosis of tumor cells.[@CIT0001] In this study, the antitumor activity of costunolide was evaluated by detecting the effect of costunolide on the proliferation and apoptosis of human lung cancer A549 cells and the possible mechanism of action.

A549 cells were obtained from the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) at 37°C in a humidified atmosphere of 5% CO~2~.

Cell viability was detected using the CCK-8 assay (Dojindo Laboratories, Kumamoto, Japan). A549 cells were seeded in 96-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  COTI-2is a drug that inhibits
 
Response: COTI-2is a drug that inhibits the function of T cells and, thus, reduces the intensity of the immune response against the self-antigens. It has been used in a large number of patients with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Crohn's disease. However, there are very few reports on the use of COTI-2 in patients with inflammatory bowel disease (IBD). This study investigated the clinical efficacy of COTI-2 in the treatment of patients with IBD.

Patients and methods: Patients with active ulcerative colitis or Crohn's disease were included in this study. The activity of their disease was measured by their symptoms, endoscopic findings, and blood C-reactive protein (CRP) levels. After treatment with oral COTI-2 (500 mg/day) for 4 weeks, the activity of their disease was re
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Coumarinis a drug that inhibits
 
Response: Coumarinis a drug that inhibits the synthesis of coagulation factors by the liver and their hepatic reuptake by the liver. Coumarin derivatives, in particular, inhibit the action of vitamin K. The use of Coumarin is prohibited in the United States and Europe because of the risk of liver damage. In addition, a high dose of Coumarin may cause a reduction in the platelet count. Coumarin may also cause dermatological problems, including, for example, hemorrhaging.

The generic name Coumadin is derived from coumarin.

Brand Names

The following brand names of Coumadin are available in the United States:

Description

Coumadin is used to treat and prevent thromboembolic disorders. It also is used to prevent blood clots that form in the veins after surgery, to prevent blood clots that form in the arteries after a heart attack or stroke, and to prevent blood
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CP21R7is a drug that inhibits
 
Response: CP21R7is a drug that inhibits the proliferation of various human cancer cell lines. However, its effects on leukemia cells have not been investigated. In this study, we examined the effects of CP21R7 on the proliferation and cell cycle distribution of the human leukemia cell line U937. The U937 cells were incubated with CP21R7 for 24 h, and then the proliferation was evaluated by measuring the cellular protein content and by staining the cells with trypan blue. CP21R7 suppressed the proliferation of U937 cells in a dose-dependent manner. The cell cycle analysis showed that CP21R7 arrested the U937 cells in the G1 phase. The number of cells in the G2 phase increased with the CP21R7 dose. The inhibitory effect of CP21R7 on U937 cell proliferation was due to G1 arrest.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CP-690550is a drug that inhibits
 
Response: CP-690550is a drug that inhibits the ability of protein kinase C (PKC) to phosphorylate the epidermal growth factor receptor (EGFR) on tyrosine residues. Its effect is to cause an increase in the level of tyrosine phosphorylation of the EGFR. The net result of this is to decrease the ability of the EGFR to transmit the signals which activate cellular proliferation.

References

Category:Antineoplastic drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CP868569is a drug that inhibits
 
Response: CP868569is a drug that inhibits multiple CYP3A4 isoforms and a potential drug-drug interaction (DDI) risk with drugs that are substrates for CYP3A4. As part of the clinical development of crizotinib, the magnitude and clinical significance of crizotinib DDIs with CYP3A4 substrates were investigated. Patients with advanced non-small cell lung cancer (NSCLC) were administered crizotinib 250 mg twice daily and crizotinib 250 mg twice daily plus rifampin 600 mg once daily, and the pharmacokinetics of crizotinib and rifampin were compared. Safety was assessed by recording adverse events and monitoring vital signs. Crizotinib concentrations were determined by high-performance liquid chromatography with tandem mass spectrometry. Fifty-one patients were enrolled. In the presence of rifampin, the mean (SD) crizotinib area under the concentration
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CPI-1205is a drug that inhibits
 
Response: CPI-1205is a drug that inhibits the enzyme cyclophilin A, which is essential for the replication of HIV.

It is used to treat HIV-infected people who have failed to respond to other treatments.

It is also used to treat a number of other diseases, including:

Other uses

CPI-1205 has also been used as a treatment for non-HIV infections. It has been used to treat several types of cancer, including non-small cell lung cancer and cervical cancer. It has also been used to treat other conditions, such as liver cirrhosis and autoimmune disease.

The effects of CPI-1205 on HIV infection have been studied in vitro and in animal models. It has been shown to be effective against HIV in vitro, in animal models, and in people. However, it is not known whether CPI-1205 is safe and effective in children.

The safety and effectiveness of CPI-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CPI-444is a drug that inhibits
 
Response: CPI-444is a drug that inhibits the actions of thrombin.

C-P-I-444is used to prevent the formation of blood clots that can form inside the blood vessels, especially in the legs, and to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).

How does it work?

C-P-I-444 works by binding to thrombin and inhibiting its actions. Thrombin is a protein that is found in the blood and it is the primary activator of the coagulation system, which is a series of chemical reactions that results in blood clotting.

When C-P-I-444 binds to thrombin, it prevents it from binding to its natural substrates. This prevents thrombin from activating the coagulation cascade, and it also inhibits thrombin from cleaving fibrinogen, a protein that helps form
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CPI-613is a drug that inhibits
 
Response: CPI-613is a drug that inhibits the enzyme cyclooxygenase-2 (COX-2). It was approved by the FDA for the treatment of pain and inflammation in August 2004. The manufacturer, Abbott Laboratories, announced on November 1, 2006 that it had terminated its development program for the drug due to the fact that the drug failed to demonstrate a benefit over NSAIDs in clinical trials.

In September 2006, the FDA approved the drug as a second-line treatment for moderately to severely active rheumatoid arthritis (RA). It was the first FDA-approved COX-2 inhibitor for this indication.

In September 2007, the FDA approved the drug for treatment of osteoarthritis of the knee in patients who are candidates for, but not eligible for, tumor necrosis factor alpha inhibitors. It is the first FDA-approved drug for this indication.

The prescribing information for the drug, as approved by the FDA, recommends that patients who are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Creatineis a drug that inhibits
 
Response: Creatineis a drug that inhibits the enzyme that breaks down creatine. When taken as a dietary supplement, creatine can help improve athletic performance. It can also be used to treat muscle wasting diseases. It is commonly sold as creatine monohydrate or creatine citrate.

What Is Creatine?

Creatine is a small organic molecule that is a byproduct of the metabolism of meat. It is the most abundant muscle-building nutrient in the body.

Creatine is essential for maintaining muscle mass. The creatine in the body is stored in the muscle cells. When you exercise, your body breaks down the creatine to supply energy for muscle contractions.

Creatine can also be stored in the liver, where it is converted into creatine phosphate, which helps to provide energy to muscles. The conversion of creatine into creatine phosphate can be affected by the levels of ammonia in the body. High levels of ammonia can cause the conversion to stop, so it is important to avoid getting too much
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Creatinineis a drug that inhibits
 
Response: Creatinineis a drug that inhibits muscle metabolism. It is the final product of the breakdown of creatine phosphate. Creatine is a major component of muscle cells, and is stored as creatine phosphate in the cells.

Ad

Creatine is normally excreted from the body in urine. In healthy individuals, creatine is excreted in urine within 2 to 3 hours after it is consumed. If there is a deficiency of creatine in the body, creatine is not excreted and is therefore retained. Creatine is primarily used by the brain for energy.

An increase in creatine concentration in the body can be a sign of liver disease, and can also be caused by muscle damage. Creatine is also used to treat brain injuries. Creatine is a dietary supplement that is available in a powder form and is also used to treat various other conditions.

Discuss this Article

Post your comments

Please enter the code:

Login

Register


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Crystalis a drug that inhibits
 
Response: Crystalis a drug that inhibits the amyloid-beta peptide from aggregating into amyloid fibrils and prevents the formation of plaques. It is a proprietary drug developed by Eisai Co.

The drug is a potent inhibitor of Aβ aggregation and is currently being developed for the treatment of Alzheimer's disease. The drug is currently in Phase II trials in Japan, and a first-in-human Phase I study in the United States was recently completed.

Crystalis is also a drug that was developed by the company CogRx, Inc., which was acquired by Eisai in 2003. It is a proprietary drug being developed for the treatment of cognitive impairment.

Phase I trial results 

The first-in-human Phase I clinical trial in the United States was completed in November 2010 and published in the Journal of Alzheimer's Disease in February 2011. The trial was conducted by the Eisai Co., in collaboration with Jans
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CUDC-907is a drug that inhibits
 
Response: CUDC-907is a drug that inhibits the function of the telomerase enzyme and it has been approved for clinical use in patients with recurrent ovarian cancer. In this study, we compared the antitumor activity of the telomerase inhibitor with cisplatin in cell culture and in a mouse model. In the in vitro assay, CUDC-907 was more effective than cisplatin in suppressing the growth of ovarian cancer cells. The IC50 of CUDC-907 for A2780 and OVCAR-8 cells was 2.8 and 5.8 μM, respectively. Cisplatin had IC50 values of 14.3 and 26.4 μM, respectively. The IC50 of CUDC-907 for A2780-R cells was 6.2 μM, which was approximately 10-fold higher than the IC50 of CUDC-907 for A2780 cells. In contrast, the IC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Curcuminis a drug that inhibits
 
Response: Curcuminis a drug that inhibits tumor growth by activating the caspase-3, -8, and -9 pathways, which leads to the induction of apoptosis and cell cycle arrest at the G1 phase. It can induce the expression of the pro-apoptotic protein Bax, while suppressing the expression of the anti-apoptotic protein Bcl-2, which in turn triggers apoptosis in tumor cells ([@b15-ijo-48-05-1781],[@b16-ijo-48-05-1781]). Our results indicate that curcumin inhibits cell proliferation by decreasing the cell number and the expression of Ki-67, and increasing the expression of p21. In addition, the anti-proliferative activity of curcumin was higher than that of cisplatin.

The tumor suppressor protein p53 is known to play a key role in apoptosis ([@b17-ijo-48-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CX-4945is a drug that inhibits
 
Response: CX-4945is a drug that inhibits the activity of the enzyme IDH. CX-4945 is currently in phase I clinical trials. Preclinical data suggest that it may be effective in reducing brain lactate levels and, thereby, restoring oxygen delivery to hypoxic cells. In this study, we investigated the effects of CX-4945 on brain lactate metabolism in vivo. Rats were administered a bolus dose of CX-4945 (10 mg/kg) followed by a continuous infusion of the drug at the same dose for 6 h. Brain lactate levels decreased from approximately 3.5 to 1.5 mmol/g in response to CX-4945. A corresponding decrease in cerebral blood flow was observed. However, cerebral oxygen delivery remained unchanged, suggesting that the decrease in lactate levels was a consequence of a reduction in lactate production rather than an increase in its clearance. The decrease in lactate levels was paralleled by a reduction in the expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CX-5461is a drug that inhibits
 
Response: CX-5461is a drug that inhibits Polycomb Repressive Complex 2 (PRC2), a protein complex involved in chromatin remodeling, and thereby activates genes involved in the cell cycle, senescence, and apoptosis. We found that treatment of a human colorectal cancer cell line, HCT116, withCX-5461for 72 hours caused growth arrest, senescence, and apoptosis, but not senescence or apoptosis in a cell line derived from the human mammary epithelium, MCF10A. However, treatment of MCF10A cells withCX-5461for 72 hours caused growth arrest and senescence. Further studies revealed thatCX-5461treatment of MCF10A cells causes an increase in p21CIP1 and p16INK4a expression, but not p53, and treatment of HCT116 cells withCX-5461leads to an increase in p
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclandelateis a drug that inhibits
 
Response: Cyclandelateis a drug that inhibits the growth of tumors by slowing down cell division. It works by blocking the enzymes that produce the building blocks for cell growth. The cells become stressed and stop growing. Cyclandelate is a prescription drug and is available only with a doctor's prescription. It is a vitamin K antagonist.

Celiprolol

Celiprolol is a beta blocker that lowers blood pressure and is used to treat hypertension and heart disease. It may also be used to treat high blood pressure, angina, irregular heartbeat, and heart failure. Celiprolol may also be used for other purposes not listed here. Celiprolol belongs to a class of drugs called beta blockers. It works by slowing down the heart rate and relaxing the blood vessels.

Cefadroxil

Cefadroxil is an antibiotic. It may be used to treat bacterial infections of the ear, throat, lungs, urinary tract, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclizineis a drug that inhibits
 
Response: Cyclizineis a drug that inhibits the central nervous system. It is used to treat allergies. The recommended dose is 10 mg daily.

For use in the eye

Cyclizineis a drug that inhibits the central nervous system. It is used to treat allergies. The recommended dose is 10 mg daily.

For use in the eye

Cyclizineis a drug that inhibits the central nervous system. It is used to treat allergies. The recommended dose is 10 mg daily.

For use in the eye

Cyclizineis a drug that inhibits the central nervous system. It is used to treat allergies. The recommended dose is 10 mg daily.

For use in the eye

Cyclizineis a drug that inhibits the central nervous system. It is used to treat allergies. The recommended dose is 10 mg daily.

For use in the eye

Cyclizineis a drug that inhibits the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclobenzaprineis a drug that inhibits
 
Response: Cyclobenzaprineis a drug that inhibits both serotonin and norepinephrine reuptake. It is used to treat muscle spasms associated with neuropathic pain and to relieve the symptoms of fibromyalgia. This medication may also be used for purposes not listed in this medication guide.

How should I take Cyclobenzaprine?

Take this medication by mouth, usually in the morning. Your pharmacist will tell you how much to take. Follow the directions on your prescription label. If you do not understand these directions, ask your pharmacist for help.

If you are taking this medication at the same time as another muscle relaxant, your doctor may change the dose or how often you take it.

Take Cyclobenzaprine with a full glass of water. Take your dose on an empty stomach.

Continue to take Cyclobenzaprine even if you feel well. Do not stop taking Cyclobenzaprine without first
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclopentolateis a drug that inhibits
 
Response: Cyclopentolateis a drug that inhibits the synthesis of cerebroside. It is used to dilate the pupil and to enhance vision. Cyclopentolate is available as a powder, an injection, and a syrup. Cyclopentolate is a white to slightly yellowish powder with a faint fishy odor. It is highly soluble in water and slightly soluble in alcohol. The molecular formula of cyclopentolate is C5H9NO and its molecular weight is 109.15 g/mol.

Uses

Cyclopentolate is used to dilate the pupil and to enhance vision. Cyclopentolate is a fast-acting, non-selective adrenergic receptor antagonist. It has also been used in the treatment of tinnitus and in the management of iritis. It is used in conjunction with tropicamide and phenylephrine to increase the pupil size. Cyclopentolate has been used to enhance visual acuity in patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclophosphamideis a drug that inhibits
 
Response: Cyclophosphamideis a drug that inhibits DNA repair by interfering with the action of DNA-dependent protein kinase, which is required for DNA repair.

Drug: cyclophosphamide

The principle of chemotherapy is to use a drug that will destroy cancer cells but is not toxic to normal cells.

Drug: cyclophosphamide

If you are going to treat a disease, you should treat it with a drug that is specifically directed to that disease.

Drug: cyclophosphamide

Chemotherapy is the use of drugs to destroy cancer cells.

Drug: cyclophosphamide

If the treatment is successful, the cancer will be cured and the normal cells will remain normal.

Drug: cyclophosphamide

CYCLOPHOSPHAMIDE

USANIMAL

ADMINISTRATION

CYCLOPHOSPHAMIDE

SOLUTION

IN
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  cyclo(RGDfK)is a drug that inhibits
 
Response: cyclo(RGDfK)is a drug that inhibits the growth of several cancer cell lines. We tested the effect of the RGD-containing peptide on tumor cell adhesion to a monolayer of endothelial cells and examined the capacity of endothelial cells to stimulate the adhesion of cancer cells to extracellular matrix proteins. In the presence of 1 microM RGD, there was a statistically significant inhibition of the adhesion of a panel of human cancer cell lines to both the endothelial cells and fibronectin. RGD had no effect on the adhesion of normal human peripheral blood lymphocytes or human dermal fibroblasts to the endothelial cells or fibronectin. The peptide RGD also inhibited the adhesion of a murine melanoma cell line to a fibronectin matrix. The inhibitory effect of RGD on the adhesion of tumor cells to the endothelium and to extracellular matrix proteins is due,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclosporinis a drug that inhibits
 
Response: Cyclosporinis a drug that inhibits the P450 enzymes that break down tocopherol, a type of vitamin E, can help prevent cancer. And some studies have shown that taking tocopherol-rich foods such as grapes and spinach can lower the risk of cancer.

Exercise. Regular exercise has many benefits, including improved immune system functioning and a reduced risk of cardiovascular disease and diabetes. Studies have shown that people who exercise regularly are at a lower risk of developing cancer.

However, some evidence suggests that exercise may increase the risk of some cancers. Women who exercise may be at a slightly increased risk of breast cancer, and people who are sedentary and overweight are at higher risk of developing colon cancer.

Try to make physical activity a part of your daily life. Even small amounts of exercise, such as walking, can have a big impact on your health.

Vitamin D. Vitamin D is found in few foods, but can be made
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyclothiazideis a drug that inhibits
 
Response: Cyclothiazideis a drug that inhibits aldosterone synthase and also blocks the effect of aldosterone. It is used in the treatment of hypertension. The action of cyclothiazide is independent of any changes in blood volume.

Uses

Uses:

Cyclothiazide is used in the treatment of hypertension. It is also used in the treatment of hyperkalemia, hypermagnesemia, hypercalcemia, and other electrolyte abnormalities.

Dosage

Uses:

Dosage:

The usual recommended dose is 10 to 20 mg orally three times a day, taken after breakfast, lunch, and dinner. The dose may be increased to 25 mg after 1 week of therapy, and then increased by 10 mg per week.

Dosage:

The usual recommended dose is 10 to 20 mg orally three times a day, taken after breakfast, lunch, and dinner. The dose
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyproheptadineis a drug that inhibits
 
Response: Cyproheptadineis a drug that inhibits the conversion of histamine to its active form, which can lead to relief of symptoms such as wheezing and congestion. It can be taken in tablet form and is available without a prescription.

Ad

Consult your doctor before taking cyproheptadine if you have heart problems, liver disease, or if you have ever had problems with alcohol. Taking this drug for long periods of time may increase your risk of side effects such as blurred vision, stomach upset, trouble sleeping, or unusual behavior.

Cyproheptadine is often used to treat children with allergies and asthma, although it may also be used to treat adults with allergies. Your doctor may suggest this drug if you have symptoms that can be relieved by reducing histamine activity in the body.

Cyproheptadine is available without a prescription and may be purchased at drug stores.

Cyproheptadine is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyproteroneis a drug that inhibits
 
Response: Cyproteroneis a drug that inhibits the production of testosterone by the testes. This medication is used to treat males with certain types of prostate cancer. The most common side effects include: changes in sex drive, problems with erection, and other sexual problems. Other side effects may include: depression, headache, low blood pressure, weight gain, trouble sleeping, and loss of hair. This medication is available as a tablet, a gel, a cream, a patch, and a spray.

How to use Cyproterone

Cyproterone is taken once daily at bedtime. The tablet or gel is applied to the skin and should be used at least three hours before sexual activity. A spray or cream is applied to the skin and should be used within the next 12 hours of sexual activity.

Cyproterone Gel

Use Cyproterone Gel for the treatment of benign prostatic hyperplasia (BPH).

Do not use Cy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cyromazineis a drug that inhibits
 
Response: Cyromazineis a drug that inhibits the acetylcholinesterase enzyme and the cell division. Cyromazine, and the closely related compound, roxicam, are marketed in many countries. Cyromazine is used for the treatment of Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression, bipolar disorder, anxiety, insomnia, fibromyalgia, and arthritis.

Lithium is a drug that is commonly used to treat bipolar disorder. Lithium is also used to treat various cancers, for example, cancer of the bladder, breast, colon, prostate, stomach, and thyroid.

Many other drugs have been developed and marketed. This article will cover the development of the drugs that are listed in the box above.

Drugs that were not initially marketed as a medicine

Nicotine is the most commonly used drug to quit smoking. Nicotine is also a natural product of the tobacco plant, but it is not normally used in the treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cysteamineis a drug that inhibits
 
Response: Cysteamineis a drug that inhibits the activity of enzymes involved in the production of thyroid hormones. It can be administered orally or intravenously. Cysteamine has been used to treat patients with cystinosis, an inborn error of metabolism. Cysteamine is also used to treat chronic fatigue syndrome, rheumatoid arthritis, and Parkinson's disease. Cysteamine has been approved by the Food and Drug Administration (FDA) for treatment of cystinosis and for treatment of patients with chronic fatigue syndrome. Cysteamine is sold as the hydrochloride salt under the brand name Cystagon®. Cysteamine is available in tablet form.
In the past, cysteamine has been administered orally in the form of tablets or capsules. Unfortunately, oral administration of cysteamine can be difficult to control due to the inherent instability of cysteamine. Oral administration of cysteamine is often associated with gastrointestinal side effects such as nausea, vomiting, diarrhea,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  CYTis a drug that inhibits
 
Response: CYTis a drug that inhibits the enzyme cyclooxygenase-2 (COX-2) and has been used for many years to treat inflammation, pain, and other symptoms associated with chronic inflammatory conditions such as arthritis. Recent studies suggest that it also has anti-carcinogenic properties. Researchers at the University of Minnesota found that low doses of the drug reduce the number of mammary tumors that develop in mice.

These results are intriguing, but how does it work? According to Dr. Robert Spiegelman, professor of pathology and oncology, the team's experiments suggest that indomethacin can prevent the growth of breast cancer cells by inhibiting the formation of a protein called HIF-1alpha.

What is HIF-1alpha?

HIF-1alpha is a protein that plays a role in regulating cellular oxygen levels and activating the process of angiogenesis. It is normally expressed at very low levels in the body
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cytidineis a drug that inhibits
 
Response: Cytidineis a drug that inhibits DNA methylation and is used in cancer treatment. A phase II clinical trial showed that low-dose cytidine could increase the overall survival rate of cancer patients. However, its exact mechanism of action remains unclear. Here, we used a combination of in vitro and in vivo models to determine the effect of cytidine on DNA methylation and to investigate its mode of action. Our results showed that cytidine could reduce the overall methylation level of DNA by inhibiting DNA methyltransferase 1 and 3a. Additionally, we found that cytidine could increase the overall expression of DNA methylation-related genes and lead to the derepression of cancer-related genes, such as Wnt, Notch, and hedgehog signaling pathway genes. Finally, we demonstrated that cytidine could suppress the growth of human cancer cells in a nude mouse xenograft model. Our results suggest that cytidine has the potential to be developed as a novel anticancer agent.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Cytisineis a drug that inhibits
 
Response: Cytisineis a drug that inhibits 5-HT reuptake in the central nervous system. Cytisine is a component of the French smokeless tobacco product "Marlboro." It has been hypothesized that cytisine acts as a partial agonist at the 5-HT1A receptor, with the consequence that cytisine might induce antidepressant effects in smokers. We tested the hypothesis that cytisine has antidepressant effects in rats and the potential mechanisms of action. We administered cytisine to rats using the chronic mild stress model. We measured the concentrations of monoamine neurotransmitters in the hippocampus and prefrontal cortex, and examined the levels of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in the hippocampus. In the forced swim test, rats treated with cytisine showed an antidepressant-like effect. In the chronic mild stress model, cytisine significantly decreased the concentrations of serotonin and its metabolite 5-hydroxyindoleacetic acid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dabigatranis a drug that inhibits
 
Response: Dabigatranis a drug that inhibits thrombin, which is a protease that plays an important role in the blood coagulation system. This medication has been shown to be effective in preventing blood clots from forming and in reducing the likelihood of re-clotting after a blood clot has formed. Dabigatranis is the brand name for the medication Dabigatran.

Dabigatranis may also be marketed as:

Dabigatran Etexilate

Dabigatran Etexilate

Dabigatran etexilate

Dabigatran etexilate

Dabigatran

Dabigatran

Eptifibatide

Eptifibatide

Generic Dabigatran

Generic Dabigatran

Dabigatran

Dabig
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dacarbazineis a drug that inhibits
 
Response: Dacarbazineis a drug that inhibits DNA synthesis by binding to DNA. It is approved by the FDA for the treatment of malignant melanoma. It is also used in other cancers.

Dacarbazineis a drug that inhibits DNA synthesis by binding to DNA. It is approved by the FDA for the treatment of malignant melanoma. It is also used in other cancers.

Dacarbazine

0.1 mg/kg

Maximum Single Dose

80 mg/m2

Range

60-90 mg/m2

Dose Modification

Each cycle:

Grade 4 neutropenia or thrombocytopenia

If the dose is reduced to 60 mg/m2 for more than 2 cycles

Dacarbazineis a drug that inhibits DNA synthesis by binding to DNA. It is approved by the FDA for the treatment of malignant melanoma. It is also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daidzeinis a drug that inhibits
 
Response: Daidzeinis a drug that inhibits the process of bone resorption. Daidzein is a form of oestrogen that occurs naturally in soybeans and other plants. It is also a component of many Chinese herbal medicines.

Daidzein can be used alone or in combination with other hormones. It is also available as a cream or a tablet that you apply to the skin. It is not used for the treatment of endometriosis, as this would increase the risk of ovarian cancer.

**Dong quai** _(Angelica sinensis)_

This herb is sometimes known as Angelica root, and it is a member of the Apiaceae family of herbs. It is native to China, and has been used as a traditional medicine in China for thousands of years.

The dried root of dong quai is a powerful and effective remedy for the treatment of endometriosis. Dong quai can be used as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daidzinis a drug that inhibits
 
Response: Daidzinis a drug that inhibits the growth of tumor cells. Daidzein is the primary metabolite of daidzein, a plant-derived compound with estrogenic activity. Previous studies showed that daidzein was selectively toxic to estrogen-dependent human breast cancer cells, including MCF-7 cells. To elucidate the molecular mechanism of daidzein's anticancer effects, we investigated the effect of daidzein on the proliferation of MCF-7 cells. Daidzein dose-dependently inhibited the proliferation of MCF-7 cells, and induced G(2)/M phase arrest. Daidzein increased the levels of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) in MCF-7 cells. Daidzein treatment resulted in a marked decrease in cyclin B1, cyclin A and CDK1 levels in MCF-7 cells. In addition, daidze
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dalcetrapibis a drug that inhibits
 
Response: Dalcetrapibis a drug that inhibits the cholesteryl ester transfer protein (CETP) and thereby reduces the catabolism of high density lipoprotein cholesterol (HDL-C) and increases the amount of HDL-C in the plasma.

“The global impact of the high levels of cholesterol in the blood and the accompanying heart disease is well known. A variety of clinical studies have shown that the risk of heart disease is reduced in patients with high HDL-C levels. In contrast, low HDL-C levels are associated with an increased risk of cardiovascular disease. Thus, increased HDL-C levels may be one way of reducing the risk of heart disease.”

“A unique property of CETP is that it facilitates the transfer of cholesterol from HDL to other lipoproteins. This property is very important in the metabolism of triglyceride-rich lipoproteins and may play a role in the pathogenesis of atheros
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Danazolis a drug that inhibits
 
Response: Danazolis a drug that inhibits angiogenesis, which in turn suppresses tumor growth and metastasis. The purpose of this study was to determine the efficacy and toxicity of doxazosin, which is the 4-alpha- and 7-alpha-hydroxy derivative of Danazol, in the treatment of ovarian cancer. The results indicated that doxazosin significantly reduced the growth of ovarian cancer xenografts and produced significant toxicity. These results support the use of doxazosin as a chemotherapeutic agent for the treatment of ovarian cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Danirixinis a drug that inhibits
 
Response: Danirixinis a drug that inhibits the enzyme SIRT1 and SIRT2, which are present in the central nervous system, as well as in the peripheral nervous system, and is involved in the pathogenesis of Alzheimer's disease. By inhibiting SIRT1 and SIRT2, Danirixin enhances the acetylation of alpha-synuclein, thus resulting in the inhibition of its aggregation and subsequent neurodegeneration \[[@B41-ijms-21-01798]\].

6. Conclusions {#sec6-ijms-21-01798}
==============

Despite significant progress in the last years, no pharmacological treatment has been approved to date for PD. A large number of preclinical and clinical studies have focused on finding compounds that are able to modulate the activity of the dopaminergic system and/or the metabolism of alpha-synuclein. In this sense, the identification of new potential pharmacological
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Danofloxacinis a drug that inhibits
 
Response: Danofloxacinis a drug that inhibits both COX-1 and COX-2 and was approved for the treatment of rheumatoid arthritis in Europe in 1995. It was withdrawn from the market in 1998 because of side effects. The active metabolite, diflunisal, was developed as a prodrug and is now marketed in the USA and other countries.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Danopreviris a drug that inhibits
 
Response: Danopreviris a drug that inhibits the enzymatic activity of the angiotensin-converting enzyme (ACE). Dalazatide, an antidiabetic drug that is a prodrug of glucagon-like peptide-1 (GLP-1), was investigated as a new therapy for type 2 diabetes mellitus (T2DM).

On the basis of the results of preclinical and clinical studies, in December 2010, the U.S. Food and Drug Administration (FDA) approved dalazatide as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.

"While a number of studies have shown that GLP-1 receptor agonists (GLP-1RAs) are effective in lowering blood glucose levels in patients with T2DM, their use is limited because of gastrointestinal side effects, such as nausea and vomiting," said Laura M. Cappola, M.D., assistant professor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Danthronis a drug that inhibits
 
Response: Danthronis a drug that inhibits prolactin synthesis and secretion in man. It is a naturally occurring substance which occurs in the wild and is used in small amounts in human foodstuffs. The substance has also been synthesized chemically.
The chemical synthesis of danthron has been described by F. Danthron in U.S. Pat. No. 2,652,510 and is based on the cyclization of 1,3-bis-(4-hydroxyphenyl)-propane (catechol) to form 2,3-dihydroxy-1,4-bis-(4-hydroxyphenyl)-butane (danthron). This compound has the formula: ##STR1##
Danthron has been reported to be a potent inhibitor of prolactin secretion in man. It is believed that the pharmacological activity of danthron results from the ability of the compound to inhibit the conversion of luteinizing hormone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dantroleneis a drug that inhibits
 
Response: Dantroleneis a drug that inhibits the function of the ryanodine receptor (RyR), which is a sarcoplasmic reticulum calcium release channel located in the skeletal muscle. It has been used in the treatment of rhabdomyolysis. There is no systematic literature review on dantroleneis. This study aimed to systematically review the efficacy and safety of dantroleneis in the treatment of rhabdomyolysis. We searched the Cochrane Library, PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang Data up to January 2016. We identified relevant studies by screening the titles and abstracts. We assessed the methodological quality of included studies using the Jadad scale. Two reviewers independently extracted data and assessed the risk of bias. We used RevMan software for statistical analysis. We included seven studies in the review, of which four studies were included in the meta-analysis. The meta-analysis showed
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dapagliflozinis a drug that inhibits
 
Response: Dapagliflozinis a drug that inhibits the phosphatase PP2A to induce caspase-independent cell death in cancer cells. Dapagliflozin (DA) and its analogues, including LY2495655, CUDC-101, and PX-12, are selective PP2A inhibitors that induce apoptosis in various cancer cells. The molecular mechanisms underlying DA-induced apoptosis have been reported to be associated with the release of the apoptosis-inducing factor (AIF) from mitochondria, the generation of reactive oxygen species (ROS), and the modulation of the PI3K/AKT and MAPK signaling pathways. However, the mechanisms by which DA and its analogues induce caspase-independent cell death remain poorly understood. Here, we show that DA and its analogues trigger the mitochondrial translocation of the cytosolic protein Atg9, and that this translocation is associated with the accumulation of aut
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dapansutrileis a drug that inhibits
 
Response: Dapansutrileis a drug that inhibits NF-κB activation in a broad range of cell types, including the T cells and dendritic cells. To study the mechanism of action of dapansutrileis, we first investigated the effect of this compound on NF-κB activation. We show that dapansutrileis strongly inhibits TNFα-induced NF-κB activation in a dose-dependent manner. Dapansutrileis also inhibits LPS-induced NF-κB activation in human monocyte-derived dendritic cells (DCs) and DC-derived mature IL-12 secretion. The effect of dapansutrileis on NF-κB activation was not related to inhibition of IKK activity. We then analyzed the effects of dapansutrileis on the signal transduction pathway that leads to NF-κB activation. We show that dapansutrileis strongly
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daphnetinis a drug that inhibits
 
Response: Daphnetinis a drug that inhibits cell growth and causes cell cycle arrest in human tumor cell lines.
The genus Daphnia is a highly branched and diverse group of crustaceans with many species. Of the six daphnids, Daphnia magna and Daphnia pulex are most commonly used in toxicity tests. The species Daphnia obtusa and Daphnia tibetana are occasionally used in ecotoxicological studies, and a third species, Daphnia galeata, has recently been identified. The bioactive compounds from the genus Daphnia have not been reported. Here, we report the isolation of a bioactive compound from Daphnia obtusa and Daphnia tibetana, which is a new member of the indolocarbazole class of cytotoxic agents. Daphnetinis A (1) was isolated from the organic extract of Daphnia obtusa and D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dapivirineis a drug that inhibits
 
Response: Dapivirineis a drug that inhibits the replication of the human immunodeficiency virus type 1 (HIV-1) by binding to the reverse transcriptase (RT) and is currently approved in combination with other antiretroviral agents as pre-exposure prophylaxis (PrEP) and as a component of the highly active antiretroviral therapy (HAART) for treatment of HIV-1 infection. Its antiretroviral mechanism of action is distinct from other RT inhibitors, and it has a unique pharmacokinetic and safety profile.

Introduction

Dapivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by binding to the enzyme’s active site and blocking reverse transcription. It is a substrate for P-glycoprotein, a drug efflux transporter. Dapivirine is well tolerated in combination with other ant
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dapoxetineis a drug that inhibits
 
Response: Dapoxetineis a drug that inhibits the release of serotonin from the nerve endings. Dapoxetine works by inhibiting serotonin reuptake and by blocking serotonin receptors. It works in the same way as other antidepressants like Prozac, Paxil, Zoloft, and Lexapro.

It is not known whether dapoxetine is safe for use during pregnancy. Dapoxetine may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Dapoxetine is used to treat premature ejaculation in men. It works by preventing ejaculation by inhibiting serotonin reuptake in the nerve endings.

This medication is sometimes used to treat premature ejaculation in men. It works by preventing ejaculation by inhibiting serotonin reuptake in the nerve endings.

This medication is sometimes used to treat premature ejaculation in men. It works by preventing ejaculation by inhibiting serotonin reupt
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daprodustatis a drug that inhibits
 
Response: Daprodustatis a drug that inhibits the formation of cartilage and reduces its destruction, or the a drug that blocks the effects of the natural hormone progesterone on the lining of the uterus. Other drugs are used to control blood pressure and cholesterol. These include anti-inflammatories, anti-depressants and anticoagulants.

This page provides a summary of what these drugs do and lists the most common side effects.

Medicines used to treat osteoarthritis are classified as non-steroidal anti-inflammatory drugs (NSAIDs). They work by stopping the production of a substance that normally causes inflammation and pain.

Anti-depressants

Anti-depressants are medicines that can help to control depression and reduce anxiety. They can also be used to treat bipolar disorder.

The most commonly prescribed anti-depressants are called selective serotonin reuptake inhibitors (SSRIs). These include:

Cital
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daptomycinis a drug that inhibits
 
Response: Daptomycinis a drug that inhibits the growth of cancer cells and has already been approved for the treatment of cutaneous T-cell lymphoma. Credit: Ralf Herold, A*STAR

Research conducted by scientists at the Agency for Science, Technology and Research (A*STAR) has led to the discovery of a drug that targets a key enzyme that is required for the growth of some forms of cancer. The discovery is a first for the agency and has led to the discovery of a novel therapeutic drug, called daptomycin, that can be used to treat cancer.

Daptomycin is a drug that inhibits the growth of cancer cells and has already been approved for the treatment of cutaneous T-cell lymphoma. The new discovery is a first for the agency and has led to the discovery of a novel therapeutic drug, called daptomycin, that can be used to treat cancer.

The discovery of daptomycin was made by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Darifenacinis a drug that inhibits
 
Response: Darifenacinis a drug that inhibits the enzyme responsible for the breakdown of serotonin. This will increase the level of serotonin in the brain, making you feel happier and more relaxed. This is why it is often prescribed for depression. However, you should only use it for a short time to prevent side effects. It is also used to treat anxiety and panic attacks.

One of the reasons why many people choose to try supplements to treat depression is because they believe that they are a safer alternative to traditional antidepressant medications. However, many of these supplements contain harmful ingredients. This can lead to severe side effects and long-term problems. If you are thinking of using a supplement to treat depression, you should always speak to your doctor first.

Other Natural Treatments for Depression

In addition to medication, there are other natural treatments that you can try to treat depression. Many people use natural remedies because they think that they are safer and have fewer side effects. However, there are also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dasatinibis a drug that inhibits
 
Response: Dasatinibis a drug that inhibits multiple tyrosine kinases (TKs), including the BCR-ABL, SRC family, KIT, and PDGFR. Dasatinib is approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph^+^ALL). Dasatinib is also under investigation in a number of solid tumors, including breast cancer, lung cancer, prostate cancer, and head and neck cancer.

CML is a myeloproliferative neoplasm characterized by the presence of the BCR-ABL fusion protein. Dasatinib potently inhibits the activity of BCR-ABL and other TKs in vitro, and the drug has been shown to be effective in treating CML in clinical trials.[@b1-ott-6-1381]

Dasatinib was approved for the treatment of Ph^+^
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Daunomycinis a drug that inhibits
 
Response: Daunomycinis a drug that inhibits the growth of cancer cells and that is a chemotherapy drug for the treatment of cancer. It is a broad spectrum antifungal antibiotic and has been used as an antineoplastic agent. It is an antifungal and antitumor agent and is used for treatment of fungal infections and as a chemotherapy drug for the treatment of cancer. Daunomycin is a mitotic inhibitor. The mechanism of action of daunomycin is by binding to DNA, inhibiting DNA replication, and thus preventing the growth of cancer cells.

Daunomycin has also been used to treat a type of eye cancer called retinoblastoma. Retinoblastoma is the most common malignant eye tumor in children. Retinoblastoma is a cancer that starts in the retina of the eye. Retinoblastoma can occur at any age. Retinoblastoma can occur in one eye or in both
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DCC-2036is a drug that inhibits
 
Response: DCC-2036is a drug that inhibits a specific enzymatic activity of the enzyme fatty acid synthase (FASN). This enzyme is responsible for the synthesis of saturated and unsaturated fatty acids, which are major components of the cell membrane and are necessary for the proliferation of many types of cells. It is important to note that in many cases, the membrane composition of cancer cells differs from that of normal cells. Therefore, it is not surprising that drugs that inhibit the synthesis of fatty acids in cancer cells can cause cell death by the same mechanism as that of apoptosis.
DCC-2036 was discovered by D3 Therapeutics and is being developed for the treatment of cancer. DCC-2036 inhibits the activity of FASN, a key enzyme involved in the synthesis of fatty acids in the cell membrane. FASN is responsible for the synthesis of saturated and unsaturated fatty acids, which are major components of the cell membrane and are necessary for the proliferation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DCC-2618is a drug that inhibits
 
Response: DCC-2618is a drug that inhibits the synthesis of DNA and can be used to treat leukemia. In vitro, it selectively kills leukemic cells by inhibiting ribonucleotide reductase, an enzyme involved in DNA synthesis. The overall goal of this study was to develop a method to evaluate the pharmacokinetics and toxicity of this drug in vivo in a model that closely mimics the clinical situation. We developed a novel method to measure DCC-2618 in mice. This method was validated by the ability to measure the drug levels in mouse blood after intravenous (i.v.) and oral administration of DCC-2618. The levels of DCC-2618 in mouse blood were approximately 3.0 to 4.0 microg/ml after a single i.v. injection. The levels in blood after oral administration of DCC-2618 were approximately 3.0 to 5.0 microg/ml, depending on the time of administration.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Decamethoniumis a drug that inhibits
 
Response: Decamethoniumis a drug that inhibits acetylcholine receptors. This inhibits the effects of acetylcholine on muscles. This drug is a very potent relaxant.

Decamethoniumis a drug that inhibits acetylcholine receptors. This inhibits the effects of acetylcholine on muscles. This drug is a very potent relaxant.

Decamethoniumis a drug that inhibits acetylcholine receptors. This inhibits the effects of acetylcholine on muscles. This drug is a very potent relaxant.

When used as a relaxant for children and adults, this drug can be used to reverse a neuromuscular blockade (reversal of paralysis). This drug can be used to stimulate the heart. This drug can be used to stimulate a blocked or paralyzed diaphragm muscle.

When used as a relaxant for children and adults, this drug can be used to reverse a neuromuscular
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  decitabineis a drug that inhibits
 
Response: decitabineis a drug that inhibits DNA methyltransferase and in combination with chemotherapy has shown activity in acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). To date, there are only a few reports of venetoclax combined with decitabine. We report the case of a patient with CLL who was treated with venetoclax, decitabine and bendamustine. She was previously treated with chlorambucil and rituximab with minimal response. After four cycles of decitabine, she received a single dose of bendamustine. The patient achieved a partial remission, as assessed by peripheral blood counts and bone marrow aspirate, and was in remission at the time of this report. We describe a new and promising combination of venetoclax, decitabine and bendamustine in a patient with CLL.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Defactinibis a drug that inhibits
 
Response: Defactinibis a drug that inhibits a type of enzyme called a phosphatase, thereby preventing cells from deactivating the AMP-activated protein kinase (AMPK). AMPK is a metabolic regulator that keeps the cell in a resting state by activating the metabolic processes that produce energy. Inhibition of AMPK allows the cell to use its energy resources in an unbridled manner, leading to the buildup of fats and the cell’s eventual death.

The drug is an important tool for researchers studying the causes of obesity and type 2 diabetes. The two diseases share a common cause: a buildup of fat in the body. Normally, the cells that store fats in the body use their energy to produce hormones and other proteins. This is fine when the body has enough energy. But in the obese, this process is often not activated, and the cells use their energy to build fat instead.

Defactinibis a new drug that is designed to turn
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Deferiproneis a drug that inhibits
 
Response: Deferiproneis a drug that inhibits the accumulation of iron in the liver. Deferiprone is approved for use in Europe, and is being investigated for treatment of patients with hereditary hemochromatosis and transfusion-dependent anemias. In this study, we evaluated the pharmacokinetics of deferiprone and its effect on iron absorption in healthy volunteers.

Deferiprone is an oral iron chelator approved in Europe for treatment of hereditary hemochromatosis and transfusion-dependent anemias. We evaluated the pharmacokinetics of deferiprone and its effect on iron absorption in healthy volunteers.

Hemochromatosis is a disorder of iron overload characterized by accumulation of iron in the body. Iron-overloaded patients may present with a wide range of clinical manifestations, including arthropathy, cirrhosis, diabetes mellitus, cardiomyopathy, and hypogonadism. Iron-overloaded patients with hereditary hem
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Deferoxamineis a drug that inhibits
 
Response: Deferoxamineis a drug that inhibits iron-dependent free radical formation. It was initially used to treat Wilson disease. Now it is used to treat a variety of other disorders. In this study, we evaluated the potential use of deferoxamine in preventing or reducing injury caused by prolonged low-flow ischemia of the brain. Ischemic injury was induced by ligation of the common carotid artery in cats. Five days after carotid ligation, animals were randomly assigned to receive an intravenous injection of normal saline (control group), deferoxamine (2.5 mg/kg/day) for 5 days, or deferoxamine for 5 days and then normal saline for 2 days (recovery group). A second group of animals was subjected to the same protocol, but the carotid artery was ligated 5 days before the treatment. This group was used to evaluate the effect of carotid ligation on cerebral blood flow. Deferoxamine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Deflazacortis a drug that inhibits
 
Response: Deflazacortis a drug that inhibits the conversion of steroid precursors to the active steroid hormone. It has been used to treat inflammatory conditions, such as asthma and rheumatoid arthritis, and is also used to treat male infertility. It has been used for treating acne, male pattern baldness, hirsutism, and to prevent post-partum uterine bleeding. It is also used for treating osteoporosis. Deflazacort is the trade name for deflazacort (deflazacortate).

1. What is deflazacort?

Deflazacort is a synthetic corticosteroid. It is used to treat inflammatory conditions, such as asthma and rheumatoid arthritis, and is also used to treat male infertility. It has been used for treating acne, male pattern baldness, hirsutism, and to prevent post-partum uterine bleeding. It is also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dehydroepiandrosteroneis a drug that inhibits
 
Response: Dehydroepiandrosteroneis a drug that inhibits the production of free radicals in vivo. Dehydroepiandrosterone (DHEA) is the most abundant circulating steroid in humans, and is present in higher concentrations in females than in males. DHEA is a precursor of androgens, estrogens and estradiol. DHEA has been used in the treatment of many diseases, including: neurodegenerative diseases, cardiovascular diseases, metabolic diseases, psychiatric diseases, diabetes, and immune system diseases.
DHEA is commercially available as an oral dosage form (e.g., DHEA sulfate) and as a parenteral (e.g., DHEA hemisuccinate) formulation. The parenteral formulation is sold under the trade name NEUROMET® and is indicated for the treatment of central nervous system disorders, including, but not limited to, anxiety, depression, fatigue, memory loss, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Delavirdineis a drug that inhibits
 
Response: Delavirdineis a drug that inhibits the reverse transcriptase of human immunodeficiency virus type 1 (HIV-1). The drug was approved by the Food and Drug Administration (FDA) in 1995. It was the first drug to be approved for the treatment of HIV infection.\[[@ref1]\]

The drug is well tolerated and has a long half-life. Its major side effects are neutropenia and thrombocytopenia.\[[@ref2]\]

Delavirdine is known to cause lipoatrophy in patients. This has been reported in a case report of an HIV-infected patient.\[[@ref3]\] Lipoatrophy is an unusual side effect of antiretroviral therapy. We present a case of HIV-infected patient who developed lipoatrophy after 2 years of delavirdine therapy.

Case Report {#sec
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DEMADEXis a drug that inhibits
 
Response: DEMADEXis a drug that inhibits an enzyme, cyclooxygenase-2, that converts arachidonic acid into prostaglandins. It has been shown to reduce the formation of prostaglandins in a number of animal models. (2)

"The study was supported by a grant from GlaxoSmithKline and by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

"The drug is currently being tested in phase 2 trials in patients with multiple sclerosis and is being investigated in a phase 3 trial in Alzheimer's disease," said Richard J. Hodes, M.D., chief of the division of neurology at the National Institute of Neurological Disorders and Stroke. "The data from this study suggest that the drug may be effective in Alzheimer's disease."

The research team found that in the brain of animals with Alzheimer's disease, the level of a key protein called tau was much higher
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Demecariumis a drug that inhibits
 
Response: Demecariumis a drug that inhibits the release of the neurotransmitter glutamate, the brain's main excitatory neurotransmitter. In the body, glutamate is primarily produced by astrocytes and other glial cells, but neurons also make glutamate and release it as a neurotransmitter. Glutamate is released in response to nerve signals and is a major mediator of communication between the nervous system and the rest of the body. Glutamate is released in a controlled way, and the process of releasing it is called exocytosis. When glutamate is released, it causes nearby cells to become more or less excitable, which causes a response in the body. Glutamate is involved in a variety of functions, including the regulation of muscle contraction and maintenance of muscle tone, control of respiration, and production of the sensation of pain.

Glutamate can be released by the nervous system in two ways: synaptic transmission and vesicular release. In synaptic transmission, glutamate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Demeclocyclineis a drug that inhibits
 
Response: Demeclocyclineis a drug that inhibits cell division, and has been used to treat rheumatoid arthritis. The evidence is conflicting about whether it reduces pain and swelling, and increases joint mobility. However, it does not prevent joint destruction.

The safety of long-term use of the drug is unknown. There is evidence that it may increase the risk of skin cancer.

It may be given by injection or by mouth.

INTRODUCTION

What

De-escalocycline is a tetracycline antibiotic used to treat a number of bacterial infections, including rheumatoid arthritis. It may also be used to treat acne, and is used to treat other conditions as well.

How

It is given by injection or by mouth.

Uses

The drug is used to treat a number of bacterial infections, including skin and soft tissue infections, bronchitis, and lower respiratory tract infections
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Deoxycorticosteroneis a drug that inhibits
 
Response: Deoxycorticosteroneis a drug that inhibits the biosynthesis of aldosterone from deoxycorticosterone. It is used to treat high blood pressure and other medical conditions. Deoxycorticosterone can also be used for research purposes.

It is a glucocorticoid. Deoxycorticosterone is used in medicine as an anti-inflammatory and to reduce the amount of water retained by the body. It is used to treat the symptoms of high blood pressure, particularly when this is caused by excess production of aldosterone. Deoxycorticosterone is also used to reduce the amount of water retained by the body, for example in the treatment of edema (swelling).

Deoxycorticosterone belongs to the corticosteroid group of hormones. Corticosteroids are produced in the adrenal cortex.

It works by blocking the production of aldosterone from deoxycorticosterone, resulting
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DEPENis a drug that inhibits
 
Response: DEPENis a drug that inhibits fibroblast proliferation and decreases wound contraction in animal models. The aim of this study was to determine the efficacy and safety of a newly developed nanoparticle formulation of DEPEN in a randomized, double-blind, vehicle-controlled clinical trial in patients with severe pressure ulcers. In a prospective, randomized, double-blind, vehicle-controlled clinical trial, 34 patients with stage III and IV pressure ulcers were treated with topical DEPEN (n = 17) or a vehicle (n = 17) twice daily for 4 weeks. Primary outcome measures included time to ulcer closure, complete ulcer closure, and adverse events. The time to ulcer closure was not significantly different between the DEPEN and vehicle groups (9.7 ± 3.5 vs. 11.5 ± 4.2 days; P = 0.26). The number of ulcers with complete closure was similar in both groups (8/17 [47%] vs. 9
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DEPOCYTis a drug that inhibits
 
Response: DEPOCYTis a drug that inhibits cytokinesis. Its major target is the spindle assembly checkpoint. In a normal cell, the SAC prevents cells from entering anaphase before all the chromosomes have been properly aligned at the metaphase plate. If the SAC is inhibited, the cell may continue through the cell cycle and undergo aneuploidy. DePocytin is the active metabolite of BKM120.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Derazantinib(ARQ-087)is a drug that inhibits
 
Response: Derazantinib(ARQ-087)is a drug that inhibits fibroblast growth factor receptor (FGFR) tyrosine kinases. It is currently in phase II clinical trials for a variety of malignancies. It is also being investigated for the treatment of myelofibrosis (MF) and solid tumors. It is the first orally active tyrosine kinase inhibitor to be tested in a phase II trial in MF.

The inhibition of FGFR by this drug may have several important effects in the treatment of MF. Inhibition of the FGFR-mediated signaling pathway may reduce fibroblast proliferation, which could slow or halt the progression of MF. In addition, the drug may reduce the secretion of inflammatory cytokines and growth factors that contribute to the disease.

Patients and Methods
====================

Twenty-three patients were enrolled on this trial at the University of Chicago, St. Mary's Hospital, and the Medical University of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DESLORATADINEis a drug that inhibits
 
Response: DESLORATADINEis a drug that inhibits the production of histamine in the body. Histamine is a naturally occurring substance that is normally released in the body when you are bitten by an insect. Histamine stimulates the release of additional histamine in the body and also stimulates your body to release other chemicals such as prostaglandins. These substances are responsible for swelling, redness, and pain.

DESLORATADINEis a drug that inhibits the production of histamine in the body. Histamine is a naturally occurring substance that is normally released in the body when you are bitten by an insect. Histamine stimulates the release of additional histamine in the body and also stimulates your body to release other chemicals such as prostaglandins. These substances are responsible for swelling, redness, and pain.

DESLORATADINEis a drug that inhibits the production of histamine in the body. Histamine is a naturally occurring substance that is normally
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Desmopressinis a drug that inhibits
 
Response: Desmopressinis a drug that inhibits protein synthesis (at the level of ribosomes), and therefore has broad-spectrum antibacterial activity.

Macrolides and lincosamides: These antibiotics inhibit bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. They are also called macrolide antibiotics.

Amoxicillin: Amoxicillin is an aminopenicillin that inhibits bacterial cell wall synthesis.

Penicillins: Penicillins are broad-spectrum antibiotics that inhibit bacterial cell wall synthesis.

Chloramphenicol: Chloramphenicol is an antibiotic that inhibits protein synthesis (by inhibiting bacterial cell wall synthesis).

Cephalosporins: Cephalosporins are antibiotics that inhibit bacterial cell wall synthesis.

Aminoglycosides: Aminoglycosides are antibiotics that inhibit protein synthesis (by inhibiting bacterial cell wall synthesis).

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DESOWENis a drug that inhibits
 
Response: DESOWENis a drug that inhibits the activity of proteases called serine proteases.

Serine proteases are important in many physiological processes, such as blood clotting, the digestive process, and cell growth.

Serine proteases are a major target for drug design, because they are involved in the development of a number of serious diseases, such as heart attacks, strokes, and arthritis.

There are several classes of serine proteases, such as thrombin, chymotrypsin, elastase, trypsin, and the kallikreins.

They all share the same catalytic mechanism, involving the serine protease active site, and they have a common fold.

They all have a central beta sheet and an alpha helix.

The structure of the active site, which is involved in catalysis, is conserved in all serine proteases.

In the active site,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Desoximetasoneis a drug that inhibits
 
Response: Desoximetasoneis a drug that inhibits both the release and action of a number of hormones and has been used to treat dermatological conditions including eczema and psoriasis. It can be used alone or in combination with other topical corticosteroids, as well as systemic corticosteroids. It may be used to treat allergic conditions such as asthma and hay fever. It is used as an anti-inflammatory agent to treat inflammation of the lining of the nose (rhinitis) and for treating a condition called erythema nodosum. It is also used to treat inflammatory skin conditions such as urticaria, angioedema, and atopic dermatitis.

Medications that are in the same class as desoximetasone may be used for the same conditions. These medications include:

desonide

mometasone

fluocinonide

halcinonide

clobetasol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Desvenlafaxineis a drug that inhibits
 
Response: Desvenlafaxineis a drug that inhibits the reuptake of norepinephrine and serotonin. It is prescribed to treat depression, panic disorder, obsessive compulsive disorder, and post-traumatic stress disorder. The drug is also used to treat hot flashes and migraine headaches. The FDA has approvedvenlafaxine for use in the treatment of generalized anxiety disorder.

What is venlafaxine?

Venlafaxine is a type of serotonin and norepinephrine reuptake inhibitor (SNRI) that is used to treat depression, anxiety, and other mental health conditions.

Venlafaxine is available in several different doses and formulations.

The brand name for venlafaxine is Effexor.

Venlafaxine is taken by mouth.

The drug is available in a number of different forms, including:

tablets

extended-release capsules

ext
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Detomidineis a drug that inhibits
 
Response: Detomidineis a drug that inhibits the alpha-2 receptor subtype of the adrenergic receptor. It is a highly potent agonist for the alpha-2 receptor. It has been used as a sedative and anesthetic agent for veterinary purposes. It has also been used in a number of clinical studies in humans. It is administered intravenously.

INTRODUCTION

Drugs are substances that alter or influence the structure or function of the body. They can be divided into two broad categories, namely, drugs that alter or influence the structure or function of the body, and those that act on an existing disease. Drugs that alter the structure or function of the body include, but are not limited to, antibiotics, analgesics, anti-inflammatories, antipyretics, anesthetics, anticonvulsants, antidiabetics, antifungals, antianxiety agents, antipsychotics, antineoplastics, antiretrov
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dexamethasoneis a drug that inhibits
 
Response: Dexamethasoneis a drug that inhibits the release of inflammatory cytokines from immune cells. It is a synthetic corticosteroid used to treat a wide range of disorders including inflammatory diseases and autoimmune disorders. Dexamethasone is the most commonly used corticosteroid in the treatment of autoimmune diseases.

When it comes to diseases, it is essential to know the benefits and side effects of a drug. In this article, we have listed down some of the important benefits of dexamethasone.

Benefits of Dexamethasone

1. Treatment of autoimmune diseases

Dexamethasone is a synthetic corticosteroid that can be used to treat autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, dermatomyositis, polymyositis, Wegener’s granulomatosis, systemic vasculitis, polymyalgia rheumatic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dexlansoprazoleis a drug that inhibits
 
Response: Dexlansoprazoleis a drug that inhibits gastric acid secretion. It is used to treat peptic ulcers and gastroesophageal reflux disease.

Common side effects include:

Headache

Diarrhea

Dizziness

Anxiety

Abdominal pain

Nausea

Vomiting

Loss of appetite

How should I take dexlansoprazole?

Take dexlansoprazole exactly as prescribed by your doctor.

Your doctor may have you take dexlansoprazole with food to help decrease stomach upset.

Do not stop taking dexlansoprazole or increase the dose without first talking to your doctor.

Store dexlansoprazole at room temperature, between 68 and 77 degrees F (20 and 25 degrees C).

What are the possible side effects of dexlansoprazole?


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dexmedetomidineis a drug that inhibits
 
Response: Dexmedetomidineis a drug that inhibits alpha 2 adrenergic receptors. Alpha2 adrenergic receptors are located in the medulla, cortex, and spinal cord. It also decreases sympathetic activity and has a sedative effect. It has been used as an anesthetic in cardiac surgeries. Dexmedetomidine is indicated for sedation in mechanically ventilated patients, and for sedation in intensive care unit patients. It is also used for sedation during painful procedures, and as an adjunctive therapy in the treatment of status epilepticus. The mechanism of action is inhibition of alpha2 adrenergic receptors. It has a wide therapeutic window, and minimal side effects. It is used in patients with hypersensitivity to other sedatives. It is administered by intravenous, intranasal, or subcutaneous routes.

Case Report {#sec1-1}
===========

A 28-year-old male patient presented with history of dull aching pain in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dexrazoxaneis a drug that inhibits
 
Response: Dexrazoxaneis a drug that inhibits the breakdown of adenosine triphosphate (ATP). It was developed by Sigma-Tau Pharmaceuticals and was approved in 2006 for use in the treatment of acute myocardial infarction (AMI). In 2006, the European Medicines Agency (EMEA) approved it for the treatment of patients with AMI and with chronic heart failure (CHF). In 2007, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of AMI and CHF. In 2008, the FDA approved it for the treatment of adult patients with ST-elevation myocardial infarction (STEMI) who are being administered primary percutaneous coronary intervention (PCI).

Mechanism of Action

DEXrazoxane is a triazole compound. It inhibits the breakdown of adenosine triphosphate (ATP), thereby increasing the levels of ad
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  dextroseis a drug that inhibits
 
Response: dextroseis a drug that inhibits the digestion of proteins.

## 11.2 Pathophysiology of the Diabetic Ketoacidosis

Diabetic ketoacidosis (DKA) is the most common metabolic complication of diabetes mellitus and results from the extreme metabolic derangements associated with diabetes. The increased anabolic activity of insulin in the liver is the most important pathogenic factor in DKA. Insulin stimulates the breakdown of fatty acids, proteins, and glucose in the liver, and ketogenesis is the main hepatic metabolic pathway. During DKA, insulin's metabolic actions in the liver are excessive and ketogenesis is accelerated. The rate of ketogenesis is regulated by the amount of circulating insulin and the availability of substrate in the liver.

During fasting, the concentration of circulating glucose is reduced, which stimulates the release of insulin from the pancreas. When the concentration of circulating glucose drops below the threshold level, the release of insulin is stopped. During
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  D-Glucuronicis a drug that inhibits
 
Response: D-Glucuronicis a drug that inhibits the enzyme UDP-glucuronyltransferase (UGT) and is the precursor to both mercapturic acid and steroid glucuronides. It has been used for many years to treat patients with gout. More recently, it has been suggested that UGT may be a target for the treatment of hyperlipidemia, atherosclerosis and cancer. It is known that the UGT pathway has an important role in the detoxification of many toxic and carcinogenic substances. It is therefore important to understand the metabolic fate of this drug and to develop sensitive and selective analytical methods for its detection.
The compound is chemically described as N-[[4-(1-benzimidazol-2-yl)-1-piperidinyl]methyl]-5-methyl-1,3-thiazolidine-2,4-dione, also known as 1-benzimidazol-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diacereinis a drug that inhibits
 
Response: Diacereinis a drug that inhibits tyrosine kinase and is used in the treatment of non-small cell lung cancer and metastatic breast cancer.

Eribulin (Eisai Co., Ltd., Tokyo, Japan) is a microtubule dynamics inhibitor that acts by binding to the N-terminal lateral surface of tubulin. Eribulin is used in the treatment of locally advanced or metastatic breast cancer.

Dasatinib (Bristol-Myers Squibb, New York, NY, USA) is an oral tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Sorafenib (Bayer HealthCare, Leverkusen, Germany) is an oral multikinase inhibitor that is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diastaseis a drug that inhibits
 
Response: Diastaseis a drug that inhibits the enzyme diastase, which is found in some foods. It is available in pill form. It is sometimes prescribed for the treatment of symptoms of lactose intolerance.

Side effects

The side effects of diastaseis are rare, but they can include nausea, vomiting, diarrhea, stomach pain, or headache.

Storage

Store diastaseis at room temperature away from moisture, heat, and light.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diatrizoicis a drug that inhibits
 
Response: Diatrizoicis a drug that inhibits tumor growth by reducing angiogenesis. It is used to treat non-small cell lung cancer (NSCLC) and head and neck cancer.

Pharmacology

Mechanism of action
Diatrizoic acid inhibits angiogenesis by binding to and inhibiting the action of vascular endothelial growth factor (VEGF).

History
Diatrizoic acid was first isolated in 1982.

Research

Cancer

Diatrizoic acid is a promising anti-cancer agent.  It has been shown to reduce the number of metastases and the size of metastatic tumors.

Other
Diatrizoic acid has been shown to inhibit human tumor xenograft growth in nude mice.

References

Category:Anti-cancer drugs
Category:Cancer treatments
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dibucaineis a drug that inhibits
 
Response: Dibucaineis a drug that inhibits the nerve impulse in the
nerve fibres that cause the muscles to contract. The drug
tries to stop the impulses from reaching the muscle and
stops the muscle from being contracted.

Dibucaine is used to treat:

bleeding from the gums, nose, ears and the
tongue

abdominal pain caused by spasms of the
abdominal muscles

irritable bowel syndrome

urinary problems that cause pain in the
kidneys, bladder or prostate gland

Dibucaine is also used to relieve:

heartburn

cramps in the stomach and intestines

pain caused by a hernia or appendix

pain in the lower back, side and stomach

pain caused by a blocked intestine

pain in the muscles of the neck and
shoulders

migraine

Dibucaine comes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dibutylis a drug that inhibits
 
Response: Dibutylis a drug that inhibits the production of androgens, which are hormones that control male sexual development. This drug is available by prescription in the United States, Canada, and other countries.

Brand name(s)

In the United States, this drug is sold under the trade names Fembido and Fembido Solution.

Other brand names include:

Fembido, Fembido Solution

Indications and usage

Fembido is used in the treatment of conditions related to androgen insufficiency.

Fembido Solution is used to treat androgen deficiency in men.

Contraindications

Before you start taking Fembido or Fembido Solution, tell your doctor if you have:

Other medical conditions

Fembido may increase your risk of developing high blood pressure. Tell your doctor if you have any high blood pressure problems, including:

S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dibutyryl-cAMPis a drug that inhibits
 
Response: Dibutyryl-cAMPis a drug that inhibits phosphodiesterase activity, and thereby enhances cAMP concentrations in cells. cAMP activates protein kinase A (PKA), which in turn phosphorylates a large number of substrates. PKA phosphorylation of CREB leads to CREB activation, which can be assessed by increased CREB-mediated transcription of a reporter gene. Dibutyryl-cAMP was previously shown to activate CREB in several neuronal cell types, and we report here that it also activates CREB in neuroblastoma cells. In addition, dibutyryl-cAMP activates CREB in glial cells, and we show that it does so by a cAMP-independent mechanism. This work reveals a possible role for cAMP-independent activation of CREB in glial cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dichlorphenamideis a drug that inhibits
 
Response: Dichlorphenamideis a drug that inhibits the production of dihydrotestosterone (DHT) in the body, thereby reducing the level of DHT and lowering the amount of testosterone in the blood. This causes an increase in the level of oestrogen in the body, resulting in a reduction in the amount of testosterone that is needed to maintain a normal sex drive. In some cases, a man with high levels of testosterone can have a reduced sex drive and be impotent.

Dichlorphenamideis available in the form of tablets, oral liquid, suppositories, creams, and patches.

Uses

Dichlorphenamideis used to treat the following conditions:

Hirsutism (excessive hair growth in women) and hirsutism (excessive hair growth in men)

Benign prostatic hypertrophy (enlarged prostate) in men

To reduce the level of testosterone in the blood
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diclazurilis a drug that inhibits
 
Response: Diclazurilis a drug that inhibits trypanosome kinetoplastid parasites. It is active against animal trypanosomes (e.g. in cattle, horses, and camels), as well as against human African trypanosomiasis (HAT) and nagana in cattle.

The drug is available as a white crystalline powder for oral administration. It has a bitter taste and must be administered as a suspension, preferably with an emulsifier, for example as a micronized suspension. It is poorly absorbed when administered as a suspension.

Diclazuril is classified as a second-generation trypanocidal drug. It is the only trypanocidal drug available for use in animals, and its efficacy is related to the duration of the patent.

Pharmacokinetics

Diclazuril has a high oral bioavailability of approximately 50%. The drug is rapidly absorbed after
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diclofenacis a drug that inhibits
 
Response: Diclofenacis a drug that inhibits the production of the inflammatory mediator, prostaglandin, by inhibiting cyclooxygenase (COX). Diclofenac is also a weak non-selective inhibitor of the metabolism of arachidonic acid to prostaglandins and leukotrienes. Diclofenac is currently used to treat acute, painful musculoskeletal conditions, such as sprains, contusions, strains and synovitis. It is also used for the relief of moderate to severe pain in patients with osteoarthritis.
Diclofenac is commercially available as the free acid and the potassium salt, both under the brand name VICTORIN.RTM.. The VICTORIN.RTM. brand is the potassium salt of the drug, i.e., sodium diclofenac potassium.
U.S. Pat. No. 4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dicloxacillinis a drug that inhibits
 
Response: Dicloxacillinis a drug that inhibits the action of renin, a hormone that is essential for the regulation of blood pressure. This drug is used in combination with diuretics and ACE inhibitors to treat hypertension.

The side effects of this drug include:

Severe liver damage

Tinnitus

Dizziness

Seizures

The recommended dose of this drug is:

Adults: 500mg orally once a day

Children: 2-6 years: 10mg/kg orally once a day

7-12 years: 20mg/kg orally once a day

12-18 years: 40mg/kg orally once a day

Children below 12 years: 10mg/kg orally once a day

Adults over 65 years: 20mg/kg orally once a day

Children over 6 years: 10mg/kg orally once a day

Renin Inhibitors


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dicoumarolis a drug that inhibits
 
Response: Dicoumarolis a drug that inhibits a protein that promotes tumor growth and metastasis. By doing this, they can prevent cancer from spreading to other parts of the body.

This work has been funded by the Cancer Research UK (C8741/A18081) and by the European Research Council (ERC). The funding body did not have a role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

The authors declare no conflict of interest.

![The structure of the proteins mentioned in the paper. The blue part of the proteins is the bromodomain, the green part is the ATPase domain, and the orange part is the helical region. (**a**) The structure of the BRD4 protein. The part of the protein that binds to the cancer drug (N-\[2-amino-4-\[\[\[3-(
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DicycloMineis a drug that inhibits
 
Response: DicycloMineis a drug that inhibits the activity of CYP2D6. In addition, this drug may increase the activity of CYP3A4. Therefore, dicyclomine is used to treat painful bladder syndrome (PBS) and the treatment of opioid withdrawal symptoms. It is also used to treat irritable bowel syndrome. In this study, the pharmacokinetics of dicyclomine was studied in three healthy male volunteers after a single oral administration of 10 mg dicyclomine hydrochloride. The plasma concentration of dicyclomine was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters were determined by non-compartmental analysis. The t1/2 of dicyclomine was 4.05 h, and the Cmax was 2.56 μg/mL. The AUC(0-24h) was 6.32 μg h/mL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DIDANOSINEis a drug that inhibits
 
Response: DIDANOSINEis a drug that inhibits the action of the enzyme reverse transcriptase in the HIV virus. It was the first drug approved for treatment of HIV infection and is still in use. It is also used in the treatment of Hepatitis B, herpes, and other viral infections. The following description of the structure and use of DIDANOSINE was published in the International Journal of Pharmaceutical Compounding, vol. 14, no. 2, pp. 137-141 (1998).

There are three kinds of drug-drug interactions, namely pharmacokinetic, pharmacodynamic, and toxicologic interactions. In pharmacokinetic interactions, a drug may alter the absorption, distribution, metabolism, or excretion of another drug. In pharmacodynamic interactions, the effects of a drug may be altered by another drug. In toxicologic interactions, a drug may cause adverse effects. A drug-drug interaction is a combination of a pharmacokinetic, pharmacodynamic, or toxicologic interaction.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dienestrolis a drug that inhibits
 
Response: Dienestrolis a drug that inhibits the enzyme aromatase, which converts testosterone to estrogen. It is prescribed to prevent pregnancy in women who have had their uterus removed, or who have undergone treatment for cancer, or who have had chemotherapy or radiation therapy.

How does dienestrolis work?

Dienestrolis belongs to a group of drugs called aromatase inhibitors. It works by preventing the body from making estrogen. Dienestrolis may also have other effects. These effects may be useful in treating some types of cancer. Dienestrolis is taken by mouth.

Dienestrolis side effects

The following are possible side effects of dienestrolis. Although not all of these side effects may occur, if they do occur they may need medical attention:

Irregular menstrual periods

Muscle and joint pain

Mood changes, such as anxiety, irritability, and depression


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dienogestis a drug that inhibits
 
Response: Dienogestis a drug that inhibits estrogen activity by binding to the estrogen receptor and exerts progestational effects. It is used in treatment of endometriosis and uterine fibroids. It is also used to treat symptomatic uterine fibroids and endometriosis, which can be effectively treated with an oral progestin.

For the treatment of endometriosis, the following doses are recommended: 50-100 mg daily or 50 mg twice daily, depending on the degree of symptoms.

For uterine fibroids, the recommended dose is: 1 mg daily.

The recommended dose for patients with breast cancer is: 100 mg daily or 50 mg twice daily, depending on the symptoms.

For the treatment of myomas, the recommended dose is: 1 mg daily.

If your doctor prescribes Dienogest for you, you will need to take it with a meal to help prevent nausea. You may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diethylcarbamazineis a drug that inhibits
 
Response: Diethylcarbamazineis a drug that inhibits larval stages of filarial worms (in humans). This is a very old drug (first synthesized in 1912), which was in use in the 1950s for mass drug administration (MDA) to control onchocerciasis. The drug is a macrocyclic lactone that is used to treat onchocerciasis. The most important disease caused by Onchocerca volvulus is onchocerciasis. Onchocerciasis is caused by Onchocerca volvulus, a filarial worm which lives in the eye and the skin. The disease is transmitted by blackflies. Infection in the eye causes onchocerciasis, which can cause blindness. Infection in the skin causes severe itching.

Diethylcarbamazine was also used to treat the skin disease cutaneous leishmaniasis (caused by the protozoan parasite
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DIETHYLSTILBESTROLis a drug that inhibits
 
Response: DIETHYLSTILBESTROLis a drug that inhibits the activity of 5-lipoxygenase. It is used to treat asthma and other inflammatory conditions.

DETERMINATION OF VIABILITY

Reconstituted Diluent: The reconstituted diluent contained 5.4% polysorbate 80, 45.2% cremophor EL, 2.6% ethanol, 0.8% polyethylene glycol 400, and 0.8% polypropylene glycol 400. Reconstituted Diluent: The reconstituted diluent contained 5.4% polysorbate 80, 45.2% cremophor EL, 2.6% ethanol, 0.8% polyethylene glycol 400, and 0.8% polypropylene glycol 400.

Reconstituted Diluent: The reconstituted diluent contained 5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Difluoxacinis a drug that inhibits
 
Response: Difluoxacinis a drug that inhibits bacterial DNA gyrase and Topoisomerase IV, and is effective in the treatment of a wide range of bacterial infections. It is marketed as Diflucan and Diflucan ODT in the USA and as Fluconazole in other countries.

Fluconazole is a synthetic triazole derivative used in the treatment of fungal infections of the skin, nails, hair, vagina, and urinary tract.

It is the active metabolite of the antifungal drug fluconazole, and is available as oral capsules, tablets, granules, and liquid solutions.

In humans, fluconazole is rapidly and extensively absorbed from the gastrointestinal tract after oral administration, and its bioavailability is not affected by food.

It is distributed in body tissues and excreted in the urine, but does not cross the blood–brain barrier. It has a half
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Difluprednateis a drug that inhibits
 
Response: Difluprednateis a drug that inhibits phospholipase A2 and the liberation of arachidonic acid from the outer surface of the cell. It is used for treatment of allergic conjunctivitis and other ocular surface diseases, including dry eye and blepharitis.\[[@ref1]\]

Ocular surface epithelial cell damage and apoptosis can occur in various conditions such as exposure to chemicals, radiation, and viral infection.\[[@ref2]\] One of the most important etiologic factors for dry eye is contact lens wear.\[[@ref3]\] Chemical irritants,\[[@ref4]\] and physical trauma to the ocular surface\[[@ref5]\] may also be a causative factor in the pathogenesis of dry eye.

Many studies have reported that the reduction in tear secretion and tear film stability are the main mechanisms of dry eye.\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Digoxigeninis a drug that inhibits
 
Response: Digoxigeninis a drug that inhibits telomerase activity is currently in clinical trials for use in the treatment of various types of cancer, including prostate cancer.

[13] Inhibition of cancer cell proliferation and induction of apoptosis by telomerase-specific antisense oligonucleotides. Zhang, Y., X. Yu, A. F. Liu, et al. Anticancer Res. 20: 1713-1718 (2000).

[14] Telomerase-mediated telomere maintenance and cellular immortality. Heidmann, A. H., and J. N. Greider. Genes Dev. 14: 1876-1890 (2000).

[15] Telomerase activity and cell proliferation in human carcinomas. Blasco, M. A., and A. Esteller. Nature Genet. 24: 69-73 (2000).

[16] Telomerase activation and telomere maintenance in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Digoxinis a drug that inhibits
 
Response: Digoxinis a drug that inhibits monoamine oxidase and increases the synthesis of dopamine, norepinephrine, and serotonin. It is available as oral and injectable preparations.

**_BARBITURATES_**

**CASES:** Abruptio placentae, postpartum depression, vasospasm, coronary artery spasm, pulmonary edema. **_Barbiturates_** **CAUSES:** Chronic use may cause the following adverse reactions: hypotension, muscle weakness, hypothermia, excessive sedation, dry mouth, urinary retention, dizziness, drowsiness, ataxia, nystagmus, vertigo, respiratory depression, depression of the CNS. **ACTION:** Causes central nervous system depression by decreasing the activity of the brainstem reticular formation. **THERAPEUTIC INDICATIONS:** Adjunct to general anesthesia, chronic pain, status epilepticus, reflex sympathetic dy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  dihydroartemisininis a drug that inhibits
 
Response: dihydroartemisininis a drug that inhibits enzymes that are involved in the formation of haemozoin, the pigment that forms in malaria-infected red blood cells and is toxic to the parasite.

A partial list of drugs under development for the treatment of malaria is provided in Table [1](#Tab1){ref-type="table"}. In this table, the classes of drugs are indicated by colour. The drugs that have progressed furthest to the clinic are indicated by an asterisk. Artemisinin derivatives are highlighted in red. Artemisinin derivatives are drugs that are derived from the plant *Artemisia annua*. The mechanism of action of artemisinin derivatives is unclear but it is thought that they exert their effect by inhibiting an enzyme that is involved in the formation of haemozoin. The haemozoin formation is toxic to the parasite. The drug resistance to artemisinin derivatives is due to mutations in the enzyme
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dihydroergotamineis a drug that inhibits
 
Response: Dihydroergotamineis a drug that inhibits the effects of the neurotransmitter serotonin, which causes drowsiness. It was approved for the treatment of migraine and cluster headache in the United States in 1989. It was approved for migraine prophylaxis in the United States in 1990 and is available by prescription in Europe. It is also used to treat premenstrual dysphoric disorder (PMDD).

Dihydroergotamine is a drug that inhibits the effects of the neurotransmitter serotonin, which causes drowsiness. It was approved for the treatment of migraine and cluster headache in the United States in 1989. It was approved for migraine prophylaxis in the United States in 1990 and is available by prescription in Europe. It is also used to treat premenstrual dysphoric disorder (PMDD).

Dihydroergotamine is a drug that inhibits the effects of the neurotransmitter serotonin, which causes drowsiness. It was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dihydrostreptomycinis a drug that inhibits
 
Response: Dihydrostreptomycinis a drug that inhibits the activity of Streptomyces cytochrome P450. It is used in the treatment of some fungal infections. It is available in tablet form.

Dihydrostreptomycinis is an antimicrobial agent used in the treatment of bacterial infections. It is used in combination with other antibiotics. It works by preventing the growth of bacteria and by destroying the cells.

Dihydrostreptomycin is used to treat severe, life-threatening infections caused by Gram-negative bacteria. It is also used to treat infections caused by some types of streptococci.

Dihydrostreptomycin is an antibacterial agent. It works by blocking the replication of the DNA of the bacteria.

Dihydrostreptomycin is a bacteriostatic antibiotic. It inhibits the growth of bacteria and is used in the treatment of severe bacterial infections.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diltiazemis a drug that inhibits
 
Response: Diltiazemis a drug that inhibits parasite gametocyte activation and thus prevents the development of gametocytes in the blood. Gametocytes are formed by gametogenesis and only gametocytes that mature to gametes are infective. This treatment is used to treat malaria in pregnant women, to prevent malaria in travellers and to reduce the risk of malaria transmission in malaria endemic areas.

Dapsone a drug that is used to treat leprosy. It is also used to prevent and treat malaria in pregnant women. It works by reducing the number of infective erythrocytes in the blood.

Desethylamodiaquine a drug that is used to treat malaria. It is also used to prevent malaria in pregnant women. It works by inhibiting the action of a protein that is involved in the maturation of the parasite's sexual organs.

Dihydroartemisinin a drug that is used to treat malaria. It is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dimenhydrinateis a drug that inhibits
 
Response: Dimenhydrinateis a drug that inhibits gastrointestinal movement and is prescribed to treat nausea and vomiting. In addition, it is commonly used in animals to treat motion sickness.

Side Effects

Side effects may include:

Dry mouth

Nausea

Diarrhea

Fatigue

Constipation

Muscle cramps

Cough

Seizures

Loss of appetite

Elevated temperature

Irregular heart rate

Abdominal pain

Yellowing of the skin or eyes

Pale skin

Weakness

Vomiting

Pregnancy/Lactation

When used during pregnancy, dimenhydrinate may cause serious side effects in a developing baby. Do not use dimenhydrinate during pregnancy unless clearly needed.

When used during lactation, dimenhydrinate may cause serious side effects in the nursing baby. Do not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dimesnais a drug that inhibits
 
Response: Dimesnais a drug that inhibits the interaction between the beta1 and beta2 integrins and functions by blocking the adhesion of leukocytes to endothelial cells. The purpose of this study was to investigate the pharmacokinetics of dimesna and its metabolites in patients with severe sepsis. Twelve patients with severe sepsis were enrolled in this study. On days 1, 3, and 5 after dimesna administration, blood samples were obtained at 1, 2, 4, 8, 12, and 24 h. Plasma concentrations of dimesna and its metabolites were measured by a validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The data were analyzed using non-compartmental methods. Mean plasma dimesna and desmethyl-dimesna concentrations were, respectively, 6.1 +/- 2.4 microg/mL and 3.6 +/- 1.6 microg/mL on day 1, 3.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dimethylis a drug that inhibits
 
Response: Dimethylis a drug that inhibits the growth of some tumours by blocking the function of DNA methyltransferases.

References

Category:Antineoplastic drugs
Category:Piperidines
Category:Catechols
Category:Hepatotoxins
Category:Nitrogen heterocycles
Category:Pyrazoles
Category:Carboxamides
Category:Alkylating agents
Category:Organochlorides
Category:World Health Organization essential medicines
Category:RTT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dimethylamineis a drug that inhibits
 
Response: Dimethylamineis a drug that inhibits dopamine reuptake in the brain, and therefore increases dopamine levels.

It has long been used as a "nootropic" drug, to treat conditions such as schizophrenia, but it has been controversial as to whether it is safe or effective.

More recently, it has been repurposed for treating ADHD.

It is available as an over-the-counter supplement in many countries, including the UK, but is available only by prescription in Australia.

In the past, some research suggested that it might be useful in treating substance use disorders, but there was some controversy about its efficacy and safety.

A 2018 review of studies suggests that it might be helpful in reducing some of the symptoms of schizophrenia, although it is not a first-line treatment.

The review found that, although it is not recommended as a first-line treatment, it is effective for reducing symptoms of psychosis in people who have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diminazeneis a drug that inhibits
 
Response: Diminazeneis a drug that inhibits the formation of testosterone from cholesterol and can thus be used to lower testosterone levels in men. It is most commonly used to treat prostate cancer. A single dose of the drug is effective for 3 to 5 days, and multiple doses are used to maintain lower testosterone levels. The dose is titrated to achieve the desired effect. A single dose of 2 mg is usually sufficient.

Adverse Effects

Rarely, the drug may cause an increase in liver enzymes in people with underlying liver disease. People with type 1 diabetes or hypothyroidism may have a worsening of these conditions.

Other Side Effects

The most common side effects are diarrhea, nausea, and vomiting.

Dosage

How to Use

Dosage is based on the effect desired.

Dosage in Men

Dosage is based on the desired effect and the person's response.

A single dose of 2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dinitolmideis a drug that inhibits
 
Response: Dinitolmideis a drug that inhibits thymidylate synthase, an enzyme that is required for the synthesis of thymidylate. It was developed by Ciba-Geigy and is marketed in the US as Methotrexate and in the UK as Mefotaxate.

Methotrexate is used to treat certain types of leukemia and to prevent the rejection of transplanted organs. It is also used to treat rheumatoid arthritis, psoriasis, and some types of psoriatic arthritis. It is also used to treat various forms of cancer.

Methotrexate has been used in the treatment of breast cancer since the late 1970s. Its use in the treatment of breast cancer has increased dramatically since that time. Methotrexate has been used to treat metastatic breast cancer for at least the last 30 years. In 2002, the National Institutes of Health Consensus Conference on Breast Cancer recommended that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diosmetinis a drug that inhibits
 
Response: Diosmetinis a drug that inhibits the histamine release and potentiates the bronchodilatory effect of methacholine.
Diosmetin (5,7-dihydroxy-3,4-dihydroflavone) was shown to inhibit histamine release from mast cells in a concentration-dependent manner. In guinea pig lung slices, diosmetin (10(-5) M) inhibited the acetylcholine (ACh)-induced histamine release. In guinea pig isolated tracheal muscle, diosmetin (10(-5) M) also inhibited the ACh-induced histamine release and enhanced the contractile response to ACh. In addition, diosmetin (10(-5) M) inhibited the ACh-induced increase in cAMP level in tracheal smooth muscle. In the guinea pig isolated tracheal muscle, diosmetin (10(-5) M) also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diosminis a drug that inhibits
 
Response: Diosminis a drug that inhibits the production of collagen and elastin by fibroblasts and the proliferation of smooth muscle cells. It is commonly used to treat hypertrophic scars and keloids, but its effect on cutaneous aging is still unknown. To determine the effect of diosmin on cutaneous aging, a 12-week randomized, double-blinded, placebo-controlled study was performed. Ninety-five healthy volunteers were randomized into 2 groups and applied with a topical cream containing diosmin or placebo twice daily for 12 weeks. The cosmetic and clinical changes were evaluated at baseline and after 12 weeks of treatment. Topical application of diosmin resulted in significant improvements in skin texture, wrinkles, and color and increased skin hydration. The diosmin-treated group also had a significant reduction in the degree of photodamage, fine lines, and skin texture compared to the placebo group. The results of the present study demonstrate that topical application of di
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  diperodonis a drug that inhibits
 
Response: diperodonis a drug that inhibits tumor cell growth.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diphemanilis a drug that inhibits
 
Response: Diphemanilis a drug that inhibits P-glycoprotein (P-gp) function.^[@bib1]^ P-gp is a transmembrane protein that has an important role in regulating the absorption, distribution, metabolism, and excretion of a wide range of drugs.^[@bib2]^ Although many drugs are substrates for P-gp, there are also many drugs that are not substrates for P-gp. P-gp substrates are classified into four categories: (i) P-gp substrates, which are transported out of cells by P-gp; (ii) P-gp non-substrates, which are not transported by P-gp; (iii) P-gp inhibitors, which block the efflux of substrates from cells; and (iv) P-gp inducers, which activate the efflux of substrates from cells.^[@bib3]^ The P
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diphenhydramineis a drug that inhibits
 
Response: Diphenhydramineis a drug that inhibits histamine release from mast cells. It is commonly used as an antihistamine, an anticholinergic, and a sedative. It is also used to treat symptoms of motion sickness. The usual dose of diphenhydramine is 50 to 100 mg once or twice daily. The usual dose of diphenhydramine is 50 to 100 mg once or twice daily. The usual dose of diphenhydramine is 2 to 4 mg/kg of body weight once or twice daily.

Diphenhydramine is the hydrate of diphenhydramine. The molecular formula is C15H14N2O. The molecular weight is 244.32. The chemical structure of diphenhydramine is:

1. What is the chemical name of diphenhydramine?

2. What is the molecular formula of diphenhydramine?

3. What is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diphenidolis a drug that inhibits
 
Response: Diphenidolis a drug that inhibits the production of testosterone and is used in the treatment of prostate cancer.

#####  PHARMACOKINETICS

Readily absorbed after PO administration. Protein binding: 99%. Widely distributed. Metabolized in liver. Eliminated in feces (52%), urine (40%). **Half-life:** 2–4 hrs.

#####    ​LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** May cause fetal harm. Avoid pregnancy. May cause infertility in males. Must either discontinue drug or discontinue breastfeeding. Unknown if distributed in breast milk. Must use effective contraception during treatment and for at least 2 mos after discontinuation. **Pregnancy Category X. Children:** Safety and efficacy not established. **Elderly:** No age-related precautions noted.

#####  INTERACTIONS

**DRUG:** **C
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diphenylamineis a drug that inhibits
 
Response: Diphenylamineis a drug that inhibits monoamine oxidase.  It is used as a pharmaceutical and a cosmetic ingredient.

Diphenylamine is a compound that has been found to be mutagenic in bacterial assays.

See also
 Diaminophenyl
 Phenethylamine
 Phenylacetone
 Phenylacetaldehyde

References

Category:Primary alcohols
Category:Phenyl compounds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diphenylpyralineis a drug that inhibits
 
Response: Diphenylpyralineis a drug that inhibits the reuptake of serotonin (5-hydroxytryptamine or 5-HT). The drug is used to treat a number of psychiatric disorders including depression and obsessive compulsive disorder (OCD). See, e.g., Physicians' Desk Reference, 55th ed., pp. 1441-1442 (1999).
Diphenylpyraline has been prepared from 1-(2,3-dimethyl-phenyl)-2-(3-chlorophenyl)ethan-1-ol in two steps. See U.S. Pat. No. 4,066,711. The compound 1-(2,3-dimethyl-phenyl)-2-(3-chlorophenyl)ethan-1-ol is obtained by chlorinating 1-(2,3-dimethyl-phenyl)-2-(3-methylphenyl)ethan-1-ol. See U.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dipyridamoleis a drug that inhibits
 
Response: Dipyridamoleis a drug that inhibits the reuptake of adenosine into cells, increasing the amount of adenosine available for binding to its receptors. Adenosine receptors are found throughout the body, particularly in the heart, lungs, and kidneys. The adenosine A2A receptor is found in the striatum, hippocampus, cortex, and basal ganglia, and the adenosine A2B receptor is found in the lungs, kidneys, and liver.

In one study, 24 patients with chronic heart failure received a low dose of dipyridamole (300 mg orally every 12 hours for 2 days) in addition to standard therapy. The drug was well tolerated, and no significant adverse events were observed. The dose of dipyridamole was increased to 500 mg orally every 12 hours for an additional 2 days. The addition of dipyridamole to standard therapy did not significantly alter left ventricular function or blood pressure. However
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diquafosolis a drug that inhibits
 
Response: Diquafosolis a drug that inhibits an enzyme that breaks down nicotine.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit, you will not get any support from your wife or kids.

But you should see a dentist and a dermatologist.

Quit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  dirithromycinis a drug that inhibits
 
Response: dirithromycinis a drug that inhibits synthesis of RNA, protein and DNA, and thus is very effective against parasitic fungi. It is the most commonly used drug to treat candidiasis. It is a pyrimidine analog and a triazole derivative. 

Cyclosporin A is a cyclic peptide produced by the soil fungus Tolypocladium inflatum. It is used as an immunosuppressant, primarily for preventing organ rejection in transplantation surgery.

Other
Bleomycin is a natural antineoplastic antibiotic isolated from Streptomyces verticillus. It is used to treat testicular cancer.
Chlorambucil is a bifunctional alkylating agent that acts by covalently linking to DNA, and causes cell death by disrupting the DNA replication and transcription processes.
Ciprofloxacin is an antibiotic of the fluoroquinolone class used to treat bacterial infections
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Diroximelis a drug that inhibits
 
Response: Diroximelis a drug that inhibits the uptake of cholesterol by hepatocytes. Its role in the management of familial hypercholesterolaemia (FH) has been assessed in several trials. However, the mechanism of action of diroximelis in patients with FH has not been fully understood. To assess the impact of diroximelis on plasma lipids, hepatic lipids, cholesterol absorption and cholesterol biosynthesis in patients with FH. Open-label, randomized, controlled trial in 12 patients with FH, compared with 6 patients with FH treated with statins. Patients were treated for 3 months with placebo (group 1) or diroximelis at a dose of 600 mg/day (group 2). In group 2, diroximelis reduced plasma total cholesterol (P = 0.007), low-density lipoprotein cholesterol (P = 0.014) and apolipoprotein B (P = 0.003) and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Disodiumis a drug that inhibits
 
Response: Disodiumis a drug that inhibits the production of sodium chloride and potassium chloride by the kidneys. It is commonly used to treat high blood pressure and to reduce the amount of sodium in the blood.

What is it used for?

Disodium is used to treat high blood pressure (hypertension). It is also used to reduce the amount of sodium in the blood, which can help prevent high blood pressure and reduce the risk of kidney disease. It is also used to treat heart failure and for treatment of some types of arrhythmias.

How does it work?

Disodium is used to treat high blood pressure by reducing the amount of sodium in the blood. This helps the kidneys remove sodium from the body, which reduces the amount of sodium in the blood and helps to lower blood pressure.

Disodium also works by inhibiting the absorption of sodium from the intestine. This reduces the amount of sodium in the blood and lowers blood pressure.

How
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  disopyramideis a drug that inhibits
 
Response: disopyramideis a drug that inhibits the rapid component of the delayed rectifier potassium current, and it has been used to treat ventricular tachyarrhythmias and atrial fibrillation. Some of the side effects associated with the use of this drug include headache, dizziness, and nausea.1

Doxepin is a tricyclic antidepressant.1 It is used to treat major depression and anxiety disorders.1 Doxepin is metabolized in the liver to the active metabolite desmethyldoxepin.1 It is available as a capsule or oral tablet.1

Zolpidem is a sedative-hypnotic agent that has been used to treat insomnia.1 Zolpidem is a nonbenzodiazepine compound that acts as a partial agonist at the benzodiazepine receptor.1

Timolol is a beta-adrenergic blocking agent.1 It is used to treat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Disopyramideis a drug that inhibits
 
Response: Disopyramideis a drug that inhibits the cardiac sodium channel. It is used in the treatment of atrial fibrillation and to slow the heart rate in patients with paroxysmal atrial fibrillation or atrial flutter.1 It is also used in the treatment of paroxysmal supraventricular tachycardia (PSVT), atrial tachycardia, and atrial flutter.

Drug Facts: Disopyramide is a white, crystalline powder with a bitter taste. It is very soluble in water and slightly soluble in methanol. It is freely soluble in ethanol. The drug is very slightly soluble in chloroform and insoluble in ether, benzene, petroleum ether, and toluene.

Therapeutic Effect: Disopyramide is an antiarrhythmic agent that slows the heart rate and the contractions of the atria. It also inhibits the rapid ventricular response to atrial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DIVALPROEXis a drug that inhibits
 
Response: DIVALPROEXis a drug that inhibits the division of tumor cells, but its mechanism of action is not known. Divalidomide is being developed as an anticancer agent in a number of different cancer types. We have developed a monoclonal antibody (mAb) that specifically binds to divalidomide. The purpose of this study was to determine the effects of mAb treatment on the activity of divalidomide in vitro. The cytotoxicity of divalidomide was determined in mouse T cell lymphoma (CTLL) and mouse T cell leukemia (P388) cell lines. We have demonstrated that divalidomide kills these cell lines in a dose- and time-dependent manner. A combination of divalidomide and mAb completely blocks the growth of CTLL and P388 cells in vitro. A combination of mAb and drug was also effective in reducing the tumor burden in vivo. This combination of drug and mAb may be useful in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DL-Carnitineis a drug that inhibits
 
Response: DL-Carnitineis a drug that inhibits the action of carnitine, an essential amino acid found in the human body. It has been used to treat various medical conditions.

What is it prescribed for?

L-Carnitineis used in the treatment of heart and kidney disease, cancer, certain metabolic disorders and other conditions. It may also be used for other purposes not listed in this medication guide.

What are the benefits?

What are the risks?

Do not take L-Carnitine if you are allergic to any of its ingredients, or if you have severe liver or kidney disease.

If you are also taking a medication for heart failure, consult your doctor before using L-Carnitine.

Tell your doctor right away if you develop symptoms of low blood sugar, such as sweating, hunger, weakness, cold sweats, rapid heartbeat, confusion, slurred speech, or trouble breathing.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DL-Mentholis a drug that inhibits
 
Response: DL-Mentholis a drug that inhibits the first step of transcellular permeation of capsaicin (CAP) and menthol, and thus prevents the sensory nerve activation and the onset of migraine. The efficacy and safety of the drug have been demonstrated in numerous clinical trials. We have investigated the pharmacokinetics of DL-Mentholis in healthy volunteers after single oral administration of a single tablet of 500 mg. Plasma concentrations of DL-Mentholis were quantified using liquid chromatography-mass spectrometry with a highly sensitive and selective method. Pharmacokinetic parameters were calculated using a non-compartmental method. The mean peak plasma concentration of DL-Mentholis was 12.5 ng/mL at 3 h after administration. The half-life of DL-Mentholis was approximately 3.5 h. No dose dependency was observed in the pharmacokinetic parameters of DL-Mentholis. DL-Mentholis is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  D-Mannitolis a drug that inhibits
 
Response: D-Mannitolis a drug that inhibits the synthesis of DNA, thereby arresting the growth of the cancer cells. Thus, the initial cytotoxic effect of this drug is the inhibition of DNA synthesis, but a direct cytotoxic effect can be achieved only after the drug is metabolized. When the drug is administered to a patient, the parent compound is converted to its active form, and then the active drug binds to DNA, where it interferes with DNA synthesis. Thus, if the active drug is not metabolized to its inactive form, it can only be activated at a site where DNA synthesis is occurring, such as in rapidly dividing cancer cells.
M-D-Mannitol is the major metabolite of D-mannitol in mammals. The mechanism by which D-mannitol is metabolized is not known. It has been shown that the activity of D-mannitol in mammals is determined by its ability to undergo metabolic activation to form M-D-M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  D-Mannoseis a drug that inhibits
 
Response: D-Mannoseis a drug that inhibits the growth of the parasitic protozoan Trypanosoma brucei. It binds to the parasite glycoprotein, which is required for host-parasite interaction and invasion of the host cells. When the D-mannose is enzymatically removed from the glycoprotein, it is no longer recognized by the receptor on the host cell surface, and the parasites cannot invade the host cells. This project has two major goals: to develop a robust method for production of D-mannose and to study the biosynthetic pathway of D-mannose in T. brucei. Both goals will be accomplished by identifying the enzyme(s) responsible for the conversion of D-mannose to GDP-mannose.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Docetaxelis a drug that inhibits
 
Response: Docetaxelis a drug that inhibits microtubule formation and thereby disrupts the mitotic spindle, resulting in cell cycle arrest in the G2/M phase. It has been used in combination with other chemotherapeutic agents for treatment of metastatic breast cancer.

Introduction {#sec1-1}
============

Breast cancer is the most common malignancy among women in the United States and is a leading cause of cancer-related deaths in women.\[[@ref1]\] In the United States, the estimated new cases of breast cancer are 182,690 and the estimated death rate due to breast cancer is estimated to be 40,430.\[[@ref2]\] Current treatment options for breast cancer include surgery, chemotherapy, radiation, and hormonal therapy.\[[@ref3]\] Chemotherapy is used for metastatic breast cancer and neoadjuvant therapy in the primary tumor to reduce tumor size before surgery.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Docosahexaenoicis a drug that inhibits
 
Response: Docosahexaenoicis a drug that inhibits the action of serotonin reuptake. It is also used for the treatment of attention deficit hyperactivity disorder.

Dosage and administration

Vigabatrin:

Children (1-5 years): 0.1 to 0.2 mg/kg once daily.

Children (6-12 years): 0.15 to 0.2 mg/kg once daily.

Children (12-17 years): 0.2 to 0.3 mg/kg once daily.

Children (12-17 years): 0.3 to 0.4 mg/kg once daily.

Children (12-17 years): 0.4 to 0.5 mg/kg once daily.

Adults: 0.4 to 0.5 mg/kg once daily.

Cranberries

Grapefruit

Grapefruit juice is also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dolasetronis a drug that inhibits
 
Response: Dolasetronis a drug that inhibits 5-HT3 receptors. It is used for prevention of chemotherapy-induced nausea and vomiting.

Olanzapine is a typical antipsychotic drug used for the treatment of schizophrenia and bipolar disorder.

Trifluoperazine is an antipsychotic drug used for the treatment of psychotic disorders, and tardive dyskinesia.

Indications

Dolasetron is used to prevent and treat nausea and vomiting that occur after administration of cytotoxic drugs and radiation therapy. It is also used for prevention of nausea and vomiting associated with motion sickness.

Olanzapine is used to treat psychotic disorders such as schizophrenia, schizoaffective disorder, and bipolar disorder. It is also used to treat insomnia.

Trifluoperazine is used to treat the signs and symptoms of psychosis in schizophrenia and bipolar disorder. It may also be used for the treatment of tardive dys
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dolutegraviris a drug that inhibits
 
Response: Dolutegraviris a drug that inhibits the growth of cancer cells.

The company was acquired by Zonagen in 2014.

In 2016, the FDA approved Kisseya’s NK-104 for the treatment of relapsed/refractory multiple myeloma.

Kisseya is a portfolio company of Amgen.

In 2018, the FDA approved Kisseya’s NK-100 for the treatment of relapsed/refractory multiple myeloma.

Clinical Trials

On December 12, 2018, Kisseya announced that the FDA approved NK-100 for the treatment of relapsed/refractory multiple myeloma.

Kisseya said that it is expected to file a New Drug Application for NK-100 in 2019.

In January 2019, Kisseya announced that it had begun a phase 2 trial for NK-104 in combination with cyclophosphamide in multiple myel
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  domiphenis a drug that inhibits
 
Response: domiphenis a drug that inhibits 5-lipoxygenase (5-LO) and has been shown to inhibit in vitro the release of eosinophil granule proteins in patients with eosinophilic asthma. The objective of this study was to determine whether treatment with fluticasone propionate (FP) plus zileuton (Z) is superior to FP plus placebo in the prevention of asthma exacerbations. In a double-blind, double-dummy, placebo-controlled, multicenter trial, 822 patients with mild to moderate asthma were randomly assigned to receive either placebo, fluticasone propionate, 100 microg twice daily, fluticasone propionate, 200 microg twice daily, or fluticasone propionate, 400 microg twice daily, plus zileuton, 100 mg twice daily. Treatment was initiated at the time of the first asthma exacerbation and was continued for 6 months. The primary outcome
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Domperidoneis a drug that inhibits
 
Response: Domperidoneis a drug that inhibits the gastric acid secretion, which is a key mechanism for the digestion of food. It also has been used to treat the gastric dysmotility. However, recent studies showed that domperidone is also a dopamine D2 receptor antagonist, and this drug can cause the symptoms of extrapyramidal symptoms, which are caused by the abnormal stimulation of the dopaminergic system in the brain. The abnormal stimulation can be either the result of excessive dopamine levels in the brain, or the result of the overactivity of dopamine receptors in the brain. These symptoms include movement disorders such as tardive dyskinesia.

Domperidone is used to treat nausea and vomiting. Domperidone is usually prescribed as a prescription medication. However, some over-the-counter (OTC) versions of domperidone are available, and some of them are available in combination with a liquid form of domperidone.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Donepezilis a drug that inhibits
 
Response: Donepezilis a drug that inhibits the action of the enzyme acetylcholinesterase. It is used to treat the symptoms of dementia, particularly Alzheimer's disease. It is also used to treat vascular dementia, depression, mild to moderate anxiety, and restless leg syndrome. It is available as an oral tablet and an injection. It can also be given in a slow-release capsule. It may also be given in combination with other medications.

HOW IT WORKS

Donepezil is a cholinesterase inhibitor. It works by preventing the action of the enzyme acetylcholinesterase. As a result, the amount of acetylcholine in the brain is increased, which increases the amount of dopamine released. This leads to increased alertness, better memory, and a better mood.

WHAT DOES IT MEAN IF IT DOESN'T WORK?

Donepezil doesn't always work. The response is variable. This means
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dopamineis a drug that inhibits
 
Response: Dopamineis a drug that inhibits an enzyme called monoamine oxidase, and helps the body use the neurotransmitter dopamine. Dopamine is produced in the brain, and has a number of important functions, including the regulation of motor activity, mood, and reward. It is also a major modulator of attention, working memory, and motivation.

Dopamine is also an important part of the reward pathway, which allows us to enjoy the pleasant effects of eating, drinking, smoking, and other pleasurable activities. In fact, this pathway plays a major role in addiction to drugs and alcohol. Dopamine can also be found in some brain regions that play a role in addiction, and its levels are altered in some brain regions in people with substance use disorders.

The Dopamine Hypothesis

In 1965, the idea that dopamine plays a role in addiction was proposed by an Italian neuroscientist named Antonio E. Capparelli. He theorized
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doravirineis a drug that inhibits
 
Response: Doravirineis a drug that inhibits the enzyme integrase. It is used for treatment of HIV-1 infection in combination with other antiretroviral agents. It is an integrase strand transfer inhibitor (INSTI) and is the second integrase inhibitor approved by the FDA. It has been approved in India in May 2012 and has been recently approved by FDA in the USA in June 2013.\[[@ref1]\]

HIV-1 integrase is a viral enzyme that plays a vital role in the life cycle of the virus. HIV-1 integrase is a nuclear enzyme that catalyzes the insertion of the proviral DNA into the host cell genome. The HIV-1 integrase catalyzes the 3'-end processing of the viral DNA ends as well as the strand transfer reaction. The integration process involves the removal of two nucleotides from the 3'-ends of the viral DNA and the insertion of a copy of the viral DNA into the host
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doripenemis a drug that inhibits
 
Response: Doripenemis a drug that inhibits the action of P-glycoprotein (P-gp), a membrane transporter protein that pumps drugs out of cells, could be useful for treating infections by multi-drug resistant (MDR) bacteria, according to new research published in Science Translational Medicine.

MDR bacteria are becoming more prevalent in hospitals and are responsible for a growing number of infections. According to the CDC, over half a million people are infected with MDR bacteria in the U.S. each year, and over 100,000 people die.

Current antibiotics are losing their effectiveness, and the only drugs that are still effective against MDR bacteria are those that target the last step of bacterial cell division.

“These drugs are still in the pipeline and some are nearing the market, but they’re going to be very expensive and very hard to get a hold of,” said Laura R. Zoloth, Ph.D.,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dorzolamideis a drug that inhibits
 
Response: Dorzolamideis a drug that inhibits the production of aqueous humor, thereby decreasing the production of intraocular pressure. This medication is used to treat glaucoma.

Naftazone (Tazopt) is used to treat glaucoma. It is a prostaglandin analog.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxapramis a drug that inhibits
 
Response: Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic drug.

Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic drug.

Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic drug.

Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic drug.

Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic drug.

Doxapramis a drug that inhibits the release of acetylcholine from postsynaptic neurons and acts as a sedative and hypnotic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxazosinis a drug that inhibits
 
Response: Doxazosinis a drug that inhibits CYP3A4 activity, thereby inhibiting the metabolism of various drugs, such as ritonavir. The concomitant administration of indinavir and ritonavir results in increased concentrations of indinavir. However, concomitant administration of ritonavir and indinavir may result in the decreased bioavailability of indinavir, and increased plasma concentrations of ritonavir. Thus, patients receiving indinavir and ritonavir concomitantly should be monitored for decreased indinavir bioavailability and increased ritonavir plasma concentrations. See Package Insert, Apotex Corporation, September 1996.

HIV protease inhibitors are metabolized by cytochrome P450 3A4 (CYP3A4) and its metabolites. Ritonavir, nelfinavir, saquinavir, indinavir, and atazanavir are metabolized by CYP
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxercalciferolis a drug that inhibits
 
Response: Doxercalciferolis a drug that inhibits osteoclast formation. Studies suggest that it might be useful in preventing bone loss in the elderly.

Doxycycline a drug that inhibits the formation of bone marrow cells. It is prescribed for infections. It may also be used to treat some cases of periodontal disease.

Drugs that are often prescribed for cardiovascular disease. These include aspirin, aspirin, the beta blocker carvedilol, calcium channel blockers (such as verapamil and diltiazem), the statin simvastatin, and ACE inhibitors.

Dronedarone a drug that is prescribed for the prevention of atrial fibrillation.

Drotrecogin alfa a drug that is prescribed for severe sepsis.

Dual antiplatelet therapy a combination of aspirin and clopidogrel.

Duchenne muscular dystrophy a disease of muscle. It causes progressive muscle
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxifluridineis a drug that inhibits
 
Response: Doxifluridineis a drug that inhibits DNA synthesis by acting as a prodrug for the metabolite 5-fluorouracil. This drug is used to treat colorectal cancer and also in combination with other drugs to treat a variety of cancers. This drug is usually taken orally. It can be used as a monotherapy, but it is most commonly used in combination with 5-fluorouracil.

Active Ingredients

5-Fluorouracil (5-FU)

Doxifluridine

Doxifluridine is the prodrug of 5-fluorouracil. This prodrug can be activated in the liver and then converted into the active form. This drug is usually used in combination with other drugs to treat a variety of cancers.

Uses

Colorectal Cancer

Doxifluridine is used to treat patients with colorectal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxofyllineis a drug that inhibits
 
Response: Doxofyllineis a drug that inhibits phosphodiesterase (PDE) and thereby elevates the concentration of cyclic AMP (cAMP) in the cell. PDE inhibitors increase the intracellular concentration of cAMP by blocking the degradation of cAMP by the enzyme. By inhibiting PDE, doxofylline has been found to stimulate glucose transport in insulin-stimulated and non-insulin-stimulated cells and to stimulate glucose metabolism.
In an effort to identify drugs that are useful for the treatment of diabetes, diabetes-related disorders, or hyperglycemia, various PDE inhibitors have been screened for their ability to stimulate glucose transport and/or metabolism in cells. For example, some PDE inhibitors stimulate glucose transport in adipocytes, hepatocytes, myocytes, or erythrocytes. These results suggest that these compounds would be useful for the treatment of type II diabetes and/or diabetic complications. For example, in a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxycyclineis a drug that inhibits
 
Response: Doxycyclineis a drug that inhibits bacterial protein synthesis. Doxycycline is a broad spectrum antibiotic that has been used to treat a wide variety of infections. Although the mechanism of action of doxycycline has been studied for many years, the details of its mechanism of action are not well understood. The mechanism of action of doxycycline involves binding to the 30S subunit of bacterial ribosomes and inhibiting the initiation of protein synthesis. This causes a decrease in the rate of bacterial growth.
Doxycycline is currently the drug of choice for treating acne and rosacea, and it is often used to treat staphylococcal skin infections. Doxycycline is also used to treat periodontal disease, respiratory tract infections, and other bacterial infections. Doxycycline is also used to treat protozoal infections.
Although doxycycline is an effective drug, the use of doxycycline has been limited by the adverse
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Doxylamineis a drug that inhibits
 
Response: Doxylamineis a drug that inhibits the re-uptake of the neurotransmitter norepinephrine. It is used to treat stress and tension headaches.

Name: Doxylamine

Dose: 10 mg, 15 mg

Effects: Nausea, light-headedness, dry mouth

Potential Side Effects: Confusion, dry mouth, headache, drowsiness, dizziness, upset stomach, blurred vision, rapid heartbeat, shortness of breath, confusion, irritability, seizures

Dosage Information: The most commonly prescribed dose is 15 mg once a day. This is a higher dose than the 10 mg tablets.

How it works: Doxylamine inhibits the re-uptake of norepinephrine, a neurotransmitter that plays a role in the regulation of blood pressure, heart rate, and other functions. Doxylamine also increases the amount of serotonin in the brain. Serotonin plays a role
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  D-Phenylalanineis a drug that inhibits
 
Response: D-Phenylalanineis a drug that inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). It is used to treat type 2 diabetes by increasing the levels of insulin and glucose-dependent insulinotropic polypeptide in the blood.

The name "metformin" comes from the Greek word for'mushroom'. The drug was originally discovered as an antidiabetic agent, but was not pursued as a treatment for diabetes because of its lack of effect on serum glucose. Metformin was later re-examined and shown to be a powerful hypoglycaemic agent in the 1980s. It is the most widely prescribed antidiabetic agent worldwide.

Metformin was approved for use in the United States in 1994 and was approved in Canada in 1997. In 2002, metformin was approved in the European Union (EU).

In clinical trials, metformin reduced fasting plasma glucose levels by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Drofenineis a drug that inhibits
 
Response: Drofenineis a drug that inhibits slow-reacting substance of anaphylaxis (SRS-A) and blocks the action of histamine at H1 receptors. Drofenineis effective in the treatment of bronchial asthma. Drofenine is metabolized in the liver and excreted in the urine. The dose of the drug is related to the amount of time the patient takes the drug.

Possible side effects of drofenine include decreased appetite, nausea, vomiting, diarrhea, headache, insomnia, dizziness, heartburn, and stomach pain.

If you are taking drofenine, tell your doctor if you have any of the following:

anemia, or low levels of red blood cells in your blood

anorexia (appetite loss), or a decreased appetite

bronchitis, or an infection of the airways in your lungs

depression, or low mood

fluid retention
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dronedaroneis a drug that inhibits
 
Response: Dronedaroneis a drug that inhibits hERG, a potassium channel, which is one of the factors that cause the delayed ventricular repolarization, which can result in the prolongation of QT interval. It has been known that prolongation of QT interval is a risk factor of Torsade de Pointes (TdP), a kind of arrhythmia that is sometimes fatal. Dronedarone is indicated for the treatment of patients with atrial fibrillation (AF), but is contraindicated for the patients with long QT syndrome (LQTS) due to the risk of TdP. LQTS is a hereditary disease caused by genetic defects, and there are at least 14 kinds of LQTS genes. There are two types of LQTS, one is type 1 LQTS, and the other is type 2 LQTS. LQTS type 1 is caused by mutations in KCNQ1, and L
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Droperidolis a drug that inhibits
 
Response: Droperidolis a drug that inhibits histone deacetylase, thereby activating tumour suppressor genes and inducing apoptosis in cancer cells. In this study, we have investigated the anti-tumour effect of droperidol in vivo. Mice bearing Ehrlich ascites tumour were injected intraperitoneally with droperidol. Droperidol induced apoptosis in tumour cells and caused regression of tumours in a dose-dependent manner. In contrast, droperidol had no effect on the viability of normal splenocytes or thymocytes. Our results suggest that droperidol may be a candidate for anti-cancer therapy.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dropropizineis a drug that inhibits
 
Response: Dropropizineis a drug that inhibits dopamine reuptake, preventing the dopaminergic transmission. It is a strong and long-lasting antiparkinsonian drug, with effects comparable to those of levodopa, but without its side effects. Dropropizine has been used for many years in the treatment of Parkinson's disease, but has never been commercially available in the United States. The drug is not approved for use in the United States, but is used in other countries.

Dropropizine was developed in Italy by Rotta Research and Industria Farmaceutici, and approved in Italy in 1970. It was developed in Germany by Schwarz Pharma, and first marketed there in 1971. It was developed in France by Eli Lilly, and first marketed there in 1971. It was developed in Sweden by Astra and first marketed there in 1973. It was developed in Switzerland by Astra and first marketed there in 1975. It was developed in the United States by Parke
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Drospirenoneis a drug that inhibits
 
Response: Drospirenoneis a drug that inhibits the production of estrogen in the body. It is used to treat certain medical conditions in women who are pregnant or may become pregnant. It is also used to treat certain symptoms of menopause. It is a synthetic progestin that is chemically similar to progesterone. Drospirenone has the same effect as progesterone in the body, which is to cause the lining of the uterus to thicken and soften. This lining is called the endometrium. When the lining of the uterus thickens and softens, it can be shed during menstruation. When the endometrium is thicker than usual, it can cause heavy menstrual bleeding. Drospirenone is a steroid that is used to treat irregular menstrual periods.

It is used to treat:

Hormone replacement therapy in women who are not pregnant.

Polycystic ovary syndrome (PCOS).

Endometriosis.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Droxidopais a drug that inhibits
 
Response: Droxidopais a drug that inhibits the activity of the enzyme 5-alpha-reductase. This drug is used to treat acne vulgaris and hirsutism. It may also be used for other conditions as determined by your doctor.

Uses

Droxidopa is used to treat symptoms of low blood pressure, which include lightheadedness, dizziness, fainting, or loss of consciousness, that are associated with high blood pressure.

Droxidopa is also used to treat restless leg syndrome.

Droxidopa is also used to treat erectile dysfunction in men.

Droxidopa is also used to treat chronic pain, including chronic back pain, in adults.

Droxidopa is used in the treatment of narcolepsy.

Droxidopa is used in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Duloxetineis a drug that inhibits
 
Response: Duloxetineis a drug that inhibits the reuptake of serotonin and norepinephrine. It is used for the treatment of major depressive disorder (MDD) and neuropathic pain (NP). In addition to depression and NP, it is also used for the treatment of stress urinary incontinence and premature ejaculation. Duloxetine is not indicated for the treatment of anxiety or social anxiety.

SURGICAL MANAGEMENT

Approximately 5% of patients experience moderate to severe nausea and/or vomiting. These patients may require antiemetic treatment prior to surgery. Other common side effects include constipation, dry mouth, headache, dizziness, fatigue, decreased appetite, sexual dysfunction, somnolence, fatigue, and insomnia. Serious side effects include urinary retention, blurred vision, seizure, and other psychiatric symptoms. Treatment of these side effects includes reducing the dose of the drug and/or withholding the drug for a short period of time.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dutasterideis a drug that inhibits
 
Response: Dutasterideis a drug that inhibits the action of the enzyme 5-alpha reductase. It is used to treat the signs and symptoms of BPH, also known as benign prostatic hyperplasia (BPH), a condition that affects men over age 50. BPH is a non-cancerous condition that affects the prostate gland and may cause urinary problems such as weak urine flow, difficulty urinating, and frequent urination.

Dutasteride blocks the action of the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT), a hormone that causes prostate growth. The results of clinical trials have shown that dutasteride effectively reduces the size of the prostate gland and relieves urinary symptoms. Dutasteride also has been shown to improve sexual function.

What Is Dutasteride?

Dutasteride is a drug that is used to treat the signs and symptoms of BPH, also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Dyclonineis a drug that inhibits
 
Response: Dyclonineis a drug that inhibits the synthesis of acetylcholine.

Dyclonine is an organic compound with the chemical formula C8H12N2O3S2.

It is a natural toxin that can be extracted from the root of the genus Hyoscyamus.

It is classified as an acetylcholinesterase inhibitor.

Dyclonine can be used to treat some types of brain tumors.

It is used in the treatment of migraine and as a component of insecticides.

The use of dyclonine as a treatment for migraine has not been proven.

A 2018 systematic review found no evidence to support the use of dyclonine for treating migraine.

Dyclonine has been used in the treatment of some types of cancer.

The evidence for the use of dyclonine in the treatment of cancer is inconsistent.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DYNACIRCis a drug that inhibits
 
Response: DYNACIRCis a drug that inhibits the enzyme purine nucleoside phosphorylase, an enzyme that is essential for the conversion of a nucleoside to its corresponding nucleotide.^[@bibr1-2324709616660745]^ DYNACIRC has a high affinity for purine nucleoside phosphorylase, resulting in inhibition of the enzyme. DYNACIRC is also a prodrug that undergoes hydrolysis to the active form, a deoxyguanosine analog. The active form of the drug is deoxyguanosine triphosphate, which is a substrate for DNA polymerase and results in chain termination during DNA replication. The active form of DYNACIRC is deoxyguanosine monophosphate, which is a substrate for ribonucleotide reductase and results in chain termination during DNA synthesis. DYNACIRC is metabolized to its active form by deoxyguanos
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  DYRENIUMis a drug that inhibits
 
Response: DYRENIUMis a drug that inhibits the transcriptional activity of estrogen receptors (ERs). DYRENIUM was originally developed as an anti-cancer agent, but it also has a potent anti-proliferative effect on ER-positive (ER+) breast cancer cells, and it has been shown to have an anti-proliferative effect on both ER+ and ER-negative (ER-) breast cancer cells. In addition, DYRENIUM has been shown to inhibit cell growth in other tissues, such as prostate, liver, and lung. The anti-proliferative effect of DYRENIUM in ER+ breast cancer cells is mediated by the induction of the tumor suppressor gene, P21, and a decrease in cyclin D1 expression. Furthermore, the anti-proliferative effect of DYRENIUM in ER- breast cancer cells is mediated by the inhibition of ERK1/2 and AKT signaling. In addition, D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  E7080is a drug that inhibits
 
Response: E7080is a drug that inhibits a protein called sphingosine kinase (SphK), which catalyzes the formation of sphingosine-1-phosphate (S1P). S1P is a sphingolipid which is found in the body. It’s an important component of a signaling system that regulates blood pressure, blood clotting, inflammation, and other processes. S1P is formed in cells, then transported out of the cell and shuttled to other cells. S1P has two effects on cells: It inhibits blood clotting, and it promotes the movement of white blood cells out of the blood stream into other tissues. This can be beneficial for fighting infection, but it can also contribute to autoimmune disorders. S1P also helps blood cells stick to each other, and in this way it helps the blood form clots.

E7080 works by inhibiting SphK1, a protein in the body
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  E7449is a drug that inhibits
 
Response: E7449is a drug that inhibits the HIV-1 protease. It is currently in phase II clinical trials. Although it has been demonstrated that ritonavir increases levels of other PIs, it is not known if the mechanism is similar to other PIs. Therefore, the goal of this study was to investigate if ritonavir affects PIs that are not substrates of CYP3A4. Our results indicate that ritonavir increases the accumulation of indinavir, nelfinavir, saquinavir, and ritonavir, in vitro. Furthermore, we found that the presence of ritonavir enhanced the activity of saquinavir and indinavir in cell culture. Our results indicate that ritonavir may enhance the potency of other PIs by increasing their accumulation in the cell.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  E7820is a drug that inhibits
 
Response: E7820is a drug that inhibits a gene known as STAT3. This gene is known to be activated in several cancers, including lung cancer. Therefore, this drug may have potential in treating lung cancer.

STAT3 is also known as Signal Transducer and Activator of Transcription 3. It is a transcription factor that is found in all human cells. STAT3 is activated when cells are exposed to growth factors or cytokines. STAT3 can then interact with DNA and promote the transcription of certain genes.

STAT3 can be found in many types of cells including cancer cells, endothelial cells, and immune cells. In some types of cancer, STAT3 can be found in more than 50% of the cells. This makes STAT3 an attractive target for drugs to inhibit its activity.

Researchers have shown that STAT3 can promote the growth of tumors in mice. This has led to the development of drugs that target STAT3.

Glioblastoma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ebastineis a drug that inhibits
 
Response: Ebastineis a drug that inhibits histamine H1 receptors. It has the effect of calming the brain and nervous system and can be used to treat migraine and motion sickness.

There are three ways of taking the medication: orally, sublingually (under the tongue), and as an injection.

If you are taking the drug orally, it is usually taken one hour before a meal. It is also available in a liquid form.

If you are taking the drug sublingually, you can take it at any time, but you will usually need to wait at least 15 minutes before eating.

If you are taking the drug as an injection, you will need to wait at least 30 minutes after eating before you take the injection.

Ebastine is available in tablet form, and you will be advised of the correct dose to take.

Do not take more than the recommended dose of the drug. If you take too much, you
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ebselenis a drug that inhibits
 
Response: Ebselenis a drug that inhibits the activity of a family of isoenzymes called cytochrome P450 (CYP450). Ebselen inhibits the activity of CYP450 and prevents the formation of carcinogens from polycyclic hydrocarbons. In the liver, ebselen is rapidly and extensively metabolized to ebselen disulfide (ebselen-S-S-ebselen). In vivo, ebselen is primarily excreted in the urine and in vitro ebselen-S-S-ebselen is excreted in the urine.
The structure of ebselen-S-S-ebselen has been elucidated by 1H and 13C NMR spectroscopy. The two sulfur atoms of ebselen-S-S-ebselen are bound to the two carbons of ebselen (S. L. Fieser, S. B. Wu, K. D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Econazoleis a drug that inhibits
 
Response: Econazoleis a drug that inhibits the synthesis of lanosterol, an essential component of the membrane of yeast cells. It is a common, well-tolerated, fungistatic agent used for topical and oral treatment of a variety of fungal infections. Econazole, a member of the azole class of drugs, is available in a number of oral forms and in topical formulations. It is available in the United States in an oral tablet form, known as Stromectol, which is indicated for the treatment of ringworm, tinea, jock itch, athlete's foot, and similar superficial mycotic infections of the skin. It is also available in an oral suspension, known as Sheets, which is indicated for the treatment of oral candidiasis and oral thrush.

Econazole is a triazole with a chemical structure that contains a hydroxyl group on the 2-position of the 1,2,4-tri
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Edaravoneis a drug that inhibits
 
Response: Edaravoneis a drug that inhibits oxidative damage to cell membranes. Edaravone is known to be effective in the treatment of acute cerebral infarction, particularly when given within 48 hours of the onset of stroke symptoms. It has also been shown to be effective in the treatment of acute ischemic heart disease and in the prevention of reperfusion injury in heart attacks. Edaravone was originally developed in Japan and has been widely used there. It has been approved in the U.S. for the treatment of acute cerebral infarction.

In recent years, there have been several reports of edaravone-induced liver damage. Although the pathogenesis of edaravone-induced liver damage is not completely understood, edaravone has been shown to cause hepatotoxicity in some patients, and the mechanism of hepatotoxicity may be related to oxidative damage to mitochondria.

Iatrogenic drug-induced liver injury (DIL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  edetateis a drug that inhibits
 
Response: edetateis a drug that inhibits the uptake of D-glucose in the liver by competitive inhibition of the glucose transporter. It is used in the treatment of diabetes mellitus.

SGLT2 inhibitors have also been proposed as an approach to combat the progression of diabetic nephropathy (DN). SGLT2 inhibitors inhibit the reabsorption of filtered glucose in the proximal tubules of the kidney, resulting in a reduction in hyperglycemia and a decrease in the urinary glucose excretion. The result is a decrease in glomerular hyperfiltration, and consequently a decrease in the albuminuria. This effect on the kidney was observed in a number of large, randomized, double-blind, placebo-controlled clinical trials, such as EMPA-REG OUTCOME and CANVAS, where canagliflozin and dapagliflozin, respectively, were administered. Both EMPA-REG OUTCOME and CANVAS
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Edonerpicis a drug that inhibits
 
Response: Edonerpicis a drug that inhibits the production of testosterone.

When it was approved by the FDA in July 2005, edonerpicis was touted as the "first drug to target male sexual function."

The FDA approved the drug to treat erectile dysfunction (ED), but its label warned of side effects that include the possibility of infertility.

ED is a common condition among men. According to the National Institutes of Health, erectile dysfunction is estimated to affect an estimated 28 million men in the United States.

More than two million American men have been diagnosed with the condition. The incidence of ED is expected to rise as men age.

"Erectile dysfunction is an issue that many men are afraid to talk about," says Dr. Adib Haghdoost, a urologist and associate professor at the Medical College of Georgia. "I think there are a lot of men who don't want to admit that they have the problem."


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Edoxabanis a drug that inhibits
 
Response: Edoxabanis a drug that inhibits factor Xa (FXa), a key factor in blood clotting. It works by binding to the active site of the enzyme, blocking its activity. Edoxaban is available as a pill that is taken once a day, and it does not need to be monitored.

Edoxabanis approved by the U.S. Food and Drug Administration (FDA) to treat and prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation (AF).

AF is the most common type of irregular heartbeat. It is most common in older adults and is more common in women. AF can cause blood clots to form in the arteries that supply blood to the heart. These clots may block blood flow to the heart, which can lead to chest pain, heart failure, or even death.

In a recent study published in The New England Journal of Medicine, edoxabanis compared to war
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Edrophoniumis a drug that inhibits
 
Response: Edrophoniumis a drug that inhibits acetylcholinesterase, thus enhancing the cholinergic effects of acetylcholine at the neuromuscular junction. It is used to treat myasthenia gravis. It is also used in the diagnosis of myasthenia gravis, to increase the effectiveness of thymectomy, and in the treatment of neonatal myasthenia gravis. It is a racemic mixture of two enantiomers, rocuronium and eseroline, which are used as anticholinesterase agents in medicine. The two enantiomers are equipotent, but the major active component of edrophonium is the (R)-enantiomer.

1. INTRODUCTION {#sec1-1}
===============

Edrophonium is a drug that inhibits acetylcholinesterase, thus enhancing the cholinergic effects of acetylcholine at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Efaproxiralis a drug that inhibits
 
Response: Efaproxiralis a drug that inhibits the production of the hormone cortisol by the adrenal glands. It is used to treat the signs and symptoms of anxiety, depression, and some medical conditions.

Efaproxiralis the only drug approved by the Food and Drug Administration (FDA) for the treatment of depression in people with liver problems.

Efaproxiralis a prescription medicine used to treat the signs and symptoms of anxiety, depression, and other medical conditions. It works by inhibiting the production of cortisol by the adrenal glands.

Efaproxiralis (efaproxiral) is an injectable drug used to treat the signs and symptoms of depression in people with liver problems. It works by inhibiting the production of cortisol by the adrenal glands.

Efaproxiralis a prescription medicine used to treat the signs and symptoms of anxiety, depression, and other medical conditions. It works by inhibiting the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eicosapentaenoicis a drug that inhibits
 
Response: Eicosapentaenoicis a drug that inhibits the aggregation of platelets and may reduce the risk of heart attack.

These drugs can cause bleeding and other side effects. Talk to your doctor about the risks and benefits.

How to take omega-3 fatty acids

Fish oil supplements are available in liquid, capsule, and tablet forms. You can take them with or without food.

Your doctor may give you a special diet to take with your fish oil supplements. Your doctor may also recommend that you take them for a specific length of time. Follow the instructions carefully.

It is important to take fish oil supplements for at least a few weeks before seeing if they are helping you. Fish oil supplements can take up to 3 months to work.

Side effects

The side effects of fish oil supplements may include:

Irregular heartbeat

Flushing

A rise in blood pressure

Dizziness

Anxiety

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eletriptanis a drug that inhibits
 
Response: Eletriptanis a drug that inhibits the serotonin 5-HT1D receptor, which causes vasoconstriction of blood vessels in the head and upper body. It is indicated for the acute treatment of migraine, and has a rapid onset of action and a duration of action of 4 hours.

It was first approved by the FDA in 2004.

Treatment with eletriptan was shown to be effective in patients who had a history of a previous inadequate response to treatment with the triptans.

Treatment with eletriptan was shown to be effective in patients who had a history of a previous inadequate response to treatment with the triptans.

The following is an example of a patient report.

Brief Report of Eletriptan Treatment for Migraine

"I was very fortunate to have found eletriptan. I had suffered with migraines for over 20 years, usually lasting 5-6 days, and usually
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eliglustatis a drug that inhibits
 
Response: Eliglustatis a drug that inhibits both PDE5 and PDE11 have been studied in the treatment of erectile dysfunction.

The term penile erections are not synonymous with ejaculation. An erection can be of a shorter duration than ejaculation and can occur in response to stimuli other than intercourse.

The term climax is synonymous with ejaculation. An ejaculation is a single explosive release of semen from the penis and is normally the final step in the sexual response cycle.

A number of other pharmacological agents have been used in the treatment of impotence.

The following drugs have been used to treat impotence:

Alprostadil is an analog of prostaglandin E1. It is injected directly into the penis during sexual stimulation. Alprostadil is the only treatment that has been approved by the Food and Drug Administration (FDA) for the treatment of impotence.

Alprostadil can be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ellenceis a drug that inhibits
 
Response: Ellenceis a drug that inhibits cell proliferation by affecting DNA synthesis, and is also known as efstatin.

Introduction {#sec1-1}
============

Ellenceis, also known as efstatin, is a drug that inhibits cell proliferation by affecting DNA synthesis.\[[@ref1]\] It was originally isolated from *Streptomyces achromogenes* and later synthesized by Noguchi and associates in the early 1980s.\[[@ref2]\] It has been reported to be active against various malignancies including melanoma,\[[@ref3]\] ovarian,\[[@ref4]\] breast,\[[@ref5]\] and non-small cell lung cancer (NSCLC).\[[@ref6]\] The drug also has potential in the treatment of metastatic colorectal cancer (CRC) and cervical cancer.\[[@
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eloxatinis a drug that inhibits
 
Response: Eloxatinis a drug that inhibits the degradation of AChE by blocking the action of the protease of a multienzyme system (mainly AChE and chymotrypsin). Eloxatinis administered as a suspension in polyethylene glycol (PEG) 400. The drug is available as an oral solution and as a suspension in PEG 400.

#####  INDICATIONS/ROUTES/DOSAGE

**PO:** **ADULTS, ELDERLY:** 25–75 mg twice daily for 4–6 wks.

Dosage in Renal Impairment

**Mild to Moderate:** No dose adjustment. **Severe:** 25 mg once daily.

Dosage in Hepatic Impairment

**Mild to Moderate:** No dose adjustment. **Severe:** 25 mg once daily.

#####  SIDE EFFEC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eltrombopagis a drug that inhibits
 
Response: Eltrombopagis a drug that inhibits the function of the thrombopoietin (TPO) receptor.

About half of patients with chronic lymphocytic leukemia (CLL) experience an adverse event during treatment with an antibody-based therapy. This complication is referred to as antibody-related adverse event. In a recently published study, researchers from the University of Texas MD Anderson Cancer Center and the University of Texas MD Anderson Cancer Center in Houston evaluated the use of the thrombopoietin receptor agonist, eltrombopag, in patients with CLL who were treated with a monoclonal antibody-based therapy.

“Our results showed that the use of eltrombopag resulted in fewer adverse events than those reported in clinical trials with the antibody-based therapy alone,” says lead author Tien H. Le, PharmD, a PharmD candidate at the University of Texas MD Anderson Cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Embelinis a drug that inhibits
 
Response: Embelinis a drug that inhibits an enzyme called Cdk5. It was used to kill tumours in mice, but it has since been withdrawn from the market because it caused headaches and hallucinations in people.

Cdk5 inhibitors are also being tested as treatments for neurological diseases such as Alzheimer's and Parkinson's.

The new study was led by Susan Lindquist, who is based at Harvard University and the Massachusetts Institute of Technology in the US.

Ms Lindquist said: "There are several compounds in development that target the cyclin-dependent kinase Cdk5, and we found one that was selective for the enzyme and, in animal models, did not cause the severe side effects that have been seen in earlier studies.

"Our work is the first to show that a selective Cdk5 inhibitor can improve memory in a mouse model of Alzheimer's disease."

But Professor Douglas Black, a molecular biologist at King's College London, said that, while
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EMDis a drug that inhibits
 
Response: EMDis a drug that inhibits P-gp-mediated drug efflux. When given with docetaxel, it increases the concentration of docetaxel in the brain, reducing the incidence of central nervous system metastases. Clinical trials are currently underway.

A recently developed P-gp inhibitor that has entered clinical trials. It has a long plasma half-life and can be administered once a week. Clinical trials are currently underway.

A drug that binds to P-gp and increases the intracellular concentration of docetaxel. It can be administered once a week. It is currently being tested in a phase II clinical trial in patients with non-small cell lung cancer.

In this section, you will learn about

How the nervous system works

What happens when you have a stroke

How a stroke can be treated

The nervous system

The nervous system is the part of the body that makes us able to think, move,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Emodinis a drug that inhibits
 
Response: Emodinis a drug that inhibits angiogenesis. The potential use of Emodin as a drug that inhibits angiogenesis is presented.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Empagliflozinis a drug that inhibits
 
Response: Empagliflozinis a drug that inhibits aromatase activity

Empagliflozin has been approved in Japan as an anti-diabetic drug. A recent study demonstrated that empagliflozin inhibits aromatase activity.

(EN)

The effects of empagliflozin, a new anti-diabetic agent, on aromatase activity were examined in human adipose tissue and a murine model. In vitro, empagliflozin significantly inhibited aromatase activity in a dose-dependent manner. Furthermore, empagliflozin also inhibited aromatase activity in the epididymal fat of C57BL/6 mice. These findings suggest that empagliflozin can inhibit aromatase activity and might exert anti-obesity effects by suppressing the production of estrogen.

Introduction

Obesity is a major risk factor for the development of several metabolic diseases, such as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Emricasanis a drug that inhibits
 
Response: Emricasanis a drug that inhibits proliferation of human fibroblasts, and hence might be useful in the treatment of hypertrophic scars, keloids, and other fibroproliferative skin disorders.^[@R1]^ In this study, we performed the first evaluation of the safety and efficacy of emricasan in humans.

PATIENTS AND METHODS
====================

Patients
--------

We performed a double-blind, randomized, placebo-controlled trial of the efficacy and safety of emricasan for treatment of fibroproliferative skin disorders in the United States. Subjects were recruited from the dermatology clinic of the Massachusetts General Hospital.

The protocol was approved by the institutional review board at Massachusetts General Hospital, and all patients provided written informed consent. The trial was registered at [www.clinicaltrials.gov](www.clinicaltrials.gov) (NCT008988
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Emtricitabineis a drug that inhibits
 
Response: Emtricitabineis a drug that inhibits the activity of HIV reverse transcriptase, a key enzyme required for the replication of HIV. Emtricitabine is approved for the treatment of HIV infection in the United States, the European Union, and elsewhere.

In September 2012, the U.S. Food and Drug Administration approved emtricitabine/tenofovir disoproxil fumarate (Truvada®) for pre-exposure prophylaxis (PrEP) in combination with emtricitabine and tenofovir alafenamide (Truvada®) (also known as TAF) as a PrEP agent for people who are at substantial risk for acquiring HIV infection. Emtricitabine is available as a generic drug and is marketed in many countries.

The European Medicines Agency has approved emtricitabine as a component of combination antiret
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ENALAPRILATis a drug that inhibits
 
Response: ENALAPRILATis a drug that inhibits the action of phosphodiesterase-4, which breaks down cyclic adenosine monophosphate (cAMP).

TIBALEPAN is used in the treatment of fever, arthritis, and osteoarthritis.

CLONIPRIL is a drug that is used in the treatment of ulcerative colitis.

AZATIDINE is used in the treatment of hyperammonemia, seizures, and narcolepsy.

CYCLOPENTOCIN is a drug that is used in the treatment of mastitis and gastric ulcers.

PREDNISONE is a drug that is used in the treatment of diabetes, polycystic ovarian syndrome, and osteoporosis.

NAPROXEN is used in the treatment of acne vulgaris.

FENOFIBRATE is a drug that is used in the treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ENDOMETRINis a drug that inhibits
 
Response: ENDOMETRINis a drug that inhibits ovulation in women with polycystic ovarian syndrome (PCOS). It is used as a second-line treatment in the UK after a period of ineffective first-line treatment. In the US, it is available only as an oral contraceptive.

The active ingredient, letrozole, was developed in the 1990s and approved for use in Europe in 1997. The drug is a selective aromatase inhibitor. It is a derivative of aminoglutethimide, which was developed in the 1960s as an anti-cancer agent and was withdrawn in the 1970s because of its severe side effects.

Letrozole is given once a day and is taken in the morning. The first three cycles of treatment are given as a once-daily dose, with the dose being doubled after three cycles. After this period, the dose is kept constant for the remainder of the treatment.

Side effects include


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Endoxifenis a drug that inhibits
 
Response: Endoxifenis a drug that inhibits the growth of human breast cancer cells in a selective manner. It is a synthetic estrogen that acts by binding to the estrogen receptor (ER). Breast cancer cells have the ability to respond to the anti-estrogenic effects of endoxifen. The response to endoxifen differs in a tumor-specific manner. In particular, ER-positive tumors are relatively sensitive to endoxifen. ER-negative tumors are relatively resistant to endoxifen. This differential sensitivity to endoxifen makes it possible to treat ER-positive tumors with endoxifen and ER-negative tumors with tamoxifen.

The Endoxifen Receptor
======================

ER is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. It is a member of the steroid hormone receptor superfamily. The ER family is a group of proteins that function in regulating gene expression in response to estrogen.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ENMD-2076is a drug that inhibits
 
Response: ENMD-2076is a drug that inhibits an enzyme called p70S6 kinase, which is known to play a role in cell proliferation and differentiation.

Studies of mice have shown that ED-2076 blocks cell division, causing cell death in mice, and inhibits the growth of tumours. In mice, ED-2076 also causes regression of tumours.

In animal studies, ED-2076 has been shown to be well tolerated and to have few side effects.

A new trial of ED-2076 has been announced by Pfizer to assess its effectiveness and safety in treating people with acute lymphoblastic leukaemia (ALL).

Pharmacokinetics and metabolism

In healthy people, ED-2076 is rapidly and almost completely absorbed from the gut after oral administration. It is distributed to most tissues and organs, and is metabolised by liver enzymes. It is eliminated from the body mainly by metabolism in the liver. The metabolites
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Enoxoloneis a drug that inhibits
 
Response: Enoxoloneis a drug that inhibits hepatic metabolism of estradiol. In the clinical setting, enoxoloneis is administered in combination with a progestogen to block ovulation. Estradiol is converted to estrone by aromatase. In contrast, progesterone is converted to androstenedione by aromatase. This difference is critical in that the ovulation-blocking activity of enoxoloneis is not dependent on inhibition of aromatase. The objective of this study was to determine whether enoxoloneis, administered in combination with a progestogen, would affect the normal physiological increase in androstenedione, a progestogen-induced increase in androstenedione, and the concentrations of androstenedione and estradiol in the circulation. Ten healthy, ovulating women participated in this study. All women received oral enoxoloneis (10 mg daily) and an oral progestogen (10 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Enrofloxacinis a drug that inhibits
 
Response: Enrofloxacinis a drug that inhibits the COX-2 enzyme. The NSAIDs have been implicated in causing a wide range of side effects including gastrointestinal, cardiovascular, respiratory, and neurological problems. One study indicated that a high percentage of dogs and cats have had reactions to these drugs, especially when administered for more than a week. The NSAIDs are now only prescribed for short periods of time, such as a few days, and usually only when other drugs have failed.

2. Steroids

Steroids are another type of drug that is used to treat inflammation. However, unlike the NSAIDs, steroids have a wide range of side effects that include fluid retention, muscle wasting, bone thinning, cataracts, and liver damage. Many people are reluctant to give their pets steroids because they fear the long-term side effects. Steroids should only be prescribed for the shortest period of time possible and then only when there is no other treatment option.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ensartinibis a drug that inhibits
 
Response: Ensartinibis a drug that inhibits K-ras (in red) from binding to the farnesyl transferase enzyme. It is also a derivative of the drug lonafarnib.

New drug prevents growth of lung cancer cells

Patients with K-ras-positive lung cancer can benefit from a new drug called ensartinibis a drug that inhibits K-ras (in red) from binding to the farnesyl transferase enzyme. It is also a derivative of the drug lonafarnib.

A new drug called ensartinib has been developed that inhibits K-ras (in red) from binding to the farnesyl transferase enzyme.

In addition, ensartinib is also a derivative of the drug lonafarnib, which was recently approved by the U.S. Food and Drug Administration for patients with advanced non-small cell lung cancer.

K-ras is a membrane
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Entacaponeis a drug that inhibits
 
Response: Entacaponeis a drug that inhibits the activity of the dopamine transporter. It is used to treat Parkinson's disease, a condition caused by a lack of dopamine. The drug has also been shown to have potential in the treatment of depression. It is also being investigated for the treatment of other conditions, including schizophrenia, bipolar disorder, Tourette syndrome, and attention deficit hyperactivity disorder.

Encapsulation of the drug in lipid microspheres is the basis for the drug's formulation. The microspheres can be coated with various materials to help them adhere to the gastrointestinal tract. The encapsulated drug can be administered by mouth or injection.

Medical uses

Parkinson's disease

Entacapone is approved for the treatment of patients with idiopathic Parkinson's disease (PD) who are not adequately controlled by levodopa and dopamine receptor agonists alone.

The efficacy of entacapone in the treatment of PD was demonstrated in two large
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Entecaviris a drug that inhibits
 
Response: Entecaviris a drug that inhibits the fusion of HIV with the host cell is shown to be safe in humans, but its effectiveness against the virus is unproven.

In a randomized trial, researchers tested whether adding entecavir to a standard regimen of three antiretroviral drugs, which were already known to be effective against HIV, would slow the progress of the disease in a group of 30 patients with HIV-related lymphoma or leukemia.

The study, published in the New England Journal of Medicine, was stopped early after 10 of the patients in the entecavir group showed signs of disease progression. Four of the 10 patients died of the disease, compared with six of 20 patients in the control group.

The researchers said the benefits of entecavir were not proven, but the study was halted before all of the patients had completed treatment because of the early deaths.

Although the entecavir group showed a trend toward more frequent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Entrectinibis a drug that inhibits
 
Response: Entrectinibis a drug that inhibits the tyrosine kinase activity of the hepatocyte growth factor receptor (MET) \[[@B1-cancers-12-01168]\]. The first-in-class drug has demonstrated activity in several tumor types, including hepatocellular carcinoma (HCC), gastric cancer, non-small cell lung cancer (NSCLC), and squamous cell carcinoma of the head and neck (SCCHN) \[[@B2-cancers-12-01168],[@B3-cancers-12-01168],[@B4-cancers-12-01168],[@B5-cancers-12-01168]\]. Phase III clinical trials have been conducted in HCC, gastric cancer, and NSCLC, but failed to demonstrate superiority over current standard-of-care regimens \[[@B6-cancers-12-01168],[@
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Epacadostatis a drug that inhibits
 
Response: Epacadostatis a drug that inhibits the Epac2 subtype of adenosine receptor.

You need to keep in mind that some individuals do experience some negative effects when taking Adderall. If you are among them, you should be very careful when taking Adderall and it should be prescribed by a medical professional who knows you well.

Adderall Side Effects:

The following are some of the more common Adderall side effects and how to deal with them:

– Irritability:

Adderall can cause irritability. This is usually because the stimulant effect of the drug takes over and causes you to feel very irritated. If you experience irritability when taking Adderall, you should try to calm yourself.

You can do this by taking a nice long walk or listening to your favorite music. You should also try to exercise and get plenty of sleep. This will help you feel better and get rid of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Epalrestatis a drug that inhibits
 
Response: Epalrestatis a drug that inhibits the liver’s production of cholesterol. It is also sold as TriCor, Vytorin, Zetia, Mevacor, Zocor, Novo-Selecia, and Simcor. Epalrestat is the only drug approved for the treatment of high cholesterol.

Isotretinoin (Roche/Schering-Plough) a drug used to treat severe acne. It is also sold as Accutane.

Lovastatin (Pfizer) a drug used to treat high cholesterol.

Mevacor (Merck) a combination of two cholesterol-lowering drugs, simvastatin and niacin.

Simcor (Schering-Plough) a combination of two cholesterol-lowering drugs, lovastatin and niacin.

TriCor (Sanofi-Aventis) a combination of two cholesterol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Epiandrosteroneis a drug that inhibits
 
Response: Epiandrosteroneis a drug that inhibits the action of androgens and stimulates the action of estrogens. It is also known as synthetic androgen, androstenedione, and 5-androstene-3b-ol-17-one. It is used in the treatment of prostate cancer, as a component of birth control pills, and as a treatment for acne.

Epiandrosteroneis an androgenic steroid.

Mechanism of Action

In the male, epiandrosterone acts as an androgenic steroid. It causes an increase in male sex characteristics and a decrease in female sex characteristics. In the female, it acts as an estrogen. In the male, it may be used in the treatment of benign prostatic hyperplasia and prostatic cancer. In the female, it may be used in the treatment of acne and hirsutism.

Epiandrosteroneis also used in the treatment of end
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Epinastineis a drug that inhibits
 
Response: Epinastineis a drug that inhibits mast cell degranulation and is commonly used for the treatment of allergic conjunctivitis and rhinitis.\[[@ref1]\] It is also effective in the treatment of pruritus associated with atopic dermatitis.\[[@ref2]\] We report a case of severe pruritus after the initiation of epinastine treatment in a patient with severe urticaria.

Case Report {#sec1-1}
===========

A 22-year-old female patient was admitted to the dermatology ward of a tertiary care hospital in India for generalized pruritus and erythematous urticarial plaques of 10 days duration. The patient was diagnosed with urticaria at the age of 1 year and had a history of urticaria since childhood. There was no history of any other cutaneous or systemic diseases, and she had not taken any medication in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Epinephrineis a drug that inhibits
 
Response: Epinephrineis a drug that inhibits the action of acetylcholine and blocks the transmission of impulses at the neuromuscular junction.

Inhaledformulation.

Epinephrineis usually given as a premedicant or to treat a bronchospasm. It is administered by inhalation through a metered dose inhaler (MDI) or by nebulization. It may be combined with corticosteroids, antihistamines, and bronchodilators.

Carcinogenic effects: Carcinogenicitystudies in animals have not been conducted. Animal studies in rodents have shown that epinephrine causes tumors of the adrenal glands and of the parathyroid glands. There is no evidence that epinephrine is carcinogenic to humans.

Carcinogenic effects: Carcinogenicitystudies in animals have not been conducted. Animal studies in rodents have shown that epinephrine causes tumors of the adren
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EPIVIRis a drug that inhibits
 
Response: EPIVIRis a drug that inhibits the hepatitis C virus (HCV) and has been used as an interferon (IFN)-free, IFN-sparing, direct-acting antiviral agent. We evaluated the efficacy and safety of ETV-LAM in a large population of Japanese patients with HCV genotype 2 or 3 infection who were previously treated with pegIFN and RBV. We conducted a phase IIIb, randomized, double-blind, active-controlled, multicenter study in a Japanese population. The study consisted of a 24-week core period, followed by an extension period of up to 96 weeks. The primary endpoint was the proportion of patients with sustained virological response (SVR), which was defined as undetectable HCV RNA at post-treatment week 24 (SVR24). A total of 306 patients were randomly assigned to receive ETV-LAM or IFN-alpha (Roferon-A; Hoffmann-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EPLERENONEis a drug that inhibits
 
Response: EPLERENONEis a drug that inhibits the body’s production of certain hormones that are essential to the production of testosterone. This means that the male hormone is prevented from reaching the reproductive system. The effect of eplerenone is reversible and so once the male hormone is present again the drug will stop working. Eplerenone can only be taken by a man who is a candidate for having a hysterectomy.

EPLERENONE works by preventing the testicles from producing testosterone and the drugs effects are only reversible if the drug is taken away and the male hormone returns. Eplerenone is used for the treatment of male hypogonadism and the drug will reduce the risk of prostate cancer.

This drug is only available to men who have had a hysterectomy and the doctors who prescribe it will always tell you that you can’t get pregnant. If you do want to have children you should consult your
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eprazinoneis a drug that inhibits
 
Response: Eprazinoneis a drug that inhibits MAO-A and MAO-B. It is also known as DIA-5 and Zinepro. It is used to treat certain mental illnesses and anxiety disorders.

What is the dosage of phentermine and how to take it?

How much do you need to take? You should be prescribed the proper dose of phentermine based on your weight, age, and other medical conditions. The dose of phentermine that is appropriate for you may vary depending on the strength of the medication you are prescribed. You should also check with your doctor or pharmacist if you have any questions about how to take your medication.

How long do you take phentermine?

Phentermine can be taken once or twice a day. It is usually taken as a single dose.

How long do you take phentermine for?

You may need to take phentermine for a period
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eprodisateis a drug that inhibits
 
Response: Eprodisateis a drug that inhibits platelet aggregation, but its action is short lived. This article describes a series of seven patients with non-Hodgkin's lymphoma who had fever and thrombocytopenia following treatment with etoposide, prednisone, and eprodisate. Etoposide and eprodisate were administered at doses of 50 to 75 mg/m2/day for 3 to 6 days, followed by prednisone 1 mg/kg/day for 7 days. All seven patients had a response to therapy. Platelet counts rose rapidly to the normal range, and the patients were afebrile. These findings suggest that eprodisate can be used safely with moderate doses of etoposide to treat lymphoma.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eprosartanis a drug that inhibits
 
Response: Eprosartanis a drug that inhibits the angiotensin II type 1 receptor (AT1R) and prevents the binding of angiotensin II to its receptors. The antihypertensive activity of eprosartan is caused by its ability to reduce blood pressure by inhibiting the vasoconstrictor effects of angiotensin II. The drug is well tolerated in patients and is a useful agent in the treatment of hypertension. Eprosartan has been shown to be effective in reducing blood pressure in patients with hypertension and to prevent myocardial infarction, stroke and other cardiovascular events. Eprosartan also has been shown to be effective in patients with diabetic nephropathy.
The chemical name for eprosartan is (E)-1-[2-ethoxy-1-[(1S,2S,3S,5S)-3-carboxy-2-phenyl-1-ox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Eptifibatideis a drug that inhibits
 
Response: Eptifibatideis a drug that inhibits platelet aggregation. It is a small synthetic glycoprotein (GP IIb/IIIa receptor antagonist) and inhibits platelet aggregation by blocking the GP IIb/IIIa receptor. The drug is used to prevent thrombosis and stroke in patients with acute coronary syndromes. It is administered in bolus doses (e.g., 15 mg/kg or 180 micrograms/kg) by IV infusion or IV bolus. The agent can be given as a single bolus or infusion or as a single bolus followed by a continuous infusion.

Eptifibatideis manufactured by Novartis Pharmaceuticals Corporation. It is supplied as the disodium salt of ethyl-2-sulfo-5-[2-[bis(carboxymethyl)amino]-2-oxoethyl]-2-thiophenecarboxylate and it is available in a lyophil
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EPZ-6438is a drug that inhibits
 
Response: EPZ-6438is a drug that inhibits VPS34, an important enzyme in the early steps of autophagy. In this study, we show that the mTOR inhibitor everolimus is also a potent inducer of autophagy, but unlike AZD8055, it is not capable of inducing autophagy in some melanoma cell lines. We further demonstrate that mTOR inhibition by AZD8055 induces autophagy through a dual mechanism: mTOR inhibition by AZD8055 is required for efficient induction of the autophagy gene ATG12 and it is also required for the degradation of the protein ATG12.

These results suggest that the mechanism of autophagy induction by AZD8055 is different from that of other mTOR inhibitors. However, the results are not surprising since mTOR is a key kinase in the regulation of autophagy, but it is not the only key kinase. AZD8055 targets both PI
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EQUIPINis a drug that inhibits
 
Response: EQUIPINis a drug that inhibits the release of serotonin from platelets. It works in two ways: first, it prevents the release of serotonin from the platelets, which leads to a reduction in the serotonin in the brain; second, it blocks the reuptake of serotonin into the brain. The result is an increase in the amount of serotonin in the brain. This increases the ability of the brain to regulate body temperature, blood pressure, heart rate, and breathing. EQUIPIN can be used to treat people with high blood pressure and anxiety. It is also used to treat hot flashes, a common symptom of menopause. It can also be used to prevent migraine headaches. It may also be used to treat or prevent depression.

INHALERis a drug that is used to treat asthma. It is inhaled through a nebulizer or through a mouthpiece that is held in the mouth. INHALER does not work as fast as some other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Equolis a drug that inhibits
 
Response: Equolis a drug that inhibits the production of the excess levels of amyloid-beta protein (Aβ) found in the brain of people with Alzheimer's disease (AD). This drug may slow the progress of AD and reduce the severity of symptoms. However, it may also cause serious side effects, including memory loss and mood changes. This study is designed to evaluate the effectiveness of Equilis in slowing the progression of AD and to determine the safety of Equilis.

Primary Objective:

To evaluate the effectiveness of Equilis in slowing the progression of AD.

Secondary Objectives:

To evaluate the safety of Equilis in patients with mild to moderate AD.

To evaluate the safety of Equilis in patients with mild AD.

To evaluate the effectiveness of Equilis in improving memory in patients with mild to moderate AD.

Eligibility

Ages Eligible for Study:

50 Years to 90
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Equolis a drug that inhibits
 
Response: Equolis a drug that inhibits the enzymes responsible for converting glucose to fat and may have the potential to lower cholesterol levels.

Diet and lifestyle changes should be the first step in reducing cholesterol levels, says James F. Black, MD, PhD, a professor of medicine and chief of cardiology at the University of North Carolina at Chapel Hill.

However, some patients who have high cholesterol levels are unable to make lifestyle changes.

“If the cholesterol level is over 250 and you have no risk factors for coronary artery disease, then I would advise you to start on a cholesterol-lowering drug,” Black says.

If your cholesterol is between 200 and 250, then a low-fat diet and weight loss may be the best option. If you have a higher cholesterol level, or if you have other risk factors for heart disease, Black says you should discuss the use of cholesterol-lowering drugs with your doctor.

Some of the cholesterol-lower
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Erdosteineis a drug that inhibits
 
Response: Erdosteineis a drug that inhibits the production of AGEs, which have been linked to cardiovascular and neurodegenerative diseases. In rats, Erdosteine increased the expression of genes involved in the clearance of AGEs and promoted the formation of long-term memory. The effects were greater in animals that were pre-treated with Erdosteine. The research also found that Erdosteine was able to protect cells from the effects of AGEs.

Many of the drugs used to treat Alzheimer’s are very toxic and have many side effects.

Dr. Leila Tarakji of the University of Toronto and her team have found a way to inhibit the formation of AGEs and, thus, may have a therapeutic effect. The researchers found that the drug Erdosteine (which has been shown to improve cognitive function in older people) was able to protect cells from the effects of AGEs.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ergoloidis a drug that inhibits
 
Response: Ergoloidis a drug that inhibits the enzyme that is involved in the breakdown of catecholamines. Catecholamines are the chemicals that transmit signals from the brain to the rest of the body. The drug is used to treat patients with hypertension, pheochromocytoma and cardiac failure. It is also used to treat migraine headaches.

Who is it for?

This drug is used to treat hypertension, pheochromocytoma and cardiac failure. It is also used to treat migraine headaches.

What does it do?

Ergoloidis a drug that inhibits the enzyme that is involved in the breakdown of catecholamines. Catecholamines are the chemicals that transmit signals from the brain to the rest of the body. The drug is used to treat patients with hypertension, pheochromocytoma and cardiac failure. It is also used to treat migraine headaches.

How does it work?

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Erlotinibis a drug that inhibits
 
Response: Erlotinibis a drug that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Erlotinib has been shown to improve survival and quality of life in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) when used as first-line therapy ([@bib5]; [@bib15]; [@bib22]; [@bib1]; [@bib2]; [@bib6]; [@bib13]; [@bib14]).

Toxicity is the major dose-limiting side effect of erlotinib. The most common erlotinib-related adverse events (AEs) include rash, diarrhoea, nausea, vomiting, headache, asthenia, cough, anorexia, dyspnoea, paronychia, mucositis, stomatitis, photosensitivity and infections. The most common
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Erythritolis a drug that inhibits
 
Response: Erythritolis a drug that inhibits angiogenesis, and which is currently in clinical trials for cancer. It has been suggested that this agent may also be effective for the treatment of AMD (reviewed in Ross, et al., Am. J. Ophthalmol. 2004, 142, 628-635).
Vascular endothelial growth factor (VEGF) has been identified as a key mediator of neovascularization in AMD (Connolly, et al., Br. J. Ophthalmol. 2002, 86, 1193-1198; Connolly, et al., Exp. Eye Res. 2002, 73, 459-465; Ferrara, et al., Endocrine. 2001, 12, 195-202; Linn, et al., Invest. Ophthalmol. Vis. Sci. 2000, 41, S244-S250; Nakamura, et al., Arch. Ophthalmol. 2000, 118, 40-45; Quig
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  erythromycinis a drug that inhibits
 
Response: erythromycinis a drug that inhibits chitin synthesis in pathogenic fungi, and the idea of using it as a potential drug is being studied \[[@CR41]\].

An interesting possibility is the use of phytocannabinoids (including CBD) to increase crop yields and/or tolerance to drought stress. The fact that both CBD and ARA have been shown to induce stress tolerance in plants is promising, since this trait is essential to survive in the presence of drought and other stresses \[[@CR42]\]. For instance, ARA induces the expression of *LEA proteins* (late embryogenesis abundant proteins), which are protective proteins that prevent the dehydration of the cells and, therefore, preserve plant viability \[[@CR43]\]. CBD has also been shown to induce the expression of stress tolerance-related genes in plants, and CBD-treated plants were able to maintain their photosynthetic activity at a lower level than control plants in a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Erythromycinis a drug that inhibits
 
Response: Erythromycinis a drug that inhibits the growth of all gram-positive bacteria and many gram-negative bacteria. The most common cause of infection with erythromycin is Staphylococcus aureus. 
Erythromycin is the most commonly prescribed drug in the world. Erythromycin is an antibiotic used to treat a variety of infections, including respiratory infections, skin infections, urinary tract infections, and sexually transmitted diseases.

Contents

The following side effects are known to occur when taking erythromycin. If any of these effects persist or worsen, please consult your doctor or pharmacist.

Allergic reactions

Nausea

Vomiting

Diarrhea

Constipation

Abdominal cramps

Flatulence

Rash

Itching

Hives

Sore throat

Muscle or bone pain

Swelling of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Escitalopramis a drug that inhibits
 
Response: Escitalopramis a drug that inhibits serotonin reuptake in the brain. It is used to treat depression and is usually prescribed for periods of up to 12 weeks. It is a selective serotonin reuptake inhibitor (SSRI). It is manufactured by AstraZeneca.

If you are thinking of using escitalopram, you will need to discuss this with your doctor. You should not use escitalopram if you are allergic to it. You should not use it if you have a history of bleeding in the brain, liver problems, or low blood pressure. If you are pregnant, it is not recommended that you use escitalopram.

Escitalopram is available as a tablet that you take by mouth once a day. It can also be given as a subcutaneous injection once a day.

How does escitalopram work?

Escitalopram works by inhibiting the reuptake of serotonin in the brain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Esmololis a drug that inhibits
 
Response: Esmololis a drug that inhibits the cytochrome P450 enzymes and, therefore, increases the levels of the substrate of these enzymes, cyclosporine. Cyclosporine is a powerful immunosuppressant drug that has revolutionized the treatment of many immune-mediated diseases. The drug is widely used for the prevention of allograft rejection after organ transplantation and is also used for the treatment of psoriasis, Crohn's disease, and rheumatoid arthritis. Because of its many uses, it is a common cause of drug-induced hepatotoxicity. The drug also has many side effects, including hypertension, nausea, vomiting, hirsutism, amenorrhea, gingival hyperplasia, and hypertrichosis. In most cases, the side effects are dose-related and can be minimized by the use of lower doses. However, some patients are at increased risk of developing serious side effects, and there is a need for alternative
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Esomeprazoleis a drug that inhibits
 
Response: Esomeprazoleis a drug that inhibits the action of the enzyme H+/K+-ATPase (or H+-K+-ATPase) on the surface of the gastric parietal cells, resulting in an increased production of gastric acid (HCl) in the gastric lumen. The drug is marketed as Odomzo® and Zantac®. The chemical name for esomeprazole is 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole, 1,2-dihydro-5-methyl-2-(4-pyridinylmethylsulfinyl)-1H-benzimidazole, and 5-methoxy-1-[[[4-(3-methoxypropoxy)phenyl]methyl]sulf
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  estradiolis a drug that inhibits
 
Response: estradiolis a drug that inhibits the development of uterine fibroids. Aromatase inhibitors are the most effective drugs for treating women with this condition. This review describes the pathogenesis of uterine fibroids and summarizes the clinical trials and meta-analyses of aromatase inhibitors in the treatment of uterine fibroids. In addition, this review provides a detailed summary of the recent advances in the treatment of this disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Estradiolis a drug that inhibits
 
Response: Estradiolis a drug that inhibits the aromatase enzyme, which is responsible for the conversion of androgens to estrogens in the ovaries and adrenal glands. The administration of estradiol to postmenopausal women results in a significant decrease in serum levels of estrogens and a parallel increase in serum levels of androgens. The estrogen/androgen ratio is significantly increased in postmenopausal women compared to premenopausal women, and the ratio of estrogen to androgen in the serum of postmenopausal women is an important determinant of bone density.
As a consequence of these observations, a number of studies have been conducted in the last decade to evaluate the effects of estradiol on bone mass. In one study, serum estradiol levels were found to be inversely correlated with the bone density of the lumbar spine (Shibata, T., et al., J. Bone Miner. Res. (1992) 7:699-705). Another study
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Estramustineis a drug that inhibits
 
Response: Estramustineis a drug that inhibits the growth of prostate cancer cells and that has been used to treat patients with hormone-resistant prostate cancer. However, it has limited therapeutic activity and is only effective in approximately 50% of patients. In particular, it has been reported that most patients develop resistance to this drug within approximately 2 years of treatment. The mechanisms underlying the development of resistance to this drug are still not fully understood. However, it has been suggested that the main mechanisms underlying resistance to this drug involve: (1) the overexpression of DNA repair enzymes such as the human DNA repair enzyme ERCC1, which has a role in repairing damaged DNA; (2) the overexpression of transcription factors, such as the human nuclear factor I/C, which has a role in regulating the expression of genes involved in the response to drugs; (3) the activation of the expression of growth factors such as vascular endothelial growth factor, which has a role in promoting angiogenesis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Estriolis a drug that inhibits
 
Response: Estriolis a drug that inhibits cancer growth in the testes. We are already working on a new project to understand how to deliver the drugs in a more targeted way.

“What we are doing here is very simple,” says Doctor Schumacher. “We have removed the genes that make testosterone. This allows the body to make its own testosterone.”

But they need your help to continue the research. “This is a one-off project and is really just a proof of concept. We need more funding to build on this work.”

But what does the future hold?

“I believe that within a few years, we will have a cure for infertility in the mouse,” says Doctor Schumacher. “In a few years, this work will be used to cure other cancers in the testes. And we can take that work to the next level.”

If you would
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ESTROGENICis a drug that inhibits
 
Response: ESTROGENICis a drug that inhibits growth in both breast and ovarian cancer cells. It is thought to work by interfering with a signalling pathway called the mTOR pathway, which is important in cancer cell growth.

HOW DOES IT WORK?

DESTROGENICIS A drug that inhibits growth in both breast and ovarian cancer cells. It is thought to work by interfering with a signalling pathway called the mTOR pathway, which is important in cancer cell growth.

IS IT SAFE?

YES

The drug is very well tolerated and is not associated with any serious side effects.

WHAT DO THE RESEARCH TRIALS SHOW?

It has been shown to be effective in combination with tamoxifen in breast cancer.

It is also being investigated in combination with chemotherapy in ovarian cancer.

The results of the drug's effectiveness in breast cancer have been very encouraging.

The results of the drug's effectiveness in ovarian
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ETC-1002is a drug that inhibits
 
Response: ETC-1002is a drug that inhibits angiogenesis, which is a process by which new blood vessels form in the body. This is how the growth of cancer and other diseases are facilitated. It is important to understand that the development of cancer is a multistep process and the endothelial cells, which line the blood vessels, are the first to be involved. The initial stages of angiogenesis are therefore important to control and reduce the number of endothelial cells in the body. By blocking angiogenesis, the number of endothelial cells in the body is reduced and this in turn has an effect on the growth of cancer.

How does it work?

As mentioned above, the endothelial cells are the first cells involved in angiogenesis. This is why it is important to understand that drugs such as ETC-1002 are only effective if they can reach these cells before they have the chance to proliferate. If this is not possible, the drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethacridineis a drug that inhibits
 
Response: Ethacridineis a drug that inhibits DNA and RNA synthesis by blocking the activity of topoisomerase II. It is a broad spectrum anti-tumor agent and is used in the treatment of various cancers including acute leukemia, acute lymphoblastic leukemia, ovarian cancer, and small cell lung cancer. It has also been used to treat cutaneous T cell lymphoma.

A common side effect of etacridine is bone marrow suppression, which may lead to anemia, leukopenia, and thrombocytopenia. This is a very serious side effect and must be taken into account when prescribing etacridine.

What is etacridine used for?

Etacridine is a potent inhibitor of topoisomerase II. This enzyme is responsible for relaxing the topological strain of DNA that is caused by the winding of the DNA helix around itself. This enzyme is also essential for transcription and replication. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethacrynateis a drug that inhibits
 
Response: Ethacrynateis a drug that inhibits the synthesis of DNA and RNA, and is used in combination with other anticancer drugs to treat cancers of the breast, prostate, and colon. It is the 3-hydroxy analogue of the chemotherapeutic agent, bleomycin.

Research
Ethacrynateis an antineoplastic drug used in combination with other drugs in the treatment of cancer. It is the 3-hydroxy analogue of the chemotherapeutic agent, bleomycin. The mechanism of action of ethacrynateis as an anticancer drug is unknown. It has been reported to inhibit DNA and RNA synthesis. Ethacrynatehas been found to be a potent inhibitor of thymidylate synthetase, which is the enzyme that converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). This inhibits the production of thymidine triphosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethacrynicis a drug that inhibits
 
Response: Ethacrynicis a drug that inhibits the transport of anions (or cations) across the blood-brain barrier. In particular, ethacrynic acid (also known as 2-amino-3-methoxy-1,4-naphthoquinone, or ethacrynic acid, or 2-amino-3-methoxy-1,4-naphthoquinone) is an effective diuretic and natriuretic agent that has been used for the treatment of congestive heart failure. It has also been used for the treatment of glaucoma and edema. Ethacrynic acid is a poorly soluble, slightly acidic, water-soluble drug that is hydrolyzed in the body to its active metabolite, 2-amino-3-methoxy-1,4-naphthoquinone. The solubility of ethacrynic acid is low in a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethambutolis a drug that inhibits
 
Response: Ethambutolis a drug that inhibits the growth of fungi, such as Candida albicans. There are many side effects with this drug. It is recommended that you do not use this medication if you have an infection in the mouth. Also, do not use this medication if you have been prescribed any other medications to treat an infection.

Epinephrine

Epinephrine is a drug that helps to increase blood pressure. It is used to treat allergic reactions and severe asthma attacks.

Exforge

Exforge is a drug that helps to lower blood pressure. It is used to treat high blood pressure and heart failure. It is also used to treat heartburn and to relieve symptoms of an ulcer.

Fluconazole

Fluconazole is a drug that treats fungal infections. It is used to treat Candida albicans infections of the skin, mouth, vagina, and urinary tract. It may also be used to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethamsylateis a drug that inhibits
 
Response: Ethamsylateis a drug that inhibits the production of urine by the kidney. It is used to treat infections caused by a certain type of bacteria that causes cystitis, a bladder infection. It is also used to treat bladder cancer.

Esterphenes, which is a type of NSAID (non-steroidal anti-inflammatory drug), works by inhibiting the activity of an enzyme called cyclooxygenase.

Esterphenes is used to treat a number of conditions, including painful menstrual cramps, to relieve the symptoms of rheumatoid arthritis, and to reduce inflammation in patients with osteoarthritis. It is also used to treat fever, pain and inflammation of the gums and throat, and to reduce swelling, pain and inflammation caused by inflammation of the digestive tract, including the esophagus, stomach and intestine.

Esterphenes is a prescription medicine that must be taken by mouth.

Possible Side Effects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethanolamineis a drug that inhibits
 
Response: Ethanolamineis a drug that inhibits tumor cell proliferation and can prevent tumor growth and metastasis in experimental models. The goal of this project is to identify the molecular mechanisms by which ethanolamine inhibits tumor cell proliferation and growth. Recent results from our laboratory suggest that ethanolamine inhibits growth by increasing intracellular levels of cyclic AMP and inhibiting protein kinase A (PKA). We hypothesize that ethanolamine inhibits growth by decreasing cyclic AMP-dependent protein kinase (PKA) activity, which results in the activation of c-myc and the repression of the cell cycle inhibitor p21WAF1/Cip1. The specific aims of this project are: 1) to test the hypothesis that ethanolamine increases cyclic AMP and inhibits PKA, 2) to determine the role of cyclic AMP and PKA in ethanolamine-mediated inhibition of tumor cell proliferation, and 3) to determine the role of c-myc and p21W
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethisteroneis a drug that inhibits
 
Response: Ethisteroneis a drug that inhibits androgen production.

It has been marketed in some countries as a combined oral contraceptive pill, and is available in some European countries under the trade name Ortho-Cyclen. It is used as an injectable contraceptive in combination with a progestogen, and in the treatment of hirsutism and acne. It is also used to treat premenstrual dysphoric disorder and endometriosis.

Indications

Indication

Dosage

Duration of treatment

Estrogen only contraception

5 mg/day

21 days

Combined oral contraceptive

50–150 mg/day

21 days

Injectable contraceptive

75 mg/week

3 months

Treatment of hirsutism

2.5 mg/day

4 weeks

Treatment of acne

100 mg/day

6 months


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethotoinis a drug that inhibits
 
Response: Ethotoinis a drug that inhibits enzymes that convert a chemical called acetylcholine into an active form of that chemical. The enzyme that converts acetylcholine into acetylcholine is called acetylcholinesterase. Acetylcholine is a chemical that is found in the nerves and the brain. Acetylcholine is released into the brain to send signals from one nerve cell to another. Acetylcholine also helps muscles to contract and to send signals from the brain to muscles. Acetylcholine also helps the heart to beat and the lungs to work.

Nembutal is used to treat people who have had a stroke. Nembutal is also used to help people who are dying from other causes, such as cancer, to go peacefully. Nembutal is also used to help people who have had a heart attack or a problem with the circulation of their blood. Nembutal helps to stop the heart from beating so
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ethoxzolamideis a drug that inhibits
 
Response: ethoxzolamideis a drug that inhibits carbonic anhydrase in the cornea, which leads to a decrease in corneal hydration and thereby reduces corneal swelling. It has been used in combination with soft contact lenses to treat keratoconus.  It is marketed as Alphagan in the United States and Australia, and Lumigan in Canada and Europe.

Side effects 
There are many reports of possible side effects with the use of dorzolamide, including allergic reactions, systemic side effects, and elevated intraocular pressure.

Chemistry 

Dorzolamide is a white crystalline solid that is soluble in acetone, ethanol, and chloroform.  The chemical formula of dorzolamide is C15H17N3O3.  It is the conjugate base of dorzolamide hydrochloride.

Mechanism of action 

The active ingredient in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethylparabenis a drug that inhibits
 
Response: Ethylparabenis a drug that inhibits the growth of the prostate gland. In a study of 3,000 men, only 2 had prostate cancer and the number was small. But because there is a possibility that this drug may cause prostate cancer, it is best to be cautious.

Do not use diuretics if you have a history of prostate cancer. Diuretics can cause the prostate to enlarge and cancer can spread to the lymph nodes.

Nursing Mothers: There are no adequate studies in pregnant women, but use is probably safe. However, parabens are known to cross the placenta and have been found in breast milk. Women should not breastfeed.

Children: Not recommended for children.

Pregnancy Category C. It is not known whether this drug can cause birth defects or other problems in unborn babies. Women who are pregnant or may become pregnant should not take this medication. It is also not known whether it passes into breast
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ethynodiolis a drug that inhibits
 
Response: Ethynodiolis a drug that inhibits a key enzyme in the body's production of estrogen.

Ethynodiolis is used to treat breast cancer.

It works by blocking the enzyme aromatase.

This enzyme converts androgens to estrogens.

How does ethynodiolis work?

Ethynodiolis works by blocking the enzyme aromatase.

This enzyme converts androgens to estrogens.

This conversion is needed for the body to produce estrogen.

This conversion is needed for the body to produce estrogen.

Ethynodiolis inhibits the aromatase enzyme and reduces the amount of estrogen produced in the body.

When ethynodiolis is taken by mouth, it works by inhibiting the aromatase enzyme.

When ethynodiolis is taken by mouth, it works by inhibiting the aromatase enzyme.

The aromatase enzyme
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etidronateis a drug that inhibits
 
Response: Etidronateis a drug that inhibits the activity of the enzyme farnesyl diphosphate synthase (FPPS) and consequently blocks the synthesis of the prenyl diphosphate farnesyl diphosphate (FPP). FPPS is a rate-limiting enzyme of the mevalonate pathway and is therefore important for the production of cholesterol and other important lipids in the body. Etidronate, and a series of related compounds, have been used to treat hypercalcemia, Paget's disease, and bone resorption diseases. (Etidronate is the commercial name for ethylidene bis-hydroxymethylene bis-phosphonic acid).
Etidronate and a series of related compounds have been disclosed in U.S. Pat. Nos. 4,670,444; 4,847,216; 4,957,829; 4,957,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etodolacis a drug that inhibits
 
Response: Etodolacis a drug that inhibits prostaglandin synthetase, which is responsible for the production of prostaglandins. It is used for the relief of mild to moderate pain and to treat arthritis.

Dosing

The usual dosage is 200 to 400 mg taken 3 times daily. It may be used as needed for up to 4 weeks. The drug should not be used for more than 8 weeks at a time.

Contraindications

Doses of 100 mg or more should not be used in patients with history of asthma or other allergic reactions. Use of the drug is contraindicated in patients with:

Etodolac is not recommended for patients with liver disease.

Side Effects

The most common side effects are stomach upset, headache, diarrhea, nausea, and constipation.

Warnings/Precautions

The drug should be used with caution in patients with history of asthma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etofenamateis a drug that inhibits
 
Response: Etofenamateis a drug that inhibits cyclooxygenase and inhibits the production of prostaglandins.

Etofenamate is marketed as Arthrotec (trade name) and Eluxadol (trade name) for the treatment of pain and inflammation.

Uses of Etofenamate

Etofenamate is used for the relief of mild to moderate pain and inflammation.

Side Effects of Etofenamate

There is no information available on the possible side effects of Etofenamate.

There is no information available on the safety of Etofenamate in the
following conditions:

Pregnancy

Breastfeeding

Children

Geriatric population

Lactating women

Diabetes

Kidney disease

Warnings & Precautions

Before using Etofenamate, tell your doctor or pharmacist if you are allergic to it; or to other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etofibrateis a drug that inhibits
 
Response: Etofibrateis a drug that inhibits the synthesis of hepatic VLDL (very low density lipoprotein) in the liver. As the plasma concentration of VLDL is reduced, the concentration of LDL (low density lipoprotein) and HDL (high density lipoprotein) increases. The effect of Etofibrate is most apparent in hypertriglyceridemia and in hypercholesterolemia. However, it also has beneficial effects in hypertriglyceridemia in which hyperlipidemia is due to increased production of triglyceride-rich lipoproteins (TRL) by the liver. TRL are very large lipoproteins which are removed from the blood by lipoprotein lipase (LPL) and are metabolized by the liver. This action of Etofibrate lowers the concentration of TRL, and as a consequence, lowers the concentration of plasma triglycerides and cholesterol.
The most commonly used oral
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etomidateis a drug that inhibits
 
Response: Etomidateis a drug that inhibits the stress response in the hypothalamus and has been used to reduce the stress response in surgical patients. Etomidate reduces blood pressure, heart rate, oxygen consumption, and lactate levels in surgical patients. In one study, patients were given etomidate or fentanyl/propofol and underwent an elective abdominal surgery. Postoperatively, the patients given etomidate had significantly less oxygen consumption and heart rate than the patients given fentanyl/propofol. (Mayo Clinic, A. P. Chen et al. “Etomidate as an Analgesic and Anesthetic Sedative in Patients Undergoing Elective Abdominal Surgery,” Anesthesiology, Vol. 97, pp. 1150-1156 (2003).)
In addition, etomidate has been shown to be useful for patients undergoing neurosurgery, particularly for those with a high risk of postoperative neurological deficits. (J. F.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Etoposideis a drug that inhibits
 
Response: Etoposideis a drug that inhibits the enzyme topoisomerase II (TOP2) and thereby causes cell death. TOP2 is an enzyme that cuts and religates DNA strands during the DNA replication process. Because TOP2 is involved in the regulation of the genetic material, inhibition of TOP2 can cause cell death and affect the genetic material. Etoposide can be used to treat a number of types of cancer, including testicular, lung, head and neck, breast, and bladder cancer.
In addition to cancer treatment, etoposide can be used to treat malaria. Malaria is a deadly disease that infects humans and causes the death of over a million people each year. Current treatment for malaria involves a combination of at least three drugs. However, there are some concerns about the side effects of the combination of drugs. For example, quinine can cause allergic reactions in some patients.
Etoposide has been used to treat malaria in mice.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  etravirineis a drug that inhibits
 
Response: etravirineis a drug that inhibits the HIV protease. In clinical trials, it has shown modest efficacy. A dose of 200mg, twice a day, is recommended.

**CYPROTEC:** Induces or enhances the immunologic effects of granulocyte-macrophage colony-stimulating factor.

**DABISCOVIR:** (HIV-1 integrase inhibitor) An integrase strand transfer inhibitor (INSTI) with a potent activity against HIV-1. It has been shown to be superior to other antiretroviral drugs.

**DELAVIR:** (Indinavir) A protease inhibitor. It is used in combination with ritonavir.

**DRUG:** (HIV-1) Protease inhibitor.

**DUPA:** (Azidothymidine) An inhibitor of the reverse transcriptase enzyme, used in combination with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Everolimusis a drug that inhibits
 
Response: Everolimusis a drug that inhibits mTOR. It is used to treat some cancers. Everolimus is a non-specific mTOR inhibitor, and it does not only target mTOR but also other kinases and proteins, such as tuberous sclerosis complex (TSC), AKT, p70 S6K, and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1).

Everolimus was approved by the US FDA in 2011 for use in combination with exemestane and/or letrozole in women with HR+/HER2− advanced breast cancer who have previously received endocrine therapy. It was also approved for the treatment of adult patients with renal cell carcinoma (RCC) after failure of prior therapy.

Everolimus was developed by Novartis, and is marketed by Novartis under the trade name Certican. The recommended dose of everolimus is 10 mg orally once daily
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Evistais a drug that inhibits
 
Response: Evistais a drug that inhibits the activity of the renin-angiotensin system (RAS). This system plays an important role in the development of hypertension and other cardiovascular diseases. The purpose of the present study was to investigate the effect of Evista on endothelial function in normotensive and hypertensive patients. A total of 23 patients with hypertension (12 men and 11 women) and 23 healthy subjects (12 men and 11 women) were included in the study. All the subjects underwent echocardiography and radial artery tonometry. In addition, an endothelium-dependent vasodilation test was performed. Baseline data were similar in the two groups. In the hypertensive group, after the Evista treatment, the flow-mediated vasodilation was significantly higher than the pre-Evista value (7.14 ± 1.5 vs. 5.05 ± 1.1%, p < 0.05). In the control group, no significant changes were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Evobrutinibis a drug that inhibits
 
Response: Evobrutinibis a drug that inhibits the tyrosine kinase activity of the BCR-ABL fusion protein, a key driver of chronic myeloid leukemia (CML). Its safety and efficacy were established in a pivotal phase III trial ([@r1]).

CML is a rare disease, with an estimated incidence of 1 in 100,000 in the general population ([@r2]). The disease is typically diagnosed between the ages of 15 and 40 years, with a median age of diagnosis of 31 years ([@r3]). There is a peak incidence in the third decade of life, followed by a slight decline in incidence after age 50 ([@r3]). The disease is most common in men, and there is a slightly higher incidence of the disease in whites compared with other ethnic groups ([@r3]). The disease is characterized by the expansion of a myeloid precursor cell with a reciprocal translocation of chromosome 9 and 22, resulting in a fusion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Evodiamineis a drug that inhibits
 
Response: Evodiamineis a drug that inhibits Na+/K+-ATPase, an enzyme that is present in the basolateral membrane of renal epithelial cells. This drug has been shown to increase blood urea nitrogen and serum creatinine levels. The latter effect was more pronounced in patients with impaired renal function. In addition, this drug has been associated with severe, sometimes fatal, renal failure. Because this drug has a half-life of only 2 hours, it is important to consider its use with caution.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EW-7197is a drug that inhibits
 
Response: EW-7197is a drug that inhibits protein kinase C (PKC) activity and acts as a calcium antagonist. The drug is an effective inhibitor of T-cell activation and interleukin-2 production in vitro. We examined the effect of the drug on natural killer (NK) cell activity in vivo and in vitro. Injection of the drug in mice led to a significant decrease in the number of cells recovered from spleens, peritoneal exudates, and bone marrow. In contrast, in vitro incubation of cells with the drug in the presence of interleukin-2 had no effect on NK cell activity. These data suggest that the inhibitory effect of the drug on NK cell activity is mediated by a mechanism other than the direct effect on the cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Exemestaneis a drug that inhibits
 
Response: Exemestaneis a drug that inhibits the action of estradiol on the estrogen receptors, thereby reducing the effect of estradiol in the body. The side effects associated with the use of exemestane include hot flashes, vaginal dryness, and nausea.

Exemestane is a steroidal estrogen, and like other estrogen hormones, it binds to the estrogen receptor and stimulates the growth of the breasts, uterus, and vagina. The exact mechanism by which exemestane causes these effects is unknown, but it appears that the hormone’s action on the breast tissue is mediated through the estrogen receptor.

Exemestane is used to treat breast cancer and can also be used to treat prostate cancer.

Exemestaneis a drug that inhibits the action of estradiol on the estrogen receptors, thereby reducing the effect of estradiol in the body. The side effects associated with the use of exemestane include hot flashes,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EXJADEis a drug that inhibits
 
Response: EXJADEis a drug that inhibits the absorption of estrogen from the intestines, thereby decreasing the amount of estrogen circulating in the body. It is indicated for the treatment of conditions caused by excessive production of estrogen, such as endometriosis, and for relief of premenstrual syndrome. It is also used in combination with a progestin for emergency contraception and treatment of endometriosis.

EXJADE is a synthetic, oral progestin. It is the progestin component of the oral contraceptive pill (OCP) "Celestodal". It is available in the form of an injectable preparation, as well as a tablet and film.

Exjade is an estrogenic progestin used in the treatment of endometriosis. It acts as an anti-progestin, meaning that it opposes the action of progesterone.

How to use EXJADE

Take EXJADE by mouth once a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  EZETIMIBEis a drug that inhibits
 
Response: EZETIMIBEis a drug that inhibits the enzyme ezetimibe (EZT), which lowers cholesterol by inhibiting the absorption of cholesterol from the intestine. Ezetimibe is approved for the treatment of primary hypercholesterolemia in combination with a HMG-CoA reductase inhibitor. It is also used for the treatment of mixed dyslipidemia in combination with other lipid-lowering medications.

EZETIMIBEis a drug that inhibits the enzyme ezetimibe (EZT), which lowers cholesterol by inhibiting the absorption of cholesterol from the intestine. Ezetimibe is approved for the treatment of primary hypercholesterolemia in combination with a HMG-CoA reductase inhibitor. It is also used for the treatment of mixed dyslipidemia in combination with other lipid-lowering medications.

Other names:

EZT

Ezetimibe

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fadrozoleis a drug that inhibits
 
Response: Fadrozoleis a drug that inhibits aromatase, a key enzyme in the conversion of androgens to estrogens.

Fadrozole was approved in the US in 1992 for the treatment of metastatic breast cancer. The drug has been shown to prolong survival in patients with hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer and in patients with advanced breast cancer. In a large randomized trial, fadrozole was found to be superior to tamoxifen in terms of disease-free survival.

The recommended dose of fadrozole is 2.5 mg per day for 5 days of every month, or 10 mg per day for 5 days of every month.

Fadrozole is a prodrug and it is converted to fadrozole-metabolite that has higher aromatase inhibitory activity.

There are two types of fad
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Famcicloviris a drug that inhibits
 
Response: Famcicloviris a drug that inhibits the action of cytokines, including interleukin-1, is approved for the treatment of rheumatoid arthritis (RA). In a phase 2 trial, patients with moderate to severe RA were treated with intravenous (i.v.) doses of famciclovir (FAM; 100 mg/m2/day for 2 days) or methotrexate (MTX; 7.5 mg/week for 2 weeks). Patients were randomized to receive an additional 2 weeks of FAM (200 mg/m2/day for 2 days) or MTX (7.5 mg/week for 2 weeks). Efficacy was assessed at week 4, and safety was evaluated at week 6. A total of 84 patients were randomized. No statistically significant differences were observed in disease activity measures, as well as in the efficacy and safety profiles of the two treatment groups. The number of adverse events was significantly lower in the MT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Famotidineis a drug that inhibits
 
Response: Famotidineis a drug that inhibits gastric acid secretion by the interaction of the drug with histamine H2 receptors, thereby preventing the formation of histamine in the parietal cells of the stomach. Famotidine is a synthetic analogue of histamine, which has been chemically modified to have a longer half-life, greater oral bioavailability, and greater potency. It has been shown to be effective in the treatment of gastric and duodenal ulcers and gastric acid hypersecretion in patients with Zollinger-Ellison syndrome, a rare cause of gastric acid hypersecretion. Famotidine has also been shown to be effective in the treatment of gastric ulcers, erosive oesophagitis, and reflux oesophagitis, and has been used as a gastric antisecretory agent in patients with non-ulcer dyspepsia.
The chemical name of famotidine is (4R)-2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Farrerolis a drug that inhibits
 
Response: Farrerolis a drug that inhibits the immune system and causes diarrhea, weight loss, and fever.

While some people may tolerate it, the majority of people who take farrolis end up with diarrhea and other gastrointestinal problems.

SJS is a severe and potentially fatal skin reaction.

SJS is a severe and potentially fatal skin reaction.

Farerolis is a drug that inhibits the immune system and causes diarrhea, weight loss, and fever.

While some people may tolerate it, the majority of people who take farrolis end up with diarrhea and other gastrointestinal problems.

SJS is a severe and potentially fatal skin reaction.

SJS is a severe and potentially fatal skin reaction.

Farerolis is a drug that inhibits the immune system and causes diarrhea, weight loss, and fever.

While some people may tolerate it, the majority of people who take farrolis end up with diarrhea and other gastrointestinal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fasudilis a drug that inhibits
 
Response: Fasudilis a drug that inhibits the activity of Rho-associated protein kinase (ROCK), a key downstream effector of Rho GTPase. In a phase II trial of Fasudil in patients with acute stroke, Fasudil treatment significantly reduced the proportion of patients who died or had an increased NIH Stroke Scale score at 90 days (from 21.1% to 14.8%, P = 0.034) ([@B1]). Moreover, the same group also showed that Fasudil reduced the occurrence of a second stroke and improved long-term neurological outcome in patients with acute stroke. In addition, the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Scale score at 90 days was significantly better in the Fasudil group than in the control group (3.5 ± 3.4 vs. 2.7 ± 2.8, P = 0.034) ([@B2]). However, the trial did
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FCE28073is a drug that inhibits
 
Response: FCE28073is a drug that inhibits T-cell proliferation. This effect is associated with the inhibition of aryl hydrocarbon receptor nuclear translocator (ARNT) protein, and it is not mediated by the inhibition of IL-2 transcription. Our findings show that, although the exact mechanism of action is not known, CFE28073 is a promising new drug candidate for the treatment of autoimmune diseases.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FDL169is a drug that inhibits
 
Response: FDL169is a drug that inhibits HIV-1 replication.

Introduction {#sec1}
============

HIV-1 is a pathogenic retrovirus that has caused a global epidemic and continues to be a major public health problem. A growing number of approved drugs have been developed to treat HIV-1 infection, but treatment of HIV-1 infection is still a challenge. Many patients fail to respond to therapy and viral replication can be restored by the emergence of drug-resistant virus.^[@ref1]^ The first approved drug, AZT, was a nucleoside reverse transcriptase inhibitor (NRTI), which is used to treat HIV-1 infection.^[@ref2]^ Currently, there are nine NRTIs in clinical use, including AZT, tenofovir disoproxil fumarate (TDF), abacavir, lamivudine, emtricitabine, nevirapine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Febuxostatis a drug that inhibits
 
Response: Febuxostatis a drug that inhibits the production of the hormone oxytocin. It is usually used to prevent or treat preterm contractions, and may be used to treat uterine atony or uterine inertia, or as a cervical ripening agent. It is also used to prevent or treat postpartum hemorrhage, including atonic bleeding. It is also used to prevent or treat preterm labor. It is also used to treat and prevent postpartum hemorrhage, and as a cervical ripening agent.

Beclomethasone a drug that inhibits the production of the hormone cortisone. It is used to prevent and treat inflammation and allergic reactions. It is also used to treat skin diseases, such as eczema and dermatitis.

Bendroflumethiazide a drug that inhibits the production of the hormone aldosterone. It is used to treat high blood pressure, such as hypertension.

Benfotiamine a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Felbamateis a drug that inhibits
 
Response: Felbamateis a drug that inhibits the cytochrome P450 enzymes that metabolize many other drugs, including the major liver enzyme involved in the metabolism of acetaminophen (the active ingredient in Tylenol). In clinical trials, it was associated with a higher incidence of liver failure than other antiepileptic drugs (AEDs).2 The US Food and Drug Administration (FDA) has approved the use ofFelbamatein combination with another AED for the treatment of partial seizures. This report summarizes a warning that was issued by the FDA on the labeling of the drug.

Background

Felbamate was developed in the 1980s as an anticonvulsant for the treatment of epilepsy. It was approved in the United States in 1996 for the treatment of partial seizures. It is marketed as a generic drug. It has been approved in Europe since 1992 and in Canada since 1994.

The FDA and other agencies in Europe have received a number
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FELDENEis a drug that inhibits
 
Response: FELDENEis a drug that inhibits the synthesis of melanin. Melanin is the dark pigment found in the skin and hair of all humans and animals. The normal skin and hair color is determined by the presence or absence of melanin in the skin and hair. If melanin is present in the skin and hair, the skin and hair will be dark. If melanin is absent, the skin and hair will be light. The FELDENEis used in cosmetics to lighten the skin. The FELDENEis is applied to the skin by spraying, rubbing or wiping.

BACKGROUND: An injection of the alpha-2-adrenoceptor agonist clonidine was reported to induce miosis in humans, but the effect of clonidine on pupillary diameter in rodents is controversial. METHODS: The effects of a single injection of clonidine on pupillary diameter in Sprague-Dawley rats and Mongolian gerbils were examined
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Felodipineis a drug that inhibits
 
Response: Felodipineis a drug that inhibits the action of angiotensin II. Angiotensin II is the major effector hormone in the renin-angiotensin-aldosterone system (RAAS). It plays a key role in regulating blood pressure, body fluid volume, and blood volume. Angiotensin II increases vasoconstriction, vasopressin release, aldosterone release, and sympathetic nerve activity. These responses cause increased cardiac output, increased arterial blood pressure, and increased fluid retention, respectively.

Felodipine is a dihydropyridine calcium antagonist. It is an analog of nifedipine and a member of the verapamil family of calcium channel blockers.

Felodipine is a vasodilator and also a weak negative inotropic agent. It blocks calcium channels in the heart and vascular smooth muscle. Felodipine blocks the slow component of the delayed rectifier potassium current
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenbendazoleis a drug that inhibits
 
Response: Fenbendazoleis a drug that inhibits cytochrome P450 (CYP) 1A2 and 3A4. The objectives of this study were to evaluate the pharmacokinetics of fenbendazole and its metabolites after a single oral dose in patients with hepatic impairment and in patients receiving or not receiving a strong CYP3A4 inducer. After obtaining written informed consent, 20 patients were enrolled in this open-label, single-dose, parallel-group, pharmacokinetic study. Patients received either 20 mg of fenbendazole (n = 10) or placebo (n = 10). Blood samples were collected up to 120 hours after dosing and were analyzed for fenbendazole and its metabolites, fenbendazole sulfoxide, fenbendazole sulfone, and N-desmethyl fenbendazole. Patients with moderate hepatic impairment (Child-Pugh Class B)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenbufenis a drug that inhibits
 
Response: Fenbufenis a drug that inhibits the action of a brain enzyme, thus affecting the levels of chemicals in the brain that produce the “feel good” chemical, serotonin.

Fenbufenis has been used in Europe for many years to help treat patients suffering from depression, but recently it has been approved by the FDA for use in the U.S. to treat acute major depressive disorder.

According to the FDA, “Fenbufenis is the first drug approved for the treatment of depression in the United States.”

It’s one of the most popular drugs for treating depression. In a recent study, people who took the drug were able to decrease their depression scores by 70 percent.

I can personally attest to the effectiveness of Fenbufenis.

Fenbufenis is an example of how science is finally making progress in the fight against depression.

What Is Depression?

Dep
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenchoneis a drug that inhibits
 
Response: Fenchoneis a drug that inhibits monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Fenchone is used in the treatment of depression, and as a fragrance additive. Fenchone has been detected in the pheromone of human sweat.

Mechanism of action

The MAO enzyme is responsible for metabolizing dopamine, norepinephrine, and serotonin in the body. Fenchone inhibits MAO-A and MAO-B by binding to the enzyme in the mitochondria. Fenchone binds to the MAO-A enzyme at a high concentration, while it binds to the MAO-B enzyme at a lower concentration.

Fenchone has a strong antioxidant effect and is considered a neurotoxin.

Effects

Fenchone has a mild sedative effect.

Fenchone is toxic to the kidneys, the liver, and the lungs.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FENOFIBRATEis a drug that inhibits
 
Response: FENOFIBRATEis a drug that inhibits an enzyme in the body that helps the body to lower the levels of a certain substance in the blood that causes plaque to build up in the arteries. This drug is used to treat certain conditions that cause the arteries to become clogged.

FENOFIBRATE (inclomiphene) is used to treat infertility in women. It is used alone or in combination with clomiphene citrate (a drug that is taken orally) to treat women who have a specific form of infertility called anovulation. FENOFIBRATE is used in combination with clomiphene citrate in women who have a specific form of infertility called polycystic ovary syndrome (PCOS). It may also be used to prevent ovulation in women who are undergoing in vitro fertilization (IVF) treatment.

FENOFIBRATE (inclomiphene) is also used to treat end
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenofibricis a drug that inhibits
 
Response: Fenofibricis a drug that inhibits the activity of peroxisome proliferator-activated receptor alpha (PPARalpha) and has been approved for use in the treatment of hypertriglyceridemia. The effect of this drug on inflammation is unknown. The aim of this study was to evaluate the effect of fenofibric acid on inflammatory parameters in vitro and in vivo. The effect of fenofibric acid on lipopolysaccharide (LPS)-induced proinflammatory cytokine production in RAW264.7 macrophages and on carrageenan-induced paw edema in rats was evaluated. In RAW264.7 cells, LPS-induced production of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha was significantly inhibited by fenofibric acid. In contrast, LPS-induced production of IL-1beta was not affected by fenofibric acid. In vivo, f
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenoprofenis a drug that inhibits
 
Response: Fenoprofenis a drug that inhibits cyclooxygenase-2 and has anti-inflammatory properties. Fenoprofen has been used to treat various types of pain. For example, it has been used to treat pain resulting from osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis.
The preparation of Fenoprofen is disclosed in U.S. Pat. No. 3,773,788. The synthesis is generally carried out in three steps. First, 2-methyl-4-phenyl-2-propionylacetic acid is reacted with thionyl chloride to form 2-methyl-4-phenyl-2-propionylthioacetyl chloride. The second step is the reaction of 2-methyl-4-phenyl-2-propionylthioacetyl chloride with a substituted phenol to form 2-methyl-4-phenyl-2-prop
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenoterolis a drug that inhibits
 
Response: Fenoterolis a drug that inhibits the release of fatty acids and inhibits the proliferation of prostate cancer cells, but it is less toxic than other existing drugs and is not currently approved for the treatment of prostate cancer.

[Click here for more Fenoterol info]

[Click here for more Fenoterol info]

[Click here for more Fenoterol info]

[Click here for more Fenoterol info]

[Click here for more Fenoterol info]

Fenoterol

Rationale: Fenoterol is a synthetic beta2-adrenergic agonist that was approved by the FDA in 1997 for the treatment of bronchospasm in patients with asthma. Fenoterol is a partial agonist of the beta2-adrenergic receptor and has high selectivity for the beta2-adrenergic receptor. Fenoterol is also an antagonist of the beta1-adrenergic receptor.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenspirideis a drug that inhibits
 
Response: Fenspirideis a drug that inhibits the action of the enzyme phosphodiesterase (PDE) type 4. It is an FDA-approved medication for the treatment of erectile dysfunction (ED) and premature ejaculation (PE). Although fenspiride is available in generic form, there is a difference in potency between generic and brand-name versions of the medication. Fenspiride is marketed as both a tablet and a liquid form.

Fenspiride is available in a variety of formulations.

Fenspiride is available in generic form, as well as under the brand name Finpecia.

Generic fenspiride tablets

Fenspiride is available in generic form as a tablet. There are two generic formulations of fenspiride. One generic tablet formulation is fenofibric acid fumarate (tablet), and the other is fenofibric acid lactate (tablet). Both formulations are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fenticonazoleis a drug that inhibits
 
Response: Fenticonazoleis a drug that inhibits cytochrome P450-dependent enzymes. It is the active metabolite offluconazole, a drug used to treat fungal infections in humans and animals. Fluconazole has a half-life of 1.5 to 3 hours in humans. Fenticonazole has a half-life of 1.5 to 3 hours in humans.

Dosage and Administration

Fenticonazole is available in the form of oral suspension. Fenticonazole is given by mouth. Dosage is based on weight.

Infection or suspected infection: 100 mg per day for at least 2 days, or until infection is resolved.

Otitis externa (swelling of the ear): 100 mg every 12 hours for 2 to 4 days, or until the infection is resolved.

Intestinal coccidiosis: 100 mg every 12 hours for 5 days.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FERNISONEis a drug that inhibits
 
Response: FERNISONEis a drug that inhibits the production of insulin by the pancreas.

2.

FUJISU is the name of a pharmaceutical company that manufactures the drug.

3.

If you are taking FUJISU, you should monitor your blood sugar levels closely.

4.

You can take FUJISU either with food or without food.

5.

The usual dose of FUJISU is 100 mg per day.

6.

The maximum dose of FUJISU is 400 mg per day.

7.

FUJISU may cause severe and sometimes fatal reactions, especially if you have low blood sugar levels.

8.

You may need to reduce the dose of FUJISU if you have liver or kidney problems.

9.

You may need to reduce the dose of FUJ
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fesoterodineis a drug that inhibits
 
Response: Fesoterodineis a drug that inhibits detrusor overactivity (DO), an abnormally increased spontaneous activity of the bladder, and that increases the tone of the bladder neck. It is a competitive antagonist of the muscarinic receptor and is used to treat overactive bladder (OAB) in women, alone or in combination with other drugs.

Contents

Fesoterodine is the 5-hydroxymethylene analogue of tolterodine, a drug that is also used to treat OAB, and that is a competitive antagonist of the muscarinic receptor.

Fesoterodine was developed by Pfizer, and has been on the market since June 2006.

The recommended dose is 8 mg twice daily, with a dose of 4 mg twice daily as an alternative. The maximum dose is 16 mg daily, taken at 8-hour intervals. The drug has a half-life of approximately 10 hours.

Fes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fexinidazoleis a drug that inhibits
 
Response: Fexinidazoleis a drug that inhibits asexual and sexual development in the
malaria parasite, Plasmodium falciparum.1 It is used in combination with
chloroquine and pyrimethamine to treat uncomplicated falciparum malaria
in adults and children over two years of age.2 It is available in oral
tablets and in a suspension for oral use. The suspension is used
in infants from two months of age to one year of age and in children
over one year of age.3

Fexinidazoleis not approved for use in the United States and is not
available in the United States.

WHAT IS THE MECHANISM OF ACTION?

Fexinidazoleis a substituted piperazine derivative. It is a nitroimidazole
antimalarial drug with a unique mode of action.4 Its antimalarial
activity
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fexofenadineis a drug that inhibits
 
Response: Fexofenadineis a drug that inhibits the enzyme cytochrome P450 1A2 (CYP1A2) and may have anti-allergic, anti-anginal, and anti-analgesic properties.1-4 It is the prodrug of the active metabolite,diflunisal, and is commonly prescribed for the relief of the symptoms of seasonal allergic rhinitis and urticaria.5 
The chemical structure of the active metabolite of fexofenadine is shown in FIG. 1.6 The chemical name of the active metabolite of fexofenadine is 5-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-1,3-dihydro-2H-1,4-benzodiazepin-2-one.7 The empirical formula is C24H32N4O2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FF-10101is a drug that inhibits
 
Response: FF-10101is a drug that inhibits CDK5, a serine/threonine kinase that is part of the CDK family. In a phase I clinical trial, single oral doses of NUCC-357 were well tolerated in patients with advanced solid tumors.

Abstract

The success of cancer immunotherapy depends on the generation of potent, tumor-specific T cells that recognize tumor antigens. The expression of MHC class I molecules on tumors is a major impediment to the generation of a tumor-specific T cell response. Although there is evidence that a number of tumor-associated antigens are naturally processed and presented on MHC class I molecules, in most cases, antigen presentation on MHC class I molecules requires transfection of tumor cells with MHC class I genes. Here we describe a method for inducing the expression of MHC class I on tumor cells using RNA interference. A short-interfering RNA was designed to target the human
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FG-4592is a drug that inhibits
 
Response: FG-4592is a drug that inhibits phosphorylation of Akt and its downstream target GSK3β in a similar way to LY294002. To determine the role of Akt in CIN25-induced apoptosis, CIN25 was incubated with CIN25 and/or LY294002 for 24 h. LY294002 (10 μM) was found to significantly inhibit CIN25-induced apoptosis (Figure [3](#F3){ref-type="fig"}A). Furthermore, LY294002 significantly reduced the number of annexin V-positive cells (Figure [3](#F3){ref-type="fig"}B). These results suggest that Akt plays a critical role in CIN25-induced apoptosis in HUVECs.

![**The PI3K inhibitor LY294002 reduces CIN25-induced apoptosis in HUVECs**.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FGF401is a drug that inhibits
 
Response: FGF401is a drug that inhibits TGFβ signaling and is used in the treatment of certain types of cancer. The effects of FGF401 on tumor cells have not been investigated. We show that FGF401 inhibits proliferation of HCT116 colon cancer cells and induces apoptosis, but not autophagy. FGF401 causes accumulation of p53 and downregulation of cyclin D1, Bcl-2, and XIAP, but has no effect on p21 or p27. FGF401 induces phosphorylation of Akt and activation of caspase-3. FGF401 treatment leads to loss of clonogenicity and tumorigenicity of HCT116 cells in vivo. Treatment of HCT116 cells with FGF401 also results in increased expression of E-cadherin and decreased expression of vimentin, fibronectin, and N-cadherin. Finally, we show that FGF401 treatment decreases migration of H
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  fidaxomicinis a drug that inhibits
 
Response: fidaxomicinis a drug that inhibits the synthesis of the toxins A and B, which are two of the most virulent components of the spore. It is known to be active against other bacterial diseases in animals and humans, including those caused by the B. anthracis bacteria. It is also active against human cancer cell lines.

Bacillus sphaericus
Bacillus sphaericus (B. sphaericus) is a species of bacteria, with spores that have the same structure as those of Bacillus anthracis. B. sphaericus is a Gram-positive, spore-forming, rod-shaped bacterium that is found in a variety of soils and waters, such as those found in soil and water that has been impacted by volcanic eruptions, as well as water that is in contact with creeks, rivers, lakes, and the like. It is also found in sea water and soils that have been impacted
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  filgotinibis a drug that inhibits
 
Response: filgotinibis a drug that inhibits the production of interleukin (IL)-31. A total of five patients with psoriasis and six healthy volunteers were enrolled in a double-blind, placebo-controlled, single-dose study. Patients received 0.5 mg/kg, 1 mg/kg or 2 mg/kg of pomalidomide with placebo or 1 mg/kg of tofacitinib. After 24 hours, the patients received a second dose of pomalidomide, tofacitinib or placebo. Plasma levels of IL-31 were measured at baseline and 0.5, 1, 2, 4, 8, 12 and 24 hours after drug administration. Pomalidomide decreased IL-31 plasma levels compared with baseline and placebo at 0.5 hours (P=0.009 and P=0.004, respectively) and at 2 hours (P=0.039 and P=0.007, respectively).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Finasterideis a drug that inhibits
 
Response: Finasterideis a drug that inhibits 5-alpha-reductase and thus prevents the conversion of testosterone into dihydrotestosterone, a potent androgen that is responsible for the development of male hair, voice and body hair. It is prescribed to treat androgenic alopecia, also known as male pattern baldness. It is also used to treat benign prostatic hyperplasia and enlargement of the prostate gland.

In 2003, the Food and Drug Administration (FDA) approved finasteride to treat androgenic alopecia in men over the age of 18, but it has been on the market since 1997. The FDA granted finasteride an indication for androgenic alopecia in the first year of approval, but it took another ten years before the agency approved it for the treatment of alopecia areata. Finasteride is also approved to treat hair loss associated with alopecia in women.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fingolimodis a drug that inhibits
 
Response: Fingolimodis a drug that inhibits the egress of lymphocytes from lymph nodes and other lymphoid tissues. It is used in the treatment of relapsing-remitting multiple sclerosis (RRMS) in patients who have had an inadequate response to a previous treatment. This article reviews the pharmacology, pharmacokinetics, clinical efficacy, tolerability, and safety of fingolimod. It discusses the mechanism of action, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, and safety of fingolimod. The article provides a brief overview of the use of fingolimod in patients with RRMS.

The purpose of this study was to examine the relationship between subjective feelings of anxiety and depressive symptoms and quality of life in multiple sclerosis (MS) patients and controls. A total of 69 MS patients and 68 healthy controls completed the Hospital Anxiety and Depression Scale (HADS), and the Multiple Sclerosis Quality of Life Inventory (MSQOL-54
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fipexideis a drug that inhibits
 
Response: Fipexideis a drug that inhibits the function of the pituitary gland, causing it to release growth hormone (GH). It works by binding to the growth hormone receptor (GHR), and stopping the hormone from attaching to the receptor. This in turn causes the pituitary gland to release less growth hormone.

The active ingredient in Fipexideis a synthetic version of a hormone called somatostatin. Somatostatin is found naturally in the body, and is released by the pituitary gland. The pituitary gland then releases growth hormone (GH) in response to this hormone. The synthetic version of somatostatin is the same as the natural hormone, but it is much more stable and has been designed to work at a much higher concentration. This means that you only need to take one dose of Fipexideis to get the same effect as taking one dose of the natural hormone.

The purpose of Fipexide
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FLAGYLis a drug that inhibits
 
Response: FLAGYLis a drug that inhibits fatty acid synthase (FASN) and reduces fatty acid synthesis. The potential therapeutic effect of this agent has been assessed in several clinical trials, including a phase I trial in cancer patients. In the phase II study, patients with advanced solid tumors received a daily dose of 200 mg of PF- 06835939, and the results were disappointing. The objective of this study was to evaluate the efficacy of a higher dose of PF- 06835939.

MATERIALS AND METHODS

The trial design and patient population were the same as in the phase I trial. The primary endpoint was the proportion of patients who had stable disease at 6 months, which was determined by an independent review committee. The secondary endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, and pharmacokinetics.

RESULTS

A total of 50 patients were enrolled, and all
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flavopiridolis a drug that inhibits
 
Response: Flavopiridolis a drug that inhibits the action of TGF-beta, has been used to treat non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease. However, no clear consensus exists as to the best treatment strategy for NSCLC.

In a previous report, we demonstrated that epidermal growth factor receptor (EGFR) mutation is an independent prognostic factor for NSCLC patients who received the combination of gefitinib and cisplatin. In the present study, we investigated whether TGF-beta expression is a prognostic factor in the same population.

We retrospectively reviewed the medical records of NSCLC patients who received gefitinib as first-line chemotherapy at the National Cancer Center Hospital between June 2001 and June 2004.

A total of 52 patients were eligible for analysis. The median age was 61 years (range 33-78). There were 39 males and 13 females
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flavoxateis a drug that inhibits
 
Response: Flavoxateis a drug that inhibits P-glycoprotein (P-gp) transport in the small intestine and bile canalicular efflux of the hepatobiliary system. In humans, oral administration of flavoxate results in increased systemic exposure of a variety of drugs (e.g., theophylline, verapamil, and digoxin) that are P-gp substrates. The absorption and disposition of flavoxate and its active metabolite, 4-methylumbelliferone, have been studied in healthy volunteers and in patients with hepatic or renal impairment. The absorption of flavoxate and 4-methylumbelliferone is complete, and both compounds are primarily eliminated in urine. In vitro studies show that the activity of P-gp is inhibited by flavoxate and 4-methylumbelliferone. In humans, P-gp inhibition results in increased systemic exposure of a variety of P-gp substrates, including theophyll
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flopropioneis a drug that inhibits
 
Response: Flopropioneis a drug that inhibits the enzyme which converts levodopa into dopamine. Dopamine is one of the brain chemicals that affects movement. Levodopa is a drug that helps the brain produce dopamine. It is prescribed for people with Parkinson’s disease.

The reason why flopropioneis prescribed for people with Parkinson’s disease is that it helps them to control their tremor. In people with Parkinson’s disease, dopamine is not produced in the brain in sufficient amounts. This means that their muscles cannot contract and relax. Flopropioneis helps to produce more dopamine.

Dopamine is also produced in the brain in people without Parkinson’s disease. It helps the brain to control movement and emotions.

Flopropioneis works by increasing the amount of dopamine produced in the brain. It is also used to treat depression.

Adverse effects of flopropioneis

If you
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Florfenicolis a drug that inhibits
 
Response: Florfenicolis a drug that inhibits angiogenesis. The following is a review of its preclinical and clinical development. We have reviewed previously the drugs currently in use for the treatment of glioblastoma. There is now a large body of literature describing the pathophysiology of glioblastoma. This is the reason why we have chosen to focus on this malignancy in the following review.

Introduction {#s2}
============

The classical definition of angiogenesis, as given by Hanahan and Folkman in 1971 \[[@ref1]\], was "a set of events by which new blood vessels are formed from pre-existing vessels" and it is a dynamic and multistep process in which endothelial cells proliferate, migrate, and form tubular structures. The interaction between endothelial cells and their surrounding stromal cells is a key step in this process, and several factors have been implicated in the regulation of this interaction
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Floxuridineis a drug that inhibits
 
Response: Floxuridineis a drug that inhibits thymidylate synthetase and the synthesis of DNA. It is active against various types of tumors, especially those of the gastrointestinal tract, but it is generally considered to be ineffective against leukemia and other types of malignancy.
Because of the potentially severe side effects of floxuridine, and the fact that its effects are generally short-lived, the use of floxuridine is limited. In addition, the floxuridine that is currently available is available in a salt form that must be dissolved in water prior to administration, and this makes it difficult to use floxuridine in the parenteral administration.
The present invention provides a new form of floxuridine, which can be administered orally, in an emulsion, and is more stable than floxuridine itself. This form of floxuridine can be used in the treatment of tumors and in other applications in which it is desirable
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flubendazoleis a drug that inhibits
 
Response: Flubendazoleis a drug that inhibits the synthesis of microtubules. In addition, flubendazole is a proton pump inhibitor and is used to treat cestodes, protozoans, and helminths. It is also used to treat clostridial infections and cestodiasis. It is also used in the treatment of bile-duct infections and paragonimiasis. It is also used in the treatment of actinomycetes infections, aspergillosis, and nocardiosis. Flubendazole is also used to treat diarrhea in the horse.

How is flubendazole used?

Flubendazole is used in the treatment of helminths. It is used in the treatment of cestodes, including tapeworms. It is also used in the treatment of protozoans, including trichomoniasis. It is also used in the treatment of paragon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluconazoleis a drug that inhibits
 
Response: Fluconazoleis a drug that inhibits the enzyme CYP 3A4, and this drug is metabolized in the liver. In vitro, the maximum concentration (Cmax) of fluconazole after oral administration is about 1.2-2.0 µg/mL, and the minimum concentration (Cmin) is about 0.1 µg/mL. The pharmacokinetic parameters of fluconazole are known to be affected by age, body weight, and disease. Fluconazole is a frequently used drug in the treatment of infections caused by Candida, Aspergillus, and other fungi. A pharmacokinetic evaluation of fluconazole in healthy subjects is necessary in order to ensure that the drug is properly administered to patients. In this study, we evaluated the pharmacokinetics of fluconazole in a healthy Japanese male volunteer after a single oral administration of fluconazole (100 mg) using a sensitive and selective high-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fludarais a drug that inhibits
 
Response: Fludarais a drug that inhibits the human estrogen receptor, which can result in menopausal symptoms such as hot flashes and bone loss. It is an anti-estrogen and has no effect on progesterone receptors, and therefore, should not be used as a contraceptive.

It is a strong inhibitor of the estrogen receptor. It acts in a different way from other anti-estrogens such as tamoxifen and clomiphene.

Fludara is a drug that inhibits the human estrogen receptor. It is an anti-estrogen and has no effect on progesterone receptors, and therefore, should not be used as a contraceptive.

What is the name of the medication I am taking?

You can give the generic name of the medication you are taking, or the brand name of the medication you are taking. If you know the name of the medication you are taking, you can enter it into the form below. Otherwise, click the button
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fludarabineis a drug that inhibits
 
Response: Fludarabineis a drug that inhibits DNA synthesis in dividing cells by targeting the enzyme ribonucleotide reductase (RR). It is used to treat chronic lymphocytic leukemia (CLL), and to reduce the incidence of relapse in children with acute lymphoblastic leukemia (ALL). It has also been studied in a number of solid tumors, including multiple myeloma, lymphoma, myelodysplastic syndrome (MDS), and breast cancer. It is also being investigated in clinical trials as a possible treatment for other malignancies.

CLL is the most common leukemia in adults, accounting for 20-25% of all leukemias in the United States. CLL is characterized by the accumulation of a monoclonal population of mature B lymphocytes in the peripheral blood, lymph nodes, and bone marrow.

The most common initial presentation of CLL is a gradual onset of fatigue, fever, and enlarged lymph nodes in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flufenamicis a drug that inhibits
 
Response: Flufenamicis a drug that inhibits the production of prostaglandins by inhibiting the enzyme cyclooxygenase (COX). This drug has been used in the treatment of headache and inflammation in the nasal and sinus area, and for treatment of menstrual disorders, and in the treatment of other conditions such as diarrhea and dysmenorrhea. The recommended dosage is 100-200 mg per day, and a typical therapeutic dose is 200-300 mg per day.
Flufenamic acid and its salts have been used in the form of powders and tablets. These formulations suffer from the disadvantage that the tablet or powder form is very inconvenient for the patient. A powder or tablet form which is easy to administer, and is stable for long periods of time is highly desirable.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flumazenilis a drug that inhibits
 
Response: Flumazenilis a drug that inhibits the binding of benzodiazepines to their receptors. It is used to reverse the sedative effects of benzodiazepines.

Flumazenil is used to reverse the sedative effects of benzodiazepines such as diazepam, triazolam, flurazepam, and others.

Dosage and administration

Flumazenil is given intravenously. It is usually given within 30 minutes after discontinuation of a benzodiazepine. It should be administered slowly and infused at a rate not to exceed 1.5 mg/min. The dose of flumazenil varies from 1 to 4 mg.

Side effects

Flumazenil can cause nausea, dizziness, headaches, and confusion. The more sedative the benzodiazepine, the greater the risk of these side effects.

Interactions

Flumazenil
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flumequineis a drug that inhibits
 
Response: Flumequineis a drug that inhibits the metabolism of paracetamol. It is used to treat pain and fever. It is also used to treat cough and cold. It is an analgesic and antipyretic.

Dosage and Administration

The dose of flumequine is 1.25-2.5 mg/kg/day in divided doses. It can be taken orally or intravenously.

Contraindications

This drug is contraindicated in children below the age of 3 years and pregnant and nursing mothers.

Side Effects

Nausea, vomiting, diarrhea, abdominal pain, increased frequency of micturition, drowsiness, and decreased appetite are the most common side effects of this drug.

Interactions

It is contraindicated in combination with phenytoin, valproic acid, or carbamazepine.

Precaution

This drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  flumethasoneis a drug that inhibits
 
Response: flumethasoneis a drug that inhibits the production of TNF-alpha, an inflammatory cytokine that can damage the kidneys. This drug is prescribed to patients who have had a heart attack, in order to prevent kidney damage.

B

adenosine is a molecule that can be produced in the body. It is produced when cells are damaged.

C

flunisolide is a corticosteroid that can be used to treat an allergic reaction. It is prescribed to patients with a skin condition called dermatitis, as well as those who have an allergic reaction to insect bites.

D

dexamethasoneis a corticosteroid that can be used to treat a severe allergic reaction. It is prescribed to patients who have a heart attack, to prevent damage to the heart.

E

epinephrine is a hormone that is used to treat an allergic reaction. It is prescribed to patients who have a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flunarizineis a drug that inhibits
 
Response: Flunarizineis a drug that inhibits the release of neurotransmitters in the central nervous system. It is also called 2-fluoro-4-amino-7-chloro-1,2,3,4-tetrahydro-quinoline. It is a peripheral vasodilator and antihistamine. Flunarizine is useful in the treatment of vertigo, headaches, and other types of disorders involving increased levels of calcium in the brain.

In order to receive this medicine, you must first call your doctor to find out if it is right for you. Your doctor may want to do a blood test to make sure that your kidneys are working properly. You may also be told to take a liver test. Your doctor will discuss your risk factors and other medications you are taking, and will probably ask you many questions about your symptoms. You may also be asked to come back for a follow-up visit to check how you are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flunixinis a drug that inhibits
 
Response: Flunixinis a drug that inhibits the same enzyme that makes the painkiller hydrocodone, and is the same one that makes OxyContin more effective at treating pain.

If a new study published in the New England Journal of Medicine proves correct, that would be good news for people who are trying to avoid opioid addiction.

And it would also be good news for people who use drugs recreationally, but who don't want to risk the side effects of addiction, or who don't want to take painkillers that are not as effective as they should be.

Flunixin, which is commonly sold as a non-steroidal anti-inflammatory drug, is the active ingredient in a common painkiller that is used in horses.

Flunixin is not an opioid, and so does not have the same potential for abuse.

However, the drug is used in some horses that are injured or ill, and the painkiller can be absorbed
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluorometholoneis a drug that inhibits
 
Response: Fluorometholoneis a drug that inhibits the growth of skin cells and it can cause serious side effects like skin darkening and thinning of the skin. There are certain circumstances where the application of fluorometholone can be beneficial and it is used in ophthalmic preparations like ointments, drops, gels, etc.

As an anti-inflammatory, it is used for relieving pain and swelling of the eyes and can also be used for treating acute red eye conditions. It is a popular choice of eye doctors and ophthalmologists as it is very effective in reducing the symptoms of eye infections like conjunctivitis, iritis, keratitis, blepharitis, etc. It can also be used to treat allergic eye conditions like seasonal allergic conjunctivitis and perennial allergic conjunctivitis.

In this post, we will discuss how to use fluorometholone for treating eye infections. The dosage and duration of treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluoxetineis a drug that inhibits
 
Response: Fluoxetineis a drug that inhibits serotonin reuptake. It is used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also used for premarital therapy and for treating borderline personality disorder. This article provides information about the uses, side effects, and risks of fluoxetine.

What is fluoxetine?

Fluoxetine is a prescription medication that is used to treat depression, obsessive-compulsive disorder (OCD), and bulimia nervosa. It is also used for premarital therapy and for treating borderline personality disorder.

Fluoxetine is available in tablet form, and it is taken by mouth. The recommended starting dose for adults is 20 milligrams (mg) twice a day. This dose is taken in the morning and in the evening. A maintenance dose of 20 to 80 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluphenazineis a drug that inhibits
 
Response: Fluphenazineis a drug that inhibits the dopamine receptor. This drug is used to treat schizophrenia, but it also is used to treat other conditions. This article provides information about fluphenazine, including its side effects, how to take the medication, its dosage, and how it works.

What is fluphenazine?

Fluphenazine is a drug that is used to treat schizophrenia. It is also used to treat other conditions. This medication works by blocking dopamine receptors in the brain. This causes the brain to stop producing dopamine, which is a chemical that is associated with mental disorders.

Fluphenazine was approved by the FDA in 1963, but it has been used to treat mental disorders for a long time. It is used to treat mental disorders that include:

Schizophrenia

Bipolar disorder

Depression

What are the uses of fluphenazine?

Fluphenazine is used to treat schizophrenia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flupirtineis a drug that inhibits
 
Response: Flupirtineis a drug that inhibits a voltage-dependent sodium channel, which is responsible for action potential generation and conduction in the central nervous system. Flupirtine, the (R)-enantiomer of mexiletine, is a substituted 3-chloro-4-fluoropyridine. It is a weak non-selective sodium channel blocker with high affinity for neuronal sodium channels (IC50=5 nM) and is clinically used in the treatment of trigeminal neuralgia and postherpetic neuralgia.

This review article aims to provide an up-to-date account of the pharmacology of flupirtine.

Pharmacokinetics

Flupirtine is rapidly absorbed from the gastrointestinal tract and undergoes first-pass metabolism in the liver. It is excreted primarily in the urine (70-80% of the dose) and only a small proportion is excreted in the fa
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluralaneris a drug that inhibits
 
Response: Fluralaneris a drug that inhibits the human 5-HT2A receptor. It has also been found to have therapeutic activity in the treatment of a variety of disorders including schizophrenia, anxiety, depression, pain, obesity, and eating disorders. See e.g., U.S. Pat. No. 6,926,876; U.S. Pat. No. 6,790,749; U.S. Pat. No. 6,599,974; U.S. Pat. No. 6,576,718; U.S. Pat. No. 6,599,973; U.S. Pat. No. 6,569,434; U.S. Pat. No. 6,579,898; U.S. Pat. No. 6,559,155; U.S. Pat. No. 6,560,851; U.S. Pat. No. 6,586
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flurbiprofenis a drug that inhibits
 
Response: Flurbiprofenis a drug that inhibits the activity of COX-2. This enzyme is responsible for the production of prostaglandins (PGs), which are implicated in inflammation and fever. The structure of flurbiprofen is shown in FIG. 1.

Flurbiprofen has been found to be effective in the treatment of various types of pain. However, flurbiprofen is a relatively weak NSAID, which is a classification of drugs that have the potential to produce GI side effects. It is thought that the weaker the NSAID, the less chance there is of GI side effects.

There are two classes of NSAIDs: (1) cyclooxygenase (COX)-1 inhibitors, which block the synthesis of PGs at the beginning of the biosynthetic pathway, and (2) COX-2 inhibitors, which block the synthesis of PGs at the end of the biosynthetic pathway. In the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Flutamideis a drug that inhibits
 
Response: Flutamideis a drug that inhibits androgen action in the testes. It is used in the treatment of advanced prostate cancer. It is a steroidal antiandrogen, and it is used as a contraceptive to block ovulation and as an antiandrogen in the treatment of benign prostatic hyperplasia (BPH). Flutamide is a potent inhibitor of both the high-affinity and low-affinity states of the androgen receptor (AR).

The androgenic effects of flutamide are mediated by competitive antagonism of androgen binding to the AR. The precise mechanism of action of flutamide is unknown, but it may act by competing with testosterone for receptor binding or by inducing receptor conformational changes. In vitro studies have shown that flutamide also inhibits the transcriptional activity of the AR and the production of androgen-responsive genes.

The androgenic effects of flutamide are mediated by competitive antagonism of androgen binding
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  fluticasoneis a drug that inhibits
 
Response: fluticasoneis a drug that inhibits the production of inflammation mediators (eg, cytokines, chemokines, and leukotrienes) and reduces the recruitment of leukocytes into the site of inflammation. It also inhibits the activity of mast cells and basophils. It is a steroidal drug with a long half-life, so it may be useful in the treatment of long-term inflammatory diseases such as asthma. It is also used in the treatment of eczema.

▪ INDICATIONS: It is used to treat mild to moderate asthma in adults and children 12 years of age and older.

▪ CONTRAINDICATIONS: Factors that prohibit its use include hypersensitivity to fluticasone, pregnancy, lactation, and Cushing's disease.

▪ ADVERSE EFFECTS: Among the more serious adverse effects are severe adrenal suppression, glaucoma, and cataracts.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluticasoneis a drug that inhibits
 
Response: Fluticasoneis a drug that inhibits the conversion of cortisol to cortisone, which can also be used to treat inflammation. Fluticasone is used in combination with oral contraceptives, and is a common ingredient in products used to treat and prevent asthma, hay fever, and other allergies. It is also used to treat eczema and rosacea.

Drug Facts

Fluticasone is available in the form of an inhaled spray, ointment, and drops. The drug is most commonly used to treat and prevent the symptoms of asthma and allergic rhinitis (hay fever).

Indications and Usage

Fluticasone is used to treat and prevent the symptoms of asthma and allergic rhinitis (hay fever). It is also used to treat eczema and rosacea.

How to Take

Fluticasone is taken once a day at the same time each day. Inhaled steroids should
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FLUVASTATINis a drug that inhibits
 
Response: FLUVASTATINis a drug that inhibits the synthesis of uric acid by the kidney and liver, making the kidneys excrete uric acid more slowly. It is used in the treatment of gout and other conditions in which uric acid levels are high. It is usually prescribed as an injection, but may also be taken by mouth.

**A:** | **E:**

---|---

Fluvastatin Tablets, US | Fluvastatin (Hyzaar)

Fluvastatin Sodium Injection, US | Fluvastatin (Hyzaar)

Fluvastatin Tablets, Canada | Fluvastatin (Hyzaar)

**Brand Name** | **Generic Name**

---|---

Algenist | Fluvastatin

Fluvastatin | Fluvastatin

Fluvastatin | Fluvastatin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fluvoxamineis a drug that inhibits
 
Response: Fluvoxamineis a drug that inhibits the uptake of serotonin by the presynaptic serotonin transporter. It is used in the treatment of major depressive disorder, obsessive-compulsive disorder, and panic disorder. In recent years, fluvoxamine has become one of the most widely prescribed antidepressants.

Molecular and Physicochemical Properties

Fluvoxamine is a phenylamino substituted 1-amino-1,4-dihydro-4-oxo-quinoline. The compound is very soluble in water (95.5 mg/mL). It is freely soluble in chloroform, DMSO, ethanol, methanol, and diethyl ether. It is practically insoluble in petroleum ether, but soluble in benzene. The drug is a weak base and the protonated form is more soluble than the non-protonated form. The acid-base titration shows that fluvoxamine is not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  FOMEPIZOLEis a drug that inhibits
 
Response: FOMEPIZOLEis a drug that inhibits the formation of the enzyme dipeptidyl peptidase-4 (DPP-4), and is therefore used to treat type 2 diabetes. This enzyme breaks down the hormone glucagon-like peptide-1 (GLP-1) which, among other things, regulates the secretion of insulin and reduces appetite. In a large study in 2010, FOMEPIZOLE significantly reduced the incidence of type 2 diabetes in patients with prediabetes.

In this study, 973 patients with a history of type 2 diabetes or impaired glucose tolerance were given FOMEPIZOLE or placebo for 2 years. After 2 years, FOMEPIZOLE reduced the incidence of diabetes by 54% (from 16.6% to 8.2%) compared to a 38% reduction in the placebo group (from 20.1% to 14.0%). The number needed to treat was 14 patients.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Formestaneis a drug that inhibits
 
Response: Formestaneis a drug that inhibits the enzyme aromatase, which is responsible for the conversion of testosterone into estrogens. The clinical efficacy of anastrozole has been well established for the treatment of postmenopausal women with breast cancer ([@bib5]; [@bib3]). This agent has also been shown to reduce bone turnover in women with breast cancer and osteoporosis ([@bib11]; [@bib2]).

Although the addition of an aromatase inhibitor to the standard regimen of anastrozole and tamoxifen in postmenopausal women with early breast cancer was associated with improved clinical outcomes, this regimen has not been compared with tamoxifen alone in women with advanced breast cancer. The combination of an aromatase inhibitor and an antiestrogen may provide superior efficacy over antiestrogen monotherapy in advanced breast cancer. This possibility is supported by data from a large, phase III trial in postmenopausal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Formononetinis a drug that inhibits
 
Response: Formononetinis a drug that inhibits the hormone which increases a woman's sex drive (hormone in the body which stimulates sexual desire) and also, helps the body to be able to cope with the extra blood flow to the pelvic area during intercourse.

The following are some of the side effects that you may experience if you take this medication.

Nausea

Itching

Rash

Abdominal pain

Pain in the limbs

Abdominal discomfort

Diarrhoea

Bloody diarrhoea

If you have experienced any of the above side effects, please inform your doctor immediately.

In case you notice the following side effects, inform your doctor immediately.

The side effects may be caused by the following reasons.

Miss dose

Skip dose

Wrong time interval

Drug interaction

Missed a dose

Side effects not listed above

Disclaimer


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Formoterolis a drug that inhibits
 
Response: Formoterolis a drug that inhibits the growth of cancer cells by preventing them from dividing. Formoterol has been used in Europe for years as a drug for treating asthma and chronic obstructive pulmonary disease (COPD). Formoterol is an inhaled corticosteroid (ICS) that works by reducing the production of mucus, which helps keep the lungs clear of mucus. The mucus produced by the body is the same as the mucus produced by the airways in the lungs.

As you inhale the drug, it helps prevent the release of mucus from the lungs and blocks the growth of lung cancer cells.

What is the most important information I should know about formoterol?

Formoterol is used to treat asthma and COPD.

Do not use this medication if you have a history of seizures or have a condition that increases the risk of having seizures (e.g., a history of depression, bipolar disorder, or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fosamprenaviris a drug that inhibits
 
Response: Fosamprenaviris a drug that inhibits the production of certain enzymes that the virus needs to reproduce. Antiviral treatment with Fosamprenavir-ritonavir (Kaletra) was initiated, and the patient\'s symptoms resolved.

Fever, cough, and chest pain are common symptoms of pneumonia, and many patients with influenza have radiographic abnormalities on chest radiography. It is important to rule out other causes of chest pain in patients with influenza. Many drugs, including NSAIDs, can cause chest pain. [Table 3](#tbl3){ref-type="table"} provides a summary of the etiologies of chest pain in patients with influenza. [Table 4](#tbl4){ref-type="table"} summarizes the role of various imaging modalities in patients with influenza.

Clinical Presentation of COVID-19 {#sec3}
=================================

COVID-19, which
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fosaprepitantis a drug that inhibits
 
Response: Fosaprepitantis a drug that inhibits the ability of the parasite to invade the host cell, and there are now two drugs, pyrimethamine and mefloquine, which are used to treat malaria.

What is a parasite?

A parasite is an organism that lives in another organism (host) and uses the host to complete its life cycle. There are thousands of different parasites and most of them are not harmful. Some parasites are useful to humans, like tapeworms, which use the human intestine to complete their life cycle. Some parasites are harmful, like malaria, which lives in the red blood cells and is transmitted to humans by the bite of an infected mosquito.

How do you get malaria?

Malaria is transmitted to humans by the bite of an infected mosquito. Mosquitoes acquire malaria by feeding on infected blood. The female mosquito bites an infected person, and then sucks up blood. The blood then passes from the mosquito
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Foscarnetis a drug that inhibits
 
Response: Foscarnetis a drug that inhibits the viral polymerase, nucleoside reverse transcriptase. In combination with other drugs it may be used for the treatment of CMV retinitis in AIDS. It is available in oral and intravenous formulations.

Foscarnet should be used with caution in patients with renal insufficiency. Foscarnet is not recommended for use in pregnant women, due to the risk of teratogenicity.

Oral

Oral form: Capsules, 200 mg, 600 mg, 1200 mg

Dosage

Intravenous

Dosage:

500 mg/m2 twice a day, 12 hours apart

Concomitant use of other drugs:

May be used in combination with other antiviral drugs, including AZT and ganciclovir, to treat CMV retinitis in AIDS.

Dosage in Renal Impairment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fosfluconazoleis a drug that inhibits
 
Response: Fosfluconazoleis a drug that inhibits the synthesis of ergosterol in fungal cells. The ergosterol is an essential component of the fungal cell membrane. Without the ergosterol, the cell membrane cannot function. Fosfluconazole, a triazole fungicide, inhibits the synthesis of ergosterol by inhibiting the enzyme squalene epoxidase. Fosfluconazole is marketed in the United States as “Fungicide 25” and is sold by Bayer Corporation under the trade name of Baycrol.

Fosfluconazole has been shown to be effective against certain fungi, including Aspergillus spp., Coccidioides spp., Fusarium spp., Penicillium spp., Trichophyton spp., and yeast, such as Candida spp.

U.S. Pat. No. 4,991,856
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  fosfomycinis a drug that inhibits
 
Response: fosfomycinis a drug that inhibits the production of a lipid called phosphatidylinositol-3-phosphate (PI3P) by blocking a step in the pathway that produces PI3P. This is important because PI3P is a key regulator of the function of some intracellular pathogens, including bacteria and viruses, and so this drug is expected to be a broad-spectrum anti-infective.

See also
 List of investigational antivirals

References

Category:Antivirals
Category:Experimental drugs
Category:Isopropyl compounds
Category:Quinolines
Category:Acetamides
Category:Diols
Category:Isopropyl compounds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fosinoprilis a drug that inhibits
 
Response: Fosinoprilis a drug that inhibits the enzyme, angiotensin-converting enzyme, and thereby lowers blood pressure. It is available as a tablet that is administered once daily. Fosinopril is indicated for the treatment of mild to moderate essential hypertension. Fosinopril is used to treat patients with a history of heart failure, stroke, diabetes, or other conditions that are treated with antihypertensive drugs.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fosphenytoinis a drug that inhibits
 
Response: Fosphenytoinis a drug that inhibits the synthesis of DNA. The result is a lack of new cells that can be formed. The lack of new cells means that cells are dying. This is not a permanent condition, but rather a result of the cessation of use.

Fosphenytoin is an anticonvulsant. It is used to prevent seizures in some types of epilepsy.

Dosing of Fosphenytoin

The dosage of Fosphenytoin is based on the child’s weight. This is because the drug is administered intravenously. The following doses are available for children:

Infants 0 to 6 months old: 10 milligrams per kilogram of body weight.

Children 7 to 12 months old: 20 milligrams per kilogram of body weight.

Children 1 to 3 years old: 30 milligrams per kilogram of body weight.

Children 4 to 5 years old:
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Frovatriptanis a drug that inhibits
 
Response: Frovatriptanis a drug that inhibits serotonin (5-HT) receptors that have been identified in migraineurs. In a large-scale, randomized, double-blind, placebo-controlled study, frovatriptan 2.5 mg (maximum dose) was compared with placebo and other triptans (almotriptan, eletriptan, and rizatriptan) in the treatment of patients with migraine.

The results showed that the drug was superior to placebo and was as effective as the other triptans in the acute treatment of migraine, and that it was more effective than the other triptans in relieving the symptoms of migraine.

Frovatriptan is a selective 5-HT1F receptor agonist that is effective in the acute treatment of migraine. It is the first triptan to have been approved for the treatment of migraine in patients with a history of migraine.

INTRODUCTION

M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fructoseis a drug that inhibits
 
Response: Fructoseis a drug that inhibits the action of insulin. Ingestion of large amounts of fructose can cause high blood sugar, and thus, insulin resistance. Insulin resistance can cause high blood sugar and Type 2 diabetes.Fructosecan also cause fatty liver disease. For this reason, people with fatty liver disease are advised to avoid fructose.

Alcohol is another drug that inhibits the action of insulin. Heavy alcohol consumption causes high blood sugar, and thus, insulin resistance.

3.2 High fat diets

As previously mentioned, a high fat diet causes fatty liver disease. The following foods contain high amounts of fat. These foods should be avoided by people with fatty liver disease:

4. Treatments for fatty liver disease

People with fatty liver disease may need to be treated for a variety of conditions. In particular, the following treatments are helpful in treating fatty liver disease:

4.1 Low fat diets

As previously mentioned, a high fat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ftorafuris a drug that inhibits
 
Response: Ftorafuris a drug that inhibits the conversion of a nucleoside analog into a nucleobase and its further conversion into the respective nucleoside. It is a prodrug, the activated form being the active drug, 5-fluorouracil (5-FU).
Ftorafuris is an oral, single agent, antitumor agent. It is an antineoplastic agent used in the treatment of various solid tumors, such as colon, breast, stomach, pancreas, and head and neck cancers. It has a wide spectrum of activity, including gastrointestinal and lung cancer, melanoma, renal cell carcinoma, leukemia, and lymphomas.
The antitumor activity of ftorafuris has been shown to be superior to that of the parent compound, 5-FU, in certain tumor types. See, e.g., Koeller et al., Semin. Oncol. 20:69-75 (1993); Tomp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  fty720is a drug that inhibits
 
Response: fty720is a drug that inhibits lysosomal function and has been shown to reduce the production of Aβ peptides in vitro and in vivo.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fudosteineis a drug that inhibits
 
Response: Fudosteineis a drug that inhibits cell proliferation by inhibiting the growth of new blood vessels, or angiogenesis. It is used to treat conditions in which the growth of new blood vessels is a problem. For example, fudosteineis is used to treat diabetic retinopathy, in which new blood vessels grow in the retina. Fudosteineis is also used to treat rheumatoid arthritis, in which new blood vessels grow into the synovial lining of the joints. Fudosteineis is also used to treat psoriasis, in which new blood vessels grow into the skin. Fudosteineis is used to treat cancerous tumors, in which new blood vessels grow into the tumor to supply the tumor with nutrients.

Fudosteineis is not yet available for prescription in the United States.

Side Effects

The most common side effects of fudosteineis include eye
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fulvestrantis a drug that inhibits
 
Response: Fulvestrantis a drug that inhibits the production of estrogen in the body. The drug is used to treat breast cancer in postmenopausal women who have had an aromatase inhibitor. Fulvestrant is approved for use in combination with an aromatase inhibitor in the first-line treatment of postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer who have not received prior chemotherapy for their disease. It is also used in the second-line treatment of postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer who have not received prior chemotherapy and an aromatase inhibitor for their disease.

Fulvestrant is a member of the selective estrogen receptor modulator (SERM) class of drugs. SERMs have different effects on the body depending on whether they are binding to estrogen receptors in the breast tissue (estrogen receptor-positive) or elsewhere in the body (estrogen receptor-negative).

What are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fumagillinis a drug that inhibits
 
Response: Fumagillinis a drug that inhibits the activity of P-glycoprotein, an efflux pump that is expressed in cancer cells and is one of the mechanisms by which cells eliminate chemotherapeutic drugs. The Phase II study reported an objective response rate of 20.8% and stable disease rate of 25.0%. Based on these results, the researchers in the study decided to continue the trial to evaluate the use of Fumagillins in combination with chemotherapy.

ClinicalTrials.gov Identifier: NCT01297813

One Response

Respond to this Question

Pamela Caruso MD

President, American Association of Clinical Oncology

In this particular case, there is no evidence of benefit to combining Fumagillin with chemotherapy. In fact, in the largest randomized study to date, in which Fumagillin was combined with a placebo, it actually led to a reduction in survival. In that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fumalicis a drug that inhibits
 
Response: Fumalicis a drug that inhibits protein synthesis by blocking the elongation phase of protein synthesis. The drug has been used for the treatment of tuberculosis and also in the treatment of multiple myeloma. It has been shown that fumalicin, in combination with an anti-tumor agent such as adriamycin or cyclophosphamide, enhances the anti-tumor activity of the drug (Ribes, C. et al., Cancer Res. (1984) 44:1844-1848; Del Pizzo, P. et al., Biochem. Biophys. Res. Commun. (1984) 125:716-723). It has also been shown that fumalicin in combination with other anti-tumor agents such as cytosine arabinoside, vincristine, and cis-diamminedichloroplatinum (II) inhibits the growth of tumors in vivo (R
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Furaltadoneis a drug that inhibits
 
Response: Furaltadoneis a drug that inhibits the activity of PDE-4, an enzyme that plays a major role in the inhibition of cytokines and other inflammatory mediators. Furaltadone was initially developed by NIDDK as an agent for the treatment of rheumatoid arthritis (RA) and has been used in Japan for the treatment of rheumatic diseases for several years. The current formulation of furaltadone consists of a lyophilized powder for oral administration, which is reconstituted in water for injection before use. The oral formulation was developed to be an immediate release preparation with the aim of providing an adequate and continuous supply of drug to the body. The formulation also includes lactose, which has been added as a disintegrant to facilitate tablet formation and to enhance the dissolution of the active ingredient. The tablets contain furaltadone in the form of its free base. In addition, furaltadone can also be administered
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Furazolidoneis a drug that inhibits
 
Response: Furazolidoneis a drug that inhibits the growth of microorganisms. Furazolidone has been found to have a particularly wide range of antibacterial activity, including activity against a number of gram-positive and gram-negative organisms, such as E. coli, Shigella, Salmonella, Klebsiella, Enterobacter, Serratia, Proteus, Pseudomonas, Haemophilus, Moraxella, and Neisseria species. In addition, it has been found to have activity against a number of anaerobic organisms. Furazolidone is a racemic mixture of the two (R and S) optical isomers, and it is believed that the antibacterial activity of the drug resides in the S-isomer. The U.S. Food and Drug Administration has approved furazolidone for the treatment of swine dysentery, paratyphoid fever, and postweaning diarrhea in swine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Furfuralis a drug that inhibits
 
Response: Furfuralis a drug that inhibits the action of insulin, and, as a result, it may cause some people to gain weight and to become obese. If you have diabetes or are at risk of developing diabetes, ask your doctor if furfuralis is right for you.

Before taking furfuralis

Before you take furfuralis, tell your doctor if you:

are pregnant or plan to become pregnant. Furfuralis may harm your unborn baby.

have any medical conditions.

are taking any other medicines.

are allergic to furfuralis, other drugs, or other substances.

Tell your doctor if you are taking any of the following medicines:

other medicines to lower your blood sugar (sugar).

are pregnant or plan to become pregnant. Furfuralis may harm your unborn baby.

have diabetes. Furfuralis may make diabetes worse.

are allergic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Furosemideis a drug that inhibits
 
Response: Furosemideis a drug that inhibits the reabsorption of sodium by the kidneys. It is used to treat high blood pressure, edema, and heart failure. It is also used to reduce potassium in people who have kidney problems.

Furosemideis a drug that inhibits the reabsorption of sodium by the kidneys. It is used to treat high blood pressure, edema, and heart failure. It is also used to reduce potassium in people who have kidney problems.

What are the different uses of furosemide?

Dosage for furosemide

The usual dosage of furosemide is 40 mg taken once a day. The lowest dose that should be used is 10 mg. The highest dose is 80 mg. This is because the drug can cause heart problems if used in high doses. The lowest effective dose should be used to treat edema.

How does furosemide work?

Furo
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Fursultiamineis a drug that inhibits
 
Response: Fursultiamineis a drug that inhibits the production of melanin. It is used to treat mild to moderate hyperpigmentation, such as melasma and post-inflammatory hyperpigmentation.

Fursultiamine is a synthetic derivative of 4-aminobenzoic acid (PABA) and is sold as an oral tablet. It is manufactured by Novartis, as is 4-aminobenzoic acid.

Common side effects include headache, nausea, vomiting, dizziness, insomnia, and abdominal pain. It may also increase blood pressure. Other side effects include skin rashes, a metallic taste in the mouth, and a temporary decrease in sexual desire.

Fursultiamine was approved for medical use in the United States in 1998. It is not approved for use in people under 18 years of age.

What is fursultiamine used for?

Fursultiamine is used to treat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  G1T38is a drug that inhibits
 
Response: G1T38is a drug that inhibits MCL1, a protein that can keep cancer cells alive. T-cell lymphomas make a lot of MCL1 and one of the big things in this disease is that the cells don’t die. So this is a drug that’s been tested in patients and it seems to be very effective.

I want to get some input from other researchers and patients and talk about some of the potential side effects of this drug and the way we’re thinking about using it. So the first question I’d like to get some input on is: What do you think about the idea of using this drug in the first-line treatment of this disease?

The reason we’re thinking about it is that it seems to be really effective and we know that it doesn’t have a lot of side effects. So the idea is that we might be able to start treating people early, get them
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  G-418is a drug that inhibits
 
Response: G-418is a drug that inhibits the DNA-dependent protein kinase, an enzyme that is essential for cell proliferation. It was discovered as a component of the potent antibiotic bleomycin, which is used in the treatment of skin cancers. This drug is now widely used in cancer therapy.

The drug was discovered by accident. In 1962, a colleague of Nobel Laureate Murray Horwitz, working in the laboratory of the American Cancer Society, accidentally spilled a vial of bleomycin on a Petri dish. The cell cultures died, but not before they had produced many metaphases, each with a chromosome with an extra chromosome, the extra chromosome being called a marker. This was a "positive" result, but no one knew what the marker was. Bleomycin had not been tested on cultured cells, and so the laboratory continued to culture the cells, now testing bleomycin. At a concentration of 10 µg/ml, the drug killed the cells within one or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gabapentinis a drug that inhibits
 
Response: Gabapentinis a drug that inhibits TNF-α, which is associated with tumorigenesis, invasiveness, and metastasis. Recently, the drug has been approved for the treatment of rheumatoid arthritis (RA).

1. Introduction {#sec1-toxins-12-00662}
===============

Grapes (*Vitis vinifera* L.) are an important crop in the Mediterranean area, especially in Italy, and are one of the most widely consumed fruit crops in the world.

They are considered as an important source of important phenolic compounds (e.g., resveratrol, quercetin, and ellagic acid) \[[@B1-toxins-12-00662],[@B2-toxins-12-00662],[@B3-toxins-12-00662],[@B4-toxins-12-00662]
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gabexateis a drug that inhibits
 
Response: Gabexateis a drug that inhibits the synthesis of heparan sulfate proteoglycans (HSPG) in tissues.\[[@CIT1]\] The drug is mainly used in the treatment of acute pancreatitis (AP) and acute necrotizing pancreatitis (ANP).\[[@CIT2]\] The drug inhibits HSPG in the liver and intestine and thus has anti-inflammatory and anti-fibrotic properties. It is also known to inhibit the growth of endothelial cells, and this effect is thought to be due to the down-regulation of vascular endothelial growth factor (VEGF).\[[@CIT3]\] The effect of gabexate in preventing end-organ damage in severe AP and ANP has been demonstrated in several studies.\[[@CIT4][@CIT5]\]

Gabexate is also used for the treatment of severe sepsis and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gadoversetamideis a drug that inhibits
 
Response: Gadoversetamideis a drug that inhibits growth hormone release and is used in the treatment of short stature.

You may have heard that the U.S. Food and Drug Administration (FDA) recently issued a warning to physicians regarding Gadoversetamide, a drug that inhibits growth hormone release and is used in the treatment of short stature.1 The warning resulted from a manufacturer’s voluntary recall of lots of Gadoversetamide, and the FDA subsequently sent a letter to manufacturers and distributors requesting information about their distribution and sale of the recalled lots.

Gadoversetamide is a hormone regulator, meaning that it helps regulate the amount of growth hormone (GH) produced by the pituitary gland. GH is secreted by the pituitary gland into the bloodstream, where it stimulates growth in many different body tissues. GH is a natural hormone produced by the body, but when it is produced in excessive amounts, it can cause abnormal growth of bones
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gadoxetateis a drug that inhibits
 
Response: Gadoxetateis a drug that inhibits gadolinium accumulation in the body, reducing the risk of gadolinium deposition in the brain. This drug is indicated in adults with:

T1-weighted magnetic resonance imaging (MRI) of the brain or spinal cord (see Patient Information).

This drug may be used to treat nephrogenic systemic fibrosis (NSF), a rare condition in which a person has a kidney disease that can cause abnormal tissue growth in the skin. The abnormal tissue growth can affect the joints, lungs, heart, blood vessels, and skin. NSF usually occurs after gadolinium-based MRI contrast agent is given to a person with a kidney disease. Gadoxetate does not prevent the use of a gadolinium-based MRI contrast agent.

What is the most important information I should know about gadoxetate?

Do not use gadoxetate if you are allergic to gadolinium.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Galanthamineis a drug that inhibits
 
Response: Galanthamineis a drug that inhibits the degradation of the neurotransmitteracetylcholine by the enzyme cholinesterase. It has a potent and relatively selective action on cholinesterase in the central nervous system. The main use of this drug is in the treatment of Alzheimer's disease, but it also has been used to treat patients with atropine poisoning, a condition caused by exposure to high doses of an insecticide called paraquat.

Mechanism of action

When cholinesterase breaks down acetylcholine in the brain, a neurotransmitter, it causes the muscles of the body to contract. The contractions are followed by a wave of relaxation and are referred to as cholinergic (muscle contraction) waves. Galanthamine prevents this wave of relaxation, thereby stopping the muscles from relaxing. The net result is that the muscles remain contracted for a longer time than they would normally be.

This results in the patient
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gallamineis a drug that inhibits
 
Response: Gallamineis a drug that inhibits the reabsorption of tyrosine and other amino acids by the renal tubule and therefore increases their excretion in urine. It was introduced for the treatment of chronic liver disease in patients with high dietary tyrosine intake, but it is now also used in patients with cirrhosis and other disorders of amino acid metabolism. Gallamine is also used in the treatment of cerebral oedema.

Mechanism of action

Gallamine has been shown to increase the excretion of tyrosine and other amino acids in urine, thus increasing the urinary excretion of ammonia and, to a lesser extent, nitrogen. The effect of gallamine is probably due to its direct inhibition of the reabsorption of amino acids in the renal tubule. The plasma level of ammonia decreases as a result.

Gallamine is metabolised by the liver to an inactive metabolite. It is excreted in the urine unchanged.

Chemistry

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gamithromycinis a drug that inhibits
 
Response: Gamithromycinis a drug that inhibits hyaluronidase and hyaluronate lyase.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gancicloviris a drug that inhibits
 
Response: Gancicloviris a drug that inhibits the activity of a key enzyme in the cancer cell.

The enzyme, called indoleamine 2,3-dioxygenase, is involved in the production of a substance called tryptophan. The body needs this substance to make serotonin and melatonin.

The drug has been shown to inhibit the growth of several types of cancer in animals and to prolong the survival of mice with certain kinds of leukemia.

The drug also suppresses the growth of some types of solid cancer, but it has not yet been tested in humans.

The drug is made by Ganciclovir.

The drug has been available in some European countries since 1997, but it is not approved for sale in the United States.

Treatment with Ganciclovir in early-stage patients was not associated with increased toxicity, compared with other drugs used in cancer chemotherapy, according to a review of the data published
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ganetespib(STA-9090)is a drug that inhibits
 
Response: Ganetespib(STA-9090)is a drug that inhibits the protein kinase CK2. It is being developed by the biopharmaceutical company Arrimed Pharmaceuticals. The chemical name for ganetespib is 1-(4-amino-2-methyl-5-methoxy-phenyl)-3-{4-[2-[(methylsulfonyl)amino]ethyl]-2,6-dimethyl-phenyl}-4-piperidinone.

How does ganetespib work?

Ganetespib is an investigational anticancer agent that inhibits the protein kinase CK2. It is designed to inhibit the CK2 holoenzyme by targeting a regulatory subunit of the holoenzyme, which is not involved in the catalytic activity of the holoenzyme. Inhibition of CK2 by ganetespib results in the disruption of cell cycle regulation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GANTANOLis a drug that inhibits
 
Response: GANTANOLis a drug that inhibits the release of eicosanoids (prostaglandins and leukotrienes) by reducing the production of arachidonic acid in the arachidonic acid cascade. It is indicated for the relief of the symptoms of allergic rhinitis and is used in the management of asthma.

**INDICATIONS:**

**◀ ALERT ▶** Contraindicated in active peptic ulcer. Avoid use with anticoagulants.

**◀ ALERT ▶** Avoid use in pts with asthma or aspirin intolerance.

**OFF-LABEL:** **None currently known.**

#####  PRECAUTIONS

**◀ ALERT ▶** Read full Prescribing Information for contraindications, adverse reactions, drug interactions, and precautions.

**Contraindications:** Hypersensitivity to ned
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GANTRISINis a drug that inhibits
 
Response: GANTRISINis a drug that inhibits the action of the enzyme renin, which is the initial step in the production of angiotensin II. Angiotensin II, a hormone that causes vasoconstriction and aldosterone release, is responsible for the increase in blood pressure that occurs in hypertensive patients. Inhibiting renin by means of an angiotensin-converting enzyme inhibitor (ACEI) prevents the increase in blood pressure, which is why ACEIs are the first-line drugs for the treatment of hypertension. However, ACEIs also inhibit the production of bradykinin, a potent vasodilator, which means that they have the potential to cause adverse effects, such as cough. GENTRISIN is a combination of two different drugs, enalapril and losartan, which have different mechanisms of action. Enalapril is an ACEI, which inhibits the production of angiotensin II. Los
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Garenoxacinis a drug that inhibits
 
Response: Garenoxacinis a drug that inhibits the phosphodiesterase activity of cyclic guanosine monophosphate (cGMP) type 5, also known as phosphodiesterase type 5 (PDE5), is a therapeutic agent for erectile dysfunction. A synthetic nitric oxide donor, nitroglycerin, is a PDE5 inhibitor. Sildenafil, a drug used to treat erectile dysfunction, is an inhibitor of PDE5.
Sildenafil citrate is a drug which has been used to treat male erectile dysfunction for a number of years. Sildenafil citrate is a potent and selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5), the primary cGMP-specific phosphodiesterase isozyme in the corpus cavernosum of the penis. Sildenafil citrate (Viagra®, Pfizer Inc.) is a potent and selective inhibitor of the enzyme phosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gastrodenolis a drug that inhibits
 
Response: Gastrodenolis a drug that inhibits acetylcholine esterase. Gastrodenol does not inhibit the oxidation of dopamine by monoamine oxidase.

L-DOPA

An aromatic amino acid that is decarboxylated to dopamine in the body. L-DOPA is used in the treatment of Parkinson’s disease.

Neurotransmitters

The chemical messengers that are carried from one nerve cell to another in the brain and the rest of the nervous system.

Monoamine oxidase

An enzyme that breaks down monoamines in the body. Monoamine oxidase inhibitors are used in the treatment of depression.

Pharmacological classification

A classification of drugs based on their chemical and physical properties.

Receptor

A structure on a cell or an organ that binds a drug.

Serotonin

A neurotransmitter that helps control movement and the sensation of pain.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gastrodinis a drug that inhibits
 
Response: Gastrodinis a drug that inhibits the action of the central nervous system. It is not recommended for children, pregnant women, or women who are nursing.

Overdose

The most serious effects of gastrodin are nervous system disorders. Symptoms of overdose include headache, dizziness, convulsions, and paralysis. Seek emergency medical attention immediately if any of these symptoms occur.

Missed Dose

Take your dose as soon as you remember. If it is almost time for your next dose, wait until then.

Storage

Store at room temperature away from light and moisture.

Additional Info

Do not take with other medications unless directed by your doctor.

Sublingual tablets may be used instead of oral administration.

Store your medication in a cool, dry place.

Side Effects

The following are side effects that may occur from using Gastrodin. If you experience any of these symptoms, contact your doctor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gatifloxacinis a drug that inhibits
 
Response: Gatifloxacinis a drug that inhibits the action of a key enzyme that converts testosterone to the hormone DHT. DHT causes the skin to be oily, thick and greasy. This can lead to acne.

Azelaic acid a drug that breaks down the sebum in the sebaceous glands, so the sebum cannot be produced and excreted.

Triamcinolone acetonide a drug that reduces the inflammation of the sebaceous glands, so the sebum production is reduced.

Liposuction This is a surgical procedure where fat is removed from the body. It can be done to remove fat from the abdomen, buttocks, thighs, chin and face. The results of liposuction can be long-lasting.

Body contouring is a term used to describe a cosmetic procedure that tightens loose skin. These procedures are used to reduce the appearance of large areas of loose skin. They can be performed on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GBT440is a drug that inhibits
 
Response: GBT440is a drug that inhibits the enzyme, glutathione-S-transferase. It is effective against hepatic metastasis in mice.

4. **D** The question asks about the effectiveness of using cyclophosphamide in cancer treatment. There are many different types of cancers, so your job is to choose the correct answer. There are many drugs used to treat cancers, but the ones you are most likely to find on a cancer treatment center's formulary are chemotherapy drugs, which are drugs that interfere with the way cells multiply. The most common types of chemotherapy drugs are the alkylating agents. The best answer is (D).

5. **A** Since the cancer cells are multiplying and need a way to survive, the presence of the nucleic acid DNA must be important to them. Because DNA is important, the presence of a nucleic acid binding agent in the chemotherapy drug's name would indicate that it works to inhibit the multiplication of cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GDC-0068is a drug that inhibits
 
Response: GDC-0068is a drug that inhibits the activity of ALK. It is a first-in-class, oral, small molecule inhibitor of ALK.

Mechanism of Action

Treatment with GDC-0068 inhibits tumor cell growth and induces tumor cell death in a broad spectrum of ALK-positive cancers, including ALK-positive lung cancer, ALK-positive anaplastic large cell lymphoma (ALCL), ALK-positive neuroblastoma, ALK-positive small cell lung cancer (SCLC), ALK-positive non-small cell lung cancer (NSCLC), ALK-positive mesothelioma, and ALK-positive renal cell carcinoma. GDC-0068 is highly selective for ALK, as demonstrated in clinical trials.

Mechanism of Resistance

Crizotinib resistance has been reported to occur through several mechanisms, including:

Activating mutations in ALK

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GDC-0084is a drug that inhibits
 
Response: GDC-0084is a drug that inhibits the activation of aldosterone synthase (CYP11B2) in adrenocortical cells. The aim of the present study was to investigate whether GDC-0084 also affects the transcription of CYP11B2. The study was performed in two human adrenocortical cell lines, NCI-H295R and SW-13. GDC-0084 was added to the cells in concentrations of 0.01, 0.1, 1, and 10 µM. CYP11B2 mRNA levels were quantified by real-time polymerase chain reaction (PCR) at different time points (6, 12, 24, and 48 h). The CYP11B2 protein levels were quantified by Western blot. GDC-0084 significantly decreased CYP11B2 mRNA and protein levels at the lowest concentration of 0.01 µM in both cell lines. In NCI-H295
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GDC-0973(XL518,RG7420is a drug that inhibits
 
Response: GDC-0973(XL518,RG7420is a drug that inhibits VEGFR2 signaling by binding to the kinase domain of VEGFR2, a molecule involved in the activation of angiogenesis. XL518 is a novel kinase inhibitor with oral bioavailability, a half-life of 10.5 hours, and a systemic clearance of approximately 30 mL/min/kg. RG7420 inhibits VEGFR2 signaling in preclinical models of cancer. RG7420 has an acceptable safety profile and was selected for evaluation in patients with advanced solid tumors.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gemcitabineis a drug that inhibits
 
Response: Gemcitabineis a drug that inhibits the growth of tumor cells. Gemcitabineis a prodrug, which is converted to gemcitabine diphosphate (dFdCDP) in the cell cytoplasm. The activated gemcitabine is transported into the nucleus and inhibits the synthesis of DNA, causing tumor cell death.[@b1-asm-3-253] Gemcitabine has shown good activity against pancreatic cancer and non-small cell lung cancer (NSCLC) in clinical trials. However, the activity of gemcitabine in NSCLC has not been as good as in pancreatic cancer. One possible reason for this is the inherent resistance of NSCLC cells to gemcitabine.[@b2-asm-3-253] Another reason for the lower activity of gemcitabine in NSCLC is the higher activity of dihydropyrimidine dehydrogenase (DPD) in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GEMCITABINEis a drug that inhibits
 
Response: GEMCITABINEis a drug that inhibits the formation of a chemical called prostaglandin E2. This drug is used to treat diarrhea and other GI conditions. Prostaglandin E2 is produced in the GI tract by cells called enterocytes. The enterocytes produce the prostaglandin to make the fluid that passes through the GI tract.

GEMCITABINE is a prescription medicine. This medicine is only available by prescription.

HOW TO USE GEMCITABINE

Follow all directions on your prescription label. Do not take in larger or smaller amounts or for longer than recommended.

Drink plenty of water to help your kidneys remove the drug from your body.

To take GEMCITABINE by mouth:

Take your dose at the same time each day.

Swallow your dose whole. Do not chew, crush, or open the capsule.

Take GEMCIT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Geniposideis a drug that inhibits
 
Response: Geniposideis a drug that inhibits the phosphatidylinositol 3-kinase (PI3K) pathway. A previous study suggested that cGMP-dependent protein kinase (PKG) activity is necessary for the phosphorylation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB/Akt) \[[@B1]\]. PI3K is a kinase that regulates cellular proliferation and growth through phosphorylation of phosphatidylinositol (PI) \[[@B2]\]. In addition, the PI3K/Akt signaling pathway plays a role in the cell cycle, apoptosis, and angiogenesis \[[@B3][@B4][@B5]\].

Recently, studies have demonstrated that the inhibition of the PI3K/Akt signaling pathway by geniposide is associated with the treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Genisteinis a drug that inhibits
 
Response: Genisteinis a drug that inhibits an enzyme involved in the biosynthesis of prostaglandins. They are used to treat peptic ulcers and relieve symptoms of menstrual cramps. Prostaglandins are naturally produced in the body to help regulate blood flow, regulate the movement of tissue fluids, and protect the mucous membranes. However, overproduction of prostaglandins is associated with inflammation and pain. Genistein is an isoflavone and a phytoestrogen. Isoflavones are a class of plant estrogenic compounds. Isoflavones and their metabolites may be the active ingredients in some herbal preparations. The usual dose of genistein is 50 mg, twice a day.

Antifungal Agents

The drug, griseofulvin, is a broad-spectrum antifungal. It is used to treat fungal infections of the skin, nails, hair, and genitalia. Griseo
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gestodeneis a drug that inhibits
 
Response: Gestodeneis a drug that inhibits steroidogenesis and aromatase, the enzyme responsible for estrogen production in postmenopausal women. A major side effect of this drug is the stimulation of the endometrium and breast tissue, and the subsequent development of endometrial cancer and breast cancer. However, a subset of women with endometrial cancer will develop estrogen-independent tumors that do not respond to the drug. In contrast, some women who develop estrogen-independent breast cancer are treated with an aromatase inhibitor. It is unclear whether there is a genetic component to the sensitivity of breast and endometrial tumors to this drug. We propose to study the role of the estrogen-related receptor gamma (ERRgamma) gene in the response of breast and endometrial cancer to this drug. ERRgamma belongs to the nuclear hormone receptor family of transcription factors. ERRgamma regulates the expression of a number of genes involved in glucose and lipid metabolism. We hypothesize
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GHRP-2is a drug that inhibits
 
Response: GHRP-2is a drug that inhibits the release of growth hormone. The use of GHRP-2 as a growth hormone releasing agent (GHRP-2) has a number of clinical applications, particularly in the treatment of growth hormone deficiency.

Introduction

Growth hormone (GH) is released from the pituitary in a pulsatile manner, with the average secretory rate of GH ranging from approximately 1.5 to 3.0 ng/mL per pulse. The average GH concentration in serum is approximately 0.2 ng/mL, with the normal range of GH levels varying from 2.2 to 13.3 ng/mL. GH is secreted in a pulsatile manner, with an average pulse frequency of approximately 15 minutes, and a duration of 2 to 4 hours.

Pulsatile GH secretion is under direct control of hypothalamic somatostatin and GH-releasing hormone (GHRH) neurons. GHRH is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gilteritinibis a drug that inhibits
 
Response: Gilteritinibis a drug that inhibits a certain type of protein kinase that is involved in the progression of cancer. It is a kind of highly selective inhibitor of TEC kinase (also known as vascular endothelial growth factor receptor 2, or VEGFR-2), which is a type of protein kinase that is expressed on the surface of cells that line blood vessels. The cells that line blood vessels are called endothelial cells. VEGFR-2 has been identified as a major regulator of blood vessel growth and is thought to be involved in angiogenesis.

How does Gilteritinib work?

The way that Gilteritinib works is by stopping the blood vessel growth that is needed for cancer cells to grow and spread. This type of treatment is called anti-angiogenic treatment.

Gilteritinib is an orally available, highly selective inhibitor of TEC kinase. It binds to the active site of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gimeracilis a drug that inhibits
 
Response: Gimeracilis a drug that inhibits DNA synthesis and induces apoptosis in cancer cells. The current research used the thymidine kinase-deficient (TK-) human prostate cancer cell line, PC3. The purpose of this study was to examine the molecular mechanisms of gimeracilis-induced apoptosis and identify novel targets of gimeracilis. Gimeracilis treatment induced apoptosis in PC3 cells. After gimeracilis treatment, apoptosis was induced through the activation of p53, caspase-9, caspase-3, and PARP. The p53 inhibitor, pifithrin-α, and the caspase-9 inhibitor, Z-LETD-FMK, suppressed gimeracilis-induced apoptosis. Additionally, gimeracilis induced reactive oxygen species (ROS) generation, and ROS scavengers, N-acetyl-cysteine and ascorb
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GKT137831is a drug that inhibits
 
Response: GKT137831is a drug that inhibits LPL and decreases circulating TG levels by inhibiting the action of LPL in adipose tissue and skeletal muscle, reducing the mobilization of TG-rich lipoproteins, and promoting the catabolism of TG-rich lipoproteins in these tissues. In the studies in humans, GTK137831 was well tolerated, with no serious adverse events and no dose-limiting toxicities, and dose-dependent reductions in fasting plasma TG levels were observed in healthy men and women.[@b42-cpaa-2-039]

As the TG-lowering effects of GTK137831 were seen after only a few days of dosing, a 24-week, Phase IIa clinical trial was conducted to assess the efficacy and safety of GTK137831 for the treatment of TG-rich lipoprotein disorders, including non-alcoholic fatty liver disease (NAFLD) and familial combined
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  glafenineis a drug that inhibits
 
Response: glafenineis a drug that inhibits sodium channels in the cell membranes of the nerve and muscle cells of the body.

It can be used to treat symptoms of overactive bladder and chronic prostatitis/chronic pelvic pain syndrome.

It can also be used to treat pain in other parts of the body.

Uses

Glafenineis used to treat:

Overactive bladder (urgency, frequency, urgency incontinence)

Chronic prostatitis/chronic pelvic pain syndrome

Pain

Side effects

The side effects of glafenine include:

Dizziness

Fatigue

Headache

Mood changes

Stomach upset

Trouble sleeping

Urinary tract infection

Withdrawal symptoms

Weight loss

Increased frequency of bowel movements

Fainting

Glafenine may also cause other side effects.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glecapreviris a drug that inhibits
 
Response: Glecapreviris a drug that inhibits alpha5beta1 integrin-mediated attachment to vitronectin.
The integrin alpha5beta1 plays a key role in the attachment of human platelets to extracellular matrix proteins. We have examined the effects of Glecapreviris, a drug that inhibits the function of alpha5beta1, on the function of human platelets. Preincubation of platelets with Glecapreviris inhibited adhesion to vitronectin and to fibrinogen. The drug did not affect adhesion to fibronectin or to collagen. In addition, adhesion of platelets to immobilized fibrinogen was inhibited by Glecapreviris. In the presence of prostaglandin I2, platelets adhere to fibrinogen and the interaction is partly inhibited by Glecapreviris. These results suggest that alpha5beta1 plays an important role in platelet adhesion to fibrinogen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gliclazideis a drug that inhibits
 
Response: Gliclazideis a drug that inhibits the action of gastric juice and that lowers blood glucose levels in patients with type 2 diabetes. The drug is generally administered twice a day, i.e., in the morning and in the evening, as it does not have any significant adverse effects on the pancreas.

In the US, gliclazide is marketed as a combination drug, Gliclazide/Metformin, which contains two drugs: gliclazide, which is marketed as Gliclazide and Metformin. Gliclazide/Metformin is the only antidiabetic drug that is prescribed as monotherapy.

Gliclazide was first introduced in 1977. It was approved by the US Food and Drug Administration (FDA) in 1978 and in 1981, and is marketed in the US as Gliclazide/Metformin. The drug is marketed in other countries, including
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glimepirideis a drug that inhibits
 
Response: Glimepirideis a drug that inhibits glucose-induced insulin secretion by binding to the sulfonylurea receptor (SUR1). Glimepiride is indicated for the treatment of type 2 diabetes.

The primary active metabolite of glimepiride is the sulfonamide O-sulfonyloxymethyl metabolite (SM). The SM metabolite has been shown to be about 5-fold less potent than the parent drug, but may be more active than the parent drug when it is administered as a sulfonamide ester.1

Drug metabolism

Glimepiride is rapidly metabolized to the SM metabolite by the liver and is primarily eliminated in the urine as this metabolite.1

The pharmacokinetics of glimepiride are linear in the therapeutic dose range. The half-life of glimepiride is approximately 10-12 hours, while the half-life of SM is approximately 1.5 hours.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GLIPIZIDEis a drug that inhibits
 
Response: GLIPIZIDEis a drug that inhibits the activity of the enzyme lipase and reduces fat absorption. It is used to treat high blood sugar levels in patients with diabetes.

GLIPIZIDE is used in the treatment of diabetes.

GLIPIZIDE is used in the treatment of diabetes.

Dosage and Administration

Take GLIPIZIDE by mouth, usually twice daily with meals, or as directed by your doctor.

Take GLIPIZIDE with or without food.

Take GLIPIZIDE on an empty stomach (no food or liquids).

If you miss a dose of GLIPIZIDE, take it as soon as you remember. If it is almost time for your next dose, wait until then and take the next dose. Do not take 2 doses at once.

Storage

Store at room temperature away from moisture.

Keep from heat, light, and moisture.

Do not store in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gliquidoneis a drug that inhibits
 
Response: Gliquidoneis a drug that inhibits the uptake of glucose from the blood by the liver, and has a hypoglycemic effect. It is available in the form of capsules or tablets. Gliquidone is a generic drug, and its manufacturers are allowed to sell the drug without first going through a brand approval process.

The medication is prescribed to patients who have diabetes and who need to control their blood sugar levels. It works by decreasing the amount of glucose that enters the blood stream.

In this way, the amount of glucose entering the blood stream is lowered, which helps control blood sugar levels.

Gliquidone works by increasing the amount of insulin in the body. The drug is also prescribed to patients who have Type 2 diabetes and who have elevated blood sugar levels.

However, the medication may not be suitable for patients who have had problems with glucose control in the past.

Gliquidone may be prescribed to patients who have liver or kidney problems.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GLPG1837is a drug that inhibits
 
Response: GLPG1837is a drug that inhibits a number of isoforms of human monoamine oxidase A (MAO-A). It is the second generation of reversible MAO-A inhibitors. Its discovery was based on the rational design of a potent, non-covalent inhibitor of MAO-A. PG1837 has shown anti-depressant activity in preclinical models of depression. However, a human study has shown that PG1837 is a weak MAO-A inhibitor.

Introduction

Monoamine oxidase (MAO) is an enzyme that catalyses the oxidative deamination of neurotransmitters and metabolites in the central nervous system. It is involved in the metabolism of dopamine, serotonin and noradrenaline. There are two types of MAO: MAO-A and MAO-B. MAO-A is expressed in the brain, heart, liver, and kidney, and it is the predominant form in the brain.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gluconolactoneis a drug that inhibits
 
Response: Gluconolactoneis a drug that inhibits lactate dehydrogenase and stimulates lactate formation, causing acidosis and diuresis. It is used for metabolic acidosis, cystitis, nephritis, and to prevent hypoglycemia in diabetics. It is also used to decrease uric acid levels in gouty arthritis and as an antioxidant for healthy tissues.

Gluconolactone, also known as γ-D-glucopyranosyl-D-lactate or glucuronolactone, is a colorless crystalline solid with a pungent odor. It is insoluble in water but soluble in ethanol, acetone, and ether. It is used as a chemical intermediate and as a sweetening agent. It is an active ingredient in cough syrups and other medicinal products for the treatment of upper respiratory tract infections and bronchitis.

Gluconolactone is available as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glucosamineis a drug that inhibits
 
Response: Glucosamineis a drug that inhibits enzymes that break down collagen in the body.

Aids in treating joint pain.

Aids in treating muscle and tendon pain.

Aids in treating rheumatoid arthritis.

Glucosamine and chondroitin are available in many different forms.

Read on to find out about some of the most popular forms of glucosamine and chondroitin and the most effective ways to use them.

Glucosamine

A naturally occurring amino sugar. It’s the most popular supplement used for joint pain.

A naturally occurring amino sugar. It’s the most popular supplement used for joint pain. Chondroitin

A naturally occurring glycosaminoglycan (GAG).

A naturally occurring glycosaminoglycan (GAG). Glucosamine & Chondroitin

A combination of glucosamine and chond
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GLYBURIDEis a drug that inhibits
 
Response: GLYBURIDEis a drug that inhibits aldose reductase and prevents the formation of polyol, sorbitol. It is used to treat diabetes. It is also used to treat diabetic eye disease, to control hypertension, to treat heart failure, to reduce edema, to reduce angina, and to reduce the need for surgery in heart disease.

GLYCEMIC THERAPY

is a treatment that involves reducing the blood glucose level by administering a drug or insulin. It is used to treat diabetes mellitus.

HEMOGLOBIN

is a substance that carries oxygen from the lungs to the body tissues. It is made by the liver and contains two components: red blood cells and hemoglobin.

HEMOLYTIC ANEMIA

is a condition that causes low levels of hemoglobin. It is caused by low levels of iron in the blood.

HEPATIC INFECTION


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glycolicis a drug that inhibits
 
Response: Glycolicis a drug that inhibits both non-enzymatic and enzymatic glycation of proteins. It inhibits both Maillard and non-Maillard glycation pathways and decreases the formation of advanced glycation end products (AGEs). Glycolic acid is a product of glycolysis and a precursor of lactic acid and its consumption may have a metabolic benefit by shifting glucose metabolism towards lactic acid metabolism.\[[@ref1]\] Glycolic acid is a weak acid that is more hydrophilic than lactic acid. It can cross cell membranes and reach the intracellular space where it is reduced to glycolic acid-1-phosphate. It also undergoes active transport in the kidney and colon. It is absorbed from the gut into the blood and can be used as a topical agent. It has been used in ophthalmology as a lubricant in the cornea.\[[@ref2]\]


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glycyrrhetinicis a drug that inhibits
 
Response: Glycyrrhetinicis a drug that inhibits the enzyme that makes cholesterol. This drug is effective for treating people who have an enlarged prostate.

What does this medicine do?

Glycyrrhetinicis a drug that inhibits the enzyme that makes cholesterol. This drug is effective for treating people who have an enlarged prostate.

When this medicine is used, it is important to tell your doctor if you have:

kidney disease or a history of kidney disease.

an enlarged prostate.

high levels of cholesterol in your blood.

a history of cancer of the stomach or intestine.

an infection with a virus, bacteria, or yeast.

a history of allergies.

What should I tell my doctor before I take this medicine?

You should not use this medicine if you have:

kidney disease or a history of kidney disease.

an enlarged prostate.

high levels of cholesterol in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Glycyrrhizicis a drug that inhibits
 
Response: Glycyrrhizicis a drug that inhibits the growth of hepatocellular carcinoma cells and induces apoptosis. The present study evaluated the effects of glycyrrhizic acid (GA) on cell cycle distribution and cell proliferation of HCCLM3 cells. HCCLM3 cells were treated with GA at various concentrations (0, 10, 20, 30, 40, 50 and 60 µg/mL) for 24, 48 and 72 h. The cell cycle was analyzed by flow cytometry, and cell proliferation was evaluated by the MTT assay. Western blotting was performed to detect the expression of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2, CDK4, CDK6 and cyclin-dependent kinase inhibitors (CDKIs), p21, p27 and p53. GA induced G0/G1 phase arrest in H
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gonadorelinis a drug that inhibits
 
Response: Gonadorelinis a drug that inhibits the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, resulting in the decrease of FSH and LH.

Gonadorelinis a drug that inhibits the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, resulting in the decrease of FSH and LH.

Gonadorelinis a drug that inhibits the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, resulting in the decrease of FSH and LH.

Gonadorelinis a drug that inhibits the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, resulting in the decrease
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Goserelinis a drug that inhibits
 
Response: Goserelinis a drug that inhibits the action of an enzyme called telomerase. This enzyme helps to protect against cancer and other age-related diseases by keeping telomeres, which are the tips of chromosomes, from shortening too much.

Goserelin is used to treat advanced breast cancer and prostate cancer that has not responded to treatment with other medications. It may also be used to treat prostate cancer that has not responded to treatment with other medications and to treat hormone-dependent breast cancer that has spread to other parts of the body.

Side Effects

The most common side effects of goserelin include:

Menstrual changes

Menstrual bleeding, or spotting, may occur during treatment with goserelin. This is because the medication may affect the hormones that regulate menstruation. Menstrual bleeding may occur during the first 2 weeks of treatment. However, this usually stops within a few days after treatment begins.

Men
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gossypol-ais a drug that inhibits
 
Response: Gossypol-ais a drug that inhibits the function of aldehyde oxidase and the enzyme responsible for the reduction of estrogen and other xenobiotics in the liver. It was used in the past to treat hyperprolactinemia in pregnant women and to control libido in men. The drug was used as an anti-fertility agent and to prevent miscarriages in humans. It is also used to induce hypothermia in the treatment of cerebral edema.

Gossypol, which is derived from cotton plants, is a tricyclic compound that is the most potent inhibitor of the enzyme aldehyde oxidase. It was used as a male contraceptive for a time. The substance is also effective in the treatment of hyperprolactinemia in pregnancy.

Gossypol was first synthesized in 1937.

The gossypol-induced inhibition of aldehyde oxidase in the liver is an important factor in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Gramineis a drug that inhibits
 
Response: Gramineis a drug that inhibits the enzyme D-amino acid oxidase, which is involved in the degradation of D-serine, an important co-agonist at the glycine binding site of the NMDA receptor. It is being developed by Sumitomo Dainippon Pharma Co. for the treatment of schizophrenia. It is a racemic mixture, and the levorotatory isomer has been found to be twice as potent as the dextrorotatory isomer. In Phase II trials, it was found to be well tolerated, with minimal effects on behavior, and to have antipsychotic efficacy. It is under investigation in Phase III trials for schizophrenia.

Efficacy

In a double-blind, placebo-controlled trial in patients with schizophrenia, subjects were randomized to receive either the racemic mixture or the dextrorotatory isomer of gramineis at a daily dose of 800 mg for 12 weeks. The results showed that the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Granisetronis a drug that inhibits
 
Response: Granisetronis a drug that inhibits serotonin receptors in the gut. It is prescribed to treat motion sickness, prevent nausea and vomiting in the early stages of chemotherapy, and to treat anxiety, depression, and migraine headaches. It is also used as an adjunct to prevent nausea and vomiting in patients undergoing radiotherapy or chemotherapy.

Medications

Granisetron

Metoclopramide

Capsule

Dosage

Granisetron (Titanon)

3-4 mg

Metoclopramide (Reglan)

10-15 mg

1 tablet

Treatment

Granisetron (Titanon) is a 5-HT3 receptor antagonist. It is used to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, or anesthesia.

Metoclopramide (Reglan) is a prokinetic drug used to treat nausea and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Griseofulvinis a drug that inhibits
 
Response: Griseofulvinis a drug that inhibits the growth of molds, fungi and other microorganisms. It is used for the treatment of ringworm infections, such as athlete's foot, tinea pedis and tinea unguium, in dogs and cats. It is also used to treat the fungus infections that occur in people. Griseofulvinis also known as griseomycin and is used to treat fungal infections of the scalp and nails.

Griseofulvinis an antifungal agent that is used in the treatment of ringworm, athlete's foot, tinea pedis and tinea unguium. It is also used to treat the fungal infections that occur in people.

Griseofulvinis a drug that inhibits the growth of molds, fungi and other microorganisms. It is used for the treatment of ringworm infections, such as athlete's foot, tinea pedis and tinea ungu
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GS-9620is a drug that inhibits
 
Response: GS-9620is a drug that inhibits the mTOR signaling pathway, and is also a potential candidate for treating several types of cancer. In this study, we investigated the potential of the GS-9620 drug in the treatment of bone metastases. A human osteosarcoma cell line (U2OS) was treated with the GS-9620 drug, and the effect of this treatment on U2OS cell viability, migration and invasion was investigated. In addition, the influence of GS-9620 on U2OS cell apoptosis and the expression of proteins related to the mTOR signaling pathway were analyzed. The results showed that GS-9620 inhibited the viability, migration and invasion of U2OS cells in a dose-dependent manner, and promoted U2OS cell apoptosis. In addition, GS-9620 inhibited the expression of phosphorylated mTOR and its downstream proteins. GS-9620 inhibits the proliferation, migration and invasion of U2OS cells by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GS-9973is a drug that inhibits
 
Response: GS-9973is a drug that inhibits the action of ATP on the potassium channel in heart cells. It was found that GS-9973 is a blocker of the hERG potassium channel and that it causes a prolongation of the QT interval in the ECG. This effect is especially important in the development of drugs for the treatment of cardiovascular diseases, since prolongation of the QT interval can cause a life-threatening ventricular arrhythmia, namely torsade de pointes.

The objective of the present study was to examine the influence of GS-9973 on the myocardial repolarization in dogs. The study was performed in anesthetized dogs and on isolated canine left ventricular papillary muscles. The influence of GS-9973 on the action potential duration (APD), action potential upstroke velocity (APV), action potential duration at 50% repolarization (APD50), action potential duration at 90% repolarization (APD90
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK1070916is a drug that inhibits
 
Response: GSK1070916is a drug that inhibits the action of the protein kinase, CDK7. CDK7 is involved in cell cycle progression and is a key component of the pre-initiation complex. In this study, we assessed the antitumor activity of the drug in two breast cancer models. We observed that treatment with GSK1070916 causes cell cycle arrest and apoptosis in MDA-MB-231 and MDA-MB-468 cells. Furthermore, the drug was able to sensitize the cells to the chemotherapeutic drug, cisplatin. In conclusion, GSK1070916 can be used as a new therapeutic option in breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK1120212is a drug that inhibits
 
Response: GSK1120212is a drug that inhibits the binding of CDK2 to cyclin A and cyclin E and, therefore, inhibits CDK2-dependent phosphorylation. GSK1120212 is being developed by GlaxoSmithKline (GSK) for the treatment of patients with advanced solid tumors, including colorectal cancer. In this study, we analyzed GSK1120212 in vitro activity and determined the levels of GSK1120212 in patient plasma and tumor tissue. We found that GSK1120212 was active in colorectal cancer cell lines and tumor tissue from patients with advanced colorectal cancer. GSK1120212 treatment was associated with cell cycle arrest in G1 phase, induction of apoptosis, and inhibition of migration and invasion. Treatment of colorectal cancer cell lines with GSK1120212 was associated with downregulation of CDK2 and phosphorylation of the retinoblastoma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK1265744is a drug that inhibits
 
Response: GSK1265744is a drug that inhibits tumor growth and metastasis by modulating the PI3K/Akt/mTOR signaling pathway. However, the impact of the drug on autophagy has not been evaluated. Here, we investigated the effects of GSK1265744 on autophagy and explored the mechanisms by which the drug induces autophagy. We found that GSK1265744 suppressed the proliferation of lung cancer cells by activating autophagy and induced apoptosis in A549 and H1975 cells. Moreover, GSK1265744 inhibited the metastasis of lung cancer cells by suppressing the expression of matrix metalloproteinase-2 (MMP-2) and E-cadherin, as well as by increasing the expression of E-cadherin-associated proteins (E-cadherin, claudin-1, ZO-1, and occludin). In addition, GSK1265744
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK1349572is a drug that inhibits
 
Response: GSK1349572is a drug that inhibits EZH2. The best response was seen in patients with EZH2-mutant DLBCL. GSK1349572 monotherapy had manageable toxicity and was well tolerated in the majority of patients, suggesting that it may be a suitable treatment for patients with EZH2-mutant DLBCL.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2118436is a drug that inhibits
 
Response: GSK2118436is a drug that inhibits IL-1 and IL-18 signaling. It is a novel dual IL-1R/IL-18R antagonist that is effective against IL-1- and IL-18-mediated disorders. The present study was undertaken to evaluate the safety and efficacy of GSK2118436 in a phase 1 dose escalation study in healthy volunteers. GSK2118436 was administered by oral or intravenous infusion. Safety, pharmacokinetics, and immunogenicity were evaluated. GSK2118436 was well tolerated. The most frequent adverse events were mild gastrointestinal symptoms and injection site reactions. No treatment-related serious adverse events were observed. GSK2118436 was well tolerated and effectively inhibited IL-1 and IL-18-mediated disorders. In conclusion, GSK2118436 is a promising drug for the treatment of IL-1 and IL-18-mediated diseases.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2141795is a drug that inhibits
 
Response: GSK2141795is a drug that inhibits phosphorylation of FGF-2, resulting in reduced binding to FGFR1c, decreased tumor growth and improved survival in a murine model of human cancer. In vitro, GSK2141795 inhibits growth of human cancer cells, and in vivo, GSK2141795 is well tolerated in animal models.

GSK2141795 is being developed by GSK for the treatment of cancer. In March 2017, GSK was granted orphan drug designation for GSK2141795 by the FDA. In June 2017, GSK announced that it had entered into a license agreement with DORA Therapeutics for GSK2141795. In July 2017, GSK announced that it would seek FDA approval for GSK2141795.

GSK2141795 is a drug that inhibits phosphorylation of FGF-2, resulting in reduced binding to FGFR1c, decreased tumor growth and improved
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2256098is a drug that inhibits
 
Response: GSK2256098is a drug that inhibits the enzyme glycogen synthase kinase-3 beta (GSK-3β). GSK-3β is involved in the regulation of cell survival and differentiation and the Wnt signaling pathway, and plays an important role in several signaling pathways, including the TGF-β, Notch, and insulin signaling pathways.

GSK-3β has also been found to be a key component in the development of neurodegenerative diseases such as Alzheimer's disease (AD). Aβ is a toxic protein fragment generated by the cleavage of the amyloid precursor protein (APP) by β- and γ-secretase. APP is also a substrate for GSK-3β, and APP phosphorylation by GSK-3β promotes its proteolytic cleavage.

GSK-3β is also implicated in the regulation of other processes that are relevant to the pathogenesis of AD. For example,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2269557is a drug that inhibits
 
Response: GSK2269557is a drug that inhibits TNF-induced IkappaB phosphorylation. It is being developed by Eli Lilly for the treatment of inflammatory bowel disease (IBD). The drug has completed phase 2 trials in patients with ulcerative colitis and Crohn's disease, and phase 3 trials are planned. It is also being investigated in combination with anti-TNF agents in IBD patients who have failed anti-TNF therapy. It is also being studied in patients with rheumatoid arthritis.Golimumabis a drug that inhibits TNF-induced IkappaB phosphorylation. It is being developed by Janssen for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis. It is also being investigated in patients with IBD. In phase 3 trials it was found to be more effective than placebo for patients with RA. It is also being studied in patients with psoriatic arthritis. CDP-571is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2636771is a drug that inhibits
 
Response: GSK2636771is a drug that inhibits the PI3K-Akt-mTOR pathway. This agent has been studied in patients with advanced or metastatic melanoma and renal cell carcinoma, and is currently being studied in other cancers, including ovarian cancer, breast cancer, and lymphoma. Based on promising results in these trials, it was studied in patients with relapsed/refractory MM. The authors concluded that this agent had promising activity in this setting.

Phase I {#Sec1}
=======

Trial design and patient population {#Sec2}
-----------------------------------

This study was a single-arm, open-label, multicenter trial. Patients were enrolled at 28 centers in North America, Europe, and South America. Eligible patients were required to have a histologically or cytologically confirmed diagnosis of MM and a disease recurrence or progression while on or within 12 months of completion of their last therapy. The population was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2879552is a drug that inhibits
 
Response: GSK2879552is a drug that inhibits GSK3 activity. It is in Phase II clinical trials for type 2 diabetes and neurodegenerative disorders. Here, we show that in rat brain slices, LY2160160, like lithium, enhanced synaptic transmission. LY2160160 also enhanced evoked release of dopamine and glutamate, and it enhanced the frequency and amplitude of spontaneous synaptic events. The LY2160160-induced enhancement of synaptic transmission was blocked by the GSK3 inhibitor, LY2090314, suggesting that GSK3 is involved in the effects of LY2160160. Furthermore, LY2160160 enhanced the levels of phosphorylated CREB, and it increased the number of phosphorylated CREB positive cells. LY2160160, like lithium, also enhanced synaptic plasticity, and enhanced the expression of Arc, a plasticity-related immediate early gene. Thus, LY2160160 enhances synaptic transmission,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2981278is a drug that inhibits
 
Response: GSK2981278is a drug that inhibits the activity of AKT and S6 kinase. It was used in this study because of its ability to promote cell cycle arrest and inhibit the growth of melanoma cells, in vitro and in vivo, while having little effect on normal cells. In addition, the drug showed no toxicity to the liver, kidney, heart, or brain, as measured by the MTS assay. As mentioned above, cell proliferation, cell cycle progression, and apoptosis were measured in A375 cells after treatment with GSK2981278 or DMSO. GSK2981278 inhibited the proliferation of A375 cells in a dose-dependent manner, with an IC50 of 0.65 µM ([Figure 3A](#f3-ott-11-4283){ref-type="fig"}). We also examined the cell cycle distribution of A375 cells after GSK2981278 treatment. GSK2981278 treatment caused a significant accumulation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK2982772is a drug that inhibits
 
Response: GSK2982772is a drug that inhibits the phosphorylation of GSK-3β and thereby prevents its inactivation. This drug has been demonstrated to protect against cell death in a number of different disease states. We have previously demonstrated that GSK2982772, in addition to reducing apoptosis, also reduced caspase-3 activity in a cellular model of HD. However, the effect of this drug on caspase-3 activity in the R6/2 mouse brain has not been investigated. We hypothesized that GSK2982772 would reduce caspase-3 activity in the R6/2 mouse brain. We therefore assessed caspase-3 activity in the striatum and cortex of the R6/2 mouse brain following oral administration of GSK2982772. We also investigated the effect of GSK2982772 on the levels of the autophagy marker LC3-II. We found that oral administration of GSK2982772 to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GSK525762is a drug that inhibits
 
Response: GSK525762is a drug that inhibits the activation of extracellular signal-regulated kinase (ERK) 1/2 and p38 MAP kinase and has been developed as a treatment for inflammatory diseases. In the present study, we investigated the potential effects of GSK525762 on cigarette smoke-induced inflammatory responses in the lungs of mice. We demonstrated that GSK525762 inhibited the expression of chemokines such as MIP-2 and MCP-1, as well as the infiltration of inflammatory cells into the lungs, in mice exposed to cigarette smoke. GSK525762 also inhibited the production of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in the lungs of cigarette smoke-exposed mice. Furthermore, GSK525762 inhibited the production of NO in LPS-stimulated RAW 264.7 cells. In conclusion, our results indicate that GSK525762 attenuates cigarette smoke-induced lung inflammation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Guanabenzis a drug that inhibits
 
Response: Guanabenzis a drug that inhibits the activity of the alpha1 adrenergic receptor (alpha1-AR) in the peripheral nervous system and the brain.

The alpha1-AR subtypes are a family of G-protein coupled receptors that regulate neurotransmitter release and are expressed in the central and peripheral nervous system. Guanabenz has been reported to have a number of actions including inhibition of the release of neurotransmitters, including noradrenaline and acetylcholine.

It has been used to treat attention deficit hyperactivity disorder (ADHD), the elderly and certain conditions of the cardiovascular system.

It is available as a tablet and liquid formulation and is generally administered once or twice daily.

1.2 What are the possible side effects of guanabenz?

Adverse effects of guanabenz include drowsiness, headache, dizziness, weakness, muscle cramps, increased sweating, tachycardia, chest pain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  guanethidineis a drug that inhibits
 
Response: guanethidineis a drug that inhibits the sympathetic nervous system. It is commonly used to treat patients with high blood pressure and/or heart disease.

Patients with advanced kidney disease who have symptoms of high blood pressure may be given guanethidine to treat the hypertension.

Guanethidine is available as a tablet, an injection, and an oral solution. It is used with caution in people with allergies to any ingredient in guanethidine.

Guanethidine Side Effects

Guanethidine can cause side effects, including:

Nausea, dizziness, and fainting when you first start taking the drug

Irregular heartbeat

Drowsiness, dizziness, weakness, and headache

Liver problems, including jaundice, loss of appetite, and fatigue

Other side effects include allergic reactions (rash, hives, itching, and/or shortness of breath), nausea, vomiting
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Guanidineis a drug that inhibits
 
Response: Guanidineis a drug that inhibits proliferation of most tumor cells. Inhibition of ribonucleotide reductase by 8-aminoguanosine, an inhibitor of the p53 tumor suppressor, results in accumulation of hypoxanthine and adenine nucleotides. Guanidine increases nucleotide pool levels, and promotes G1/S phase arrest in some cell lines. Guanidine also inhibits poly(ADP-ribose)polymerase (PARP), which, along with telomerase, are important for maintaining telomere length. It has been proposed that the inhibition of PARP is responsible for the anti-tumor activity of guanidine. We studied the effects of guanidine on the expression of p53 and its downstream targets. Guanidine decreased the steady state levels of p53, p21, and MDM2 in cell lines with wild-type p53. The half-life of p53 was also increased in cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Guanosineis a drug that inhibits
 
Response: Guanosineis a drug that inhibits human immunodeficiency virus (HIV) replication by interacting with the reverse transcriptase of the virus, but it also has activity against other viruses.\[[@ref1]\] A novel guanosine analogue, 3′-deoxy-3′-fluoroguanosine (F-araG), has been synthesized with improved anti-HIV activity.\[[@ref2]\] F-araG is a prodrug that is converted to the active form by phosphorylation and deamination.\[[@ref3]\] The objective of this study was to evaluate the antiviral activity of F-araG in combination with zidovudine (ZDV) and the drug-drug interaction between F-araG and ZDV in healthy volunteers.

A randomized, open-label, two-period, crossover study was conducted in healthy male volunteers at the Clinical
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  GZD824is a drug that inhibits
 
Response: GZD824is a drug that inhibits the biosynthesis of catecholamines. It is also known as theophylline, because of its similarity to the chemical structure of theophylline. This drug has a high affinity for adenosine receptors.

When given orally, it is available in a dosage of 1 to 3 mg/kg. The most common dosage is 1.25 to 2.5 mg/kg/day. In severe cases, doses of up to 10 mg/kg/day may be necessary. The recommended initial dose is 500 mg, and the maximum dose is 1,000 mg/day.

Phenobarbital

Phenobarbital is a barbiturate. It is used to treat tonic-clonic seizures and status epilepticus. It is also used to treat partial and general seizures.

When given orally, it is available in a dosage of 5 to 20 mg/kg. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Halazoneis a drug that inhibits
 
Response: Halazoneis a drug that inhibits respiration in the protozoan parasite *Leishmania* spp. It is used in the treatment of cutaneous leishmaniasis and is available in the form of an emulsion of 0.5% ointment, with a recommended dose of 2.5 g/kg/day for 7 days.

After a few days of treatment, the patients present with various forms of cutaneous leishmaniasis (CL) (Fig. [1](#Fig1){ref-type="fig"}), and treatment is continued for 2 weeks in a step-up approach. After the first 2 weeks, the treatment is extended for another 2 weeks, and after that the treatment is extended until all lesions are healed. The drug should be applied every day and the patient must not stop taking it until all lesions have been healed. Fig. 1Lesions of cutaneous leishman
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Halcinonideis a drug that inhibits
 
Response: Halcinonideis a drug that inhibits androgenic hormone production by the prostate gland and has been shown to be effective in the treatment of benign prostatic hyperplasia.

Active Ingredients

5-alpha-reductase inhibitor

Bicalutamide

Formulation

Soft Gel

Uses

Prostate cancer

Cystitis

Prostatic hyperplasia

Active Ingredients

Bicalutamide

Dutasteride

Formulation

Soft Gel

Uses

Benign prostatic hyperplasia

Active Ingredients

Bicalutamide

Dutasteride

Formulation

Soft Gel

Uses

Prostate cancer

Cystitis

Prostatic hyperplasia

Active Ingredients

Bicalutamide

Dutasteride

Formulation

Soft Gel

Uses

Benign prost
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HALDOLis a drug that inhibits
 
Response: HALDOLis a drug that inhibits the activity of the liver enzyme CYP3A4. It is marketed as a prescription drug for treatment of certain types of viral hepatitis.

ALZALIS is a drug that is used to treat type 2 diabetes mellitus (T2DM).

PIROGLUZAL is a drug that is used to treat overactive bladder (OAB).

KARVONIC ACID is a drug that is used to treat type 2 diabetes mellitus (T2DM).

LARVOSIM is a drug that is used to treat overactive bladder (OAB).

AVIVASTAT is a drug that is used to treat overactive bladder (OAB).

DIABETOL is a drug that is used to treat overactive bladder (OAB).

CHLORAMPHENES is a drug that is used to treat overactive bladder (OAB).

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  halobetasolis a drug that inhibits
 
Response: halobetasolis a drug that inhibits the production of serotonin and, as a result, decreases the need for sleep. Some people find it helps them sleep. But it has a few disadvantages. For example, it makes it hard to eat, and it can have some nasty side effects.

Tobacco: There is an herb called _nicotine_ that is found in tobacco leaves. It can be smoked or taken in an herbal tea. It is an alkaloid that stimulates the brain's production of the chemical dopamine. When it is inhaled, it is absorbed into the bloodstream.

_Nicotine_ is the addictive ingredient in cigarettes. It is a powerful stimulant that can be used to treat depression. It can also increase your energy, which can help you cope with depression.

In Europe, people used to smoke and chew tobacco for medicinal purposes. The tobacco plant was a very valuable herb. It has been used for centuries in medicine. For example
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Halofuginoneis a drug that inhibits
 
Response: Halofuginoneis a drug that inhibits the enzyme lanosterol 14α-demethylase (CYP51A1) and prevents the biosynthesis of ergosterol, which is a critical component of the fungal cell membrane.^[@bib1]^ This drug was first discovered as a potential anticancer drug in an in vitro screening of plant extracts.^[@bib2]^ Later, the drug was found to be effective against various fungal pathogens and currently it is used to treat the common and severe systemic mycosis (deep-seated candidiasis and mucormycosis).^[@bib3]^ It is also used to treat leishmaniasis,^[@bib4]^ pityriasis versicolor,^[@bib5]^ and tocolysis.^[@bib6]^ The oral bioavailability of the drug is low and it is metabolized by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Haloperidolis a drug that inhibits
 
Response: Haloperidolis a drug that inhibits the production of certain enzymes and slows the growth of bacteria and fungi. It is used to treat certain types of skin infections, fungal infections of the skin, mouth, vagina, and the urinary tract, and bacterial infections of the vagina and urinary tract. It is also used to treat chronic otitis media in children. It is available as a solution, tablets, and ointment.

acenocoumarol (a-sen-oh-koo-mar-ol)

A drug that is used to prevent and treat certain types of blood clots. It works by slowing the formation of new blood clots and by preventing them from breaking down. It is used to prevent or treat deep vein thrombosis, pulmonary embolism, and stroke. It is also used to prevent the formation of blood clots in people who have had a hip replacement or spinal cord injury. It is available as a solution for injection
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Halothaneis a drug that inhibits
 
Response: Halothaneis a drug that inhibits the synthesis of an enzyme that controls the ratio of carbon dioxide to oxygen in the blood. The drug has been widely used in anesthesia for almost 50 years. It is a short-acting agent with a duration of action of about four hours.
Halothane has a strong narcotic-like effect on the central nervous system and is associated with an increased risk of respiratory depression and cardiac arrest. In particular, patients who have or are recovering from chronic alcoholism are at a greater risk of developing complications due to the side effects of the drug. This is especially true when the drug is used for the induction of anesthesia.
In the past, halothane has been administered to patients as a vaporized mixture of halothane in a carrier gas such as oxygen or nitrous oxide. The method of administration is not completely satisfactory because the drug is administered in a highly flammable gas.
Halothane is a widely used anesthetic. Halothane
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HEDULINis a drug that inhibits
 
Response: HEDULINis a drug that inhibits the development of blood vessels. It is the treatment of choice for the management of patients with high blood pressure and end-stage renal disease.

In the heart, HEDULIN prevents heart cells from growing into each other. This prevents the buildup of scar tissue in the heart, which can lead to heart failure.

HEDULIN is the most effective treatment for people with severe pulmonary hypertension.

HEDULIN has been shown to help prevent heart failure after a heart attack.

In people with kidney failure, HEDULIN improves kidney function.

HEDULIN can also be used to treat children who have a severe, inherited condition called sickle cell disease.

People who take HEDULIN for the prevention of kidney disease are less likely to develop kidney disease later in life.

HOW IT WORKS

HEDULIN works by inhibiting the development of blood vessels
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hematoxylinis a drug that inhibits
 
Response: Hematoxylinis a drug that inhibits an enzyme, inhibiting the biosynthesis of riboflavin. This is a common supplement for rabbits.

Can't find what you are looking for? See more ads from nearby locations.

My rabbits are on a healthy diet, I am feeding them greens, bones, pellets, carrots, and other supplements. I feed them with a bottle opener, a spoon and a cup. I make sure they have plenty of fresh clean water.

I also do this for my cats.

My rabbits are on a healthy diet, I am feeding them greens, bones, pellets, carrots, and other supplements. I feed them with a bottle opener, a spoon and a cup. I make sure they have plenty of fresh clean water.

I also do this for my cats.

Why are you selling your rabbits?

Please don't contact me again. Thank you for contacting me.

For more
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Heparinis a drug that inhibits
 
Response: Heparinis a drug that inhibits a key enzyme (e.g., HCV NS3 protease) in the HCV lifecycle, and used as a monotherapy or in combination with other direct-acting antiviral agents (e.g., boceprevir, telaprevir, and simeprevir). It is an HCV NS3/4A protease inhibitor that can be used in combination with pegylated interferon and ribavirin. It is marketed as an oral agent.

Brand name(s)

Epclusa

Indication(s)

Hepatitis C

Dosage

Take the recommended dose once daily with or without food.

When used in combination with pegylated interferon and ribavirin, take the dose of Epclusa with food.

Adverse effects

Side effects

Dose-related adverse effects

Mild
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HEPSERAis a drug that inhibits
 
Response: HEPSERAis a drug that inhibits the synthesis of eicosanoids, which are fatty acid metabolites that can cause allergic reactions and inflammation. It is used to treat asthma and allergic rhinitis. Inhaled heparin (or heparin sulfate) can help prevent the body from producing inflammatory chemicals and help reduce inflammation. It is also used to prevent blood clots in people who have had a heart attack.

HEPSERA is available in two different strengths:

1.

Hepsaact (80 units/inhalation): This strength is for inhalation and is available in a single inhaler (Metered Dose Inhaler, MDI). It is not intended for oral use. It is a fast-acting, short-term asthma medication that is available in a single dose.

2.

Hepsaact 80/12 (120 units/inhalation): This strength is for inhalation and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hesperidinis a drug that inhibits
 
Response: Hesperidinis a drug that inhibits protein kinase C activity has been shown to inhibit the production of IL-2 in T-cells stimulated with anti-CD3 and concanavalin A. We found that the production of IL-2 in peripheral blood mononuclear cells stimulated with PHA was also inhibited by the drug. However, the production of IL-2 in the cultures stimulated with anti-CD3 was not affected by the drug. The production of IL-2 in the culture stimulated with PMA and ionomycin was also not affected by the drug. These results indicate that Hesperidinis inhibits the production of IL-2 in human peripheral blood mononuclear cells stimulated with anti-CD3 and PHA.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hexestrolis a drug that inhibits
 
Response: Hexestrolis a drug that inhibits estradiol synthesis by competitively binding to the aromatase enzyme, preventing its conversion of androgen to estrogen. This drug is used in veterinary medicine for estrogenic conditions in animals such as equine polycystic ovary syndrome (PCOS) and in sows to prevent retained placenta. The drug is a synthetic estrogen, and was developed in the 1960s for medical use. The compound is highly lipophilic and is administered orally or parenterally. It is a progestin with progestogenic activity and has weak androgenic activity. In animals, the drug can have the following effects:
1. Suppression of ovarian follicular development and maturation
2. Inhibition of luteinizing hormone (LH) secretion
3. Inhibition of LH-induced progesterone secretion
4. Decreased ovarian estradiol secretion
5. Inhibition of estradiol synthesis
6
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hexetidineis a drug that inhibits
 
Response: Hexetidineis a drug that inhibits the action of acetylcholine. The medicine is used to treat pain and to treat and prevent ulcers in the stomach and intestines. The active ingredient in this drug is N-methyl-4-piperidinyl-N-phenylpropionamide.

Hexetidine is prescribed to treat the symptoms of painful ulcers and gastritis. The drug may also be used to treat patients with gastroesophageal reflux disease. It is a controlled substance that is available by prescription.

Hexetidine is a narcotic that works by blocking the action of the chemical acetylcholine. The chemical acetylcholine is found in the brain and is a neurotransmitter that helps send messages between nerve cells. It also affects other systems in the body.

Hexetidine works by blocking the action of acetylcholine. Acetylcholine is a neurotransmitter that helps to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Histamineis a drug that inhibits
 
Response: Histamineis a drug that inhibits platelet aggregation and has been used for decades to treat migraine and other conditions. A great deal of research has been conducted to find out how it works, and a range of mechanisms have been proposed, including activation of H1-receptors on platelets and activation of vascular H1-receptors on smooth muscle cells. This article looks at the potential for histamine to have a therapeutic role in the treatment of migraine and related conditions.

HISTAMINE

What is histamine?

Histamine is a chemical compound found in the body that acts as a neurotransmitter in the brain. It has a number of different actions in the body, including effects on the heart, blood vessels, smooth muscle, bones, and the central nervous system. Histamine is found in both mammals and plants, and is one of the main chemicals involved in the response of plants to injury.

Histamine in the body

The most
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HIVIDis a drug that inhibits
 
Response: HIVIDis a drug that inhibits the CCR5 co-receptor. CCR5 is the major co-receptor for HIV-1 entry into human CD4+ T cells. The overall goal of this project is to test whether this drug will have therapeutic value in HIV infection.

Consequences of the loss of CD4+ T cells during HIV infection

After the acute phase of infection, HIV-1 causes progressive immune system damage, referred to as AIDS. The virus causes death of CD4+ T cells, which are essential for immune function. HIV-1 replicates at a high level in the lymph nodes, causing an overproduction of virus and inflammatory immune cells.

HIV-1 infects CD4+ T cells in the gut, where the virus can hide from the immune system. Infected cells migrate to the blood, causing immune dysfunction. The virus then infects cells in the brain, causing neurological symptoms and dementia.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HMN-214is a drug that inhibits
 
Response: HMN-214is a drug that inhibits a class of enzymes called protein kinases. Protein kinases are enzymes that transfer phosphate groups from high energy molecules called ATP to other molecules. These phosphate groups attach to specific amino acids in other proteins, and the modified proteins perform different functions.

When the body makes a protein, it attaches a phosphate group to a specific amino acid in the protein. The phosphate group, along with other amino acids, helps to form the shape of the protein.

In most proteins, a phosphate group is attached to an amino acid called serine. Serine is a small amino acid that is often found in the middle of the protein. If the phosphate group is attached to the wrong amino acid, the protein may not work properly.

Protein kinases attach phosphate groups to proteins by attaching ATP molecules to serine. The protein kinases are activated when they are attached to ATP, and they use the energy from the ATP to attach a phosphate group
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HMPL-504(AZD6094,is a drug that inhibits
 
Response: HMPL-504(AZD6094,is a drug that inhibits the mevalonate pathway. In cells where the mevalonate pathway is inhibited, a unique phosphorylated form of the alpha subunit of the nuclear hormone receptor LXR (NR1H3) accumulates in the nucleus. This phosphorylated form is not activated by the natural ligand, oxysterols, but it can be activated by synthetic agonists. LXR agonists have been shown to be effective in lowering cholesterol in animal models. We are using this pathway to deliver gene therapy for familial hypercholesterolemia (FH). LXR agonists are also being used in clinical trials to reduce cholesterol levels in humans. We have also recently shown that LXR agonists can reduce triglyceride levels in animal models. This is of particular importance as obesity is a major risk factor for the development of diabetes. In addition to LXR agonists, LXR antagonists have been developed to treat metabolic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Homatropineis a drug that inhibits
 
Response: Homatropineis a drug that inhibits acetylcholine (ACh) at the muscarinic receptor, but has also been shown to act as a full agonist at the alpha 1 adrenergic receptor. The pharmacology of homatropine and its stereoisomers has been studied in a variety of in vitro and in vivo models. This review describes the pharmacology of homatropine and its stereoisomers, and the effect of racemic homatropine on memory in humans. The paper also considers the neurochemical basis for the effects of racemic homatropine on memory in humans, and the pharmacokinetics and pharmacology of the various homatropine enantiomers.

Introduction

Homatropine is a drug that inhibits acetylcholine (ACh) at the muscarinic receptor, but has also been shown to act as a full agonist at the alpha 1 adrenergic receptor (McIntyre et al.,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Honokiolis a drug that inhibits
 
Response: Honokiolis a drug that inhibits the action of acetylcholinesterase (AChE) and monoamine oxidase A (MAO-A) and has been found to possess antioxidant properties. It is obtained from the leaves of a Chinese medicinal plant, *A. frutescens* and is used to treat neurological disorders and inflammation. It is the major constituent of *A. frutescens* and is used in various folk medicines in the Orient for the treatment of various diseases, including arthritis, inflammation, diabetes, and dementia. Several reports have indicated that Honokiol is a potential candidate for the treatment of various neurological disorders such as dementia, Alzheimer's disease (AD), and stroke[@b1][@b2][@b3]. A previous study has shown that treatment with Honokiol decreased the accumulation of amyloid-β (Aβ) in the brains of Aβ-infused rats and that the treatment also improved the behavioral performance
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  HS-10296is a drug that inhibits
 
Response: HS-10296is a drug that inhibits the c-jun NH2-terminal kinase (JNK) 1,2 and MAPK kinase kinase 1 (MKK1), 2, and 3 and prevents activation of c-jun. In the present study, we investigated the effects of JNK inhibition on monocyte adhesion to endothelial cells in vitro. Adhesion of human peripheral blood monocytes to human umbilical vein endothelial cells (HUVECs) was measured by using a flow cytometry-based assay. JNK inhibition by SP600125 inhibited monocyte adhesion to HUVECs in a dose-dependent manner. Furthermore, JNK inhibition also inhibited tumor necrosis factor (TNF)-alpha-induced monocyte adhesion. TNF-alpha treatment increased c-jun expression and phosphorylation in monocytes. In addition, TNF-alpha increased JNK phosphorylation in monocytes. These results indicate that TNF
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Huperzineis a drug that inhibits
 
Response: Huperzineis a drug that inhibits the breakdown of acetylcholine (ACh) in the brain. This causes the release of more ACh, which stimulates the ACh receptors. This can lead to feelings of relaxation, alertness, and energy.

Hypericum is a drug that is used to treat depression. It can also help treat bipolar disorder and schizophrenia. It works by boosting levels of serotonin in the brain.

Piperine is a natural chemical that is found in black pepper. It is thought to improve the absorption of other drugs.

L-Theanine is a natural chemical that is found in green tea. It is thought to boost the effectiveness of caffeine.

Caffeine is a natural chemical that is found in coffee, tea, and chocolate. It is thought to improve the effectiveness of other drugs.

Milk thistle is a natural plant that is found in the northern hemisphere. It is used to treat liver problems
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hyaluronicis a drug that inhibits
 
Response: Hyaluronicis a drug that inhibits the production of hyaluronic acid. It is used to treat inflammatory conditions of the eyes and the joints.

You can also get a preservative-free formula of this drug if you are allergic to this.

Hyaluronic acid is a naturally occurring substance that is found in human tissues and can be used to maintain the skin's moisture. It is a naturally occurring substance that is found in human tissues and can be used to maintain the skin's moisture.

Preservative-free Hyaluronic Acid Ophthalmic Solution

Hyaluronic acid is a naturally occurring substance that is found in human tissues and can be used to maintain the skin's moisture. It is a naturally occurring substance that is found in human tissues and can be used to maintain the skin's moisture.

There are no preservatives in this formula. It is preservative-free.

Hyaluronic Acid Inject
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hydralazineis a drug that inhibits
 
Response: Hydralazineis a drug that inhibits the Na+/H+ antiporter in the erythrocyte and is used to treat the symptoms of mild to moderate hypertension. It is a non-selective vasodilator that causes sodium and water retention in the erythrocyte and other tissues, and it has little effect on systemic blood pressure. Hydrochlorothiazide (HCT) is a diuretic that is used to treat hypertension. It is a thiazide diuretic that acts by inhibiting Na+/Cl- cotransport in the distal nephron.

Case Report {#sec1-1}
===========

A 60-year-old female patient, with hypertension and dyslipidemia, was referred to the outpatient clinic of the outpatient hypertension clinic. The patient had a past medical history of primary hypertension, and was treated with a combination of nifedipine and hydrochlorothiazide
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hydrocortisoneis a drug that inhibits
 
Response: Hydrocortisoneis a drug that inhibits the conversion of cortisone to the active form of the hormone. It is used to treat skin inflammation, certain types of allergies, eczema, and skin ulcers. It is also used to reduce the inflammation in patients who have asthma.

Hydrocortisone, which is also known as hydrocortisone acetate, is used to treat various skin conditions. It may also be used to treat the following conditions:

Asthma

Allergic rhinitis

Injection site reactions

Severe, chronic skin ulcers

Other uses for hydrocortisone:

Inhaled form of hydrocortisone is used to treat the following conditions:

Asthma

Allergic rhinitis

Skin inflammation

Dosage

Your doctor will prescribe a dose of hydrocortisone that is best for you. You may be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hydroxychloroquineis a drug that inhibits
 
Response: Hydroxychloroquineis a drug that inhibits the disease-causing parasite in the blood and tissues. It is used to treat and prevent malaria. Hydroxychloroquine has also been used to treat rheumatoid arthritis, lupus, and systemic lupus erythematosus. Hydroxychloroquine is a useful treatment for rheumatoid arthritis because it reduces the swelling and stiffness of the joints. It also has some pain-relieving effects. It may be used alone or with other medications.

Sudden cardiac death is a very sudden, unexpected, and sometimes fatal event. It may occur without warning and without any previous signs or symptoms. The cause of sudden cardiac death is usually unknown. Some of the most common causes of sudden cardiac death are the following:

The sudden death of someone who is healthy is not always a cause for concern. However, when the cause of death is unknown, it is important to investigate further.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hydroxyureais a drug that inhibits
 
Response: Hydroxyureais a drug that inhibits angiogenesis by blocking the formation of new blood vessels from existing vessels, including those of the retina. Hydroxyurea is used to treat sickle cell anemia and some other diseases. Hydroxyurea also has been used in combination with other drugs, such as cytotoxic drugs, for cancer treatment.

This article covers the following topics:

What is angiogenesis?

What is the treatment of cancer with cytotoxic drugs?

What is hydroxyurea?

What are the side effects of hydroxyurea?

What are the side effects of hydroxyurea in children?

What is the treatment of sickle cell disease with hydroxyurea?

What are the side effects of hydroxyurea in children?

What is the treatment of sickle cell disease with hydroxyurea?

What is the treatment of sickle cell disease
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hydroxyzineis a drug that inhibits
 
Response: Hydroxyzineis a drug that inhibits the reuptake of norepinephrine. It is used for the treatment of a number of disorders such as:

It is used to treat:

ADHD

Migraine

Anxiety

Depression

Aneurysms

Breast Cancer

Stroke

HIV

Rheumatoid Arthritis

Sickle Cell Anemia

Dry Eye Syndrome

Lupus

Cervical Dysplasia

Chronic Obstructive Pulmonary Disease (COPD)

Allergies

Hepatitis C

Seizures

Premature Birth

Cancer

Other Disorders

The chemical name of Hydroxyzine is 4-(Hydroxy-3-methoxyphenyl)-N,N-dimethyl-2-pyrrolidinone.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hygromycinis a drug that inhibits
 
Response: Hygromycinis a drug that inhibits the growth of Cryptococcus neoformans in vitro.
The azole drugs used to treat cryptococcosis are fungistatic in vitro and fungicidal in vivo. To better understand how azole drugs function, we used a high-throughput assay to screen a diverse collection of fungi for compounds that inhibit the growth of Cryptococcus neoformans. An analog of hygromycin B, designated hygromycin A, was isolated from an unidentified species of Streptomyces and was found to inhibit the growth of C. neoformans in vitro. Hygromycin A had a MIC of 12.5 microg/mL, an activity comparable to that of itraconazole. Hygromycin A did not affect the growth of Saccharomyces cerevisiae, Aspergillus nidulans, or Trichophyton rubrum, suggesting that it targets a specific pathway in C.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hyodeoxycholicis a drug that inhibits
 
Response: Hyodeoxycholicis a drug that inhibits the synthesis of cholesterol. It is also the only bile acid that contains hydroxylated side chains. This can be distinguished from the primary bile acids by gas-liquid chromatography. The first published use of hyodeoxycholic acid was in the treatment of cholestasis of pregnancy in 1937. Hyodeoxycholic acid is used to treat cholesterol gallstones. It is a combination of deoxycholic acid and hyodeoxycholic acid.

See also
 Bile acid

References

Category:Bile acids
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hyoscyamineis a drug that inhibits
 
Response: Hyoscyamineis a drug that inhibits the action of cholinergic nerves. The drug is used in treating muscle spasms and convulsions. It is a sympathomimetic agent. The drug may be taken orally or it may be injected.

Uses

What is it used for?

Hyoscyamineis a drug that inhibits the action of cholinergic nerves. The drug is used in treating muscle spasms and convulsions. It is a sympathomimetic agent. The drug may be taken orally or it may be injected.

How does it work?

Hyoscyamine is a derivative of scopolamine. It works by inhibiting the action of acetylcholine. It blocks the effects of the neurotransmitter on postganglionic nerves. The drug increases the levels of acetylcholine in the synapse. This results in increased cholinergic stimulation.

What does it do?


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Hypoxanthineis a drug that inhibits
 
Response: Hypoxanthineis a drug that inhibits purine metabolism. It is used to treat a variety of conditions, including low red blood cell counts and cancer.

Cautions

When used for short periods, high doses, or with other drugs that affect bone marrow, it may cause life-threatening bone marrow damage. It is not recommended for long-term use in cancer patients, especially those who are undergoing chemotherapy.

Uses

Hypoxanthine is used to treat:

Low red blood cell counts in adults.

Hypoxanthine is used to treat:

Low red blood cell counts in adults.

Anemia due to deficiency of red blood cells.

Anemia due to deficiency of red blood cells.

Pneumonia due to low blood oxygen levels.

Other uses for Hypoxanthine

What is it used for?

Hypoxanthine is used to treat:

Low red
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ibandronateis a drug that inhibits
 
Response: Ibandronateis a drug that inhibits bone resorption, reducing bone loss and the risk of fractures. It is approved for the treatment of postmenopausal osteoporosis, in combination with estrogen in the USA, in Europe and in Japan. It is also approved in Japan for the treatment of Paget\'s disease of bone, hypercalcemia of malignancy and osteolytic bone metastases of solid tumors. Ibandronate is also available in many countries for the treatment of osteoporosis in postmenopausal women who have not yet undergone menopause and for the prevention of postmenopausal osteoporosis.

The main route of elimination of ibandronate is the kidneys, and a large part of the dose is excreted unchanged in the urine. However, as in other bisphosphonates, some of the active drug is metabolized by the liver to inactive metabolites, which are then excreted in the b
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Iberdomide(CC220)is a drug that inhibits
 
Response: Iberdomide(CC220)is a drug that inhibits the endothelin-converting enzyme (ECE) which inactivates endothelin-1 (ET-1) by converting it to ET-3. The main clinical use of Iberdomide(CC220) is in patients with severe heart failure, with or without pulmonary hypertension, in whom it may prevent progression of heart failure.

PURPOSE OF THE STUDY:

To evaluate the safety and efficacy of Iberdomide(CC220)when administered intravenously in patients with severe heart failure.

RESEARCH METHODS:

Randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients were randomized to Iberdomide(CC220)or placebo, both at 2.5 mg/kg (total dose of 5 mg/kg) intravenously over 15 minutes every 24 hours for 14 days. The primary endpoint
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ibuprofenis a drug that inhibits
 
Response: Ibuprofenis a drug that inhibits cyclooxygenase (COX), which is a rate-limiting enzyme in the synthesis of prostaglandins, including prostaglandin E2 (PGE2). Ibuprofen can be used to treat pain, fever, inflammation, and arthritis. The pharmaceutical form of ibuprofen is generally sold as a racemic mixture, which contains equal amounts of the two enantiomers (S- and R-forms) of ibuprofen.
The (S)-enantiomer is about 30 to 50 times more potent than the (R)-enantiomer as an anti-inflammatory agent. Accordingly, the (S)-enantiomer is currently used to prepare ibuprofen in the pharmaceutical industry. However, the (S)-enantiomer is a racemic mixture, which contains equal amounts of the two enantiomers. The (S)-enantiomer is not only expensive to manufacture
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ibutilideis a drug that inhibits
 
Response: Ibutilideis a drug that inhibits I~Kr~ (in humans, hERG) and prolongs the QT interval. The compound was approved by the FDA for the treatment of atrial fibrillation in 2003 and was withdrawn from the market in 2008 after reports of ventricular tachyarrhythmias (in patients without structural heart disease) associated with its use.^[@ref1]^ In 2008, a search of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database revealed 10 reports of QT interval prolongation, torsade de pointes (TdP), and ventricular fibrillation (VF) associated with ibutilide use.^[@ref2]^ These reports prompted the FDA to initiate an investigation of ibutilide,^[@ref3]^ and the company that developed the drug (Corvus Pharmaceuticals) voluntarily withdrew it from the market.

The search for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Icatibantis a drug that inhibits
 
Response: Icatibantis a drug that inhibits platelet aggregation. In addition to aspirin, clopidogrel is an antiplatelet agent that inhibits platelet aggregation by inhibiting the P2Y12 receptor. A P2Y12 receptor antagonist is an Icatibant.

Phenprocoumon:

The prodrug is hydrolyzed to phenprocoumon in the body.

Drug:

Thromboxane A2 (TXA2) receptor antagonist

P-Phenylephrine:

P-Phenylephrine is used to treat hypotension, cardiac arrest, and increased ICP in hypotensive patients.

Adrenergic receptor agonist

Drug:

Epinephrine

Prodrug:

Metoprolol (Benebron)

Drug:

Ipratropium

Prodrug:

Albuterol (Proventil)

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  icotinibis a drug that inhibits
 
Response: icotinibis a drug that inhibits ALK and ROS1 tyrosine kinases, but not EML4-ALK, which is a frequent cause of ALK-positive ALCL.[@b37-bctt-9-393]--[@b39-bctt-9-393]

### The therapeutic landscape

Crizotinib was the first targeted agent to be approved for the treatment of ALK-positive ALCL. The success of crizotinib in ALK-positive ALCL was based on its efficacy and the rapid expansion of this subgroup of patients. In the first randomized phase III trial, the use of crizotinib was compared to standard chemotherapy (CHOP or CHOP-like regimens) in patients with ALK-positive ALCL.[@b40-bctt-9-393] Crizotinib was superior to chemotherapy in terms of PFS (15.4 months vs 4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Idebenoneis a drug that inhibits
 
Response: Idebenoneis a drug that inhibits mitochondrial complex I. It has been used for the treatment of Parkinson's disease for more than 40 years. We recently demonstrated that idebenone acts by enhancing superoxide dismutase 2 (SOD2) activity and by activating the p38 mitogen-activated protein kinase (MAPK) pathway. We hypothesized that idebenone might exert neuroprotective effects in neurodegenerative diseases. Here, we demonstrate that idebenone has beneficial effects in Alzheimer's disease (AD). We used organotypic hippocampal slice cultures, which contain neurons and glial cells. We found that idebenone decreased the amount of soluble amyloid-β (Aβ) peptides, tau protein phosphorylation, and reactive oxygen species (ROS) levels in hippocampal slices exposed to Aβ. In an AD mouse model, the application of idebenone decreased ROS levels and amyloid plaque load. Furthermore, the use
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Idoxuridineis a drug that inhibits
 
Response: Idoxuridineis a drug that inhibits thymidylate synthase and is used to treat condylomata acuminata, a disease of the mucous membranes of the cervix and anus. It is also used in the treatment of certain herpesvirus infections and cancers. It has been reported to have cytotoxic activity against tumor cells and is also a substrate for P-glycoprotein.

Citation Manager Formats

A simple method of providing a citation for the drug idoxuridine is to use the Drug Listings link at the top of the Drug Summary and then select the appropriate "drugs" to the left. Alternatively, if you are using PubMed, you can use the IDOXURIDINE query, as described in the "Drug Information" link at the top of the "Searching the Literature" section.

Usage Notes

The dosage of idoxuridine is variable and dependent on the drug's therapeutic index and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ifenprodilis a drug that inhibits
 
Response: ifenprodilis a drug that inhibits calcium channels and causes vasodilation and is used in the treatment of migraine. A. Noceti, N. Theodoulou, D. Barouh, A. B. Verkman, J. Med. Chem. 38, 3261-3268 (1995) disclose certain derivatives of ibuprofen, flurbiprofen and ketoprofen.
Flurbiprofen is the ethyl ester of 2-(3-phenoxyphenyl)propionic acid and is disclosed in U.S. Pat. No. 3,883,577. It is an effective analgesic and anti-inflammatory agent. U.S. Pat. No. 4,283,431 discloses the ethyl ester of 3-(4-fluorophenyl)phenylacetic acid. This compound is an analgesic and anti-inflammatory agent.
U.S. Pat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ifosfamideis a drug that inhibits
 
Response: Ifosfamideis a drug that inhibits topoisomerase II and causes double-strand breaks in DNA, leading to apoptosis. It has been used for a wide variety of cancers, including lymphomas and sarcomas. In a meta-analysis, a total of 6,000 patients were included and treated with different doses and schedules of ifosfamide. The overall response rate was 17% in patients treated with \<3.5 g/m^2^/day for \>3 days. The response rate increased to 25% in patients treated with 3.5--4 g/m^2^/day for \>3 days. Patients treated with \>4 g/m^2^/day had a response rate of 30% \[[@B1]\]. The response rate was lower in patients treated with ifosfamide monotherapy compared to patients treated with combination therapy \[[@B2]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ilaprazoleis a drug that inhibits
 
Response: Ilaprazoleis a drug that inhibits gastric acid secretion, it is widely used to treat ulcers and peptic ulcers. It has also been found to be effective in the treatment of non-ulcer dyspepsia, gastritis, gastroesophageal reflux, and hypergastrinemia. Its most important side effects are nausea, vomiting, diarrhea, dizziness, headaches, and a bitter taste. Other side effects include loss of appetite, dry mouth, anorexia, weight loss, rash, pruritus, dermatitis, urticaria, and drug fever. Ilaprazole has been shown to be effective in treating duodenal ulcers and in healing gastric ulcers in general.
Ilaprazole is chemically named as 4-[4-(2-pyridylsulfinyl)phenyl]-3,5-dihydro-2(1H)-pyridinone. Il
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Iloperidoneis a drug that inhibits
 
Response: Iloperidoneis a drug that inhibits the actions of serotonin in the brain. It is also known as ZYPREXA, INVEGA and STILUTERA.

Iloperidone is used to treat psychotic symptoms associated with schizophrenia and bipolar disorder.

It is also used to treat agitation in patients with Alzheimer’s disease and dementia.

Iloperidone is an atypical antipsychotic medication that works by blocking the actions of serotonin. It was approved for sale in the US in 2011.

Iloperidone is an antipsychotic drug that belongs to a class of medications called second generation antipsychotics (SGAs). Iloperidone is chemically related to clozapine, risperidone, and olanzapine.

Iloperidone is available as a tablet, oral solution, and injection.

Iloperidone is taken once daily in the morning.

It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Imatinibis a drug that inhibits
 
Response: Imatinibis a drug that inhibits the tyrosine kinase activity of the oncogenic protein Bcr-Abl. Although approved for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML), imatinib has a number of side effects, including gastrointestinal (GI) toxicity, including mucositis, diarrhea, nausea, vomiting, and abdominal pain.\[[@ref1]\] However, patients with CML can tolerate this side effect and still benefit from imatinib.\[[@ref2]\]

There is an association between the degree of toxicity and the dose of imatinib. A higher dose of imatinib can lead to a greater incidence of adverse events. In addition, a higher dose of imatinib has a greater impact on the GI tract and can cause more severe GI toxicity. The recommended starting dose of imatinib is 400 mg once daily.\[[@ref3]\] The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Imidaprilis a drug that inhibits
 
Response: Imidaprilis a drug that inhibits angiotensin-converting enzyme (ACE) in humans and other animals. It is used in the treatment of hypertension, congestive heart failure, and chronic renal failure. Imidapril is the diacid salt of N-{2-[1-(2-imidazol-1-yl-ethyl)-4-methoxy-benzyl]-2-phenyl-ethyl}-2-methyl-benzamide. It has the following chemical structure:

The preparation and use of imidapril as an antihypertensive agent is described in U.S. Pat. No. 4,335,121.
U.S. Pat. No. 4,743,671 discloses the preparation of imidapril by a multistep synthesis. The process involves conversion of 2-methyl-benzamide to 2-methyl-benzyl-acetic acid, conversion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Imidazoleis a drug that inhibits
 
Response: Imidazoleis a drug that inhibits the enzyme carbonic anhydrase. It can cause acute toxicity, ranging from mild dizziness to severe headaches, blurred vision, weakness, and in extreme cases, coma and death.

Contraindications

Imidazole is contraindicated in patients with history of hypersensitivity to imidazole, sulfonamide, or sulfamethoxazole. Imidazole is also contraindicated in pregnant women and in patients with renal impairment.

Adverse effects

Common side effects include:

Dizziness

Headache

Nausea

Irritability

Increased appetite

Loss of appetite

Lethargy

Tremors

Tremor of the upper extremities

Diarrhea

Abdominal pain

Vomiting

Anorexia

In some cases, these effects may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  IMipraMineis a drug that inhibits
 
Response: IMipraMineis a drug that inhibits cell proliferation by blocking the production of ribonucleotide reductase, a key enzyme in DNA synthesis.\[[@ref1]\] It is being used for treatment of advanced cancers, and is well tolerated.\[[@ref2]\] There is an unmet need for drugs that have a better safety profile and efficacy in comparison to the current standard of care for solid organ malignancies.\[[@ref3]\] We report here a case of leiomyosarcoma of the right kidney with lung metastasis, which responded well to IMipraMine.

Case Report {#sec1-1}
===========

A 61-year-old man presented with right flank pain, fever, and weight loss of 2 months' duration. The patient had no history of trauma or urological illness. On examination, the patient had a temperature of 38°C, pulse rate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Imiquimodis a drug that inhibits
 
Response: Imiquimodis a drug that inhibits the innate immune response in keratinocytes. This drug causes a mild and transient erythema at the site of application, which is followed by a burning and stinging sensation. These symptoms are generally well tolerated, although in some patients the reaction may be severe and can last up to 6 weeks \[[@B1]\]. This is a great advantage for patients with resistant or disseminated cutaneous T-cell lymphoma (CTCL), but it is not a suitable option for patients with skin phototoxicity, allergic contact dermatitis, or systemic diseases such as lupus erythematosus \[[@B2]\]. It has been shown that the topical application of IFN-α2b in patients with CTCL results in a decrease in the clinical and molecular signs of disease \[[@B3]\]. Topical IFN-α2b is also used to treat recurrent respiratory papill
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  IMURANis a drug that inhibits
 
Response: IMURANis a drug that inhibits Mdm2 activity, thus enhancing the function of p53, the tumor suppressor protein encoded by the TP53 gene. IMURANis currently in phase II clinical trials for the treatment of various cancers, including prostate cancer, and is currently being developed for use in combination with taxanes. To evaluate the role of p53 in IMURAN activity, IMURAN was examined in a variety of cell lines with different TP53 statuses. In IMURAN-sensitive cell lines, IMURAN enhanced the ability of the drug to activate p53 and inhibit cell growth, induce cell-cycle arrest, and promote apoptosis. In contrast, IMURAN did not induce these effects in IMURAN-resistant cell lines. In IMURAN-sensitive cell lines, IMURAN induced p53-dependent apoptosis in a dose-dependent manner. In addition, IMURAN induced the accumulation of the p53 target gene products p21
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB054329is a drug that inhibits
 
Response: INCB054329is a drug that inhibits an enzyme called ileal cytosolic fatty acid binding protein (IFABP) in the small intestine. It is used to treat a condition called Crohn's disease.

Indications

FDA-approved

To treat Crohn's disease.

It is also used to treat some other conditions:

Other uses

ICF115958is a drug that is used to treat the skin disease called chronic plaque psoriasis.

ICF106098is a drug that is used to treat the skin disease called chronic plaque psoriasis.

ICF108273is a drug that is used to treat the skin disease called chronic plaque psoriasis.

ICF108274is a drug that is used to treat the skin disease called chronic plaque psoriasis.

ICF108433is a drug that is used to treat the skin disease called chronic plaque
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB-054329is a drug that inhibits
 
Response: INCB-054329is a drug that inhibits cancer cells growth and induces apoptosis in various human cancer cells. The aim of this study was to examine the effect of this compound on the apoptosis in human melanoma cells. The drug was added to melanoma cells in vitro and apoptosis was assessed by the use of flow cytometry. Apoptosis was measured in cells treated with various concentrations of INCB-054329 for 24 and 48 hours. We also examined the effects of INCB-054329 on the cell cycle in melanoma cells. Apoptosis was observed in melanoma cells treated with INCB-054329 in a time- and dose-dependent manner. Treatment of melanoma cells with INCB-054329 caused G2/M arrest and the cell cycle arrest was reversed after 48 hours of drug exposure. INCB-054329-induced apoptosis was also associated with increased expression of the proapoptotic protein Bax and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB-54329is a drug that inhibits
 
Response: INCB-54329is a drug that inhibits the function of the enzyme farnesyl diphosphate farnesyltransferase (FTase), which is responsible for catalyzing the formation of farnesyl pyrophosphate (FPP) from farnesyl diphosphate (FDP). Inhibiting the activity of FTase is an approach to the treatment of cancer.

A publication in the New England Journal of Medicine on August 2, 2009 (Volume 360, Issue 4, page 320) reports the use of farnesyltransferase inhibitors in patients with advanced solid tumors and in patients with acute myeloid leukemia. The abstract reads as follows:

"Farnesyltransferase inhibitors are a new class of anticancer agents that target farnesylation, a post-translational modification that is essential for protein function. We conducted a randomized, double-blind, phase 2 study to assess the efficacy and safety of two new far
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB057643is a drug that inhibits
 
Response: INCB057643is a drug that inhibits the GSK3β (glycogen synthase kinase-3β) and activates the PI3K/AKT (phosphoinositide 3-kinase/protein kinase B) pathways. It is widely used for the treatment of bipolar disorder, type II diabetes and various other diseases. However, its efficacy in treating the cognitive impairment in AD has not been determined. We studied the effect of INCB057643 on Aβ-induced neurodegeneration in vitro and in vivo. Here, we report that INCB057643 treatment protects against Aβ-induced cell death in primary neurons and in a neuronal cell line. It also reduces the amount of Aβ aggregates in neuronal cells. INCB057643 treatment improves the short-term and long-term memory deficits in a mouse model of AD. Moreover, it reduces the Aβ-induced neuroinflammation and gliosis in the brain. Thus, our results
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB28060is a drug that inhibits
 
Response: INCB28060is a drug that inhibits cell division, and has been approved for use in treating acute lymphoblastic leukaemia (ALL). The aim of this study was to determine whether INCB28060 would inhibit the growth of Ewing's sarcoma (EWS) cells. INCB28060 was used at various concentrations and time periods to determine its effects on the proliferation of three EWS cell lines (RD, TC71 and SK-N-MC). These cells were cultured in the presence of INCB28060 and proliferation was assessed by the MTT assay. The effects of INCB28060 on apoptosis were determined by measuring Annexin V-FITC staining and TUNEL assay. EWS cells were treated with INCB28060 at a concentration of 100 nM for 24, 48 and 72 h. After treatment, the cells were trypsinized and counted. Cell cycle analysis was performed using flow cytometry. INCB28060
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INCB39110is a drug that inhibits
 
Response: INCB39110is a drug that inhibits HDAC6, a deacetylase enzyme that is responsible for the removal of acetyl groups from histones, thereby promoting the formation of heterochromatin and gene silencing. HDAC6 has been shown to be up-regulated in breast cancer cells, and therefore the drug has potential as an anticancer agent.

Previous studies have shown that inhibition of HDAC6 increases apoptosis in various cancer cell types, including pancreatic cancer cells.

A study conducted in 2008 investigated the effect of INCB39110 in two human pancreatic cancer cell lines.

The researchers found that the drug was able to increase the expression of p21 and Bax, which are genes involved in the cell cycle and apoptosis. The drug also induced an increase in the activity of caspase 3, an enzyme that is involved in the apoptotic process.

This was the first study to show that HDAC6 inhibitors could
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Indacaterolis a drug that inhibits
 
Response: Indacaterolis a drug that inhibits aromatase, which is the enzyme responsible for converting androgens to estrogens. Studies in mice show that indacaterol reduces the secretion of FSH and LH, and may thus lower testosterone levels, which could help relieve symptoms of BPH and andropause.

Clinical trials show that indacaterol is effective and well tolerated in men with BPH-related LUTS.

Indacaterol, also called indacaterol sulfate, is the active pharmaceutical ingredient in UPLIFT (uplift spiriva), which is a prescription drug used to treat the symptoms of asthma and COPD.

Indacaterol sulfate is a highly selective beta2-adrenergic agonist.

Indacaterol sulfate is used to treat COPD (chronic obstructive pulmonary disease) and asthma.

Indacaterol sulfate is a highly selective beta2-ad
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Indinaviris a drug that inhibits
 
Response: Indinaviris a drug that inhibits the human monoamine oxidase B, or MAO-B.

MAO-B inhibitors have been in development for over thirty years. Indinavir has been used to treat HIV and AIDS. Indinavir is in the family of phenylpropanolamine inhibitors.

The search for a potent, selective, and orally active MAO-B inhibitor began in the early 1980s, with the goal of finding a compound with a lower incidence of gastrointestinal side effects than tranylcypromine (TCP), a potent, irreversible inhibitor of MAO-A. TCN (tranylcypromine) is currently used to treat depression. TCP irreversibly binds to MAO-A and MAO-B, but only MAO-B activity is blocked by TCN.

In the 1980s, the HIV drug indinavir was found to be a potent and selective MAO-B inhibitor. Indinav
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Indirubinis a drug that inhibits
 
Response: Indirubinis a drug that inhibits the release of the gonadotropin hormones.

Ketoconazole a drug that blocks the synthesis of sex steroids and androgens in the body.

Ketoconazole

Ketoconazole

What is a placebo?

A placebo is an inactive substance that is used to test the effect of a new medicine. It is often a sugar pill that looks and tastes the same as the active medicine. Placebos can also be used to see how the body reacts to taking an inactive medicine.

What is a placebo controlled trial?

In a placebo controlled trial, the patients are divided into two groups. One group receives the active medicine and the other receives a placebo. Both groups are given the same tests and measurements and are then compared to see which group has the best results.

How is a placebo used in clinical trials?

In clinical trials, a placebo is used to see
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INDOCINis a drug that inhibits
 
Response: INDOCINis a drug that inhibits the production of pain-producing chemicals in the brain called prostaglandins. These chemicals are produced by certain cells that line the membranes of your body’s blood vessels.

INDOCIN is used to treat pain, such as the pain caused by certain kinds of injuries and diseases.

INDOCIN is also used to reduce the amount of inflammation that occurs in the body.

INDOCIN is used to treat arthritis.

INDOCIN is used to treat nerve pain, such as pain from shingles (herpes zoster) or pain from a pinched nerve.

INDOCIN is used to treat pain caused by fibromyalgia.

INDOCIN is used to treat the pain of endometriosis.

INDOCIN is used to treat certain types of headache pain.

INDOCIN is used to treat the pain of lupus.

INDOC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Indoximodis a drug that inhibits
 
Response: Indoximodis a drug that inhibits M2-type macrophages and T-regulatory cells (Tregs) with no effect on M1-type macrophages.

Phase II clinical trial of Indoximod in the treatment of patients with relapsing remitting multiple sclerosis (MS) showed no clinical benefit and was associated with significant reductions in the number of circulating monocytes and reduced activation of Tregs.

Indoximod (NL-101) is an oral immunomodulator that is currently in phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Introduction

Indoximod (NL-101) is an orally active agent that inhibits M2-type macrophages and Tregs, with no effect on M1-type macrophages (1). In addition, Indoximod inhibits indoleamine 2,3-dioxygenase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INKis a drug that inhibits
 
Response: INKis a drug that inhibits multiple signaling pathways including mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and p38 kinase. It is approved for the treatment of adult patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and for the treatment of adults with r/r or relapsed/refractory chronic lymphocytic leukemia (CLL). The current review summarizes the most recent data regarding the efficacy and safety of NKis, focusing on the current literature and the results of a phase II study conducted by the European LeukemiaNet (ELN) in r/r AML. In the ELN trial, NKis (n = 53) were administered at a median of 5 days (range, 1-16 days) after the start of induction chemotherapy, and the overall response rate (ORR) was 30% (95
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Inosineis a drug that inhibits
 
Response: Inosineis a drug that inhibits purine synthesis and can be used in cancer treatment. This drug was found to induce HIF-1-mediated changes in glucose metabolism and cell growth in several tumor cell lines. Here, we show that inosine can also increase the levels of the nuclear HIF-1α protein in HCT116 colon cancer cells. This was associated with a decrease in HIF-1α ubiquitination, leading to a stabilization of the HIF-1α protein. In addition, inosine caused a reduction in the levels of VHL, an E3 ubiquitin ligase involved in the regulation of HIF-1α protein stability. Inosine induced changes in glucose metabolism in HCT116 cells, which could be partially prevented by inhibiting the synthesis of purines. These changes were accompanied by a decrease in lactate production and in the expression of lactate dehydrogenase-A (LDHA), which is the rate-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Inulinis a drug that inhibits
 
Response: Inulinis a drug that inhibits the breakdown of inulin by bacteria in the gut.

Vitamin D deficiency

This is the most common cause of low levels of vitamin D. It is also known as a vitamin D-deficiency rickets. It occurs when there is a lack of sunlight or the body cannot produce enough vitamin D in the skin. The effects of vitamin D deficiency are often seen in children, especially those with darker skin. Vitamin D is essential for a healthy immune system, bone health and muscle function.

Sickle cell disease

Sickle cell disease is a genetic disorder in which a person has one or two copies of the sickle cell gene. The sickle cell gene is a gene that causes red blood cells to be misshapen and sickle-shaped. People with sickle cell disease have a lower resistance to infections and a greater risk of developing blood clots. Sickle cell disease is most commonly seen in people of African descent.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  INVEGAis a drug that inhibits
 
Response: INVEGAis a drug that inhibits a certain receptor, known as 5-HT2c, which is involved in certain types of tumours. It was approved for use in Europe in November 2000 and in the US in May 2001. The drug is marketed by Merck under the trade name INVEGA.

INVEGAis the generic name forthe drug INVEGANT.

INVEGAis an anti-tumour drug, which is used to treat various types of cancer. INVEGA was approved by the FDA in 2001 for the treatment of adults with advanced renal cell carcinoma (RCC) and by the European Medicines Agency (EMA) in November 2000 for the treatment of adults with advanced RCC who have failed previous treatment. INVEGA was developed by Medivation, a subsidiary of Pfizer.

INVEGAis a combination of two drugs, both of which are already on the market: INVEGANT (INN
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Iopamidolis a drug that inhibits
 
Response: Iopamidolis a drug that inhibits myosin phosphatase activity.
The inhibitor of myosin phosphatase (IOP) was developed by us as a potential novel antineoplastic agent. IOP was tested in vitro for its activity on cellular phosphatases. IOP inhibited PP1, PP2A, PP2B, PP4, PP5, and PP6 activities. PP2A activity was the most sensitive to IOP inhibition, with IC50 values of 1-2 microM. IOP also inhibited PP1 and PP5 activities, with IC50 values of 8-15 microM. The enzyme specificity of IOP was studied using various myosin light chain (MLC) substrates, revealing that the phosphatase-2B-like substrate was the most sensitive to inhibition. In vivo IOP activity was examined in the murine colon 38 tumor cell line. A 10-fold concentration of IOP reduced PP2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Iopromideis a drug that inhibits
 
Response: Iopromideis a drug that inhibits platelet aggregation and is used in the prevention and treatment of thromboembolic events. Iopromide is a nonionic, amphoteric, water-soluble, macrocyclic iodinated contrast agent. It is available in injectable and oral forms. It is given by intravenous injection, but it is also available as an oral formulation.

Iopromide is used in computed tomography (CT) scans of the abdomen and pelvis, intravenous angiography, magnetic resonance imaging (MRI) and CT angiography. It is also used in transcatheter arterial embolization (TAE).

When given intravenously, iopromide is excreted almost entirely by the kidneys. It is also excreted by the hepatobiliary system. When given orally, it is partially absorbed by the gastrointestinal tract.

The active ingredient in iopromide is the nonionic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  IOSATis a drug that inhibits
 
Response: IOSATis a drug that inhibits p38 and can prevent the development of murine arthritis. This paper shows that inhibition of p38 MAP kinase activity by IOSAT in vitro leads to suppression of IL-1β-induced NF-κB activation, TNF-α and MMP-1 production in human fibroblasts and synovial cells. The beneficial effect of IOSAT on collagen-induced arthritis in DBA/1 mice was confirmed in this study. Our data demonstrate that p38 MAP kinase activation is a common mechanism by which inflammatory cytokines and enzymes are produced in human fibroblasts and synovial cells. Therefore, p38 MAP kinase may be a therapeutic target for RA.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  IPI-145is a drug that inhibits
 
Response: IPI-145is a drug that inhibits the production of interferon gamma (IFN-γ) by activated T-cells. It is being developed for the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. It is a prodrug, and must be converted to its active form by hydrolysis. One of the goals of the design of the prodrug was to improve the oral bioavailability of the drug, and several candidate prodrugs were synthesized and evaluated in rats. We evaluated the stability of the prodrugs in rat plasma and liver homogenate and the release of the drug from the prodrugs in the rat intestinal homogenate. The prodrugs of N-methylpiperazine (NMP), piperidine (PN) and piperazine (PZ) are more stable in rat plasma than the parent drug. In contrast, the prodrugs of 2,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ipragliflozin(ASP1941)is a drug that inhibits
 
Response: Ipragliflozin(ASP1941)is a drug that inhibits the sodium glucose transporter-2 (SGLT2) and the urinary glucose reabsorption, thus decreases the reabsorption of glucose in the kidney, which decreases the reabsorption of glucose in the kidney, decreases the reabsorption of glucose in the kidney, thus reduces the renal threshold of glucose and reduces the urinary glucose excretion. It can be used for the treatment of diabetes mellitus.

Ipragliflozin(ASP1941)is a drug that inhibits the sodium glucose transporter-2 (SGLT2) and the urinary glucose reabsorption, thus decreases the reabsorption of glucose in the kidney, which decreases the reabsorption of glucose in the kidney, decreases the reabsorption of glucose in the kidney, thus reduces the renal threshold of glucose and reduces the urinary glucose excretion. It can be used for the treatment of diabetes mellitus.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ipriflavoneis a drug that inhibits
 
Response: Ipriflavoneis a drug that inhibits bone resorption by the osteoclast. It is approved in Japan and some other countries for the treatment of postmenopausal osteoporosis. We previously showed that ipriflavone induced apoptosis in human promyelocytic leukemia (HL-60) cells and in U937 cells, and that it caused growth inhibition of U937 cells by apoptosis-dependent and -independent mechanisms. The present study was undertaken to determine the possible involvement of mitogen-activated protein (MAP) kinase pathways in the induction of apoptosis and growth inhibition by ipriflavone in U937 cells. The results showed that the MAP kinase kinase (MEK) inhibitor PD98059 partially inhibited the apoptosis induced by ipriflavone in U937 cells, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin completely abolished the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  IRBESARTANis a drug that inhibits
 
Response: IRBESARTANis a drug that inhibits the production of the hormone angiotensin II, a key regulator of blood pressure. It is prescribed for the treatment of high blood pressure, heart failure and chronic kidney disease. It is also used to prevent strokes in people with heart disease.

REVASCAT is a drug that inhibits the production of the hormone angiotensin II, a key regulator of blood pressure. It is prescribed for the treatment of heart failure and high blood pressure. It is also used to prevent strokes in people with heart disease.

RENIPROST is a drug that inhibits the production of the hormone angiotensin II, a key regulator of blood pressure. It is prescribed for the treatment of high blood pressure and heart failure. It is also used to prevent strokes in people with heart disease.

RESTORIN is a drug that inhibits the production of the hormone angiotensin II, a key regulator of blood pressure
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  irinotecanis a drug that inhibits
 
Response: irinotecanis a drug that inhibits topoisomerase I and is approved for use in colorectal cancer. Topotecan, when administered as a single agent, has demonstrated antitumor activity in a wide variety of solid tumors. However, topotecan is only active against a limited number of tumors and its activity is usually accompanied by significant side effects. We have evaluated the effect of the topoisomerase I inhibitor topotecan in combination with several cytotoxic agents in a panel of eight human cancer cell lines. The combination of topotecan with melphalan or cisplatin was synergistic in all cell lines tested, with the highest synergistic ratio observed in ovarian carcinoma cells. The combination of topotecan with vinblastine or gemcitabine was synergistic in two cell lines and additive in the other six cell lines. The combination of topotecan with paclitaxel was synergistic in one
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Irsogladineis a drug that inhibits
 
Response: Irsogladineis a drug that inhibits the formation of blood clots, allowing blood to flow more easily through the arteries and veins.

It is used to prevent stroke, heart attack, pulmonary embolism, deep vein thrombosis, unstable angina, and pulmonary embolism in patients who have already suffered a stroke or heart attack.

It is also used in patients who are scheduled to undergo elective surgery or diagnostic tests that may cause a blood clot, such as dental surgery or an angiogram.

It is also used to prevent the formation of blood clots that may form during chemotherapy, in patients with an increased risk of developing blood clots.

It is also used in patients with an increased risk of developing blood clots, including those with cancer, high blood pressure, or diabetes.

It is also used in patients who have undergone a surgical procedure or have had a blood transfusion.

It is also used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isepamicinis a drug that inhibits
 
Response: Isepamicinis a drug that inhibits the enzyme that converts A to G on the right hand strand of the gene for the virus. This is an important enzyme for replication of the virus and thus is the site of the enzyme that gives Tamiflu its name.

Clindamycin A drug that inhibits protein synthesis. Clindamycin is an anti-inflammatory drug and is used for the treatment of acne.

Corticosteroids steroidal anti-inflammatory drugs. They work by blocking the effect of prostaglandins and other substances that cause inflammation.

Coxsackie virus an RNA virus of the Picornaviridae family. The virus causes hand-foot-and-mouth disease, which causes fever, sore throat, mouth sores and sometimes rash.

Dapsone An antibiotic used for treatment of skin and soft tissue infections. It works by inhibiting an enzyme involved in production of a substance that helps bacteria to attach to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isocarboxazidis a drug that inhibits
 
Response: Isocarboxazidis a drug that inhibits the synthesis of nucleic acids. Isocarboxazid causes the cessation of cell division in all cells, but it has only limited effects on the immune system. It is also used to treat chronic fatigue syndrome and to help with depression.

Phenylbutazone a drug that is used to treat joint pain and inflammation.

Prednisone a corticosteroid that is used to treat arthritis, asthma, autoimmune disorders, and inflammatory diseases.

Rifampin a drug that is used to treat tuberculosis and other infections. It can cause temporary skin darkening and skin color changes in some people.

Theophylline a bronchodilator drug that is used to treat asthma and chronic obstructive pulmonary disease. It may cause the loss of color vision and sensitivity to light.

Sulfasalazine a drug that is used to treat Crohn's disease and ulcerative col
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isoconazoleis a drug that inhibits
 
Response: Isoconazoleis a drug that inhibits the activity of lanosterol 14α-demethylase. Isoconazole is the active metabolite of itraconazole, which is an antifungal agent that is used to treat fungal infections of the skin and the nails. Isoconazole is also used as an ingredient in a variety of over-the-counter oral and topical antifungal preparations. The manufacturer of the oral antifungal preparation fluconazole recommends that patients receiving fluconazole concurrently with other medications that are metabolized by the cytochrome P450 3A4 enzyme system be carefully monitored. The manufacturer also warns that concurrent use of fluconazole and itraconazole may increase the risk of adverse effects.

In patients with human immunodeficiency virus (HIV) infection, isoconazole can inhibit the growth of some of the organisms that cause fungal infections, such as Cand
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  isoetharineis a drug that inhibits
 
Response: isoetharineis a drug that inhibits the synthesis of certain compounds that make up the brains of vertebrates. This can lead to stunted growth, among other things. The drug was originally developed for use in cattle and sheep, but it was found to be effective against mice, rats, and rabbits as well. In recent years, scientists have begun to investigate the effects of low-dose etomidate on human brains, in order to see if it can be used as a sedative for human patients in the operating room.

Side effects

Etomidate is considered to be safe and effective in most situations. However, it does have a few side effects. The most common of these are restlessness and nausea. It can also cause some people to become anxious and claustrophobic. There are also some rare, but potentially serious, side effects of etomidate. One of these is hemolysis, in which red blood cells are destroyed and can cause kidney failure.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isoeugenolis a drug that inhibits
 
Response: Isoeugenolis a drug that inhibits the adrenal steroidogenic enzyme cytochrome P450 side-chain cleavage enzyme (P450scc) and is widely used to induce ovulation in humans and livestock. Isoeugenolis is thought to exert its action by competitively inhibiting the cytochrome P450scc enzyme, thereby blocking the production of progesterone and estrogen. It has also been shown to stimulate prostaglandin synthesis in the ovary, and thereby induce ovulation.
Isoeugenolis has been used as an ovulation induction agent in livestock, especially cattle. It has been used in cattle as a treatment for anovulation or for inducing ovulation after superovulation treatment. Isoeugenolis has also been used to induce estrus in cattle and to induce ovulation in cows in order to increase the number of calves born.
A method of administering isoeugenolis is described in U.S. Pat.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isonicotinicis a drug that inhibits
 
Response: Isonicotinicis a drug that inhibits the activity of the acetylcholine-receptor (AChR). This drug is an inhibitor of the muscle-type AChR (i.e. AChR subtype 2) and it is used in the treatment of myasthenia gravis (MG). MG is a neurological disorder caused by the immune-mediated destruction of the neuromuscular junction. MG is characterized by fatigable muscle weakness and fatigable muscle cramps. The symptoms of MG can be alleviated by increasing the AChR activity, but this effect is limited. AChR is also present in the central nervous system, and the drug, known as “Isonicotinic”, is a powerful central-nervous-system-type-AChR (i.e. AChR subtype 3) inhibitor. The central nervous system-type AChR is also a target for a drug used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isoprenalineis a drug that inhibits
 
Response: Isoprenalineis a drug that inhibits the β-adrenergic receptors. Its effect is similar to that of adrenaline and noradrenaline, but it is more selective for the β1 receptor. It is used to treat the symptoms of high blood pressure and congestive heart failure.

(the side effects can be different, depending on the person and the dose. The side effects include, but are not limited to:

• Hypotension (low blood pressure)

• Arrhythmias (irregular heartbeats)

• Flushing

• Palpitations (fast or irregular heartbeats)

• Bronchospasm (exacerbation of breathing problems)

• Increased heart rate (increased heartbeats)

• Headache

• Flushing

• Palpitations

•

• Hypotension

• Tachycardia

• Increased blood pressure


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isopropamideis a drug that inhibits
 
Response: Isopropamideis a drug that inhibits an enzyme that can be found in the heart, blood vessels and lungs. It is used to treat high blood pressure, asthma and diabetes.

When taken as prescribed, isopropamide is safe and effective. It is not addictive. However, taking too much can cause some side effects. Some of these side effects are nausea, drowsiness, dizziness, and vomiting. In rare cases, taking isopropamide can cause loss of vision or confusion.

Isopropamide is available as an inhaler, tablet, syrup and eye drops. Your doctor will need to monitor your progress while you are taking the medication. He or she will be able to tell if you are getting better.

Your doctor may ask you to take a urine test to check for changes in your blood pressure before and after taking isopropamide.

What is the most important information I should know about isopropamide?

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isopropylis a drug that inhibits
 
Response: Isopropylis a drug that inhibits cytochrome P450 2C9, thereby preventing the metabolism of certain drugs and increasing their blood levels and their effectiveness. Examples of drugs that may be affected include warfarin, aspirin, clopidogrel, losartan, and omeprazole.

If your medication has been changed, you may need to follow the new instructions. If you do not follow the new instructions, you may experience a change in the effectiveness of the drug or a possible increase in side effects.

Isopropyl Alcohol

An isopropyl alcohol swab is an alcohol-based cleaning agent that is applied to the skin. It may be used for disinfecting cuts and abrasions, wounds, and minor burns. It is also used as a pre-operative disinfectant. It may be used for general cleansing and for disinfecting surgical and dental instruments. It is available in both single- and double-use packages.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isoproterenolis a drug that inhibits
 
Response: Isoproterenolis a drug that inhibits 5-lipoxygenase. Inhibition of 5-lipoxygenase is used in the treatment of leukotriene mediated diseases.
A recent article in The Lancet reports that the leukotriene synthesis inhibitor zileuton is efficacious in the treatment of asthma in patients who have responded inadequately to conventional therapy. (see, "Zileuton, A Novel Antileukotriene Antagonist in the Treatment of Asthma," Chest 1996; 110:347-352).
Zileuton, (1R-1-[3-(4-chlorobenzoyl)propyl]-3-(2-fluorophenyl)-5-[(1-methylpyrrolidin-2-yl)methyl]-1H-1,2,4-triazole-3-carboxylic acid), is currently in Phase III clinical trials for the treatment of asthma.
Various processes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isosorbideis a drug that inhibits
 
Response: Isosorbideis a drug that inhibits the conversion of D-glucose to D-fructose in the liver and thus reduces blood glucose.

It is also used in combination with some other drugs, such as theophylline, to treat high blood pressure.

Mechanism of action
Isosorbide mononitrate inhibits the enzyme D-glucose-6-phosphate dehydrogenase, the first enzyme in the hepatic pentose phosphate pathway. The inhibition of the enzyme decreases the production of nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+ and thus reduces the regeneration of glutathione from glutathione disulfide. This leads to the accumulation of the oxidized form of glutathione (glutathione disulfide) and a reduction in the level of reduced glutathione. This decrease in glutathione concentration leads to an increase in the concentration of ROS, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isotretinoinis a drug that inhibits
 
Response: Isotretinoinis a drug that inhibits or decreases the production of certain chemicals in the body, and that are associated with some types of cancer. These are called Retinoids. Isotretinoin is a vitamin A derivative, that is prescribed for treating acne and psoriasis. It is used in combination with other drugs. Isotretinoin is a drug that is used to treat severe forms of acne. It is also used in the treatment of severe psoriasis. It is also used in combination with other drugs.

What is isotretinoin?

Isotretinoin is a drug that inhibits or decreases the production of certain chemicals in the body, and that are associated with some types of cancer. These are called Retinoids. Isotretinoin is a vitamin A derivative, that is prescribed for treating acne and psoriasis. It is used in combination with other drugs. Isotretinoin is a drug that is used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Isoxsuprineis a drug that inhibits
 
Response: Isoxsuprineis a drug that inhibits muscarinic receptors, and is used to treat gastrointestinal disorders, neurogenic bladder, and urinary incontinence. It is also used as a treatment for peptic ulcers and other gastric disorders. In humans, the drug is used as an antispasmodic agent to treat spastic conditions of the gastrointestinal tract. Isoxsuprine is also used to treat myoclonus.

Isoxsuprine (trade name Tardivel) is used to treat patients who are at risk for or who have problems with constipation or diarrhea, and for urinary incontinence.

IMPORTANT SAFETY INFORMATION

• Serum levels of isoxsuprine are monitored in patients treated with this drug.

• Serious, even fatal, reactions can occur in patients treated with isoxsuprine. A slow, controlled withdrawal from the drug is recommended.

Do not give this medication
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Istradefyllineis a drug that inhibits
 
Response: Istradefyllineis a drug that inhibits the reuptake of dopamine and serotonin in the brain. This results in increased dopamine and serotonin levels, which may help to reduce symptoms of Parkinson's disease and depression. It is marketed as Atamet in the UK and is marketed as Deplin in the US.

Medical uses

Parkinson's disease
Istradefylline has been found to have effects on neurotransmitters in the brain that are similar to the effects of levodopa, the most effective treatment for Parkinson's disease.

Depression
In a 2006 study, the effect of istradefylline on depression was investigated.

Side effects
The most common side effects of istradefylline include nausea, headache, and dizziness.

Pharmacology

Mechanism of action
Istradefylline acts as a potent, selective, and selective inhibitor of the serotonin transporter.

Pharmac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ITF2357is a drug that inhibits
 
Response: ITF2357is a drug that inhibits the activity of the cyclin-dependent kinase Cdk5. It has been suggested that is a potential therapeutic target for AD, as its inhibition has been shown to protect against Aβ-induced neurotoxicity.

In this study, we assessed the efficacy of ITF2357 as a possible therapeutic for AD. We found that treatment with ITF2357 decreased Aβ1-42 levels and Aβ1-42-induced neurotoxicity in SH-SY5Y cells. We also showed that the phosphorylation of tau at the AD-related sites Ser262 and Ser396 was reduced by ITF2357. Our data suggest that ITF2357 may have potential as a therapeutic for AD.

As AD is the most common form of dementia, research to find therapeutic targets is of critical importance. There are two major forms of AD: familial AD (FAD) and sporadic AD (SAD). FAD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Itraconazoleis a drug that inhibits
 
Response: Itraconazoleis a drug that inhibits the synthesis of lanosterol in the fungal cell. It acts by inhibiting cytochrome P450 (CYP) 14α-demethylase, which is required for the synthesis of ergosterol, the main sterol in the cell membrane. Itraconazole is effective against a number of fungal species including *Candida albicans*, *Candida glabrata*, *Candida krusei*, *Candida tropicalis*, *Aspergillus fumigatus*, *Sporothrix schenckii*, *Cryptococcus neoformans*, and *Histoplasma capsulatum*.\[[@ref1]\]

Itraconazole has been reported to cause both hyper- and hypo-cholestasis.\[[@ref2]\] We report the first case of acute hepatic failure with jaundice secondary to it
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ivabradineis a drug that inhibits
 
Response: Ivabradineis a drug that inhibits sinus node function and can prevent the onset of atrial fibrillation and atrial flutter. It has been shown that is effective in decreasing the ventricular rate in patients with atrial fibrillation or flutter.\[[@ref1]\] A meta-analysis of five randomized controlled trials showed that ivabradine significantly reduced the rate of recurrence of atrial fibrillation by 17% and increased the proportion of patients free of atrial fibrillation or atrial flutter by 18%.\[[@ref2]\]

Several studies have shown that ivabradine may have beneficial effects in patients with chronic heart failure (CHF).\[[@ref3][@ref4][@ref5]\] In addition, ivabradine has been shown to improve the prognosis of patients with CHF and reduced ejection fraction.\[[@ref6]\] However,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ivermectinis a drug that inhibits
 
Response: ivermectinis a drug that inhibits the production of vitamin D.

There are also important vitamins that the body needs to make it work properly. Biotin is the vitamin that helps convert the fat in food into energy and is needed for the synthesis of biotin in the body. Biotin is the body's best source of energy.

Vitamin D is important for the production of calcium in the bones. It is also important for the immune system.

Calcium is important for the formation of bones and teeth. It is also important for the formation of muscles. It is also important for blood clotting.

Zinc is a trace mineral that is needed for the formation of hair, skin, nails, and teeth. It is also needed for growth. It is important for the immune system.

Iron is important for the formation of blood. It is also needed for the formation of hemoglobin. It is also important for the growth of bones and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  JNJ-38877618(OMO-1)is a drug that inhibits
 
Response: JNJ-38877618(OMO-1)is a drug that inhibits C5a-induced neutrophil chemotaxis and adhesion. It is approved by the FDA in January 2016 for the treatment of the manifestations of paroxysmal nocturnal hemoglobinuria (PNH). Here we describe a novel finding that JNJ-38877618(OMO-1)exerts its anti-inflammatory effects by blocking TNF-α induced C5a-dependent pro-inflammatory cytokine and chemokine secretion by human synovial fibroblasts.

TNF-α and C5a are implicated in the pathogenesis of rheumatoid arthritis (RA) and other inflammatory diseases[@b1][@b2][@b3][@b4]. Anti-TNF therapy has been shown to be effective in RA[@b5][@b6][@b7]. However, a significant proportion of patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  JNJ-42756493is a drug that inhibits
 
Response: JNJ-42756493is a drug that inhibits both the VEGF and the PDGF receptors. It is also an oral inhibitor of the receptor tyrosine kinase KIT and of the oncogene FLT3. It has been studied in phase II trials in patients with advanced cancer, such as soft tissue sarcoma, GIST and colorectal cancer. An analysis of data from seven trials in over 300 patients showed that the response rate was 5.8% and the median duration of response was 4.3 months. The main toxicity was a rise in hepatic enzymes (especially ALT and AST), which was reversible after drug discontinuation.

The combination of mTOR inhibitors with other agents has been investigated in several studies, with variable results. A combination of sirolimus with the epidermal growth factor receptor (EGFR) inhibitor cetuximab was investigated in a phase II trial in patients with advanced GIST. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Josamycinis a drug that inhibits
 
Response: Josamycinis a drug that inhibits replication of Epstein-Barr virus, also known as the human herpesvirus 4 (HHV-4), and is used in the treatment of patients with EBV-associated diseases, such as mononucleosis, infectious mononucleosis, post-transplant lymphoproliferative disorder, and EBV-associated nasopharyngeal carcinoma (see U.S. Pat. No. 6,248,740). Acyclovir (9-((2-hydroxyethoxy)methyl)guanine) is a nucleoside analogue of guanine and a potent inhibitor of herpes simplex virus and varicella zoster virus. Acyclovir is used in the treatment of herpesvirus infections and the resulting diseases (see U.S. Pat. No. 4,423,049). It has also been reported that acyclovir treatment of patients with herpesvirus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Kaempferolis a drug that inhibits
 
Response: Kaempferolis a drug that inhibits alpha-glucosidase and is known to be effective for diabetes and obesity. Its administration reduced food intake, body weight, and body fat. The anti-obesity effects of kaepeferol are caused by decreased expression of hypothalamic neuropeptide Y and agouti-related peptide in the arcuate nucleus, and suppression of neuronal responses to orexigenic neuropeptide Y and anorexigenic melanin-concentrating hormone in the lateral hypothalamus. Thus, kaepeferol is a potent anti-obesity agent that inhibits the development of obesity by suppressing appetite and energy expenditure.

Kaepeferol (4′,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxychromen-4-one) is a flavonoid compound that is present in a variety of edible fruits, vegetables, and medicinal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Kanamycinis a drug that inhibits
 
Response: Kanamycinis a drug that inhibits IL-1-induced IL-6 production and chemokine gene expression in human chondrocytes.
In the present study, we evaluated the effect of kanamycin on interleukin-1 (IL-1)-induced IL-6 production and chemokine gene expression in human chondrocytes. Chondrocytes were cultured in the presence of kanamycin at concentrations of 10-500 ng/ml. IL-1beta (1 ng/ml) induced IL-6 production in chondrocytes, which was dose-dependently suppressed by kanamycin (10-500 ng/ml). IL-1beta induced CXCL8 and CCL2 gene expression, which were also dose-dependently suppressed by kanamycin. IL-1beta induced CXCL8 and CCL2 production was suppressed by kanamycin in a time-dependent manner. Moreover,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  KD025is a drug that inhibits
 
Response: KD025is a drug that inhibits cyclin-dependent kinase 4 (CDK4) and CDK6. It is currently being evaluated in Phase II and III trials in combination with the anti-hormonal agent exemestane (Aromasin) in patients with postmenopausal women with HR+/HER2− ABC. To our knowledge, there are no published results of its use in TNBC. In this Phase II trial, we evaluated the efficacy and safety of KD025 in patients with TNBC who had progressed on a taxane-based chemotherapy regimen.

Patients were enrolled in this open-label, single-arm study if they had an ECOG performance status of 0 or 1, and measurable disease by RECIST criteria. All patients had been previously treated with a taxane-based chemotherapy regimen, which had been given at least 4 weeks prior to enrollment. Eligible patients had been pretreated with one prior chemotherapy regimen for metastatic disease. Patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  KENACORTis a drug that inhibits
 
Response: KENACORTis a drug that inhibits glucocorticoid (GC) receptor activity. It has been approved for use in pediatric pts with Cushing's disease and in adult pts with severe GC-dependent asthma, in combination with fluticasone propionate. It is indicated for the treatment of inflammatory conditions in which inflammation is exacerbated by GC excess.

LENAMURatopical, intramuscular injection.

**TREATMENT ROUTE** **IV** **(IV, IM)** **:** **ADULTS, ELDERLY:** **◀◀◀** **CUSHING'S DISEASE:** Initially, 0.05 mg/kg/day. May increase by 0.05 mg/kg/day every 3–4 days. **Maximum:** 0.15 mg/kg/day. **Severe asthma:** Initially, 0.1 mg/kg/day.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ketanserinis a drug that inhibits
 
Response: Ketanserinis a drug that inhibits the absorption of carbohydrates.

In vitro – testing a drug in a petri dish.

Meds. – Medications.

Mental status. – A pet’s mental status.

Ophthalmology – The branch of medicine that deals with the eyes.

Pharmacokinetics – The study of the absorption, distribution, metabolism, and excretion of drugs.

Physiology – The branch of medicine that deals with the body’s systems, processes, and functions.

Phenobarbital – A sedative that is used to treat convulsions and other conditions.

Phenobarbital is a type of barbiturate.

Phenobarbital

PO – The preferred route of administration.

Pulmonary – Pertaining to the lungs.

Pulmonary function test – A medical test that measures how well the lungs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ketoconazoleis a drug that inhibits
 
Response: Ketoconazoleis a drug that inhibits P-glycoprotein (P-gp) activity in the blood-brain barrier (BBB) and increases the concentration of many drugs in the brain. A small number of clinical studies have been published. However, there is no evidence to support the use of ketoconazole in the treatment of psychiatric disorders.

This study aimed to assess the efficacy and safety of ketoconazole in the treatment of schizophrenia.

In total, 120 patients were enrolled in the study, including 40 in the ketoconazole group and 80 in the placebo group.

Ketoconazole was administered at a dose of 200 mg/day for the first week and 100 mg/day thereafter. The dose was then increased to 400 mg/day after 4 weeks.

The study consisted of two phases: an 8-week open-label phase and a 4-week randomized, double-blind phase.

Patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ketorolacis a drug that inhibits
 
Response: Ketorolacis a drug that inhibits the enzyme cyclooxygenase, which is involved in the synthesis of prostaglandins, a group of chemical compounds that play an important role in the inflammatory response. The action of the drug is to inhibit the inflammatory response by inhibiting the production of prostaglandins.

There are two types of cyclooxygenase: cyclooxygenase-1 and cyclooxygenase-2. Cyclooxygenase-1 is a constitutive enzyme and is involved in the synthesis of prostaglandins, thromboxanes, and other chemical compounds. Cyclooxygenase-2 is an inducible enzyme and is responsible for the synthesis of prostaglandins. The level of cyclooxygenase-2 activity is low under normal conditions. In response to various stimuli, such as infection, trauma, and cytokines, cyclooxygenase-2 is activated.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ketotifenis a drug that inhibits
 
Response: Ketotifenis a drug that inhibits the action of histamine on the H1 receptors of the brain, decreasing the release of histamine, acetylcholine, and other neuroactive substances.

Nomenclature:

Ketotifenis a drug that inhibits the action of histamine on the H1 receptors of the brain, decreasing the release of histamine, acetylcholine, and other neuroactive substances.

Efficacy:

Cures or reduces the frequency of symptoms in people with allergic rhinitis, urticaria, and other allergies, chronic idiopathic urticaria, and asthma.

Dosage and Administration:

Adults, children older than 2 years of age: 20 mg once daily or 50 mg once daily in the evening.

Children younger than 2 years of age: 10 mg once daily or 20 mg once daily in the evening.

For more information,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Kevetrinis a drug that inhibits
 
Response: Kevetrinis a drug that inhibits virus replication in vitro, is active against wild-type HIV, and does not have any cross-resistance to existing drugs, can be administered in a single daily dose, is a non-nucleoside reverse transcriptase inhibitor, and is well tolerated by the majority of patients. It has been shown to be effective in preventing disease progression and transmission in two phase II clinical trials. Data from a phase III clinical trial are expected to be available in the first quarter of 2002.

Reduction in the risk of HIV infection through pre-exposure prophylaxis (PrEP)

The development of new and better methods to reduce the risk of HIV infection is a priority for the research community. A range of strategies are being tested in different populations.

Pre-exposure prophylaxis (PrEP) involves the use of a preventive agent (e.g. an antiretroviral agent) to prevent HIV
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Khellinis a drug that inhibits
 
Response: Khellinis a drug that inhibits fatty acid synthase (FAS) to prevent and reverse hepatic steatosis in obese humans and mice, and also in animal models of nonalcoholic fatty liver disease (NAFLD).^[@bib1]^

We have recently shown that Khellin (5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one), a natural flavonoid isolated from the roots of *I. tinctoria*, can induce autophagy, apoptosis, and G0/G1 arrest in HepG2 and Huh7 cells.^[@bib2]^ The anticancer properties of Khellin have been reported in several studies.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Kinetinis a drug that inhibits
 
Response: Kinetinis a drug that inhibits kinesin-5 by binding to the coiled-coil of the motor domain.^[@bib1]^ The binding site is near the neck-linker of the kinesin-5, where it interferes with binding of microtubule-binding protein 2 (MAP2). The drug acts on kinesin-5 with nanomolar affinity, with an IC~50~ of \~50 n[M]{.smallcaps} in the presence of ATP,^[@bib1]^ whereas in the absence of ATP it binds with micromolar affinity, with an IC~50~ of \~3 μ[M]{.smallcaps}.^[@bib2]^ Kinetin binds in the same pocket of the kinesin-5 motor domain as other compounds that target the same site, such as an analogue of kinesin-5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  KPT-330is a drug that inhibits
 
Response: KPT-330is a drug that inhibits a protein called Nrf2, and has been shown to inhibit the development of colon cancer in animals. Nrf2 is the transcription factor that turns on the genes for detoxifying enzymes, and thus is critical for the body's ability to detoxify and to repair damaged cells.

Nrf2 is also activated by certain cancer therapies, such as chemotherapy.

The team from the Mayo Clinic in Rochester, Minnesota, and the University of California San Francisco, USA, decided to test the drug in human colon cancer cells in the laboratory.

They found that the drug killed the cells by triggering the process of apoptosis, or cell death.

"Our study demonstrates the potential of KPT-330 as a cancer therapeutic, and its mechanisms of action," says Professor Chris Tye, from the Mayo Clinic.

"The drug is effective against colon cancer in animals, and it's already safe and well tolerated in humans."
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  KPT-8602is a drug that inhibits
 
Response: KPT-8602is a drug that inhibits the histone deacetylase HDAC6. It was designed as a cancer drug and has been tested in clinical trials. But, this is the first time it has been tested in a study of Alzheimer's. Researchers studied the effects of KPT-8602 on mice that were genetically modified to develop the disease. They found that KPT-8602 decreased the buildup of amyloid plaques in the brains of these mice. And, the plaques were much smaller in size than in the control group. These results suggest that HDAC6 inhibitors could be a treatment for Alzheimer's disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  KX2-391is a drug that inhibits
 
Response: KX2-391is a drug that inhibits FKBP51 (also known as FKBP52) which in turn reduces the levels of glucocorticoid receptor and thus has anti-inflammatory and immunosuppressive properties.

Isoxazole-9-carboxamides are a class of synthetic compounds that were originally discovered as novel inhibitors of human immunodeficiency virus (HIV) protease, but were subsequently shown to inhibit FKBP51 as well.

References

Category:Benzamides
Category:Fluoroarenes
Category:Piperidines
Category:Abandoned drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Labetalolis a drug that inhibits
 
Response: Labetalolis a drug that inhibits Na/K-ATPase activity and its effects on the transport of Na and K ions and on intracellular calcium levels were studied. The drug was given to rats in doses of 10, 25, 50 and 100 mg/kg body weight for 2 weeks. The drug significantly increased the serum levels of Na and K and the activity of Na/K-ATPase in erythrocytes and kidney cortex. It also caused an increase in the intracellular Ca level in all cell types studied. The study showed that the drug induced an increase in the permeability of the cell membrane and the activity of the enzyme Na/K-ATPase.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lacidipineis a drug that inhibits
 
Response: Lacidipineis a drug that inhibits the binding of calcium ions (Ca2+) to calcium-binding sites in calmodulin, and thereby inhibits the activation of calmodulin-dependent enzymes, such as phosphodiesterase.
Lacidipineis chemically represented by the following formula (1) and has a chemical name of 2-acetyl-3-trifluoromethyl-N-(3-pyridyl)-5-methyl-phenylamino)-2-cyclohexyl-acetamide.
Lacidipineis approved for the treatment of hypertension and acute myocardial infarction in Japan.

As an intermediate in the synthesis of acidipine, the compound of the formula (2) below is disclosed in the publication of Patent Application Kokai (JP-A) No. 8-79433 (JP-A-8-79433).
The compound of the formula (2) is a compound
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lactoseis a drug that inhibits
 
Response: Lactoseis a drug that inhibits lactase, the enzyme responsible for the digestion of lactose. This means that the body has to use other sources of energy to break down the lactose in milk. When the body uses its energy sources to breakdown lactose, it is called a Lactose Intolerance. In the case of children, the age range is from 2 to 6 years. Lactose is used as a prescription drug to treat certain conditions, such as diarrhea.

There are many types of Lactose Intolerance, including:

Intermittent Lactose Intolerance (I-Lactose Intolerance)

This type of lactose intolerance is very common. It can happen if the body is not producing the necessary enzymes to digest lactose. Lactose is a natural sugar, but because the body is not producing the necessary enzymes, the body will have to use other sources of energy to break down the lactose in milk.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Adrenalineis a drug that inhibits
 
Response: L-Adrenalineis a drug that inhibits the reuptake of norepinephrine. It is used in the treatment of certain heart problems, but is also used as an appetite suppressant. This can be a very good weight loss drug. It causes the release of norepinephrine which results in the increased production of a hormone that makes you feel hungry. By blocking the reuptake of norepinephrine it also increases the amount of norepinephrine in the brain, and that makes you feel more energized and focused.

Adcirca is used to treat heart failure. It works by blocking the action of a protein called PDE-5. This protein is responsible for keeping blood vessels dilated. When it is blocked, blood vessels become more constricted. This makes blood flow to the heart and lungs more difficult. This can cause a patient to have an episode of dizziness, fainting, or even have a heart attack. Adcirca
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lafutidineis a drug that inhibits
 
Response: Lafutidineis a drug that inhibits the histamine H2-receptor and thereby acts as an antihistamine. It has the ability to bind to histamine H2-receptors, and also inhibits acetylcholine, dopamine and serotonin receptors. It can be used for the treatment of peptic ulcer, irritable bowel syndrome and dyspepsia.

Lafutidine was developed in China in 1987 by Shanxi TAIYUAN Pharmaceutical Co. Ltd. Lafutidine is manufactured in different dosage forms like tablets, capsules, suspension, and injection, for the treatment of peptic ulcer and gastritis. Lafutidine is not indicated for the treatment of dyspepsia, although it is widely used in China for this indication.

Lafutidine is available in the market in China in the form of a film-coated tablet. Lafutidine is available in the market in India as an oral tablet in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lamotrigineis a drug that inhibits
 
Response: Lamotrigineis a drug that inhibits glutamate release in the CNS. In vitro studies have shown that lamotrigine reverses the increase in spontaneous activity that is induced by N-methyl-D-aspartate (NMDA) antagonists in dissociated neurons. This suggests that lamotrigine may reduce the effects of drugs that enhance glutamate neurotransmission.

1. The in vitro studies showing that lamotrigine reverses the increase in spontaneous activity that is induced by NMDA antagonists were done with brainstem-spinal cord slices from neonatal rats. Were similar studies done in adult rats?

2. What are the characteristics of spontaneous activity in brainstem-spinal cord slices from adult rats?

3. What are the characteristics of spontaneous activity in brainstem-spinal cord slices from neonatal rats?

4. In the study, NMDA antagonists induced a marked increase in spontaneous activity. What was the rationale for using this particular
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LANIAZIDis a drug that inhibits
 
Response: LANIAZIDis a drug that inhibits the growth of viruses. The two approved drugs, adefovir and tenofovir, are synthetic analogs of adenosine and guanosine, respectively. They are chain terminators that prevent the chain elongation process by which DNA is made. They are usually used to treat chronic hepatitis B and C. However, adefovir and tenofovir can cause bone marrow suppression and renal failure.

Amphotericin B is a polyene antibiotic that binds to sterols in the membrane of fungi and other microorganisms. It is used to treat systemic fungal infections such as histoplasmosis and blastomycosis.

AZT is an antiviral drug that is used to treat HIV. AZT prevents HIV from replicating by preventing the HIV reverse transcriptase enzyme from forming the RNA strands that the virus uses to make its DNA. It is used to treat HIV infection.

Chloroqu
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lanifibranor(IVA-337)is a drug that inhibits
 
Response: Lanifibranor(IVA-337)is a drug that inhibits the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2) that is involved in atherosclerosis. A phase IIb trial of lanifibranor in patients with coronary artery disease showed a significant reduction in the risk of cardiovascular events.

Lanifibranor has a number of important properties that make it a potentially useful drug. Firstly, it is a low-molecular-weight agent (molecular weight of 741 g/mol), which is expected to be associated with less toxicity. Secondly, the drug is not a phospholipase inhibitor. Thirdly, Lp-PLA2 has been implicated in a number of pathologies besides atherosclerosis, including stroke and Alzheimer’s disease. Finally, the drug has an acceptable safety profile.

The article will discuss the preclinical development of lanifibranor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lanolinis a drug that inhibits
 
Response: Lanolinis a drug that inhibits liver fibrosis in rats. The long-term effects of Lanolinis in the treatment of hepatic fibrosis are being assessed in a clinical trial.

Saponins are a class of steroid glycosides found in many plants, including agave and yerba santa.

Yerba santa has been shown to reduce liver damage in animal models of liver disease.

Yerba santa is in phase 2 clinical trials for its ability to reduce liver damage.

Lanolin and similar fatty substances have been used as anti-inflammatory agents since ancient times. The antiseptic properties of Lanolin were discovered by Edward Jenner in the 1790s, and the use of Lanolin in wound dressings was established in the early 1900s.

The liver is a large, vital organ that plays a central role in the regulation of many bodily functions. The liver is a primary site for the metabolism of drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lansoprazoleis a drug that inhibits
 
Response: Lansoprazoleis a drug that inhibits gastric acid secretion. It is a member of the class of medications known as proton pump inhibitors (PPIs). PPIs, such as lansoprazole, are used to treat conditions that result from excess acid production in the stomach. These include heartburn, ulcers, gastroesophageal reflux disease (GERD), and other conditions. Lansoprazole is also used to prevent stress ulcers and to treat other conditions that cause gastrointestinal bleeding, such as ulcers, erosive esophagitis, and bleeding from the upper gastrointestinal tract.

Lansoprazole is available as both a prescription and over-the-counter (OTC) drug. The prescription form of the drug is a capsule that is taken once a day. The OTC form of the drug is a tablet that is taken twice a day. The OTC form of lansoprazole may also be available in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lapachoneis a drug that inhibits
 
Response: Lapachoneis a drug that inhibits a particular type of enzyme called topoisomerase. This enzyme is responsible for making DNA that is normally tightly coiled inside a cell more open, which can make it more likely that the cell will die. If the enzyme is not active, DNA can stay coiled and is less likely to kill the cell.

The topoisomerase inhibitor lapachone has been found to be effective against leukemia and some solid tumors.

Lapachone is approved for use in combination with certain other cancer drugs, such as dexamethasone, in the treatment of acute myeloid leukemia (AML) in adults who have relapsed or are refractory to previous therapy.

It is a naturally occurring substance found in the bark of the periwinkle plant.

In laboratory experiments, lapachone was found to have an effect on blood cells in mice.

Lapachone is generally well-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lapatinibis a drug that inhibits
 
Response: Lapatinibis a drug that inhibits HER2 (human epidermal growth factor receptor 2) and the tyrosine kinase activity of EGFR (epidermal growth factor receptor) in the treatment of advanced or metastatic breast cancer.^[@R1]^ Patients with HER2-positive advanced or metastatic breast cancer, who have not received prior trastuzumab, were randomized to receive lapatinib plus capecitabine (LC) or capecitabine alone (C).^[@R2]^ Lapatinib is associated with an increased incidence of diarrhea, which was greater with LC than with C (38% vs. 17%).^[@R2]^ Diarrhea was the most common adverse event (AE) leading to discontinuation of lapatinib.^[@R2]^

The efficacy of lapatinib in combination with capecitabine has been evaluated in 2 phase III trials (E
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lappaconitineis a drug that inhibits
 
Response: Lappaconitineis a drug that inhibits the enzyme acetylcholinesterase (AChE), increasing acetylcholine (ACh) in the synapses. The increase of ACh allows for a greater interaction between ACh and the muscarinic acetylcholine receptor.

Muscarinic receptors (mAChRs) are part of a large family of G-protein-coupled receptors. The most common mAChR is m1, also known as the M1 receptor. The M1 receptor is expressed in the striatum, nucleus accumbens, amygdala, hippocampus, hypothalamus, and thalamus. It is also expressed in the heart, liver, kidney, lungs, pancreas, adrenal glands, and GI tract. The M1 receptor is the major mAChR that controls motor function, regulating motor learning and motor coordination.

Lappaconitine is derived from the lappaconit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Laquinimod(ABR-215062)is a drug that inhibits
 
Response: Laquinimod(ABR-215062)is a drug that inhibits the activation of the N-formyl peptide receptor-1 (FPR-1) and the resulting signalling cascade. This receptor plays a key role in the clearance of pathogens by phagocytes and is highly expressed on the surface of macrophages. It has also been implicated in the regulation of bone resorption, haemostasis, cell migration and inflammatory responses. In experimental models of EAE, quinimod has been shown to attenuate the progression of disease. The development of FPR-1 antagonism is currently being pursued for the treatment of a variety of disorders.

Background

The neuropeptide N-formyl peptide receptor-1 (FPR-1) is a seven transmembrane G protein-coupled receptor that plays a key role in the recognition and clearance of microbial pathogens. FPR-1 is expressed by a number
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-(+)-Arabinoseis a drug that inhibits
 
Response: L-(+)-Arabinoseis a drug that inhibits the production of bacterial toxin and may be used to treat gastroenteritis, a condition characterized by diarrhea and abdominal cramps. This medication may also be used for other conditions as determined by your doctor.

What is the most important information I should know about L-Arabinose?

You should not use L-Arabinose if you are allergic to L-Arabinose or any of the ingredients in L-Arabinose.

If you are pregnant or are breast-feeding, use L-Arabinose with caution. L-Arabinose may be absorbed into the breast milk and may be passed to the baby.

L-Arabinose may cause a serious skin reaction. If you have had a severe skin reaction to L-Arabinose, or if you are allergic to L-Arabinose, tell your doctor before you use this medication.

L-Arabin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Arginineis a drug that inhibits
 
Response: L-Arginineis a drug that inhibits the enzyme arginase, which breaks down arginine.

L-Arginine is a natural amino acid that helps the body to make nitric oxide (NO). NO is a potent vasodilator and helps to relax blood vessels. It also helps to relax the walls of the bladder, which can cause increased bladder pressure.

The presence of L-Arginine helps to reduce blood pressure, and the L-Arginine/NO pathway is thought to be a major contributor to the cardiovascular and renal protective effects of arginine.

L-Arginine can also help to prevent kidney stones.

Uses

In addition to being used to treat bladder outlet obstruction, L-Arginine can also be used for a number of other purposes.

L-Arginine has been used for the treatment of high blood pressure, especially in combination with diuretics, but
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lasmiditanis a drug that inhibits
 
Response: Lasmiditanis a drug that inhibits the production of an enzyme called 5-lipoxygenase, and is marketed in Europe as Diclofenac Voltaren and in the United States as Apo-Lipo. This drug has been approved for use in Europe since 1998, and has been marketed in the United States since 2006. Lasmiditan is a selective 5-lipoxygenase inhibitor. It is indicated in the management of migraine headache with or without aura.

Drugs that inhibit the production of an enzyme called 5-lipoxygenase, and are marketed in Europe as Diclofenac Voltaren and in the United States as Apo-Lipo. This drug has been approved for use in Europe since 1998, and has been marketed in the United States since 2006. Lasmiditan is a selective 5-lipoxygenase inhibitor. It is indicated in the management of migraine headache with or without aura.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lasofoxifeneis a drug that inhibits
 
Response: Lasofoxifeneis a drug that inhibits the production of estrogen in the body, thereby decreasing the amount of estrogen in the blood. It can also decrease the amount of circulating testosterone. The reduced amount of estrogen may reduce the growth of certain tumors. It is sometimes used in combination with other anti-estrogens such as tamoxifen.

Side effects of Lasofoxifene

Like other anti-estrogens, Lasofoxifene can cause side effects, including:

Hot flashes. Hot flashes can occur during or after treatment.

Breast tenderness or enlargement.

Headaches.

Irregular menstrual cycles.

Increased risk of endometrial cancer.

Increased risk of thromboembolic events.

Liver problems.

Some patients may also have the following side effects:

Fatigue.

Upset stomach.

Weight gain.

In the short term
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L(+)-Asparagineis a drug that inhibits
 
Response: L(+)-Asparagineis a drug that inhibits growth of tumor cells. It is also used to prevent or treat conditions in which a deficiency of the amino acid L-asparagine is present, including for example, cystic fibrosis. It is also used to treat acute, painful episodes of herpes labialis, an infection caused by the herpes virus. It is used to treat AIDS dementia complex and symptoms of AIDS. It is used to treat osteoarthritis and prevent joint degeneration. It is also used to treat and prevent osteoporosis and osteopenia.

Molecular formula

Molecular Weight

Melting point

Amphetamine

136.27

155-158

Fluoxetine

252.41

201-220

Zolpidem

344.40

263-284

Guanfacine

327.42

268-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lathyrolis a drug that inhibits
 
Response: Lathyrolis a drug that inhibits IL-1-induced bone resorption. It has been developed as a therapeutic agent for treating diseases characterized by excessive bone resorption. For example, in patients suffering from Paget's disease, an excessive rate of bone resorption causes the bone to become weak and deformed, with a concomitant pain and deformity. This disease is associated with osteoclast activity. Thus, lathyrolis is useful in treating patients suffering from Paget's disease, and the disease is referred to herein as Paget's disease.
In addition, the drug has been shown to be effective in the treatment of other bone-resorption disorders, such as osteoporosis. Osteoporosis is a condition characterized by low bone mass and deterioration of bone tissue, leading to fragile bones and an increased risk of fracture. Bone mass is influenced by a number of factors, such as sex, age, weight, diet, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lazertinibis a drug that inhibits
 
Response: Lazertinibis a drug that inhibits EGFR tyrosine kinase and blocks the autophosphorylation of EGFR \[[@B1]\]. It is currently used in the treatment of non-small cell lung cancer (NSCLC) \[[@B2]\]. The results of a recent Phase III trial of erlotinib versus gefitinib in patients with advanced NSCLC suggested that gefitinib was more effective than erlotinib \[[@B3]\]. In contrast, another Phase III trial comparing erlotinib versus gefitinib in patients with advanced NSCLC showed that erlotinib was more effective than gefitinib \[[@B4]\]. These studies, which showed that gefitinib and erlotinib were not equivalent in terms of efficacy, indicated that gefitinib was a more selective EGFR tyrosine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-carnitineis a drug that inhibits
 
Response: L-carnitineis a drug that inhibits the enzyme carnitine acyltransferase, which is needed for the transport of long-chain fatty acids into the mitochondria for energy production. L-carnitine also increases the amount of energy-producing fuel (ketone bodies) in the liver. It may also have other uses, such as the treatment of muscle weakness in a number of diseases.

L-carnitine has been used for the treatment of skeletal muscle weakness in the newborn. The first clinical trial of L-carnitine for this purpose was in infants with congenital disorders of organic acid metabolism, such as carnitine deficiency.

In adults, L-carnitine has been used in the treatment of alcoholic fatty liver and other liver disorders. The L-carnitine content of milk is often used as a marker of nutritional status. The L-carnitine content of milk is decreased by certain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Carnitineis a drug that inhibits
 
Response: L-Carnitineis a drug that inhibits the conversion of long-chain fatty acids to fatty-acid CoA esters. It is commonly used to treat primary carnitine deficiency, a rare genetic disorder, and as an aid in weight loss. It is also used to treat fatigue and exercise-induced asthma.

L-Carnitine may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about L-Carnitine?

Do not use L-Carnitine if you have an allergic reaction to L-Carnitine or a similar drug.

Do not use L-Carnitine if you have kidney problems.

L-Carnitine may cause side effects. Tell your doctor if you have any side effects, including:

chest pain

muscle weakness

muscle cramps

shortness of breath

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LCI699is a drug that inhibits
 
Response: LCI699is a drug that inhibits lysosomal enzymes and can be used to treat diseases like Gaucher’s and Fabry’s diseases. It is a small molecule which is approved for treatment of Gaucher’s disease in the US and in the European Union.

“We have successfully made this compound in the lab, and our data shows that it is very effective in treating Gaucher’s disease. The mechanism of action is through the inhibition of the enzyme glucocerebrosidase, which is responsible for the breakdown of the glycosphingolipids.”

“We have also shown that it can treat Fabry’s disease,” says the team, which also includes Professor Jeremy Nicholson from University College London. “Fabry’s disease is an inherited disorder in which the body does not produce enough of the lysosomal enzyme alpha-galactosidase A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LCL161is a drug that inhibits
 
Response: LCL161is a drug that inhibits B-cell receptor signaling by binding to the BTK kinase, resulting in inhibition of B-cell proliferation and induction of apoptosis. In phase 1 trials, this drug was found to be safe and well tolerated. The primary objective of this study was to determine the MTD of LCL161 when administered on days 1 and 8 of a 21-day cycle. LCL161 was administered to patients with relapsed/refractory NHL, excluding patients with known secondary leukemias or lymphomas, with no known sensitivity to LCL161.

This is a randomized, multicenter, phase 1 trial. Patients were randomized to receive either 3 mg/kg LCL161 or 9 mg/kg LCL161, administered on days 1 and 8 of a 21-day cycle. Patients were treated for up to 8 cycles. The primary endpoint was safety and tolerability of LCL161 at the MTD, defined as the highest dose
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LDE225is a drug that inhibits
 
Response: LDE225is a drug that inhibits the protein tyrosine kinase activity of EGFR, which is frequently mutated in lung cancer \[[@R3]\]. EGFR mutations have been reported to occur in about 50% of lung adenocarcinomas \[[@R4]\]. A subset of these EGFR-mutant lung cancers respond to TKIs \[[@R4]\]. We report here that an immunohistochemical study of EGFR expression in an NSCLC cell line showed that the cells were negative for EGFR expression. A previous report indicated that the levels of EGFR expression in lung cancer cells were not always correlated with the presence of EGFR mutations \[[@R5]\]. The present case was a lung cancer with a large deletion mutation of the EGFR gene. The large deletion mutation was not detected in DNA from the NSCLC cell line by PCR. The immunohistochemical study showed that the NS
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LDK378is a drug that inhibits
 
Response: LDK378is a drug that inhibits A~2A~R signaling and has been proposed as a potential treatment for AD, but its potential therapeutic efficacy is hampered by its high lipophilicity. In order to improve the therapeutic potential of LNK378, we have developed two new hydrophilic prodrugs of LNK378 (Figure [2](#fig2){ref-type="fig"}). Prodrugs **2** and **3** are based on two different strategies: **2** is an esterification of the carboxylic acid with *p*-toluenesulfonyl hydrazine, and **3** is an acylation of the carboxylic acid with 1-hydroxybenzotriazole (HOBt).^[@ref10]^ The parent compound **1** was also synthesized to provide the reference standard for assessing the prodrugs. The results from the pharmacological ass
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ledipasviris a drug that inhibits
 
Response: Ledipasviris a drug that inhibits the enzyme Src kinase.

Drugs
------

Leukotriene antagonists, such as montelukast, are used to treat the symptoms of asthma. Cinanserin, which is an antihistamine, and levocetirizine, a second-generation antihistamine, are used for the treatment of allergic rhinitis. Topical corticosteroids are commonly used to treat the symptoms of asthma. These drugs are sometimes used in combination with other antihistamines or bronchodilators to treat rhinitis and asthma. These drugs are also used to treat pruritus, or itching, in atopic dermatitis.

Leukotriene antagonists, such as montelukast, are used to treat the symptoms of asthma. Cinanserin, which is an antihistamine, and levocetirizine, a second-generation anti
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LEE011-2is a drug that inhibits
 
Response: LEE011-2is a drug that inhibits the protein complex which is essential for the assembly of the viral envelope, thus preventing the entry of the virus into the cell. This drug is used in combination with other antiviral agents in order to prevent the emergence of viral resistance.

Abstract

LEE011-2 is a drug that inhibits the protein complex which is essential for the assembly of the viral envelope, thus preventing the entry of the virus into the cell. This drug is used in combination with other antiviral agents in order to prevent the emergence of viral resistance.

abstract = "LEE011-2 is a drug that inhibits the protein complex which is essential for the assembly of the viral envelope, thus preventing the entry of the virus into the cell. This drug is used in combination with other antiviral agents in order to prevent the emergence of viral resistance.",

N2 - LEE011-2 is a drug that inhibits the protein complex which is essential
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  leflunomideis a drug that inhibits
 
Response: leflunomideis a drug that inhibits de novo synthesis of pyrimidine. The drug is used to treat relapsing-remitting MS. It is the only DMT that has been approved by the US FDA. Its efficacy in reducing the relapse rate and progression of disability is now well established.^[@R33]^ However, its mode of action is not yet fully understood, and the potential mechanisms of action include reducing T cell proliferation and increasing T cell apoptosis,^[@R34]^ inhibiting autoantigen-presenting cells,^[@R35]^ reducing production of proinflammatory cytokines,^[@R36]^ and blocking activation of microglia and macrophages.^[@R37]^

Rituximab is a monoclonal antibody directed against the B cell surface protein CD20. Rituximab is FDA approved for the treatment of non-Hodg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  leniolisib(CDZis a drug that inhibits
 
Response: leniolisib(CDZis a drug that inhibits the activity of PI3K-δ and is being developed by Eisai and Novartis as a potential cancer treatment. It is also in clinical trials for use in multiple myeloma and leukaemia. 
Pimozide(used in psychiatry and sometimes referred to as pimethiazide or pimethylphenazone) is an antiemetic and antipsychotic drug. 
Ribavirin is a broad spectrum antiviral drug. It is used in combination with interferon in the treatment of chronic hepatitis C, but is associated with side effects such as haemolytic anaemia. 
Rivastigmine is an acetylcholinesterase inhibitor that has been approved for the treatment of Alzheimer's disease. 
Sildenafil(vardenafil) is a potent and selective inhibitor of the enzyme phosphodiesterase 5, the therapeutic effect
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lercanidipineis a drug that inhibits
 
Response: Lercanidipineis a drug that inhibits calcium channels. Lercanidipine is currently used in the treatment of hypertension, but its clinical effectiveness in the management of acute coronary syndrome has been demonstrated in several clinical trials. However, its use in the acute coronary syndrome setting is not approved in the USA. Lercanidipine may be a valuable option in the management of patients with acute coronary syndrome and/or left ventricular dysfunction.

Keywords

1. Introduction

1.1. The Coronary Atherosclerotic Disease Study Group (CADASIL)

1.2. The New York State Cardiovascular Consortium (NYSCC)

1.3. The Thrombolysis in Myocardial Infarction (TIMI) Study Group

1.4. The Antiplatelet Therapy in Unstable Angina to Prevent Myocardial Reinfarction Trial (ATLANT)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Letermovir(AIC246)is a drug that inhibits
 
Response: Letermovir(AIC246)is a drug that inhibits herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) replication by inhibiting the UL27 gene product, a helicase/primase. A number of phase II and III clinical trials have shown that Letermovir is a safe and effective antiviral for the treatment of genital herpes and recurrent ocular herpes in adults and children.[@b1-idr-8-245]--[@b3-idr-8-245] Letermovir is a prodrug that is metabolized to the active antiviral triphosphate triadtide derivative, Acyclovir-Penetrant (ACV-Penetrant) and Penciclovir. Letermovir is administered orally, once daily, at a dose of 300 mg/m^2^ in adults, and at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Letrozoleis a drug that inhibits
 
Response: Letrozoleis a drug that inhibits aromatase, the enzyme that converts testosterone to estrogen. This drug has been shown to be effective in increasing pregnancy rates in patients undergoing controlled ovarian hyperstimulation. It has been demonstrated that this drug improves oocyte quality and pregnancy rates when it is administered during the final days of controlled ovarian hyperstimulation. The drug should be administered for 2 days prior to embryo transfer. It should be used for 5 days after embryo transfer. It should not be used more than once in a cycle. The combination of letrozole and gonadotropins has been shown to be effective in improving oocyte quality.

Ovarian stimulation

Patients undergoing ovarian stimulation for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) may be treated with the aromatase inhibitor letrozole. Letrozole is a potent, nonsteroidal aromatase inhibitor. It inhibits the conversion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Leucovorinis a drug that inhibits
 
Response: Leucovorinis a drug that inhibits enzymes. Antibiotics that act on bacteria or viruses. A pain reliever. In some medicines, it is used to relieve pain. An antibiotic that kills the bacteria that cause infectious diseases. An oral medication used to treat bacterial infections of the urinary tract and vagina. It is also used to treat some types of bacterial infections in the intestines. An oral medication used to treat infections caused by bacteria that are resistant to other antibiotics. A medicine that is used to prevent or treat bacterial infections of the skin and other areas of the body. A pain reliever. In some medicines, it is used to treat painful conditions in the body. A pain reliever. In some medicines, it is used to treat infections caused by bacteria. An antibiotic that is used to treat urinary tract infections. A medicine that is used to prevent or treat bacterial infections of the respiratory tract. A medicine that is used to prevent or treat bacterial infections of the digestive tract. A medicine that is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Leuprorelinis a drug that inhibits
 
Response: Leuprorelinis a drug that inhibits the activity of some bacteria and helps in the healing of ulcers. This drug can be used to treat ulcers of the stomach, duodenum, esophagus, and other areas of the gastrointestinal tract. This drug is also used to treat the proctitis, which is an inflammation of the rectum.

Leuprorelin

The leuprorelin (Lupron) is a drug that inhibits the activity of some bacteria and helps in the healing of ulcers. This drug can be used to treat ulcers of the stomach, duodenum, esophagus, and other areas of the gastrointestinal tract. This drug is also used to treat the proctitis, which is an inflammation of the rectum.

Leuprolide

The leuprolide (Lupron) is a drug that inhibits the activity of some bacteria and helps in the healing of ulcers. This
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  levalbuterolis a drug that inhibits
 
Response: levalbuterolis a drug that inhibits the synthesis of cholesterol. By the late 1950s, the U.S. government had taken control of the drug industry, and several other pharmaceutical companies joined in the research. But, in 1963, Merck finally stopped the research. It did not have enough money to support the drug and the medical community rejected the idea that an artificial cholesterol-lowering drug could be used to lower blood cholesterol levels.

In the 1970s, the new U.S. Food and Drug Administration required the companies to prove that the cholesterol-lowering drugs could reduce the risk of heart disease, not just cholesterol. The new drug industry came up with a more effective way to lower cholesterol and its use has been very popular.

Today, the U.S. government requires the companies to show that the drugs can prevent heart disease, not just lower cholesterol. The medical community has now come to recognize that cholesterol is not a heart-disease risk
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levamisoleis a drug that inhibits
 
Response: Levamisoleis a drug that inhibits the growth of certain cancer cells by binding to the cells and inhibiting the function of a certain receptor on the cell surface. It is currently used as a drug to treat patients with various types of cancer. A number of clinical trials have demonstrated the effectiveness of leucovorin calcium (the sodium salt of leucovorin) with leucovorin calcium and levamisole (the sodium salt of leucovorin) in the treatment of various types of cancer, including non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, colon cancer, and gastric cancer. Levamisole is sold under the brand name Levamisole Oral Solution and Levamisole HCl. The current leucovorin calcium and levamisole product on the market is sold under the brand name Megace®. Levamisole HCl (2.5 mg/mL) is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levetiracetamis a drug that inhibits
 
Response: Levetiracetamis a drug that inhibits the binding of vesicular acetylcholine transporter (VAChT) to the neurotransmitter acetylcholine (ACh). It is used to treat the seizures associated with Lennox-Gastaut syndrome (LGS) and infantile spasms (IS). Levetiracetam is approved in the United States and Canada, but not in Europe, Japan, or the United Kingdom.

How is it used?

Levetiracetam is usually used to treat seizures associated with LGS or IS. In a double-blind, placebo-controlled study, the median time to seizure freedom after starting levetiracetam was 2.6 months. However, the median time to seizure freedom was not reached in the placebo group. The most common adverse effects of levetiracetam were headache and somnolence. Levetiracetam can also be used for other conditions.

What
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  levobetaxololis a drug that inhibits
 
Response: levobetaxololis a drug that inhibits the enzyme P-glycoprotein (P-gp), which is expressed on the membrane of cells and can reduce the effectiveness of many other drugs by preventing them from entering the cell. The drug is used to treat cancer, especially of the colon, ovary, and breast, and can also be used in combination with other drugs to treat cancers. Valspodar is being developed by Keryx Biopharmaceuticals, Inc.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  levobupivacaineis a drug that inhibits
 
Response: levobupivacaineis a drug that inhibits the peripheral and central nervous system. It is used for pain relief during and after surgery. In many countries, levobupivacaineis used for local anaesthesia and for surgery. In India, it is also used for nerve block.

3. Role of levobupivacaine

Levobupivacaineis used for pain relief during and after surgery. It is the most commonly used local anaesthetic agent for regional anaesthesia.

4. Mechanism of action of levobupivacaine

Levobupivacaineis a racemic mixture of the stereoisomers of the amino acid l-2-(2-chloropropyl) -N,N-dimethyl amino acid, where one of the chiral centres has been replaced by a methyl group. The two stereoisomers are (S)- and (R)-levobupivacaine. Levob
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levodropropizineis a drug that inhibits
 
Response: Levodropropizineis a drug that inhibits acetylcholinesterase (AChE). It is used to relieve symptoms of dry mouth and irritation of the mouth and throat caused by dryness of the mouth. Levodropropizine is also used to relieve cough and shortness of breath caused by asthma. It is also used to relieve symptoms of nausea and vomiting caused by cancer chemotherapy. Levodropropizine is a racemic mixture of levodropropizine and the mirror image (enantiomer) of levodropropizine. The active ingredient of the drug is the R enantiomer. The chemical name of the active ingredient is 1-[2-[(2-hydroxy-3-pyridinyl)methoxy]ethyl]-4-piperidinyl-1,3-dihydro-2,4-benzodiazepin-2-one. The drug is marketed under the brand
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LEVOFLOXACINis a drug that inhibits
 
Response: LEVOFLOXACINis a drug that inhibits bacterial DNA gyrase. It is an anti-bacterial agent that is used to treat urinary tract infections, lower respiratory tract infections, sexually transmitted diseases and gastrointestinal infections.

LORAZEPAM (ATRANOLDA)

LORAZEPAM is a drug that has been used to treat anxiety, insomnia and to reduce nausea and vomiting. It is available in tablets, capsules, syrup and injectable form.

LYCOPHYLLUM (FULLEROLAM)

LYCOPHYLLUM is a drug that has been used to treat certain kinds of cancer. It is available in tablets, capsules and injectable form.

MALTOFORTIN (OPTIPHOSPHATE)

MALTOFORTIN is a drug that has been used to treat intestinal disorders. It is available in tablets, capsules, syrup and injectable form.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levomilnacipranis a drug that inhibits
 
Response: Levomilnacipranis a drug that inhibits serotonin and norepinephrine reuptake.

Levomilnacipran is the generic form of the drugFluvoxamine. Fluvoxamine is used to treat major depression and obsessive-compulsive disorder.

Levomilnacipran is also used to treat stress urinary incontinence and neuropathic pain.

Levomilnacipran was developed by Forest Laboratories.

Levomilnacipran may also be marketed as a generic medication.

This medication is not approved for use in the United States. It is only approved for use in other countries.

WARNING: THIS MEDICATION IS NOT DESIGNED TO PREVENT PREGNANCY. It may be used to prevent pregnancy only if clearly indicated by a doctor. Do not use this medication if you are pregnant.

To receive the most benefit from this medication,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levonorgestrelis a drug that inhibits
 
Response: Levonorgestrelis a drug that inhibits ovulation in women and prevents pregnancy. It is used as a contraceptive, especially for women who have already had a baby, and is used in some countries as a second-line treatment for acne. Levonorgestrelis also has a protective effect against breast cancer. It works by inhibiting the release of luteinizing hormone from the pituitary gland, thereby preventing ovulation. Levonorgestrelis is most commonly used as a combined oral contraceptive (COC), which is also called a combined hormonal contraceptive. The combined contraceptive pill consists of a progestin, which is levonorgestrelis, and an estrogen, usually ethinyl estradiol. The pill is a highly effective contraceptive, with a typical failure rate of less than 1%.[1]

Levonorgestrelis was developed in the 1950s by the Schering Corporation.[2] In 1957, a method of synthesis was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levosimendanis a drug that inhibits
 
Response: Levosimendanis a drug that inhibits calcium uptake into the heart muscle and prevents calcium-dependent inotropic stimulation, thereby reducing afterload. It is used in patients with left ventricular dysfunction and pulmonary hypertension to decrease afterload and improve oxygen consumption.

Introduction {#sec1-1}
============

Levosimendan (Simdax®, Orion Pharma, Finland) is a calcium sensitizer that acts by increasing the sensitivity of myocardial contraction to calcium without increasing the intracellular concentration of calcium.\[[@ref1]\] The pharmacologic effects of levosimendan are exerted by its binding to troponin C, thus enhancing the affinity of troponin for calcium, and by its phosphorylation of troponin I, which reduces the rate of myofilament calcium dissociation.\[[@ref2]\]

This article presents a case report of a 45-year-old male with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levosulpirideis a drug that inhibits
 
Response: Levosulpirideis a drug that inhibits the secretion of prolactin from the pituitary gland, and also has dopamine-2-receptor blocking properties. It is used to treat the symptoms of depression, such as fatigue, sleep disorders, anxiety, restlessness, and weight gain. It is also used to treat nausea and vomiting during chemotherapy, and is sometimes used to treat hot flashes in menopausal women. It is a selective serotonin reuptake inhibitor (SSRI).

Levosulpiride

In the United States, levosulpiride is sold as the sulfate salt, and is available as a generic drug. It is also available in combination with a selective serotonin reuptake inhibitor (SSRI) for the treatment of schizophrenia.

Levosulpiride is available in the following dosage forms:

Suspension

Orally disintegrating tablet

Suspension

Tablets

Orally disintegrating
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Levulinicis a drug that inhibits
 
Response: Levulinicis a drug that inhibits the enzyme levulose dehydrogenase. This enzyme is involved in the conversion of xylose into levulinic acid. The resulting acid is an important precursor for a number of chemical products such as succinic acid, lactic acid, and formic acid.

Levulinicis marketed under the brand name Levulox and is used to treat non-alcoholic fatty liver disease and in combination with other treatments for the treatment of adult acute myeloid leukaemia. Levulinicis is also used to treat or prevent herpes simplex virus and varicella-zoster virus infections, as well as bacterial infections.

Mechanism of action

Levulinicis inhibits the enzyme levulose dehydrogenase. This enzyme is involved in the conversion of xylose into levulinic acid. The resulting acid is an important precursor for a number of chemical products such as succinic acid, lactic acid,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LEXXELis a drug that inhibits
 
Response: LEXXELis a drug that inhibits expression of the cancerous cell's angiogenesis (i.e., formation of new blood vessels) and metastasis (i.e., spreading of cancer cells to other areas of the body) factors. AVEXELis a drug that is designed to specifically target and destroy cancer cells. AVEXELis not known to cause heart failure or other cardiovascular problems.

CASE REPORT
===========

A 55-year-old man was admitted to our hospital because of left back pain. His past medical history was unremarkable, and he had no history of smoking or drinking. Laboratory tests showed elevated levels of serum alkaline phosphatase (230 U/L), γ-glutamyltransferase (243 U/L), lactate dehydrogenase (1223 U/L), and carcinoembryonic antigen (15.4 ng/mL). These levels were within normal limits, except for alk
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LGD-4033(VK-5211)is a drug that inhibits
 
Response: LGD-4033(VK-5211)is a drug that inhibits VEGF and other angiogenic growth factors and has been approved by the FDA for the treatment of colon cancer and renal cell carcinoma. This study evaluated the activity of LGD-4033(VK-5211)in combination with the anti-EGFR monoclonal antibody cetuximab and carboplatin (CBDCA) in advanced colorectal cancer (CRC).

METHODS: Patients with stage III or IV CRC and at least one bidimensionally measurable lesion were enrolled. The primary end point was the response rate. Secondary end points were overall survival, progression-free survival, and safety. Patients received treatment with CBDCA (400 mg/m2, day 1) and cetuximab (initial dose of 250 mg/m2, day 1) followed by weekly CBDCA (400 mg/m2, day 1)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LGK-974is a drug that inhibits
 
Response: LGK-974is a drug that inhibits the growth of cancer cells by targeting the ALK receptor tyrosine kinase. It is under investigation for the treatment of non-small cell lung cancer (NSCLC).

Biosimilars

If the price of a biosimilar is similar to that of the reference product, it may be cheaper for a healthcare system to switch to the biosimilar rather than to switch to the reference product.

Market research

GlaxoSmithKline is conducting research into the usage of biosimilars in certain countries.

Product 

LGK-974is a fully humanized monoclonal antibody that targets the ALK receptor tyrosine kinase, which is a fusion protein that is found in certain cancer cells. The antibody binds to the extracellular domain of ALK and prevents it from binding to its natural ligand, thereby inhibiting the ALK receptor tyrosine kinase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Hydroxyprolineis a drug that inhibits
 
Response: L-Hydroxyprolineis a drug that inhibits the collagenase activity of Matrix metalloproteinases (MMPs). In the last few years, MMPs have been implicated in a wide variety of physiological and pathological processes. These enzymes have been implicated in the breakdown of normal extracellular matrix and are believed to play a role in the pathogenesis of diseases such as rheumatoid arthritis, tumor metastasis, periodontal disease, multiple sclerosis, aortic aneurysm, emphysema, corneal ulceration, proteinuria, heart disease, osteoporosis, arthritis and cystic fibrosis. See, for example, Kessenich, J. P. (1994) FASEB J. 8, A1113; Birkedal-Hansen, H. (1994) Crit. Rev. Oral Biol. Med. 5, 197; Wojciak-Stothard, R. (1993)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LIDEX-Eis a drug that inhibits
 
Response: LIDEX-Eis a drug that inhibits the growth of malignant cells, especially in the lungs. It is used in the treatment of some types of cancer. It is not a cure, but may prolong the life of the patient. It is sometimes used to help chemotherapy.

LIDEX-Eis is used to treat some types of cancer, including non-small cell lung cancer, small cell lung cancer, colorectal cancer, and others.

LIDEX-Eis is also used to treat patients with acute myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia.

It is not used to treat other conditions.

How does LIDEX-Eis work?

LIDEX-Eis is an anticancer agent that works by stopping the growth of malignant cells, especially in the lungs.

LIDEX-Eis stops the growth of cancer cells by inhibiting the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Linagliptinis a drug that inhibits
 
Response: Linagliptinis a drug that inhibits TGF-β and is used to treat myocardial fibrosis and nonalcoholic steatohepatitis (NASH) in humans. This drug is a bifunctional molecule that can also inhibit NF-κB and MAPK. In this study, we examined the effect of Linagliptin on the growth and invasion of CRC cells and investigated the molecular mechanisms involved. We used CRC cell lines (DLD-1, HCT116, and HT29) and a normal colonic epithelial cell line (FHC) in this study. Linagliptin inhibited cell proliferation in a dose- and time-dependent manner in CRC cell lines, but not in FHC cells. Linagliptin also inhibited cell invasion in CRC cell lines in a dose-dependent manner. We examined the molecular mechanisms involved in the Linagliptin-induced growth inhibition of CRC cells and found that Linagliptin inhibited the expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lincomycinis a drug that inhibits
 
Response: Lincomycinis a drug that inhibits microtubule assembly. Inhibitors of microtubule assembly are also useful for the treatment of malignant diseases.
Inhibitors of microtubule assembly are useful in the treatment of cancer, since they inhibit the formation of mitotic spindles necessary for cell division, thus inhibiting the proliferation of cancer cells. One such microtubule inhibitor is the taxoid drug paclitaxel.
Paclitaxel is a complex diterpenoid originally isolated from the Pacific yew tree, Taxus brevifolia. The isolation and structural elucidation of paclitaxel was reported by Wani et al. (J. Am. Chem. Soc., 110:7597 (1988), incorporated herein by reference). Paclitaxel has been found to be an effective anti-cancer agent, especially in the treatment of ovarian and breast cancers. Paclitaxel is now commercially available as TAXOL® from Bristol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Linezolidis a drug that inhibits
 
Response: Linezolidis a drug that inhibits bacterial protein synthesis by blocking the 50S subunit of the ribosome. It is active against a broad spectrum of Gram-positive organisms, including Staphylococcus aureus and Enterococcus faecalis.\[[@CIT1]\] Linezolid is a unique oxazolidinone antibiotic.\[[@CIT2]\] It is effective in the treatment of serious infections caused by organisms with low-level resistance to other antimicrobial agents, and in the treatment of skin and soft tissue infections caused by Gram-positive organisms.\[[@CIT3]\]

Linezolid is available as a sterile lyophilized powder in an oral suspension formulation (Zyvox^®^, Pfizer Inc., USA). The oral suspension contains 300 mg of linezolid, 5.0% polysorbate 80, and 1.0% sucrose. The recommended
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Linoleicis a drug that inhibits
 
Response: Linoleicis a drug that inhibits the production of the pro-inflammatory fatty acid leukotriene B4 (LTB4). LTB4 is a product of the 5-lipoxygenase pathway. When it binds to its receptors, LTB4 stimulates the release of other inflammatory mediators such as prostaglandins and cytokines.

It is indicated for the treatment of atopic dermatitis, contact dermatitis, allergic rhinitis, and urticaria.

Ocular side effects include dry eye, blurred vision, eye pain, eye irritation, burning sensation, increased intraocular pressure, conjunctival hemorrhage, and conjunctival inflammation. Other side effects include insomnia, headache, dizziness, nausea, vomiting, abdominal pain, flatulence, diarrhea, dyspepsia, hypertension, cough, chest pain, and sinusitis.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Liothyronineis a drug that inhibits
 
Response: Liothyronineis a drug that inhibits the production of thyroid hormone in the body. It is used to treat patients with a variety of thyroid problems.

**Famotidine** is used to treat and prevent stomach ulcers and duodenal ulcers.

**Gelatin capsules** are used to treat some of the symptoms of a urinary tract infection (UTI).

**Glucosamine** is used to treat arthritis and joint pain.

**Glucose tablets** are used to treat diabetes.

**Glyburide** is used to treat type 2 diabetes.

**Glycerin** is used to treat sore throat, cracked lips, and chapped skin.

**Glycopyrrolate** is used to treat stomach ulcers and irritable bowel syndrome (IBS).

**Glycopyrrolate, triprolidine** is used to treat peptic ulcers.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LIQUIDis a drug that inhibits
 
Response: LIQUIDis a drug that inhibits human neutrophil elastase. It was approved by the US Food and Drug Administration (FDA) in 1997 for the treatment of the acute exudative form of age-related macular degeneration (AMD). Intravitreal injections of LIQUID are usually administered every 4--6 weeks, and a 2-year phase III clinical trial of the efficacy of LIQUID versus the other anti-VEGF agents for the treatment of neovascular AMD has shown that LIQUID had better long-term outcomes in terms of the mean change in visual acuity and central macular thickness.^[@R1]^

However, some patients with neovascular AMD experience persistent intraocular inflammation after LIQUID injections. It is possible that the cytokines released from the inflammatory cells after the initial intravitreal injection are responsible for the persistent inflammation. Cytokines such as interleukin (IL)-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lithocholicis a drug that inhibits
 
Response: Lithocholicis a drug that inhibits the reabsorption of bile acids in the ileum, and reduces cholesterol absorption from the intestine. It is used in the treatment of primary biliary cirrhosis, and chronic idiopathic cholestasis, as well as gallstone prevention in combination with a ursodeoxycholic acid (Ursodiol) preparation.

A 28-year-old woman was admitted to our hospital because of abdominal distention, bloating, nausea, and anorexia. She had been diagnosed with primary biliary cirrhosis in 2004. She had been treated with Ursodiol, 20 mg/day, for 2 years. On admission, her body weight was 45 kg (body mass index, 16.9 kg/m2). Physical examination revealed tenderness in the epigastrium and distention of the whole abdomen. Laboratory tests revealed a normal white blood cell count, a slightly increased aspartate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Lacticis a drug that inhibits
 
Response: L-Lacticis a drug that inhibits collagenase and helps retain collagen fibers in the vagina. There are some side effects but these are usually only mild.

The Vaginal Ring

The vaginal ring is an implant that you insert into the vagina. The ring contains the drug, norethisterone, which is a synthetic form of the female hormone, progesterone.

The vaginal ring contains a reservoir that slowly releases norethisterone into the vagina. This allows you to get a continuous supply of the drug over a period of time.

The ring can be worn for three months, although most women only wear them for a few weeks.

How does the Vaginal Ring work?

The vaginal ring is made of soft, flexible plastic. It has a ring at one end and a soft plug at the other end. The ring is placed in the vagina and the plug is inserted into the vagina and up against the cervix. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LM-3093is a drug that inhibits
 
Response: LM-3093is a drug that inhibits the biosynthesis of cholesterol in the liver and decreases the amount of LDL cholesterol in the blood.

Because it is a relatively new drug, the clinical information available about the effectiveness of this drug in the treatment of high cholesterol is limited. In clinical trials, the dose of simvastatin used to lower LDL cholesterol in people with high cholesterol ranged from 10 to 80 mg per day. In people with mild hypercholesterolemia, doses of simvastatin as high as 80 mg per day were used. In clinical trials, simvastatin reduced LDL cholesterol by about 50 percent to 70 percent in people with high cholesterol.

Because of the importance of maintaining the level of LDL cholesterol in the blood, the U.S. Food and Drug Administration (FDA) has approved simvastatin for treating people with high cholesterol. The manufacturer of simvastatin, Merck, has reported that simvastatin can help
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LM-3264is a drug that inhibits
 
Response: LM-3264is a drug that inhibits TGF-beta receptor 1. It is a specific small molecule antagonist of the TGF-beta type 1 receptor and inhibits TGF-beta-induced SMAD2/3 phosphorylation, expression of TGF-beta-induced genes, and TGF-beta-mediated cellular effects. It has been investigated in various models of fibrosis and in vivo in an animal model of pulmonary fibrosis.

IMPORTANT SAFETY INFORMATION

Pregnancy:

Caution should be used when using this drug in women who are pregnant, or who may become pregnant during treatment or for whom contraception is not appropriate.

Breastfeeding:

It is not known whether this drug is excreted in human milk. If you are breastfeeding, discuss with your doctor the risks and benefits of breastfeeding while using this drug.

Immunocompromised:

Caution should be used in patients with severe
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LM-3572is a drug that inhibits
 
Response: LM-3572is a drug that inhibits proteolytic activity of human leukocyte elastase (HLE) and is useful for treating inflammation. In this study, the oral absorption and bioavailability of an experimental formulation of LM-3572 were investigated in beagle dogs. The formulation consisted of an aqueous dispersion of LM-3572 (LM-3572-SD) in water containing a phosphatidylcholine derivative (LM-3572-PDC). The LM-3572-SD was administered orally to six beagle dogs. Plasma concentrations of LM-3572 were determined by a high-performance liquid chromatography method. LM-3572 was absorbed from the GI tract, and LM-3572 was absorbed rapidly and completely. The oral bioavailability of LM-3572 was significantly higher than that of LM-3572-PDC.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LM-3573is a drug that inhibits
 
Response: LM-3573is a drug that inhibits the proliferation of human lung cancer cells, including A549, H460, and H292, and has an effect of inducing apoptosis in human lung cancer cells.[@b14-dddt-12-2223] As shown in [Figure 1A and B](#f1-dddt-12-2223){ref-type="fig"}, the A549 and H460 cell viability was inhibited in a dose-dependent manner by LM-3573. Moreover, the inhibitory effect was more significant at 48 hours after LM-3573 treatment. However, there was no obvious inhibitory effect on the viability of H292 cells. The results of cell apoptosis indicated that LM-3573 induced a dose-dependent increase in apoptosis in A549 and H460 cells. At 24 hours after LM-3573 treatment, the apoptotic rate of A549 and H460 cells was increased from 2.5% to 29.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LM-3632is a drug that inhibits
 
Response: LM-3632is a drug that inhibits TNF and is under development by Genentech. It has been shown to be safe in a phase 1 study.

References

External links

Category:Antineoplastic and immunomodulating drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-NAMEis a drug that inhibits
 
Response: L-NAMEis a drug that inhibits the activity of nitric oxide synthase (NOS) by binding to the heme of the enzyme. It was used to study the role of nitric oxide in brain and spinal cord injury. This article examines the basic biology of NO, the major role of NO in the central nervous system (CNS), and the significance of the findings in the experimental and clinical setting. It reviews the current state of knowledge on NO and NOS, including the development of NOS inhibitors, and the physiological and pathophysiological role of NO in the CNS. The results of experimental studies that tested the effects of NOS inhibition in models of brain and spinal cord injury are discussed. Finally, the possible role of NOS inhibition in the treatment of CNS injury is considered.

Introduction

The role of nitric oxide (NO) in the CNS is complicated. In the healthy brain, NO is synthesized in glial cells by three isoforms of nit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lodoxamideis a drug that inhibits
 
Response: Lodoxamideis a drug that inhibits an enzyme in the eye that is involved in production of inflammation and the wetting of the eye. Lodoxamide is used to treat eye irritation, redness, itching, and burning of the eye. Lodoxamide may also be used for other purposes not listed in this medication guide.

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

Get a daily health tip

Stay in touch

The information on Health24 is for educational purposes only, and is not intended as medical advice, diagnosis or treatment. If you are experiencing symptoms or need health advice, please consult a healthcare professional. See additional information.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lomefloxacinis a drug that inhibits
 
Response: Lomefloxacinis a drug that inhibits the activity of TNF-alpha and may also be effective in treating a number of other diseases, such as systemic lupus erythematosus, juvenile arthritis, rheumatoid arthritis, osteoarthritis, psoriasis, ulcerative colitis, septic shock, and other inflammatory conditions.
Loxapine a drug that is used in the treatment of schizophrenia and bipolar disorder. It also has been found to be useful in treating children with cerebral palsy.
Lumefantrine a drug that is used to treat malaria.
Macimorelin a drug that is used to treat certain conditions such as obesity, acute pancreatitis, and diabetes.
Macoxamidopyrine a drug that is used to treat certain conditions such as obesity, acute pancreatitis, and diabetes.
Methylprednisolone a corticosteroid drug that is used to treat arthritis, asthma,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  lomerizineis a drug that inhibits
 
Response: lomerizineis a drug that inhibits peripheral and central histamine H1-receptors and is used in the treatment of allergic rhinitis and urticaria. The drug also has antipsychotic and antinociceptive effects. The goal of this study was to investigate the effects of histamine H1-receptor blockade on the memory-impairing effects of a single dose of ketamine in healthy subjects. A randomized, double-blind, placebo-controlled, crossover study. A research laboratory in an academic medical center. Thirty healthy volunteers (15 men and 15 women) with a mean age of 27.3 years (range, 20-42 years). Subjects received a single oral dose of either 50 mg of lomerizine or placebo at 0800 hours, followed by a single oral dose of ketamine (50 mg) or placebo at 1600 hours. Memory and mood were evaluated with a battery of neuropsychological tests. One hour after ketamine,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lomitapideis a drug that inhibits
 
Response: Lomitapideis a drug that inhibits the activity of a lipoprotein lipase enzyme, an enzyme that helps in the breakdown of fats in the blood.

A study in the journal JAMA Internal Medicine in May 2013 showed that lomitapide reduced levels of low-density lipoprotein (LDL) cholesterol by 40 percent.

Lomitapideis approved in the US for use in people with homozygous familial hypercholesterolemia (HoFH), and is currently being tested in a large clinical trial in people with heterozygous familial hypercholesterolemia (HeFH).

The medication is approved for use in people who are at least 12 years old.

What is lomitapide?

Lomitapide is a medication that is used to lower cholesterol levels.

It is also used to treat people who have an inherited condition called homozygous familial hypercholesterolemia (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lonafarnibis a drug that inhibits
 
Response: Lonafarnibis a drug that inhibits the farnesyltransferase enzyme. The enzyme is part of the protein-making machinery that builds the cell's plasma membrane. Without it, the plasma membrane isn't as solid, which can lead to changes in cell behavior. In fact, this enzyme is so important to the cell that it's the only one of the more than 3,000 proteins encoded by the human genome that gets turned off when the cell dies. In a sense, it's the ultimate control switch, and it's the target of lonafarnibib.

Lonafarnibib works by blocking the production of the farnesyl group, which is attached to the farnesyltransferase enzyme. This farnesyl group is one of the first things added to a protein when it's made.

So far, the drug has shown promise in phase II clinical trials for people with prostate cancer, and is in phase III trials for breast
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lonidamineis a drug that inhibits
 
Response: Lonidamineis a drug that inhibits a specific step in the process of cell division called the initiation of DNA replication. It was discovered in 1964 as a plant growth regulator, and it has been used since then as a treatment for breast cancer. A recent study in animals showed that it is also an effective treatment for Huntington's disease. This means that it may be possible to stop or delay the progress of the disease. It may also be possible to find a way to slow down the progression of other neurodegenerative diseases.

What Lonidamine does

Lonidamine is an inhibitor of the enzyme ribonucleotide reductase. It blocks the enzyme's ability to reduce ribonucleotides to deoxyribonucleotides. The deoxyribonucleotides then form the strands of DNA that are used to replicate the genetic information that makes up our bodies. This step in the process of cell division is called the initiation of DNA replication.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Loperamideis a drug that inhibits
 
Response: Loperamideis a drug that inhibits gastrointestinal motility and is used to treat diarrhea. In this study, we investigated the mechanism of loperamide-induced apoptosis in human esophageal carcinoma EC109 cells. Loperamide treatment significantly induced apoptosis, DNA fragmentation, and phosphatidylserine externalization in EC109 cells. In contrast, loperamide had no effect on apoptosis and phosphatidylserine externalization in normal esophageal epithelial cells (EECs). Loperamide also increased reactive oxygen species (ROS) production and decreased the levels of Bcl-2 and the Bcl-2/Bax ratio in EC109 cells. Pretreatment with the antioxidant N-acetyl-l-cysteine (NAC) or diphenyleneiodonium (DPI) abolished the apoptotic effect of loperamide on EC109 cells. However, pretreatment with NAC did not inhibit ROS production
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LOPIDis a drug that inhibits
 
Response: LOPIDis a drug that inhibits the enzyme CYP3A4, which is the major drug-metabolizing enzyme in the liver.

LOPIDis a drug that inhibits the enzyme CYP3A4, which is the major drug-metabolizing enzyme in the liver.

LOPIDis a drug that inhibits the enzyme CYP3A4, which is the major drug-metabolizing enzyme in the liver.

LOPIDis a drug that inhibits the enzyme CYP3A4, which is the major drug-metabolizing enzyme in the liver.

The most common side effects of LOPID include fatigue, nausea, diarrhea, dizziness, and decreased appetite. Other side effects include vomiting, weakness, and headache.

Nervous system side effects include tingling or numbness of the hands or feet, or numbness or tingling of the face, mouth, arms, legs,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LOPINAVIRis a drug that inhibits
 
Response: LOPINAVIRis a drug that inhibits the viral polymerase of hepatitis C virus (HCV) and is used in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) in the treatment of chronic hepatitis C. The treatment has several side effects and a number of patients fail to respond to the treatment. This study was undertaken to investigate the correlation between the response to treatment and polymorphisms of the interferon-γ gene. A total of 132 patients with chronic hepatitis C, all of whom had received a combination of PEG-IFN and RBV, were genotyped for the interferon-γ gene polymorphisms at positions -1677, -874, and +874. Of the 132 patients, 85 (65%) had a sustained virological response (SVR) to the treatment. The SVR rate in patients with the -874 A/A genotype was significantly higher than
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Loratadineis a drug that inhibits
 
Response: Loratadineis a drug that inhibits the histamine receptors H1 and H2. It is used to treat seasonal allergic rhinitis, chronic idiopathic urticaria, and atopic dermatitis.

Loratadine is available in generic form. The brand name of loratadine is Claritin.

Common side effects of loratadine include:

Headache

Nausea

Vomiting

Dizziness

Fainting

Chest pain

Abdominal pain

Stomach pain

Indigestion

Loratadine is classified as a histamine receptor antagonist.

Loratadine is an antihistamine drug used to treat allergic reactions, such as allergic rhinitis and urticaria. It is also used to treat chronic idiopathic urticaria (CIU), and seasonal allergic rhin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Alavertis a drug that inhibits
 
Response: Alavertis a drug that inhibits NF-kappaB activation.
Alavert is a new agent that inhibits the activation of the transcription factor NF-kappaB. The compound was isolated from a Japanese traditional medicine. It inhibits the activation of NF-kappaB by preventing the degradation of IkappaB alpha and by blocking the phosphorylation of IkappaB alpha. In a rat model of colitis, Alavert decreased the activity of NF-kappaB in the colon. In a mouse model of systemic lupus erythematosus, Alavert decreased the activity of NF-kappaB in the spleen. These results indicate that Alavert may be useful in the treatment of autoimmune and inflammatory diseases.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LORELCOis a drug that inhibits
 
Response: LORELCOis a drug that inhibits the action of prolactin.

Lorlatin--

LORLATIN--a mild cathartic and stimulant laxative.

LORTIC--(See SORIC).

LORTELLIC--(See CATHARTIC).

LORTIUM--a colourless, odorless, volatile liquid, soluble in alcohol,
ether, and benzene. It consists of two parts, a carbide and an acid, and
is the base of the following salts:--

Lorvite--an artificial product used as a substitute for blood.

LORZ--a transparent, vitreous substance, obtained from several species of
the mushroom genus. It is insoluble in water and is chiefly used as a
setting material for glass and porcelain. It is also employed in
optical, electro-chemical, and photographic work.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lornoxicamis a drug that inhibits
 
Response: Lornoxicamis a drug that inhibits COX-2 enzyme and thus the synthesis of prostaglandins and thromboxanes. These enzymes are responsible for the conversion of arachidonic acid to prostaglandins and thromboxanes which are mediators of inflammation and pain. Prostaglandins and thromboxanes have a major role in the modulation of vascular tone and microcirculation, hence, lornoxicam may be used for the treatment of pain and inflammation. It is a parenteral anti-inflammatory drug. It is a non-steroidal anti-inflammatory drug. It is used to treat rheumatoid arthritis and osteoarthritis, and it is also used to prevent and treat gout. It is also used for the treatment of the pain of ankylosing spondylitis, painful bursitis, and painful shoulder. It is used to prevent the pain of sports injuries and for relief of arth
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Losartanis a drug that inhibits
 
Response: Losartanis a drug that inhibits the renin-angiotensin system, is used to treat high blood pressure. Common side effects of losartan include dizziness, cough, and changes in taste. Losartan may also cause allergic reactions such as a rash, hives, itching, swelling, or trouble breathing. If you experience these symptoms, seek medical attention.

Celexais a drug used to treat major depression. It works by increasing the levels of serotonin and norepinephrine in the brain. It also increases the levels of these neurotransmitters in the blood. Common side effects of Celexa include nausea, diarrhea, dizziness, headache, dry mouth, and changes in taste. If you experience these symptoms, seek medical attention.

Ciprofloxacinis a drug that treats certain infections. It works by stopping the growth of bacteria. Common side effects of ciprofloxacin include changes in taste
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LOTRIMINis a drug that inhibits
 
Response: LOTRIMINis a drug that inhibits neutrophil elastase, a protease that plays a key role in the degradation of the pulmonary extracellular matrix. Inhaled LOTRIMIN was recently shown to significantly improve the clinical outcomes in patients with acute respiratory distress syndrome (ARDS) in a phase III trial \[[@CR1]\]. The drug was well tolerated and its safety profile was similar to placebo. Although the results of this trial are encouraging, the use of inhaled LOTRIMIN as a therapeutic agent in the treatment of ARDS is not without limitations.

Inhaled loteprednol etabonate (LOT) is a synthetic glucocorticoid with a long duration of action. It is a potent anti-inflammatory agent that is administered in the form of a suspension that can be nebulized. LOT is used in the treatment of inflammatory conditions, including those of the upper and lower respiratory tract. Its
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  loxapineis a drug that inhibits
 
Response: loxapineis a drug that inhibits the reuptake of serotonin. It is the drug of choice for acute mania and treatment of major depression. It has a low incidence of side effects, the most serious being anticholinergic and extrapyramidal effects. Doses of 400-800 mg/day are required for treatment of mania, and a dose of 200-400 mg/day is used for depression. In this paper, we will review the current evidence for the use of amlodipine as an adjunct to treatment of depression.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LOXO-101is a drug that inhibits
 
Response: LOXO-101is a drug that inhibits COX-2. It is a cyclooxygenase-2 inhibitor, which is approved by FDA for the treatment of arthritis and is in phase III clinical trial for the treatment of cancer. As it is the case with many other drugs, LOXO-101 is often accompanied by drug-drug interactions (DDIs) due to the co-administration of other drugs. Therefore, it is important to be able to detect such interactions.

As is often the case with DDI detection, it is important to be able to detect these interactions at early stages. In the past, DDI detection has mostly relied on off-label usage of expensive and often complicated techniques, such as mass spectrometry, HPLC-MS/MS, LC-MS/MS, and NMR. Unfortunately, these methods are not widely used in the pharmaceutical industry because of their cost and complexity. As a result, these methods are often
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LOZOLis a drug that inhibits
 
Response: LOZOLis a drug that inhibits production of TNF-alpha, a cytokine produced by macrophages and other immune cells. LOZOL is an experimental agent under development by Abbott Laboratories (Abbott Park, IL) for the treatment of rheumatoid arthritis (RA). Because RA is a chronic disease characterized by persistent inflammation, the clinical benefits of LOZOL are expected to be realized over time. In a double-blind, randomized, placebo-controlled trial, patients with active RA were treated with LOZOL or placebo for 24 weeks. During the double-blind phase of the study, LOZOL significantly reduced the American College of Rheumatology (ACR) index of disease activity compared with placebo, and the beneficial effects of LOZOL were maintained throughout the study. Patients receiving LOZOL had a lower rate of radiographic progression of joint damage. The most common adverse events (AEs) were headache, upper respiratory tract infection, and dizziness
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L(+)-Rhamnoseis a drug that inhibits
 
Response: L(+)-Rhamnoseis a drug that inhibits the activity of β-1,4-galactosyltransferase, an enzyme that is involved in the biosynthesis of N-linked glycoproteins. β-1,4-Galactosyltransferase catalyzes the addition of β-1,4-galactose from uridine diphosphate-β-D-galactose to N-linked oligosaccharides on glycoproteins and lipids, and thereby initiates the process of N-linked glycosylation. N-linked glycosylation is a common post-translational modification found on eukaryotic proteins and lipids. It is a co-translational process in which a protein is synthesized on ribosomes as an unglycosylated protein and then glycosylated after the protein leaves the ribosome.
The synthesis of glycoproteins and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Threonineis a drug that inhibits
 
Response: L-Threonineis a drug that inhibits glycine decarboxylase, the enzyme that converts glycine to the neurotransmitter, GABA. It can also increase GABA-mediated inhibition in the brain.

Dosage and administration

L-Threonine is available as a drug, as well as a dietary supplement. It is used in conjunction with another drug to treat depression. It is also used to treat dystonia, a movement disorder.

L-Threonine is available as an oral tablet, as well as an injection.

L-Threonine is usually taken with an antidepressant, such as bupropion. It can also be used in conjunction with other medications.

How to use

Take this medication with a meal or snack. It is usually taken three times a day. Do not take it more often than recommended.

Store at room temperature.

Side effects

Serious side effects may include
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  L-Thyroxineis a drug that inhibits
 
Response: L-Thyroxineis a drug that inhibits thyroid hormone production. It is used in the treatment of hypothyroidism.

L-Thyroxine has the chemical name 4-(4-Hydroxyphenyl)-3,5-diiodo-L-thyronine. It is a thyroxine hormone. Thyroxine is an important hormone that is required for the proper growth and development of all vertebrates.

The therapeutic effect of L-Thyroxine is a significant decrease in the serum concentration of T4 and T3.

L-Thyroxine is commonly prescribed to children and adolescents. L-Thyroxine may also be prescribed for adults.

Apo-L-Thyroxine (a)

Chemical Name: 4-(4-Hydroxyphenyl)-3,5-diiodo-L-thyronine

Formula: C17H21
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LTI-291is a drug that inhibits
 
Response: LTI-291is a drug that inhibits the activity of CYP3A4, the most important CYP enzyme for the metabolism of many drugs. LTI-291 inhibits CYP3A4 with a K(i) of about 10 nM, and the K(i) for CYP3A4 in human liver microsomes is about 0.5 nM. LTI-291 has a significant effect on the pharmacokinetics of CYP3A substrates, but not on CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1. LTI-291 is metabolized in vivo to an active metabolite, LTI-304, with a t(1/2) of about 5-10 h in humans. LTI-304 is a potent inhibitor of CYP3A4, with a K(i) of about 0.1 nM,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LTX-315is a drug that inhibits
 
Response: LTX-315is a drug that inhibits pyrimidine biosynthesis and induces apoptosis in cancer cells. We previously showed that mocetinostat, a novel HDACi, exhibits potent anti-cancer activity in human colon cancer cells. In the present study, we evaluated the anticancer activity of LTX-315 in a human colorectal cancer cell line, HT-29, and in a human colorectal cancer xenograft model. We also investigated the molecular mechanisms of action of LTX-315 in HT-29 cells. The antiproliferative effects of LTX-315 were assessed by MTT assay and apoptosis analysis. Western blotting and real-time RT-PCR were used to examine the effects of LTX-315 on the expression of HDACs and p53, and on the activity of p53. HT-29 cells were injected into nude mice, and the anticancer effects of LTX-315 were evaluated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Luis a drug that inhibits
 
Response: Luis a drug that inhibits the enzyme and increases the production of adrenaline and noradrenaline, but that is commonly used in patients with anxiety, to help them relax. The person who takes it, can still move and think.

Anabolic steroid

These substances are normally given to athletes and bodybuilders to increase their muscle mass and improve their performance. They are sometimes used in bodybuilding competitions, but in larger quantities, and with different types of steroids, they can cause serious health problems.

Cycloheximide

It is a substance that prevents the production of proteins, in particular in the liver, and that is used in some medications to treat viral infections.

Aminoglycosides

These are a group of antibiotics that are used to treat certain infections. The most common ones are amikacin and gentamicin.

Sulfonamides

These are a group of drugs that are used to treat infections and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lubiprostoneis a drug that inhibits
 
Response: Lubiprostoneis a drug that inhibits an ion channel found in the intestines. It is a motility agent and therefore helps improve the movement of food through the intestines.

Side Effects

This drug is safe for most people. However, it may cause abdominal cramps, vomiting, diarrhea, headache, and allergic reactions.

Storage

This drug should be stored at room temperature. Do not freeze. Keep it away from children and pets.

Dosage

The recommended dose is 4 mcg once daily. The dose should be taken with a full glass of water.

Missed Dose

It is recommended that the dose be taken on an empty stomach. If the dose is missed, take it as soon as you remember. However, if it is near the time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not double the dose to make up for a missed dose
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Luliconazoleis a drug that inhibits
 
Response: Luliconazoleis a drug that inhibits the fungal enzyme lanosterol 14-α-demethylase, an enzyme that converts lanosterol to ergosterol. This inhibition results in a reduction of the fungal cell membrane and an increase in the permeability of the cell membrane. Luliconazole inhibits the growth of a wide range of fungi, including dermatophytes and yeasts.

Terbinafine is a drug that inhibits the fungal enzyme squalene epoxidase, an enzyme that is essential for the biosynthesis of ergosterol. This inhibition results in a reduction of the fungal cell membrane and an increase in the permeability of the cell membrane. Terbinafine inhibits the growth of a wide range of fungi, including dermatophytes and yeasts.

Fluconazole is a drug that inhibits the fungal enzyme lanosterol 14-α-demethylase, an enzyme that converts lanoster
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lumiracoxibis a drug that inhibits
 
Response: Lumiracoxibis a drug that inhibits the production of interleukin-1 (IL-1) which is the most powerful biological mediator of inflammatory and immune reactions. This drug is effective in treating inflammatory diseases like osteoarthritis and rheumatoid arthritis. Lumiracoxibis is a unique drug and is of great value to the pharmaceutical industry and physicians worldwide. Lumiracoxibis is the only NSAID that has no adverse effects on the gastric mucosa.

The company is working to bring out an oral dosage form of the drug. Lumiracoxibis is a solid oral dosage form and the company has developed a capsule formulation that can be marketed under the trade name Lumiracoxib. The drug is suitable for oral administration. The drug is available in oral liquid form. Lumiracoxibis capsule has been launched in Japan and the product is being rolled out in other countries in the near future.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Luteolinis a drug that inhibits
 
Response: Luteolinis a drug that inhibits the activity of the growth factor receptor tyrosine kinase, the epidermal growth factor receptor (EGFR), has been approved for use in combination with gemcitabine for the treatment of pancreatic cancer. Although luteolin has a number of molecular effects that contribute to its cytotoxicity, including inhibition of multiple cellular signaling pathways and induction of apoptosis, the molecular mechanisms underlying the antitumor activity of luteolin remain unclear. In this study, we examined the effects of luteolin on the proliferation and motility of pancreatic cancer cells. We report that luteolin induced apoptosis in both AsPC-1 and PANC-1 pancreatic cancer cells, and inhibited cell proliferation and motility in both cell lines. We also demonstrate that luteolin-induced apoptosis is mediated by the down-regulation of c-Myc and EGFR expression and that luteolin induces a change in the phosphorylation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LX1606is a drug that inhibits
 
Response: LX1606is a drug that inhibits an enzyme called Phosphodiesterase 4 (PDE4), which is responsible for breaking down cyclic adenosine monophosphate (cAMP) in the brain. PDE4 is the predominant enzyme in the brain that breaks down cAMP.

LX1606 is a once-daily oral medication that works by increasing levels of cAMP in the brain. cAMP is a molecule that helps to transmit signals within cells and is essential for normal brain function. cAMP is produced naturally in the body and in the brain by the enzyme Phosphodiesterase 4 (PDE4).

LX1606 may help improve the memory and attention in children with ADHD, reduce hyperactivity in children with ADHD, and help children with ADHD have fewer impulsive or hyperactive episodes.

LX1606 is not a cure for ADHD, but may help treat the symptoms of ADHD in children. LX1606
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LXS-196is a drug that inhibits
 
Response: LXS-196is a drug that inhibits protein kinase C (PKC) and is therefore thought to mimic the action of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. It was first synthesized by ourselves, and we are continuing to study its properties and mechanisms of action. It has a relatively high binding affinity for PKC and inhibits its phosphorylation in intact cells and in isolated membranes. The drug is very active in inducing differentiation of human leukemia HL-60 cells. This induction is accompanied by inhibition of phosphorylation of the epidermal growth factor receptor (EGF-R), a cellular protein which is a substrate for PKC. A similar inhibition of EGF-R phosphorylation occurs in human leukemia K562 cells. We are now studying the effects of LXS-196 on the PKC-induced phosphorylation of other cellular proteins. We have also studied the effects of LXS-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LYis a drug that inhibits
 
Response: LYis a drug that inhibits the ATP-binding cassette (ABC) transporter P-glycoprotein, which is responsible for multidrug resistance (MDR) in human tumor cells. We examined the ability of verapamil to reverse MDR in murine leukemic cells, and found that it does not affect the level of P-glycoprotein expression. The verapamil-induced reversal of MDR was associated with a reversal of the increase in rhodamine 123 efflux. It is suggested that verapamil may not affect the function of P-glycoprotein and may not be a good choice for reversal of MDR in tumor cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2157299is a drug that inhibits
 
Response: LY2157299is a drug that inhibits the growth of cancer cells by causing the cells to undergo apoptosis. It works by inhibiting the activity of a protein called MDM2. The drug can also be used to treat blood disorders, such as chronic myeloid leukemia.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2228820is a drug that inhibits
 
Response: LY2228820is a drug that inhibits a protein kinase (PKC) in cells. PKC plays a role in cell proliferation, differentiation, migration, and survival. In the long term, the goal of this research is to test the hypothesis that PKC inhibition with YM-2228820 will reduce the risk of developing and/or metastasizing cancer in human subjects. We propose to conduct a randomized, double-blind, placebo-controlled, multi-center, Phase 2 clinical trial to determine the efficacy of YM-2228820 in patients with solid tumors who have developed one or more solid tumor-related symptoms and who have progressive disease after one or more prior systemic anticancer treatments. The trial will be carried out in two stages: a dose-escalation phase followed by a dose-finding phase. During the dose-escalation phase, we will determine the recommended phase 2 dose of YM-2228820 in terms of the maximum tolerated dose (MT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2784544is a drug that inhibits
 
Response: LY2784544is a drug that inhibits platelet activation and reduces blood loss after injury or surgery. The major side effect of the drug is thrombocytopenia, which can be controlled by dose reduction. In clinical practice, the patient's history and clinical course are important for decision making regarding whether to continue or stop the drug.

CASE REPORT
===========

A 56-year-old male was referred to our emergency department with a two-day history of chest pain and shortness of breath. He was admitted to our hospital for further evaluation. His past medical history was significant for hypertension, hyperlipidemia, and chronic kidney disease.

On admission, his blood pressure was 168/100 mmHg, pulse rate was 96 beats per minute, and respiratory rate was 24 breaths per minute. He was tachypneic and had jugular venous distention. His skin was warm and dry, and his mental status was alert.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2801653is a drug that inhibits
 
Response: LY2801653is a drug that inhibits the activity of the enzyme telomerase, a protein that stabilizes and lengthens telomeres, which are caps on the ends of chromosomes. The result of the action of telomerase is that the length of telomeres is maintained, and in the absence of telomerase, telomeres are shortened, leading to cellular senescence and death. The hypothesis is that administration of PYLE will lead to increased telomerase activity, thereby preventing cellular senescence and death, and thus promoting increased regeneration of injured cells and tissues.

The information presented here is for educational purposes only and is not intended as medical advice for individual conditions. Consult your health care professional for medical advice specific to your situation.

PYLE and Inclusion Body Myositis

PYLE and Inclusion Body Myositis

The effect of PYLE on the rate of decline of the upper limb muscle strength in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2835219is a drug that inhibits
 
Response: LY2835219is a drug that inhibits the proteasome.

If you are concerned that your child has been exposed to a toxin that may be responsible for this clinical presentation, it is recommended that you consult with your child's physician.

Thank you for helping us Maintain Caringbridge.org

The medical and scientific information provided on Caringbridge.org is not a substitute for professional medical advice, diagnosis, or treatment. Never delay or disregard seeking professional medical advice from your physician or other qualified health provider because of something you have read on Caringbridge.org.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY2874455is a drug that inhibits
 
Response: LY2874455is a drug that inhibits the binding of miR-23a to the 3′ UTR of the BCL2 protein, leading to the induction of apoptosis in cells. This drug is already being used in clinical trials for the treatment of some types of cancer (in particular, solid tumours such as non-small cell lung cancer and multiple myeloma).

Recently, it has been shown that MYC oncogene can also promote the survival of tumour cells by directly repressing the expression of miR-23a in a process involving the binding of MYC to the E-box promoter of miR-23a.

miR-23a is overexpressed in multiple myeloma and has been associated with a poor prognosis. Therefore, it has been proposed that miR-23a could be a potential therapeutic target for multiple myeloma treatment. However, further studies are required to confirm this hypothesis.

See
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY3023414is a drug that inhibits
 
Response: LY3023414is a drug that inhibits cell growth and induces cell death. In this study, we examined the molecular mechanism underlying the apoptosis-inducing activity of TY3023414. Treatment of HL-60 cells with TY3023414 resulted in the formation of the apoptotic bodies, which was inhibited by pretreatment with the caspase-3 inhibitor, z-DEVD-FMK. Treatment of HL-60 cells with TY3023414 resulted in the degradation of poly (ADP-ribose) polymerase (PARP) and lamin B, which was inhibited by pretreatment with the caspase-3 inhibitor, z-DEVD-FMK. TY3023414 also induced the activation of caspase-3. The activation of caspase-3 was inhibited by pretreatment with the caspase-9 inhibitor, z-LEHD-FMK. Treatment of HL-60 cells with TY3023414 resulted in the cle
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY3039478is a drug that inhibits
 
Response: LY3039478is a drug that inhibits the MAPK pathway by specifically binding to the ERK3 protein, resulting in decreased proliferation and increased apoptosis in HNSCC cells. The authors of this paper have now extended their findings by showing that MEG3 is upregulated in HNSCC and that knockdown of MEG3 results in decreased proliferation and increased apoptosis. This finding has implications for future research into HNSCC.

![](fx1)

**He Chen** obtained his B.S. degree in Microbiology and Immunology from Tsinghua University in China in 2016. He is currently a Ph.D. student in the Department of Microbiology and Immunology, Duke University, Durham, NC, USA. His research interests include mechanisms of tumorigenesis and tumor immunity.

![](fx2)

**Linjie Xu** is a Ph.D. candidate in the Department of Microbiology and Immunology,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  LY333531is a drug that inhibits
 
Response: LY333531is a drug that inhibits the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, which is activated in response to several cellular stresses, including viral infection, ionizing radiation, and chemotherapy. Because the TRAIL pathway is constitutively activated in some cancer cells, such as malignant glioma cells, the combined use of TRAIL with conventional chemotherapy is expected to induce cell death in cancer cells more efficiently than single-agent therapy. The present study evaluated the combined effect of TRAIL and 5-fluorouracil (5-FU) on human malignant glioma cell lines. To investigate the mechanism of TRAIL-mediated cytotoxicity, we examined the TRAIL receptor expression pattern and the effect of TRAIL on the apoptotic machinery in malignant glioma cells. In addition, we evaluated the effect of the combined use of TRAIL and 5-FU on the viability of malignant glioma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Lypressinis a drug that inhibits
 
Response: Lypressinis a drug that inhibits bone resorption by directly binding to and inactivating the enzyme that breaks down collagen, which is an essential component of bone.

"Osteoporosis is a chronic disease that affects many people. If you can find a drug that prevents or slows the progression of the disease, you can provide significant relief," said Dr. James Andrews, the team's medical director.

Although the drug, called romosozumab, is still under study, Andrews and the other team members say it is the first to show potential for both prevention and treatment.

According to Andrews, the drug could be approved for clinical use in about two years.

"Osteoporosis is a disease that we can do something about," he said. "We can slow the progression of the disease. We can reduce the incidence of fractures. We can delay the time until people need to have a hip fracture or a spinal fracture."
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Macitentanis a drug that inhibits
 
Response: Macitentanis a drug that inhibits the activity of the enzyme endothelial nitric oxide synthase (eNOS). This enzyme is involved in the formation of nitric oxide (NO), a molecule that is essential for the relaxation of blood vessels and is responsible for the vasodilation of blood vessels. This drug is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The drug has been developed by Actelion and has been approved by the US FDA for this indication. Macitentan is also in development for the treatment of other cardiovascular conditions, such as pulmonary hypertension (PH) in patients with chronic heart failure (CHF), and acute heart failure. This article discusses the clinical development of macitentan for the treatment of PAH and PH-COPD, and for the treatment of CHF.

Macitentan was developed by Actelion (now a part of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ACT-064992is a drug that inhibits
 
Response: ACT-064992is a drug that inhibits phosphodiesterase-5 (PDE5) and has been used to treat erectile dysfunction. However, when given orally, ACT-064992 is quickly metabolized and eliminated from the body. To address this problem, scientists have developed a bioconjugate of ACT-064992. This new drug, known as CVT-313, is being developed by Dainippon Sumitomo Pharma. CVT-313 is a conjugate of ACT-064992 and a polyethylene glycol derivative of cholesterol. As a result, CVT-313 has a longer half-life and is less likely to be metabolized. A clinical trial has begun to determine the efficacy of CVT-313.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Madecassicis a drug that inhibits
 
Response: Madecassicis a drug that inhibits the enzyme farnesyl diphosphate farnesyl transferase, an enzyme that is essential for the post-translational modification of proteins by the addition of a fatty acid (farnesyl) to a C-terminal cysteine residue. This enzyme is required for the assembly of the H-Ras oncoprotein, which is a key signaling component of the Ras pathway.

References

External links
 

Category:Benzamides
Category:Farnesyltransferase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Magnololis a drug that inhibits
 
Response: Magnololis a drug that inhibits STAT3 phosphorylation by blocking the catalytic activity of JAK2 {#Sec1}
====================================================================================================

Magnolol is a biphenolic compound isolated from the bark of the magnolia tree. Magnolol is a natural product with a phenolic hydroxyl group and a phenyl ring structure, which was first isolated from the bark of the magnolia tree and has been used for thousands of years in traditional medicine. In the past few decades, magnolol has been widely used in the treatment of various diseases, such as atherosclerosis, diabetic retinopathy, and Alzheimer's disease.

JAK2 is a cytoplasmic tyrosine kinase, which has a critical role in mediating cytokine and growth factor signals. STAT3 is a transcription factor that is activated by JAK2. The activation of STAT3 promotes cell proliferation, angiogenesis, and metastasis, which are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Malachiteis a drug that inhibits
 
Response: Malachiteis a drug that inhibits the synthesis of tetrahydrobiopterin (BH4) in cells and which has been used to treat hyperphenylalaninaemia and BH4-responsive dystonia. The drug binds to the quinonoid dihydropteridine reductase (DHPR) which is the first enzyme in the synthesis of BH4 in vivo. The drug has been shown to bind with high affinity to the DHPR of mouse liver microsomes. However, its ability to bind to the human DHPR is unknown. We have investigated the binding of the drug to human DHPR expressed in yeast. We found that the drug bound to the human DHPR with an affinity (KD) of approximately 2.5 nM. Binding was highly dependent on the concentration of BH4 and was displaced by GTP. Binding of the drug to the human DHPR was not observed with a mutant of the human DHPR (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Malotilateis a drug that inhibits
 
Response: Malotilateis a drug that inhibits aldose reductase (AR) and may help treat diabetic retinopathy (DR). The goal of this study was to evaluate the effects of a single intravitreal injection of 6.25 µg of malotilate in the cynomolgus monkey. A pilot study was performed to determine the safety of a single intravitreal injection of malotilate. Four cynomolgus monkeys received a single intravitreal injection of malotilate. Intravitreal injections were well tolerated. No ocular or systemic toxicity was observed. In this study, four monkeys received a single intravitreal injection of 6.25 µg of malotilate. The vitreous concentration of malotilate at 4 hours was 0.45 ± 0.13 µg/mL. This study suggests that intravitreal injection of malotilate is well tolerated and that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Maltotrioseis a drug that inhibits
 
Response: Maltotrioseis a drug that inhibits amyloid-β protein precursor (APP) and is used in patients with Alzheimer's disease. To evaluate the risk of maltotriose on the gastrointestinal tract, the experiment was performed with six male rats. In a first experiment, the maltotriose solution was administered orally at 50, 100, 200, and 400 mg/kg body weight for 4 weeks. After 4 weeks, a significant decrease in body weight gain and a significant increase in stool output and stool frequency were observed in all maltotriose-treated rats. In a second experiment, maltotriose was administered orally at 50, 100, 200, and 400 mg/kg body weight for 8 weeks. No significant differences in the biochemical parameters examined were observed between the maltotriose-treated and the control groups. These results suggest that maltotriose could be an effective drug for the treatment of gastrointestinal diseases.

Amphetamine is a psychost
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mangafodipiris a drug that inhibits
 
Response: Mangafodipiris a drug that inhibits angiogenesis has been found to reduce growth of various tumor cells in mouse models. However, this drug has been associated with increased risk of death in patients with advanced cancer. Therefore, we have developed a novel class of peptides that inhibit the angiogenic activity of VEGF. The overall objective of this project is to establish proof-of-principle that these peptides can inhibit tumor growth and metastasis. The specific aims of this proposal are: (1) To synthesize and characterize peptides that inhibit VEGF-induced angiogenesis in vitro; (2) To develop novel therapeutic agents that inhibit VEGF-induced angiogenesis in mouse models; (3) To investigate the therapeutic potential of peptides that inhibit VEGF-induced angiogenesis in mouse models of human cancer. The proposed studies will establish proof-of-principle that these peptides inhibit tumor growth and metastasis in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Manidipineis a drug that inhibits
 
Response: Manidipineis a drug that inhibits the calcium influx in vascular smooth muscle cells.

It has been shown to be effective in the treatment of hypertension, diabetic microangiopathy, and chronic stable angina pectoris.

The effect of manidipine on patients with type 2 diabetes mellitus has been evaluated in several clinical trials, in which the drug was administered in doses of 5-10 mg/day.

The effect of manidipine on insulin resistance and glucose tolerance has been evaluated in several clinical trials, in which the drug was administered in doses of 5-10 mg/day.

The results of these trials have shown that manidipine improves insulin sensitivity, without significantly affecting glucose tolerance.

Manidipine may also exert a beneficial effect on lipids.

Efficacy and tolerability of manidipine have been shown in several clinical trials in patients with chronic stable angina pectoris and micro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Maprotilineis a drug that inhibits
 
Response: Maprotilineis a drug that inhibits monoamine oxidase, and which is known to have a powerful anxiolytic effect. It is used in the treatment of anxiety disorders and depression. The most serious side effect of meprobamate is anorexia, which is characterized by a marked loss of appetite. This can be severe enough to lead to a life-threatening condition, oedema coma.

Meprobamate is a compound that is used to treat anxiety, sleep disturbances, seizures, and convulsions. It is also used to treat depression. This drug can cause addiction. It can cause physical dependence, withdrawal symptoms, and tolerance. If you stop taking meprobamate suddenly, you may have anorexia, agitation, drowsiness, fatigue, and vomiting.

If you have any of the following conditions, you should not take meprobamate, as it can cause serious side effects:

When meprobamate is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Marbofloxacinis a drug that inhibits
 
Response: Marbofloxacinis a drug that inhibits the production of enolase by inhibiting the enzyme enolase. The drug is used in combination with streptomycin for the treatment of infectious diseases.

Marbofloxacin

MAR-boh-flox-AK-sin

(Marbocyl)

Brand Name(s)

Marbocyl

USES

Marbofloxacin is used in the treatment of respiratory tract infections (such as bronchitis, bronchopneumonia, and otitis media) caused by susceptible strains of bacteria, such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus.

The exact mechanism of action of marbofloxacin is unknown. Marbofloxacin may be absorbed from the GI
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Marimastatis a drug that inhibits
 
Response: Marimastatis a drug that inhibits apoptosis (programmed cell death) and promotes angiogenesis (growth of new blood vessels). Marimastat is a protease inhibitor that has been used in the treatment of cancer, Alzheimer's disease, and other diseases. Marimastat and its use are described in U.S. Pat. No. 4,595,700, issued Jun. 17, 1986.
Marimastat is one of a group of compounds called hydroxamic acids. Hydroxamic acids are described in, for example, U.S. Pat. No. 4,542,254, issued Sep. 17, 1985, U.S. Pat. No. 4,616,069, issued Oct. 7, 1986, U.S. Pat. No. 4,766,105, issued Aug. 23, 1988, U.S. Pat. No. 4,943,579, issued Jul. 24
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mavacamtenis a drug that inhibits
 
Response: Mavacamtenis a drug that inhibits cell proliferation in several cancer cell lines. To further characterize this compound, we investigated the effect of mavacamten on the induction of differentiation in neuroblastoma cells. We observed that mavacamten was a potent inducer of differentiation in N2a neuroblastoma cells, in a concentration-dependent manner, reaching a plateau at 2 microM. Induction of differentiation was observed with a time course of 12 hours, but not with a shorter incubation time. This induction was specific for neuronal differentiation, as evidenced by the expression of neuron-specific enolase, a neuronal specific marker. The process of differentiation induced by mavacamten was preceded by a short increase in the levels of phospho-Akt and phospho-ERK1/2. These changes in protein phosphorylation were also associated with a change in cell morphology. Indeed, the morphological transformation that occurs during the differentiation process was observed
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MAXALTis a drug that inhibits
 
Response: MAXALTis a drug that inhibits pro-tumorigenic inflammation by inhibiting T-cell migration and T-cell activation. It is a potent inhibitor of monocyte migration and T-cell migration and activation. It is used for the treatment of rheumatoid arthritis and plaque psoriasis. It is also being developed as a treatment for Crohn's disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  m-Cresolis a drug that inhibits
 
Response: m-Cresolis a drug that inhibits tumor growth. The effects of FPL 64176 were studied in rats bearing mammary tumors induced by 7,12-dimethylbenz[a]anthracene (DMBA). Oral administration of FPL 64176 (0.25 mg/kg/day) for 28 days reduced tumor weight by 50% and decreased the mitotic index by 70%. A single dose of FPL 64176 given 3 h after DMBA reduced tumor growth and induced cell cycle arrest in S phase. DNA binding activity of the AP-1 transcription factor was reduced in FPL 64176-treated tumors. The expression of the c-fos and c-jun genes was also decreased in FPL 64176-treated tumors. These results suggest that FPL 64176 may inhibit mammary tumor growth by blocking the activation of AP-1.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MDV3100is a drug that inhibits
 
Response: MDV3100is a drug that inhibits the production of HIV in infected cells. But the virus can quickly develop resistance to the drug. Now researchers have found that a combination of the drug with two other drugs could block the virus even more effectively. The study was published today in Nature.

The drug combo, called 3TC, DTG and ABC, was originally developed to treat people infected with the Hepatitis C virus. Hepatitis C is a virus that can cause serious liver problems. But a new generation of Hepatitis C drugs called DAAs (direct-acting antivirals) can eliminate the virus without causing the problems associated with the old drugs. The new drugs, however, cost about $90,000 for a single treatment, which is more than the average annual income in some countries.

To develop a more affordable version of the drug combo, the researchers took advantage of a protein called NS5A that helps the virus to replicate. Because NS5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mecamylamineis a drug that inhibits
 
Response: Mecamylamineis a drug that inhibits the reuptake of noradrenaline and serotonin from the synaptic cleft, resulting in their enhanced action. The agent was first synthesized by a group in the University of Alberta in 1970, and is now sold under the trade name of Galantamine. It is also used as an anti-depressant, anti-epileptic and neuroprotective agent, as well as for the treatment of restless legs syndrome and Alzheimer’s disease.

Mechanism of Action

Mecamylamine acts as an antagonist of the reuptake of the neurotransmitters noradrenaline and serotonin. These agents act in the brain and in the periphery by preventing the reuptake of neurotransmitters, resulting in their enhanced action.

It is postulated that the actions of mecamylamine are primarily mediated through a presynaptic site. Mecamylamine also acts as an antagonist of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mechlorethamineis a drug that inhibits
 
Response: Mechlorethamineis a drug that inhibits topoisomerase II and is active against a variety of solid tumors, including lung cancer, lymphoma, leukemia, head and neck cancer, and others. It is currently approved for the treatment of Hodgkin's disease and as a single agent for the treatment of cutaneous T-cell lymphoma. However, in combination with vinblastine and cisplatin, mechlorethamine is approved for the treatment of advanced Hodgkin's disease.

Mechlorethamine is also the active agent in Neutrogena® Cold Sore Pain Relief, which is a topical cream that contains a variety of active ingredients including mechlorethamine.

Mechlorethamine was originally developed in Germany by Dr. Werner Spies and his colleagues in the early 1950s. The drug was later developed in the U.S. by his American colleague, Dr. Clarence Bagshaw, who began clinical testing in the mid-1950s.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meclizineis a drug that inhibits
 
Response: Meclizineis a drug that inhibits the body's ability to make a substance called histamine. Histamine is produced in the body and triggers the itchiness and swelling of the nose and throat that often accompanies a cold or allergy. It also triggers itching and flushing of the skin.

Meclizine can relieve the symptoms of the common cold, but it doesn't stop the cold from getting worse. It also doesn't prevent the spread of the virus that causes colds. It can also cause side effects, such as drowsiness, dizziness, and diarrhea.

If you are using meclizine to treat colds, it's best to stop taking it as soon as you feel better. You should also stop taking meclizine as soon as your cold is gone. If you continue taking it, you may have a recurrence of your cold.

How do I take meclizine?

Take the capsules, one at
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meclocyclineis a drug that inhibits
 
Response: Meclocyclineis a drug that inhibits the production of collagen and is a tetracycline derivative. It is commonly used for treating skin conditions, such as acne. It is also used for treating the symptoms of rheumatoid arthritis. It can be taken by mouth or by injection. It is a highly effective drug for treating acne. It is also used for treating conditions of the musculoskeletal system. It is not usually recommended for people who are pregnant.

There are two forms of meclocycline, known as meclocycline and its active metabolite, 7-deoxymecocycline. Meclocycline is available in a variety of strengths, including 30 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, and 400 mg. The active metabolite is only available in 100 mg and 200 mg strengths.

What is meclocycline used for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meclofenamateis a drug that inhibits
 
Response: Meclofenamateis a drug that inhibits prostaglandin synthesis. It has been used in a number of different medical indications including acute gout and rheumatoid arthritis. It is also used in the treatment of menstrual cramps and acute and chronic pain.

Ahead of the introduction of meclofenamate, paracetamol had been used as a first line treatment for menstrual cramps.

However, it is possible that meclofenamate has been responsible for more than a million cases of acute liver damage. This is a significant number of cases and is estimated to be about 1 in 200 patients.

How is meclofenamate liver damage treated?

If meclofenamate is the cause of the liver damage, then it is not likely that the damage is severe. However, if the damage is severe, then it is important to seek medical help.

If you think that you are experiencing acute liver damage
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meclofenoxateis a drug that inhibits
 
Response: Meclofenoxateis a drug that inhibits neuronal K^+^ channels in the brain. It is used in the treatment of epilepsy and migraine.\[[@ref1]\] The drug is available in the form of the racemate (meclofenoxate and *RS*-meclofenoxate) in the market. The *R*-isomer is active and is about 40 times more potent than the *S*-isomer.\[[@ref2]\] The drug has a poor oral bioavailability due to the poor permeability of the drug.\[[@ref3]\] The drug is rapidly and extensively metabolized in the liver to inactive metabolites. The metabolites are also rapidly excreted in the urine and feces.\[[@ref4]\] The drug is extensively metabolized in the liver by CYP3A4.\[[@ref5]\] CYP3A4 is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Medetomidineis a drug that inhibits
 
Response: Medetomidineis a drug that inhibits the excitatory effects of acetylcholine at post-synaptic muscarinic receptors. The drug has sedative, hypnotic, anxiolytic, and analgesic properties. It is commonly used for sedation in the veterinary setting, but it is also used in human medicine.\[[@ref1]\] It is the most widely used α~2~-agonist in veterinary medicine.\[[@ref2]\] The drug has a wide margin of safety. The mean lethal dose (LD~50~) of medetomidine in dogs is approximately 4 μg/kg.\[[@ref3]\] The sedative and hypnotic effects of medetomidine are dose-dependent.\[[@ref4]\] Medetomidine can be used in combination with other drugs.\[[@ref5]\] There is limited data on the safety of combination therapy of med
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MEDROLis a drug that inhibits
 
Response: MEDROLis a drug that inhibits the biosynthesis of TNF-α and thereby prevents the inflammatory cascade that is induced by TNF-α. It has been reported to be effective in treating arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, sepsis, septic shock, graft-versus-host disease, myeloma, myeloid leukaemia, acute myelogenous leukaemia, acute lymphocytic leukaemia, non-Hodgkin lymphoma, breast cancer, renal cancer, metastatic melanoma, acute lymphoblastic leukaemia, acute myelogenous leukaemia, malignant glioma, multiple myeloma, and soft tissue sarcoma.
However, the long-term administration of the above mentioned anti-inflammatory drugs is associated with serious side effects such as gastrointestinal intolerance, anorexia, weight loss, gastrointestinal bleeding
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Medroxyprogesteroneis a drug that inhibits
 
Response: Medroxyprogesteroneis a drug that inhibits the development of the uterus and can help prevent pregnancy. It is also used to treat some forms of cancer, including breast and endometrial cancer.

Hormonal Birth Control

Hormonal birth control, also known as oral contraceptives, are medications that can help prevent pregnancy. They are most often prescribed for women who are planning to have children or who have had children.

Hormonal birth control can be divided into three categories:

Oral contraceptives, which are also called combined oral contraceptives. These are the most commonly prescribed contraceptives. They contain estrogen and progestin, two hormones that can help regulate your periods and reduce your risk of developing breast cancer.

Hormone replacement therapy, which is used to treat symptoms of menopause, such as hot flashes, mood swings, and vaginal dryness.

Progestin-only contraceptives, which are used by some women who do not want to use
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Medrysoneis a drug that inhibits
 
Response: Medrysoneis a drug that inhibits an enzyme called 17-beta-hydroxysteroid dehydrogenase, which is needed to convert the testosterone and estradiol in the body into their less active forms, thereby increasing the testosterone to estradiol ratio. Testosterone is an androgen and estradiol is an estrogen. Androgens and estrogens are the two types of sex hormones.

Ad

As the ratio of testosterone to estradiol increases, this drug increases the amount of testosterone available to bind with the androgen receptor in the body. As a result, the body's androgen receptors become saturated with testosterone, and the testosterone receptors are not available for binding with the estradiol receptors.

This drug also increases the amount of testosterone available to bind with the estrogen receptors in the body. As a result, the estradiol receptors become saturated with testosterone, and the testosterone receptors are not available for binding with the estradiol receptors.

If
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mefenamicis a drug that inhibits
 
Response: Mefenamicis a drug that inhibits the COX-1 enzyme and has been used for the treatment of pain and fever in patients. However, in January 2006, the FDA advised that mefenamic acid be withdrawn from the market because it is a weak NSAID and can lead to ulcers in some patients. This warning came on the heels of a warning from the FDA that Cox-2 inhibitors can cause ulcers and bleeding in some patients. These two agents have since been withdrawn from the market.

However, many people still take the drug in the hope that it will not cause any problems. As with all drugs, there is the possibility of side effects, including the development of ulcers. There are many other drugs that can cause ulcers. NSAIDs are not the only ones. Steroids, antacids, and antibiotics can all cause ulcers. A person who takes NSAIDs to treat a minor problem may have to go through a period of abstinence before the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mefloquineis a drug that inhibits
 
Response: Mefloquineis a drug that inhibits the action of certain enzymes. The drug is used to treat malaria. Mefloquine has been used in pregnant women for many years. In the past, the drug has been associated with a wide range of adverse effects including birth defects. In the United States, the drug is not approved for use during pregnancy.

Birth Defects

There are several types of birth defects that can be caused by the use of mefloquine during pregnancy. These include neural tube defects, eye defects, cleft palate, heart defects, and gastrointestinal defects.

Neural Tube Defects

Neural tube defects are a group of birth defects that can affect the brain and spinal cord. Neural tube defects can occur at any time during pregnancy. The cause of neural tube defects is unknown.

The following are the types of neural tube defects that can be caused by mefloquine use during pregnancy:

Sp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Megestrolis a drug that inhibits
 
Response: Megestrolis a drug that inhibits the production of the gonadotropic hormones FSH and LH. It is used in the treatment of amenorrhea and hirsutism in women and for the treatment of endometriosis, uterine fibroids, male pattern baldness and certain types of prostate cancer in men.

A. Overview

Megestrolis a drug that inhibits the production of the gonadotropic hormones FSH and LH. It is used in the treatment of amenorrhea and hirsutism in women and for the treatment of endometriosis, uterine fibroids, male pattern baldness and certain types of prostate cancer in men.

B. Pharmacology

Megestrol is a synthetic androgen with a number of hormonal actions, including stimulation of the hypothalamic-pituitary-ovarian axis and the pituitary-testicular axis. In addition, it has been shown to decrease serum est
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meglumineis a drug that inhibits
 
Response: Meglumineis a drug that inhibits cytochrome P450 enzymes (CYP) and is an important immunosuppressive agent in the treatment of severe, life-threatening cases of autoimmune disease.^[@bib1]^ It has been widely used to prevent and treat allograft rejection and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and psoriasis.^[@bib2]^ However, due to the toxicity and adverse side effects of meglumine, such as diarrhea, leukopenia, anemia, and neutropenia,^[@bib3]^ it has been replaced by other immunosuppressive drugs such as cyclosporine, tacrolimus, and sirolimus.^[@bib4]^

Leflunomide (LFM) is an isoxazole
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MEK162is a drug that inhibits
 
Response: MEK162is a drug that inhibits the RAF/MEK/ERK pathway. In a Phase I trial in patients with solid tumors, patients were administered orally with different doses of MEK162. The best tolerated dose was determined to be 10 mg/m2. Based on the observed safety and pharmacokinetic profiles, a Phase II study in patients with recurrent or refractory advanced solid tumors was initiated. This study is evaluating the combination of MEK162 with bevacizumab in patients with advanced solid tumors. The pharmacokinetics of the combination of bevacizumab and MEK162 have been determined in patients with solid tumors. No drug-drug interaction was observed between the two drugs. Based on these results, the combination of MEK162 and bevacizumab is being investigated in patients with advanced solid tumors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Melatoninis a drug that inhibits
 
Response: Melatoninis a drug that inhibits the secretion of melatonin, resulting in a delayed sleep phase syndrome.

• Kava-kava.

• Melatonin.

• Melitracen.

• Risperidone.

**Niacinamide**,  _See_ Nicotinamide.

**Nicardipine**,  _(Cardene)_,  _(Cardene XL)_,  _(Cardene 20)_,  _(Cardene 40)_,  _(Cardene 50)_,  _(Cardene 60)_,  _(Cardene 20 Mg)_,  _(Cardene 40 Mg)_,  _(Cardene 60 Mg)_,  _(Cardene 20/40 Mg)_,  _(Cardene 20/40 Mg)_,  _(Cardene 60/40 M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MELOXICAMis a drug that inhibits
 
Response: MELOXICAMis a drug that inhibits the production of certain enzymes.

MELOTRANSPIROMETERA device used to measure the amount of oxygen in a patient's blood.

MEMBRANEIntegral part of the cell wall that surrounds all cells.

MEMORYA storehouse of information that we use to recall and understand the world around us.

MENOPAUSALA state of life characterized by reduced fertility and other physical changes in women.

MENOPAUSALIA OR PERIODOF THE LIVING DAYS OF WOMEN IN WHICH FEMALES HAVE REDUCED FERTILITY.

MENOPSYPhysical examination of the prostate, bladder, and testes.

MENORRHAGIA OR UTERINE IRREGULARITYEXCESSIVE MENSTRUAL FLOW.

MENSTRUAL A BLEEDINGOF THE FEMALE UTER
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Melphalanis a drug that inhibits
 
Response: Melphalanis a drug that inhibits DNA synthesis in cancer cells. Melphalan, also known as chlorambucil, is used in the treatment of multiple myeloma, a type of cancer that affects the bone marrow.

**Side effects:** When given by mouth, melphalan can cause mouth sores, fever, severe diarrhea, anemia, nausea, vomiting, stomach pain, severe pain, and jaundice.

**Potential side effects:** Oral melphalan may cause liver damage, which may lead to liver failure.

#####  ADMINISTRATION/HANDLING

**◀ ALERT ▶** Discontinue melphalan if it causes a severe allergic reaction.

IM

• Infuse into large vein (greater than 18 G).

• Give over 15–30 min.

PO

• Give with food, milk, antacids (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Memantineis a drug that inhibits
 
Response: Memantineis a drug that inhibits the glutamate NMDA receptor in the brain. A major side effect of memantine is dyskinesia. We measured the maximum velocity of dyskinesia by dyskinesia rating scale (DRS) and Dyskinesia Rating Scale (DRS). The maximum velocity of dyskinesia was defined as the maximum rate of increase in DRS, which can be detected in all tasks of the DRS. To determine the maximum velocity of dyskinesia, we examined the relationship between the maximum velocity of dyskinesia and DRS in 6 tasks. In task 2, we evaluated the efficacy of memantine. In task 2, the maximum velocity of dyskinesia was increased significantly after administration of memantine. In task 3, we evaluated the efficacy of diazepam (0.2 mg/kg) and diazepam (0.4 mg/kg) with memantine (5 mg/kg) by D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MENADIONEis a drug that inhibits
 
Response: MENADIONEis a drug that inhibits the enzyme aldose reductase and thereby reduces accumulation of sorbitol in cells. Its primary effect is to reduce the elevated plasma glucose concentration in diabetic patients.

ADOPT is a new term to describe a new way of thinking about disease and medical practice.

Alfa, Beta, Delta, and Gamma - Alpha, Beta, Delta, and Gamma - the five elements of the atomic table.

Amaranthus blitum, also known as pigweed, is a biennial weed in the family Amaranthaceae. It has erect stems with some of the leaves smaller than the others. The leaves are opposite, the stems are erect, and the flowers are in a head at the top of the stem. The flowers are yellow and the seeds are black and shiny.

Amiloride is a potassium channel blocker that is used in the treatment of hypertension and congestive heart failure.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  mepenzolateis a drug that inhibits
 
Response: mepenzolateis a drug that inhibits mast cell degranulation and stabilizes mast cell membranes. It is an FDA-approved treatment for allergic reactions.

Sensitization to this drug is relatively common.

Aripiprazole 

Aripiprazole is a first-generation antipsychotic. 

It is also used as an antiemetic. 

Aripiprazole may cause movement disorders. 

It is often used to treat bipolar disorder.

Zonisamide 

Zonisamide is an anticonvulsant and an antiepileptic.

It is also used as an antiemetic. 

Aripiprazole may cause movement disorders. 

It is often used to treat bipolar disorder.

References 

Category:Drug classes defined by psychological effects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mepivacaineis a drug that inhibits
 
Response: Mepivacaineis a drug that inhibits nerve conduction, thereby relieving pain and reducing local anaesthetic requirement for surgery and other procedures. Mepivacaine has long been known to cause the burning and other side effects that limit its use in surgery and other invasive procedures.

Mepivacaine was developed by John S. Armstrong at the Merck pharmaceutical company in 1963 and came into use in the 1970s. It was introduced in the United States in 1972 and was widely used for regional anaesthesia in surgery and other procedures. Mepivacaine has also been used in clinical studies for pain relief in patients with cancer. In these studies, however, the patients often complained of burning, and in some cases were treated with morphine. In the 1980s, many doctors began to prescribe the drug for pain relief, and by the 1990s, it was being used for pain relief and in obstetrics. In the 1990s, researchers discovered that mepiv
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meptazinolis a drug that inhibits
 
Response: Meptazinolis a drug that inhibits the action of histamine on the central nervous system.

▪ INDICATIONS: It is prescribed to treat migraine and to prevent migraines in adults.

▪ CONTRAINDICATIONS: It should not be used in children younger than 12 years or in patients with an allergy to meptazinol.

▪ ADVERSE EFFECTS: Adverse effects of meptazinol include blurred vision, allergic reactions, agitation, anxiety, constipation, dizziness, dry mouth, difficulty in swallowing, headache, irritability, memory loss, nausea, sedation, sweating, vomiting, weakness, and weight gain.

Mepyramine [muh-pe-rah-min], an antihistamine that reduces histamine effects on the central nervous system.

▪ INDICATIONS: It is prescribed in the treatment of allergic rhinitis, allergic conjunct
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mequinolis a drug that inhibits
 
Response: Mequinolis a drug that inhibits myeloid-derived suppressor cells and induces tumor-specific CD8^+^ T cells ([@bib16]).

Immunotherapy using CAR T cells targeting the antigen PD-1 has been reported in patients with relapsed/refractory B-cell lymphoma ([@bib1]; [@bib17]). PD-1-expressing cells, which normally dampen T-cell responses, are upregulated in chronic inflammation, cancer, and autoimmune diseases ([@bib7]). We hypothesized that PD-1--expressing cells also contribute to the immunosuppression of GBM.

RESULTS AND DISCUSSION
======================

PD-1 expression in GBM
----------------------

We performed immunohistochemistry to investigate PD-1 expression in GBM. We found that PD-1 is expressed on a variety of tumor cells, including microglia, macrophages,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mequitazineis a drug that inhibits
 
Response: Mequitazineis a drug that inhibits the production of melatonin. It was originally designed to be used as a chronotherapeutic agent to treat insomnia. It is also used to treat premenstrual dysphoric disorder.

1. What is mequitazine?

Mequitazine is a drug that inhibits the production of melatonin. It was originally designed to be used as a chronotherapeutic agent to treat insomnia. It is also used to treat premenstrual dysphoric disorder.

2. How does mequitazine work?

Mequitazine is a drug that inhibits the production of melatonin. It was originally designed to be used as a chronotherapeutic agent to treat insomnia. It is also used to treat premenstrual dysphoric disorder.

3. What is the mechanism of action of mequitazine?

Mequitazine is a drug that inhibits the production of melatonin. It was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mercaptopurineis a drug that inhibits
 
Response: Mercaptopurineis a drug that inhibits the formation of purine nucleotides, which are necessary for cell growth. It has been shown to be an effective agent in the treatment of a number of hematological malignancies. It is also used to treat chronic inflammatory conditions, including Crohn\'s disease, ulcerative colitis, and rheumatoid arthritis. The safety of mercaptopurine has been established in large clinical trials for over 20 years.

Mercaptopurine is an analogue of the purine nucleoside 6-mercaptopurine (6-MP), which is converted by xanthine oxidase to 6-thioguanine nucleotide (6-TGN), which is then incorporated into DNA and incorporated into RNA, where it is degraded. This is known as the purine nucleotide cycle. In contrast, mercaptopurine is converted to 6-methylmercaptopurine nucleotide (6-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Meropenemis a drug that inhibits
 
Response: Meropenemis a drug that inhibits platelet aggregation and prevents platelet activation. It is a well tolerated drug with an overall tolerability profile similar to that of acetylsalicylic acid. However, the drug has a high risk of severe bleeding, and therefore is not indicated for the prevention of thromboembolic events. It should be used only in patients with high risk of thromboembolic events or patients with an increased risk of bleeding \[[@B10]\].

Prevention of DVT and PE in hip or knee replacement surgery
-----------------------------------------------------------

A meta-analysis of the use of heparin for the prevention of DVT and PE after hip or knee replacement surgery showed that it is effective in reducing the risk of thromboembolic events, but the results are variable \[[@B11]\]. A recent Cochrane review showed that, compared with placebo, heparin was effective in reducing the risk of DVT and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mesnais a drug that inhibits
 
Response: Mesnais a drug that inhibits the growth of colon cancer cells. At high concentrations, however, mesna induces apoptosis in human colon cancer cells. We tested the ability of a mesna prodrug, MM-398, to inhibit growth of human colon cancer cells. We found that MM-398 was highly toxic to human colon cancer cells in vitro. It inhibited the growth of HCT116 colon cancer cells at concentrations that did not cause cytotoxicity in normal colon cells. MM-398 caused apoptosis in HCT116 cells and inhibited the growth of HCT116 tumors in nude mice. The growth of tumors was inhibited in a dose-dependent manner and, in the highest dose group, tumor growth was completely inhibited. MM-398 also inhibited the growth of tumors derived from HT29 colon cancer cells, which express the drug-metabolizing enzyme, thymidine phosphorylase (TP), at a rate of approximately one-tenth that of HCT116 cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  mesoridazineis a drug that inhibits
 
Response: mesoridazineis a drug that inhibits mitosis in cultured human cancer cells. It is used in the treatment of cancer, as it is active in vitro against most types of human cancer cells. Its exact mechanism of action is not fully understood, but it has been shown to inhibit mitosis and induce apoptosis. It is also an inhibitor of protein kinase C.

Chemistry

Mechanism of action

Medication

Pharmacokinetics

Pharmacodynamics

History

Mesoridazine was discovered by researchers at the Bristol-Myers Squibb company. It is a phenothiazine antipsychotic medication.

Mesoridazine is one of a group of antipsychotic drugs called phenothiazines. It has the chemical formula C17H16ClN2S and the molecular weight of 341.96 g/mol. It is a white to off-white crystalline powder. It is soluble
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MESTINONis a drug that inhibits
 
Response: MESTINONis a drug that inhibits cancer cell proliferation and tumor growth. Several *in vitro* studies have demonstrated that MESTINON induces apoptosis in a variety of cancer cell lines \[[@B26],[@B27]\]. Furthermore, MESTINON showed a significant anti-tumor effect in mouse models of prostate cancer \[[@B28]\], breast cancer \[[@B29]\], and colon cancer \[[@B30]\]. Although MESTINON has a strong inhibitory effect on cancer cell proliferation, the mechanisms by which MESTINON exerts this effect are not yet fully understood. In this study, we showed that MESTINON suppressed cancer cell proliferation and tumor growth by inducing cell cycle arrest and apoptosis.

MESTINON is a bifunctional nonpeptide compound that inhibits proliferation of cancer cells via cell cycle arrest and apoptosis induction \[[@B31]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  mestranolis a drug that inhibits
 
Response: mestranolis a drug that inhibits GSK-3beta, but there are no data on the effect of this drug on neuropathic pain in humans. The aim of the present study was to evaluate the effect of the pharmacological inhibition of GSK-3beta on the development of mechanical allodynia in the rat spared nerve injury (SNI) model of neuropathic pain. The effects of SB216763, a selective GSK-3beta inhibitor, on SNI-induced allodynia were assessed using the von Frey filament test and compared with those of the opioid receptor antagonist naloxone. The effect of SB216763 on the induction of phosphorylated GSK-3beta (p-GSK-3beta) in the dorsal root ganglion (DRG) was also investigated. SNI induced allodynia in rats that was significantly attenuated by the intrathecal injection of SB216763 (2 microg). The inhibitory effect of SB
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  metaproterenolis a drug that inhibits
 
Response: metaproterenolis a drug that inhibits the expression of CD40 on monocytes and the production of IL-1, IL-6, IL-8, and TNF-α by monocytes and macrophages. It is available in an oral and intravenous form.  It is also available as the combination drug Aralen.

Interleukin-1 inhibitors
A number of medications have been developed to inhibit the action of IL-1. These include anakinra, an IL-1 receptor antagonist, and canakinumab, a monoclonal antibody against IL-1β.

Interleukin-6 inhibitors
Interleukin-6 (IL-6) is an inflammatory cytokine. There are two types of IL-6 inhibitors: monoclonal antibodies (tocilizumab and siltuximab) and small-molecule inhibitors (sarilumab and tocilizum
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  metaraminolis a drug that inhibits
 
Response: metaraminolis a drug that inhibits the enzyme, tryptophan hydroxylase. In humans, this enzyme is responsible for producing serotonin. It is a long-term treatment that takes effect on the first day of treatment and can be repeated every three months.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Metforminis a drug that inhibits
 
Response: Metforminis a drug that inhibits the cytochrome P450 (CYP) 2D6 enzyme.

See also 
 Hydroxylated methylenedioxyphenyl-4-one (4-MOP)

References 

Category:Drugs acting on the respiratory system
Category:Phenol ethers
Category:Phenyl compounds
Category:Sedatives
Category:Analgesics
Category:Carboxylate esters
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methacyclineis a drug that inhibits
 
Response: Methacyclineis a drug that inhibits the bacterial ribosome, and is therefore active against most Gram-positive and Gram-negative bacteria. It has a broad spectrum of activity against aerobic and anaerobic organisms. It is a derivative of tetracycline, a natural product produced by Streptomyces aureofaciens, but methacycline is much more stable than tetracycline.

History

Methacycline was discovered by the same group that discovered tetracycline. In 1961, it was approved for use in humans, and was the first member of the tetracycline family to be introduced. The compound was marketed under the trade name Zoritetracycline by the Pfizer Corporation. Zoritetracycline was the first member of the tetracycline family to be marketed in the United States.

The most important difference between tetracycline
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  methazolamideis a drug that inhibits
 
Response: methazolamideis a drug that inhibits the uptake of carbon dioxide and water from the blood to the cells, which is usually used to treat glaucoma.

**CYCLOPHOSPHAMIDE** is a drug that lowers intraocular pressure by relaxing the muscles that cause eye pressure to increase. It is prescribed to treat open-angle glaucoma and ocular hypertension.

**CYCLOPHOSPHATE** is a drug that lowers intraocular pressure by relaxing the muscles that cause eye pressure to increase. It is prescribed to treat open-angle glaucoma and ocular hypertension.

**CYCLOSPORINE** is a drug that lowers intraocular pressure by relaxing the muscles that cause eye pressure to increase. It is prescribed to treat open-angle glaucoma and ocular hypertension.

**CYCLOTHROSINE** is a drug that lowers intraocular pressure by relaxing the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methazolastoneis a drug that inhibits
 
Response: Methazolastoneis a drug that inhibits the production of cholesterol by inhibiting the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the first step in the cholesterol biosynthetic pathway. The formation of mevalonate from HMG-CoA is rate limiting in the pathway. Inhibition of this enzyme decreases the amount of cholesterol that can be made by the cell. In addition, mevalonate is also a precursor to isoprenoid compounds.

As mentioned, mevalonate is the precursor to isoprenoid compounds. Isoprenoid compounds are the precursors to hormones, such as steroids and vitamin D, and the side chain of coenzyme A. Inhibition of HMG-CoA
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methenamineis a drug that inhibits
 
Response: Methenamineis a drug that inhibits the growth of bacteria, fungi, and protozoa. It is used as an oral disinfectant and as a topical antibacterial and antifungal agent.

1.2 What is methenamine?

Methenamine is a white crystalline powder that is soluble in water. It is produced by reacting methanol and ammonia. It is available in the form of tablets, syrups, creams, and ointments.

1.3 How does methenamine work?

Methenamine is a broad-spectrum antibacterial and antifungal agent that is active against gram-positive and gram-negative bacteria. It is also effective against fungi and yeast. It is a disinfectant that can be used on a variety of surfaces and can be used on skin and mucous membranes.

1.4 What is the recommended dose?

The dose for oral methenamine is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  METHIMAZOLEis a drug that inhibits
 
Response: METHIMAZOLEis a drug that inhibits the enzyme CYP3A4 and can be used to prevent liver damage and to treat various parasitic infections, including malaria.1,2

Although its antimalarial activity was first described in the early 1940s, it was not until the mid-1950s that the potential utility of the drug in preventing drug-induced liver damage was recognized.3 The recognition that drug-induced liver injury could be reduced by using METHIMAZOLE was primarily based on the experience with another drug, chlorpromazine.4

METHIMAZOLE was approved for use as an antimalarial agent in the United States in the early 1960s.5 The drug was subsequently approved for the prevention of opportunistic infections in patients with acquired immunodeficiency syndrome (AIDS).6

MAINSTREAM USE OF METHIMAZOLE

In general, METHIMAZOLE is a safe and effective
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  METHOCARBAMOLis a drug that inhibits
 
Response: METHOCARBAMOLis a drug that inhibits catecholamine and serotonin reuptake. The effect of METH on sleep is variable and may be due to a central stimulatory action or to a sedative effect. Sleep is impaired in some METH users and this has been shown to be related to METH use. This study investigates the effects of METH on sleep in a group of METH users who were selected to have abstained from METH for 3 days prior to admission to the sleep laboratory. The study design was a cross-over study with a washout period of at least 1 week between two treatment sessions. Sleep was recorded with a portable recording device (Ambulatory Monitoring System). After a baseline night of sleep, subjects received METH (10 mg) or placebo at bedtime and sleep was recorded for 6 h. Results showed that METH produced an increase in stage 2 sleep (9.4 +/- 2.3 min) compared to placebo (5.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methoxamineis a drug that inhibits
 
Response: Methoxamineis a drug that inhibits the enzyme monoamine oxidase A (MAO-A) which leads to an increase in the level of neurotransmitters serotonin, dopamine and noradrenaline.

Mechanism of action

Methoxamine acts on the central nervous system (CNS) by inhibiting the enzyme monoamine oxidase A (MAO-A) which is responsible for the degradation of monoamines (e.g. serotonin, norepinephrine, and dopamine) in the CNS.

Methoxamine is metabolized by the enzyme MAO-B.

It is a non-selective monoamine oxidase inhibitor, which means that it is a reversible, non-selective, reversible inhibitor of the enzyme monoamine oxidase A (MAO-A). It is used in the treatment of depression.

Dosage and administration

The recommended dosage is 100 mg twice a day or 250 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methoxsalenis a drug that inhibits
 
Response: Methoxsalenis a drug that inhibits growth of cancer cells in vitro. It has been tested in clinical trials. Methoxsalenis a red light substance, that is applied topically to the skin. Its effects are caused by a photochemical reaction that is initiated by red light. This reaction leads to the formation of singlet oxygen. This is a powerful oxidant that causes damage to the DNA of the cancer cells. In vitro studies show that methoxsalen is an effective substance for killing of various cancer cells. The drug has also been tested in several clinical trials.

Prognosis

Treatment with methoxsalen has been shown to increase survival of patients with melanoma and non-melanoma skin cancer. Methoxsalen has also been shown to be an effective treatment for metastatic breast cancer.

Side effects

The most common side effect is skin photosensitivity. This may be of limited duration. Other side effects include nausea
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  methyclothiazideis a drug that inhibits
 
Response: methyclothiazideis a drug that inhibits the Na+/K+-ATPase, an enzyme that maintains the sodium gradient across the plasma membrane. The drug is used to treat high blood pressure and heart failure. It is not for people with renal or hepatic disease.

Other drugs
Aldosterone
Diuretics
ACE inhibitors

References

Category:Thiazides
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methylis a drug that inhibits
 
Response: Methylis a drug that inhibits the growth of androgen-dependent and independent prostate cancer cells. We have previously shown that methylis inhibits the expression of several key enzymes of the androgen-signaling pathway. However, the mechanisms by which this occurs are not well understood. Here, we show that methylis-induced inhibition of prostate cancer cell growth and androgen-dependent gene expression occurs in part through the down-regulation of the protein levels of androgen receptor (AR) and the steroid receptor coactivator-1 (SRC-1). Methylis inhibited the growth of prostate cancer cells in part through the down-regulation of the protein levels of AR and SRC-1. Methylis treatment resulted in a marked decrease in AR and SRC-1 protein levels. In addition, treatment of prostate cancer cells with methylis caused a decrease in the transcriptional activity of AR, but not SRC-1. In addition, treatment of prostate cancer cells with methylis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methyleneis a drug that inhibits
 
Response: Methyleneis a drug that inhibits the absorption of estrogens and androgens by the small intestine. It is also a highly potent inhibitor of the hepatic microsomal mixed-function oxidase system. It is used to treat breast cancer in postmenopausal women. The drug is also used to treat benign prostatic hyperplasia in men.

Methylene-dianiline is a drug that is used to treat severe asthma. It is also used to treat hyperthyroidism and certain types of cardiac arrhythmias.

Methylene-bis-benzyl-amine is a drug that is used to treat high blood pressure. It is also used to treat hypothyroidism.

Methylene-dianiline is a drug that is used to treat hyperthyroidism. It is also used to treat chronic hepatitis.

Methylene-dianiline is a drug that is used to treat high blood
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methyl-Hesperidinis a drug that inhibits
 
Response: Methyl-Hesperidinis a drug that inhibits the growth of human lung cancer cells.
Methyl-Hesperidin, a bioactive flavanone, was isolated from the rhizome of Anemarrhena asphodeloides. The growth-inhibitory effect of Methyl-Hesperidin on human lung cancer cell line A549 was investigated. Methyl-Hesperidin exhibited significant growth-inhibitory activity against A549 cells in a dose-dependent manner, with an IC(50) of 2.3 microM. The cell cycle analysis showed that the growth-inhibitory effect of Methyl-Hesperidin on A549 cells was associated with G(2)/M arrest. The effects of Methyl-Hesperidin on the expression of cyclin B1, cdc2, and cdc25C in A549 cells were examined by western blot analysis. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methylprednisoloneis a drug that inhibits
 
Response: Methylprednisoloneis a drug that inhibits the activity of the phosphodiesterase enzyme. It is used to treat a number of conditions, such as inflammation, shock, allergy, asthma, multiple sclerosis, rheumatoid arthritis, lupus, and osteoarthritis. This is a non-selective drug, and as such, it is usually given in combination with another corticosteroid to achieve the desired effect.

Methylprednisolone may be given orally or intravenously, but the usual route of administration is by intravenous injection.

Methylprednisolone is usually administered as an intravenous injection, and doses of the drug vary depending on the condition being treated.

Methylprednisolone is usually given by injection. It may be given intravenously, or it may be given by mouth.

Methylprednisoloneis used to treat a number of conditions. It is usually given in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methylthiouracilis a drug that inhibits
 
Response: Methylthiouracilis a drug that inhibits the activity of the enzyme xanthine oxidase. It is prescribed in the treatment of hyperuricemia and uric acid disorders. The efficacy of methylthiouracil has been shown in experimental models of the following diseases: psoriasis, psoriatic arthritis, lichen planus, systemic lupus erythematosus, and arthritis. Methylthiouracil was used as a topically applied drug for the treatment of cutaneous disorders. Methylthiouracil is also used as a dietary supplement in the treatment of hyperuricemia.

Methylthiouracil is a purine derivative, a heterocyclic compound. It is a white to off-white crystalline solid. Methylthiouracil is soluble in alcohol and ether. It is slightly soluble in water.

Methylthiouracil is available as the free base. The dosage
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Methysergideis a drug that inhibits
 
Response: Methysergideis a drug that inhibits serotonin synthesis by blocking the enzyme tryptophan hydroxylase. Methysergide is used to treat nausea and vomiting associated with cancer chemotherapy. It is also used to treat migraine headaches.

What is methysergide used for?

Methysergide is used to treat nausea and vomiting associated with cancer chemotherapy. It is also used to treat migraine headaches.

What are the side effects of methysergide?

The most common side effects of methysergide are:

headache

dizziness

light-headedness

feeling of heat or cold

feeling of tightness in chest or stomach

dry mouth

nausea

diarrhea

drowsiness

What are the side effects of methysergide?

The most common side effects of methysergide are:

headache
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  meticraneis a drug that inhibits
 
Response: meticraneis a drug that inhibits the growth of prostate cancer cells by binding to the androgen receptor (AR) and causing its degradation. This drug has recently been approved by the FDA for treatment of metastatic castration-resistant prostate cancer. This study aims to evaluate the in vivo activity of palbociclib, an inhibitor of CDK4 and CDK6, alone and in combination with abiraterone acetate in a new preclinical model of castration-resistant prostate cancer. A human AR-expressing, androgen-independent prostate cancer cell line, PC3, was subcutaneously implanted into the right flank of male SCID mice. Once the tumors reached a size of approximately 100 mm(3), the mice were randomly assigned to one of four treatment groups (n = 10 per group): (i) control, (ii) palbociclib, (iii) palbociclib + abiraterone acetate, or (iv)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  METI-DERMis a drug that inhibits
 
Response: METI-DERMis a drug that inhibits heparin cofactor II, a serine protease inhibitor (serpin) in the complement system. The clinical effects of the drug have been investigated in experimental and clinical studies. To assess the effect of metilprednisolone on serum complement levels in patients with disseminated intravascular coagulation (DIC). A prospective, open-label, single-centre, pharmacokinetic and clinical study was performed. Fourteen patients with DIC were enrolled. After 1 week of pre-treatment with low-dose metilprednisolone (20 mg/day) and after 1 week of pre-treatment with high-dose metilprednisolone (80 mg/day), blood samples were collected for complement measurements. The serum levels of complement components C3, C4, factor B and C5a were measured using enzyme-linked immunosorbent assays. Pharmacokinetic parameters were determined using the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Metoclopramideis a drug that inhibits
 
Response: Metoclopramideis a drug that inhibits gastric acid secretion. It is used to prevent and treat nausea and vomiting. Metoclopramide is an ergot derivative and is a member of the class of medications known as ergot alkaloids. Metoclopramide is a white, crystalline powder that is practically insoluble in water. It is available as a tablet or an oral suspension.

Metoclopramide comes in a variety of forms, including a tablet and an oral suspension. The tablet is an immediate-release formulation. The oral suspension is an extended-release formulation. Metoclopramide is most commonly used to treat motion sickness. It may also be used to prevent and treat nausea and vomiting in patients undergoing cancer chemotherapy. It may be used to prevent and treat nausea and vomiting during pregnancy.

Metoclopramide is used to prevent and treat motion sickness, including seasickness.

Metoclopramide is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MetoclopraMideis a drug that inhibits
 
Response: MetoclopraMideis a drug that inhibits metoclopramide. It works by blocking the effects of metoclopramide, which is used to treat gastrointestinal disorders.

Metoclopramide has been shown to increase the risk of low blood pressure, chest pain, seizures, and abnormal heart rhythms in some people. It can cause prolonged QT interval (a condition that can lead to sudden death) and may cause hallucinations, a serious allergic reaction, and abdominal pain.

Do not use metoclopramide if you are pregnant. Use of the drug may harm an unborn baby.

You may not be able to get metoclopramide at the pharmacy. Ask your doctor for a prescription or contact your pharmacist.

Other drugs that can interact with metoclopramide

Drugs that can cause unwanted side effects when used with metoclopramide include:

Acetaminophen (Tylenol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  METOLAZONEis a drug that inhibits
 
Response: METOLAZONEis a drug that inhibits the absorption of vitamin B12 from the gastrointestinal tract, resulting in the depletion of this vitamin in the body. In some patients, it may cause nerve damage. It may be prescribed in a hospital setting for treatment of severe vitamin B12 deficiency. It may also be prescribed in the home to treat mild vitamin B12 deficiency in patients who have trouble swallowing tablets. In some cases, metformin is prescribed in combination with other drugs to treat high blood sugar (diabetes). Metformin can be used alone to treat some types of diabetes. It is usually used to treat type 2 diabetes. Metformin is also used to treat polycystic ovary syndrome (PCOS) and to treat type 2 diabetes in overweight or obese patients. Metformin may also be used to treat obesity and certain liver problems.

It is used to treat type 2 diabetes, a condition in which blood sugar levels are too high. This results in many health
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Metoprololis a drug that inhibits
 
Response: Metoprololis a drug that inhibits erythrocyte surface receptors and is an integral part of the therapeutic arsenal for treating sickle cell disease. It is a low-molecular-weight heparin-like molecule, with potent anticoagulant properties. However, it also has an important anti-inflammatory effect.

In the last years, there has been an increasing interest in the use of metoprolol as a novel therapy for patients with sickle cell disease (SCD) ([@B1]). Indeed, the drug has been used in some patients with SCD, especially those who have experienced complications related to sickling of red blood cells (RBCs) ([@B2]). Metoprolol is a drug that inhibits erythrocyte surface receptors and is an integral part of the therapeutic arsenal for treating sickle cell disease. It is a low-molecular-weight heparin-like molecule, with potent ant
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Metronidazoleis a drug that inhibits
 
Response: Metronidazoleis a drug that inhibits nitroreductase.\[[@ref1]\] It is an antibacterial drug and has been used in the treatment of bacterial vaginosis, bacterial infections of the urinary tract, trichomoniasis, proctitis, chronic diarrhea, amebiasis, amoebic liver abscess, amoebic encephalitis, and bacterial prostatitis.\[[@ref2]\] In India, it is widely used for the treatment of recurrent diarrhea and as a substitute for metronidazole in the treatment of giardiasis and trichomoniasis.\[[@ref3]\]

The drug has a bitter taste, and hence, there is the need for taste masking to make it more palatable. Taste masking is an important consideration for pharmaceutical development.\[[@ref4]\] Various techniques have been used for taste masking of drugs such as taste mask
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  mevastatinis a drug that inhibits
 
Response: mevastatinis a drug that inhibits cholesterol synthesis and can reduce the levels of low-density lipoprotein cholesterol. The drug has been shown to reduce the risk of heart disease. Side effects include upset stomach, muscle aches, and liver problems. The drug may also cause irregular heartbeats.

It is a cholesterol-lowering agent that has been shown to lower cholesterol. It lowers LDL cholesterol and triglycerides and raises HDL cholesterol.

It may also be used to treat high cholesterol.

Posology and dosage

The usual dose of atorvastatin is 10 mg once daily. Dosage is increased in the presence of hepatic dysfunction to 20 mg once daily, 40 mg once daily, or 80 mg once daily.

It is usually administered as 10 mg once daily in combination with fenofibrate. The recommended dosage of atorvastatin is 20 mg once daily in combination with fen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mexenoneis a drug that inhibits
 
Response: Mexenoneis a drug that inhibits NOX activity, and in turn, is a positive regulator of ROS production. In this study, we evaluated the effects of Mexenoneis on mitochondrial and endoplasmic reticulum (ER) stress, and cell death in the human prostate cancer cell line, LNCaP. Cells were treated with Mexenoneis at 0, 10, 20, 40, 80, and 100 µM for 48 h, and cell viability was assessed using MTT assay. Western blot analysis was performed to determine the levels of ER stress markers. Cell death was assessed using annexin V/PI staining and flow cytometry. The results indicated that Mexenoneis decreased the cell viability in a dose-dependent manner, and reduced the expression of ATF6, GRP78, and CHOP. Furthermore, Mexenoneis increased the phosphorylation of eIF2α, which was accompanied by an increase in the phosphorylation of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mexiletineis a drug that inhibits
 
Response: Mexiletineis a drug that inhibits sodium channel action potentials. It is used to control the symptoms of severe migraine headaches. It has been demonstrated to be an effective abortive agent. It is also used to control some symptoms of atrial fibrillation. It is available as a transdermal patch, a gel and a solution. The drug was approved by the FDA in 1992.

Uses

Mexiletine is used to treat severe migraine headaches. It can be used as a first line treatment for migraine. It can also be used as a second line treatment for migraine if a patient has been unsuccessful with other migraine treatments.

Dosage

Mexiletine is available as a gel, a patch and a solution. The solution is an oral solution that is used to treat atrial fibrillation.

Adults

To treat migraine, the initial dose is 100 mg once a day, taken in the morning. This dose can be increased
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mezlocillinis a drug that inhibits
 
Response: Mezlocillinis a drug that inhibits the CYP3A4 enzyme can be taken to increase the levels of other drugs, such as statins, which can have serious side effects if taken in high doses. If your doctor prescribes you mezlocilline to treat a bacterial infection, you should take it at the lowest possible dose for the shortest possible time.

My dog, Cinnamon, was put down on Tuesday. We went to a humane society and they let us come in and choose a dog. We brought her home. She was really really skinny, so we gave her a bath. She looked so much better after that. She is much bigger and stronger now.

She is about 5 months old. We have been taking her for three months now. She has been the best dog we have ever had. She has never barked. She has never jumped up. She is really sweet and gentle. She loves to cuddle. She is our baby.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MGL-3196is a drug that inhibits
 
Response: MGL-3196is a drug that inhibits the B-cell receptor (BCR) signaling pathway, resulting in a marked reduction of the number of B-cells and a reduction of immunoglobulin levels in the serum. In a clinical study, CLL patients treated with MGL-3196 demonstrated a rapid reduction of peripheral blood lymphocytes and an increase in lymphocytes in the bone marrow.

Medication for chronic lymphocytic leukemia (CLL) is typically based on a combination of corticosteroids, monoclonal antibodies, and chemotherapeutic agents. However, long-term treatment with chemotherapy may result in adverse effects, including cardiac toxicity and secondary malignancies.1 A more recently developed class of agents, called B-cell receptor (BCR) signaling inhibitors, are designed to block the BCR pathway, resulting in a rapid reduction of peripheral blood lymphocytes and an increase in bone marrow lymphocytes.1 These agents are being investigated in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mianserinis a drug that inhibits
 
Response: Mianserinis a drug that inhibits gonadotropin-releasing hormone (GnRH) release has been used for decades in women with fertility problems.

How do you like this article?

How do you like this article?

Mianserin, also known as mianserin hydrochloride, is a phenylpiperidine derivative of tryptamine and originally synthesized in 1958 by the French pharmaceutical company Miford-Levallois (now part of Sanofi-Aventis). Mianserin is marketed in Europe as an antidepressant and anti-anxiety agent and has been approved for these uses in the United States.

It is not recommended for use in pregnancy, however, because of potential fetal and neonatal adverse effects, including death, respiratory depression, bradycardia, hypotension, hypothermia, hypoglycemia, hypocalcemia, hypomagnesemia, hyperkalemia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Micafunginis a drug that inhibits
 
Response: Micafunginis a drug that inhibits the fungal enzyme (fungus specific target) lanosterol 14-α demethylase (CYP51A1). It was developed by the Novartis Corporation (Basel, Switzerland) in the mid-1990s and is approved for the treatment of patients with serious fungal infections. It was approved by the US Food and Drug Administration (FDA) in 1997 for the treatment of patients with invasive candidiasis and was subsequently approved for the treatment of patients with esophageal candidiasis and candidemia, the first of its kind, and for the treatment of patients with invasive aspergillosis. The drug has also been approved in Europe for the treatment of patients with invasive aspergillosis and in Japan for the treatment of patients with invasive *Fusarium* infections.[@b1-tcrm-11-1231]

Although the use of micafungin in the treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MICARDISis
 
Response: MICARDISis a software platform for efficient and easy creation, modification, and management of high-throughput screening (HTS) data. It provides a number of tools for data visualization, data management, and statistical analysis. MDD is designed to be used by biologists, chemical and pharmaceutical researchers, and HTS specialists in academia and industry. MDD is a web-based software and can be accessed through any modern web browser. MDD is free for academic use. MDD is the subject of a published patent (U.S. Patent Publication No. 2013/0179441 A1, published Aug. 15, 2013).

MDD has been used for screening and testing thousands of compounds. MDD is freely available for academic use. MDD is freely available on the Internet at https://mdd.heuritech.com.

Introduction

This document provides a brief overview of the features of the MDD platform. The goal of this document is to provide
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Miconazoleis a drug that inhibits
 
Response: Miconazoleis a drug that inhibits an enzyme that metabolizes testosterone. It is commonly used to treat the skin conditions caused by excessive androgen production. It is also used to treat the fungal infections of the skin and nails. It is used to treat other conditions such as seborrheic dermatitis and atopic dermatitis. It is used to treat athlete’s foot, ringworm, and dandruff. It is also used to treat and prevent the spread of fungal infections such as tinea pedis.

What is Miconazole used for?

Miconazole is used to treat and prevent the spread of fungal infections such as tinea pedis. It is used to treat athlete’s foot, ringworm, and dandruff. It is used to treat other conditions such as seborrheic dermatitis and atopic dermatitis. It is used to treat other conditions such as seborrhe
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MICROSULis a drug that inhibits
 
Response: MICROSULis a drug that inhibits mitochondrial translation. When taken with
coenzyme Q10, MICROSUL increases coenzyme Q10 levels in the liver, which
may have beneficial effects.

Phentermine

Phentermine, a prescription drug used to treat obesity, has also been shown to
have a beneficial effect on insulin resistance and Type 2 diabetes.

What's more, phentermine may also help to reverse Type 2 diabetes.

For more information, see the information on
phentermine and Type 2 diabetes.

Phentermine (also known as AD-5-1731 and 5-hydroxydephedrine) is a
prescription weight-loss drug used to treat obesity. In fact, it's the only
prescription drug approved by the FDA for the short-term (up to one year)
treatment of obesity.

According to the FDA, phenter
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Midodrineis a drug that inhibits
 
Response: Midodrineis a drug that inhibits the renin-angiotensin system (RAS) in the brain, which results in an increase in the plasma concentration of noradrenaline and adrenaline, which in turn stimulates the heart and peripheral circulation. In clinical practice, the effectiveness of midodrine in patients with orthostatic hypotension is limited by a short half-life, frequent adverse effects and high cost. Midodrine can increase the heart rate (HR) by a maximum of 10-15 beats per minute, which may result in arrhythmia and even sudden death, particularly in patients with cardiac disease. This adverse effect of midodrine is related to its conversion to desglymidodrine in the liver and kidneys.\[[@ref1]\] Desglymidodrine has a very short half-life (1-2 h), which limits the duration of action of midodrine.\[[@ref2]\] The half-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MIFEPREXis a drug that inhibits
 
Response: MIFEPREXis a drug that inhibits an enzyme called COX-2. This enzyme helps create the inflammation-causing chemicals that cause your arthritis to flare up. These chemicals are known as prostaglandins. Mifeprex is used to treat premenstrual syndrome and endometriosis.

Side effects include nausea, diarrhea, headaches, skin rash, and other problems. Mifeprex is most effective if it is taken within a few days of ovulation.

The active ingredient in Mifeprex is misoprostol. It is available in many over-the-counter and prescription drug stores.

Oral Mifeprex (Mifeprex, Mifeprex ODT, Mifeprex OTC)

The active ingredient in Mifeprex is misoprostol. Misoprostol is a prostaglandin analogue.

It can be taken by mouth. It is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Miglitolis a drug that inhibits
 
Response: Miglitolis a drug that inhibits androgens from binding to the androgen receptor. It was originally used to treat prostate cancer and then later it was found to also have activity against breast cancer. It was approved by the FDA in March 2004 for the treatment of metastatic hormone-sensitive prostate cancer in men who have not responded to or who are not tolerant of other hormonal therapies.

Miglitol is an orally active, reversible inhibitor of α-glucosidase (the enzyme that breaks down glucose). It does not bind to the receptor and thus does not affect the activity of the hormone. It is a small molecule that is absorbed quickly after oral ingestion. The drug is generally well tolerated.

Miglitol is generally well tolerated and well absorbed, but it is not very soluble in water. It is usually given as an oral tablet, but may be given in an IV infusion. It is available in a generic form.

How is miglitol used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mildronateis a drug that inhibits
 
Response: Mildronateis a drug that inhibits the resorption of calcium and phosphate from the bones. It has been approved by the FDA for treatment of osteoporosis. It is a bisphosphonate and has the following chemical formula.

It has been in use since 1980 and was originally used for treating Paget's disease and hypercalcemia of malignancy. It is also used in Japan for the treatment of idiopathic hypercalcemia of malignancy.

Treatment with Mildronate has been associated with acute renal failure, rhabdomyolysis, gastrointestinal symptoms, and thrombotic microangiopathy.

Acute renal failure

It has been observed that acute renal failure has occurred in about 0.5% to 2.0% of the patients taking mildronate. This has been observed in both clinical trials and in clinical practice. It is believed that the reason for this side effect is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Milnacipranis a drug that inhibits
 
Response: Milnacipranis a drug that inhibits serotonin reuptake. It is approved for the treatment of fibromyalgia. There is no evidence that milnacipran is effective for the treatment of PTSD.

Cipramil

Cipramil is a drug that inhibits serotonin reuptake. It is approved for the treatment of depression. There is no evidence that cipramil is effective for the treatment of PTSD.

Paxil

Paxil is a drug that inhibits serotonin reuptake. It is approved for the treatment of depression. There is no evidence that paxil is effective for the treatment of PTSD.

Prozac

Prozac is a drug that inhibits serotonin reuptake. It is approved for the treatment of depression. There is no evidence that Prozac is effective for the treatment of PTSD.

Sertraline

Sertraline is a drug that inhibits serotonin reuptake
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Milrinoneis a drug that inhibits
 
Response: Milrinoneis a drug that inhibits phosphodiesterase type 3 (PDE3). Inhibition of PDE3 results in a decrease in cyclic AMP levels and, as a consequence, inhibition of the relaxation of vascular smooth muscle and increased myocardial contractility. This drug has been shown to improve clinical outcomes in patients with heart failure and acute myocardial infarction. The efficacy of milrinone is limited by the short half-life and low bioavailability of the drug. The oral bioavailability of milrinone is low (approximately 4%). Milrinone is highly bound to plasma proteins (approximately 97%) and undergoes extensive hepatic metabolism. The cytochrome P450 (CYP) enzymes responsible for milrinone metabolism are CYP3A4 and CYP3A5. The metabolic pathways include hydroxylation, N-dealkylation, O-dealkylation, and O-demethylation. The main metabolites
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Minocyclineis a drug that inhibits
 
Response: Minocyclineis a drug that inhibits the growth of the gram-positive bacterium, *M.tuberculosis* and has been used to treat *M.tuberculosis* infections for several years. Minocycline also appears to have a variety of other actions, including antifungal and antibacterial activity.

Minocycline is approved in the United States for use in the treatment of acne vulgaris. A number of reports in the literature have described its use in the treatment of various types of periodontitis. The aim of this study was to evaluate the safety and efficacy of minocycline in the treatment of periodontitis in humans.

MATERIALS AND METHODS
=====================

The protocol was approved by the Medical Ethics Committee of the University of Hong Kong and informed consent was obtained from all patients.

Twenty-four subjects were recruited from the dental clinic of the Hong Kong University of Science and Technology
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MINTEZOLis a drug that inhibits
 
Response: MINTEZOLis a drug that inhibits the formation of cancer. You could be receiving the drug in the next few weeks.

The world-leading global specialist cancer centre in Newcastle, has been granted a licence by the Pharmaceutical Benefits Scheme to import the drug into Australia.

Bristol-Myers Squibb supplied a special batch of the drug to Newcastle for clinical trials and has now agreed to donate the drug for use in Australia.

Newcastle’s Peter McCallum said the move would make it easier for people with a rare form of blood cancer to access a potentially life-saving treatment.

“We are delighted that Newcastle has been given the opportunity to provide this important treatment,” he said.

“For many years the drug has only been available to patients in the United States.”

Mr McCallum said the drug, called gemtuzumab ozogamicin, or MINE,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mirabegronis a drug that inhibits
 
Response: Mirabegronis a drug that inhibits the binding of the α-subunit of the prostaglandin receptor to prostaglandin. It is used in the treatment of overactive bladder syndrome.1

The safety of mirabegron is based on two large, well-designed clinical trials in patients with overactive bladder syndrome (OAB) who were treated for up to 52 weeks.2,3 Mirabegron is also approved in Japan for the treatment of OAB in men.

Mirabegron is available as a tablet and a transdermal patch, and the latter is not recommended for use in men.4

The main adverse effects associated with mirabegron are dry mouth, gastrointestinal effects, and headache.5,6

The incidence of adverse events (AEs) was greater with mirabegron than with placebo in the pooled analysis of the 2 clinical trials.2,3 The most common AEs with mir
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mirogabalinis a drug that inhibits
 
Response: Mirogabalinis a drug that inhibits the pain of diabetic neuropathy by increasing the level of anandamide, which is a cannabinoid (endogenous cannabinoid) that is naturally present in the body. It is indicated for the treatment of moderate to severe diabetic peripheral neuropathic pain in adults.

▪ INDICATIONS AND USAGE

The following uses have been approved by the U.S. Food and Drug Administration (FDA) for Migrabalin:

Dosage and Administration

Take 1 to 2 capsules 2 times a day with or without food. For pts with normal hepatic function, the recommended starting dose is 300 mg/day.

Monitor for adverse reactions, particularly psychiatric.

Storage

Store at room temperature.

Dosage in Renal Impairment

No dose adjustment.

Dosage in Hepatic Impairment

Do not use.

#####  SIDE EFFEC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MIRTAZAPINEis a drug that inhibits
 
Response: MIRTAZAPINEis a drug that inhibits the release of dopamine in the brain. It is used to treat anxiety, depression and bipolar disorder.

It is a tricyclic antidepressant that is used to treat anxiety and panic disorders.

It can also be used to treat major depressive disorder and bipolar disorder.

It is used to treat obsessive-compulsive disorder (OCD).

It is also used to treat neuropathic pain.

It is also used to treat bipolar disorder.

MIRTAZAPINEis an antidepressant that works by inhibiting the release of dopamine in the brain. It is used to treat depression and anxiety.

MIRTAZAPINEis an antidepressant that works by inhibiting the release of dopamine in the brain. It is used to treat depression and anxiety.

MIRTAZAPINEis an antidepressant that works by inhibiting the release of dopamine in the brain. It is used to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Misoprostolis a drug that inhibits
 
Response: Misoprostolis a drug that inhibits the growth of tumor cells and decreases tumorigenesis and the growth of tumors. This drug also has an inhibitory effect on the proliferation of B cells and inhibits the growth of the immune system. Inhibiting the growth of tumor cells, B cells and the immune system, the effects of the drugs can be summarized as follows:
1) an antitumor effect by inhibiting the growth of tumor cells,
2) an immunosuppressive effect by inhibiting the growth of B cells,
3) an immunosuppressive effect by inhibiting the proliferation of the immune system, and
4) an antitumor effect by decreasing the possibility of tumor growth.
Therefore, the drugs have an effect of inhibiting the growth of tumor cells, an effect of decreasing the possibility of tumor growth, and an effect of decreasing the tumorigenicity. However, there is no report that the combination of the drugs mentioned above can increase the antit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mitapivatis a drug that inhibits
 
Response: Mitapivatis a drug that inhibits the action of cyclooxygenase (COX) enzymes and blocks the production of prostaglandins. This action helps reduce inflammation and pain associated with the body's response to a painful stimulus. Mitapivatis is used to treat acute pain, pain associated with minor surgery, and pain caused by rheumatoid arthritis and osteoarthritis. It may also be used for other conditions as determined by your doctor.

Mitapivatis Oral Suspension, 50 mg, is used to treat acute pain, pain associated with minor surgery, and pain caused by rheumatoid arthritis and osteoarthritis. It may also be used for other conditions as determined by your doctor.

Mitapivatis is a prescription medicine that is used to treat acute pain, pain associated with minor surgery, and pain caused by rheumatoid arthritis and osteoarthritis. Mitapivatis may also be used for other conditions
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mitomycinis a drug that inhibits
 
Response: Mitomycinis a drug that inhibits the formation of cancer cells. It works in the same way as the male contraceptive pill, preventing sperm from reaching the egg. It is thought that the drug could prevent cancer cells from growing in the first place, by blocking their reproduction.

The treatment will be used on women with a specific type of ovarian cancer, where the cancer cells are genetically unstable. It is hoped that the drug will work by keeping these cancer cells from reproducing.

The drug has been given the nickname "mito-gene" by the scientists who developed it.

Dr Nadeem Merali, from Cancer Research UK, said: "The new drugs are a big step forward.

"But we are not quite there yet. They are still experimental and need to be tested in clinical trials before they can be used in people.

"We also need to make sure they work as well as possible. It's important to remember that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mitotaneis a drug that inhibits
 
Response: Mitotaneis a drug that inhibits the enzyme androgen-DHEA-S-reductase (ADR). As such, it is used in the treatment of adrenocortical carcinoma, a rare and aggressive form of cancer that originates in the adrenal gland. Mitotane is well tolerated and has a low toxicity profile; however, it can cause a variety of adverse effects that may require dose reduction or discontinuation. The purpose of this study was to describe the side effects of mitotane in the treatment of adrenocortical carcinoma. We conducted a retrospective study at a single centre. All patients with adrenocortical carcinoma treated with mitotane between 2004 and 2012 were included. We recorded demographic and clinical data, treatment-related side effects and response to treatment. We identified 21 patients with adrenocortical carcinoma who were treated with mitotane. The mean duration of treatment was 15.5 months. Mitotane was given
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mitoxantroneis a drug that inhibits
 
Response: Mitoxantroneis a drug that inhibits the growth of cancer cells by causing the death of cells. Mitoxantrone is used to treat certain types of breast cancer and is also used to treat prostate cancer.

Mitoxantrone is used to treat acute leukemia. It is given by injection into a vein or by mouth.

How to use mitoxantrone

Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.

Take mitoxantrone as prescribed. Your doctor may want you to take the drug for a longer time than is listed on your prescription label.

How to store mitoxantrone

Store mitoxantrone at room temperature away from moisture and heat.

Keep track of your medicine. Take this medication regularly to get the most benefit from it. Do not miss any doses.

Side effects

Along with its needed effects, a medicine may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mivacuriumis a drug that inhibits
 
Response: Mivacuriumis a drug that inhibits neuromuscular transmission. Its principal use is to facilitate tracheal intubation and mechanical ventilation in the intensive care unit. The principal adverse effect is prolonged neuromuscular blockade, and it is used as an adjunct to general anesthesia. We describe the clinical management of a patient who received a bolus of mivacurium and who subsequently had severe acute respiratory failure. Mivacurium was re-administered and a new episode of respiratory failure occurred.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mizoribineis a drug that inhibits
 
Response: Mizoribineis a drug that inhibits the enzyme ribonuclease (RNase) and can be used in the treatment of certain forms of lupus. The drug is usually given by injection.

How is mizoribine used?

Mizoribine is used in the treatment of some forms of lupus. It may be used alone or with other drugs.

How does mizoribine work?

Mizoribine works by inhibiting the enzyme ribonuclease (RNase). This reduces the activity of interferon gamma, which is produced by the immune system in response to an infection. In this way, the immune system is less able to produce the antibodies that cause inflammation.

Mizoribine is usually given by injection into a muscle or into a vein.

What are the possible side effects of mizoribine?

The side effects of miz
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK-1775is a drug that inhibits
 
Response: MK-1775is a drug that inhibits a group of enzymes called PI3Ks. This group of enzymes play a key role in the activation of cell signaling pathways and are critical to cell growth, cell survival and cell cycle regulation. Inhibiting these enzymes has been shown to have anti-tumor activity and is being tested in multiple clinical trials for a variety of tumor types.

Here are some of the major types of cancers that are being evaluated in clinical trials:

Pancreatic Cancer

Melanoma

Lung Cancer

Leukemia

Breast Cancer

Multiple Myeloma

Gastric Cancer

Ovarian Cancer

Ewing Sarcoma

Urothelial Carcinoma

Hepatocellular Carcinoma

Colorectal Cancer

Cholangiocarcinoma

Lymphoma

Non-Small Cell Lung Cancer


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK-2048is a drug that inhibits
 
Response: MK-2048is a drug that inhibits OXPHOS by binding to complex III, and hence reduces the amount of ATP available to the ATP-dependent protein kinase, which then causes cell death. This mechanism is thought to be the basis of the synergistic effects observed with cisplatin and rapamycin.

While this drug has shown some promise in patients, its high toxicity has meant that it has not yet been approved for clinical use. This article reviews the mechanisms of action and clinical trials of MK-2048, and also discusses the future of the use of this drug in cancer treatment.

Brief History of MK-2048
========================

The synthesis of the oxazole derivative MK-2048 was first described in 1999 by the group of Stacey McKee at the University of California, San Francisco (UCSF). McKee and colleagues had been investigating the role of the mitochondrial respiratory chain in apoptosis. They found that cells that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK-2206is a drug that inhibits
 
Response: MK-2206is a drug that inhibits mTOR. Its mechanism of action is related to its ability to bind to the mTOR kinase domain, thus inhibiting its kinase activity \[[@B52-ijms-18-01991]\]. This drug is currently used for the treatment of different types of cancers. A phase II clinical trial is being conducted in relapsed/refractory acute myeloid leukemia (AML) patients \[[@B53-ijms-18-01991]\]. A phase I trial in patients with relapsed/refractory AML and MDS has also been completed. In this trial, MK-2206 was given as a single agent at the dose of 50 mg twice daily (BID) for 7 days. In this study, the most common drug-related adverse events were hypertriglyceridemia, hypophosphatemia, hyperglycemia, and hyperglycemia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK4827is a drug that inhibits
 
Response: MK4827is a drug that inhibits the protein kinase Cθ (PKCθ) and is a promising drug for the treatment of leukemia. In this study, we investigated the potential of MK4827 for the treatment of leukemia. First, we assessed the effect of MK4827 on the viability of leukemia cells. MK4827 treatment significantly inhibited the viability of leukemia cells in a dose- and time-dependent manner. We then examined the molecular mechanisms underlying the cytotoxicity of MK4827. MK4827 induced apoptosis in leukemia cells in a dose- and time-dependent manner. MK4827 treatment induced apoptosis in leukemia cells through the activation of the caspase cascade. We then examined the efficacy of MK4827 in vivo. MK4827 treatment resulted in a marked reduction in tumor size and a significant increase in survival time in a murine leukemia model. MK4827 also induced apoptosis in the tumor cells in vivo. Our findings suggest that MK
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK-4827is a drug that inhibits
 
Response: MK-4827is a drug that inhibits the glycogen synthase kinase 3 (GSK3) enzyme. This is a serine/threonine kinase which is involved in the regulation of cell metabolism and the Wnt signalling pathway. This can lead to an improvement in energy metabolism, insulin sensitivity and muscle metabolism. In the context of DMD, this may improve muscle mass, strength and function, which is particularly relevant in light of the age of onset of the disease.

MK-4827 has been shown to have a positive effect on DMD muscle in both pre-clinical and clinical trials.

It has been shown to have a favourable benefit/risk ratio and has a long-term safety profile.

There are no known significant safety issues or interactions.

Mechanism of action

GSK3 inhibition

GSK3 is a serine/threonine kinase enzyme involved in the regulation of cell metabolism, apoptosis and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Niraparibis a drug that inhibits
 
Response: Niraparibis a drug that inhibits PARP1, a protein that repairs single-strand DNA breaks. As a result, cancer cells with BRCA mutations cannot repair DNA damage, leading to their death. In April 2015, the U.S. Food and Drug Administration approved niraparib for the treatment of people with BRCA-mutated ovarian cancer. The drug works only for patients with a BRCA mutation and no other mutations in other cancer genes.

For all women, the most effective treatment is a hysterectomy (removal of the uterus) to remove the ovaries, followed by bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries) to remove all of the remaining tissue in the abdomen and pelvis. The ovaries contain oocytes, which can be fertilized to produce eggs. Once the eggs mature, they are released from the ovaries. After the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MLN2238is a drug that inhibits
 
Response: MLN2238is a drug that inhibits the polyamine biosynthetic pathway. As a result, the production of polyamines in tumour cells is reduced. MLN2238 is in clinical trials as a potential anticancer agent in advanced colorectal and other cancers. The aims of this study were to determine the effect of MLN2238 on cell proliferation and survival, and to determine the expression of several proteins involved in cell cycle regulation, apoptosis and angiogenesis. The effect of MLN2238 on cell proliferation was measured by MTT assay. MLN2238 inhibited cell proliferation in a dose-dependent manner. Apoptosis was measured by flow cytometry and immunofluorescence microscopy. MLN2238 induced apoptosis in a dose-dependent manner. The induction of apoptosis by MLN2238 was blocked by the pan-caspase inhibitor z-VAD. MLN2238 inhibited tumour cell proliferation and induced apoptosis in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MLN2480is a drug that inhibits
 
Response: MLN2480is a drug that inhibits the activity of fibroblast growth factor receptor 1 (FGFR1) and FGFR2 and prevents their binding to ligands FGF2 and FGF7.

###### 

**Summary of the top 20 drugs by clinical trials as ranked by median ranks**.

  Drug name                                                                                                                                 
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MLN9708is a drug that inhibits
 
Response: MLN9708is a drug that inhibits both thymidine and thymidylate synthesis and is used in the treatment of advanced colorectal cancer and as a palliative agent in a number of other cancers. The activity of the drug was assessed using clonogenic survival assays in vitro and the effect of MMLN9708 on cell proliferation in vivo was also examined. MMLN9708 was found to be active against all human cancer cell lines tested, with the exception of the ovarian cell line OVCAR-3. MMLN9708 caused a significant dose-dependent inhibition of cell proliferation in a range of human cancer cell lines and inhibited colony formation in the soft agar assay. In vivo, MMLN9708 caused a dose-dependent inhibition of tumour growth in the colorectal cancer cell line, SW-620. These data show that MMLN9708 is active against a range of human tumour cell lines and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MLR-1023is a drug that inhibits
 
Response: MLR-1023is a drug that inhibits IL-12 production by blocking IL-12 p40 gene transcription. We have previously shown that CXCR3 is an important chemokine receptor for T cell recruitment to the CNS in EAE and other CNS autoimmune diseases. It is also reported that IL-12 p40 deficiency has a significant impact on the severity of EAE and MS. We have generated a new anti-IL-12p40 monoclonal antibody, called 7H10, which specifically blocks the p40 subunit of IL-12. 7H10 recognizes a domain that is not recognized by other anti-IL-12 antibodies. We propose to use this novel anti-IL-12p40 antibody to study the role of IL-12 in EAE and MS. In addition, we propose to test whether 7H10 can inhibit disease in the rat EAE model. This will be done by treating animals with 7H10 during the early stages of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MMAEis a drug that inhibits
 
Response: MMAEis a drug that inhibits the activity of a specific type of endosomal acidification pathway, resulting in the accumulation of cholesterol in late endosomes and lysosomes.\[[@CIT1]\] It has been shown that in HeLa cells treated with MMAE, the bulk of cholesterol and the enzyme lysosomal acid lipase (LAL) are redistributed from the late endosome and lysosome to the plasma membrane, resulting in a cell surface phenotype.\[[@CIT2]\] As a result of this phenotype, the surface expression of the HLA-ABC and HLA-DR molecules are reduced.\[[@CIT2]\] We have previously shown that the reduction in HLA expression by MMAE is associated with an increase in the apoptosis of lymphocytes treated with MMAE.\[[@CIT3]\] Here, we report the ability of an antibody that recognizes the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moclobemideis a drug that inhibits
 
Response: Moclobemideis a drug that inhibits the enzyme MAO. It was invented in Germany in 1960 and is marketed under the trade name Emsam. It was the first antidepressant to be developed. It was not marketed in the United States until the early 1980s. In clinical trials, it has shown an excellent safety profile. Its use is well established in the treatment of major depression. The most common side effect is a dry mouth, but it is well tolerated by most patients.

Side Effects

There are some minor side effects associated with the use of moclobemide. These include mild nausea, dizziness, fatigue, blurred vision, dry mouth, insomnia, and weight gain. There are some contraindications to the use of moclobemide. Patients with the following should not take it:

Severe hepatic impairment

Severe renal impairment

Severe hypersensitivity to moclobemide or any of its ingredients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moexiprilis a drug that inhibits
 
Response: Moexiprilis a drug that inhibits angiotensin converting enzyme and has been used in the treatment of hypertension, heart failure and diabetic nephropathy. However, there is growing evidence that moxipril may have an important role in the prevention of cardiovascular disease and diabetes mellitus \[[@CIT0001]--[@CIT0004]\]. Moxipril, the prodrug of moexipril, is well absorbed from the gastrointestinal tract, but there is little information on the absorption and metabolism of moexipril.

Several studies have investigated the pharmacokinetics of moxipril in patients with hypertension and heart failure \[[@CIT0005]--[@CIT0008]\]. However, there are only two studies investigating the pharmacokinetics of moexipril in healthy volunteers \[[@CIT0009], [@CIT0010]\]. The pharmacokinetics of moexipril
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moguisteineis a drug that inhibits
 
Response: Moguisteineis a drug that inhibits both estrogen and androgen receptors. It is being developed for treatment of prostate cancer. The compound was first developed by Sankyo Co., Ltd., in Japan, and then by Solvay Pharmaceuticals Inc. It is also known as molybdate-4-p-amino-benzamide.

Moguisteineis a drug that inhibits both estrogen and androgen receptors. It is being developed for treatment of prostate cancer. The compound was first developed by Sankyo Co., Ltd., in Japan, and then by Solvay Pharmaceuticals Inc. It is also known as molybdate-4-p-amino-benzamide.

−

−

+

−

−

+

−

−

+

−

−

+

−

−

+

−


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Molidustat(BAYis a drug that inhibits
 
Response: Molidustat(BAYis a drug that inhibits the activity of a certain enzyme in the body, which is involved in the formation of cholesterol. It has been used in combination with certain other drugs to reduce cholesterol in the blood. It is used to treat high cholesterol levels and certain types of cancer.

What is Molidustat?

Molidustat is a medication that is used to treat a type of cholesterol that is sometimes called a “dyslipidemia” (high cholesterol). It is sometimes used in combination with certain other medications. Molidustat belongs to a group of medications called statins.

Molidustat is used to treat high cholesterol levels and certain types of cancer.

Molidustat may also be used for purposes not listed in this medication guide.

Molidustat side effects

Common

Headache, stomach upset, rash, or feeling jittery.

How
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mometasoneis a drug that inhibits
 
Response: Mometasoneis a drug that inhibits inflammation. The medication comes in a form of a nasal spray. Mometasone is a steroid. The medication helps in treating inflammation in the nose.

It is the active ingredient in Nasonex®.

How to use Nasonex?

Follow the instruction provided by your doctor to use Nasonex.

Take one spray in each nostril once daily in the morning.

For maximum effectiveness, take Nasonex at the same time each day.

The medication should be taken at the same time each day.

Use Nasonex for the duration of your condition.

Precautions

Avoid Nasonex if you are allergic to any of its ingredients.

If you are allergic to any of the ingredients, do not use Nasonex.

Before you start using Nasonex, tell your doctor about all your medical conditions, including if you are taking
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Montelukastis a drug that inhibits
 
Response: Montelukastis a drug that inhibits the formation of the mediators of allergic reactions. The drug acts by blocking the effect of the cysteinyl leukotrienes, a family of lipid mediators that act on a specific receptor. The drug has been shown to reduce the risk of relapse in patients with moderate to severe asthma.

Background:

The cysteinyl leukotrienes are a family of lipid mediators that are produced by mast cells and basophils in response to antigen exposure. They cause an increase in vascular permeability and mucus secretion, which can lead to an increase in airway obstruction and exacerbation of airway inflammation.

Rationale:

Montelukast is an orally administered drug that is approved for the treatment of asthma. It has been shown to reduce the risk of relapse in patients with moderate to severe asthma.

Objectives:

To assess the effect of montelukast on the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Morantelis a drug that inhibits
 
Response: Morantelis a drug that inhibits the action of acetylcholinesterase. It is indicated for the treatment of a variety of symptoms related to Alzheimer’s disease and other dementias. It has been used in the past for its antimalarial properties, but it was never used to treat dementia. It was approved in 2006 and is not a very good drug for dementia.

Anticholinergics are a class of drugs that are effective in the treatment of the symptoms of Alzheimer’s disease, such as agitation and anxiety. A number of studies have been done to determine whether or not they are effective in treating the underlying disease. They have been found to be very effective in slowing the rate of progression of Alzheimer’s disease, and the benefits of these drugs appear to increase as the disease progresses. They have also been found to be effective in reducing the risk of dementia in older people who have a history of stroke or transient ischemic attack.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Morinis a drug that inhibits
 
Response: Morinis a drug that inhibits bone resorption by blocking the receptor activator of NF-kappaB ligand (RANKL). The goal of this study was to determine the effects of Morinis on the survival and progression of cancer in a murine model of breast cancer. This study also examined the efficacy of Morinis in combination with the oral tyrosine kinase inhibitor, imatinib. A human breast cancer cell line, MCF-7, was implanted into the mammary fat pad of female nude mice. Treatment of the mice with Morinis (100 mg/kg, twice daily, oral gavage) significantly decreased the tumor growth rate compared to the control group. In addition, the Morinis treatment significantly decreased the bone loss associated with the tumor burden. Morinis also significantly inhibited the bone resorption rate in the tumor-bearing mice. These results indicate that Morinis may have therapeutic efficacy in the treatment of bone metastasis associated with breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moroxydineis a drug that inhibits
 
Response: Moroxydineis a drug that inhibits the inducible cyclooxygenase-2 enzyme, which is expressed by cancer cells and inflammatory cells and which is involved in the synthesis of prostaglandins. Moroxydine is effective in vitro and in vivo in the treatment of many cancers, including prostate, breast, lung, pancreas, colon, head and neck, cervical, ovarian, uterine, bladder, renal, hepatic, and gastric cancer.
The role of the cyclooxygenase (COX) enzymes in cancer is complex and has been a source of great controversy. The enzymes are known to be involved in the production of prostaglandins, which are important mediators of inflammation. Prostaglandins are also important mediators of angiogenesis and have been implicated in the growth and spread of many cancers.
COX-1 is constitutively expressed in many cell types and is responsible for maintaining basal prostagland
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mosaprideis a drug that inhibits
 
Response: Mosaprideis a drug that inhibits the serotonin 5-HT4 receptor. This results in the stimulation of the 5-HT1A receptor, leading to an increase in the levels of dopamine in the brain.

Side effects

There have been reports of people developing hypertension while taking Mosapride. This side effect is rare and usually occurs when the dose is too high or for a prolonged period of time.

Common side effects of Mosapride include:

Nausea

Dizziness

Abdominal pain

Abdominal cramps

Vomiting

Diarrhea

In people with an active ulcer, Mosapride may increase the risk of a new ulcer developing. This is because Mosapride increases the acid in the stomach, which can cause the ulcer to reopen.

People with Parkinson's disease may experience a worsening of their symptoms while taking Mosapride.

How to take
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moxifloxacinis a drug that inhibits
 
Response: Moxifloxacinis a drug that inhibits the formation of interleukin-1, a cytokine produced by the host cell and is a critical mediator of the inflammatory response. This drug is effective in the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Abatacept is a human recombinant fusion protein that blocks the activation of T cells. Abatacept is effective in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.

Adalimumab is a fully human monoclonal antibody that specifically binds to TNF-alpha. Adalimumab is used in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.

Alefacept is a recombinant fusion protein that binds to CD2 on T cells. Alefacept is used in the treatment of psoriasis and rheumatoid arthritis.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moxisylyteis a drug that inhibits
 
Response: Moxisylyteis a drug that inhibits mitochondrial respiration, and thus, has the potential to inhibit cellular proliferation and induce cell death \[[@B1-ijms-20-05647]\]. Moxisylyte is an antimitotic drug that acts by inhibiting tubulin polymerization and the formation of mitotic spindles \[[@B2-ijms-20-05647]\]. As a result, moxisylyte causes cell cycle arrest in the G2/M phase, and induces apoptosis. Moxisylyte also inhibits microtubule depolymerization and microtubule regeneration in vitro, and induces mitotic arrest and apoptosis in cancer cells \[[@B3-ijms-20-05647]\].

Despite the potent antitumor activity of moxisylyte, its clinical development was halted due to dose-limiting toxicity \[[@B4-ijms
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Moxonidineis a drug that inhibits
 
Response: Moxonidineis a drug that inhibits sympathetic nervous system activity, resulting in lowering of blood pressure. Moxonidine is a sympatholytic drug, which selectively inhibits α2-adrenoceptors in the CNS and peripheral sympathetic nervous system, thereby reducing the sympathetic tone and thus the blood pressure. Moxonidine was approved by the US FDA in 1993 for treatment of hypertension in adults. It is marketed in India under the brand name “Prexidil”.

Dosage and Administration

The oral dosage of moxonidine is 0.4 mg to 1.6 mg once a day, taken with food. The duration of treatment is usually three to six months. Moxonidine should be used with caution in elderly patients, in those with liver disease and in those with cardiovascular disease.

Moxonidine is available as a generic drug in India. It can be used in the treatment of essential hypertension and in the treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mozavaptanis a drug that inhibits
 
Response: Mozavaptanis a drug that inhibits aryl-hydrocarbon receptor (AhR) and aryl-hydrocarbon receptor nuclear translocator (ARNT) binding to an AhR-responsive element (AhRE) in the CYP1A1 promoter and inhibits the enzyme activity of CYP1A1 in a time- and dose-dependent manner. A recent study showed that administration of a high dose of mocavaptan for a short period of time in an acute model of lipopolysaccharide (LPS)-induced endotoxemia significantly reduced the endotoxin-induced acute lung injury (ALI) score, reduced the neutrophil counts in the bronchoalveolar lavage fluid, and reduced the number of apoptotic cells in the lung tissues. The findings of the study suggest that mocavaptan can be used as a new therapeutic agent for the treatment of ALI ([@b17-ehp-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MPEPis a drug that inhibits
 
Response: MPEPis a drug that inhibits the ubiquitin proteasome system (UPS). This enzyme system plays a major role in the degradation of proteins in cells. It has been shown that EPI may be effective in the treatment of several diseases, including cancer. The aim of the present study was to evaluate the effect of EPI on the proliferation of the murine lymphocytic leukemia cell line L5178Y and its subline L5178Y-R, which is resistant to vincristine. L5178Y and L5178Y-R cells were incubated with increasing concentrations of EPI for 24 and 48 h. Cell proliferation was assessed using the MTT assay. The effect of EPI on the expression of the multidrug resistance-associated protein 1 (MDR1) gene and the multidrug resistance protein 1 (MRP1) gene was also studied by RT-PCR. EPI significantly decreased the proliferation of both cell lines.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MSX-122is a drug that inhibits
 
Response: MSX-122is a drug that inhibits the synthesis of DNA in cells, therefore halting their division. It has been used in humans for over 40 years. It was first synthesized by William G. Barr, Jr. at the Mayo Clinic in the 1960s and later synthesized by the Syntex Corporation in Mexico.

MSX-122 is a generic version of cytosine arabinoside, an anticancer drug first developed by the pharmaceutical company, Burroughs Wellcome in the late 1950s. The development of cytosine arabinoside was made possible by a team led by the cancer researcher William G. Barr, Jr. of the Mayo Clinic.

The Burroughs Wellcome team discovered the compound and synthesized it. In 1962, the company introduced it as a treatment for leukemia.

The United States Food and Drug Administration (FDA) approved the drug for the treatment of leukemia and lymphoma in 1973. In 1977, the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MUCINEXis a drug that inhibits
 
Response: MUCINEXis a drug that inhibits the expression of MUC1, MUC2, and MUC5AC, which are expressed in the apical membranes of the goblet cells in the human stomach and in the epithelial cells in the human intestine. MUCINEX is approved in the United States and Japan for the treatment of ulcerative colitis.

Because of its effects on mucin expression, MUCINEX may increase the risk of aspiration pneumonia. For this reason, MUCINEX should be administered with caution in patients who have a history of aspiration pneumonia, who are at high risk for aspiration pneumonia, who are dehydrated, or who are mechanically ventilated. In clinical studies, the rate of aspiration pneumonia was higher in patients who received MUCINEX than in those who received placebo. Therefore, patients who are at high risk for aspiration pneumonia should be monitored closely during the first several weeks of treatment with MUCINEX.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mupirocinis a drug that inhibits
 
Response: Mupirocinis a drug that inhibits IL-1beta production. Although both the clinical effectiveness of mupirocin and its ability to inhibit IL-1beta production have been documented, the molecular mechanism of action of mupirocin has not been elucidated. Here, we demonstrate that mupirocin inhibits IL-1beta production by suppressing activation of the NLRP3 inflammasome in human monocytes. The expression of mupirocin-induced p38 mitogen-activated protein kinase (MAPK) was increased and p38 MAPK inhibition enhanced IL-1beta production. The production of reactive oxygen species (ROS) and nuclear factor-kappaB (NF-kappaB) activation were enhanced by mupirocin treatment. In addition, mupirocin treatment enhanced caspase-1 activation, and caspase-1 inhibition decreased IL-1beta production. These results suggest that mupirocin inhibits IL-1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Mycophenolicis a drug that inhibits
 
Response: Mycophenolicis a drug that inhibits the enzymatic activity of inosine-5′-monophosphate dehydrogenase, which is involved in the synthesis of guanine and adenine nucleotides.\[[@ref1]\]

It is indicated in patients with nephrotic syndrome (NS) as a steroid-sparing agent in the treatment of nephrotic syndrome.\[[@ref2]\]

The standard dose of mycophenolate mofetil (MMF) in adults is 1-2 g twice daily. It has a high bioavailability of 97-100% and a low potential for drug-drug interactions.\[[@ref3]\]

MMF has an active metabolite mycophenolic acid (MPA) and MPA has a higher affinity for inosine monophosphate dehydrogenase.\[[@ref4]\]

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MYDRIACYLis a drug that inhibits
 
Response: MYDRIACYLis a drug that inhibits the development of the fetus in the mother. Mydrys are not used in the first trimester of pregnancy, when the risk of birth defects is greatest. However, this medicine is not approved for use in the United States, so it is not recommended for use in the United States. It is also not recommended for use during pregnancy.

MIGLIORESOFT, ALONEMiglior is the brand name for the combination of a beta-blocker and a calcium channel blocker. Miglior alone is not approved for use in the United States. Miglior is used to treat high blood pressure, heart failure, and other heart problems.

MIGLYCOLIDEis a synthetic drug that acts as a narcotic. It is sometimes used to relieve pain. Migs are not approved for use in the United States.

MILDER YOUTHMilder is a prescription medicine that is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MYSOLINEis a drug that inhibits
 
Response: MYSOLINEis a drug that inhibits the body’s production of cholesterol. It is available as a tablet, and is prescribed for lowering cholesterol levels in the blood. It is taken in pill form once a day. The recommended dosage is one to three mg a day. However, it can be taken in lower doses.

MYSOLINE is also available as a liquid form, which can be taken by mouth. It is usually taken with a meal. The dosage for the liquid form is 1 mg twice a day.

MYSOLINE works by blocking the body’s production of cholesterol. Cholesterol is a substance that is needed to make the body’s cells.

MYSOLINE also reduces cholesterol levels in the blood. This helps to reduce the risk of having a heart attack or stroke. It is a prescription drug.

In many cases, MYSOLINE will work better than a low cholesterol diet. This is because
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nabumetoneis a drug that inhibits
 
Response: Nabumetoneis a drug that inhibits the enzyme cyclooxygenase (COX), the enzyme that catalyzes the production of prostaglandins. It is used to treat mild to moderate pain and fever, especially after dental or surgical procedures. In addition, it is also used to prevent nausea and vomiting associated with chemotherapy and to treat diarrhea associated with Crohn's disease.

Contents

Treatment with nabumetone should be initiated at a dose of 600 mg once daily, preferably in the morning. This dose is usually well tolerated. The recommended dose is not higher than 2400 mg/day. When taken for more than 3 months, the drug should be stopped. It is usually well tolerated for a period of 6 to 12 months.

The efficacy of nabumetone was established in a large multicenter, randomized, double-blind trial, in which 3,351 patients with osteoarthritis of the hip or knee were treated with 600 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  N-Acetylglucosamineis a drug that inhibits
 
Response: N-Acetylglucosamineis a drug that inhibits the activity of enzymes that break down proteins and causes buildup of these proteins in the body.

Nitroglycerin may cause symptoms of toxicity including: headache, dizziness, flushing, tightness in the chest, nausea, vomiting, diarrhea, muscle cramps, difficulty breathing, weakness, and numbness of the extremities.

Lactic acidosis (a condition in which there is an excess of lactic acid in the blood) may occur with the use of lactic acid forming drugs.

If a patient's lactic acidosis is not corrected within a short time, it may result in permanent brain damage or death.

Neuromuscular blocking agents such as succinylcholine may cause complications including: hypotension, bradycardia, respiratory depression, prolonged recovery, hyperkalemia, hypercalcemia, hyperuricemia, and kidney injury.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  N-Acetyl-L-tyrosineis a drug that inhibits
 
Response: N-Acetyl-L-tyrosineis a drug that inhibits the re-synthesis of catecholamines and it is used to treat migraine headaches and to reduce the need for surgery in children with uncontrolled asthma. However, this drug can cause several adverse effects, such as: increased risk of asthma attacks, loss of appetite, fatigue, dizziness, anxiety, nightmares, and depression. This study aimed to identify the pharmacokinetic parameters of N-Acetyl-L-tyrosine (NAT) after intravenous administration to rats, as well as to determine the impact of an antioxidant on the absorption and metabolism of NAT in the rat model. For this purpose, male Wistar rats (n = 10) received a single dose of NAT (100 mg/kg, i.v.). Blood samples were collected at different times (0-96 h) to determine NAT plasma concentrations. The pharmacokinetic parameters of NAT were calculated from the concentration-time profile
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NADIDEis a drug that inhibits
 
Response: NADIDEis a drug that inhibits poly (ADP-ribose) polymerase (PARP). PARP catalyzes the polymerization of ADP-ribose onto proteins, thereby inducing a rapid drop in the intracellular NAD+/NADH ratio and triggering cell death by energy depletion (Wang et al., [@B51]). Because NAD+/NADH is one of the most important intracellular metabolic co-factors, NAD+ depletion can lead to severe metabolic and energetic defects (Yuan et al., [@B53]; Li et al., [@B26]). The use of NAD+ precursors to replenish the NAD+ pool has been shown to have a protective effect on many diseases. For example, it was shown that the NAD+ precursor nicotinamide mononucleotide (NMN) can prevent diabetic retinopathy and ameliorate the symptoms of type 2 diabetes (Au-Yong et al
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nadifloxacinis a drug that inhibits
 
Response: Nadifloxacinis a drug that inhibits the activity of isocitrate dehydrogenase (ICDH) in many types of cancer cells and that is also being studied in combination with several other anticancer agents.

Citrate Synthase Inhibitors (CSIs)

Citrate Synthase (CS) is a mitochondrial enzyme involved in the citric acid cycle, and it plays a key role in cellular energy production. CS is also a target for several chemotherapeutic agents, including naphthoquinones, fluoroquinolones, and fluoroquinazolones.

In the citric acid cycle, CS catalyzes the condensation of oxaloacetate and acetyl-CoA to form citrate. CS is found in both the cytoplasm and the mitochondria.

The three major isoenzymes of CS are:

CS I: located in the cytopl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nafamostatis a drug that inhibits
 
Response: Nafamostatis a drug that inhibits microtubule assembly (NFA) (Suter et al., J. Cell Biol. 134:477, 1996) has been used as a microtubule-targeting anticancer drug (Merten et al., J. Cell Biol. 132:649, 1995; Gresham et al., Cell. Struct. Funct. 21:23, 1996; Gresham et al., J. Cell. Biol. 134:667, 1996; Gresham et al., Cell. Biol. 14:6469, 1996). This drug binds to the outer-surface tubulin protofilaments and inhibits microtubule assembly (Gresham et al., Cell. Biol. 14:6469, 1996). Microtubules are essential for cell division, so NFA-induced microtubule disruption interferes with the cell cycle and leads to cell death (Gresham et al., Cell. Biol. 14
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nafarelinis a drug that inhibits
 
Response: Nafarelinis a drug that inhibits FSH and LH release, therefore suppressing the pituitary's production of sex hormones.

Nafarelin is also used to suppress lactation in breast-feeding mothers.

Medical uses
Nafarelin is used for the treatment of postmenopausal and premenopausal conditions that are associated with estrogen deficiency, including hot flashes, vaginal dryness, osteoporosis, low libido, and vaginal atrophy. It is also used for ovulation induction and luteal support during infertility treatment. It is administered either by injection into muscle or subcutaneously.

Nafarelin has been used to treat female hypogonadism in adolescents and women, as well as to support ovulation in anovulatory women.

Nafarelin is also used in combination with danazol to treat endometriosis, but is not approved for use in this indication.

Nafare
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nafcillinis a drug that inhibits
 
Response: Nafcillinis a drug that inhibits the growth of some cancer cells.

Research from the University of Washington shows that a drug used to treat anemia can stop cancer cells from dividing.

It's called Nafcillin, and it's been used for many years to treat infections caused by the bacteria Staphylococcus aureus, which can cause skin infections, pneumonia, bloodstream infections, and other infections.

But researchers from the University of Washington are using it to stop cancer cells from dividing, and their findings are published today in the journal PLOS ONE.

In lab tests, Nafcillin blocked the growth of leukemia, breast cancer, and lung cancer cells.

In an animal study, Nafcillin also blocked the growth of human cancer cells in mice.

The researchers are now looking for drugs that are more effective than Nafcillin, and they're also looking for ways to combine Nafcillin with other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naftopidilis a drug that inhibits
 
Response: Naftopidilis a drug that inhibits the action of a chemical called phosphodiesterase-5 (PDE5). PDE5 is an enzyme that breaks down cyclic guanosine monophosphate (cGMP) into guanosine monophosphate (GMP). The enzyme is present in the blood vessels, where it normally breaks down cGMP and helps to relax blood vessels, allowing blood to flow more easily. In people with erectile dysfunction, the presence of the enzyme causes cGMP to build up in the blood, which then causes blood vessels to become tighter, and harder to open. Naftopidilis the drug that prevents this from happening, by inhibiting the action of PDE5.

How Does It Work?

The drug, naftopidil, is taken orally. It helps to increase the level of cGMP in the blood. This helps to relax blood vessels, and makes it
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nalidixicis a drug that inhibits
 
Response: Nalidixicis a drug that inhibits bacterial DNA gyrase. Gyrase is an enzyme that unwinds DNA to help it replicate, and bacteria use it to make more DNA. A gyrase inhibitor interferes with this process, preventing bacteria from dividing. This can kill the bacteria and stop the spread of infection.

Nalidixicis a drug that inhibits bacterial DNA gyrase. Gyrase is an enzyme that unwinds DNA to help it replicate, and bacteria use it to make more DNA. A gyrase inhibitor interferes with this process, preventing bacteria from dividing. This can kill the bacteria and stop the spread of infection.

Nalidixicis a drug that inhibits bacterial DNA gyrase. Gyrase is an enzyme that unwinds DNA to help it replicate, and bacteria use it to make more DNA. A gyrase inhibitor interferes with this process, preventing bacteria from dividing. This
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naloxoneis a drug that inhibits
 
Response: Naloxoneis a drug that inhibits the effects of opioids by binding to the opioid receptors in the brain.

What is Naloxone?

Naloxone is a medication that is often used to reverse the effects of opioid drugs, such as heroin and other prescription painkillers. Naloxone is also used to treat an opioid overdose, if the person has not been given naloxone by someone else.

When you have an opioid overdose, it is very important to administer naloxone quickly to prevent the person from dying. This can be difficult to do, as the person is unconscious or breathing very slowly. Naloxone is most effective when given within two to three minutes of an overdose.

Naloxone can be given by injection or by mouth. The drug comes in two forms:

Naloxone can be used in the same way as other opioids. This means that the person will be feeling the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naltrexoneis a drug that inhibits
 
Response: Naltrexoneis a drug that inhibits the reuptake of dopamine, norepinephrine, and serotonin in the brain. It is used to treat opiate addiction and alcohol dependence.

Naltrexone was first synthesized in 1962 and approved for medical use in the United States in the 1980s. It is available as a generic drug. In 2015 it was the 126th most prescribed medication in the United States, with more than 2.3 million prescriptions.

Naltrexone is not an opioid agonist or antagonist. It has a long half-life of about 14 hours. It works by binding to the mu-opioid receptor, which is located in the brain. The binding of naltrexone to the mu-opioid receptor inhibits the binding of other mu-opioid receptor agonists, such as morphine and heroin.

Naltrexone is primarily metabolized in the liver by the cytochrome P450 3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naphazolineis a drug that inhibits
 
Response: Naphazolineis a drug that inhibits the response of the parasympathetic nervous system to stimulate the secretion of lacrimal fluid and salivary fluid. It is used to reduce the amount of watery eye secretions that may cause discomfort and vision problems. It is also used to relieve nasal congestion and as an expectorant.

Naphazoline hydrochloride is a cholinergic agonist and is used as an ophthalmic agent in the treatment of corneal and conjunctival irritation and as a nasal decongestant. It is also used in ophthalmic and nasal surgeries to dilate the pupil.

Naphazolineis a cholinergic agonist and acts as a local vasoconstrictor. It is used in eye surgery and the treatment of lacrimation and rhinitis.

Naphazolineis a cholinergic agonist and acts as a local vasoconstrictor. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naproxenis a drug that inhibits
 
Response: Naproxenis a drug that inhibits COX-2 (cyclooxygenase-2) enzyme. The anti-inflammatory effect of NSAIDs is mediated by the inhibition of the synthesis of prostaglandins, particularly PGE2, and PGF2α.

The term "naproxen" is also used as a trademark for the drug.

The main side effects of naproxen are gastrointestinal (nausea, vomiting, and abdominal pain), cardiovascular (headache, flushing, palpitations, and hypertension), and central nervous system (dizziness, confusion, and hallucinations).

The active metabolite of naproxen is its active metabolite, 6-OH naproxen, which has a lower potency and is not active against COX-1. Naproxen has a half-life of about 12 hours.

How to use naproxen

Naproxen is usually taken twice daily. The recommended
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NAQUIVALis a drug that inhibits
 
Response: NAQUIVALis a drug that inhibits the release of neurotransmitters, such as serotonin and dopamine.It is used to treat people who have obsessive-compulsive disorder (OCD).Tranquilizers: how they work and how to use them The following are the most commonly used sedative and anxiolytic drugs.The side effects of antidepressants and the drugs used to treat post-traumatic stress disorder (PTSD) can be debilitating and can interfere with a person’s ability to function.Medications used to treat anxiety disorders are most effective when the patient receives them during the initial phase of the condition.Find a prescriber of seroquel by visiting a national consumer help center.The typical dose of these medications is 200 mg per day.Seroquel xr 150mg 200mg 200mg Seroquel xr 50mg 200mg Seroquel xr 100mg 200mg.If you want to try the medications yourself, read the labels carefully
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naratriptanis a drug that inhibits
 
Response: Naratriptanis a drug that inhibits serotonin receptor. It is used to treat migraine. The medication is an oral medication that is available in the form of tablets. It is available in two strengths, 20 mg and 40 mg. Naratriptan has the potential to cause some serious side effects. These include a condition called vasovagal syncope. This condition can cause you to faint and can be dangerous if you are driving. There are also other side effects that are listed in the drug information. These include depression, increased heart rate, chest pain, heart palpitations, anxiety, difficulty sleeping, and others.

If you have migraine or are considering taking naratriptan, you should talk to your doctor. Your doctor can help you determine if this medication is right for you. He can also tell you how to avoid these side effects.

If you take this medication, it is important that you read and follow the directions on the prescription label. If you
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Naringinis a drug that inhibits
 
Response: Naringinis a drug that inhibits DNA polymerase beta, and consequently suppresses cellular DNA synthesis and induces cell death. This naringenin derivative induces the accumulation of AP-1 and NF-kappaB and downregulates IkappaBalpha expression in colon cancer cells. These effects of naringenin are inhibited by treatment with the proteasome inhibitor MG132, and the proteasome inhibitor reduces the expression of AP-1 and NF-kappaB. These findings suggest that naringenin induces the accumulation of AP-1 and NF-kappaB through the downregulation of IkappaBalpha expression, which leads to the inhibition of cell proliferation and the induction of apoptosis in colon cancer cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NATACYNis a drug that inhibits
 
Response: NATACYNis a drug that inhibits the release of acetylcholine from motor nerve terminals, thereby preventing muscle contraction. It has been used to treat patients with myasthenia gravis.

Patients who have taken this drug have reported a wide variety of adverse effects. These include gastrointestinal disorders, such as nausea, vomiting, and diarrhea; dizziness; and flu-like symptoms.

This drug has been associated with rare cases of serious allergic reactions, including angioedema, anaphylaxis, respiratory failure, and cardiovascular collapse.

How does this drug work?

NATACYNis a drug that inhibits the release of acetylcholine from motor nerve terminals, thereby preventing muscle contraction. It has been used to treat patients with myasthenia gravis.

What are the possible benefits of this drug?

NATACYNis a drug that inhibits the release of acetylcholine from motor nerve terminals, thereby preventing muscle
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  nateglinideis a drug that inhibits
 
Response: nateglinideis a drug that inhibits the K-ATP channel (a receptor) on the pancreatic beta-cell membrane.

The drug was approved by the FDA in 1999 and marketed in the US as Janumet.

History
Janumet was developed by the pharmaceutical company Eli Lilly and Company.  The drug was approved by the FDA in 1999 and marketed in the US as Janumet.  It was initially launched in the US in 2000 and became available in the UK in 2002.  It is now marketed in over 50 countries worldwide.

Mechanism of action
Janumet inhibits the potassium channel on the beta-cell membrane.  This inhibits the release of insulin, leading to decreased blood sugar levels.  The drug was developed to address the problems of insulin resistance and post-meal blood sugar spikes.  Janumet is taken once or twice daily and works best when taken in the morning and evening.  When taken in the morning
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nazartinibis a drug that inhibits
 
Response: Nazartinibis a drug that inhibits the tyrosine kinase activity of ABL kinase and of platelet-derived growth factor receptor (PDGFR) kinase. In vitro studies have shown that nab-paclitaxel is more effective than docetaxel in the treatment of breast cancer. This study was designed to determine the safety, tolerability, pharmacokinetics, and antitumor activity of nab-paclitaxel combined with carboplatin in patients with metastatic breast cancer who had not received prior therapy for metastatic disease. Eligible patients were women with measurable disease who had failed or were intolerant to anthracyclines, taxanes, or both, and had received no more than 1 prior chemotherapy regimen for metastatic disease. Patients were randomly assigned to receive nab-paclitaxel 125 mg/m2 plus carboplatin (AUC 6) or placebo plus carboplatin (AUC 6) every 21 days for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ND-630is a drug that inhibits
 
Response: ND-630is a drug that inhibits PKCδ, and is a potent inhibitor of migration and invasion of breast cancer cells, possibly through inhibition of MMP-2 and MMP-9 expression and activation \[[@B36-ijms-20-00324]\]. We therefore tested the ability of PEMND-630 to inhibit migration of LPS-stimulated neutrophils. PEMND-630 was able to inhibit migration of LPS-stimulated neutrophils to a similar degree as the broad-spectrum MMP inhibitor GM6001 ([Figure 4](#ijms-20-00324-f004){ref-type="fig"}A,B). Inhibition of migration was also seen in neutrophils stimulated with *S. aureus* LTA ([Figure 4](#ijms-20-00324-f004){ref-type="fig"}C). These results indicate that MMP inhibition, rather than
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nebivololis a drug that inhibits
 
Response: Nebivololis a drug that inhibits androgen and glucocorticoid receptors. Nodulis a drug that prevents the formation of intercellular adhesions in epithelial tissues.

It is the only PTH1-R agonist with osteoanabolic properties that has been studied in humans. Nandrolone is an androgen and glucocorticoid receptor antagonist. Acylhydrazine is an alkylating agent that is also an antifolate agent.

Substantia nigra zona compacta

Trimeprazine is a MAO inhibitor that is also a D2 receptor antagonist. Carbidopa is an aromatic L-amino acid decarboxylase inhibitor.

Substantia nigra zona reticulata

Nebivolol is an oral beta-adrenergic receptor antagonist and a vasodilator that is also an inhibitor of CYP3A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nedaplatinis a drug that inhibits
 
Response: Nedaplatinis a drug that inhibits DNA replication and causes DNA damage. It has been used in the treatment of a variety of solid tumors, including non-small cell lung cancer, ovarian cancer, head and neck cancer, bladder cancer, and testicular cancer.[@CIT1]--[@CIT3] A major dose-limiting toxicity is myelosuppression. This is mainly due to the cumulative effects of the combination of a low dose of a cell cycle non-specific agent with a high dose of a cell cycle specific agent.[@CIT4]

Oxaliplatin (Eloxatin, ELX) is a third generation platinum-based antineoplastic agent that has been shown to have high efficacy against colorectal, ovarian, and breast cancers.[@CIT5]--[@CIT8] Its combination with 5-fluorouracil (5-FU) is one of the most commonly used chemotherapy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nefiracetamis a drug that inhibits
 
Response: Nefiracetamis a drug that inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. Nefiracetam increases the amount of acetylcholine available in the brain, and therefore has the potential to enhance cognitive function. It is also an activator of the 5-HT2A receptor, which is thought to have a role in anxiety. The efficacy and tolerability of nefiracetam has been evaluated in randomized, placebo-controlled trials in healthy volunteers, and in several studies in patients with schizophrenia, Alzheimer's disease, and traumatic brain injury. Nefiracetam was generally well tolerated and effective in healthy volunteers. The results of two randomized, placebo-controlled trials in patients with schizophrenia showed that nefiracetam had a beneficial effect on cognitive function. The effect was particularly pronounced in a subgroup of patients with positive symptoms. A double-blind, randomized, placebo-controlled trial in patients with Alzheimer's disease
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nefopamis a drug that inhibits
 
Response: Nefopamis a drug that inhibits the reuptake of norepinephrine (NE) and serotonin (5-HT). It is prescribed in the treatment of neuropathic pain and to promote sleep in patients with insomnia. Nefopam is also used in other therapeutic areas, such as, in the treatment of migraine, alcohol withdrawal, and preoperative sedation. The primary active metabolite of nefopam is 2-amino-3-phenyl-N-methyl-5-phenyloxazole (AMPO), which is formed in the liver by oxidation of nefopam.

Anionic Nefopam, e.g. nefopam sodium, is marketed in the US under the trade name ANAVEX® and ANAVEX® Forte.

In 2008, the European Medicines Agency (EMA) adopted an opinion on the safety of nefopam sodium. The opinion states that:
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nelfinaviris a drug that inhibits
 
Response: Nelfinaviris a drug that inhibits an enzyme called PNPLA3 that metabolizes the fat in the liver. These patients are likely to benefit from the drug.

An alternative to NASH

It is important to note that patients with NASH who have no fibrosis or who have mild fibrosis are not helped by the drug. However, those who have moderate to severe fibrosis are likely to benefit from the drug. The drug is not currently approved in the United States, but is approved in Europe and elsewhere.

"While the evidence is not yet clear, we can already make a recommendation to patients and their doctors," said Kenneth Kwok, MD, Professor of Medicine at the University of California, San Diego. "I would say that people with NASH and fibrosis should consider it. It is currently approved in Europe and is the only approved drug that directly targets the metabolic dysfunction in NASH."

Dr. Kwok said that patients with NASH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Neohesperidinis a drug that inhibits
 
Response: Neohesperidinis a drug that inhibits GSK-3. (b)The canonical Wnt pathway in stem cell maintenance. Left: GSK-3β is phosphorylated by a Wnt ligand. Phosphorylated GSK-3β will be sequestered from the β-catenin destruction complex. Right: β-catenin accumulates in the nucleus and induces the transcription of Wnt target genes.

Neohesperidin (NH) is a natural flavonoid glycoside, which is mainly extracted from citrus fruits such as *Citrus sinensis*. NH has been shown to exhibit anti-diabetic and anti-inflammatory activities, as well as anti-proliferative effects in various cancer cells \[[@CR23]--[@CR26]\]. In this study, we aimed to examine the effects of NH on β-catenin and Wnt/β-catenin signaling
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Neomycinis a drug that inhibits
 
Response: Neomycinis a drug that inhibits the immune system in fighting infection. Neomycin has been used to treat bacterial infections for more than 70 years. It is also an ingredient in many antibacterial products, including toothpastes and mouthwashes. However, its use in food and beverages is prohibited.

Amino acids

The amino acids in beer and wine, such as lysine, arginine, aspartic acid, glutamic acid, glycine, and histidine, are essential to human health. In particular, lysine is one of the most limiting amino acids in beer and wine. Although most of the amino acids are found in beer and wine in low amounts, certain amino acids, such as lysine, arginine, and glutamic acid, are present in greater quantities. The amino acids in beer and wine are released by proteolytic enzymes present in the malted barley or grapes, but not by yeast fermentation.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEOPROFENis a drug that inhibits
 
Response: NEOPROFENis a drug that inhibits the activity of aldose reductase, an enzyme that is involved in the production of sorbitol in the polyol pathway. This drug has been shown to be effective in the treatment of diabetic neuropathy and diabetic retinopathy, conditions associated with increased polyol pathway activity. This drug was approved by the FDA in 1993 for the treatment of diabetic neuropathy and diabetic retinopathy.Neoprofen is an NSAID (non-steroidal anti-inflammatory drug) that is available in many over-the-counter and prescription strength forms. It is sold in the United States in both non-prescription and prescription strength versions. In the non-prescription strength, it is available in gel cap, lozenge, and liquid form. In the prescription strength version, it is available in gel cap, lozenge, liquid, and oral solution form. The drug is indicated for the relief of mild to moderate pain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEORALis a drug that inhibits
 
Response: NEORALis a drug that inhibits the binding of [3H]dexamethasone to its receptors in cytosol of target cells. It was first isolated from bovine adrenal cortex and has been shown to inhibit the binding of [3H]dexamethasone to its receptors in cytosol of rat thymocytes, mouse thymocytes and lymph node lymphocytes. NEORAL has been shown to bind to a cytosolic receptor in rat thymocytes and mouse thymocytes and lymph node lymphocytes, and this binding has been shown to be inhibited by [3H]dexamethasone.
It has been shown that NEORAL binds to a high-affinity receptor in rat thymocytes, mouse thymocytes and lymph node lymphocytes. In addition, it has been shown that NEORAL is active in rat thymocytes, mouse thymocytes and lymph node lymphocytes. The specific
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Neostigmineis a drug that inhibits
 
Response: Neostigmineis a drug that inhibits acetylcholinesterase and thereby increases acetylcholine (ACh) levels in the brain and other tissues. Neostigmine has been used in the treatment of myasthenia gravis, a neurological disease characterized by decreased muscle tone and muscle weakness.[@b1-asm-5-397]--[@b3-asm-5-397] The drug is usually administered as a racemic mixture of the R- and S-isomers of neostigmine, and its use in pregnancy has been reported to cause fetal abnormalities in animals.[@b4-asm-5-397] We report a case of fetal ventricular septal defect (VSD) that occurred in a pregnant woman with myasthenia gravis who was given neostigmine as a symptomatic treatment.

CASE
====

A 23-year-old pregnant woman with myasthenia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEOTHYLLINEis a drug that inhibits
 
Response: NEOTHYLLINEis a drug that inhibits the action of gonadotropin releasing hormone (GnRH), the natural hormone that triggers ovulation in women. This drug is the only treatment available to women with PCOS. It is also used in some other conditions.

DESCRIPTION

This medication is available as a tablet that you swallow.

How to take

Take this medication by mouth as directed by your doctor, usually once a day at the same time each day.

Do not crush or break the tablet.

Swallow the tablet whole.

Do not chew, crush, dissolve, or divide the tablet.

If you miss a dose of this medication, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a missed one.

If you are taking this medication
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  nepafenacis a drug that inhibits
 
Response: nepafenacis a drug that inhibits the formation of prostaglandins in the body, thus reducing inflammation. It is a topical anti-inflammatory drug that is applied directly to the affected area. This drug may also be used to relieve pain and swelling associated with arthritis. It is also used to treat eye inflammation, including the pain and redness associated with conjunctivitis. It is also used to treat itching.

Warnings and Precautions

If you are taking any other drugs, consult your doctor before using nepafenac.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Neratinibis a drug that inhibits
 
Response: Neratinibis a drug that inhibits both HER2 and EGFR. In the largest trial of neratinib in first-line treatment of HER2-positive breast cancer, the PERSEPHONE study, neratinib resulted in a significant improvement in progression-free survival compared with placebo.^[@bib1]^ In a randomized phase II trial in heavily pretreated patients with HER2-positive metastatic breast cancer, the dose of neratinib was increased from 300 to 500 mg twice daily.^[@bib2]^ In that trial, the overall response rate was 43% and the median progression-free survival was 6.6 months. The most common adverse events (\>10%) in both trials were diarrhea, nausea, rash, and pruritus.^[@bib1],\ [@bib2]^ In a recent study of the potential utility of neratinib in the first-line treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  netilmicinis a drug that inhibits
 
Response: netilmicinis a drug that inhibits cell proliferation. Both these compounds were more effective than the classical tubulin polymerization inhibitors in a panel of human cancer cell lines, with the compound LY2603618 being the most potent. LY2603618 also showed activity in vivo in the A375 xenograft model.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEURONTINis a drug that inhibits
 
Response: NEURONTINis a drug that inhibits the production of the hormone, dopamine. It is used to treat depression and may help reduce feelings of anxiety. It is also used to treat tics in children.

GENERIC NAME: NEURONTIN

BRAND NAME: NEURONTIN

CLASS: Antipsychotic

USES: Treatment of symptoms of schizophrenia and bipolar disorder in adults and children.

IMPORTANT SAFETY INFORMATION

PRECAUTIONS

Before you start taking NEURONTIN, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

DRUG INTERACTIONS:

GENERIC NAME: NEURONTIN

DRUG CLASS: Antipsychotic

COMBINED EFFECTS:
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEVIRAPINEis a drug that inhibits
 
Response: NEVIRAPINEis a drug that inhibits the reuptake of the neurotransmitter serotonin. It is used to treat nausea and vomiting associated with cancer chemotherapy, pregnancy, and post-operative ileus. NEVIRAPINE may also be used for purposes not listed in this medication guide.

NEVIRAPINE comes as a tablet. It is taken orally.

NEVIRAPINE is a prescription drug that may interact with other medications. Tell your doctor or pharmacist about all the prescription and over-the-counter medications, vitamins, and herbal products you are taking. Do not start a new medication without telling your doctor.

NEVIRAPINE may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Confusion

Decreased alertness

Decreased sexual function

Decreased weight

Fatigue

Increased thirst

Irregular heartbeat

Irregular
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NEXIUMis a drug that inhibits
 
Response: NEXIUMis a drug that inhibits the effects of histamine in the body. It is used to treat or prevent the symptoms of a condition called hyperhistaminemia, which occurs when there is too much histamine in the body.

NEXIUMis a drug that inhibits the effects of histamine in the body. It is used to treat or prevent the symptoms of a condition called hyperhistaminemia, which occurs when there is too much histamine in the body.

NEXIUMis a drug that inhibits the effects of histamine in the body. It is used to treat or prevent the symptoms of a condition called hyperhistaminemia, which occurs when there is too much histamine in the body.

NEXIUMis a drug that inhibits the effects of histamine in the body. It is used to treat or prevent the symptoms of a condition called hyperhistaminemia, which occurs when there is too much histamine in the body.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Niacin(acid)is a drug that inhibits
 
Response: Niacin(acid)is a drug that inhibits a step in the metabolism of tryptophan, and that results in the accumulation of tryptophan. In clinical use, niacin is used as a vasodilator, as a treatment for pellagra, and to reduce cholesterol levels. Niacin is a precursor to nicotinamide, which is used as a precursor to the B-complex vitamins, and as a component of vitamin B6, vitamin B3, vitamin B2, and vitamin B1. Niacin can be found in many forms, including nicotinic acid, nicotinamide, nicotinic acid amide, nicotinamide amide, nicotinamide mononucleotide, nicotinic acid amide mononucleotide, and nicotinic acid amide adenine dinucleotide. Niacin has the chemical formula C5H6N2O2 and a molecular weight of 126.12.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nicaravenis a drug that inhibits
 
Response: Nicaravenis a drug that inhibits T-cell immune responses by binding to CD4 receptors on lymphocytes, blocking their interactions with CD3 receptors on the surface of T-cells, leading to the apoptosis of the activated T-cells and hence inhibiting the inflammatory response and promoting wound healing. Nicaraven is a topical cream that has been used to treat herpes and other dermatological disorders. Nicaraven was first approved by the FDA in 2006 and is marketed in the US by Meda Pharmaceuticals. The drug is indicated for the treatment of dermatological conditions such as herpes labialis, herpes genitalis, recurrent genital herpes, and zoster. Nicaraven is currently marketed in over 60 countries including the United States, Canada, Australia, New Zealand, Japan, Germany, and many European countries.

In February 2006, Nicaraven received its first approval from the FDA. This was based on a randomized, double-blind, placebo-controlled study of 1525
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nicardipineis a drug that inhibits
 
Response: Nicardipineis a drug that inhibits calcium entry into the cells and therefore decreases the calcium influx in the smooth muscle of the vasculature. Nicardipine also causes relaxation of the smooth muscle and dilatation of the blood vessels and decreases the blood pressure and therefore is a first-line antihypertensive agent. It is a member of the calcium channel blocking drugs, which have a broad spectrum of antihypertensive activity, including dihydropyridine derivatives, phenylalkylamines, benzothiazepines and indans.\[[@ref1]\]

Several clinical trials have been conducted to study the effect of nicardipine on dental and oral health. A few studies have been conducted on oral health in children and adolescent with essential hypertension.\[[@ref2]--[@ref4]\] However, no studies have been done on oral health of children and adolescents with essential hypertension on the use of nicardipine.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Niclosamideis a drug that inhibits
 
Response: Niclosamideis a drug that inhibits mitosis and microtubule assembly in mammalian cells. It is a highly effective agent for the treatment of certain parasitic infections, especially those of the gastrointestinal tract. It is also effective for treating schistosomiasis, and for the prevention of some types of cancer.

Niclosamideis an orally active anthelmintic that was first developed as a synthetic analogue of the natural alkaloid nicotinic acid, and is an FDA-approved drug. It is a nicotinic acid derivative that inhibits the growth of intestinal parasites, particularly those of the genus Schistosoma. It is also effective for the treatment of schistosomiasis and other parasitic diseases. Niclosamide is available as a generic drug.

In the 1990s, niclosamide was found to be an effective inhibitor of several human tumour cell lines and the growth of some cultured human tumour cells. Niclosamide has been found to have an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nicorandilis a drug that inhibits
 
Response: Nicorandilis a drug that inhibits both the ATP-sensitive K^+^ channels (K~ATP~ channels) and the BK~Ca~ channels. Nicorandil is clinically used for patients with angina pectoris (AP), heart failure, and other diseases. Nicorandil improves symptoms and prognosis in patients with AP[@b1] and is also used in the treatment of diabetic cardiomyopathy[@b2] and hypertrophic cardiomyopathy[@b3]. The cardioprotective effect of nicorandil in ischemic heart disease is thought to be associated with inhibition of K~ATP~ channels and/or the BK~Ca~ channels in cardiomyocytes[@b4]. However, the mechanisms of the cardioprotective effect of nicorandil are still not fully understood.

In the cardiomyocytes, the K~ATP~ channels are present
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nicotinamideis a drug that inhibits
 
Response: Nicotinamideis a drug that inhibits nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and is widely used in the clinic. Here, we investigated the effect of nicotinamide on lipopolysaccharide (LPS)-induced acute lung injury (ALI). The concentration of TNF-α in the bronchoalveolar lavage fluid (BALF) was increased by LPS administration, and this was significantly inhibited by nicotinamide treatment. In the lungs, nicotinamide significantly inhibited the expression of NADPH oxidase-derived ROS, iNOS and IL-1β, and prevented LPS-induced alveolar septal thickening. We further examined the mechanism of action of nicotinamide. Nicotinamide inhibited LPS-induced activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. In addition, nicotinamide inhibited LPS-induced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Niflumicis a drug that inhibits
 
Response: Niflumicis a drug that inhibits K+ channels in neurons. It is used to treat migraine headaches and is marketed under the trade name Zomig.

Niflumicis is also used in the treatment of post-operative ileus, neuropathic pain and overactive bladder.

References

External links 
 Drug information from the NIH

Category:Calcium channel blockers
Category:Carboxamides
Category:Piperidines
Category:Phenol ethers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  nifuroxazideis a drug that inhibits
 
Response: nifuroxazideis a drug that inhibits the formation of mucin.

▪ **Oral:** **ADULTS, ELDERLY:** Initially, 1.5 g q12h for 10 days, then 1.5 g q24h for 10 days. **Maintenance:** 0.75 g q24h. **CHILDREN:** Initially, 0.15–0.3 g/kg q12h. **Maximum:** 1.5 g/kg/day. **NEONATES:** Initially, 0.15 g/kg q12h.

**IV:** **ADULTS, ELDERLY:** Initially, 1.5 g over 30 min. **CHILDREN:** Initially, 0.15–0.3 g/kg over 30 min. **Maximum:** 1.5 g/kg over 30 min.

Dosage in Renal Imp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nifurtimoxis a drug that inhibits
 
Response: Nifurtimoxis a drug that inhibits the growth of amastigotes of the parasite Leishmania. This parasite is responsible for causing the leishmaniasis. Nifurtimoxis has been used for treating this disease in humans since 1970.
Leishmaniasis is an endemic disease in many countries in Latin America, Africa, Asia, Europe and North America. It has been estimated that there are between 12 and 20 million cases of leishmaniasis worldwide, with about 2 million cases in Brazil alone. The disease is also present in the Middle East, Central Asia and parts of the United States.
In the last few years, the number of cases of leishmaniasis has increased. This disease has been known for centuries, but the situation has become worse due to the presence of HIV and other diseases that have made it more difficult to treat.
Leishmaniasis has a worldwide distribution. This disease is endemic in more than 90 countries and is considered
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nimesulideis a drug that inhibits
 
Response: Nimesulideis a drug that inhibits prostaglandin biosynthesis, specifically the cyclooxygenase pathway. It has been used for the treatment of mild to moderate pain, dysmenorrhea, and arthritis, and has been studied for use in asthma and other inflammatory diseases. It is available as an oral tablet, an injectable solution, and an intranasal spray. The oral tablet has been marketed as Nimesulide Riechsthal (Riechsthal AG, Basel, Switzerland) and Cenasul (Dainippon Sumitomo Pharma, Osaka, Japan). Nimesulide is chemically (S)-3-(4-chlorobenzoyl)-2-methyl-1-[[(2,6-dichlorophenyl)sulfonyl]amino]-1-oxopropan-2-ol. It is a white to off-white crystalline powder with a molecular weight of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nimorazoleis a drug that inhibits
 
Response: Nimorazoleis a drug that inhibits the growth of some fungi. It may also help to reduce the risk of oral thrush in people who are taking fluconazole. It is used to treat a fungal infection of the vagina called yeast vaginitis.

It is also used to treat fungal infections of the skin, such as athlete's foot.

How to use nimorazole

Nimorazole is taken by mouth. It is usually taken once daily. Your doctor will tell you how much to take and how often.

How it works

Nimorazole works by preventing the growth of certain types of fungus. It also kills some types of fungus that are already growing.

Nimorazole may also have some anti-inflammatory effects.

Nimorazole is not available in all countries. Check with your doctor before use if you are from

This site is intended
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NIMOTOPis a drug that inhibits
 
Response: NIMOTOPis a drug that inhibits the M phase of the cell cycle, thus allowing cells to complete cytokinesis. It is used to treat acute myeloid leukemia and some solid tumors.

NIMOTOPis a drug that inhibits the M phase of the cell cycle, thus allowing cells to complete cytokinesis. It is used to treat acute myeloid leukemia and some solid tumors.

It is an injectable solution of a derivative of nimodipine, a calcium channel blocker that also inhibits the M phase of the cell cycle.

It is given intravenously as a single dose or divided doses every 6 hours for 7–10 days.

NIMOTOPis given to patients with acute myeloid leukemia and acute lymphoblastic leukemia who are in a complete remission and who are at high risk for relapse.

NIMOTOPis given to patients with acute myeloid leukemia and acute lymphoblastic leukemia who
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nisoldipineis a drug that inhibits
 
Response: Nisoldipineis a drug that inhibits the rate-limiting enzyme in the synthesis of the neurotransmitter norepinephrine. It is also used to control high blood pressure.

The National Heart, Lung, and Blood Institute (NHLBI) recommends that nisoldipine be used in conjunction with a calcium channel blocker, or other antihypertensive drugs, to treat patients with severe hypertension.

However, the Food and Drug Administration (FDA) warns that the use of nisoldipine may cause dangerous side effects.

What is Nisoldipine?

Nisoldipine, also known as 3-dipropyl-N-[2-[(2-methoxy-1,4-benzodioxan-2-yl)oxy]ethyl]-1-piperazineacetamide, is a calcium channel blocker that works by slowing down the speed at which calcium moves through the calcium channels
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nitrendipineis a drug that inhibits
 
Response: Nitrendipineis a drug that inhibits the calcium channel (also called calcium antagonist). It is used to treat patients with high blood pressure. In this way it lowers the blood pressure by relaxing the muscles of the blood vessels.

How is it used?

Nitrendipine is usually taken once a day, at night, or when a patient is asleep.

When taken regularly, nitrendipine is usually well-tolerated. Side effects are usually mild and include dizziness, nausea, and lightheadedness. Patients who experience such side effects usually feel better when the medication is stopped.

When nitrendipine is used for high blood pressure, it may be taken with or without food. The dose of nitrendipine should be increased gradually over several days or weeks.

This drug is sometimes used with other medications to treat high blood pressure. It may also be used to prevent angina, chest pain caused by heart disease.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nitrofurantoinis a drug that inhibits
 
Response: Nitrofurantoinis a drug that inhibits the growth of bacteria, such as Escherichia coli, Staphylococcus aureus, and Streptococcus faecalis. It is used to treat bacterial infections of the skin, urinary tract, or digestive tract. It is also used to treat certain infections of the eyes, ear, or respiratory tract. It is used to treat cat-scratch disease. It is also used to prevent infection in people with HIV. It is also used to treat people with diabetes.

Nitrofurantoin is also known as:

Nitrofurantoin

Nitrofurantoin sodium

Nitrofurantoin tromethamine

Nitorfurantoin

Nifuroxazide

Nitrofuran

Nitrofuracin

Nitrofurazone

Furosine

Dosage and Administration

Nitro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nizatidineis a drug that inhibits
 
Response: Nizatidineis a drug that inhibits gastric acid secretion by blocking the H+/K+ ATPase pump in the gastric parietal cell. It is a prodrug, and is converted in the intestine to its active metabolite nizatidine, a histamine H2 receptor antagonist. Nizatidine is indicated for the treatment of active duodenal ulcer.

Gastroesophageal reflux disease (GERD) is a chronic condition that develops when the reflux of gastric contents into the esophagus occurs more than two times per week. It is the most common disease of the upper gastrointestinal tract.

Antacids, H2 antagonists, proton pump inhibitors, and other drugs are used to treat GERD. The treatment of choice is the proton pump inhibitor.

Dosage and Administration

The recommended initial dose is 150 mg daily. The dose should be increased by 50 mg at weekly intervals
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NMS-P937is a drug that inhibits
 
Response: NMS-P937is a drug that inhibits histone deacetylase (HDAC) enzyme, and therefore may induce apoptosis. The aim of this study was to determine the influence of the NMS-P937 on the viability of human umbilical vein endothelial cells (HUVECs). The influence of NMS-P937 on the expression of anti-apoptotic and pro-apoptotic proteins and on the DNA damage was also investigated. Cell viability was measured by the MTT assay, and the expression of apoptotic proteins was determined by Western blot analysis. The influence of NMS-P937 on DNA damage was determined by the comet assay. NMS-P937 inhibited HUVEC viability in a dose-dependent manner, as well as the expression of Bcl-2 protein, and increased the expression of Bax protein. The comet assay revealed that NMS-P937 caused DNA damage in HUVEC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nolvadexis a drug that inhibits
 
Response: Nolvadexis a drug that inhibits the production of estrogen. This is usually prescribed for women who have gone through menopause. It can also be used by women who have breast cancer, or by men who have prostate cancer.

The most common side effects of Nolvadexis are:

Menstrual changes

Breast tenderness

Feeling tired

Headaches

Muscle pain

Infections

Trouble sleeping

Diarrhea

Hot flashes

Heart palpitations

Mood changes

Rashes

Swelling

Stomach pain

Swelling of hands and feet

Unusual bleeding or bruising

The most serious side effects are:

Nausea

Diarrhea

Nausea

This is usually caused by the anti-estrogen effects of Nolvadexis. Nausea
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nonadecanoicis a drug that inhibits
 
Response: Nonadecanoicis a drug that inhibits the activity of acetylcholinesterase and is used in the treatment of the central and peripheral neurodegenerative diseases.^[@ref1]−[@ref3]^ In addition to the physiological functions of acetylcholinesterase,^[@ref4]^ this enzyme also serves as a therapeutic target for the treatment of Alzheimer's disease.^[@ref5]^ Because of the need to develop a new therapeutic strategy for Alzheimer's disease, the design and synthesis of a new inhibitor of acetylcholinesterase are highly desirable.^[@ref6]^ In this work, a series of novel tetrahydroacridine derivatives were designed and synthesized by linking the 9-amino-1,2,3,4-tetrahydroacridine (AAT) scaffold with the carboxylic acid group of the benzoic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Noradrenalineis a drug that inhibits
 
Response: Noradrenalineis a drug that inhibits the action of the neurotransmitter norepinephrine, one of the most important catecholamines in the body. Norepinephrine is a natural substance, but also the most common drug for stress reduction. Noradrenaline is used to treat panic attacks, post-traumatic stress disorder, generalized anxiety disorder, and various other mental disorders.

What is Noradrenaline?

Noradrenaline is a neurotransmitter that plays an important role in the body. It is one of the most important catecholamines, meaning that it has an effect on the brain. The body produces a lot of norepinephrine, but noradrenaline is the active substance in the brain.

Noradrenaline is a neurotransmitter that regulates many processes in the body. The neurotransmitter is produced by the brain, and it travels to the body through the bloodstream. Noradrenaline stimulates the adrenal glands to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (?)-Norepinephrineis a drug that inhibits
 
Response: (?)-Norepinephrineis a drug that inhibits beta-adrenergic receptors. Norepinephrine is a neurotransmitter that acts on beta-adrenergic receptors in the brain. Beta-adrenergic receptors have been implicated in the pathophysiology of depression. The current studies have evaluated the effects of the acute and chronic administration of (-)noradrenaline on the performance of rats in the elevated plus maze. It was found that (-)noradrenaline increased the number of entries into the open arms and decreased the number of closed arm entries in a dose-dependent manner. The present findings are discussed in terms of their implications for the pathophysiology of depression.

)

Is a medication used to treat a type of heart disease that causes the heart to pump less effectively. It is also used to treat some types of high blood pressure. The long-term effects of this drug are not known.

?

A drug that acts on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  norethindroneis a drug that inhibits
 
Response: norethindroneis a drug that inhibits the conversion of progesterone to its active form by inhibiting 5α-reductase. The drug is used for the treatment of hirsutism, acne, and menstrual irregularities.

Mechanism of action
The action of norethindrone is mediated by the inhibition of progesterone.

Chemistry

Norethindrone is a synthetic progestin and a derivative of progesterone, and is a 19-nortestosterone derivative with a side chain attached at position C17α.

History
Norethindrone was first synthesized in 1958 and was developed as a contraceptive and antifertility agent. It was introduced for medical use in the United States in 1975.

Society and culture

Generic names
Norethindrone is the generic name of the drug and its.

Brand names
Norethindrone is marketed under the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Norethisteroneis a drug that inhibits
 
Response: Norethisteroneis a drug that inhibits the production of oestrogen. It is also known as an oestrogen receptor modulator. It is a synthetic steroid and is used to prevent pregnancy in women.

Norethisterone is a form of progestogen, a synthetic steroid and an anti-androgen, which is used in contraception. It is a potent progestogen, which also acts as an anti-androgen.

This medication can be used for birth control, also known as pregnancy prevention, and it can be used to treat certain types of breast cancer.

The chemical name of norethisterone is 17α-ethinyl-19-nortestosterone.

Norethisterone has the following structure:

Norethisterone is also known as:

17α-ethinyl-19-nortestosterone

17α-ethinyl-19-nortestosterone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Novobiocinis a drug that inhibits
 
Response: Novobiocinis a drug that inhibits one of the proteins in the HIV virus that are needed for the virus to replicate and cause infection.

So in a nutshell the news on Genvoya is good. It looks like the second drug is working and the first is in the works.

I will post a more detailed update once I get it.

But for now, it looks like the whole Genvoya deal is back on track.

Friday, August 14, 2010

It's been a long day of visits to the hospital.

Yesterday, I went to see if there was any news on the Genvoya deal.

When I went, they told me there was no news.

So I didn't go in to see if there was any news.

I just went in to visit.

And to make a long story short, they were able to put my on the list.

Now, I just
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NPI2358is a drug that inhibits
 
Response: NPI2358is a drug that inhibits the
b-catenin pathway. It is
currently undergoing Phase III
trials in the United States. It
was first approved in Europe in
2010 and was launched in the
U.S. in March 2011. This drug is
the first drug of its kind to be
approved for the treatment of
metastatic prostate cancer.
The safety of this drug was
tested in clinical trials in the
United States and in a
controlled study of patients in
Europe.

What is the use of this drug?

NPI2358 is a
b-catenin
inhibitor that can be used to
treat patients with metastatic
prostate cancer that has
progressed beyond hormone
therapy. The drug works by
inhibiting the production of
b-catenin, a protein that
allows cancer cells to
multiply. NPI
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  NUTRESTOREis a drug that inhibits
 
Response: NUTRESTOREis a drug that inhibits the N-terminal proteolytic processing of APP. To date, the clinical development of NUTRESTOREis based on the use of APP and amyloid beta peptide (Aβ) to monitor the efficacy of the drug in AD patients. However, it is well known that APP is also cleaved by β-secretase at the position of the transmembrane domain, generating a soluble form of APP (sAPPβ) that has been shown to be an endogenous antagonist of Aβ neurotoxicity. It is not known if the pharmacological modulation of APP metabolism by NUTRESTORE could also affect sAPPβ metabolism. We have therefore investigated the effects of NUTRESTORE on the processing of APP in primary neuronal cultures. We demonstrate that NUTRESTORE induces the cleavage of APP at the β-secretase site by upregulating the expression of BACE1. We also demonstrate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Nystatinis a drug that inhibits
 
Response: Nystatinis a drug that inhibits the formation of a hygroscopic, highly infectious mold (Candida albicans) by inhibiting the synthesis of the cell wall component chitin. The agent was first used to treat patients with severe systemic candidiasis and was then used as a topical agent for the treatment of a variety of superficial fungal infections, including onychomycosis.
The term “onychomycosis” is used herein to mean a fungal infection of the nail apparatus. This infection is most commonly caused by dermatophytes, especially Trichophyton rubrum. Other species of dermatophytes, including T. mentagrophytes, T. violaceum, and T. tonsurans, are also frequently implicated. Less commonly, onychomycosis may be caused by nondermatophyte fungi, such as Candida, Malassezia, or Aspergillus species.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Obeticholicis a drug that inhibits
 
Response: Obeticholicis a drug that inhibits the synthesis of bile acid in the liver.

• It is used for the treatment of bile acid diarrhea, certain forms of liver cirrhosis, and primary biliary cirrhosis.

• It is sometimes used to decrease the production of bile acid and increase the elimination of bile acid in the urine.

• Obeticholic acid is a reagent for the radiolabeling of compounds that are used in the synthesis of bile acid analogs for biological studies.

Obeticholic acid is a synthetic derivative of 7-keto-cholic acid. It is available as a racemic mixture of two optical isomers.

▪ INDICATIONS: It is used to treat bile acid diarrhea, primary biliary cirrhosis, and certain forms of liver cirrhosis.

▪ CONTRAINDICATIONS: It is not recommended in children. Known
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OC000459is a drug that inhibits
 
Response: OC000459is a drug that inhibits the protein-tyrosine kinase activity of Syk and prevents Syk from phosphorylating itself and the Tec family tyrosine kinase ITAM-bearing adaptors. Since Syk is activated in SLE B cells, this agent has been proposed as a potential therapeutic for the treatment of SLE. The present study was designed to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of FCP. FCP was administered to dogs as an intravenous (IV) bolus at doses of 0.01, 0.1, and 1 mg/kg, followed by a continuous infusion of 1 mg/kg/hr for 2 hrs. Serial blood samples were collected over 24 hrs after administration of FCP and analyzed for FCP concentration by high-performance liquid chromatography. For the PD analysis, anti-nuclear antibody (ANA) and serum IgG levels were determined by ELISA. The terminal half-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oclacitinibis a drug that inhibits
 
Response: Oclacitinibis a drug that inhibits JAK1 and JAK2, and was recently approved for the treatment of JIA and moderate to severe psoriasis. This study is designed to assess the safety, efficacy, and immunogenicity of oclacitinib in children with JIA.

Methods

This phase 2, open-label, dose-escalation study enrolled children ages 6–17 years with active polyarticular JIA (≥3 active joints). Patients received oclacitinib at doses of 0.05, 0.1, 0.25, or 0.5 mg/kg/day in 2-week cycles. The primary objective was to assess the safety and tolerability of oclacitinib. The key secondary objective was to assess efficacy in terms of clinical improvement. Additional objectives included evaluation of radiographic progression, disease activity, and measures of immunogenicity. Patients received at least 3 cycles
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  o-Cresolis a drug that inhibits
 
Response: o-Cresolis a drug that inhibits the metabolism of the psychoactive ingredient in marijuana, THC. This drug is not approved by the FDA but will likely become a mainstay in the treatment of pain.

• Tetrahydrocannabinol (THC) — is the main psychoactive ingredient in marijuana. THC is responsible for the high that marijuana smokers experience. THC is a partial agonist at the CB1 and CB2 cannabinoid receptors, the body’s two primary cannabinoid receptors. THC also interacts with other neurotransmitter receptors including the NMDA, serotonin and dopamine receptors.

• Cannabidiol (CBD) — is a non-psychoactive cannabinoid that has significant therapeutic effects and may prove useful for certain medical conditions.

• Cannabinoids — is a class of compounds that interact with cannabinoid receptors.

The combination of these ingredients results in the therapeutic effects of marijuana, including pain relief.

There are two main ways to administer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Octanoicis a drug that inhibits
 
Response: Octanoicis a drug that inhibits adipose tissue and hence the metabolism of glucose and lipids, thereby decreasing the level of insulin and increasing the release of glucagon. It is indicated for patients with diabetic mellitus type II and is contraindicated in patients with impaired liver or kidney function, and patients with known hypersensitivity to the drug. The common side effects of octanoic acid include nausea, diarrhea, dizziness, weakness, and vomiting. Other side effects include gastric ulceration and constipation.

1.1 Medical uses

Octanoic acid is used as a drug to reduce the level of glucose and lipids, and hence to reduce the level of insulin and increase the release of glucagon. It is indicated for the treatment of type II diabetes mellitus and for patients with impaired liver or kidney function.

1.2 Pharmacology

Octanoic acid is a carboxylic acid that is a weak acid. It is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Octisalateis a drug that inhibits
 
Response: Octisalateis a drug that inhibits the action of aldosterone. It is indicated for use in the treatment of primary hyperaldosteronism (PA) and other disorders. It may be used with other drugs to treat hypertension.

The recommended dose is 40 mg once daily.

INSTRUCTIONS

For Oral Use

Use as directed by your doctor, usually once daily in the morning. Swallow tablets whole. Do not break, crush, or open.

SIDE EFFECTS

Common side effects include drowsiness, headache, and nausea.

What to do if you forget a dose

Take the missed dose as soon as you remember it. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

OVERDOSAGE

If you think you have overdosed the medicine seek emergency medical help at once. The overdose symptoms are high blood
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  octocryleneis a drug that inhibits
 
Response: octocryleneis a drug that inhibits the phosphorylation of TSC2, a GTPase-activating protein (GAP) for the small GTPase Rheb, thereby inhibiting mTORC1 signaling and promoting the inhibition of mTORC1 signaling.[@CIT0036]

Conversely, overexpression of TSC2 has been reported to inhibit mTORC1 signaling, as TSC2 interacts with the GAP-activity of Rheb.[@CIT0037] The mTORC1/TSC2/Rheb signaling pathway is considered a key regulator of mTORC1 signaling. The TSC2-mTORC1-Rheb signaling pathway plays an important role in cancer development and progression, and is a potential target for cancer treatment.[@CIT0038] In the present study, we found that a low expression of TSC2 in BCa cells was significantly associated with a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (+,-)-Octopamineis a drug that inhibits
 
Response: (+,-)-Octopamineis a drug that inhibits the action of the catecholamines dopamine, noradrenaline, and adrenaline in the brain and is sometimes used to treat drug addiction. The drug is a potent serotonin (5-HT) agonist and an antagonist of 5-HT receptors. The stereochemistry of (+)-octopamine is (2R,3R)-2,3-dihydroxy-N-methyl-5-phenyl-tetrahydro-2H-pyran-4-amine.

Etymology
The compound is named after octopus.

History

Octopamine was first synthesized in 1957 by the French chemist Jean-Louis Gervais and colleagues at the laboratory of R. Lefèvre at the Pasteur Institute in Paris. The authors of the synthesis, in collaboration with the pharmacologist M. Chirivella, published their results in the Journal of the American
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OCUSULF-10is a drug that inhibits
 
Response: OCUSULF-10is a drug that inhibits the activity of a receptor known as the VEGFR-2, which is a protein that plays a role in angiogenesis, the growth of new blood vessels from existing ones.

USAMRIID-developed Ocusulf-10 has the potential to be an effective therapy against malaria, because the malaria parasite that causes malaria causes the body to release a chemical called histamine. Histamine is a neurotransmitter that plays a role in many body processes, including the immune system. Ocusulf-10 inhibits the activity of the VEGFR-2, which plays a role in the body’s response to histamine.

Ocusulf-10 is also being developed as a therapy for Crohn’s disease. Crohn’s disease is an autoimmune disorder that causes inflammation of the gastrointestinal tract. In Crohn’s disease, there is a buildup of mucus in the intestinal tract
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ODM-201is a drug that inhibits
 
Response: ODM-201is a drug that inhibits KDM1A (LSD1), an enzyme that demethylates histone H3 at lysine 4 (H3K4). Inhibition of KDM1A results in an increase in H3K4me2, and subsequently an increase in H3K4me3, which leads to an increase in H3K4me3-modified chromatin-associated gene expression, and subsequent gene activation \[[@B2-cells-09-01684]\]. The Phase I clinical trial (NCT00789983) was a dose-escalation study of ODM-201. The maximum tolerated dose was determined to be 600 mg/day. The pharmacokinetics (PK) and pharmacodynamics (PD) of ODM-201 were determined. Pharmacokinetics demonstrated a time-dependent decline in plasma concentrations. In addition, at a dose of 600 mg, ODM-201 resulted in an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ODM-203is a drug that inhibits
 
Response: ODM-203is a drug that inhibits the enzyme ATP-citrate lyase (ACLY), which is involved in de novo synthesis of fatty acids, lipids and cholesterol. ACLY inhibition causes accumulation of fatty acids and other lipids in the cytosol and mitochondria, resulting in cell death. ODM-203 is an example of an allosteric inhibitor of ACLY, a strategy for drug discovery that was first developed by Prof. Young-Joon Choi at the University of Illinois, USA. The drug was licensed to Eisai Co., Ltd. for further development and is currently in phase I clinical trials for the treatment of prostate cancer.

About Janssen Oncology, LLCJanssen Oncology, LLC is a subsidiary of Janssen Pharmaceuticals, Inc., a member of Johnson & Johnson, that focuses on the development and commercialization of novel oncology products in both the US and internationally. The company has a multi
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ofloxacinis a drug that inhibits
 
Response: Ofloxacinis a drug that inhibits angiogenesis. It was approved in the United States for the treatment of metastatic breast cancer, but has also been shown to be effective in treating lung cancer, head and neck cancer, bladder cancer, ovarian cancer, and other solid tumors.

Off-label use of afloxacin for the treatment of AIDS has been suggested by the US FDA.

Aminoglycosides
Aminoglycosides are broad-spectrum antibiotics. They bind to the bacterial ribosome and inhibit protein synthesis. They have been shown to have synergistic activity when used in combination with other antibiotics.

Daptomycin
Daptomycin is a lipopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the bacterial membrane. It is used to treat a variety of bacterial infections, including MRSA, MSSA, S. aureus, E. coli, E. faecalis, and E
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olanexidineis a drug that inhibits
 
Response: Olanexidineis a drug that inhibits aldehyde dehydrogenase 2, and has been used to treat patients with alcoholic hepatitis, and for the treatment of head and neck cancer. The chemical structure of olanexidine is shown in Formula I.

Olanexidine has been described in U.S. Pat. No. 4,812,475. In U.S. Pat. No. 4,812,475, olanexidine is described as a useful inhibitor of liver alcohol dehydrogenase, aldehyde dehydrogenase and carbonic anhydrase.
The chemical structure of olanexidine is shown in Formula I.

Olanexidine is a drug that inhibits aldehyde dehydrogenase 2, and has been used to treat patients with alcoholic hepatitis, and for the treatment of head and neck cancer. The chemical structure of olanexidine is shown in Formula I.

Olanexidine has been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olanzapineis a drug that inhibits
 
Response: Olanzapineis a drug that inhibits the D2 dopamine receptor and has a good efficacy in the treatment of schizophrenia and bipolar disorders. It is administered orally in the form of tablets. Because of its long half-life, olanzapine has been found to accumulate in the adipose tissue and cause olanzapine-induced weight gain (OIWG). The relationship between OIWG and the long half-life of olanzapine has been widely investigated. In addition, its mechanism of OIWG is also investigated in various ways. However, the mechanism of OIWG has not been elucidated fully.

In the current study, the effect of olanzapine on insulin sensitivity and the signaling pathway of the insulin receptor in adipose tissue were examined. Insulin signaling is mediated by phosphatidylinositol 3-kinase (PI3K), which is activated by phosphorylation. Protein
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oleanolicis a drug that inhibits
 
Response: Oleanolicis a drug that inhibits lipid accumulation in adipocytes, thereby improving insulin sensitivity and glucose tolerance in type 2 diabetes mellitus ([@b1-mmr-15-03-1217],[@b2-mmr-15-03-1217]). Oleanolic acid is a pentacyclic triterpenoid that has been shown to improve insulin resistance and glucose tolerance in animals ([@b3-mmr-15-03-1217],[@b4-mmr-15-03-1217]). It has been shown to reduce hepatic triglyceride accumulation and to increase fatty acid oxidation ([@b5-mmr-15-03-1217],[@b6-mmr-15-03-1217]). It has been shown to enhance the expression of genes associated with glucose metabolism and to inhibit adipogenesis ([@b7-mmr-15-03-1217]). However, the effect of oleanolic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oleuropeinis a drug that inhibits
 
Response: Oleuropeinis a drug that inhibits several oncogenes and which is also an excellent source of vitamin E, an antioxidant and a lipid-soluble antioxidant that is known to protect against cancer.

Oleuropein is the bitter, bitter, bitter component of olive oil.

An important chemical that is found in olives, capers, herbs, and vegetables.

OLIVAROLEIN is a common name for the compound 1,3-O-D-glycosyl-D-arabinitol.

Oleuropein, a bitter and reddish-brown chemical compound found in olives, capers, herbs, and vegetables, is an important food additive that has antioxidant and anti-cancer properties.

Inhibition of DNA topoisomerase II (in vitro) by an extract of Olea europaea.

Inhibition of tumor cell growth (in vitro) by a water extract of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olmutinibis a drug that inhibits
 
Response: Olmutinibis a drug that inhibits a protein called the anaplastic lymphoma kinase (ALK) that is found in certain cancers. This drug is effective for some patients with these cancers.

The manufacturer of Olmutinib (Glembatumumab vedotin) is Seattle Genetics.

The U.S. Food and Drug Administration (FDA) has approved the use of Olmutinib for the treatment of patients with certain types of non-small cell lung cancer (NSCLC) that have become resistant to treatment with at least one other approved therapy.

The U.S. National Institutes of Health (NIH) is studying Olmutinib in clinical trials to see if it may be used to treat other types of cancer.

This drug is available in the United States.

Important safety information

Olmutinibis associated with life-threatening and potentially fatal adverse reactions, including liver injury. Patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olodaterolis a drug that inhibits
 
Response: Olodaterolis a drug that inhibits oestrogen and androgen receptors. There are a number of studies showing that oestrogen and androgen receptors are present in the prostate. It is thought that these receptors may be involved in the pathogenesis of prostate cancer. The potential usefulness of Olodaterol in the treatment of benign prostatic hyperplasia (BPH) and prostatic carcinoma is being investigated in the UK and USA. A phase II study of Olodaterol in men with moderate to severe lower urinary tract symptoms due to BPH and prostatic carcinoma is in progress in the UK. Olodaterol is currently being investigated in a phase III trial in the USA. Olodaterol is being investigated in combination with antimuscarinic agents in a phase II trial in the UK. The agent is being investigated in a phase II trial in the USA in combination with prazosin.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olopatadineis a drug that inhibits
 
Response: Olopatadineis a drug that inhibits both histamine and leukotriene pathways and is used for the treatment of allergic conjunctivitis, allergic rhinitis, urticaria, and pruritus.[@b1-asm-4-287]--[@b4-asm-4-287] The half-life of ophthalmic ointment is more than 24 hours.[@b5-asm-4-287] We present a case of a patient who developed acute hypersensitivity reaction (HRS) after the instillation of ophthalmic ointment of this drug and was successfully treated.

CASE
====

A 16-year-old male patient with a history of urticaria and wheezing episodes presented to the emergency department with a one-day history of generalized pruritus and erythema of the skin and lips, as well as dyspnea, generalized urticaria, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  olsalazineis a drug that inhibits
 
Response: olsalazineis a drug that inhibits the activity of TNF. 

It is used to treat inflammatory bowel disease.

References

Category:Pyrimidinediones
Category:Cyclohexanes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oltiprazis a drug that inhibits
 
Response: Oltiprazis a drug that inhibits the enzyme poly (ADP-ribose) polymerase (PARP), which is activated during cellular damage and repair processes. Oltiprazis is marketed under the trade name ZOLOFT® and is indicated for the treatment of patients with non-Hodgkin lymphoma who have received at least two prior regimens, including a regimen that contained rituximab. ZOLOFT® has been marketed in the United States since 2001.
Oltipraz is also known to be useful in treating other diseases. For example, oltipraz has been reported to have antifatigue activity in mice (Coulson et al., Mol. Pharmacol., 53:442-448 (1997)). Oltipraz has also been reported to have antifatigue activity in humans (Takiguchi et al., Biochem. Biophys. Res. Commun., 244:487-492 (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Olutasidenibis a drug that inhibits
 
Response: Olutasidenibis a drug that inhibits Bruton tyrosine kinase, a protein involved in B cell signaling. This drug has been shown to induce remissions in CLL patients who have failed prior therapies.[@bib1]

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with an incidence of 4.2 per 100,000.[@bib2] CLL has an indolent clinical course, and the median survival of untreated patients is 9--10 years.[@bib3] Standard therapy for CLL consists of alkylating agents, such as chlorambucil, fludarabine, or cyclophosphamide, which are used in combination with monoclonal antibodies, such as rituximab.[@bib4] The addition of the B cell-specific antibody rituximab to chemotherapy is associated with a survival benefit in both untreated and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Omadacyclineis a drug that inhibits
 
Response: Omadacyclineis a drug that inhibits topoisomerase IV. Topoisomerase IV is an enzyme that is required for bacterial DNA replication and it is essential for DNA repair and bacterial survival. Omadacycline is approved by the FDA for the treatment of complicated urinary tract infections and community acquired bacterial pneumonia. It has been shown to be effective against all strains of gram-positive and gram-negative bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Omadacycline has a unique mechanism of action. It is a tetracycline derivative that binds to the bacterial topoisomerase IV enzyme, not the human topoisomerase IV enzyme. Omadacycline is unique in its mechanism of action, which differs from other antibacterial agents. The mechanism of action of this drug allows for greater bactericidal activity and greater bacterial killing than other tetracyclines. Omadacycline has shown greater
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Omarigliptinis a drug that inhibits
 
Response: Omarigliptinis a drug that inhibits RAS (Retinoic Acid Receptor, Associated Protein, and Signal) was initially approved for use in Japan in 2011, with the aim of improving facial wrinkles and reducing the effects of photo-aging.[@bib1]^,^[@bib2] It was approved in the United States in 2015 for treatment of signs and symptoms of photodamage and skin laxity in patients with non-scarring photo-aging, including periorbital rhytides, nasolabial folds, jowls, marionette lines, and moderate to severe laxity of the neck.[@bib3] It was approved in the United Kingdom in 2016 for treatment of periorbital rhytides, nasolabial folds, jowls, marionette lines, and moderate to severe laxity of the neck.[@bib4] It is also indicated for treatment of non-scar
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Omeprazoleis a drug that inhibits
 
Response: Omeprazoleis a drug that inhibits gastric acid secretion by binding to the H+/K+-ATPase in the gastric parietal cells. It is administered orally in order to inhibit gastric acid secretion and to prevent or treat various diseases caused by gastric hyperacidity. Omeprazole is widely used for treating diseases of the gastrointestinal tract such as gastric ulcer, duodenal ulcer, reflux esophagitis, gastritis, and gastric hyperacidity associated with Zollinger-Ellison syndrome. Omeprazole is also used for preventing gastric acid secretion after gastric surgery. In Japan, omeprazole is available as an oral formulation in a dosage of 5 to 40 mg per day. In the United States, omeprazole is available as a capsule formulation containing 20, 40, or 80 mg of omeprazole, which is prescribed in a dosage of 20 to 40 mg per day
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OMNISCANis a drug that inhibits
 
Response: OMNISCANis a drug that inhibits protein synthesis by blocking peptide chain elongation. It was originally used to treat cancer and infections. Today, it is used to treat viral infections.

Treatment with OMC-201 in Combination with Dexamethasone for Patients with Severe Influenza A Infection: A Phase 1, Open-Label, Single-Dose, Randomized, Crossover StudyThe safety and tolerability of oral oseltamivir (Tamiflu®) in combination with dexamethasone in hospitalized patients with severe influenza A infection were evaluated. The study evaluated the safety of the combination in 60 patients and the tolerability of oseltamivir in 30 patients.

Double-blind, Placebo-controlled, Randomized, Crossover Study of Oral Oseltamivir (Tamiflu®) in Healthy VolunteersTreatment with oseltamivir (Tamiflu®)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ON-01910is a drug that inhibits
 
Response: ON-01910is a drug that inhibits the binding of the ligand, peptide b (gp 120), to the CD4 receptor on the surface of T-lymphocytes.

Abstract

INTRODUCTION: Analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, have been shown to increase the risk of serious liver injury in HIV-infected patients. We examined the association between the use of specific analgesics and serious liver injury in HIV-infected patients.

METHODS: Using a large cohort of HIV-infected patients in the HIV Outpatient Study, we examined the association between use of specific analgesics and serious liver injury, as defined by an elevation of serum transaminase levels above three times the upper limit of normal (ULN) in the absence of hepatitis B or C virus infection or other causes of liver injury.

RESULTS: The use of acetaminophen and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ONC201is a drug that inhibits
 
Response: ONC201is a drug that inhibits the ubiquitin-proteasome pathway and is a promising therapeutic agent for the treatment of cancers.[@bib1] The first-in-class drug, ONC201, has shown good efficacy and safety in Phase I clinical trials.[@bib2] The therapeutic potential of ONC201 is supported by the fact that it can inhibit tumor growth, induce apoptosis, and increase the sensitivity of cancer cells to chemotherapy.[@bib3]

Protein ubiquitination is an important posttranslational modification of proteins and a common process for many important biological processes.[@bib4]^,^[@bib5] Ubiquitin ligases are a group of enzymes that mediate the ubiquitination process.[@bib6] They can be divided into three classes based on their domain structures and enzymatic activities: the RING (really interesting new gene) domain-containing E3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ondansetronis a drug that inhibits
 
Response: Ondansetronis a drug that inhibits serotonin (5-HT) receptors in the brain and is approved for use in patients who are undergoing a course of radiation therapy to the head and neck and for the prevention of nausea and vomiting after major abdominal surgery. It is generally well tolerated, although the most common side effects include constipation and abdominal discomfort.

A multicenter, randomized, double-blind, placebo-controlled trial of ondansetron in patients with metastatic melanoma showed that patients who received ondansetron plus dacarbazine as first-line therapy for metastatic melanoma had a significantly longer median overall survival than patients who received dacarbazine alone (15.1 vs. 11.1 months; *p* \< 0.001) ([@B1]).

A post hoc analysis of the randomized trial of ondansetron plus dacarbazine in metastatic melanoma suggested that patients who had a partial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ONO-4059is a drug that inhibits
 
Response: ONO-4059is a drug that inhibits class I phosphatidylinositol 3-kinase (PI3K) by binding to the ATP-binding pocket of the catalytic domain of the enzyme \[[@CR23]\]. Therefore, LY-294002 inhibits the PI3K/Akt pathway and thus causes a blockade of cell growth and proliferation \[[@CR24]\]. Therefore, we investigated whether or not LY-294002 could affect the expression of the proteins involved in the Wnt/β-catenin signaling pathway. As shown in Fig. [3](#Fig3){ref-type="fig"}, LY-294002 inhibited the phosphorylation of Akt (Ser473) and GSK-3β (Ser9), which is a downstream effector of Akt, in the cells treated with β-catenin siRNA, but not in the cells treated with control si
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oprozomibis a drug that inhibits
 
Response: Oprozomibis a drug that inhibits proteasome activity and that is in clinical trials for the treatment of multiple myeloma. We examined the effect of oprozomib on B cell viability and activation. Oprozomib did not affect B cell viability. However, it induced cell death by activating caspase-3 and inhibiting protein synthesis. We also found that oprozomib induced surface expression of BCR, CD19, CD86, and CD80 in a dose-dependent manner. Oprozomib also induced phosphorylation of Syk and phosphorylation of Akt, and this was abrogated by inhibitors of the Syk and PI3K pathways. In addition, oprozomib induced phosphorylation of Btk and phosphorylation of Bruton's tyrosine kinase (Btk). Oprozomib did not affect B cell activation in the presence of LPS. Opro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ornidazoleis a drug that inhibits
 
Response: Ornidazoleis a drug that inhibits the biosynthesis of folate and thymidylate in susceptible bacteria. It is an alternative to sulfonamides and trimethoprim. Ornidazole is administered orally in the form of a capsule.

Ornidazole was introduced in 1969. It was the first drug of the class of antimicrobial agents called azoles.

Description

Ornidazole is a 5-nitroimidazole derivative with antibacterial activity against aerobic and anaerobic bacteria. It is administered orally. The recommended dose is 2 g once a day for 5 days.

Ornidazole has a low potential for resistance development and is widely used to treat bacterial vaginosis, Helicobacter pylori infection, and enteric infections. It is also used to treat amebiasis, trichomoniasis, and mycoplasma infection.

Mechanism of action
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OROTICis a drug that inhibits
 
Response: OROTICis a drug that inhibits the action of
methamphetamine, an amphetamine-like
substance, and helps the body to eliminate
it. It may also help to stop the addiction
to methamphetamine and other drugs that
cause hyperactivity and loss of sleep.

Antipsychotic drugs that help treat
conditions like schizophrenia, mania,
schizo-affective disorder, and bipolar
disorder. They also treat obsessive
compulsive disorder.

Ritalin, a drug used to treat attention
deficit disorder (ADD), attention deficit
hyperactivity disorder (ADHD), and
bipolar disorder.

Fluoxetine, a drug used to treat
depression.

Cogentin, a drug used to treat
cognitive disorders like delirium,
dementia, and brain injury.

Cannabidiol (CBD), a naturally occurring
compound found
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Orphenadrineis a drug that inhibits
 
Response: Orphenadrineis a drug that inhibits the noradrenaline reuptake, thus increasing its concentration in the synaptic cleft. Its clinical effects are manifested by a strong antihistaminic, anticholinergic, sympathomimetic and local anaesthetic activity. In order to prevent the side effects associated with high dosages, new derivatives have been synthesized and their activity in relation to the antihistaminic and anti-muscarinic effects has been compared. The aim of this work is to evaluate the anti-muscarinic and anti-histaminic activity of the synthesized derivatives, both atropine and scopolamine, in order to find out which of the new derivatives is the most effective. The activity of the compounds was tested by a potentiometric technique using the method of fast inhibition of the spontaneous activity of the frog rectum. The compounds were tested at a concentration of 10(-4) M, which is near the in vivo concentration. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ORY-1001is a drug that inhibits
 
Response: ORY-1001is a drug that inhibits the function of certain enzymes. Inhibition of these enzymes by vorinostat leads to growth arrest and apoptosis of cancer cells. This drug is a derivative of suberoylanilide hydroxamic acid (SAHA), which is already approved for treatment of cutaneous T-cell lymphoma (CTCL). This Phase I study will assess the safety and tolerability of vorinostat in combination with the fluorouracil and leucovorin (folinic acid) used in the treatment of colon cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Osimertinibis a drug that inhibits
 
Response: Osimertinibis a drug that inhibits EGFR T790M and has shown promising activity in T790M-positive patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Here, we present the case of a patient with EGFR T790M-positive lung adenocarcinoma who achieved a complete response to osimertinib, and we discuss the implications of this case for the management of EGFR T790M-positive lung adenocarcinoma.

Case presentation

A 64-year-old man presented with an abnormal chest radiograph. Chest computed tomography revealed a left upper lobe mass with an associated ipsilateral hilar lymphadenopathy and left pleural effusion. He had a past medical history of stage IIIb squamous cell lung cancer, treated with neoadjuvant chemoradiation therapy and subsequent resection in 2007. He was diagnosed with stage IV adenocarc
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ospemifeneis a drug that inhibits
 
Response: Ospemifeneis a drug that inhibits estrogenic actions by blocking the estrogen receptor (ER). It was developed for the treatment of moderate to severe vulvar and vaginal atrophy (VVA) and was approved in the United States in 2010.[@b1-rmmj-7-1-e0015] The drug has also been studied in patients with androgenetic alopecia (AGA), a type of androgen-dependent alopecia that can be induced by female sex hormones.[@b2-rmmj-7-1-e0015]

INTRODUCTION
============

Female sex hormones, such as estrogen, play an important role in the development and progression of female-related diseases, such as osteoporosis, cardiovascular disease, and breast and endometrial cancer.[@b3-rmmj-7-1-e0015]--[@b5-rmmj-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ostarineis a drug that inhibits
 
Response: Ostarineis a drug that inhibits the release of prolactin from the pituitary gland. It is a dopamine agonist, and is used in the treatment of pituitary prolactinomas.

Contents

Ostarineis a drug that inhibits the release of prolactin from the pituitary gland. It is a dopamine agonist, and is used in the treatment of pituitary prolactinomas.

Ostarine has a number of side effects, including:

prolactinoma

dry mouth

dizziness

facial flushing

tremor

seizures

severe headache

irregular menstrual cycles

drowsiness

Other side effects include:

Allergic reactions (including rash, itching, hives, or difficulty breathing)

Vomiting

Headache

Rash

Dizziness

Facial fl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  MK-2866is a drug that inhibits
 
Response: MK-2866is a drug that inhibits class I phosphoinositide 3-kinase (PI3K) and is currently in Phase II clinical trials. In the present study, we used this drug to explore the potential of PI3K inhibitors in augmenting the cytotoxicity of TRAIL in hepatocellular carcinoma (HCC) cells. We found that MK-2866 increased TRAIL-induced apoptosis in TRAIL-resistant HCC cells and sensitized them to TRAIL-induced apoptosis. In addition, we demonstrated that MK-2866 and TRAIL synergistically induced apoptosis in TRAIL-resistant HCC cells. Moreover, MK-2866 and TRAIL cooperatively induced apoptosis in TRAIL-sensitive HCC cells, suggesting that MK-2866 and TRAIL may have a therapeutic effect in patients with TRAIL-resistant HCC. MK-2866 and TRAIL cooperatively induced apoptosis in TRAIL-sensitive H
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ostholeis a drug that inhibits
 
Response: Ostholeis a drug that inhibits the secretion of gastric acid, lowers the gastrointestinal pH, and inhibits gastrointestinal motility.^[@bibr1-1534735418777117]^ Its use is associated with fewer adverse events than proton pump inhibitors.^[@bibr2-1534735418777117]^ However, there is little data on the effect of osthole on tumor growth and survival in patients with advanced cancers.^[@bibr3-1534735418777117]^

We used a large prospective clinical trial data set from patients with advanced cancers treated with chemotherapy in a randomized clinical trial to investigate the effects of osthole on tumor growth and survival. The study was approved by the Human Research Ethics Committee of The University of Hong Kong/Hospital Authority Hong Kong West Cluster. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All participants gave written informed consent.

Patients were randomized to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Otiloniumis a drug that inhibits
 
Response: Otiloniumis a drug that inhibits histamine release. It is used to prevent vasospasm and as an antiemetic.

Mechanism of action
Otilonium is a non-competitive antagonist of histamine H1 receptors. It is thought to act at the H1 receptors located on pre- and postsynaptic sites in the peripheral nervous system and at H1 receptors in the central nervous system.

Effects

Pharmacodynamics
Otilonium is used to treat migraine and nausea and vomiting associated with cancer chemotherapy.

Pharmacokinetics
Otilonium is rapidly absorbed after subcutaneous injection and is eliminated in urine.

Chemistry
Otilonium is an aminopyridine derivative with the formula C17H19N3O. It is a pale-yellow, crystalline solid.

History
Otilonium was first synthesized in 1951. It was approved for medical use in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  o-Toluicis a drug that inhibits
 
Response: o-Toluicis a drug that inhibits the formation of a specific isozyme of phosphatidylinositol-specific phospholipase C, which in turn blocks the phosphatidylinositol 3-kinase pathway, resulting in the inhibition of cellular growth.

A large phase III trial of toluicis in combination with the fluorouracil-based regimens CapeOX (capecitabine and oxaliplatin) or FOLFOX (leucovorin, fluorouracil, and oxaliplatin) in mCRC did not show any benefit compared to fluorouracil-based regimens alone \[[@B48-ijms-19-00139]\]. However, a large phase II trial with toluicis plus irinotecan in patients with KRAS-mutated mCRC reported a promising efficacy in terms of PFS and OS \[[@B49
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OTX015is a drug that inhibits
 
Response: OTX015is a drug that inhibits the transport of serotonin into the synaptic cleft. This means that serotonin levels are higher in the brain. It is believed that this is the reason for the well-known side effects associated with SSRIs. There are some scientific studies that show that CBD can reduce the amount of serotonin in the brain and is thus thought to reduce the side effects of SSRIs.

2.2 CBD and SSRIs

In scientific studies that examine the interaction between CBD and SSRIs, they usually look at the antidepressant effects of CBD. Some studies also examine the effects of CBD on anxiety, stress, and sleep disorders.

For example, the Journal of Psychopharmacology published a study in 2017 that examined the effect of CBD on depression. This study examined the effects of CBD on depression in two groups of participants. The participants in the first group were diagnosed with depression. They received either a placebo or CBD and then were examined for their
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ouabainis a drug that inhibits
 
Response: Ouabainis a drug that inhibits the Na^+^/K^+^-ATPase in cardiomyocytes and reduces cardiac contractility. The drug is used in the treatment of hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy, and heart failure. The drug is also used as a proarrhythmic agent. The estimated incidence of serious cardiac events with ouabain is 0.1--0.2% per patient per year ([@B1]). The cardiac effects of ouabain have been reported to be associated with genetic factors, particularly with polymorphisms of the Na^+^/K^+^-ATPase α1-subunit ([@B2]).

Several studies have reported an association between polymorphisms of the Na^+^/K^+^-ATPase α1-subunit and the incidence of sudden cardiac death (SCD) in HCM patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxacillinis a drug that inhibits
 
Response: Oxacillinis a drug that inhibits bacterial DNA gyrase. One of the reasons for this inhibition is that it stabilizes the topoisomerase cleavage complex, which is a complex of the enzyme and a DNA strand. The drug is currently in clinical trials for the treatment of a variety of bacterial infections, including acne. It is currently in phase II clinical trials for the treatment of osteomyelitis, acute bacterial arthritis, and complicated skin and skin structure infections.

Oxytetracycline is a semi-synthetic tetracycline that is active against most gram-positive and gram-negative bacteria. It is effective against a broad range of bacterial infections, including those of the respiratory tract, urinary tract, gastrointestinal tract, and skin. It has been used as a broad-spectrum antibiotic in the treatment of respiratory tract infections, skin infections, and cellulitis. It has also been used to treat acne.

Penicillins are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxantelis a drug that inhibits
 
Response: Oxantelis a drug that inhibits the hatching of the eggs of a parasitic worm that causes elephantiasis, and which also has some effect against tapeworms. This drug is a mixture of oxantel and praziquantel, which is also sold under the name of Oxantel-praziquantel, which is a mixture of oxantel and praziquantel. Oxantel is also sold as the potassium salt, oxantel potassium, and praziquantel as the sodium salt, praziquantel sodium. Oxantel and praziquantel are also available as capsules. Oxantel and praziquantel are currently being marketed in the United States under the trade names of Nolvadex® and Triquindex®.

Oxantel is indicated for the treatment of tapeworms and other parasitic infections, including ascariasis and trichuriasis. Oxant
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxaprozinis a drug that inhibits
 
Response: Oxaprozinis a drug that inhibits phosphodiesterase type 5, an enzyme that metabolizes cGMP, thereby increasing cGMP in the smooth muscle cells of the vascular wall and causing vasodilation. When diltiazem is used in combination with nitroglycerin or with verapamil, a calcium channel blocker, it increases the effect of nitroglycerin and verapamil. In contrast, when used with papaverine, a phosphodiesterase type 5 inhibitor, it reduces the vasodilator effect of papaverine. The drug has been shown to reduce the incidence of serious side effects, such as acute hypotension and angina, when used in combination with nitroglycerin.

Mechanism of action

Oxaprozin works by inhibiting the enzyme phosphodiesterase type 5 (PDE5), which is responsible for metabolizing cGMP. As a result, cGMP accumulates in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxcarbazepineis a drug that inhibits
 
Response: Oxcarbazepineis a drug that inhibits the activity of sodium channels. Its activity is blocked by carbamazepine and oxcarbazepine, and in some cases, other drugs. These drugs are also used to treat some forms of epilepsy.

What Is Oxcarbazepine Used For?

Oxcarbazepine is used to treat some forms of epilepsy. It is used in combination with other drugs to treat epilepsy that is not controlled by other drugs. It is used to treat some types of pain and bipolar disorder.

How Does Oxcarbazepine Work?

Oxcarbazepine works by blocking sodium channels in the brain. This causes the brain to be less excitable.

Oxcarbazepine Side Effects

Oxcarbazepine may cause a number of side effects, including:

Dizziness

Headaches

Sensitivity to light

Vomiting

Nausea
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  oxethazaineis a drug that inhibits
 
Response: oxethazaineis a drug that inhibits adrenergic transmission. It is used in the treatment of myocardial infarction and angina pectoris. In Japan, it is mainly used to prevent angina pectoris after heart surgery. The aim of this study was to evaluate the effect of propranolol on myocardial oxygen consumption in anesthetized dogs. Myocardial oxygen consumption was measured with a needle electrode placed in the left ventricular wall. After an intravenous administration of propranolol, oxygen consumption was decreased in a dose-dependent manner. The decreased oxygen consumption was associated with a decrease in myocardial blood flow. A decrease in oxygen consumption with propranolol was also observed in anesthetized dogs with ischemic myocardium. The decrease in oxygen consumption was associated with a decrease in myocardial blood flow in the ischemic myocardium. These results indicate that propranolol can be used safely
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxfendazoleis a drug that inhibits
 
Response: Oxfendazoleis a drug that inhibits mitochondrial protein synthesis and is used in the treatment of roundworm infection in animals and also in humans. In this study, the effects of oxfendazole on rat hepatocytes were investigated in vitro. Rat hepatocytes were isolated by collagenase perfusion of the liver and plated on plastic culture dishes. Oxfendazole was added to the medium at concentrations of 10, 100, and 500 microM. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Oxfendazole induced dose-dependent cell death. At 100 microM, cell death occurred after 4 h, and at 500 microM, cell death was seen after 8 h. The percentage of dead cells was significantly higher than that of control cells (0 microM) at each time point. In
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxibendazoleis a drug that inhibits
 
Response: Oxibendazoleis a drug that inhibits the biosynthesis of microtubules in microtubule-dependent processes such as mitosis, including metaphase arrest, the cell-division process, and the formation of the mitotic spindle, and also inhibits the biosynthesis of proteins in microtubule-dependent processes. It has been used for the treatment of a variety of human infections, including infections caused by microsporidia, trypanosomes, and Trichomonas. Oxibendazole has been used in the treatment of trypanosomiasis (African sleeping sickness) and microsporidiosis (intestinal and extra-intestinal) and also has been used in the treatment of certain parasitic diseases, such as infections by Encephalitozoon cuniculi, Encephalitozoon hellem, and Encephalitozoon intestinalis, Trichomonas vaginalis, and Leishmania infantum.

This section provides
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxiracetamis a drug that inhibits
 
Response: Oxiracetamis a drug that inhibits acetylcholinesterase. The mechanism of action is to increase the concentration of acetylcholine in the brain, thus increasing cognitive function. The drug is used for the treatment of Alzheimer's disease.

Oxiracetam is not FDA approved. There are no long term safety data available.

Adverse effects:

Some of the side effects that have been reported include headaches, nausea, and vomiting. There are no known interactions with any other drugs.

Precautions:

Oxiracetam should not be used by people with history of seizures.

Storage:

Oxiracetam is stable when stored at room temperature. It is not recommended to be stored at room temperature for longer than two weeks.

Oxiracetam Drug Interactions:

Oxiracetam should not be used by people who are allergic to oxiracetam or acetylcholine.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxprenololis a drug that inhibits
 
Response: Oxprenololis a drug that inhibits steroid 5α-reductase, thereby inhibiting the conversion of testosterone into dihydrotestosterone (DHT) ([@B1]). It is currently used for the treatment of benign prostatic hyperplasia (BPH) ([@B2], [@B3]).

Testosterone plays an important role in maintaining sexual function, growth, and development. In males, testosterone has an anabolic effect in muscle, bone, and connective tissue. In women, it has an anabolic effect in the uterus and breast ([@B4]).

Oxybutynin, a drug that is used to treat urinary incontinence, has been shown to increase plasma testosterone levels in men and women ([@B5]). Oxprenolol is metabolized to form norketotifen, a drug that has an antihistaminic effect. Norketotifen is also known to inhibit testosterone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxtriphyllineis a drug that inhibits
 
Response: Oxtriphyllineis a drug that inhibits acetylcholinesterase and is used for the treatment of diseases associated with the cholinergic system. Oxtriphyllineis a chiral drug, but only one enantiomeric form has been commercialized. Oxtriphyllineis marketed as the racemic mixture of the two enantiomers.
The enantiomers of oxtriphyllineare produced by separation of the racemic mixture of oxtriphylline, using classical methods such as the use of crystallization or chromatography. For example, U.S. Pat. No. 4,985,507 describes a method for separating the enantiomers of oxtriphylline. The enantiomers are obtained by crystallization of oxtriphylline in a water/alcohol mixture at a temperature of from 10 to 20° C.
One disadvantage of classical separation methods is that they require large
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxybuprocaineis a drug that inhibits
 
Response: Oxybuprocaineis a drug that inhibits the contraction of muscle and causes analgesia, amnesia, and sedation. It is a local anesthetic that has a low incidence of side effects and a rapid onset and short duration of action. It is a short-acting amide local anesthetic. It has a higher lipid solubility than procaine. It is most often used in dentistry and phlebotomy. It is also used to treat migraine headaches. It can also be used as a local anesthetic for oral surgery. It is used for the treatment of dental anxiety.

Bupropion is a drug used to treat depression. It is a nicotinic receptor antagonist. It can cause dry mouth, constipation, and a fast heart rate. It may cause seizures. It may cause insomnia, agitation, anxiety, and hallucinations. It can cause birth defects if taken while pregnant. It is a non-nicotinic receptor antagonist.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxybutyninis a drug that inhibits
 
Response: Oxybutyninis a drug that inhibits cholinesterase activity. (Maurice, T. A. et al. Pharmacol. Biochem. Behav. 39:1235-1240 (1992)).
An experimental antidiabetic drug, T-1095, is an acetamide that binds reversibly to the active site of acetylcholinesterase and prevents the hydrolysis of acetylcholine (Huang, W. et al. Science 261:1014-1016 (1993)). The antidiabetic activity of this drug was found to be associated with a reduction in hepatic glucose output, and not insulin secretion (Guan, Y. et al. J. Biol. Chem. 268:24293-24296 (1993)). T-1095 has been shown to decrease blood glucose levels by inhibiting the hydrolysis of acetylcholine in the peripheral nervous system. (Ling, W. et al.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxymatrineis a drug that inhibits
 
Response: Oxymatrineis a drug that inhibits the growth of cancer cells, primarily by causing cell death. However, the exact mechanism by which this drug induces cell death is unknown. In this study, we examined the effect of oxygen free radical scavengers and inhibitors of apoptosis on the growth-inhibitory activity of oxymatrine. Oxymatrine-induced cell death was found to be dose-dependent, and it was significantly reduced by superoxide dismutase (SOD) and catalase. However, only SOD prevented oxymatrine-induced growth inhibition of H1299 cells, which suggests that oxymatrine-induced growth inhibition is mediated by oxygen free radicals. Furthermore, we found that oxymatrine induced DNA laddering in H1299 cells. Oxymatrine-induced DNA laddering was not inhibited by SOD, but was inhibited by N-acetylcysteine (NAC), which suggests that oxymatrine-induced DNA laddering is mediated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxytetracyclineis a drug that inhibits
 
Response: Oxytetracyclineis a drug that inhibits protein synthesis by binding to the 50S subunit of the ribosome. It has a broad spectrum of activity, and is effective against both gram-positive and gram-negative organisms.It has been widely used to treat bacterial infections, particularly in the dairy industry, for decades.

We have examined the ability of oxytetracycline to inhibit the growth of bovine mastitis pathogens. The following strains of Staphylococcus aureus and Streptococcus agalactiae were tested:

Oxytetracycline (Sigma-Aldrich, St. Louis, MO) was added to tryptic soy broth (TSB) at concentrations ranging from 0.1 to 10 mg/ml. In addition, oxytetracycline was dissolved in sterile, distilled water at concentrations of 10, 50, and 100 mg/ml. Mastitis pathogens were suspended
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Oxytocinis a drug that inhibits
 
Response: Oxytocinis a drug that inhibits uterine contractions and prevents premature labor, also called “pessary”. This drug has been in use for over a hundred years, and is available as a powder that is mixed with water and administered vaginally. It is effective in preventing premature labor and is effective in the treatment of dysmenorrhea, painful periods and heavy bleeding. It is also used in combination with a second drug, called nifedipine, which helps to control preterm labor and can be given orally or by injection.

Cocaine and methamphetamine. The popularity of cocaine and methamphetamine has been rising steadily over the past several years. Cocaine is available in a number of forms including powder, crack, and rock. Methamphetamine is available in various forms including methamphetamine pills, crystal, and speed. These drugs are typically taken orally and come in various doses. The dangers of these drugs are numerous and include brain damage, heart attack, psychosis,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  OXYTROLis a drug that inhibits
 
Response: OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in the ovaries. It is used in the treatment of menopausal symptoms.

OXYTROLis a drug that inhibits oestrogen production in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ozagrelis a drug that inhibits
 
Response: Ozagrelis a drug that inhibits a key enzyme in the production of triglycerides. It's already being used to treat rare genetic disorders, but researchers say it could be a game-changer for Type 2 diabetes.

One of the things that make type 2 diabetes so hard to treat is that there are a lot of different types of the disease, and it's not easy to know which drugs will work for each person. But new research shows that some people with type 2 diabetes have a genetic variation that prevents them from producing the hormone insulin, which controls blood sugar levels. The new drug is designed to restore that production. It's called ogrelizumab, and it could potentially work for as many as 10 million Americans with the disease.

Ogrelizumab has been shown to be effective for people with the rare genetic disorder lysosomal acid lipase deficiency, and the drug's developer, Janssen, is planning a Phase 3 trial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ozanimodis a drug that inhibits
 
Response: Ozanimodis a drug that inhibits an enzyme in the liver, called indoleamine 2,3-dioxygenase (IDO), and therefore blocks the breakdown of tryptophan. The consequence is an increase in the levels of tryptophan in the blood, which means more serotonin, and also a reduction in the activity of the immune system. These are the most important mechanisms of action. It is a well-tolerated drug, with a good safety profile, and has a good efficacy profile, in particular in the treatment of multiple sclerosis (MS).

**Advantages:**

• It is a new drug, with a novel mechanism of action, and it is still being developed. It is not yet approved for any indication, but there are several Phase III trials ongoing in different conditions.

• It has shown good efficacy in clinical trials in patients with relapsing-remitting MS.

• It is not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ozenoxacinis a drug that inhibits
 
Response: Ozenoxacinis a drug that inhibits the formation of white fat and lowers cholesterol. A combination of alpha-linolenic acid, zinc, vitamin B6, and vitamin B12. The effect is particularly notable in individuals who are overweight. Studies have shown that the best way to incorporate this type of diet into a long-term plan is to add it to a basic diet that already includes a healthy, low-fat, whole-foods diet.

In a small study of people with type 2 diabetes, taking chromium picolinate, a form of chromium, for three months was associated with a drop in A1C. This study also suggests that chromium picolinate may be more effective than chromium chloride in lowering A1C. Chromium picolinate is thought to work by helping the body use glucose more efficiently, and is also a component of insulin.

Chromium has a strong link to insulin, which is the hormone that regulates
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  P1017is a drug that inhibits
 
Response: P1017is a drug that inhibits the activity of a protease (Protease X) which is a homolog of the human PACE4 protease. P1017 is in Phase II trials in humans for the treatment of Sjögren's syndrome, a chronic autoimmune disease.

In an article in the August 2007 issue of Autoimmunity, Dr. Oksenberg discusses P1017, and how it might be useful in the treatment of certain autoimmune diseases.

References

Category:Dietary supplements
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PA-824is a drug that inhibits
 
Response: PA-824is a drug that inhibits the growth of melanoma cells, as well as lung, ovarian, prostate, and colon cancers. When given to cancer patients, it can stop the growth of tumors and shrink them, even if they have already spread. In a study of 62 patients with advanced melanoma, 27% showed partial response, 38% had stable disease, and 25% had progressive disease. Among the patients who showed partial response, 86% had skin metastases. In a similar study of 26 patients with metastatic melanoma, the partial response rate was 27% (with 8% showing complete response). Side effects of PA-824 include gastrointestinal distress, nausea, and fatigue. The most common side effect was diarrhea, but it was usually mild and could be controlled with medications. Patients were required to have a minimum weight of 40 kg (88 lbs) to qualify for the trial. In the Phase II study, patients were given a dose of PA-824 twice
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Paclitaxelis a drug that inhibits
 
Response: Paclitaxelis a drug that inhibits microtubule dynamics and is widely used in the treatment of breast cancer and ovarian cancer. This drug can cause significant side effects including severe bone marrow toxicity and peripheral neuropathy. To reduce the side effects of paclitaxel, a variety of drug delivery systems have been developed and used to target drugs to tumor sites. However, these drug delivery systems are expensive and often ineffective in targeting the drugs to the tumor sites. Therefore, a cost effective and safe approach is required to increase the efficacy of drug delivery to tumor sites. In the present study, we evaluated the anti-tumor efficacy of the amphiphilic prodrug of paclitaxel (DSP-TAX) in mice bearing human ovarian cancer (OVCAR-3) xenografts. DSP-TAX was prepared by covalently linking the hydrophobic paclitaxel to the hydrophilic dextran sulfate (DS) chain of de
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pacritinibis a drug that inhibits
 
Response: Pacritinibis a drug that inhibits two enzymes, JAK1 and JAK2. It is currently approved for the treatment of myelofibrosis. We aimed to determine the toxicity profile of pacritinib in a Phase 1 dose-escalation study in adult patients with solid tumors.

METHODS:

We performed a Phase 1 dose-escalation study of pacritinib, a selective oral JAK1/2 inhibitor, in patients with solid tumors. In a modified 3+3 design, patients were enrolled in sequential cohorts. Dose escalation was based on toxicity. A total of 42 patients were enrolled, and 41 were evaluable for safety and 39 were evaluable for efficacy.

RESULTS:

Pacritinib was well tolerated at doses up to 40 mg/d, with the most common treatment-related adverse events (TRAEs) being fatigue (51%), nausea (29%), and diarrhea (25%). Most TRAEs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Paeoniflorinis a drug that inhibits
 
Response: Paeoniflorinis a drug that inhibits inflammatory processes and is used for treating arthritis and various autoimmune diseases. However, its efficacy is limited by the fact that the level of the active component is not high enough in the bloodstream. A common strategy to increase the level of a drug in the bloodstream is to enhance the efficiency of absorption from the gastrointestinal tract. This can be achieved by the use of surfactants, e.g., cationic, anionic, and nonionic surfactants. These compounds are well known for their ability to increase the solubility of poorly soluble drugs. Surfactants have also been shown to increase the bioavailability of drugs through various mechanisms, including increasing the rate of absorption and decreasing the rate of metabolism and elimination of the drug (R. B. Richman, Surfactant Drug Delivery, Marcel Dekker, Inc., New York, 1991).
Anionic surfactants are the most common surfactants used in drug delivery. However
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Paeonolis a drug that inhibits
 
Response: Paeonolis a drug that inhibits the synthesis of tumor necrosis factor-alpha, also known as TNF-alpha, in humans.

7

Paeonol (aka. Albizia julibrissin)

Paeonol is the major bioactive component of the traditional Chinese medicine, albizia julibrissin. Paeonol has been shown to have antioxidant, anti-inflammatory, and immunomodulatory activities.

8

Resveratrol (3,5,4'-trihydroxy-trans-stilbene)

Resveratrol is a phytoalexin found in grapes, blueberries, and other berries. In addition to being a potent antioxidant, resveratrol has been shown to have anti-inflammatory, anti-carcinogenic, and neuroprotective effects.

9

Spinosad (S)-spinosyn D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Palifosfamideis a drug that inhibits
 
Response: Palifosfamideis a drug that inhibits an enzyme called DNA polymerase beta (pol β) that is a part of the DNA repair system. The goal of this study was to evaluate the safety and activity of this drug when given in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer.

A Phase I study was conducted to determine the maximum tolerated dose (MTD) of this drug when given in combination with irinotecan and oxaliplatin. The study was also designed to determine the dose-limiting toxicities (DLTs) and recommended dose of this drug.

The study enrolled 43 patients with advanced colorectal cancer. They were given the following doses of the drug:

•100 mg/m2 on day 1

•120 mg/m2 on day 2

•140 mg/m2 on day 3

•150 mg/m2 on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Palmatineis a drug that inhibits
 
Response: Palmatineis a drug that inhibits cytochrome P450 (CYP450) enzymes in the liver. It is an ingredient in a number of herbal products and may cause side effects such as liver problems, nausea, stomach upset, allergic reactions, headache, and rash.

Pranolone(Latanoprost) is an anti-glaucoma medication that lowers the eye pressure.

Vasoconstrictors cause blood vessels to narrow. Examples of vasoconstrictors include epinephrine, norepinephrine, and isoproterenol.

Vasodilators cause blood vessels to widen. Examples of vasodilators include nitroglycerin and dopamine.

Bromocriptine(Parlodel) is a dopamine agonist used to treat Parkinson's disease.

Bromocriptine(Parlodel) is a dopamine agonist used to treat Parkinson's disease.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Palonosetronis a drug that inhibits
 
Response: Palonosetronis a drug that inhibits the actions of serotonin on the human gastrointestinal tract. It is administered as a single dose to prevent chemotherapy-induced nausea and vomiting (CINV). Palonosetron is chemically related to azasetron, but differs in that palonosetron does not possess the piperazine moiety found in azasetron.[@b1-asm-1-33] The recommended dose of palonosetron is 0.5 mg for patients receiving a single moderately or highly emetogenic chemotherapy agent. The agent is also recommended for patients who are receiving more than two emetogenic agents or who are experiencing CINV that is resistant to treatment with a 5-HT~3~ receptor antagonist (RA) or a corticosteroid.[@b2-asm-1-33]

The active metabolite of palonosetron, is the hydroxylated compound that acts as a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pamidronateis a drug that inhibits
 
Response: Pamidronateis a drug that inhibits the growth of tumor cells by inducing apoptosis and inhibiting the migration of tumor cells. It has been shown to be useful for treating patients with multiple myeloma (MM) and other tumors such as breast cancer and prostate cancer. The mechanism of action of pamidronate is unknown. However, it has been reported that pamidronate inhibits the secretion of several growth factors, including TGF-beta and IGF-1, from tumor cells, thereby causing apoptosis.
The compound of the present invention is pamidronate with a piperazine group in the structure. The compound has the structure: 
wherein R is a hydroxy group, an alkoxy group, a halogen atom, or a nitro group, and the pharmaceutically acceptable salts thereof.
Pamidronate is marketed in the form of the zwitterionic pamoate salt (Aredia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PAMINEis a drug that inhibits
 
Response: PAMINEis a drug that inhibits both the degradation and the recycling of the synaptic vesicle glycoprotein 2A (SV2A) ([@bib26]). The precise site of action of PAMINE is not yet known, but recent data suggest that it may act by binding to the phosphatidylinositol 4,5-bisphosphate (PIP~2~) head group of the membrane, in particular at the site of the Golgi apparatus ([@bib4]).

PAMINE was originally developed as a treatment for schizophrenia, but it is now known to have a broader spectrum of activity ([@bib14]). It is reported to have a modest efficacy in the treatment of acute and chronic schizophrenia, as well as the symptoms of bipolar disorder and in depression ([@bib12]; [@bib16]; [@bib23]; [@bib14]; [@bib18]; [@b
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pamiparibis a drug that inhibits
 
Response: Pamiparibis a drug that inhibits PARP, an enzyme that plays a role in repairing damaged DNA. It works by stopping the repair of single-strand breaks in DNA, which causes the body to try to repair it again and again. This eventually leads to the accumulation of single-strand DNA, which in turn causes cells to die off.

To get the full effects of the drug, it is best to start taking it within a week of your chemotherapy. It can also be used for breast cancer, ovarian cancer, prostate cancer, lung cancer, and brain cancer.

Prostate cancer

Side effects of temozolomide in prostate cancer include fatigue, hair loss, and bone marrow suppression.

Nivolumab

This is an immune-suppressing drug that targets the immune system to treat cancer. It is used to treat advanced melanoma and lung cancer.

It can cause severe immune system suppression, leading to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pancuroniumis a drug that inhibits
 
Response: Pancuroniumis a drug that inhibits the normal contraction of the
muscles, and thus paralyzes the patient, rendering it useless for
surgery. It was used as a chemical anaesthetic, and is used in the
form of a white, crystalline, tasteless, odorless, slightly bitter
powder, usually dissolved in water. It is also sometimes used
in the form of a prill, which is a fine white powder of the
crystalline nature, and is absorbed into the blood in the form of a
particulate substance, but does not produce any anaesthetic effect
until it has passed into the blood. It is insoluble in water, but
it dissolves in ether, alcohol, chloroform, and many other solvents.
It is also soluble in ether in a cold state. The action of the
paralytic depends on the nature of the part in which it is used,
and the duration of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pantoprazoleis a drug that inhibits
 
Response: Pantoprazoleis a drug that inhibits the gastric acid pump, H+/K+ ATPase, and thereby reduces the secretion of gastric acid in the stomach. It is used to treat peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Pantoprazole is marketed as esomeprazole, esoprazole, and as a generic drug as omeprazole. It is a white to off-white crystalline powder, with a molecular formula of C24H30N4O3S and a molecular weight of 456.56 g/mol.

Introduction

Pantoprazole is a proton pump inhibitor, used in the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Pantoprazole is a member of the phenylsulfon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Paromomycinis a drug that inhibits
 
Response: Paromomycinis a drug that inhibits the activity of caspases and is used in the treatment of chronic myelogenous leukemia. This drug is used as a control to determine the specificity of the cell death induced by TRAIL.\[[@CIT6]\]

Effect of oncogenic Ras on the death receptor induced apoptosis {#sec2-6}
---------------------------------------------------------------

Cell lines expressing oncogenic H-Ras have a high level of resistance to death receptor induced apoptosis. In H-Ras transformed cells, Fas-induced apoptosis is inhibited. In contrast, FasL-induced apoptosis is enhanced.\[[@CIT7]\] The same effect is observed in other Ras-transformed cell lines. The expression of oncogenic Ras increases the expression of FLIP and decreases the expression of caspase-8 and FADD.\[[@CIT7]\] Ras induces an autocrine stimulation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Paroxetineis a drug that inhibits
 
Response: Paroxetineis a drug that inhibits the reuptake of serotonin in the brain. It is a member of the SSRI group of antidepressants. It is prescribed to treat conditions such as major depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and generalized pain. It is available as a generic drug.

What is Paroxetine?

Paroxetine is a selective serotonin reuptake inhibitor. It is used to treat depression, anxiety, and panic attacks. It is available as a generic drug.

It is a drug that is effective for the treatment of major depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and generalized pain. It is also used to treat postpartum depression.

It belongs to the SSRI class of antidepressants. It works by increasing the amount of serotonin in the brain.

Paroxetine is used to treat a number
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Parthenolideis a drug that inhibits
 
Response: Parthenolideis a drug that inhibits NF-κB activation and cytokine production in LPS-stimulated monocytes and macrophages.^[@bib1],\ [@bib2]^ It is also known to inhibit the proliferation of human colon cancer cells.^[@bib3]^ Parthenolide has been used in human trials as an anti-inflammatory agent, and has shown beneficial effects in the treatment of rheumatoid arthritis and in multiple sclerosis.^[@bib4],\ [@bib5]^ Parthenolide has also been reported to inhibit the proliferation of melanoma cells and inhibit metastasis of lung cancer cells.^[@bib6],\ [@bib7]^

In contrast, parthenolide was shown to increase the metastasis of prostate cancer cells in a mouse model of prostate cancer, and the ability of parthenolide to inhibit the growth of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pasiniazidis a drug that inhibits
 
Response: pasiniazidis a drug that inhibits the growth of tumors by targeting on the vasculature of the tumors.

Sarcomas
Sarcomas are a heterogeneous group of malignant neoplasms derived from connective tissue, the cells of which grow in a variety of patterns and may have a different morphology. Sarcomas may be of bone, cartilage, fat, muscle, nerve, blood vessels, or connective tissue origin. Sarcomas are further classified by their tissue of origin into: soft tissue sarcomas, bone sarcomas, and sarcomas that arise in the blood vessels, nerve sheaths, or connective tissue. Sarcomas of the bone are further classified by their site of origin into osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Sarcomas are more common in men than in women. They occur most often in adults over age 60, and are more common
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pazopanibis a drug that inhibits
 
Response: Pazopanibis a drug that inhibits multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor (PDGFR) α and β, c-kit, and stem cell factor receptor (KIT) \[[@B1],[@B2]\]. It is used for the treatment of various solid tumors, including renal cell carcinoma, non-small cell lung cancer, and soft tissue sarcoma \[[@B3]\].

Pazopanib is known to cause hypertension, which is characterized by an increase in blood pressure (BP). However, its mechanism of action has not been fully elucidated. In a previous study, BP increased after the first administration of pazopanib in five patients \[[@B4]\]. This is consistent with a previous report \[[@B5]\]. The incidence of hypertension
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  p-Benzoquinoneis a drug that inhibits
 
Response: p-Benzoquinoneis a drug that inhibits protein synthesis by blocking the activity of a single tRNA synthetase.

1-p-Benzoquinone is a highly reactive chemical. It is a white solid with a bitter taste. Its molecular formula is C8H6O2.

It is used as an intermediate in the production of medicines.

It is used in photographic development.

It is used in the manufacture of dyes, and in pharmaceuticals and pesticides.

It is used as a catalyst for polymerization of phenolic resins.

It is used as a stabilizer for latex emulsions.

It is used in preparing paper pulp and cardboard.

It is used in photography.

2-p-Benzoquinone is a colorless crystalline compound. Its molecular formula is C8H6O2.

It is a powerful oxidizing agent. It can be used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PCI-32765is a drug that inhibits
 
Response: PCI-32765is a drug that inhibits the adenosine triphosphate-binding cassette (ABC) transporter P-glycoprotein (P-gp). The drug was developed to combat multidrug resistance in cancer cells, but has also been found to affect drug disposition in normal tissues. This study investigated the effect of concomitant use of P-gp and cytochrome P450 (CYP) 3A4 inhibitors on the pharmacokinetics of digoxin. In a randomized crossover study, 10 healthy volunteers received a single oral dose of digoxin (0.5 mg) on two occasions. On one occasion, the volunteers received digoxin alone, and on the other occasion digoxin with the P-gp inhibitor verapamil (CYP3A4 inhibitor) and on a third occasion digoxin with both verapamil and ketoconazole (CYP3A4 and P-gp inhibitor). Plasma concentrations of digoxin were determined for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  p-Cresolis a drug that inhibits
 
Response: p-Cresolis a drug that inhibits the biosynthesis of the aromatic amino acids, which are required for porphyrin synthesis. Treatment with either compound induces a rapid accumulation of pre-ribosomal particles that carry no mRNAs. These particles are immediately recognized and rapidly degraded in a proteasome-dependent manner. We show that the accumulation of these particles is associated with the induction of an mRNA decay pathway that appears to involve NMD. Our data indicate that this pathway is triggered by the accumulation of premature termination codons (PTCs) in some mRNAs. We also show that PTCs in some mRNAs are present in pre-ribosomal particles and that this pre-ribosomal PTCs accumulation is due to the inhibition of pre-rRNA processing.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PD-0332991is a drug that inhibits
 
Response: PD-0332991is a drug that inhibits the activity of the PD-1/PD-L1 immune checkpoint. In preclinical studies, PD-0332991 has shown anti-tumor activity against multiple tumor types. In clinical trials, PD-0332991 has shown anti-tumor activity against melanoma, non-small cell lung cancer, head and neck cancer, and urothelial cancer. In April 2014, it was approved by the US FDA for the treatment of patients with advanced melanoma. PD-0332991 is being developed by Pfizer Inc. and is currently being investigated in several other cancer types. PD-L1, the target of PD-0332991, is expressed on the surface of tumor cells and is often upregulated by IFN-γ. However, PD-L1 expression is not always correlated with clinical response to PD-0332991.

A new study in Nature Cancer Cell suggests that in contrast
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pefloxacinis a drug that inhibits
 
Response: Pefloxacinis a drug that inhibits human angiotensin-converting enzyme (ACE). It also has potent vasodilatory properties and can be used in treating high blood pressure. It has been used in combination with diuretics to treat edema. It also is used in treating heart failure and asthma.

Cimetidine, ranitidine, nizatidine, and the oral antihistamine diphenhydramine are used to treat ulcers. Cimetidine and ranitidine are also used in treating ulcers in people who have taken the ulcer drug ranitidine.

Chlorpheniramine is used to treat allergies. It can be used alone or in combination with other drugs. It is sometimes used in combination with a drug called pseudoephedrine to treat congestion and nasal allergies.

Chlorpromazine is used to treat mental disorders. It also is used to treat depression and schizophrenia. It is sometimes used
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pefloxacineis a drug that inhibits
 
Response: Pefloxacineis a drug that inhibits the replication of bacteria that cause diseases such as sinusitis, pneumonia, tonsillitis, mastoiditis, and scarlet fever. It is used to treat infections caused by bacteria.

This drug is also used to treat inflammation of the bladder, gonad, ovary, uterus, and other parts of the body.

Pefloxacineis a topical drug that is used to treat certain types of skin infections. It is also used to treat certain skin conditions such as acne.

It is used to treat some types of fungal infections, such as athlete's foot.

This drug is also used to treat or prevent diseases such as meningitis, respiratory tract infections, and some forms of pneumonia.

This drug is also used to treat and prevent some types of pneumonia.

Pefloxacineis a drug that treats bacterial infections of the skin, including boils, carb
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pemetrexedis a drug that inhibits
 
Response: Pemetrexedis a drug that inhibits multiple sites of the enzymatic machinery responsible for DNA replication and transcription, and thus exerts its cytotoxic activity in multiple ways \[[@b1]\]. It is used in non-small cell lung cancer (NSCLC) to treat both squamous cell carcinoma and adenocarcinoma, and is currently approved for the treatment of advanced-stage disease. In addition, it is used in combination with cisplatin and gemcitabine in the treatment of metastatic urothelial carcinoma. In the second-line treatment of advanced NSCLC, the median survival is 4.5 months, with a median overall survival of 8.5 months in patients treated with a combination of gemcitabine and cisplatin, and 3.8 months in patients treated with pemetrexed \[[@b2]\]. The National Comprehensive Cancer Network (NCCN) guidelines recommend pemet
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pemirolastis a drug that inhibits
 
Response: Pemirolastis a drug that inhibits mast cell mediator release, but not histamine. The effect of the drug on human intestinal mast cells has not been investigated.

The pharmacology of the drug is discussed, including absorption, metabolism, excretion, and toxicity.

Abstract

Pemirolast (AR-L 115 BS) is a new leukotriene modifier that has been shown to be effective in clinical trials in patients with chronic urticaria and in patients with aspirin-induced urticaria. Because the drug inhibits the release of inflammatory mediators from mast cells, we investigated its effects on human intestinal mast cells. Mast cells were isolated from duodenal mucosa obtained at surgery for removal of a malignant tumor. Mast cells were studied with respect to their mediator content, histamine release, and response to pemirolast. The presence of the drug in the media was determined by high-performance liquid chromatography. Pemi
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Penbutololis a drug that inhibits
 
Response: Penbutololis a drug that inhibits both PDE4 and PDE5. It is thought to have both the anti-inflammatory and the erectogenic effects of sildenafil, but is absorbed more rapidly and has fewer side effects. Its side effects include headaches, flushing, and visual disturbances.

References

External links
 
 

Category:PDE inhibitors
Category:Phosphodiesterase inhibitors
Category:Phosphate esters
Category:Piperidines
Category:Carboxylate esters
Category:Cyclopentanes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pencicloviris a drug that inhibits
 
Response: Pencicloviris a drug that inhibits the fusion of cells

Adsorption, flocculation, and sedimentation: What you need to know about these three key steps in water treatment, including treatment methods, controls, and mitigation. Findings from the first of a series of papers on polymer science and water treatment. The most widely used microorganisms for treatment of wastewater are bacteria and fungi, and in some cases, algae. A few examples include the algal blooms in Lake Erie and the Florida Everglades, as well as the algal blooms that are prevalent in China's lakes. A large variety of bacteria are also present in the human body, as well as on plant surfaces, in soil, and in water. The number of species is believed to be in the millions, although the exact number is unknown. Research on the various microbes has revealed their usefulness in a variety of applications, including bioremediation, biotransformation, and even space
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PENETREXis a drug that inhibits
 
Response: PENETREXis a drug that inhibits tumor growth in animal models by inducing apoptosis of tumor cells. It has been approved for the treatment of hormone refractory prostate cancer. Recent studies have shown that PENETREXis may also be useful for treating breast cancer. PENETREXis is an anti-tumor drug that is derived from natural compounds. It has been used in the treatment of prostate cancer for several years, and more recently, in the treatment of breast cancer. The effect of PENETREXis on tumor growth is associated with its effect on tumor cell apoptosis. PENETREXis is thought to induce tumor cell apoptosis by inhibiting caspase activity and by activating transcription factor NF-kappaB. This review will discuss the preclinical and clinical studies on the effect of PENETREXis on tumor cell apoptosis and tumor growth, and the potential mechanism of PENETREXis in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  penfluridolis a drug that inhibits
 
Response: penfluridolis a drug that inhibits the formation of the proteins that form the blood clots. In February, FDA officials said a study of the drug showed that it worked to prevent strokes in people with carotid artery stenosis.

The study showed that the drug reduced the risk of a stroke in patients with carotid artery stenosis by 40 percent. But patients who took the drug were more likely to have major bleeding and had higher rates of heart attacks.

In addition, FDA officials said they were concerned about the drug’s potential for bleeding in patients who already have a blood clot in the brain.

FDA officials have said the drug, marketed as Xarelto, was approved to treat patients who have had a stroke. But the drug’s label says it can be used for other conditions, including deep vein thrombosis, pulmonary embolism and unstable angina.

The FDA said it would consider whether the drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pentadecanoicis a drug that inhibits
 
Response: Pentadecanoicis a drug that inhibits S1P receptors, including S1P1, S1P2, and S1P3, to induce neurogenesis, promote neuronal differentiation, and inhibit apoptosis. It has been reported that pentadecanoic acid can improve neurogenesis, promote neuronal differentiation, and inhibit apoptosis in animal models of brain damage (Kuo et al., J. Pharmacol. Exp. Ther. 301:86-93 (2002); Oki et al., Neuroreport. 12:2535-2539 (2001); Oki et al., J. Pharmacol. Exp. Ther. 296:1370-1377 (2001)). Further, it has been reported that pentadecanoic acid can be used for treating neurodegenerative diseases (WO 2004/062286 A2; WO 2005/058263 A2).
A mouse model of traumatic brain injury (TBI) was prepared by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pentamidineis a drug that inhibits
 
Response: Pentamidineis a drug that inhibits the lysosomal enzyme, hexosaminidase, which plays a key role in the formation of hyaluronan (HA). HA is a glycosaminoglycan (GAG) which is a major component of the extracellular matrix. It is found in the brain, spinal cord, lung, heart, placenta, and in other tissues and fluids. It has a high molecular weight (MW) and has been shown to play an important role in cell proliferation and differentiation. HA has also been shown to be involved in angiogenesis, metastasis, wound healing, and inflammation.
HA is a polysaccharide consisting of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. The most abundant GAG is HA, which is present in the intercellular matrix and in the basement membranes of epithelial cells. It is also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pentetateis a drug that inhibits
 
Response: pentetateis a drug that inhibits the formation of histamine from histidine by acting as an inhibitor of histidine decarboxylase. It has also been shown to reduce the intensity of allergic symptoms, and has been used to treat atopic dermatitis. Pentetate can be given orally or by injection, and is available in tablet form.

Side effects
In addition to being very toxic, pentetate can cause seizures, particularly in children, so it is only used in patients who have been monitored for adverse effects.

References

Category:Antihistamines
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pentoxifyllineis a drug that inhibits
 
Response: pentoxifyllineis a drug that inhibits leukocyte adhesion to the endothelium and also blocks platelet aggregation. In recent years, its use has been extended to other diseases, including thrombotic disorders, such as thrombotic thrombocytopenic purpura (TTP) and sickle cell disease. There is evidence that pentoxifylline has other biological effects, including the ability to inhibit the proliferation of human malignant cells, such as melanoma cells. This review discusses the biological and clinical aspects of pentoxifylline and its role in thrombotic disorders, in particular, TTP.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pergolideis a drug that inhibits
 
Response: Pergolideis a drug that inhibits the release of acetylcholine and dopamine. It is prescribed to treat Parkinson’s disease, restless leg syndrome, and sleep apnea. It is available in a variety of dosages and forms, including a long-acting injection. It is also sold as a generic drug.

We compared the cost of a 1-year supply of pergolide with the cost of a 1-year supply of levodopa/carbidopa, a generic form of pergolide.

The data for our analysis came from Truven Health Analytics. The Truven Health Analytics data for this analysis are proprietary, and we were not given direct access to this data.

Methodology

To calculate the cost of a 1-year supply of pergolide, we subtracted the average wholesale price of a 1-year supply of pergolide (which is available as a generic drug) from the average
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Permethrinis a drug that inhibits
 
Response: Permethrinis a drug that inhibits the production of the nerve impulse in the nerve cell. It is one of the most effective insecticides for the treatment of head lice, body lice, and pubic lice.

Oral route of administration

Permethrin is available in a variety of formulations including:

Wear clothing treated with permethrin at least 6 hours before applying the product.

For external use only.

For treatment of the head, pubic areas, and intimate areas only.

For treatment of the head, pubic areas, and intimate areas only.

For treatment of the head, pubic areas, and intimate areas only.

For treatment of the head, pubic areas, and intimate areas only.

For treatment of the head, pubic areas, and intimate areas only.

For treatment of the head, pubic areas, and intimate areas only.

For
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PERPHENAZINEis a drug that inhibits
 
Response: PERPHENAZINEis a drug that inhibits the action of the hormone epinephrine. It is used in the treatment of colds, fevers, asthma, and hypertension.

CASRN172691-86-6

PERPHENAZINEis a drug that inhibits the action of the hormone epinephrine. It is used in the treatment of colds, fevers, asthma, and hypertension.

CASRN172691-87-3

PERPHENAZINEis a drug that inhibits the action of the hormone epinephrine. It is used in the treatment of colds, fevers, asthma, and hypertension.

CASRN172691-88-7

PERPHENAZINEis a drug that inhibits the action of the hormone epinephrine. It is used in the treatment of colds, fevers, asthma, and hypertension.

CASRN172691-89
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-00080665is a drug that inhibits
 
Response: PF-00080665is a drug that inhibits the receptor of P2Y12 and its therapeutic effects on platelet aggregation, thrombus formation and inflammation have been investigated in clinical trials.[@CIT0018],[@CIT0019] Therefore, the effect of MPF-00080665 on RBCs was also examined in the present study.

A novel platelet agonist-induced aggregation assay was used to assess the effect of MPF-00080665 on platelet aggregation in platelet-rich plasma (PRP) from healthy volunteers. Our data showed that MPF-00080665 had a dose-dependent inhibitory effect on the platelet aggregation induced by adenosine diphosphate (ADP), epinephrine (EPI) and collagen (COL), with the inhibition rate of 22.9%, 26.5% and 28.3%, respectively. The concentration of MPF-00080665 that inhibited 50% of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-03084014is a drug that inhibits
 
Response: PF-03084014is a drug that inhibits the replication of the virus by interfering with the virus's ability to translate its RNA genome into proteins.

The FDA has approved PF-03084014 for the treatment of adult patients with chronic hepatitis C genotype 1 infection who have failed to respond to, or are intolerant of, prior therapy with an NS3/4A protease inhibitor.

Patients who are considered for treatment with PF-03084014 should be closely monitored for evidence of decompensated liver disease and signs and symptoms of an acute exacerbation of underlying hepatitis C.

Because patients may have an increased risk of decompensated liver disease and a worsening of their underlying hepatitis C infection, patients should be monitored for the emergence of adverse events, including worsening of chronic hepatitis C or the development of an acute exacerbation of underlying hepatitis C, while taking PF-03084014.

PF-03084014 should be used in combination with other antiv
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-04449913is a drug that inhibits
 
Response: PF-04449913is a drug that inhibits caspase-3 and caspase-7 in human lung fibroblasts, it has been shown to be safe and well tolerated in humans at doses up to 15 mg/kg. This study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04449913 in healthy volunteers.

Study 1: Effect of Single Doses of PF-04449913 on Caspase-3 and Caspase-7 Activity in Human Lung Fibroblasts in Vitro

Study 2: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-04449913 in Healthy Volunteers

The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04449913 in healthy volunteers were assessed in two double-blind, placebo-controlled, randomized, ascending dose, single-center, multiple-dose, Phase I studies. In each
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-04457845is a drug that inhibits
 
Response: PF-04457845is a drug that inhibits the CXCL12/CXCR4 interaction by binding to the extracellular domain of CXCR4, thereby preventing CXCL12 from binding to CXCR4.

As described in the *Introduction*, hBM-MSCs were cultured in the presence of 1 μM PF-04457845 or vehicle for 24 h. Next, hBM-MSCs were harvested and CXCL12 expression was measured by real-time PCR. As shown in [Fig. 3](#f0015){ref-type="fig"}A, CXCL12 mRNA expression was decreased in the presence of PF-04457845. To investigate the effects of PF-04457845 on CXCL12 expression, hBM-MSCs were treated with 1 μM PF-04457845 for 24 h. The protein levels of CXCL12 were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-04965842is a drug that inhibits
 
Response: PF-04965842is a drug that inhibits the CXCR4 receptor, which is expressed in the lymph nodes and where HIV-1 is known to establish a persistent infection. Preclinical studies have shown that this drug can inhibit the ability of HIV-1 to infect CD4+ T cells and macrophages and can block the infection of these cells by HIV-1 variants. This drug is under evaluation in clinical trials. It has also been shown that administration of this drug to rhesus macaques infected with SIV (simian immunodeficiency virus) resulted in a delay in the appearance of virus in the peripheral blood and in a significant decrease in the number of CD4+ T cells. These data suggest that this drug may be effective in blocking the infection of cells that are the targets for HIV-1 and in slowing the progression of HIV-1 infection.

Safety profile

In the phase I trial, 12 of the 15 patients who received more than
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-05208749is a drug that inhibits
 
Response: PF-05208749is a drug that inhibits Cdk9 and Cdk7. It has shown a strong inhibitory activity in preclinical studies \[[@B28-ijms-18-00785],[@B29-ijms-18-00785]\]. PF-05208749 inhibits the growth of colon cancer cells \[[@B30-ijms-18-00785]\] and induces the apoptosis of breast cancer cells \[[@B31-ijms-18-00785]\]. PF-05208749 also has an inhibitory effect on pancreatic cancer \[[@B32-ijms-18-00785]\]. Recently, a Phase I study of PF-05208749 in advanced solid tumors was conducted. A dose-limiting toxicity was observed at dose level 4. However, a Phase II study is ongoing.

2.2. BI2536 {#sec2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-06463922is a drug that inhibits
 
Response: PF-06463922is a drug that inhibits c-Met. The c-Met inhibitor is a potent and selective tyrosine kinase inhibitor that inhibits c-Met activity, and exhibits antitumor activity in vitro and in vivo in models of human cancers. However, no therapeutic effects were observed in clinical trials, due to the high toxicity associated with the drug. The present study was undertaken to examine the safety and tolerability of PF-06463922 when administered as a single oral dose to healthy male volunteers in a randomized, placebo-controlled, double-blind study.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-06651600is a drug that inhibits
 
Response: PF-06651600is a drug that inhibits the mitotic kinesin Eg5. The drug is in clinical development for the treatment of cancer.

MGS-039 (Figure [1](#Fig1){ref-type="fig"}A) is a new small molecule inhibitor of Eg5, a mitotic kinesin required for spindle assembly and chromosome segregation during mitosis. The drug is currently in Phase II clinical trials for the treatment of multiple myeloma (MM).Figure 1**Structures of MGS-039 and PF-06651600. (A)** Chemical structure of MGS-039. **(B)** Chemical structure of PF-06651600.

Eg5 is a microtubule-based motor protein that is required for proper spindle formation and chromosome segregation. Eg5 is highly overexpressed in multiple myeloma, and it has been demonstrated that inhibition of Eg5 with mon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-06700841is a drug that inhibits
 
Response: PF-06700841is a drug that inhibits the mitotic kinesin Eg5, thereby arresting the cell cycle in the G2/M phase and leading to mitotic arrest and apoptosis. In a phase I clinical trial, the drug demonstrated significant anti-tumor activity in a broad range of solid tumors. Unfortunately, clinical trials in which the drug was administered at dose levels up to its MTD resulted in an unacceptable number of dose-limiting toxicities. One such toxicity was a reversible, but severe, visual impairment that resulted in blindness in a number of patients. Although this effect is reversible, there is no treatment available that is currently effective in mitigating the toxicity.

PF-06700841 is a thiadiazole compound that is structurally similar to the clinically available anticancer drug flavopiridol. Both drugs are inhibitors of the mitotic kinesin Eg5.

A number of thiadiazole compounds have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF-2341066is a drug that inhibits
 
Response: PF-2341066is a drug that inhibits cell proliferation and induces apoptosis in human prostate cancer cells, and has shown clinical activity in patients with prostate cancer (WO 01/76549; WO 01/85935).
Cancer Therapy Agents
As described above, cell proliferation and apoptosis are regulated by a variety of cell cycle checkpoint proteins. Some checkpoint proteins have been shown to be involved in the development and progression of cancer, and are thus attractive targets for the development of anti-cancer drugs. The checkpoint proteins may act in combination or independently, and it is desirable to target combinations of proteins to maximize the efficacy of the anti-cancer drugs.
In addition, it has been reported that checkpoint proteins are expressed in both normal and cancer cells, and may be a target for anti-cancer drugs. For example, BUB1 is expressed in both cancer and normal cells, and inhibition of BUB1 with small molecule inhibitors results in a selective inhibition of cancer cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PF299804is a drug that inhibits
 
Response: PF299804is a drug that inhibits the activity of the human drug target purine nucleoside phosphorylase (PNP), an enzyme that plays a key role in the metabolism of purine nucleosides. PNP is a cytosolic enzyme that catalyzes the reversible conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP). IMP is a substrate for inosine 5′-monophosphate dehydrogenase (IMPDH) which produces xanthosine 5′-monophosphate (XMP), the metabolite that is the precursor of guanosine triphosphate (GTP). GTP is the energy currency of the cell.
PNP has also been shown to convert inosine and deoxyadenosine to hypoxanthine and deoxyguanosine, respectively. Thus, PNP is important for the regulation of purine nucleoside
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PHA-848125is a drug that inhibits
 
Response: PHA-848125is a drug that inhibits the activity of the enzyme phosphoinositide 3-kinase (PI3K). PI3K is a lipid kinase that plays a central role in signal transduction. Activation of PI3K results in the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn binds to pleckstrin homology (PH) domain-containing proteins. The activity of the PI3K enzyme is regulated by a variety of extracellular stimuli, and can be activated by receptor tyrosine kinases, G-protein coupled receptors, cytokines and other signaling molecules. PI3K activity is implicated in a number of cellular functions, including proliferation, differentiation, migration, apoptosis and glucose transport.
PI3K is a heter
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenacetinis a drug that inhibits
 
Response: Phenacetinis a drug that inhibits the growth of cancer cells. The dosage of phenacetin is similar to the dosage of acetaminophen. The recommended dosage of phenacetin is 40 mg/kg/day, which is equivalent to approximately 2.5 g/day for a 70 kg person. Phenacetin has been available for many years as a nonprescription product and is still available over the counter in the United States. The Food and Drug Administration has determined that phenacetin is a carcinogen and the risk of cancer increases with the dosage of phenacetin. For this reason, the use of phenacetin is contraindicated in children and young adults.
Phenacetin is also known as acetaminophen, N-acetyl-p-aminophenol, and p-acetamidophenol. Phenacetin is a synthetic analgesic drug that is used for the relief of mild to moderate pain. The recommended dosage of phenacetin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenazopyridineis a drug that inhibits
 
Response: Phenazopyridineis a drug that inhibits the platelet function. This drug is used to treat the symptoms of acute coronary syndrome such as angina, heart attacks, and unstable angina. Phenazopyridine may also be used to prevent the formation of blood clots in patients who are taking anticoagulants such as warfarin or Coumadin.

Q: Is Phenazopyridine available over the counter?

A: No. Phenazopyridine is available by prescription only.

Q: How does phenazopyridine work?

A: Phenazopyridine is a drug that inhibits the platelet function. This drug is used to treat the symptoms of acute coronary syndrome such as angina, heart attacks, and unstable angina. Phenazopyridine may also be used to prevent the formation of blood clots in patients who are taking anticoagulants such as warfarin or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenforminis a drug that inhibits
 
Response: Phenforminis a drug that inhibits the bacterial protein synthesis. It has been approved by FDA for the treatment of human amebiasis.^[@R1]^

Sulfonamides are a large group of heterocyclic compounds. They were first introduced in 1940s for the treatment of bacterial infections.^[@R2]^ There are two general types of sulfonamides:

1.  aryl sulfonamides

2.  heterocyclic sulfonamides

The aryl sulfonamides are the oldest and most common class of sulfonamides. The drugs in this class are highly effective against bacteria, parasites, and fungi. They are widely used in the treatment of bacterial infections. The most common sulfonamides are the sulfamethoxazole (SMZ), sulfadiazine (SDZ), sulfadoxine (SDX), sulfamethazine (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pheniramineis a drug that inhibits
 
Response: pheniramineis a drug that inhibits histamine release. It is used to treat hay fever and allergic rhinitis.

phenobarbital

a barbiturate.

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital

phenobarbital
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenoxybenzamineis a drug that inhibits
 
Response: Phenoxybenzamineis a drug that inhibits the action of the sympathetic nervous system. It was originally used as a local treatment for angina pectoris, and is now used as a diagnostic tool for pheochromocytoma, and to treat erectile dysfunction. It is also used as a nasal decongestant.

Its mode of action is by blocking alpha1- and alpha2-adrenoceptors, resulting in decreased sympathetic tone.

It is a highly selective α1-adrenergic receptor antagonist and acts peripherally at the post-synaptic level, where it is believed to interfere with the release of norepinephrine. It is also a weak antagonist at the post-synaptic α2-adrenergic receptors, and a weak agonist at α1-adrenergic receptors.

Phenoxybenzamine acts primarily in the central nervous system, where it binds to presynaptic α1-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenprocoumonis a drug that inhibits
 
Response: Phenprocoumonis a drug that inhibits the production of vitamin K-dependent coagulation factors. It is mainly used to treat excessive bleeding in patients with a history of stroke or thromboembolic events. It is also used in the treatment of atrial fibrillation, acute deep vein thrombosis, pulmonary embolism and other indications. This drug is a member of the coumarin class of anticoagulants.

2.2. Overview of Anticoagulant Drugs {#sec2dot2-ijerph-15-02876}
------------------------------------

Anticoagulants are used to prevent blood clots from forming in the blood vessels. Blood clots can form in a variety of places in the body, including the arteries and veins. Anticoagulants prevent the blood from clotting and causing clots to form. There are four main types of anticoagulants: Vitamin K antagonists
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phensuximideis a drug that inhibits
 
Response: Phensuximideis a drug that inhibits the release of histamine from mast cells and basophils. It is used to treat allergies and is also used as an anti-spasmodic.

Some research suggests that phensuximide can help to reduce symptoms of fibromyalgia, but the quality of this research is poor. It is unclear whether phensuximide can be used to treat other conditions.

Common side effects include drowsiness, headaches, and blurred vision. If you experience any side effects that are especially bothersome or don't go away, stop taking the medication and contact your doctor.

Does This Medication Interact With Other Medications?

Phensuximide is known to interact with the following medications:

alprazolam (Xanax)

caffeine

cyclobenzaprine (Flexeril)

fentanyl

fluox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phentolamineis a drug that inhibits
 
Response: Phentolamineis a drug that inhibits the alpha1-adrenoceptor, it is a selective alpha1-adrenoceptor antagonist. This action makes it useful for treating high blood pressure and some forms of glaucoma. It is also used to relax the uterus and intestines, treat Raynaud’s syndrome and reduce blood pressure in people with hypertrophic cardiomyopathy.

Phentolamine has been shown to reduce blood flow to the prostate and testes in animals, which may explain the possible association of this drug with a decrease in male fertility. However, no such association has been observed in humans. It is therefore not considered to be a cause of male infertility.

What does this drug look like?

Phentolamine comes in the form of a white to off-white or yellowish powder.

It is available as a solution, an oral tablet, and a topical cream.

How do I
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenylephrineis a drug that inhibits
 
Response: Phenylephrineis a drug that inhibits alpha1-adrenergic receptors in the brain. The main effect is to increase blood pressure.

Phenylephrine is an alpha1-adrenergic agonist, which is a partial agonist at the alpha1B-adrenergic receptor. It is also a relatively weak partial agonist at the alpha1A-adrenergic receptor. In addition to increasing blood pressure, phenylephrine increases heart rate and contractility of the heart. It has a shorter duration of action than epinephrine and is more potent than norepinephrine, and thus may be useful in certain situations where norepinephrine or epinephrine would not be used.

Phenylephrine is an alpha1-adrenergic agonist, a class of drug that mimics the effects of adrenaline. This is a very useful drug when one wants to increase blood pressure or increase heart rate, but it is not a good choice
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenylglyoxylicis a drug that inhibits
 
Response: Phenylglyoxylicis a drug that inhibits collagenase and gelatinase.

Morphine is a semi-synthetic opioid, with similar effects to codeine, which is a semi-synthetic opioid derived from morphine.

Morphine is an opiate derived from opium, and is an agonist at the mu-opioid receptor. It is also an antagonist at the delta-opioid receptor. It is a strong analgesic and a sedative, and can be used to treat moderate to severe pain, nausea, vomiting, and diarrhea.

Morphine is a potent agonist of the mu-opioid receptor. It produces effects similar to other opioids such as fentanyl and meperidine, but it has a shorter half-life and is less likely to cause respiratory depression than other opioids.

Morphine has a similar efficacy to other opioids in pain relief, but has a slightly higher risk of respiratory depression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phenytoinis a drug that inhibits
 
Response: Phenytoinis a drug that inhibits growth of cancer cells by inducing apoptosis (programmed cell death). It works by interfering with the production of a protein called Ras. Ras is a small protein that is produced in every cell.

Gemcitabine is a drug that prevents DNA from being replicated by cancer cells. It works by preventing the DNA from being copied.

Mesna is a drug that helps prevent the toxicity of chemotherapy drugs. Mesna works by binding to chemotherapy drugs that cause toxic effects in the body.

Capecitabine is a drug that prevents DNA from being replicated by cancer cells. It works by preventing the DNA from being copied.

Folic acid is a vitamin that is important for healthy growth and development of the baby. It is a natural form of folic acid. It is found in foods such as beans, lentils, peas, and spinach.

The "8s" of nutrition: 8 healthful
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Phthalicis a drug that inhibits
 
Response: Phthalicis a drug that inhibits
the effects of corticosteroids in the body. It is used to treat some
types of inflammation, such as in the middle ear, where corticosteroids
would have a suppressive effect. It can also be used in the eye to treat
inflammation of the eye. It is given by injection.

Aromatase Inhibitors:

Aromatase inhibitors (AI) are a
class of drugs used to treat women with breast cancer who have estrogen
receptor positive (ER+) tumors that are responsive to hormone therapy.
They are also used to treat women with estrogen-sensitive early stage
breast cancer.

It is important to note that the AI class
of drugs is not a type of hormone therapy (HT). HT includes the drugs
letrozole, anastrozole, exemestane, and goserelin. AI is used as a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  phthalylsulfacetamideis a drug that inhibits
 
Response: phthalylsulfacetamideis a drug that inhibits acetylation. In order to investigate its action mechanism, we used it as a tool to study the effect of the acetylation status of serum albumin on the anticonvulsant activity of phenytoin. The results indicated that phenytoin was most effective when the acetylation status of serum albumin was in the hypoacetylated state.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Picolinicis a drug that inhibits
 
Response: Picolinicis a drug that inhibits the enzyme acetyl-CoA carboxylase (ACC). Inhibition of ACC results in increased fatty acid oxidation, decreased triglyceride synthesis and decreased insulin-stimulated glucose uptake and glycogen synthesis. Picolinic acid has been used to treat type 2 diabetes and obesity in animals and in humans, but it is not currently approved for use in humans. The oral bioavailability of picolinic acid is low and extensive first pass metabolism occurs in the liver. It is metabolized to N-acetyl-p-amino-benzoic acid, which is the major circulating metabolite.
The chemical structure of picolinic acid is:

Dihydropicolinic acid (DHP) is a structural analog of picolinic acid that is a prodrug for picolinic acid. DHP is a water-soluble salt of picolinic acid that can be administered orally and that has a bioavailability
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Picrotoxininis a drug that inhibits
 
Response: Picrotoxininis a drug that inhibits the release of neurotransmitters from their receptors, thus it is used in the treatment of epilepsy.

It is widely used in veterinary medicine to treat horses and cattle.

The first use of picrotoxinin was by John Tyndall (1821–1893) who isolated it in 1858. It was originally used as a nerve poison, but it was discovered to be a potent antagonist of the GABA receptor. It was also found to have use in the treatment of human epilepsy.

In humans, picrotoxinin is a controlled substance in the United States, while it is a restricted substance in Australia.

Mode of action
Picrotoxinin binds to the gamma-aminobutyric acid (GABA) receptor. This prevents the GABA from binding to the receptor and inhibiting the transmission of the message.

References

External links
 

Category:Gamma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pidotimodis a drug that inhibits
 
Response: Pidotimodis a drug that inhibits IFN-γ in a similar way to anti-TNF-α agents. It is used to treat autoimmune disorders, including multiple sclerosis, Crohn's disease, ulcerative colitis, and psoriasis.[@b1-mjhid-3-1-e2011032]--[@b3-mjhid-3-1-e2011032] We describe a patient with a history of anti-TNF-α therapy, who developed acute liver failure and cholestatic jaundice after two weeks of treatment with a combination of anakinra and pidotimod.

Case Report
===========

A 38-year-old man, with a history of ulcerative colitis, was admitted to our hospital for acute hepatitis with jaundice. The patient had been treated with adalimumab for 5 months, in combination with methotrexate,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pilocarpineis a drug that inhibits
 
Response: Pilocarpineis a drug that inhibits the parasympathetic nervous system. Pilocarpineis an alkaloid that is a derivative of the mandrake plant (Mandragora officinarum). The plant is native to Europe, Asia, and Africa. In Asia, it is a component of a traditional medicine called kampo (Japanese) or kyoho (Korean). It is an ingredient in the following traditional Chinese medicine preparations: Xiao-chai-hu-tang (Wu-Chai-Hu-Tang), and Ban-xia-Xie-Xin-Tang. Pilocarpinehas been used as a therapeutic agent for glaucoma, including chronic open-angle glaucoma, and for epilepsy, as a local anesthetic agent, and as an agent to prevent postoperative nausea and vomiting.

Pilocarpineis the active ingredient in Pilocarpine-HCl (Marketed as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pimavanserinis a drug that inhibits
 
Response: Pimavanserinis a drug that inhibits angiogenesis, has been used to treat a number of human malignancies.\[[@ref1]\] Vascular endothelial growth factor (VEGF) is a major angiogenic factor and has been implicated in the growth of various human cancers. VEGF receptors are found on the endothelial cells and its binding induces the proliferation of endothelial cells, migration of endothelial cells and angiogenesis.\[[@ref2]\]

Pimavanserin (previously known as AL-108 or ML-1038) is a novel non-immunosuppressive antipsychotic agent which selectively binds to the 5-hydroxytryptamine (5-HT~2A~) receptor with a much higher affinity than to the 5-HT~2C~ receptor. Pimavanserin binds to the 5-HT~2A~ receptor, resulting in inhibition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pimobendanis a drug that inhibits
 
Response: Pimobendanis a drug that inhibits the conversion of phosphoenolpyruvate to oxalacetate, which in turn inhibits the activity of the enzyme phosphofructokinase-1. Pimobendan has been used clinically for over a decade for the treatment of heart failure. The heart failure drug is used as a diuretic to decrease fluid retention. The use of the drug is contraindicated in patients with an acute myocardial infarction, diabetes, or thyroid disease.
Pimobendan is chemically described as 2-ethyl-4-methyl-5-oxo-1,4,5,6,7,8,8a-octahydro-3H-imidazo[4,5-c]pyridazino[3,4-d]pyrimidine-3-carboxylic acid. The chemical structure of pimobendan is illustrated below:

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pimozideis a drug that inhibits
 
Response: pimozideis a drug that inhibits the enzyme dopamine-beta-hydroxylase, an enzyme responsible for the synthesis of dopamine. It is used to treat the psychotic symptoms of schizophrenia and for the treatment of pheochromocytoma, as it also inhibits the enzyme catechol-O-methyltransferase. It has been shown to be effective in the treatment of akathisia, a symptom of antipsychotic drug withdrawal. It is marketed under the brand name Prozac.

Pimozide was introduced for the treatment of depression in the United States in 1969. In 1976, the Food and Drug Administration approved it for the treatment of akathisia.

Pimozide is rapidly and almost completely absorbed after oral administration. The absolute bioavailability is 93%.

Pharmacology

Pimozide is an inhibitor of dopamine-beta-hydroxylase and catechol-O-methyltransferase. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pinacidilis a drug that inhibits
 
Response: Pinacidilis a drug that inhibits the activity of a certain type of potassium channel in the heart and blood vessels, thereby increasing blood flow to the heart and the brain. It has also been used to treat high blood pressure, angina, and heart rhythm problems.

Like many other prescription medications, you can purchase pinacidil in generic form. The cost of generic pinacidil is lower than the cost of the brand-name drug.

Brand-name and generic forms of pinacidil are both available in the United States. The drug is usually dispensed by prescription.

Brand-name Pinacidil (Diovan)

The brand-name version of pinacidil is known as Diovan. This drug is available only by prescription. The generic form of Diovan is used in many countries.

The brand-name version of pinacidil was developed in the 1970s by Merck & Co. The company began to market the drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pinaveriumis a drug that inhibits
 
Response: Pinaveriumis a drug that inhibits fatty acid synthesis. Pinaverium is a mixture of 2-hydroxy-2-methyl-2-pentadecyl-2-methylpropanenitrile and 2-hydroxy-2-methyl-2-pentadecyl-2-methylpropanenitrile, also known as phenylpropanolamine and aminorex, respectively. It is manufactured by the drug company ApoPharma, and it was first introduced in the United States in 1989. Pinaverium is used to treat obesity, especially for the treatment of morbid obesity, and is the only weight loss drug available in the United States with an FDA-approved indication for weight loss in adults.

This article is intended to be an educational resource for health professionals and others interested in weight loss.

The Merck Manual of Diagnosis and Therapy. 15th Edition. Editor: Cecil G. Davis, M.D.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pindololis a drug that inhibits
 
Response: Pindololis a drug that inhibits cyclic AMP phosphodiesterase and has been used for treating anxiety and depression.

According to the New York Times, "Mr. Vittori said the company has been told to stop selling the drug and has not yet figured out what to do with the remaining stock. It has offered some of the tablets for sale at bargain prices to health-care providers.

The FDA has been notified of the situation and has been monitoring the situation," said Jeffrey Shuren, director of the FDA's division of drug evaluation and research.

In April, FDA officials warned that Pindolol can cause birth defects and banned its use in pregnant women. The drug is approved for use in women of childbearing age who are at high risk for cardiovascular problems.

A spokeswoman for Pfizer Inc., which makes Pindolol, said that the company was not aware of any patient who has been harmed by the drug.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pineneis a drug that inhibits
 
Response: Pineneis a drug that inhibits the enzyme aromatase, the only one of its kind to have been used for the treatment of breast cancer. In fact, this compound is the only one to be approved by the FDA. But what is it? How does it work? And what is the evidence that it’s effective?

What is the aromatase enzyme?

The aromatase enzyme converts the hormones testosterone and estrogen into estrogen and testosterone, respectively. Testosterone and estrogen are the primary hormones that stimulate breast and prostate growth, respectively.

There are two types of aromatase enzymes. Type I is located in the ovaries, while Type II is located in the testes. Type I aromatase converts androgen to estrogen. Type II aromatase converts androgen to testosterone.

There are a number of different forms of aromatase, all of which have different functions and different levels of expression. One form, aromatase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pioglitazoneis a drug that inhibits
 
Response: Pioglitazoneis a drug that inhibits the enzyme that breaks down insulin and is used to treat type 2 diabetes. There are many side effects of pioglitazone including heart failure and increased risk of fractures, especially in the spine. The evidence for the benefits of pioglitazone is conflicting and it is not clear if it has any impact on cardiovascular risk. To assess the effect of pioglitazone on cardiovascular events and death in people with type 2 diabetes. The Cochrane Peripheral Vascular Diseases Group searched the Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to March 2008), EMBASE (January 1980 to March 2008), and CENTRAL (The Cochrane Library 2008, Issue 3). We also searched conference proceedings, scanned reference lists, and contacted pharmaceutical companies. Randomised controlled trials comparing pioglitazone with placebo, no treatment, or another active treatment for people with type 2 diabetes. Two review authors extracted data and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Piperacillinis a drug that inhibits
 
Response: Piperacillinis a drug that inhibits inflammation in your body. It is used to treat many inflammatory diseases, such as psoriasis, ulcerative colitis, and arthritis. Pipes are the name of a number of plants that contain the compound piperacillin.

Medical Uses of Pipes:

1. Reduces inflammation

The reason why you need to use piperacillin for reducing inflammation is because it inhibits the release of chemicals that cause inflammation. This happens when the cells become irritated or infected. It is the reason why you need to use piperacillin for treating many diseases, such as:

· Colitis (inflammation of the colon)

· Crohn’s disease

· Psoriasis

· Rheumatoid arthritis

· Scleroderma

· Uveitis

· Vulvitis

2. Decreases pain

The reason why you need to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Piperineis a drug that inhibits
 
Response: Piperineis a drug that inhibits the bioactivation of curcumin in vivo and that alters the pharmacokinetics of curcumin. A dose-dependent increase in the Cmax and AUC of curcumin was observed after co-administration of piperine, indicating a possible interaction between the two compounds. A possible mechanism of this interaction is presented, in which piperine inhibits the activity of the cytochrome P450 enzymes CYP1A2 and CYP2C19, resulting in a decreased conversion of curcumin to the active metabolite (1-7-dichloro-4-hydroxy-2-methoxynaphthalene) and an increase in the bioavailability of curcumin. Piperine, at the dose of 500 mg/kg, also significantly reduced the Cmax and AUC of the co-administered drug celecoxib (a non-steroidal anti-inflammatory drug). These findings suggest that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pirarubicinis a drug that inhibits
 
Response: Pirarubicinis a drug that inhibits the production of uric acid by the liver is commonly used to treat gout. This drug is administered orally as a tablet or a solution.

Side Effects

Taking too much pararubicin can cause severe side effects, such as

irregular heartbeat

chest pain

weakness or numbness in your arms or legs

trouble breathing

unusual bleeding or bruising

feeling tired or dizzy

weakness in your fingers or toes

nausea

weakness in your neck, arms, or legs

swelling

trouble swallowing

blurred vision

Changes in urination

Less serious side effects include

abdominal pain

back pain

chest pain

diarrhea

headache

mild itching

stomach pain

unusual tiredness or weakness

weight
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pircetamis a drug that inhibits
 
Response: Pircetamis a drug that inhibits the effect of acetylcholine.

According to a clinical trial, perampanel seems to be effective for the treatment of Tic disorders, but more research is needed to determine whether it is more effective than alternative medications.

Chronic Tic Disorder

Tic disorders are often chronic. This means that symptoms can be long lasting. Most people have tics for many years. The term “chronic” usually refers to tics that are less frequent or less severe.

Chronic tic disorders are sometimes called Gilles de la Tourette syndrome (GTS) or chronic tic disorder.

Chronic tic disorders are different from other tic disorders.

There are three types of tic disorders.

Chronic tic disorders include:

A chronic form of Tourette syndrome

A chronic form of Gilles de la Tourette syndrome

A chronic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pirfenidoneis a drug that inhibits
 
Response: Pirfenidoneis a drug that inhibits the proliferation of fibroblasts in the development of fibrosis. This drug can prevent the occurrence of IPF and is widely used clinically. It is reported that the pathological manifestations of IPF are mainly manifested in the form of pulmonary fibrosis. There are multiple animal models of pulmonary fibrosis, including animal models of bleomycin-induced pulmonary fibrosis (BOPF), and animal models of bleomycin-induced lung fibrosis. Among them, BOPF is the most commonly used model for the study of IPF.

The specific mechanisms of pulmonary fibrosis remain unclear. Recent studies have shown that the formation of fibrosis in the lungs is related to the accumulation of inflammatory cells and the excessive production of inflammatory factors, such as TGF-β, IL-1, IL-6, and TNF-α, which stimulate the proliferation and differentiation of fibroblasts and the production of ECM components. These
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  piromidicis a drug that inhibits
 
Response: piromidicis a drug that inhibits the action of squalene synthetase, a key enzyme in the cholesterol biosynthetic pathway.

The pharmacokinetic profile of sparfloxacin is similar to that of other fluoroquinolones, including ciprofloxacin and ofloxacin.

The excretion of the active moiety, a metabolite of sparfloxacin, in urine is mainly unchanged.

A clinical study has shown that sparfloxacin is well tolerated in children and adults with bacterial infections. The most common adverse effects are diarrhea, nausea, headache, and dizziness.

Society and culture

Generic names
Sparfloxacin is the generic name of the drug and its.

References

External links
 
 

Category:Fluoroquinolone antibiotics
Category:Quinolines
Category:Chloroare
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pitavastatinis a drug that inhibits
 
Response: Pitavastatinis a drug that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase. This results in the inhibition of cholesterol synthesis and the reduction of cholesterol levels in blood. Pitavastatin has been shown to be a potent anti-atherosclerotic agent in patients with hypercholesterolemia, a well-known risk factor for coronary heart disease. However, a recent large-scale study suggested that it does not reduce the incidence of cardiovascular events. In this study, the authors evaluated the effect of pitavastatin on the progression of coronary atherosclerosis in patients with hypercholesterolemia and found that it does not reduce the progression of atherosclerosis.[@b1-asm-5-380]

The development of atherosclerosis is a multifactorial process, which involves many factors, including inflammatory processes, endothelial dysfunction, endothelial cell injury, smooth muscle cell proliferation, and the accumulation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pitolisantis a drug that inhibits
 
Response: Pitolisantis a drug that inhibits microtubule assembly in the brain by binding to microtubule protein tubulin. It is an anti-psychotic and sedative-hypnotic drug. Pitolisant is used to treat obesity and gastro-esophageal reflux disease (GERD). Pitolisant has also been used to treat narcolepsy and schizophrenia, although it is not approved for these uses in the U.S.

A combination of two or more different antidepressants, sometimes in different dosage strengths. In most cases, the antidepressants in the combination act at different sites in the brain and are thought to work together to provide better relief from symptoms. Antidepressants are also used to treat other conditions, such as anxiety, pain, and attention deficit hyperactivity disorder (ADHD).

Also called diphenhydramine. A member of the antihistamine group of medications, diphenhydramine acts by blocking the action of histamine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pizotifenis a drug that inhibits
 
Response: Pizotifenis a drug that inhibits serotonin-induced hyperthermia. Serotonin is an endogenous monoamine neurotransmitter in the central nervous system. Serotonin acts on the brain to influence mood, sleep, appetite, body temperature, memory, and other brain functions. When applied to the skin, serotonin stimulates sweat glands and increases blood flow. The effects of serotonin on the body may be enhanced or blocked by a drug called a serotonin antagonist. Drugs that block serotonin receptors in the brain can be used to treat depression, anxiety, and insomnia. They are also used to treat migraine headaches. Pizotifen is used to treat hyperhidrosis, excessive sweating of the hands, feet, face, and/or scalp.

What is Pizotifen?

Pizotifen is used to treat excessive sweating in people who do not have other conditions that cause excessive sweating. It may also be used to treat anxiety, depression, migraine headaches, and other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PK-1587is a drug that inhibits
 
Response: PK-1587is a drug that inhibits the progression of liver cancer and other cancer types. We sought to examine the mechanisms of action of this drug and whether it is toxic to normal cells.

1. Introduction {#sec1-toxins-11-00288}
===============

Cancer is the leading cause of death worldwide, and the burden of cancer is projected to increase in the coming decades \[[@B1-toxins-11-00288]\]. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the fifth most common cause of cancer-related deaths \[[@B2-toxins-11-00288]\]. In China, the age-standardized HCC incidence and mortality rates have increased rapidly over the past few decades \[[@B3-toxins-11-00288]\]. Unfortunately, most patients are diagnosed at an advanced stage of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Plerixaforis a drug that inhibits
 
Response: Plerixaforis a drug that inhibits homing of leukocytes to bone marrow, thereby reducing the number of neutrophils in circulation.^[@R1]^ It is being investigated in patients with high-risk myeloma, and has shown promising activity in this setting.^[@R2],[@R3]^ As this is an investigational drug, it is not yet approved by the US Food and Drug Administration (FDA). The drug is currently under review by the European Medicines Agency (EMA) for approval in the EU.

The EMA approved plerixafor in 2012, but subsequently removed it from the market after a series of patient deaths were reported in France and Germany. These deaths were due to cardiotoxicity, thought to be caused by plerixafor causing myocardial infarction.^[@R4]^ This has led to the withdrawal of plerixafor from the EU
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PLX3397is a drug that inhibits
 
Response: PLX3397is a drug that inhibits an enzyme called PLK1. It has been shown to inhibit cancer cell growth and is currently in Phase I/II clinical trials. PLX3397 is being developed by Plexxikon, Inc. (San Diego, CA, USA).

KAI1/CD82 is a cell surface protein that has been shown to inhibit the growth of cancer cells by inhibiting the function of the protein Plk1. This is one of the first steps in the cancer cell growth cycle and is blocked by KAI1/CD82. KAI1/CD82 has been shown to be a tumour suppressor gene in breast, prostate, colon and lung cancer and has also been shown to inhibit metastasis in mouse models. KAI1/CD82 is being developed by Zyngenia, Inc. (San Francisco, CA, USA).

The role of plk1 in cancer

The role of plk
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PLX-4032is a drug that inhibits
 
Response: PLX-4032is a drug that inhibits the enzymatic activity of the nuclear export receptor XPB (also known as XPD) by covalently binding to the catalytic site of the enzyme, which prevents the XPB-mediated export of proteins from the nucleus. This leads to inhibition of the progression of the cell cycle and ultimately cell death.[@b16-bctt-8-163]

It has been suggested that PLX-4032 may have a dual mechanism of action. It has been reported that PLX-4032 inhibits the XPB enzyme by covalent binding to the catalytic site of the enzyme, and also it has been reported that PLX-4032 may also be acting by inhibiting the interaction between XPB and Ran GTPase. The latter mechanism has been proposed to be more important than the former, since it leads to an immediate block of the nuclear export of proteins. PLX-4032 has also been
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PLX8394is a drug that inhibits
 
Response: PLX8394is a drug that inhibits the assembly of the vesicular trafficking complex, the macromolecular assembly that carries proteins from the Golgi apparatus to the plasma membrane.

3.  Bortezomib is a drug that inhibits the activity of the proteasome, an intracellular protein-destruction complex that is responsible for the degradation of proteins that have been targeted for destruction.

4.  Anakinra is a drug that blocks the activity of the proinflammatory cytokine interleukin-1 (IL-1). IL-1 plays a key role in the regulation of inflammation and immunity.

5.  Rituximab is a drug that blocks the B cell-specific surface antigen CD20. CD20 is a protein that is expressed on the surface of B cells. CD20 is an important therapeutic target for the treatment of a number of diseases, including B cell lymphomas, rheumatoid arthritis,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Polydatinis a drug that inhibits
 
Response: Polydatinis a drug that inhibits the oxidation of glucose in liver cells. It has a very low incidence of side effects and has been widely used in the clinic.

The majority of diabetic complications are caused by hyperglycemia-induced oxidative stress. Polydatin can effectively protect liver cells from the damage caused by oxidative stress by regulating glucose metabolism, and thus has an effect on diabetic liver injury.

Results
=======

Polydatin can protect the liver from the damage caused by high glucose
-----------------------------------------------------------------------

A CCK8 assay was used to test the effect of polydatin on cell viability. After 24, 48, and 72 h of treatment, the cell viability of HepG2 cells treated with different concentrations of polydatin (0, 25, 50, 100, and 200 μg/mL) was not significantly different from that of the control group (*P* \> 0.05). This result indicated that polydatin had no cyt
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Polymyxinis a drug that inhibits
 
Response: Polymyxinis a drug that inhibits glycolysis and fermentation in yeasts (Sauer & Sauer, 1976, Agric. Biol. Chem. 40, 1197-1201). This drug, which is currently in clinical trials for the treatment of respiratory tract infections in humans, has the general structure of Formula 1.

This compound is active against both gram positive and gram negative bacteria, as well as yeast and protozoa. It also has a spectrum of activity similar to that of amphotericin B, which is used for the treatment of fungal infections.
A major disadvantage of this drug is that it is not soluble in aqueous media and is rapidly hydrolyzed by serum esterases. The compound is metabolized rapidly and excreted in the urine.
A compound related to polymyxin B, namely polymyxin E, has been prepared by a solid-phase synthesis using the methods of Merrifield (Merr
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ponesimodis a drug that inhibits
 
Response: Ponesimodis a drug that inhibits the binding of T-cell activation factors to T-cell receptor, resulting in decreased immune response \[[@CR1]\]. A 12-week open-label study showed that treatment with ponesimod in patients with active relapsing-remitting multiple sclerosis (RRMS) resulted in a significant reduction in magnetic resonance imaging (MRI) activity compared with placebo \[[@CR2]\].

A recently published Phase II study (EudraCT no. 2011-004491-23) of ponesimod was conducted to assess the efficacy and safety of this drug in patients with relapsing-remitting MS (RRMS) \[[@CR3]\]. Patients were randomized in a 1:1 ratio to receive ponesimod (10 mg) or placebo for 12 weeks. Primary outcome was the number of new or enlarging T2-hyperintense lesions on brain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Posaconazoleis a drug that inhibits
 
Response: Posaconazoleis a drug that inhibits CYP3A4 and P-glycoprotein. The drug is metabolized in the liver by CYP3A4 and P-glycoprotein. It has been studied in several clinical trials. It is a synthetic triazole antifungal agent. It is used to treat mild to moderate oropharyngeal candidiasis, mild to moderate esophageal candidiasis, severe or moderate vulvovaginal candidiasis, and moderate to severe vaginal candidiasis. It is also used to treat oropharyngeal candidiasis and esophageal candidiasis caused by fluconazole-resistant Candida species.

#####  INDICATIONS/ROUTES/DOSAGE

Vaginal Candidiasis

**PO:** **ADULTS, ELDERLY:** 200 mg once daily for 7 days.

Oropharyngeal Candidiasis


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Poziotinibis a drug that inhibits
 
Response: Poziotinibis a drug that inhibits protein tyrosine kinases and is used in the treatment of chronic myeloid leukemia. In vitro studies have shown that it is an inhibitor of BCR-ABL1 in chronic myeloid leukemia cells.[@b1-cpaa-7-109]--[@b4-cpaa-7-109] The drug has been approved for use in chronic myeloid leukemia patients in chronic phase, accelerated phase, and blast crisis, and it is also approved for use in other hematological malignancies. In vitro, it has been shown to inhibit the proliferation of chronic myeloid leukemia cells and inhibit the proliferation of acute myeloid leukemia cells.[@b1-cpaa-7-109]--[@b4-cpaa-7-109] In vivo, it has been shown to inhibit the growth of BCR-ABL1-expressing cells.[@b1-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pramipexoleis a drug that inhibits
 
Response: Pramipexoleis a drug that inhibits the dopamine D2 receptor. It has been approved by the FDA for the treatment of Parkinson's disease. This is the first in a series of four articles on this subject.

Introduction {#s0010}
============

The dopamine D2 receptor (DRD2) is one of the most widely expressed receptors in the human brain. DRD2 is primarily expressed in the mesolimbic and mesocortical dopaminergic systems in the brain. DRD2 is involved in the pathogenesis of a number of psychiatric and neurodegenerative disorders. Pramipexole (PPX) is a dopamine D2 receptor antagonist that is effective in the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS).

DRD2-Mediated Pathophysiology {#s0015}
=============================

DRD2-Mediated Pathophysiology in PD {#s
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pramiracetamis a drug that inhibits
 
Response: Pramiracetamis a drug that inhibits the reuptake of neurotransmitters, including acetylcholine and norepinephrine. It is used in the treatment of cognitive impairment associated with various neurological disorders, including chronic fatigue syndrome, Alzheimer's disease, and dementia associated with HIV infection. In an open-label trial, pramiracetam increased free and total levels of acetylcholine in the cerebrospinal fluid. There was no increase in cognitive function as measured by the Alzheimer's Disease Assessment Scale (ADAS) and Mini Mental State Examination (MMSE) scores, but some participants reported improved memory.

Aripiprazole, a dopamine receptor agonist, is used in the treatment of schizophrenia. A randomized, double-blind, placebo-controlled trial found that it was more effective than placebo in the treatment of negative symptoms of schizophrenia, as measured by the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pramoxineis a drug that inhibits
 
Response: Pramoxineis a drug that inhibits prolactin secretion.

The effective and safe dose of the drug for men is 400 mg per day, whereas the effective and safe dose for women is 200 mg per day.

When this drug is taken for pregnancy, the dosage is 400 mg per day in women who are pregnant, and 200 mg per day in those who are not pregnant.

This drug can be taken with food.

Precautions of the drug

The drug can be taken with or without food.

When the drug is taken in conjunction with another drug, it should be taken at least 1 hour before or 2 hours after the other drug.

The drug should be taken with caution if used with other medications.

Side effects of the drug

The side effects of the drug include nausea, diarrhea, and constipation.

Interactions of the drug

The drug is not recommended to be taken in conjunction with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pranlukastis a drug that inhibits
 
Response: Pranlukastis a drug that inhibits both PAF-induced and A23187-induced human platelet aggregation. It has been used in the treatment of asthma, hay fever, atopic dermatitis and other inflammatory diseases.
Pranlukast is described in U.S. Pat. No. 4,689,393, and the process for its preparation is described in U.S. Pat. No. 4,732,940.
The pranlukast produced by the process of the '940 patent has a water content of less than 10% by weight. Water is an undesirable impurity in a pharmaceutical formulation. The presence of water in a pharmaceutical formulation has the potential to affect the solubility, stability and/or dissolution characteristics of the formulation.
In the preparation of pranlukast, a significant amount of water is released from the organic solvent used as a starting material. A water-containing crude pranlukast
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pranoprofenis a drug that inhibits
 
Response: Pranoprofenis a drug that inhibits the activity of COX-1 and COX-2.

It has analgesic, antipyretic, and anti-inflammatory properties.

In the form of pranoprofen lysinate, it is a white to off-white powder with a bitter taste.

This is the inactive ester form of pranoprofen.

When taken orally, pranoprofen is absorbed by the small intestine.

It is then hydrolyzed in the stomach to pranoprofen acid, which is absorbed by the intestines.

It is then converted to pranoprofen lysinate in the liver.

Pranoprofen lysinate is not absorbed from the intestines and is eliminated in the urine.

It is used to treat mild to moderate pain and fever.

Pranoprofen is taken orally.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  prasugrelis a drug that inhibits
 
Response: prasugrelis a drug that inhibits platelet aggregation and is widely used for secondary prevention of acute coronary syndrome. This drug has an important effect on the balance between bleeding and thrombotic risk. Thrombotic events in the early phase of the treatment are uncommon. We present the case of a patient with acute coronary syndrome, with a very low bleeding risk profile who suffered a subarachnoid haemorrhage at the beginning of prasugrel treatment. This complication is unusual in the early phase of the treatment and is usually related to the use of an antiplatelet drug other than clopidogrel. It may be related to a concomitant use of a proton pump inhibitor. The patient recovered with no sequelae. We believe that this is the first case of a patient who received prasugrel without clopidogrel for secondary prevention of acute coronary syndrome and who suffered a subarachnoid haemorrhage
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pravastatinis a drug that inhibits
 
Response: Pravastatinis a drug that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the mevalonate pathway. This is a lipid-lowering drug that can be used in combination with other cholesterol-lowering drugs. It is used to treat or prevent cardiovascular disease and other conditions in adults. Pravastatin is also used to treat osteoporosis.

Pravastatinis available as an oral tablet, a chewable tablet, a syrup, and an extended-release tablet. The chewable tablet and syrup are taken twice a day, while the extended-release tablet is taken once a day.

In this section, you will learn:

What pravastatin is used for

When pravastatin is used

Possible side effects

How to take pravastatin

How to store pravastatin

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prazosinis a drug that inhibits
 
Response: Prazosinis a drug that inhibits the production of melanin. It works by slowing the production of the enzyme tyrosinase, which helps the body to produce melanin.

Pyridoxine is a vitamin B that is a key component of vitamin B6, which is used in the metabolism of amino acids and helps the body to metabolize proteins.

Quercetin is a flavonoid that is an antioxidant and has anti-inflammatory properties.

Raspberry ketone is a chemical found in raspberries that has been found to have weight loss properties.

Resveratrol is a compound found in red grapes that has been found to have weight loss properties.

Rhodiola rosea is a root that has been used in traditional Chinese medicine for hundreds of years to increase energy and stamina.

Salicylic acid is a chemical that is found in willow bark that has been used to reduce fever and pain and is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prednisoloneis a drug that inhibits
 
Response: Prednisoloneis a drug that inhibits the synthesis of cortisol. It is used to treat conditions like rheumatoid arthritis and asthma. It is available in two forms, tablets and injections.

Procaine is a local anaesthetic used in many over the counter products. It is used for local anaesthesia and as a numbing agent.

Methotrexate is a drug used to treat certain types of arthritis. It is available as tablets and injections.

In this video, I will show you how to prepare a steroid injection for a dog that is being treated for arthritis. This video shows you how to prepare the injection in a syringe. The steroid you use in this video is Prednisolone, which is a corticosteroid that works by suppressing the immune system.

My first point of discussion is about the benefits of steroids for arthritis.

I'll be using the scientific literature to show you that steroids can be effective for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pregnenoloneis a drug that inhibits
 
Response: Pregnenoloneis a drug that inhibits several immune functions in vitro, and inhibits the humoral response and the synthesis of IgE in vivo.

Actions

Mechanism of Action

The mechanism of action of pregnenoloneis not fully understood. It is thought that pregnenolone may directly influence the synthesis of several cytokines, as well as indirectly via the steroid hormone-induced production of glucocorticoids.

In addition, pregnenolone may influence the synthesis of interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, and transforming growth factor (TGF)-beta.

Pregnenolone may also be active at the level of the B cell.

Therapeutic Effect

Pregnenolone inhibits several immune functions in vitro.

It inhibits the synthesis of IgE in vivo.

Indications

P
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PREZISTAis a drug that inhibits
 
Response: PREZISTAis a drug that inhibits the production of lipids and/or cholesterol in the liver.

The reduction of hepatic lipids can have beneficial effects in patients with hypercholesterolemia, hypertriglyceridemia, or mixed hyperlipidemia. In addition, it can be used as a preoperative medication in bariatric surgery.

In a clinical study, a total of 32 patients were treated with Prezista for one month before and one month after bariatric surgery. They were all overweight patients and were included in the study if they had a BMI of 30 or more.

As a result, the average weight loss after one month of treatment was about 4.5 kg.

Some patients showed significant reductions in their triglyceride levels, and about a third of them showed significant reductions in their cholesterol levels.

Another advantage of Prezista is that it can be taken without regard to food intake, and so patients do not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prilocaineis a drug that inhibits
 
Response: Prilocaineis a drug that inhibits the release of pain mediators in the central nervous system, such as serotonin, noradrenaline, substance P, and glutamate.^[@r1]^ It has been used in the treatment of chronic pain syndromes, such as complex regional pain syndrome and fibromyalgia, and in the treatment of pruritus.^[@r2]^ It is also used in the treatment of pain associated with herpes zoster and shingles.^[@r3]^ It has been shown that prilocaine decreases the pain threshold and facilitates the burning sensation caused by capsaicin.^[@r4]^ Prilocaine has been used for the treatment of postherpetic neuralgia (PHN) since the 1980s.^[@r5]^ However, the use of prilocaine in the treatment of PHN has not been widely adopted in clinical practice.^
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Primaquineis a drug that inhibits
 
Response: Primaquineis a drug that inhibits the action of the enzyme hypoxanthine-guanine phosphoribosyl transferase (HPRT), a key enzyme in the purine salvage pathway and the synthesis of nucleotides. This results in the inhibition of erythrocyte division, which is an essential process for the growth of malaria parasites in their human host. It is also used in combination with chloroquine for the treatment of *Plasmodium vivax* malaria, a species that is commonly responsible for the majority of malaria infections in South and South East Asia. It is an effective treatment for *Plasmodium falciparum* malaria when administered within the first few days of infection, but is not useful for the treatment of chronic infections.

Primaquine has been used to clear malaria parasites from patients who have relapsed after chloroquine therapy and to prevent malaria recrudescence in patients who have recovered from
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  proadifenis a drug that inhibits
 
Response: proadifenis a drug that inhibits p21-activated kinase 1 (PAK1) in an irreversible manner, thereby allowing cancer cells to overcome senescence and enter into mitosis. In this study, we showed that p21-induced senescence and subsequent apoptosis in cancer cells is dependent on PAK1. We found that overexpression of PAK1 in HCT116 colon cancer cells enhanced proliferation and suppressed senescence, whereas knockdown of PAK1 induced senescence and apoptosis. p21-induced apoptosis was blocked by inhibition of PAK1 in a p53-independent manner. In addition, we showed that treatment of HCT116 cells with FH535, a novel and selective PAK1 inhibitor, caused apoptosis and suppressed cell proliferation in vitro. We also demonstrated that FH535 suppressed tumor growth in a mouse xenograft model. In conclusion, our results indicate that PAK1 is an important regulator of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Procainamideis a drug that inhibits
 
Response: Procainamideis a drug that inhibits the rapidly activating component of the delayed rectifier potassium current (I~Kr~). Inhibition of I~Kr~ causes prolongation of the QT interval on the electrocardiogram (ECG), and can cause a potentially fatal form of ventricular tachyarrhythmia, torsades de pointes (TdP). The drug has been withdrawn from the market in many countries because of its association with potentially fatal drug-induced QT prolongation, and the use of prophylactic ECG monitoring has been mandated in the USA. In recent years, it has become apparent that some drugs are capable of inducing an increase in I~Kr~ and a prolongation of the QT interval in patients. Although prophylactic ECG monitoring is useful in identifying these patients, this is not a practical solution for patients with an existing condition that is exacerbated by a prolongation of the QT interval.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  procaineis a drug that inhibits
 
Response: procaineis a drug that inhibits the voltage-gated sodium channels. In vitro studies have demonstrated that these channels are important in neuropathic pain. This study aimed to evaluate the effect of local anaesthetic bupivacaine and piritramide on the electrical activity of dorsal root ganglion (DRG) neurons in a rat model of neuropathic pain. The effects of bupivacaine and piritramide on sodium current density and on sodium current kinetics were studied using the whole-cell patch-clamp technique in acutely dissociated DRG neurons from Sprague-Dawley rats. The concentrations of bupivacaine and piritramide required to produce 50% inhibition of sodium current (IC50) were 0.08 +/- 0.01 microM and 6.8 +/- 0.7 microM, respectively. The kinetics of the current was unchanged by either drug. Bupivacaine and piritramide reduce sodium currents
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Procarbazineis a drug that inhibits
 
Response: Procarbazineis a drug that inhibits growth of certain tumors in animals. It is also known as *N*-methyl-*N*-propyl-2-acetamido-4-oxobutanoate, methyl-*N*-propyl-2-acetamido-4-oxobutanoate, *N*-methyl-*N*-propyl-4-oxobutanamide, and isopropyl 2-acetamido-4-oxobutanoate. The drug was introduced in the United States as a prescription drug under the name *Me*-PCE (methyl-*N*-propyl-2-carbamoyloxy-4-oxobutanoate hydrochloride) for the treatment of patients with mycosis fungoides and in Germany as *Prograf* (trophosporin) for the treatment of certain tumors in animals. Procarbazine is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Procaterolis a drug that inhibits
 
Response: Procaterolis a drug that inhibits MMP-9, thereby inhibiting the breakdown of collagen, resulting in increased bone formation. A variety of drugs have been shown to be effective in treating osteoporosis, and among these are bisphosphonates. Bisphosphonates have been shown to be highly effective in preventing osteoporotic fractures. They are very potent inhibitors of bone resorption and have been shown to increase bone density and reduce fracture risk. They are also known to inhibit the growth of osteoclasts. In particular, alendronate is currently one of the most commonly prescribed drugs for the treatment of osteoporosis. In addition, risedronate and ibandronate have been approved for the treatment of osteoporosis.
Bisphosphonates have been shown to be highly effective in the treatment of osteoporosis and their use is common among postmenopausal women and elderly men at risk for osteopor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prochlorperazineis a drug that inhibits
 
Response: Prochlorperazineis a drug that inhibits the action of acetylcholine in the central nervous system. It is used in the treatment of schizophrenia and other mental disorders, and also in the treatment of motion sickness.

Prochlorperazineis a drug that inhibits the action of acetylcholine in the central nervous system. It is used in the treatment of schizophrenia and other mental disorders, and also in the treatment of motion sickness.

Prochlorperazineis a drug that inhibits the action of acetylcholine in the central nervous system. It is used in the treatment of schizophrenia and other mental disorders, and also in the treatment of motion sickness.

Prochlorperazineis a drug that inhibits the action of acetylcholine in the central nervous system. It is used in the treatment of schizophrenia and other mental disorders, and also in the treatment of motion sickness.

Prochlorperazineis a drug that inhibits the action of acetylcholine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  procyclidineis a drug that inhibits
 
Response: procyclidineis a drug that inhibits neurotransmission in the brain by blocking the postsynaptic action of the neurotransmitter dopamine. Procyclidine is used to treat severe anxiety and to reduce the effects of alcohol and cocaine withdrawal.

Procyclidine

Procyclidine

(Cyclopropanecarboxylate1,2-diamine, 1-oxide)

Theophylline

Theophylline

A respiratory stimulant. It relaxes the bronchial muscles and increases the flow of air in the lungs. It is used to treat bronchial asthma and chronic obstructive pulmonary disease.

Theophylline

Theophylline

A bronchodilator. It is used to treat bronchial asthma and chronic obstructive pulmonary disease.

Theophylline

Theophylline

Theophylline

Theophylline

A bronch
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PROFENALis a drug that inhibits
 
Response: PROFENALis a drug that inhibits the production of the hormone prolactin in the brain. It is used to treat certain types of hyperprolactinaemia, and also in the treatment of other conditions, such as hyperprolactinaemia caused by certain other drugs. PROFENAL is used to prevent lactation in breastfeeding mothers.

Prolactin is produced by the anterior pituitary gland. It stimulates the development and maintenance of lactation in women and the growth and maintenance of male and female reproductive organs. It is also a regulator of reproductive function. It increases the levels of gonadotrophin-releasing hormone (GnRH) and gonadotrophins (FSH and LH) in the pituitary gland. It also increases the levels of sex steroids and androgens. Prolactin levels are normally increased in pregnancy and lactation, and decreased in other conditions. PROFENAL reduces prolactin levels.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Proflavineis a drug that inhibits
 
Response: Proflavineis a drug that inhibits the activity of an enzyme called ribonucleotide reductase, which is essential for DNA synthesis and repair. It has been shown to be effective against cancers that depend on rapid cell division, including those of the cervix, breast, lung, and head and neck. It is also effective against cancers that are resistant to radiation therapy and other treatments, such as Hodgkin’s lymphoma, melanoma, and mesothelioma.

Side effects

Proflavineis known to cause mild to moderate nausea, vomiting, diarrhea, and fatigue. Other side effects include a decreased appetite, stomatitis, alopecia, anemia, rash, fever, and a skin rash.

Proflavineis an oral medication. It is available as tablets and capsules, and can be administered once or twice daily.

Pregnancy and breastfeeding

Proflavineis not known to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PROGRAFis a drug that inhibits
 
Response: PROGRAFis a drug that inhibits HIV-1 replication in cells of the monocyte/macrophage lineage, especially by suppressing reverse transcription and integration of the virus into the host cell genome. A clinical trial of prograf (ZDV) was performed at the Naval Medical Center, San Diego. A total of 96 patients with AIDS were randomized to receive either placebo or ZDV (100 mg/m2/d) for 14 days, followed by ZDV for 28 days. After 28 days of therapy, 48% of the ZDV-treated patients were asymptomatic and showed a significant decrease in their mean CD4+ lymphocyte count. After discontinuation of ZDV, symptomatic progression occurred in 56% of the placebo-treated patients. This trial demonstrated the efficacy of ZDV in HIV-infected patients. A second trial was performed at the San Francisco Veterans Affairs Medical Center. A total of 45 patients with AIDS were randomized to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Proguanilis a drug that inhibits
 
Response: Proguanilis a drug that inhibits the enzyme in the plasmamembrane of the parasite, and thus prevents the conversion of the proguanil free acid into its active form. This drug is administered orally as an antimalarial.

A

Artesunate is a drug that inhibits the enzyme in the plasmamembrane of the parasite, and thus prevents the conversion of the proguanil free acid into its active form. This drug is administered orally as an antimalarial.

Azithromycin is a macrolide antibiotic that acts by binding to the 50S subunit of the bacterial ribosome, preventing the elongation of protein chains.

A

Atovaquone is an antimalarial that inhibits the enzyme in the plasmamembrane of the parasite, and thus prevents the conversion of the proguanil free acid into its active form. This drug is administered orally as an antimal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Promethazineis a drug that inhibits
 
Response: Promethazineis a drug that inhibits histamine H1 receptor. It has a number of uses in veterinary medicine including as an antihistamine for the treatment of allergic conditions such as pruritus and atopic dermatitis in dogs. It is also used as an antiemetic for dogs and cats.

Promethazine is an antihistamine used to relieve symptoms of allergies and the common cold. It is used to relieve symptoms of hay fever and to prevent nausea and vomiting in patients receiving chemotherapy. It is also used to treat motion sickness, particularly in long-haul truck drivers.

Promethazine is a member of a class of medications called antihistamines, which reduce the effects of histamine in the body. Histamine is a naturally occurring substance that is produced by cells throughout the body.

Promethazine is available as an injection (diphenhydramine), tablet (promethazine hydrochloride), oral solution (promethazine hydrochlor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Propafenoneis a drug that inhibits
 
Response: Propafenoneis a drug that inhibits the rapid firing of the heart muscle by blocking a specific site on the sodium channel. Propafenone is used to treat and prevent paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AF). It is also used to prevent AF in patients with a history of AF. It is used for short-term management of ventricular arrhythmias in patients who are hemodynamically stable. It is also used to prevent ventricular arrhythmias in patients who are hemodynamically stable.

WHAT IS PROPAFENONE USED FOR?

Uses:

Inhibits the rapid firing of the heart muscle by blocking a specific site on the sodium channel.

Prevention of AF in patients with a history of AF

Short-term management of ventricular arrhythmias in patients who are hemodynamically stable

Inhibits the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Proparacaineis a drug that inhibits
 
Response: Proparacaineis a drug that inhibits the voltage-gated sodium channels. Sodium channels play an important role in the generation and propagation of action potentials in the nervous system. Blockade of sodium channels, particularly in the peripheral nervous system, produces a local anaesthetic effect (i.e., a reduction of nerve conduction velocity). Para-aminobenzoic acid esters, including lidocaine and mexiletine, are a class of drugs that are useful in treating arrhythmias.
The present invention relates to compounds that are useful in the treatment of various neurological and psychiatric disorders. More specifically, the present invention relates to compounds that act as sodium channel blockers and that are useful in the treatment of neurological and psychiatric disorders, such as epilepsy, seizures, pain, anxiety, depression, schizophrenia, and other disorders.
U.S. Pat. No. 5,767,108 discloses a method of treating or preventing diseases or conditions such as epilepsy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Propranololis a drug that inhibits
 
Response: Propranololis a drug that inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. It was first developed in the 1980s as a contraceptive. However, it has since been used in treating various hormone-dependent cancers, such as breast cancer, prostate cancer, and endometrial cancer.

The drug works by blocking the conversion of androgens to estrogens. The result is that the amount of estrogen in the body decreases, and the amount of androgen in the body increases. In other words, the body becomes less sensitive to estrogen. Propranolol is used to treat the symptoms of estrogen dominance.

The first reported study of the effects of propranolol in treating premenstrual syndrome was published in the Journal of the American Medical Association in 1980. Since then, propranolol has been shown to be effective in treating the symptoms of premenstrual syndrome.

Propranolol is also used in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PROPYLTHIOURACILis a drug that inhibits
 
Response: PROPYLTHIOURACILis a drug that inhibits the enzyme thymidylate synthase. This enzyme is essential for DNA replication and cell proliferation. It is commonly used in combination with fluorouracil (5-FU) in the treatment of a variety of malignancies.

FOLFOXPROPYLTHIOURACILand FOLFIRINOX (see below) are drugs that contain a fluoropyrimidine (5-FU or capecitabine), a platinum compound (cisplatin or oxaliplatin), and an inhibitor of thymidylate synthase. They are the standard first-line treatments for metastatic colorectal cancer.

THIOMYCINIs an antibiotic derived from the bacterium Streptomyces hygroscopicus. It is used in the treatment of various infections. It is a cell-cycle specific agent that acts as a topoisomerase II inhibitor.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Protionamideis a drug that inhibits
 
Response: Protionamideis a drug that inhibits the action of a peptide that is normally present in the blood. Protionamide is used to treat certain types of inflammatory diseases, such as ulcerative colitis, as well as other inflammatory diseases.

Protionamide may also be used in the treatment of herpes zoster and zoster ophthalmicus. Protionamide is also used to treat some cases of psoriasis.

Protionamide should be used with caution in patients with liver or kidney disease, as well as those taking drugs that are metabolized by the liver. Protionamide should also be used with caution in patients with impaired immune function, and those who are allergic to or have an intolerance to other drugs.

Side Effects

The most common side effects of protionamide are mild and include abdominal pain, diarrhea, nausea, vomiting, and heartburn.

Seek medical attention immediately if you experience any of the following serious side effects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Protriptylineis a drug that inhibits
 
Response: Protriptylineis a drug that inhibits the reuptake of serotonin. It is used to treat depression. Common side effects include nausea, dizziness, and sexual dysfunction.

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter. It is the primary neurotransmitter that conveys messages between the neurons of the brain and the rest of the body.

Serotonin is released from neurons into the synapse, where it interacts with receptors on the surface of the target cells. When serotonin binds to its receptors, it activates a number of signal transduction pathways that ultimately trigger a number of cellular events, including the release of other neurotransmitters.

The Serotonin Reuptake Inhibitors (SRI) class of antidepressants is a subclass of tricyclic antidepressants that inhibit the reuptake of serotonin. They are used to treat depression.

Dosage and Administration

The dose
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prucaloprideis a drug that inhibits
 
Response: Prucaloprideis a drug that inhibits the binding of serotonin to the serotonin receptors 5-HT~4~ and 5-HT~7~. It is marketed as an over-the-counter treatment for gastro-intestinal disorders in the United States and Europe. This paper discusses the effects of prucalopride on serotonin-mediated signaling and its potential for treating irritable bowel syndrome (IBS).

IBS is a functional bowel disorder that is characterized by chronic, recurrent abdominal pain and bowel changes that do not have an organic cause ([@R1]). The most common symptoms of IBS are abdominal pain and diarrhea ([@R2]). IBS is a highly prevalent disorder that is frequently seen in primary care practices ([@R3]). There is no cure for IBS. Treatments include diet modification, behavior therapy, and pharmacotherapy ([@R4]). The currently approved medications for IBS include loperamide and alosetron ([@R4]).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Prulifloxacinis a drug that inhibits
 
Response: Prulifloxacinis a drug that inhibits the growth of tumor cells. In the early stages of the disease, the effects of Prulifloxacin are good.

Qingkailing injection, Qingkailing oral solution, Qingkailing tablet, Qingkailing suspension. Qingkailing injection, a prescription medicine, can help prevent and treat bacterial pneumonia.

How do I use it?

You can use Qingkailing injection orally. If you do not know how to use it, please ask your doctor.

When should I use it?

You should use it when you feel cold. It is recommended that you take it for a period of at least one week.

What are the side effects?

Qingkailing injection can cause side effects such as a fever, rash, headache, vomiting, diarrhea, dizziness, insomnia, weakness, and even heart palpitations. If you are taking other medicines
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PT2385is a drug that inhibits
 
Response: PT2385is a drug that inhibits the interaction of Smad proteins with the transcriptional co-activator CBP. TGF-beta signaling through Smad proteins is essential for the induction of epithelial to mesenchymal transition (EMT) in epithelial cells and for EMT in tumor cells, a process that is essential for the progression of metastatic cancers. TGF-beta signaling is also required for the suppression of E-cadherin and the induction of vimentin, and the expression of other genes associated with the EMT. Our recent studies have shown that Smad3 is required for TGF-beta-induced transcriptional activation of genes that are important for the EMT. In the previous funding period we showed that Smad3 can function as a transcriptional co-activator with CBP, and that the ability of Smad3 to act as a transcriptional co-activator is dependent on the interaction of the Smad3 MH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  p-Toluenesulfonicis a drug that inhibits
 
Response: p-Toluenesulfonicis a drug that inhibits the enzyme of the urea cycle, which results in ammonia accumulation.

References

Category:Antineoplastics
Category:Amines
Category:Bromides
Category:Phenol ethers
Category:Chloroarenes
Category:Chloroethyl compounds
Category:Chloroarenes
Category:Ureas
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Puerarinis a drug that inhibits
 
Response: Puerarinis a drug that inhibits follicular development and ovarian hormone secretion, when given to women of child-bearing age, can cause them to develop an early menopause. However, Pueraria mirifica is a unique, safe herbal medicine that has been found to actually stimulate the development of new follicles and restore reproductive function in the ovaries of aging women.

Description

When you think of Pueraria mirifica, what comes to mind? Perhaps you picture the familiar plants with their frilly green leaves and pale pink flowers that are used to make herbal medicines. Or maybe you picture the shiny black seeds that are used in a popular supplement for promoting hair growth. But Pueraria mirifica is much more than a traditional herb used in folk medicine. This plant has been used for centuries by the people of South and Southeast Asia to restore and maintain health.

It is best known for its use in restoring and maintaining women’s health
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Puromycinis a drug that inhibits
 
Response: Puromycinis a drug that inhibits RNA polymerase II (RNAPII) in T cells, and causes premature transcription termination at cryptic sites, thereby inducing lymphopenia and apoptosis in these cells. Subsequent clinical trials have shown that POMi to be effective in treating patients with relapsed/refractory lymphoid malignancies. However, in several clinical trials, the duration of POMi treatment was shortened due to its side effects, and the patients were switched to a different regimen. Although it is unclear whether the lack of response was due to a loss of efficacy or drug resistance, the development of drug resistance is a major concern in the clinical application of POMi. To address this problem, we established a patient-derived xenograft (PDX) model using a patient with relapsed/refractory T-cell lymphoma who was treated with POMi. We show that PDX models are useful for evaluating the sensitivity of patient-derived tumor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  PYRAZINAMIDEis a drug that inhibits
 
Response: PYRAZINAMIDEis a drug that inhibits the growth of many types of tumor cells, but not normal cells. It is used to treat a wide variety of cancers, including lymphomas, leukemia, lung cancer, breast cancer, and skin cancer.

PYRAZINAMIDE is also known by the following names:Pyrazinamidem (INN),Ligustrazine, Ligustrazine Hydrochloride,Isopyridazine-2-sulfonamide,Pyrazinamide,Pyrazinamide-Sulfamoyl-L-Cysteine-S-oxide,Pyrazinamide,Pyrazinamide-Sulfamoyl-L-Cysteine, and Pyridazine-2-sulfonamide.

The chemical name of PYRAZINAMIDE is 2-amino-4-methyl-5-sulfamoyl-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pyridoxineis a drug that inhibits
 
Response: Pyridoxineis a drug that inhibits the conversion of tryptophan to niacin in the body. It is used in the treatment of low niacin levels in the blood (niacin deficiency). In rare cases it can cause an increase in niacin levels (niacin excess). Niacin is a vitamin that plays an important role in the metabolism of fats and proteins.

In combination with zinc and vitamin B6, pyridoxine is used in the treatment of the skin condition known as rosacea.

How to take pyridoxine

Take pyridoxine at the same time each day, as directed by your doctor.

The recommended dose is 200 to 500 mg daily, taken with meals. Your dose may be increased or decreased as needed.

Do not take more than 500 mg of pyridoxine per day.

If you are taking more than 500 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pyrilamineis a drug that inhibits
 
Response: Pyrilamineis a drug that inhibits histamine release from mast cells. It is a non-sedating antihistamine that can be used as a single agent or in combination with other drugs, especially to treat the side effects of those drugs. It is an H1-receptor antagonist, and acts by blocking the effects of histamine. Pyrilamine is indicated for use in combination with other antihistamines, and for use as monotherapy for allergic rhinitis and urticaria.

Pyrilamine is available in the form of tablets and capsules. It is supplied in both immediate and extended release formulations.

Sodium pyrilamine is a salt of pyrilamine. Pyrilamine hydrochloride is a salt of pyrilamine with hydrochloric acid. The CAS number for sodium pyrilamine is [15778-41-9], and the CAS number for pyrilamine hydrochloride is [65998
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pyrimethamineis a drug that inhibits
 
Response: pyrimethamineis a drug that inhibits the enzyme dihydrofolate reductase (DHFR) which is essential for the synthesis of thymidylate and purines. Because of this action, pyrimethamine is effective in the treatment of *Plasmodium* infections. Unfortunately, resistance to pyrimethamine has been reported and its use as a single drug in the treatment of malaria is not recommended \[[@CR19]\]. The lack of efficacy of pyrimethamine as a single drug in malaria treatment has been well established and other DHFR inhibitors, such as trimethoprim, have been used as an alternative. The mechanism of action of trimethoprim has been described in detail elsewhere \[[@CR19]\].

Based on the mode of action of trimethoprim and pyrimethamine, the efficacy of combination therapy of these two drugs has been tested against *Plasmod
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Pyrrolidineis a drug that inhibits
 
Response: Pyrrolidineis a drug that inhibits S100A4 protein expression in vivo and in vitro.^[@bib1]^ S100A4 protein is expressed by a number of malignant cells and is associated with metastatic potential,^[@bib2],\ [@bib3]^ angiogenesis,^[@bib4]^ invasion and migration,^[@bib5],\ [@bib6]^ tumor progression,^[@bib7]^ epithelial--mesenchymal transition (EMT),^[@bib8]^ chemoresistance^[@bib9]^ and stemness.^[@bib10]^ In recent years, increasing evidence suggests that S100A4 has an important role in the maintenance of cancer stem cells (CSCs).^[@bib11]^ Therefore, S100A4 might be a promising target for the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  pyrviniumis a drug that inhibits
 
Response: pyrviniumis a drug that inhibits myosin light chain kinase. It has been used to treat lower urinary tract symptoms (LUTS), and has been shown to improve storage symptoms and the voiding phase of the micturition cycle. The aim of this study was to evaluate the efficacy of pyrviniumis in the treatment of storage symptoms in men with BPH. This was a prospective, randomized, placebo-controlled, double-blind, crossover study. Patients were randomized to receive pyrviniumis (300 mg twice daily) or placebo for 3 months, with a 2-month washout period between treatment periods. At the end of each treatment period, patients were asked to complete a voiding diary, and the International Prostate Symptom Score (IPSS), the quality of life (QoL) score, and the peak urinary flow rate (Qmax) were measured. Of the 38 patients who completed the study, 16 (42
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Quercetinis a drug that inhibits
 
Response: Quercetinis a drug that inhibits proteases (protease inhibitors), such as a protease inhibitor, a serine protease inhibitor, a metalloprotease inhibitor, and the like, are useful as an agent for inhibiting the production of various inflammatory cytokines, and the like. However, quercetin has the disadvantage that it is unstable in a living body and, therefore, has poor bioavailability. Therefore, there is a demand for a quercetin derivative that has improved stability in a living body.
On the other hand, quercetin derivatives having an ether bond, a thioether bond, or a sulfone bond are disclosed in Patent Documents 1 to 5, for example. However, in the conventional quercetin derivatives, there is a demand for a quercetin derivative that has a novel structure and excellent pharmacological activity.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Quetiapineis a drug that inhibits
 
Response: Quetiapineis a drug that inhibits the metabolism of both serotonin and dopamine.

It is used to treat depression, schizophrenia, and mania.

It has been found to be helpful in bipolar disorder.

It is often used in the treatment of bipolar disorder and schizophrenia.

The drug is available in different forms like oral, liquid, and pill.

Read below about Quetiapine.

1. What is Quetiapine?

Quetiapine is an atypical antipsychotic that is used to treat bipolar disorder, schizophrenia, and major depressive disorder.

It is also used to treat mania.

The drug works by decreasing the effects of dopamine and serotonin in the brain.

The drug is used to treat symptoms of mania, depression, and schizophrenia.

Quetiapine has the following effects:

Decreases the effects of dopamine and serotonin

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  QUETIAPINEis a drug that inhibits
 
Response: QUETIAPINEis a drug that inhibits the reuptake of the neurotransmitters dopamine and serotonin. It is used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, premenstrual dysphoric disorder, and more. It is also used to reduce the severity of symptoms of schizophrenia.

QUINAPRINE, an antidepressant drug, has been shown to increase the number of serotonin receptors in the brain, which may be a key to its effectiveness in treating depression.

QUINOLONEANTIBIOTICS

Some of these drugs are used to treat acne. These drugs work by slowing the growth of bacteria in the oil glands of the skin. They are called quinolone antibiotics because they contain a chemical group called quinolone.

QUITTER

QUITTER is an antidepressant drug. It was developed to treat depression and anxiety disorders. It has been shown to be as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  quinacrineis a drug that inhibits
 
Response: quinacrineis a drug that inhibits a type of potassium channel. It is used in the treatment of glaucoma and migraine headaches. It is also used to treat neuropathic pain.

How does it work?

It works by blocking the flow of potassium ions through potassium channels in the membrane of cells. This is particularly effective in blocking the inward flow of potassium. This helps to prevent the neurons from over-stimulating and being over-excited.

The potassium channels in the membrane of the cell open and close in a way that allows the cell to maintain a certain amount of potassium in the cell. If too much potassium is in the cell, the cell will become over-excited. This causes the neurons to fire at a rate that can lead to tissue damage.

Some types of potassium channels open when there is too much potassium in the cell. Other types of potassium channels open when there is too little potassium in the cell. The quinac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Quinaprilis a drug that inhibits
 
Response: Quinaprilis a drug that inhibits the production of angiotensin II. Angiotensin II is a naturally occurring hormone produced by the liver. In addition to its role in controlling blood pressure, angiotensin II plays a role in many other bodily functions, including regulating salt and water balance, stimulating the secretion of aldosterone, and stimulating the production of blood clotting factors. Quinapril is used in the treatment of hypertension, alone or in combination with other drugs.

Quinapril is the S-enantiomer of an angiotensin-converting enzyme (ACE) inhibitor. The S-enantiomer of a drug is a mirror image of the R-enantiomer, and vice versa.

Drugs that contain the S-enantiomer of a drug are sometimes called enantiomeric or enantiomer-containing drugs.

Quinapril belongs to the drug class of ACE inhibitors.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Quinineis a drug that inhibits
 
Response: Quinineis a drug that inhibits the body’s ability to make malaria parasites. The World Health Organization says that most malaria cases occur in Africa, Asia and South America. According to the Centers for Disease Control and Prevention, there were 212 million cases of malaria in 2010, and about 585,000 deaths.

This drug is most commonly used to treat malaria caused by the P. falciparum strain. This strain of malaria is the most deadly. In the United States, most people are infected with the P. vivax strain, which is not as dangerous.

There are many forms of quinine, including:

• Quinine sulfate (C8H8NO4S)

• Quinine base (C8H8NO4)

• Quinine hydrochloride (C8H8ClNO4)

• Quinidine (C8H8N4)

• Quinidine sulf
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  QUTENZAis a drug that inhibits
 
Response: QUTENZAis a drug that inhibits the release of norepinephrine and dopamine in the brain. It's used to treat some people with Parkinson's disease. And it can cause some of the side effects of some of the medications that people with Parkinson's use.

In a recent study, QTENZA helped people with Parkinson's live longer and live better. But it also caused some problems.

The study was designed to see if QTENZA could slow the progression of Parkinson's disease. It's a study of people with early-stage Parkinson's disease. And it lasted for three years.

There were 186 people who participated in the study. Half of them took QTENZA, and half took a placebo. All the participants were already taking other medications.

Some of the people who took QTENZA did well. Others did not. But the most important result was that more of the people who took QTENZA lived
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ris a drug that inhibits
 
Response: Ris a drug that inhibits the polymerization of microtubules. It is approved by the Food and Drug Administration for the treatment of relapsed acute myeloid leukemia (AML) and relapsed or refractory AML in patients older than 60 years.^[@bib1]^ A multicenter phase 2 trial in elderly patients with relapsed AML demonstrated that a single dose of the drug led to sustained complete remissions in 25% of the patients, a median of 2.6 months in duration.^[@bib2]^ In the absence of a well-established biomarker, clinicians often use the serum lactate dehydrogenase (LDH) level as a biomarker for disease response to the drug. The reported ranges of LDH levels in the trials are between 758 and 8061 U/L.^[@bib1],\ [@bib2]^ The current guidelines recommend the use of a single
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  R406is a drug that inhibits
 
Response: R406is a drug that inhibits the action of the enzyme renin, thereby inhibiting the formation of angiotensin II, a potent vasoconstrictor and stimulator of aldosterone release from the adrenal cortex. This results in a decrease in blood pressure. It is marketed under the brand name Aliskiren.

The most common side effect of this drug is headache. Other possible side effects include nausea, dizziness, muscle aches, leg cramps, coughing, skin rash, nasal congestion, vomiting, and sinusitis. It is not recommended for people with a history of kidney problems.

More Info

R406is a drug that inhibits the action of the enzyme renin, thereby inhibiting the formation of angiotensin II, a potent vasoconstrictor and stimulator of aldosterone release from the adrenal cortex. This results in a decrease in blood pressure. It is marketed under the brand name Aliskiren
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  R7935788is a drug that inhibits
 
Response: R7935788is a drug that inhibits protein synthesis and has been shown to inhibit Bax-mediated apoptosis by stabilizing Mcl-1 \[[@B26]\]. Treatment with R7935788 (2 μM) for 12 h inhibited the up-regulation of Bax and down-regulation of Mcl-1 in response to SAA stimulation ([Figure 3(b)](#fig3){ref-type="fig"}). Treatment with R7935788 also reduced the translocation of Bax from the cytosol to the mitochondria in response to SAA stimulation ([Figure 3(c)](#fig3){ref-type="fig"}). These results indicate that Bax is a target of R7935788.

3.4. Bax Is Required for SAA-Mediated Apoptosis {#sec3.4}
-----------------------------------------------

To determine the role of Bax in SAA-induced apoptosis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Racecadotrilis a drug that inhibits
 
Response: Racecadotrilis a drug that inhibits the conversion of certain trypsin-like enzymes to their active form by binding to trypsin-like enzymes in the pancreas. It is prescribed to reduce the production of pancreatic enzymes in people with chronic pancreatitis, pancreatic cancer, or pancreatic insufficiency. It is also prescribed to reduce the production of pancreatic enzymes in people with pancreatitis who are recovering from the acute phase of their illness.

Buy Proventil (albuterol) 2mg/5ml online. Buy Proventil HFA (albuterol) 2mg/5ml online. Order Proventil HFA (albuterol) 2mg/5ml online. Order Proventil (albuterol) online.

The drug is indicated for use in the treatment of acute and chronic bronchospasm associated with asthma. It works by reducing the production of mucus in the air
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ractopamineis a drug that inhibits
 
Response: ractopamineis a drug that inhibits the reuptake of dopamine, which
increases its concentration in the synapse. This results in the
potentiation of dopamine's effect. Dopamine is a key neurotransmitter
in the reward circuitry of the brain. It is released during sex,
when you see something beautiful or wonderful, and is responsible for
the feeling of pleasure. Dopamine increases the feeling of pleasure
you get from doing something, such as seeing a beautiful sunset or
eating a delicious meal. Dopamine is also responsible for the
experience of craving a drug, such as cocaine or methamphetamine.

"Dopamine
is one of the key neurotransmitters involved in reward, motivation
and the drive to repeat behaviours that yield pleasure. It's a
neurotransmitter that promotes pleasure and reward. Dopamine also
plays a role in the drug addiction process. In a process called
reinforcement, drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Radotinibis a drug that inhibits
 
Response: Radotinibis a drug that inhibits the tyrosine kinase activity of the BCR-ABL1 oncogene, and it has demonstrated superior efficacy over imatinib in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph^+^ALL).^[@bib1]--[@bib4]^ The development of resistance to the drug, and of mutations in the BCR-ABL1 kinase domain, are major causes of treatment failure.^[@bib5]--[@bib7]^ However, the drug is also effective against the T315I mutation,^[@bib8]^ which is resistant to all approved tyrosine kinase inhibitors (TKIs).^[@bib9]^ Recent studies demonstrated that the drug is effective against some other TKIs-resistant mutations, including the F359V mutation, which
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Raloxifeneis a drug that inhibits
 
Response: Raloxifeneis a drug that inhibits the growth of hormone-dependent and hormone-independent breast cancers and increases survival of women with breast cancer who have not yet had a recurrence. It is a selective estrogen receptor modulator (SERM) that does not activate or inhibit estrogen receptors in the same way as estrogen. It may be a useful treatment for breast cancer and other estrogen-dependent conditions such as endometrial and uterine cancers. It may also be useful in preventing the development of breast cancer in women at high risk of developing the disease.

I. GENERAL INFORMATION

Raloxifene hydrochloride (raloxifene, trans-4-hydroxy-N-[4-[2-(5-hydroxy-2-phenyl-2H-1,2-benzothiazine-3-yl)ethyl]-1-piperazinyl]trans-2- hydroxy-cyclohexane carboxamide hydrochlor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Raltegraviris a drug that inhibits
 
Response: Raltegraviris a drug that inhibits both C-terminal and N-terminal geranylgeranyl transferase-I (GGTase-I), is currently in clinical trials for the treatment of Alzheimer's disease. Here, we show that Raltegravir treatment enhances mitochondrial fission and decreases mitochondrial membrane potential in primary hippocampal neurons. Moreover, we show that the inhibition of mitochondrial fission by dominant negative Drp1 mutant blocks the anti-amyloidogenic effect of Raltegravir in the APP/PS1 mice model of Alzheimer's disease. These results suggest that Raltegravir is a promising anti-amyloidogenic drug, and might have the potential to reduce amyloid burden in Alzheimer's disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Raltitrexedis a drug that inhibits
 
Response: Raltitrexedis a drug that inhibits the activity of dihydrofolate reductase, which is responsible for the production of active folate cofactors involved in DNA and RNA synthesis. The drug is a folate analog and is activated by the hepatic enzyme dihydropyrimidine dehydrogenase (DPD) to produce its active form, 5-amino-4-imidazolecarboxamide riboside (AICAr), which is subsequently phosphorylated to form 5-amino-4-imidazolecarboxamide (AIC). AICAr is a potent inhibitor of thymidylate synthase, the enzyme that converts dUMP to dTMP. DPD activity is genetically polymorphic and is the most important determinant of the sensitivity of tumors to fluoropyrimidine therapy.

Objective: The objectives of this study were to determine the pharmacokinetics and safety of raltitrex
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ramelteonis a drug that inhibits
 
Response: Ramelteonis a drug that inhibits HIV. The first phase I study of the drug was conducted in India in 2005, with the second phase I study conducted in the United States in 2006. A phase II study was completed in India in 2009, and a phase IIb study was completed in the United States in 2012.

Phase III trials of the drug are ongoing in India, Kenya, South Africa, and the United States.

References

External links
 Drug profile at ViiV Healthcare

Category:Hepatotoxins
Category:Hepatitis C
Category:Experimental drugs
Category:Tricyclic antidepressants
Category:World Health Organization essential medicines
Category:RTT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RANEXAis a drug that inhibits
 
Response: RANEXAis a drug that inhibits fibroblast proliferation and is used in the treatment of liver fibrosis and renal fibrosis.[@b1-ijn-11-3731],[@b2-ijn-11-3731] As a protein-binding ligand, RANEXA can bind to and block the activity of transforming growth factor β1 (TGF-β1), which is a critical mediator of the development of liver fibrosis and renal fibrosis.[@b3-ijn-11-3731],[@b4-ijn-11-3731]

As one of the most commonly used nanoparticles, poly(lactic-co-glycolic acid) (PLGA) is approved by the US Food and Drug Administration (FDA) for clinical applications. Due to its biodegradable and biocompatible characteristics, PLGA has been widely used in drug delivery and tissue engineering. As a major component of R
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RANITIDINEis a drug that inhibits
 
Response: RANITIDINEis a drug that inhibits the multiplication of virus and also protects the lung cells from getting infected by virus. It is used to treat the cases of measles, herpes, chicken pox, rubella, shingles, flu, and other viral diseases. It can be taken orally as a tablet or can be given by injection. It is not a cure for the disease, but it helps in preventing and treating the symptoms. It has to be taken regularly to get maximum benefits. It is the only drug that is known to have no side effects. It is the only drug that can be taken without a prescription. It is an anti-viral agent. It has been approved by the FDA.

SYMPTOMS

Ranitidine is used to treat different kinds of viral infections. It is used to treat the symptoms of viral infections like:

Measles

Herpes

Chickenpox

Rubella

F
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ranolazineis a drug that inhibits
 
Response: Ranolazineis a drug that inhibits the late sodium current (INaL), and is approved for the treatment of angina pectoris, a condition associated with chronic heart disease. The goal of this study was to assess the safety and efficacy of ranolazine in patients with chronic heart failure.

Methods

This was a double-blind, randomized, placebo-controlled, dose-ranging, phase IIb trial. After a screening visit, eligible patients were randomized to receive a single oral dose of placebo, ranolazine, 100 mg, or 200 mg, on days 1 and 15 of a 28-day treatment period. The primary efficacy endpoint was change in 6-minute walk distance (6MWD) from baseline to day 15. Secondary efficacy endpoints included change in quality of life, exercise tolerance, and New York Heart Association functional class.

Results

Of the 52 patients enrolled, 48 completed the study (23 in the placebo group, 15 in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RAPAFLOis a drug that inhibits
 
Response: RAPAFLOis a drug that inhibits the enzyme protein kinase C (PKC) and that blocks the proliferation of certain cancer cells. It also has an anti-inflammatory action. A single infusion of RAPAFLO results in increased serum concentrations of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-10 and C-reactive protein (CRP). A combination of RAPAFLO and silymarin, a flavonoid, also increases TNF-alpha and IL-6. This study investigated whether a single infusion of RAPAFLO or a combination of RAPAFLO and silymarin induces the production of the inflammatory cytokines TNF-alpha and IL-6 in healthy subjects. Twenty healthy volunteers (10 men and 10 women) received single intravenous infusions of RAPAFLO (20 mg), silymarin (200
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RAPAMYCINis a drug that inhibits
 
Response: RAPAMYCINis a drug that inhibits the activity of the enzyme called Topoisomerase 1 (Topo 1) which is a very important enzyme for DNA replication. Inhibition of Topo 1 causes DNA damage and the cell becomes a "dead end". The "dead end" cell will die. So, the goal of this study is to see if RAPAMYCIN can cure a patient with cancer.

Treatment with RAPAMYCIN will be given as a combination therapy.

CANCER PATIENTS RECEIVING RAPAMYCIN ARE BEING TREATED WITH VINORELBINE (BOM)

BOM (Vinorelbine) is an anti-cancer drug. It is a drug that works by interfering with the cell cycle of the tumor cell.

The cell cycle is the series of events that occur in a cell after it is created in the body. During this time, the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rasagilineis a drug that inhibits
 
Response: Rasagilineis a drug that inhibits the degradation of dopamine and increases its levels in the brain. In combination with levodopa, it has been shown to increase the effectiveness of the latter.

Common side effects include nausea, vomiting, headache, and blurred vision.

It has been associated with a risk of blood clots, so users should be advised to take the medication on an empty stomach and to avoid excessive alcohol consumption.

The safety and effectiveness of rasagiline in people with Parkinson's disease has been evaluated in two large-scale, randomized, double-blind clinical trials (the Treatment of Early Parkinson's Disease with Rasagiline trial and the Monotherapy in Early Parkinson's Disease with Rasagiline trial). These studies included 1,167 people with early-stage Parkinson's disease who were randomly assigned to receive either rasagiline or placebo. The studies lasted a total of 18 months.

Researchers at Columbia University Medical
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (R)-baclofenis a drug that inhibits
 
Response: (R)-baclofenis a drug that inhibits the GABAB receptor. It is marketed in the United States under the brand name Opus and is used in the treatment of spasticity.

References

External links
 U.S. National Library of Medicine: Drug Information Portal - baclofen

Category:GABAB receptor agonists
Category:Lactams
Category:Muscarinic antagonists
Category:Pyrrolidines
Category:Pyrrolidines derivatives
Category:Quinuclidines
Category:Sedatives
Category:Tropanes
Category:Withdrawn drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rebamipideis a drug that inhibits
 
Response: Rebamipideis a drug that inhibits gastric acid secretion and that is used to treat peptic ulcers. However, there are many side effects, including headache, nausea, diarrhea, and so on, which result from the strong inhibition of gastric acid secretion. Moreover, the treatment is continued for a long time because it is difficult to maintain the sufficient drug concentration in the body.
Rebamipide is an ester of the carboxylic acid, 5-amino-2-sulfonylaminobenzoyl-L-glutamic acid, of the formula (1) (hereinafter referred to as “reagent (1)”).
The reagent (1) is used as a medicine.
                Reagent (1)                       
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Reboxetineis a drug that inhibits
 
Response: Reboxetineis a drug that inhibits the reuptake of norepinephrine and serotonin. In the last years, it has been approved by the FDA for the treatment of major depressive disorder (MDD). Reboxetine has been shown to have antidepressant activity in MDD and is also effective in the treatment of patients with other psychiatric disorders. In fact, it is used for the treatment of depression in the United States, Japan, and Europe, and is also indicated for the treatment of obsessive-compulsive disorder and bulimia nervosa in some countries. In general, reboxetine is well tolerated.

Preclinical studies have shown that reboxetine has the potential to reverse a number of effects of depression. Reboxetine has antidepressant effects in the forced swim test and the tail suspension test, both in rats and in mice, and in the learned helplessness test in rats. It is able to reverse the decrease in the levels of brain-derived
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Refametinibis a drug that inhibits
 
Response: Refametinibis a drug that inhibits the activity of the MEK (MAPK) kinase and prevents the phosphorylation of ERK. It is a second-line therapy in the treatment of BRAF-mutated melanoma, although it has a modest response rate (10% to 20%) and a high rate of adverse events. It is the first oral drug that has been approved for the treatment of this disease. In this article, we summarize the pharmacology, efficacy, and safety of refametinib.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RELENZAis a drug that inhibits
 
Response: RELENZAis a drug that inhibits the effects of Renin, an enzyme that converts prorenin to active renin. It is used in the treatment of hypertension and congestive heart failure. Renin acts to convert angiotensinogen to angiotensin I, which in turn is converted to angiotensin II.

REPAIROF the endothelium of the arteries and veins is a goal of vascular medicine. Repair of the endothelium requires three phases: 1) initiation of endothelial cell migration and proliferation; 2) stabilization of the endothelial lining; and 3) remodeling of the endothelial layer to produce a smooth and antithrombotic surface.

REPARATION OF THEENDOTHELIAL lining of the arteries and veins is a goal of vascular medicine.Repair of the endothelium requires three phases: initiation of endothelial cell migration and proliferation; stabilization of the endothelial lining; and remodeling of the endot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Relugolixis a drug that inhibits
 
Response: Relugolixis a drug that inhibits the replication of adenovirus. It is being developed by Enzon Pharmaceuticals as a treatment for colds and flu.

The proposed dose of Relugolix is 100 mg taken orally once a day for five days. It is intended to inhibit viral replication and help to reduce the duration of a cold or flu.

Adverse effects
In animal studies, the oral administration of Relugolix was well tolerated and had no adverse effects.

Chemistry

Structure
Relugolix is a synthetic compound that contains a 2-oxopyridine-3-carboxamide and a 4-oxo-1,4-dihydroquinoline. It is structurally related to vidarabine and pyrrolo[2,3-d]pyrimidines.

Mechanism of action
The mechanism of action of Relugolix is not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Repaglinideis a drug that inhibits
 
Response: Repaglinideis a drug that inhibits the action of insulin and thus reduces the blood sugar level.

Generic drugs are therapeutically equivalent to the branded drugs and can be marketed at the same prices. But if you are wondering why there is no difference in the name and the packaging of the branded and the generic drugs, then you need to understand that the generic drugs are not same as the branded drugs. The only difference is that the generic drugs are sold at the lower prices.

Do not be confused that they are the same as the branded drugs. The generic drugs are different from the branded drugs in their formulation, active ingredient and their dosage. This is why the generic drugs are always marketed at the lower prices than the branded drugs.

This is the reason that there is no difference in the name and the packaging of the branded and the generic drugs.

In this article, we will discuss the difference between the branded and the generic drugs, their benefits and their
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Reparixin(Repertaxin)is a drug that inhibits
 
Response: Reparixin(Repertaxin)is a drug that inhibits collagenases and inactivates TGF-β1, thus inhibiting the activation of the Smad pathway, and plays a role in inhibiting the TGF-β1-induced myofibroblast transdifferentiation of smooth muscle cells, thus promoting the degradation of collagen, inhibiting the expression of extracellular matrix and inhibiting the occurrence of the process of interstitial fibrosis. Reparixin can be used in the treatment of myocardial fibrosis, myocardial fibrosis after myocardial infarction, and the prevention and treatment of post-operative interstitial fibrosis and renal interstitial fibrosis. Reparixin can also be used to prevent and treat liver fibrosis. Reparixin is a small molecule drug with a molecular weight of 244.3 kDa, and its structure is shown in FIG. 1. The molecular formula of Reparixin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Reserpineis a drug that inhibits
 
Response: Reserpineis a drug that inhibits the action of the enzyme dopamine-beta-hydroxylase (DBH) in the adrenal medulla and sympathetic nerve endings. It is used to treat hypertension and hyperkinesis (tremor and hyperreflexia).

Adverse Effects

Serotonin syndrome is a potentially life-threatening condition. It is characterized by an abrupt onset of autonomic instability, hyperthermia, and CNS symptoms. The autonomic instability can manifest as changes in blood pressure, heart rate, temperature, respiration, and gastrointestinal function. The CNS symptoms include confusion, agitation, hallucinations, seizures, and coma.

Laboratory Values

In the plasma, the drug is bound to plasma proteins, mainly albumin. The binding is pH-dependent. In a pH range of 6.0 to 7.0, the drug is bound about 90% of the time. In a pH range of 8.0 to 9.0
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Resiquimodis a drug that inhibits
 
Response: Resiquimodis a drug that inhibits interferon (IFN) signaling, is used for the treatment of multiple sclerosis (MS) \[[@B1-ijms-20-05315],[@B2-ijms-20-05315]\]. Resiquimod has been shown to suppress IFN-γ production from T cells, B cells, and natural killer (NK) cells, and it has also been shown to modulate cytokine production by dendritic cells (DCs) \[[@B3-ijms-20-05315],[@B4-ijms-20-05315],[@B5-ijms-20-05315],[@B6-ijms-20-05315]\]. In MS patients, DCs play an important role in the induction of T cell responses, and they also promote differentiation of naïve T cells into Th1 cells. Resiquimod is known to be a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Resorcinolis a drug that inhibits
 
Response: Resorcinolis a drug that inhibits calcium channels in the muscle, and it can be used to treat a variety of conditions including migraines, epilepsy, anxiety, insomnia, high blood pressure, stress and depression.

One of the most interesting effects of this drug is that it can increase blood flow in the brain, improving the blood flow to the brain and allowing for better cognitive function.

Advantages of Resorcinol

–Resorcinol is a drug that can be purchased over the counter.

–It is a safe drug with no known side effects.

–Resorcinol is an over the counter drug that can be used to treat a variety of conditions including migraines, epilepsy, anxiety, insomnia, high blood pressure, stress and depression.

–It is known to improve cognitive function.

–It is known to increase blood flow to the brain.

Disadvantages of Resorcinol

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  resveratrolis a drug that inhibits
 
Response: resveratrolis a drug that inhibits cyclooxygenase (COX-2) and stimulates the enzyme 5-lipoxygenase (5-LOX). It is effective against pain in a wide variety of animal models and also has antinociceptive properties in humans. It is thought to have central nervous system effects and can increase endogenous opioid levels. In this study, we determined the effects of resveratrol on the analgesic effect of morphine. Analgesia was induced in mice using the hot plate test. Morphine produced a dose-dependent increase in the latency of the response. Resveratrol (25, 50 and 100 mg/kg, i.p.) did not change the response to morphine (10 mg/kg, s.c.) when administered alone. However, it potentiated the analgesic effect of morphine in a dose-dependent manner. Resveratrol alone did not induce any antinociceptive effect in mice
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  retapamulinis a drug that inhibits
 
Response: retapamulinis a drug that inhibits the activity of a protein, allowing the function of other proteins to take over. However, some drugs can act on multiple proteins. One of these is mycophenolate, a drug used to prevent rejection of transplanted organs. Mycophenolate is the generic name for a number of related compounds.

Drugs are sometimes used in a slightly different form to prevent rejection of transplanted organs. This is called immunosuppression. Immunosuppression is the inhibition of the immune system. This is important, because the immune system is the body's main defence against foreign organisms. The body's immune system is made up of two main components: white blood cells and antibodies. White blood cells are made up of two different types of cells: lymphocytes and phagocytes. Lymphocytes are cells that circulate in the lymph nodes, and they are involved in the body's immune response. Phagocytes are cells that eat bacteria and other
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RG7388is a drug that inhibits
 
Response: RG7388is a drug that inhibits cyclin-dependent kinases, CDK4 and CDK6, and thereby causes cell cycle arrest in G1. G1 arrest causes a decrease in S-phase entry and, consequently, an accumulation of cells in G2/M. It also causes an accumulation of cells in G2/M, because CDK4/6 is required for progression from G2 to M. In the absence of CDK4/6, the major mitotic kinase, CDK1, is not activated. The cell cycle arrest induced by RG7388 can be rapidly reversed by addition of exogenous CDK4/6, indicating that CDK4/6 is required for cell cycle progression through G2/M.^[@bib1]^

Since G1 arrest by RG7388 induces apoptosis in B-cell lymphoma cells,^[@bib2]^ we hypothesized that the apoptotic effect of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ribavirinis a drug that inhibits
 
Response: Ribavirinis a drug that inhibits viral replication in cell culture, which is known as a prodrug, was developed in the early 1990s. In the following years, the compound was tested in clinical trials for its therapeutic potential in hepatitis C virus (HCV) infection. However, the results were not encouraging, since the treatment with ribavirin was associated with side effects, and a subgroup of patients experienced relapse after therapy with the drug. The introduction of new direct-acting antiviral agents (DAAs) for the treatment of HCV has renewed the interest in the use of ribavirin, and several clinical trials have been initiated in the past few years. The purpose of this review is to provide an update on the history of ribavirin and to discuss the results of the most recent clinical trials of the compound.

HCV is a positive-stranded RNA virus, and it belongs to the *Flaviviridae* family. It is the leading
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Riboflavinis a drug that inhibits
 
Response: Riboflavinis a drug that inhibits HIV replication and has a very low toxicity. It was designed by [@bib1] and has been developed by [@bib2] and [@bib3]. This article reviews the history of riboflavin and its development as a potential HIV treatment.

History
=======

Riboflavin is a naturally occurring vitamin that has a key role in the production of flavin mononucleotide (FMN), a coenzyme that is essential for many cellular functions. It is produced in most of the tissues of the body, and is found in meat, eggs, milk, and cheese. The compound has been used in medicine for over 50 years and is used to treat severe vitamin B2 deficiency ([@bib4]). In 1985, [@bib5] published the first article on the antiviral properties of riboflavin. This paper described the first successful attempt to inhibit the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ribostamycinis a drug that inhibits
 
Response: Ribostamycinis a drug that inhibits the secretion of gastric acid, thus suppressing the symptoms of peptic ulcer. The first ribostamycin (or salicylic acid) was isolated from the culture broth of Streptomyces murinus in 1963.

Ribostamycins are a group of chemically related antibiotics produced by various strains of Streptomyces species.

References

External links
 Ribostamycin (CAS RN) at Drugs.com

Category:Macrolides
Category:Benzamides
Category:Quinolines
Category:Pyrrolidines
Category:Salicylic acids
Category:Chloroarenes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rifabutinis a drug that inhibits
 
Response: Rifabutinis a drug that inhibits the activity of a virus. When the virus replicates in the body, it infects healthy cells and damages them. Rifabutin inhibits the virus and therefore reduces the spread of the virus. It can also reduce the amount of HIV in the blood. This is one of the most effective drugs to treat people with HIV.

Rifabutin is a long-acting antibiotic. It works by stopping the growth of bacteria that infects the body. Rifabutin also has anti-inflammatory effects. This means that it reduces the amount of white blood cells and reduces the amount of infection.

Rifabutin is one of the most effective drugs for treating people with HIV. It has a good safety record and has few side effects.

It is not recommended for people who have problems with their heart, stomach, liver or kidneys. It is also not recommended for pregnant women.

Rif
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rifampinis a drug that inhibits
 
Response: Rifampinis a drug that inhibits the development of resistance in *M. tuberculosis* \[[@CR34]\]. It is also the first drug approved by the US FDA for treatment of drug-resistant tuberculosis. There is a correlation between the development of resistance and decreased drug susceptibility to rifampin in patients with tuberculosis \[[@CR35]\]. Rifampin is a prodrug that requires bioactivation to exert its bactericidal effect \[[@CR36]\]. The drug is rapidly metabolized in the liver by enzymes that require NADPH for their activity \[[@CR37]\]. Rifampin resistance is the most common cause of treatment failure in tuberculosis.

Rifampin is an effective drug against a wide range of bacterial species including *M. tuberculosis* \[[@CR38]\]. It is also effective against other mycobacteria, including *M. kansasii* \[[@CR39]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rifapentineis a drug that inhibits
 
Response: Rifapentineis a drug that inhibits the development of latent tuberculosis. It is used to treat tuberculosis (TB) in people who have failed to respond to the standard six-month treatment regimen.

It is available in a liquid form and in a tablet. The tablet is more convenient and easier to take than the liquid form, but people with liver disease or who are taking other medications should be monitored carefully.

Rifapentine is the active ingredient in INH PLUS, a fixed-dose combination drug that is approved for the treatment of latent TB.

INH PLUS is taken by mouth once daily for nine months.

Rifapentine may cause serious side effects. It can cause an allergic reaction in people who are allergic to rifampin or rifapentine.

Rifapentine is a second-line treatment for latent TB.

Rifapentine is an injectable.

It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rilmenidineis a drug that inhibits
 
Response: Rilmenidineis a drug that inhibits the conversion of histamine to histamine in the brain, and may also have other effects. It is used to treat insomnia and lower blood pressure. Rilmenidine is a selective, non-competitive antagonist of H1-histamine receptors. In clinical trials, rilmenidine was effective in reducing sleep onset latency and improving sleep maintenance, and was well tolerated in the short-term (4-6 weeks) treatment of primary insomnia. Adverse events were mild and transient, and consisted of dizziness, fatigue, headache, and insomnia. Rilmenidine was not associated with clinically important changes in blood pressure or pulse rate, and did not alter glucose metabolism or lipid levels. These results were confirmed in long-term studies (6-12 months). Rilmenidine was more effective than placebo in improving sleep parameters, with no significant differences in blood pressure or pulse rate. Rilmenidine was more effective than imipramine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rilpivirineis a drug that inhibits
 
Response: Rilpivirineis a drug that inhibits the reverse transcriptase of the Human Immunodeficiency Virus (HIV). Rilpivirine inhibits a mutation of HIV-1 that causes resistance to other nucleoside reverse transcriptase inhibitors (NRTIs) including the standard drug, zidovudine. The results of a clinical trial comparing rilpivirine with a standard treatment in people with HIV were published in the New England Journal of Medicine (NEJM) in October 2010. The study found that people taking rilpivirine had a much lower chance of developing resistance to the drug and it was better at preventing the spread of HIV.

People with HIV are often treated with a combination of drugs to slow the progression of the disease and to prevent resistance to treatment from developing. A problem with standard treatment is that resistance to one drug can lead to resistance to another. The NEJM study found that people taking rilpivir
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RILUZOLEis a drug that inhibits
 
Response: RILUZOLEis a drug that inhibits tumor cell proliferation, angiogenesis, and metastasis by inhibiting the activity of VEGF, a pro-angiogenic factor that promotes tumor growth and metastasis.

1. Introduction {#sec1-ijms-18-01991}
===============

Lung cancer is the leading cause of cancer death worldwide. In 2016, 1.8 million new lung cancer cases were diagnosed, and 1.6 million people died from lung cancer \[[@B1-ijms-18-01991]\]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and has a 5-year survival rate of less than 20% \[[@B2-ijms-18-01991]\]. Although there have been many advances in the diagnosis and treatment of lung cancer, its prognosis remains poor, and there is an
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RIMADYLis a drug that inhibits
 
Response: RIMADYLis a drug that inhibits multiple targets and can be used in combination with other drugs, either to enhance their efficacy or to lower their toxicity. It is currently in phase II clinical trials in children with acute lymphoblastic leukemia (ALL). It is also in phase I clinical trials for the treatment of recurrent glioblastoma and relapsed/refractory acute myeloid leukemia. RIMADYL is also being investigated for the treatment of a wide variety of other malignancies.

ABOUT BIOQUINOL-TESTS

We offer reliable tests for the determination of the metabolic activity of bioquinol.

How to use

The test kit includes:

1.5 ml of assay buffer

5 ml of the test solution

15 x 4.5 mm test strips

A plastic pipette

Measuring equipment

Specifications

Bioquimica Ltd is a registered company based
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rimantadineis a drug that inhibits
 
Response: Rimantadineis a drug that inhibits the spread of influenza A viruses in the body. It was approved by the FDA in 1995.

**_Anatomical Therapeutic Chemical (ATC) Classification:_** R01AC10

**_Therapeutic Class:_** Antiviral

#####  USES

Treatment of influenza A and B. Treatment of prophylaxis against influenza A virus infection.

#####  PRECAUTIONS

**Contraindications:** Hypersensitivity to rimantadine. **Cautions:** Hepatic impairment, children younger than 6 yrs.

#####  ACTION

Prevents virus from uncoating in host cell, inhibiting viral replication. **Therapeutic Effect:** Inhibits replication of influenza A and B viruses.

#####  PHARMACOKINETICS

Rapidly absorbed after PO
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rimonabantis a drug that inhibits
 
Response: Rimonabantis a drug that inhibits the release of serotonin, thereby reducing anxiety. If you have not been taking any, do so for a few weeks and see if it helps.

1) I will start taking Imipramine again, and see if that helps.

2) I will try to stay off it for a few months and see if it helps.

3) I will continue to take it for a while and see if it helps.

4) I will continue to take it for a while and see if it helps.

5) I will continue to take it for a while and see if it helps.

6) I will continue to take it for a while and see if it helps.

7) I will continue to take it for a while and see if it helps.

8) I will continue to take it for a while and see if it helps.

9) I will continue to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Riociguat(BAYis a drug that inhibits
 
Response: Riociguat(BAYis a drug that inhibits the effects of endogenous nitric oxide by selectively blocking the soluble guanylate cyclase. It is currently approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and is also being evaluated in the treatment of heart failure.

Placebo-controlled trials have demonstrated the safety and efficacy of riociguat for the treatment of patients with pulmonary arterial hypertension.

Riociguat in combination with epoprostenol was superior to epoprostenol monotherapy in patients with pulmonary arterial hypertension who had a response to treatment.

The use of riociguat in combination with selexipag was more effective than selexipag monotherapy in patients with pulmonary arterial hypertension.

Use in other conditions

Riociguat has also been investigated in patients with heart failure.

An international
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ripasudilis a drug that inhibits
 
Response: Ripasudilis a drug that inhibits the Rho-associated coiled-coil forming protein kinase (ROCK). ROCK is a serine/threonine kinase that belongs to the family of AGC kinases (cAMP-dependent, cGMP-dependent, and protein kinase C (PKC) family of kinases) (Wang, C. J. et al. (1998) Proc. Natl. Acad. Sci. USA 95, 6038-6043; Itoh, K. et al. (1999) Nature 402, 682-687; Charnewidthaya, A. et al. (1999) Nature Biotechnology 17, 305-308). ROCKs are downstream effectors of Rho family GTPases, particularly RhoA (ROCK-I) and Cdc42 (ROCK-II) (Charnewidthaya, A. et al. (1999) Nature Bi
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ripretinibis a drug that inhibits
 
Response: Ripretinibis a drug that inhibits the protein encoded by the C-C motif chemokine receptor 2 gene, or CCR2. It is approved by the FDA to treat adults with locally advanced or metastatic urothelial carcinoma that has progressed following platinum-based chemotherapy. It is also being investigated in adults with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). In patients with HNSCC, CCR2 is upregulated and contributes to tumor cell migration and invasion. However, the role of CCR2 in other tumor types, such as breast cancer, remains unclear.

In this study, we examined the effect of ripretinib on tumor cell proliferation, migration, and invasion. We also investigated whether the inhibition of CCR2 affects tumor cell growth in vitro and in vivo. Our results demonstrated that ripretinib inhibited cell proliferation, migration, and invasion, and induced cell apoptosis in vitro and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Risedronateis a drug that inhibits
 
Response: Risedronateis a drug that inhibits bone resorption. It is used to treat osteoporosis in postmenopausal women. Risedronate reduces the risk of hip fractures in older people.

What is it used for?

Risedronate is used to treat osteoporosis in postmenopausal women. It may also be used to treat Paget's disease.

Risedronate is also used to treat Paget's disease of bone. It may also be used to treat osteoporosis in people who are at risk of fractures.

Risedronate is also used to treat osteoporosis in men who have low levels of testosterone.

It may also be used to treat osteoporosis in children who have a disorder called osteogenesis imperfecta.

Risedronate is also used to treat bone loss in people who have been treated with high doses of steroids for a long time.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RISPERIDONEis a drug that inhibits
 
Response: RISPERIDONEis a drug that inhibits dopamine and serotonin reuptake, and therefore increases the activity of the dopamine and serotonin systems. It has the effect of increasing the activity of the neurotransmitters dopamine and serotonin in the brain. The main use of Risperidone is in the treatment of schizophrenia.

In Australia, the drug is available only on prescription from your doctor. You can only buy Risperidone from a pharmacy. It is not available over the counter.

SIDE EFFECTS

Like all drugs, Risperidone can cause side effects. The most common side effects are:

dry mouth

sleeplessness

headache

nausea

sensitivity to light

swelling of the face, tongue, lips, fingers or feet

stomach pain

tingling or numbness in the hands or feet

blurred vision

back pain


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ritodrineis a drug that inhibits
 
Response: Ritodrineis a drug that inhibits the activity of the enzyme beta adrenergic receptor and thus has the potential to improve the cardiovascular response to pregnancy and labor. In this study we evaluated the effects of ritodrine on the arterial blood pressure and the contractility of the myometrium during pregnancy. We compared the effects of ritodrine (2 mg/kg) with those of metoprolol (5 mg/kg) in 10 women with uncomplicated pregnancy. Both drugs were administered orally, 1 h before cesarean section, and their effects were assessed by measuring the mean arterial blood pressure and the isometric tension of the uterus. Ritodrine decreased the mean arterial blood pressure by 16% and the isometric tension of the uterus by 24%. In contrast, metoprolol decreased the mean arterial blood pressure by 14% and the isometric tension of the uterus by 21%. In the group of women receiving ritodrine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ritonaviris a drug that inhibits
 
Response: Ritonaviris a drug that inhibits the function of the enzyme, lecithin:cholesterol acyltransferase (LCAT). In humans, this drug has been approved to lower serum cholesterol levels and to reduce the incidence of coronary heart disease. Although its use has been associated with increased incidence of adverse drug reactions, it is one of the most commonly prescribed drugs for the treatment of hypercholesterolemia.
Ritonavir, a broad spectrum inhibitor of human cytochrome P450 3A4 (CYP3A4) and 1A2, is an approved anti-retroviral agent used to treat HIV-1 infection. Ritonavir has been used to inhibit the metabolism of a number of drugs, including cyclosporine, midazolam, nelfinavir, nisoxetine, and sertraline, as well as for the prevention of AIDS-associated opportunistic infections. However, ritonavir has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rivastigmineis a drug that inhibits
 
Response: Rivastigmineis a drug that inhibits the activity of acetylcholinesterase (AChE), an enzyme that breaks down the neurotransmitter acetylcholine. Acetylcholine is involved in the signaling of memory, and reduced activity of AChE results in an increase in the amount of acetylcholine that is available to bind to and stimulate memory-related receptors. As a result, people with Alzheimer's disease experience less impairment in memory. Rivastigmine was approved for use in the United States in 1996 and is available in an oral tablet formulation, in an oral solution, and as an injection.

Rivastigmine is a member of the carbamate class of medications and works by blocking the breakdown of acetylcholine in the synapses (the gap between two nerve cells). It also increases the amount of acetylcholine available for binding to the receptors on the postsynaptic neuron (the neuron that receives the signal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rocuroniumis a drug that inhibits
 
Response: Rocuroniumis a drug that inhibits the motor endplate function and neuromuscular transmission. Its clinical application in anesthesia is often used to induce general anesthesia and neuromuscular blockade. It is widely used in regional anesthesia for abdominal and orthopedic surgeries, and it is also applied in the treatment of status epilepticus, spinal cord injury, and myasthenia gravis.[@b1-asm-4-358]--[@b4-asm-4-358] The clinical effects of rocuronium include the inhibition of neuromuscular transmission and the inhibition of muscle contraction.[@b5-asm-4-358] The clinical effects of rocuronium on the cardiovascular system are still controversial. The findings of previous studies have suggested that rocuronium could induce a transient hypertension and tachycardia during induction.[@b6-asm-4-358],[@b7-asm-4-358] However,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Roflumilastis a drug that inhibits
 
Response: Roflumilastis a drug that inhibits phosphodiesterase 4 (PDE4) and has been developed for the treatment of COPD. It is used in the EU in combination with salmeterol and tiotropium. The dose is administered once daily in the morning. It is available in a 200-mg and 400-mg tablet. It is marketed in the US as a 200-mg tablet under the brand name Aclasta®.

The efficacy of roflumilast was investigated in four studies (T20, T22, T23, T24) with a total of 1086 patients (overall population). T20 investigated the effects of the drug on clinical and lung function endpoints (dyspnea and pulmonary function). T22 investigated the effects of roflumilast on health-related quality of life (HRQoL). T23 investigated the effects of roflumilast on the reduction of exacerbations
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rolipramis a drug that inhibits
 
Response: Rolipramis a drug that inhibits the synthesis of cyclic adenosine monophosphate (cAMP) and is used in the treatment of insomnia. In animal models of insomnia, rolipram produced effects that were similar to those produced by other drugs used in the treatment of insomnia, such as zolpidem and trazodone. To examine the effects of rolipram on sleep in humans, a placebo-controlled, double-blind study was conducted. Healthy men and women (n = 33) were administered oral doses of placebo, rolipram (2.5 mg, 5 mg, or 10 mg), or zolpidem (10 mg) on separate days. Sleep was monitored for 3 h after drug administration. The effects of the drugs on the parameters of sleep were measured, including sleep onset latency, time to persistent sleep, number of awakenings, total sleep time, sleep efficiency, and wakefulness after sleep onset. The study drugs were well
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ronidazoleis a drug that inhibits
 
Response: ronidazoleis a drug that inhibits cell division. It is usually given for short periods of time and in high doses, however, it can be useful for the treatment of candidiasis. It is usually used as a component of a combined regimen. In a similar fashion to azoles, amphotericin B is used to treat systemic fungal infections. The primary side effects are kidney damage and allergic reactions.

Prophylactic use of nystatin in patients at risk of developing fungal infections such as those with HIV or those undergoing bone marrow transplant. The recommended dose is one gram taken orally once daily.

Sulphamethoxazole/trimethoprim (Septrin) is a drug combination used to treat bacterial infections. The combination of sulphamethoxazole and trimethoprim was first used in the 1950s and was shown to be effective against several bacterial infections. It is given as a single dose of 400 mg of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ropiniroleis a drug that inhibits
 
Response: Ropiniroleis a drug that inhibits D2 and D3 receptors and was the first of a new class of dopamine receptor antagonists to be approved for the treatment of Parkinson’s disease (PD). Although ropinirole is a potent drug with a long duration of action, its oral bioavailability is only 15-20%. Consequently, it must be administered by injection or transdermal patch to be effective. Furthermore, because ropinirole is administered once or twice daily, compliance is an issue for many patients.

The purpose of this study was to evaluate the potential of a novel, long-acting, injectable formulation of ropinirole for the treatment of PD. The goal was to develop a formulation with an onset of action similar to that of oral ropinirole, with a duration of action of at least 24 hours.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ropivacaineis a drug that inhibits
 
Response: ropivacaineis a drug that inhibits the action of sodium channels. The drug is indicated for the relief of moderate to severe pain, and its efficacy is dose dependent. The drug is an anesthetic of the central nervous system, and is usually administered intravenously. It is also a muscle relaxant. It has an onset of action of 5 to 10 minutes and a duration of action of 2 to 3 hours. The drug can cause nausea, vomiting, hypotension, respiratory depression, and, rarely, death. The drug is relatively expensive, costing $600 to $700 per treatment.

Cerebral Palsy (CP)

CP is a disorder of movement and posture, usually occurring in infants, children, and adolescents. It can be caused by brain damage, including the brain stem, cerebellum, or cerebral cortex. It can also be caused by metabolic disorders, infections, toxins, or genetic factors. It is characterized by a wide variety of symptoms, including
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ropivacaineis a drug that inhibits
 
Response: Ropivacaineis a drug that inhibits the generation of action potentials in nerve cells. It is the first of a new generation of local anesthetics. Its duration of action is twice as long as that of bupivacaine. It is about twice as potent as lignocaine. Ropivacaine can be used for the regional block of nerves and in peripheral nerve blocks, and also for the treatment of postoperative pain and of breakthrough pain. Ropivacaine is approved for use in many countries, including the United States.

Ropivacaine is the major ingredient in a new drug that is now being widely used. This new drug is Ropivacaine HCl. Ropivacaine HCl is the freebase of the pure enantiomer of Ropivacaine, the active component of the drug. It is the first of a new generation of local anesthetics. It is a long-acting
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Roquinimexis a drug that inhibits
 
Response: Roquinimexis a drug that inhibits the activity of proteasome and it was approved for treatment of multiple myeloma by FDA in 2016. The drug was also approved for treatment of mantle cell lymphoma and Waldenström macroglobulinemia in 2018.

Mechanism of action

The ubiquitin-proteasome system (UPS) is a multi-enzyme complex that degrades misfolded and damaged proteins. In cells, misfolded proteins are recognized by heat shock protein 70 (Hsp70) and transferred to the surface of the proteasome, where they are degraded. Proteasome is a large protease complex with three main subunits: β1, β2 and β5. The proteasome subunit β5 is known as the regulatory β5 subunit, which contains a catalytic pocket that binds to a group of small molecules known as the immunosubunits. The interaction
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rosiglitazoneis a drug that inhibits
 
Response: Rosiglitazoneis a drug that inhibits the formation of fatty acids from their precursor, glycerol, in the liver, reducing hepatic triglyceride levels and thereby reducing serum triglyceride levels. It has been shown that the drug may also be useful for treating other conditions such as diabetes. Rosiglitazone has the following structure:

Rosiglitazone is a member of a class of drugs known as thiazolidinediones, which are used in the treatment of type 2 diabetes. Rosiglitazone is currently marketed in Europe as Avandia®, and in the United States as Avandaryl®.
The utility of Rosiglitazone is believed to be based on its ability to increase insulin sensitivity in muscle and fat tissue. In addition, it has been suggested that rosiglitazone may also improve the lipid profile of diabetic patients by reducing serum triglycerides and cholesterol levels. However, in a number of animal and human studies
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rosuvastatinis a drug that inhibits
 
Response: Rosuvastatinis a drug that inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway. It is used to lower the level of cholesterol in the blood and reduce the risk of heart disease. Rosuvastatin is the brand name for the drug, which is manufactured by Merck.

Rosuvastatin is a potent inhibitor of HMG-CoA reductase. Rosuvastatin inhibits the production of cholesterol in the liver and also in the small intestine. The effect of the drug is to reduce the level of cholesterol in the blood and thus reduce the risk of heart disease.

Rosuvastatin is indicated in the treatment of hypercholesterolemia (high cholesterol levels in the blood). The recommended dose of rosuvastatin is 10 mg/day.

Rosuvastatin is a drug that is used in the treatment of high cholesterol. It works by lowering the amount of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rotenoneis a drug that inhibits
 
Response: Rotenoneis a drug that inhibits the mitochondrial respiratory chain and can be used to selectively induce the death of cells that are actively metabolizing oxygen.^[@bib1]^ In addition, rotenone has been used in numerous animal studies to assess the role of the mitochondrial respiratory chain in cell death and in neurodegenerative diseases, such as Parkinson\'s disease (PD), and in aging.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ Rotenone has been reported to inhibit several enzymes of the mitochondrial respiratory chain in different animal models, including PD models.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ However, the cellular and molecular mechanisms by which rotenone exert
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rotigotineis a drug that inhibits
 
Response: Rotigotineis a drug that inhibits the reuptake of the neurotransmitter dopamine. It was developed by Elan Pharmaceuticals in the 1990s. The drug was approved by the FDA in 2006 for the treatment of Parkinson's disease. It was marketed as the generic drug Rotigotine.

Rotigotine is a long-acting agonist for the dopamine D2 receptor. The dopamine receptor is part of a large family of receptors. They all have similar structures, but they all have a different function. Dopamine is a chemical messenger in the brain that controls certain body functions. When dopamine binds to a receptor, it activates the receptor and this makes the body perform a certain action. Rotigotine works by binding to a dopamine receptor.

Rotigotine is used for treating the symptoms of Parkinson's disease.

The exact mechanism of action of rotigotine is not known.

Rotigotine may have effects on dopamine receptors other than those involved in Parkinson
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rotundineis a drug that inhibits
 
Response: Rotundineis a drug that inhibits calcineurin.

Lithium also inhibits calcineurin, but it is much less effective than the other drugs in this class.

Possible adverse effects

The side effects of lithium are similar to those of other drugs that have the same mode of action, and include

Serum Lithium Levels

Normal lithium levels are typically between 0.5 and 1.2 mmol/L (mM) in adults. Levels between 0.5 and 0.9 mmol/L are considered to be optimal. Lithium levels of 0.4 mmol/L are occasionally seen in elderly patients, but are rarely associated with clinical toxicity. Lithium levels above 1.2 mmol/L can cause a wide variety of symptoms, including:

fatigue

headache

dizziness

difficulty concentrating

loss of appetite

weakness

confusion

agitation

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Roxatidineis a drug that inhibits
 
Response: Roxatidineis a drug that inhibits the enzyme histidine decarboxylase (HDC) which is responsible for converting histidine to histamine. It also inhibits gastric acid secretion. The gastric acid is necessary to dissolve the protein in the food and also the mucus layer of the stomach. In addition, the presence of histamine is essential for the release of gastrin. Histamine can be released from the enterochromaffin-like (ECL) cells in the stomach. Histamine is a potent mediator of the physiologic effects of gastrin. Gastrin stimulates the release of histamine from the gastric mucosa. Histamine in turn stimulates the secretion of gastrin from the gastric glands and stimulates gastric acid secretion. Histamine also activates the vagal afferent nerve fibers in the stomach. Histamine and gastrin play an important role in the homeostasis of the stomach.

The drug, like other H2 antagonists
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Roxithromycinis a drug that inhibits
 
Response: Roxithromycinis a drug that inhibits a viral enzyme essential for reproduction.  It is used to prevent abortion.

It is used in the treatment of coccidiosis in chickens.

The fungus Myrothecium roridum is also used as a medication.

References

External links
 Rx-Roxithromycin website

Category:Macrolide antibiotics
Category:Oxathiolanes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  R-Ruxolitinibis a drug that inhibits
 
Response: R-Ruxolitinibis a drug that inhibits JAK1 and JAK2, two kinases that play a key role in the signaling of several cytokines. Ruxolitinib is approved in the United States for the treatment of patients with polycythemia vera (PV) or essential thrombocythemia (ET) who have a JAK2 V617F mutation.^[@R1]^ In patients with myelofibrosis, a myeloproliferative neoplasm with bone marrow fibrosis and splenomegaly, ruxolitinib is approved for the treatment of anemia in patients with intermediate or high-risk myelofibrosis (MF) who have received a stem cell transplant or have received ≥2 myelosuppressive chemotherapy regimens.^[@R2]^ Ruxolitinib is also approved in the European Union for the treatment of MF in patients who
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RRx-001is a drug that inhibits
 
Response: RRx-001is a drug that inhibits Sirtuin 1, a class of enzymes known to regulate many cellular functions including cellular senescence. We examined the effects of PNU-100480 (a selective Sirtuin 1 inhibitor) on the proliferation of various cancer cell lines in vitro. We observed that PNU-100480 induced apoptosis in all cell lines examined. We also observed that PNU-100480 induced G2/M cell cycle arrest in all cell lines. Finally, we found that PNU-100480 inhibited proliferation in an in vivo mouse model.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (R)-Serineis a drug that inhibits
 
Response: (R)-Serineis a drug that inhibits the growth of melanoma cells. However, the exact mechanism of action of the drug remains unclear. We previously reported that PPP1R15A, a subunit of protein phosphatase 1 (PP1), plays an important role in regulating the phosphorylation of serine in response to a change in the concentration of Serine. In the present study, we analyzed the effect of PPP1R15A on the activity of serine kinase, and the role of PPP1R15A in the cell growth and migration of melanoma cells. The PPP1R15A expression was decreased in melanoma cells compared to normal melanocytes, and the phosphorylation of serine was increased in the cells. Knockdown of PPP1R15A in melanoma cells by small interfering RNA increased the phosphorylation of serine, the cell growth and migration. On the other hand, overexpression of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RTAis a drug that inhibits
 
Response: RTAis a drug that inhibits angiogenesis by selectively targeting microvessels. We investigated the effect of RTA on intratumoral vasculature in the rat fibrosarcoma tumor, RIF-1, and the human melanoma, HTB-77, and the human renal carcinoma, ACHN, in vitro. In RIF-1 and HTB-77, the number of microvessels decreased to less than 10% of control values by 0.5 microM RTA, but in ACHN, the number of microvessels was reduced by less than 20% of control values at 1 microM RTA. These results suggest that RTA is a potential drug for the treatment of solid tumors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rucaparibis a drug that inhibits
 
Response: Rucaparibis a drug that inhibits poly (ADP-ribose) polymerase (PARP). PARP enzymes are involved in repairing DNA strand breaks. In some cancers, this repair pathway can lead to a greater accumulation of DNA damage and cell death.Rucaparib is approved for the treatment of patients with ovarian cancer with germline *BRCA* mutations, patients with metastatic breast cancer with germline *BRCA* mutations, and patients with metastatic breast cancer with somatic *BRCA* mutations. This summary reviews the clinical development of rucaparib in patients with ovarian cancer, breast cancer, and prostate cancer.

Introduction {#s0005}
============

PARP inhibitors are potent agents for the treatment of germline *BRCA* mutation--associated cancers. The success of PARP inhibitors in the treatment of patients with germline *BRCA* mutations has spurred interest in using these agents
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rufinamideis a drug that inhibits
 
Response: Rufinamideis a drug that inhibits a class of voltage-gated sodium channels. It is used to treat seizure disorders such as absence epilepsy, complex partial seizures, and Lennox-Gastaut syndrome.[@b1-asm-5-385] The drug has been approved for the treatment of partial-onset seizures in adults and children. Its main adverse effects are drowsiness and ataxia, and are dose-dependent. Adverse effects may be transient or persistent.[@b2-asm-5-385] The main metabolite of rufinamide is N-desmethylrufinamide, and is known to be inactive.[@b3-asm-5-385] Although rufinamide is relatively safe, there have been reports of serious adverse effects including coma, ataxia, and encephalopathy. The aim of this study was to review the adverse effects and pharmacokinetic data of rufinamide.

M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rupatadineis a drug that inhibits
 
Response: Rupatadineis a drug that inhibits both the release and reuptake of serotonin. It is widely used in Japan and in Europe for the treatment of nasal congestion associated with allergic rhinitis. It has been approved for use in Japan, the European Union, the United States, Canada, and some other countries.

As of February 2010, there is one generic equivalent of rupatadine available in the United States.

The following dosage is effective for the relief of nasal congestion associated with seasonal allergic rhinitis.

Adults and children 10 years of age and older: The recommended dose is one 20-mg tablet daily.

Children 6 to 9 years of age: The recommended dose is one 10-mg tablet daily.

Children 5 years of age and younger: The recommended dose is one 5-mg tablet daily.

The following dosage is effective for the relief of nasal congestion associated with perennial allergic rhinitis.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Rutinis a drug that inhibits
 
Response: Rutinis a drug that inhibits JAK3, a key enzyme in cytokine signalling.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  RVX-208(RVX-000222)is a drug that inhibits
 
Response: RVX-208(RVX-000222)is a drug that inhibits the production of human interleukin-2 (IL-2). IL-2 is a protein that stimulates the proliferation of T cells and is required for the normal immune response to a variety of infectious agents. It has been shown that patients treated with RVX-208 have decreased T cell activity. In animal models, RVX-208 treatment resulted in the inhibition of T cell mediated inflammatory reactions. In addition, the administration of RVX-208 to a patient infected with human immunodeficiency virus type 1 (HIV-1) resulted in a decrease in the viral load.

RVX-208 is a drug that inhibits the production of human interleukin-2 (IL-2). IL-2 is a protein that stimulates the proliferation of T cells and is required for the normal immune response to a variety of infectious agents. It has been shown that patients treated with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sis a drug that inhibits
 
Response: Sis a drug that inhibits the growth of some cancer cells. Inhibiting angiogenesis is an important strategy for cancer treatment, and has been used to develop anti-cancer drugs for many years. To date, several anti-angiogenic agents have been approved by the FDA for cancer treatment. However, these agents have severe side effects, and only a few patients benefit from them. Therefore, it is necessary to develop novel anti-angiogenic agents with improved efficacy and fewer side effects.

Endostatin, a potent endogenous inhibitor of angiogenesis, is a 20-kDa C-terminal fragment of collagen XVIII, and is a broad-spectrum anti-angiogenic agent. Its anti-tumor effects have been reported in various cancer models. Endostatin inhibits tumor growth and metastasis by directly inhibiting tumor angiogenesis, and suppressing tumor cell proliferation, invasion, and metastasis.[@b1-ott-11-59
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  s1023is a drug that inhibits
 
Response: s1023is a drug that inhibits phosphatase and tensin homolog (PTEN), a tumor suppressor protein that negatively regulates the PI3K/Akt pathway.^[@bibr19-1758835920922055]^ Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to block the angiogenic effects of VEGF.^[@bibr20-1758835920922055]^ Sunitinib is a multitargeted tyrosine kinase inhibitor (TKI) that targets the receptor tyrosine kinases of the VEGF receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).^[@bibr21-1758835920922055]^ It has also been shown to inhibit angiogenesis through an anti-angiogenic effect by targeting the VEGF pathway.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S1037is a drug that inhibits
 
Response: S1037is a drug that inhibits the Src kinase, which is required for the survival of chronic lymphocytic leukaemia cells. This study examined the efficacy of the drug in relapsed/refractory CLL patients in a phase I trial. The primary objective was to determine the maximum tolerated dose (MTD). The secondary objectives were to determine the safety profile, and to explore the immunomodulatory activity of S1037 in this patient population. Patients received S1037 by continuous intravenous infusion. The MTD was determined to be 25 mg/m2/day. S1037 was well tolerated with no dose-limiting toxicities. Pharmacokinetic analysis showed that steady-state plasma levels of S1037 were above the IC50 of target cells. S1037 induced rapid and sustained inhibition of target cells in vivo. Patients with low levels of circulating lymphocytes at baseline had a greater reduction in lymphocyte counts after S1037 therapy. Two
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S1096-JNJ26481585is a drug that inhibits
 
Response: S1096-JNJ26481585is a drug that inhibits TNF-α converting enzyme (TACE). It is a decoy receptor that binds to TNF-α. This causes the TNF-α to remain in the extracellular space and prevents it from binding to its receptor on the surface of the cell, thus, preventing the inflammatory response.

**AIMS&METHODS:** To investigate the effects of IFX in the treatment of SJS/TEN and toxic epidermal necrolysis (TEN) in comparison to its current standard of care, the standard of care, and placebo.

**RESULTS:** We found that the frequency of total body surface area affected by SJS/TEN decreased from 82.5% to 33.3% in the IFX group compared to only 14.3% in the standard of care group.

The mortality rate was significantly decreased in the IFX group compared
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S1499is a drug that inhibits
 
Response: S1499is a drug that inhibits the growth of certain types of cancer cells by blocking a pathway in which cells communicate with each other. This pathway is called the Wnt pathway. S1499 works by inhibiting the Wnt pathway. S1499is a small molecule inhibitor of the Wnt pathway. It may be a drug that could be used in the treatment of certain types of cancer.

Synthesis

S1499is an experimental drug. It was developed by scientists at Eli Lilly and Company. S1499 is an investigational new drug. Eli Lilly and Company has a drug development program in place for S1499. Eli Lilly and Company has a development plan for S1499. Eli Lilly and Company may conduct additional research and development of S1499.

Mechanism of Action

S1499 is an investigational new drug. It is an experimental drug. It may work by inhibiting the Wnt pathway. S1499 inhibits
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S1RAis a drug that inhibits
 
Response: S1RAis a drug that inhibits RANKL (Receptor Activator of NF-kB Ligand) signalling in osteoclastogenesis, and thereby prevents bone loss in RA. However, the effect of S1RA on the rate of joint destruction is unclear.

Objective {#s1}
=========

To assess the effect of S1RA on joint destruction in RA patients with early erosive disease.

Methods {#s2}
=======

This was a 12-month, randomised, double-blind, placebo-controlled study in patients with RA, with or without prior treatment with methotrexate. Eligible patients had a disease duration of \<2 years and an erosive index score of ≥0.8, and were randomised to receive S1RA (20 mg once daily) or placebo for 12 months. Efficacy endpoints were the proportion of patients with at least one joint erosion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S2501is a drug that inhibits
 
Response: S2501is a drug that inhibits cell proliferation by inducing G1 cell cycle arrest in human cancer cells and also inhibits the activity of the Wnt/β-catenin pathway. S2501, a novel derivative of BBR, has been found to be more effective than BBR in inhibiting tumor growth in a variety of animal models, including a mouse model of hepatocellular carcinoma (HCC) and a xenograft mouse model of HCC. The underlying mechanisms are likely to be the inhibition of β-catenin/Tcf4-dependent transcription and the downregulation of cyclin D1 and c-Myc. S2501 also significantly inhibited HCC cell invasion and migration in vitro and the formation of lung metastases in vivo. In addition, S2501 could effectively inhibit HCC cell growth and induce apoptosis in vitro and in vivo.

This study showed that S2501 significantly inhibited cell proliferation and induced G1 cell cycle
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S2597-Oseltamiviris a drug that inhibits
 
Response: S2597-Oseltamiviris a drug that inhibits the formation of Aβ plaques by interfering with the enzymatic activity of β-secretase (BACE1) and, thus, with the production of Aβ peptides. The compound also inhibits the production of CTFs by preventing the production of the β-CTF from the amyloid precursor protein (APP). CTFs are in turn converted to Aβ peptides. In the process of the formation of Aβ peptides, the compound acts by blocking the γ-secretase activity. It also prevents the processing of the Notch receptor.

Dosing

Treatment of Alzheimer's disease in humans
In humans, oseltamivir is dosed orally at 75 mg twice daily, or 75 mg once daily.

References

External links
 http://www.guidetopharmacology.org/GRAC/Ligand
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3003is a drug that inhibits
 
Response: S3003is a drug that inhibits histone deacetylase, thereby promoting transcription of certain genes. In cancer cells, S3003 inhibits growth and induces apoptosis, in part, by increasing expression of BIM, a pro-apoptotic member of the BCL-2 family of proteins. To determine whether this BIM induction is responsible for the apoptosis induced by S3003 in a subset of neuroblastoma cell lines, we treated NB-2a cells with S3003 and assessed BIM induction, cell death, and cell cycle effects. We found that, in contrast to other cell lines tested, S3003-induced apoptosis in NB-2a cells and that this apoptosis was accompanied by BIM induction. The NB-2a cells were more sensitive to S3003-induced apoptosis than other neuroblastoma cell lines. NB-2a cells are also sensitive to TNF-related apoptosis-inducing ligand (TRA
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3027is a drug that inhibits
 
Response: S3027is a drug that inhibits the ATP-dependent helicase activity of the NS3 helicase, which has been shown to inhibit the release of RNA from the 5' end of the HCV RNA genome. This drug is not specific for HCV, however, and has also been shown to inhibit HIV-1 RNA strand-displacement synthesis.

References

Category:Hepatitis C
Category:NS3/4A protease inhibitors
Category:NS5B polymerase inhibitors
Category:Abandoned drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3074is a drug that inhibits
 
Response: S3074is a drug that inhibits eNOS uncoupling. The eNOS uncoupling reaction converts the energy-conserving reaction, the L-arginine-ADP-eNOS reaction to a proton-generating reaction that consumes oxygen. This reaction causes production of ROS and loss of bioavailable NO. S3074 may also be a relatively specific inhibitor of eNOS uncoupling because S3074 is not known to affect other NOS isoforms. The development of novel eNOS uncoupling inhibitors would provide a potential therapeutic strategy for treatment of cardiovascular disease. We have demonstrated that S3074 inhibits the L-arginine-induced uncoupling of eNOS. This study demonstrates that S3074 is a potent inhibitor of eNOS uncoupling and a potential therapeutic strategy for the treatment of cardiovascular disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3120is a drug that inhibits
 
Response: S3120is a drug that inhibits farnesylation of RAS proteins. As a consequence, farnesylated RAS proteins are not able to bind to the cell membrane and are therefore unable to activate the MAPK pathway. Therefore, this drug inhibits tumor growth by interfering with tumor cell proliferation and migration.^[@R21]^ In our study, S3120 treatment led to increased tumor growth inhibition compared to the monotherapy in combination with Pemetrexed. S3120 has previously been shown to increase tumor cell apoptosis and necrosis.^[@R22]^ However, in our study, the levels of apoptosis and necrosis were not significantly changed in the combination therapy compared to the monotherapy.

In summary, our study suggests that the combined treatment of Pemetrexed and S3120 can improve the survival of lung cancer patients. S3120 inhibits the growth of NSCLC cells, which may be partly through the inhibition of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3605is a drug that inhibits
 
Response: S3605is a drug that inhibits the activation of GSK3, a kinase that promotes the formation of the Aβ peptide, which is believed to be the main cause of Alzheimer's disease. In this study, the effect of S3605 on memory deficits and Aβ pathology in APP transgenic mice was investigated. S3605 was administered to transgenic mice (APP23 mice) at a dose of 1 mg/kg i.p. or 5 mg/kg i.p. for 7 days. The Morris water maze was used to evaluate the spatial memory. In addition, Aβ levels in the hippocampus and cortex were measured by Western blotting and ELISA. The spatial memory was significantly impaired in APP23 mice and treatment with S3605 significantly improved the impaired memory in APP23 mice. Furthermore, S3605 reduced Aβ levels in the hippocampus and cortex of APP23 mice. The results of this study suggest that S3605 may be a potential drug for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3606is a drug that inhibits
 
Response: S3606is a drug that inhibits the effects of dopamine, and the brain responds to the lack of dopamine by increasing the amount of norepinephrine in the brain. If this is taken in large enough doses, the brain will respond by shutting down all processes that are related to mood, thought, and action. In other words, it is a suicide drug.

I found this information online, and I’m hoping that I can get some opinions on it. I have taken the drug a couple of times, and it has made me very, very depressed. I haven’t felt like doing anything since I’ve taken it.

My psychiatrist said that this was not a good thing, and that I shouldn’t use it anymore. I’m hoping that you guys can tell me what to do.

For the past couple of weeks, I’ve been using a really good thing. I can’t really explain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3609is a drug that inhibits
 
Response: S3609is a drug that inhibits sirtuins, which are a class of protein deacetylases, and is in phase II clinical trials. However, the effect of S3609 on bone has not been evaluated. Here, we examined the effect of S3609 on bone in a murine model of bone loss. Sirtinol (0.01 mg/kg) or S3609 (10 mg/kg) were orally administered to mice once a day for 28 days. Sirtinol or S3609 significantly reduced the bone mineral density (BMD) in femur and lumbar spine of ovariectomized (OVX) mice. Sirtinol treatment significantly increased the serum levels of osteoclastogenic factors, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), but not receptor activator of NF-κB (RANK). S3609 treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3611is a drug that inhibits
 
Response: S3611is a drug that inhibits platelet-derived growth factor (PDGF) receptor beta, thereby inhibiting the binding of PDGF to the PDGF receptor beta and, consequently, PDGF-induced cell proliferation. The purpose of this study was to investigate the effect of S3611 on PDGF-induced angiogenesis and tumor growth in an animal model. Human umbilical vein endothelial cells (HUVECs) were cultured in a microtiter plate, and their proliferation was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. S3611 was administered intraperitoneally to mice with tumor xenografts. To examine the effect of S3611 on angiogenesis, we measured microvessel density (MVD) and the expression of vascular endothelial growth factor (VEGF) and its receptors in the tumor xen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3612is a drug that inhibits
 
Response: S3612is a drug that inhibits tumor cell growth by suppressing telomerase activity. It is currently in phase I/II clinical trials.

### 4.3.2. Multidrug resistance {#s0115}

MDR (multi-drug resistance) is one of the most common causes of failure in chemotherapy. The clinical outcome of cancer chemotherapy is usually related to the development of resistance to the drugs that were used in the initial treatment. MDR is often the result of a specific pattern of resistance, which may involve either the tumor cell itself or the microenvironment of the tumor cells. These mechanisms include (1) increased drug efflux, (2) decreased intracellular drug accumulation, (3) increased DNA repair, (4) changes in the drug target, and (5) activation of alternative pathways.

The ATP-binding cassette (ABC) transporter family is a large group of membrane-bound proteins that transport a variety of substrates across
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3615is a drug that inhibits
 
Response: S3615is a drug that inhibits the GSK-3 beta protein. This results in an increase in tau phosphorylation at Serine-396 and Serine-404, which is a key factor in AD. In addition, this drug is able to reduce Aβ plaque formation and increase synaptic plasticity. Thus, a link between GSK-3 beta, tau and Aβ is beginning to emerge. This is supported by the observation that other drugs that target GSK-3 beta are able to decrease Aβ plaque formation. For example, lithium, an inhibitor of GSK-3 beta, has been shown to inhibit Aβ plaque formation and reduce tau hyperphosphorylation in transgenic mice (Lewis et al., PNAS, 97: 1468-1473, 2000).
It is believed that Aβ plaque formation is a causative factor in the development of AD. This hypothesis is consistent with the fact that the most common form of AD is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3616is a drug that inhibits
 
Response: S3616is a drug that inhibits microtubule polymerization. It is used to treat fungal infections such as aspergillosis and mucormycosis. In aspergillosis, the azole component is given in combination with amphotericin B. In mucormycosis, the azole component is given alone.S3596(the non-proprietary name of this drug) is a synthetic antifungal drug. It is used to treat a variety of fungal infections, including candidiasis, cryptococcosis, aspergillosis, histoplasmosis, and mucormycosis.

Discussion {#s0055}
==========

S3616is a drug that inhibits microtubule polymerization. It is used to treat fungal infections such as aspergillosis and mucormycosis. In aspergillosis, the azole component is given in combination with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3618is a drug that inhibits
 
Response: S3618is a drug that inhibits the synthesis of nucleic acids in cells.  It is a nucleoside analog, and a chain terminator, and is structurally similar to the anti-viral drug 3'-azido-3'-deoxythymidine (AZT).  It is a broad spectrum agent that has been shown to inhibit HIV, HSV, CMV, varicella zoster virus, HSV-1, HSV-2, and the Epstein-Barr virus.  S3618 has been shown to inhibit the replication of human cytomegalovirus in human embryonic fibroblasts.

References 

Category:Purines
Category:Nucleosides
Category:Pyrimidinediones
Category:Benzimidazoles
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3619is a drug that inhibits
 
Response: S3619is a drug that inhibits both AC and cyclic nucleotide phosphodiesterases (PDEs). The result of this inhibition is a buildup of cAMP in the cell. The cAMP then activates PKA. When PKA is activated it phosphorylates a number of substrates, which ultimately results in inhibition of certain ion channels, resulting in a reduction in the frequency of excitatory post-synaptic potentials (EPSPs). It has been shown that S3619can inhibit the spread of epileptic activity in the brain, as well as seizures induced by chemical convulsants. Additionally, S3619was found to have an anticonvulsant effect in vivo in the maximal electroshock seizure (MES) test in mice.

S3619is a drug that inhibits both AC and cyclic nucleotide phosphodiesterases (PDEs). The result of this inhibition is a buildup of cAMP in the cell. The cAMP
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3621is a drug that inhibits
 
Response: S3621is a drug that inhibits Wnt signaling. This results in the downregulation of Wnt target genes, such as cyclin D1, β-catenin, and c-Myc, which ultimately leads to the inhibition of tumor cell proliferation, induction of cell cycle arrest, and apoptosis.\[[@CIT42]\] In a phase II trial of patients with advanced or metastatic breast cancer, S3621 was well tolerated and exhibited a response rate of 7%.\[[@CIT43]\] In a phase II trial of patients with advanced prostate cancer, S3621 was found to be safe and well tolerated and to produce a partial response in 11% of patients.\[[@CIT44]\] In a phase II trial of patients with advanced colorectal cancer, S3621 was found to be safe and well tolerated and to produce a partial response in 13% of patients.\[[@CIT45]
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3622is a drug that inhibits
 
Response: S3622is a drug that inhibits the activity of the P-glycoprotein (P-gp) transporter. It has been approved in the USA for the treatment of nausea and vomiting associated with chemotherapy. The drug is currently being evaluated in Phase II trials for the treatment of HIV-1 infection and prevention of CNS toxicity in HIV-1-infected individuals. S3622 has also been tested in animal models of HIV-1 infection. S3622 is a member of a new class of compounds called'multidrug resistance inhibitors' (MDRIs) that are structurally unrelated to other HIV-1 antiretroviral drugs. In this article we describe the structure and function of P-gp, review the evidence that P-gp is important in HIV-1 pathogenesis and discuss the rationale for targeting P-gp as a therapeutic strategy.

HIV-1 infection of CD4+ T cells is dependent on viral entry, which occurs via the CD4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3623is a drug that inhibits
 
Response: S3623is a drug that inhibits the S-adenosylhomocysteine hydrolase (SAHase), which has a role in epigenetic regulation.^[@bibr2-1559325820926735]^ Its effect on DNMT1 was evaluated using an in vitro methyltransferase assay. S3623 inhibited DNMT1 activity in a dose-dependent manner with a *K* ~i~ value of 1.3 μmol/L.^[@bibr2-1559325820926735]^ S3623 has a short half-life in vivo. A pharmacokinetic study in rats revealed a *t* ~1/2~ of only 10 minutes, which is considerably shorter than that of a DNA hypomethylating agent, 5-azacytidine.^[@bibr2-1559325820926735]^ The high turnover rate of S3623 was attributed to the highly reactive
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3625is a drug that inhibits
 
Response: S3625is a drug that inhibits NMDARs.

S3625 was shown to be an allosteric NMDAR antagonist, with selectivity for GluN1/GluN2A receptors over GluN1/GluN2B receptors. In particular, S3625 has higher potency at GluN1/GluN2A than at GluN1/GluN2B receptors. S3625 inhibits NMDARs at concentrations as low as 1 μM and can reverse the glutamate-induced currents of GluN1/GluN2A receptors in a concentration-dependent manner \[[@CR28]\]. S3625 is an antagonist of NMDARs, with a pK~i~ of 9.2. S3625 is currently under investigation in clinical trials for the treatment of schizophrenia and major depressive disorder.

The S3625-induced inhibition of NMD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3635is a drug that inhibits
 
Response: S3635is a drug that inhibits the in vitro enzymatic activity of Hsp90 by binding to the N-terminal ATP-binding site of the chaperone. In this study, we investigated the in vivo activity of S3635 in tumor-bearing mice. The antitumor activity of S3635 was evaluated in a human non-small cell lung cancer (NSCLC) xenograft model. We found that S3635 caused a significant reduction in tumor volume and weight in the xenograft model. In addition, S3635 decreased the expression of Hsp90, c-Myc, and Akt, which are involved in cell cycle progression, apoptosis, and metastasis. In summary, our results show that S3635 is a potent Hsp90 inhibitor and can be used as a potential therapeutic agent for the treatment of NSCLC.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3636is a drug that inhibits
 
Response: S3636is a drug that inhibits p-glycoprotein function, a transporter that effluxes drugs from cells. It may increase the bioavailability of antiretroviral drugs, thus enhancing the effect of the antiretroviral drugs. S3636 is currently being evaluated in a Phase II trial in combination with efavirenz in HIV-infected adults.

It is contraindicated in patients with hypersensitivity to piperaquine.

Side effects
S3636 is generally well tolerated. The most common adverse effects include nausea, dizziness, and headache.

Mechanism of action

S3636 has a unique mechanism of action, with the ability to potentiate the action of antiretroviral drugs.

References

Category:Antiretroviral drugs
Category:Chloroarenes
Category:Quinolines
Category:Piperidines
Category:Tetraz
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3637is a drug that inhibits
 
Response: S3637is a drug that inhibits HSP90 activity, and the other is the anti-inflammatory agent (Adriamycin). Both of these drugs are used as anticancer agents. We used them to test whether the two drugs affect the protein quality control system.

The anti-cancer drug, S3637, has been shown to be an inhibitor of HSP90 \[[@B29-ijms-21-03987]\]. However, we have no idea whether this drug affects the proteasome or the ERAD pathway. We have no idea whether this drug affects the function of ERAD-related proteins. Therefore, we used Adriamycin, which has been used as an anticancer drug for many years. The anti-inflammatory activity of Adriamycin has been well studied \[[@B30-ijms-21-03987]\].

As shown in [Figure 1](#ijms-21-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3638is a drug that inhibits
 
Response: S3638is a drug that inhibits the enzyme myristoyl-CoA:protein N-myristoyltransferase (NMT), which is responsible for the transfer of the myristate moiety from myristoyl-CoA to the N-terminal glycine of certain proteins, including oncoproteins and transcription factors. NMT inhibitors can act on the proliferation and differentiation of cancer cells, and are known to exhibit antitumor activity against human cancer cell lines.
S3638 is currently in Phase I clinical trials. It is being developed by Spectrum Pharmaceuticals and is a member of the bis-amino alcohol family of drugs. The structure of S3638 has been described in U.S. Pat. No. 5,576,289.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3639is a drug that inhibits
 
Response: S3639is a drug that inhibits the cyclic guanosine monophosphate (cGMP)-dependent phosphodiesterase (PDE) activity of PDE5, a PDE enzyme that metabolizes the second messenger cGMP. It has been suggested that Sildenafil acts by binding to a site within the catalytic pocket of PDE5 and inhibiting the activity of PDE5, thus prolonging the duration of the action of cGMP and the erection that it elicits. Sildenafil is also used to treat pulmonary hypertension and to prevent and treat benign prostatic hyperplasia.
The main side effects of Sildenafil are headaches, flushing, nasal congestion, facial flushing, and hypotension. Side effects may be more common with higher doses and/or longer use.
Patients using Sildenafil are advised to avoid grapefruit juice, and also foods that are high in vitamin C
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3640is a drug that inhibits
 
Response: S3640is a drug that inhibits microtubule depolymerization. The drug has the ability to bind to microtubules and block their depolymerization in cells, and was used as a microtubule stabilizer. S3640 inhibits the growth of tumor cells and was found to inhibit the growth of cancer cells.

S3640 was the first drug to demonstrate the microtubule-stabilizing effect in vitro. It is a potential anticancer agent that can be used as a microtubule-stabilizing agent for cancer therapy. It was approved by the FDA for the treatment of colon cancer.

S3640 was discovered in 1976 by Charles Whitebread and Bruce Walker at the Johns Hopkins University. S3640 is a 4,6-disubstituted pyrimidine that binds to microtubules. The drug was developed by F. Hoffmann-La Roche Ltd. and is currently being investigated for the treatment of colon cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3641is a drug that inhibits
 
Response: S3641is a drug that inhibits protein synthesis in cells by binding to the elongation factor EF-Tu. It is a clinically active agent for the treatment of bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).

The development of resistance to S3641 is a concern, as is the fact that S3641 may be less effective against methicillin-resistant S. aureus than is linezolid.

When applied topically, S3641 may be an effective agent for the treatment of MRSA skin infections.

Introduction

Staphylococcus aureus is a bacterium that causes a range of infections, from minor skin infections such as pimples to life-threatening infections such as pneumonia. Staphylococcus aureus infections are becoming more common and difficult to treat. For example, methicillin-resistant Staphylococcus aureus (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3642is a drug that inhibits
 
Response: S3642is a drug that inhibits MMP-2, MMP-9, and MT1-MMP. This drug is effective for the treatment of Alzheimer's disease (AD) and the prevention of cognitive decline in patients with mild cognitive impairment (MCI). In the present study, we examined the effect of silymarin on oxidative stress-induced apoptosis in cultured rat hippocampal cells. Silymarin (SIL) is a natural antioxidant that has been shown to be effective for the treatment of liver diseases. We have previously reported that SIL exerts protective effects against cerebral ischemia in rats. To investigate the neuroprotective effect of SIL, we examined its effects on H(2)O(2)-induced oxidative stress in cultured rat hippocampal cells. We found that SIL suppressed H(2)O(2)-induced cell death and the release of lactate dehydrogenase (LDH). We also found that SIL inhibited H(2)O
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3643is a drug that inhibits
 
Response: S3643is a drug that inhibits the enzyme cathepsin S, a cysteine protease involved in the lysosomal degradation of the TGF-beta1 receptor, the binding of which to TGF-beta1 is essential for its signaling. The treatment of SK-hepatoma cells with S3643 inhibits TGF-beta1-induced cell proliferation and induces apoptosis. Here, we investigated the effect of S3643 on human primary hepatocytes, which play a critical role in the clearance of toxins and xenobiotics, and have an important role in the regulation of bile flow and hepatic metabolism. The treatment of human primary hepatocytes with S3643 significantly increased the activity of cathepsin S, which was accompanied by a reduction of TGF-beta1 receptor levels. S3643 treatment also decreased the TGF-beta1-induced expression of cyclin D1 and the levels of Smad2/3 phosphorylation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3644is a drug that inhibits
 
Response: S3644is a drug that inhibits the activity of the enzyme thymidylate synthase (TS). This enzyme is essential for DNA synthesis, and its inhibition results in apoptosis. In vivo, the compound is phosphorylated and activated by thymidine kinase 1 (TK1).

**A.** Mechanism of action of S-1. The fluoropyrimidine 5-fluorouracil (5-FU) is phosphorylated by TK1 to 5-FU-triphosphate (5-FU-TP), which is incorporated into the DNA and results in cell death. The S-1 combination is more effective than 5-FU in many solid tumors. In the colon cancer cell lines (HCT-116, HT-29, and KM12C), S-1 treatment results in accumulation of 5-FU-TP, which inhibits TS and causes DNA damage. 5-FU-TP is then converted to 5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3645is a drug that inhibits
 
Response: S3645is a drug that inhibits the Hsp90-p23 interaction and causes destabilization of the Hsp90-Hsp70 heterodimer. In addition, S3645 induces degradation of the Hsp90 client protein p53. Here we have examined the ability of S3645 to kill human cancer cells. We found that S3645 has potent cytotoxic activity in vitro against a broad range of human cancer cells, including cells resistant to current anticancer therapies. In addition, S3645 treatment in vivo causes tumor regression and eradication in a xenograft mouse model. Importantly, S3645 did not cause adverse effects in normal tissues in mice. Our results show that S3645 is a potential anticancer drug and suggests that S3645 may be useful for the treatment of cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3646is a drug that inhibits
 
Response: S3646is a drug that inhibits the enzyme responsible for breaking down the neurotransmitter serotonin. It was originally developed for the treatment of depression, and it is now used for the treatment of anxiety and OCD. The first evidence for a potential link between the use of SSRIs and OCD was in an open trial of fluoxetine in OCD patients. The drug was found to have an immediate effect on OCD symptoms and some benefit in reducing OCD-related anxiety. Subsequent controlled studies have confirmed the efficacy of fluoxetine in OCD.

Although it is effective in the short term, it has a high rate of side effects, including nausea, headache, and sexual problems. It can also cause weight gain and fatigue. Other drugs used to treat OCD are clomipramine and fluvoxamine.

A recent study has found that there is a potential role for transcranial magnetic stimulation (TMS) in the treatment of OCD. A single session of T
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3647is a drug that inhibits
 
Response: S3647is a drug that inhibits the mTORC1/2-mediated autophagy pathway and is currently in phase I/II clinical trials for advanced solid tumors. Here, we investigated the effects of PX-866 on the induction of autophagy and the antitumor activity of doxorubicin in the triple-negative breast cancer cell line MDA-MB-231. PX-866 inhibited mTORC1/2 activity and induced autophagy in MDA-MB-231 cells. PX-866 and doxorubicin treatment synergistically induced apoptosis in MDA-MB-231 cells. We found that PX-866 suppressed the mTORC1/2-mediated phosphorylation of ULK1, Atg13, and FIP200. Moreover, PX-866 and doxorubicin treatment synergistically induced cleavage of caspase-9 and caspase-3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3648is a drug that inhibits
 
Response: S3648is a drug that inhibits sialidase. It has been developed as a potential treatment for SARS and MERS, but there is little data on its safety and efficacy. We report a case of severe acute respiratory syndrome (SARS) that was treated with tocilizumab. The patient presented with a fever and rapidly progressing dyspnoea. Chest CT showed diffuse ground-glass opacities and bronchial wall thickening. After initiation of tocilizumab, the patient's clinical symptoms improved rapidly and laboratory tests showed a marked reduction in CRP levels.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3649is a drug that inhibits
 
Response: S3649is a drug that inhibits the conversion of cortisol into cortisone. It is an oral medication. S3649is used to treat type 2 diabetes mellitus (T2DM) and pre-diabetes (PDM). It also helps reduce the symptoms of stress. S3649is is also used to treat post-menopausal symptoms such as hot flashes and night sweats.

S3649 is available in the following dosage forms:

Tablet (400 mg, 200 mg)

What is S3649?

S3649 is a drug that inhibits the conversion of cortisol into cortisone. It is an oral medication. S3649 is used to treat type 2 diabetes mellitus (T2DM) and pre-diabetes (PDM). It also helps reduce the symptoms of stress. S3649 is also used to treat post-menopausal symptoms such as hot flashes and night sweats.

What is S3649
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3650is a drug that inhibits
 
Response: S3650is a drug that inhibits Aurora B kinase and induces mitotic arrest and apoptosis in tumor cells.^[@bib1]^ It has a unique mechanism of action because it only inhibits Aurora B kinase, and not other members of the Aurora kinase family.^[@bib2]^ Thus, S3650 is a highly selective inhibitor of Aurora B kinase. It has demonstrated promising activity against various cancer types in preclinical models.^[@bib3]^ It is currently in Phase I/II clinical trials for the treatment of a number of cancers.^[@bib4]^

One of the critical steps for drug development is the identification of biomarkers that can be used to predict the efficacy of a drug. Currently, there is no reliable biomarker to predict the response of cancer patients to S3650. To develop a predictive biomarker, we performed gene expression profiling of cells treated with S3650.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3654is a drug that inhibits
 
Response: S3654is a drug that inhibits the first step of the methionine salvage pathway and is currently in phase III clinical trials for the treatment of acute lymphoblastic leukemia (ALL). Here, we investigate the effects of S3654 on the growth and viability of acute myeloid leukemia (AML) cells and the molecular mechanisms underlying these effects. We demonstrate that S3654 inhibits the growth of AML cells, induces apoptosis, and inhibits their ability to form colonies. This drug was also able to block the clonogenic growth of leukemia cells in the presence of cytokines. Consistent with these findings, S3654 induced cell cycle arrest at G0/G1 in leukemia cells and induced apoptosis. We found that S3654 inhibited the methionine salvage pathway by decreasing the levels of methionine, and this effect was reversed by adding excess methionine. These results demonstrate that S3654 is a potential novel anticancer agent that inhibits the methion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3655is a drug that inhibits
 
Response: S3655is a drug that inhibits the binding of the HIV-1 gp120 envelope glycoprotein to the chemokine receptor CCR5. In a recent study, it was shown that S3655 could prevent the infection of CD4+ T cells by primary R5 and X4 HIV-1 strains \[[@B17-viruses-05-02767]\]. This drug is an important addition to the armamentarium of antiretroviral drugs for HIV-1 infection.

4. Targeting of the Envelope Glycoprotein for HIV-1
===================================================

The HIV-1 envelope glycoprotein gp120 is the primary target for the immune system and the first step in the virus entry process. HIV-1 entry involves the interaction of the gp120 subunit with the cellular receptor CCR5 or CXCR4, which are expressed on the surface of CD4+ T cells, macrophages, d
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3656is a drug that inhibits
 
Response: S3656is a drug that inhibits
phosphodiesterase 4. It is
used to treat the symptoms of
psoriasis. It can also
be used to treat symptoms
of COPD and multiple
sclerosis. It may also be
used for purposes not
specified in this medication
guide.

S3656is a drug that inhibits
phosphodiesterase 4. It is
used to treat the symptoms of
psoriasis. It can also
be used to treat symptoms
of COPD and multiple
sclerosis. It may also be
used for purposes not
specified in this medication
guide.

S3656is a drug that inhibits
phosphodiesterase 4. It is
used to treat the symptoms of
psoriasis. It can also
be used to treat symptoms
of COPD and multiple
sclerosis. It may also be
used for purposes not
specified in this medication

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3657is a drug that inhibits
 
Response: S3657is a drug that inhibits the RNA polymerase activity of P-TEFb and thereby reduces the level of H3K4me3 and H3K36me3 at gene promoters, leading to downregulation of gene expression. We show that treatment of AML cells with the drug induces apoptosis in a subset of cells, which depends on the expression of the c-Myc oncogene. This finding is consistent with the association of c-Myc overexpression with drug resistance in AML and has important implications for the development of combination therapies to overcome drug resistance in AML.

Abstract

The c-Myc oncogene is overexpressed in a significant fraction of AML cases and has been associated with resistance to standard chemotherapy. We show that, in AML cells, c-Myc is recruited to the promoters of its target genes and that the resulting induction of H3K4me3 and H3K36me3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3658is a drug that inhibits
 
Response: S3658is a drug that inhibits angiogenesis by blocking VEGF signaling, thereby preventing tumor growth and metastasis.^[@bib34]^ [Table 2](#tbl2){ref-type="table"} summarizes the results of the pharmacological and toxicological evaluation of *S. aureus* JF-2S3658 in animal models. In particular, the oral LD~50~ of *S. aureus* JF-2S3658 was found to be greater than 10 g/kg in mice. Furthermore, a dose of 30 mg/kg did not induce any adverse effect, and did not alter the histology of major organs in mice.

Discussion
==========

A previous study reported that VEGF signaling is required for *S. aureus*-induced lung infection.^[@bib7]^ However, the pathogenic mechanism of *S. a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3659is a drug that inhibits
 
Response: S3659is a drug that inhibits the growth of cells by inhibiting the kinase activity of mTOR. It has been shown to have anti-tumor activity in vivo in a variety of cancers, including pancreatic cancer. In vitro, S3659 causes the apoptosis of cells that are actively dividing, including pancreatic cancer cells. In a recent Phase I study, S3659 was administered intravenously to patients with advanced solid tumors. The dose-limiting toxicities (DLTs) were grade 3 to 4 nausea and vomiting. In addition, a dose-dependent decrease in blood pressure was seen. Of the 36 patients who received the drug, there were no complete or partial responses. However, 7 patients (19%) had stable disease. The recommended Phase II dose was determined to be 240 mg/m2 given on a weekly schedule. S3659 is being tested in a Phase II study in patients with pancreatic cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3662is a drug that inhibits
 
Response: S3662is a drug that inhibits cell division and induces apoptosis in cancer cells. This drug has been investigated in many clinical trials for treating patients with various cancers, including ovarian cancer, but the clinical results have been disappointing. It has been reported that the combination of cisplatin and S3662 is effective in treating cancer patients, although it is unclear how S3662 sensitizes cancer cells to cisplatin. We found that S3662 down-regulates the expression of c-Myc and cyclin D1, which are known to play a crucial role in cisplatin resistance. S3662 also down-regulates the expression of NF-κB1, a transcription factor that regulates the expression of many genes including c-Myc and cyclin D1. Moreover, the knockdown of NF-κB1 by siRNA enhanced the cisplatin sensitivity of cancer cells. The c-Myc expression was down-regulated by the treatment with S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3663is a drug that inhibits
 
Response: S3663is a drug that inhibits caspase-1 (IL-1β-converting enzyme), which plays an important role in the processing of pro-IL-1β to mature IL-1β, thereby preventing the production of the proinflammatory cytokine IL-1β.

S3663 has been shown to be efficacious in murine models of inflammatory diseases. In an acute colitis model, S3663 suppressed the severity of disease and reduced the production of IL-1β, IL-6, and TNF-α \[[@CR85]\]. S3663 has also been shown to be efficacious in a murine model of arthritis \[[@CR86]\]. S3663 treatment led to reduced inflammation and cartilage damage in a murine model of collagen-induced arthritis (CIA) \[[@CR86]\]. These studies show that S3663 is effective in the treatment of inflammatory diseases.

S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3664is a drug that inhibits
 
Response: S3664is a drug that inhibits the P-glycoprotein (P-gp) and inhibits the transport of many different drugs across the BBB. P-gp is an efflux transporter located in the luminal side of the endothelial cells of the BBB. The main function of P-gp is to transport the substrates of P-gp out of the brain. P-gp can be found in all cell types of the BBB including astrocytes, pericytes, and endothelial cells. P-gp is present in the normal brain, but the expression levels are lower in normal conditions. P-gp is expressed in the endothelial cells in a development-dependent manner, increasing from P7 to P21 and decreasing at P42. P-gp expression levels are higher in the adult than in the developing brain. P-gp expression increases with aging. P-gp expression levels in the human brain are also higher in the cerebellum than in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3666is a drug that inhibits
 
Response: S3666is a drug that inhibits the production of the cytokine TNF-alpha, and is approved for use in patients with rheumatoid arthritis and Crohn's disease. TNF-alpha is an inflammatory cytokine that is released from activated macrophages and monocytes. TNF-alpha stimulates the expression of other inflammatory cytokines such as IL-1, IL-6 and IL-8. Inhibition of TNF-alpha production therefore has a dual effect: it reduces the inflammatory response, and also prevents the development of other inflammatory cytokines. TNF-alpha is also an important regulator of bone resorption. Inhibition of TNF-alpha production therefore has an effect on both bone resorption and formation.
The exact mechanism by which TNF-alpha is produced is not known. It is believed that an initial trigger, for example an infection, activates a macrophage, causing the release of TNF-alpha. TNF-alpha
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3667is a drug that inhibits
 
Response: S3667is a drug that inhibits vascular endothelial growth factor (VEGF), which is a potent mediator of angiogenesis. The study aims to determine the effects of S3667 on wound healing in a rat excisional wound model. Thirty-two male Sprague-Dawley rats were randomly assigned to four groups of eight animals each. A full-thickness wound was created on the back of the animals, and S3667 was applied topically to the wound. Animals were euthanized on post-wounding days 3, 7, and 14. The tissue samples were examined histologically. The data were analysed using ANOVA and Tukey's post-hoc tests. The mean wound area was significantly lower in the S3667-treated group than in the control group on post-wounding days 3, 7, and 14. The mean number of proliferating cells was significantly higher in the S3667-treated group than in the control group
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3668is a drug that inhibits
 
Response: S3668is a drug that inhibits aldosterone-induced sodium reabsorption in the renal collecting duct, where it blocks the effect of aldosterone on ENaC. AICS3668 is an inhibitor of aldosterone-induced ENaC in the kidney. In a phase II trial, patients with sodium retention and hypokalemia secondary to primary aldosteronism, and patients with metabolic alkalosis and renal insufficiency due to sarcoidosis or Cushing's syndrome, showed substantial sodium and fluid loss with AICS3668.

AICS3668 is a drug that inhibits aldosterone-induced sodium reabsorption in the renal collecting duct, where it blocks the effect of aldosterone on ENaC. AICS3668 is an inhibitor of aldosterone-induced ENaC in the kidney. In a phase II trial, patients with sodium retention and hypokalemia secondary to primary a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3669is a drug that inhibits
 
Response: S3669is a drug that inhibits bacterial DNA synthesis. In addition, it has been reported that its side-effects include diarrhea, constipation, abdominal pain, anorexia, and diarrhea. Furthermore, since S3669 is a triazole derivative, it is likely to cause side-effects such as arthralgia and malaise, and it is reported that it is difficult to maintain the drug's effective blood concentration (Non-patent document 2).
It has been reported that CDP323 is a small-molecule cyclin-dependent kinase inhibitor, and that it has a potent antibacterial activity against MRSA (Methicillin-resistant Staphylococcus aureus), MRSE (Methicillin-resistant Staphylococcus epidermidis), and VRE (Vancomycin-resistant Enterococcus). However, CDP323 has been reported to cause a slight side-effect of diarrhea.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3670is a drug that inhibits
 
Response: S3670is a drug that inhibits the inactivation of AMPK by blocking the binding of AMP to the γ-subunit. In this study, we evaluated the effects of metformin and S3670 on energy metabolism in human umbilical vein endothelial cells (HUVECs). Metformin increased the intracellular AMP concentration and activated AMPK in a concentration-dependent manner. Metformin increased the cell viability of HUVECs under high glucose conditions. Metformin inhibited the high glucose-induced decrease in intracellular ATP concentration, the increase in lactate concentration, and the increase in reactive oxygen species production. S3670 also increased the AMP concentration and activated AMPK in a concentration-dependent manner. S3670 also inhibited the high glucose-induced decrease in intracellular ATP concentration and the increase in lactate concentration. However, S3670 did not inhibit the high glucose-induced increase in reactive oxygen species production.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3671is a drug that inhibits
 
Response: S3671is a drug that inhibits topoisomerase I and II. The induction of S3671-induced DNA damage, as well as its accumulation in the nucleus, were significantly reduced in cells expressing the wild-type FANCD2. These data demonstrate that FANCD2 is a critical factor for S3671-induced DNA damage. The loss of the FA pathway may partially account for the relatively high chemosensitivity of cells deficient in the FANCD2 pathway.

The current study suggests that S3671 induces DNA damage by activating the ATR-Chk1 pathway. In the FANCD2-deficient cells, the level of phosphorylated ATR and Chk1 was increased by S3671 treatment. However, the level of phosphorylated Chk1 was not altered in the FANCD2-complemented cells, and the level of phosphorylated Chk1 was not affected by S3671 treatment. Thus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3672is a drug that inhibits
 
Response: S3672is a drug that inhibits the activation of protein kinase C (PKC). In human umbilical vein endothelial cells (HUVECs), S3672 attenuated the platelet-induced activation of PKC, and in parallel, inhibited platelet-induced secretion of the proinflammatory cytokine interleukin (IL)-6. S3672, when administered to mice, reduced thrombus formation in a laser-induced thrombosis model. We now show that S3672 attenuates the platelet-induced secretion of IL-6 in human endothelial cells and the subsequent inflammatory response in human blood. The inhibition of IL-6 secretion was a direct effect of S3672 on endothelial cells and not mediated by an effect on the secretion of IL-1beta. In conclusion, S3672 inhibits platelet-induced endothelial cell secretion of IL-6, thereby reducing the inflammatory response in the microcirculation.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3673is a drug that inhibits
 
Response: S3673is a drug that inhibits viral DNA polymerase, the major enzyme involved in DNA replication. We report the first study of the effect of S3673 on the development of the human placenta. S3673 was given to women in the second trimester of pregnancy. The treated women received doses of 400 mg daily for a period of five days and were compared with untreated women who received a placebo. In the treated group, there was a statistically significant reduction in the rate of weight gain and an increase in the length of gestation at delivery.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3674is a drug that inhibits
 
Response: S3674is a drug that inhibits protein kinase C (PKC) and may be useful in the treatment of diseases associated with dysregulated PKC activity. S3674 inhibits PKC-dependent enzyme activity in vitro, as well as the ability of the enzyme to translocate from the cytosol to the membrane in response to the phorbol ester, phorbol 12-myristate 13-acetate (PMA). S3674 is active in vitro at concentrations as low as 5 nM, and is a potent inhibitor of PKC in intact cells. S3674 is active in vivo in mouse models of acute inflammation and atherosclerosis. It is well tolerated in animals. The oral bioavailability of S3674 is about 50%. S3674 inhibits the phosphorylation of several endogenous substrates in intact cells. It is a competitive inhibitor of PKC in vitro, with an IC50 of 6.8 nM. S3674 is a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3675is a drug that inhibits
 
Response: S3675is a drug that inhibits pro-inflammatory cytokine release, particularly TNF-α, in the presence of LPS \[[@B55-ijms-19-02208]\]. It also inhibits the transcriptional activity of NF-κB \[[@B55-ijms-19-02208]\]. The pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, have been shown to contribute to bone loss and aseptic loosening after TKA \[[@B1-ijms-19-02208],[@B2-ijms-19-02208],[@B3-ijms-19-02208],[@B4-ijms-19-02208],[@B5-ijms-19-02208],[@B6-ijms-19-02208],[@B7-ijms-19-02208],[@B
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3677is a drug that inhibits
 
Response: S3677is a drug that inhibits DNA polymerase δ. It is used in combination with ara-C to treat acute myeloid leukemia (AML). It has been approved for use in AML that has relapsed or relapsed following an initial remission. S3677 has also been investigated in other forms of cancer.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3681is a drug that inhibits
 
Response: S3681is a drug that inhibits the polymerization of actin filaments by binding to the barbed end of actin filaments and prevents the addition of new actin subunits. It is currently used as an anti-cancer drug in several cancers. The effect of S3681 on human osteosarcoma cell proliferation and migration has not been studied yet. We therefore investigated the effect of S3681 on the growth and migration of osteosarcoma cells. We used MG-63, U2OS, and 143B human osteosarcoma cell lines. The viability of the cells was measured using a CellTiter-Glo® Luminescent Cell Viability Assay. Cell migration was measured using the CytoSelect™ Cell Migration Assay. The expression of markers for cell proliferation, cell cycle, and apoptosis were also measured using RT-PCR. S3681 did not affect the viability of osteosarcoma cells. S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3684is a drug that inhibits
 
Response: S3684is a drug that inhibits BMP-4 induced differentiation of mouse myoblast cells C2C12. This drug has been shown to induce apoptosis in hematopoietic cells in vitro. S3684 is a small molecule that inhibits bone morphogenetic protein (BMP) signaling and causes apoptosis of hematopoietic cells. S3684 has been shown to be an effective therapy for treating blood disorders.

BMP4-Induced Mouse Myoblast Cell Differentiation {#s2a}
------------------------------------------------

S3684 inhibits the differentiation of mouse myoblast cells C2C12 induced by BMP4. These cells were derived from C2C12 myoblasts, which are derived from the muscle tissue of mice. Mouse myoblast cells C2C12 were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3685is a drug that inhibits
 
Response: S3685is a drug that inhibits a kinase called CDK7, which is required for activation of RNA polymerase II and thus transcription of genes. S3685 works by inhibiting the enzyme CDK7, which stops transcription of the gene.

S3685 is used to treat different types of cancer, such as prostate cancer, breast cancer, non-Hodgkin's lymphoma, multiple myeloma, melanoma, lung cancer, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, esophageal cancer, and leukemia. S3685 is also used to treat symptoms of some types of cancer, such as Kaposi's sarcoma, a cancer that occurs in people with HIV infection, and symptoms of multiple myeloma, a cancer that affects the bone marrow.

S3685 is usually taken by mouth, but it may also be used intravenously. S3685 is taken by mouth to treat symptoms
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3689is a drug that inhibits
 
Response: S3689is a drug that inhibits the binding of the retinoblastoma protein (Rb) to the E2F family of transcription factors, leading to the activation of E2F-regulated genes required for S phase progression. We show here that S3689 causes rapid growth arrest and apoptosis in multiple human cancer cell lines. This effect is mediated by transcriptional up-regulation of p21, which is a well-characterized Rb-regulated gene. Moreover, we show that S3689 treatment induces G1 arrest in a panel of human cancer cell lines. These findings demonstrate that S3689 is a potent anti-tumor agent that inhibits growth of a variety of human cancers, including breast, prostate, and colon carcinomas.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3690is a drug that inhibits
 
Response: S3690is a drug that inhibits RNA polymerase II. This is an extremely potent drug that causes apoptosis. S3690 induces DNA damage, increases phosphorylation of H2AX and CHK1, and causes G2/M arrest. S3690 causes p53-independent apoptosis and has no effect on TP53-deficient cells. Our findings suggest that TP53-dependent and -independent mechanisms are involved in S3690-induced apoptosis. The TP53-dependent mechanism involves the upregulation of PUMA, and the TP53-independent mechanism involves the upregulation of DRAM. This is the first study to demonstrate the involvement of DRAM in TP53-independent apoptosis.

Materials and Methods

Cell lines and reagents

A375 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). P53-deficient H1299 cells were kindly provided by Dr Shigenori Iwai (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3692is a drug that inhibits
 
Response: S3692is a drug that inhibits protein kinase CK2. It was originally developed as a potential anticancer drug, and was recently shown to inhibit the oncogene-driven activation of the mammalian target of rapamycin (mTOR) pathway, which is known to be activated in a variety of human cancers. In the present study, we examined the effects of S3692 on protein kinase CK2 in human melanoma cells. We found that S3692 inhibited cell proliferation in a dose-dependent manner, and induced a dose-dependent increase in the proportion of cells in G2/M phase. The induction of G2/M arrest was associated with a significant increase in the levels of phosphorylated p53, p21 and the cyclin-dependent kinase inhibitor p27(Kip1). S3692 also induced the phosphorylation of the Cdc25C-Thr145 residue and decreased the levels of phosphorylated Cdc25C.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3694is a drug that inhibits
 
Response: S3694is a drug that inhibits type I interferon production, thus preventing the initiation of the antiviral immune response. S3694 does not bind to or inhibit RNA polymerase II. The purpose of this study was to determine the safety and efficacy of S3694 in a mouse model of HIV infection. Thirty-six male and female BALB/c mice were infected with a dose of HIV-1(YU-2) that resulted in ~70-80% of animals becoming infected after a short incubation period. S3694 was administered orally once daily for 28 days at a dose of 20 mg/kg/day, 10 mg/kg/day, or 2.5 mg/kg/day. Animals receiving S3694 at doses of 10 mg/kg/day or 20 mg/kg/day exhibited reduced peak plasma HIV-1 RNA levels, delayed onset of HIV-1 RNA elevation, and a longer duration of undetectable plasma HIV-1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3697is a drug that inhibits
 
Response: S3697is a drug that inhibits poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme involved in base excision repair. In the present study, we evaluated the effects of S3697 on the cell cycle and apoptosis in the U251 cell line. S3697 caused a G1 arrest and induced apoptosis. These effects were mediated by p21, p27, p53, and p21-activated kinase (PAK)-1. The effect of S3697 on PAK-1 was associated with the phosphorylation of PAK-1 and of its downstream effector, the mitogen-activated protein kinase (MAPK). Our results suggest that S3697-induced apoptosis in U251 cells involves the regulation of cell cycle-related proteins.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3698is a drug that inhibits
 
Response: S3698is a drug that inhibits the activity of the cyclin-dependent kinases (CDKs) CDK2 and CDK4 and has demonstrated efficacy in the treatment of solid tumors. Here we report that S3698 is a potent inhibitor of the Drosophila homologs of the CDK2 and CDK4 kinases. S3698 causes the disruption of cellular proliferation, the overgrowth of imaginal discs, and the formation of small, irregularly shaped tissues. We further show that S3698 causes the upregulation of dCK, the Drosophila homolog of the mammalian CDK-inhibitory protein, CKI, and that dCK is required for the inhibition of proliferation by S3698. These results suggest that the inhibition of CDKs in Drosophila is similar to the inhibition of CDKs in mammalian cells and support the idea that the CDKs and CKI are the primary target of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3701is a drug that inhibits
 
Response: S3701is a drug that inhibits the enzyme histidine decarboxylase. The enzyme converts histamine into histamine-4-methyl-7-amino-4-ciclopropanecarboxylic acid (H4MCP) which is then conjugated to glutamic acid. This amino acid is then converted to gamma-aminobutyric acid (GABA) by the enzyme glutamate decarboxylase. GABA then activates the GABA receptors, which then results in inhibition of neuronal activity.

S3701 has been used in research to see if it is an effective drug to treat patients with severe pain.

Indications
S3701 is used for the treatment of pain.

Contraindications
S3701 is contraindicated in patients with allergy or hypersensitivity to S3701, H4MCP, or any of the excipients listed in the S3701 product monograph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3703is a drug that inhibits
 
Response: S3703is a drug that inhibits SREBP-2 cleavage and has been shown to increase plasma levels of LDL-C and apoB-48 in healthy human subjects \[[@CR1]\]. The purpose of this study was to determine the effects of S3703 on apoB-48 levels in subjects with hyperlipidemia and/or the metabolic syndrome. This was a single-center, open-label, randomized, crossover study conducted at a tertiary medical center. Subjects received either S3703 or placebo for 5 days, separated by a washout period of at least 4 weeks. Lipids, lipoproteins, and apoB-48 levels were measured at baseline and at the end of each treatment period. A total of 32 subjects were randomized to receive either S3703 or placebo. Of these, 26 subjects completed the study. There were no statistically significant changes in apoB-48 levels during the S370
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3704is a drug that inhibits
 
Response: S3704is a drug that inhibits a protein called Nedd4-2. It is under investigation for treatment of Alzheimer’s disease. However, in people with diabetes, it can cause severe side effects.

It’s not the first time the drug has been used in people with diabetes. But there are side effects.

The drug is given as a slow infusion over a long period of time. It’s taken in a hospital, in a special centre.

It can cause side effects that are not common with insulin, and that can be life-threatening.

It can cause swelling in the hands, feet and face. It can cause serious blood clots. It can cause swelling of the stomach and intestines, and bleeding in the lungs. It can cause chest pain, trouble breathing and irregular heartbeats.

These are the side effects that the drug has been shown to cause in people with diabetes.

People with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3705is a drug that inhibits
 
Response: S3705is a drug that inhibits the formation of, and thus, the activity of, TGF-β. TGF-β is an important regulatory cytokine in wound healing and other biological processes (Vartanian et al., 1996, J. Clin. Invest. 98:1951-1957).
The corneal endothelium, a single layer of cells located in the posterior surface of the cornea, plays an important role in maintaining corneal transparency by forming a barrier between the aqueous humor of the anterior chamber of the eye and the posterior corneal stroma (Lai et al., 1996, Ophthalmic Res. 28:507-512). The corneal endothelium also provides a barrier to the diffusion of nutrients and other molecules to the stroma. It is essential for maintaining the metabolic activity of the cornea. Any damage or dysfunction of the corneal endothelium will result in the breakdown of the barrier and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3706is a drug that inhibits
 
Response: S3706is a drug that inhibits the signaling of the growth factor receptor ERBB3, and has shown promising activity in a range of solid tumors in phase I and II trials. The combination of GSK1120212 and erlotinib, a selective ERBB1/2 inhibitor, is currently in phase I/II clinical trials. In the present study, we found that the combination of GSK1120212 and erlotinib induced tumor regression in an erlotinib-sensitive mouse xenograft model of non-small cell lung cancer. We also found that GSK1120212 and erlotinib synergistically induced apoptosis and suppressed tumor cell growth in vitro. Furthermore, the combination of GSK1120212 and erlotinib induced cell cycle arrest in G2/M phase and caused caspase-3 activation in erlotinib-sensitive cells. In contrast, GSK1120212 and erlotinib did not induce
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3707is a drug that inhibits
 
Response: S3707is a drug that inhibits the synthesis of polyunsaturated fatty acids, which are essential components of cell membranes and therefore of living organisms. This results in a decrease in cell growth, the activation of apoptosis and the appearance of cytopathic effects. The cytotoxic effects are in addition associated with the inhibition of the expression of certain proteins and of the functions they perform in the cell, and also the inhibition of cell migration.

The aim of the study was to compare the efficacy and tolerability of the treatment with S3707 compared to etoposide in patients with relapsed or refractory acute myeloid leukemia.

The study was conducted on a group of 22 patients with relapsed or refractory AML who were administered oral S3707 at a dose of 50 mg/m2/d for 14 days (starting from day 1) in combination with intravenous etoposide at a dose of 50 mg/m2/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3708is a drug that inhibits
 
Response: S3708is a drug that inhibits the activity of the enzyme glutamate carboxypeptidase II (GCPII), a key enzyme involved in the metabolism of the neurotransmitter glutamate. GCPII is present in the brain where it hydrolyzes N-acetylaspartylglutamate (NAAG) to N-acetylaspartate and glutamate. NAAG is present in brain and peripheral tissues and can be released from cells and taken up by neighboring cells to regulate intracellular calcium levels. NAAG is involved in a variety of important physiological processes such as long term potentiation (LTP) and memory formation. In the brain, glutamate is released from presynaptic terminals and binds to postsynaptic glutamate receptors, causing a change in the postsynaptic membrane potential. The presynaptic terminal is then able to release more glutamate in response to this depolarization, which creates a positive feedback loop that leads to the generation of a signal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3711is a drug that inhibits
 
Response: S3711is a drug that inhibits the protein kinase activity of PIM1 and PIM2 and has been shown to induce apoptosis in AML cells \[[@B57-cancers-11-00561]\]. PIM kinases are a family of serine/threonine kinases that play important roles in the regulation of proliferation, differentiation, survival, and migration of leukemic cells. They are upregulated in AML, especially in *FLT3*-ITD-positive AML. PIM kinases are attractive therapeutic targets in AML, and some PIM kinase inhibitors are currently in phase I and II clinical trials \[[@B58-cancers-11-00561],[@B59-cancers-11-00561]\]. PIM kinases are highly activated in CD34^+^ AML cells and patients with high PIM expression in AML have shorter OS \[[@B60
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3713is a drug that inhibits
 
Response: S3713is a drug that inhibits the proton-pumping P-type ATPase of mitochondria. In animal cells, it causes an inhibition of protein synthesis, which leads to cell death. S3713 has been studied as a potential chemotherapeutic agent, and in combination with doxorubicin and etoposide has been tested in clinical trials.^[@ref1]^

To better understand the biological effects of S3713, we characterized the DNA-binding properties of the drug. We have previously shown that S3713 binds DNA through a sequence-independent mechanism, and its sequence specificity is weak.^[@ref2]^ This behavior contrasts with the sequence-specific DNA-binding mode of topoisomerase II.^[@ref3]^ To elucidate the mechanism by which S3713 binds DNA, we performed a series of fluorescence experiments on DNA duplexes containing a single S3713 intercal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3714is a drug that inhibits
 
Response: S3714is a drug that inhibits VEGFR-2 and EGFR tyrosine kinase activity. It has been shown that this compound has activity in vivo against human tumors that overexpress these receptors. This compound is currently in phase II clinical trials.
In addition, the compound Sulfonamide 4 is reported in WO01/10289 to be a potent, selective, orally active EGFR inhibitor.
The compound CGP5374 is reported in WO01/052518 to be an EGFR tyrosine kinase inhibitor that inhibits EGFR tyrosine kinase activity.
The compound KU0059436 is reported in WO02/13593 to be a potent, orally active EGFR inhibitor.
The compound LY294002 is reported in WO01/068112 to be a potent, orally active, selective inhibitor of the EGFR tyrosine kinase.
The compound ZD1839 is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3716is a drug that inhibits
 
Response: S3716is a drug that inhibits the acetylcholine esterase enzyme. The action of this enzyme prevents the reuptake of acetylcholine, thus allowing more acetylcholine to reach the brain. As a result, the brain experiences a greater concentration of acetylcholine and this results in an increased signal transmission to the brain and hence a therapeutic effect. S3716is approved in several countries, including Australia, Brazil, China, India, and Singapore, and it is also currently in phase II clinical trials in the United States. S3716has shown some efficacy in the treatment of schizophrenia, but it has not been approved for this indication in any country.

This article has been cited by: PubMed | Medline | Web of Science

Abstract

A phase I trial of S3716, a prodrug of a novel selective inhibitor of acetylcholine esterase, was performed in healthy volunteers. In this trial, two intravenous
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3717is a drug that inhibits
 
Response: S3717is a drug that inhibits the transport of nucleosides across the blood-brain barrier and has been shown to enhance the efficacy of some nucleoside analogs in the treatment of HIV infection. The mechanisms of S3717 are complex, involving both inhibition of nucleoside transporters and modulation of purine salvage pathway enzymes. A specific inhibitor of the enzyme adenosine kinase (ADK) was also developed. In collaboration with other members of the Laboratory of Molecular Pharmacology, the metabolism of both S3717 and its ADK inhibitor, 9-beta-D-arabinofuranosyladenine (ara-A), has been examined in mouse, rat, dog, monkey, and human liver microsomes. The results of these studies show that the metabolism of both compounds is not species-specific, and there is little interspecies variation in the major metabolic pathways. Thus, in mouse, rat, dog, monkey, and human, the major
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3718is a drug that inhibits
 
Response: S3718is a drug that inhibits platelet aggregation by blocking the activation of a receptor on platelets. Its main indication is for the prevention of thrombosis after an acute coronary syndrome. We present a case of rhabdomyolysis after oral administration of clopidogrel, which was attributed to an allergic reaction to the drug. The patient was subsequently diagnosed with S3718is allergy.

Introduction

Clopidogrel is an antiplatelet agent that inhibits platelet aggregation by blocking the activation of a receptor on platelets.1 S3718is is a prodrug of clopidogrel and its main indication is for the prevention of thrombosis after an acute coronary syndrome.2,3 This agent is administered as a single oral dose of 300 mg followed by 75 mg daily for at least 12 months.4 The manufacturer states that the drug should be taken with food to avoid delayed absorption and with water to reduce the risk of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3719is a drug that inhibits
 
Response: S3719is a drug that inhibits tubulin polymerization by binding to the vinca alkaloid binding site. It is highly selective for the microtubules and not for the actin filaments and can be used to study the effects of drugs on the cytoskeleton.

SUBSTRATES AND CHEMICAL PROTOCOLS

Tubulin is the target of several anti-cancer drugs. These include taxanes (paclitaxel and docetaxel), vinca alkaloids (vincristine, vinblastine, vinorelbine and vindesine), and epothilones (epothilone B and epothilone D).

PROCESSING AND STORAGE

Store at 4°C in the dark.

RECOMMENDATIONS FOR STORAGE AND USE

Storage

Keep in the dark at 4°C.

Pipette or disp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3720is a drug that inhibits
 
Response: S3720is a drug that inhibits platelet aggregation and suppresses thrombus formation in animal models. It also exerts anti-inflammatory effects and increases microcirculation in the peripheral circulation. However, it has not been established whether S3720 is a safe and effective drug for the treatment of ischemic heart disease. This study investigated the effects of S3720 on cardiac function and myocardial infarction in a rat model. The rat model of myocardial infarction was produced by the left anterior descending coronary artery ligation. The effects of S3720 on cardiac function and myocardial infarction were examined using a left ventricular pressure-volume system. S3720 (3 mg/kg/day, p.o.) was administered orally for 4 weeks starting on the day of myocardial infarction. After 4 weeks of treatment with S3720, cardiac function was not significantly different from that in the sham-operated group. However
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3721is a drug that inhibits
 
Response: S3721is a drug that inhibits the release of vesicles containing ATP. The drug acts by inhibiting the uptake of ATP into vesicles by blocking a membrane transporter (the H(+)-ATPase). ATP is then released from the vesicles by passive diffusion. The drug has shown anti-cancer activity in vitro and in vivo and is currently being investigated for use in clinical trials.

**Objectives:** To investigate the role of P2X7 receptors in the delivery of the drug to the cytosol of cells.

**Methods:** We have examined the uptake of S3721 in various cells, including the P2X7 receptor positive, the P2X7 receptor negative, the P2X7 receptor positive and the P2X7 receptor negative, P2X7 receptor positive and P2X7 receptor negative, and the P2X7 receptor negative cells.

**Results:** The uptake of S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3722is a drug that inhibits
 
Response: S3722is a drug that inhibits CYP3A4. It was reported that the S3722 dosage of 0.5 mg/kg was effective in an experimental model of colitis and S3722 was also reported to reduce the development of brain injury in experimental models of ischemia/reperfusion \[[@B10]\].

CYP3A4 is the major metabolizing enzyme in the human liver, and it metabolizes many drugs and xenobiotics \[[@B14]\]. S3722 is a potent CYP3A4 inhibitor. S3722 is a pyridine derivative, and its structure is closely related to that of ketoconazole, a potent CYP3A4 inhibitor. The pharmacokinetics of S3722 was evaluated in a phase I clinical trial. The half-life of S3722 was 9.7-10.9 hours and the maximum concentration was 0.54-0.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3723is a drug that inhibits
 
Response: S3723is a drug that inhibits MMP-2 and MMP-9.^[@bibr35-1758835920922055]^ This molecule has been demonstrated to be safe and to have good pharmacokinetics, and phase I/II studies have demonstrated the feasibility and safety of the compound in a variety of tumor types.^[@bibr36-1758835920922055]^ We therefore evaluated the combination of TKIs with ABT-737 in a mouse xenograft model of TNBC.

Results {#section17-1758835920922055}
=======

Synergistic effects of ABT-737 and TKIs on cell growth and apoptosis in vitro {#section18-1758835920922055}
-----------------------------------------------------------------------------

We first evaluated the effect of ABT-737 and the four TKIs (erlotinib, gef
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3724is a drug that inhibits
 
Response: S3724is a drug that inhibits mitotic arrest induced by anti-mitotic drugs. Cells were incubated for 2 h in the presence or absence of S3724. (**A**) After 2 h, cells were stained with the fluorescent anti-tubulin antibody. (**B**) Cells were collected by centrifugation and cell viability was measured using the MTT assay. Values are the means ± SD of three independent experiments. \**P*\<0.05, \*\**P*\<0.01.](pone.0026359.g002){#pone-0026359-g002}

S3724 inhibits the degradation of α-tubulin in the cytoplasm and induces mitotic arrest {#s2c}
---------------------------------------------------------------------------------------

We then investigated the mechanism of the anti-proliferative activity of S3724 by examining the expression and localization of α-tubulin. Western
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3726is a drug that inhibits
 
Response: S3726is a drug that inhibits dihydrofolate reductase and has anti-tumor activity. In this study, we compared the antitumor activity of S3726 against human lung cancer cell lines in vitro and in vivo. Our results showed that S3726 had a higher inhibitory effect on human lung cancer cell lines than on normal cells. In vivo, S3726 exhibited more significant antitumor activity in human lung cancer than in non-small cell lung cancer. We found that S3726 induced apoptosis in A549 cells, but not in BEAS-2B cells. In addition, the combination of S3726 and cisplatin enhanced the antitumor activity of S3726 in human lung cancer. We conclude that S3726 may be an effective agent for the treatment of human lung cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3727is a drug that inhibits
 
Response: S3727is a drug that inhibits the myosin light chain kinase and results in the increase of intracellular Ca2+ concentration. This study aimed to investigate the protective effects of S3727 on the myocardial injury in rats with acute heart failure. The acute heart failure was induced by intravenous injection of isoprenaline (0.3 mg/kg). The myocardial enzyme activities of rats with acute heart failure were determined. The myocardial histopathological changes were observed by the hematoxylin and eosin staining. The myocardial apoptosis was determined by the terminal deoxynucleotidyl transferase dUTP nick end labeling assay. The results showed that the myocardial enzyme activities and myocardial histopathological changes were markedly improved by S3727. Moreover, the myocardial apoptosis was significantly reduced by S3727. These results indicated that S3727 has a cardioprotective
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3728is a drug that inhibits
 
Response: S3728is a drug that inhibits SLCO2A1. At the same time, it can be seen that the value of r^2^ is not very high, so there is still some error in the prediction.

### 3.3.4. Screening by Comparative Molecular Field Analysis (CoMFA) {#sec3dot3dot4-molecules-25-00772}

A CoMFA model is constructed to predict the activity of other compounds based on the best-fit model of S3728. As shown in [Table 5](#molecules-25-00772-t005){ref-type="table"}, the pIC~50~ of the training set is from 6.5 to 8.3, and the test set is from 6.2 to 8.2. The predictive correlation coefficient (q^2^) of the training set is 0.529, and the predicted correlation coefficient (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3729is a drug that inhibits
 
Response: S3729is a drug that inhibits cysteine protease activity. It has been shown to inhibit calpain, the enzymes that cleave fodrin, and in vivo S3729 reduced the calpain-mediated proteolysis of fodrin. The objective of this study was to determine whether S3729 reduced the acute cardiotoxic effects of doxorubicin in the rat. In the acute studies, S3729 was given as a single dose of 50 mg/kg iv. Two hours later, doxorubicin (2.5 mg/kg iv) was administered. Cardiac function was monitored in vivo for 24 h. S3729 significantly reduced the doxorubicin-induced cardiotoxicity. The drug did not have any effect on doxorubicin-induced lethality, myelosuppression, or the disposition of doxorubicin. The protective effect of S3729 was specific
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3730is a drug that inhibits
 
Response: S3730is a drug that inhibits the enzyme CYP3A4 and thus enhances the bioavailability of other drugs that are substrates for this enzyme.

Moclobemide, a reversible inhibitor of monoamine oxidase, has also been reported to be an inducer of CYP3A4 \[[@B20-ijms-20-01109]\]. Thus, its use may result in interactions with CYP3A4 substrates. In addition, due to its pharmacological activity, moclobemide has been shown to inhibit the metabolism of antidepressants, and thus the therapeutic efficacy of these drugs may be reduced \[[@B21-ijms-20-01109]\]. However, no interaction has been reported between moclobemide and CYP3A4 substrates, such as statins, and no changes in the pharmacokinetics of statins have been observed in patients receiving concomitant moclobem
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3731is a drug that inhibits
 
Response: S3731is a drug that inhibits a kinase (MPS1) required for centriole duplication. The centrioles, in turn, form the main building blocks of the centrosome, a structure that duplicates once each cell cycle to support the production of a new mitotic spindle. When a centriole does not duplicate properly, cells with the resulting extra centrioles are known as aneuploid cells.

Abstract

The molecular mechanisms that regulate centriole duplication in mammalian cells are poorly understood. A specific inhibitor of MPS1 (mammalian homolog of the budding yeast SPS3/PLK1), S3731, was recently identified. S3731 potently inhibits MPS1 kinase activity in vivo, resulting in centriole duplication defects and the formation of extra centrioles in cycling cells. S3731 also prevents the accumulation of excess centrioles in MPS1-deficient cells, thus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3732is a drug that inhibits
 
Response: S3732is a drug that inhibits Mcl-1 and Bcl-2 in cancer cells, and induces apoptosis in a variety of cancer cells and hematological cells.^[@bib1],\ [@bib2],\ [@bib3]^ In the present study, we have examined the effects of S3732 on human non-Hodgkin lymphoma (NHL) cell lines. Our results indicate that S3732 has potent antiproliferative activity against B-cell NHL cell lines. In addition, we also examined the potential of S3732 to induce apoptosis in NHL cell lines, and its effects on mitochondrial function.

S3732 was synthesized at the Pharmacy Department of University of Michigan as described previously.^[@bib1]^ The compound was dissolved in dimethylsulfoxide (DMSO) to a stock concentration of 10 mM.

The following cell
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3735is a drug that inhibits
 
Response: S3735is a drug that inhibits cell cycle progression, thus arresting cells in the G1 phase. The cell cycle is the series of events by which cells replicate and divide. This process is a series of ordered events in which the cells must pass through a defined sequence of checkpoints. A cell cycle checkpoint is a point in the cell cycle at which a cell can decide whether to continue or to arrest. In many cancer cells, cell cycle progression is frequently disrupted at one or more checkpoints.
The main function of cell cycle checkpoints is to provide time for repair of DNA damage or for correct completion of other processes, such as mitosis. The cell cycle is divided into 4 phases: the G1 phase, S phase, G2 phase and M phase. During the G1 phase, a cell prepares for DNA synthesis and growth. The G2 phase is a period of DNA synthesis and growth. The S phase is a period of DNA synthesis. The M phase is a period of mitosis,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3736is a drug that inhibits
 
Response: S3736is a drug that inhibits VEGFR2. The mechanism of action of this drug is described in \[[@B38]\]. It is used in the treatment of a number of diseases including breast cancer and myeloma. The details of this drug can be found in the DrugBank database \[[@B39]\]. The IC~50~value of S3736 against VEGFR2 is 0.1 nM. The IC~50~value of S3736 against VEGFR2 is 1.8 nM when we apply the concentration used for cancer treatment. In \[[@B40]\] it is shown that S3736 inhibits VEGFR2 at the level of the kinase activity with an IC~50~value of 1.8 nM. The high concentration of S3736 used for cancer treatment in \[[@B40]\] (0.1 μM) is within the IC~50
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3737is a drug that inhibits
 
Response: S3737is a drug that inhibits CDK7, which is a kinase that phosphorylates the CDKs. This drug also inhibits the CDK9 that phosphorylates the T-cell factor (TCF) and blocks transcription by RNA polymerase II. A second drug, THZ1, also inhibits CDK7 and CDK9, and is a potent inhibitor of transcription in T cells. The first compound, SGI-1776, was developed by Servier, a pharmaceutical company. SGI-1776 is a small molecule inhibitor of CDK7 and CDK9 that inhibits cell growth and tumor growth in a mouse model of melanoma. It has been evaluated in a Phase I clinical trial in patients with melanoma. The clinical trial was not able to identify a dose that was well tolerated. However, a phase II clinical trial of SGI-1776 in patients with advanced solid tumors is currently being conducted by SGI and Vertex
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3738is a drug that inhibits
 
Response: S3738is a drug that inhibits HIV replication by suppressing the HIV-1 long terminal repeat (LTR) promoter.

The question remains whether the effect of S3738 is due to the inhibition of the HIV-1 LTR promoter, or if the compound affects another cellular pathway involved in the regulation of HIV-1 replication.

To investigate this, we first tested the effect of S3738 on cell proliferation in HIV-1-negative cells. Treatment of HeLa cells with S3738 for 48 hours did not alter the growth rate of HeLa cells ([Figure 3A](#pone-0064313-g003){ref-type="fig"}). To further test the effect of S3738 on cell proliferation, we tested the effect of S3738 on the growth of HeLa cells that had been stably transfected with the HIV-1 LTR-luciferase construct. S3738 treatment of these cells for 48 hours
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3739is a drug that inhibits
 
Response: S3739is a drug that inhibits the S3739 is a drug that inhibits the activity of phosphatidylinositol 3-kinase (PI3K). S3739 is a kinase inhibitor that specifically inhibits the activity of the p110alpha catalytic subunit of PI3K, and has been shown to inhibit the proliferation of cells, including leukemic cells, that have high levels of p110alpha expression. The S3739 also causes cell cycle arrest and apoptosis in these cells. The effects of the S3739 on leukemia cells are at least partially dependent on the activation of p53 and its downstream effector, the transcription factor p21. S3739 was also found to inhibit the growth of a mouse model of human acute lymphoblastic leukemia. The drug has been shown to be effective in treating other types of cancer, including breast cancer, prostate cancer, colon cancer, and lung cancer. The anti-cancer activity of the S3739
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3741is a drug that inhibits
 
Response: S3741is a drug that inhibits histone deacetylase (HDAC) activity. It has a number of applications in the cancer field, including cell proliferation, differentiation, cell cycle arrest and apoptosis. The N-terminal fragment of the core histones H3 and H4 are acetylated on lysine residues, and this post-translational modification has been linked to gene regulation and cell cycle progression. In addition, S3741 has been shown to cause cell cycle arrest at the G1/S transition and to induce apoptosis in a number of cancer cell lines. This review discusses the anti-cancer properties of S3741, its mechanism of action, its toxicity, and the potential clinical application of this drug.

Abstract

The importance of epigenetic regulation in the development and progression of cancer has been recognized for a number of years. A number of important therapeutic approaches have been developed that target the enzymes involved in epigenetic regulation. HD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3742is a drug that inhibits
 
Response: S3742is a drug that inhibits the proliferation of B lymphocytes by inducing apoptosis. However, the molecular mechanism by which this occurs is not well understood. In this study, we show that S3742 induces apoptosis in human and mouse B lymphocytes via an increase in the ratio of Bax/Bcl-2 and the activation of caspase-3. We also demonstrate that S3742 does not affect the viability of resting B lymphocytes. In addition, we show that the upregulation of Bax expression is preceded by the inhibition of Akt phosphorylation. Furthermore, the inhibition of Akt phosphorylation by S3742 is mediated by a decrease in phosphatidylinositol 3-kinase (PI3K) activity. Thus, S3742 is a novel PI3K inhibitor that induces apoptosis in B lymphocytes via the Bax/Bcl-2-dependent caspase-3 pathway.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3745is a drug that inhibits
 
Response: S3745is a drug that inhibits NF-kappaB activation.
S3745 is a new pyridylisoxazoline compound. It was previously shown to inhibit the activation of NF-kappaB. In the present study, we investigated the activity of S3745 in vivo and its possible molecular mechanism of action. The in vivo activity of S3745 was investigated in mice that had been given intraperitoneal injections of LPS (lipopolysaccharide). S3745 significantly suppressed LPS-induced TNF-alpha production in the serum and in the peritoneal macrophages of the mice. In order to understand the mechanism of action of S3745, we first determined the IC(50) of S3745 against the LPS-induced activation of NF-kappaB in RAW264.7 cells. S3745 inhibited the LPS-induced NF-kappaB activation with an IC(50) of 8.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3746is a drug that inhibits
 
Response: S3746is a drug that inhibits the proliferation of myeloid leukaemia cells by preventing the activity of a protein known as aurora kinase A (AURKA). This drug has been tested in clinical trials for the treatment of leukaemia and a number of solid tumours, but so far it has failed to show any clear benefit. AURKA is an oncogene that is activated in a variety of different cancers. The gene codes for a protein that acts as a'molecular motor' in the cell. It moves around the chromosomes in a process called chromatin remodelling. This is necessary for the cell to replicate its DNA and make more copies of itself.

This article is about the drug, not about the gene. The article that accompanies this news item has more details about the gene and about AURKA.

AURKA is an oncogene that is overexpressed in many different types of cancer, including leukaemia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3747is a drug that inhibits
 
Response: S3747is a drug that inhibits the activity of the DYRK1A protein kinase. It is also known as SCH900776, SKI-73, and DYRK-1 inhibitor-37. It is being developed by AstraZeneca and was initially known as AZD1236. The drug was discovered and developed by AstraZeneca. It is an orally available, selective DYRK1A inhibitor being developed for the treatment of Alzheimer’s disease.

S3747is a drug that inhibits the activity of the DYRK1A protein kinase. It is also known as SCH900776, SKI-73, and DYRK-1 inhibitor-37. It is being developed by AstraZeneca and was initially known as AZD1236. The drug was discovered and developed by AstraZeneca. It is an orally available, selective DYRK1A inhibitor being developed for the treatment of Alzheimer�
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3748is a drug that inhibits
 
Response: S3748is a drug that inhibits the proteasome and is being investigated as a possible treatment for multiple myeloma. To further understand the mechanism of action of S3748, we have used a combination of immunohistochemistry, confocal microscopy, flow cytometry and cytotoxicity assays to characterize the localization and regulation of ubiquitinated proteins and cyclin D1 in response to S3748 treatment. Treatment of U266 cells with S3748 resulted in the accumulation of ubiquitinated proteins in the nucleus and the nucleoli. This effect was accompanied by the rapid and transient induction of cyclin D1. Inhibition of proteasome function by MG132 or bortezomib prevented S3748-induced accumulation of ubiquitinated proteins and induction of cyclin D1, indicating that the effect of S3748 on cyclin D1 induction is dependent on proteasome function. In addition, treatment of cells with S3748 resulted in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3749is a drug that inhibits
 
Response: S3749is a drug that inhibits VDAC1 and is used to treat different types of cancer \[[@B56-ijms-21-03987]\]. To test if S3749 exerts any effect on the activity of AC-cAMP signaling, we analyzed its effect on cAMP-dependent signaling in cells expressing EYFP-STIM1 or EYFP-STIM1-E232A. We found that S3749 treatment did not affect the cAMP-induced ERK1/2 phosphorylation ([Figure 6](#ijms-21-03987-f006){ref-type="fig"}E,F). The same was true for the effect of S3749 on the AC activity ([Figure 6](#ijms-21-03987-f006){ref-type="fig"}G).

3. Discussion {#sec3-ijms-21-03987}
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3750is a drug that inhibits
 
Response: S3750is a drug that inhibits thrombin generation by inhibiting FXa.^[@bibr16-1076029617741261]^ The clinical use of S3750 has been approved for treating VTE, including for use in patients undergoing major orthopedic surgery.^[@bibr18-1076029617741261]^ In this study, we found that rivaroxaban, which inhibits both FXa and thrombin,^[@bibr20-1076029617741261]^ significantly reduced the blood loss, transfusion requirements, and thrombotic complications of ABO-incompatible living donor LT. This finding was in accordance with a recent study by Chen et al^[@bibr19-1076029617741261]^ that demonstrated the efficacy of rivaroxaban in reducing blood loss and transfusion requirements after ABO-incompatible LT. The use of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3751is a drug that inhibits
 
Response: S3751is a drug that inhibits the farnesylation of Ras. In normal cells, Ras is modified by farnesylation at a cysteine residue within the CAAX motif, which is then anchored to the plasma membrane, where it is important for cell proliferation. The attachment of the farnesyl group is the first step in the post-translational modification of Ras. Ras is an important signal transduction protein that mediates cell proliferation and differentiation.

1S3752is a drug that inhibits the farnesylation of Ras. In normal cells, Ras is modified by farnesylation at a cysteine residue within the CAAX motif, which is then anchored to the plasma membrane, where it is important for cell proliferation. The attachment of the farnesyl group is the first step in the post-translational modification of Ras. Ras is an important signal transduction protein that mediates cell proliferation and differentiation.

1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3752is a drug that inhibits
 
Response: S3752is a drug that inhibits p-Akt. In the presence of a high concentration of HGF, p-Akt expression was reduced. However, the expression of total Akt protein was not affected by this treatment ([Fig. 4B](#f4-ol-0-0-11020){ref-type="fig"}).

Discussion
==========

The Akt pathway is activated by HGF, and this leads to a variety of cellular responses, including proliferation, migration, invasion and anti-apoptosis ([@b13-ol-0-0-11020]). Previous studies have shown that Akt is activated in various types of cancer ([@b13-ol-0-0-11020],[@b14-ol-0-0-11020]). In breast cancer, HGF expression is increased, and it promotes cancer progression through the activation of Akt ([@b15-ol-0-0-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3753is a drug that inhibits
 
Response: S3753is a drug that inhibits dihydrofolate reductase (DHFR) by binding to the catalytic pocket of the enzyme. It is primarily used to inhibit the growth of tumor cells. It is a broad spectrum inhibitor that affects many species of bacteria, yeast, fungi, protozoa, and viruses. S-Methoprene was first identified as a folate antagonist and a selective inhibitor of the growth of L1210 cells in culture in 1975.

S-Methoprene is a synthetic, enantiomerically pure, dihydrofolate reductase inhibitor (DHFRi) used as a folate antagonist in cancer chemotherapy. It was first synthesized in 1974, and is a prodrug that is converted to S-methoprene in vivo, which is the active form of the drug. It is also a weak and selective inhibitor of mammalian dihydrofolate reductase (DHFR) and a more
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3754is a drug that inhibits
 
Response: S3754is a drug that inhibits the action of MLCK and inactivates its action. There is some evidence that S-3942 has been developed as a cancer drug, but the pharmacokinetics of S-3942 has not been studied in humans. To assess the tolerability and safety of S-3942 in humans, and to determine the pharmacokinetics of S-3942 in humans, and to determine the pharmacokinetics of S-3942 in humans, we studied six healthy male volunteers. A single dose of S-3942 was given orally. Blood and urine samples were collected and assayed for S-3942 by a specific high-performance liquid chromatographic method. The results indicated that S-3942 was rapidly absorbed and rapidly eliminated. Peak plasma concentrations occurred 1 to 2 hours after dosing. The terminal half-life of S-3942 ranged from 6 to 13 hours. The mean maximum plasma concentration of S-3942 was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3755is a drug that inhibits
 
Response: S3755is a drug that inhibits platelet aggregation by the inhibition of thromboxane A2 synthesis. This drug is marketed as an antiplatelet drug for the treatment of ischemic heart disease and acute coronary syndrome. The most common side effect of this drug is headache. We report a case of reversible thrombocytopenia with severe thrombocytopenia, platelet destruction, and giant platelets that were associated with this drug.

Case Report {#ccr31262-sec-0001}
===========

A 55‐year‐old male presented to our hospital with severe thrombocytopenia. The patient was on S3755is for ischemic heart disease. His platelet count was 9 × 10^3^/mm^3^. He had no history of fever, bleeding, bruising, or trauma. His other laboratory tests were within normal limits. There was no significant past medical
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3756is a drug that inhibits
 
Response: S3756is a drug that inhibits the epidermal growth factor receptor (EGFR), which is involved in many cancers, including lung cancer. In a clinical trial, it was found to prolong progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) that had progressed after chemotherapy.[@b1-itt-3-055]--[@b4-itt-3-055] Its efficacy was confirmed in a Phase III trial that compared the drug with placebo in NSCLC patients who had progressed after chemotherapy. In that trial, a subgroup analysis of patients with adenocarcinoma showed that the drug prolonged PFS compared with placebo.[@b5-itt-3-055] Although S3756is was approved by the US Food and Drug Administration in August 2011, the role of EGFR inhibitors in the treatment of NSCLC remains unclear.

The drug S3756is is a new
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3758is a drug that inhibits
 
Response: S3758is a drug that inhibits the activity of the SLCO1B1 transporter (SLCO1B1-inhibition) by binding to the protein, and therefore inhibits the transport of some substrate drugs, including lopinavir (LPV) and ritonavir (RTV), in the liver and intestine, respectively. The S3758is a small-molecule drug that is being developed as an alternative to LPV/RTV-containing protease inhibitor regimens. It has been shown to have good efficacy and tolerability in HIV-infected patients and, in a phase IIb clinical trial, in combination with LPV/RTV-containing regimens, it resulted in a similar virologic response as LPV/RTV-containing regimens in treatment-naive and LPV/RTV-experienced patients, as well as in patients with RTV-associated resistance.[@b28-dddt-10
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3761is a drug that inhibits
 
Response: S3761is a drug that inhibits one of the main enzymes responsible for making the painkiller hydrocodone. It works by binding to the active site of this enzyme and preventing the enzyme from working properly. This leads to a drop in the amount of hydrocodone in your system. It also prevents the body from making hydrocodone.

This drug was approved in 2008 and is marketed by Endo Pharmaceuticals. It is used for the relief of moderate to severe pain in adults. It is usually taken every 4 to 8 hours.

Hydrocodone S3761 is a schedule II controlled substance. It has a high potential for abuse. Abuse of hydrocodone can result in severe medical problems. If you have any questions or concerns, you should not use this drug without first talking to a doctor.

IMPORTANT SAFETY INFORMATION

SAFETY INFORMATION

Hydrocodone is an opioid agonist that has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3763is a drug that inhibits
 
Response: S3763is a drug that inhibits ER-alpha and ER-beta. The molecular target of S3763 is the steroid binding domain of the receptor.  In addition, it binds to progesterone receptors (PRs) and retinoid X receptors (RXRs). It is a progestin-receptor antagonist, a selective progesterone receptor modulator, and a partial agonist of the progesterone receptor. It is also a partial agonist of the androgen receptor (AR) and the glucocorticoid receptor (GR).

Pharmacology

Pharmacodynamics
S3763 is a progestin-receptor antagonist. It binds to the progesterone receptor (PR) with high affinity and inhibits the biological effects of progesterone.

Pharmacokinetics
The pharmacokinetics of S3763 have been investigated in rats and rhesus monkeys. In rats, S3763 was absorbed rapidly after
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3766is a drug that inhibits
 
Response: S3766is a drug that inhibits GSK3β and has been used in the clinic to treat certain types of cancer, including lung cancer. We evaluated the effects of selumetinib in the context of ALK-positive lung cancer. S3766 potently inhibited proliferation and clonogenicity of the H3122, H2228 and HCC78 ALK-positive lung cancer cell lines in a dose-dependent manner. These effects were accompanied by apoptosis, cell cycle arrest, and loss of cell viability. In addition, S3766 potently inhibited the phosphorylation of GSK3β and inhibited the phosphorylation of AKT. We found that S3766 suppressed growth of ALK-positive lung cancer cells in vivo. Our findings suggest that S3766 has potential for the treatment of ALK-positive lung cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3769is a drug that inhibits
 
Response: S3769is a drug that inhibits the function of TNF. It has been approved for the treatment of Crohn's disease and rheumatoid arthritis. The molecular target of S3769 is TNF-R1.

####  Clinical Effects

Inhibition of TNF function reduces inflammation.

#####  PHARMACOKINETICS

Route| Onset| Peak| Duration  
---|---|---|---  
PO| 1–2 hrs| —| 8 hrs

Minimal systemic absorption following PO administration. Rapidly metabolized. Peak plasma concentration: 2–4 hrs.

#####    ​LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** Unknown if distributed in breast milk. **Pregnancy Category C. Children:** Safety and efficacy not established. **Elderly:** May have increased risk of adverse reactions, including hepatot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3770is a drug that inhibits
 
Response: S3770is a drug that inhibits the formation of homodimers and heterodimers of the glucocorticoid receptor (GR). It also inhibits the association of GR with other transcription factors. It has a half-life of 1.5 hours and a clearance of 0.6 L/h. The pharmacokinetics of S3770 in adults are dose proportional. It is well absorbed following oral administration. Food has no effect on the pharmacokinetics of S3770. S3770 is metabolized by the liver and has a volume of distribution of approximately 500 L. S3770 does not appear to undergo significant first-pass metabolism. It is a substrate for the P-glycoprotein transporter. The primary route of excretion is via biliary elimination.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3772is a drug that inhibits
 
Response: S3772is a drug that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), an enzyme that controls the blood levels of low-density lipoprotein cholesterol (LDL-C) in the blood. The recommended starting dose of alirocumab is 150 mg subcutaneously every two weeks, and the dose may be increased to a maximum of 600 mg every two weeks. Alirocumab is currently approved in the EU for the treatment of patients with heterozygous familial hypercholesterolemia (FH), patients with homozygous FH (HoFH) and patients with atherosclerotic cardiovascular disease (ASCVD) at high risk of cardiovascular disease who require additional lowering of LDL-C, and in the US for the treatment of patients with HoFH and patients with high LDL-C levels and multiple risk factors for ASCVD.

The purpose of this review is to discuss the pharmacology, pharmacokinetics, pharmacodynamics
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3773is a drug that inhibits
 
Response: S3773is a drug that inhibits the activity of the ubiquitin ligase MDM2 (p53) by binding to the ligand binding pocket. MDM2 binds to the p53 protein and inhibits its function by blocking the p53 transactivation domain. MDM2 also mediates p53 ubiquitination and degradation by the proteasome. The binding of S3773 to MDM2 results in the release of p53 from the ligand binding pocket and increases the stability of p53 by preventing its degradation.

History
The drug was discovered and developed by The Salk Institute and Vertex Pharmaceuticals in collaboration with the company Biotica.

S3773 was initially discovered by Prof. Michael Apfeld at the Salk Institute in the 1990s. It was then developed by Vertex and Biotica.

Preclinical studies
S3773 was originally developed for the treatment of p53-deficient cancer, but its efficacy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3775is a drug that inhibits
 
Response: S3775is a drug that inhibits CDK7, which is involved in cell cycle progression, transcription and DNA repair \[[@B57-ijms-21-00457]\]. The compound has been shown to inhibit breast cancer cell proliferation, induce apoptosis and reduce tumor growth in vivo \[[@B58-ijms-21-00457],[@B59-ijms-21-00457],[@B60-ijms-21-00457]\]. The drug was also shown to suppress breast cancer stem cells \[[@B61-ijms-21-00457]\]. Moreover, it has been reported that S3775 induces caspase-dependent apoptosis in leukemia cells \[[@B62-ijms-21-00457]\]. In this study, we evaluated the anti-proliferative and pro-apoptotic effects of S3775 in A2780 cells. Our results showed that S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3779is a drug that inhibits
 
Response: S3779is a drug that inhibits a specific type of phosphatase, PP2A, which has been implicated in regulating gene expression, and is therefore a candidate for further studies on the mechanism of action of myocardial protection.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3781is a drug that inhibits
 
Response: S3781is a drug that inhibits the inducible nitric oxide synthase, an enzyme that catalyzes the production of nitric oxide from arginine. A similar drug, S-methylisothiourea, inhibits the enzyme inducible cyclooxygenase, which produces prostaglandins. These drugs have a number of well known effects including vasodilation, bronchodilation, hypotension, and suppression of platelet aggregation. They have also been shown to prevent the damage of retinal ganglion cells in animal models of glaucoma and optic nerve head damage.

S-Methylisothiourea has been used in several clinical trials as a neuroprotective agent. It has been administered to patients with head trauma and cerebral ischemia. In these trials, S-methylisothiourea was administered intravenously at a dose of 5 mg/kg. The effects of S-methylisothiou
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3783is a drug that inhibits
 
Response: S3783is a drug that inhibits a number of viruses. It is not an approved drug but a compound under development by a number of pharmaceutical companies. It has been shown to be effective in the treatment of HIV, Hepatitis C and Hepatitis B.

It is not in the database and the mode of action has not been identified.

S3783is a drug that inhibits a number of viruses. It is not an approved drug but a compound under development by a number of pharmaceutical companies. It has been shown to be effective in the treatment of HIV, Hepatitis C and Hepatitis B.

It is not in the database and the mode of action has not been identified.

S3783is a drug that inhibits a number of viruses. It is not an approved drug but a compound under development by a number of pharmaceutical companies. It has been shown to be effective in the treatment of HIV, Hepatitis C and Hepatitis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3785is a drug that inhibits
 
Response: S3785is a drug that inhibits the Na+/K+-ATPase and is used to treat high blood pressure. A recent study reported that S3785 causes vacuolation in the inner ear. The aim of this study was to investigate whether this inner ear vacuolation is a result of the drug’s pharmacological action on the inner ear. In the study, the S3785 dose of 2 mg/kg was used. S3785 is known to inhibit the Na+/K+-ATPase. It is assumed that when the drug reaches the inner ear, it acts on the Na+/K+-ATPase in the cochlear duct, resulting in a decrease in ionic concentration and osmotic pressure, causing vacuolation. The study used immunohistochemistry, light microscopy, transmission electron microscopy, and scanning electron microscopy. Vacuoles were detected in the inner ear of mice treated with S37
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3788is a drug that inhibits
 
Response: S3788is a drug that inhibits the growth of many cancer cells.
S3788 is a synthetic analog of 4-hydroxy-3-amino-3-nitrobutanamide (HABN), an antitumor agent that we had shown in a previous study to act by inhibition of lysyl oxidase. S3788 is a potent inhibitor of lysyl oxidase, a copper-dependent enzyme that is critical for extracellular matrix (ECM) formation. We have studied the effects of S3788 on cell proliferation and on cell cycle progression. S3788 was able to inhibit the growth of a number of cancer cell lines in vitro, including breast, colon, lung, and melanoma cells. S3788-induced inhibition of cell growth was accompanied by accumulation of cells in the G0/G1 phase of the cell cycle. S3788-induced cell cycle arrest was dependent on the presence of the drug, since preinc
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3791is a drug that inhibits
 
Response: S3791is a drug that inhibits the ATP-dependent RNA helicase, DHX9, which is required for the biogenesis of small nuclear ribonucleoprotein particles (snRNPs) in the nucleus and assembly of the spliceosome in the cytoplasm \[[@B22-molecules-19-20197]\]. It is used to treat chronic myelogenous leukemia (CML) and cutaneous T-cell lymphoma (CTCL) and it is also being tested for its potential to treat other malignancies \[[@B23-molecules-19-20197]\]. DHX9 inhibition by S3791 is thought to be the basis for its efficacy in the treatment of CML and CTCL. The compound is a competitive inhibitor of ATP hydrolysis, but does not appear to inhibit the binding of ATP to DHX9 \[[@B24-molecules-19-201
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3794is a drug that inhibits
 
Response: S3794is a drug that inhibits the expression of a protein (FKBP-12) required for cell division in human cells.

It is an oral drug, which is being developed for the treatment of human leukaemia and myelodysplastic syndrome.

Chemical name:

N-[(4S,4aR,8aR,12aS)-1,2,3,4,4a,5,6,7,8,8a,9,10,11,12,12a,12b-octahydro-4,12-methanocyclopenta[a]cyclopropa[f]naphthalen-4-yl]acetamide

S3794 Chemical Formula

C22H29NO2

S3794 Molecular weight

351.45

S3794 IUPAC Name

(4S,4aR,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3797is a drug that inhibits
 
Response: S3797is a drug that inhibits the activation of T cells. There is a series of reports of using anti-CD4 antibody in animal models of autoimmune disease. However, there is no report of its effect on systemic sclerosis. This study investigated the effect of anti-CD4 antibody on the development of experimental systemic sclerosis in NZB/W F1 mice. The mice were divided into 3 groups: a control group, a CD4 group and a CD4+S3797 group. The mice were injected with 200 mg/kg of anti-CD4 antibody (clone GK1.5) on days 0, 2, 4, and 6. After treatment, the mice were evaluated for severity of arthritis and survival time. T cell subsets in the spleen and lymph nodes were also examined. In the CD4+S3797 group, disease activity score was lower than that of the CD4 group and was comparable to that of the control group. The survival time of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3798is a drug that inhibits
 
Response: S3798is a drug that inhibits mitochondrial oxidative phosphorylation and results in ATP depletion. A reduction in ATP is a common mechanism for death in a variety of cell types. We hypothesized that S3798 would cause cell death in B cells via a mechanism similar to that of azidothymidine (AZT). The effect of S3798 on B cell viability was tested in human B cell lines and primary human B cells. The mechanism of S3798-induced cell death was studied by measuring the activity of apoptosis-inducing factor (AIF) and the release of mitochondrial cytochrome c. AIF was localized in the mitochondria of B cells and its release from mitochondria was blocked by S3798. However, cytochrome c release was not observed in B cells. The addition of AZT, which was reported to be associated with a defect in mitochondrial oxidative phosphorylation, resulted in AIF release from the mitochondria and cytochrome c release.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3801is a drug that inhibits
 
Response: S3801is a drug that inhibits the reuptake of serotonin. This drug was initially
used as a treatment for depression. It is used to treat migraine headaches and
anxiety. The effects of this drug last for up to two weeks. The effect of this
drug lasts for four to six weeks.

Side Effects: The side effects of S3801 can include:

• High blood pressure

• Nausea

• Tremor

• Anxiety

• Seizures

• Urinary retention

• Vomiting

• Low blood pressure

• Feeling hot

• Heartburn

• Confusion

• Memory loss

• Fainting

• Depression

• Memory loss

• Heartburn

• Seizures

• Urinary retention

• Nausea

• Confusion

• Memory loss

• Feeling hot

•
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3802is a drug that inhibits
 
Response: S3802is a drug that inhibits human fibroblast collagenase. It is an oral preparation of chemically modified, non-peptide synthetic inhibitors. This is a derivative of the tetrapeptide RGD. It was developed by Roche. It was used in clinical trials for treatment of osteoarthritis. It was approved by FDA in 1995.

Phenylbutazone (PBZ) is a synthetic non-steroidal anti-inflammatory drug (NSAID). It is a potent inhibitor of cyclooxygenase (COX) in the inflammatory process. It is a strong analgesic and anti-pyretic. PBZ is also used in the treatment of rheumatoid arthritis and juvenile arthritis.

Albendazole is an anthelmintic. It is used in the treatment of various helminthic infections including schistosomiasis. It is a member of benzimidazole family of anthelmint
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3805is a drug that inhibits
 
Response: S3805is a drug that inhibits calcium channels, resulting in the hyperpolarization of the membrane potential and in the suppression of electrical activity.\[[@ref1]\]

Severity of delirium has been shown to be related to the duration of exposure to sedatives and antipsychotics.\[[@ref2]\]

S3805 has a pharmacokinetic profile that is independent of age, sex, weight, and ethnicity.\[[@ref3]\]

We report a case of a 55-year-old man with chronic schizophrenia who developed acute psychotic relapse.

CASE REPORT {#sec1-2}
===========

A 55-year-old man was admitted to our ward with psychotic relapse. He was diagnosed with schizophrenia about 2 years ago. His initial presentation was of disorganized behavior and a global aphasia, with cognitive impairment. He was admitted to a psychiatric ward and was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3807is a drug that inhibits
 
Response: S3807is a drug that inhibits a specific gene called TNF-alpha. The TNF-alpha gene has two forms: one that is always expressed and one that is turned on in the presence of certain bacteria and viruses. If you have Crohn’s disease, you have a bacteria that makes TNF-alpha and inflames your gut. The S3807is drug can be given orally, and it prevents your body from making TNF-alpha, thereby stopping the inflammation.

The data on S3807is were submitted by its manufacturer, AstraZeneca, in support of its New Drug Application (NDA) for the drug.

The NDA is for a Phase III trial called ADAPT, and this trial was a three-arm, double-blind, placebo-controlled trial with a total of 522 patients. The purpose of the trial was to evaluate the safety and efficacy of the drug. The ADAPT trial was conducted
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3809is a drug that inhibits
 
Response: S3809is a drug that inhibits PTP1B and thus, the insulin receptor dephosphorylation and activation. Its main side effect is hypoglycemia. In the present study, we evaluated the effect of S3809 on glucose metabolism in HFD-fed obese rats. We demonstrated that HFD-fed rats had a reduced glucose disposal rate and that S3809 improved these metabolic changes. In addition, S3809 decreased lipid accumulation and increased insulin sensitivity in HFD-fed obese rats. Moreover, S3809 also reduced the insulin receptor substrate-1 (IRS-1) phosphorylation and increased the IRS-1 and PI3K expression in the liver and skeletal muscle of HFD-fed obese rats. Our findings suggest that S3809 is a novel antidiabetic agent that improves glucose and lipid metabolism by inhibiting PTP1B and subsequently increasing insulin sensitivity.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3810is a drug that inhibits
 
Response: S3810is a drug that inhibits the enzyme that converts vitamin D into its active form. In clinical trials it was shown to be effective in reducing the incidence of MS relapses, MS disability and radiological progression. In one study, an open label study of treatment with S3810, only 9% of patients who received placebo showed no relapses over the year.[@b67-btt-7-091] In another open-label study of patients with MS with baseline EDSS of 2.0--5.0, S3810 treatment for 1 year reduced the annualized relapse rate by 70% and the cumulative number of new T2 lesions by 83%.[@b68-btt-7-091] It is currently approved for the treatment of MS relapses and for treatment of progressive forms of MS in some countries.

There is a similar agent in development called ESM-101. It is currently in phase II clinical trials for the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3811is a drug that inhibits
 
Response: S3811is a drug that inhibits an enzyme called the cGMP-specific phosphodiesterase. This enzyme is responsible for hydrolyzing cGMP.

COPD is the fourth leading cause of death in the United States and is the third leading cause of disability. It is also the only major cause of disability that can be prevented. Smoking is the major cause of COPD. When you smoke, the lining of your lungs is damaged. This damage leads to inflammation and airway obstruction. In addition, the flow of air is impaired. As a result, your lungs lose their ability to clear out waste products.

When the lining of your lungs is damaged, your immune system is not as effective at protecting you from infections. This results in frequent infections of the lungs. In addition, the lungs do not produce as much mucus. This results in excess mucus in the airways. This mucus plugs the airways and prevents air from flowing out of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3817is a drug that inhibits
 
Response: S3817is a drug that inhibits the synthesis of pyrimidine nucleotides in eukaryotic cells and is now being evaluated in clinical trials as a potential cancer chemotherapeutic agent. We have used a combination of the temperature-sensitive ts-RSV and the drug-resistance mutations in poliovirus 3D to construct a temperature-sensitive mutant of S3817. The ts-S3817-3D protein has normal 3D activity at permissive temperature (33 degrees C) but the activity of the protein is inhibited at the nonpermissive temperature (39 degrees C). When ts-S3817-3D was expressed in transfected cells, it produced high levels of infectious virus at 33 degrees C and produced only small amounts of infectious virus at 39 degrees C. The ts-S3817-3D protein was defective in the assembly of infectious virus at both 33 and 39 degrees C.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3821is a drug that inhibits
 
Response: S3821is a drug that inhibits the activity of the enzyme acetylcholinesterase (AChE). AChE is an enzyme that terminates the nerve impulse in the brain and nervous system. When acetylcholine is released, it activates a set of receptors in the brain and nervous system, which are important for cognitive function. S3821 blocks the effects of acetylcholine at the receptor sites.

There is evidence that S3821 is effective in the treatment of Alzheimer’s disease. AChE activity is increased in the brain in Alzheimer’s disease. S3821 is thought to block the actions of the enzyme AChE and reduce the effects of acetylcholine.

The manufacturer states that the drug is “highly effective in the treatment of Alzheimer’s disease.” S3821 is also marketed for the treatment of other conditions such as myasthenia gravis, anxiety, Parkinson�
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3824is a drug that inhibits
 
Response: S3824is a drug that inhibits the enzyme S-adenosylhomocysteine hydrolase, also known as SAHH. It was developed by Nabi Biopharmaceuticals, Inc., and is approved in the US for the treatment of myelodysplastic syndromes (MDS) and for use in combination with other drugs in the treatment of acute myeloid leukemia (AML). The drug is a prodrug, requiring activation by hydrolysis to S-adenosylmethionine (SAMe) by SAHH, the first step in the biosynthesis of polyamines and methylation reactions. It is the only drug in this class that has been approved in the US for the treatment of MDS.

![The chemical structure of S3824 is shown. In addition to the thio-derivative, the prodrug contains a phenolic moiety (R~2~), which is removed by enzymes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3835is a drug that inhibits
 
Response: S3835is a drug that inhibits tumor cell proliferation by inhibiting the growth of cancer cells and tumor growth. The drug can be used for the treatment of breast cancer and lung cancer. The drug can also be used for the treatment of colorectal cancer, stomach cancer, and prostate cancer.

S3835 is a drug that inhibits tumor cell proliferation by inhibiting the growth of cancer cells and tumor growth. The drug can be used for the treatment of breast cancer and lung cancer. The drug can also be used for the treatment of colorectal cancer, stomach cancer, and prostate cancer.

S3835is a drug that inhibits tumor cell proliferation by inhibiting the growth of cancer cells and tumor growth. The drug can be used for the treatment of breast cancer and lung cancer. The drug can also be used for the treatment of colorectal cancer, stomach cancer, and prostate cancer.

S3835 is a drug that inhibits tumor cell proliferation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3839is a drug that inhibits
 
Response: S3839is a drug that inhibits DNA methylation, and thus, increases gene expression.

Lanes 1 and 3, 25 μM S3839; lanes 2 and 4, 0.01% DMSO.

(TIF)

###### 

Click here for additional data file.

###### Nucleosome occupancy of the CTCF sites in HCT116 cells.

(TIF)

###### 

Click here for additional data file.

###### 

**A.** HCT116 cells were treated with the indicated siRNAs for 24 hours. Cells were then fixed and stained for 53BP1 and γH2AX. **B.** The percentage of γH2AX foci that colocalized with 53BP1 foci in the presence of the indicated siRNAs was quantified and plotted. **C.** The percentage of cells with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3842is a drug that inhibits
 
Response: S3842is a drug that inhibits the transcription of viral genes by interfering with the assembly of the viral ribonucleoprotein complex \[[@CR17]\]. Its mechanisms of action are the same as those of other antiviral drugs that inhibit the early phase of the viral life cycle, such as remdesivir, an adenosine analog that inhibits viral RNA synthesis by competing with the natural substrates of the RdRp \[[@CR18]\]. In this case, the mechanism of action of S3842 is different from that of adenosine analogs. This is probably due to the different target of the compound, the viral polymerase. The RNA-dependent RNA polymerase of SARS-CoV-2, which is essential for viral replication, is similar to the RNA polymerase of other coronaviruses.

The high rate of SARS-CoV-2 transmission from human to human indicates that the disease has a high fat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3843is a drug that inhibits
 
Response: S3843is a drug that inhibits the inducible nitric oxide synthase (iNOS) and the expression of interleukin-1β (IL-1β) in monocytes, a process that involves the nuclear factor κB (NF-κB) and the mitogen-activated protein kinases (MAPKs) pathways. The effects of S3843 on iNOS, IL-1β, and nitrite (NO(2)(-)) production in monocytes were studied in this work. S3843 inhibited iNOS, IL-1β, and NO(2)(-) production in lipopolysaccharide (LPS)-stimulated monocytes, as determined by enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (PCR), and Griess reagent. In addition, S3843 inhibited the expression of NF-κB p65, inhibitor of κB
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3846is a drug that inhibits
 
Response: S3846is a drug that inhibits the activity of Src tyrosine kinase. It has been shown to be effective in preventing and treating various forms of arthritis. The study found that S3846 inhibited both acute and chronic inflammation, including arthritis in the mouse, rat and dog. This agent was shown to be a potent inhibitor of the production of the cytokine IL-1β, and thus could be a candidate for treatment of diseases in which IL-1β is involved.

A.7.1.S3924is a protein that is thought to function as a tumor suppressor. It is involved in several important signaling pathways, including those that are regulated by Akt, RhoA, and PKC, and also is involved in cellular growth and survival.

A.7.1.S3924is a drug that was developed to be a more specific inhibitor of one of the proteins in the Ras/Raf/MEK/ERK
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3847is a drug that inhibits
 
Response: S3847is a drug that inhibits the action of the enzyme cyclic GMP phosphodiesterase (PDE) in platelets. It is used to treat arterial and venous thrombosis, ischaemia, and acute pulmonary hypertension. S3847 may also be used to prevent the complications of pre-eclampsia, eclampsia and severe pre-eclampsia.

S3847 is a prodrug. It is metabolised to S-adenosyl-L-methionine (SAMe) by the liver. SAMe is then incorporated into the platelet membrane where it inhibits the action of PDE. The effects of S3847 are reversed by removal of SAMe by dialysis.

Indications

S3847 is used in the treatment of arterial and venous thrombosis, ischaemia, and acute pulmonary hypertension.

S3847 is also used to prevent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3849is a drug that inhibits
 
Response: S3849is a drug that inhibits nuclear export and is being investigated in Phase II clinical trials for treating lymphoid malignancies. The drug acts by preventing the interaction of CRM1 with NES-containing proteins, which in turn results in the retention of the cargo proteins in the nucleus and a reduction in their levels in the cytoplasm. This study has investigated the mechanism of action of S3849 and whether the drug can sensitise lymphoid tumour cells to the chemotherapeutic agents etoposide and doxorubicin. The results indicate that S3849 is able to sensitise cells to these agents, although the mechanism of sensitisation is different to that previously reported for leptomycin B. In particular, S3849 inhibits nuclear export of the anti-apoptotic protein MCL-1 and the down-regulation of MCL-1 sensitizes cells to the chemotherapeutic agents. Furthermore, S3849 treatment induces
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3850is a drug that inhibits
 
Response: S3850is a drug that inhibits TGFβ-mediated signalling. In the present study, we investigated the effects of S3850 on tumor progression and metastasis in a mouse breast cancer model. In vitro, S3850 inhibited the growth of mouse mammary tumor cells, including 4T1 and 67NR cells, which are highly metastatic. S3850 also inhibited the motility and invasion of 4T1 cells in vitro. In vivo, the growth of 4T1 cells was significantly inhibited by S3850 treatment. Moreover, S3850 inhibited lung metastasis of 4T1 cells in a mouse model. Furthermore, S3850 significantly inhibited the phosphorylation of Smad2/3 in 4T1 cells. Our results suggest that S3850 may be a promising drug for the treatment of breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3851is a drug that inhibits
 
Response: S3851is a drug that inhibits glycolysis, an important step in energy metabolism. To better understand the effects of S3851 on cells, we treated MDA-MB-231 cells with S3851. Treatment with S3851 significantly inhibited cell proliferation in a dose-dependent manner (Figure [2A](#F2){ref-type="fig"}). To further examine the effect of S3851 on cell proliferation, we also used an MTT assay to measure cell proliferation in response to different concentrations of S3851. The results demonstrated that treatment with S3851 reduced cell viability in a dose-dependent manner (Figure [2B](#F2){ref-type="fig"}). We also determined the effect of S3851 on the cell cycle of MDA-MB-231 cells. Flow cytometry revealed that S3851 caused G2/M phase arrest in a dose-dependent manner (Figure [2C](#F2){
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3852is a drug that inhibits
 
Response: S3852is a drug that inhibits protein synthesis by binding to the ribosomal 50S subunit. A proposed mechanism for its action is that the drug binds to the GTPase center of the ribosome and prevents the formation of the functional GTPase center. In the drug-ribosome complex, the GDP-lid domain of the ribosome is shifted and the catalytic site is exposed. As a result, aminoacyl-tRNA (aa-tRNA) is hydrolyzed, and aa-tRNA and the peptidyl-tRNA are dissociated from the ribosome. Therefore, the drug inhibits protein synthesis.

The primary effect of S-3592 is inhibition of protein synthesis. In the drug-ribosome complex, the GDP-lid domain of the ribosome is shifted and the catalytic site is exposed. As a result, aminoacyl-tRNA (aa-tRNA)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3853is a drug that inhibits
 
Response: S3853is a drug that inhibits the activity of dihydrofolate reductase (DHFR) in combination with an inhibitor of thymidylate synthase (TS) such as 5-fluorouracil (5-FU) and is used in cancer chemotherapy. This compound is a prodrug that is metabolized by enzymes in the body to produce the active drug (Pettit et al., 1994, J. Natl. Cancer Inst. 86:1571-1577). Because of the widespread use of this drug in cancer chemotherapy, it is essential to understand its disposition in order to assure safe and effective use.
It has been shown that the disposition of S-S3853 is determined by a series of metabolic steps (Kalinina et al., 2000, Clin. Cancer Res. 6:3311-3319). S-S3853 is a substrate for cytochrome P450 enzymes, which convert the compound to S-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3854is a drug that inhibits
 
Response: S3854is a drug that inhibits growth of human and animal tumour cells by inducing apoptosis. It is one of the novel cancer-selective tubulin inhibitors which was discovered by the scientists of the Department of Cell and Molecular Biology at the University of Gothenburg. In order to study the effect of S3854 on growth and differentiation of human haematopoietic cells, a human cell line with lymphoid differentiation potential (HUT102) was used. S3854 was found to be cytotoxic for HUT102 cells with an IC50 of 1.6 +/- 0.3 microM. However, when the cells were treated with a combination of S3854 and a differentiation-inducing agent, 1 alpha, 25-dihydroxyvitamin D3 (1 alpha, 25(OH)2D3), the cytotoxicity was significantly enhanced. When cells were treated with a combination of S3854 and 1 alpha, 25(OH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3856is a drug that inhibits
 
Response: S3856is a drug that inhibits the transport of phosphatidylserine from the inner to the outer leaflet of the plasma membrane. It is used for the treatment of patients with hypercholesterolemia, and the current recommended dose is 25 mg/kg body weight twice a day. The current work has evaluated the potential of S3856 to protect against cell death caused by TNF-α in microglial cells. The viability of primary cultures of microglial cells was measured by the MTT assay. S3856 (1-100 µM) protected against the cytotoxicity of TNF-α (20 ng/mL) in a dose-dependent manner. S3856 (10 and 20 µM) completely prevented the increase in lactate dehydrogenase release induced by TNF-α, indicating that S3856 inhibits TNF-α-induced membrane damage. TNF-α (20 ng/mL) induced an increase in intrace
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3858is a drug that inhibits
 
Response: S3858is a drug that inhibits the proteasome, but not the lysosome. I have used this drug for the past 6 years to treat some of my patients with MS.

What is interesting is that the drug has been studied in the human body for over 50 years. It was discovered in 1961, but was never approved by the FDA until 2007. I am still in shock that the FDA took so long to approve this drug. I have been using it for 6 years, and have seen many of my patients experience improvement. I have never had any side effects. The drug has been shown to be safe, and it has been studied extensively.

I am extremely excited that a drug that has been used for over 50 years is now being used by the majority of my patients with MS.

Thursday, September 10, 2008

Well, the time has finally come. I am scheduled to take my first injection of Copaxone on Monday, September
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3861is a drug that inhibits
 
Response: S3861is a drug that inhibits E1-S-S-E2 formation in the hepatitis C virus (HCV) life cycle. S3861 binds to the N-terminal hydrophobic pocket of the NS5A protein, which is known to be important for HCV RNA replication. S3861 has demonstrated antiviral activity in chimpanzees infected with a range of HCV genotypes. In this study, we show that S3861 is also active in patients infected with HCV genotype 1, 2, 3, and 4. This activity was demonstrated by a significant reduction in serum HCV RNA in a phase I trial of S3861 in combination with pegylated interferon alfa-2a and ribavirin in chronically infected HCV genotype 1 and 2 patients. S3861 was generally well tolerated, and the combination was well tolerated and produced an antiviral response in HCV genotype 1 and 2 patients. S3861 is the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3866is a drug that inhibits
 
Response: S3866is a drug that inhibits cAMP phosphodiesterase activity in human platelets. We have found that S3866 increases cytosolic calcium in human platelets. We also found that S3866 causes a calcium rise in platelets from mice, rats, rabbits and guinea pigs, but not in guinea pig platelets. The calcium rise is not due to inositol 1,4,5-trisphosphate (IP3) release because S3866 did not release 45Ca from intracellular stores in human platelets. We also found that S3866 potentiates the platelet response to platelet-activating factor (PAF) and arachidonic acid. The mechanism of S3866-induced calcium rise is still unclear.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3868is a drug that inhibits
 
Response: S3868is a drug that inhibits calcineurin, a calcium-dependent phosphatase that has been implicated in the regulation of T-cell activation. S3868is a potent inhibitor of T-cell proliferation, but the mechanisms underlying this effect are not known. We found that S3868inhibits T-cell activation in vitro by preventing nuclear translocation of NF-AT and by blocking IL-2 production. In vivo, S3868blocks activation-induced proliferation and IFN-gamma production in response to low doses of ovalbumin and in response to immunization with inactivated influenza virus. S3868treatment significantly inhibited the development of acute graft-versus-host disease in mice and prolonged survival in a model of acute GVHD. These findings demonstrate that calcineurin inhibitors are a new class of immunosuppressive agents that may be useful in the treatment of autoimmune disorders.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3872is a drug that inhibits
 
Response: S3872is a drug that inhibits the G2/M checkpoint and is used in the clinic to treat a range of cancer types, including glioblastoma. In this study, we investigated the effect of S3872 on the phenotype of glioblastoma cells and the relationship between the phenotype and the effect of S3872 on the G2/M checkpoint. We found that S3872 induced senescence in glioblastoma cells, but did not cause apoptosis. Inhibition of autophagy with Bafilomycin A1 attenuated S3872-induced senescence. In addition, S3872 reduced the expression of the stem cell markers CD133, SOX2 and nestin, and the stem cell marker OCT4 was downregulated in S3872-treated glioblastoma cells. S3872 inhibited the growth of glioblastoma in vivo. These findings indicate that S3872 is a potential
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3876is a drug that inhibits
 
Response: S3876is a drug that inhibits Pgp and has been used as a Pgp inhibitor to study the functional role of Pgp in a variety of tissues including intestine, liver, brain and cancer cells (Gottesman et al., [@B9]; Friesen et al., [@B7]; Vandenberg et al., [@B26]; Wunder et al., [@B31]; Bijkerk et al., [@B3]; Steensma et al., [@B24]; Versantvoort et al., [@B28]; van der Burg et al., [@B27]; Aktas et al., [@B1]; Ruiz-Linares et al., [@B20]).

![**Time-course analysis of the functional role of Pgp in intestinal transport of the Pgp substrate androstenedione (AD) in MDR1-transfected MDCKII cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3881is a drug that inhibits
 
Response: S3881is a drug that inhibits T cell activation and proliferation by selectively blocking the ERK/MAPK pathway. It has been demonstrated that a single oral dose of S3881 significantly suppresses in vivo proliferation of allogeneic and syngeneic cells and prolongs the survival of allogeneic grafts in vivo. The immunosuppressive effect of S3881 is mediated by the blockade of both early and late events in T cell activation, including induction of early activation markers (CD69, CD25, and CD134) and inhibition of T cell proliferation. The suppression of early activation markers is accompanied by a reduction in the production of IL-2, IL-4, and IFN-gamma. In addition, the proliferation of naive T cells is blocked. S3881 also inhibits the secretion of IL-2, IL-4, and IFN-gamma by alloreactive T cells. The induction of the early activation markers on T cells by IL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3883is a drug that inhibits
 
Response: S3883is a drug that inhibits the activity of the serotonin 5-HT2A receptor. The drug was originally discovered in the late 1980s as an antagonist of serotonin-induced platelet aggregation and vascular contraction, but its mode of action has remained unclear. Recently, it has been demonstrated that the S3883-induced inhibition of serotonin-induced contraction in rat aorta is caused by a reduction in serotonin-induced phosphatidylinositol hydrolysis and Ca2+ mobilization, and that the drug does not inhibit the enzyme phospholipase C-beta. In the present study, the effects of S3883 on Ca2+ mobilization and protein kinase C (PKC) activation in Swiss 3T3 cells have been investigated. S3883 induced a concentration-dependent inhibition of the inositol phosphate response to stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), and also inhibited the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3885is a drug that inhibits
 
Response: S3885is a drug that inhibits deacetylation of α-tubulin and promotes microtubule acetylation, and is under clinical development for cancer treatment ([@bib10]). Several previous studies have shown that S3885 enhances the stability of microtubules in cancer cells, and promotes mitotic arrest and cell death in cancer cells ([@bib10]; [@bib21]). We examined the effects of S3885 on cell proliferation, apoptosis, and the cell cycle in several cancer cell lines. We found that S3885 inhibited the proliferation of various cancer cell lines. In contrast, S3885 did not induce cell death in normal cells. The results of the cell cycle analysis showed that S3885 arrested cancer cells at the G2/M phase, and reduced the percentage of cancer cells in the S phase. We also found that S3885 induced apoptosis in cancer cells. In contrast, S3885 did not induce apoptosis in normal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3887is a drug that inhibits
 
Response: S3887is a drug that inhibits the production of GTP cyclohydrolase I (GTPCH I) and thereby leads to an accumulation of 7,8-dihydroneopterin. A certain dosage of S3887 is used to treat various types of diseases. However, the concentration of S3887 in blood is difficult to control, so that the treatment is not completely effective. The problem of insufficient treatment efficacy has been addressed by the present inventors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3889is a drug that inhibits
 
Response: S3889is a drug that inhibits the activation of V-ATPase, and has been shown to protect against brain injury in rats and to reduce infarct volume and neurological deficits in rats subjected to focal ischemia.^[@R36],[@R37]^ However, this compound is highly unstable and is therefore difficult to prepare. We therefore synthesized two stable and structurally similar derivatives, S13N and S3880, which are based on the structure of S3889 ([Figure 3A](#F3){ref-type="fig"}). As shown in [Figure 3B](#F3){ref-type="fig"}, both S13N and S3880 inhibited the accumulation of PrP^Sc^ in N2a cells in a dose-dependent manner. The inhibitory effect of S3880 was slightly stronger than that of S13N.

The above data indicate that S13N and S3880 inhibit the accumulation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3890is a drug that inhibits
 
Response: S3890is a drug that inhibits angiogenesis by binding to the N-terminal portion of the fibroblast growth factor receptor-1 (FGFR1) tyrosine kinase domain. A phase II trial of S3890 as monotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEJAC) is underway ([NCT02136972](https://clinicaltrials.gov/ct2/show/NCT02136972)). S3890 is being evaluated in combination with epirubicin in a phase I trial in patients with advanced gastric cancer ([NCT01882269](https://clinicaltrials.gov/ct2/show/NCT01882269)).

Cancer Immunotherapy {#S7}
====================

Gastric cancer has an exceptionally low tumor mutational burden (TMB) \[[@R8]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3891is a drug that inhibits
 
Response: S3891is a drug that inhibits caspase 3 and caspase 8.

T-Lymphocytes, which are critical to the adaptive immune system, play a vital role in both autoimmunity and transplant rejection. During T-cell activation, caspase-3 activation occurs early, but apoptosis occurs late. Inhibition of caspase-3 may prevent apoptosis of T-cells and can inhibit the development of an autoimmune disease.

References

External links 
 The MEROPS online database for peptidases and their inhibitors: C14.001

Category:EC 3.4.22
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3892is a drug that inhibits
 
Response: S3892is a drug that inhibits a gene that causes cancer. The drug was created by Genentech. But in May of 2012, the FDA ordered Genentech to stop all human trials because it was too dangerous.

Sipuleucel-T is a man-made immune cell that is taken by injection into the patient’s blood stream. It collects a sample of the patient’s cancer cells and grows them in a laboratory.

The result is that the patient’s immune system attacks the cancer cells and causes them to die. It is an experimental treatment that only some patients benefit from.

The trials were stopped after a small number of patients died from the treatment.

But the trials weren’t stopped because the treatment was dangerous.

The FDA told Genentech that the drug would not be approved until the company performed another study that showed the treatment was safe.

Genentech told the FDA that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3893is a drug that inhibits
 
Response: S3893is a drug that inhibits the formation of the active subunit of nitric oxide synthase (NOS) and therefore prevents the production of nitric oxide. As a result, NO production is prevented. S-Nitroso-N-acetylpenicillamine (SNAP) is an isomer of S-nitrosoglutathione (GSNO), a potent NO donor. GSNO has been shown to protect endothelial cells from apoptosis induced by high glucose in a dose-dependent manner. S-Nitroso-N-acetylpenicillamine (SNAP) has been shown to have a vasorelaxant effect in isolated vascular smooth muscle. It also inhibits apoptosis in various cell types. The role of NO in the protective effect of SNAP is not clear. SNAP has been shown to inhibit TNF-alpha-induced NF-kappaB activation and prevent the induction of iNOS. It has also been shown
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3895is a drug that inhibits
 
Response: S3895is a drug that inhibits human and rat phosphodiesterase type 5 (PDE5) \[[@CR1]\]. Sildenafil (S3895) was developed as an anti-impotence drug. It was first approved in 1998 by the US FDA as the first orally active drug for erectile dysfunction. Since then, it has been used for the treatment of male sexual dysfunction. Currently, it is marketed under the brand name Viagra^®^ and has a good reputation as a highly effective drug for treating erectile dysfunction.

Sildenafil is the active pharmaceutical ingredient of several generic drugs including Viagra^®^ and Viagra Soft^®^. These drugs have a similar structure to that of sildenafil, but their chemical compositions are different from that of sildenafil. The main differences are in the contents of active ingredients and excipients. These differences may cause differences in the pharmac
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3897is a drug that inhibits
 
Response: S3897is a drug that inhibits RNA polymerase II (RNAP II) \[[@B33-ijms-19-02208]\]. It has been found to have anti-cancer effects, both in vitro and in vivo \[[@B34-ijms-19-02208]\]. In this study, we found that NU7026 effectively decreased the mRNA expression of cyclin D1 and promoted apoptosis in SGC7901 and MGC803 cells, suggesting that NU7026 could inhibit the proliferation of gastric cancer cells.

The PI3K/Akt signaling pathway plays an important role in the regulation of apoptosis and cell proliferation \[[@B35-ijms-19-02208]\]. In addition, many reports have shown that NU7026 inhibits the proliferation of tumor cells through the PI3K/Akt signaling pathway \[[@B36-ijms-19-02208],[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3898is a drug that inhibits
 
Response: S3898is a drug that inhibits cell cycle progression and proliferation of human breast cancer cells. To explore the possible molecular mechanism, we used a proteomic approach to analyze the effect of S3898 on the expression of cell cycle-related proteins. Our results show that S3898 inhibited the expression of cyclin A2, cyclin B1, CDK2, CDK4, and CDK6 in MCF-7 cells. In addition, S3898 treatment reduced the expression of several members of the APC/C, such as Cdc20, Cdh1, Cdc20, Cdh1, and Cdc20. In summary, S3898 is a novel cell cycle inhibitor that acts by regulating the expression of the cell cycle-related proteins.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3899is a drug that inhibits
 
Response: S3899is a drug that inhibits the synthesis of the second messenger adenosine 3′,5′-cyclic monophosphate (cAMP) by the adenylate cyclase of target cells. As such, it blocks the effects of hormones that are mediated by the cAMP-dependent pathway, such as the effects of thyroid hormones and glucagon. This action of S3899is similar to that of the adenylate cyclase inhibitor, 2′,5′-dideoxyadenosine (ddAdo), which is used to block the effects of cAMP. Thus, S3899is also useful in treating certain thyroid disorders.
The present invention provides S3899, a process for its preparation, and pharmaceutical compositions containing S3899. The process for preparing S3899 is described in U.S. Pat. No. 5,278,150, the entire disclosure of which is incorporated herein by reference. S3899is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3901is a drug that inhibits
 
Response: S3901is a drug that inhibits Mcl-1 expression and causes mitochondrial apoptosis. (a) Hep3B and Huh7 cells were treated with or without S3901 for 48 h. The protein levels of Mcl-1 were analyzed by Western blotting. (b) Hep3B and Huh7 cells were treated with or without S3901 for 24 h. The mRNA levels of Mcl-1 were analyzed by RT-PCR. (c) Hep3B and Huh7 cells were treated with or without S3901 for 24 h. The protein levels of Mcl-1 were analyzed by Western blotting. (d) Hep3B and Huh7 cells were treated with or without S3901 for 48 h. The cell death was measured by flow cytometry analysis. The data represent the mean ± SD of three independent experiments. ^*∗*^ *P* \< 0.05.](
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3905is a drug that inhibits
 
Response: S3905is a drug that inhibits the enzyme acetyl-CoA synthetase. The rationale for this approach is based on the hypothesis that by inhibiting acetyl-CoA synthetase, fatty acids are diverted from the de novo synthesis pathway into the fatty acid oxidation pathway. Since fatty acids cannot be metabolized without being oxidized, the accumulation of fatty acids in the liver and other tissues should lead to their oxidation. It has been shown that this hypothesis is correct. In mice, S3905 is highly effective in preventing and reversing fatty liver. The long-term goal of this research is to develop S3905 into a clinically useful drug. Phase I will involve: 1) synthesizing S3905; 2) establishing a solid-phase procedure for its preparation; 3) evaluating its stability in vitro and in vivo; 4) testing its pharmacokinetic profile in mice and rats; 5) establishing its LD50 and acute toxicity in mice and rats; and 6
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3909is a drug that inhibits
 
Response: S3909is a drug that inhibits the activity of the protein MMP-2 (matrix metalloproteinase-2) and the enzyme MT1-MMP (matrix metalloproteinase-14), which are known to be associated with tumor cell invasion and metastasis \[[@CR33]\]. Although S3909 did not significantly inhibit the growth of LNCaP cells, it reduced the growth of PC-3 and DU145 cells, in a dose-dependent manner (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Effect of S3909 on cell growth of LNCaP, PC-3 and DU145 prostate cancer cell lines. **a**, **b** and **c** are, respectively, the dose--response curves for S3909 on the cell growth of LNCaP, PC-3 and DU145 cells

Effect of S3909 on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3914is a drug that inhibits
 
Response: S3914is a drug that inhibits the production of nitric oxide (NO) in macrophages, and prevents the activation of macrophages by endotoxin or lipopolysaccharide (LPS) in vitro and in vivo. It is effective in the treatment of gram-negative bacterial septic shock and endotoxemia. In addition, S3914 is an effective suppressor of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis.

Synthesis

1.

Interaction of endotoxin (lipopolysaccharide) with its receptors in macrophages is shown in the scheme below. Lipopolysaccharide binds to CD14 on the surface of macrophages and subsequently to TLR4/MD2 receptor complex. The TLR4/MD2 receptor complex initiates a signaling cascade, which leads to the production of inflammatory cytokines. S3914 inhibits the production of NO and the activation of macrophages
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3919is a drug that inhibits
 
Response: S3919is a drug that inhibits the MDR1 gene.

S3919 is a clinically used MDR1 inhibitor. It is a sulfonamide derivative that was designed by Merck and was approved by the FDA in 2003 for use in children with acute myeloid leukemia (AML) that is refractory to induction therapy or for children with relapsed AML who are in first relapse. S3919 acts by inhibiting the MDR1 gene that encodes for the P-glycoprotein (P-gp) pump. P-gp is a drug efflux pump that causes drug resistance in cancer cells. The ability of S3919 to inhibit the MDR1 gene and the effect of S3919 on MDR1 gene expression was confirmed in vitro in a panel of human cancer cell lines.

S3919 is in phase II clinical trials in combination with etoposide for the treatment of AML.

S3919
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3923is a drug that inhibits
 
Response: S3923is a drug that inhibits the activity of *S. aureus* MurF, an enzyme that is essential for the biosynthesis of the peptidoglycan, and has a bactericidal effect \[[@B46-antibiotics-09-00144]\]. As for the chloramphenicol and ciprofloxacin, we obtained the highest inhibition with the S3923 at 2 µg/mL, being close to the value obtained for the negative control. The MICs obtained for the peptidoglycan biosynthesis inhibitor (S3923) are close to the MICs obtained for the two β-lactams tested. In the case of the β-lactam-based inhibitors, the lowest MICs were obtained for oxacillin and penicillin G.

4. Materials and Methods {#sec4-antibiotics-09-00144}
========================

4.1. Materials
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3924is a drug that inhibits
 
Response: S3924is a drug that inhibits TDP-43 mediated translation by binding to the C-terminal RNA binding domain of TDP-43. We found that S3924 was effective at reducing TDP-43 toxicity in primary cortical neurons and improved survival in TDP-43^A315T^ expressing flies. These data suggest that TDP-43-mediated toxicity may be a potential target for drug development.

4. Materials and Methods {#sec4-ijms-20-03004}
========================

4.1. Fly Stocks and Genetic Constructs {#sec4dot1-ijms-20-03004}
--------------------------------------

Flies were reared at 25 °C on standard fly food (autoclaved brewer's yeast, cornmeal, molasses, agar, and propionic acid) under a 12 h light/dark cycle. Flies expressing human TDP-43 were a gift from the J
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3925is a drug that inhibits
 
Response: S3925is a drug that inhibits cyclin-dependent kinases, and is thus a potent growth inhibitor in cancer cells. Its effects on the cell cycle have been examined by flow cytometry. A low dose of S3925 (10 nM) inhibited S phase entry in an acute lymphoblastic leukemia cell line, but at a higher dose (50 nM), the same drug inhibited both S and G2 phases. A correlation between the inhibition of DNA synthesis and mitotic entry was observed. S3925, at a dose of 10 nM, did not inhibit the cell cycle of a B cell line, but at 50 nM, it induced a mitotic arrest. In the B cell line, S3925 also caused a G2/M arrest, and a slight G1 arrest. In vitro, S3925 induces apoptosis in cells that are arrested in S phase, and not in those that are in G2 or M. The molecular target of S39
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3926is a drug that inhibits
 
Response: S3926is a drug that inhibits V-ATPase. S3926 can induce apoptosis in tumor cells by increasing the intracellular pH, and it has been shown to inhibit the growth of several types of tumor cells \[[@B12-cancers-12-01034],[@B13-cancers-12-01034],[@B14-cancers-12-01034]\]. S3926 has been shown to be more effective than other V-ATPase inhibitors such as Bafilomycin A1 or Concanamycin A in reducing the viability of malignant melanoma cells \[[@B15-cancers-12-01034]\]. S3926 was also effective in suppressing tumor growth and inducing apoptosis in an orthotopic xenograft mouse model of human malignant melanoma \[[@B16-cancers-12-01034]\]. These results suggest that V-ATP
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3927is a drug that inhibits
 
Response: S3927is a drug that inhibits D-type cyclins, and has shown activity in a number of in vitro and in vivo systems. A number of side effects have been noted with its use. The present study investigated the efficacy of combining S3927 with etoposide (VP-16) in a murine model of Ewing's sarcoma. We found that the combination of S3927 and VP-16 was more effective than either agent alone. Combination therapy also significantly prolonged the life of mice bearing Ewing's sarcoma cells. This suggests that the combination of S3927 and VP-16 may be a useful therapeutic regimen in the treatment of Ewing's sarcoma.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3930is a drug that inhibits
 
Response: S3930is a drug that inhibits the ability of HIV to reproduce.S3930is an experimental drug that has been used in mice to cure HIV.

In vitrostudies of the drug have been done in cell cultures.

Results of in vitro studies of S3930 have shown that it is not toxic to healthy cells.

In vitrostudies of the drug have shown that it works in a variety of cell types.

Results of in vitro studies of S3930 have shown that it can reduce the ability of HIV to replicate in cell cultures.

The mechanism of action of S3930 is not known.

In vivostudies of the drug have been done in mice.

Results of in vivo studies of S3930 have shown that it has an anti-HIV effect in mice.

S3930 has been studied in mice with humanized immune systems.

Results of S3930 in mice with humanized
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3935is a drug that inhibits
 
Response: S3935is a drug that inhibits the activity of P-glycoprotein (P-gp) in the blood-brain barrier (BBB). A central nervous system (CNS) effective dose of S3935 (6 mg/kg) has been shown to be at least 3-fold higher than that of the clinically relevant P-gp inhibitor verapamil (Ver). In the present study, the interaction of S3935 with the GABA(A) receptor complex was investigated using whole-cell patch-clamp techniques in cultured mouse cerebellar granule cells. In these cells, S3935 inhibited the binding of [(3)H]muscimol, a ligand for the GABA(A) receptor, with a Ki value of 3.8+/-0.7 microM. S3935 also inhibited the binding of [(3)H]muscimol to the cerebellar membrane with a Ki value of 6.0+/-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3944is a drug that inhibits
 
Response: S3944is a drug that inhibits a transporter, but that is unlikely to be a factor in the development of CML. The fact that we could not detect a difference in the frequency of any of the specific types of chromosomal abnormality in Ph-positive ALL suggests that there is no particular sensitivity of CML to a particular type of chromosomal abnormality.

In conclusion, we have shown that both ALL and CML cells are sensitive to the cell cycle-specific microtubule inhibitor S3944. These results have implications for the use of this drug in the treatment of hematological malignancies.

We thank Professor Mark Greenberg and Dr Zvonimir Striepen for the provision of the MOLT-4 cell line and Dr Jill Bennett for the provision of the Jurkat cell line.

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**This work was supported by a programme
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3945is a drug that inhibits
 
Response: S3945is a drug that inhibits the assembly of HIV-1 capsid proteins. When tested against the HIV-1-infected cell lines TZM-bl and H9, S3945 inhibited HIV-1 replication in a dose-dependent manner with IC50 values of 5 and 8 μM, respectively. In a TZM-bl neutralization assay, S3945 was shown to be active against a broad range of HIV-1 isolates, including the primary isolate of HIV-1~BAL~, the primary isolate of HIV-1~NL4-3~, and the isolates of HIV-1~A17~, HIV-1~NL43~, HIV-1~CM235~, HIV-1~CH40~, and HIV-1~SF162~. In a preliminary study, S3945 was shown to have a very low potential for human cytotoxicity (CC50 \>10 μM) and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3946is a drug that inhibits
 
Response: S3946is a drug that inhibits the activity of one of the enzymes that metabolize dopamine, the enzyme that is responsible for clearing the neurotransmitter from the synapse.

That means that it’s not just that people with ADHD are deficient in dopamine, it’s that they are deficient in the enzyme that metabolizes dopamine. This explains why people with ADHD often have a difficult time calming down after stressful situations and why they can’t concentrate and focus for long periods of time. They are literally overstimulated by their brain’s reward system.

When they have difficulty focusing and concentrating, their brain is flooded with the neurotransmitter dopamine, which is also known as the “pleasure hormone.” It’s the same neurotransmitter that’s responsible for the “high” that we feel when we have sex or when we eat chocolate. It’s the same neurotransmitter that’s released when we
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3948is a drug that inhibits
 
Response: S3948is a drug that inhibits both cAMP- and cGMP-dependent protein kinases, but not protein kinase C. It has been shown to inhibit proliferation and transformation in cell culture, and also to inhibit tumor growth in a number of animal models. S3948 is currently in Phase I clinical trials.

History
S3948 was discovered by the research group of Tetsuo Nakashima at The Institute of Physical and Chemical Research, Wako, Japan, in a screen for new protein kinase inhibitors. It was discovered in collaboration with Daiichi Sankyo Co. Ltd., Japan. The discovery and development of S3948 was conducted by Daiichi Sankyo Co. Ltd.

References

Category:Abandoned drugs
Category:Aminopyrimidines
Category:Protein kinase inhibitors
Category:Chloroarenes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3950is a drug that inhibits
 
Response: S3950is a drug that inhibits both *Mtb* growth and autophagy and it has been shown to be active against both drug-susceptible and -resistant strains of *Mtb*[@b30]. The most relevant observation from this study was that S3950 and RvD1, which are known to activate autophagy in mycobacteria, have synergistic effects on the killing of *Mtb* H37Rv ([Fig. 5](#f5){ref-type="fig"}). We speculate that S3950 could induce the expression of RvD1 receptors on the *Mtb* surface, which could then increase the binding of RvD1 and promote the activation of the autophagy pathway in *Mtb*. The observed synergy between S3950 and RvD1 may provide a strategy for improving the killing of *Mtb* by directly targeting *Mtb
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3951is a drug that inhibits
 
Response: S3951is a drug that inhibits the synthesis of RNA. It was isolated from Streptomyces sp. S3951, which was isolated from soil samples from the Jinguaji Mountain in Beijing, China.

S3951is a natural product that is used to prevent infections by several bacterial and fungal species. It is effective against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, Clostridium difficile, Candida albicans, and C. glabrata. It is effective against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium smegmatis. It also inhibits the replication of HIV-1.

History

S3951was discovered in a Chinese soil sample by a team of researchers at the Institute of Medicinal Plant Development (IMPLAD) of the Chinese Academy of Medical Sciences. It was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3953is a drug that inhibits
 
Response: S3953is a drug that inhibits the catalytic activity of dihydroorotate dehydrogenase (DHODH) ([@B1]). DHODH is the key enzyme in the de novo pyrimidine biosynthesis pathway and a critical target for treatment of *Pneumocystis* pneumonia (PCP) and toxoplasmosis ([@B2]). S3953 is a potent inhibitor of DHODH with an IC~50~ of \~0.1 μM *in vitro* ([@B1]). S3953 also inhibits the proliferation of *Toxoplasma* in cell culture and the growth of *Pneumocystis* in an animal model of infection ([@B1]).

S3953 has been in clinical development for the treatment of toxoplasmosis since the 1970s ([@B3]). However, this agent has not been advanced to clinical testing in humans. A recent publication reported the pharmacokin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3957is a drug that inhibits
 
Response: S3957is a drug that inhibits the production of CCL5 by human monocytes. The present study was conducted to evaluate the safety and efficacy of S3957 in patients with recurrent genital herpes simplex virus type 2 (HSV-2) infection. Patients were treated with S3957 (50, 100, or 200 mg, 3 times daily) for 6 weeks. Of 24 patients, 15 completed the study. Of these, 11 (73%) had a decrease in the number of genital lesions, and 6 (40%) had no new lesions. The median number of new lesions per patient per week decreased from 1.0 (range, 0-4.0) to 0.0 (range, 0-3.0) (P <.001). No serious adverse events were reported. Two patients withdrew because of allergic reaction. There was no apparent difference in the decrease in the number of lesions or the rate of recurrence among the 3 groups. S3957 was well
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3959is a drug that inhibits
 
Response: S3959is a drug that inhibits mitochondrial complex I, and is considered as a specific inhibitor of complex I. It has been widely used as a model to study the pathophysiology of Alzheimer\'s disease. Recently, we showed that TSTS3959 could be a potent agent for prevention and treatment of a neurodegenerative disease \[[@R1]\]. In this study, we explored the neuroprotective effect of TSTS3959 on MPTP-induced Parkinson\'s disease.

MPTP is a well-known neurotoxin that can cause parkinsonism and Parkinson\'s disease \[[@R2]\]. The dopaminergic system is particularly vulnerable to MPTP-induced damage \[[@R3]\]. MPTP produces its neurotoxicity by inhibiting complex I in the mitochondrial electron transport chain, and by producing oxidative stress \[[@R4]\]. The nigrostriatal pathway is most vulnerable to the neurotoxicity
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3963is a drug that inhibits
 
Response: S3963is a drug that inhibits cyclin-dependent kinases and induces G1/S arrest and apoptosis in a variety of tumor cells including non-small cell lung cancer (NSCLC) cell lines and in tumor xenografts in vivo. Here we show that S3963 potently inhibits the growth of NSCLC cell lines in vitro and in vivo. S3963 induces apoptosis in NSCLC cell lines through activation of caspases 3 and 7, cleavage of PARP and degradation of poly (ADP-ribose) polymerase (PARP). S3963 also induces caspase-independent apoptosis in NSCLC cells. In contrast to other cell cycle arrest agents such as paclitaxel, S3963 induced G1/S arrest and cell death in NSCLC cells, which was associated with an increase in p21(Waf1/Cip1) expression. S3963 inhibited phosphorylation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3965is a drug that inhibits
 
Response: S3965is a drug that inhibits a key enzyme in the Krebs cycle and can be used to treat cancer. S3965is a potential new drug to treat some types of cancer. S3965is in phase II clinical trials. It is an anti-cancer drug candidate. S3965is currently being tested in patients with advanced cancer. The safety and effectiveness of S3965in patients with cancer have not been established. Patients taking S3965may experience side effects such as diarrhea, fatigue, nausea, vomiting, dizziness, headache, decreased appetite, confusion, constipation, difficulty sleeping, and shortness of breath. S3965is a potential new drug to treat some types of cancer. S3965is an anti-cancer drug candidate. S3965is currently being tested in patients with advanced cancer. The safety and effectiveness of S3965in patients with cancer have not been established. Patients taking S3965may experience side effects such as diarrhea, fatigue,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3966is a drug that inhibits
 
Response: S3966is a drug that inhibits phosphodiesterase 4 (PDE4) activity. This enzyme has been implicated in the modulation of cyclic nucleotide levels and their intracellular signalling pathways in a variety of cells and tissues. S3966 is currently in Phase II clinical trials for the treatment of a number of inflammatory and allergic diseases.

S3966 is a potent inhibitor of the enzyme PDE4 and is currently being developed for the treatment of inflammatory and allergic diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. S3966 is in Phase II clinical trials for the treatment of these conditions. S3966 has been shown to be efficacious in animal models of COPD, allergic rhinitis, and asthma, and is currently being tested in Phase II clinical trials for these indications. S3966 has been shown to be effective in animal models of the following diseases: asthma, chronic obstructive pulmonary disease (C
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3967is a drug that inhibits
 
Response: S3967is a drug that inhibits VEGF signaling. A randomized, double-blind, placebo-controlled study of S3967 (NCT01755796) in NSCLC is currently ongoing. The anti-angiogenic activity of S3967 is associated with its effects on VEGF, as well as its ability to downregulate multiple angiogenic factors. The combination of S3967 with gemcitabine in pancreatic cancer is currently being evaluated in a phase I/II study (NCT01502379).

Summary {#S0011}
=======

The recent approval of the first generation of EGFR TKIs in NSCLC has dramatically changed the treatment landscape of patients with EGFR mutant advanced NSCLC. Unfortunately, resistance to first generation EGFR TKIs is inevitable, and most patients will eventually relapse and require alternative treatment options. Several novel agents that target different mechanisms of EGFR-mediated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3968is a drug that inhibits
 
Response: S3968is a drug that inhibits Nrf2, an oncogenic transcription factor, by binding to its N-terminal region and promoting its ubiquitination and degradation by the proteasome \[[@B38-antioxidants-09-00231]\]. However, it is not yet clear whether this drug is able to activate the Nrf2 pathway in vivo.

4.3. Nrf2 Modulators for the Treatment of Alzheimer's Disease {#sec4dot3-antioxidants-09-00231}
-------------------------------------------------------------

A significant number of studies have been conducted to investigate the therapeutic potential of Nrf2 activators for the treatment of neurodegenerative diseases. Currently, Nrf2 activators are in clinical trials for the treatment of AD, PD, ALS, and HD ([Table 2](#antioxidants-09-00231-t002){ref-type="table"}). The Nrf2 activ
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3969is a drug that inhibits
 
Response: S3969is a drug that inhibits the replication of DNA in human cells. The growth of HT29 cells is inhibited by S3969 in a dose-dependent manner. The IC50 value of S3969 for HT29 cells is 3.4 μM.
S3969 is a cell cycle-specific inhibitor of DNA replication. It blocks the synthesis of DNA in S phase of the cell cycle and the inhibition of S3969 on HT29 cells is reversible.
The mechanism of action of S3969 is that it binds to the template region of DNA and inhibits DNA polymerase δ, resulting in the inhibition of DNA replication. S3969 inhibits DNA replication by interacting with the template region of DNA. The region that S3969 interacts with is known as the template region, which is located on the DNA. This region is known as the template region of DNA. S3969 is a small molecule compound that inhibits the synthesis of DNA by interacting with the template region of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3970is a drug that inhibits
 
Response: S3970is a drug that inhibits the growth of breast cancer cells and induces apoptosis, by suppressing Akt activity, while ERK1/2 activation is less affected. Thus, S3970 is a promising drug for the treatment of ER-positive breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3971is a drug that inhibits
 
Response: S3971is a drug that inhibits the renin-angiotensin system (RAS) by directly blocking the angiotensin II (Ang II) type 1 receptor (AT1R) in the vascular wall and has recently been shown to improve endothelial dysfunction in patients with hypertension ([@b8-vhrm-4-1361]). In a large, randomized, placebo-controlled trial, S3971 was shown to be an effective antihypertensive agent that reduced systolic blood pressure (BP) by 18.8 mmHg in patients with mild to moderate hypertension and a BP reduction of 19.3 mmHg in patients with severe hypertension. In addition, S3971 was associated with a modest reduction in the incidence of cardiovascular events ([@b9-vhrm-4-1361]).

S3971 was shown to be well tolerated and did not increase the incidence of adverse events. However, S3971 did increase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3972is a drug that inhibits
 
Response: S3972is a drug that inhibits a mitochondrial membrane protein called ATP synthase, and is used in the treatment of cancer.

S3972 is an analogue of quinacrine, and is a competitive inhibitor of the enzyme. It has a unique pharmacological profile compared to quinacrine, in that it is both a lipophilic cationic dye and an anti-cancer drug. It is a selective, potent inhibitor of mitochondrial ATP synthase and a DNA-damaging agent. It is more potent and has a broader spectrum of activity than quinacrine.

See also
 Quinacrine
 Quinalizarin

References

External links
 FDA Summary of S3972

Category:Antineoplastic drugs
Category:Quinoline ethers
Category:Abandoned drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3973is a drug that inhibits
 
Response: S3973is a drug that inhibits angiogenesis, in a broad spectrum of cancer types.^[@bib1]^ The mechanism of S3973 action is attributed to inhibition of phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway.^[@bib2]^ AKT regulates various cell functions such as cell survival, cell cycle, metabolism and migration, and is activated in response to growth factors and cytokines.^[@bib3]^ Several studies have reported that PI3K/AKT signaling is dysregulated in cancer,^[@bib4],\ [@bib5]^ and PI3K inhibitors are in clinical development for various types of cancer.^[@bib6],\ [@bib7]^

We have previously reported that S3973-induced cell death is caspase-independent, and is mediated by mitochondrial dysfunction.^[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3975is a drug that inhibits
 
Response: S3975is a drug that inhibits DNA methylation and induces transcriptional activity in cancer cells. It is currently in Phase I and II clinical trials for treatment of hematological malignancies. It has been reported that S3975 inhibits tumor cell growth in vitro and in vivo. The present study was designed to elucidate the mechanism of action of S3975 on DNA methylation and transcriptional activity in MOLT-4 cells. We found that S3975 inhibited DNA methylation and transcriptional activity in MOLT-4 cells. It increased the levels of transcriptional co-activator PGC-1alpha and transcriptional co-repressor MeCP2 in a dose-dependent manner. PGC-1alpha and MeCP2 have been implicated in DNA methylation and transcriptional regulation. The increase in PGC-1alpha and MeCP2 may be responsible for the anti-cancer activity of S3975.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3977is a drug that inhibits
 
Response: S3977is a drug that inhibits the proliferation of myeloma cells and induces cell death by activation of the extrinsic apoptotic pathway.^[@bib1],\ [@bib2]^ A previous study demonstrated that treatment with S3977 reduced proliferation of plasma cells *in vitro* and improved survival of myeloma mice.^[@bib1]^ In addition, another study showed that S3977 has anti-inflammatory effects in myeloma.^[@bib3]^ In this study, we explored the effects of S3977 on myeloma cells and monocytes in an *in vitro* coculture system. We found that S3977 inhibited the proliferation of myeloma cells, induced the differentiation of monocytes, and inhibited the differentiation of monocytes to osteoclasts.

Results
=======

S3977 inhibits proliferation of myeloma cells
---------------------------------------------

The inhibitory effects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3979is a drug that inhibits
 
Response: S3979is a drug that inhibits aldose reductase. It was designed to prevent the deleterious effects of high glucose levels on the kidneys. In this study, the safety and pharmacokinetics of S3979 have been assessed in healthy subjects. In a randomized, double-blind, placebo-controlled, dose-escalation study, eight healthy male subjects received single doses of oral S3979 or placebo on day 1. A single oral dose of S3979 was safe and well tolerated at all doses studied. S3979 was rapidly absorbed, with peak plasma concentrations occurring within 1-2 hours. The mean time to maximum concentration (tmax) of S3979 was 1.6 hours. S3979 had a terminal half-life of approximately 7 hours. S3979 was well tolerated and had a safety profile similar to that of placebo. No dose-dependent adverse events were observed. S3979 was rapidly absorbed and had a short elimination half-life
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3980is a drug that inhibits
 
Response: S3980is a drug that inhibits the mitochondrial respiratory chain. Its effect on *E. coli* growth was monitored in M9-glucose medium. The concentration of 0.1 μM S3980 was sufficient to inhibit growth, but higher concentrations (\>0.3 μM) were required to completely inhibit growth ([Fig. 1](#F1){ref-type="fig"}).

![S3980 inhibits growth of *E. coli*. The effect of S3980 on growth of *E. coli* was monitored by measuring the optical density at 600 nm. Bacteria were grown in M9-glucose medium and the addition of S3980 was at time zero. Error bars represent the standard deviation of the mean.](mgen-3-104-g001){#F1}

To investigate the effect of S3980 on the transcriptome of *E. coli*, samples were taken before and after the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3982is a drug that inhibits
 
Response: S3982is a drug that inhibits DNA methyltransferase and histone deacetylase. In mice, S3982 has been shown to improve motor function and memory, reduce brain edema, and increase cell proliferation and differentiation, without causing adverse side effects (see, e.g., refs. \[[@CR37], [@CR38]\]).

### Rescue and Immunohistochemistry {#Sec21}

At DIV 7, hippocampal neurons were treated with S3982 at a concentration of 0.5 μM. The medium was changed to S3982-containing medium or control medium after 1 h, and the cells were incubated for 1 h. The medium was then replaced with control medium and the cells were incubated for a further 24 h. Neurons were fixed with 4% PFA and incubated with mouse anti-MAP2 (1:200; M1406, Sigma-Ald
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3983is a drug that inhibits
 
Response: S3983is a drug that inhibits the key enzyme in the citric acid cycle (i.e., fumarate hydratase). This drug has been approved by the FDA for the treatment of certain types of anemia and, to a lesser extent, solid tumors. S-trityl-L-cysteine (STC) is a specific inhibitor of S3983. We report that STC has little effect on the growth of primary human myeloid leukemia cells but has a potent and selective effect on their leukemic progenitors, thus providing the basis for a new treatment for this disease.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3984is a drug that inhibits
 
Response: S3984is a drug that inhibits tyrosine kinase. Tyrosine kinase are cellular enzymes that catalyze the transfer of a phosphate group from adenosine triphosphate to tyrosine residues on protein substrates.
S3984is a compound of the formula:

The preparation of S3984 is described in the U.S. Pat. No. 5,939,590 and the International Application WO 99/05105.
S3984is a compound of the formula:

It is disclosed in WO 03/086516 that S3984 is a potent inhibitor of the BCR-ABL tyrosine kinase, which is an important target for the treatment of chronic myelogenous leukemia (CML). The compound S3984 was reported to have an IC50 value of approximately 1 nM.
S3984was found to be active in an in vitro human tyrosine kinase enzyme assay
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3985is a drug that inhibits
 
Response: S3985is a drug that inhibits phosphatidylinositol-3-kinase (PI3K) and induces the degradation of the tumor suppressor protein, PTEN. The mechanism of action of S3985 and its effects on PTEN and PTEN-associated signal transduction pathways are described in the literature. PTEN inhibits PI3K and hence inhibits phosphorylation of Akt and other downstream effectors. S3985 induces the degradation of PTEN.

Structure and metabolism {#Sec5}
========================

S3985 is a non-small-molecule PI3K inhibitor, and it inhibits the activity of the PI3K/Akt/mTOR signaling pathway in tumor cells \[[@CR8]\]. S3985 is a novel synthetic PI3K inhibitor that binds to the active site of PI3K, thereby inhibiting the phosphorylation of the Akt/mTOR pathway \[[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3986is a drug that inhibits
 
Response: S3986is a drug that inhibits the beta-secretase (BACE1) enzyme, which is involved in the production of beta-amyloid peptides, a primary component of senile plaques in the brains of Alzheimer’s disease patients. S3986 is a BACE1 inhibitor that blocks the production of the Aβ peptides, including Aβ40 and Aβ42, which are known to be toxic to neurons.

S3986 inhibits BACE1 in a dose-dependent manner and, at the concentrations tested, has no effect on the activity of the related aspartyl protease BACE2. S3986 inhibits BACE1 in vitro with a K(i) of 0.7 nM and in vivo in the mouse brain, where it lowers Aβ levels by up to 50% without affecting Aβ40 or Aβ42 levels. S3986 is active in animal models of Alzheimer’s disease, and it
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3987is a drug that inhibits
 
Response: S3987is a drug that inhibits the growth of malignant cells in culture and has been tested in Phase I and II clinical trials. This study is a dose escalation Phase I trial of C225 in patients with relapsed or refractory ALL.

Patients receive C225 by continuous infusion for 14 days.

Response is assessed at day 21 by physical examination, blood count, and bone marrow biopsy.

Dose limiting toxicity (DLT) is defined as Grade 4 neutropenia lasting more than 7 days or Grade 3 thrombocytopenia.

The primary objectives are to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) in this patient population.

Secondary objectives are to evaluate the pharmacokinetics of C225 in this patient population and to determine the anti-tumor activity of C225 in this patient population.

DLT is defined as:

Grade 4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3992is a drug that inhibits
 
Response: S3992is a drug that inhibits the growth of various cancer cell lines. We show that it also inhibits proliferation of cells from myeloid and lymphoid malignancies, including a mouse model of MDS/AML. In MDS/AML patients, S3992 reduces the size of the MDS/AML clone and increases the number of apoptotic cells in the bone marrow. The latter is associated with reduced numbers of bone marrow-derived cells in the peripheral blood, including blasts and immature myeloid cells. S3992 also induces apoptosis of MDS/AML cells in vitro and in vivo. We propose that S3992 could be a new drug for MDS/AML.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3995is a drug that inhibits
 
Response: S3995is a drug that inhibits the CaMKII phosphorylation of the AMPA receptor subunit GluA1 at serine 845, and is therefore able to prevent the accumulation of CaMKII at the postsynaptic density of excitatory synapses and consequently the development of LTP.^[@R37]^ We investigated the effect of S3995 on LTP in the presence of our first generation lead compound compound, compound 3 ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Compound 3 induced a modest increase in LTP, which was significantly greater than the effect of S3995 (0.1 µM) and reached significance at 1 µM. In contrast, the inhibition of LTP by S3995 was concentration-dependent, with an IC~50~ of 0.45 µM. S3995 did not significantly affect basal synaptic transmission, consistent with its mechanism of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3996is a drug that inhibits
 
Response: S3996is a drug that inhibits the enzyme S3996, which is required for cell wall synthesis. The combination of S3996 with the polyene antibiotic, amphotericin B, results in a synergistic effect in killing yeasts.
The present invention is a process for preparing 4-amino-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid and its salts, intermediates therefor and pharmaceutical compositions containing said compounds.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3997is a drug that inhibits
 
Response: S3997is a drug that inhibits SARS-CoV 3CL^pro^, a cysteine protease. It has been shown to inhibit SARS-CoV replication in a plaque reduction assay in Vero E6 cells with an IC~50~ of 1.9 μM \[[@B19-pharmaceuticals-13-00175]\]. SARS-CoV S protein-mediated cell--cell fusion is inhibited by S3997, with an IC~50~ of 2.2 μM \[[@B19-pharmaceuticals-13-00175]\]. SARS-CoV S protein-mediated membrane fusion is inhibited by S3997 with an IC~50~ of 1.3 μM \[[@B19-pharmaceuticals-13-00175]\]. SARS-CoV S protein-mediated entry into target cells is inhibited by S3997 with an IC~50
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S3998is a drug that inhibits
 
Response: S3998is a drug that inhibits Bcl-2 family protein Bcl-2 and Bcl-XL, which regulate apoptosis and also regulate the mitochondrial permeability transition pore, and thus is a potential anticancer agent. Here we found that S3998 induces apoptosis in both human leukemia HL-60 cells and human lung cancer H460 cells. S3998 increased the release of cytochrome c from mitochondria and activated caspase-9, caspase-3, and PARP. Moreover, S3998 induced autophagy in HL-60 cells. Inhibition of autophagy with 3-MA decreased S3998-induced apoptosis. We also found that S3998 increased ROS levels in HL-60 cells, which were significantly reduced by N-acetyl-L-cysteine (NAC), a ROS scavenger. Treatment with NAC also decreased the expression of Bcl-2, Bcl-XL, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4002is a drug that inhibits
 
Response: S4002is a drug that inhibits several members of the metallo-beta-lactamase family. This enzyme hydrolyzes penicillins, cephalosporins, carbapenems, monobactams, aztreonam, and beta-lactam/beta-lactamase inhibitor combinations. The antibacterial spectrum includes most common bacterial species including *Staphylococcus* spp. *(S. aureus, S. epidermidis), Streptococcus* spp. *(S. agalactiae, S. pneumoniae, S. pyogenes, S. anginosus), Haemophilus influenzae, Enterococcus* spp., and *Neisseria* spp. \[[@CR12]\].

PEN-S4002 is a hydrophilic, neutral, bile salt- and pH-independent molecule. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  s4030is a drug that inhibits
 
Response: s4030is a drug that inhibits the activity of the sodium pump. It is used to treat the following conditions: high blood pressure, heart failure, heart block, atrial fibrillation, cardiac arrest and angina. Its common side effects include headache, dizziness, nausea, vomiting, confusion, constipation, dry mouth, leg cramps, itching, difficulty sleeping, and blurred vision.

S4030is a drug that inhibits the activity of the sodium pump. It is used to treat the following conditions: high blood pressure, heart failure, heart block, atrial fibrillation, cardiac arrest and angina. Its common side effects include headache, dizziness, nausea, vomiting, confusion, constipation, dry mouth, leg cramps, itching, difficulty sleeping, and blurred vision.

S4030is a drug that inhibits the activity of the sodium pump. It is used to treat the following conditions: high blood pressure, heart failure, heart block,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4059is a drug that inhibits
 
Response: S4059is a drug that inhibits TGF-beta1 signaling by preventing binding of TGF-beta1 to its receptor, type I. This study evaluated the safety and pharmacokinetics of S4059 in healthy subjects.

Methods

This was a single-center, open-label, single-dose study. S4059 was administered orally at 20, 50, and 100 mg to 18 healthy subjects. The subjects were observed for up to 7 days after dosing. Blood samples were taken before dosing and at 1, 2, 3, 4, 6, and 8 hours after dosing.

Results

The geometric mean area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) and maximum plasma concentration (Cmax) were 393 ng · h/mL and 562 ng/mL, respectively. S4059 was rapidly absorbed, with a median Tmax of 1.5 hours. S40
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  s4075is a drug that inhibits
 
Response: s4075is a drug that inhibits Mcl-1. We found that BH3-mimetics, such as S4075, can be used to induce Mcl-1 degradation and apoptosis in PANC-1 cells. However, we also observed that BH3-mimetics may not be effective for all pancreatic cancer cells. We also found that Mcl-1 levels in PANC-1 cells are quite high, and we hypothesize that this is due to the low levels of Bak. We will explore this hypothesis by using PANC-1 cells in which Bak expression is either increased or decreased, and by using other pancreatic cancer cell lines in which Bak is either increased or decreased. This may be one reason why BH3-mimetics have only modest effects on some pancreatic cancer cells. The second is that we do not know how the levels of Mcl-1 are regulated in pancreatic cancer cells. This is important because
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4117is a drug that inhibits
 
Response: S4117is a drug that inhibits the T cell receptor (TCR) signalosome, the macromolecular complex of signaling proteins that ultimately results in gene transcription. S4117 is an irreversible inhibitor of TCR signalosome assembly, and S4117 has been shown to completely abrogate CD3ζ phosphorylation and nuclear translocation in a human T cell line.[@R1] S4117 treatment also blocks TCR-mediated IL-2 production in human and mouse T cells.[@R1]^,^[@R2] The combination of these observations suggests that S4117 may be a highly specific and potent inhibitor of T cell function. Indeed, in vitro studies have shown that S4117 has minimal effects on resting B cells, monocytes, neutrophils, dendritic cells, macrophages, and NK cells.[@R1]^,^[@R2]

Here, we show that S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4246is a drug that inhibits
 
Response: S4246is a drug that inhibits the farnesyltransferase enzyme and consequently interferes with the addition of the farnesyl group to Ras. S4246 inhibits the growth of Ras-transformed cells, blocks Ras-dependent transformation, and inhibits the growth of human pancreatic and colorectal carcinomas. S4246 may be a useful agent in the treatment of cancer.

We report a case of lymphomatoid papulosis (LyP) that evolved into diffuse large B-cell lymphoma (DLBCL) in a patient with a history of a nevus of the eyelid.

LyP is a rare, chronic skin condition characterized by papules that evolve into a single or multiple cutaneous nodules and plaques, and may be associated with systemic symptoms. Histopathologically, LyP is characterized by a proliferation of atypical lymphocytes in the epidermis, which may be accompanied by ulceration and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4281is a drug that inhibits
 
Response: S4281is a drug that inhibits mTOR.^[@bib18]^ In contrast, PI3K is known to be involved in the survival of tumor cells.^[@bib20]^

In summary, our data show that low-dose metformin reduces cell viability and induces apoptosis of ECA109 cells via the inhibition of the mTOR/PI3K/AKT signaling pathway.

This work was supported by the Natural Science Foundation of Shandong Province (ZR2013HM055) and the Foundation of Independent Innovation of Shandong Province (2014ZZCX061).

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by G Raschellà

The authors declare no conflict of interest.

Supplementary Material {#sup
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  s4515is a drug that inhibits
 
Response: s4515is a drug that inhibits aldosterone synthase. It does not increase the levels of other steroids. It has a long half-life of about 8 h.

Steroid hormones 

Steroid hormones are chemicals that act on the body's cells to cause changes in their structure and function. They are produced in the adrenal glands and ovaries, and can be further modified in the liver.

There are several different types of steroid hormones:

Corticosteroids 

Corticosteroids are a type of steroid hormones. They are used as medicines, including those to treat asthma and arthritis. They are also used to suppress inflammation and to prevent rejection of transplanted organs.

Estradiol 

Estradiol is a steroid hormone produced by the ovaries. It is used as a medication for menopausal symptoms.

Estriol 

Estriol is a steroid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4516is a drug that inhibits
 
Response: S4516is a drug that inhibits the synthesis of DNA, RNA and proteins in the body. Inhibition of protein synthesis can cause the body to become less able to repair and replace damaged cells. S4516is a powerful drug that is a form of interferon. It can cause depression, confusion, sleepiness, tiredness, fever, nausea and a decreased sex drive. The effects can be severe and can cause death if treatment is not stopped. S4516is an injectable drug. S4516is usually injected into the vein. S4516is is given by a health professional.

Read the information leaflet provided by your pharmacist before you start taking S4516 and each time you get a prescription. If you have any concerns or queries, ask your doctor or pharmacist.

Before using S4516

•tell your doctor if you are pregnant or breast-feeding. S4516is not recommended in these circumstances.

•
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4520is a drug that inhibits
 
Response: S4520is a drug that inhibits P-gp, one of the most important drug efflux pumps.^[@bibr45-1559325820926735]^ S-3307, an inhibitor of MRP1, is the first agent identified that can reverse the resistance of tumor cells to cisplatin.^[@bibr46-1559325820926735]^ E-5143, a verapamil derivative, is a P-gp and MRP1 inhibitor.^[@bibr47-1559325820926735]^

Nasopharyngeal carcinoma is one of the most common head and neck cancers, especially in Southeast Asia.^[@bibr48-1559325820926735]^ Radiotherapy is one of the most common treatments for nasopharyngeal carcinoma, but the therapeutic effect is not ideal.^[@bibr49-15593258209267
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4550is a drug that inhibits
 
Response: S4550is a drug that inhibits the synthesis of DNA, and has an IC50 of 10 nM. It is also a thymidine kinase inhibitor. It was developed by Syntex (now Pfizer) as a chemotherapeutic agent. It is currently marketed as a tablet in the United States as a treatment for HIV-associated Kaposi's sarcoma. It was also studied as a treatment for prostate cancer and cervical cancer. It is a nucleoside analogue, a purine analogue.

S4550 was designed as a potential treatment for AIDS-associated Kaposi's sarcoma. It is the active metabolite of azidothymidine (AZT), an antiretroviral drug that has been used in combination with other anti-HIV drugs for the treatment of AIDS. The active form of S4550 is the monophosphate, while AZT is a diphosphate.

S4550 was shown
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4553is a drug that inhibits
 
Response: S4553is a drug that inhibits the activity of the enzyme phosphodiesterase-5 (PDE-5), an enzyme responsible for degradation of the second messenger cGMP, which is known to be involved in relaxation of smooth muscle cells. PDE-5 is a cGMP-specific PDE. The ability of sildenafil to increase the amount of cGMP in the corpus cavernosum of patients with erectile dysfunction is well documented. This action on the corpus cavernosum of the penis leads to smooth muscle relaxation and this is the basis of its use in the treatment of erectile dysfunction. Sildenafil, like other PDE-5 inhibitors, works only in patients with erectile dysfunction and does not restore erections in patients with normal erectile function. Sildenafil is marketed as Viagra, Revatio and Skycara.

B1954 is a drug that inhibits the enzyme phosphodiesterase-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4556is a drug that inhibits
 
Response: S4556is a drug that inhibits phosphodiesterase (PDE) isoenzymes, specifically PDE 5 and PDE 3. Its mechanism of action is complex, involving a variety of actions on the end organ, as well as interactions with the cardiovascular system.

Sildenafil is a competitive inhibitor of PDE5. Its effect on the central nervous system is still being explored. The most common adverse reactions are mild and transient headaches, flushing of the face, myalgia, dyspepsia, and nasal congestion.

Adverse reactions include:

• Flushing of the face, arms, and legs

• Nasal congestion

• Headache

• Abnormal vision

• Abnormal hearing

• Nausea and diarrhea

• Abdominal pain

• Dyspepsia

• Vomiting

• Blurred vision

• Palpitations

• Ast
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4558is a drug that inhibits
 
Response: S4558is a drug that inhibits protein kinase C (PKC) activity. In this study, we have shown that S4558 suppresses the proliferation of leukemic cells, including human leukemic cell lines (HL-60 and U937) and primary acute myeloid leukemia (AML) cells. We also found that S4558 induces apoptosis in AML cells. Further analysis revealed that S4558 induces the degradation of phosphorylated PKC substrates in AML cells. Finally, S4558 suppressed the growth of leukemic cells and induced apoptosis in vivo. These results indicate that S4558 has potential as a therapeutic agent for the treatment of AML.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4559is a drug that inhibits
 
Response: S4559is a drug that inhibits, by binding to the α1 subunit of the nicotinic acetylcholine receptor, the neuronal nicotinic acetylcholine receptor (nAChR) and reduces its activity.

Indication

S4559 is an investigational drug being developed for the treatment of cognitive impairment associated with schizophrenia. The efficacy of S4559 in improving cognitive impairment associated with schizophrenia has been demonstrated in a double-blind, placebo-controlled study.

S4559 is under development by Aptinyx, Inc. for the treatment of cognitive impairment associated with schizophrenia.

Clinical trials are ongoing to determine if S4559 has the potential to treat other psychiatric disorders and medical conditions associated with cognitive impairment.

S4559 has not been studied for the treatment of cognitive impairment in other psychiatric disorders or medical conditions.

Eligibility criteria

There are no specific eligibility criteria for this study.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4562is a drug that inhibits
 
Response: S4562is a drug that inhibits cyclin-dependent kinases (CDKs) and thus blocks the progression of cells through the cell cycle. This phase of the cell cycle is regulated by cyclins, a family of proteins that bind to and activate CDKs, which in turn phosphorylate and inactivate the retinoblastoma protein (pRb) ([Bold *et al*, 1992](#bib4){ref-type="other"}). Phosphorylation of pRb by CDKs leads to release of transcription factors E2F, which induce the expression of genes required for cell-cycle progression ([Rosen *et al*, 1994](#bib24){ref-type="other"}). Thus, S4562 inhibits the proliferation of cells by blocking the progression of cells through the cell cycle. S4562 has been shown to be a potent inhibitor of CDKs, including CDK1, CDK2, CD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4565is a drug that inhibits
 
Response: S4565is a drug that inhibits osteoclastic bone resorption, thereby increasing bone density. S4565 has been reported to prevent the loss of bone mass in animal models of bone disease, as well as in humans. The effects of S4565 have been studied in many experimental animal models of bone loss. In humans, S4565 has been administered to humans with osteoporosis and in a small number of patients with glucocorticoid-induced osteoporosis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4566is a drug that inhibits
 
Response: S4566is a drug that inhibits the release of dopamine from the presynaptic nerve endings.

S4567it has been used as an adjunct to other antipsychotic drugs in the treatment of schizophrenia.

S4568It has also been used to treat neuroleptic malignant syndrome (NMS) and tardive dyskinesia.

S4569There are two major metabolites of aripiprazole: 6-O-desmethylaripiprazole (A-56) and 3-O-desmethylaripiprazole (A-58).

S4570Aripiprazole has been used to treat bipolar I depression, with or without a history of mania.

S4571Aripiprazole has also been used to treat binge eating disorder (BED).

S4572It has been used to treat anorexia nervosa.

S4573It has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4571is a drug that inhibits
 
Response: S4571is a drug that inhibits HIV replication by inhibiting reverse transcriptase. It is the only FDA-approved drug that directly targets HIV. However, a large fraction of patients develop resistance to S4571. We show that resistant HIV populations develop in cells infected with drug-resistant HIV. These drug-resistant HIV populations were detected by the ultrasensitive deep sequencing of viral cDNA. S4571-resistant HIV populations were obtained in humanized mice infected with HIV. However, S4571-resistant HIV populations were not observed in mice infected with drug-resistant HIV carrying non-synonymous substitutions in reverse transcriptase. The finding of drug-resistant HIV populations in infected mice suggests that drug-resistant HIV populations can be generated in vivo. This observation could lead to new strategies for treatment of HIV infection.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4574is a drug that inhibits
 
Response: S4574is a drug that inhibits a critical enzyme in the biosynthesis of folate, thus, depriving cells of a required nutrient for cell division and growth. It is FDA approved for treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) and other malignancies. It is also being studied in the treatment of solid tumors. This study is designed to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of S-1 in patients with solid tumors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4575is a drug that inhibits
 
Response: S4575is a drug that inhibits Wnt signaling and has been shown to inhibit bone loss in animal models of osteoporosis and to increase bone mineral density in humans. In this study, we examined the effects of S4575 on human bone metabolism in vivo and in vitro. In clinical studies, single oral doses of 50 mg of S4575 were given to 5 healthy postmenopausal women and to 7 women with osteoporosis. The S4575 treatment increased bone mineral density of the lumbar spine and proximal femur, and improved the bone turnover markers (bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase 5b) and the balance of osteocalcin and cross-linked N-telopeptides of type I collagen. In an in vitro study, we investigated the effects of S4575 on osteoblast and osteoclast differentiation, and on the expression of bone markers in bone marrow stromal cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4576is a drug that inhibits
 
Response: S4576is a drug that inhibits the synthesis of the tumour cell growth factor IGF-1. It has been tested in two large Phase III clinical trials, one of which showed a benefit for the drug compared with placebo. S4576 has a unique mechanism of action and is different from other anti-cancer drugs in the class. It does not kill cancer cells, but rather stops them growing.

S4576 is a drug that inhibits the synthesis of the tumour cell growth factor IGF-1. It has been tested in two large Phase III clinical trials, one of which showed a benefit for the drug compared with placebo. S4576 has a unique mechanism of action and is different from other anti-cancer drugs in the class. It does not kill cancer cells, but rather stops them growing.

S4576 is a drug that inhibits the synthesis of the tumour cell growth factor IGF-1. It has been tested in two large Phase III clinical trials, one
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4580is a drug that inhibits
 
Response: S4580is a drug that inhibits androgen receptor (AR) signaling in PCa.^[@R5],[@R6]^ However, S4580 is also a non-steroidal AR antagonist that has been shown to inhibit AR nuclear translocation,^[@R7]^ and to cause cell death by both AR-dependent and AR-independent mechanisms.^[@R8]^ In a previous study, we showed that S4580 can induce apoptosis in AR-negative PCa cells, which is mediated by the upregulation of DR5.^[@R8]^ In the present study, we explored the ability of S4580 to inhibit the growth of AR-positive PCa cells. We found that S4580 inhibited the growth of LNCaP and 22Rv1 cells, as measured by crystal violet staining, which was associated with a reduction in the number of viable cells. We then explored the molecular mechanisms underlying
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4582is a drug that inhibits
 
Response: S4582is a drug that inhibits phosphatase 2A (PP2A) by competing with the endogenous substrate phosphorylase b.
S4582 is a non-selective, reversible, and potent inhibitor of PP2A. S4582 is a metabolically stable compound that has been shown to increase phosphorylase b phosphorylation and inhibit glycogenolysis in skeletal muscle in vivo. This is consistent with the effects of PP2A inhibitors on glycogenolysis. In addition, S4582 has been shown to reduce the fasting blood glucose level in both human and rat. In the present study, we report that S4582 increases phosphorylase b phosphorylation and reduces the fasting blood glucose level in mice. Furthermore, we show that S4582 increases the phosphorylation of Akt in the skeletal muscle and heart, and activates Akt in a PP2A-dependent manner. This indicates that the PP2A inhibitor,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4583is a drug that inhibits
 
Response: S4583is a drug that inhibits protein kinase C (PKC) and causes prolonged ER stress, we used it to examine the possibility that the induction of ER chaperones, which occurs during ER stress, is caused by the inhibition of PKC. As shown in [Fig. 3A](#f3-ijo-48-06-2277){ref-type="fig"}, treatment of J82 cells with S4583 induced the expression of ER chaperones such as GRP78, GRP94, and calreticulin. In addition, treatment of J82 cells with S4583 induced the expression of ATF6 ([Fig. 3B](#f3-ijo-48-06-2277){ref-type="fig"}). These data suggest that PKC inhibition by S4583 is sufficient to induce ER stress. To further examine whether PKC inhibition is sufficient to induce ER stress, we treated J82 cells with the PK
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4584is a drug that inhibits
 
Response: S4584is a drug that inhibits the key enzyme for the production of cholesterol in the liver.

However, the amount of cholesterol in the blood can be decreased by several other ways besides by blocking cholesterol production. For example, you can also eat foods that are rich in omega-3 fatty acids and can help to reduce the amount of cholesterol in the blood. Omega-3 fatty acids can help the liver to produce more bile acids, which in turn can increase the excretion of cholesterol in the bile.

In fact, there are several ways to reduce cholesterol in the blood and these are the following:

Reduce the intake of cholesterol. It is recommended that you eat a low-cholesterol diet. You can eat foods that are low in cholesterol like eggs, fish, poultry, and foods that are rich in fiber like fruits, vegetables, whole grains, and legumes.

You can eat foods that are low in cholesterol like eggs, fish, poultry
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4585is a drug that inhibits
 
Response: S4585is a drug that inhibits osteoclast-mediated bone resorption by blocking the formation of F-actin rings that form at the ruffled border of osteoclasts.

Treatment with S4585 also led to a reduction in the number of osteoclasts in the metaphysis and diaphysis of the long bones in rats.^[@bibr54-1759091415587502]^ The reduction in osteoclast numbers was associated with a decrease in serum TRACP5b, and the long bones were thinner. In addition, treatment with S4585 also led to a reduction in the number of osteoclasts in the alveolar bone of mice.^[@bibr55-1759091415587502]^ This study suggests that osteoclast activity is a primary target for S4585, as the reduction in osteoclast number was not associated with a change in serum TRACP5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4588is a drug that inhibits
 
Response: S4588is a drug that inhibits the formation of both, superoxide and hydroxyl radicals, as well as the lipid peroxidation of cellular membranes. Therefore, it is an antioxidant, and may also be effective in the treatment of diseases that are associated with the production of oxygen radicals.

This study was funded by grants from the NIH, HL003673, HL065228, HL108859, HL068100, and the R. M. and M. M. Falk Medical Research Trust.

Sixty-six patients with the diagnosis of systemic sclerosis were enrolled in this study. The demographic characteristics of these patients are shown in [Table 1](#tab1){ref-type="table"}. The majority of patients were white, with female predominance (63%). Mean age at diagnosis was 55.7 ± 1.4 years. Most of the patients (81%) had systemic sclerosis of limited cutaneous involvement. Disease duration at time of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4590is a drug that inhibits
 
Response: S4590is a drug that inhibits angiogenesis, induces apoptosis and inhibits proliferation of tumor cells. It is one of the most promising anti-cancer drugs in preclinical and clinical studies. In the present study, we investigated the effects of S4590 on proliferation, apoptosis and motility of HCT116 cells. The results showed that S4590 inhibited proliferation of HCT116 cells in a dose- and time-dependent manner, and the inhibitory effect was stronger than that of oxaliplatin. S4590 also induced apoptosis in HCT116 cells in a dose- and time-dependent manner, and the induction of apoptosis was stronger than that of oxaliplatin. S4590 also inhibited the motility of HCT116 cells in a dose- and time-dependent manner, and the inhibitory effect was stronger than that of oxaliplatin. The data obtained in the present study showed that S4590 inhibited proliferation and induced apoptosis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4591is a drug that inhibits
 
Response: S4591is a drug that inhibits the enzyme choline acetyltransferase, which normally metabolizes the neurotransmitter acetylcholine (ACh) in the brain. As a result, ACh is not removed from the synapse and this neurotransmitter remains available to bind to the ACh receptor, causing an increase in post-synaptic cell activity. It is used in the treatment of movement disorders and as an adjunct to the treatment of schizophrenia. The drug is used in the treatment of Huntington's disease, but the only indications for which it has been approved are those of schizophrenia and the treatment of motor symptoms in Huntington's disease. The only FDA-approved indications for S4591 are in the treatment of schizophrenia and in the treatment of tardive dyskinesia. S4591 has been investigated for other indications as well, but no formal studies have been published.

S4591 can be purchased over the counter in the United States as a racemic mixture of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4592is a drug that inhibits
 
Response: S4592is a drug that inhibits the growth of cells. It was identified by a drug discovery program at the Johns Hopkins School of Medicine in Baltimore. The original lead compound, CX-4945, was selected as a potential cancer treatment for advanced solid tumors based on its activity in a panel of cell lines and because of its selectivity for killing cancer cells.

Research at the time led by Dr. Nasser El-Naggar at the Johns Hopkins School of Medicine in Baltimore, Maryland, discovered that CX-4945 could inhibit the growth of a variety of solid tumor cell lines and showed anti-cancer activity in preclinical models.

The Phase I trial of S4592 in the United States was conducted by an international team of scientists led by Dr. Jeffrey Brown, the JHU-SB Cancer Center’s Scientific Director. The Johns Hopkins team also included Dr. Ian McLeod, the JHU-SB Cancer Center’s Vice
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4593is a drug that inhibits
 
Response: S4593is a drug that inhibits the CYP3A4 enzyme, which is responsible for the metabolism of a number of therapeutic agents, and is often responsible for the elimination of these agents. It has been suggested that S4593 can induce oxidative stress and cause liver damage, as seen in preclinical studies. In the current study, the potential hepatotoxicity of S4593 was investigated in human hepatocytes.

2. Materials and Methods {#sec2-ijms-19-00139}
========================

2.1. Materials {#sec2dot1-ijms-19-00139}
--------------

S4593 was provided by the SRI. DMSO was obtained from VWR International (Preston, UK). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and trypsin-EDTA were obtained from Invitrogen (Paisley,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4594is a drug that inhibits
 
Response: S4594is a drug that inhibits androgen receptor (AR) signaling by binding to the ligand binding domain (LBD) of the receptor and inhibiting androgen binding and activation of the receptor. In vivo studies show that S4594 blocks androgen-induced prostate cancer growth and metastasis in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

The receptor binding assay, performed by competition with tritiated dihydrotestosterone, showed that S4594 has a half-maximal inhibitory concentration (IC50) of 2.1 nM. This is equivalent to the reported binding affinity of other synthetic androgens, including methyltrienolone (R1881) and bicalutamide. S4594 also inhibited the ability of androgens to stimulate reporter gene activity in an androgen-responsive prostate cancer cell line, LNCaP.

A study in castrated mice showed that S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4595is a drug that inhibits
 
Response: S4595is a drug that inhibits P2Y~2~ receptor in macrophages, which reduces their inflammatory response and increases apoptosis. In our previous studies, we have shown that S4595 treatment leads to an increase in apoptosis in the macrophages from mice with PAH and in macrophages from patients with PAH.^[@bib16],\ [@bib17]^ In the current study, we evaluated the effect of S4595 on macrophage migration and polarization *in vitro*.

After S4595 treatment, the macrophages were isolated and their morphology and migration were examined by light microscopy. S4595 treatment did not affect the morphology of the macrophages, but the migration of the macrophages was markedly decreased after S4595 treatment. We also found that S4595 treatment decreased the expression of M1 markers (iNOS, CD80 and CD86) and increased the expression of M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4596is a drug that inhibits
 
Response: S4596is a drug that inhibits the protein translation initiation factor eIF4E. As a consequence of the drug's mechanism of action, mTOR is inhibited, which has led to the development of Sirolimus as an immunosuppressant. Sirolimus has been used to prevent rejection in kidney and liver transplantation.

S4596 is also used to treat peripheral T-cell lymphoma (PTCL).

S4596 has also been tested in phase II trials for treatment of HIV-1 infection, with early evidence that the drug may slow the progression of HIV infection in patients.

S4596 is under development by Celgene as an oral treatment for multiple myeloma and T-cell acute lymphoblastic leukemia (T-ALL).

See also
 mTOR

References

Category:Hepatotoxins
Category:Protein synthesis inhibitors
Category:Thiadiazoles
Category
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4597is a drug that inhibits
 
Response: S4597is a drug that inhibits the activity of phosphodiesterase (PDE), which hydrolyzes the intracellular second messenger cAMP. PDE inhibitors have been used clinically to treat various diseases, including cardiovascular disorders, depression, and diabetes. For example, rolipram, an FDA-approved PDE4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease (COPD) and has been used for the treatment of depression. It has also been shown that cilomilast, an FDA-approved PDE3 inhibitor, has potent anti-inflammatory effects in a rat model of asthma.
S4597is an analog of cilomilast that is effective in the treatment of COPD. S4597 has been shown to be more potent than cilomilast in the treatment of asthma in a mouse model.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4599is a drug that inhibits
 
Response: S4599is a drug that inhibits an enzyme called HDAC, which is a part of a protein called histone deacetylase. It is being used to treat certain kinds of cancer. It is also used to treat rheumatoid arthritis and ulcerative colitis.

**Table 2.3** **Safety information for aripiprazole (Abilify)**

| **Adults** | **Pediatrics**  
---|---|---  
**Immediate-Release Capsules (Abilify)** | **0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg** | **0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg**  
**Orally Disintegrating Tablets (Abilify)** | **5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4600is a drug that inhibits
 
Response: S4600is a drug that inhibits a specific isoform of the transcription factor SREBP-1, resulting in reduced expression of genes for cholesterol biosynthesis and cholesterol uptake. It is the first drug to be used for the treatment of patients with low HDL-C and hypertriglyceridemia.

#### SREBP-1

SREBP-1 is a member of the nuclear receptor superfamily. It is activated by sterols, which are required for the maturation of the SREBP-1 protein. The mature SREBP-1 protein is then translocated to the nucleus, where it acts as a transcription factor.

The first human trial with SREBP-1 inhibitors was published in 2003 \[[@b74-dic.212249]\]. It demonstrated a beneficial effect of this class of drugs on LDL-C and HDL-C. Subsequently, the same group showed that SREBP-1 inhibition decreased the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4601is a drug that inhibits
 
Response: S4601is a drug that inhibits the synthesis of the cell's cholesterol and that has the ability to decrease the body's production of the high-density lipoprotein, a high-density lipoprotein that is good for the body and a low-density lipoprotein, which is bad for the body.

S4577is a drug that is used to treat high blood pressure and certain types of cancer.

S8442is a drug that is used to treat patients with multiple myeloma and certain types of lymphoma.

S2848is a drug that is used to treat children and adults with mild to moderate asthma.

S2247is a drug that is used to treat people with Duchenne muscular dystrophy.

S2240is a drug that is used to treat patients with myelodysplastic syndrome.

S2240is a drug that is used to treat patients with myelodyspl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4602is a drug that inhibits
 
Response: S4602is a drug that inhibits aldose reductase (AR) and prevents the development of diabetic complications. We investigated the effect of S4602 on endothelial function in patients with type 2 diabetes. In a double-blind, placebo-controlled, randomized trial, we studied the effect of S4602 on endothelial function in 22 patients with type 2 diabetes. Patients received oral S4602, 300 mg daily for 4 weeks, followed by a 2-week washout period and 4 weeks of placebo treatment. Endothelial function was assessed by the flow-mediated dilatation (FMD) of the brachial artery using high-resolution ultrasound. The effect of S4602 on blood pressure, HbA1c, and the lipid profile was also investigated. After S4602 treatment, FMD increased from 2.0+/-0.7% to 4.5+/-1.0% (P<0.001). After placebo treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4603is a drug that inhibits
 
Response: S4603is a drug that inhibits phosphodiesterase 4 (PDE4), which is responsible for regulating intracellular cyclic adenosine monophosphate (cAMP) levels in the central nervous system (CNS). The PDE4 inhibitors have been shown to be effective in the treatment of chronic obstructive pulmonary disease (COPD), and there are some anecdotal reports of their efficacy in the treatment of other respiratory disorders. This study was undertaken to assess the safety and efficacy of inhaled PDE4 inhibitor, S-15557, in the treatment of COPD. In a 12-week, multicenter, randomized, double-blind, placebo-controlled trial, PDE4 inhibitor S-15557 was administered at doses of 1, 2, and 4 mg/d to patients with COPD (n = 952). The primary efficacy variable was the mean change from baseline in trough forced expiratory volume in 1 second (FEV1). Secondary
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4604is a drug that inhibits
 
Response: S4604is a drug that inhibits HCMV replication.^[@CR47]^ The compound was used in a dose-escalation study of patients with CMV infection. A total of 10 patients received the drug orally twice daily, and 9 of these patients showed a significant reduction in viral load.^[@CR47]^

Another anti-HCMV drug, GS-5806, was tested in a phase I/II clinical trial.^[@CR48]^ Twenty-four patients were treated with GS-5806 for at least 3 months. Twenty-one of these patients were HCMV-positive. Eight of these patients showed a significant reduction in viral load.^[@CR48]^ In another phase I/II trial, the antiviral effect of GS-5806 was assessed in a total of 33 patients with HCMV retinitis.^[@CR49]^ Twenty-four of these patients were treated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4605is a drug that inhibits
 
Response: S4605is a drug that inhibits PLC-β2 and therefore the synthesis of inositol-1,4,5-trisphosphate (IP3), which is the second messenger for the activation of intracellular calcium release from the ER, and as a consequence inhibits the secretion of insulin. It also blocks the PI3K/Akt/mTOR pathway. There are a number of phase II and III clinical trials underway in different types of cancer ([@b34-etm-0-0-8070]). However, a Phase III clinical trial in patients with PCa ([@b35-etm-0-0-8070]) and a Phase III trial in patients with CRPC ([@b36-etm-0-0-8070]) were terminated in 2011 due to lack of efficacy.

### Targeting the Wnt/β-catenin signaling pathway

Wnt/β-catenin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4606is a drug that inhibits
 
Response: S4606is a drug that inhibits the DNA repair enzyme PARP1. It has been reported to enhance the efficacy of PARP1 inhibitors in cancer cells that are dependent on the activity of PARP1 for survival, but not in cells that are not dependent on PARP1 for survival. Our objective was to investigate the effect of S4606 on cancer cells in which DNA repair by PARP1 is not required for survival. We report here that S4606 is cytotoxic to human cancer cell lines of diverse origin and shows no apparent selectivity for cancer cells over normal cells. We also report that S4606 has cytotoxic effects on cancer cells that are not sensitive to PARP1 inhibitors and that it shows synergistic cytotoxicity with cisplatin. The clinical development of PARP1 inhibitors for cancer treatment is limited by their lack of selectivity for cancer cells. We show that S4606 is a potent inhibitor of PARP1 that is cytotoxic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4609is a drug that inhibits
 
Response: S4609is a drug that inhibits the phosphorylation of ERK by inhibiting the activity of the Ras-Raf-MEK-ERK pathway. We tested whether this drug could reverse the differentiation defect induced by treatment with the anti-diabetic drug pioglitazone. We found that the addition of S4609 alone did not induce differentiation of C3H10T1/2 cells, but did induce differentiation of these cells when they were treated with pioglitazone. Addition of S4609 to the pioglitazone-treated cells resulted in a substantial increase in alkaline phosphatase activity, indicating that the differentiation defect induced by pioglitazone was reversible by treatment with S4609 ([Fig. 4a](#f4){ref-type="fig"}). Similar results were obtained when the cells were treated with S4609 and with a second inhibitor of the Ras-Raf-MEK-ERK pathway
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4610is a drug that inhibits
 
Response: S4610is a drug that inhibits the growth of some kinds of cancer cells by inducing apoptosis and/or suppressing the invasion of cancer cells \[[@B28]\]. In the present study, we first examined the effect of DMSO on the expression of CXCR4, MMP-9 and the phosphorylation of AKT and ERK. DMSO alone did not affect the expression of CXCR4, MMP-9 or the phosphorylation of AKT and ERK in SK-Hep1 cells ([Figure 1](#F1){ref-type="fig"}A,B). In addition, we examined the effect of DMSO on the expression of CXCR4, MMP-9 and the phosphorylation of AKT and ERK in Huh7 cells. The results indicated that DMSO alone did not affect the expression of CXCR4, MMP-9 or the phosphorylation of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4612is a drug that inhibits
 
Response: S4612is a drug that inhibits the binding of thrombin to fibrinogen, resulting in the prevention of the coagulation cascade, and also reduces thrombin-induced platelet aggregation \[[@b17-asj-2018-0123]\]. This is the first case report of a successful surgical treatment for a traumatic fracture of the C2 lamina using rhS4612. The patient recovered well without any complications. This suggests that rhS4612 can be an effective treatment for traumatic fractures of the C2 lamina.

Conclusions
===========

A traumatic fracture of the C2 lamina should be suspected in patients with sudden neck pain following minor trauma, particularly in patients with a history of trauma. CT is the first diagnostic modality for C2 lamina fractures. In patients with a suspected fracture of the C2 lamina, rhS4612 may be an effective treatment.

No potential conflict of interest relevant
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4617is a drug that inhibits
 
Response: S4617is a drug that inhibits angiogenesis and has shown promise in the treatment of cancer. However, its toxicity, particularly at high doses, has limited its therapeutic application. We investigated the antitumor activity of S4617 in a mouse model of prostate cancer, and the potential underlying mechanisms of action. Mice were injected with the androgen-sensitive LNCaP cell line and treated with S4617, a prodrug of S-1. The mice were then sacrificed, and the tumor and serum samples were collected for histological and molecular analyses. We found that the treatment of LNCaP tumors with S4617 inhibited tumor growth, and this effect was associated with reduced expression of angiogenic factors and decreased tumor cell proliferation. We also found that S4617 was metabolized to S-1 in vivo, and the conversion of S4617 to S-1 was mediated by the CYP3A enzyme family. Furthermore, the antitumor activity
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4618is a drug that inhibits
 
Response: S4618is a drug that inhibits the function of CDK7, a key kinase for the initiation of pre-initiation complex assembly at the start of RNA polymerase II transcription ([@B46]). CDK7 inhibitors are being developed as a treatment for lymphomas ([@B48]) and leukaemia ([@B49]), and their role in RNA processing is increasingly appreciated. CDK7 has been shown to phosphorylate the RNA processing factors TAP and p15, and thereby regulate pre-mRNA splicing ([@B50]).

In addition to kinase inhibitors, there are a number of small molecule inhibitors of transcription factors that have been developed for cancer therapy. The BET (bromodomain and extraterminal) family of proteins are transcriptional co-activators that interact with histones, chromatin and the transcription machinery ([@B51]). These proteins are of particular interest as a therapeutic target, as they play a role in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4619is a drug that inhibits
 
Response: S4619is a drug that inhibits the efflux of numerous compounds from the cytoplasm and nucleus. These compounds include those used in chemotherapy, such as vincristine, vinblastine, doxorubicin, daunorubicin, actinomycin, colchicine, etoposide, and cytarabine, and the anti-neoplastic agents mitoxantrone and idarubicin. These agents have also been shown to be useful in the treatment of bacterial infections and in immunosuppression.
The anticancer agents typically include a central nitrogen-containing heterocyclic ring system, typically including a quinoline, isoquinoline, pyridine, pyrimidine, or purine nucleus. In addition, the anticancer agents typically include one or more additional ring systems, including a benzo, furan, thiophene, or benzothiophene ring system. The antic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4623is a drug that inhibits
 
Response: S4623is a drug that inhibits inositol polyphosphate 1-phosphatase, and thereby increases the inositol 1,4,5-trisphosphate concentration, and thereby activates the inositol 1,4,5-trisphosphate-gated Ca2+ channel. The increase in Ca2+ concentration in the endoplasmic reticulum activates calpain, and this, in turn, activates calcineurin. As a result, calcineurin dephosphorylates NFATc2, and thereby the NFATc2 moves from the nucleus to the cytosol. In the cytosol, NFATc2 activates the transcription of the target genes, including the gene for Fas ligand, which induces apoptosis of the cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4624is a drug that inhibits
 
Response: S4624is a drug that inhibits a subset of ATP-binding cassette (ABC) transporters and functions as a potent inhibitor of MDR in MDR cancer cells. This study was designed to investigate the molecular mechanism of S4624-induced apoptosis in the human cancer cell line, SK-OV-3. We show that S4624 induces apoptosis in a time- and dose-dependent manner and that it is associated with the downregulation of the antiapoptotic protein, Bcl-2, but not with the upregulation of the proapoptotic protein, Bax. S4624 induces the release of cytochrome c from mitochondria and the activation of caspase-3, -8, and -9. Furthermore, S4624 induced the cleavage of poly (ADP-ribose) polymerase (PARP) and the activation of c-Jun N-terminal kinase (JNK). These data suggest that S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4625is a drug that inhibits
 
Response: S4625is a drug that inhibits fatty acid oxidation and that, when used in combination with 2-deoxyglucose (2DG), can selectively kill cancer cells by blocking glucose metabolism \[[@RSTB20180319C43]\]. These findings were not expected because neither drug alone is able to induce cell death. Thus, the mechanism of cell death induced by the combination of these drugs is a mystery. By coupling ^13^C metabolic flux analysis with a ^13^C-labeling experiment, the authors were able to show that CPT-S4625 treatment leads to a loss of the TCA cycle flux. The treatment also led to an increase in the fatty acid oxidation flux. To determine the metabolic changes leading to cell death, the authors performed a flux analysis in the presence of 2DG. The 2DG was able to block the CPT-S4625-induced increase in fatty acid oxidation, suggesting that this pathway is required
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4626is a drug that inhibits
 
Response: S4626is a drug that inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII) by binding to the catalytic site. We have studied the interaction of T4626 with calmodulin (CaM) using stopped-flow fluorescence and electrospray ionization mass spectrometry (ESI-MS). The results indicate that T4626 binds to CaM with a binding constant of 5.4 microM and that the stoichiometry of the complex is 1:1. ESI-MS also indicates that T4626 binds to CaM at the C-terminal lobe of CaM, while fluorescence measurements indicate that the T4626-CaM complex is located on the N-terminal lobe of CaM. The results suggest that T4626 binds to CaM in a similar manner as calmodulin antagonists such as calmidazolium. The binding of T4626 to CaM inhibits the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4628is a drug that inhibits
 
Response: S4628is a drug that inhibits DYRK1A activity and therefore has the potential to treat neurodegenerative disorders associated with DYRK1A dysfunction, including Huntington's disease.

M.B. is the recipient of a Fellowship from the Portuguese Foundation for Science and Technology (FCT) and FEDER (Fundo Europeu de Desenvolvimento Regional) under the scope of the project PTDC/SAU-TOX/113141/2009 and the European Union under the scope of the project PIRSES-GA-2011-290021. M.S.P.S. is supported by a PhD fellowship from FCT and by a postdoctoral fellowship from the Portuguese Foundation for Science and Technology (FCT).

**Author Contributions** M.B., M.S.P.S. and J.M.L.M. designed the study, analyzed the data and wrote the manuscript. M.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4629is a drug that inhibits
 
Response: S4629is a drug that inhibits the accumulation of serotonin and dopamine in the brain.

s4629: role in mental health

s4629 is used for the treatment of depression. It has been used as an antidepressant in Japan and China.

What is s4629?

s4629 is a drug that inhibits the accumulation of serotonin and dopamine in the brain. It is used for the treatment of depression.

How does s4629 work?

It is not known how s4629 works.

What does s4629 do?

s4629 is a drug that inhibits the accumulation of serotonin and dopamine in the brain.

s4629: side effects

The side effects of s4629 are unknown.

s4629: overdose

An overdose of s4629 is not known.

What is the risk with s4629?

The risk of a serious overdose is not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4630is a drug that inhibits
 
Response: S4630is a drug that inhibits NF-κB signaling, and it can be used to treat a variety of diseases including cancer and chronic inflammation. As a multi-functional drug, S4630 can inhibit tumor growth, and it has been reported to induce apoptosis in cancer cells by inhibiting the expression of anti-apoptotic genes such as *Bcl-2*, *Bcl-xL*, *Mcl-1*, and *survivin*. In addition, S4630 can inhibit tumor angiogenesis by inhibiting the expression of angiogenic factors such as VEGF and MMPs \[[@B23-ijms-18-01991]\]. In this study, we observed that S4630 can suppress the growth of the CRC cell lines DLD-1 and HCT116 in a dose-dependent manner. This result suggests that S4630 is an effective drug for CRC.

The PI3K/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4632is a drug that inhibits
 
Response: S4632is a drug that inhibits the activity of the enzyme 5-lipoxygenase.5-LOX is responsible for the formation of leukotrienes, which have been shown to have an inflammatory role in a number of different disease states.

**5-LOX**

5-LOX is found in the cytoplasm and is associated with the endoplasmic reticulum. It has a key role in inflammation. It is present in the cytosol of monocytes and neutrophils and in the cytosol and nuclei of a variety of other cell types. It is also found in the vascular endothelium, epithelium, and the interstitium of the lung.5-LOX is present in the cytoplasm and the nuclei of most cell types. It is an intracellular enzyme that is present in the cytoplasm of leukocytes and other cells and it has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4633is a drug that inhibits
 
Response: S4633is a drug that inhibits F-actin polymerization. We found that it does not have any effect on actin polymerization, and that the drug does not inhibit H-ferritin assembly, although it slightly enhances it. These results indicate that the drug does not inhibit the polymerization of actin, and suggest that H-ferritin assembles by a mechanism that is different from that of F-actin.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4634is a drug that inhibits
 
Response: S4634is a drug that inhibits the acetylation of tubulin. This drug is currently used in the clinic for the treatment of fungal infections, however, it also induces apoptosis in various cancer cell lines. In this study, we evaluated the antitumor effects of S4634 on prostate cancer cell lines. S4634 treatment resulted in decreased viability of PC-3, DU145, LNCaP, and C4-2 cells. This drug also induced apoptosis, as indicated by an increase in the number of cells with a sub-G1 DNA content and by the activation of caspase-3 and caspase-9. S4634 treatment resulted in a decrease in phosphorylation of Akt, mTOR, and S6K1. This drug also inhibited the activation of cyclin D1 and PCNA. In conclusion, our data suggest that S4634 inhibits the growth of prostate cancer cells through the inhibition of Akt/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4635is a drug that inhibits
 
Response: S4635is a drug that inhibits the production of IGF-1 and is the first small molecule IGF-1 receptor antagonist to be developed. It has been tested in various Phase I and II trials in cancer patients with IGF-1R-expressing solid tumors and is currently being tested in Phase III trials in prostate cancer and colorectal cancer.

References

External links
 
 
 

Category:Experimental cancer drugs
Category:Small molecule drugs
Category:Merck brands
Category:IGF-1 receptor antagonists
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4636is a drug that inhibits
 
Response: S4636is a drug that inhibits cyclin-dependent kinases. It is currently in phase II clinical trials for the treatment of cancer. To date, the anticancer activity of S4636 has been demonstrated in a variety of tumor types. In this study, we show that S4636 exhibits potent antitumor activity in a variety of cell lines derived from a range of solid tumors, including those derived from the lung, breast, colon, and pancreas. S4636 treatment results in significant induction of G1 arrest and apoptosis in a panel of tumor cell lines, and is more effective in tumor cell lines that are p53-deficient. The drug does not appear to be genotoxic as determined by colony-forming assays and chromosomal analysis. Finally, in vivo studies show that S4636 treatment results in tumor regression in a xenograft model. Taken together, these data suggest that S4636 has potential as a new anticancer drug.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4637is a drug that inhibits
 
Response: S4637is a drug that inhibits proliferation and induces apoptosis in cancer cells. It has been approved for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in Japan, and for the treatment of relapsed/refractory adult AML and MDS in the United States.^[@bib1],\ [@bib2]^ It is an inhibitor of the Src family kinases, including Src, Fyn and Lyn. Src is a non-receptor tyrosine kinase and regulates multiple cellular processes, including cell proliferation, migration and survival.^[@bib3],\ [@bib4]^ Previous studies have shown that Src is overexpressed in various types of cancer, including AML,^[@bib5],\ [@bib6],\ [@bib7],\ [@
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4638is a drug that inhibits
 
Response: S4638is a drug that inhibits the transcriptional activity of STAT3 and the expression of genes that are activated by STAT3. S4638 is a potent inhibitor of STAT3 activity and may represent a novel therapy for the treatment of cancers that have constitutive STAT3 activation.

PRELIMINARY DATA
================

The following article has been published as part of *Molecular Oncology* Volume 51 Supplement 2, 2013: Selected articles from the 9th International Congress of Chemotherapy. The full contents of the supplement are available online at <http://www.molonc.org/supplements/51/S2>.

We thank Dr. Jianfeng Zhang and Dr. Jianrong Li from The University of Texas MD Anderson Cancer Center for providing the TC71 and TC32 cells, respectively. This work was supported by grants from the National Natural Science Foundation of China (81072048 and 81272408) and the Natural
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4639is a drug that inhibits
 
Response: S4639is a drug that inhibits thymidylate synthase and thus induces growth arrest in cells with a defective mismatch repair system. Its efficacy is evaluated in the treatment of advanced solid tumors that are mutated for the mismatch repair system.^[@bibr71-1758835920922055]^ Clinical trials with this drug are ongoing.

Oral S-1, an oral fluoropyrimidine, is an antimetabolite drug. It combines 5-FU with a combination of a thymidylate synthase inhibitor, oxaliplatin, and a folate antagonist, l-leucovorin. This combination acts synergistically in inhibiting cell proliferation, inducing apoptosis, and impairing DNA repair.^[@bibr72-1758835920922055]^ S-1 is approved for the treatment of gastric cancer and other solid tumors.^[@bibr73-175883592092
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4640is a drug that inhibits
 
Response: S4640is a drug that inhibits phosphatidylinositol 3-kinase (PI3K), a protein that is a major player in the growth, survival, and motility of cancer cells. The drug has shown promise in a number of cancers, including breast cancer, melanoma, and pancreatic cancer. To help researchers better understand the potential of this drug in cancer treatment, the NCI has tested its effect in hundreds of cell lines and in a large number of cancer patients. In this review, we highlight what is known about S4640, including its use in patients, and we outline the ongoing and future studies of this drug in breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4641is a drug that inhibits
 
Response: S4641is a drug that inhibits AURKB activity and thereby disrupts mitosis and cell proliferation ([@bib24]). We observed that, although AZD1152 did not significantly inhibit cell proliferation, it caused the accumulation of cells in G2/M, which correlated with the induction of phosphorylated histone H3 (pH3), an indicator of mitotic arrest ([Figure 5C](#fig5){ref-type="fig"}). To examine whether the accumulation of pH3-positive cells was due to mitotic arrest, we performed flow cytometry analyses using pH3 and phosphorylated histone H3 serine 10 (pH3S10) antibodies. The percentage of pH3S10-positive cells increased in a time-dependent manner, reaching more than 60% at 12 hr after the treatment ([Figure 5D](#fig5){ref-type="fig"}). Furthermore, we observed that AZD1152 induced apoptosis in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4646is a drug that inhibits
 
Response: S4646is a drug that inhibits the renin-angiotensin system (RAS) and is used to treat hypertension. In addition to its therapeutic effect, it has been suggested that S4646is effective for the treatment of several diseases, including obesity, type 2 diabetes, and neurodegenerative disorders. However, its mechanism of action remains unknown. In the present study, we show that S4646significantly improves the hyperphagia and the body weight gain of leptin-deficient (ob/ob) mice, and that this effect is blocked by pretreatment with an angiotensin receptor type 1 (AT1) antagonist. Consistent with this observation, S4646increased blood pressure in normal mice. In addition, S4646increased blood pressure in AT1 receptor-deficient (AT1-/-) mice. In ob/ob mice, S4646also increased the blood pressure in a dose-dependent manner, although the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4647is a drug that inhibits
 
Response: S4647is a drug that inhibits aldose reductase (AR) in cells. By inhibiting AR, it decreases the levels of GSH in cells. Since GSH is required for cells to maintain the redox status of their membranes, the membrane's lipid peroxidation is prevented. The overall effect is to decrease the rate of the accumulation of lipid peroxides in cells.

The compound was originally discovered in the course of a search for AR inhibitors. The molecule was a series of aldose reductase inhibitors, of which anhydro derivatives of an ethylcarbamoyl-amino group and an ethylthio group. However, the compound was inactive in a human clinical trial and was subsequently abandoned.

References

Category:Amines
Category:Carbamates
Category:Primary alcohols
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4649is a drug that inhibits
 
Response: S4649is a drug that inhibits cell division in a variety of cancers. It has been investigated in clinical trials for a variety of cancer types. We sought to investigate the role of P4S4649 in oral cancer and to explore the mechanism of action. The effect of P4S4649 on cell proliferation, migration, invasion, and apoptosis in oral cancer cells was determined by cell proliferation assay, wound healing assay, Transwell invasion assay, and flow cytometry, respectively. The role of P4S4649 in cancer cells was investigated by silencing the expression of cyclin-dependent kinase 6 (CDK6) with siRNA. The effect of P4S4649 on the CDK6-dependent pathway was investigated by Western blot analysis. We demonstrated that P4S4649 inhibited cell proliferation, migration, and invasion in oral cancer cells. We also found that P4S4649 induced apoptosis in oral cancer cells. Moreover, we showed that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4650is a drug that inhibits
 
Response: S4650is a drug that inhibits TNF-α-induced ICAM-1 expression in the C6 glioma cell line. The inhibitory effect of TNF-α on ICAM-1 expression in the C6 cell line is time and dose dependent, and TNF-α inhibition by TNF-αS4650 is accompanied by a reduction in ICAM-1 protein expression. In addition, TNF-αS4650 also inhibited ICAM-1 expression induced by TNF-α in the U-373MG glioma cell line. Our results demonstrate that TNF-αS4650 is a potent inhibitor of TNF-α-induced ICAM-1 expression in the glioma cell line.

C6 cells were incubated with the ICAM-1 antibody for 1 hour before the addition of TNF-α. The cells were then incubated for 4 hours in the presence of TNF-α. ICAM
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4651is a drug that inhibits
 
Response: S4651is a drug that inhibits the adenosine-sensitive potassium channels (A-K(+)channels) in the plasma membrane of cardiac myocytes. However, its cardioprotective effect against ischemia/reperfusion (I/R) injury remains controversial. We examined whether and how S4651 improves the contractile function of the left ventricle (LV) and whether it exerts its cardioprotective effect through the activation of mitochondrial adenosine triphosphate (ATP) production in isolated mouse hearts after global I/R injury. Isolated hearts were subjected to 20-min regional ischemia and 60-min reperfusion. Infarct size, LVDP, LVEDP, and functional recovery after I/R injury were evaluated. S4651 was infused into the coronary circulation 5 min before the onset of ischemia. The effects of S4651 on the ATP level in the LV were examined.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4652is a drug that inhibits
 
Response: S4652is a drug that inhibits the P-gp efflux pump and increases the intracellular concentration of digoxin, a cardiotoxic drug. It has been approved by the Food and Drug Administration for the treatment of life-threatening digitalis intoxication in children and adolescents, and in adults with congestive heart failure (CHF). We examined the effect of S-1275 on digoxin disposition and on the electrocardiogram (ECG) in adult dogs with CHF. Digoxin, 10 microg/kg, was administered intravenously to 18-hour fasted dogs, followed by an infusion of either S-1275 (0.3 mg/kg/hr) or placebo (control). Plasma concentrations of digoxin were determined by a radioimmunoassay. The ECG was monitored continuously. During placebo, the digoxin-induced QTc interval lengthened from 0.42 +/- 0.03 to 0.52 +/- 0.03
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4653is a drug that inhibits
 
Response: S4653is a drug that inhibits the mitotic kinase Aurora B (polo-like kinase 1) and has been used in cancer research. We examined its effects on the G2/M transition in PtK2 cells. We found that S4653 blocks G2/M transition with a half-maximal concentration of 6.8 nM, which is comparable to the EC50 for Aurora B inhibition in vitro. S4653 caused metaphase arrest and polyploidy with increasing concentrations. A combination of S4653 and nocodazole produced a synergistic effect. The effect of S4653 was irreversible, and cells could not progress into G1 or G2. Cell cycle analysis revealed that S4653 induced mitotic arrest by decreasing the levels of cyclin B1 and phosphorylated histone H3. The protein levels of cdc25C and cdc2 were decreased by S4653, and cdc25C was localized
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4654is a drug that inhibits
 
Response: S4654is a drug that inhibits growth of PTC cells. (**A**) Chemical structure of S4654. (**B**) Viability of TPC1 cells treated with S4654 at various concentrations for 72 h. (**C**) Viability of Nthy-ori-3-1 cells treated with S4654 at various concentrations for 72 h. (**D**) Effects of S4654 on PTC cell viability in the presence or absence of the MEK inhibitor PD0325901 (10 μM). (**E**) Effects of S4654 on PTC cell viability in the presence or absence of the PI3K inhibitor LY294002 (10 μM). (**F**) Effects of S4654 on PTC cell viability in the presence or absence of the AKT inhibitor MK-2206 (1 μM). (**G**) Effects of S4654 on PTC cell viability in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4655is a drug that inhibits
 
Response: S4655is a drug that inhibits glycogenolysis, preventing glucose from being released from the liver, which results in increased glucose in the blood. This in turn results in an increased insulin response to this increased glucose, which can cause severe hypoglycemia. S4655 is a drug that causes a big increase in insulin levels, and then a big drop in blood glucose levels, and this can lead to a coma.

This study looked at the effect of S4655 on people who had had a coma. The results showed that people who had had a coma had lower blood glucose levels after receiving S4655 than they did before receiving S4655. In fact, the results showed that there was no difference in blood glucose levels between people who had had a coma and people who had not had a coma before they received S4655.

The researchers found that people who had had a coma were more sensitive to the effects of S4655 than people who had not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4656is a drug that inhibits
 
Response: S4656is a drug that inhibits the transport of cholesterol and fatty acids from the peripheral tissues into the liver and also inhibits the transport of fatty acids from the liver into peripheral tissues. Because it is believed that atherosclerosis is caused by the accumulation of cholesterol and fatty acids in the arterial wall, the action of S4656is to inhibit the transport of cholesterol and fatty acids into the liver and from the liver into peripheral tissues should prevent the accumulation of cholesterol and fatty acids in the arterial wall and should inhibit the formation of atherosclerotic plaques.
In addition to its effects on the transport of cholesterol and fatty acids, S4656is is believed to be a dipeptidyl peptidase IV (DPP-IV) inhibitor. The inhibition of DPP-IV should prevent the rapid degradation of incretins and should thereby increase the incretin effect. The incretin effect is the increase in insulin secretion and the inhibition of glucagon secretion that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4657is a drug that inhibits
 
Response: S4657is a drug that inhibits the proliferation of androgen-dependent PCa cells by targeting androgen receptor (AR) and the kinase B-Raf, which promotes PCa cell survival and growth \[[@B1]\]. In patients with castration-resistant PCa (CRPC), S4657 is an approved therapy and the first AR inhibitor to demonstrate a significant survival benefit in a randomized phase III trial. However, its activity is not as robust as first-generation AR inhibitors such as enzalutamide, and it also lacks anti-androgenic activity. Thus, S4657 treatment leads to increased AR expression and resistance to further AR inhibition \[[@B2]\].

In the clinical setting, the progression of PCa is characterized by the development of new lesions in the bone, and this is often accompanied by bone metastases. A recently published study revealed that the majority of patients with CRPC have bone metastases at the time
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4658is a drug that inhibits
 
Response: S4658is a drug that inhibits the function of hMLH1. Here, we examined the ability of C4658 to induce and inhibit the mismatch repair (MMR) system. We found that the cytotoxicity of C4658 is reduced in hMLH1-deficient HCT116 and LS174T colon cancer cells, which express high levels of the MMR protein hMSH2. Moreover, the cytotoxicity of C4658 is not affected by p53 or p21 expression in these cells. C4658 is not cytotoxic to wild-type HCT116 cells. To further evaluate the effect of C4658 on MMR, we examined its ability to inhibit the growth of several hMLH1-deficient human tumor cell lines, which are MMR-deficient and have been selected for resistance to MMR inhibitors. We found that C4658 induces apoptosis in hMLH1-deficient cells that are resistant to the MMR inhibitor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4660is a drug that inhibits
 
Response: S4660is a drug that inhibits platelet aggregation by selectively targeting GPVI, a key platelet receptor involved in platelet activation and thrombus formation. An ongoing clinical trial is evaluating the use of sutimlimab for treatment of acute coronary syndromes.

Interactions 

S4660is a humanized IgG1 monoclonal antibody that binds to GPVI. It has been shown to inhibit platelet aggregation by targeting the extracellular domain of GPVI, which results in the loss of function of GPVI.

Mechanism of action 

S4660is a selective antagonist of GPVI that inhibits platelet aggregation and thrombus formation.

History 

S4660is being developed by Soligenix Inc. as a potential treatment for acute coronary syndromes.

References

External links 
 

Category:Antibodies
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4661is a drug that inhibits
 
Response: S4661is a drug that inhibits the Ras-Raf-MEK-ERK cascade and is being developed as an anti-cancer drug. In this study, we investigated the effects of BISP-S4661 on cancer cell proliferation, apoptosis, and gene expression. BISP-S4661 was more effective in inducing apoptosis than in inhibiting cell proliferation in cancer cell lines, such as human pancreatic cancer cell lines. BISP-S4661 inhibited cell proliferation by decreasing the expression of the anti-apoptotic proteins Bcl-2 and survivin. BISP-S4661 increased the expression of p53 and Bax, and the Bax/Bcl-2 ratio. BISP-S4661 also induced the expression of several pro-apoptotic genes, such as caspase-3, caspase-8, and caspase-9. Furthermore, BISP-S466
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4663is a drug that inhibits
 
Response: S4663is a drug that inhibits the growth of cancer cells. However, its mechanisms of action are not fully understood. Here, we report that S4663 inhibits the phosphorylation of the RAS oncogene, which results in the suppression of the PI3K/AKT and RAS/ERK signaling pathways. We show that S4663 suppressed the proliferation of several cancer cell lines, including lung cancer cells. We also show that S4663 induced G1-phase cell cycle arrest in cancer cells. Further analysis showed that S4663 suppressed the phosphorylation of AKT and ERK1/2 in cancer cells. These results suggest that S4663 suppresses the proliferation of cancer cells by inhibiting the activation of RAS and the downstream signaling pathways.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4664is a drug that inhibits
 
Response: S4664is a drug that inhibits the activity of a key enzyme involved in the growth of human breast cancer cells. A phase I clinical trial was conducted to determine the maximum tolerated dose and safety of S4664 in patients with advanced solid tumors. In a dose-escalation study, five patients were treated with S4664 daily for 14 days followed by a 14-day rest period. The maximum tolerated dose of S4664 was 25 mg/m2/day, which was well tolerated, and the most common adverse events were mild to moderate diarrhea, nausea, and alopecia. No dose-limiting toxicities were observed. In a dose-expansion study, 18 patients with metastatic breast cancer were treated with S4664 at 25 mg/m2/day. Four patients achieved stable disease for > or =4 months, and 1 patient had a partial response lasting > or =12 months. A phase II study is underway to determine the efficacy of S46
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4665is a drug that inhibits
 
Response: S4665is a drug that inhibits cell proliferation and induces cell cycle arrest at G1 phase. S4665 also suppresses cell migration and invasion. We recently demonstrated that S4665 inhibited the tumor growth of murine breast cancer cells implanted in the mammary glands of immunocompetent mice \[[@B14-ijms-20-00140]\]. We also showed that S4665 induced apoptosis and cell cycle arrest in the human breast cancer cell line MCF7 \[[@B12-ijms-20-00140]\]. In the present study, we evaluated the effect of S4665 on cell proliferation, apoptosis, cell cycle, and migration and invasion in two human gastric cancer cell lines, SNU-5 and SNU-16.

In our previous study, we demonstrated that S4665 inhibited the tumor growth of human breast cancer cells implanted in the mammary glands of immunocompetent mice \[[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4667is a drug that inhibits
 
Response: S4667is a drug that inhibits an enzyme called poly(ADP-ribose) polymerase (PARP). This enzyme helps repair damaged DNA. There is evidence that it may help repair damage to brain cells. It may also help to prevent inflammation.

Tigecycline (TIG) is an antibiotic used to treat serious infections caused by bacteria. It is administered as a tablet and may be given intravenously.

Clinical Trials

More information about this trial is available here.

News and Resources

More information about this trial is available here.

Side effects and safety

Side effects of ciprofloxacin (CIP)

Side effects of the active ingredient in ciprofloxacin (CIP) are usually mild and temporary. They may include:

Irritation and inflammation of the eyes, skin, mouth, and/or digestive tract.

Soreness
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4668is a drug that inhibits
 
Response: S4668is a drug that inhibits the formation of GSK3 and has been shown to protect against both neuronal and vascular death (Chen et al., [@B20]). We show that AAV2/2-GFP-S4668 treatment reduces the level of insoluble tau in the P301L mutant mouse brain and also decreases the accumulation of the truncated form of the tau protein (Tau441). Tau441 is the truncated form of the tau protein, containing the microtubule binding domain, and is believed to contribute to the formation of neurofibrillary tangles in AD (Mishra et al., [@B69]).

We also show that the S4668 compound decreases the phosphorylation of tau at multiple AD-associated sites. In particular, we found that the phosphorylation of Ser262, Ser396, and Ser396/404 were decreased in the P301L tau transgenic mice treated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4669is a drug that inhibits
 
Response: S4669is a drug that inhibits thrombin (a serine protease) and prevents the conversion of fibrinogen to fibrin (fibrin formation). This reduces the formation of clots in the blood and thus prevents the formation of thrombi. It is used to treat patients with venous thromboembolism (deep vein thrombosis or pulmonary embolism). It can be used in combination with low molecular weight heparin to treat deep vein thrombosis and pulmonary embolism.

This medicine is used in adults and children of all ages. It is used for short term treatment (5 days to 6 weeks) and long term treatment (longer than 6 weeks).

What are the possible side effects of S4669is?

S4669is can cause side effects, but they are not common. The most common side effects are:

There are other side effects not listed here.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4671is a drug that inhibits
 
Response: S4671is a drug that inhibits the production of arachidonic acid by blocking phospholipase A2 (PLA2). It is used for the treatment of some types of colitis and is licensed for this indication in Australia, the United States, and Canada. The objectives of this study were to evaluate the efficacy and safety of S4671 in Crohn's disease (CD) and ulcerative colitis (UC). The study was a double-blind, placebo-controlled, randomized withdrawal trial. Patients who had received at least 1 month of open-label S4671 in a previous study were randomized to receive open-label S4671 for 3 months. Thereafter, patients who were responders to open-label S4671 were randomized to receive either open-label S4671 or placebo for another 3 months. The primary outcome measure was clinical response, defined as a reduction in Crohn's Disease Activity Index (CDAI) score of at least 70 points
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4673is a drug that inhibits
 
Response: S4673is a drug that inhibits the activity of P-glycoprotein (P-gp) and thereby increases the absorption of P-gp substrates such as digoxin, cyclosporin A, and paclitaxel. The drug is a potent inhibitor of P-gp and is administered orally to enhance the bioavailability of these P-gp substrates. S-4673 also enhances the absorption of fenofibrate and rosuvastatin. The drug is a non-peptide P-gp inhibitor and is orally administered.

Mechanism of action

S-4673 is a non-peptide inhibitor of P-glycoprotein (P-gp) that acts as an allosteric modulator of the transport function of P-gp. S-4673 is a highly potent inhibitor of P-gp and is a potent and selective inhibitor of P-gp with a Ki of 0.16 nM. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4674is a drug that inhibits
 
Response: S4674is a drug that inhibits the enzyme acetylcholinesterase, and is used to treat various forms of dementia and Alzheimer's disease. It is approved by the FDA for use in patients with mild to moderate Alzheimer's disease and for the treatment of Alzheimer's disease in patients with mild to moderate dementia.

Brief description of the method

Treatment time

The recommended starting dose of ropinirole is 0.25 mg three times daily. The dose should be increased to 0.5 mg three times daily after 3 days. The dose should be increased to 1 mg three times daily after 7 days. The dose should be increased to 2 mg three times daily after 14 days. The dose should be increased to 3 mg three times daily after 28 days.

For maintenance therapy, the recommended dose is 1 mg three times daily. The dose may be increased to 2 mg three times daily if there is a clinical need.

Storage

Store
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4675is a drug that inhibits
 
Response: S4675is a drug that inhibits, or at least slows down, the activity of the protein kinase C (PKC) and induces apoptosis of the cells. As such, it has been tested in the treatment of many diseases, such as cancer, inflammatory diseases, metabolic disorders, autoimmune diseases, cardiovascular diseases, central nervous system diseases, gastrointestinal diseases, and pulmonary diseases. The potential use of S4675 in the treatment of human cancer has been investigated in several phase I clinical trials. A number of studies have demonstrated that the apoptosis induced by S4675 is a cell type-specific process.

We have shown that S4675 inhibits the growth of human tumor cell lines in culture, as well as the growth of tumors in nude mice. The anti-tumor activity of S4675 was found to be dependent on its ability to inhibit PKC. In addition, S4675 has been shown to induce apoptosis in human tumor cells in culture. These effects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4678is a drug that inhibits
 
Response: S4678is a drug that inhibits the phosphorylation of eIF4E. It has been used in phase I clinical trials in patients with advanced cancer. In this study, we have used a lung cancer cell line (A549) to examine the effects of GQS4678 on cell growth, apoptosis and cell cycle distribution. In the present study, GQS4678 was found to inhibit the growth of A549 cells in a dose-dependent manner, with an IC50 of 0.8μM. GQS4678-induced cell growth inhibition was associated with G1 cell cycle arrest and increased apoptosis. GQS4678-induced apoptosis was accompanied by increased levels of the pro-apoptotic proteins Bax and Bad, decreased levels of the anti-apoptotic protein Bcl-2 and cleavage of caspase-9 and caspase-3. GQS4678-induced cell cycle arrest was associated
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4679is a drug that inhibits
 
Response: S4679is a drug that inhibits histone deacetylase and leads to chromatin relaxation. A decrease in HDAC activity increases the sensitivity of CLL cells to certain chemotherapeutic agents. Combination treatment of CLL cells with R-S4679 and fludarabine (Flu) has been shown to be synergistic. A phase I study of R-S4679 and Flu in relapsed/refractory CLL is underway.

**Methods**

Fifty-six patients were treated with R-S4679 at doses ranging from 1 to 6 mg/m^2^. Blood and bone marrow samples were collected for pharmacokinetic analysis.

**Results**

Pharmacokinetic studies were performed in 54 patients (27 treated with R-S4679 alone and 27 with R-S4679 and Flu). R-S4679 was rapidly absorbed and showed linear pharmacokinetics. R-S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4680is a drug that inhibits
 
Response: S4680is a drug that inhibits the *in vitro* replication of SARS-CoV in Vero E6 cells with an EC~50~ of 7.7 μM ([@B21]). It also has activity against other human coronaviruses, including 229E, OC43, and NL63 ([@B22], [@B23]). It was originally isolated from the roots of *Sophora flavescens* Ait. (Leguminosae), a Chinese medicinal herb ([@B24]). Its antiviral mechanism of action is unknown.

###### 

**Amino acid substitutions in the Spike glycoprotein (S) protein of the SARS-CoV**.

  **Strain**                                           
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4682is a drug that inhibits
 
Response: S4682is a drug that inhibits vascular smooth muscle cell proliferation by blocking a transcriptional factor, serum response factor (SRF), that controls the expression of immediate early genes, c-fos, and c-myc. It is an extremely selective, noncompetitive inhibitor of SRF and is a useful tool for studying the role of SRF in vascular smooth muscle cell proliferation and gene expression.

It is also a very potent inhibitor of platelet aggregation in platelet-rich plasma, platelet-activating factor-induced aggregation, and collagen-induced aggregation, and has potent inhibitory effects on arachidonic acid-, ADP-, and epinephrine-induced aggregation in washed rabbit platelets. In addition, S-4682 inhibited the release of [3H]5-HT and [3H]dopamine from isolated rabbit platelets.

S-4682 is a potent inhibitor of thrombin-induced platelet aggregation in platelet
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4683is a drug that inhibits
 
Response: S4683is a drug that inhibits a protein kinase called glycogen synthase kinase-3 (GSK-3). GSK-3 is a protein kinase that is a component of the signal transduction pathway that leads to the activation of certain transcription factors that regulate gene expression.
S6363is a drug that inhibits a protein kinase called protein kinase CK2. CK2 is a protein kinase that plays an important role in the cell cycle. It phosphorylates a number of substrates that are involved in a wide variety of biological processes.

References 

Category:Antineoplastic and immunomodulating drugs
Category:Hepatology
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4684is a drug that inhibits
 
Response: S4684is a drug that inhibits ABL kinase, a non-receptor tyrosine kinase that regulates the growth and survival of leukemic cells.^[@bib1]^ It was originally developed to treat chronic myeloid leukemia (CML), but its potential in treating acute myeloid leukemia (AML) is also being explored. In this issue of the *Journal of Hematology and Oncology*, Guan *et al.*^[@bib2]^ present the results of a phase I trial of S-IBT, a 2-week infusion of S-IBT, in combination with standard-of-care induction chemotherapy in patients with newly diagnosed AML. They found that S-IBT can be safely administered with chemotherapy, and it can be given as a short infusion (100 mg/m^2^) and without prophylactic growth factors.

S-IBT was originally
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4685is a drug that inhibits
 
Response: S4685is a drug that inhibits inositol-requiring enzyme 1 (IRE1), which is a key player in the unfolded protein response (UPR). However, the precise mechanism by which IRE1 regulates the UPR remains to be elucidated. In this study, we show that, in cells that have an activated UPR, IRE1 is located in the cytoplasm, rather than the nucleus, where it functions. IRE1 interacts with the tumour necrosis factor receptor-associated factor 2 (TRAF2), which is known to function as a scaffold protein. Furthermore, IRE1 phosphorylates TRAF2 at serine 332, which induces its ubiquitination and degradation. Consequently, TRAF2 is downregulated in cells that have activated the UPR. IRE1 also binds to the apoptosis signal-regulating kinase 1 (ASK1), which is a MAP kinase kinase kinase (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4686is a drug that inhibits
 
Response: S4686is a drug that inhibits farnesyltransferase, the enzyme that transfers the farnesyl group to Ras. Ras is a critical part of the signal transduction pathway, and Ras mutations are a common cause of cancer. The drug S4686 causes tumor regression in mouse models of a wide range of cancers. Tumors that are resistant to S4686 can be treated with the drug lonafarnib, a structurally related farnesyltransferase inhibitor that is being tested in clinical trials.

As cancer cells develop resistance to Ras inhibitors, it is important to identify additional targets that are effective in tumors that have developed resistance to Ras inhibitors.

S4686 and lonafarnib cause profound downregulation of ERK1/2 and AKT in cells that have become resistant to Ras inhibitors. These pathways play a role in regulating cell proliferation and survival. By reducing the activity of these pathways, the drug combination causes increased apoptosis in tumor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4689is a drug that inhibits
 
Response: S4689is a drug that inhibits eosinophil adhesion to vascular endothelium. This is a novel anti-inflammatory agent that may be useful in the treatment of inflammatory disorders including asthma.

Abstract

A family of four glycoproteins, including CD23, is expressed on the surface of B cells. The CD23 protein is the low-affinity receptor for IgE and is a marker for mature B cells. CD23 is a type II membrane protein that lacks an intracellular domain and is synthesized as a single chain glycoprotein of 233 amino acids. The primary structure of CD23 is highly conserved and similar to that of the leukocyte adhesion receptors. We recently described the cloning of CD23 from a human B-cell cDNA library and demonstrated that the CD23 cDNA is identical to the low-affinity receptor for IgE (Fcepsilon RII) of the murine B cell line B10
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4690is a drug that inhibits
 
Response: S4690is a drug that inhibits, the activity of human prolyl 4-hydroxylase (PH4H), an enzyme that is responsible for the post-translational modification of the collagenous matrix proteins. Collagen is the major component of the ECM and, therefore, is a key component of the structural integrity of tissues. Collagen and its cross-linking with other ECM proteins is critical to maintaining the structural integrity of the ECM, as collagen molecules are the most abundant ECM proteins. The activity of PH4H is essential to the biosynthesis of collagen, which is required for tissue growth, maintenance, and repair. As a result, PH4H inhibition results in a reduction in the production of ECM proteins, which in turn leads to a reduction in the structural integrity of tissues. The structural integrity of tissues is a critical factor in the healing of soft tissue wounds.

S4690has demonstrated activity in the treatment of fibrosis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4691is a drug that inhibits
 
Response: S4691is a drug that inhibits the proliferation of vascular smooth muscle cells (VSMC) and is currently under evaluation in a Phase III trial for the treatment of atherosclerosis. However, the effects of A4671 on VSMC function and the mechanism by which it exerts its effects have not been elucidated. We evaluated the effects of A4671 on human aortic smooth muscle cell (HASMC) function and growth and compared the effects of A4671 to those of the traditional growth inhibitor, aspirin. HASMC were exposed to A4671 or aspirin for 48 hours, and the effect of each agent on proliferation, apoptosis, and the expression of proteins involved in apoptosis, cell cycle regulation, and inflammation were evaluated. A4671 inhibited HASMC proliferation by 65% compared to control (P<0.001), whereas aspirin inhibited proliferation by only 13% (P<0.01). A4671 inhibited HASMC apoptosis by approximately 80% (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4693is a drug that inhibits
 
Response: S4693is a drug that inhibits the biosynthesis of catecholamines. In this study, we evaluated the effects of S4693 on chronic intermittent hypoxia (CIH)-induced vascular remodeling in the mouse carotid artery. Thirty-six mice were exposed to CIH for 28 days. Mice were randomly divided into four groups: sham, CIH, S4693 (10 mg/kg) and S4693 (20 mg/kg). After 28 days of CIH, the diameter of the carotid artery and mRNA and protein expression of P-glycoprotein (P-gp) and CSE in the carotid artery were determined. The mRNA expression of CSE and protein expression of P-gp were significantly increased in the CIH group. The diameter of the carotid artery was significantly increased in the CIH group. The administration of S4693 (10 and 20 mg/kg) attenuated the CIH-induced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4694is a drug that inhibits
 
Response: S4694is a drug that inhibits the replication of human immunodeficiency virus (HIV) and herpes simplex virus (HSV) in cell culture. We are investigating its effect on the replication of HIV and HSV in patients with AIDS and genital herpes. Patients receive drug orally, once daily, for a period of 6 months. Dose escalation will be done based on the results of the first phase of the study. Patients are studied by a standardized protocol to assess the effect of the drug on the frequency and severity of genital herpes lesions. The drug is also being studied in the treatment of ocular HSV infections.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4695is a drug that inhibits
 
Response: S4695is a drug that inhibits the proliferation of human melanoma cells in vitro and in vivo.\[[@CIT13]\] *Borax* is a natural compound isolated from the boron-rich salt springs of Kolar and Deccan basins in Karnataka. *Borax* inhibits proliferation of a variety of tumor cells in vitro and in vivo.\[[@CIT14]\] *Borax* inhibited cell proliferation and induced cell cycle arrest at the G2/M phase in the tumor cell lines (MDA-MB-231, Hs 578T, MCF-7, and PC-3) in a dose-dependent manner.\[[@CIT15]\] *Borax* was also shown to induce apoptosis in a dose-dependent manner in tumor cells.\[[@CIT16]\] In our study, we have evaluated the effect of *Borax
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4696is a drug that inhibits
 
Response: S4696is a drug that inhibits TRPA1 channel activity. S4696 has been shown to be an effective analgesic in mouse models of inflammatory and neuropathic pain, as well as migraine.^[@R25]^ Although the role of TRPA1 in migraine has not been established, TRPA1 channels are activated in trigeminal nociceptors during the headache phase of migraine^[@R11]^ and in primary sensory neurons after the induction of peripheral neuropathy.^[@R24]^ In this study, we found that S4696 inhibits AITC-induced migraine-like behaviors and attenuates both mechanical allodynia and thermal hyperalgesia. Furthermore, we observed that the onset of the migraine-like behaviors is preceded by the activation of TRPA1. Finally, we found that the levels of TNF-α and IL-1β were elevated in the brains of S4696-treated animals. These findings
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4697is a drug that inhibits
 
Response: S4697is a drug that inhibits IL-4-mediated signaling, leading to an inhibition of IL-4-induced JAK3 phosphorylation, STAT6 activation, and STAT6 nuclear translocation. This resulted in a decreased expression of STAT6-regulated genes, such as CCL17, CCL22, CCL26, and CCL1, which are all involved in the recruitment of T~H~2 cells.

5. Conclusions {#sec5-ijms-21-01798}
==============

The pathogenesis of allergic diseases involves multiple cytokines, such as IL-4, IL-13, IL-5, and IL-33. These cytokines are mainly produced by T~H~2 cells, basophils, and mast cells. In this review, we focused on the role of IL-4 in allergic diseases, and in particular, on IL-4-mediated T~H~2 cell-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4698is a drug that inhibits
 
Response: S4698is a drug that inhibits the fusion of HIV with host cells. In the laboratory, it is used to treat patients with HIV infection, particularly those who are treatment-experienced and those who have not responded to other treatments. It is also used to treat HIV-associated dementia. It is in a class of drugs called non-nucleoside reverse transcriptase inhibitors. In addition to S4698, other drugs in this class include abacavir (Ziagen) and lamivudine (Epivir).

It is important to remember that not all drugs in the same class are the same. All of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) work by binding to the reverse transcriptase of the HIV virus, but they differ in how they do this. This makes them different in their effect. S4698 is an NNRTI, but it is not like other NNRTIs.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4701is a drug that inhibits
 
Response: S4701is a drug that inhibits ATPase and is reported to be an effective antifungal agent. S4701 inhibits fungal cell growth in a dose-dependent manner. However, S4701-induced inhibition of fungal cell growth is highly variable among different fungal species. In this study, we identified the mode of action of S4701 in Saccharomyces cerevisiae. The S. cerevisiae cells expressing ATPase and target of rapamycin (TOR) signaling mutants were more sensitive to S4701 than the wild-type cells. Furthermore, S4701 did not affect cell wall composition or cell wall thickness. These results suggest that S4701 inhibits the TOR pathway, resulting in decreased protein synthesis and cell growth.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4702is a drug that inhibits
 
Response: S4702is a drug that inhibits platelet aggregation. It is commonly used in patients with acute coronary syndrome. Its mechanism of action is related to its direct action on the fibrinogen receptor. A new class of non-peptide antagonists for the GPIIb/IIIa receptor has been synthesized. Their structure was designed to be based on the 5-amino-4-carboxamid-6-methyl-2,4(1H,3H)-pyrimidinedione (MCP) scaffold, which has previously been used to generate antagonists for the CXCR4 receptor. The N-methyl-D-aspartate (NMDA) antagonists, D-2-amino-5-phosphonovaleric acid (APV) and 2-amino-5-phosphonopentanoic acid (AP5), have also been included as reference compounds. All compounds were synthesized using a microwave-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4703is a drug that inhibits
 
Response: S4703is a drug that inhibits, with a potency of IC50 < or =1 microM, the thrombin-induced platelet aggregation and adenosine diphosphate (ADP)-induced platelet aggregation. This drug has been used to control the bleeding of patients undergoing coronary angioplasty and of those suffering from acute myocardial infarction. The drug is also used for the treatment of acute thrombosis. In addition, S4703 has been shown to be an effective inhibitor of thrombin-induced fibrin clot formation. In the present study, we have investigated the effect of S4703 on the adhesion of human platelets to fibrinogen, collagen, and von Willebrand factor (vWf). S4703 inhibits, in a concentration-dependent manner, the adhesion of platelets to all three proteins, the inhibitory potency being similar for all three proteins. Inhibition of platelet ad
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4704is a drug that inhibits
 
Response: S4704is a drug that inhibits VEGF receptors and is approved by the FDA for treatment of lung cancer, metastatic colorectal cancer and metastatic renal cell carcinoma. In this study, we evaluated the efficacy of S4704 in the treatment of prostate cancer. We evaluated the effects of S4704 on prostate cancer cells in vitro and in vivo using both human and mouse models. We evaluated the effects of S4704 on prostate cancer cell growth and invasion using both human and mouse models. We assessed the effects of S4704 on tumor angiogenesis in human prostate cancer xenograft models and in mouse models of prostate cancer. We evaluated the effects of S4704 on tumor growth in mice with orthotopic prostate cancer and mice with castration-resistant prostate cancer. We evaluated the effects of S4704 on prostate cancer growth and angiogenesis in a mouse model of castration-resistant prostate cancer. We also evaluated the effects of S4704 on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4706is a drug that inhibits
 
Response: S4706is a drug that inhibits a new class of kinases called CDK7/CyclinH complexes. These kinases are important for phosphorylating the RNA polymerase II C-terminal domain (CTD) to allow for the elongation of RNA transcription. The CDK7/CyclinH kinases are activated by phosphorylation by another protein called CDK9. S4706 is a specific inhibitor of CDK7/CyclinH and has been shown to inhibit transcription and induce apoptosis in a wide range of cancer cells. The S4706 drug has been studied in a Phase I clinical trial for the treatment of solid tumors.

The Cancer Genome Atlas (TCGA) project is a collaboration of researchers from the National Cancer Institute, the National Human Genome Research Institute, the National Center for Biotechnology Information, and the National Institute of General Medical Sciences. The project is working to catalogue the mutations that occur in cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4707is a drug that inhibits
 
Response: S4707is a drug that inhibits the farnesylation of RAS proteins, and is in phase III clinical trials for the treatment of advanced cancers. The goal of this proposal is to use the high-throughput, genome-wide siRNA screen to identify genes that modulate sensitivity to CCT020312, and identify novel molecular targets for cancer therapy. The specific aims of this proposal are: (1) to identify genes that are critical for sensitivity to CCT020312, and validate their role in drug sensitivity in cell-based and patient-derived tumor models; (2) to validate genes identified in Specific Aim 1 as novel molecular targets for cancer therapy. These studies will reveal the novel genes and molecular mechanisms that underlie the sensitivity of cancer cells to farnesyltransferase inhibitors, and will identify potential molecular targets for cancer therapy. The proposal is innovative because it will use a novel high-throughput, genome-wide siRNA screen to identify genes that mod
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4709is a drug that inhibits
 
Response: S4709is a drug that inhibits mTOR, and is approved for treatment of advanced renal cell carcinoma. Although it has shown promising efficacy in several phase II trials, its efficacy has not been validated in a randomized phase III trial. We sought to determine whether a phase III trial of temsirolimus should be performed. We searched MEDLINE for studies of temsirolimus in renal cell carcinoma, and for trials comparing temsirolimus to other systemic treatments. We also searched for studies of temsirolimus in patients with other solid tumors. We contacted the primary investigators of all studies for additional data. We used meta-analysis to combine study results. Fourteen studies of temsirolimus in patients with renal cell carcinoma were identified. The use of temsirolimus in combination with interferon-alpha or interleukin-2 showed a substantial survival advantage over interferon-alpha or interleukin-2 alone
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4711is a drug that inhibits
 
Response: S4711is a drug that inhibits cell proliferation, cell invasion and cell migration of gastric cancer cells *in vitro* and *in vivo* ([@b33-ol-0-0-10118],[@b34-ol-0-0-10118]). As a T-box transcription factor, S4711 may inhibit tumorigenesis by inducing cell cycle arrest, apoptosis, and promoting autophagy ([@b35-ol-0-0-10118]). Previous studies have reported that S4711 induces apoptosis and autophagy in human glioma U251 cells by regulating Bcl-2, Bax and LC3B ([@b36-ol-0-0-10118],[@b37-ol-0-0-10118]). These results suggested that S4711 may inhibit the proliferation, invasion and migration of GC cells through multiple pathways.

In conclusion, S4711 inhibits the proliferation, invasion and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4714is a drug that inhibits
 
Response: S4714is a drug that inhibits GSK-3.

It was developed by Shionogi Pharmaceuticals and it was in Phase III of clinical trials for the treatment of type 2 diabetes, and had been discontinued due to safety concerns.

Mechanism of action

S4714 inhibits glycogen synthase kinase 3 (GSK-3) by binding to the ATP binding site of the enzyme, thereby inhibiting GSK-3 activity. This inhibition prevents the phosphorylation of glycogen synthase (GS) and glycogenin, resulting in increased glycogen levels.

GSK-3 has two isoforms, GSK-3α and GSK-3β, which are ubiquitously expressed in most tissues. GSK-3α is primarily expressed in the central nervous system and has been shown to play a role in neurogenesis and in memory. GSK-3β is found ubiquitously and has been implicated in a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4716is a drug that inhibits
 
Response: S4716is a drug that inhibits STAT3 activity by directly binding to it and then inducing its degradation. In this study, we found that the proliferation of oral cancer cells was inhibited by S4716 treatment, and this inhibition was not due to apoptosis. In addition, S4716 induced G1 cell cycle arrest by downregulating the expression of cyclin D1 and c-myc, which were key regulators of G1 to S transition. Finally, S4716 was shown to have in vivo anti-tumor activity in mice inoculated with human oral cancer cells. Taken together, these data suggest that S4716 is a promising drug for the treatment of oral cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4717is a drug that inhibits
 
Response: S4717is a drug that inhibits the enzyme COX-2. It was designed as a safer alternative to traditional NSAIDs that have been linked to gastrointestinal ulceration and bleeding. It has been shown to have anti-inflammatory, analgesic and antipyretic effects in animal models.

INDICATIONS AND USAGE

S4717is indicated for the treatment of pain associated with osteoarthritis (OA) of the knee and hip in adults. It may be used alone or in combination with other anti-inflammatory medications for the treatment of OA. It may be used in combination with other pain medications to manage moderate to severe pain in adults.

WARNINGS

Cautions should be used when prescribing S4717 to patients with asthma or other lung disease or with a history of asthma or chronic obstructive pulmonary disease (COPD). The combination of S4717 and corticosteroids may increase the risk of side effects. In patients with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4718is a drug that inhibits
 
Response: S4718is a drug that inhibits NF-kappaB activation, and which was originally identified as an inhibitor of the cellular replication of the herpes simplex virus. S4718 has been shown to be an inhibitor of the replication of both human and murine retroviruses. S4718 has been shown to inhibit HIV replication in infected cells by several mechanisms, including inhibition of NF-kappaB activation. S4718 has also been shown to inhibit the replication of the following viruses: human immunodeficiency virus type 1, human T-cell leukemia virus type I, human T-cell leukemia virus type II, Moloney murine leukemia virus, murine leukemia virus, and Rous sarcoma virus.

S4718 inhibits the cellular replication of the human herpesvirus, Kaposi's sarcoma associated herpesvirus, and inhibits the replication of human cytomegalovirus in cell culture.

S4718 inhibits the replication of human immun
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4721is a drug that inhibits
 
Response: S4721is a drug that inhibits the HIF pathway by binding to the von Hippel-Lindau protein (pVHL) in the ubiquitin-proteasome pathway. This drug has been shown to induce HIF-1α degradation and inhibit HIF-1-dependent gene expression in vitro.^[@bib47]^ In a phase I trial, oral administration of S-4 sulfonamides induced clinical responses in three patients with advanced solid tumors and stabilized their disease for 3--12 months.^[@bib48]^ To our knowledge, there are no studies regarding the effect of S-4 sulfonamides on RCC.

### EGFR and VEGFR inhibitors

The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib are FDA-approved for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4722is a drug that inhibits
 
Response: S4722is a drug that inhibits the NF-kappaB signaling pathway by inhibiting the kinase activity of IKK-alpha and IKK-beta. The aim of this study was to investigate the potential use of S4722 as a therapeutic agent for pulmonary hypertension. Mice with a deletion of the p50 subunit of NF-kappaB were used as a model of pulmonary hypertension. S4722 was given to the mice in a chronic oral treatment regimen, and its effect on pulmonary vascular remodeling and the right ventricular systolic pressure (RVSP) was measured. To evaluate the effect of S4722 on pulmonary vascular remodeling, S4722 was administered to mice from the beginning of the disease. S4722 treatment decreased RVSP and attenuated the morphological changes in the pulmonary arteries and pulmonary veins. The effect of S4722 on the NF-kappaB signaling pathway was also investigated. S4722 inhibited the activation of NF
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4723is a drug that inhibits
 
Response: S4723is a drug that inhibits synthesis of sterols in the liver and therefore interferes with cholesterol absorption and transport. It can be administered orally as a liquid suspension, or intravenously as a sterile lyophilized powder. It is most often used in conjunction with statins, but can be used alone in patients with hypercholesterolemia.

In patients with high triglycerides and low HDL, the S4723is a good option. S4723is used for lowering the triglycerides and raising the HDL. In addition, it is a very good option for those who have taken an oral lipid-lowering drug and have not seen an improvement in their cholesterol. It is usually taken in conjunction with a statin.

S4723is not usually recommended for those who have low HDL levels and low triglycerides, as the combination of these conditions can cause cardiovascular problems.

Adverse Effects

Like all drugs, S4723is has some
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4725is a drug that inhibits
 
Response: S4725is a drug that inhibits the proliferation of both glioblastoma and primary glioblastoma cells and induce apoptosis. It also induces cell cycle arrest in G2/M phase in glioblastoma cells. We investigated the effects of S4725 on glioblastoma cells that were resistant to temozolomide. The expression of the O6-methylguanine DNA methyltransferase (MGMT) gene was analyzed by RT-PCR and methylation-specific PCR. Cells were treated with S4725 in the presence of temozolomide. Drug-resistant cell lines (U251-TMZ and T98G-TMZ) and glioblastoma cell lines (T98G, U251, and U87) were exposed to S4725 for 72 h. S4725 inhibited the proliferation of both temozolomide-sensitive and -resistant cells. S4725 also induced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4726is a drug that inhibits
 
Response: S4726is a drug that inhibits the tyrosine kinase activity of VEGF receptor (VEGFR) and has been approved for the treatment of multiple myeloma and metastatic colorectal cancer. Previous reports have shown that S4726 induces apoptosis and inhibits proliferation in colon cancer cells. We studied the effects of S4726 on gastric cancer cell lines. S4726 decreased cell viability and induced apoptosis in two human gastric cancer cell lines, SNU-5 and KATO-III, in a dose- and time-dependent manner. It also inhibited phosphorylation of Akt, Erk, and STAT3. The effects of S4726 on the growth of gastric cancer cells were greater than those of trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2). However, trastuzumab did not show cytotoxicity in the absence of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4727is a drug that inhibits
 
Response: S4727is a drug that inhibits S4727 is a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved by the FDA in December 2004. This drug has shown a high potency against HIV-1 strains, especially against multidrug resistant strains. It has also shown a high genetic barrier, which is defined as the resistance mutation rate being low, and an excellent safety profile. It has been shown to be active against resistant viruses when used as a single drug and as part of a multidrug regimen. S4727 is the active metabolite of tenofovir (TDF), which was the first NNRTI approved for the treatment of HIV-1 infection. TDF has been shown to be active against HIV-1 and HIV-2, and has been shown to have an excellent safety profile.

1. Introduction {#sec1-viruses-12-00850}
===============

H
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4733is a drug that inhibits
 
Response: S4733is a drug that inhibits a step in the eukaryotic translation pathway. The presence of the 5-phenylacetamido group at the 5-position of the thiazolyl-thiazolidine ring confers a unique pharmacological profile, with this compound being a potent and specific inhibitor of protein synthesis. The compound is highly selective for bacterial and mammalian protein synthesis. It is active in vivo against a broad spectrum of bacteria, including Gram-positive and Gram-negative bacteria, and is highly active in vivo against S. aureus.

There are several classes of antibacterial agents that have been described in the literature, including the polymyxins, the cyclic peptides, the fluoroquinolones, the lipopeptides, and the oxazolidinones.
Polymyxins (polymyxin B and colistin) are a group of cyclic polypeptides with potent antibacterial activity.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4734is a drug that inhibits
 
Response: S4734is a drug that inhibits the serotonin transporter, which is responsible for the uptake of serotonin from the synaptic cleft into the pre-synaptic neuron. This leads to an increase in the concentration of serotonin in the synapse. As a result, there is increased inhibition of the post-synaptic neuron.

The recommended dose is 25 mg, taken once daily, preferably at bedtime.

The first two weeks of treatment may be associated with a transient increase in serotonin levels in the synapse. If this occurs, the dose of citalopram should be gradually increased over the first 2 weeks of treatment.

The maximum recommended dose is 60 mg/day.

Side effects

As with all drugs, there are some possible side effects. They may be minor and go away after stopping treatment, or they may be serious and need medical attention. It is important to tell your doctor about any of the following side effects, especially if they are severe or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4735is a drug that inhibits
 
Response: S4735is a drug that inhibits the action of proteasome in the cells and is used to treat multiple myeloma. The purpose of this study was to evaluate the antitumor effects of S4735 in mouse tumor models. A nude mouse xenograft model of human ovarian carcinoma was established and treated with S4735 or cisplatin (CDDP). S4735 (5 mg/kg) or CDDP (3 mg/kg) was given by intraperitoneal injection twice a week for 3 weeks. In this study, the antitumor effects of S4735 were significantly superior to those of CDDP in both the primary and metastatic tumors. Immunohistochemical staining of Ki-67 showed that the proportion of proliferating cells was lower in the S4735-treated group than in the CDDP-treated group. These findings suggest that S4735 has a stronger antitumor effect than CDDP in this model.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4736is a drug that inhibits
 
Response: S4736is a drug that inhibits an enzyme, cyclooxygenase-2 (COX-2), which is involved in inflammation.

The M5020exhibited an inhibition of prostaglandin E2 (PGE2) production at an IC50 of 0.23 microM.

M5020 is a specific inhibitor of cyclooxygenase-2 (COX-2) and shows a significant anti-inflammatory activity in various animal models. It inhibits the production of pro-inflammatory mediators in vivo, in the following rank order: PGE2 > thromboxane B2 > PGD2 > 6-keto-PGF1alpha. It also inhibits IL-1beta-induced expression of the cyclooxygenase-2 gene in human dermal fibroblasts.

A study in healthy human volunteers found that M5020 was safe and well tolerated when administered at doses up to 1.0
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4737is a drug that inhibits
 
Response: S4737is a drug that inhibits the activation of Src and inhibits the activation of c-Jun and JNK. In the present study, we examined the effects of S4737 on cellular proliferation and motility. We observed that S4737 inhibited the proliferation of NFS-60 cells. In addition, we found that S4737 inhibited the migration of NFS-60 cells. S4737 did not induce cell death, and it also did not induce apoptosis. However, S4737 inhibited the phosphorylation of Src, and the phosphorylation of c-Jun and JNK. The present study suggests that S4737 inhibited the migration of NFS-60 cells by inhibiting the phosphorylation of Src, and the phosphorylation of c-Jun and JNK.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4740is a drug that inhibits
 
Response: S4740is a drug that inhibits angiogenesis and it was designed to target the vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1). In preclinical studies, this agent was found to reduce tumor burden in animal models and to be safe in humans.\[[@ref1][@ref2][@ref3]\] A phase I/II trial was conducted to evaluate the efficacy and safety of S-2 in patients with recurrent/refractory solid tumors.\[[@ref4]\] This study was conducted to evaluate the safety and efficacy of S-2 in patients with advanced solid tumors.

PATIENTS AND METHODS {#sec1-1}
====================

This is a multicenter, single arm, phase II study. The primary objective was to evaluate the efficacy and safety of S-2 in patients with advanced solid tumors. The secondary objectives
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4741is a drug that inhibits
 
Response: S4741is a drug that inhibits the synthesis of new RNA from the DNA template in the nucleus of the cell. It is commonly used in the treatment of hematological malignancies, such as acute myeloid leukemia (AML), to kill the cells. But, the effect of this drug is also associated with adverse effects such as bone marrow suppression, cardiac failure, and alopecia.

Therefore, to avoid the negative effects of S4741 on bone marrow, it is important to identify an effective drug that is similar to S4741, but does not have the adverse effects.

In this study, we used S4741 and tested several other drugs to find an effective drug that is similar to S4741, but does not have the adverse effects.

Materials and Methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

The animal experiments were performed in accordance with the guidelines of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4748is a drug that inhibits
 
Response: S4748is a drug that inhibits the action of HGF/SF, which is known to stimulate cell motility, cell growth and cell invasion (see U.S. Pat. No. 5,643,884, incorporated herein by reference). S4748is currently being investigated in clinical trials for treatment of solid tumors. However, it is desirable to improve the efficacy of S4748 and/or reduce its toxicity.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4749is a drug that inhibits
 
Response: S4749is a drug that inhibits the synthesis of ribosomal RNA (rRNA) by binding to the 28S subunit. A.H. is an academic career award from the U.S. Department of Education. This work was supported by a grant from the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (R01AI049626). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Conceived and designed the experiments: A.H. Performed the experiments: A.H. Analyzed the data: A.H. Contributed reagents/materials/analysis tools: A.H. Wrote the paper: A.H.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4750is a drug that inhibits
 
Response: S4750is a drug that inhibits NF-κB, and we have shown that it has an anticancer effect in TNBC.

Taken together, these data indicate that it is important to consider the presence of a TNBC subtype when choosing a patient's treatment. In addition, the molecular basis of resistance to treatment should be taken into account when choosing a treatment.

The authors would like to thank Yuki Kimura, Sachiko Ueda, and Yuko Ohno for technical assistance.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: YI. Performed the experiments: KK KI KA YT. Analyzed the data: KK YT. Contributed reagents/materials/analysis tools: YI. Wrote the paper: KK YI.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4751is a drug that inhibits
 
Response: S4751is a drug that inhibits TGFβ-Smad2/3 signalling. In this study, we tested the ability of this agent to inhibit prostate tumour growth and examined the effects of TGFβ-Smad2/3 inhibition on tumour-stromal interactions in an orthotopic xenograft model. A syngeneic mouse prostate cancer cell line (TRAMP-C2) was stably transfected with a dominant-negative mutant of Smad2 (dnSmad2) or with a control vector (Vc). TRAMP-C2/dnSmad2 and TRAMP-C2/Vc cells were orthotopically injected into the prostates of male athymic nude mice. Intratumour injections of the TGFβ-Smad2/3 inhibitor S4751 were given to some of the mice at the time of cell implantation. Tumour growth and prostate-specific antigen (PS
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4752is a drug that inhibits
 
Response: S4752is a drug that inhibits the activity of T-cell receptor.

S4752 is an orally active, potent, and selective antagonist of T-cell receptor signaling that inhibits T-cell receptor-mediated cytokine production in vivo.

Pharmacokinetics

Absorption

S4752 is well absorbed after oral administration. Peak plasma concentrations are reached in 2–3 hours. It is metabolized by the liver and the kidney. The major metabolite is formed by CYP3A4 and is eliminated in the feces. The metabolites are formed via oxidation of the nitrogen atoms in the piperidine moiety and the terminal nitrogen in the benzimidazole moiety.

Distribution

S4752 is well distributed throughout the body. The distribution volume is about 4 L/kg.

Elimination

S4752 is eliminated by biliary and fecal routes. It is excreted mainly in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4754is a drug that inhibits
 
Response: S4754is a drug that inhibits the activity of the enzyme thymidylate synthase (TS) by binding to its active site. This enzyme is responsible for the de novo synthesis of thymidylate (dTMP), which is required for DNA replication and repair. S-2-(fluoromethyl)thymidine (FdUMP) is a thymidylate analog, and is one of the active metabolites of S4754. In addition to its cytotoxic activity, FdUMP inhibits TS, thus blocking the de novo synthesis of dTMP and preventing DNA synthesis.

In vitro

Studies in cell lines have shown that FdUMP is more potent than S4754, with a 50% inhibitory concentration (IC50) in the low nanomolar range. In addition, FdUMP is more potent than its parent compound S4754 in the inhibition of the growth of cells.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4757is a drug that inhibits
 
Response: S4757is a drug that inhibits the synthesis of serotonin, a neurotransmitter that is involved in sleep, appetite, mood, pain, temperature, and circadian rhythms. It has been studied in preclinical models of depression and has shown promise in human clinical trials. The present studies tested the hypothesis that the S4757 compound would ameliorate the behavioral deficits observed in the Forced Swimming Test (FST) in rats. S4757 (10-30 mg/kg) significantly reduced the immobility time of rats in the FST. S4757 (10-30 mg/kg) also significantly reduced immobility time in the Tail Suspension Test (TST) and the Forced Swim Test (FST) in rats. The antidepressant-like effects of S4757 were blocked by the serotonin 5-HT2A receptor antagonist, ritanserin (3 mg/kg). Thus, S4757 ameliorated the behavioral deficits observed in the F
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4759is a drug that inhibits
 
Response: S4759is a drug that inhibits the TGF-β signaling pathway by binding to the intracellular portion of TGF-β receptors. In this study, we evaluated the safety and pharmacokinetics of S-4759 after a single intravenous dose in healthy volunteers. In a single ascending dose study, 20 subjects were randomly assigned to one of five groups (10 subjects per group) and received S-4759 by intravenous infusion. The subjects received a single dose of S-4759 at 0.25, 0.5, 1, 2, or 4 mg/kg, or placebo. S-4759 was well tolerated at all dose levels. Adverse events were reported in three subjects (two in the 0.25-mg/kg group and one in the 4-mg/kg group). There were no serious adverse events. S-4759 was rapidly absorbed after administration. The peak plasma concentration (Cmax) was achieved at approximately 2.5 h
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4768is a drug that inhibits
 
Response: S4768is a drug that inhibits the cyclin-dependent kinase 4 (CDK4), a key regulator of cell cycle progression. CDK4 activity is important for tumor cell growth and, in particular, for the regulation of the cell cycle transition from the G1 to the S phase. It is believed that this agent may be useful for the treatment of certain tumors.

MATERIALS AND METHODS
=====================

Cell culture
------------

All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 100 μg/mL penicillin and streptomycin. Cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and were maintained in the above medium at 37°C in a humidified atmosphere of 5% CO~2~. Cells were cultured in 100-mm dishes and harvested when they reached about 80% confluence.

Cell proliferation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4769is a drug that inhibits
 
Response: S4769is a drug that inhibits a number of kinases involved in cell cycle progression. We are using the NCI-H460 human non-small cell lung cancer cell line to identify those kinases inhibited by S4769 and to identify the molecular events leading to its antitumor activity. These studies are being performed in collaboration with the laboratory of Dr. Paul Meltzer (NCI). Preliminary results suggest that S4769 has activity against a number of human cancers. In collaboration with Dr. Debra Bailey (NCI), we are evaluating S4769 in combination with other chemotherapeutic agents against ovarian cancer. In addition, we are evaluating S4769 in combination with gemcitabine and other agents against a variety of tumor types. These studies are being performed in collaboration with the laboratory of Dr. Donald Kufe (NIDDK). We have also developed a novel immunoassay for the detection of circulating cell-free DNA (cfDNA)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4770is a drug that inhibits
 
Response: S4770is a drug that inhibits the proliferation of cancer cells. In fact, it is the first synthetic small-molecule drug to be developed and approved by the US FDA for the treatment of advanced RCC. It was approved by the FDA in November 2011. It was also approved by the European Medicines Agency (EMA) in September 2012.^[@R2]^ S4770 was developed by the National Cancer Institute (NCI), and it was developed as a promising anticancer drug.^[@R3]^ It is a derivative of the anthracycline-derived natural product, aclarubicin.

S4770 is a small-molecule protein synthesis inhibitor that acts by binding to the large ribosomal subunit and inhibiting the function of the peptidyltransferase center.^[@R4]^ S4770 is a broad-spectrum inhibitor of cell growth.^[@R
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4776is a drug that inhibits
 
Response: S4776is a drug that inhibits fatty acid synthase, the enzyme that synthesizes fatty acids in cells. Fatty acids, which are components of cell membranes, can be used as building blocks for making hormones, bile acids, and steroid hormones. These hormones are important to health.

S4776 has been studied in a wide range of human cancers, including breast, colon, endometrial, and ovarian. It is being studied in a number of other cancers, including leukemia, lung, prostate, and thyroid.

The chemical structure of S4776 is shown in the figure. It consists of a two-carbon tail attached to a six-carbon ring.

S4776 was developed by the US National Cancer Institute. It was initially named PC-6180, but the US Food and Drug Administration (FDA) insisted on the change to S4776.

Clinical trials

Two clinical trials of S4776 have been completed.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4779is a drug that inhibits
 
Response: S4779is a drug that inhibits the growth of non-small cell lung cancer (NSCLC) by suppressing the NF-κB signaling pathway and inducing cell cycle arrest. The purpose of this study was to determine whether S4779 can suppress the growth of lung cancer by targeting the Akt signaling pathway. In this study, we examined the effects of S4779 on the growth of NSCLC cells and found that S4779 suppressed the growth of A549 and H1975 cells by inducing apoptosis. We also found that S4779 suppressed the activation of the Akt signaling pathway. We further examined whether the effect of S4779 was mediated by the Akt signaling pathway. We found that S4779 induced the degradation of IκBα, which is an inhibitor of the NF-κB signaling pathway, and the subsequent activation of NF-κB, which resulted in the suppression of the growth of NSCLC cells. We further examined whether S4779
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4783is a drug that inhibits
 
Response: S4783is a drug that inhibits the V-ATPase and blocks the P2X7 receptor, the molecular target of which is the P2X7 receptor. This drug has recently been developed as a treatment for neurodegenerative diseases and pain. The *in vivo* effects of S4783 have been evaluated using animal models of neurodegenerative diseases and pain. The results obtained are discussed in the present review.

2. Methods {#sec2-ijms-19-01992}
==========

2.1. Experimental Studies {#sec2dot1-ijms-19-01992}
-------------------------

### 2.1.1. Parkinson's Disease {#sec2dot1dot1-ijms-19-01992}

The effect of S4783 on Parkinson's disease (PD) was studied in the 1-methyl-4-phenyl-1,2,3,6
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4792is a drug that inhibits
 
Response: S4792is a drug that inhibits the protein kinase C (PKC) isoenzyme, PKC-beta, which is expressed in several cell types, including neurons, and in activated T cells. It has been shown to be effective in the treatment of multiple sclerosis (MS) and in the prevention of experimental autoimmune encephalomyelitis (EAE). However, the molecular mechanisms by which this drug exerts its effect in these diseases is still unclear. To investigate the effects of S4792 in MS, EAE and antigen-specific T cell activation, we used a well-characterized mouse model of MS. We found that S4792 prevents T cell proliferation and activation, inhibits the expression of costimulatory molecules, and induces apoptosis in CD4+ T cells in vitro. In addition, S4792 suppresses disease severity and reduces the demyelination and infiltration of inflammatory cells in EAE. These data demonstrate that S4792 inhibits T cell proliferation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4794is a drug that inhibits
 
Response: S4794is a drug that inhibits the ubiquitin ligase activity of the HIV-1 viral infectivity factor (Vif), an E3 ubiquitin ligase. The COOH-terminal part of Vif interacts with the E2 ubiquitin-conjugating enzyme Ube2N, a ubiquitin-conjugating enzyme, and the catalytic cysteine of Ube2N is critical for Vif-dependent degradation of the host factor SAMHD1. S4794 specifically inhibits the degradation of SAMHD1 by Vif and is a potential candidate for a drug to combat HIV infection.

1. Introduction {#sec1-toxins-12-00462}
===============

Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of acquired immunodeficiency syndrome (AIDS). It is estimated that more than 30 million people are living with HIV-1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4795is a drug that inhibits
 
Response: S4795is a drug that inhibits a phosphodiesterase. It has the potential to enhance the actions of a wide variety of catecholamines and also has the potential to prolong the duration of action of these agents. S4795 has been studied in humans, and its pharmacokinetics, pharmacodynamics, safety, and efficacy have been evaluated in a variety of clinical situations, including septic shock, congestive heart failure, hypertension, and treatment of tachycardia. The available data indicate that S4795 is a potent, selective, and orally active phosphodiesterase inhibitor. The clinical pharmacology of S4795 in man is discussed in the following sections.

#####  PHARMACOKINETICS

######  Distribution

S4795 is distributed into red blood cells, plasma, and tissues.

######  Elimination

The primary route of elimination of S4795 is through metabolism by the liver and the kidneys
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4796is a drug that inhibits
 
Response: S4796is a drug that inhibits the activity of the gene that encodes a particular enzyme that is essential for the growth of the bacteria.

The drug can be used to treat a range of infections caused by _S. pneumoniae_.

**Fluoroquinolones**

**Quinupristin/dalfopristin**

**Trade name: Zyvox**

**Class:** quinolone

**Mode of action:** inhibits DNA gyrase, an enzyme required for DNA replication

**Target:** DNA gyrase, an enzyme required for DNA replication

**Route:** IV

**Class:** fluoroquinolone

**Target:** DNA gyrase, an enzyme required for DNA replication

**Route:** IV

**Class:** quinolone

**Mode of action:** inhibits DNA gyrase, an enzyme
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4797is a drug that inhibits
 
Response: S4797is a drug that inhibits platelet aggregation, and its effect on coronary artery blood flow has been studied in a large number of patients with coronary artery disease (CAD) who have undergone angioplasty. S4797 is an analog of clopidogrel, and its mechanism of action is independent of the cytochrome P450 2C19 enzyme, the enzyme responsible for the metabolism of clopidogrel. The present study was designed to evaluate the efficacy and safety of S4797 in patients with CAD who underwent percutaneous coronary intervention (PCI) with stent implantation. The study was conducted at 16 hospitals in Japan. Patients with CAD who had undergone PCI with stent implantation were enrolled. The drug was administered orally (150 mg once daily for 7 days before PCI) and the effect of S4797 on platelet aggregation was evaluated. The primary end point was the composite of cardiac death, myocardial infarction, or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4800is a drug that inhibits
 
Response: S4800is a drug that inhibits androgen biosynthesis in the prostate. It has been used for more than 30 years in Europe to treat prostate cancer. A meta-analysis of 12 clinical trials showed a significant reduction in prostate-specific antigen (PSA) levels and in the percentage of patients with bone metastases, in particular those with visceral metastases. However, the results of the studies were inconsistent, and many authors questioned the benefits of treatment. To address these issues, we conducted a systematic review and meta-analysis of the literature on the effects of S-4,008 in patients with prostate cancer. We identified 15 studies (12 randomized controlled trials and 3 randomized trials) involving 862 patients. The results of the meta-analysis of the randomized controlled trials showed that the risk of bone metastases was significantly reduced by 36% (risk ratio [RR], 0.64; 95% confidence interval [CI], 0.44-0.93; P =.02). No
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4803is a drug that inhibits
 
Response: S4803is a drug that inhibits both caspase-3 and caspase-7. As expected, both caspase-3 and caspase-7 activity were inhibited by S4803. In contrast, S4803 had no effect on caspase-8 activity (Fig. [3](#Fig3){ref-type="fig"}). The inhibition of caspase-3 and caspase-7 by S4803 suggests that S4803 inhibits apoptosis induced by TNFα in RA-FLS.Fig. 3Effect of S4803 on caspase-3 and caspase-7 activities. Caspase-3 and caspase-7 activities were measured using the caspase-3/7 Glo® Assay Systems and expressed as fold induction of control. \**p* \< 0.05 vs. control

Effects of S4803 on proliferation and apopt
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4810is a drug that inhibits
 
Response: S4810is a drug that inhibits the mTORC1 signaling pathway.^[@R36]^ Rapamycin was used as a positive control in this study. Our results showed that rapamycin (20 nM) and S4810 (20 nM) could decrease the phosphorylation of mTOR and p70S6K, but had no obvious effect on the phosphorylation of 4E-BP1. Interestingly, S4810 had more obvious effects than rapamycin. This might be because of the combined effect of inhibiting the mTORC1 and mTORC2 signaling pathways. In contrast, metformin (20 mM) had no obvious effects on the phosphorylation of mTOR, p70S6K, and 4E-BP1. The mechanism of action of metformin is not completely understood. It has been reported that metformin inhibits the mTORC1 signaling pathway, and the effect is not dependent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4811is a drug that inhibits
 
Response: S4811is a drug that inhibits the activity of human cyclin-dependent kinase 2 (CDK2). It has been used in the treatment of solid tumors, especially for patients with estrogen-receptor-positive breast cancer. The primary objective of this study was to determine the maximum tolerated dose (MTD) of S-1 and S-1/Cis in combination with S4811 in Japanese patients with advanced solid tumors. Patients were enrolled in this study if they had an Eastern Cooperative Oncology Group performance status of 0 or 1 and had histologically or cytologically confirmed solid tumors. Patients were treated with S-1 (30-60 mg/m2, q.d. on days 1-21) and S-1/Cis (60/30 mg/m2, q.d. on days 1-21) for 21 days. S-1 was administered on days 1-14, and S-1/Cis was administered on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4812is a drug that inhibits
 
Response: S4812is a drug that inhibits L-type calcium channels. It is used to treat hypertension and is a component of some antiarrhythmic drugs. It is the only drug in its class that is not metabolized by CYP3A4 and has a longer half-life than amiodarone (2-3 days).

What is the dose?

You should take S4812 twice a day with a meal.

What should I watch for?

Avoid taking S4812 with rifampin (Rifadin, Rimactane), it may decrease the effectiveness of S4812.

Avoid S4812 in patients who are allergic to amiodarone or iodine.

Do not use S4812 with other drugs that may increase the risk of bradycardia, such as digoxin (Lanoxin, Lopressor), lisinopril (Zestril), quinidine (Quin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4815is a drug that inhibits
 
Response: S4815is a drug that inhibits poly (ADP-ribose) polymerase-1 (PARP-1) by competitive binding at the catalytic site. The use of PARP-1 inhibitors in the treatment of cancer has been investigated extensively. PARP-1 is an important target for chemotherapy because of its involvement in DNA repair. It has been reported that S4815 causes synthetic lethality in *BRCA1* and *BRCA2* mutated breast cancer cells, and induces cancer cell death. It has also been shown to be effective in the treatment of non-*BRCA1/2* mutated breast cancers. A previous study has reported that PARP-1 inhibition induced poly-ADP-ribosylation of histones, which resulted in chromatin condensation, fragmentation and ultimately in apoptosis ([@b22-ijo-48-06-2277]). In this study, the effect of S4815 on the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4816is a drug that inhibits
 
Response: S4816is a drug that inhibits microtubule assembly. The drug has also been found to have antiproliferative activity against a wide variety of human cancer cells and to have some activity in clinical trials against non-small cell lung cancer. The drug is undergoing further development by a number of pharmaceutical companies. The principal active metabolite of S4816 is a quinone-like compound called S4816-Quinone.

References

External links
 
 

Category:Quinolines
Category:Phenol ethers
Category:Hepatotoxins
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4817is a drug that inhibits
 
Response: S4817is a drug that inhibits *de novo* purine synthesis by competing with phosphoribosyl pyrophosphate (PRPP) for binding to the enzyme PRPP synthetase.\[[@ref1]\] This drug is used for treatment of leukemia and lymphoma in combination with other anticancer drugs.\[[@ref2]\] The objective of this study was to compare the toxicity and pharmacokinetic parameters of gemcitabine and S-1 in combination with S-4817 in rats.

Materials and Methods {#sec1-1}
=====================

S-4817 (Nakayama Pharmaceutical Co., Osaka, Japan) was dissolved in sterile distilled water to give a 10 mg/ml stock solution and diluted in 5% dextrose injection (Daiichi Sankyo Co., Tokyo, Japan) to a final concentration of 5 mg/ml. Gemcitabine (Sigma
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4819is a drug that inhibits
 
Response: S4819is a drug that inhibits the adenosine kinase and blocks the effects of adenosine. It has been shown to be effective in the treatment of chronic myelogenous leukemia (CML), a disease that arises when an abnormality of a gene, called BCR-ABL, leads to uncontrolled proliferation of white blood cells. This article was prepared by Pamela A. Anderson, MA, CRC, and Joanne D. Moore, PharmD, BCPS, of the School of Pharmacy at the University of California, San Diego, CA.

Introduction {#s0010}
============

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the bone marrow characterized by the proliferation of abnormal, granulocytic cells in the bone marrow, spleen, and blood.[@bib1] In CML, a chromosomal abnormality called the Philadelphia chromosome arises from the translocation of chromosome
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4821is a drug that inhibits
 
Response: S4821is a drug that inhibits the P2X7 receptor (P2X7R) in the central nervous system. P2X7R activation results in an influx of calcium ions (Ca2+) into the cell and activates the transcription factor nuclear factor κB (NF-κB). P2X7R antagonists have been shown to have neuroprotective effects in several models of neurodegenerative diseases, including Alzheimer's disease (AD). Thus, the present study aimed to investigate the neuroprotective effect of P2X7R antagonist on behavioral deficits and neuropathology in an animal model of AD. Mice were administered with the P2X7R antagonist (P2X7R-ANT) by the intraperitoneal route. A water maze test was performed to evaluate spatial learning and memory. Histopathological analysis was performed in the hippocampus and cortex. Immunohistochemical staining for amyloid beta peptide (Aβ),
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4826is a drug that inhibits
 
Response: S4826is a drug that inhibits the production of adenosine. It was first synthesized in 1964 and was tested in animal models of schizophrenia, depression, and anxiety. It was discontinued in 1972.

The D4 receptor is a G-protein coupled receptor that is coupled to Gαs and inhibits adenylyl cyclase. The D4 receptor is expressed in the brain, pituitary, heart, and kidney.

Adenosine is a nucleoside that is naturally produced in the body and acts as a modulator of the nervous system. It can act as an extracellular messenger and has multiple functions.

The adenosine A2A receptor is a G-protein coupled receptor that inhibits adenylyl cyclase. It is expressed in the brain, spinal cord, heart, kidneys, liver, and lungs.

Antipsychotic

Risperidone

Quetiapine

A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4827is a drug that inhibits
 
Response: S4827is a drug that inhibits the synthesis of a protein (tryptophan) that is essential for the growth of bacteria. The specific target is a transcription factor called “tryptophanase” (TrpR). TrpR has a structure similar to other bacterial transcription factors (e.g., CysB and GyrB). It is a homodimer with two identical monomers in each subunit. The binding sites of TrpR are similar to the binding sites of the homologous transcription factors, so the drug will bind to TrpR in a similar fashion. Inhibition of TrpR causes the bacteria to stop growing, because TrpR is essential for bacterial growth.

We tested the ability of S4827 to inhibit the growth of several strains of B. burgdorferi. S4827 had a strong bactericidal effect against the spirochetes. In particular, S4827 killed B. burg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4828is a drug that inhibits
 
Response: S4828is a drug that inhibits LFA-1 function and blocks leukocyte migration.

L-816,186, an anti-LFA-1 antibody, is an inhibitor of T cell migration and homing to the skin.

References

Further reading 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4830is a drug that inhibits
 
Response: S4830is a drug that inhibits human myeloid cell adhesion to extracellular matrix proteins and decreases cellular invasion through matrigel^[@R11]^. However, S4830 has only modest effects on the growth of a number of human cancers, including AML and T-ALL^[@R11],[@R12]^.

Given the known association of *Notch* with the *AML1*/*RUNX1* oncogene in T-ALL^[@R9]^, we assessed the effect of S4830 on the growth of *AML1/Runx1*-transformed T-cell progenitors (T-ALL-progenitors)^[@R13]^. In contrast to normal T-cells, *AML1/Runx1*-transformed T-cells display stem-like properties and are highly tumorigenic *in vivo*^
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4831is a drug that inhibits
 
Response: S4831is a drug that inhibits cyclic adenosine monophosphate (cAMP) dependent protein kinase (PKA) by binding to the regulatory (R) subunit of the enzyme. The compound was designed to compete with cAMP for binding to the R subunit, thereby preventing cAMP from binding to the catalytic (C) subunit of PKA and inhibiting the enzyme. S4831 inhibits growth of a variety of human tumor cell lines and is currently in phase I and II clinical trials for the treatment of advanced and refractory malignancies. Inhibition of PKA activity also has potential therapeutic benefit in the treatment of depression. However, S4831 has been shown to induce the expression of a variety of genes involved in stress response and apoptosis. For example, in an animal model of depression, S4831 induced an antidepressant-like response.
S4831 has been shown to inhibit the growth of a variety of human tumor cell
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4832is a drug that inhibits
 
Response: S4832is a drug that inhibits inositol polyphosphate 5-phosphatase 1 (INPP5E), which is involved in the regulation of phosphoinositide-3 kinase (PI3K)/AKT signalling.^[@bib1],\ [@bib2]^ As a result, S4832 can inhibit the growth of multiple myeloma (MM) cells, and has been used as a therapeutic drug in preclinical and clinical trials.^[@bib3],\ [@bib4],\ [@bib5]^ We previously reported that a combination of S4832 and PI3K inhibitors is more effective than S4832 alone in MM cell lines and primary MM cells,^[@bib6]^ and it was also reported that S4832 and PI3K inhibitors induce apoptosis in MM cells.^[@bib7]^ In addition, we previously reported
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4833is a drug that inhibits
 
Response: S4833is a drug that inhibits S-adenosylhomocysteine hydrolase (SAHH), an enzyme that regulates the metabolism of the essential nutrient S-adenosylmethionine (SAM). S-adenosylmethionine is the primary methyl donor for methylation reactions that occur in DNA, proteins, and lipids. S-adenosylhomocysteine (SAH) is the byproduct of these reactions, and SAH hydrolase (SAHH) removes it from the system. S-adenosylmethionine is also a major precursor of the neurotransmitter serotonin, and some researchers have suggested that the drug increases serotonin levels in the brain, although the scientific community has been unable to identify the mechanism(s) that mediate this action. The FDA approved S-adenosylmethionine for the treatment of mild to moderate depression in 1997, and the drug has been approved for treatment of schizophrenia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4834is a drug that inhibits
 
Response: S4834is a drug that inhibits sigma receptor, a brain receptor, and may be effective in the treatment of some mental illnesses. It has been reported that L-S4834 attenuates the symptoms of psychosis in a number of psychiatric disorders, including schizophrenia. However, the potential of this drug for the treatment of Parkinson's disease (PD) is still unclear. The aim of the present study was to investigate the effects of L-S4834 on the symptoms of PD in rats. L-S4834 (1 and 10 mg/kg, i.p.) or haloperidol (1 mg/kg, i.p.) was administered to male Sprague-Dawley rats. Then, the rats were subjected to a series of behavioral tests, including the open field test, the rotarod test, and the conditioned avoidance response test. The rats were sacrificed and the brains were used for the immunohistochemical analysis of dopamine and acetylcholine receptor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4835is a drug that inhibits
 
Response: S4835is a drug that inhibits NHE1 by a mechanism that involves an active transport into the cell. NHE1 inhibition was assessed by measuring intracellular pH recovery after the addition of 20 mM NH~4~Cl to the extracellular solution (20 min, 37 °C). The data represent the mean ± SEM of *n* = 5 independent experiments. ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.001 versus control (one-way ANOVA followed by the Bonferroni test).Figure 5

The specific role of NHE1 was confirmed by siRNA-mediated silencing. After siRNA transfection, HEK-293 cells were incubated with S4835 (10 μM) for 1 h. NHE1 silencing was verified by Western blotting (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4836is a drug that inhibits
 
Response: S4836is a drug that inhibits Hsp90 chaperone activity and induces proteasome-dependent degradation of oncogenic client proteins including mutant p53. S4836 has shown activity in several phase I clinical trials for the treatment of solid tumours, lymphomas and myeloma. Here we show that, in contrast to the traditional cytotoxic chemotherapeutic agents, S4836 treatment of non-transformed cells induces apoptosis, not senescence, and does so in a p53-dependent manner. S4836-induced apoptosis requires mitochondrial outer membrane permeabilization, as evidenced by the loss of the mitochondrial membrane potential and release of cytochrome c into the cytosol. Moreover, treatment of cells with S4836 induces apoptosis in the absence of p53 but requires functional p53 for cell death to occur. Mechanistically, S4836 induces p53-dependent transcription of the Bcl-2 family pro-apopt
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4837is a drug that inhibits
 
Response: S4837is a drug that inhibits the expression of P-gp and MRP2. The inhibitory effect of S4837 on P-gp expression was examined in the presence of cycloheximide, an inhibitor of protein synthesis. P-gp expression was not detected in the presence of cycloheximide. These results suggest that the inhibitory effect of S4837 on P-gp expression is caused by its direct action on the protein itself and not by the inhibition of protein synthesis. S4837 inhibits MRP2 expression. The inhibitory effect of S4837 on MRP2 expression was examined in the presence of cycloheximide. MRP2 expression was not detected in the presence of cycloheximide. These results suggest that the inhibitory effect of S4837 on MRP2 expression is caused by its direct action on the protein itself and not by the inhibition of protein synthesis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4838is a drug that inhibits
 
Response: S4838is a drug that inhibits Rho kinase and also has the ability to upregulate vascular endothelial growth factor, which has the ability to increase blood vessel growth. It has been shown that S4838 can inhibit tumor growth in several types of cancer. In an early study, S4838 was given to patients with recurrent ovarian cancer and, while the treatment did not result in an improvement in overall survival, it did lead to improved disease-free survival. Another study showed that S4838 had anti-angiogenic properties in patients with breast cancer, and this resulted in a significant reduction in the size of the tumor.

In addition, S4838 has been shown to reduce levels of plasma VEGF and platelet derived growth factor. S4838 has also been shown to have a strong anti-angiogenic effect in human tumor xenografts, as well as an anti-proliferative effect in human cancer cells.

It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4839is a drug that inhibits
 
Response: S4839is a drug that inhibits L-type Ca2+ channels. It can be used in a wide range of studies that involve the cardiac L-type Ca2+ channels. It has been used to study many aspects of cardiac physiology including: 1) how changes in heart rate affect contractility; 2) the role of voltage-gated Ca2+ channels in cardiac pacemaking; 3) how drugs that block L-type Ca2+ channels influence the electrical activity of the heart; 4) the relationship between Ca2+ channels and Na+ channels in the heart; 5) the role of Ca2+ channels in the initiation and propagation of ventricular arrhythmias; and 6) the effects of different types of antiarrhythmic drugs on cardiac function.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4841is a drug that inhibits
 
Response: S4841is a drug that inhibits cell proliferation by interfering with the cell cycle, inducing apoptosis and affecting cell migration. We used this drug to investigate whether the miRNA expression profile of HeLa cells could be altered by this treatment. To this end, miRNA expression profiling was performed on HeLa cells treated with S4841. We identified 23 differentially expressed miRNAs, 11 of which were down-regulated and 12 up-regulated. These changes were consistent with the known mechanism of action of S4841. The 11 down-regulated miRNAs included miR-221, miR-222, miR-146a, miR-200c, miR-203, miR-17, miR-20a, miR-18a, miR-181b, miR-20b, miR-21 and miR-27b, which were all involved in the regulation of cell proliferation and apoptosis. We selected miR
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4843is a drug that inhibits
 
Response: S4843is a drug that inhibits caspase 3. However, it is not used as a potential treatment for PD because of the presence of unwanted side effects. PD, unlike caspase 3, is a well-characterized and less toxic therapeutic target. For this reason, the aim of this study was to examine the role of caspase 3 in the induction of cell death in RGC-5 cells treated with dopamine. RGC-5 cells were cultured and treated with dopamine in the presence or absence of a caspase 3 inhibitor, Z-DEVD-FMK. Cell death was determined by measuring LDH release. Apoptosis was determined by flow cytometry and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Caspase 3 activity was determined by Western blotting. The involvement of caspase 3 in dopamine-induced cell death was demonstrated by the fact that dopamine induced apoptosis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4844is a drug that inhibits
 
Response: S4844is a drug that inhibits CDK9/Cyclin T1 activity. When administered to cells, it binds to the pTEFb complex and disrupts its association with elongating RNA polymerase II, leading to decreased transcription of HIV-1 genes. In HIV-1 infected individuals, the S4844 is a component of the antiretroviral drug cocktail. 

S4844 is a selective inhibitor of the CDK9-Cyclin T1 complex, and of HIV transcription. It is one of the components of the HIV therapeutic cocktail, Sustiva. It has also been shown to be effective against Hepatitis B virus.

It is in clinical trials for treating other diseases such as cancer.

References

Category:Antiretroviral drugs
Category:Carboxamides
Category:Quinazolines
Category:Trifluoromethyl compounds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4845is a drug that inhibits
 
Response: S4845is a drug that inhibits histone deacetylase (HDAC). It has been shown to be highly effective in preclinical models of human leukemia and solid tumors. The objectives of this project are to determine the pharmacokinetics of S-5-Amino-4-carbamoyl-1,2-dihydro-6-methyl-7-p-tolyl-3H-pyrido[2,3-d]pyrimidin-4-one, S-5-Amino-4-carbamoyl-1,2-dihydro-6-methyl-7-p-tolyl-3H-pyrido[2,3-d]pyrimidin-4-one in tumor-bearing mice, and to determine the effects of S-5-Amino-4-carbamoyl-1,2-dihydro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4846is a drug that inhibits
 
Response: S4846is a drug that inhibits cytochrome P450 3A4 (CYP3A4), which is an important drug metabolizing enzyme that plays a major role in drug-drug interactions, especially for the metabolism of a number of important drugs. This study was conducted to evaluate the effect of S-4846 on the pharmacokinetics of the CYP3A4 substrates, clarithromycin and midazolam, in healthy subjects. Twelve subjects received a single oral dose of clarithromycin (500 mg) or midazolam (15 mg) alone or with S-4846 (500 mg). Blood samples were taken up to 24 hours after drug administration for measurement of plasma concentrations of clarithromycin and midazolam. The plasma concentrations of clarithromycin were not significantly different when S-4846 was coadministered with clarithromycin compared with clarithromycin alone. The mean peak plasma concentration of midaz
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4847is a drug that inhibits
 
Response: S4847is a drug that inhibits inosine monophosphate dehydrogenase (IMPDH), which is involved in the de novo biosynthesis of guanosine nucleotides. This inhibition results in a decrease in cellular de novo purine nucleotide synthesis, which is associated with growth arrest and cell death. The drug has been used for the treatment of cancer in combination with radiation therapy and in the treatment of hairy cell leukemia.

Nucleoside analogues are a class of compounds with important therapeutic uses in the treatment of viral infections, cancer, and autoimmune disorders. One of the most potent and selective nucleoside analogues is S-2-(3-azido-2-hydroxypropyl)cytosine (S-AZA-C, S-2-HPMPA, NSC 69766). It is an inhibitor of S-adenosylhomocysteine hydrolase (SAHase), a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4848is a drug that inhibits
 
Response: S4848is a drug that inhibits cyclin-dependent kinase (CDK) 4 and CDK6, which in turn inhibits the transcription of the cell cycle genes and cell proliferation. S4848is an oral CDK4/CDK6 inhibitor that was developed as a potential anticancer agent.

S4848 is a novel, potent, orally active, small-molecule CDK4/CDK6 inhibitor that selectively inhibits cell proliferation in a variety of human tumor cell lines. S4848 potently inhibits the proliferation of human tumor cell lines that are dependent on CDK4 and CDK6, including tumor cell lines with deregulated cell cycle progression, but not tumor cell lines that are dependent on CDK2. S4848 has demonstrated single-agent antitumor activity in xenograft models of non-small cell lung cancer, ovarian cancer, and melanoma. S4848 inhibited the growth of tumor xenografts and induced tumor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4849is a drug that inhibits
 
Response: S4849is a drug that inhibits DNA replication by targeting the polymerase β subunit. We demonstrate that S4849 is a potent inhibitor of cancer cell proliferation and induces cell cycle arrest and apoptosis in several cancer cell lines, including HCT-116, MDA-MB-231, A549, SK-OV-3 and HepG2. In addition, we found that S4849 caused marked reduction of the tumor size in an HCT-116 xenograft model. The antitumor activity of S4849 was significantly enhanced by the combination of gemcitabine. S4849 was not toxic to mice at the tested doses. S4849 is a potent and selective DNA polymerase β inhibitor that induces apoptosis and inhibits cancer cell proliferation. S4849 may have potential as a novel antitumor agent.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4850is a drug that inhibits
 
Response: S4850is a drug that inhibits dihydrofolate reductase (DHFR) and, consequently, inhibits thymidylate synthase (TS). This drug is an analogue of the folic acid molecule and its mechanism of action is based on the competition with folic acid for the binding sites of the enzyme DHFR.

S4850 is a drug that inhibits dihydrofolate reductase (DHFR) and, consequently, inhibits thymidylate synthase (TS). This drug is an analogue of the folic acid molecule and its mechanism of action is based on the competition with folic acid for the binding sites of the enzyme DHFR. S4850 is also a prodrug of 5-fluorouracil (5-FU) and, therefore, the active metabolite of the drug is 5-FU.

5-FU is an antimetabolite that inhibits thymidylate synthase (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4851is a drug that inhibits
 
Response: S4851is a drug that inhibits CDK4 and CDK6 by binding to their ATP-binding site and acts as an anticancer agent. In this study, the pharmacokinetics of S4851 was evaluated in mice, rats, dogs and monkeys. The results indicated that S4851 was metabolized to a major metabolite (M-1) by cytochrome P450 (CYP) 3A, but not by CYP1A, CYP2C, CYP2E1, or CYP2J. In addition, S4851 was distributed into the tissues, including the liver, lung, heart, kidney, and spleen, and was metabolized to M-1 in the liver. M-1 was eliminated into the bile in the liver. In vivo experiments showed that the Cmax of S4851 was higher in the group with high-dose S4851 treatment (15 mg/kg) than in the group with low
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4852is a drug that inhibits
 
Response: S4852is a drug that inhibits caspase-3 activation and prevents apoptosis in leukemic cells. S4852 is currently undergoing phase I/II clinical trials in patients with leukemia and lymphoma.^[@bib30]^ As an alternative to the inhibition of the intrinsic apoptotic pathway, we found that S4852 triggers caspase-independent necrosis. Our results are in line with a recent report showing that inhibition of apoptosis-inducing factor (AIF) by a small molecule or antisense oligonucleotides causes necrosis in the absence of caspase activation.^[@bib31]^ In this context, it is interesting to note that the inactivation of AIF is also observed in malignant gliomas.^[@bib32]^ In our model, the death receptor-induced apoptotic pathway is blocked, but AIF is not affected, indicating that S4852 causes necrosis. A
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4853is a drug that inhibits
 
Response: S4853is a drug that inhibits the synthesis of tetrahydrobiopterin (BH4) in the brain, which is the essential cofactor for the biosynthesis of neurotransmitters, such as dopamine, serotonin and norepinephrine, and that has neuroprotective effects. S-methyl-L-cysteine (SMC) is a BH4 precursor that can pass through the blood-brain barrier and is used as a positive control drug for BH4 deficiency. This study investigated the effect of S-methyl-L-cysteine on schizophrenia and assessed the potential mechanism. Twenty-eight patients with schizophrenia and 25 healthy subjects were recruited in this study. The effects of S-methyl-L-cysteine on the behavioral changes and serum homovanillic acid (HVA) levels in patients with schizophrenia were examined. The BH4 levels in the serum, platelets and urine of patients with schizophrenia and healthy subjects were also measured
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4854is a drug that inhibits
 
Response: S4854is a drug that inhibits GSK3 and induces differentiation in leukemic cells by activating Wnt signaling. It has been approved for the treatment of CML in chronic phase, but its use in AP is not recommended. T315I is the most frequent mutation observed in patients treated with TKIs. Our results showed that T315I-mutated BCR-ABL1 has a higher basal activity than the wild-type enzyme and that TKIs are able to decrease its activity. We also demonstrated that this mutant is more resistant to nilotinib and TAS-60 than to imatinib. We observed that T315I-mutated BCR-ABL1 is able to interact with Grb2, Grap, and Sos1, and this interaction was not affected by TKI treatment. However, the phosphorylation of Y412 in BCR-ABL1, which is required for its interaction with Grb2 and G
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4856is a drug that inhibits
 
Response: S4856is a drug that inhibits the cellular uptake of cholesterol and its synthesis. It has a short half-life and is eliminated by the kidneys. Its safety and efficacy have been studied in the treatment of cardiovascular disease in several large-scale clinical trials.[@R1] In combination with statins, it lowers the incidence of major cardiovascular events.[@R2]

Severity of coronary artery disease is an important determinant of clinical outcome. It has been reported that patients with three-vessel disease had a worse prognosis than those with one- or two-vessel disease.[@R3] Furthermore, patients with three-vessel disease had a higher incidence of sudden death than those with one- or two-vessel disease.[@R4] These findings suggest that there is a high risk of arrhythmia in patients with severe coronary artery disease.

Sevoflurane is a widely used volatile anesthetic. Sevoflur
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4859is a drug that inhibits
 
Response: S4859is a drug that inhibits the secretion of pro-inflammatory cytokines and mediates their suppression through the action of peroxisome proliferator-activated receptor gamma (PPARγ). This study aimed to evaluate the protective effects of S4859 on hippocampal neuronal damage and learning and memory impairment in a model of amyloid beta (Aβ)-induced Alzheimer's disease (AD). Aβ1-42 was injected into the hippocampus of Sprague-Dawley rats to induce learning and memory impairment. Then, S4859 was injected daily and animals were subjected to Morris water maze test. Hippocampal neuronal damage was determined by immunohistochemical staining and hippocampal expression of PPARγ, inflammatory cytokines, and matrix metalloproteinases (MMPs) were assessed by western blotting. We found that treatment with S4859 significantly improved spatial learning and memory impairment in Aβ-injected rats. Moreover, treatment with S4859
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4860is a drug that inhibits
 
Response: S4860is a drug that inhibits tyrosine kinase activity of epidermal growth factor receptor (EGFR) by binding to the ATP binding pocket of EGFR \[[@B1],[@B2]\]. It was approved by the US Food and Drug Administration (FDA) in 2007 and the European Medicines Agency (EMA) in 2008 for the treatment of patients with metastatic colorectal cancer (mCRC) whose tumors express wild-type (WT) *KRAS* and whose tumors are resistant to treatment with anti-EGFR antibodies.

Sorafenib is an oral multikinase inhibitor with activity against VEGFR, PDGFR, Raf, and FLT3. In a randomized phase III trial (REGARD study) \[[@B3]\], it showed a statistically significant prolongation of overall survival (OS) compared with placebo in patients with mCRC.

The combination of c
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4862is a drug that inhibits
 
Response: S4862is a drug that inhibits the synthesis of bile acids.  It is marketed as Naltrexone Hydrochloride, and is an opioid antagonist that is used to treat alcohol and opioid addiction.  It is available in both immediate-release and extended-release forms.

Naltrexone is a highly polar compound, and is poorly absorbed from the gastrointestinal tract.  When orally administered, it is almost completely metabolized in the liver by the enzyme CYP3A4, to a metabolite that is primarily excreted in the bile.

The drug was first synthesized in the 1960s.  It was developed for the treatment of alcoholism, but was found to be an effective treatment for opioid addiction.  It is administered orally, either as a single dose or as a daily dose.  The recommended starting dose is 0.25 mg, and the usual maintenance dose is 0.50 mg per day.  The most common side
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4865is a drug that inhibits
 
Response: S4865is a drug that inhibits the phosphatase activity of PTEN (phosphatase and tensin homolog deleted on chromosome 10). It is a synthetic molecule with high selectivity and affinity for the active site of PTEN and inhibits its phosphatase activity, resulting in increased levels of phosphorylated Akt. This compound has been investigated in preclinical and early phase I clinical trials in cancer patients, but it has shown limited efficacy.

**Objectives:** To assess the safety and efficacy of S4865 in patients with refractory solid tumors.

**Design:** Open-label, phase I study.

**Patients:** A total of 17 patients with advanced solid tumors refractory to standard therapy were enrolled.

**Treatment:** S4865 was administered intravenously on a 21-day schedule, repeated every 21 days. Dose escalation was performed in cohorts of 3 patients, starting with 5 mg/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4866is a drug that inhibits
 
Response: S4866is a drug that inhibits telomerase.\
**A**. U2OS cells were treated with increasing concentrations of BIBR1532 (3.3 μM, 6.6 μM, 13 μM) for 24 hours and the expression of the CDK inhibitor p21 was assessed by western blotting. **B**. U2OS cells were treated with increasing concentrations of BIBR1532 (3.3 μM, 6.6 μM, 13 μM) for 24 hours and cell viability was measured using the MTT assay. **C**. U2OS cells were treated with increasing concentrations of BIBR1532 (3.3 μM, 6.6 μM, 13 μM) for 24 hours and cell proliferation was assessed by flow cytometry. **D**. U2OS cells were treated with increasing concentrations of BIBR1532 (3.3 μM, 6.6 μM
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4867is a drug that inhibits
 
Response: S4867is a drug that inhibits the enzyme glycogen synthase kinase-3 (GSK-3) and has potential use in treating diabetes. The drug is administered orally and is absorbed from the gastrointestinal tract.
The metabolism of S4867is complex. It is a prodrug and the majority of the administered dose is metabolized in the liver to form S8457, a more potent and more stable inhibitor of GSK-3. Inhibition of GSK-3 results in increased glycogen accumulation in the liver. The liver glycogen is converted into glucose in the liver and released into the blood stream. Increased glucose levels in the blood stream result in reduced glucose levels in the blood stream. The clinical use of S4867has been limited by the fact that the dose needed to produce a significant effect is very high.
This invention provides compositions and methods for treating a subject suffering from a disease or condition in which glycogen accumulation is desired, the compositions comprising an effective
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4868is a drug that inhibits
 
Response: S4868is a drug that inhibits a key protein that helps the brain grow.

S4868is an antidepressant that affects the neurotransmitters that play a role in mood.

S4868is a drug that helps the body process fats and cholesterol.

S4868is a drug that lowers blood pressure.

S4868is a drug that relieves symptoms of pain.

S4868is a drug that is used to treat people with bipolar disorder.

S4868is a drug that is used to treat a group of diseases that affect the blood, including multiple myeloma, myelodysplastic syndrome, polycythemia vera, primary myelofibrosis, and acute myelogenous leukemia.

S4868is a drug that is used to treat schizophrenia.

S4868is a drug that is used to treat ulcerative colitis.

S4868is a drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4869is a drug that inhibits
 
Response: S4869is a drug that inhibits the action of protein phosphatase-1 and has been used in clinical trials for a number of diseases, including rheumatoid arthritis, multiple sclerosis and cancer. S4869 has been reported to have a variety of pharmacological activities, including inhibition of cell proliferation and promotion of apoptosis. However, there is limited information about the cellular effects of S4869 and its relationship to apoptosis. The purpose of this study was to investigate the effects of S4869 on cell cycle and apoptosis in the human pancreatic cancer cell line PANC-1. S4869 caused G2/M arrest in a dose-dependent manner. The sub-G1 phase and phosphatidylserine externalization were also increased in S4869-treated cells. S4869 induced caspase-dependent apoptosis, as evidenced by increased caspase-3/7 activity and cleavage of caspase-3, casp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4870is a drug that inhibits
 
Response: S4870is a drug that inhibits the intracellular effects of a wide range of cytokines. It is a small molecule that has been in development for more than 20 years. It is a monoclonal antibody that has been in development for over 20 years. In the first part of this review, we will look at the mechanisms of action of tocilizumab and rilonacept. In the second part, we will review the pharmacokinetics, clinical efficacy and safety profile of tocilizumab and rilonacept in rheumatoid arthritis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4871is a drug that inhibits
 
Response: S4871is a drug that inhibits the enzyme farnesyltransferase, thereby blocking the attachment of the farnesyl group to the oncogenic protein Ras, a critical step in Ras oncogenic activity. FRAX597 is a prodrug that is activated by a broad spectrum of carboxylesterases (CES) to FRAX486. FRAX486 is then hydrolyzed by CES to release FRAX2358. FRAX2358 is a substrate for CES, and is released from the CES-mediated reaction to form FRAX2359, which is further hydrolyzed to release FRAX4929. FRAX4929 inhibits farnesyltransferase. Inhibition of Ras farnesylation by FRAX4929 results in inhibition of Ras activation, cell cycle arrest and apoptosis.

Aprepitant (EMEND) is an inhibitor of the 5-HT3 receptor. This receptor has
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4874is a drug that inhibits
 
Response: S4874is a drug that inhibits the enzyme monoamine oxidase A (MAO-A) and may be used for the treatment of patients with major depression and other psychiatric disorders. To date, clinical trials with a large number of subjects have been conducted in the US and other countries. In this report, we describe the results of an observational study of subjects enrolled in these trials.

In March 2001, the US Food and Drug Administration approved the use of m-Tyr-Pro-Leu-Gly-NH2 (mTPLG) as a diagnostic aid in subjects suspected of having hyperhidrosis. In June 2003, the manufacturer of mTPLG terminated all ongoing clinical trials with this drug and stated that it would no longer produce or market mTPLG. We conducted an observational study of subjects enrolled in clinical trials with mTPLG to examine the incidence of adverse events and the safety of this drug.

Results

Study Population

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4875is a drug that inhibits
 
Response: S4875is a drug that inhibits the growth of new blood vessels (angiogenesis) in tumors, thus blocking the growth of tumors and reducing their size. It also works by inhibiting the ability of tumor cells to grow and spread. In cancer treatment, the anticancer effects of S4875 are combined with conventional treatments.

S4875 is an oral medicine that works by blocking the production of the Vascular Endothelial Growth Factor (VEGF) protein. This is a protein that stimulates the growth of new blood vessels in tumors. It also works by inhibiting the ability of tumor cells to grow and spread. In cancer treatment, the anticancer effects of S4875 are combined with conventional treatments.

S4875is a drug that inhibits the growth of new blood vessels (angiogenesis) in tumors, thus blocking the growth of tumors and reducing their size. It also works by inhibiting the ability of tumor cells to grow and spread. In cancer treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4876is a drug that inhibits
 
Response: S4876is a drug that inhibits NF-κB activation by binding to the IKKγ subunit, thereby blocking NF-κB signaling. S4876 was originally discovered by screening for compounds that inhibit the NF-κB-dependent reporter activity in LPS-stimulated HEK293 cells ([@bib3]).

S4876 was found to be effective in a mouse model of chronic colitis, an IL-10--deficient mouse model of colitis. In this model, mice were treated with 2.5% dextran sodium sulfate in drinking water for 7 days to induce colitis. S4876 was administered orally for 7 days after the start of the dextran sodium sulfate treatment. This dose of S4876 significantly reduced the clinical symptoms of colitis. The effect of S4876 was comparable to that of a recombinant IL-10 treatment. S4876 treatment also inhibited IL-6 and IL-1β production
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4877is a drug that inhibits
 
Response: S4877is a drug that inhibits protein synthesis and the cell cycle in tumour cells and has been shown to inhibit growth of a number of tumours. The aim of this study was to determine whether administration of S4877 can prolong the survival of mice bearing a human colorectal carcinoma. We studied the effects of continuous oral administration of S4877 on the growth of human colorectal carcinoma in mice. Mice were treated with S4877 at a dose of 10 mg/kg, administered by gavage daily, 5 days a week for 10 weeks. This dose of S4877 was found to inhibit tumour growth by 50% in mice carrying the colorectal carcinoma. Administration of S4877 at a dose of 20 mg/kg, 5 days a week for 10 weeks, prolonged the median survival of the mice from 22 to 43 days (P = 0.03). A maximum tolerated dose of S4877 was not reached in this
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4878is a drug that inhibits
 
Response: S4878is a drug that inhibits the human aldose reductase (hAR) enzyme. This enzyme catalyzes the reduction of aldoses to the corresponding alcohols and was found to be the first enzyme in the polyol pathway. Polyols, including sorbitol, mannitol, and myo-inositol, are toxic to cells, especially to those of the nervous system, and are believed to play a role in the formation of senile plaques, a hallmark of Alzheimer's disease.

S4878is a drug that inhibits the human aldose reductase (hAR) enzyme. This enzyme catalyzes the reduction of aldoses to the corresponding alcohols and was found to be the first enzyme in the polyol pathway. Polyols, including sorbitol, mannitol, and myo-inositol, are toxic to cells, especially to those of the nervous system, and are believed to play a role
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4880is a drug that inhibits
 
Response: S4880is a drug that inhibits ATP production, and has been reported to induce cell cycle arrest and apoptosis in several cancer cell lines \[[@R32]--[@R34]\]. To determine whether EGCG or SB203580 can also inhibit the cell proliferation of RCC, the cells were treated with EGCG or SB203580, respectively, for 72 h, and then MTT assay was used to measure cell viability. As shown in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}, both EGCG and SB203580 decreased the cell viability of RCC cells in a dose-dependent manner. These results indicated that EGCG or SB203580 can inhibit cell proliferation of RCC cells.

![EGCG and SB203580 can inhibit the cell proliferation of RCC cells\
A and B. Cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4881is a drug that inhibits
 
Response: S4881is a drug that inhibits mammalian target of rapamycin (mTOR) and is being tested in several Phase I and II clinical trials for various cancers, such as breast, lung, and prostate cancer.^[@bib1]^ This drug was also shown to suppress autophagy, a cellular response that has been proposed as a promising strategy to overcome chemoresistance.^[@bib2]^ However, a major concern with mTOR inhibition is the lack of specificity of the drug.^[@bib3]^

We have recently shown that the Akt inhibitor MK-2206 (MK)^[@bib4]^ and the mTOR inhibitor rapamycin (Rapa)^[@bib5]^ can inhibit autophagy by acting on a single node in the autophagy signaling pathway, the Unc-51-like kinase 1/2 (ULK1/2) complex. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4883is a drug that inhibits
 
Response: S4883is a drug that inhibits viral replication and stimulates the immune system. It has been used for treating hepatitis B and C. S4883 has been found to be effective in combination with interferon and ribavirin.

S4883 has been used as an immunomodulator for treating diseases such as hepatitis B and C.

S4883is a drug that inhibits viral replication and stimulates the immune system. It has been used for treating hepatitis B and C. S4883 has been found to be effective in combination with interferon and ribavirin.

S4883has been used for treating hepatitis B and C. It has been found to be effective in combination with interferon and ribavirin. S4883has been found to inhibit replication of hepatitis B virus in the human liver cell line HepG2.

S4883is a drug that inhibits viral replication and stimulates the immune system. It has been used for treating
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4885is a drug that inhibits
 
Response: S4885is a drug that inhibits *D. discoideum* cell cycle progression, in particular the G1/S transition \[[@RSOB170047C16]\]. The drug is a cell-permeable inhibitor of phosphatidylinositol 3-kinase (PI3K) that has a dual effect: it increases the amount of phosphatidylinositol 3,4,5-trisphosphate (PIP~3~), a lipid messenger produced by PI3K, and it blocks PIP~3~-dependent activation of Akt \[[@RSOB170047C16]\]. A large body of work has shown that PIP~3~ is essential for the G1/S transition and cell proliferation, in particular for the transcriptional activation of the cyclin D1 gene, a key regulator of cell cycle progression \[[@RSOB170047C20]\].
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4886is a drug that inhibits
 
Response: S4886is a drug that inhibits the cell cycle by preventing progression from the G1 to the S phase.^[@R48]^

To determine whether AMPK is involved in regulating cell cycle progression, we analyzed cell cycle phase distribution by flow cytometry. Cells were treated with DMSO, A769662, or S4886 for 24 hours. Cells were then harvested, washed with cold PBS, fixed in ice-cold 70% ethanol, and stored at 4°C for 24 hours. The cells were then washed with PBS and stained with propidium iodide (PI) for 30 minutes. The cell cycle phase distribution was then analyzed using a BD FACS Canto flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The results showed that AMPK activation reduced the percentage of cells in S phase, but increased the percentage of cells in G2/M phase ([Fig. 4A](#F4){ref-type
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4887is a drug that inhibits
 
Response: S4887is a drug that inhibits the enzyme RNA polymerase and has been widely used as an antibiotic in the clinic. We reported previously that S4887 had a high potential to induce genomic DNA damage and genotoxicity. In the present study, the effects of S4887 on chromosomal damage in peripheral blood lymphocytes (PBLs) of Chinese healthy donors were investigated. The results indicated that S4887 caused chromosomal damage and genotoxicity, which was mainly characterized by chromosomal aberration (CA) and micronucleus (MN) formation. The CA and MN frequencies were 1.8% and 2.2%, respectively, in the PBLs of normal controls (NCs). S4887 induced dose-dependent increases in the CA and MN frequencies. In addition, S4887 induced a significant increase in the level of the cyclin-dependent kinase (CDK) inhibitor p21, a key regulator of cell cycle progression. In conclusion,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4889is a drug that inhibits
 
Response: S4889is a drug that inhibits a protein called ROCK. It is used in many countries for treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is also used to treat resistant chronic heart failure. The drug can be used alone or in combination with other drugs.

Sildenafil is a drug that is used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is also used to treat resistant chronic heart failure. The drug can be used alone or in combination with other drugs.

Imatinib is a drug that is used to treat chronic myeloid leukemia (CML).

Ambrisentan is a drug that is used to treat pulmonary arterial hypertension (PAH).

Tracleer is a drug that is used to treat chronic thromboembolic pulmonary hypertension (CTEPH).

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4890is a drug that inhibits
 
Response: S4890is a drug that inhibits Cdk2/cyclin A. Cdk2/cyclin A is a key component of the cell cycle machinery that regulates the G1/S transition and it is overexpressed in a number of different cancer types. In a phase I clinical trial of Cdk2/cyclin A in solid tumors, 7 of 17 patients with pancreatic cancer had a partial response and 5 had stable disease, indicating that Cdk2/cyclin A is a valid target in this disease ([@bib1]). It is therefore a rational strategy to target Cdk2/cyclin A in patients with GIST.

GISTs are usually characterized by mutations in either the KIT or PDGFRA genes. Activating mutations in the KIT or PDGFRA genes are present in ∼95% of GISTs and result in the constitutive activation of downstream signaling pathways ([@bib2]). Imatinib, a small-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4893is a drug that inhibits
 
Response: S4893is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8294Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8329Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8332Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8337Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8338Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8339Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8345Is a drug that inhibits calcium channel function and thereby may reduce proliferation of HNSCC cells.

S8346Is a drug that inhibits
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4896is a drug that inhibits
 
Response: S4896is a drug that inhibits the synthesis of DNA. It is currently undergoing Phase II clinical trials in the United States.

See also 
 9-Hydroxy-7,8,9,10-tetrahydro-2-acridine carboxamide

References 

Category:Chromenes
Category:Pyrrolidines
Category:Acridines
Category:Catechol ethers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4899is a drug that inhibits
 
Response: S4899is a drug that inhibits thrombin and factor Xa, and reduces the risk of major bleeding. However, this agent has a risk of serious adverse effects, including intracranial bleeding, as a result of a high dose. Although it is not approved for use in patients with acute coronary syndrome (ACS), several clinical trials have demonstrated the efficacy of a high dose of enoxaparin in preventing VTE and reducing mortality and major bleeding in this setting. Although enoxaparin has not been approved for use in patients with ACS, several clinical trials have demonstrated the efficacy of a high dose of enoxaparin in preventing VTE and reducing mortality and major bleeding in this setting.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S49076is a drug that inhibits
 
Response: S49076is a drug that inhibits the activation of the dopamine D1 receptor and acts as a 5-HT2 receptor antagonist and serotonin uptake inhibitor. The effect of this drug on striatal dopamine and serotonin release has been studied in the rat brain using in vivo microdialysis. The results of this study suggest that the effect of S49076 on dopamine and serotonin release in the striatum is biphasic, the effect being maximal at low doses and reaching a plateau at high doses. S49076, at doses that are ineffective on extracellular dopamine and serotonin, was able to increase extracellular levels of dopamine and serotonin when given alone. In the case of dopamine, the increase was significant only at doses of S49076 higher than those that were effective in the inhibition of 5-HT release. In the case of serotonin, the increase in extracellular levels of this neurotransmitter was significant only at doses of S49076 higher than those that were
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4930is a drug that inhibits
 
Response: S4930is a drug that inhibits VEGFR2 phosphorylation by Src-dependent pathway \[[@B64-cancers-12-01034]\]. A Phase II clinical trial with S4920 in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer was conducted by U.S. National Cancer Institute \[[@B65-cancers-12-01034]\]. A single-agent Phase I/II trial of S4920 in patients with advanced solid tumors was also conducted by U.S. National Cancer Institute \[[@B66-cancers-12-01034]\]. The results indicated that S4920 is well tolerated and has antitumor activity in patients with solid tumors. A Phase II clinical trial of S4920 in combination with paclitaxel in patients with metastatic breast cancer is currently ongoing (NCT03392922).

Dasatin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4931is a drug that inhibits
 
Response: S4931is a drug that inhibits eIF2α phosphorylation by blocking eIF2α kinase (GCN2). To test whether S4931 affected the ability of FMDV to induce the IFN response, the concentration of S4931 in the culture medium was increased. The result showed that the dose-dependent inhibition of FMDV replication by S4931 was correlated with its concentration in the medium. At the same time, S4931 was found to promote the accumulation of FMDV RNA in the cells. However, S4931 did not affect the induction of IFN-β by FMDV infection. We also found that S4931 promoted the degradation of FMDV RNA, which was caused by the inhibition of the PKR-dependent phosphorylation of eIF2α, and this effect was not correlated with the dose of S4931 in the medium. Taken together, our results showed that the PKR-dependent phosphory
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4932is a drug that inhibits
 
Response: S4932is a drug that inhibits the fusion of endosomes with lysosomes. When taken by mouth, it may help reduce the risk of fluid build-up in the lungs, and has been used to treat cystic fibrosis.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4933is a drug that inhibits
 
Response: S4933is a drug that inhibits the Nox1 and Nox2-mediated generation of ROS in neutrophils and monocytes/macrophages. We first studied the effects of S4933 on cell death in murine neutrophils, as determined by monitoring phosphatidylserine externalization and propidium iodide uptake. S4933 was found to be a potent inhibitor of ROS production and cytotoxicity in murine neutrophils. The effects of S4933 on ROS production were abolished in neutrophils from Nox2-deficient mice. Moreover, S4933 did not inhibit ROS production in murine monocytes and macrophages. These results indicate that S4933 inhibits ROS production in murine neutrophils by targeting Nox2. We then studied the effects of S4933 on cytokine production by LPS-stimulated neutrophils. The production of TNF-α, IL-1β, and IL-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4935is a drug that inhibits
 
Response: S4935is a drug that inhibits an enzyme called telomerase, which is essential for the replication of the telomeres that protect our chromosomes. If we can inhibit telomerase in cancer cells, they will die because their telomeres are too short to replicate any more. So, we have to give the cells time to die. The reason we give them time to die is that they are still going to cause damage to our tissues, so we need to protect the tissue that is going to receive the cell that is going to die. So, S4935is used in conjunction with a radiation therapy called XRT, which means that it is not used in isolation. The drug has to be given after XRT, and it has to be given for at least five days, and usually for seven days.

But the reason that we need to use it for so long is because we don't want to cause damage to normal tissues. If we give the cells just a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4939is a drug that inhibits
 
Response: S4939is a drug that inhibits the DNA methyltransferase (DNMT) 1 and 3 enzymes and restores the DNA methylation status. *In vitro* studies showed that S4939 has antitumor activity against human cancer cell lines (HeLa, HT-29, HCT116, SW480, HCT8, and SW620) and has antiangiogenic activity in a murine model of tumorigenesis \[[@B79-ijms-15-12972]\]. S4939 has been evaluated in a phase I study of patients with advanced solid tumors and lymphoma and was well tolerated with no dose-limiting toxicities \[[@B80-ijms-15-12972]\]. S4939 was shown to induce global demethylation in primary human breast tumor xenografts and inhibited the growth of breast cancer cells by induction of cell cycle arrest and apoptosis \[[@B81-ijms-15-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4940is a drug that inhibits
 
Response: S4940is a drug that inhibits phosphatidylinositol 3-kinase and is currently in Phase I clinical trials. We assessed the efficacy of S4940 in the treatment of CDI in a mouse model of infection. Infected mice were treated with S4940 or placebo for 7 days and were then monitored for diarrhea and survival. The severity of diarrhea was assessed by the number of days the animals had diarrhea and the amount of liquid they produced. The number of S. flexneri c.f.u. in the stool was determined on days 2 and 4 post-infection. S4940 significantly reduced the severity of diarrhea, the amount of stool produced and the number of c.f.u. in the stool. The mice treated with S4940 also had significantly fewer deaths. The results of this study demonstrate that S4940 is a potent inhibitor of CDI in mice.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4949is a drug that inhibits
 
Response: S4949is a drug that inhibits the growth of breast cancer cells. We have demonstrated that S4949 treatment decreases cell proliferation, enhances cell death, and decreases cell migration. In addition, we have shown that S4949 has no effect on cell proliferation of the immortalized breast epithelial cell line, MCF10A, and has only a modest effect on cell proliferation of the human mammary epithelial cell line, MCF12A.

**Conclusions:** Our results indicate that S4949 inhibits breast cancer cell proliferation by inducing apoptosis, decreasing cell migration, and inhibiting cell proliferation. Our results also demonstrate that S4949 has little effect on breast epithelial cells and that the cell line MCF10A is not suitable as a model system for testing S4949.

P908: Cytotoxic effects of Nelarabine on breast cancer cells are potentiated by radiation {#cesec2080}
------------------------------------------------------------------------------------------
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4952is a drug that inhibits
 
Response: S4952is a drug that inhibits TGF-beta-activated kinase 1 (TAK1) and is currently in clinical development as a potential therapeutic agent for autoimmune diseases and inflammatory conditions such as systemic sclerosis.^[@R1]^ TAK1 is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family and a key regulator of the MAPK signaling pathway.^[@R2]^ TAK1 activation is initiated by the phosphorylation of its C-terminal regulatory region by the MAP3Ks TAK1-binding protein 1 (TAB1) and TAK1-binding protein 2 (TAB2).^[@R3],[@R4]^ TAK1 then phosphorylates the downstream effector kinases, MKK3/6 and p38, which activate the proinflammatory transcription factors, NF-κB and AP-1, respectively.^[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4953is a drug that inhibits
 
Response: S4953is a drug that inhibits tyrosine kinase activity.

The hypothesis is that VEGF-R2/KDR signaling pathway is involved in cell migration and invasion. This hypothesis is based on our previous finding that VEGF-R2/KDR signaling pathway is involved in MDA-MB-231 cell migration and invasion ([@b13-bt-23-301]).

As shown in [Fig. 2A](#f2-bt-23-301){ref-type="fig"}, [2B](#f2-bt-23-301){ref-type="fig"}, S4953 blocked the migration and invasion of MDA-MB-231 cells in a dose-dependent manner.

S4953 inhibits VEGF-induced angiogenesis
----------------------------------------

We performed *in vitro* angiogenesis assays to determine the anti-angiogenic activity of S4953. In this
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4957is a drug that inhibits
 
Response: S4957is a drug that inhibits a protein called PI-3 kinase, a cell signalling molecule which plays a role in a number of cellular processes including proliferation and migration. It is used in the treatment of a number of different types of cancer, such as prostate, ovarian, breast, lung and gastrointestinal cancers.

RAD001is an inhibitor of mammalian target of rapamycin (mTOR) and the second generation of mTOR inhibitor to be developed.

Gefitinibis an oral EGFR tyrosine kinase inhibitor. It inhibits the tyrosine kinase activity of the EGFR and blocks downstream signalling pathways, resulting in growth inhibition and apoptosis in vitro and in vivo. It is used in the treatment of non-small cell lung cancer.

Iressais a reversible inhibitor of the tyrosine kinase activity of the EGFR, and blocks downstream signalling pathways, resulting in growth inhibition and apoptosis in vitro and in vivo
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4958is a drug that inhibits
 
Response: S4958is a drug that inhibits calcineurin and has been used for many years in humans. However, its use in children has been limited due to the known toxicity and the possibility of systemic side effects. We report a patient with steroid-resistant nephrotic syndrome (SRNS) who was successfully treated with intravenous S4958.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4964is a drug that inhibits
 
Response: S4964is a drug that inhibits the conversion of cytochrome P450 3A4 (CYP3A4) into active metabolite. In the present study, we examined the effects of S4964 on the pharmacokinetics of midazolam and digoxin in the rat. The influence of S4964 on the in vitro metabolism of midazolam and digoxin was also examined. Midazolam (2 mg/kg) was administered to rats by intravenous injection, and the blood samples were collected at intervals. The concentrations of midazolam and its metabolites were determined by high-performance liquid chromatography. S4964 was orally administered at a dose of 20 mg/kg for 14 days, and the pharmacokinetics of midazolam was then examined. In addition, the effect of S4964 on the pharmacokinetics of digoxin was examined by administering the drug (1 mg/kg) with or without S4964.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4971is a drug that inhibits
 
Response: S4971is a drug that inhibits HIF-1α prolyl-4-hydroxylase and thereby prevents its proteasomal degradation. To date, S4071 has been tested in various cancers, including pancreatic cancer. S4071 was also found to be effective in HCT116 cells, a human colon cancer cell line with a *Kras* mutation. In this study, the authors found that the *Kras* mutation was the major determinant of sensitivity to S4071, and that the HCT116 cells were resistant to S4071 due to a p53 mutation. Moreover, S4071 inhibited tumor growth in nude mice carrying HCT116 xenografts. These results suggest that HIF-1α inhibitors may be promising anticancer agents for colon cancer, and that the HCT116 xenograft model could be used for preclinical evaluation of HIF-1α inhibitors in human colon cancer.

Taken together,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4972is a drug that inhibits
 
Response: S4972is a drug that inhibits the enzyme cyclin-dependent kinase (CDK) 9, and inactivates the transcription factor C-EBPβ. Both these proteins are required for the survival of virus-infected cells and therefore, inhibition of CDK9 and C-EBPβ leads to a decrease in viral load. S4972 is being developed by a company called Boehringer Ingelheim.

By increasing the expression of C-EBPβ, Noxa (a protein involved in apoptosis) is also increased. Noxa then interacts with the anti-apoptotic protein Mcl-1 and promotes apoptosis. The combined effect of S4972 and Noxa results in an increase in the apoptosis of infected cells and therefore, a decrease in the viral load.

Interactions
S4972 has been shown to interact with CDK9 and C-EBPβ.

References


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4973is a drug that inhibits
 
Response: S4973is a drug that inhibits mammalian ras farnesyltransferase, and has been shown to be effective in the treatment of cancers that are dependent on farnesylation of ras for growth. However, the mechanism by which S-4973 exerts its effects has not been established. Here, we show that S-4973 specifically induces the degradation of oncogenic H-Ras. In H-Ras-transformed cells, S-4973 rapidly induced the formation of a detergent-insoluble fraction containing H-Ras and c-Raf-1, which contained ubiquitin-conjugated proteins. Inhibition of proteasome activity by MG-132 and lactacystin prevented the accumulation of H-Ras in the detergent-insoluble fraction. These data suggest that S-4973 causes the accumulation of ubiquitinated proteins in cells through the inhibition of proteasome activity. Consistent with this
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4975is a drug that inhibits
 
Response: S4975is a drug that inhibits GSK3beta.

SBIR/STTR

Project Summary/Abstract

Glutamate (Glu) is the major excitatory neurotransmitter in the mammalian central nervous system (CNS). In addition to mediating fast excitatory synaptic transmission, Glu also modulates synaptic transmission through activation of ionotropic Glu receptors and metabotropic Glu receptors. In the hippocampus, Glu signaling has been shown to play an important role in spatial learning and memory. In fact, studies using Glu receptor antagonists have shown that blockade of Glu receptors impairs the ability of animals to learn a variety of tasks. In the hippocampus, Glu receptors are expressed in both pre- and post-synaptic sites. The pre-synaptic Glu receptors are of the N-methyl-D-aspartate (NMDA) type. The NMDA receptor is a heteromeric complex composed of the obligatory G
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4976is a drug that inhibits
 
Response: S4976is a drug that inhibits cyclin-dependent kinases (CDKs) and is effective in cell cycle arrest and apoptosis of a wide variety of human cancer cell lines. The aim of the present study was to investigate the mechanism of S4976-induced apoptosis of K562 cells. Cell cycle analysis and annexin V/PI staining revealed that S4976 treatment resulted in accumulation of cells in the G0/G1 phase. In addition, expression of p21 and p27, two important CDK inhibitors, was induced by S4976. Furthermore, inhibition of CDK2 by RNA interference (RNAi) or CDK2 kinase activity by roscovitine significantly increased S4976-induced apoptosis. Taken together, these data suggest that S4976 induces apoptosis of K562 cells by suppressing CDK2 kinase activity, leading to induction of CDK inhibitors p21 and p27.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4977is a drug that inhibits
 
Response: S4977is a drug that inhibits the mTOR (mechanistic Target Of Rapamycin) protein kinase. mTOR is a master regulator of cell growth and proliferation, and has emerged as a major target for anticancer drug development. mTOR is a serine/threonine kinase that exists in two functionally distinct multiprotein complexes. The mTORC1 complex contains mTOR, raptor, mLST8, PRAS40 and DEPTOR, and is the most well characterized mTOR signaling complex. The mTORC2 complex contains mTOR, rictor, mSin1, mLST8, DEPTOR and protor.
Temsirolimus (CCI-779) is a drug approved by the U.S. FDA for the treatment of advanced renal cell carcinoma (RCC) and is currently in phase III clinical trials for the treatment of a variety of solid tumors. Temsirolimus is a macrol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4978is a drug that inhibits
 
Response: S4978is a drug that inhibits CDK4/6. Phase I clinical trials in patients with advanced cancer have demonstrated a high degree of tolerability. It has been administered once every 3 weeks, and it has been well-tolerated at doses up to 40 mg. The most common adverse events reported in the phase I clinical trial were nausea, fatigue, and vomiting. The most common grade 3 or 4 adverse events were fatigue and vomiting. A phase I trial of pan-CDK inhibitors is underway. These agents have shown activity in preclinical studies. One trial has been completed and reported. The recommended phase II dose of this agent is 600 mg twice daily.

**Dabrafenib**

**Mechanism of action**

This agent inhibits BRAF, an oncogene associated with melanoma. It blocks the mitogen-activated protein kinase (MAPK) pathway. This pathway is activated in many types of cancer. The FDA approved dab
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4980is a drug that inhibits
 
Response: S4980is a drug that inhibits the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway. In this study, we investigated the effect of S4980 on the proliferation and invasion of breast cancer cells and the expression of the PI3K/Akt/mTOR signaling pathway. S4980 inhibited the proliferation of MDA-MB-231 and MCF-7 cells in a dose-dependent manner. The invasion of MDA-MB-231 cells was inhibited by S4980, and the effect of S4980 was reversed by treatment with the PI3K inhibitor LY294002. Furthermore, S4980 inhibited the expression of the phosphorylated Akt, mTOR, and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) proteins, which are key proteins of the PI3K/Akt/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4983is a drug that inhibits
 
Response: S4983is a drug that inhibits GSK3β by increasing phosphorylation of GSK3β at Ser9, and promotes β-catenin translocation into the nucleus \[[@B63-ijms-21-00509]\]. A recent study showed that S4983 could be used to target GSK3β in the cytoplasm of GBM cells \[[@B64-ijms-21-00509]\]. The authors showed that S4983-treated GBM cells underwent autophagy and cell death.

The non-steroidal anti-inflammatory drug ibuprofen is an inhibitor of cyclooxygenase-2 (COX-2) that also activates AMPK, a kinase that phosphorylates GSK3β, promoting its activation \[[@B65-ijms-21-00509]\]. The expression of COX-2 is upregulated in GBM
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4986is a drug that inhibits
 
Response: S4986is a drug that inhibits proliferation of prostate cancer cells by suppressing activation of the androgen receptor (AR) and androgen-dependent signaling. To investigate the anti-tumor effects of S4986 in a mouse model of prostate cancer, S4986 was administered daily for 14 days at a dose of 50 or 100 mg/kg, and the anti-tumor effect was compared with that of an AR antagonist, bicalutamide. S4986 at both doses suppressed tumor growth by inhibiting proliferation of cancer cells. Interestingly, S4986 at a dose of 50 mg/kg was effective in suppressing tumor growth, whereas bicalutamide at a dose of 10 mg/kg was not. S4986 also inhibited tumor growth by suppressing activation of the AR and AR-dependent signaling in the prostate cancer cells. These results suggest that S4986 is a promising drug for the treatment of prostate cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4988is a drug that inhibits
 
Response: S4988is a drug that inhibits proliferation of breast cancer cells, in part, by blocking the expression of FGF2.[@bib0165]Fig. 2Alkylating agents: alkylating agents and DNA-cross-linking agents induce DNA damage.

### Other classes of agents {#sec0040}

Among the most widely used anticancer agents, anthracyclines, the DNA-cross-linking agent mitomycin C, the topoisomerase inhibitors, the taxanes, the Vinca alkaloids, the boronates, and platinum-based compounds have been demonstrated to act by inhibiting the expression of FGF2.[@bib0170], [@bib0175], [@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200] A recent study has suggested that inhibition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4991is a drug that inhibits
 
Response: S4991is a drug that inhibits both Kv11.1 and Kv11.3 channels, as well as Kv1.3 and Kv1.5 channels, at a concentration of 5 µM. In contrast, APS4985 has a higher selectivity for Kv11.1 and Kv11.3 channels (IC~50~ = 6.3 µM) than for Kv1.3 and Kv1.5 channels (IC~50~ = 45 µM) [@B049]. Moreover, in the same study, it was shown that APS4991 is able to block Kv11.1 and Kv11.3 channels, with an efficacy similar to that of tertiapin-Q, and to block Kv1.3 and Kv1.5 channels, with an efficacy similar to that of tertiapin-Q. APS4991 can therefore be considered a Kv
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4994is a drug that inhibits
 
Response: S4994is a drug that inhibits the acetylcholinesterase and was approved for the treatment of Alzheimer\'s disease in the year 2002. It has been found that S4994 binds to the AChE in the brain and inhibits the neurotransmitter acetylcholine, resulting in improvement of the cognitive function. The most important action of S4994 is the inhibition of acetylcholinesterase in the brain and the correction of cholinergic deficiency, which leads to the improvement of the cognitive function of the patient.\[[@ref1]\]

S4994 is administered orally. The drug is given in the form of a tablet and a suspension in water. The dose of S4994 is 15 mg/day.\[[@ref2]\]

The drug has been marketed as Eszopiclone in the United States of America.\[[@ref3]\]

S4994 is classified as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4996is a drug that inhibits
 
Response: S4996is a drug that inhibits the acetylcholine-induced influx of extracellular Ca2+ in smooth muscle. The present study investigated the effects of S4996 on various contractile responses to cholinergic agonists in isolated guinea pig ileum. The order of potency of cholinergic agonists in producing contraction in the ileum was carbachol > acetylcholine > or = methacholine > or = histamine. S4996 produced a concentration-dependent inhibition of carbachol-, acetylcholine- and histamine-induced contractions. The inhibitory effects of S4996 on carbachol-induced contractions were reversible and the pA2 value for S4996 was 9.6 +/- 0.2. S4996 shifted the concentration-response curves for acetylcholine and carbachol to the right in a parallel fashion, but S4996 did not affect the concentration-response curve for hist
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S4999is a drug that inhibits
 
Response: S4999is a drug that inhibits the ability of bone cells to resorb bone. It may help to relieve the pain of osteoporosis in postmenopausal women, and is sometimes used in the treatment of bone fractures. In animal models, it appears to be a selective inhibitor of osteoclasts and an activator of bone formation.

SAXILOR is a drug that inhibits the ability of bone cells to resorb bone. It may help to relieve the pain of osteoporosis in postmenopausal women, and is sometimes used in the treatment of bone fractures. In animal models, it appears to be a selective inhibitor of osteoclasts and an activator of bone formation.

Other brands in this category include:

SIROPROS is a drug that inhibits the ability of bone cells to resorb bone. It may help to relieve the pain of osteoporosis in postmenopausal women, and is sometimes used in the treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5005is a drug that inhibits
 
Response: S5005is a drug that inhibits the biosynthesis of adenosine in the brain. It is not used clinically in the USA.

Clinical trials 
Clinical trials were conducted in patients with ALS or FTD, as well as other neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.   The first Phase II clinical trial was conducted in patients with ALS in 2003. In the following year, the trial was expanded to include patients with FTD.

The clinical trials with S5005 were initially conducted at Columbia University, then moved to the University of Michigan. The phase II clinical trial with S5005 was completed in 2005. The initial trial was a 6-month, double-blind, placebo-controlled trial, in which the effects of S5005 on patients with ALS or FTD were evaluated.  The results of this trial showed that the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5006is a drug that inhibits
 
Response: S5006is a drug that inhibits
the enzyme cyclooxygenase (COX-2) that is involved in the
production of the inflammatory prostaglandin 2 (PGE2) in the
body.

S-5006 is a potent and highly selective
COX-2 inhibitor that selectively inhibits PGE2 synthesis in
vitro. In the rat, oral administration of S-5006 resulted in
significant inhibition of PGE2 formation in the stomach,
intestine, colon and liver, as well as the kidneys. S-5006
also significantly inhibited the PGE2 formation in human
epithelial cell lines. The compound showed a high degree of
selectivity for COX-2, with IC50 values in the range of
10 to 40 nM for COX-1 and 2, respectively.

S-5006 significantly inhibited the induction of
IL-1β and TNF-α
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5007is a drug that inhibits
 
Response: S5007is a drug that inhibits the protein kinase, BCR-ABL1, which causes chronic myeloid leukemia (CML).

Marketed as STI571, S5007 was approved by the US FDA in March of 2002 for use in the treatment of adult patients with CML who are resistant or intolerant to treatment with imatinib mesylate (Gleevec). S5007 is administered by mouth twice daily.

In February of 2004, the FDA approved a once-daily formulation of S5007.

S5007 is a reversible inhibitor of the tyrosine kinase activity of BCR-ABL1. S5007 binds to the ATP-binding pocket of the kinase domain of BCR-ABL1, but does not bind to other tyrosine kinases. S5007 also inhibits several other kinases that are activated by BCR-ABL1.

S5007 can
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5009is a drug that inhibits
 
Response: S5009is a drug that inhibits PDE4, but there are many other PDE inhibitors, and all of them inhibit the enzyme.

CYP2D6 metabolizes MDMA, so it is not surprising that it also metabolizes 4-methylcathinone.

[MDMA] causes more nausea than other sympathomimetics, including [MDMA]. The evidence is weak, but there are some data to suggest that it may cause more nausea than the sympathomimetics in the amphetamine family.

Methylone is a very dangerous drug.

MDMA is more neurotoxic than PCP, so it is important to keep MDMA and other amphetamines out of the hands of people who may take them as "legal highs."

MDMA is a very dangerous drug.

MDMA, in the amounts that are being used recreationally, does not cause severe withdrawal symptoms.

MDMA is a Schedule I drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5010is a drug that inhibits
 
Response: S5010is a drug that inhibits an enzyme in the pathway that metabolizes catecholamines. This results in a buildup of catecholamines, which in turn causes the adrenal glands to increase production of cortisol. If you have a lot of catecholamines, cortisol can over-stimulate the adrenals, causing them to produce too much cortisol, leading to too much cortisol in the blood. This leads to cortisol resistance, meaning that the adrenals aren't responding to normal amounts of cortisol. So instead of the adrenals producing normal amounts of cortisol, they're producing more cortisol than the body needs, leading to low blood cortisol levels. It also has an effect on the adrenal glands, which can lead to other problems, including adrenal insufficiency.

S5010is the only drug that has been shown to increase blood cortisol levels. It's been shown to increase blood cortisol levels by 25-40% in patients who are resistant to cortisol. This
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5012is a drug that inhibits
 
Response: S5012is a drug that inhibits the formation of an activated complex of the Raf-MEK-ERK pathway in a manner similar to Raf inhibitors. The RAS-RAF-MEK-ERK signaling pathway is activated in several human cancers and its inhibition leads to a decreased cell proliferation and increased apoptosis. Inhibition of this pathway has been shown to be effective in several animal models of cancer. The drug has shown to have potent anti-proliferative and anti-tumor activity in patients with solid tumors, particularly in combination with other anticancer agents. It is currently in Phase III clinical trials for treatment of patients with advanced cancer.

Necitumumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It was developed by Hoffmann-La Roche.

Cetuximab is a chimeric monoclonal antibody against EGFR, which is approved in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5013is a drug that inhibits
 
Response: S5013is a drug that inhibits the replication of SARS-CoV and, to a lesser extent, MERS-CoV in Vero E6 cells \[[@CR45]\]. SARS-CoV-2 infection of Vero E6 cells showed a reduction in viral replication by about 80% at 72 h post infection, and a reduction of about 90% in SARS-CoV-2 infection was observed at 96 h post infection \[[@CR45]\]. SARS-CoV-2 replication was also inhibited by approximately 70% at 48 h post infection in Calu-3 cells \[[@CR45]\]. Therefore, a direct comparison of the effect of S5013 on SARS-CoV-2 and SARS-CoV replication is not possible.

In a mouse model of SARS-CoV infection, S5013 was shown to inhibit viral replication by about 80% in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5014is a drug that inhibits
 
Response: S5014is a drug that inhibits tubulin polymerization. It has a potency of approximately 100-fold less than nocodazole, which is used clinically to treat cancer. Thus, while PIK3CA mutants and AKT phosphorylation are known to contribute to tumorigenesis, the relationship between these events and tumor formation in vivo is not known.

In our previous studies, we showed that a small percentage of human breast tumors (2.3%) have PIK3CA mutations (Hickey et al., [@B19]; Lee et al., [@B28]). However, in this study, we show that loss of *p53* in combination with a PIK3CA mutation is sufficient to promote the formation of mammary tumors in mice. Importantly, these tumors were not observed in the presence of the *p53* mutation alone. This indicates that loss of *p53* in combination with a PIK3CA mutation can be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5015is a drug that inhibits
 
Response: S5015is a drug that inhibits the enzymatic activity of Cdk5. In the current study, the authors examined the effects of S5015 on learning and memory in a novel object recognition task. The results of the behavioral experiments demonstrated that S5015 improved the memory deficits induced by Aβ1-42 oligomers. These effects were associated with a reduction in the formation of autophagosomes and a decrease in the number of cleaved caspase-3 positive cells in the hippocampus. However, these effects were not observed when the Aβ1-42 oligomers were injected into the dentate gyrus. This suggests that the therapeutic effect of S5015 is likely due to the activation of the autophagy-lysosome pathway in the dentate gyrus. In addition, S5015 also prevented the Aβ1-42 oligomers-induced reduction in dendritic spine density. Taken together, these results suggest that S5015 may have therapeutic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5016is a drug that inhibits
 
Response: S5016is a drug that inhibits the action of a hormone called growth hormone (GH) that is produced by the pituitary gland. It is used to treat adults who have certain types of cancer, such as breast cancer, lung cancer, and prostate cancer, and to reduce the size of the growth of bones in children with certain types of cancer and to treat children with Noonan syndrome.

It is sometimes given with another drug called pegvisomant, which inhibits the action of a hormone called somatostatin.

There are several brands of S5016is, including:

S5016is Tablets (Tablets)

S5016is Film-Coated Tablets (Tablets)

S5016is Solution (Injection)

S5016is (Powder for Oral Use)

How does S5016is work?

S5016is works by reducing the amount of growth hormone that is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5017is a drug that inhibits
 
Response: S5017is a drug that inhibits Rho kinase and has been shown to be effective in a number of different diseases including hypertension, heart failure and diabetes, as well as pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) (Natarajan, A. et al. 2009. Nat Rev Drug Discov 8:98-111; Banno, M. et al. 2010. Clin Exp Pharmacol Physiol 37:695-700; and Banno, M. et al. 2009. J Am Coll Cardiol 55:2129-2139). In animal models of PH, S5017is has been shown to be effective in the prevention and treatment of the disease. The drug is also currently being evaluated in clinical trials for PH. S5017is has been shown to be effective in animal models of PAH. PAH is a severe disease with a poor prognosis, with the average survival time of PAH patients being less
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5018is a drug that inhibits
 
Response: S5018is a drug that inhibits the biosynthesis of folic acid, a B vitamin essential for cell growth and the production of nucleic acids, proteins, and other substances necessary for life. It is administered by mouth to treat leukopenia, a low white blood cell count, caused by chemotherapy or radiation therapy. In addition, S5018 is used in the treatment of tuberculosis. In the United States, S5018 is available as an oral suspension containing sodium metabisulfite and sulfadiazine.

Adverse Events

S5018 may cause a number of side effects, including nausea, vomiting, diarrhea, and skin rash. The most serious side effect is agranulocytosis, a decrease in the number of white blood cells. This may result in increased risk of infection. S5018 may also cause other serious side effects, including seizures, abnormal heart rhythm, low blood pressure, chest pain, or blurred vision. S5018 may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5019is a drug that inhibits
 
Response: S5019is a drug that inhibits STAT5 and NFκB, two molecules that are central to the action of IL-2. In both IL-2 dependent T cells and the RCC cell line 786-O, STAT5 and NFκB were inhibited by S5019. These data suggest that S5019 is a novel inhibitor of IL-2 and may be useful in the treatment of patients with IL-2 independent RCC.

It has been proposed that IL-2 is a key molecule in the transition from innate to acquired immunity ([@b19-ijo-45-05-1634]). Our study showed that S5019 treatment resulted in a significant reduction of the number of tumor-associated macrophages, which are a major source of TNFα. These results suggest that S5019 treatment may prevent the tumor progression in the RCC mouse model. Further studies are required to determine whether the tumor progression is affected by S5019 in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5020is a drug that inhibits
 
Response: S5020is a drug that inhibits the activity of an enzyme called FK506-binding protein (FKBP), which is part of the mechanism by which HIV disables the immune system. S5020 is a derivative of the drug Tacrolimus (Prograf) which is used to treat kidney transplant patients. It is an active ingredient in the antiviral drug Tivicay. It was developed by Tibotec (which has since been acquired by Johnson & Johnson). The company's product is known as Sublimate and is used to treat the symptoms of Shingles. Sublimate is not FDA approved.

S5020 is a prodrug of an active metabolite of tacrolimus. It is used to treat organ rejection in kidney transplant patients. Tacrolimus is a calcineurin inhibitor and is used to prevent the immune system from attacking the transplanted kidney. S5020 is given orally, and it is metabolized in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5023is a drug that inhibits
 
Response: S5023is a drug that inhibits the renin-angiotensin system (RAS) and thereby reduces blood pressure. We investigated the long-term effects of sotalol on left ventricular (LV) function in patients with LV dysfunction (LVD). LVD was defined as LV ejection fraction (LVEF) ≤ 50%. We enrolled 20 patients (12 men, mean age 56 ± 13 years) with LVD who were taking sotalol for at least 1 year and who had LVEF ≤ 50%. We evaluated LV function using speckle tracking echocardiography and conventional echocardiography before and after 6 months of sotalol therapy. The parameters of LV function were measured using a modified Simpson's rule and compared before and after sotalol therapy. LVEF increased significantly from 31 ± 8% to 42 ± 9% after 6 months of sotalol therapy (p < 0.001). LV end-syst
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5025is a drug that inhibits
 
Response: S5025is a drug that inhibits the cell cycle at the G2/M phase, and the drug acts on the inner cell membrane. Because the cells at the G2/M phase are vulnerable to drug toxicity, cell cycle arrest is an important factor in cell death. Therefore, S5025 could induce cell death by inhibiting the cell cycle at the G2/M phase. In the present study, we found that S5025 induced cell death in SNU-449 and MKN-45 cells. The activation of caspase-3 and PARP cleavage was involved in the apoptotic cell death induced by S5025. However, the effects of S5025 on cell cycle regulation were weaker than those of S5024. These results suggest that the anti-cancer effects of S5024 and S5025 are different.

The present study also showed that the expression of CSC markers was significantly down-regulated by S5024 and S5025
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5027is a drug that inhibits
 
Response: S5027is a drug that inhibits FtsZ, a bacterial cell division protein, and has the potential to treat bacterial infections.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5028is a drug that inhibits
 
Response: S5028is a drug that inhibits tumor cell proliferation by inducing apoptosis and arresting cell cycle progression. S5028 is a potent inducer of p53, and it is being developed as a single agent and in combination with a variety of anticancer drugs for the treatment of a wide range of solid tumors, including breast cancer, non-small cell lung cancer, colon cancer, ovarian cancer, and prostate cancer. A phase I trial of S5028 in patients with advanced solid tumors was initiated in October 2001. S5028 has demonstrated single-agent activity in several tumor types, and in combination with several other agents. S5028 has also been evaluated in a phase II trial of patients with advanced solid tumors. S5028 was well tolerated as a single agent, but when combined with carboplatin, paclitaxel, or topotecan, dose-limiting toxicities were observed. In combination with gemcitabine, S5028 demonstrated an acceptable safety profile
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5029is a drug that inhibits
 
Response: S5029is a drug that inhibits the Ca(2+)-activated K(+) channel (KCa) and reduces intracellular Ca(2+) concentration ([Ca(2+)]i). The present study was designed to examine the effects of S5029 on contractile responses to KCl and acetylcholine (ACh) in rat ventricular myocytes. The changes in [Ca(2+)]i in response to ACh were examined by use of the Ca(2+)-sensitive dye fura-2. Isolated rat ventricular myocytes were stimulated by ACh (1 microM) in the presence of 10 microM nifedipine. The cell shortening was measured as an index of the contractile responses. The amplitudes of the responses to ACh were significantly inhibited by S5029 in a concentration-dependent manner. The amplitude of the response to ACh was reduced by 52% with 1 microM S5029, whereas
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5030is a drug that inhibits
 
Response: S5030is a drug that inhibits the reuptake of serotonin (5-hydroxytryptamine) in the brain. S-methylergometrine is a methylated derivative of ergot alkaloids. S-methylergometrine has a similar pharmacological profile to S-methylergometrine but with a longer half-life and better oral bioavailability.

S-methylergometrine has been used as an abortifacient. It was originally developed as a potential oral contraceptive. S-methylergometrine acts on the brain and spinal cord to produce a sensation of warmth and pleasantness, and to increase the blood pressure. It has also been used for the treatment of migraines.

S-methylergometrine is available in oral tablet form, and as a topical gel.

Side effects

The following side effects have been reported:

Fainting
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5031is a drug that inhibits
 
Response: S5031is a drug that inhibits cyclooxygenase (COX) and thus prostaglandin synthesis. It is widely used for the treatment of rheumatoid arthritis and pain associated with osteoarthritis and gouty arthritis. S-ketamine is a structural analogue of ketamine, and it is a NMDA receptor antagonist and an anaesthetic agent.

The oral administration of S-ketamine significantly increased extracellular glutamate in the medial prefrontal cortex of rats. By contrast, the intravenous administration of S-ketamine did not increase extracellular glutamate in the medial prefrontal cortex. S-ketamine inhibited the release of glutamate in the medial prefrontal cortex of rats and was thus considered to reduce the excitatory effect of glutamate. In the medial prefrontal cortex of rats, S-ketamine inhibited the expression of COX-2 and the production of prostaglandin E2. The inhibition of COX-2 and prostaglandin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5032is a drug that inhibits
 
Response: S5032is a drug that inhibits the activity of the enzyme phosphatidylinositol-4-phosphate 5-kinase (PI-4-P 5-kinase) that catalyzes the conversion of phosphatidylinositol 4-phosphate (PI 4-P) to phosphatidylinositol 4,5-bisphosphate (PI 4,5-P2). It also increases the accumulation of PI 4,5-P2 and hence PIP2. These changes in phosphoinositide metabolism may be associated with an increase in calcium influx and Ca2+-dependent chloride currents.

See also
Akt inhibitor
AKT inhibitor
Brivanib
PDK1 inhibitor
PI-3 kinase inhibitor
PKB/AKT inhibitor
PI-3 kinase inhibitor
PI-3 kinase/Akt/mTOR pathway

References

External links
 
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5033is a drug that inhibits
 
Response: S5033is a drug that inhibits the enzyme phosphofructokinase, an enzyme that is a key regulator of glycolysis and gluconeogenesis in the liver. This drug is used in patients with glycogen storage disease type 1a and is used to treat and prevent ketosis in diabetic patients. SGLT2 inhibitors lower blood glucose by preventing glucose reabsorption in the kidney. The FDA approved this drug for type 2 diabetes and for the treatment of type 2 diabetes in combination with metformin. SGLT2 inhibitors can be used to treat patients with type 1 diabetes and to prevent diabetes in patients at high risk for developing type 2 diabetes. The only known SGLT2 inhibitor is dapagliflozin.

Therapeutic Effect

SGLT2 inhibitors increase urinary glucose excretion and decrease blood glucose levels. These drugs have a low risk of hypoglycemia. They are used to treat type 2 diabetes.

Therape
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5034is a drug that inhibits
 
Response: S5034is a drug that inhibits MMP-2 and MMP-9, resulting in the prevention of cancer cell invasion. In this study, the effect of S5034 on invasion and growth of human hepatoma cell line was investigated. We found that S5034 significantly inhibited invasion of Huh7 cells through Matrigel-coated membrane and that its growth was also suppressed. The anti-invasive effect of S5034 was due to inhibition of MMP-2 and MMP-9 activities and not due to cell proliferation inhibition. Furthermore, we observed that S5034 treatment reduced the activities of both MMP-2 and MMP-9, resulting in a significant inhibition of cancer cell invasion. In conclusion, S5034, a specific inhibitor of MMP-2 and MMP-9, has an anti-invasive effect on human hepatoma cells, which may be a promising agent for the treatment of hepatocellular carcinoma.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5035is a drug that inhibits
 
Response: S5035is a drug that inhibits osteoclast activity and thus decreases bone resorption. It has been shown to decrease fracture rates and bone turnover markers. It has also been shown to reduce bone loss in postmenopausal women and patients with osteoporosis.[@b25-cpaa-6-021]

Taken together, these studies demonstrate that ALCAR is able to decrease bone resorption in vitro and in vivo.

ALCAR and pain
==============

While the effect of ALCAR on bone is well documented, its effect on pain is less well known. We conducted a literature search using the databases Medline and PubMed with the following search terms: alcar, alcur, acetyl-L-carnitine, analgesia, pain, osteoarthritis, and rheumatoid arthritis. We found seven relevant studies that examined the effects of ALCAR on pain and/or analgesia. These studies are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5036is a drug that inhibits
 
Response: S5036is a drug that inhibits farnesyltransferase. The prenylation of proteins is an essential process that is required for the association of proteins with the plasma membrane, endocytosis, signal transduction and regulation of cellular activities. Farnesyltransferase catalyzes the post-translational modification of proteins by attaching a 15-carbon farnesyl group to the cysteine residue of CAAX motifs (Cys-Aaa-Xaa-Aaa-Xaa) (Aaa=aliphatic amino acid) at the C-terminus of proteins. Inhibition of farnesyltransferase prevents the post-translational farnesylation of proteins and blocks their function. The CAAX box is a motif in proteins that regulates their subcellular localization. In particular, proteins with CAAX box are localized in the plasma membrane. The farnesyltransferase inhibitor is also a farnesyltransferase
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5037is a drug that inhibits
 
Response: S5037is a drug that inhibits protein synthesis in eukaryotic cells. S5037 is used to treat patients with relapsed or refractory multiple myeloma and as maintenance therapy for patients with newly diagnosed multiple myeloma who have achieved a complete response (CR) or a very good partial response (VGPR) after induction therapy.

Mechanism of action

S5037 is an inhibitor of the translational elongation factor eIF-2B. It is believed that S5037 interferes with the formation of the eIF-2B-GTP-tRNAi complex and prevents the interaction of eIF-2B with eIF-2, which is required for the formation of the eIF-2-GTP-tRNAi complex. This prevents the binding of the ternary complex to the ribosome and, therefore, inhibits protein synthesis.

Pharmacokinetics

Absorption


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5039is a drug that inhibits
 
Response: S5039is a drug that inhibits the binding of the coactivator peptide to the steroid receptor. S5039 can also block the nuclear translocation of steroid receptor. It can also inhibit the interaction of the coactivator with the ligand-bound steroid receptor. This compound has a wide spectrum of biological activities and is currently in Phase II clinical trials. S5039 is also under investigation as an anti-cancer agent. S5039 is currently undergoing Phase II clinical trials in Japan for the treatment of lung cancer. In the United States, it is being tested for the treatment of breast cancer. It has also been tested in phase I clinical trials in the U.S. for the treatment of acute leukemia. The compound is currently being investigated for the treatment of prostate cancer.

History 

The discovery of S5039 was based on a high throughput screen of a chemical library.

Mechanism of action 

S5039 inhibits the binding of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5040is a drug that inhibits
 
Response: S5040is a drug that inhibits HSP90 by binding to its ATP binding pocket. A previous study demonstrated that PHT was a potent HSP90 inhibitor that showed antiproliferative activity in several cancer cell lines and enhanced the antitumor activity of a broad spectrum of chemotherapeutic drugs \[[@B36-ijms-19-00139]\]. However, the antitumor effect of PHT in AML was not evaluated in this study. To the best of our knowledge, this is the first report to demonstrate that PHT inhibited cell proliferation and induced apoptosis in human AML cell lines and primary AML cells. The IC~50~ values of PHT for KG1a and NB4 cells were 9.4 and 3.6 μM, respectively.

Heat shock protein 90 (HSP90) is an essential molecular chaperone in the eukaryotic cytosol that plays a key role in the proper
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5042is a drug that inhibits
 
Response: S5042is a drug that inhibits the action of the tumor promoter 12-0-tetradecanoylphorbol-13-acetate in the mouse skin. We studied the effects of S5042 on the skin tumors induced by initiation with 7,12-dimethylbenz(a)anthracene and promotion with croton oil in the mouse. S5042 significantly reduced the incidence and multiplicity of skin tumors in this mouse model. When applied to the tumor-bearing skin of mice after a promotion period, S5042 also inhibited the development of papillomas. In vitro experiments demonstrated that S5042 inhibited the production of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse skin. S5042 also inhibited the epidermal ornithine decarboxylase activity induced by tumor promoters, such as teleocidin and mezere
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5043is a drug that inhibits
 
Response: S5043is a drug that inhibits the protein phosphatase 2A (PP2A). It is being developed for the treatment of Huntington's disease (HD) and other disorders. In an open-label trial, SAG-517 was safe and well tolerated, with a favorable safety profile and a good tolerability profile. Furthermore, SAG-517 showed preliminary efficacy in delaying the time to clinical worsening in HD.

Objectives
==========

The aim of this study was to evaluate the safety and tolerability of SAG-517 in patients with HD.

Methods
=======

This was a 12-week, open-label, single-center, phase IIa study. A total of 12 patients with HD (diagnosed according to the HD clinical diagnostic criteria) were treated with SAG-517. Patients received SAG-517, 10 mg twice daily, for 12 weeks. Efficacy measures included the Unified Huntington's Disease Rating Scale
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5046is a drug that inhibits
 
Response: S5046is a drug that inhibits tubulin polymerization and microtubule dynamics by binding to the colchicine binding site on tubulin, and induces cell cycle arrest at G2/M. It has been approved for the treatment of patients with acute myeloid leukemia (AML) and multiple myeloma (MM).

The importance of microtubules in cell division was first recognized in the early 1900s. Colchicine, a natural compound first isolated from the autumn crocus (Colchicum autumnale), was shown to inhibit microtubule polymerization.^[@bib1]^ Colchicine has a wide range of biological effects, including inhibition of cell division, and thus it was initially used as a chemotherapeutic agent. The microtubule-binding agent vinblastine was approved by the FDA in 1972 for the treatment of patients with Hodgkin\'s lymphoma, and in 1978, paclitaxel
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5048is a drug that inhibits
 
Response: S5048is a drug that inhibits lysosomal degradation of protein aggregates. This drug is effective in models of Parkinson's disease, Alzheimer's disease, and Huntington's disease \[[@CR89]\]. Unfortunately, its efficacy in prion disease models is unknown. A new, orally active, small molecule, TZP-101, has been identified to ameliorate neurodegeneration in the RML model of prion disease. TZP-101 reduces the accumulation of insoluble PrP^Sc^, restores microglial phagocytosis, and rescues neurons \[[@CR90]\]. The FDA has approved TZP-101 for the treatment of prion disease, and clinical trials are currently underway \[[@CR90]\].

Targeting PrP^C^-Mediated Signaling {#Sec10}
-----------------------------------

Another strategy for ameliorating prion disease involves targeting
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5049is a drug that inhibits
 
Response: S5049is a drug that inhibits NF-κB activation, which is important in the regulation of the expression of many genes, including genes involved in inflammation. This drug has shown good efficacy in animal models of autoimmune diseases, including collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). We performed a double-blind, placebo-controlled, randomized study to investigate the efficacy and safety of S5049 in patients with active RA. A total of 50 patients with active RA were randomly assigned to receive 10 mg of S5049 or placebo, three times a day for 6 months. Efficacy and safety were evaluated at 2 and 6 months. After 6 months, the S5049 group had significantly greater improvement in the swollen joint count and erythrocyte sedimentation rate than the placebo group. At 6 months, the S5049 group had significantly better scores for the American College of Rheumatology (ACR) criteria and the Disease Activity Score in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5051is a drug that inhibits
 
Response: S5051is a drug that inhibits the action of a cellular enzyme called thymidylate synthase (TS). In cells, TS converts a molecule of the DNA building block thymidine into deoxyuridine. Because TS is required for the production of DNA, it is an important target for cancer chemotherapy.

The TS protein, encoded by the TYMS gene, is a 453-amino acid, type II transmembrane protein. In the body, TS is found in many cell types, including those of the gastrointestinal tract and immune system. The TYMS gene has three isoforms, TS-α, TS-β, and TS-γ. TS-α and TS-β are both active forms, while TS-γ is a non-functional form.

This drug was developed in the 1980s by the drug companies Hoffman La Roche and Hoffmann-La Roche Inc. It is currently marketed as 5-FU.

FOL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5052is a drug that inhibits
 
Response: S5052is a drug that inhibits the production of IL-2, IL-4, IL-5, and IL-10 in humans and mice.^[@bibr44-1759720X19876468]^ The role of IL-2 in EAE is well established. IL-2 is the major T-cell growth factor that promotes the development and expansion of CD4^+^ T cells.^[@bibr45-1759720X19876468]^ The IL-2 receptor consists of two subunits, the IL-2R*α* and IL-2R*β*. IL-2R*α* is constitutively expressed, whereas IL-2R*β* is inducible. IL-2R*β* is upregulated in activated CD4^+^ T cells and is important for IL-2 signal transduction. IL-2 is essential for the development of T cells in the th
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5054is a drug that inhibits
 
Response: S5054is a drug that inhibits the protein kinase C (PKC) isoenzyme PKCε. This isoenzyme has been shown to be involved in the proliferation of cancer cells. Therefore, it is likely that S5054 would inhibit the growth of cancer cells. To test this hypothesis, we examined the effect of S5054 on cell proliferation in human leukemia cell lines. We found that S5054 inhibited the proliferation of HL-60 and U937 cells in a dose-dependent manner. In addition, S5054 induced apoptosis in both cell lines. In contrast, S5054 did not inhibit the proliferation of THP-1, K562, K562-R, and U937-R cells, which are human leukemia cell lines resistant to anticancer drugs. Thus, S5054 selectively inhibits the proliferation of human leukemia cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5055is a drug that inhibits
 
Response: S5055is a drug that inhibits Src family tyrosine kinases, including Lyn and Lck, which are involved in signaling from the CD3 and CD4 receptor complexes to T cells, and is thus a potent inhibitor of T cell activation. Src family kinases are important mediators of T cell receptor-mediated signaling. These kinases are activated upon binding of the T cell receptor (TCR) to the MHC-peptide complex on antigen presenting cells, and are then recruited to the CD3 and CD4 receptors on the T cell membrane. Inhibition of Src family kinases blocks T cell activation, suggesting that Src family kinases are potential targets for therapeutic intervention. Src family kinases are also known to be involved in growth and development of the immune system.
Lyn is expressed in T cells and is involved in the early signaling events following T cell activation. Lyn associates with the cytoplasmic tail of the T cell receptor (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5056is a drug that inhibits
 
Response: S5056is a drug that inhibits the production of platelet-activating factor (PAF) in human monocytes and a variety of cell types. It is a water-soluble, synthetic phospholipid that has been used for decades as a PAF antagonist in animal models of sepsis. This randomized, double-blind, placebo-controlled, dose-ranging, phase 2 trial assessed the safety and efficacy of sivelestat in patients with severe sepsis.

Methods

Patients with severe sepsis or septic shock were randomly assigned to receive either sivelestat or placebo for 5 days. The primary efficacy endpoint was 28-day mortality. Safety endpoints included death within 28 days of enrollment, treatment-related adverse events, and abnormal liver function tests. A second prespecified exploratory analysis compared the efficacy of sivelestat to that of an intravenous immunoglobulin.

Conclusions

This trial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5058is a drug that inhibits
 
Response: S5058is a drug that inhibits the DNA repair enzyme, O6-methylguanine DNA methyltransferase (MGMT). In this phase I trial, patients with advanced solid tumors were treated with vadastuximab pyrrolobenzodiazepine (ABT-888) at doses ranging from 0.2 to 10 mg/kg given as a single intravenous (IV) infusion on day 1 of a 21-day cycle. Dose escalation was permitted after evaluation of 3 patients per dose level. Twenty-seven patients were enrolled. The maximum tolerated dose (MTD) was 10 mg/kg. The most common treatment-related toxicities were reversible hypersensitivity reactions, anemia, and thrombocytopenia. Partial responses were observed in 1 patient with head and neck cancer and 1 patient with colorectal cancer. This trial established the recommended dose of vadastuximab in phase II trials, and the clinical benefit of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5059is a drug that inhibits
 
Response: S5059is a drug that inhibits fibroblast proliferation and is currently being investigated for treatment of liver fibrosis and renal fibrosis in animal models. In this study, we investigated the anti-fibrotic effect of S5059 in a rat model of scleroderma-like skin fibrosis. S5059 significantly inhibited the fibrosis induced by bleomycin injection in the tail skin of rats. S5059 treatment resulted in significant inhibition of bleomycin-induced type I collagen expression and reduction of collagen content in skin. The degree of the reduction of collagen content was much higher than that of the inhibition of collagen expression. In addition, S5059 significantly inhibited the expression of TGF-β1 and Smad2 in the skin of bleomycin-treated rats. In vitro, S5059 also inhibited the TGF-β1-induced fibroblast proliferation and type I collagen expression. Our results suggest that S5059 inhibits bleomycin-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5060is a drug that inhibits
 
Response: S5060is a drug that inhibits HDACs 1, 2, 3, 6, and 10, but not 5. In contrast, N-acetylcysteine (NAC) is an anti-oxidant that inhibits HDACs 1, 2, 3, and 10, but not 5. Because we previously showed that the N-acetylcysteine mimics the HDAC inhibitors, we evaluated the combination of an HDAC inhibitor and N-acetylcysteine in prostate cancer cells. The combination of trichostatin A (TSA) and NAC reduced cell viability in the prostate cancer cell lines DU145, PC-3, and LNCaP. The growth inhibition was due to a synergistic interaction. In the PC-3 cells, the combination of TSA and NAC was more effective than the TSA alone. In the DU145 cells, the combination of TSA and NAC was more effective than the TSA alone. The expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5062is a drug that inhibits
 
Response: S5062is a drug that inhibits the binding of the cell surface receptor, the nuclear hormone receptor, androgen receptor (AR) to its cognate DNA sequence. Sildenafil, also known as Viagra, is used to treat pulmonary arterial hypertension, a disease that causes the blood vessels in the lungs to narrow. Sildenafil works by relaxing the blood vessels, allowing blood to flow more freely and reducing blood pressure. Sildenafil is also used to treat erectile dysfunction, a disease that impairs a man's ability to have an erection.

Sildenafil citrate is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It is used for the treatment of erectile dysfunction and pulmonary arterial hypertension. It works by increasing the blood flow to the penis by relaxing the blood vessels.

Sildenafil Citrate
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5063is a drug that inhibits
 
Response: S5063is a drug that inhibits the transcription factor nuclear factor kappaB (NF-kappaB) and reduces the production of pro-inflammatory cytokines and chemokines. It is used to treat inflammatory disorders, such as rheumatoid arthritis and Crohn's disease. A number of patients with CML have used S-1 to treat their disease, and some have reported benefits. It is possible that this drug might be effective in treating CML.

**Objectives:** The primary objective of this study is to determine the safety and efficacy of S-1 in treating CML.

**Methods:** The study design is a phase II, randomized, double-blind, placebo-controlled trial. Eligible patients will be randomized to receive oral S-1 or matching placebo for 24 weeks. The primary endpoint is complete cytogenetic response (CCyR) after 12 weeks of treatment. Secondary endpoints include complete molecular response (CMR)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5065is a drug that inhibits
 
Response: S5065is a drug that inhibits platelet aggregation and thrombus formation. It is an anti-coagulant that is widely used in the clinic. It is usually used to prevent the formation of clots after open-heart surgery and in peripheral arterial disease. It is also used in treating patients with myocardial infarction, deep vein thrombosis, and pulmonary embolism.

Background

There are two types of anti-platelet drugs: anti-platelet and anti-coagulant. Anti-platelet drugs are used to prevent the formation of clots and prevent blood clots from being formed after a heart attack, stroke, or deep vein thrombosis. Anticoagulant drugs are used to prevent the formation of clots in patients who have undergone open-heart surgery or who have had a heart attack or stroke.

What is thrombosis?

Thrombosis is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5066is a drug that inhibits
 
Response: S5066is a drug that inhibits DNA topoisomerase I. This drug has shown activity against human lymphoid leukemias and is being investigated for clinical trials. We have now examined the effects of S5066 on the growth of mouse lymphoid cells. The results show that the drug is a potent inhibitor of the growth of mouse lymphoid cells in vitro. The sensitivity of the cells to S5066 was highly dependent on the cell cycle stage at the time of drug exposure. Cells in the G2 phase of the cell cycle were most sensitive to S5066, whereas cells in the G1 phase were most resistant. Furthermore, S5066-treated cells entered apoptosis more rapidly than untreated cells, as measured by the rate of loss of mitochondrial transmembrane potential. This suggests that the sensitivity of mouse lymphoid cells to S5066 is related to their cell cycle status.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5067is a drug that inhibits
 
Response: S5067is a drug that inhibits both P-gp and MRP1 and can overcome resistance to anticancer drugs. To assess the safety of co-administration of S1031 and other drugs in humans, we investigated the effect of S1031 on the pharmacokinetics of digoxin, a substrate for P-gp and MRP1. In the presence of S1031, the systemic clearance of digoxin was decreased by 43% in healthy subjects. S1031 did not affect the disposition of digoxin after intravenous administration, but increased the area under the plasma concentration-time curve and decreased the clearance of digoxin after oral administration. These results suggest that S1031 increases the oral bioavailability of digoxin. We also examined the effect of S1031 on the pharmacokinetics of paclitaxel, which is a substrate for both P-gp and MRP1. In the presence of S1031, the clearance of paclitaxel was increased
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5069is a drug that inhibits
 
Response: S5069is a drug that inhibits the enzyme S100P and is in phase II trials for treating various cancers. S100P has a long N-terminal domain (amino acids 1-119) that binds to Ca2+ and regulates the activity of many Ca2+-dependent enzymes and proteins. A synthetic peptide derived from this domain inhibits tumor cell proliferation, but whether this peptide inhibits S100P activity is not known.

Purification and Crystallization of S100P

Purified S100P protein was crystallized in 20 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM CaCl2 and 2.5% glycerol. The crystals were soaked in mother liquor supplemented with 20% PEG3350. The crystals were flash frozen in liquid nitrogen and data were collected at beamline ID29 at the European Synchrotron Radiation Facility.

Molecular replacement was carried out using PH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5070is a drug that inhibits
 
Response: S5070is a drug that inhibits type I and II collagen and aggrecan degradation by inhibiting the activity of the enzyme, aggrecanase-1. In clinical studies, it was reported that S-2288 was effective in the treatment of osteoarthritis.
In clinical trials, the daily oral administration of S-2288 was well tolerated in healthy subjects and in patients with osteoarthritis. There were no serious adverse events associated with S-2288 treatment.
S-2288 was also shown to be effective in treating osteoarthritis when administered by injection into the affected joints.
S-2288 is a chemical analogue of 1-N-iodo-4-hydroxypyrrolidin-3-one, and is available under the trade name of “NYK-0129” from the Takeda Chemical Industries Co., Ltd.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5071is a drug that inhibits
 
Response: S5071is a drug that inhibits the expression of multiple chemokines and inflammatory cytokines, thus resulting in a significant decrease in the recruitment of immune cells and an improvement in the symptoms of UC.^[@bibr40-1756284818799071]^ In addition, DAS181 is effective in the treatment of patients with severe, active UC, even when they are refractory to anti-TNFα therapy.^[@bibr39-1756284818799071]^ In the present study, the clinical response rate was higher in the patients who received DAS181 treatment than in those who received placebo treatment, suggesting that DAS181 could be a new treatment option for patients with severe UC who are resistant to conventional therapy. However, a few studies have evaluated the effect of DAS181 in patients with mild UC. In a phase II study, the clinical response rate of patients with mild to moderate UC was higher in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5072is a drug that inhibits
 
Response: S5072is a drug that inhibits the process of angiogenesis. The result of the angiogenesis inhibition is the disappearance of the blood supply to the tumor. Because of this, the tumor cells are deprived of oxygen and nutrients. In the process of tumor development, new blood vessels are formed to support the growth of the tumor. This is the process of angiogenesis.

SUMMARY OF THE INVENTION

The present invention relates to a new method for treatment of malignant tumors, which comprises administration of a pharmaceutical composition comprising an effective amount of a bifunctional, alkylating agent and an anti-angiogenesis agent, as well as the use of this method for treatment of malignant tumors.

The term "alkylating agent" means a compound which alkylates a cellular macromolecule, such as DNA, RNA, proteins, or lipids.

The term "bifunctional alkyl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5073is a drug that inhibits
 
Response: S5073is a drug that inhibits topoisomerase I. It was approved by the FDA for treatment of advanced squamous cell carcinoma of the head and neck in 2011. This paper reviews the mechanism of action, pharmacokinetics, and efficacy of S-1 in patients with head and neck cancer.

The literature search yielded 19 clinical trials, of which 13 are randomized controlled trials (RCTs) and 4 are nonrandomized controlled trials. The study quality was assessed using the Jadad scale. The study quality was low, with a median score of 2.5.

1. Mechanism of Action

S-1 is a novel oral fluoropyrimidine that inhibits DNA synthesis and cell proliferation. It has been reported that the mechanism of action of S-1 is as follows: S-1 inhibits topoisomerase I, which is involved in the formation of DNA supercoils, and causes the accumulation of double-stranded DNA breaks
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5074is a drug that inhibits
 
Response: S5074is a drug that inhibits the synthesis of DNA, and is being used in the treatment of a number of cancers. However, a growing body of evidence suggests that S5074 has a number of unwanted side effects.

S5074 is a very potent inhibitor of the enzyme, DNA polymerase, which is required for DNA replication. It therefore has the potential to block DNA synthesis and replication in cells and to stop the growth of cancer cells.

However, S5074 is also known to have a number of side effects, including bone marrow suppression, peripheral neuropathy, nausea and vomiting, diarrhoea, alopecia, rash, dry skin, dizziness, depression, somnolence, visual impairment, dyspnoea, syncope, and death.

S5074 was first tested in a phase I clinical trial in the USA in 1995. Results showed that there was a large variation in the maximum tolerated dose of S5074,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5075is a drug that inhibits
 
Response: S5075is a drug that inhibits the proliferation of leukemic cells by targeting a protein known as bromodomain and extra-terminal domain (BET) proteins.

Patients with leukemia have been treated with BET inhibitors in clinical trials, with encouraging results.

Mechanism of action 

BET inhibitors bind BET proteins, and in doing so inhibit the transcription of genes that are required for leukemic cell proliferation. BET inhibitors have shown some clinical activity in leukemic patients.

Inhibition of transcription 

BET proteins bind to the promoter region of target genes and function as transcriptional activators.

Aberrant expression of BET proteins is a feature of certain hematological malignancies. In acute myeloid leukemia (AML), in particular, the expression of the BET protein BRD4 is elevated.

By binding to BRD4, BET inhibitors inhibit the expression of genes that are required for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5076is a drug that inhibits
 
Response: S5076is a drug that inhibits the serine-threonine protein kinase B-raf, and in cell culture has been shown to inhibit proliferation of a variety of tumor cell lines. It was selected for clinical evaluation because of its favorable safety profile and activity against rhabdomyosarcoma.

Mice treated with oral S5076 exhibit inhibition of tumor growth and regression of established rhabdomyosarcoma. The agent has been well tolerated in multiple clinical trials, and has demonstrated single-agent activity in rhabdomyosarcoma, melanoma, and ovarian cancer.

P-glycoprotein (P-gp) is a member of the ATP-binding cassette (ABC) superfamily of transmembrane proteins. P-gp is an efflux pump which actively extrudes a wide variety of toxic substances from cells. It plays an important role in the development of multidrug resistance (MDR) in cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5077is a drug that inhibits
 
Response: S5077is a drug that inhibits the platelet ADP receptor P2Y12, a major regulator of platelet activation and aggregation, and it is in phase III clinical development for the prevention of atherothrombotic events in patients undergoing percutaneous coronary intervention (PCI) and for the prevention of stroke in patients with non-valvular atrial fibrillation. P2Y12 receptor antagonists have been used in clinical practice for decades, but their use is associated with bleeding complications. P2Y12 inhibitors with a longer half-life have the potential to reduce bleeding complications and could provide a safer alternative for the treatment of atherothrombotic events. A previous phase II trial showed that ticagrelor was non-inferior to clopidogrel in reducing cardiovascular events and was associated with a lower rate of major bleeding. A subsequent phase III trial demonstrated that the incidence of major bleeding was significantly lower with ticagrelor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5079is a drug that inhibits
 
Response: S5079is a drug that inhibits a key enzyme in cholesterol biosynthesis, resulting in a lowering of the level of cholesterol in the blood. Silybin is a silymarin derivative, which is obtained from the milk thistle (Silybum marianum). The effects of S5079 in vivo are not known, but there is evidence that it may have beneficial effects in the treatment of certain disorders such as atherosclerosis, hyperlipidemia and hypercholesterolemia.
S5079 has been tested for its ability to inhibit the proliferation of a number of human cancer cell lines. In one study, the effect of S5079 on the growth of human lung cancer cell lines was investigated. S5079 was shown to inhibit the growth of NCI-H460 cells and to a lesser extent, NCI-H1299 cells. (Chemistry and Biology of Flavonoids, J. G. Deans et al., (Eds.) Academic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5081is a drug that inhibits
 
Response: S5081is a drug that inhibits D-amino acid oxidase (DAAO) and has been found to have neuroprotective effects. To elucidate the molecular mechanism underlying its protective effects on the central nervous system, the authors examined the effects of S5081 on the release of glutamate and aspartate, two excitatory amino acids, from rat cortical slices. The levels of glutamate and aspartate released from the cortical slices in the presence of S5081 were not changed, compared with those in the control slices. In addition, S5081 did not change the activities of Na(+)-K(+)-ATPase, acetylcholinesterase, and butyrylcholinesterase in the rat cortical slices. These results suggest that S5081 does not alter the release of glutamate and aspartate from the rat cortical slices, and that it has no effects on the activities of Na(+)-K(+)-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5082VitaminK2is a drug that inhibits
 
Response: S5082VitaminK2is a drug that inhibits the production of Vascular Endothelial Growth Factor (VEGF) by cells. VEGF is the most important and best studied of the various growth factors that influence vascular growth. This effect on VEGF production makes vitamin K2 useful in the treatment of vascular disease and other diseases associated with inappropriate angiogenesis. Vitamin K2 is a coenzyme of vitamin K1 and vitamin K2 is a coenzyme of vitamin K1. This has led to confusion over the nomenclature of the two vitamins. The International Union of Pure and Applied Chemistry (IUPAC) nomenclature uses the K1 form.

Vitamin K2 is used as a cofactor for a protein called gamma-glutamyl carboxylase, or GGCC. The GGCC protein is found in the liver and converts a protein called prothrombin to thrombin. Thrombin converts
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5083is a drug that inhibits
 
Response: S5083is a drug that inhibits PDK1 activity by binding to the ATP-binding pocket.^[@bib54]^ Preclinical studies show that S5209 may be a potent inhibitor of PDK1 activity.^[@bib55]^ A phase I clinical trial of S5209 was conducted in a variety of cancer types, but the results of the trial were inconclusive.^[@bib56]^ In a phase I/II clinical trial of S5209, six of 13 patients with advanced solid tumors showed stable disease.^[@bib57]^ It is unknown if S5209 will become a clinically useful PDK1 inhibitor.

Allosteric inhibition
---------------------

Allosteric inhibitors do not directly bind to the active site of PDK1, but they can allosterically modulate the activity of the kinase. These inhibitors are usually identified by screening for molecules that bind to the alloster
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5084is a drug that inhibits
 
Response: S5084is a drug that inhibits the G1/S transition in mammalian cells. To investigate the mechanism of action of S5084, we analyzed its effect on the activity of G1/S cyclins and cyclin-dependent kinases. We found that S5084 induced the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) and the cyclin-dependent kinase inhibitors p21(Cip1) and p16(INK4a) in a p53-dependent manner. In addition, S5084 arrested cells in the G1 phase of the cell cycle. These results indicate that S5084 induces G1 arrest by inhibiting the activity of cyclin-dependent kinases, and suggest that S5084 could be useful in the treatment of proliferative diseases.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5085is a drug that inhibits
 
Response: S5085is a drug that inhibits the action of a peptide hormone called insulin and can therefore reduce blood glucose levels in people with type 2 diabetes.

The new study was conducted in animals and in people and suggests that sertraline may be able to reduce the risk of type 2 diabetes. The researchers suggest that it may be possible to use sertraline as a preventative measure against type 2 diabetes.

A drug called S-5085 has been found to reduce blood glucose levels in people with type 2 diabetes. S-5085 is a drug that inhibits the action of a peptide hormone called insulin and can therefore reduce blood glucose levels in people with type 2 diabetes.

What Is S-5085?

S-5085 is a drug that inhibits the action of a peptide hormone called insulin and can therefore reduce blood glucose levels in people with type 2 diabetes. It works by blocking the effects of insulin in the liver and in muscle cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5086is a drug that inhibits
 
Response: S5086is a drug that inhibits the enzyme farnesyltransferase, which plays a role in the production of a cell membrane protein called Ras. Ras proteins are part of a signal transduction pathway that controls cell growth and division. S-5086 has been shown to be active in animal models and is currently being tested in clinical trials in patients with colorectal cancer and other solid tumors.

S-5086is a drug that inhibits the enzyme farnesyltransferase, which plays a role in the production of a cell membrane protein called Ras. Ras proteins are part of a signal transduction pathway that controls cell growth and division. S-5086 has been shown to be active in animal models and is currently being tested in clinical trials in patients with colorectal cancer and other solid tumors.

S-5086is a drug that inhibits the enzyme farnesyltransferase, which plays a role in the production of a cell membrane protein called Ras
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5087is a drug that inhibits
 
Response: S5087is a drug that inhibits the enzyme HMG-CoA reductase and thereby inhibits cholesterol synthesis.

#####  PHARMACOKINETICS

Route| Onset| Peak| Duration  
---|---|---|---  
PO| N/A| N/A| 12 hrs

Metabolized in liver. Protein binding: 92%. Peak plasma concentration: 6 hrs. Excreted in feces (76%), urine (14%). **Half-life:** 10 hrs.

#####    ​LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** Unknown if drug crosses placenta or is distributed in breast milk. **Pregnancy Category C. Children:** Safety and efficacy not established. **Elderly:** May have increased risk of developing myopathy. Age-related hepatic/renal impairment may require dosage adjustment.

####
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5091is a drug that inhibits
 
Response: S5091is a drug that inhibits thrombin and was approved by the FDA in 2000. The drug is indicated for the prevention of stroke in patients with atrial fibrillation, and for the treatment of acute deep vein thrombosis (DVT).
In the first phase of clinical development, S-2288, the most potent prodrug of S-5091, was administered by continuous infusion to healthy volunteers. The data demonstrated that S-2288 is rapidly metabolized to S-5091. Peak plasma concentrations of S-5091 were observed at approximately 30 minutes following a continuous infusion of S-2288. The half-life of S-5091 was 2.7 hours. The mean total exposure of S-5091 was 21.3% of the exposure of S-2288. In a multiple-dose study, steady state was reached after 2 days. Peak plasma concentrations of S-5091 were observed at 1.5 hours after the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5092is a drug that inhibits
 
Response: S5092is a drug that inhibits histone deacetylase (HDAC) by interfering with the binding of the Zn2+ cofactor in HDACs. S-trityl-L-cysteine (STLC) is a well-characterized, cell-permeable, non-toxic, and highly selective inhibitor of HDACs, and has been widely used in studies on the functions of HDACs. Here, we investigated the effects of S-trityl-L-cysteine (STLC) on bone morphogenetic protein (BMP) signaling and osteoblast differentiation in the MC3T3-E1 mouse osteoblast-like cell line. STLC enhanced the transcriptional activity of BMP-2 and increased the protein levels of Smad1, Smad5, Smad8, and Smad9, which are the primary Smad proteins activated by BMP signaling. The STLC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5093is a drug that inhibits
 
Response: S5093is a drug that inhibits a very specific enzyme, aldose reductase, and therefore lowers blood glucose. It is used in the treatment of diabetic peripheral neuropathy. The drug is also used in the treatment of diabetic macular edema, and can also lower blood pressure.

S5093 is a racemic mixture, but only the R-enantiomer is active. The R-enantiomer is a very effective drug, and has been shown to be able to lower blood glucose in rats. However, in humans it is less effective than the S-enantiomer. This is likely because humans have a much higher activity of the enzyme aldose reductase, and thus aldose reductase inhibition is much less effective.

The major side effect of S5093 is a potentially fatal interaction with the cytochrome P450 enzyme CYP2D6. This interaction is unlikely to be seen with S-5093.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5096is a drug that inhibits
 
Response: S5096is a drug that inhibits the serotonin transporter (SERT). The effects of S-5096 on the electrical activity of cultured human pulmonary artery smooth muscle cells (PASMC) were examined. The electrophysiological effects of S-5096 were examined by whole cell patch clamp in cultured human PASMC. The electrophysiological effects of S-5096 were examined by whole cell patch clamp in cultured human PASMC. The effects of S-5096 on the electrical activity of cultured human PASMC were examined. S-5096 (10(-8) to 10(-6) M) inhibited the 5-hydroxytryptamine (5-HT)-induced inward current and increased the outward current in a concentration-dependent manner. The effect of S-5096 on the outward current was completely reversible. S-5096 did not alter the voltage-dependent properties of K+ current. The inhibitory effect of S-5096 on the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5097is a drug that inhibits
 
Response: S5097is a drug that inhibits protein phosphatase 2A (PP2A) by binding to the B56 regulatory subunit of PP2A. This competitive inhibitor causes inhibition of tumor cell growth in vitro and in vivo, but its therapeutic potential is limited by a lack of water solubility. The purpose of this study was to synthesize a water-soluble analog of S5097 that retains PP2A inhibitory activity. The design strategy was to attach a propargyl ether group to the S5097 C-terminus to allow for covalent linkage to a water-soluble polymer. The resulting conjugate was evaluated for PP2A inhibitory activity in vitro and for anticancer activity in vivo. A series of PP2A conjugates were synthesized by a simple two-step procedure that included a one-pot conversion of the corresponding C-terminal aldehyde to the corresponding propargyl ether and a subsequent conjugation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5098is a drug that inhibits
 
Response: S5098is a drug that inhibits GTP cyclohydrolase I, which converts guanosine triphosphate to guanosine diphosphate and inorganic triphosphate. It inhibits the conversion of 7,8-dihydro-8-oxoguanosine triphosphate to guanosine monophosphate and inorganic triphosphate. As a result, the inorganic triphosphate pools of the cell are reduced. In addition, s-adenosylmethionine is produced by the reaction of 7,8-dihydro-8-oxoguanosine triphosphate with adenosine triphosphate.

References

Category:Antineoplastics
Category:Oxetanes
Category:Purines
Category:Tricarboxylic acids
Category:World Health Organization essential medicines
Category:RTT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5100is a drug that inhibits
 
Response: S5100is a drug that inhibits the tyrosine kinase activity of the EGFR receptor.\[[@ref1]\] It is approved in the United States for the treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) after progression on or following one prior chemotherapy regimen for metastatic disease.\[[@ref2]\]

To date, two phase II studies of single-agent S5100 in EGFR-mutant NSCLC have been reported.\[[@ref3][@ref4]\] The authors reported an objective response rate of 46% and 27%, respectively, in the two studies. The median duration of response was 16.5 and 14.6 weeks, respectively. In the S5100 study, the primary endpoint of response rate was not met; however, the median duration of response was similar to that reported in a previous study of gefitinib.\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5102is a drug that inhibits
 
Response: S5102is a drug that inhibits the in vitro and in vivo replication of the human immunodeficiency virus (HIV). It is an acyclic nucleoside phosphonate analog with a broad spectrum of activity against both HIV-1 and HIV-2. S5102 has a potent inhibitory effect on HIV-1 replication in human peripheral blood mononuclear cells (PBMCs) and a number of human T cell lines and primary cell cultures. S5102 also inhibits the replication of HIV-1 in macrophages. In contrast, S5102 does not inhibit the replication of HIV-2 in human PBMCs.

S5102 is the active agent in a number of experimental and clinical studies in the United States and Europe. S5102 has been studied in several clinical trials in HIV-1-infected individuals. S5102 was well tolerated and was effective in lowering plasma HIV-1 RNA levels in all of the trials that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5103is a drug that inhibits
 
Response: S5103is a drug that inhibits the phosphorylation of AKT, and the authors of this paper concluded that it would be effective in treatment of AKT-activated cancer cells. In this paper, they show that S5103 inhibits proliferation of cells derived from several human tumor types in vitro and that the drug is effective in a mouse xenograft model. The authors conclude that S5103 may be a useful tool for the treatment of cancer.

Despite the evidence that AKT activation plays an important role in cancer, most AKT inhibitors are not tumor-selective. This is probably due to the fact that the signaling pathways mediated by AKT are highly redundant and many pathways are activated by AKT. Therefore, it is possible that S5103 will be toxic to cells that are not affected by AKT. This paper provides an example of how the authors can develop more selective AKT inhibitors.

The authors have identified a specific inhibitor of AKT, S5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5105is a drug that inhibits
 
Response: S5105is a drug that inhibits cyclin-dependent kinases. It has shown promising results in clinical trials, but clinical trials were not conducted using patients with heart failure.

References

Category:Experimental cancer drugs
Category:Antineoplastic drugs
Category:Purines
Category:Phosphonic acids
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5108is a drug that inhibits
 
Response: S5108is a drug that inhibits the HIV-1 Tat protein, and as such, is currently in Phase II clinical trials. This drug is also known to inhibit NF-κB activation, an important component of HIV-1 replication and disease progression [@pone.0080545-Blanchard1]. TNF-α and IL-1β are important mediators of HIV-1 pathogenesis [@pone.0080545-Mothe1], [@pone.0080545-Pilasz1], [@pone.0080545-Blanchard1]. Our data demonstrate that this inhibition occurs in both HIV-1 infected and uninfected CD4^+^ T cells. We have previously shown that Tat-mediated NF-κB activation is mediated by its ability to inhibit TAK1 activity [@pone.0080545-Owen1]. We now show that S5108 also inhibits TAK1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5109is a drug that inhibits
 
Response: S5109is a drug that inhibits cell proliferation and induces cell apoptosis in tumor cells. In addition, it can inhibit tumor growth and prolong the survival time of tumor-bearing mice \[[@B19-ijms-16-17655]\]. Our results indicated that high expression of FOXO3a was associated with a longer OS time in ccRCC patients. Furthermore, patients with low expression of FOXO3a had a shorter OS time. Thus, FOXO3a may be an independent prognostic factor for ccRCC patients.

To further explore the relationship between FOXO3a and biological functions in ccRCC, we conducted *in vitro* and *in vivo* experiments. First, we detected the effects of FOXO3a on cell proliferation and apoptosis. We found that the expression of FOXO3a could significantly inhibit cell proliferation and induce apoptosis. Furthermore, we demonstrated that FOXO3a could regulate the expression of p21
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5112is a drug that inhibits
 
Response: S5112is a drug that inhibits DNA polymerase λ. It was developed by the National Cancer Institute (NCI) and has been tested in clinical trials for the treatment of patients with hematologic malignancies. S-S5112 was evaluated in the phase I clinical trial NCT00265714 and in the phase II clinical trial NCT00353042. In the phase I trial, S-S5112 was administered at doses ranging from 5 to 100 mg/m2 as a 30-minute intravenous infusion every 21 days. There were no dose-limiting toxicities and the most common adverse events were mild to moderate nausea, vomiting, diarrhea, and fatigue. No objective responses were observed in any patients. In the phase II trial, the objective response rate was 0%, and the median overall survival was 7.5 months. Based on the results of the phase I and phase II trials, the development of S-S5112 was discontinued.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5113is a drug that inhibits
 
Response: S5113is a drug that inhibits thymidylate synthase, and the DNA precursor for DNA synthesis. As a result, it has become the drug of choice for the treatment of advanced colorectal cancer. However, the toxicity of this drug has limited its application. We used siRNA to inhibit thymidylate synthase in human colon cancer cell lines. Inhibition of thymidylate synthase by siRNA resulted in an increase in apoptosis in both HT29 and DLD-1 cell lines. A reduction in the cell growth rate was also observed in both cell lines. The inhibitory effect of thymidylate synthase siRNA on the cell growth was enhanced by the addition of 5-fluorouracil (5-FU). A time-course study showed that thymidylate synthase siRNA induced apoptosis more rapidly than did 5-FU. Thymidylate synthase siRNA induced the expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5114is a drug that inhibits
 
Response: S5114is a drug that inhibits a number of the functions of HIV-1. The drug targets a region of HIV-1 known as the nucleocapsid. This is an essential part of the virus and it has to be there in order for the virus to function. It is thought that this drug is working by binding to the viral nucleocapsid and blocking the essential function of the nucleocapsid.

It has been used as part of an anti-HIV treatment for patients with HIV-1 infection.

Adverse effects

S5114 has been associated with increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The level of ALT and AST in the blood will need to be monitored during treatment.

S5114 is not currently licensed in the UK.

Nucleocapsid Inhibitors

S5114 belongs to a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5117is a drug that inhibits
 
Response: S5117is a drug that inhibits both serotonin and norepinephrine reuptake. It is often used in the treatment of depression. The mechanism of action is similar to SSRIs, but it is not as potent.

**Note:** SSRIs are prescribed in combination with atypical antipsychotics for the treatment of major depressive disorder.

SSRI Medications for Adolescents and Adults

SSRI medications are prescribed for depression in both children and adults. SSRI medications are also used to treat other disorders such as anxiety and obsessive compulsive disorder (OCD). The mechanism of action is similar to antidepressants, but SSRIs are not as effective as the TCAs.

SSRI Medications for Children and Adolescents

Selective serotonin reuptake inhibitors (SSRIs) are often prescribed for the treatment of anxiety in children. In fact, SSRIs are often the first-line treatment for anxiety in children
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5119is a drug that inhibits
 
Response: S5119is a drug that inhibits HMG-CoA reductase. This enzyme catalyzes the first step of cholesterol biosynthesis, thus reducing the level of cholesterol in cells. Statins are used to lower cholesterol and reduce the risk of cardiovascular disease. They are available as generic medications, and there are also brand-name statins available.

Drug Information Center

At the Drug Information Center, we provide you with reliable, evidence-based information about prescription and over-the-counter medications.

We work with professional medical organizations to ensure that the information we provide is accurate, objective, and science-based.

The Drug Information Center is part of Healthwise, a nonprofit consumer-oriented organization.

Healthwise, Healthwise Logo, and the Healthwise Vigorous Aging Research Program are trademarks of Healthwise, Incorporated.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5121is a drug that inhibits
 
Response: S5121is a drug that inhibits a subunit of the proteasome. It is currently in phase II clinical trials.^[@bib25]^ We treated our model of sporadic ALS with this compound. SOD1^G93A^ mice were injected with the drug from day 35 of life, and its effects on the disease were monitored over time. SOD1^G93A^ mice treated with P5120 did not show any change in the progression of the disease. On the contrary, a slight improvement in the performance of SOD1^G93A^ mice was observed in the P5121-treated group, which was also reflected in a decrease in the level of ubiquitinated proteins and of p62 ([Figure 5a](#fig5){ref-type="fig"}). To understand whether the beneficial effects of P5121 were due to the blockage of the NF-*κ*B pathway, we evaluated the levels of phosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5126is a drug that inhibits
 
Response: S5126is a drug that inhibits DYRK1A, a kinase that regulates the G1/S phase cell cycle transition. It has been suggested that the drug may also inhibit mTORC1, a major downstream target of Akt that regulates cell growth and protein synthesis. In this study, we used human breast cancer cell lines as models to determine whether this drug is a mTORC1 inhibitor. Our results show that S5126 does not affect mTORC1 activity in cells that are proliferating or are arrested in the G1/S phase. S5126 did not block the induction of S6K1 or 4E-BP1 phosphorylation by mTORC1 activators. S5126 did, however, inhibit S6K1 and 4E-BP1 phosphorylation and activation of S6K1 in response to growth factors and in the presence of serum. Inhibition of S6K1 by S5126 was due
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5130is a drug that inhibits
 
Response: S5130is a drug that inhibits platelet aggregation by acting on GPIIb/IIIa (CD41/CD61). It is used in coronary angioplasty to prevent ischemic complications during the procedure. It also has the potential to be used in stroke. S5130 is used in prophylactic treatment of the patients with CAD, stroke, or asymptomatic high risk for myocardial infarction (MI) and also to reduce the frequency of angina pectoris in patients with previous MI. S5130is also used in the treatment of myocardial infarction and unstable angina. The drug is used in the prevention of stroke in patients with atrial fibrillation. It is used to prevent ischemic complications in patients with coronary artery disease, including those who have had a previous MI. It also has been used in stroke prevention. It is given intravenously in a dose of 5 mg/kg. It should
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5131is a drug that inhibits
 
Response: S5131is a drug that inhibits the protein phosphatase calcineurin. It is used to treat patients with the inflammatory skin disease, atopic dermatitis. It is a potent inhibitor of inflammatory and immunological responses in vitro and in vivo. In this study we have examined the effect of S5131 on cell death induced by cytokines in a human leukemic cell line. We found that S5131 does not protect from Fas-mediated apoptosis. However, S5131 significantly reduced cell death induced by IL-1beta, TNFalpha, or TNFbeta. This protective effect was maximal at the concentration of S5131 that maximally inhibited calcineurin, and was not due to reduced expression of Fas. We conclude that S5131 protects from cell death induced by IL-1beta, TNFalpha, and TNFbeta in this cell line, and that this protection is not due to inhibition of Fas-mediated apoptosis.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5134is a drug that inhibits
 
Response: S5134is a drug that inhibits HIV-1 reverse transcriptase. In combination with tenofovir, S5134 is being developed for the treatment of HIV-1 infection. S5134 was developed by Janssen Pharmaceutica and is being co-developed by Janssen-Cilag and The Medicines Company. S5134 was discovered as part of a screen of compounds that inhibit the cellular target of tenofovir, the HIV-1 reverse transcriptase (RT). S5134 is being developed by Janssen Pharmaceutica for the treatment of HIV-1 infection. S5134 was discovered as part of a screen of compounds that inhibit the cellular target of tenofovir, the HIV-1 reverse transcriptase (RT). S5134 was developed by Janssen Pharmaceutica for the treatment of HIV-1 infection.

Dhiego M, O'Brien J, Slatore S,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5136is a drug that inhibits
 
Response: S5136is a drug that inhibits the phosphatidylinositol 3-kinase (PI3K) pathway. PI3K is an enzyme that regulates a variety of cell functions including growth, differentiation, survival, and motility. The PI3K pathway is frequently altered in human cancers, and as a result, many cancer cell lines and primary human tumor samples are sensitive to the PI3K inhibitor. Indeed, PI3K inhibitors are being tested in clinical trials for the treatment of multiple cancers. For example, in chronic lymphocytic leukemia (CLL), the B cell receptor (BCR) signaling pathway is constitutively activated in CLL B cells, and therefore, a PI3K inhibitor might be an effective treatment. However, there is limited evidence to suggest that the PI3K pathway is activated in other types of B cell lymphomas. Furthermore, the exact role of the PI3K pathway in the pathogenesis of these lymphomas is unknown.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5138is a drug that inhibits
 
Response: S5138is a drug that inhibits P450 aromatase (P450arom), an enzyme that catalyzes the conversion of androgens into estrogens. In vitro, it has been shown to be effective against the development of hormone-dependent breast cancer. We investigated the effect of S5138 on breast cancer cell growth in a model of human breast cancer xenografts. Breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-435) were injected subcutaneously into the flanks of nude mice. S5138 (5 mg/kg, daily, orally) was administered for 5 days beginning at the time of tumor cell injection. The mice were killed on day 30, and tumor volume and weight were measured. To investigate the mechanism of S5138 action, we examined the expression of the aromatase, estrogen receptor (ER), progesterone receptor (PR), and Her2/neu receptors in the tumors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5141is a drug that inhibits
 
Response: S5141is a drug that inhibits the Ras signaling pathway, leading to a G1 arrest and apoptosis. Furthermore, the phosphorylation of retinoblastoma protein (Rb) is inhibited by this drug. Since the Ras signaling pathway is involved in the pathogenesis of various human malignancies, including gliomas, a human glioma cell line was examined for sensitivity to S5141. The U-251MG cell line, which has been reported to have a high sensitivity to S5141 in vitro, was established. The effect of S5141 on cell growth was examined by a MTT assay. In addition, the apoptotic effect of S5141 was evaluated by the flow cytometric analysis of the sub-G1 DNA content. S5141 was found to have a potent growth-inhibitory effect on the U-251MG cell line, which was greater than that of the glioma cell line U-87MG. S5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5143is a drug that inhibits
 
Response: S5143is a drug that inhibits histone deacetylases (HDACs)^[@R8]^. This class of enzymes remove acetyl groups from histones and non-histone proteins. They are involved in regulating gene expression and are also involved in a wide range of cellular processes including cell cycle progression, cellular metabolism, cell death and survival, and signal transduction^[@R9]^. HDACs play important roles in controlling gene expression by deacetylating histones, transcription factors, and non-histone proteins. In the past few years, the role of HDACs in cancer has been intensively investigated. It has been found that HDACs promote cancer progression and that HDAC inhibitors can be used as anti-cancer agents.

In this study, we identified an HDAC6-specific inhibitor, S5143, and evaluated its efficacy and mechanism of action in colon cancer cells. HDAC6 is overexp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5145is a drug that inhibits
 
Response: S5145is a drug that inhibits cell cycle progression by inhibiting the expression of CDKs \[[@B46-ijms-21-01798]\]. A recent study showed that the combination of ACK2 and palbociclib in a xenograft model of ER-positive/HER2-negative breast cancer cells showed a synergistic antitumor effect. The combination of ACK2 and palbociclib induced cell cycle arrest and apoptosis, and suppressed tumor growth. The authors also demonstrated that the antitumor effect of the combination was mainly due to the suppression of CDK4/6 \[[@B47-ijms-21-01798]\].

It is noteworthy that the use of CDK inhibitors in clinical practice is a very recent strategy, and the development of resistance to these drugs has become a limiting factor in the clinical management of patients. It is likely that the same mechanism of resistance that occurs in patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5155is a drug that inhibits
 
Response: S5155is a drug that inhibits an enzyme called protein kinase C (PKC) that controls cell growth. It was first used to treat patients with prostate cancer, but has also been found to be effective in treating other types of cancer. However, its use in treating cancer has been associated with problems such as nausea, vomiting, diarrhea, fatigue, and hair loss. A new study published in the journal Cancer suggests that S5155 may have even more potential to treat cancer than we previously thought.

The researchers from the Netherlands Cancer Institute looked at the activity of S5155 in 60 different types of cancer cells. The results showed that S5155 is active in a wide range of cancer cells, including breast, colon, lung, liver, kidney, and brain cancers. They found that S5155 could reduce tumor size in mouse models of breast cancer, colon cancer, and liver cancer. The researchers also found that S5155 reduced the size of tumors in mouse models of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5157is a drug that inhibits
 
Response: S5157is a drug that inhibits Sirt1, a NAD+-dependent deacetylase. It is also a potent activator of AMPK. Our recent study has shown that S5157 is a potent inhibitor of cardiac hypertrophy, in part, through its activation of AMPK \[[@R4]\]. This study has also demonstrated that S5157 is more effective in inhibiting cardiac hypertrophy than inactivating Sirt1 in vivo. Thus, this study raises the possibility that the effect of S5157 on hypertrophy may be mediated by Sirt1-independent mechanisms.

S5157 has been reported to activate AMPK in both cell culture and in animal models. It has also been reported to activate AMPK in isolated heart perfusion model \[[@R5]\]. However, in these studies, the AMPK activation by S5157 was determined by the level of phosphorylation of the Thr172 site of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5159is a drug that inhibits
 
Response: S5159is a drug that inhibits the proliferation of cancer cells by affecting the P-gp expression.

MDR-related research is important for the development of drugs to treat MDR tumors. Recently, researchers have focused on searching for a non-toxic MDR reversal agent, which has good biocompatibility and high safety. In this study, we found that S5159 can reverse MDR in various cancer cells, such as the MDR cells of human cancer cells (KBv200, MCF-7/Adr, and HL-60/Adr), and its IC~50~ value was much lower than that of verapamil, which is an effective reversal agent for MDR. In addition, the reversal effect of S5159 on MDR was better than that of other MDR reversal agents, such as tariquidar, cyclosporine A, and verapamil. S5159 has the advantage of high safety and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5163is a drug that inhibits
 
Response: S5163is a drug that inhibits cyclin-dependent kinases (CDKs) of the G1 and S phases, and thereby, arrests the cell cycle at the G1/S boundary, resulting in cell death.^[@bib1],\ [@bib2]^ As S5163 is an orally available compound, it is expected to be clinically applicable to anticancer therapy. However, its use is limited because of its severe side effects, such as myelosuppression and gastrointestinal toxicity.^[@bib3]^

A series of S5163 analogs have been reported,^[@bib4],\ [@bib5],\ [@bib6]^ and one of them, SNS-032, was found to have potent *in vivo* anticancer activity.^[@bib4]^ SNS-032 is a potent inhibitor of the cyclin-dependent kinases CD
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5167is a drug that inhibits
 
Response: S5167is a drug that inhibits the activities of ERK and MAPK signaling pathway and can inhibit tumor growth. Our results also showed that resveratrol can enhance the apoptosis induced by s5167, suggesting that s5167 may play a synergistic effect on resveratrol.

In summary, the results of this study indicate that resveratrol inhibits the proliferation of U87MG and U251 cells and induces apoptosis by increasing the level of p53 and activating caspase-3. Furthermore, resveratrol and s5167 may have synergistic effects in the treatment of GBM.

This work was supported by the National Natural Science Foundation of China (No. 81260302).

Conflict of Interests
=====================

The authors declare that there is no conflict of interests regarding the publication of this paper.

![The chemical structure of s5167.](BMRI2014-8029
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5174is a drug that inhibits
 
Response: S5174is a drug that inhibits the formation of cAMP. When the adenylyl cyclase system is blocked, the body can't produce enough cAMP to activate the phosphodiesterase.

Sildenafil citrate is an effective oral treatment for erectile dysfunction. This is because sildenafil citrate inhibits the PDE5 enzyme that normally breaks down cGMP. When sildenafil citrate is taken, it prevents the PDE5 enzyme from being able to break down cGMP. The result is an increase in cGMP in the body, which then causes the relaxation of the smooth muscle in the penis. Sildenafil citrate has also been shown to be effective in treating premature ejaculation.

How does sildenafil citrate work?

Sildenafil citrate is a PDE5 inhibitor. PDE5 inhibitors prevent the breakdown of cGMP in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5200is a drug that inhibits
 
Response: S5200is a drug that inhibits PD-1 and its ligand, PD-L1. It has demonstrated activity in patients with non-small cell lung cancer, melanoma, renal cell carcinoma, and Hodgkin's lymphoma.

The development of BMS-663513 is in phase 1 clinical trials for patients with advanced solid tumors.

Other agents 

Alemtuzumab, an anti-CD52 monoclonal antibody, is approved for the treatment of chronic lymphocytic leukemia.  It is also being studied in combination with ipilimumab in melanoma.

Daclizumab is an anti-CD25 monoclonal antibody. It is being studied in combination with ipilimumab in melanoma.

PD-1/PD-L1 inhibitors in clinical development 

Tremelimumab is an anti-PD-1 monoclonal antibody. It is being
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5203is a drug that inhibits
 
Response: S5203is a drug that inhibits PDE3 and PDE4 and thus may increase the intracellular cAMP concentration and activation of protein kinase A (PKA) in various tissues \[[@B6-molecules-24-01353],[@B7-molecules-24-01353],[@B8-molecules-24-01353],[@B9-molecules-24-01353],[@B10-molecules-24-01353],[@B11-molecules-24-01353],[@B12-molecules-24-01353],[@B13-molecules-24-01353],[@B14-molecules-24-01353],[@B15-molecules-24-01353],[@B16-molecules-24-01353],[@B17-molecules-24-01353],[@B
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5205is a drug that inhibits
 
Response: S5205is a drug that inhibits the function of p53 and MDM2 and leads to the accumulation of p53, resulting in the induction of apoptosis and the inhibition of proliferation in tumor cells.^[@bibr43-1534735417734911]^ Previous studies have shown that the p53 pathway is a common target for cancer therapy.^[@bibr44-1534735417734911]^ The current study showed that the combined treatment of L-OHP and DHA induced p53 and p21 protein expression in a time-dependent manner. These results indicated that DHA sensitizes cancer cells to chemotherapy by inducing p53-mediated apoptosis.

Many studies have shown that many chemotherapeutic drugs are toxic to normal cells and induce various types of cell death. In our study, we showed that the combined treatment of L-OHP and DHA induced the expression of apoptosis-related proteins, such as cleaved
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5206is a drug that inhibits
 
Response: S5206is a drug that inhibits the p38 MAPK, a key enzyme in the cellular stress response pathway. In vitro, S5206 has been shown to be a highly selective and potent inhibitor of the p38 MAPK with a half maximal inhibitory concentration (IC50) of 0.063 nM and a therapeutic index of \>1000. S5206 has also been shown to inhibit inflammation in vivo, to protect mice from LPS-induced shock, and to protect rats from ischemia/reperfusion injury. S5206 is currently being tested in phase II clinical trials for the treatment of various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and diabetic foot ulcers. Here we review the literature on the in vitro and in vivo effects of S5206 and discuss its potential as a novel therapy for various inflammatory conditions.

2. The p38 MAPK {#sec2-ijms-20-01
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5208is a drug that inhibits
 
Response: S5208is a drug that inhibits cyclin-dependent kinases. A high percentage of tumor cells in the cell cycle are arrested in G1 and this has been used as a marker for the induction of apoptosis. The induction of apoptosis was evaluated by using flow cytometry. Briefly, 1 × 10^6^ cells were seeded in 6-well plates. After 24 h, the cells were treated with 25 µM of S5208 for 48 h. The cells were then harvested and stained with Annexin V-FITC and PI. The cells were then analyzed by flow cytometry.

Western blotting {#s2.11}
----------------

Western blotting was performed as described previously \[[@B22]\]. The following antibodies were used: p21 (sc-397), Bax (sc-7480), Bcl-2 (sc-509), Mcl-1 (sc-819), and GAPDH
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5209is a drug that inhibits
 
Response: S5209is a drug that inhibits the production of the enzyme angiotensin converting enzyme (ACE). When the renin-angiotensin system is activated, the enzyme ACE converts angiotensin I into angiotensin II. Angiotensin II is a powerful vasoconstrictor that also causes blood vessel wall cell proliferation, inflammation and fibrin deposition. Inhibiting the production of ACE is one way to prevent the activation of the renin-angiotensin system.

S5209is an ACE inhibitor. ACE is a key enzyme in the renin-angiotensin system. The renin-angiotensin system is a part of the endocrine system. The renin-angiotensin system plays a key role in the regulation of blood pressure and the heart. ACE inhibitors lower blood pressure. ACE inhibitors also prevent the growth of blood vessels and prevent cell proliferation.

S5209is an ACE
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5210is a drug that inhibits
 
Response: S5210is a drug that inhibits protein kinase C, the same enzyme that is inhibited by some antipsychotic drugs. It has not been tested in clinical trials for the treatment of schizophrenia. S4909is an inhibitor of PDE10A, which is a target for drugs that have been used to treat schizophrenia. It has not been tested in clinical trials for the treatment of schizophrenia. S3201is an inhibitor of glycogen synthase kinase-3, a target for some antipsychotic drugs. It has not been tested in clinical trials for the treatment of schizophrenia. S1480is an inhibitor of the androgen receptor, a target for some antipsychotic drugs. It has not been tested in clinical trials for the treatment of schizophrenia.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5211is a drug that inhibits
 
Response: S5211is a drug that inhibits the myosin ATPase and can be used to prevent and treat myasthenia gravis.^[@bib40]^ The dose and duration of treatment in these experiments was determined in a pilot study (see Supplementary Information) and based on previously published results.^[@bib40]^ All procedures were approved by the University of Alberta Animal Care Committee and conducted according to guidelines established by the Canadian Council on Animal Care.

Isolation of murine Schwann cells
---------------------------------

Schwann cells were isolated from the sciatic nerves of postnatal day 2 (P2) mice as described previously.^[@bib20]^ Briefly, the sciatic nerves were digested in Dulbecco\'s modified Eagle\'s medium (DMEM)/Ham\'s F12 medium (1 : 1) containing collagenase and dispase (1 mg/ml
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5213is a drug that inhibits
 
Response: S5213is a drug that inhibits the uptake of iron and can therefore prevent iron accumulation in the brain. Iron accumulation has been linked to Parkinson’s disease.

The drug is already in the clinic for the treatment of anaemia, but is still in the early stages of clinical development for Parkinson’s.

A third drug in the pipeline is called RO60, and it has a similar mechanism to PBT2.

The final drug is called GDC-0449, and is a completely different type of drug. It has been in clinical trials for a long time, and is used in the clinic for the treatment of cancer.

It acts by increasing the level of a protein called HIF-1a.

HIF-1a is a protein that plays a role in protecting the brain against the effects of the disease, by boosting the production of the neurotransmitter dopamine.

In this way, the drug can be used to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5214is a drug that inhibits
 
Response: S5214is a drug that inhibits the activation of macrophages, including those activated by bacterial LPS, by binding to CD14. This binding blocks the activity of CD14, and the inhibition of the interaction of LPS with CD14 is the basis of the action of this drug.

Pharmacology

Mechanism of action

S5214 is a drug that inhibits the activation of macrophages, including those activated by bacterial LPS, by binding to CD14. This binding blocks the activity of CD14, and the inhibition of the interaction of LPS with CD14 is the basis of the action of this drug.

Indications

S5214 is indicated in the treatment of Gram-negative sepsis and septic shock caused by infection with bacteria of the family Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis).

Ph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5215is a drug that inhibits
 
Response: S5215is a drug that inhibits histone deacetylase, the enzyme that removes acetyl groups from histones, which are proteins that regulate the shape of DNA and are essential for DNA transcription and replication. This results in a positive effect on cell proliferation. It is indicated for use in patients with cutaneous T-cell lymphoma, but is also being investigated for use in the treatment of solid tumors, breast cancer, myelodysplastic syndromes, and non-Hodgkin's lymphoma. It is also being investigated for use in patients with high-risk neuroblastoma and ovarian cancer. It is being investigated in a phase II study for relapsed and refractory diffuse large B-cell lymphoma.

Table 2: Drug Description and Summary of Clinical Trials for S5215

Drug Description

S5215is a drug that inhibits histone deacetylase, the enzyme that removes acetyl groups from histones,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5217is a drug that inhibits
 
Response: S5217is a drug that inhibits histone deacetylase activity. SGI-1027is a histone deacetylase inhibitor that binds to HDAC. 
Euchreuterin is an agent that is under development for the treatment of certain hematologic malignancies, especially multiple myeloma and myelodysplastic syndrome.
Suberoylanilide hydroxamic acid (SAHA) is a potent HDAC inhibitor that was discovered in a high-throughput screen for small molecules that induce cell cycle arrest and apoptosis in a number of human tumor cell lines.  It is an agent that is under development for the treatment of certain hematologic malignancies, especially multiple myeloma and myelodysplastic syndrome.
Valproic acid (VPA) is an HDAC inhibitor that has been studied for its use in the treatment of hematologic malignancies. 
Vorinostat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5220is a drug that inhibits
 
Response: S5220is a drug that inhibits EGFR signaling by binding to the ATP-binding pocket of EGFR. The current study evaluated the anti-tumor activity of S5220 alone or in combination with erlotinib in HNSCC cell lines and tumor xenografts. S5220 potently inhibited the growth of HNSCC cell lines. When S5220 was combined with erlotinib, the efficacy of S5220 was enhanced. In addition, combination treatment with S5220 and erlotinib induced apoptosis and cell cycle arrest in HNSCC cells. Further, the combination of S5220 and erlotinib markedly inhibited tumor growth in vivo. Our data suggest that the combination of S5220 and erlotinib may be a novel therapeutic strategy for the treatment of HNSCC.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5223is a drug that inhibits
 
Response: S5223is a drug that inhibits the function of protein phosphatase 2A (PP2A) by binding to its catalytic subunit (PP2Ac) and then enhances the activity of glycogen synthase kinase 3 (GSK3) in the cell. In this study, we explored the possibility that S5223 increases glycogen accumulation in hepatocytes by up-regulating the expression of glucose-6-phosphatase (G6Pase) and glucose-6-phosphate translocase (G6PT). In human hepatoma cells, the effects of S5223 on G6Pase and G6PT expression were examined. The mRNA expression of G6Pase and G6PT was enhanced by S5223 treatment. The levels of protein expression and enzymatic activity of G6Pase and G6PT were also increased by S5223. Moreover, we found that the activity of GSK3 was enhanced by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5224is a drug that inhibits
 
Response: S5224is a drug that inhibits osteoclast formation and osteoclast activity, and thereby inhibits bone resorption. This is a major goal of treating diseases of the bone, including osteoporosis. However, S5224 is a compound that is difficult to administer orally. It is poorly absorbed, and has an oral bioavailability of less than 10%. S5224 is also poorly absorbed when administered orally in the presence of food, and the bioavailability of S5224 is reduced when it is administered to an animal that is underfed.
There is a need for a compound that inhibits osteoclast formation and osteoclast activity, and thereby inhibits bone resorption. In addition, there is a need for a compound that is easy to administer orally. There is also a need for a compound that is well absorbed orally, whether administered in the presence of food or underfed. There is also a need for a compound that is well absorbed orally when administered in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5225is a drug that inhibits
 
Response: S5225is a drug that inhibits the phosphatase activity of the PP2A enzyme, which is a critical regulator of the AKT-mTOR pathway. PP2A is a serine/threonine protein phosphatase that is involved in the regulation of many cellular processes. PP2A has a diverse range of functions, including regulation of the AKT-mTOR pathway, inhibition of the MAPK pathway, regulation of cell cycle, and apoptosis. The activity of PP2A is regulated by both direct binding of PP2A to its substrates and by protein-protein interactions with other proteins.^[@bibr53-1758835918766189]^ PP2A inhibitors have been shown to sensitize cancer cells to radiation and chemotherapeutic agents.^[@bibr54-1758835918766189],[@bibr55-1758835918766189]^

This study has several limitations. The small
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5227is a drug that inhibits
 
Response: S5227is a drug that inhibits the type II protein phosphatase-2A (PP2A).^[@bib1]^ It is used in combination with the alkylating agent temozolomide (TMZ) in the treatment of malignant glioma.^[@bib2]^ There is some evidence that S5227 enhances the anti-tumor activity of TMZ.^[@bib3],\ [@bib4],\ [@bib5]^

Although the action of S5227 is complex and the mechanism of action remains unclear, PP2A has a major role in the regulation of cell proliferation, apoptosis and survival.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ In addition, PP2A has a role in the regulation of the DNA damage response (DDR).^
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5228is a drug that inhibits
 
Response: S5228is a drug that inhibits the activity of mTORC1, a master regulator of cellular metabolism, growth, proliferation, and survival. It has been shown to increase lifespan in model organisms such as *C. elegans*, *D. melanogaster*, and *S. cerevisiae*. It has also been shown to extend lifespan in mammals, including mice and non-human primates ([@bib23]; [@bib25]; [@bib17]). As mTORC1 is highly conserved and essential for cell growth and proliferation, mTORC1 inhibition is expected to be well tolerated by normal cells. In contrast, cancer cells have an active mTORC1 and are highly dependent on mTORC1 for growth and proliferation. As a result, many cancer cells are sensitive to mTORC1 inhibition ([@bib6]; [@bib18]).

There are two mTORC1 complexes, mTORC1 and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5229is a drug that inhibits
 
Response: S5229is a drug that inhibits the production of interleukin-1β (IL-1β) by human macrophages and mouse macrophages stimulated by LPS. This inhibition was not due to a decrease in the number of LPS receptors. It was found that S5229 inhibits the activity of a number of protein kinases, including PKC and tyrosine kinases. It was also found that S5229 inhibited the transcription of IL-1β by human monocytes.

Structure
S5229 is a dihydroindazole-3-carboxamide that acts as an inhibitor of PKC and c-Jun N-terminal kinase (JNK).

History
S5229 was discovered by Synta Pharmaceuticals.

References

Category:Indazoles
Category:Indazoles for pharmaceuticals
Category:Indoles
Category:Protein kinase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5232is a drug that inhibits
 
Response: S5232is a drug that inhibits a major cell division pathway in a diverse set of organisms.

Materials and methods {#s4}
=====================

Bioinformatic analysis {#s4-1}
----------------------

Domain architectures of all proteins were predicted using the Simple Modular Architecture Research Tool (SMART) ([@bib34]). Domain alignments were performed using the BLAST ([@bib1]) or HHpred ([@bib27]) program.

Gene organization of *C. crescentus* CB15 NA1000 and NA4 was obtained from <http://www.broadinstitute.org/annotation/genome/cellulomonas_crescentus>.

Identification of homologous proteins in *E. coli* K12, *S. enterica* and *V. cholerae* was performed using BLASTp ([@bib1]) and PSI-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5233is a drug that inhibits
 
Response: S5233is a drug that inhibits cyclin-dependent kinase (CDK)1, which is involved in cell cycle regulation. In the current study, we examined the relationship between exposure to this drug and a possible induction of oxidative stress in HepG2 cells. We found that exposure to S5233 caused oxidative stress in HepG2 cells, and that this stress was markedly reduced by the addition of ascorbic acid (Vc). Exposure to S5233 increased the intracellular levels of ROS, and this increase was significantly reduced by the addition of Vc. However, exposure to S5233 did not significantly change the expression of Nrf2 and the transcription of its target genes, such as heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), and superoxide dismutase 2 (SOD2). Furthermore, exposure to S5233 did not significantly change the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5234is a drug that inhibits
 
Response: S5234is a drug that inhibits the synthesis of UDP-glucuronic acid, the precursor of chondroitin sulfate. This compound has been used in humans to treat the skin disease, chronic urticaria \[[@B63]\]. The effect of T5234 on the larval *S. mansoni* worm was examined and was found to be potent at a concentration of 1 μg/mL. T5234 reduced parasite motility by 86.6% and caused swelling of the parasite \[[@B63]\].

### 6.1.5. Inhibition of Glycosylation of Parasite Proteins {#sec6.1.5}

A further approach to reduce the effectiveness of parasite invasion and survival is to block the glycosylation of parasite proteins. These include *N*-linked glycosylation of the enzyme lactate dehydrogenase (LDH), a major component of the *
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5238is a drug that inhibits
 
Response: S5238is a drug that inhibits the polymerase activity of influenza A virus NS5/PB1 protein. The *in vitro* anti-viral activity of S5238 has been reported in the previous studies. It has been reported that S5238 has anti-viral activity against influenza A viruses of the H3N2 and H1N1 subtypes in cell culture and the mouse model of infection \[[@CR11]\]. In addition, it has been reported that S5238 inhibits the growth of mouse-adapted influenza A virus in the lungs of mice \[[@CR12]\]. In this study, we investigated the anti-viral effect of S5238 on A/Sydney/5/1997(H3N2) and A/Sydney/5/1997(H1N1) influenza viruses.

S5238 showed significant anti-viral activity against both A/Sydney/5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5239is a drug that inhibits
 
Response: S5239is a drug that inhibits the polymerization of tubulin and depolymerizes microtubules. We used S5239 to study the role of microtubules in asexual blood-stage development. Inhibition of microtubule polymerization resulted in a delay in gametocyte development and the subsequent transmission of the parasite. Microtubules are required for motility and invasion of the parasite into erythrocytes. The importance of microtubules in parasite development is also highlighted by the fact that S5239-induced arrest of asexual parasites is not accompanied by the appearance of the cleavage furrow and subsequent division, as is the case for DMSO-treated parasites.

MATERIALS AND METHODS {#s4}
=====================

Parasite culture. {#s4.1}
-----------------

Asexual blood-stage parasites of *P. falciparum* (3D
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5240is a drug that inhibits
 
Response: S5240is a drug that inhibits cancer cell proliferation by blocking an intracellular signaling pathway. We analyzed the cytotoxicity of S5240 to various cancer cells and compared the cytotoxicity to that of doxorubicin, a conventional chemotherapeutic agent. In A549 cells, the IC~50~ of S5240 was 5.6 μM, which was lower than that of doxorubicin (7.7 μM) ([Figure 3](#f3-ott-11-5845){ref-type="fig"}). In A549/Taxol cells, the IC~50~ of S5240 was 5.4 μM, which was also lower than that of doxorubicin (13.3 μM).

We also examined the effect of S5240 on A549 cells that had been treated with taxol. In A549/Taxol cells, the IC~50~
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5241is a drug that inhibits
 
Response: S5241is a drug that inhibits the DNA binding of the transcription factor Ets-1, and it has been shown to prevent metastasis in breast cancer cells ([@B41]). We hypothesized that it might inhibit proliferation of these cells. Therefore, we tested whether S5241 could inhibit the growth of MCF-7 cells and to what extent it could do so. We treated MCF-7 cells with S5241 and found that it inhibited the proliferation of these cells in a dose-dependent manner ([Figure 2A](#F2){ref-type="fig"}). This effect was similar to that observed in MDA-MB-231 cells, although the IC~50~ values were higher in MCF-7 cells ([Table 2](#T2){ref-type="table"}).

![**(A)** S5241 inhibits the growth of MCF-7 cells. The cells were seeded at the density of 3 × 10^3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5242is a drug that inhibits
 
Response: S5242is a drug that inhibits the enzymatic activity of cyclin-dependent kinases (CDKs), such as CDK4 and CDK6.^[@bib1]^ It was developed by NCCN for the treatment of advanced or metastatic solid tumors, including advanced/metastatic breast cancer (mBC),^[@bib2]^ and its approval in this indication was based on data from the phase III study SUMMIT.^[@bib3]^

SUMMIT is a randomized, double-blind, placebo-controlled, phase III trial that enrolled 671 patients with mBC who were previously treated with a median of three prior therapies, including one endocrine therapy.^[@bib3]^ Patients were randomly assigned (2:1) to receive either 50 mg/day of palbociclib plus fulvestrant or placebo plus fulvestrant. In the final analysis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5243is a drug that inhibits
 
Response: S5243is a drug that inhibits NF-κB activation. We have shown that the drug causes degradation of the IKK subunits and thus impairs NF-κB activation. In addition, S5243 has been shown to be an effective agent in the treatment of rheumatoid arthritis, thus making it a very attractive candidate for clinical use \[[@B13]\]. The drug has been shown to be effective in inhibiting NF-κB activation in both murine and human cells, and to inhibit tumor necrosis factor (TNF)-α-induced NF-κB activation in cells. In murine fibroblasts, S5243 inhibits the expression of genes regulated by NF-κB, and reduces TNF-α-induced cell death. In murine rheumatoid arthritis, the drug reduced the severity of the disease. The drug was found to inhibit TNF-α-induced activation of NF-κB in synovial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5245is a drug that inhibits
 
Response: S5245is a drug that inhibits telomerase, a ribonucleoprotein complex essential for telomere maintenance. It was initially developed as an anticancer drug, but its activity in solid tumours has been disappointing. Nevertheless, the development of new and better anticancer agents is ongoing, and the potential therapeutic benefit of S5245 in combination with other anticancer agents needs to be assessed. Here, we assessed the effects of S5245 on the growth of colon cancer cells in vitro and in vivo. S5245 inhibited the growth of a panel of human colon cancer cell lines in vitro, and this effect was reversed by a mutant form of hTERT that cannot be inhibited by S5245. S5245 inhibited tumour growth in a xenograft model of human colon cancer cells. Treatment with S5245 for 10 days reduced the number of tumour cells and increased the number of apoptotic cells in tumours, suggesting that S5245 has a cytost
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5246is a drug that inhibits
 
Response: S5246is a drug that inhibits *P. aeruginosa* biofilm formation.

To further elucidate the mechanism of action of S5246, we performed a Tn-seq screen to identify the genes whose expression is required for S5246-mediated inhibition of biofilm formation. By using a transposon mutant library, we were able to isolate genes that are required for the inhibition of biofilm formation. A total of 633 genes were identified, with a total of 33 of them being essential for S5246-mediated inhibition of biofilm formation. It is important to note that this is a non-targeted screen and so not all genes that are required for S5246-mediated inhibition of biofilm formation will be identified. The transposon mutants were cultured in the presence or absence of S5246 for 24 h. Biofilm formation was measured by crystal violet staining and colony forming units (CFU). The results showed that mutants in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5247is a drug that inhibits
 
Response: S5247is a drug that inhibits the production of the TNF-alpha and IL-6 cytokines, which are both important in the regulation of the acute phase of inflammation and the subsequent resolution of the inflammatory response. The results from these two studies indicate that S5247 is safe and well tolerated in patients with moderate to severe RA. The first study also showed that S5247 has a favorable safety profile in the short-term, with no serious or unexpected adverse events observed during the 2-week treatment period. S5247 was also well tolerated when administered as monotherapy for up to 6 months.^[@bibr12-1759720X19871809]^

Treatment with S5247 did not appear to have any impact on the clinical efficacy of the patients with moderate to severe RA enrolled in the two studies. The lack of any effect of S5247 on disease activity and radiographic progression in RA patients has been demonstrated in a previous study.^
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5248is a drug that inhibits
 
Response: S5248is a drug that inhibits the RhoA/ROCK signaling pathway. It is approved by the Food and Drug Administration for the treatment of acute ST-elevation myocardial infarction. Its exact mechanism of action is still not clear. In this study, we aimed to investigate the role of RhoA/ROCK signaling pathway in the effects of S5248 on cultured neonatal rat ventricular myocytes (NRVMs). NRVMs were isolated from 1- to 2-day-old Wistar rats and cultured for 5 days. NRVMs were randomly divided into 4 groups: control, 10 µM S5248, 10 µM S5248+10 µM Y27632, and 10 µM S5248+10 µM Y27632+10 µM ROCK inhibitor. NRVMs were exposed to hypoxia for 12 hours. The levels of phosphorylated RhoA and ROCK were measured by Western blot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5250is a drug that inhibits
 
Response: S5250is a drug that inhibits multiple steps in the P450-dependent N-oxidation of N-desmethyl-loperamide (NDM) and N-desmethyl-norloperamide (NDNL) to their corresponding hydroxylated metabolites, resulting in an accumulation of the metabolite N-hydroxyl-loperamide (NHL) and N-hydroxyl-norloperamide (NHLNL) in plasma. The objective of this study was to determine the pharmacokinetics and bioavailability of S5250 after single oral administration in healthy volunteers. In a randomized, open-label, 3-period crossover study, S5250 was administered orally as a single dose of 10 mg or 30 mg. The pharmacokinetic profile of S5250 was characterized by a fast absorption phase with a median tmax of 0.75 hours for the 10 mg dose and 1.0 hour for the 30 mg dose. After oral administration of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5252is a drug that inhibits
 
Response: S5252is a drug that inhibits the cellular dihydrofolate reductase (DHFR) enzyme. It has been used as a potent chemotherapeutic agent against a variety of tumors in humans and animals. It is also used as a key reagent for the construction of other clinically important anticancer drugs.^[@ref1]^ The mechanism of action of S5252 is thought to involve the depletion of nucleotide pools, leading to the inhibition of DNA and RNA synthesis.^[@ref2]^ The effect of S5252 on the structure of RNA has been investigated previously using X-ray crystallography,^[@ref3]^ nuclear magnetic resonance (NMR),^[@ref4]^ and a variety of other spectroscopic methods.^[@ref5]^ The effect of S5252 on RNA structure has been assessed in the presence of complementary DNA and RNA,^[@ref6]^ with no clear
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5253is a drug that inhibits
 
Response: S5253is a drug that inhibits the activity of the NADPH oxidase 2 (NOX2), a flavocytochrome which is present in phagocytic cells, and reduces reactive oxygen species (ROS) production in macrophages, neutrophils, and dendritic cells. It is also an inhibitor of the NF-kB and MAPK signaling pathways, thus decreasing the production of cytokines such as TNF-α and IL-1β. Inhibition of NOX2 by S5253 has been shown to decrease ROS production and prevent atherosclerotic plaque rupture in vivo. This study aimed to determine the effect of this compound on the growth of breast cancer cells.

Materials and methods {#Sec2}
=====================

Cell culture {#Sec3}
------------

Human breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-468, and MDA-MB-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5254is a drug that inhibits
 
Response: S5254is a drug that inhibits the action of microtubules and stops the cells in mitosis. Its activity is based on the inhibition of the enzyme tubulin polymerization, which affects the cell division cycle, resulting in cell death. In contrast to other tubulin inhibitors, it is an antimitotic drug, which makes it different from other microtubule inhibitors. This class of drugs has been used in the treatment of different tumors and leukemias, with a good tolerance profile, and has demonstrated activity in the treatment of solid tumors, such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. It has been approved by the Food and Drug Administration (FDA) in 2005 for the treatment of refractory or relapsed multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone. Its mechanism of action is related to the disruption of the mitotic spindle, which is a cellular
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5255is a drug that inhibits
 
Response: S5255is a drug that inhibits the signaling molecule Lck and is used to treat lymphocytic leukemia. The Src homology 2 (SH2) domain of Lck contains a tyrosine-phosphorylated motif (Y-P-X-X-X-pY) that interacts with multiple signaling molecules. Here, we show that the SH2 domain of Lck specifically binds to the pY motif of ZAP-70, a cytoplasmic protein that is required for T cell receptor (TCR) signaling. This interaction is mediated by the pY-X-X-X-pY motif in ZAP-70, which is similar to the pY-X-X-X-pY motif in Lck. Furthermore, Src family kinases (SFKs) phosphorylate tyrosine residues in ZAP-70 that are critical for its binding to Lck. Using a combination of biochemical and genetic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5256is a drug that inhibits
 
Response: S5256is a drug that inhibits an enzyme, C-5 lysyl oxidase, that catalyzes crosslinking of collagen. A result of this inhibition is a reduction in skin wrinkling. S5256is is a proprietary, once-daily, once-per-week, and once-per-month formulation of the enzyme inhibitor. Its development is being pursued by SkinMedica.

Clinical trials

The clinical development of S5256is was first announced in August 2009. The first phase III clinical trial for S5256is was conducted at the Royal Adelaide Hospital, Australia, between October 2009 and May 2010.  The study was designed to determine the efficacy and safety of S5256is compared to a placebo in reducing the appearance of facial wrinkling in patients with moderate to severe photoaging.  The results were published in a study published in the British Journal of Dermatology in 2012.

The phase III clinical trial for S5256
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5257is a drug that inhibits
 
Response: S5257is a drug that inhibits DNA methyltransferase 1 (DNMT1) and is in clinical development for the treatment of acute myeloid leukemia (AML). The goal of this study was to investigate the potential clinical utility of S5257 in the treatment of AML. The effects of S5257 were evaluated in primary human AML samples, a mouse xenograft model of AML, and patient-derived xenograft (PDX) models of AML. S5257 was shown to be effective against human AML cells in vitro and in vivo. S5257 caused a dose-dependent decrease in the phosphorylation of AKT, mTOR, and ERK1/2 in AML cells. Inhibition of AKT, mTOR, and ERK1/2 by S5257 led to the accumulation of p53, p21, and Bax, and to the activation of caspase-3 and caspase-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5258is a drug that inhibits
 
Response: S5258is a drug that inhibits the Ras protein, and is currently being tested in clinical trials. The Ras proteins are part of the mitogen-activated protein kinase (MAPK) signaling pathway, which is one of the key pathways in the cell cycle. Activation of the MAPK pathway causes cell cycle progression.

References

External links
 

Category:Tyrosine kinase inhibitors
Category:Benzimidazoles
Category:Cinnolines
Category:Carboxylic acids
Category:Tropanes
Category:Ethers
Category:Iodoarenes
Category:Heterocyclic compounds (2 rings)
Category:Nitrogen heterocycles
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5261is a drug that inhibits
 
Response: S5261is a drug that inhibits phosphatidylinositol-3-kinase (PI3K) signaling. It has previously been shown that PTEN inhibition by LY294002 can induce apoptosis in many cell types. However, it is unclear whether PTEN is involved in LY294002-induced apoptosis in vascular smooth muscle cells (VSMCs). In this study, we demonstrated that LY294002 induced apoptosis in rat VSMCs. LY294002 increased Bax, cleaved caspase-3, and cleaved PARP expression and decreased Bcl-2 expression. These effects were blocked by PTEN small interfering RNA (siRNA). In addition, LY294002 activated the PI3K/Akt signaling pathway and PTEN siRNA attenuated this effect. In conclusion, our results demonstrate that LY294002 induced apoptosis in rat VSMCs, and that PTEN
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5266is a drug that inhibits
 
Response: S5266is a drug that inhibits the binding of the S100A1/A2 dimer to the plasma membrane and prevents S100A1/A2-dependent actin bundling and cytoskeletal organization. S5266 does not prevent the oligomerization of S100A1/A2 or S100A1/A2-dependent interactions with other proteins, but is a useful pharmacological tool to study the role of the S100A1/A2 dimer in cell migration.

The physiological role of S100A1/A2 has been extensively studied and the S100A1/A2 dimer has been implicated in several biological processes. The S100A1/A2 dimer is a Ca^2+^-dependent dimer and has been shown to be involved in many different biological processes such as cell cycle regulation, cell proliferation, and cell differentiation ([@B1], [@B3]). It has also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5267is a drug that inhibits
 
Response: S5267is a drug that inhibits the intracellular transport of the β subunit of the bacterial chaperone SecA.^[@ref9]^ This drug blocks the transport of the β subunit into the periplasm of *E. coli* and *S. enterica* but does not affect the SecA transport machinery in the inner membrane.^[@ref9]^ The drug inhibits the growth of *S. enterica* and *E. coli* cells at concentrations above 5 μg/mL, and it does not inhibit the growth of other bacterial species tested.^[@ref9]^ The mechanism of the antibacterial activity of S5267 is not known, but it is hypothesized that the drug acts on a SecA-dependent protein transport pathway in the cytoplasm.^[@ref9]^ This hypothesis is based on the finding that the antibacterial activity of S5267 is diminished by the *secA*
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5268is a drug that inhibits
 
Response: S5268is a drug that inhibits the
release of histamine from mast cells. It is indicated for the relief of the
symptoms of allergic rhinitis (hay fever) and of the pruritus of urticaria.
It is also indicated for the treatment of bronchial asthma, particularly
when symptoms are not well controlled with beta2-agonists. The clinical
effect of this drug is similar to that of a histamine H1-receptor
antagonist. S5268is available as a syrup (in combination with sodium
bicarbonate), an oral solution, an oral suspension (in combination with
polysorbate 80), and a granule.

NOVO-NORDISKA

S5265 is a drug that inhibits the
release of histamine from mast cells. It is indicated for the relief of
the symptoms of allergic rhinitis (hay fever) and of the pruritus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5273is a drug that inhibits
 
Response: S5273is a drug that inhibits viral RNA-dependent RNA polymerase (RdRP). It is believed that this drug is effective in a phase III clinical trial in China, and in a phase II clinical trial in the US and EU. In addition, several analogs of S5273 are also being developed in the field of anti-HCV drug discovery.

References 

Category:Pyrrolidines
Category:Hepatitis C
Category:Experimental drugs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5278is a drug that inhibits
 
Response: S5278is a drug that inhibits T cell costimulation, resulting in inhibition of T cell proliferation and downregulation of IFNγ production. This was observed in a Phase I trial in patients with relapsed/refractory B cell lymphoma (Brunet et al., [@B7]). There was a 3-fold reduction in circulating NK cells, and the treated group had a trend toward decreased overall survival. This study, along with other studies that showed clinical benefit in the use of anti-PD-1/PD-L1 therapies in patients with relapsed/refractory NHL, led to the approval of this combination in NHL.

Recently, results from the Phase II trial in patients with relapsed/refractory DLBCL demonstrated that pembrolizumab is well tolerated, and resulted in a CR rate of 14% and a PR rate of 43% in the 43 evaluable patients (Kern et al., [@B38
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5279is a drug that inhibits
 
Response: S5279is a drug that inhibits the phosphorylation of Aurora-A and -B, thereby inhibiting the activation of Aurora-A and -B, and consequently inhibiting the cell cycle, proliferation and migration of tumor cells. The active substance of S5279 is chemically named 4-(2-amino-4-methoxyphenyl)-2-(2-fluoro-4-pyridin-2-yl-phenyl)-N-phenyl-2,3-dihydro-1H-indole-5-sulfonamide, and its chemical formula is C25H21FN4O3S·H2O. The molecular weight of S5279 is 626.48, the drug substance is white crystal powder, and the solubility of the drug substance is about 3.85 mg/mL. S5279 has a molecular formula of C25H21FN4O3S·H2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5280is a drug that inhibits
 
Response: S5280is a drug that inhibits the synthesis of a specific peptide found in milk, beta-casein. It is used to treat and prevent mastitis in cows and ewes, and to treat the symptoms of udder inflammation and inflammation of the lungs in cattle.

Product description

RimS5280is a drug that inhibits the synthesis of a specific peptide found in milk, beta-casein. It is used to treat and prevent mastitis in cows and ewes, and to treat the symptoms of udder inflammation and inflammation of the lungs in cattle.

Active substance

The active substance of RimS5280 is S-RimS5280.

Cattle

Use: RimS5280is a drug that inhibits the synthesis of a specific peptide found in milk, beta-casein. It is used to treat and prevent mastitis in cows and ewes, and to treat the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5281is a drug that inhibits
 
Response: S5281is a drug that inhibits histone deacetylase, which results in hyperacetylation of histones and chromatin. This drug causes an increase in the expression of many genes, which results in cell cycle arrest, differentiation, and apoptosis in cancer cells. Therefore, it is a promising anticancer drug. It has been reported that the levels of acetyl-H3 and -H4 in the MCF-7 breast cancer cell line were reduced after treatment with S5281.[@b39-ijn-11-1501] The present results also showed that S5281 had a cytotoxic effect on A549 cells. The anticancer activity of S5281 was found to be greater than that of the control group, which was likely due to the effect of S5281 on the acetylation of histones. The effect of S5281 on the acetylation of histones was evaluated by the acetylation of histone H3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5282is a drug that inhibits
 
Response: S5282is a drug that inhibits CYP2C9 and CYP2C19, resulting in lower plasma concentrations of clopidogrel and the active metabolite, which is thought to contribute to an increased risk of thrombotic events. The aim of this study was to determine whether clopidogrel resistance is increased in patients with stroke/transient ischemic attack (TIA) who have undergone carotid endarterectomy (CEA). A total of 63 patients were recruited to the study. All patients received a standard 600 mg clopidogrel loading dose before CEA. Post-operative, patients were given a daily dose of 75 mg clopidogrel for 6 weeks. Clopidogrel resistance was determined using the platelet function analyzer (PFA-100) in patients at 6 weeks post-CEA. The median clopidogrel resistance index (CRI) in patients with no post
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5284is a drug that inhibits
 
Response: S5284is a drug that inhibits PD-L1-PD-1 signaling by binding to PD-1, thus preventing the inhibitory interaction between PD-1 and PD-L1. In mouse models, anti-PD-L1-S5284 treatment induced significant tumor regression and prolonged survival. Treatment with anti-PD-L1-S5284 also led to T cell-mediated tumor regression in a number of mouse models, including the KRAS-mutant pancreatic cancer models MiaPaCa-2 and AsPC-1, the Kras-mutant lung cancer model A549, and the breast cancer model 4T1.[@CIT0012] Moreover, anti-PD-L1-S5284 exhibited synergistic antitumor activity when combined with anti-PD-1 or anti-CTLA-4 in mouse models of pancreatic cancer and melanoma.[@CIT0012]

In vitro studies showed that S5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5286is a drug that inhibits
 
Response: S5286is a drug that inhibits the formation of the porphyrin heme, and is used to treat porphyria. It has been found to reduce the activity of ALAS2 in the liver.

Covalent inhibitors

As noted above, one strategy to treat porphyria is to inhibit the enzyme that is causing the disease. For this reason, many drugs have been developed that are covalent inhibitors of ALAS2. The main covalent inhibitors developed so far are shown in Table 3.

Table 3. Covalent inhibitors of ALAS2

Drug

Target

Reference

Ansamycin

Porphobilinogen synthase

Chandrasekaran, et al. (2011)

Ansamitocin

Porphobilinogen synthase

Chen, et al. (2009)

Benzamil

Porphobilinogen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5287is a drug that inhibits
 
Response: S5287is a drug that inhibits the progression of preneoplastic lesions.

CONCLUSION {#s10}
==========

Taken together, the results of the present study suggest that PGE~2~ has a dual role in gastric carcinogenesis, promoting gastric tumorigenesis at early stages and suppressing tumor progression at advanced stages. Our findings are consistent with previous studies and may be explained by the observation that PGE~2~ induces growth arrest and apoptosis in a number of cancer cell lines. In this study, we demonstrated that PGE~2~ promotes tumorigenesis by inducing tumor cell proliferation and suppressing apoptosis in the early stage of gastric tumorigenesis. The suppressive effect of PGE~2~ on tumor progression in advanced stages is likely due to the induction of apoptosis. PGE~2~ induces apoptosis through the activation of PKC and the PI3K/Akt signaling pathway, which inhibits the expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5288is a drug that inhibits
 
Response: S5288is a drug that inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthetic pathway. The drug inhibits HMG-CoA reductase by blocking the active site of the enzyme and is known to inhibit the proliferation of many different cell types in culture. S5288is was originally developed by Merck for the treatment of hypercholesterolemia and atherosclerosis, and it has been tested in a number of clinical trials. The compound has been found to be well tolerated in humans. S5288is is now in clinical trials for the treatment of a number of other conditions, including Alzheimer's disease and cancer. In the U.S. it is being developed by Targacept under the trade name Torcetrapib.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5289is a drug that inhibits
 
Response: S5289is a drug that inhibits the production of proinflammatory cytokines and thereby modulates the host immune response. The anti-inflammatory effect of S5289 is accompanied by downregulation of COX-2 and MMP-9 in stimulated cells. S5289 showed good anti-inflammatory activity in rat paw edema induced by carrageenan and in a rat model of arthritis. In addition, S5289 significantly inhibited the growth of solid tumors and prolonged the survival of mice bearing MCA-106 tumors.^[@bib47]^

Conclusion
==========

The use of natural plant products to treat inflammatory diseases has a long history. Some of these natural products are still used as an alternative therapy in many parts of the world. In the present review, we discussed some of the natural plant products that are currently used to treat inflammatory diseases. The various compounds described in this review can be used as lead molecules to design more potent and specific drugs. The
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5291is a drug that inhibits
 
Response: S5291is a drug that inhibits aldose reductase. It has been shown to have positive effects on diabetic neuropathy and peripheral vascular disease. It is currently being developed as a potential treatment for diabetic retinopathy.

3.1. Chemical Structure {#sec3dot1-molecules-24-00990}
-----------------------

S5291 is an oxindole compound. It is a potent aldose reductase inhibitor. The structure is shown in [Figure 2](#molecules-24-00990-f002){ref-type="fig"}.

3.2. Chemical Synthesis {#sec3dot2-molecules-24-00990}
-----------------------

A new method for the synthesis of oxindole S5291 was developed in the laboratory of Professor Qiancheng Wang \[[@B29-molecules-24-00990]\]. This method
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5292is a drug that inhibits
 
Response: S5292is a drug that inhibits the transport of the chemical acetylcholine (ACh) out of the synaptic vesicles of cholinergic nerve endings in the brain. It has been shown to be a safe and effective treatment for patients with severe and chronic obstructive pulmonary disease (COPD).

In the course of treating COPD, S5292 is given by inhalation. The main advantage of S5292 over other bronchodilators is that it is not cleared by the liver and, therefore, can be used to treat patients with liver failure. S5292 has been found to be effective in treating patients with both chronic and acute exacerbations of COPD, as well as in patients with other respiratory diseases.

Clinical studies have shown that S5292 is effective in reducing the need for rescue medication and improving lung function, dyspnea, and quality of life. In addition, patients treated with S5292 have reported improved sleep
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5293is a drug that inhibits
 
Response: S5293is a drug that inhibits mTOR signaling by acting as an allosteric inhibitor of the mTOR kinase and acts as a growth suppressor in a variety of tumor types \[[@B17-molecules-24-00387]\]. It has been shown to be effective in various tumor types in preclinical models, and has been shown to be active in human clinical trials. We chose to use rapamycin as a positive control for mTOR inhibition, as it is an established drug that has been tested in a variety of clinical trials.

Here, we demonstrate that S5293 is active in AML, and that the effect of the drug is mediated by mTOR inhibition, as shown by the reduction of phosphorylation of S6K and 4EBP1. The results of the primary screen showed that S5293 inhibited AML cell proliferation at 10 μM in both primary AML cells and normal human bone marrow cells. Furthermore,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5295is a drug that inhibits
 
Response: S5295is a drug that inhibits Kv11.1 (Kv1.5) channel. In a clinical study, Kv11.1 blockade has been shown to be effective in suppressing ventricular arrhythmias in patients with cardiac arrest. The aim of this study was to investigate the electrophysiological and arrhythmogenic effects of S5295 in a rabbit model. Twenty-eight rabbits were randomly assigned to four groups. After coronary ligation, each group received either vehicle, S5295 (0.3 mg/kg), or S5295 (1 mg/kg) with or without isoproterenol (ISO) infusion. At the end of the study, ventricular action potentials (VAPs) were recorded in vivo. The following electrophysiological parameters were analyzed: refractoriness, conduction velocity, effective refractory period, APD50 and APD90, action potential duration (APD), transmural disp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5296is a drug that inhibits
 
Response: S5296is a drug that inhibits EGFR signaling and has been tested in a Phase I clinical trial.^[@R29]^ The results of the Phase I trial are not yet available. However, in vitro studies have shown that it inhibits the growth of lung cancer cells and breast cancer cells.^[@R30]^ Therefore, we tested the sensitivity of a panel of lung cancer cell lines to this drug and found that it inhibited the growth of all the lung cancer cell lines tested, with the exception of H1299 cells (Figure [3](#F3){ref-type="fig"}A). In contrast, the growth of H1299 cells was unaffected. This is consistent with the lack of sensitivity to this drug of H1299 cells observed in the clinical trial.^[@R29]^ The sensitivity of the lung cancer cell lines to TKIs can be used as a surrogate marker for their sensitivity to other targeted therapies. For example, g
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5297is a drug that inhibits
 
Response: S5297is a drug that inhibits SIRT1. It is a potent and selective inhibitor of SIRT1, with an IC50 value of 3 nM, and has been used to inhibit the deacetylase activity of SIRT1 in vitro and in vivo. S5297 is a water-soluble derivative of S3167, and is a low molecular weight molecule. S5297 is an inhibitor of SIRT1 with no significant inhibitory activity against other SIRTs, including SIRT2, SIRT3, SIRT4, SIRT5, and SIRT6. S5297 can selectively and potently inhibit SIRT1 in vitro and in vivo. In cells, S5297 can suppress the deacetylation of histone H3 at Lys 9, leading to the suppression of gene transcription. It has been demonstrated that S5297 suppresses tumorigenesis and promotes apoptosis in many types of cancer cells, including human lung cancer,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5298is a drug that inhibits
 
Response: S5298is a drug that inhibits EMT. As a member of the Src family of non-receptor tyrosine kinases, Src is one of the most frequently mutated oncogenes in human cancers and is activated in response to a variety of cellular stimuli, including EGF, integrin-mediated cell-cell and cell-matrix adhesion, and growth factor receptors \[[@R2], [@R21]\]. Src activation is also a key step in EMT \[[@R4], [@R22]\]. Src-induced EMT is primarily mediated by two downstream signaling pathways, the PI3K/AKT and the ERK/MAPK pathways \[[@R2]\]. Src also has an important role in the development of resistance to EGFR-targeted therapy in lung cancer \[[@R23]\].

We showed that miR-26b directly targets Src
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5299is a drug that inhibits
 
Response: S5299is a drug that inhibits MCT-1, a plasma membrane transporter that mediates lactate uptake by cancer cells. It also binds to a secondary lactate transporter, MCT-2. Lactate is an oncometabolite produced by cancer cells. It is a metabolite of glucose, and is produced by anaerobic glycolysis. The tumor microenvironment has been shown to produce large amounts of lactate, which in turn, is transported into the cells via MCT-1. Once inside the cell, lactate is used as a substrate to produce pyruvate, which is then used in the Krebs cycle. MCT-1 inhibition blocks the uptake of lactate into the cells, resulting in the inability of cancer cells to utilize lactate as a substrate for the Krebs cycle. The net effect of this is that lactate-producing tumors will have a reduced metabolic rate, and the lactate produced will be excreted
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5302is a drug that inhibits
 
Response: S5302is a drug that inhibits the Wnt/β-catenin pathway and reduces the expression of c-myc. In this study, we showed that S5302 inhibited the growth of NSCLC cells and reduced the expression of c-myc.

Mutation or down-regulation of tumor suppressor genes and oncogenes is a common cause of tumorigenesis ([@b22-ol-0-0-11404],[@b23-ol-0-0-11404]). c-myc is a proto-oncogene that encodes a transcription factor, and its expression is frequently upregulated in various types of cancer, including NSCLC ([@b24-ol-0-0-11404],[@b25-ol-0-0-11404]). A previous study revealed that c-myc may regulate the development and progression of NSCLC ([@b26-ol-0-0
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5305is a drug that inhibits
 
Response: S5305is a drug that inhibits the phosphatase calcineurin, thereby blocking the dephosphorylation of the nuclear factor of activated T cells (NFAT). This prevents the activation of T cells, and can lead to a severe systemic reaction and even death. The drug has been used in transplant patients to prevent the activation of their T cells, and in many cases, it has led to an improvement in graft survival. S5305 is also in development for use in treating other conditions such as inflammatory bowel disease, and asthma.

An EMEA recommendation for a treatment protocol for S5305 is as follows:

Treatment of S5305 patients

Use only one of the following:

S5305 or cyclosporineA CsA

S5305 or tacrolimus (FK506)

A combination of S5305 and CsA is not recommended.

A CsA and S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5309is a drug that inhibits
 
Response: S5309is a drug that inhibits the enzyme farnesyl pyrophosphate synthetase. This enzyme plays a key role in the biosynthesis of farnesyl pyrophosphate, a key intermediate in the mevalonate pathway, the first step of which is the formation of isopentenyl pyrophosphate from dimethylallyl pyrophosphate. Farnesyl pyrophosphate synthetase catalyzes the formation of farnesyl pyrophosphate from farnesyl pyrophosphate and dimethylallyl pyrophosphate. Farnesyl pyrophosphate is a key intermediate in the formation of a variety of sterols and other important metabolites.
S5309 inhibits farnesyl pyrophosphate synthetase at concentrations of less than 1 micromolar. The inhibition of this enzyme results in a reduction in the levels of the end products of the mevalonate pathway, which are isopentenyl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5311is a drug that inhibits
 
Response: S5311is a drug that inhibits platelet aggregation, and the dose is approximately 0.5 mg/kg. It is administered orally, intravenously, or subcutaneously. In addition, the drug is often used in combination with aspirin, or it may be administered alone.

[^6]: NA, not applicable.

[^7]:  No significant differences were observed between the groups in the postoperative time periods.

[^8]: Significant differences between the groups are indicated by *P*-values.

[^9]: ^a^Group A, tricuspid valve replacement with monocusp device; group B, tricuspid valve replacement with double-leaflet device; group C, tricuspid valve replacement with monocusp device with adjunctive use of prostaglandin I~2~; group D, tricuspid valve replacement with double-leaflet device with adjunctive use
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5320is a drug that inhibits
 
Response: S5320is a drug that inhibits the platelet ADP receptor P2Y12, thereby inhibiting platelet aggregation. P2Y12is an ADP receptor, which is a receptor of ADP. ADPis a kind of a weak platelet agonist, and it is one of the important platelet activators in the process of platelet aggregation. The ADP receptor is mainly located on the platelet membrane. P2Y12is an important ADP receptor on the platelet membrane, which is also called GPIIb/IIIa receptor. This kind of receptor has a main function of combining with ADP to promote platelet aggregation, which can further activate intracellular signal transduction and lead to the release of intracellular Ca2+, which can activate a series of intracellular enzymes, promote the activation of various effector molecules, such as the calcium channel, the phospholipase, and the like, to induce the release of intr
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5322is a drug that inhibits
 
Response: S5322is a drug that inhibits phosphatase activity. In the current study, we tested whether this compound can prevent the development of angiogenesis in a murine corneal neovascularization model. We examined the effect of S5322 on corneal neovascularization induced by transplantation of fibroblasts overexpressing vascular endothelial growth factor (VEGF). S5322 was applied topically on the eye every 4 hours for a total of 4 days. The formation of corneal neovascularization was evaluated after transplantation of VEGF-transfected fibroblasts and the development of neovascularization was examined by histological analysis. To determine whether S5322 affects the proliferation of endothelial cells, we performed in vitro experiments with cultured endothelial cells. S5322 inhibited the development of neovascularization in a dose-dependent manner. The number of endothelial cells in the cornea was significantly decreased
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5325is a drug that inhibits
 
Response: S5325is a drug that inhibits a new class of bacterial RNA polymerases called σ^70^-type RNA polymerases. These enzymes are essential for bacterial growth, and inhibition of these enzymes can prevent bacterial growth.

S5325 inhibits growth of Gram-positive and Gram-negative bacteria {#Sec1}
=================================================================

S5325 is a pyrazolo\[1,5-a\]pyrimidine derivative that has been developed as a potent, specific, and orally bioavailable inhibitor of σ^70^-type RNA polymerases. These enzymes are essential for bacterial growth, and inhibition of these enzymes can prevent bacterial growth.^[@CR1]^ The *B. subtilis* σ^70^-type RNA polymerase is essential for survival of the organism. Inhibitors of σ^70^-type RNA polymerases may be useful for the treatment of bacterial infections.

S5325
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5326is a drug that inhibits
 
Response: S5326is a drug that inhibits the degradation of the TGF-β1 protein by binding to its receptor. This drug is used for the treatment of chronic kidney disease, and it is also effective for treating pulmonary fibrosis, cardiac fibrosis, liver fibrosis, and other fibrosis. In this study, we found that the expression of TGF-β1 was significantly increased in the fibrotic skin tissue of SSc patients, which was consistent with the results of our previous study \[[@B16]\]. In the current study, we further demonstrated that S5326 inhibited the degradation of the TGF-β1 protein in fibroblasts *in vitro*, which was consistent with the results of a previous study \[[@B27]\]. Moreover, we also demonstrated that the inhibitory effect of S5326 on TGF-β1 was mainly through blocking the degradation of the TGF-β1 protein in fibroblasts, which was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5327is a drug that inhibits
 
Response: S5327is a drug that inhibits the expression of matrix metalloproteinase-9 (MMP-9) and prevents the growth of H. pylori. In this study, the effects of S5327 on the proliferation of gastric cancer cells and the underlying mechanism were investigated. S5327 was administered to human gastric cancer cell line AGS in vitro and in vivo. The effects of S5327 on the proliferation of AGS cells were assessed by MTT assay. The expressions of MMP-9 and VEGF were detected by western blot. The results showed that S5327 inhibited the proliferation of AGS cells in a dose-dependent manner, and the expression of MMP-9 and VEGF was reduced by S5327. In vivo, S5327 suppressed the proliferation of AGS cells in the tumor tissues of xenograft mice. In addition, S5327 significantly reduced the expression of MMP-9 and VEGF
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5331is a drug that inhibits
 
Response: S5331is a drug that inhibits cell proliferation and induces apoptosis in human breast cancer cells. We demonstrate here that S5331 induces a significant increase in the expression of the endogenous anti-apoptotic protein, Bcl-2.

S5331 inhibits breast cancer cell proliferation {#s2_1}
-----------------------------------------------

S5331 was synthesized in a previous study \[[@R20]\] and we found that it significantly inhibited cell proliferation in a dose-dependent manner in both the MCF-7 and MDA-MB-231 breast cancer cell lines (Figure [1A](#F1){ref-type="fig"}). The MCF-7 cells were more sensitive to S5331 than the MDA-MB-231 cells. S5331 was also tested in two additional breast cancer cell lines, T47D and MDA-MB-453, and the results were similar to those obtained with MCF-7
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5333is a drug that inhibits
 
Response: S5333is a drug that inhibits the effect of c-Abl kinase and is in clinical development for the treatment of patients with chronic myeloid leukemia (CML) that has relapsed after imatinib therapy. Because imatinib resistance in CML cells occurs through the expression of c-Abl splice variants, which lack the kinase domain, we studied the effects of S5333 on the growth of imatinib-resistant cell lines. We found that S5333 had a greater inhibitory effect on the growth of the imatinib-resistant cell lines K562/AblT315I and K562/AblF311I than on K562/Abl, and induced apoptosis in K562/AblF311I cells. We also found that the growth of the imatinib-resistant cell lines was inhibited by the inhibition of phosphoinositide 3-kinase (PI3K) signaling. S5333,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5341is a drug that inhibits
 
Response: S5341is a drug that inhibits the production of certain cytokines (including IL-2, IL-4, IL-5, and IFN-gamma) by T cells. This drug was first developed to treat inflammatory bowel disease, but has since been found to be effective in treating many different autoimmune diseases. Although this drug has been available for many years, the mechanism by which it suppresses T cell activity is still poorly understood.

Although it has been observed that IL-2, IL-4, IL-5, and IFN-gamma are necessary for the development of autoimmune diseases, it has not been determined whether the suppression of these cytokines is required for the development of the disease. The ability of S5341 to block the production of these cytokines by T cells indicates that it is likely to be effective in treating autoimmune diseases, such as multiple sclerosis, arthritis, and diabetes.

The effect of S5341 on the cytokine production by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5343is a drug that inhibits
 
Response: S5343is a drug that inhibits the viral helicase helicase-primase complex (WP965). In the presence of the drug, the viral polymerase cannot start a new DNA strand, and the viral genome is thus replicated only once. It was reported that this drug reduced the size of a hepatic necroinflammatory area, and significantly improved liver function \[[@CR23]\]. We confirmed that the serum concentration of S5343 in our patients was in the therapeutic range.

As reported previously, the virus has multiple infection mechanisms that can cause immune-mediated injury. In the present study, the patients with virus infection were associated with higher levels of the immunological biomarkers, such as IL-6 and sCD163, compared with those with other etiologies. Therefore, the viral infection itself may have affected the level of the immunological biomarkers.

In the present study, we also confirmed the presence of IL-10-producing T cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5345is a drug that inhibits
 
Response: S5345is a drug that inhibits the p-glycoprotein, a protein that protects cells from harmful substances. The p-glycoprotein removes many of the chemotherapy drugs from the body. A single dose of S5345 can lower the concentration of chemotherapy drugs by 50%. It may increase the effectiveness of chemotherapy and may allow lower doses of chemotherapy to be used. The medication is being tested for effectiveness in children and adults.

Stem Cell Therapy

Researchers are using stem cells to treat a wide range of conditions, including leukemia, AIDS, diabetes, spinal cord injuries, and more. Stem cells are immature cells that have the potential to grow into other cells and tissues. They have been used to treat certain cancers, such as breast cancer and leukemia. Researchers are studying the role of stem cells in the brain to understand how they can be used to treat a wide range of neurological disorders.

Cell-Based Therapy

Researchers are developing therapies that use cells to help
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5350is a drug that inhibits
 
Response: S5350is a drug that inhibits the action of interleukin 2 (IL-2) on the T cells of patients with leukemia. In this study, we have examined the effects of S5350 on normal human T cells. IL-2-dependent proliferative responses of normal T cells were reduced by S5350 in a dose-dependent manner. The maximal inhibition was obtained with an IL-2-dependent proliferative response at a concentration of 10(-7) M S5350. The proliferative response to phytohemagglutinin (PHA) was also inhibited by S5350. The proliferative response to IL-2 was inhibited by the same concentration of S5350 as that which inhibited the IL-2-dependent proliferative response. In addition, S5350 inhibited the IL-2-dependent cytotoxicity of natural killer cells. The cytotoxic activity of S5350 was reduced to a greater extent than the proliferative
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5351is a drug that inhibits
 
Response: S5351is a drug that inhibits osteoclast differentiation and activation and has been used in clinic to treat osteoporosis[@b34]. The underlying mechanism of RANKL/RANK-induced osteoclastogenesis has been well characterized, which involves NF-κB, MAPK and Akt signaling pathways[@b35][@b36]. In the present study, we found that SB239063 significantly decreased RANKL-induced osteoclastogenesis and bone resorption in a dose-dependent manner. Meanwhile, it attenuated the RANKL-induced increase of NFATc1, TRAP and c-Src phosphorylation, and IκBα degradation. Our data indicated that SB239063 significantly suppressed the osteoclast differentiation and bone resorption *in vitro* and *in vivo*. These results suggest that SB239063 has a potent anti-osteoclastogenic effect in part through inhibition of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5352is a drug that inhibits
 
Response: S5352is a drug that inhibits the DNA polymerase alpha (DNA pol alpha) and inhibits cell proliferation in vitro. We investigated the effects of S5352 on cell proliferation and its relationship to DNA pol alpha activity in cell lines of different human tumor types. In vitro, S5352 inhibited the proliferation of human cancer cell lines of the lung, colon, pancreas, prostate, breast, and head and neck. In vivo, S5352 inhibited the growth of human lung, colon, and pancreatic tumors in nude mice. The effect of S5352 on cell proliferation was evaluated by a colony-forming assay and cell cycle analysis. The effect of S5352 on DNA pol alpha activity was determined by a nonradioactive, highly sensitive method using a novel, highly specific DNA polymerase assay system. S5352 inhibited the activity of DNA pol alpha in vitro and in vivo. The inhibitory effect of S5352 on DNA pol alpha was most potent in human lung cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5353is a drug that inhibits
 
Response: S5353is a drug that inhibits the Cdc42 protein, which is important in cell cycle regulation. The results of this study indicate that the combination of 5-FU and S5353is a very effective treatment for colon cancer cells.

MATERIALS AND METHODS {#s4}
=====================

Reagents and antibodies {#s4_1}
-----------------------

Antibodies to p-Cdc42 (Tyr41), Cdc42, p-Rac1 (Ser71), Rac1, p-JNK (Thr183/Tyr185), JNK, p-ERK (Thr202/Tyr204), ERK, p-AKT (Ser473), AKT, p-p38 (Thr180/Tyr182), p38, p-PKC (Thr410/403), PKC, p-p70S6K (Thr389
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5355is a drug that inhibits
 
Response: S5355is a drug that inhibits the binding of folic acid to the vitamin-dependent enzyme dihydrofolate reductase (DHFR), thus interfering with the ability of the cell to convert dihydrofolate to tetrahydrofolate. This results in the depletion of tetrahydrofolate cofactors needed for DNA synthesis and repair. In the presence of reduced folates, the sensitivity of tumor cells to other antifolates is increased. The first use of S5355 was in combination with MTX, and it was found to have a similar efficacy to MTX, but with less myelosuppression and bone marrow toxicity.

In clinical trials, S5355 was found to be effective against both untreated and previously treated MM. In the phase II MM.1 trial, S5355 showed an overall response rate of 44% (4/9) in previously treated MM patients who were refractory to both alky
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5356is a drug that inhibits
 
Response: S5356is a drug that inhibits the Na+/H+ exchanger (NHE-1). Its exact mechanism of action is still not fully understood. However, it is known that S5356 causes an intracellular acidification, which in turn may activate phospholipase A2. As S5356 has a stimulatory effect on glucagon release, we have investigated its effect on the activity of phospholipase A2 in isolated rat pancreatic islets. S5356 caused a rapid and transient increase in the activity of phospholipase A2. The increase was not mediated by changes in intracellular calcium concentration. It was, however, blocked by the removal of extracellular Ca2+, indicating that the enzyme is stimulated by S5356 via a Ca(2+)-dependent pathway. The S5356-induced increase in phospholipase A2 activity was observed only in islets from animals pretreated with glucagon and was absent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5357is a drug that inhibits
 
Response: S5357is a drug that inhibits the biosynthesis of polyamines and therefore is a broad spectrum anti-tumor agent. In our study, we demonstrated that the growth inhibition of B16-BL6 cells by S5357 was associated with the induction of apoptosis. This effect was evidenced by the following observations: 1) the proportion of cells in the S phase of the cell cycle was decreased; 2) S5357 treatment resulted in an increase in sub-G1 peak; 3) DNA laddering and morphological changes were observed in S5357-treated cells; 4) the expression of the anti-apoptotic protein Bcl-2 was down-regulated, and the expression of the pro-apoptotic protein Bax was up-regulated. Furthermore, S5357 also suppressed the growth of subcutaneous B16-BL6 tumors in mice, which is consistent with our in vitro results. These results suggest that S5357-induced growth inhibition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5358is a drug that inhibits
 
Response: S5358is a drug that inhibits HIF1alpha and mTOR signaling in combination with Dacarbazine, a standard drug for the treatment of metastatic melanoma. In the present study, we investigated the effect of S5358 on tumor growth, as well as the immune system. The results showed that S5358 is a very potent inhibitor of tumor growth, and that it has a positive impact on the tumor-specific immune response. These findings warrant further investigations to explore the role of S5358 in combination with other standard treatments for the treatment of melanoma.

MATERIALS AND METHODS {#s4}
=====================

Animals {#s4_1}
-------

Female C57BL/6 mice (6--8 weeks old) were purchased from Harlan Laboratories (Indianapolis, IN, USA). All animals were housed in a pathogen-free facility and all procedures were performed according to the National Institutes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5359is a drug that inhibits
 
Response: S5359is a drug that inhibits bacterial DNA synthesis and causes bacterial cell death. S5359is in development for oral use. S5359was identified as a lead compound during the discovery of the DNA gyrase inhibitor quinolones, and has demonstrated potent activity against Gram-positive and Gram-negative pathogens, including some strains resistant to the quinolone class. S5359is the only quinolone with demonstrated activity against resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
S5359has been evaluated in a phase II clinical trial in patients with lower respiratory tract infections. The results of the phase II trial showed that S5359was well tolerated, had a good safety profile and exhibited clinical efficacy against common lower respiratory tract pathogens, including those resistant to quinolones. S5359is a potent and selective inhibitor of DNA gyrase. The bacterial target is essential for DNA
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5360is a drug that inhibits
 
Response: S5360is a drug that inhibits the enzyme histidine decarboxylase (HDC), a key enzyme in the synthesis of histamine. It has been used to treat food allergies and the acute allergic reaction, anaphylaxis, in patients. It has also been used to prevent acute reactions to foods such as peanuts, tree nuts, and fish, and it is used to prevent reactions to insect stings. S5360 is currently being used in clinical trials to prevent food allergies in patients.

References

External links
 
 
 
 
 
 
 

Category:Benzoic acids
Category:Phenol ethers
Category:Benzodioxoles
Category:Sulfonamides
Category:Allergology
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5361is a drug that inhibits
 
Response: S5361is a drug that inhibits mitotic entry. We used a cell-based fluorescent complementation assay to show that the S5361--GTP exchange factor *Cdc25B* (*Cdc25B-GTP*), which regulates mitotic entry, binds to S5361 and inhibits its binding to p130 ([Fig. 6 A](#fig6){ref-type="fig"}). The *Cdc25B-GTP* fragment binds to S5361 in the absence of S5361-Tn and S5361-SN, but not to p130 ([Fig. 6 A](#fig6){ref-type="fig"}). The S5361-SN fragment binds to S5361 in the presence of p130 but not to *Cdc25B-GTP* ([Fig. 6 A](#fig6){ref-type="fig"}). These results suggest that S5361-SN binds to p130
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5363is a drug that inhibits
 
Response: S5363is a drug that inhibits the HMG-CoA reductase enzyme, an enzyme that catalyzes the rate-limiting step in the mevalonate pathway. The statins reduce the production of cholesterol and its precursors, farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These products are required for the posttranslational modification of Ras and Rho proteins, which is required for their activation. These activated proteins regulate a number of cellular functions including cell growth, differentiation, apoptosis, and angiogenesis. This inhibition of cellular growth can cause the regression of atherosclerotic plaques in the coronary arteries and peripheral arteries.\[[@ref1]\]

The statins are the most widely prescribed drugs for the treatment of hyperlipidemia. They have a proven safety record in both adults and children. There are concerns that the use of statins may be associated with an increased risk of diabetes,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5366is a drug that inhibits
 
Response: S5366is a drug that inhibits the proliferation of P-Rex1^+^ glioma stem cells by blocking the migration of tumor cells and their invasion into the surrounding normal brain tissues ([@B94]). Therefore, this could be a promising drug for the treatment of P-Rex1^+^ glioma.

In conclusion, a number of potential therapies are available for the treatment of glioma, but the clinical results of these treatments have been poor. Thus, there is a need for more effective treatment options. The findings from this review provide a novel approach to the treatment of glioma by targeting the signaling pathway downstream of P-Rex1, and they also suggest the possibility of new therapies for glioma treatment. However, additional studies are needed to investigate the mechanisms of glioma and to develop novel treatments for the disease.

Author Contributions {#S7}
====================

Z-HC and Q-QY conceived the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5367is a drug that inhibits
 
Response: S5367is a drug that inhibits PKC (protein kinase C) and the use of it can cause serious adverse effects.\[[@ref19]\] Moreover, its use in newborns is prohibited in Europe.\[[@ref19]\] Other problems of CsA and FK506 include neurotoxicity, nephrotoxicity, and potential teratogenicity.\[[@ref20]\]

All these drawbacks of CsA and FK506 led to the development of other immunosuppressants, such as Sirolimus (Rapamycin). Rapamycin, is a macrolide antibiotic produced by *Streptomyces hygroscopicus*, a soil actinomycete.\[[@ref21]\]

Rapamycin binds to a protein, FKBP-12 (FK506 binding protein), which binds to the FK506 binding domain of the target protein.\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5368is a drug that inhibits
 
Response: S5368is a drug that inhibits thrombin, or a derivative of it, and is currently in Phase II trials for use as a novel anticoagulant. S5368 has been shown to be effective in a rat model of cerebral ischemia, as measured by reduction in neurological deficit and edema. The objective of this study was to investigate the effect of S5368 on ischemic stroke using a mouse model of ischemia.

Materials and Methods

Anesthetized C57BL/6 mice (25-35 g) were placed in a custom-made induction chamber and exposed to 3% oxygen at 1 atm for 5 min. After 5 min, the animals were placed in a stereotactic device and were subjected to either sham surgery (no tMCAO) or a 60-min tMCAO, using an intraluminal filament. Mice were then administered vehicle (n = 10) or S5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5369is a drug that inhibits
 
Response: S5369is a drug that inhibits the K~v~11.1 potassium channel. It is an anti-tumor agent that has been in use since the 1990s. K~v~11.1 is a potassium channel that is often expressed in many cancers including neuroblastoma, ovarian cancer, breast cancer, prostate cancer, bladder cancer, lung cancer, and colorectal cancer. The effect of K~v~11.1 inhibition is largely determined by its on-target effects. K~v~11.1 is a critical component of many signal transduction pathways, including the cell cycle and apoptosis pathways. Because of this, K~v~11.1 has been found to play a role in cell proliferation and tumor growth in many cancers. This review will cover the current understanding of K~v~11.1's function in cancer, the on-target effects of S5369, and the development of resistance to S5369.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5371is a drug that inhibits
 
Response: S5371is a drug that inhibits PDE4 and has been reported to induce neuroprotective effects in different models of neurodegenerative disease \[[@B29-ijms-21-01798],[@B30-ijms-21-01798]\]. Moreover, it has been shown to have anti-inflammatory properties and can reduce Aβ-induced microglial activation in vivo \[[@B31-ijms-21-01798]\]. In our model, S-S5371 prevented the loss of dendritic spines and synapses and reversed the LTP deficit. These results suggest that synaptic plasticity impairment in our model is likely mediated by PDE4 inhibition.

Although our study is limited to the characterization of a single mouse model of AD, it provides a strong evidence that pharmacological PDE4 inhibition may be a valid approach to prevent the loss of synaptic function in AD. We also found that our experimental treatment is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5372is a drug that inhibits
 
Response: S5372is a drug that inhibits T-cell migration and thus T-cell infiltration into the CNS. It also prevents the ability of T cells to stimulate microglia, which can release chemokines and cytokines that may further recruit T cells into the CNS and promote an immune response.

S5372 may also have a role in preventing the immune response from targeting oligodendrocytes, which could result in myelin breakdown and axon degeneration. Oligodendrocytes are the cells that produce myelin and this process is required for the rapid conduction of nerve impulses in the brain.

S5372 is therefore thought to reduce the infiltration of T cells into the CNS and prevent an immune response from targeting myelin, resulting in a lower level of inflammatory response and damage to the brain.

There is currently no clinical trial data for S5372. The company is currently seeking partners to carry out a clinical trial.

As
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5377is a drug that inhibits
 
Response: S5377is a drug that inhibits both cell proliferation and cell migration. To confirm the effect of S5377 on cell proliferation, the effect of S5377 on cell growth was evaluated in MCF7 cells using an MTT assay. S5377 was found to inhibit the growth of MCF7 cells in a dose-dependent manner, and IC~50~ values of S5377 for 24, 48 and 72 h were found to be 12.6, 9.3 and 8.1 μM, respectively ([Figure 3A](#f3-ott-10-5459){ref-type="fig"}).

We next investigated whether S5377 affects cell migration in MCF7 cells using a wound healing assay. Cells were incubated with various concentrations of S5377 for 24 h. The migration of MCF7 cells was inhibited by S5377 in a dose-dependent manner, and the migratory inhibition rate was 37.4% in cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5378is a drug that inhibits
 
Response: S5378is a drug that inhibits BCR-ABL1, a protein which has been implicated in CML. If the drug is successful in treating CML, it will be the first drug to do so by directly targeting the oncogene. The drug is being developed by the pharmaceutical company Novartis.

“In principle, this drug is designed to be very effective against CML,” said Charles Rosen, M.D., chief of the division of hematology/oncology at the National Cancer Institute. “But we won’t know how well it works until we get patients in the study.”

The study is called the Novartis Study. Patients in the study will be given the drug on a regular basis, usually every two weeks, for three years. The study is open to patients with chronic phase CML who have received one to three prior treatments. Patients with blast crisis CML, who have a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5382is a drug that inhibits
 
Response: S5382is a drug that inhibits the glucosylceramide synthase enzyme. The enzyme is required for the formation of glucosylceramide, which is a component of the lipid rafts that are involved in the signaling pathways that regulate the apoptotic process. As a result, the drug blocks the formation of the lipid rafts and the cell death signaling.

Introduction {#cam41089-sec-0001}
============

The Bcl‐2 family proteins are key regulators of the mitochondrial apoptotic pathway. They are classified into anti‐apoptotic and pro‐apoptotic members, depending on the ratio of the expression of the two subfamilies [1](#cam41089-bib-0001){ref-type="ref"}. In general, the pro‐apoptotic members (Bax, Bak, and Bim) contain the BH3‐only domain, and the anti‐apoptotic members (Bcl‐
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5384is a drug that inhibits
 
Response: S5384is a drug that inhibits PDE10A, a phosphodiesterase that is over expressed in some neurodegenerative diseases.

![**PDE10A expression and S5384 treatment effects on phosphorylated tau in the frontal cortex of 3xTg-AD mice**. **(A)**Expression of PDE10A in the frontal cortex of 3xTg-AD mice. The graph represents PDE10A protein levels normalized to β-actin. **(B)**S5384 treatment of 3xTg-AD mice for 8 weeks significantly reduced PDE10A expression compared to vehicle-treated 3xTg-AD mice. **(C)**Immunohistochemical staining for phosphorylated tau (AT8) in the frontal cortex of 3xTg-AD mice treated with S5384 or vehicle. Note the significant reduction of phosphorylated tau in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5385is a drug that inhibits
 
Response: S5385is a drug that inhibits mitosis by binding to tubulin. Its cytotoxic effects are irreversible. It is used in the treatment of cancer, especially lymphomas. In the United States, the drug is approved for the treatment of certain types of lymphomas.

Abbreviations:
==============

5-FU: 5-fluorouracil; DMSO: dimethyl sulfoxide; FUdR: 5-fluorodeoxyuridine; GC-MS: gas chromatography-mass spectrometry; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight; mTOR: mammalian target of rapamycin; PBS: phosphate-buffered saline; PI: propidium iodide; RPMI: Roswell Park Memorial Institute.

Competing interests: None.

Acknowledgements: We thank the Centre National de la Recherche Scientifique, the Con
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5386is a drug that inhibits
 
Response: S5386is a drug that inhibits Cdc25C, a cell cycle regulatory protein that has a role in the initiation of mitosis. This drug is used in clinical trials for patients with malignant gliomas and has been shown to be effective in these patients. This study investigates the efficacy of S5386 in patients with brain metastases from primary breast carcinoma. We administered S5386 to 15 patients with brain metastases from breast cancer who had progressive disease despite prior treatment with a median of four (range, 2-6) lines of therapy. The median age of the patients was 58 years (range, 36-77 years). Patients received a median of six (range, 4-10) doses of S5386 at a median dose of 100 mg/m(2) (range, 60-120 mg/m(2)) every 3 weeks. The most common dose-limiting toxicities were reversible grade 2 fatigue, grade 2 anemia, and grade 2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5388is a drug that inhibits
 
Response: S5388is a drug that inhibits multiple Hsp90 client proteins. It inhibits the growth of human breast cancer cells in vitro and in vivo \[[@B65-ijms-21-01798]\]. Its effectiveness is dependent on the stage of breast cancer development. At early stages of the disease, the drug sensitizes cancer cells to chemotherapy. At later stages, however, it can decrease sensitivity to chemotherapy and promote cancer progression. The pro-tumorigenic effects of S5388 at later stages may be explained by the ability of the drug to promote the growth of the primary tumor by inhibiting multiple Hsp90 client proteins, which, in turn, can induce expression of HIF-1α and HIF-2α, as well as expression of VEGF. In addition, S5388 is able to activate the MEK/ERK pathway, which can in turn promote the growth of breast cancer \[[@B65-ijms
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5389is a drug that inhibits
 
Response: S5389is a drug that inhibits TGF-beta type I receptor kinase activity and is highly selective for the kinase, but lacks the receptor selectivity that is characteristic of type I receptor kinase inhibitors. As such, it was predicted to be a potent and selective inhibitor of tumor cell growth. Indeed, we have found that it inhibits the growth of many tumor cell lines in vitro and has significant activity in vivo. We have also found that it inhibits TGF-beta type I receptor kinase activity and blocks the activity of this receptor in several assays. However, it also has activity in other receptor tyrosine kinase assays, suggesting that it may be a multitarget inhibitor. This is consistent with the observation that it blocks the growth of some tumor cell lines in the absence of TGF-beta, and with the fact that it is a potent inhibitor of angiogenesis. We are currently exploring the activity of this compound in tumor xenograft models, and have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5392is a drug that inhibits
 
Response: S5392is a drug that inhibits Aurora kinase, and has been shown to have anti-tumor activity in multiple preclinical studies, especially in breast cancer^[@R12],[@R13]^. A Phase I trial of this drug in combination with paclitaxel in women with advanced solid tumors was initiated by the NCI in 2014 (NCT01857274). A Phase II trial in patients with HER2-positive breast cancer (NCT01987048) was completed in 2015, and the Phase III trial (NCT01647572) was initiated in 2016. The Phase III trial is currently open for accrual. The dose of pan-Aurora kinase inhibitor in these trials is 250 mg orally twice daily. This dose has been shown to be safe and well-tolerated in Phase I and II trials^[@R14],[@R15]^.

We developed a clinically relevant xenograft
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5393is a drug that inhibits
 
Response: S5393is a drug that inhibits the phosphatase activity of PPM1D. It can inhibit PPM1D's phosphatase activity and induce the accumulation of unphosphorylated γH2AX in the nucleus of cancer cells. In combination with cisplatin, it could enhance the anticancer effect of cisplatin in lung cancer. It also inhibits the growth of other cancer cell lines, such as breast cancer, glioblastoma, and colon cancer, indicating that S5393 may be a potential anticancer drug.

DISCUSSION {#SEC4}
==========

DNA damage can lead to DNA double-strand breaks (DSBs), which are mainly repaired by two pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). NHEJ is the most common pathway for DSB repair in mammals. The components of NHEJ include Ku70, Ku
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5394is a drug that inhibits
 
Response: S5394is a drug that inhibits the activity of the intracellular second messenger cAMP. It inhibits the response of T cells to IL-2 and IL-12, the two cytokines that most strongly stimulate proliferation and differentiation of T cells. Since T cell activation is required for the control of many intracellular pathogens, including viruses, the inhibition of T cell activation could have important implications for the development of vaccines. It is also possible that S5394 could be used to treat autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis.

**S5395** is an inhibitor of the cyclic AMP (cAMP)-dependent protein kinase (PKA) that is used to study the regulation of transcription by cAMP. PKA is a protein kinase that plays a role in the response of cells to many hormones and neurotransmitters. It is composed of two regulatory and two catalytic sub
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5395is a drug that inhibits
 
Response: S5395is a drug that inhibits CYP3A4 and is used to treat hepatitis C. The S5395 dose was based on the average daily dose (A~D~) and the total daily dose (T~D~) of each drug.

(XLSX)

###### 

Click here for additional data file.

###### Relationship between S5395 dose and the C~max~ and AUC of the drugs used in this study.

The lines are linear regressions with the slope set to 1.

(TIF)

###### 

Click here for additional data file.

###### 

**Predicted (line) and observed (markers) plasma concentration of ticagrelor and R‐biviridine.**

(TIF)

###### 

Click here for additional data file.

###### 


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5397is a drug that inhibits
 
Response: S5397is a drug that inhibits the phosphorylation of the transcription factor STAT3 (Signal Transducer and Activator of Transcription 3). STAT3 has been implicated in the development of numerous diseases including cancer. By inhibiting the phosphorylation of STAT3, S5397 may be used to treat diseases associated with STAT3 activation, including cancer.

Description

S5397 is a drug that inhibits the phosphorylation of the transcription factor STAT3 (Signal Transducer and Activator of Transcription 3). STAT3 has been implicated in the development of numerous diseases including cancer. By inhibiting the phosphorylation of STAT3, S5397 may be used to treat diseases associated with STAT3 activation, including cancer.

IUPAC name

N-(3-methyl-4-methoxyphenyl)-5-(4-methylpiperazin-1-yl)-2-phenylpyridin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5398is a drug that inhibits
 
Response: S5398is a drug that inhibits histone deacetylase (HDAC) and has anticancer activity in many types of cancer cells. We have previously shown that S5398 reduces tumor volume and enhances survival of animals with glioblastoma multiforme (GBM)^[@R2]^. The mechanistic basis of the effect of S5398 in GBM was unknown. Here, we report that S5398 reduces cell proliferation and induces cell death in GBM cells by a process involving acetylation of the tumor suppressor p53.

S5398 has anticancer activity in GBM^[@R2]^. We first examined the effect of S5398 on cell proliferation in GBM cells and normal astrocytes. U87MG cells were more sensitive to S5398 than normal astrocytes ([Fig. 1a](#F1){ref-type="fig"}). S5398 induced a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5399is a drug that inhibits
 
Response: S5399is a drug that inhibits SIRT1 activity, a member of the sirtuin family of NAD-dependent protein deacetylases. It is a synthetic pyrazolopyrimidine compound that inhibits the deacetylase activity of SIRT1, leading to increased acetylation of p53 and its activity as a transcription factor ([@b16-ijo-54-04-1209]). This compound has been widely used to study the function of SIRT1 *in vitro* and *in vivo* ([@b17-ijo-54-04-1209]). However, in the present study, the overexpression of SIRT1 was observed to inhibit HCC cell proliferation. SIRT1 may exert a different function in HCC compared with that in other types of cancer. In this study, the effects of SIRT1 on HCC cell growth were examined in SIRT1-overexpressing and SIRT1-kn
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5402is a drug that inhibits
 
Response: S5402is a drug that inhibits platelet activation and aggregation by blocking P2Y12 receptor.

The inhibition of platelet aggregation has been the main therapeutic effect of S5402 in patients with acute coronary syndrome. The results of the EPIC study showed that, in the event of non-STEMI or unstable angina pectoris, the combination of aspirin and clopidogrel is more effective than the combination of aspirin and ticagrelor in reducing the risk of death, myocardial infarction, or stroke \[[@CR31]\]. The clinical use of clopidogrel in patients with acute coronary syndrome has not been limited to inhibition of platelet aggregation. In a clinical trial, it was found that the clopidogrel-aspirin combination had a more beneficial effect on the clinical outcomes of patients with acute coronary syndrome compared with the aspirin-ticagrelor combination \[[@CR32]\]. In
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5403is a drug that inhibits
 
Response: S5403is a drug that inhibits the expression of HIV-1 in vitro. This study was designed to investigate the in vivo effect of S5403 in HIV-1-infected individuals. Fifteen antiretroviral-naive individuals with CD4 counts <300 cells/mm(3) were enrolled. Patients received 600 mg S5403 once daily for 28 days. S5403 was well tolerated and safe. In all 15 patients, there was a statistically significant reduction in HIV-1 RNA levels (p = 0.0003). The mean reduction in HIV-1 RNA was 1.94 log(10) copies/ml. There was no statistically significant difference in the mean CD4 cell count at baseline and day 28 (288 cells/mm(3) vs. 293 cells/mm(3), respectively; p = 0.8). S5403, a first-in-class nucleoside reverse transcriptase inhibitor, showed a significant effect on HIV
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5404is a drug that inhibits
 
Response: S5404is a drug that inhibits phosphorylation of protein kinase B (PKB, AKT), which plays a central role in the signaling of the insulin and IGF-1 receptors. Insulin resistance, which is a major risk factor for type 2 diabetes, is characterized by reduced responsiveness of peripheral tissues to insulin. In this study, we show that S5404 improves glucose tolerance in diet-induced obese (DIO) mice and diabetic db/db mice, as well as in lean mice treated with the insulin sensitizer rosiglitazone. Insulin-stimulated glucose uptake in muscle was significantly improved in DIO mice treated with S5404, whereas insulin-stimulated glucose uptake in fat was unaffected. S5404 did not affect insulin signaling in muscle, as measured by the insulin-induced phosphorylation of PKB and AKT, but markedly enhanced the phosphorylation of PKB and AKT in adipose tissue. S5404 also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5405is a drug that inhibits
 
Response: S5405is a drug that inhibits the cytochrome P450 3A4 (CYP3A4) enzyme. This drug has been associated with a risk of QT interval prolongation. We investigated the effects of gemfibrozil on the QT interval in healthy subjects.

Methods

A randomized, placebo-controlled, crossover study in healthy subjects. Subjects were assigned to a treatment sequence of placebo, 300 mg gemfibrozil, and 300 mg gemfibrozil plus 200 mg ranolazine, separated by a washout period of at least 5 days. The study drug was administered in the morning, and electrocardiograms were recorded at baseline, 1 h, and 3 h after drug administration. The QT interval was measured using the 12-lead electrocardiogram.

Results

Nineteen subjects completed the study. Compared with placebo, gemfibrozil significantly increased the QT interval (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5407is a drug that inhibits
 
Response: S5407is a drug that inhibits the synthesis of purines and pyrimidines, the building blocks of DNA and RNA. It is active against both Gram-positive and Gram-negative bacteria.

\[^3^H\]Uridine is a tracer used to measure the rate of synthesis of RNA in bacteria.

\[^3^H\]Thymidine is a tracer used to measure the rate of synthesis of DNA in bacteria.

A.2. S5405 {#Ch1.S5405}
----------

S5405is a cephalosporin antibiotic that is active against Gram-positive and Gram-negative bacteria. It is used to treat respiratory tract infections and sepsis.

\[^3^H\]Thymidine is a tracer used to measure the rate of synthesis of DNA in bacteria.

A.3. S5317 {#Ch
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5408is a drug that inhibits
 
Response: S5408is a drug that inhibits viral RNA polymerase and thereby the viral life cycle, in particular, the transcription of the viral genome. As a result, viral replication is blocked, which prevents the virus from multiplying. This can be done by interrupting the chain of events in the following steps:

\- transcription of the viral genome

\- translation of the viral genome

\- replication of the viral genome

S5408is a new generation drug, that inhibits viral replication by interfering with the replication process of the virus, but not with the viral life cycle.

#####  Clinical indications

The drug S5408 is a new generation drug, that has been designed to be used in the treatment of HCV-related chronic hepatitis C in combination with pegIFN and ribavirin.

#####  Posology and method of administration

S5408is administered in a dose of 800 mg per tablet once daily. The dose of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5410is a drug that inhibits
 
Response: S5410is a drug that inhibits the production of the active form of vitamin D in the kidney. It has also been reported to inhibit bone resorption by inhibiting osteoclast activity. However, it is not currently known whether S5410 has any effect on glucose metabolism. The aim of this study was to investigate the effect of S5410 on glucose metabolism in vivo. The drug was administered orally to Wistar rats (150 or 300 mg/kg/day for 5 days). Fasting blood glucose and serum insulin levels were significantly decreased at the higher dose of S5410. An oral glucose tolerance test revealed that the drug increased the serum insulin levels during the first 15 min after glucose loading, which is a typical insulin secretory response. In addition, the glucose-stimulated insulin secretion response in isolated islets was also increased by S5410. The drug significantly decreased the blood glucose level during the first hour after the oral administration of the test meal, which suggests that S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5411is a drug that inhibits
 
Response: S5411is a drug that inhibits the reuptake of serotonin (5-HT) and noradrenaline (NA). It is used to treat depression, fibromyalgia, and chronic pain. It is sometimes called 5-HT-norepinephrine reuptake inhibitor. It is sold under the brand names Desyrel, Efexor, Pexeva, Pexeva CR, Paxil CR, Serzone, and Tofranil. It is also used to treat obsessive-compulsive disorder. Sertraline is a semi-synthetic derivative of the chemical paroxetine, a selective serotonin reuptake inhibitor (SSRI). Sertraline is a structural analogue of the compound desipramine, and it has a similar structure to other tricyclic antidepressants. Sertraline has a different structure than the tricyclic antidepressants and it is the first of a new generation of antidepressants. Sertral
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5412is a drug that inhibits
 
Response: S5412is a drug that inhibits S6K1 phosphorylation in mammalian cells. It is a novel ATP-competitive inhibitor of S6K1, which has the ability to bind to S6K1 in a manner similar to that of ATP. S5412 reduces S6K1 phosphorylation in a dose-dependent manner, as shown in [Figure 3](#molecules-23-01375-f003){ref-type="fig"}. The data suggest that S5412 is a potent and selective inhibitor of S6K1.

2.3. S5412 Promotes Cell Apoptosis in MDA-MB-231 Cells {#sec2dot3-molecules-23-01375}
------------------------------------------------------

To investigate whether S5412 inhibits the proliferation of MDA-MB-231 cells by promoting apoptosis, we treated MDA-MB-231 cells with S5412 at various concentrations
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5413is a drug that inhibits
 
Response: S5413is a drug that inhibits angiogenesis and metastasis by blocking the vascular endothelial growth factor (VEGF) receptor. The antitumor activity of S-5413 has been demonstrated in a number of experimental tumor models, and has been evaluated in Phase I and II clinical trials in solid tumors and metastatic breast cancer. The results of a Phase II study with S-5413 in patients with metastatic breast cancer have been reported, and suggest that it has activity in this disease. The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of S-5413 in patients with recurrent or metastatic breast cancer. The study was designed as a Phase I, multicenter, open-label, dose-escalation study in patients with metastatic breast cancer who had not received prior therapy for their disease. S-5413 was administered as a continuous intravenous infusion at doses of 0.1, 0.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5414is a drug that inhibits
 
Response: S5414is a drug that inhibits the enzyme Src kinase and therefore has been suggested to be of benefit in rheumatoid arthritis.

When it was used to treat RA, it was a little disappointing. The trial only included a total of 120 patients, and a follow-up of only 18 months.

Sildenafil, used to treat erectile dysfunction, is also an inhibitor of Src kinase.

Sale

Dosage

The dose of tofacitinib will be increased in a stepwise fashion, starting at a dose of 10 mg twice daily. If no therapeutic effect is observed, the dose will be increased to 20 mg twice daily.

The dosage will be reduced in a stepwise fashion, starting at a dose of 20 mg twice daily. If no therapeutic effect is observed, the dose will be reduced to 10 mg twice daily.

The dose will be reduced in a stepwise fashion
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5416is a drug that inhibits
 
Response: S5416is a drug that inhibits autophagy and has been reported to inhibit growth of glioma cells \[[@CR43]\]. The expression of ATG7 and the level of p62 were reduced in the high-dose group. ATG7 is an E3 ubiquitin ligase, and the p62 protein, which is degraded by the autophagy-lysosome pathway, can also be degraded by the ubiquitin-proteasome system. The above data indicated that a high dose of MSTO-211H cells induced autophagy.

It has been reported that RAB1B is involved in the autophagy of some cancer cells \[[@CR44]\]. As shown in Fig. [5](#Fig5){ref-type="fig"}, the expression of RAB1B was higher in the high-dose group than in the control group. In addition, the level of RAB1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5418is a drug that inhibits
 
Response: S5418is a drug that inhibits ribosomal protein S6 kinase (S6K), the mediator of a mitogen-activated protein kinase (MAPK) signal transduction pathway. S6K activation occurs in response to growth factors, hormones, and cellular stress. In the present study, we investigated the effects of S6K inhibition on the induction of autophagy by a variety of stressors. S6K1 siRNA suppressed the expression of both S6K1 and the S6K1 substrate S6, and prevented the increase in LC3-II, a biomarker of autophagy, induced by amino acid starvation, heat shock, glucose starvation, and treatment with the protein synthesis inhibitor cycloheximide. Inhibition of S6K also suppressed the increase in LC3-II in cells treated with tunicamycin, an inhibitor of N-linked glycosylation. S6K inhibition also suppressed the expression of AT
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5419is a drug that inhibits
 
Response: S5419is a drug that inhibits DNA repair, specifically base excision repair. It has been used as a chemotherapeutic agent in patients with advanced solid tumours, such as prostate, breast, ovarian, non-small cell lung, colon, and pancreatic cancers. It has also been investigated as a radiosensitiser in combination with radiotherapy in patients with solid tumours.

Data for the reference compound was obtained from DrugBank, Drug Central and the literature. The remaining compounds were obtained from the University of Calgary Drug Discovery and Development Centre (D3C). The PubChem Compound database was used to obtain data for the PubChem IDs. A database of these compounds was created in Microsoft Access and converted to a MySQL database.

The database contains compounds and their reference data from DrugBank, Drug Central and PubChem Compound. It also contains the compounds' structure information, data for compound's therapeutic targets and side effects. The reference data was obtained from
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5420is a drug that inhibits
 
Response: S5420is a drug that inhibits growth of PANC-1 cells by induction of apoptosis and autophagy.

Previous studies showed that paclitaxel-induced apoptosis was mediated by the activation of caspase-3 and caspase-9 and by the cleavage of PARP ([@b21-ijo-53-05-1836]). The caspase family is a group of cysteine proteases that serve a central role in the initiation of apoptosis ([@b22-ijo-53-05-1836]). To further explore the molecular mechanism of apoptosis induced by S5420, we detected the expression of caspase-3, caspase-9 and PARP in S5420-treated PANC-1 cells. We found that S5420 significantly increased the levels of cleaved caspase-3, caspase-9 and PARP in a dose-dependent manner. Taken
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5424is a drug that inhibits
 
Response: S5424is a drug that inhibits acetylcholinesterase, which is used to treat Alzheimer’s and other types of dementia. One of its side effects is that it causes the patients to experience tremors.

One of the main side effects of S-5424is a tingling sensation that can occur in patients’ fingers, toes, and lips. This is because the patients experience nerve stimulation when they take the drug.

One of the main side effects of S-5424is that it causes muscle twitching, muscle spasms, and trembling in patients.

S-5424is a drug that is used to treat patients with severe dementia. It is not known to cause a permanent side effect.

One of the main side effects of S-5424is that it can cause muscle spasms.

S-5424is a drug that is used to treat patients with severe dementia. It is not known to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5428is a drug that inhibits
 
Response: S5428is a drug that inhibits the production of pepsinogens. The two pepsinogens are secreted by the stomach. Pepsinogens are used as biomarkers for assessing gastric function and predicting gastric cancer risk. Therefore, pepsinogen analysis can be used to predict the risk of gastric cancer. However, the current methods for pepsinogen analysis are laborious and time-consuming. In this study, we propose a high-throughput pepsinogen analysis method based on an ion-pair liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. The pepsinogen separation was achieved using a reversed-phase column (Zorbax Eclipse XDB-C18, 150 × 4.6 mm, 5 μm) at room temperature. A Zorbax Eclipse XDB-C18 column (150 × 4.6 mm, 5 μm) was used for the subsequent detection of p
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5430is a drug that inhibits
 
Response: S5430is a drug that inhibits AID in humans and mice, and also inhibits its function in B cells. I've just published a paper that we've been working on for a while, where we demonstrated that S5430 could rescue AID deficiency in mice that were deficient in the miRNA miR-17-92 cluster. We also demonstrated that S5430 could rescue AID deficiency in humans. It can be given orally. We've been working on S5430 for the past 5 years, and we have a patent on it.

I will read a summary of this research in a journal or two, and then we will start a phase 2 trial in a year or two. It's an oral drug that's relatively safe and tolerable. We can start a phase 2 trial in a year or two. It would be good to be able to give it to patients with AID deficiency.

We're hoping to get it approved for that, and also
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5433is a drug that inhibits
 
Response: S5433is a drug that inhibits the renin-angiotensin system (RAS). It is an orally active angiotensin-converting enzyme (ACE) inhibitor that has been developed for the treatment of hypertension.\[[@CIT1]\] The activity of S-5433 was evaluated in two separate randomized, double-blind, parallel-group, placebo-controlled, multicenter, single-dose, and multiple-dose studies in healthy subjects and in patients with hypertension. In the first study, a single dose of S-5433 was administered in a randomized, double-blind, placebo-controlled, parallel-group study to normotensive and hypertensive subjects. In the second study, a single dose of S-5433 was administered to normotensive and hypertensive subjects, and multiple doses were administered to patients with essential hypertension.

The aim of the study was to determine the safety, tolerability, and pharmacokinetic profile
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5435is a drug that inhibits
 
Response: S5435is a drug that inhibits Rho GTPases, and has been used as a treatment for immune disorders and cancers ([@bib5]; [@bib7]; [@bib17]). However, there are no reports on the effects of S5435 on autophagy in mammals. We used S5435 as a tool to investigate the function of Rho GTPases in autophagy. Our data show that S5435 treatment suppressed autophagy in both MEFs and hepatocytes. The inhibitory effect of S5435 on autophagy is due to the inactivation of RhoA. We found that knockdown of RhoA expression significantly increased the level of LC3-II, and increased the formation of autophagosomes. These data suggest that RhoA plays an inhibitory role in autophagy.

The activation of RhoA by ROCK1/2 is essential for the formation of autophagosomes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5440is a drug that inhibits
 
Response: S5440is a drug that inhibits VEGF and reduces the development of abnormal blood vessels (neovascularization) that can lead to diabetic retinopathy. The drug is an oral agent and has been approved by the FDA for the treatment of diabetic macular edema (DME) (see e.g., http://www.fda.gov/Drugs/DrugSafety/ucm232640.htm).
PCT Publication No. WO 2008/113812, the disclosure of which is incorporated herein by reference, discloses the use of sFlt-1 (soluble fms-like tyrosine kinase 1) as a marker of diabetic retinopathy.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5447is a drug that inhibits
 
Response: S5447is a drug that inhibits a kinase called WEE1. WEE1 is one of the main regulators of the G1-S checkpoint of the cell cycle. By inhibiting WEE1, S5447 is able to allow the cell to move into the next phase of the cell cycle (S-phase). This causes the cell to divide, allowing it to grow and develop into a new organism.

S5447is also being developed as a cancer drug. A phase II trial in patients with advanced non-small cell lung cancer (NSCLC) has been completed, but results are not yet available.

S5447is being developed as a treatment for neuroblastoma.

S5447 is being developed as a treatment for leukemia. A phase I trial is ongoing to determine the maximum tolerated dose of S5447 in children with acute lymphoblastic leukemia (ALL).

S5447is also being developed as a treatment for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5450is a drug that inhibits
 
Response: S5450is a drug that inhibits the growth of cells by causing the arrest of the cell cycle at the G2/M phase. This drug is approved for the treatment of solid tumours. The aim of the study was to determine whether S-5317 could enhance the effects of cisplatin. Human non-small cell lung cancer cell lines (A549 and H460) were treated with S-5317 and cisplatin alone or in combination. The growth inhibition of cells was determined by MTT assay. Cell apoptosis was measured by flow cytometry and DNA fragmentation. Western blot analysis was performed to determine the expression of cyclin-dependent kinase 2 (CDK2) and the phosphorylation of p21 (p21) at Thr145 and Ser130. S-5317 alone induced a dose-dependent inhibition of cell growth in A549 and H460 cells. Cisplatin alone also inhibited cell growth. S-5317 combined with cispl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5452is a drug that inhibits
 
Response: S5452is a drug that inhibits the fusion of HIV-1 with target cells and can be used to prevent the spread of HIV infection. This drug is a synthetic peptide with the sequence of HIV-1 gp41. The mechanism of action of this drug is to bind to the receptor on the surface of the target cells and block the fusion of the virus with the cell.

S5452 is available as a sterile powder for oral administration. It should be stored at room temperature.

Oral Administration:

S5452 should be administered orally with food.

If a dose of S5452 is missed, the dose should be administered as soon as possible. Do not administer the missed dose to another patient.

S5452 is used to prevent HIV infection. HIV infection is spread when an infected person's body fluids, such as blood, semen, vaginal fluid, or breast milk, come into contact with the mucous membranes of another person.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5453is a drug that inhibits
 
Response: S5453is a drug that inhibits the activity of Rho GTPases. The effect of this drug on macrophages and DCs was assessed by incubating DCs with S5453 and subsequently analysing the DCs for changes in morphology, phagocytosis, cell-surface marker expression, chemokine production and T cell stimulation.

### Effect of S5453 on DCs {#Sec17}

S5453 had no significant effect on the morphology, viability, phagocytosis or chemokine production of DCs (Fig. [3](#Fig3){ref-type="fig"}). In addition, S5453 had no effect on the expression of cell-surface markers or costimulatory molecules (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Furthermore, S5453 did not affect the ability of DCs to stimulate allogeneic T cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5454is a drug that inhibits
 
Response: S5454is a drug that inhibits telomerase activity by binding to the telomerase RNA component (TR). The effects of S5454 on the structure and stability of TR have been studied using various biophysical techniques. In this work, we examined the thermal stability of the native TR in the presence of increasing concentrations of S5454 using differential scanning calorimetry (DSC). In contrast to a previous report, we find that S5454 stabilizes the TR structure by reducing the unfolding transition temperature. The presence of S5454 stabilizes the secondary structure of TR, particularly the helix at the 3' end of the RNA. However, we also find that the affinity of S5454 for TR is very low and that S5454 has a low affinity for the native TR structure. Our results suggest that the apparent binding affinity of S5454 for TR is enhanced in the presence of telomerase. The enhancement in affinity may explain the ability of S5454
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5457is a drug that inhibits
 
Response: S5457is a drug that inhibits angiogenesis by inhibiting the enzyme phosphatidylinositol 3-kinase.

Pharmacology

Pharmacodynamics
S5457 is an inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K), a kinase involved in the signaling pathway that regulates cell growth and proliferation.

Pharmacokinetics
The drug is a PI3K inhibitor that is orally administered.

History
S5457 was originally identified as a synthetic, small molecule inhibitor of the PI3K enzyme, and was subsequently optimized for improved pharmacokinetic and pharmacodynamic properties. S5457 has been under development by Sanofi-Aventis since the mid-2000s.

The drug was in phase II clinical trials as of January 2008, and was reported to be well-tolerated and effective in preclinical studies. The drug was undergoing phase I trials in the US
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5459is a drug that inhibits
 
Response: S5459is a drug that inhibits the activity of the enzyme 5-lipoxygenase, which is an important component of the inflammatory response. It is therefore a possible candidate for the treatment of asthma. However, it was found to be effective only at high doses and is therefore likely to have side effects at these levels. This project aims to develop new derivatives of S5459 with better efficacy and fewer side effects. It will be carried out in two stages: First, the novel S5459 analogues will be designed, and then the compounds will be synthesized. At the same time, the pharmacokinetics of the new compounds will be studied.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5466is a drug that inhibits
 
Response: S5466is a drug that inhibits cyclin-dependent kinases (CDKs) that phosphorylate and inactivate the retinoblastoma (Rb) tumor suppressor protein. It is currently being evaluated in phase II and III clinical trials for the treatment of cancer. To evaluate the therapeutic potential of PNU-S5466 in a model of B-cell lymphoma, we injected the CT-2A murine B-cell lymphoma cell line into syngeneic C57BL/6 mice. Treatment of CT-2A tumor-bearing mice with PNU-S5466, alone or in combination with doxorubicin, reduced the tumor mass and prolonged the survival of tumor-bearing mice compared to vehicle-treated mice. We show that the treatment of CT-2A cells with PNU-S5466 inhibits the phosphorylation of Rb and increases the expression of p21(Cip1/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5473is a drug that inhibits
 
Response: S5473is a drug that inhibits phosphorylation of ERK1/2. To examine the contribution of the ERK pathway in the activation of MMP-9 by LPS, we pretreated THP-1 cells with S5473, an ERK inhibitor. S5473 decreased LPS-induced MMP-9 activation by \~75% ([Fig. 2](#f0010){ref-type="fig"}A). To further confirm the role of ERK1/2 in LPS-induced MMP-9 expression, we performed a transient transfection of THP-1 cells with a dominant negative ERK1 (DN-ERK1) and a constitutively active ERK1 (CA-ERK1). As shown in [Fig. 2](#f0010){ref-type="fig"}B, DN-ERK1 and CA-ERK1 inhibited and enhanced, respectively, LPS-induced MMP
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5476is a drug that inhibits
 
Response: S5476is a drug that inhibits the expression of the sirtuin SIRT1, which leads to the increase in the acetylation of p53, p65, and p300 and a decrease in the expression of the NF-κB p65, p300, and HDAC1. S5476 blocks the acetylation of p53 and p65 and then activates the apoptosis of hepatocytes, thus inhibiting the growth of liver cancer cells ([@B25]). The sirtuin inhibitor nicotinamide is an inhibitor of SIRT1, which may enhance the acetylation of p53 and p65 and then promote the apoptosis of liver cancer cells ([@B26]). However, the above-mentioned studies have not found that the acetylation of NF-κB p65, p300, and HDAC1 is involved in the mechanism of action of S5476. In the present study, we found that the inhibition of SIRT1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5477is a drug that inhibits
 
Response: S5477is a drug that inhibits TGF-β signaling by binding to TβRII and thereby blocking its interaction with TβRI, and thus interfering with TGF-β signaling and induction of SMAD2/3-mediated transcriptional responses.

We have shown that expression of *Bmpr1a* and *Bmpr1b* is strongly downregulated by S5477 in cultured chick chondrocytes. However, in a zebrafish model of the TGF-β signaling pathway, S5477 also reduced *Bmpr1a* and *Bmpr1b* expression. In the chick chondrocyte experiments, the extent of downregulation was moderate (50--70% of control), whereas in the zebrafish experiments it was very strong (90% of control). In the zebrafish experiments, S5477 also downregulated the expression of *Tgfbr2*, the gene encoding
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5478is a drug that inhibits
 
Response: S5478is a drug that inhibits histone deacetylase. In previous work, we have shown that this drug acts in the brain to induce behavioral and molecular effects similar to those observed with valproic acid, a widely used anticonvulsant. To determine if S5478 might also be effective in treating psychiatric disorders, we treated rats with S5478 and evaluated its effects on behavior. Rats were treated with S5478 (0, 0.5, 1.0, or 2.0 mg/kg/day) for 14 days. Two-way analysis of variance (ANOVA) showed a significant main effect of treatment on locomotor activity in the open field. The number of locomotor events (ambulation, rearing, and grooming) decreased as a function of increasing S5478 dose. S5478 treatment did not affect habituation or fear conditioning, and S5478 did not affect sensorimotor gating in the acoustic startle or prep
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5479is a drug that inhibits
 
Response: S5479is a drug that inhibits cancer cell proliferation by blocking the mitogen-activated protein kinase (MAPK) pathway. Recently, it has been demonstrated that inactivation of the MAPK pathway by using U0126 can induce apoptosis in various cancer cell lines, including human breast cancer cells. In the present study, we investigated whether S5479 inhibits the growth of human breast cancer cells by inducing apoptosis. To test this hypothesis, we examined whether S5479 could induce apoptosis in human breast cancer cells. Treatment with S5479 induced apoptosis in human breast cancer cells, including the ER+ MCF-7 and ER- MDA-MB-231 cells. Furthermore, S5479 also inhibited the phosphorylation of ERK1/2 in the ER+ MCF-7 cells. To determine whether the inhibition of the MAPK pathway was involved in the induction of apoptosis, we used the ER+ MCF-7 cells to determine the effect
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5480is a drug that inhibits
 
Response: S5480is a drug that inhibits the activation of the adenosine monophosphate-activated protein kinase (AMPK) pathway by directly inhibiting the activity of the catalytic subunit of AMPK (AMPKα1). The effect of S5480 on the expression of genes involved in cholesterol and triglyceride metabolism in 3T3-L1 adipocytes was investigated. S5480 inhibited the expression of the sterol regulatory element-binding protein 1c (SREBP-1c) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) genes. S5480 also reduced the expression of genes that are involved in fatty acid synthesis, such as fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1), and acetyl-CoA carboxylase alpha (ACCA). The expression of the PPARγ gene was not affected by
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5481is a drug that inhibits
 
Response: S5481is a drug that inhibits the proteasome by binding to the β5 subunit of the 20S catalytic core and thereby inhibits the degradation of misfolded and/or ubiquitinated proteins [@bib13], [@bib14], [@bib15]. This drug was initially shown to be useful for treating certain types of neurodegenerative disorders including Parkinson\'s disease, Huntington\'s disease, and frontotemporal dementia [@bib13], [@bib14], [@bib15]. More recently, S5481 has been shown to be effective in treating the mouse model of Alzheimer\'s disease [@bib13], [@bib14], [@bib15]. S5481 has also been used to treat Huntington\'s disease [@bib13], [@bib14], [@bib15], and it is being tested in a phase 2 clinical trial in patients with Huntington
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5482is a drug that inhibits
 
Response: S5482is a drug that inhibits tumor growth and metastasis.\
A, Tumor volume of the HCT-116 xenograft mouse model. Data represent mean ± SD (n=5). \*\*P\<0.01, vs. control group. B, Representative bioluminescence images of mice bearing HCT-116 xenografts in the control and shNEDD4 groups. C, Tumor weight of the HCT-116 xenograft mouse model. Data represent mean ± SD (n=5). \*\*P\<0.01, vs. control group. D, Representative H&E-stained tissue sections of HCT-116 xenografts in the control and shNEDD4 groups. Scale bars, 100 µm. E, Representative bioluminescence images of mice bearing HCT-116 xenografts in the control and shNEDD4 groups
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5483is a drug that inhibits
 
Response: S5483is a drug that inhibits the proliferation of neoplastic cells. It is also a substrate of the P-glycoprotein (P-gp) transporter, a membrane glycoprotein responsible for the multidrug resistance (MDR) phenotype.^[@bib1]^ This phenotype is characterized by resistance to multiple anticancer drugs due to the reduced drug accumulation at the cell surface.^[@bib2]^ Moreover, P-gp is often overexpressed in malignant cells and has been associated with drug resistance.^[@bib3]^ Therefore, we evaluated whether MDR1 expression is involved in the resistance of melanoma cells to BRAF^V600E^ inhibitors.

As shown in [Figure 1a](#fig1){ref-type="fig"}, all melanoma cell lines tested were sensitive to the BRAF^V600E^ inhibitor PLX4720. However, cell lines expressing high levels of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5484is a drug that inhibits
 
Response: S5484is a drug that inhibits the transport of purines (adenine and guanine) into the cell.  This action leads to an accumulation of purines inside the cell.  Purines are important for DNA replication, and as such this drug is toxic to rapidly dividing cells.

References

Category:Antineoplastic drugs
Category:Nitrobenzenes
Category:Heterocyclic compounds (2 rings)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5485is a drug that inhibits
 
Response: S5485is a drug that inhibits the formation of cyclic AMP and inhibits the activity of adenylate cyclase, in the heart, increasing the concentration of cyclic AMP, decreasing the activity of the adenylate cyclase, which causes the release of cyclic AMP from the sarcoplasmic reticulum, the active substance of the cyclic AMP system is the enzyme protein cyclic AMP-dependent protein kinase, it is a protein kinase, which catalyzes the phosphorylation of protein substrate, protein phosphorylation is an important part of the intracellular signal transduction, which can regulate the metabolism of cell activity, and other physiological processes. Cyclic AMP-dependent protein kinase is an important enzyme in the intracellular signal transduction, it has a wide range of substrate specificity, and its specific substrate is different in different tissues and cells, and can be phosphorylated by different cyclic AMP-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5486is a drug that inhibits
 
Response: S5486is a drug that inhibits type I interferon signaling and is approved for treatment of hepatitis C. S5486 has been shown to induce IL-6 in a variety of cell types, including immune cells, fibroblasts, endothelial cells, and mesangial cells.^[@R1],[@R2]^ IL-6 is a pleiotropic cytokine that has both pro- and anti-inflammatory functions.^[@R3]^ The inflammatory properties of IL-6 are mediated by binding to its cell surface receptor, IL-6R, and activation of JAK/STAT signaling.^[@R4]^ In addition, IL-6 has also been shown to promote angiogenesis and is an important driver of fibrosis in several models of disease.^[@R5]^ The pro-inflammatory properties of IL-6 are regulated by IL-6 trans-signaling, in which IL-6 binds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5487is a drug that inhibits
 
Response: S5487is a drug that inhibits tumor cell growth and metastasis by inhibiting the expression of integrin α6β4 in human hepatocellular carcinoma.
Human hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, and its incidence is gradually increasing in recent years. However, the prognosis of HCC is still poor. Therefore, it is urgent to identify new and more effective targets for the treatment of HCC. In this study, we identified a novel drug that targets integrin α6β4 and inhibits HCC cell proliferation and metastasis. We found that the expression of integrin α6β4 in human HCC cell lines was significantly increased, which was closely related to the tumor cell proliferation, migration, and invasion. However, the expression of integrin α6β4 in HCC cell lines was reduced after the cells were treated with S5487. S5487 suppressed the expression of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5488is a drug that inhibits
 
Response: S5488is a drug that inhibits DNA-PK~cs~ and is being tested in Phase I clinical trials for use in combination with radiation or chemotherapy in patients with advanced solid tumors and lymphoma. In this study, we have examined the effects of *S5488* on DNA-PK~cs~-mediated phosphorylation of the downstream targets ATM and H2AX. We found that *S5488* blocked DNA-PK~cs~-mediated phosphorylation of these proteins and also blocked their accumulation in the S-phase of the cell cycle. We further demonstrated that *S5488* inhibited the phosphorylation of RPA32 by DNA-PK~cs~. Taken together, our data suggest that *S5488* may be an effective radiosensitizer in cancer cells with intact DNA-PK~cs~-mediated repair of radiation-induced DSBs.

The effects of *S5488* on ATM and DNA-PK
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5490is a drug that inhibits
 
Response: S5490is a drug that inhibits the aldosterone synthase and thereby causes a decrease in aldosterone secretion. In some countries it is available as an over-the-counter preparation for the treatment of mild hypertension.

The inhibition of the aldosterone synthase can cause potassium and sodium retention, leading to increased blood pressure. Because the mechanism of action of S5490 is identical to that of spironolactone, it is a potentially useful antihypertensive agent. However, unlike spironolactone, S5490 does not act as a diuretic and therefore has fewer adverse effects.

Pharmacology

Pharmacodynamics
S5490 is a selective aldosterone synthase inhibitor.

Pharmacokinetics

Absorption
S5490 is poorly absorbed after oral administration.

Distribution
S5490 is well distributed into most tissues.

Metabolism
S5490 is metabol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5491is a drug that inhibits
 
Response: S5491is a drug that inhibits protein phosphatase 2A (PP2A) and causes the hyperphosphorylation of Rb and its release from the complexes with E2F. The formation of E2F/Rb complexes leads to the activation of E2F-dependent genes that are required for the entry into S phase. Therefore, S5491 is a potential anticancer drug. However, the molecular mechanism of the antitumor effect of S5491 is not clear. Here, we show that S5491 is a potent anticancer agent for several human cancer cell lines, including acute lymphoblastic leukemia (ALL) cells, in vitro and in vivo. Furthermore, we identified p53 as a key mediator of S5491-induced cell death in ALL cells. S5491 activates p53 through dephosphorylation of Rb, and p53, in turn, induces expression of the proapoptotic proteins Bax and Bak
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5492is a drug that inhibits
 
Response: S5492is a drug that inhibits the P2X7 receptor (P2X7R), a member of the P2X receptor family. It is a weak acid with a pKa of 6.6. Its actions on the P2X7R are to inhibit P2X7R-mediated apoptosis and increase the rate of receptor desensitization and deactivation. It also inhibits ATP-induced apoptosis and the P2X7R-mediated release of IL-1β, IL-18, IL-33, and HMGB1. The main pharmacological action of S5492 is to act as an antagonist of the P2X7R. S5492 is a metabolically stable analog of Brilliant Blue G, a known inhibitor of the P2X7R. It has the same binding site as Brilliant Blue G and competes with Brilliant Blue G for the P2X7R. The structural difference between S5492 and Brilliant Blue
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5493is a drug that inhibits
 
Response: S5493is a drug that inhibits the biosynthesis of chorismate by competing with its substrate, chorismate pyruvate-lyase, thereby inhibiting the synthesis of the shikimate pathway.\[[@ref1]\] It is also a member of the phenothiazine class of antipsychotics.\[[@ref2]\] Although S5493 is a synthetic derivative of S-methyl isothiourea, it has shown very different pharmacological effects compared to its parent compound.\[[@ref3]\] S5493 is effective in the treatment of neuropsychiatric disorders such as schizophrenia and anxiety.\[[@ref4]\] It is reported that S5493 can cause a loss of the pigment melanin from the hair of experimental animals.\[[@ref5]\] This has led to the hypothesis that S5493 may also be effective in the treatment of hyperpigmentation disorders
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5494is a drug that inhibits
 
Response: S5494is a drug that inhibits the receptor of advanced glycation end products (RAGE) and has been used in the treatment of diabetic nephropathy, diabetic retinopathy and other diabetic complications. In the present study, we investigated the effect of S5494 on lipid metabolism in mice with a high-fat diet (HFD). HFD-fed mice were treated with S5494 (100 or 200 mg/kg) or an equal volume of vehicle once daily for 12 weeks. The S5494-treated group had a significant reduction in body weight, adipose tissue weight and plasma triglyceride and cholesterol levels compared with the HFD-fed group. The mRNA levels of several genes associated with lipogenesis were significantly decreased in the liver of S5494-treated mice. S5494 treatment significantly increased the protein levels of AMP-activated protein kinase (AMPK) and its phosphorylated form (p-AMPK), but decreased the mRNA levels of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5496is a drug that inhibits
 
Response: S5496is a drug that inhibits the binding of adenosine to the A2A receptor and antagonizes the effect of adenosine at this receptor. This results in a reduction of the excitatory effect of adenosine at the A2A receptor. S5496is has been shown to be effective in the treatment of Parkinson’s disease and has also shown promise in the treatment of schizophrenia and as a cognitive enhancer. The results of the study suggest that the administration of S5496may also be effective in the treatment of schizophrenia.

In the study, the investigators evaluated the effect of S5496 in animal models of schizophrenia. They tested the drug in two models: one of psychosis and one of cognitive deficits. The results showed that the drug had a significant effect in both models.

In the psychosis model, the investigators evaluated the effect of S5496 in rats that were given MK-801, a drug that is known to induce psychotic behavior
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5497is a drug that inhibits
 
Response: S5497is a drug that inhibits DNA polymerase δ, resulting in accumulation of single-stranded DNA (ssDNA) and induction of apoptosis.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5498is a drug that inhibits
 
Response: S5498is a drug that inhibits telomerase and causes telomere shortening in cancer cells, which are more sensitive to this drug than normal cells \[[@B49-ijms-21-03987]\]. Telomere dysfunction and DNA damage response are common features of cancer cells.

Preliminary evidence suggests that the main mechanism of action of Iressa may be the inhibition of the PI3K/AKT/mTOR signaling pathway, which is activated in most tumors and has been reported to promote cell proliferation, survival, and angiogenesis. Another possible mechanism is that Iressa inhibits cyclin-dependent kinases (CDKs) and prevents phosphorylation of the retinoblastoma (Rb) protein, which promotes the transcription of the *c-Myc* oncogene \[[@B50-ijms-21-03987]\]. Iressa has been shown to inhibit tel
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5499is a drug that inhibits
 
Response: S5499is a drug that inhibits A~2A~ adenosine receptors, but also acts as a ligand for α~1~ adrenergic receptors. It is used as an adjunct to increase the efficacy of antipsychotic agents in schizophrenia ([@B1]). It has been shown that S5499 can improve the positive symptoms of schizophrenia in a randomized controlled trial ([@B2]). The acute effect of S5499 on the symptomatology of schizophrenia has been studied in healthy volunteers ([@B3]). S5499 is rapidly absorbed, reaches peak plasma concentration in less than 2 h and is eliminated rapidly. Its pharmacokinetic profile is linear and dose-independent ([@B4]).

The aim of the present study was to compare the effects of acute administration of S5499 and atomoxetine on attentional performance in healthy volunteers.

Materials and Methods
=====================

In this double-blind, randomized, two-way crossover study
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5500is a drug that inhibits
 
Response: S5500is a drug that inhibits the effects of acetylcholine in the peripheral and central nervous systems. It is used to treat a variety of conditions, including disorders of the central nervous system, such as attention-deficit hyperactivity disorder, depression, and Parkinson’s disease. It is available as a tablet, injection, or liquid form.

This site contains information about the use of the S5500 for the treatment of various disorders. This information does not necessarily reflect the views or the policies of the U.S. Food and Drug Administration. This site is not intended as a substitute for the advice of your physician or other health care professional. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before using the product.

CONTENTS

Frequently Asked Questions

Is S5500 safe?

S5500 is a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5501is a drug that inhibits
 
Response: S5501is a drug that inhibits the proliferation of cancer cells by inducing apoptosis. In this study, we examined the effect of S5501 on the growth of prostate cancer cell lines PC-3 and DU-145 and on the expression of apoptosis-related proteins. In the growth inhibition assay, S5501 inhibited the proliferation of PC-3 and DU-145 cells in a dose- and time-dependent manner. S5501 induced apoptosis in PC-3 and DU-145 cells in a dose-dependent manner. The expression of apoptosis-related proteins, such as Bax, Bcl-2, Bcl-xL, Bim, and Fas, was analyzed by Western blotting. The expression of Bax was increased, while that of Bcl-2, Bcl-xL, Bim, and Fas was decreased. S5501 increased the expression of Bax and decreased the expression of Bcl-2, Bcl-x
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5504is a drug that inhibits
 
Response: S5504is a drug that inhibits the enzyme S-adenosyl-l-methionine synthetase (AdoMet synthetase) which catalyzes the formation of S-adenosyl-l-methionine (AdoMet) from ATP and l-methionine. AdoMet is a methyl donor and a precursor for numerous cellular methylation reactions. The enzyme AdoMet synthetase is involved in cell proliferation, differentiation and cell-cell interactions. S5504 also inhibits the activity of the enzyme, DNA methyltransferase (DNMT). S5504 has been shown to be a potent inhibitor of cell proliferation in vitro and in vivo in a number of human cancer cell lines and xenografts (Nam et al. (1999) Oncogene 18:6517-6524; Rosenfeld et al. (1999) J. Clin. Oncol. 17:1861-1868; Rosell
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5505is a drug that inhibits
 
Response: S5505is a drug that inhibits the formation of NO and may reduce endothelial dysfunction in the microcirculation. We evaluated its effect on red blood cell (RBC) deformability in healthy volunteers. RBC deformability was assessed by the use of a micropipette, in which RBCs were sucked into a capillary tube. RBC deformability was calculated from the ratio of the aspirated volume to the initial volume of the RBC column. RBC deformability was measured at baseline and after 4 weeks of treatment with the NO donor (s)-N5-(1-iminoethyl)-ornithine (S-NIO, S5505) at a dose of 200 mg t.i.d. in a double-blind, placebo-controlled, crossover study. At baseline, RBC deformability was significantly lower in S-NIO-treated subjects than in placebo-treated subjects. After 4 weeks of treatment with S-NIO, R
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5506is a drug that inhibits
 
Response: S5506is a drug that inhibits inositol trisphosphate receptor (IP3R) activity, the only intracellular calcium channel activated by the second messenger IP3. This is the main trigger of intracellular calcium release, and IP3R are responsible for calcium storage in the sarcoplasmic reticulum of the cardiac muscle. These channels are activated by IP3 produced by the IP3/IP3R pathway, when phospholipase C (PLC) is stimulated by phosphatidylinositol (PI) hydrolysis, leading to a decrease in calcium concentration in the cytoplasm. Therefore, this drug prevents the mobilization of intracellular calcium by the IP3/IP3R pathway. This mechanism of action may be responsible for the improvement of cardiac function in patients with chronic heart failure, when the treatment is started early. This effect can be demonstrated by the improvement of the indexes of cardiac function (LVEF
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5507is a drug that inhibits
 
Response: S5507is a drug that inhibits the activity of phosphodiesterase 5 (PDE5), the enzyme that breaks down the neurotransmitter cGMP, which is essential for erection. It works by binding to the active site of PDE5, preventing it from breaking down cGMP. This helps maintain a higher level of cGMP in the penis, which causes the blood vessels to dilate and engorgement of the penis. This in turn allows for an erection to occur.

The active ingredient in sildenafil is called sildenafil citrate. It is a citrate salt that has an improved dissolution rate and bioavailability. Sildenafil citrate is manufactured as sildenafil citrate tablets and sildenafil citrate oral solution. Sildenafil citrate tablets should be taken on an empty stomach. Sildenafil citrate oral solution can be taken either with or without food
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5508is a drug that inhibits
 
Response: S5508is a drug that inhibits GSK-3 and can induce neuroprotection in animal models of ischemic stroke. In this study, we investigated the effects of S5508 on infarct volume and neurological deficits in a rat model of focal cerebral ischemia. Male Wistar rats underwent permanent middle cerebral artery occlusion (pMCAO). The infarct volume and neurological deficits were evaluated at 24h after pMCAO. S5508 (2.5mg/kg, i.v.) was injected immediately after pMCAO. At 24h after pMCAO, infarct volume was significantly reduced by S5508 (2.5mg/kg, i.v.) compared with vehicle treatment. The effect of S5508 was comparable to that of the GSK-3 inhibitor, LiCl (10mg/kg, i.v.), but less potent than that of the NMDA receptor antagonist, MK-801
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5509is a drug that inhibits
 
Response: S5509is a drug that inhibits platelet aggregation by binding to a specific receptor on platelets and thus inhibits the binding of fibrinogen to platelets. Inhibition of platelet aggregation leads to decreased platelet activation and a reduction in the formation of thrombus, which can lead to a reduced risk of thromboembolic events.

INSTRUCTIONS FOR USE

Take one tablet by mouth with a full glass of water approximately 30 minutes before a meal, or as directed by your doctor. Do not chew, crush, dissolve, or divide the tablet. If you have difficulty swallowing the tablet whole, you may crush the tablet and mix it with a small amount of applesauce, milk, or fruit juice. Swallow the mixture immediately.

STORAGE

Store at room temperature away from moisture and heat.

SAFETY INFORMATION

Do not use if the tablet is discolored or if you see any other defects
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5514is a drug that inhibits
 
Response: S5514is a drug that inhibits Src kinase and thereby interferes with the binding of growth factors to their receptors. It is being tested in a phase III trial for the treatment of renal cell carcinoma.

S7088, a drug that inhibits the kinase activity of the epidermal growth factor receptor (EGFR), has shown promise in phase II trials for the treatment of metastatic colon and non-small cell lung cancer.

The tyrosine kinase inhibitor sorafenib, which is being tested in a phase III trial for the treatment of renal cell carcinoma, inhibits angiogenesis.

Targeting angiogenesis is one of the approaches being used to develop new drugs for the treatment of cancer. The results of a phase II trial for the treatment of metastatic breast cancer with the drug bevacizumab, a monoclonal antibody that targets the VEGF receptor, have been disappointing. In this trial
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5515is a drug that inhibits
 
Response: S5515is a drug that inhibits the synthesis of cAMP by blocking the conversion of ATP to cAMP in mammalian cells. In the past, we have found that the synthesis of cAMP is an important step in the regulation of osteoblasts and osteoclasts, which is responsible for the physiological bone turnover. This process is involved in the process of bone remodeling. S5515 has been shown to be an effective therapeutic agent for the treatment of bone diseases such as osteoporosis, and bone metastases of cancer. The chemical structure of S5515 is shown in FIG. 1.

In a study of the structure-activity relationship of S5515, we found that a series of 5,6-disubstituted-4,7-dihydro-1,3-dioxolo[4,5-g]isoquinolin-2(3H)-one compounds, including compounds of the present invention, showed potent activity.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5524is a drug that inhibits
 
Response: S5524is a drug that inhibits P-glycoprotein (P-gp) activity in the intestinal wall and increases the bioavailability of the orally administered drugs. The purpose of this study was to investigate the pharmacokinetics and bioavailability of a combination of S5524 and theophylline. Male Sprague-Dawley rats were given a single oral dose of theophylline (20 mg/kg) alone or with a single oral dose of S5524 (20 mg/kg) alone or a combination of S5524 (20 mg/kg) and theophylline (20 mg/kg) in the form of a mixture. Plasma samples were collected at various times after the drug administration and analyzed by liquid chromatography with tandem mass spectrometry. The pharmacokinetic parameters of theophylline were not affected by the coadministration of S5524. The bioavailability of theophylline was increased from 21.8% to 63
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5527is a drug that inhibits
 
Response: S5527is a drug that inhibits 5-lipoxygenase, the enzyme responsible for the synthesis of leukotrienes from arachidonic acid. This drug has been used in combination with other anti-inflammatory agents in the treatment of asthma and arthritis. The efficacy of this drug in combination with other anti-inflammatory agents is uncertain.

5-Lipoxygenase Inhibitors

4-Fluoro-5-lipoxygenase inhibitor (Fluprolixac)

INN: fluprolixac

Janssen Biotech Inc.

Clinical trial identifier: NCT00842366

Patients with moderate to severe rheumatoid arthritis were randomly assigned to receive either 50 mg of fluprolixac twice daily or placebo. The primary outcome measure was the proportion of patients achieving a 20% improvement in the American College of Rheumatology (ACR) criteria. The ACR
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5528is a drug that inhibits
 
Response: S5528is a drug that inhibits HIV replication.

S5528 was identified by the U.S. National Cancer Institute in a high throughput screening assay as a candidate for the development of a broad-spectrum anti-HIV agent.

Mechanism of action
S5528 is a cell-permeable peptide that binds to HIV-1 capsid and inhibits the entry of the virus into cells.

History
S5528 is being developed by Sigma Tau, a biotechnology company headquartered in San Francisco, California. It is currently in Phase II clinical trials.

References

Category:HIV/AIDS
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5530is a drug that inhibits
 
Response: S5530is a drug that inhibits the catalytic activity of thrombin. The two main advantages of S5530 over hirudin are that it does not cause hemorrhage and that it does not interfere with the intrinsic coagulation pathway, which is mainly involved in hemostasis in the early stages of an activated coagulation cascade. Inhibition of thrombin may reduce the risk of thrombosis without increasing the risk of hemorrhage. The principal indication for thrombin inhibition is prevention of re-thrombosis after coronary artery stenting.
S5530is an oral direct thrombin inhibitor, which acts by binding directly to the active site of thrombin. It has a bioavailability of approximately 80%, and the peak plasma concentration is reached after 3 to 5 hours. S5530is a potent, selective, and direct thrombin inhibitor that binds thrombin with a Ki of 0.11 nM. The inhibition of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5531is a drug that inhibits
 
Response: S5531is a drug that inhibits vascular endothelial growth factor (VEGF) signaling by binding to the VEGF receptor (VEGFR). This agent has been shown to inhibit tumor growth and metastasis in patients with metastatic colorectal cancer. In this study, we investigated the activity of S5531 in patients with advanced or recurrent non-small cell lung cancer (NSCLC). A phase I study was conducted in patients with advanced or recurrent NSCLC. Patients received S5531 (5 mg/kg) administered intravenously daily for 5 days every 2 weeks. A total of 38 patients were treated. Among the 36 evaluable patients, the overall response rate was 8.3% (95% confidence interval [CI], 3.1%-17.7%). Stable disease was observed in 12.5% (95% CI, 5.4%-23.8%) of patients. Median time to progression was 1.6 months (95% CI
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5532is a drug that inhibits
 
Response: S5532is a drug that inhibits the production of melanin. The most important of these is S-adenosylmethionine, which is synthesized from methionine by the enzyme S-adenosylmethionine synthetase. The compound is a reversible inhibitor of this enzyme, and as a result the concentration of S-adenosylmethionine is lowered, and the synthesis of melanin is reduced. A decrease in the production of melanin means that the skin darkens.

The molecular structure of S5532is shown in the figure below.

S5532is an organic compound that belongs to the class of adenosine analogues. This drug is an antagonist of the human A2A adenosine receptor.

S5532has a molecular weight of 290.2.

S5532is a white crystalline powder that is soluble in water.

S5532is supplied as a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5533is a drug that inhibits
 
Response: S5533is a drug that inhibits both P-glycoprotein (P-gp) and the organic cation transporter (OCT1), two efflux pumps that are involved in the elimination of numerous anticancer drugs and a major obstacle in the treatment of multidrug resistance (MDR). However, because S5533 is a new agent, no data are available regarding its pharmacokinetic and toxicological properties. In the present study, the pharmacokinetic profile of S5533 was evaluated in rats after intravenous (i.v.) administration of a single dose (2.5 mg/kg) and multiple doses (10 mg/kg/day, for 7 days). S5533 was rapidly eliminated, with a total body clearance of 5.47 L/h/kg and a half-life of 0.8 h. It was mainly excreted in the urine (85%) and feces (9%). The oral bioavailability was only 6.8%, with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5534is a drug that inhibits
 
Response: S5534is a drug that inhibits the histone deacetylase (HDAC) protein. Inhibition of HDAC leads to increased acetylation of the histones. This change in histone acetylation leads to altered gene expression, resulting in apoptosis and differentiation. In clinical trials, the drug has shown to be active in the treatment of multiple myeloma and in hematological malignancies. In this paper, we present the results of a screening campaign to identify compounds that bind S5534. The campaign used the Ligand-Based Pharmacophore model and the Virtual Screening software GOLD.

Materials and Methods {#sec2}
=====================

Ligand-Based Pharmacophore Model Generation {#sec2.1}
-------------------------------------------

S5534 is a compound that has been shown to be active in the treatment of multiple myeloma and in hematological malignancies.^[@ref
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5535is a drug that inhibits
 
Response: S5535is a drug that inhibits tumor growth and metastasis. This study demonstrated that the combination of ATX-S5535 with celecoxib can enhance the inhibitory effect on colon cancer cell growth. The combination of ATX-S5535 and celecoxib synergistically suppressed cell growth in vitro and in vivo. The synergistic effect of the combination of ATX-S5535 and celecoxib was associated with inhibition of cell cycle progression, induction of apoptosis, and inhibition of the MAPK and PI3K/Akt signaling pathways. Moreover, the combination of ATX-S5535 and celecoxib was effective against the metastasis of colon cancer in vivo. In conclusion, the combination of ATX-S5535 and celecoxib may be a potential strategy for the treatment of colon cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5537is a drug that inhibits
 
Response: S5537is a drug that inhibits the entry of the HIV-1 virus into the cell. It has been developed by Janssen Research & Development, LLC (formerly Janssen Pharmaceutica).

S5537 is a highly potent and selective fusion inhibitor. It inhibits the interaction between the HIV-1 virus and the cell. This results in an inability of the virus to enter the cell.

S5537 is active against most HIV-1 strains, including primary isolates. It has activity against most HIV-1 strains, including primary isolates.

S5537 is approved in the United States for use as an adjunct to antiretroviral therapy (ART) in treatment-experienced patients. It is also approved in Australia, Canada, Germany, and Switzerland for use as an adjunct to ART in treatment-experienced patients.

S5537 is approved in the United States for use as an adjunct to ART in treatment-exper
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5538is a drug that inhibits
 
Response: S5538is a drug that inhibits the activity of mTOR (mechanistic target of rapamycin) protein kinase. mTOR is a serine/threonine kinase that acts as a downstream effector of the PI3K/Akt signaling pathway. mTOR is activated by growth factors and nutrients, and it regulates protein translation and cell growth in response to growth signals. The mTOR protein kinase complex is composed of mTOR, regulatory-associated protein of mTOR (Raptor), G protein β-subunit-like protein (GβL), mammalian lethal with Sec13 protein 8 (mLST8), and DEP domain-containing mTOR-interacting protein (Deptor). mTOR is activated by growth factors and nutrients, and it regulates protein translation and cell growth in response to growth signals. The mTOR protein kinase complex is composed of mTOR, regulatory-associated protein of mTOR (Raptor), G protein
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5539is a drug that inhibits
 
Response: S5539is a drug that inhibits thymidylate synthase and can be used in the treatment of advanced colorectal cancer and metastatic breast cancer. To determine whether the activity of S-1S5539 in combination with paclitaxel can be improved by alterations in the schedule of administration, the combination was administered at either three times per week (3xQW) or daily (D). The combination of paclitaxel and S-1S5539 was evaluated in mice bearing CT26.CL25 human colon cancer xenografts. The therapeutic efficacy was determined by measurement of tumor volume, tumor weight, and tumor histology. S-1S5539 alone produced significant tumor regression in CT26.CL25 tumor-bearing mice, but was not curative. Paclitaxel produced a significant regression of CT26.CL25 tumors and was curative. The combination of paclitaxel and S-1S5539 produced
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5540is a drug that inhibits
 
Response: S5540is a drug that inhibits a kinase called casein kinase 2 (CK2) in the cells of the brain. In the brain, CK2 is involved in a number of processes that are critical to learning and memory, and S5540 is thought to have the potential to enhance learning and memory.

S5540 has also been shown to enhance both cognitive performance and learning in rats and mice. In a study published in 2004, rats were given S5540 before being trained in a series of cognitive tasks. The researchers found that the rats had better performance in the tasks after being given S5540. The researchers also found that when they examined the rats' brains after the training, they found increased activity in certain brain regions involved in learning and memory.

In a 2007 study, researchers administered S5540 to mice before they were given the Morris Water Maze, a test for learning and memory. The mice that were given S5540 were able to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5541is a drug that inhibits
 
Response: S5541is a drug that inhibits growth of human tumor cells. In particular, the compound inhibits the growth of human tumor cells derived from lung, colon, breast, ovarian, prostate, and stomach cancer.                (2S,3R,4S,5R,6S)-2-[2-amino-3,4-dihydroxy-5-(hydroxymethyl)cyclohexyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-3-yl)-6-hydroxy-7-methyl-2,3-dihydro-4H-pyrano[3,4-b]quinoline-5,8-dione-7-sulfonamide-hexaacetate.        
U.S. Pat. No. 6,566,654
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5543is a drug that inhibits
 
Response: S5543is a drug that inhibits Src tyrosine kinase activity. In this study, we investigated the effect of S5543 on Src-mediated phosphorylation of epidermal growth factor receptor (EGFR) in human breast cancer cell lines. We used two EGFR-overexpressing cell lines, MDA-MB-231 and MCF-7, and one EGFR-negative cell line, MCF-10A. S5543 blocked EGF-induced phosphorylation of EGFR in both EGFR-overexpressing cell lines. However, S5543 did not inhibit phosphorylation of EGFR in EGFR-negative MCF-10A cells. S5543 also inhibited the EGF-induced tyrosine phosphorylation of the EGFR downstream proteins, Shc and phospholipase C-gamma1. S5543 inhibited the EGF-induced phosphorylation of Src and phosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5544is a drug that inhibits
 
Response: S5544is a drug that inhibits aldose reductase and the related enzyme sorbitol dehydrogenase, the enzymes that are believed to be responsible for the pathological accumulation of sugar in tissues and in the body fluids of diabetic patients.
S5544is a highly potent inhibitor of these enzymes, with IC50 values of around 5 nM for the aldose reductase and sorbitol dehydrogenase. In rats, S5544 lowers the blood glucose level by approximately 60% when administered orally at a dose of 0.3 mg/kg.

S5544 is not a competitive inhibitor of the two enzymes. Rather, it binds to a large, non-catalytic pocket on the surface of these enzymes.

The drug has a short half-life in plasma (t½ < 10 min) and is rapidly cleared via the kidneys.

S5544 is undergoing preclinical development as a potential treatment for diabetic nephropathy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5545is a drug that inhibits
 
Response: S5545is a drug that inhibits CYP3A4 and is also a potent inhibitor of P-glycoprotein (P-gp). In this study, we investigated the effects of S5545 on the pharmacokinetics of dexamethasone in rats. In the first set of experiments, rats were administered dexamethasone (10 mg/kg) with or without S5545 (1 mg/kg) by oral gavage. After dosing, plasma dexamethasone concentrations were determined using liquid chromatography/mass spectrometry. The results indicated that the area under the plasma concentration-time curve from time zero to time infinity (AUC0-∞) was decreased by 35% in the presence of S5545. The effects of S5545 on dexamethasone clearance (CL/F) and the apparent oral clearance (CL/F) were modest. In the second set of experiments, rats were administered dexam
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5546is a drug that inhibits
 
Response: S5546is a drug that inhibits S5546 binds to a specific sequence in the IL-2 promoter and inhibits IL-2 production. The effect of S5546 on T cell activation and on the growth of murine lymphoma cell lines is currently under investigation. The goal of this study is to characterize the role of IL-2 in the induction and regulation of IL-2 production in T cells. The studies in this proposal will provide the foundation for future studies designed to examine the effect of S5546 on human T cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5547is a drug that inhibits
 
Response: S5547is a drug that inhibits the proliferation of cancer cells by blocking the cell cycle at the G2/M checkpoint \[[@CR23]\]. A single treatment of TBB with IC~50~ concentration in HepG2 cells could cause G2/M arrest and increase the level of Cdc25C, the substrate of Cdc2, and decrease the level of Cdc2 \[[@CR24]\]. TBB could also cause G2/M arrest by downregulating the expression of Cdc25C \[[@CR25]\]. As a result, it inhibits the phosphorylation of Cdc2, which is a necessary event for the G2/M transition, and induces apoptosis in tumor cells \[[@CR26]\]. Thus, it was hypothesized that TBB might also be able to induce apoptosis in HepG2 cells. In this study, we found that TBB increased the ratio of apoptotic cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5549is a drug that inhibits
 
Response: S5549is a drug that inhibits the
cAMP-dependent protein kinase and inhibits PKA.
It inhibits the phosphorylation of CREB and the expression of
P-CREB. S5549 was found to be effective against the brain
tumor C6 glioma cells, and also inhibited the growth of
C6 cells in vivo. The effects of S5549 on the C6 cells
were mediated through the ERK signaling pathway. It also
enhanced the sensitivity of C6 cells to the chemotherapeutic
drugs. S5549 is a potent inhibitor of tumor growth in vivo.

Abstract

The cyclic AMP-dependent protein kinase (PKA) plays a
critical role in cellular proliferation and differentiation,
including the regulation of gene expression. We identified
S5549, a novel PKA inhibitor, which was found to have a
potent antitumor activity in vitro and in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5550is a drug that inhibits
 
Response: S5550is a drug that inhibits the
signal transduction pathway,
that inhibits the effector proteins of Ras,
that ultimately cause the cells to stop dividing
and they will undergo apoptosis.
Now,
this drug has been shown to be effective
in the treatment of melanoma.
And I think that if you were to look
at the study that I cited here,
you would see that they showed that it
was successful in treating melanoma.
It's not clear that they've been successful
in treating colon cancer.
And I think that we should do the same study
with colon cancer.
It's going to be hard to do because
the patient is going to have to have surgery
and then the surgery will remove
a piece of the colon.
And it will be very difficult to do
a biopsy and test it before the surgery
because the tumor may be too close
to the part that you're going
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5552is a drug that inhibits
 
Response: S5552is a drug that inhibits calcineurin, a Ca^2+^-activated phosphatase that dephosphorylates the nuclear factor of activated T cells (NFAT) in T cells. S5552 is known to have immunosuppressive effects and has been used to treat immune-mediated diseases in animals.^[@bib1]^ It has also been shown to have potent antiviral effects against human immunodeficiency virus type 1 (HIV-1).^[@bib2]^ However, the precise mechanism by which S5552 suppresses HIV-1 replication has not been established. In this study, we have used a combination of RNA interference and DNA microarray analysis to investigate the mechanism of action of S5552.

The T-cell activation and proliferation are two important mechanisms of host defense against HIV-1. T-cell activation is initiated by binding of the T-cell receptor to a foreign
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5553is a drug that inhibits
 
Response: S5553is a drug that inhibits TNF-alpha, IL-1beta and IL-6, which are cytokines produced by macrophages, monocytes and fibroblasts that mediate a wide range of inflammatory and autoimmune diseases.\[[@ref1]\]

Kaposi\'s sarcoma (KS) is a rare, vascular tumor, usually occurring in elderly patients, that affects the skin and mucosa. It is caused by infection with the Kaposi\'s sarcoma-associated herpesvirus (KSHV). The prevalence of KSHV infection is high in HIV-positive patients and is associated with AIDS.\[[@ref2]\]

The risk of developing KS is greater in HIV-infected patients. It is estimated that there are approximately 8 million people with HIV infection worldwide and in some regions the prevalence of KS is 20 times higher in HIV-infected patients than in the general population.\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5554is a drug that inhibits
 
Response: S5554is a drug that inhibits the production of proteins that enable bacteria to spread and grow. S5554 is used in combination with ciprofloxacin to treat ciprofloxacin-resistant *E. coli* infections. This drug was discovered in 2003. It is manufactured by Sandoz (now Novartis) and is not available in the United States. S5554 is the first FDA-approved oral agent for the treatment of ciprofloxacin-resistant *E. coli* infections.

S5554 has been available in Europe since 2004 and in Canada since 2005. The manufacturer recommends that S5554 be used only in patients who are not responding to ciprofloxacin.

S5554 is an antibiotic drug that inhibits the production of proteins that enable bacteria to spread and grow. S5554 is used in combination with ciprofloxacin to treat ciproflox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5555is a drug that inhibits
 
Response: S5555is a drug that inhibits 5-lipoxygenase activity.
In this study, the effects of a new type of leukotriene receptor antagonist, E5555, on rat peritoneal leukocytes, rat mast cells, and guinea pig lung and tracheal mast cells were examined. The effects of E5555 on the production of arachidonic acid metabolites were also examined in human neutrophils and in HL-60 cells. In peritoneal leukocytes, E5555 inhibited LTC4 and LTD4 production in a dose-dependent manner, and it also inhibited PAF-induced LTC4 production. In rat mast cells, E5555 inhibited histamine release induced by compound 48/80 and PAF. In guinea pig lung and tracheal mast cells, E5555 inhibited histamine release induced by compound 48/80, A23187, and PAF. E5555 also inhibited the PA
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5556is a drug that inhibits
 
Response: S5556is a drug that inhibits the
action of norepinephrine on its receptor, resulting in
nonspecific blockage of sympathetic nerve terminals and
a generalized reduction in sympathetic nerve traffic to
various tissues. S5556 is currently used as an adjunct to
narcotics for the management of acute postoperative pain
and of chronic pain associated with cancer. It is also
used to control neuropathic pain. The side effects of
S5556 are generally minor and transient.

If you are an ACS member and you do not know your PIN or have trouble unlocking your PIN in this browser, click here to view the PDF below. Please note the link to the PIN is not secure, so it is not recommended for downloading.

The content of this article does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5558is a drug that inhibits
 
Response: S5558is a drug that inhibits PDE4 activity, and is currently used in the treatment of COPD. It has also been shown to have positive effects on the symptoms of COPD, however, the effects on exercise performance and endurance have not been studied.

The primary aim of this study was to examine the effect of the PDE4 inhibitor, roflumilast, on exercise tolerance and endurance in patients with COPD. The secondary aims were to examine the effect of roflumilast on exercise capacity, health-related quality of life and inspiratory muscle strength.

Patients were randomized to receive either placebo or roflumilast 500 µg twice daily. The treatment period was 12 weeks and patients were assessed at baseline and at 12 weeks.

The primary outcome measure was the distance walked in the 6 minute walk test (6MWT). Secondary outcome measures were the distance walked in the incremental shuttle walk test (ISWT), endurance time
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5559is a drug that inhibits
 
Response: S5559is a drug that inhibits Na^+^/K^+^-ATPase, leading to cardiotoxicity and arrhythmia.

One of the most well-known drugs in this category is ouabain, which is also known as digitoxin, a cardiac glycoside obtained from the roots of *Digitalis lanata*. It has been used as a cardiac glycoside for the treatment of congestive heart failure since the early 20th century. Its mechanism of action is similar to that of digitalis.^\[[@R5]\]^ Cardiotoxicity is a well-known side effect of ouabain, and this may be caused by its inhibition of the Na^+^/K^+^-ATPase pump.^\[[@R6]\]^ It can cause tachycardia, heart failure, and cardiac arrhythmia, as well as other serious cardiac events,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5560is a drug that inhibits
 
Response: S5560is a drug that inhibits the accumulation of amyloid-beta in the brain.

The drug’s primary effect is to promote the clearance of amyloid-beta from the brain, but its effects on cognitive and motor function were minimal.

In a preclinical study of Alzheimer’s patients, S5560 had no effect on memory, but reduced the severity of dementia and slowed its progression.

S5560 was well tolerated and had no effect on the metabolism of other drugs.

S5560 is a drug that inhibits the accumulation of amyloid-beta in the brain.

The drug’s primary effect is to promote the clearance of amyloid-beta from the brain, but its effects on cognitive and motor function were minimal.

In a preclinical study of Alzheimer’s patients, S5560 had no effect on memory, but reduced the severity of dementia and slowed its progression.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5562is a drug that inhibits
 
Response: S5562is a drug that inhibits the activity of fibroblast growth factor (FGF) and FGF receptor (FGFR) kinases, as well as other kinases. A recently published phase II clinical trial found that the drug is effective in treating osteosarcoma in adults, including those with advanced disease. In the trial, the drug was given to adult patients with advanced or metastatic osteosarcoma in combination with conventional chemotherapy. The primary endpoint of the trial was the progression-free survival (PFS) rate. The trial met its primary endpoint, as the PFS rate was 23% at one year, rising to 45% at two years. The PFS rate at one year was similar to that of a previously reported phase II trial of pazopanib, another drug that inhibits FGF and FGFR kinases, and the PFS rate at two years was higher than that of pazopanib. The trial also met the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5564is a drug that inhibits
 
Response: S5564is a drug that inhibits the export of certain cancer cells. In Phase I clinical trials, S5564 was administered as a single agent to patients with advanced cancer. S5564 was well tolerated with no major toxicity and demonstrated a modest antitumor effect. S5564 also inhibited the export of radiolabeled folate in folate receptor-positive cells, and thus, could be used in combination with chemotherapeutic agents or radiopharmaceuticals. In this study, we evaluated the antitumor activity of S5564 in vivo. We studied the effect of S5564 on tumor growth and metastasis in a mouse model of ovarian cancer. In the intraperitoneal model of ovarian cancer, mice were inoculated with cells from a patient with a relapsed ovarian cancer. S5564 was administered at 1.5 mg/kg daily for 7 days, and tumor growth and metastasis were assessed. The effect of S5564 on tumor growth
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5565is a drug that inhibits
 
Response: S5565is a drug that inhibits bone resorption by inhibiting osteoclastogenesis. The possible mechanism of S5565 in the treatment of osteoporosis is shown in [Figure 2](#F0002){ref-type="fig"}.Figure 2The possible mechanism of S5565 in the treatment of osteoporosis.

Although the precise mechanisms underlying S5565 treatment for osteoporosis remain unclear, the present study has a certain clinical significance. It provides an experimental basis for the development of new drugs for the treatment of osteoporosis.

The present study had some limitations. First, this study only included a small number of patients, which might have led to selection bias. Second, the duration of the follow-up period was short. Further research with a larger sample size and a longer follow-up period is needed.

Conclusion {#S0005}
==========

In summary, S5565 may be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5566is a drug that inhibits
 
Response: S5566is a drug that inhibits Aurora-B, and so I decided to give it a try. We used the cell line derived from the SW48 colon cancer cell line, which has a mutated form of p53 and a very high Aurora-B expression. Cells were exposed to 0.5 μM S5566 for 48 hours. We first measured the phosphorylation of histone H3 at Ser10 (H3S10ph) by Western blot, as this is a good marker of Aurora-B activity. Inhibition of Aurora-B was found to decrease H3S10ph (Fig. [1](#F1){ref-type="fig"}A), in agreement with the literature. This suggests that S5566 inhibits Aurora-B in our cell line. We then checked the proliferation rate of the cells and found that it was not affected by S5566 (Fig. [1](#F1){ref-type="fig"}B).
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5567is a drug that inhibits
 
Response: S5567is a drug that inhibits the growth of tumor cells by inducing tumor cell apoptosis and arresting cell cycle. A recent study reported that S5567 induces apoptosis in hepatocellular carcinoma cells by activating caspase-9 and caspase-3 and downregulating Bcl-2 expression[@bib47]. However, the precise molecular mechanisms underlying S5567-induced apoptosis in GC cells remain unknown. In the present study, we found that S5567 significantly decreased the viability of AGS and MKN45 cells, arrested cell cycle at G2/M phase, and induced cell apoptosis. The expression of p21 was upregulated in AGS and MKN45 cells, but was downregulated in AGS cells after S5567 treatment. However, the expression of p21 was downregulated in MKN45 cells after S5567 treatment. Furthermore, we found that S5567 induced cell cycle arrest and apoptosis through p
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5568is a drug that inhibits
 
Response: S5568is a drug that inhibits the enzyme 5-lipoxygenase. This enzyme plays a role in the production of inflammatory mediators such as leukotrienes and is believed to be involved in the development of asthma. Studies have shown that leukotriene inhibitors may have clinical efficacy in the treatment of asthma.
Steroids are also known to be useful in the treatment of bronchial asthma. Some patients with asthma, however, do not respond to steroids, or cannot tolerate the side effects associated with steroids. There is, therefore, a need for a safe and effective bronchodilator which does not produce adverse side effects.
Niacin (nicotinic acid) is a water soluble vitamin which has been reported to be useful in the treatment of peptic ulcers and as an adjunct to therapy in the treatment of hyperlipidemia and atherosclerosis. In recent years it has been reported that niacinamide, a metabolite
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5569is a drug that inhibits
 
Response: S5569is a drug that inhibits a gene known as HER2.

The gene encodes a protein that helps cancer cells grow and spread.

The new study is the first to look at how quickly the drug kills cancer cells, and whether it works against other types of breast cancer.

The results, published in the journal Breast Cancer Research, suggest that HER2 inhibitors can kill cancer cells within hours of starting treatment.

Researchers hope this approach could be used to treat other cancers, as well as non-cancerous breast conditions.

Around 20,000 people in the UK are diagnosed with breast cancer each year.

One in nine of these women will develop metastatic breast cancer, which is when the cancer has spread to other parts of the body.

For these women, treatments have historically involved chemotherapy and surgery, but the side effects can be severe.

More effective treatments

Professor Helen Blower, from the University of Glasgow,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5571is a drug that inhibits
 
Response: S5571is a drug that inhibits the enzyme that catalyzes the conversion of glycogen to glucose, glycogen phosphorylase. As a result, glycogen stores are preserved and the production of glucose is prevented. In the body, this causes a reduction in blood glucose levels and an increase in the levels of glycogen in the liver and muscles. The following information is a general description of S5571.

S5571 is a prodrug that requires conversion to the active form (S5571-gluc) by liver and kidney glucuronidases. S5571-gluc is responsible for the hypoglycemic effects of S5571.

S5571 is rapidly converted to S5571-gluc by glucuronidases in the liver and kidney.

S5571-gluc is absorbed slowly, with a bioavailability of approximately 50% following oral administration.

S5571 is eliminated from the body via the kidneys and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5573is a drug that inhibits
 
Response: S5573is a drug that inhibits the proliferation of various cancer cell lines and inhibits cancer cell growth and proliferation in vivo. The present study aimed to evaluate the effects of S5573 on proliferation and cell cycle in glioma cells and the possible mechanism of action. Glioma cell lines (U87, U251, LN229, and LN308) were treated with various concentrations of S5573. Cell viability was determined using a CCK-8 assay. Cell cycle distribution was analyzed using flow cytometry. The expression of proteins involved in the cell cycle were analyzed using western blotting. S5573 significantly inhibited cell proliferation in all cell lines tested. The inhibitory effects of S5573 were associated with G1/S phase arrest and cell cycle arrest at G2/M phase. In addition, S5573 significantly inhibited the expression of cyclin D1, CDK4, and CDK6. The expression of cyclin B1 and CDC2 was
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5581is a drug that inhibits
 
Response: S5581is a drug that inhibits the enzyme responsible for the formation of the essential amino acid tryptophan. Tryptophan is essential for many processes in the body including the synthesis of serotonin. Serotonin is one of the neurotransmitters responsible for many functions in the brain including mood, sleep and appetite. Tryptophan is the precursor to serotonin. Tryptophan also has many other uses in the body, including in the production of protein, the creation of the essential amino acid tyrosine and the formation of the neurotransmitter melatonin.

S5581is used to treat depression and other mood disorders. It is an anti-depressant drug, and also a drug used to treat insomnia. S5581 is a serotonin and norepinephrine reuptake inhibitor. It is used to treat depression and also acts as a stimulant to help treat insomnia. S5581 is a medication that is used to treat depression and other mood disorders.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5582is a drug that inhibits
 
Response: S5582is a drug that inhibits the binding of IL-2 to the IL-2 receptor on T cells. This is done by blocking the formation of the high-affinity IL-2 receptor, and therefore the T cells cannot respond to IL-2. S5582 is also used to treat lymphoma and other cancers that may have the IL-2 receptor as a target. The effectiveness of S5582 in treating these cancers has not been determined. The purpose of this study was to evaluate the effectiveness of S5582 in treating B-cell lymphoma. We conducted a phase II study in patients with B-cell lymphoma who had no prior therapy. S5582 was administered intravenously every 3 weeks at doses of 2.5, 5, 10, and 20 mg/kg. Patients who had partial or complete responses were given 2 additional cycles of S5582. The response rate was 33% (95% confidence interval [CI], 18%-48%). In patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5583is a drug that inhibits
 
Response: S5583is a drug that inhibits HIV-1 replication at the reverse transcription step. The purpose of this study was to evaluate the safety and antiviral activity of S5583 in HIV-1-infected patients. In this open-label study, 16 patients were treated with S5583 at a dose of 400 mg/day for up to 3 months. Viral load was measured by a quantitative polymerase chain reaction (PCR) assay. The median baseline plasma HIV-1 RNA concentration was 4.7 log10 copies/ml (range, 4.0-5.4 log10 copies/ml). At the end of the study, 12 of the 16 patients had at least a 1.0-log10 reduction in HIV-1 RNA levels. S5583 was well tolerated; no treatment-related serious adverse events were reported. The most common adverse events were mild to moderate in severity. This study suggests that S5583 is safe and has antiviral activity in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5585is a drug that inhibits
 
Response: S5585is a drug that inhibits myocardial damage, ischemic injury and cardiomyocyte apoptosis in myocardial ischemia-reperfusion. We hypothesized that it may also have beneficial effects on ventricular remodeling after myocardial infarction (MI). We evaluated the effects of S5585 on the incidence of left ventricular remodeling after MI. Male C57BL/6 mice were randomly assigned to sham-operation (Sham) group or MI group. S5585 was administered intraperitoneally to the MI mice for 14 days, starting 1 day before the MI. The MI mice treated with S5585 showed smaller infarct sizes and less cardiomyocyte apoptosis, and more than 80% of the cardiomyocytes were in the phase of proliferation. Moreover, S5585 attenuated the deterioration of cardiac function and reduced the mortality of the MI mice. In contrast, S5585 had no effect on the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5588is a drug that inhibits
 
Response: S5588is a drug that inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) by the neuronal presynaptic membrane. It is used to treat various conditions including insomnia, pain, and depression. This product is also known as St. John's wort, which is a medicinal herb that contains high levels of S5588. It is generally regarded as safe (GRAS).

5-HT and NE are neurotransmitters that regulate a number of functions in the body, including sleep. They also play an important role in the control of pain and mood. 5-HT and NE have been shown to be involved in a number of physical, mental, and emotional disorders, including pain, depression, anxiety, insomnia, and impulsive behaviors. 5-HT and NE are synthesized in the brain and are released into the synapse to activate the postsynaptic receptor and stimulate the transmission of signals to other neurons.

5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5590is a drug that inhibits
 
Response: S5590is a drug that inhibits proliferation of both adult and pediatric glioma cells and tumor-initiating cells. We showed that S5590 could suppress cell growth, induce apoptosis, inhibit the activation of Akt, p70S6K, and mTOR, and enhance autophagy in GBM cells. Moreover, S5590 could suppress tumor growth in both orthotopic and subcutaneous GBM models.

Autophagy is an important homeostatic process that is important for cell survival. Increasing evidence suggests that autophagy plays a critical role in cancer development and progression.^[@bib26],\ [@bib27]^ However, autophagy is known to have either pro- or anti-tumor roles depending on the type of cancer.^[@bib28],\ [@bib29]^ Thus, inhibiting autophagy in cancer cells could be a promising therapeutic approach. Recently
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5592is a drug that inhibits
 
Response: S5592is a drug that inhibits the serotonin 5-HT2A receptor.

S5592 is being developed by Pfizer. The S5592 development program includes studies in animals, including dogs, and in humans. In addition, the company has initiated a Phase I study of S5592 in patients with idiopathic pulmonary fibrosis (IPF).

How does it work?

S5592 is a selective, oral 5-HT2A receptor antagonist that inhibits serotonin-mediated cellular functions.

The company believes that S5592 has potential as a treatment for a wide range of indications, including:

Stroke

Clinical studies of S5592 have been completed in dogs and are being conducted in healthy humans.

The company also has an IND (Investigational New Drug) application for a Phase I clinical trial of S5592 in patients with idiopathic pulmonary fibrosis (IPF).


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5594is a drug that inhibits
 
Response: S5594is a drug that inhibits the Na,K-ATPase and has been shown to improve memory in animal models. A small open-label study of healthy older adults showed a beneficial effect of a single dose of S5594 in enhancing recall of learned material (Perez-Lloret et al., [@B48]). However, S5594 has not been evaluated in AD.

Memantine is a low-affinity NMDAR antagonist. It has been approved for use in moderate-to-severe AD and has been shown to reduce the rate of cognitive decline in patients with mild-to-moderate AD (for a review, see Schrag et al., [@B56]). However, memantine has not been shown to affect the rate of cognitive decline in mild-to-moderate AD, and it does not modify the progression of dementia (Mukherjee et al., [@B43]; Henry et al., [@B28
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5596is a drug that inhibits
 
Response: S5596is a drug that inhibits the activity of HIV-1 integrase, the enzyme that inserts the viral DNA into the host DNA. It is a compound of the family of nucleoside analogues that also includes Elvitegravir and Raltegravir, which have been approved for the treatment of HIV infection. It is a potent inhibitor of the HIV-1 integrase enzyme, but it is also a substrate for the human and viral DNA polymerases. As a result, S5596 is a relatively short-lived drug that requires multiple doses to maintain therapeutic levels.

In the Phase 1 clinical study that led to the approval of S5596, three groups of healthy volunteers were given single doses of S5596. The first group of subjects were administered S5596 by intravenous infusion over 1 hour at doses of 0.3 mg/kg, 1 mg/kg, and 3 mg/kg. The second group were administered S5596
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5597is a drug that inhibits
 
Response: S5597is a drug that inhibits the inactivation of L-type calcium channels by calmodulin, resulting in the activation of these channels. It is used to prevent and treat high blood pressure, for which there is no cure.

References

Category:Calcium channel blockers
Category:Fluoroarenes
Category:Quinolines
Category:Nitrobenzenes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5598is a drug that inhibits
 
Response: S5598is a drug that inhibits the growth of certain types of cancer cells.

Side effects may include dizziness, constipation, loss of appetite, dry mouth, stomach pain, vomiting, hair loss, darkening of the skin, mouth sores, and changes in menstrual periods.

It is used in the treatment of advanced ovarian cancer, metastatic melanoma, and acute myeloid leukemia.

It is also used to treat Hodgkin's lymphoma and certain other types of cancer.

Your doctor may be able to reduce the dose of S5598.

There are many ways to stop taking S5598.

When your doctor tells you to stop taking S5598, you should stop taking the drug.

However, if you are taking it to treat cancer, you may be able to take it for a few weeks after your treatment ends.

How to store S5598

Store S5598 at room
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5599is a drug that inhibits
 
Response: S5599is a drug that inhibits Spleen tyrosine kinase (Syk) and is being developed for the treatment of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. However, it is not yet clear whether S5599is safe and effective for the treatment of neuropsychiatric disorders. The aim of this study was to evaluate the effect of S5599on mouse brain histopathology and behavior. Wild-type C57BL/6 mice received S5599(10, 20, or 30 mg/kg, once daily) or vehicle (0.5% methylcellulose) by oral gavage for 21 days. Histopathology was assessed by H&E and Nissl staining, and behavior was assessed using the elevated plus maze, open field, tail suspension, and forced swim tests. Compared with the vehicle-treated group, S5599did not induce any histopathological abnormalities
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5601is a drug that inhibits
 
Response: S5601is a drug that inhibits acetylcholinesterase, an enzyme involved in the cholinergic system. Acetylcholinesterase inhibitors are used in the treatment of Alzheimer's disease, myasthenia gravis, Parkinson's disease, and other neurodegenerative diseases. This study was designed to evaluate the efficacy and safety of intranasal S-5552 in patients with mild to moderate Alzheimer's disease. The primary efficacy endpoint was the effect of S-5552 on cognitive function as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). The primary safety endpoint was the occurrence of adverse events (AEs). The secondary efficacy endpoints were the effect of S-5552 on activities of daily living (ADL) and global clinical impression (G-CIG). A total of 101 patients were randomized to receive S-5552 or placebo (double-blind phase) followed by open-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5614is a drug that inhibits
 
Response: S5614is a drug that inhibits the binding of several chemokines to the CCR1 receptor. It can block the migration of monocytes and macrophages and the accumulation of these cells at the sites of inflammation. By blocking the CCR1 receptor, the drug reduces the inflammatory response and the progression of the disease.

The compound was shown to be safe in animals. In humans, it was well tolerated, even at the highest dose tested.

Further trials of the drug are ongoing. The current study investigated its efficacy in patients with systemic lupus erythematosus.

Sixty patients were recruited to the study. The patients had been diagnosed with systemic lupus erythematosus and had received standard therapy.

The patients were randomly assigned to one of three groups:

Group A: treatment with siltuximab

Group B: treatment with placebo

Group C: no treatment

At
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5617is a drug that inhibits
 
Response: S5617is a drug that inhibits eosinophil peroxidase (EPO), which is an important component of eosinophil-derived neurotoxin. We compared the efficacy and safety of S5617 and placebo in children and adolescents with active moderate-to-severe atopic dermatitis (AD) who had failed to respond to conventional therapy. In this double-blind, randomized, placebo-controlled trial, children and adolescents aged 2 to 17 years with active moderate-to-severe AD who had failed to respond to conventional therapy were randomized (2:1) to receive either S5617 (10 mg/kg per day) or placebo for 4 weeks. Primary efficacy was measured as the percentage of patients with a 50% or greater reduction in total SCORAD scores from baseline to week 4. Patients who were randomized to receive S5617 had a greater mean reduction in total SCORAD scores from baseline to week 4 (39.7% vs 13
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5618is a drug that inhibits
 
Response: S5618is a drug that inhibits the multiplication of the virus. It also prevents the virus from entering the host cells. But it doesn’t kill the virus.”

It’s unclear what will happen next.

“We will wait for the results of the test and see what the consequences will be,” added Dr. Tabet. “We will see if it will be useful in the treatment or if it will be just a placebo.”

Sudanese authorities are urging all residents to avoid using live vaccines.

“I advise everyone not to use vaccines,” said Dr. Tabet. “They may be contaminated.”

Dr. Tabet says he and his colleagues will continue to study the disease and will keep patients on a watchlist to ensure that they get a good outcome.

The American team has started its own investigation.

“The scientists are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5619is a drug that inhibits
 
Response: S5619is a drug that inhibits the platelet activating factor (PAF) receptors, and is in development for the treatment of asthma and inflammatory diseases. The mechanism of action is unknown, but one hypothesis is that it acts as an antagonist of the PAF receptors. This study investigated the mechanism of action of S5619 in an ex vivo model of platelet activation and aggregation. In vitro platelet function was assessed using a multiple electrode aggregometry system (Multiplate) and an immunobead assay. The binding of S5619 to human platelets was assessed by flow cytometry. The effect of S5619 on in vivo platelet activation was studied in a murine thrombosis model. The effect of S5619 on in vitro platelet function was as follows: S5619 dose dependently inhibited ADP-, collagen-, arachidonic acid-, and thrombin-induced platelet aggregation, and thrombin-induced platelet fibrinogen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5620is a drug that inhibits
 
Response: S5620is a drug that inhibits in vitro proliferation of PC-3 cells (a human prostate cancer cell line) by interfering with the interaction between the retinoblastoma protein and the transcription factor E2F. This interaction is required for cell cycle progression from G1 to S phase. Inhibition of E2F prevents the expression of genes that are required for the G1/S transition. S-phase progression is also inhibited in vivo in a xenograft model of human prostate cancer.

Phase II

In phase II clinical trials, S-phase progression in tumor cells was inhibited in prostate cancer patients treated with S-phase inhibitors. This treatment resulted in a significant increase in progression-free survival (PFS) and overall survival (OS). Patients with a high risk of disease progression, defined by a Gleason score of 7 or greater, a tumor volume of 5 cm3 or greater, or two or more risk factors, experienced a significant improvement in PFS
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5621is a drug that inhibits
 
Response: S5621is a drug that inhibits mitochondrial complex 1 of the electron transport chain. It inhibits the growth of leukemia cells *in vitro* and in animal models. It also has anti-cancer activity against breast cancer cells \[[@R15], [@R16]\]. Here, we showed that it has synergistic effects with TMZ in the treatment of glioblastoma.

NSC-S5621 alone reduced the growth of U87MG cells. However, TMZ alone had no significant effect. In combination, the effects of NSC-S5621 and TMZ were synergistic. These results indicate that NSC-S5621 sensitizes U87MG cells to TMZ. The NSC-S5621 alone or in combination with TMZ had no effect on the growth of normal astrocytes. These results are consistent with the previous study \[[@R16]\]. The combination of NSC-S5621 and TMZ inhibited the growth
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5623is a drug that inhibits
 
Response: S5623is a drug that inhibits phosphatidylinositol 3-kinase and that is effective in inhibiting tumor cell proliferation and angiogenesis in animal models. In a phase I study of this agent, patients with advanced solid tumors had a partial response in 4 of 30 evaluable patients. We now report the results of a phase II study of S5623 in patients with advanced renal cell carcinoma. Patients were treated with a dose of S5623 on days 1, 8, 15, and 22 of a 28-day cycle. Twenty-seven patients were treated at four dose levels. There were two partial responses (7%; 95% confidence interval [95% CI], 1%-25%) and five patients with stable disease. The median time to progression was 1.6 months (95% CI, 1.3-1.9 months). The median survival time was 7.2 months (95% CI, 4.7-9.6 months). Toxic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5625is a drug that inhibits
 
Response: S5625is a drug that inhibits the Na+/Ca2+ exchange in cardiac muscle. In guinea pig ventricular myocytes it was shown that the inhibition of Na+/Ca2+ exchange by S5625 results in a reduction of the shortening of the action potential induced by the Na+ channel blocker veratridine and that the reduction in action potential duration results from the decrease in inward current, I Na, carried by Na+ channels. The aim of this study was to investigate the action of S5625 on I Na in guinea pig ventricular myocytes using the whole cell configuration of the patch-clamp technique. In the presence of 10 mM tetraethylammonium, 10 mM 4-aminopyridine, 1 mM Ba2+, and 1 mM Cs+, I Na was recorded as a current carried by Na+ ions. S5625, added to the pipette solution, caused a concentration-dependent reduction of I Na (IC
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5626is a drug that inhibits
 
Response: S5626is a drug that inhibits the activity of farnesyltransferase, the enzyme that adds a 15-carbon farnesyl group to the protein substrate. The farnesyl group is an essential modification for the function of Ras proteins. This drug inhibits Ras-dependent cell proliferation, and it has been approved for the treatment of patients with pancreatic cancer.

**Mechanism of action**

Sipuleucel-T is a cellular immunotherapy, which means that it consists of an autologous dendritic cell population. This treatment stimulates a patient's immune system to produce a specific T-cell response to a cancer-associated antigen. The antigen is identified by taking a small sample of a patient's cancer cells and exposing them to a substance called a maturation cocktail. This cocktail causes the cells to undergo apoptosis, and the antigen is then processed and presented to T cells, which then become activated and multiply to produce a specific immune response.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5627is a drug that inhibits
 
Response: S5627is a drug that inhibits multiple proteins, including DNA polymerase, topoisomerase and DNA ligase. It was developed to overcome MDR in cancer patients by combination with a wide range of chemotherapy agents.\[[@CIT1]\] Sildenafil, another drug that acts on multiple proteins, inhibits phosphodiesterase type 5, which catalyses the degradation of cyclic guanosine monophosphate (cGMP).\[[@CIT2]\] It is a drug that is used to treat erectile dysfunction. Sildenafil citrate (Viagra) was approved by the US Food and Drug Administration (FDA) in 1998 for the treatment of erectile dysfunction.

Cases of fatal drug interactions between sildenafil and zidovudine (AZT) have been reported.\[[@CIT3]\] It has been suggested that the sildenafil
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5628is a drug that inhibits
 
Response: S5628is a drug that inhibits both P-gp and CYP3A4 and has been shown to cause an increase in exposure to ABCG2 substrates, such as rosuvastatin and paclitaxel. The interaction of S-metoprolol and S-tramadol with S-5628 is unknown. This study examined the potential for pharmacokinetic drug interactions between S-metoprolol and S-tramadol with S-5628 in healthy subjects. The effects of coadministration of S-metoprolol and S-tramadol with S-5628 on the pharmacokinetics of S-metoprolol, S-tramadol, and the active metabolite of S-tramadol, O-desmethyltramadol, were assessed. The primary end point was the area under the concentration-time curve from time zero to infinity (AUC(inf
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5629is a drug that inhibits
 
Response: S5629is a drug that inhibits the generation of nitric oxide (NO) and prevents the activity of endothelial nitric oxide synthase (eNOS) [@bib0135], [@bib0140]. S-Nitroso-*N*-acetylpenicillamine (SNAP) is an NO donor that mimics NO [@bib0145], [@bib0150]. In order to verify the role of eNOS and NO in EPCs-mediated hMSC proliferation and migration, we evaluated whether SNAP would increase the proliferation and migration of EPCs and the proliferation and migration of hMSCs in response to EPCs. In the presence of SNAP, EPCs proliferation was significantly higher than in the presence of EPCs alone. EPCs-induced hMSC proliferation was significantly increased in the presence of SNAP. The effect of SNAP on EPCs was significantly reduced in the presence
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5630is a drug that inhibits
 
Response: S5630is a drug that inhibits Cdk4/6 by blocking the binding of cyclin D/D-Cdk4/6 complex to Cks1.

The Cdk inhibitors were tested for their cytotoxicity in HCT116 colon cancer cells. The results of this study are presented in [Figure 1](#ijms-19-00139-f001){ref-type="fig"}. All compounds were nontoxic, even at a concentration of 10 µM, which was higher than the concentration required to block the activity of Cdk4/6. This result suggests that the Cdk4/6 inhibition observed in the cell-free assays was not due to cytotoxicity.

The influence of S5630 on the phosphorylation of retinoblastoma protein (Rb) was studied. Rb is a major substrate of Cdk4/6, and its phosphorylation at Serine 780 (S780)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5631is a drug that inhibits
 
Response: S5631is a drug that inhibits Src kinase. In this study, we evaluated the antitumor effect of S5631 in combination with conventional chemotherapeutic agents. The growth inhibitory effects of S5631 in human colorectal cancer cell lines were evaluated by the MTT assay. S5631 was shown to have a potent antitumor effect against all cell lines tested, with an IC50 value of 3.3 to 17.5 nmol/L. The antitumor activity of S5631 was superior to that of the Src inhibitor PP2, which was used as a positive control. The cytotoxicity of S5631 was concentration dependent and time dependent. The antitumor effect of S5631 was most prominent at a dose of 10 nmol/L, and the activity was more prominent at lower pH. Moreover, S5631 was shown to enhance the antitumor activity of 5-fluorouracil (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5632is a drug that inhibits
 
Response: S5632is a drug that inhibits the activity of P-glycoprotein, an ATP-dependent membrane efflux pump that confers multidrug resistance to cancer cells. The aim of this study was to evaluate the potential of S5632 to inhibit human immunodeficiency virus type 1 (HIV-1) replication in peripheral blood mononuclear cells (PBMCs) from patients with acquired immunodeficiency syndrome (AIDS) and to determine the safety of the drug. HIV-1 isolates obtained from the plasma of patients with AIDS were grown in PBMCs with S5632 and the level of viral replication determined by the reduction in the level of HIV-1 RNA. The antiviral effect of S5632 was dose dependent, with a 50% effective concentration of 1.5 microM. The maximal inhibition of viral replication was observed at a drug concentration of 10 microM. No evidence of toxicity was observed in any of the patients. These data indicate that
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5633is a drug that inhibits
 
Response: S5633is a drug that inhibits histone deacetylase activity and has anti-cancer activity. In this study, the antitumor effects of S5633 in combination with cisplatin (CDDP) were investigated in human head and neck squamous cell carcinoma (HNSCC) cell lines. The results showed that S5633 increased the sensitivity of HNSCC cells to CDDP in vitro and in vivo. The mechanism of action of S5633 in HNSCC cells was associated with the inhibition of NF-κB signaling, down-regulation of NF-κB target genes, and inhibition of the PI3K/AKT pathway. The results of this study suggest that S5633 is a potential candidate for the treatment of HNSCC.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5634is a drug that inhibits
 
Response: S5634is a drug that inhibits the growth of human cancer cells by blocking the PI3K/Akt/mTOR pathway. However, the anti-tumor effect of S5634 is largely unknown. In the present study, we found that S5634 decreased the phosphorylation of Akt and mTOR, induced the apoptosis of cancer cells and inhibited the tumor growth in vivo. S5634 could also reverse the epithelial-mesenchymal transition of cancer cells by inhibiting the PI3K/Akt/mTOR pathway. In addition, we found that the mTOR inhibitor, rapamycin, had a similar effect as S5634 in the treatment of lung cancer. In conclusion, our results indicated that S5634 is a potential drug for the treatment of lung cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5635is a drug that inhibits
 
Response: S5635is a drug that inhibits the enzyme carbonic anhydrase (CA), which is required for conversion of CO2 to HCO3- in the vertebrate blood. Inhibition of this enzyme is believed to have a beneficial effect on the condition of patients with certain neurological conditions. In a clinical trial conducted in the US, the compound showed some benefits in the treatment of patients with Parkinson's disease (PD).
Sildenafil citrate, marketed under the trade name Viagra, is an effective drug for treating erectile dysfunction. It has a similar mechanism of action as sildenafil, but is more potent. It is believed that it may also be effective for the treatment of Parkinson's disease.
In another patent application, PCT/US2007/004530, there is disclosed the use of certain CA inhibitors, including dorzolamide and brinzolamide, for the treatment of neurodegenerative disorders.
In W
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5637is a drug that inhibits
 
Response: S5637is a drug that inhibits the protein kinase B (PKB/Akt) and the mitogen-activated protein kinase (MAPK) pathways. It is effective against both acute and chronic models of neuropathic pain. In this study, we evaluated the effect of S5637 on thermal and mechanical hyperalgesia in a mouse model of neuropathic pain. For the neuropathic pain model, we used the chronic constriction injury (CCI) model. The mice were administered S5637 (2.5, 5, or 10 mg/kg) or vehicle by intraperitoneal injection. The administration of S5637 significantly inhibited the thermal and mechanical hyperalgesia in a dose-dependent manner. In addition, the antihyperalgesic effect of S5637 was more potent than that of gabapentin. The antihyperalgesic effect of S5637 was not due to the inhibition of glutamate release, as assessed by micro
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5638is a drug that inhibits
 
Response: S5638is a drug that inhibits the proliferation of cancer cells and induces apoptosis in tumor cells. In this study, we investigated the effects of T-S5638 on the proliferation of breast cancer cells and the underlying mechanism of action. The proliferation of the human breast cancer cell lines MCF-7 and MDA-MB-231 was inhibited by T-S5638. In addition, cell cycle analysis indicated that T-S5638 induced cell cycle arrest at the G0/G1 phase. T-S5638 induced apoptosis in both MCF-7 and MDA-MB-231 cells. Western blot analysis showed that T-S5638 induced the expression of cleaved caspase-3 and caspase-9 in both cell lines. Furthermore, T-S5638-induced apoptosis was accompanied by upregulation of the proapoptotic proteins Bak and Bax, and downregulation of the antiapoptotic proteins Bcl-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5647is a drug that inhibits
 
Response: S5647is a drug that inhibits proteasome activity. The goal of this study was to determine the mechanisms by which S5647 affects the proteasome. We examined the effect of S5647 on proteasome activity, expression, and localization in different cell lines. We also determined the effect of S5647 on the growth of prostate cancer cells. S5647 inhibits the chymotrypsin-like and trypsin-like activities of the 20S proteasome by a dose-dependent manner in a variety of cell lines. The treatment of cells with S5647 also induced accumulation of the ubiquitinated proteins and decreased the levels of free ubiquitin. S5647 inhibited the growth of PC3 and DU145 cells, but not of LNCaP cells. The effect of S5647 on the growth of prostate cancer cells is likely to be due to its effect on the proteasome, which results in accumulation of ubiquitinated proteins
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5648is a drug that inhibits
 
Response: S5648is a drug that inhibits the release of bile salts and bile acids from the liver and can be used to treat bile acid diarrhoea. It is also used in the treatment of a disease called primary biliary cirrhosis, which causes problems with the liver. It may also be used for other purposes not listed in this medication guide.

INSTRUCTIONS

Use Sulfasalazine exactly as directed by your doctor. Do not use more of it or less of it or use it more often or less often than directed.

If you are using Sulfasalazine for bile acid diarrhoea, follow your doctor's instructions for taking the medication.

Take Sulfasalazine with a meal or with food. Swallow it whole. Do not break, crush, dissolve, or divide it.

Use it as soon as possible. Sulfasalazine may take up to 4 weeks to work.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5649is a drug that inhibits
 
Response: S5649is a drug that inhibits the lysyl oxidase (LOX) enzyme. Lysyl oxidase is an enzyme that catalyzes the formation of the cross-linking enzyme, LOX, and is important in collagen cross-linking. One such reaction is the formation of the lysine-derived cross-link, hydroxylysine. S5649is also a specific inhibitor of the inducible nitric oxide synthase (iNOS) enzyme, and thus, is a nitric oxide synthase (NOS) inhibitor. Nitric oxide is a reactive molecule that is synthesized from L-arginine by the enzyme nitric oxide synthase. Inhibition of nitric oxide synthase has been shown to decrease infarct size and improve left ventricular function in the setting of myocardial infarction (Lombardi et al., 1998, Circulation, 97:2824-2832).
The in vivo activity
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5650is a drug that inhibits
 
Response: S5650is a drug that inhibits the Wnt signaling pathway and suppresses tumor growth in colon cancer cells.[@b37-ott-11-5943] This finding supports our finding that TGF-β1 is a mediator of the TGF-β1/miR-155/AEG-1 axis.

Our study had several limitations. First, the exact mechanism of the TGF-β1/miR-155/AEG-1 axis in CRC remains to be further studied. Second, we did not include a matched normal tissue control group to compare the TGF-β1 and miR-155 expression between the CRC tissues and matched normal tissues.

Conclusion
==========

In conclusion, our results demonstrate that TGF-β1 is a key mediator of the TGF-β1/miR-155/AEG-1 axis in CRC, which promotes tumor progression. This novel finding provides a novel therapeutic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5651is a drug that inhibits
 
Response: S5651is a drug that inhibits the formation of new memory. It is an irreversible inhibitor of GSK3β and is reported to be active in Alzheimer's disease (AD) \[[@B17-pharmaceuticals-10-00093]\]. S9129is an analog of S5651 and also inhibits the formation of new memory \[[@B18-pharmaceuticals-10-00093]\]. LY2090314 is a GSK3β inhibitor with a reported IC~50~ of 2.8 μM and is active in the *Aplysia* memory formation assay \[[@B19-pharmaceuticals-10-00093]\]. The positive control, TDZD-8, is a specific and reversible GSK3β inhibitor and is active in the *Aplysia* memory formation assay \[[@B19-pharmaceuticals-10-00093]\].
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5652is a drug that inhibits
 
Response: S5652is a drug that inhibits the production of the growth factor TGF-beta and also inhibits the formation of bone. It is used in the treatment of primary pulmonary hypertension, diffuse scleroderma and osteogenesis imperfecta.

####  **Effects**

• Reduces thickness of pulmonary arteries, veins and capillaries.

• Reduces the formation of fibrous connective tissue.

• Reduces production of collagen, fibrin, and fibronectin.

• Reduces vascular smooth muscle proliferation.

• Reduces serum levels of TGF-beta.

• Decreases the number of circulating fibrocytes.

• Reduces fibroblast proliferation and migration.

• Reduces the size of blebs on injured lung tissue.

• Reduces the expression of profibrotic genes.

####   **Pulmonary Hypertension**

**Oral
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5653is a drug that inhibits
 
Response: S5653is a drug that inhibits the production of thrombin, an enzyme that is produced by the liver, platelets, and endothelial cells, which can cause a blood clot to form. It is used to prevent blood clots from forming after hip or knee replacement surgery.

S5653is used to treat severe pain after total hip replacement surgery, or to prevent pain after total knee replacement surgery.

S5653is used to treat people with moderate to severe pain after knee replacement surgery.

S5653is used to prevent pain after hip or knee replacement surgery.

S5653is used to treat pain after total knee replacement surgery.

S5653is used to treat people with moderate to severe pain after hip or knee replacement surgery.

S5653is used to treat pain after total knee replacement surgery.

S5653is used to treat pain after total knee replacement surgery.

S5653is used to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5654is a drug that inhibits
 
Response: S5654is a drug that inhibits BCR-ABL and other tyrosine kinases, and is approved for use in CML patients who have developed resistance to TKIs.^[@bib25]^ A Phase I/II study with S64315 is ongoing in patients with CML who have developed resistance to TKIs.^[@bib26]^ A Phase I study with AZD 5363 (a highly selective dual inhibitor of BCR-ABL and FLT3) has been completed.^[@bib27]^

CONCLUSIONS
===========

The first-in-class TKI, imatinib, has revolutionized the treatment of CML and is highly effective against all CML cell lines and primary patient samples. Despite the success of imatinib, the majority of patients will eventually relapse and, for most, the time to relapse will be within 5 years.^[@bib1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5655is a drug that inhibits
 
Response: S5655is a drug that inhibits Src family kinases and which has been shown to be effective in reducing tumour growth in several animal models. In this study, the antitumour activity of S5655 was assessed in combination with three different anticancer drugs in human tumour xenograft models. Combinations of S5655 with the DNA topoisomerase I inhibitor irinotecan, the proteasome inhibitor bortezomib or the epidermal growth factor receptor inhibitor gefitinib were evaluated in human cancer cell lines and in xenograft models. The combination of S5655 with irinotecan, bortezomib or gefitinib showed additive or synergistic antitumour activity in human tumour xenograft models. In vitro studies showed that S5655 could sensitize tumour cells to gefitinib or bortezomib, whereas S5655 and irinotec
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5657is a drug that inhibits
 
Response: S5657is a drug that inhibits the growth of cancer cells. However, a phase II clinical trial conducted by the National Cancer Institute of the National Institutes of Health (USA) found that this drug, which has also been tested in combination with the protease inhibitor nelfinavir, does not significantly improve the outcome of patients with previously untreated HIV-associated Kaposi's sarcoma. However, a retrospective analysis of the results of a small clinical trial conducted in Europe (published in the British Journal of Haematology) suggests that the drug may be useful in the treatment of patients with Kaposi's sarcoma and chronic kidney disease (a side effect of AIDS). The drug was first isolated from the bacterium Streptomyces caespitosus and was patented in 1986. The patent has now expired.

Mechanism of action

Vorinostat inhibits the activity of histone deacetylase enzymes (HDACs), which are important for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5659is a drug that inhibits
 
Response: S5659is a drug that inhibits the phosphorylation of AKT by PTEN, and induces apoptosis in breast cancer cells. This is one of the molecular mechanisms of the anti-cancer effect of P-S5659. P-S5659 suppresses tumor growth in a mouse xenograft model of breast cancer and inhibits tumor angiogenesis in a rat corneal angiogenesis model \[[@B12]\].

In this study, we evaluated the efficacy of P-S5659 in a human xenograft model of breast cancer using MDA-MB-231 cells. P-S5659 suppressed the growth of MDA-MB-231 xenografts in a dose-dependent manner. Furthermore, it suppressed the angiogenesis of the xenograft tumors.

The major mechanism of anti-tumor action of P-S5659 is its anti-angiogenic activity. In our previous study, we
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5660is a drug that inhibits
 
Response: S5660is a drug that inhibits the replication of DNA in the nuclei of human cells, preventing the formation of new cells and reducing the number of cells that are already formed. It can be administered orally or by injection. It can be used to treat patients with the cancer known as acute myeloid leukaemia (AML). The drug has been used for this purpose in adults and children. It is used as a consolidation therapy in the induction and consolidation phases of treatment for children and adults with AML.

Indication

S-phase-specific agents (SSA)

Indication for the use of SSA in acute myeloid leukaemia

A list of indications for the use of SSA in acute myeloid leukaemia (AML) is provided below:

The use of SSA as a consolidation therapy in the induction and consolidation phases of treatment for children and adults with AML.

The use of S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5661is a drug that inhibits
 
Response: S5661is a drug that inhibits the activity of the ribosomal protein S6 kinase-1 (S6K1) which in turn inhibits the activation of mTORC1. The drug inhibits mTORC1 through the binding of its catalytic domain to the TORC1 subunit Raptor ([@bib10]).

There are currently no published preclinical studies on the effect of S5661 on glioma growth. The purpose of this study was to evaluate the effect of S5661 on the proliferation of the human glioma cell line U87MG. The results of the current study show that S5661 decreased cell proliferation in a dose-dependent manner. S5661 also inhibited U87MG cell growth when the cells were seeded at a low density (2 × 10^4^ cells/well). The results of the present study suggest that S5661 may have the potential to inhibit the growth of glioma cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5662is a drug that inhibits
 
Response: S5662is a drug that inhibits HIV-1 replication by interfering with the binding of the viral reverse transcriptase to its primer. It is used as an antiviral agent in the treatment of HIV-1 infection and as an antiretroviral in post-exposure prophylaxis for individuals exposed to HIV-1. S566 is a nucleoside analog reverse transcriptase inhibitor (NRTI) that has an oxetanocin ring system. It is a very potent and selective inhibitor of HIV-1 reverse transcriptase, with an IC50 of 5 nM. The effect of S566 on HIV-1 reverse transcriptase is reversible.

S566 binds in the nucleoside binding site of the enzyme. It has an excellent selectivity index for HIV-1 compared to human DNA polymerase, which has an IC50 of 1.6 μM.

References

Category:Nucleosides
Category:Ox
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5663is a drug that inhibits
 
Response: S5663is a drug that inhibits the nuclear export of tau protein from the nucleus. It was developed to treat neurodegenerative diseases that are caused by tau protein, but it has not been approved for use in the United States. S56633 inhibits the activity of RANBP2, a protein that is important for nuclear export of tau protein, and prevents the transport of tau protein from the nucleus to the cytoplasm. As a result, the amount of tau protein in the cytoplasm decreases, and the amount of tau protein in the brain decreases.

S56633 is in a phase II clinical trial for the treatment of AD.

See also
 Rinderpest

References

Category:Experimental drugs
Category:Antineoplastics
Category:Hepatotoxins
Category:Pyrazoles
Category:Ethers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5664is a drug that inhibits
 
Response: S5664is a drug that inhibits Hsp90, a protein that stabilizes mutant BCR-ABL in chronic myeloid leukemia (CML). This agent has shown promising results in early clinical trials. This study was conducted to assess the efficacy and safety of the combination of S-1 plus the Hsp90 inhibitor 17-AAG. A total of 36 patients with CML in chronic phase or accelerated phase received S-1 plus 17-AAG in a phase I/II trial. The primary endpoint was the rate of complete hematologic response. The secondary endpoints were the rate of complete cytogenetic response, the rate of molecular response, and the incidence of adverse events. The complete hematologic response was observed in 20 of 36 patients (55.6%), and the complete cytogenetic response was observed in 23 of 36 patients (63.9%). The major molecular response (MMR) was achieved in 11 of 31 patients (35.5%)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5667is a drug that inhibits
 
Response: S5667is a drug that inhibits the NF-κB signaling pathway and may be effective for the treatment of arthritis. This is supported by the fact that pharmacological inhibition of the NF-κB signaling pathway has been shown to ameliorate CIA in a mouse model of RA.^[@bib35]^ However, the role of the NF-κB signaling pathway in the pathogenesis of arthritis has been extensively studied in the last two decades. However, the molecular mechanisms underlying the role of the NF-κB signaling pathway in the pathogenesis of arthritis are still not fully understood. Therefore, more detailed studies are needed to fully understand the role of the NF-κB signaling pathway in the pathogenesis of arthritis.

The NF-κB signaling pathway is activated by various stimuli, including LPS, IL-1, TNF-α, and bacterial DNA. The transcription factor NF-κB is composed of five members: p65 (RelA
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5680is a drug that inhibits
 
Response: S5680is a drug that inhibits NF-κB signaling and is currently being tested in a phase I clinical trial.^[@bib37]^

We thank Michael Farber and Mark Wolff for providing antibodies. We also thank Jane Bancroft for excellent technical assistance. This work was supported by the National Cancer Institute grant CA82275 and a pilot grant from the Dana-Farber/Harvard Cancer Center (JCS), the US National Institutes of Health (JCS and YW), the Canadian Institute of Health Research (YW), the American Lebanese Syrian Associated Charities (YW), the Mathers Foundation (YW), and the American Cancer Society (YW).

The authors declare no conflict of interest.

![NF-κB activity is suppressed by co-culture with macrophages. (**a**) Co-culture of LPS-stimulated J774A.1 cells with primary macroph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5700is a drug that inhibits
 
Response: S5700is a drug that inhibits an enzyme called Caspase 3. This enzyme is the main player in the process of cell death or apoptosis. Without it, cells don’t die when they should. It is therefore very important to have it at a healthy level in the body. It is a natural, safe way to treat conditions such as cancer. The best part of this enzyme is that it is present in every single cell of our body.

S5700 works in a way similar to that of a drug called Tamoxifen. Tamoxifen has been used to treat breast cancer for decades. It is a very safe and natural way to treat cancer. This drug was found to have many side effects. S5700 is very similar to Tamoxifen and therefore, has very few side effects.

S5700 is also very effective. It is used to treat many different types of cancer including colon cancer, lung cancer, prostate cancer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5701is a drug that inhibits
 
Response: S5701is a drug that inhibits an enzyme called N-acetyl-β-D-glucosaminidase (NAGase). NAGase removes a sugar chain from glycoproteins, and, when it is inhibited, the sugar chain cannot be removed from the protein. S5701is therefore useful for preventing or treating diseases where a sugar chain is involved. For example, NAGase is involved in a sugar chain-dependent binding of glycoproteins to their receptors. Inhibiting NAGase can inhibit the binding of glycoproteins to their receptors, thereby preventing diseases that are dependent on the sugar chain-dependent binding.
NAGase has a complex structure. S5701 is a derivative of an iminosugar. Since the iminosugar does not have a sugar chain, it cannot be incorporated into a protein as a sugar chain. Accordingly, S5701 is very different from an iminosugar that is incorporated into a protein
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5702is a drug that inhibits
 
Response: S5702is a drug that inhibits the activity of the acetylcholinesterase (AChE) enzyme, which is involved in the transmission of signals between nerves and muscles. In the nervous system, the acetylcholine released at the end of the signal transmission is hydrolyzed by AChE to acetate and choline. This process is known as cholinergic transmission. The pharmacological effect of this inhibition is the activation of the muscarinic receptors, which are widely distributed in the body, especially in the central nervous system, and are responsible for the regulation of the movement of the muscle. The effect of S5702 is characterized by the fact that it increases the speed of the acetylcholine hydrolysis, which in turn leads to the increase of the speed of the transmission of the signal from the nerve to the muscle. The administration of S5702 in therapeutic doses has a well-known and beneficial effect on the central nervous system, but
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5703is a drug that inhibits
 
Response: S5703is a drug that inhibits TNF-α, a cytokine that plays a key role in the pathogenesis of inflammation and cancer. In animal models, S5703 treatment has been shown to reduce fibrosis, inflammation, and tumor growth in the lungs and livers of mice with acute and chronic inflammation, as well as in mouse models of lung cancer.

We report here the first human study to investigate the effects of S5703 in the treatment of CVD.

Methods

We randomized and treated 45 patients with mild to moderate symptomatic heart failure (HF) with S5703 (n = 22) or placebo (n = 23) in a double-blind fashion. Patients were followed for 12 weeks. Primary endpoints were changes in the following parameters: body weight, serum creatinine, and B-type natriuretic peptide (BNP) level. Secondary endpoints included: changes in the following parameters: 6-minute walk
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5705is a drug that inhibits
 
Response: S5705is a drug that inhibits protein kinase C (PKC) and has been found to be active against melanoma. In the present study, we investigated the role of S5705 in melanoma cell growth and cell death. We found that S5705 inhibited the growth of melanoma cells, in a time- and dose-dependent manner, and induced cell cycle arrest and apoptosis. We found that S5705 upregulated p21 and p27, and downregulated cyclin B1, cyclin D1, and Cdc2, which resulted in the inhibition of G2/M phase transition. S5705 also induced the activation of caspase-9 and caspase-3, and the release of cytochrome c, which led to the activation of caspase-3 and caspase-9. In addition, S5705 induced the activation of Akt, extracellular signal-regulated kinase 1/2 (ER
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5706is a drug that inhibits
 
Response: S5706is a drug that inhibits the LRRK2 protein (a kinase) and is a promising compound for the treatment of PD. This drug has also been shown to be neuroprotective in a rat model of PD. LRRK2, like SNCA, is a member of the protein kinase superfamily. In the context of PD, however, the evidence is stronger that the protein kinase activity of LRRK2 is not required for the disease.

The term "pathogenic" mutation refers to a mutation that causes disease. The vast majority of mutations that cause disease in humans do not cause a change in protein sequence, but rather a change in the expression, structure, or function of the protein. The disease caused by these mutations can be inherited or acquired.

The main focus of this chapter is on inherited mutations in genes encoding proteins that are directly involved in the pathogenesis of PD. A number of other genes have been implicated in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5709is a drug that inhibits
 
Response: S5709is a drug that inhibits a number of kinases. The most potent and selective inhibitor of PI3Kβ is the PI3Kβ inhibitor GSK2126458. In cell-based assays, GSK2126458 inhibits cell proliferation and induces apoptosis in the presence of growth factors, and inhibits tumour growth in vivo \[[@CR106]\]. Inhibition of PI3Kδ causes activation of apoptosis, cell cycle arrest, and a block in the G1/S transition \[[@CR107]\]. Inhibition of PI3Kδ leads to growth arrest and apoptosis in T-cell acute lymphoblastic leukaemia cells, and synergizes with histone deacetylase inhibitors to cause cell death \[[@CR108]\].

Biosensors {#Sec17}
----------

The integration of biosensors into microfluidic systems has been an area of great interest
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5710is a drug that inhibits
 
Response: S5710is a drug that inhibits, to varying degrees, the action of calcitonin.

The following studies, and the findings of others, have been presented in this report. These studies and findings are included to illustrate the many varied pathophysiological processes that are present in the osteoporotic patient. The findings of these studies may lead to the development of a new therapeutic agent.

2.3. Bibliographic Search {#sec2.3}
-------------------------

The following studies were included in this report: *Alendronate (fosamax) for the Treatment of Postmenopausal Osteoporosis*. PTH, Womens Health and Aging Study Group, (WHASG), June 2004. The authors of this paper discuss the evidence supporting the use of alendronate in the treatment of postmenopausal osteoporosis. They also review the results of studies that have been conducted with other bisphosph
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5712is a drug that inhibits
 
Response: S5712is a drug that inhibits the binding of certain viruses to cells, and is currently in phase 2 clinical trials. It has a relatively broad antiviral spectrum, and shows activity against HIV-1, RSV, and human herpes virus (HHV)-6. Its anti-HSV activity is thought to be related to its inhibition of the glycoprotein D (gD)-mediated fusion of viral and host membranes.

##### Mechanism of Action

Binds to the C-terminal fusion loop of the envelope glycoprotein, gp41. Inhibits the fusion of viral and cellular membranes, and reduces the infectivity of virions.

#####  Pharmocokinetics

Widely distributed in tissues. Steady-state plasma levels achieved in 2–4 weeks.

#####  Side Effects

None known.

#####  Adverse Effects

In the phase 1 trials, nausea, vomiting, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5714is a drug that inhibits
 
Response: S5714is a drug that inhibits tumor growth and metastasis in patients with glioblastoma. In addition, it is not only effective in patients with malignant glioma but also shows a good safety profile.^\[[@R15]\]^ However, the efficacy of S5714 for the treatment of patients with high-grade glioma remains unclear. Therefore, the efficacy and safety of S5714 for the treatment of patients with high-grade glioma were evaluated in the present study.

Patients with high-grade glioma who had undergone previous surgery and radiation therapy were included in this study. All patients received oral S5714 at a dose of 1 mg/kg per day for 28 days. S5714 was well tolerated in all patients, and no severe adverse events were observed. The primary endpoint was the objective response rate, and the secondary endpoints were the progression-free survival, overall survival, and adverse
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5716is a drug that inhibits
 
Response: S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-dependent K+-channels opener.

S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-dependent K+-channels opener.

S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-dependent K+-channels opener.

S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-dependent K+-channels opener.

S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-dependent K+-channels opener.

S5716is a drug that inhibits the mitochondrial permeability transition pore (mPTP) and is an ATP-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5717is a drug that inhibits
 
Response: S5717is a drug that inhibits the fusion of the viral envelope and cell membrane of the virus, which can not only prevent the virus from entering the cells, but also prevent the release of the virus from the infected cells, so as to prevent the virus from spreading. However, the antiviral effect of S5717is poor, and S5717is also found to be associated with many side effects, which are harmful to the body.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5724is a drug that inhibits
 
Response: S5724is a drug that inhibits the activity of SREBPs, and hence reduces the biosynthesis of cholesterol. The first report of a statin was published in 1984. The term statin refers to a family of compounds that all inhibit the rate-limiting step in cholesterol biosynthesis, HMG-CoA reductase, the enzyme responsible for catalyzing the conversion of HMG-CoA to mevalonate. Statins are generally well-tolerated, although some side effects have been observed, including: myopathy, myositis, rhabdomyolysis, cognitive impairment, myalgia, weakness, gastrointestinal disturbances, transaminitis, and an increased risk of diabetes. The introduction of statins into the market has revolutionized the treatment of atherosclerotic disease. The use of statins is associated with a dramatic reduction in cardiovascular morbidity and mortality. Statins are recommended as the first-line therapy for primary and secondary prevention of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5728is a drug that inhibits
 
Response: S5728is a drug that inhibits growth of T cell lines by blocking the signal transduction induced by TCR engagement. The effects of the drug on the response of T cells to various stimuli were studied in the presence of various concentrations of the drug. S5728 was found to inhibit the response of human T cells to PHA, anti-CD3 mAb, anti-CD2 mAb, alloantigens, and the cytokines IL-2, IL-3, and IL-4. S5728 also inhibited the proliferative response of human thymocytes to a single round of stimulation with PHA, and to a single round of stimulation with the cytokines IL-2, IL-3, and IL-4. The effects of S5728 on T cell function were reversible and did not appear to involve inhibition of IL-2 receptor expression. The data suggest that S5728 is a novel T cell inhibitor with potential clinical application.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5729is a drug that inhibits
 
Response: S5729is a drug that inhibits the enzymes responsible for breaking down the neurotransmitter dopamine. It is used to treat schizophrenia and other mental disorders.

Dopamine is the neurotransmitter that controls motivation, pleasure, sleep, and the movement of your body. It is also involved in the brain's reward system, which is why it is also known as the 'pleasure chemical'. Dopamine is made in the body and some of it can be found in the brain. It is broken down in the body by the enzyme catechol-O-methyl transferase (COMT).

COMT is a genetic factor that affects how much dopamine is broken down in the body. The COMT gene is also known as the Val158Met gene.

Scientists have known for a long time that people with one particular form of the gene (the Val allele) have a higher concentration of dopamine in the brain than people with the other form of the gene (the Met allele
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5730is a drug that inhibits
 
Response: S5730is a drug that inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by phosphodiesterases (PDEs). It was shown to be useful in the treatment of chronic and neuropathic pain in a Phase II study (European J. Pain 11 (2005) 625).
S5730 is the racemic mixture of the R(−) and S(+) enantiomers, which is the active principle of the marketed drug. The (+) enantiomer, as its dihydrochloride salt, is currently marketed in France under the name Rolapitant as a drug for the prevention of chemotherapy-induced nausea and vomiting.

The compound has been described in EP 2 062 817 and in US 2009/0292431.
WO 2010/122633 and WO 2010/136597 describe the synthesis of S5730 from compound (I) and the pharmacological properties of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5732is a drug that inhibits
 
Response: S5732is a drug that inhibits the activity of inosine monophosphate dehydrogenase, the rate-limiting enzyme in the de novo pathway of purine biosynthesis, which is responsible for the conversion of inosine monophosphate to xanthosine monophosphate. Xanthosine monophosphate is converted to xanthosine triphosphate by the enzyme xanthosine triphosphate synthetase. Xanthosine triphosphate is the co-factor for the enzyme guanosine triphosphate cyclohydrolase I. Cyclohydrolase I catalyzes the conversion of guanosine triphosphate to guanine triphosphate. The resulting guanine triphosphate is then converted to guanine diphosphate by guanine triphosphatase. Guanine diphosphate is a co-factor for guanine nucleotide
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S5733is a drug that inhibits
 
Response: S5733is a drug that inhibits the formation of superoxide anion radicals. This drug is a powerful antioxidant that helps in protecting cells from oxidative stress. It is useful in treating people with cataracts and age-related macular degeneration. It is available in generic form as S5733.

S5733is a drug that inhibits the formation of superoxide anion radicals. This drug is a powerful antioxidant that helps in protecting cells from oxidative stress. It is useful in treating people with cataracts and age-related macular degeneration. It is available in generic form as S5733.

S5733is a drug that inhibits the formation of superoxide anion radicals. This drug is a powerful antioxidant that helps in protecting cells from oxidative stress. It is useful in treating people with cataracts and age-related macular degeneration. It is available in generic form as S5733.

S5733is a drug that inhibits
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S7668-Picropodophyllinis a drug that inhibits
 
Response: S7668-Picropodophyllinis a drug that inhibits calcium-dependent phospholipase A2 and causes apoptosis in a cell line derived from human hepatoma.
S7668-Picropodophyllinis, a cyclic lipopeptide, was found to inhibit the calcium-dependent phospholipase A2 in the crude extracts of Streptomyces alboflavus S7668, which was isolated from soil collected in the vicinity of Urawa City, Saitama Prefecture, Japan. The cyclic lipopeptide inhibited the calcium-dependent phospholipase A2 activity of porcine pancreatic phospholipase A2 and also that of the bacterial phospholipase A2, Vibrio fischeri phospholipase A2. The IC50 values of S7668-Picropodophyllinis for the pancreatic phospholipase A2 and the V. fischer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S8275-eFT-508is a drug that inhibits
 
Response: S8275-eFT-508is a drug that inhibits the growth of estrogen receptor positive breast cancer cells, specifically, estrogen receptor positive breast cancer cells that are resistant to tamoxifen, which is an anti-estrogen.S8275-eFT-508is a drug that inhibits the growth of estrogen receptor positive breast cancer cells, specifically, estrogen receptor positive breast cancer cells that are resistant to tamoxifen, which is an anti-estrogen.

S8275-eFT-508is a drug that inhibits the growth of estrogen receptor positive breast cancer cells, specifically, estrogen receptor positive breast cancer cells that are resistant to tamoxifen, which is an anti-estrogen.

S8275-eFT-508is a drug that inhibits the growth of estrogen receptor positive breast cancer cells, specifically, estrogen receptor positive breast cancer cells that are resistant to tamoxifen, which is an anti-estrogen.

S8
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9001is a drug that inhibits
 
Response: S9001is a drug that inhibits HIV-1 reverse transcriptase and can be incorporated into HIV-1-based vectors. The effect of S9001 on HIV-1-based vectors has not been evaluated. The impact of S9001 on transduction was evaluated in a stably integrated human HeLa-based reporter cell line (HeLa-tet-puro) with a single copy of the integrated transgene. The ability of S9001 to affect the transduction of lentiviral vectors encoding the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, and to induce an antiviral response was also assessed. The half-maximal effective concentration (EC50) for S9001 was 0.9 µM. S9001 treatment had no effect on the transduction of a control vector expressing green fluorescent protein (GFP) at concentrations up to 5 µM. S9001 did not affect the transduction
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9002is a drug that inhibits
 
Response: S9002is a drug that inhibits RAS and RAF signaling and can be used in combination with RAF inhibitors. We have examined the anti-tumor efficacy of S-1 combined with RAF inhibitors (vemurafenib and dabrafenib) and/or MEK inhibitors (trametinib) in a panel of cancer cell lines. S-1 was found to enhance the growth-inhibitory activity of vemurafenib and dabrafenib, and S-1 also enhanced the growth-inhibitory activity of trametinib. The combination of S-1 with vemurafenib or dabrafenib induced apoptosis, which was associated with increased levels of cleaved caspase-3 and caspase-9. Our data suggest that the combination of S-1 with RAF inhibitors or MEK inhibitors may be a novel therapeutic strategy for patients with BRAFV600E-mutant melanoma.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9003is a drug that inhibits
 
Response: S9003is a drug that inhibits the formation of nucleotides and amino acids. When it enters the liver, it blocks a key enzyme in the synthesis of proteins. In this way, it causes a protein deficiency. The liver and kidneys are especially sensitive to protein deficiency, because they are the only organs in the body that can make new proteins.

The other major cause of death from malnutrition is infectious diseases. When a person has a protein deficiency, the body's immune system is weakened, making the person more susceptible to infections.

Lacking a Protein Supply

When a person has a severe protein deficiency, the skin, bones, and muscles can begin to break down. This is called rickets.

As rickets develops, the bones become thin and brittle. Eventually, the bones break, causing a condition called osteomalacia. This can be fatal.

A lack of protein can also weaken the immune system. Without enough protein to make antibodies, the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9007is a drug that inhibits
 
Response: S9007is a drug that inhibits the movement of calcium into cells. As a result, blood flow is blocked and the heart muscle is unable to function. Because of this, a S9007is can cause heart failure, even if the person has no heart disease. In some cases, a S9007is can even lead to death.

Dilatation of the Intestine: In some people, a S9007is can cause a disorder called “dilated colon.” This is when the intestine gets too big. This can happen if a person takes too much S9007is, or if a person has the wrong type of colon.

Breathing Problems: A S9007is can cause breathing problems in some people. This is because the medicine can block air flow in the lungs. This can make breathing difficult.

Anemia: Some people taking a S9007is may get anemia. This is because the medicine can
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9015is a drug that inhibits
 
Response: S9015is a drug that inhibits myocardial inotropy and lusitropy, and can be used to treat congestive heart failure, cardiac arrhythmia and hypertension \[[@b1-medscimonit-26-e922918]\]. S9015 is a non-competitive antagonist of α-1 adrenergic receptor (α1-AR) \[[@b2-medscimonit-26-e922918]\], and its chemical formula is 4-\[(2-ethoxy-4-methoxyphenyl)methyl\]-2-\[4-(2-hydroxy-2-phenylethyl)piperazin-1-yl\]pyrimidin-5-amine. S9015 is a synthetic non-peptide compound with a low molecular weight, good water solubility and oral bioavailability \[[@b3-medscimon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9019is a drug that inhibits
 
Response: S9019is a drug that inhibits the DNA binding activity of the NF-kappaB family of transcription factors, and thereby inhibits the transcription of genes involved in the immune response, the inflammatory response, and the acute phase response.S9019is a drug that inhibits the DNA binding activity of the NF-kappaB family of transcription factors, and thereby inhibits the transcription of genes involved in the immune response, the inflammatory response, and the acute phase response.S9019is a drug that inhibits the DNA binding activity of the NF-kappaB family of transcription factors, and thereby inhibits the transcription of genes involved in the immune response, the inflammatory response, and the acute phase response.S9019is a drug that inhibits the DNA binding activity of the NF-kappaB family of transcription factors, and thereby inhibits the transcription of genes involved in the immune response, the inflammatory response, and the acute phase response.S9019is a drug that inhibits the DNA binding activity
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9024is a drug that inhibits
 
Response: S9024is a drug that inhibits HIV-1 replication in human primary cells. S9024 has a chemical structure of (2S,4S)-2-amino-1,3,3-trimethyl-4-methylene-1,2,3,4-tetrahydro-2H-3-benzazepin-4-ol and is under development by Gilead Sciences, Inc. as an HIV therapeutic. S9024 is a specific inhibitor of HIV-1 reverse transcriptase (RT) that exhibits a high affinity for the active site of RT and has been shown to inhibit HIV-1 replication in vitro. S9024 was shown to have potent activity against HIV-1 isolates in vitro with a median effective concentration (EC50) of 0.7 nM, a median cytotoxic concentration (CC50) of 21 μM and a therapeutic index of 25.8.

References 


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9028is a drug that inhibits
 
Response: S9028is a drug that inhibits the metabolic conversion of glucocorticoids to inactive metabolites. This agent can be administered intravenously, intramuscularly, or orally. It is generally well tolerated, with the most common side effects being gastrointestinal upset and the risk of developing hepatic dysfunction. However, S9028 has a potential for hepatotoxicity, including the development of fulminant hepatic failure. Thus, clinicians must be aware of the potential risk for hepatotoxicity in patients receiving this drug. S9028 has been shown to be effective in the treatment of SLE, especially in patients who have had inadequate responses to corticosteroids. The efficacy and safety of S9028 in the treatment of SLE has been demonstrated in multiple clinical trials.

Medications such as S9028, which block the action of 11β-hydroxysteroid dehydrogenase (11β-HSD) type 2, are now being considered for the treatment
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9032is a drug that inhibits
 
Response: S9032is a drug that inhibits the action of the b-adrenergic receptor.  It is a selective β-adrenergic receptor antagonist that also blocks histamine H1 receptors. It has an affinity for the α1-adrenergic receptor of 4 nM, the α2-adrenergic receptor of 20 nM, and the β1-adrenergic receptor of 300 nM. It is also an agonist of the α1D-adrenergic receptor with an affinity of 1.4 nM and an antagonist of the α1B-adrenergic receptor with an affinity of 27 nM. It has no significant activity at the α1A-adrenergic receptor.

S9032 was developed by GlaxoSmithKline as a potential treatment for benign prostatic hyperplasia.

References

Category:Amines
Category:Aromatic amines
Category:Beta blockers
Category:Drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9042is a drug that inhibits
 
Response: S9042is a drug that inhibits the release of neurotransmitters and inhibits the activity of adenylate cyclase. It is used for the treatment of stress urinary incontinence and overactive bladder, and has also been used for the treatment of various diseases such as hypertension, acute respiratory distress syndrome, ischemia, renal disease, and glaucoma.
Amorphous drug substances are often not suitable for manufacture by direct compression of the active substance into tablets, because of the poor flow properties of the active substance. As a result, a granulate is prepared by wet granulation, by which the active substance is dissolved or dispersed in a liquid binder solution and the solution or dispersion is sprayed onto a granulation core (WO 02/27132). However, this process is time-consuming and therefore expensive, and the active substance is not sufficiently distributed in the granulate.
A process for the production of an amorphous drug substance by spray
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9046is a drug that inhibits
 
Response: S9046is a drug that inhibits NF-κB activity and TNF-α release in human monocytes. In this study, we have examined the effect of S9046 on the expression of the inflammatory cytokines in the intestinal mucosa and the peripheral blood in Crohn's disease (CD). Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) characterized by severe inflammation in the intestinal tract. Although the pathogenesis of CD is not completely understood, it is thought to be the result of a dysregulated immune response against the luminal antigens of the gut. In particular, cytokines, such as TNF-α, IL-1β, IL-6 and IL-8, are believed to play a critical role in the pathogenesis of CD. In this study, we investigated the effect of S9046 on the expression of inflammatory cytokines in the intestinal mucosa and the peripheral blood in CD. S9046 is a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9050is a drug that inhibits
 
Response: S9050is a drug that inhibits the PDE4, one of the major phosphodiesterases in the body, specifically PDE4. It is an oral formulation that provides for once-daily dosing. S-9057is an investigational oral formulation of S-9052. S-9057is under development for the treatment of COPD. The Company expects to file for approval of S-9057 in 2019.

The primary goal of our research is to discover, develop and commercialize products that improve the health and quality of life of patients with COPD.

The Company is focused on developing treatments that address the need for new, better and safer therapies for COPD. The Company’s lead product candidate, NVS-101, is in clinical development for COPD and asthma. The Company has identified several other product candidates that may have an opportunity to treat COPD.

NVS-101 is a potent, selective, oral,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9053is a drug that inhibits
 
Response: S9053is a drug that inhibits PKC and also promotes cell survival. However, if PKC is inhibited in the early phase of apoptosis, the survival of tumor cells is reduced. We investigated the effects of R9053 on tumor cells undergoing early apoptosis. The results showed that R9053 reduced the early apoptotic rate in breast cancer cells. In addition, the pro-apoptotic effects of R9053 were found to be associated with inhibition of PKC. Our results suggest that R9053 may be useful for cancer treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9063is a drug that inhibits
 
Response: S9063is a drug that inhibits the synthesis of hyaluronic acid, which is the major component of the extracellular matrix. It was shown to be effective in a rat model of osteoarthritis \[[@CR51]\]. A decrease in the inflammatory response and in the levels of pro-inflammatory cytokines was also observed in a mouse model of LPS-induced inflammatory arthritis \[[@CR52]\]. The beneficial effect of S9063 in a mouse model of DSS-induced colitis was observed, and it was attributed to a decrease in the expression of pro-inflammatory cytokines and of COX-2 \[[@CR53]\]. The beneficial effect of S9063 in a rat model of type 1 diabetes was attributed to its anti-inflammatory effect \[[@CR54]\]. It was also shown to improve liver damage and fibrosis in a mouse model of chronic hepatitis C infection \[[@CR55
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9086is a drug that inhibits
 
Response: S9086is a drug that inhibits GSK3, a kinase that plays a key role in many pathways involved in cellular growth and survival. Recently, GSK3 inhibitors have been used to treat a variety of conditions including diabetes, epilepsy, cancer, and neurodegenerative disorders. GSK3 inhibitors are also being investigated as a new class of antipsychotic drugs. (Proc. Natl. Acad. Sci. USA (2005) 102:1102-1107; Nat. Rev. Drug Discov. (2005) 4:344-357). The S9086 compound is currently being developed by Schering-Plough Corporation as an antipsychotic drug candidate.
GSK3 has been shown to be a negative regulator of Wnt signaling. It inhibits the function of the β-catenin/T-cell factor (TCF) complex, which is required for activation of Wnt target genes (D. D. Miller, J
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9102is a drug that inhibits
 
Response: S9102is a drug that inhibits the interaction of the serine/threonine kinase Akt with phosphoinositide-3-kinase. The S9102-induced activation of caspase-3 and PARP was attenuated by the pretreatment of cells with the pan-caspase inhibitor z-VAD-fmk, but not by the caspase-2-selective inhibitor z-VDVAD-fmk. In contrast, z-VAD-fmk failed to block the S9102-induced activation of caspase-3 and PARP. The pretreatment of cells with z-VAD-fmk did not affect the S9102-induced activation of caspase-9. In addition, S9102 induced an increase in the generation of ROS. The increase in ROS was attenuated by pretreatment with the antioxidant N-acetyl-L-cysteine (NAC), but not
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9110is a drug that inhibits
 
Response: S9110is a drug that inhibits cell division by disrupting the microtubule cytoskeleton. It is currently in Phase III clinical trials for the treatment of malignant melanoma and breast cancer. To better understand the mechanism of action of S9110 and other tubulin-binding agents, we used a high-throughput, cell-based assay to identify the compounds that preferentially disrupt microtubules. We then used this assay to identify tubulin-binding agents that bind to specific microtubule binding sites. Finally, we used the 3D microtubule-stabilizing assay to show that S9110 inhibits microtubule growth and stability.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9111is a drug that inhibits
 
Response: S9111is a drug that inhibits macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine that is a key regulator of the innate immune response, and therefore is thought to play a role in inflammatory diseases, autoimmune diseases, and infectious diseases. MIF is a cytokine that is expressed by macrophages and other cells. It has a central role in regulating innate immunity. MIF regulates the migration of macrophages, the activation of macrophages and other cells, the adhesion of monocytes to endothelial cells, and the activation of endothelial cells. The expression of MIF is induced by pro-inflammatory cytokines, such as interleukin (IL)-1 and tumor necrosis factor (TNF), and bacterial lipopolysaccharide (LPS). MIF is also an acute phase protein that is induced by IL-6. It has also been reported to be a key mediator of the inflammatory response in endotoxin-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9123is a drug that inhibits
 
Response: S9123is a drug that inhibits the mitotic kinesin Eg5. Eg5 is essential for the completion of the cell division process and, therefore, S9123 inhibits cancer cell growth and proliferation. In this study, we investigated the effect of S9123 on cell cycle distribution, cell apoptosis and gene expression profile in colon cancer cells. We also studied the effect of S9123 on the formation of xenograft tumors in nude mice. The cell cycle was analyzed by flow cytometry. The effect of S9123 on apoptosis was analyzed by flow cytometry. The expression profile of genes related to cell cycle and apoptosis was analyzed by quantitative real-time PCR. In vitro and in vivo assays showed that S9123 significantly inhibited the growth of HCT116 cells in a dose-dependent manner. S9123 also induced apoptosis in HCT116 cells. Microarray analysis showed that S9123 modulated the expression of a number of genes involved in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9140is a drug that inhibits
 
Response: S9140is a drug that inhibits the activation of neutrophils and monocytes, reduces the release of oxygen radicals, and inhibits the chemotactic action of various mediators \[[@B15]\].

In addition to its anticoagulant and antiplatelet effects, it has been shown to inhibit the production of interleukin (IL)-8, granulocyte-macrophage colony-stimulating factor, IL-1*β*, tumor necrosis factor-*α*, and vascular endothelial growth factor \[[@B16]--[@B18]\].

It has been suggested that DAPT may be an alternative to warfarin for the treatment of acute VTE. DAPT has a good safety profile and is effective in preventing recurrent thromboembolic events \[[@B19]\]. DAPT has also been shown to reduce the risk of thrombotic events in patients with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9141is a drug that inhibits
 
Response: S9141is a drug that inhibits HIV-1 replication by targeting the viral protease. It was the first antiretroviral drug approved for treatment of HIV infection and was approved in 1995. At the time of approval, it was shown to be effective against HIV-1 strains of different genetic subtypes and had an excellent safety profile. Atazanavir, however, has not been successful in clinical trials as a salvage therapy for treatment-experienced patients, and other protease inhibitors have not shown significant activity against primary HIV-1 isolates from patients who have failed to respond to other protease inhibitors. The aim of this study was to determine the sensitivity of HIV-1 isolates to atazanavir in vitro. We compared the sensitivity of atazanavir to other protease inhibitors, including saquinavir, ritonavir, amprenavir, lopinavir, and nelfinavir, and to reverse transcriptase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9142is a drug that inhibits
 
Response: S9142is a drug that inhibits the replication of HIV.

This is not true. S9142is a drug that is being used to treat AIDS patients in combination with other drugs.

8. How does it work?

It works by inhibiting the reverse transcriptase enzyme, which is a key enzyme in the process of HIV reproduction. It works by inhibiting the ability of the enzyme to replicate and multiply the HIV virus.

The drug inhibits the enzyme by binding to the enzyme and inhibiting its ability to do its job. The HIV virus cannot multiply, and thus the virus cannot reproduce itself.

9. Is S9142 safe?

Yes. S9142 is safe to use in humans. The U.S. Food and Drug Administration has approved S9142 for the treatment of AIDS.

10. How is it different from other drugs?

It is different from other drugs in that it works in a different way
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9143is a drug that inhibits
 
Response: S9143is a drug that inhibits the mitotic spindle checkpoint and thus promotes the formation of multi-nucleated cells in the absence of DNA damage. This drug has been tested in phase II trials in patients with advanced non-small cell lung cancer (NSCLC) and in combination with platinum-based chemotherapy for advanced NSCLC. To evaluate the efficacy of S9143 in a phase II trial in patients with advanced NSCLC, we treated a total of 56 patients with S9143. The median progression-free survival was 2.4 months, and the median overall survival was 4.9 months. However, grade 3 or 4 adverse events were observed in 22% of patients. In conclusion, this study shows that S9143 was well tolerated, but had limited activity in patients with advanced NSCLC.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9171is a drug that inhibits
 
Response: S9171is a drug that inhibits Src and p130^cas^. In addition, we found that the suppression of Src activity, either by RNAi or by using the Src inhibitor PP2, did not induce senescence, indicating that Src kinase activity is not sufficient for the induction of senescence. We also tested the effect of inhibiting p130^cas^ on the induction of senescence. Cells were transfected with a plasmid expressing Cas-DN (DN-p130^cas^) and examined for the induction of senescence. As shown in [Fig. 3C](#f3-ijo-52-05-1455){ref-type="fig"}, the induction of senescence was markedly reduced in DN-p130^cas^ transfectants. These results suggest that p130^cas^ plays a critical role in the induction of senescence.

p130^cas
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9183is a drug that inhibits
 
Response: S9183is a drug that inhibits the phosphorylation of paxillin, a protein that is phosphorylated at tyrosine 31 and pY118 in cells undergoing migration. It also inhibits migration and invasion of prostate cancer cells in vitro, and reduces tumor growth and metastasis in vivo. Thus, S9183 may be a potential therapeutic agent for prostate cancer.

We thank Professor Tetsuya Kondo and Ms. Ayako Kobayashi for providing us with prostate cancer cell lines.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: YS MI. Performed the experiments: YS. Analyzed the data: YS MI. Contributed reagents/materials/analysis tools: YS. Wrote the paper: YS MI.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9192is a drug that inhibits
 
Response: S9192is a drug that inhibits HDAC activity by binding to the catalytic site. This compound is in clinical trials for the treatment of cancer, in particular, prostate cancer.

We tested the effects of S91221 in T cells from HLA-DR4-transgenic mice. S91221 is not toxic at concentrations that block HDAC activity in T cells ([@B17]).

We first measured the induction of T-cell activation markers CD25 and CD69. We found that S91221 inhibited T-cell activation in a dose-dependent manner ([Figure 2A](#F2){ref-type="fig"}). The inhibitory effect was seen in the early phase of T-cell activation, as measured by CD25 expression. We also observed that S91221 inhibited CD25 expression in primary human CD4^+^ T cells activated by anti-CD3/CD28 antibodies ([Figure 2B](#F2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9200is a drug that inhibits
 
Response: S9200is a drug that inhibits human 11β-HSD1 activity, thereby increasing plasma levels of active glucocorticoid. It is being developed by Endocyte Inc. as a potential treatment for diabetes and metabolic syndrome. In clinical trials, S9200 has been shown to increase active glucocorticoid levels, decrease plasma glucose, and reduce glycated hemoglobin (HbA1c) levels.

A number of experimental and clinical studies suggest that increased levels of active glucocorticoid may contribute to the development of insulin resistance, a precursor to type 2 diabetes. S9200 is a drug that inhibits human 11β-HSD1 activity, thereby increasing plasma levels of active glucocorticoid. It is being developed by Endocyte Inc. as a potential treatment for diabetes and metabolic syndrome.

S9200 has been shown to increase active glucocorticoid levels, decrease plasma glucose, and reduce glycated hemoglobin (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9212is a drug that inhibits
 
Response: S9212is a drug that inhibits the growth of leukemia and lymphoma cells by binding to and inactivating telomerase, a ribonucleoprotein enzyme that adds telomeric repeats to the ends of chromosomes and thereby prevents telomere shortening, which is essential for cellular proliferation. The development of S9212 was prompted by the finding that telomerase activity was detected in virtually all human cancer cells, but not in most normal somatic cells.
There is evidence that telomerase activity is involved in the development of various human cancers, including a high percentage of cancers of the lung, breast, colon, liver, ovary, pancreas, and skin. There is also evidence that telomerase is active in the hematopoietic system.
S9212 has been tested in several Phase I clinical trials. The results of these trials are summarized in: Boultinghouse et al., Blood, 98:1805-1812 (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9222is a drug that inhibits
 
Response: S9222is a drug that inhibits the processing of SARS-CoV-2 polyproteins by cleaving the polyprotein chain between the nonstructural protein 10 (Nsp10) and the main replicase polyprotein (pp1ab). SARS-CoV-2 uses the same SARS-CoV-2 main replicase as SARS-CoV and it has been reported that SARS-CoV-2 may share more than 99% sequence identity with SARS-CoV ([@R5]). Inhibition of this main replicase may reduce the replication of SARS-CoV-2.

Pharmacokinetic properties {#s3}
==========================

Pharmacokinetic studies in animals have shown that oral administration of S9222 results in the formation of S9222-trimethylated compound (S922TMC) and S922TMC-glucuronide
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9224is a drug that inhibits
 
Response: S9224is a drug that inhibits the function of a protein called NF-kappaB (NFKB), which is a nuclear transcription factor that plays a role in the regulation of genes that help the body to fight infection. This study showed that high doses of S9224 reduced NFKB activity and decreased the production of pro-inflammatory molecules called cytokines in the blood and tissues of people with Crohn’s disease. It also improved the function of the intestine, as well as the quality of life of people with the disease.

The researchers, led by Brian Ford, an associate professor of gastroenterology at Johns Hopkins University, analyzed blood samples from 24 people with Crohn’s disease who had been given placebo or high doses of S9224. They compared these with blood samples from 21 people with the disease who were taking infliximab, a treatment that works by blocking the action of a protein called tumor necrosis factor (TNF) on the immune
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9227is a drug that inhibits
 
Response: S9227is a drug that inhibits several genes related to DNA repair and induces apoptosis in cancer cells. S9227 is a synthetic molecule that was originally developed as an inhibitor of the DNA-dependent protein kinase, a kinase involved in DNA repair, by S. Imai and coworkers ([@b37-ijo-48-03-0933],[@b38-ijo-48-03-0933]).

The effects of S9227 on DNA repair have been investigated by *in vitro* studies using cell-free extracts and purified DNA-dependent protein kinase ([@b37-ijo-48-03-0933]). S9227 inhibits the repair of DNA breaks and it has been demonstrated that it inhibits the phosphorylation of the DNA-dependent protein kinase by targeting its regulatory subunit, thus resulting in the inhibition of the kinase ([@b37-ijo-48-03-0933],[@b38
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9240is a drug that inhibits
 
Response: S9240is a drug that inhibits cellular replication and induces differentiation. S9240 induced the terminal differentiation of the human leukemia cell line, HL-60, in a concentration-dependent manner. S9240 caused the degradation of the cyclin-dependent kinase inhibitor p21 and down-regulated the expression of c-Myc, a protein that has been implicated in cell cycle progression. The differentiation of HL-60 cells by S9240 was blocked by the proteasome inhibitor, MG132. The levels of p21 and c-Myc were increased in MG132-treated cells, but the differentiation of HL-60 cells by S9240 was not affected. These results indicate that the degradation of p21 is essential for the differentiation of HL-60 cells induced by S9240. The degradation of p21 in HL-60 cells was not mediated by the ubiquitin-proteasome pathway. S9240-induced differentiation of HL-60 cells was blocked
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9248is a drug that inhibits
 
Response: S9248is a drug that inhibits the biosynthesis of sterols, such as the formation of lanosterol, by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol biosynthesis pathway \[[@B19]\]. In addition, it is known to suppress the activation of caspase-3, an executioner of apoptosis, and induce the expression of Bcl-2, a gene that inhibits apoptosis \[[@B20]\]. Although these properties suggest that S9248 has a potential as a drug for the treatment of various types of cancer, its *in vivo* effects remain unclear.

In this study, we investigated the effect of S9248 on the growth of the A549 human lung adenocarcinoma xenograft in nude mice. S9248 was administered orally to the mice at doses of 5
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9249is a drug that inhibits
 
Response: S9249is a drug that inhibits the production of amyloid-β, a peptide that accumulates in the brain of people with Alzheimer's disease. Amyloid-β is a product of the amyloid precursor protein (APP) that is normally degraded by the enzyme beta-secretase. When S9249is administered to people with Alzheimer's disease, it inhibits the production of amyloid-β. Researchers in the Division of Intramural Research of the National Institute on Aging (NIA) conducted a clinical trial to evaluate the safety and tolerability of S9249in people with mild-to-moderate Alzheimer's disease and mild cognitive impairment (MCI). In the study, S9249was administered orally for 4 months. The results of this trial indicate that S9249is safe and well-tolerated in people with mild-to-moderate Alzheimer's disease and MCI.

Mild cognitive impairment (MCI) is a term
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9263is a drug that inhibits
 
Response: S9263is a drug that inhibits the tyrosine kinase activity of the epidermal growth factor receptor. The S-1/CPT-11 combination has been reported to be effective in a phase II study in patients with unresectable metastatic gastric cancer ([@bib24]). The clinical benefits of S-1 were shown to be superior to those of other regimens, including 5-FU and leucovorin (LV), in a randomised phase III study ([@bib3]). Furthermore, it was shown to have a beneficial effect in a multivariate analysis ([@bib6]). Recently, a Japanese phase II study demonstrated that the S-1/CPT-11 combination was effective in patients with advanced gastric cancer ([@bib16]). However, there have been no phase III studies in Japan to prove the efficacy of S-1/CPT-11 in patients with unresectable metastatic gastric cancer.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9270is a drug that inhibits
 
Response: S9270is a drug that inhibits both the degradation and transcription of rRNA by a yet unknown mechanism of action. It is able to suppress the translation of proteins, since it blocks the incorporation of amino acids into the growing polypeptide chain.

S9270 inhibits the growth of all the cell lines tested, with the exception of a leukemia cell line with low expression of p53. This observation suggests that the growth inhibition exerted by S9270 is p53-independent. In agreement with this hypothesis, the inhibitory activity of S9270 was not affected by the expression of a p53-mutated form of the protein, as it is observed for other inhibitors of rRNA synthesis, such as actinomycin D and alpha-amanitin \[[@R35]\].

The effects of S9270 on cell cycle progression were studied in HCT116 cells, which express wild-type p53. As shown in Figure [5A](
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9281is a drug that inhibits
 
Response: S9281is a drug that inhibits the release of pro-inflammatory cytokines by macrophages, and that may be useful in the treatment of arthritis and other diseases in which the release of these cytokines is involved.
The following references disclose 3-substituted-1,2,4-triazolo[1,5-a]pyrimidines, including compounds of Formula 1.
WO 91/14696 describes 1,2,4-triazolo[1,5-a]pyrimidines of Formula 2. ##STR2##
In addition, these compounds are described as having analgesic activity.
WO 91/16976 describes 1,2,4-triazolo[1,5-a]pyrimidines of Formula 3. ##STR3##
WO 92/09556 describes 1,2,4-triazolo[1,5-a]pyrimidines of Formula
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9285is a drug that inhibits
 
Response: S9285is a drug that inhibits the phosphorylation of p38 MAPK by a dominant negative p38α or p38β, which subsequently prevents the binding of p38 to its substrates. These experiments demonstrate that JNK activation is required for the inhibition of NF-κB and p38 MAPK activity by anti-CD40 and anti-CD40-ligand, but not by lipopolysaccharide.

**Conclusions**

JNK activation is necessary for the regulation of NF-κB and p38 MAPK by anti-CD40 and anti-CD40-ligand in a murine B-cell line. This study provides a potential mechanism for the synergistic effects of JNK inhibition on NF-κB and p38 MAPK activities.

P834: Evaluation of the cytotoxic activity of VE-821, a novel anti-CD30 antibody, on B-cell lymphomas {#Sec
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9288is a drug that inhibits
 
Response: S9288is a drug that inhibits cell proliferation by inducing apoptosis in human breast cancer cells, as shown in a previous study \[[@B13-ijms-21-00557]\]. In the present study, we confirmed that treatment with S9288 induced apoptosis in breast cancer cells, including TNBCs. The cells underwent apoptosis in a dose-dependent manner, and a concentration of 10 μM S9288 induced the most pronounced apoptosis.

In this study, we investigated the effects of S9288 on TNBC cell migration and invasion. S9288 inhibited the migration and invasion of breast cancer cells, suggesting that S9288 could be a potential anti-cancer agent for TNBC. The cells treated with S9288 had a round and small cell morphology, as well as reduced cell migration and invasion. In particular, S9288 was effective in reducing migration and invasion in MDA-MB-231 cells.

The Wnt
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9294is a drug that inhibits
 
Response: S9294is a drug that inhibits the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α)^[@CR37]^. This drug has been used in a clinical trial to reduce brain inflammation in patients with AD^[@CR38]^. *In vitro* studies have shown that the S9294 drug can cross the BBB^[@CR39]^. The gene expression data for S9294 in the CSF of AD patients were similar to the TNF-α expression in the same CSF. The expression of the S9294 drug in the AD CSF suggests that it may be able to reduce the brain inflammation in AD patients.

There are two other drugs, MTX and fluoxetine, that can cross the BBB and reduce brain inflammation. MTX is an anti-inflammatory drug used to treat autoimmune disorders, including rheumatoid arthritis^[@CR40]^. MTX
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9311is a drug that inhibits
 
Response: S9311is a drug that inhibits CDK5 activity and thus reduces phosphorylation of tau at Ser-9. In vivo studies demonstrated that S9311 improved the cognitive performance in an AD mouse model. We also demonstrated that S9311 reversed tau hyperphosphorylation in the APP/PS1 mouse model. These data suggest that CDK5/tau signaling pathway is involved in the pathogenesis of AD and that CDK5 inhibition could be a promising strategy for AD treatment.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9321is a drug that inhibits
 
Response: S9321is a drug that inhibits the replication of HIV and is currently in clinical trials for this purpose. In a series of studies, Murset et al. (1997) have shown that S9321 prevents the replication of a panel of HIV-1 and HIV-2 isolates in T cells.

Leflunomide is a drug that is used in the treatment of rheumatoid arthritis. A study of the effect of Leflunomide on HIV replication was carried out by Murset et al. (1997) who used MT-4 cells and PBMCs from HIV-infected patients. It was found that Leflunomide inhibits HIV replication in MT-4 cells and PBMCs. In fact, the IC50 of Leflunomide for HIV-1 was in the range of 10-20 μM.

An inhibitor of the late stages of HIV-1 replication, AZT,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9326is a drug that inhibits
 
Response: S9326is a drug that inhibits p70 S6K. Treatment of the cells with LY2584702 resulted in a dose-dependent reduction in cyclin D1 expression, and in the inhibition of cell proliferation and colony formation. Treatment with LY2584702 reduced the expression of the CDK4, CDK6, cyclin D1, c-Myc, E2F1, p-RB and p-p70 S6K proteins. The LY2584702-induced inhibition of cyclin D1 expression was completely blocked by pretreatment with a PI3K inhibitor, LY294002, but not with a MAPK inhibitor, U0126. We demonstrated that the reduction in cyclin D1 expression by LY2584702 was accompanied by an increase in the level of miR-23a. LY2584702 reduced the expression of the miR-23a target gene, cyclin D1, in a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9327is a drug that inhibits
 
Response: S9327is a drug that inhibits SIRT1. Since the cell death induced by SIRT1 inhibition can be reversed by adding the *SIRT1* gene in HeLa cells \[[@R63]\], the protective effect of polyphenols could be attributed to the overexpression of *SIRT1* induced by the action of these compounds. The results also showed that SIRT1 is involved in the apoptosis induced by resveratrol and other polyphenols.

The molecular mechanism of the anti-cancer activity of resveratrol is controversial. The first suggestion that the compound could act as an anti-cancer agent was made in the early 1990s. It was suggested that resveratrol could inhibit cell proliferation, DNA replication, cell migration and tumorigenesis by inducing apoptosis in cancer cells \[[@R64]\]. A recent review on the subject concluded that resveratrol acts as an anti-cancer agent by mod
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9329is a drug that inhibits
 
Response: S9329is a drug that inhibits the FASN enzyme, and which has been shown to have anticancer activity in various tumor cell lines (including both colon and breast cancer cells). The combination of 5-FU and S9329 was shown to have enhanced anticancer activity compared to 5-FU alone in the human colon cancer cell line SW480. We also showed that the combination of 5-FU and S9329 was effective in a xenograft mouse model of colon cancer. We have also shown that S9329 is a potent inhibitor of FASN in the mammary cancer cell line MCF7 and that the combination of S9329 and paclitaxel was effective in this model. We propose to extend these studies to other human breast cancer cell lines. In addition, we will determine the effect of S9329 on the sensitivity of tumor cells to other chemotherapeutic agents. We will also determine the effect of S9329 on the sensitivity of tumor cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9338is a drug that inhibits
 
Response: S9338is a drug that inhibits HIV-1 replication at the level of reverse transcription. The compound targets HIV-1 RT after its binding to the HIV-1 IN and proviral DNA. It was designed as a next generation INSTI-based therapy for treatment-naive patients infected with HIV-1. It is a thiosemicarbazone derivative of efavirenz, with the same potency as efavirenz, but with a more favourable pharmacokinetic profile.

The S9338 analogue RAL has been approved in the US and Europe for the treatment of HIV-1 infection in treatment-naive adults, as an alternative to first-line regimens that include a PI and/or a NNRTI. In a recent Phase III trial, S9338 was superior to the standard-of-care (SOC) regimen of raltegravir and efavirenz (EFV) in terms
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9344is a drug that inhibits
 
Response: S9344is a drug that inhibits both P-gp and MRP2.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9348is a drug that inhibits
 
Response: S9348is a drug that inhibits IκB kinase (IKK) and thereby suppresses NF-κB activation by blocking the activation of the IKK complex. It is used for the treatment of rheumatoid arthritis. Although it has been reported that S9348 suppresses osteoclastogenesis and bone resorption *in vitro*, the effects of S9348 on bone metabolism *in vivo* remain to be elucidated. To investigate the effects of S9348 on bone metabolism *in vivo*, we orally administered S9348 to 5-week-old female OVX mice, and then assessed the effects on bone mass and bone metabolism. S9348 was administered to OVX mice for 8 weeks. Administration of S9348 did not affect the body weight of OVX mice (Fig. [2A](#Fig2){ref-type="fig"}). The serum levels of the bone resorption marker CTX-I
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9349is a drug that inhibits
 
Response: S9349is a drug that inhibits protein kinase C. As S9349 had an IC50 of about 0.1 microM, it should be used with caution. S9349 is also a poor substrate for P-glycoprotein, which limits its use as a probe to study the involvement of P-glycoprotein in the intestinal absorption of peptides.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9351is a drug that inhibits
 
Response: S9351is a drug that inhibits a subunit of phosphatidylinositol 3-kinase (PI3K) and has antitumor activity. Here, we show that LY294002 and wortmannin, two PI3K inhibitors, induced caspase-3-independent apoptosis in PANC-1 cells. In contrast, LY294002 and wortmannin had no effect on cell viability of other cell lines. However, LY294002 and wortmannin synergistically induced apoptosis in PANC-1 cells in a dose-dependent manner. Moreover, LY294002 and wortmannin also induced apoptosis in other cancer cells. LY294002 and wortmannin synergistically induced caspase-3-independent apoptosis in PANC-1 cells. We conclude that LY294002 and wortmannin synergistically induce apoptosis in PANC-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9353is a drug that inhibits
 
Response: S9353is a drug that inhibits the inducible transcriptional activity of NF-kappaB by interfering with the DNA binding function of p65/RelA. In order to further evaluate the anti-inflammatory potential of S9353, we have studied the effects of the compound on carrageenan-induced paw edema and on the production of inflammatory mediators by mouse macrophages and mouse peritoneal macrophages in vitro. S9353 was found to inhibit the production of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) by lipopolysaccharide (LPS)-stimulated macrophages. Furthermore, S9353 inhibited carrageenan-induced paw edema in mice, and its effects were comparable to those of dexamethasone. We also found that S9353 inhibits the inducible transcriptional activity of NF-k
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9354is a drug that inhibits
 
Response: S9354is a drug that inhibits the production of thyroid hormone. It has been used in Japan for over 30 years to treat children with hyperthyroidism. The drug has been shown to be effective in improving thyroid function and reducing hyperthyroidism-associated symptoms.

One of the most interesting features of the drug is that it also has a unique safety profile. It does not appear to cause serious side effects and is generally well tolerated. Although S9354 has been used to treat hyperthyroidism for over 30 years, its mechanisms of action and effects on the brain have not been investigated in detail.

What is known about the safety and efficacy of S9354?

The most recent systematic review and meta-analysis of S9354 was published in 2013.

A recent review of the safety and efficacy of S9354 in patients with hyperthyroidism was published in the Journal of Clinical Endocrinology and Metabolism in 2014.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9367is a drug that inhibits
 
Response: S9367is a drug that inhibits STAT3 and has anti-tumor effects on various cancer cells. In this study, we aimed to investigate the effects of S9367 on the radiosensitivity of lung cancer cells and to determine the possible mechanism of action. S9367 inhibited the viability of A549 cells and the expression of STAT3 and p-STAT3 in A549 cells. The viability of A549 cells was significantly inhibited by S9367 after exposure to X-ray irradiation. The expression of p-STAT3 in A549 cells was significantly inhibited by S9367 after exposure to X-ray irradiation. Furthermore, the inhibition of p-STAT3 by S9367 was reversed by STAT3 siRNA. These results suggest that S9367 may enhance the radiosensitivity of lung cancer cells by inhibiting the expression of p-STAT3.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9368is a drug that inhibits
 
Response: S9368is a drug that inhibits both the M~1~ and M~3~ receptors, and we previously showed that both the M~1~ and M~3~ receptors were involved in the upregulation of CRH expression induced by inflammation \[[@B19-ijms-20-01167]\]. The upregulation of CRH expression in the PVN induced by LPS administration was significantly suppressed by pretreatment with SR9011 ([Figure 6](#ijms-20-01167-f006){ref-type="fig"}B,C). In contrast, the upregulation of CRH expression induced by the intravenous administration of CRH was not affected by pretreatment with SR9011 ([Figure 6](#ijms-20-01167-f006){ref-type="fig"}D,E). These results indicate that CRH-R1 is involved in the upregulation of CRH expression induced by LPS administration.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9373is a drug that inhibits
 
Response: S9373is a drug that inhibits cancer cells by binding to the P-glycoprotein (P-gp) transporter on the cell membrane.^[@bibr23-1178223418759296]^ However, several studies have shown that S9373is not a substrate of P-gp.^[@bibr24-1178223418759296],[@bibr25-1178223418759296]^ It has been suggested that the anti-cancer effects of S9373is are due to its pro-apoptotic properties and that S9373is is a modulator of the intracellular signaling pathways involved in the development of cancer.^[@bibr24-1178223418759296]^

S9373is is a biaryl imidazole derivative that acts as a cyclin-dependent kinase (CDK) inhibitor, and its activity is blocked by the presence of Thr
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9380is a drug that inhibits
 
Response: S9380is a drug that inhibits VEGFR-2 and PDGFR, and has been developed as a treatment for cancer and metastatic disease. In a previous study, we used 2D cell culture models to demonstrate that S2C3 inhibits cell migration in response to VEGF, PDGF, and other pro-angiogenic factors (Wang et al., [@B62]). In the present study, we extend these findings by using 3D models to demonstrate that S2C3 inhibits the migration of tumor cells *in vivo* and that this effect is mediated by its ability to inhibit VEGF- and PDGF-induced signaling.

There is increasing evidence that cancer cells that are able to metastasize utilize different signaling pathways to promote their growth, survival, and migration (Vajravelu et al., [@B57]; Chen et al., [@B9]; Orsulic et al., [@B45]). In addition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9382is a drug that inhibits
 
Response: S9382is a drug that inhibits the action of P-glycoprotein (P-gp), an efflux pump that prevents drugs from entering cells. The inhibition of P-gp results in an increased accumulation of the drug within the cell and an increased cytotoxicity.^[@ref3]^ In this study, we investigated the cytotoxicity of S9382 in MDR1-transfected cells, which exhibit P-gp overexpression. As shown in Figure [2](#fig2){ref-type="fig"}A, the cytotoxicity of S9382 was significantly increased in the MDR1-transfected cells compared to the control MDA-MB-231 cells. This result indicates that S9382 has the potential to overcome P-gp-mediated MDR.

![S9382 increases the cytotoxicity of taxanes and vinca alkaloids in MDR1-transfected cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9383is a drug that inhibits
 
Response: S9383is a drug that inhibits the interaction of tubulin with microtubules, causing them to depolymerize and the spindle to disintegrate. Cells that are blocked in mitosis are unable to divide and stop growing. S9383is being developed for the treatment of advanced or recurrent cancer in adults, including advanced or recurrent ovarian cancer. S9383is being developed by Ascenta Therapeutics.

Ascenta is currently evaluating S9383in a Phase I/II study in combination with gemcitabine and paclitaxel for the treatment of advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Shares of Ascenta were suspended on December 19, 2012. On February 15, 2013, Ascenta issued a press release indicating that the company has filed a request with the U.S. Food and Drug Administration to commence a Phase II clinical trial in patients with recurrent ovarian cancer.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9385is a drug that inhibits
 
Response: S9385is a drug that inhibits CCR2-dependent cell migration and adhesion by acting on the downstream signaling of CCR2, and that it has a significant therapeutic potential for the treatment of inflammatory and immune diseases.

There are no conflicts of interest to declare.

This study was supported by the Science Research Promotion Fund of the Japan Promotion of Science (KAKENHI Grant Number: 25293069, 25462233 and 15K07508).

[^1]: Contributed equally

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9400is a drug that inhibits
 
Response: S9400is a drug that inhibits the activation of the protein-tyrosine kinase p56lck and blocks T cell receptor-mediated T cell activation. S9400 has been shown to be effective in the treatment of autoimmune diseases in both murine and human systems. We have tested the ability of S9400 to block arthritis in the murine collagen-induced arthritis model. Mice with collagen-induced arthritis were treated with S9400 and evaluated for clinical arthritis, histopathology and immune parameters. S9400 blocked arthritis in a dose-dependent manner and was effective in blocking the disease at oral doses as low as 0.1 mg/kg. The arthritis was prevented without any detectable toxicity in the animals. S9400 suppressed the proliferation of peripheral blood lymphocytes from arthritic mice and significantly decreased the proportion of CD4+ cells producing interferon-gamma in vivo. S9400 is a promising candidate for the treatment of autoimmune diseases such as r
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9413is a drug that inhibits
 
Response: S9413is a drug that inhibits calcineurin, a key component of the NFAT pathway. In an effort to understand how to use this drug to enhance the expansion of HSCs in vitro, we examined the effect of S9413 on the survival of long-term HSCs in culture. As shown in Fig. [3](#Fig3){ref-type="fig"}a, b, and d, S9413 at 1--5 μM does not alter the survival of short-term HSCs in culture. In contrast, 10 μM S9413 has a moderate effect on the survival of long-term HSCs (Fig. [3](#Fig3){ref-type="fig"}c). These data indicate that S9413 has a selective effect on the expansion of long-term HSCs.Fig. 3Effect of S9413 on the survival of HSCs in culture. **
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9416is a drug that inhibits
 
Response: S9416is a drug that inhibits the migration of cancer cells and has potential as an anti-cancer agent.

3.2. Compounds Affecting the Expression of Cytoskeletal Proteins {#sec3dot2-ijms-18-01991}
----------------------------------------------------------------

The cytoskeleton is a network of filaments, cross-linked proteins, and membranes that are associated with cell morphology and intracellular transport \[[@B24-ijms-18-01991]\]. Inhibition of the actin cytoskeleton can lead to the loss of cell adhesion and cell--cell interaction, resulting in the inhibition of cell proliferation and metastasis \[[@B25-ijms-18-01991]\].

Cytoskeletal proteins are regulated by Rho GTPases, which are activated by various growth factors and play a key role in the regulation of actin cytoskeleton dynamics
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S9500is a drug that inhibits
 
Response: S9500is a drug that inhibits the enzyme 5-lipoxygenase and therefore is used to treat the inflammation and pain associated with arthritis and psoriasis.

New formulation of this drug that has been approved for treating arthritis and psoriasis

The benefits of the drug in the treatment of arthritis

This drug has been proven to be effective in treating rheumatoid arthritis, a painful and disabling autoimmune disease that affects the joints and causes inflammation and pain.

New formulation of this drug that has been approved for treating psoriasis

This drug has been proven to be effective in treating psoriasis, a skin condition that causes skin inflammation and redness.

New formulation of this drug that has been approved for treating psoriasis

This drug has been proven to be effective in treating psoriasis, a skin condition that causes skin inflammation and redness.

What are the benefits of taking this drug for arthritis and psoriasis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Saccharinis a drug that inhibits
 
Response: Saccharinis a drug that inhibits the growth of Candida species and the formation of biofilms, and is thus used to treat vaginal candidiasis. It can be used in patients with recurrent vaginal candidiasis, or in combination with nystatin. It is also used in the treatment of esophageal candidiasis and oral candidiasis.

Econazole is a broad spectrum azole antifungal agent used to treat a variety of fungal infections, including vaginal candidiasis. It is available as a topical cream or vaginal suppository. It is also available as a systemic treatment in a suspension form for oral use. It is usually prescribed in combination with nystatin or clotrimazole.

Clotrimazole is a synthetic imidazole antifungal agent used to treat vaginal candidiasis. It can be used in patients with recurrent vaginal candidiasis, or in combination with nystatin or econazole.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salbutamolis a drug that inhibits
 
Response: Salbutamolis a drug that inhibits growth of breast cancer cells. The drug inhibits the growth of breast cancer cells by binding to and inhibiting the function of two proteins that are critical to cell growth and survival. Salbutamol inhibits protein kinase C-ζ (PKC-ζ), which is a protein that is important in growth and survival of cancer cells. Salbutamol inhibits the enzyme diacylglycerol kinase-ζ (DGK-ζ), which is an enzyme that is critical to growth and survival of cancer cells. The binding of salbutamol to these two proteins leads to the inhibition of their functions. The drug is approved by the FDA for the treatment of asthma.

The purpose of this study was to determine whether the drug salbutamol inhibits the growth of cancer cells. The study used the human breast cancer cell line, MCF-7, which was grown in culture dishes. The drug salbut
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salicinis a drug that inhibits
 
Response: Salicinis a drug that inhibits tumor growth, improves prognosis and increases the survival of patients with cancer. (a) and (b) The tumor growth of subcutaneous xenografts of A549 cells in nude mice was suppressed by Sal. (c) The body weight of the nude mice was not significantly affected by Sal treatment. (d) Sal did not affect the survival of the nude mice (\*p\<0.05, \*\*p\<0.01, and \*\*\*p\<0.001 vs. vehicle control).](IJO-47-03-0933-g00){#f1-ijo-47-03-0933}

![Salicinis a drug that inhibits tumor growth, improves prognosis and increases the survival of patients with cancer. (a) and (b) The tumor growth of subcutaneous xenografts of A549 cells in nude mice was suppressed
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salicylamideis a drug that inhibits
 
Response: Salicylamideis a drug that inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase, an enzyme that catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP) to AMP. Salicylamide is a drug used to treat certain forms of rheumatoid arthritis and migraine. The salicylamide portion of the drug is a relatively weak inhibitor of cAMP phosphodiesterase, but its side effects are minimized by the use of a less potent but more specific inhibitor of cAMP phosphodiesterase, theophylline.
Salicylamide and theophylline were first synthesized in the late 19th century and were originally developed for use as anti-inflammatory agents. Salicylamide has been used in clinical medicine for over 40 years and is still an important drug for the treatment of rheumatoid arthritis and migraine.
The pharmacokinetics of salicylam
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salicylanilideis a drug that inhibits
 
Response: Salicylanilideis a drug that inhibits the enzyme S-adenosylhomocysteine hydrolase (SAHH), and thereby elevates the levels of homocysteine. SAHH is involved in the regulation of S-adenosylhomocysteine (SAH) levels, a metabolite of the methylation pathway. Elevated SAH levels have been implicated in a number of diseases and conditions, including Alzheimer's disease, cardiovascular disease, diabetes, and cancer. (Vitols, A. F. et al. (2003) J. Med. Chem. 46, 452-464; Nastri, P. et al. (2003) Curr. Med. Chem. 10, 921-932; Lu, Y. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 5245-5249; Simanek, R. et al. (2001) J. Clin.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salicylicis a drug that inhibits
 
Response: Salicylicis a drug that inhibits prostaglandin synthesis. Its use as an antipyretic and analgesic is limited by its side effects. More specifically, it causes gastrointestinal bleeding. In the gastrointestinal tract, salicylic acid is converted to salicylate, which is a toxic metabolite. Thus, salicylic acid has been the subject of considerable research in an effort to reduce the side effects of this drug without impairing its antipyretic and analgesic activity. The primary mechanism of action of the salicylates is thought to be the inhibition of prostaglandin synthetase.
In the past, salicylates have been administered orally. The salicylates are metabolized in the gastrointestinal tract to form toxic metabolites. In particular, salicylate is converted to salicyluric acid. Salicyluric acid is further metabolized to toxic compounds such as salicyluric acid. In addition,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salidrosideis a drug that inhibits
 
Response: Salidrosideis a drug that inhibits the activity of the multidrug resistance-associated protein (MRP), a member of the ABC transporter family, which has a broad substrate specificity \[[@B1]\]. MRP is a protein with 6 transmembrane domains, a single nucleotide polymorphism in the *MRP2* gene (C1236T) causes the T1249A polymorphism, and this polymorphism is related to decreased MRP activity \[[@B2]\].

The most common side effects of salidroside are nausea, vomiting, and diarrhea, but they are not severe \[[@B3]\]. However, there have been reports of agranulocytosis and thrombocytopenia induced by salidroside. Agranulocytosis is defined as a white blood cell count of \<2,000 cells/µL, and thrombocytop
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salmeterolis a drug that inhibits
 
Response: Salmeterolis a drug that inhibits vasodilatation induced by bradykinin, 5-HT, histamine and acetylcholine and in a rat model of hypertension. It is known that salsolinol causes vasodilatation by inhibiting calcium uptake by the cell membrane of vascular smooth muscle.
The following references describe the synthesis of salsolinol and its pharmacological activity:
Y. Shibasaki et al., J. Med. Chem. 1990, 33, 3442-3447; PA1 K. D. Sliwkowski et al., Biochem. Pharmacol. 1990, 40, 2195-2199; PA1 R. P. Hanu et al., J. Med. Chem. 1991, 34, 3164-3171; PA1 M. J. Almond et al., Eur. J. Pharmacol. 1990, 196, 313-316; PA1 S. S. Swarup et al
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Salmonis a drug that inhibits
 
Response: Salmonis a drug that inhibits the alpha1B subunit of the voltage-dependent calcium channel. It has been used to treat a number of disorders, including overactive bladder and other symptoms of OAB. The objective of this study was to determine the effects of a 4-week treatment with salmonis on the lower urinary tract symptoms and quality of life of patients with overactive bladder. In a randomized, double-blind, placebo-controlled study, patients with OAB symptoms were treated with 3 mg/day of salmonis or placebo for 4 weeks. Before and after treatment, patients completed the OAB-q and Incontinence Impact Questionnaire-7 (IIQ-7) questionnaires. In total, 44 patients were enrolled in the study; 21 were randomized to the salmonis group and 23 to the placebo group. There was no significant difference in the total OAB-q score or the OAB-q symptom and bother subscale scores between the groups at baseline.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sapropterinis a drug that inhibits
 
Response: Sapropterinis a drug that inhibits the spread of tumors, by limiting the ability of tumor cells to migrate and invade. Sapropterin also appears to inhibit the growth of a few kinds of cancer cells.

What Is It Used For?

Sapropterin is used to treat a rare form of pediatric seizure disorder called Dravet syndrome.

Dravet syndrome is a rare genetic disorder that affects the brain and causes children to have frequent seizures.

A type of mutation in the SCN1A gene can cause Dravet syndrome. This gene codes for a protein called sodium channel, voltage-gated, type I, alpha.

The mutation causes the protein to be defective, which can affect the way the brain works.

Sapropterin is used to treat Dravet syndrome in children who have this mutation.

It works by increasing the levels of a brain chemical called gamma-aminobutyric
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SAR125844is a drug that inhibits
 
Response: SAR125844is a drug that inhibits the signaling pathways of platelet-derived growth factor receptor and epidermal growth factor receptor, and is currently under phase II clinical trials for the treatment of various cancers. In this study, we examined the effect of a combination of this drug with radiation in two different models of pancreatic cancer, one of which was orthotopically xenografted into the pancreas of nude mice. Combination treatment with SAR125844 and radiation induced significant cell death in both xenografts and patient-derived tumor tissue. This effect was observed with doses of SAR125844 as low as 0.5 µM. The increase in radiation-induced cell death was accompanied by the inhibition of DNA repair, and was dependent on the radiation dose and the cell type. Moreover, we found that combination treatment with SAR125844 and radiation increased the radiosensitivity of tumors with low levels of KRAS expression. In addition, SAR125844
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sarafloxacinis a drug that inhibits
 
Response: Sarafloxacinis a drug that inhibits an enzyme called a topoisomerase that regulates DNA replication. It is approved in the US for treatment of acute myeloid leukemia and myelodysplastic syndrome.

Rifabutin and rifapentine are antimycobacterial drugs that inhibit bacterial RNA polymerase and interfere with DNA synthesis. Rifabutin is approved for treatment of tuberculosis and rifapentine is approved for the treatment of latent tuberculosis infection.

Isoniazid is an antimicrobial agent that inhibits bacterial enzyme isocitrate lyase. It is used for the treatment of latent tuberculosis infection.

Ethambutol inhibits an enzyme that is necessary for cell wall biosynthesis. It is used for treatment of tuberculosis.

Ciprofloxacin is a fluoroquinolone that is a potent inhibitor of DNA gyrase. It is used for treatment of infections caused
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S.A.S.-500is a drug that inhibits
 
Response: S.A.S.-500is a drug that inhibits telomerase and slows the growth of tumours. It is now in Phase III clinical trials for the treatment of solid tumours. It is not known whether S.A.S.-500is has any effect on the development of other tumours such as brain tumours.

The use of telomerase inhibitors in the treatment of brain tumours was explored in an early study of the effects of S.A.S.-500on cell lines that were derived from patients with malignant gliomas. Cells were exposed to S.A.S.-500for up to three months. The effect of S.A.S.-500was evaluated by measuring cell proliferation and tumour growth in a xenograft mouse model. The growth of cells derived from the two patients who received S.A.S.-500was significantly slower than that of cells derived from the two patients who received a placebo. In the cells derived
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sasapyrineis a drug that inhibits
 
Response: Sasapyrineis a drug that inhibits the production of prostaglandins by inhibiting the enzyme cyclooxygenase (COX) by blocking the enzyme’s activity, thereby reducing inflammation and pain.

It is a cyclooxygenase-2 (COX-2) inhibitor. It was developed as an anti-inflammatory drug and painkiller.

In 2006, the FDA approved its use in osteoarthritis (OA) and rheumatoid arthritis (RA)

It is taken orally, as an antalgic and anti-inflammatory.

Side effects

The side effects of sasapyrin include:

Abdominal pain

Dizziness

Fever

Headache

Nausea

Sore throat

Urinary retention

Vomiting

The side effects are usually mild and disappear with the passage of time.

How to use
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Saxagliptinis a drug that inhibits
 
Response: Saxagliptinis a drug that inhibits the formation of amyloid plaques in a transgenic mouse model of Alzheimer's disease, and a series of sulfonamides that inhibit the synthesis of amyloid peptides. These compounds have now been found to exhibit a variety of effects in normal cell culture. They promote the production of cellular amyloid proteins and protect the cells from death induced by oxidative stress. They also protect against the toxicity of A beta, and can be used to identify amyloid peptides. The first three effects are not dependent on inhibition of the synthesis of amyloid peptides, suggesting that they may operate through other mechanisms.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SBis a drug that inhibits
 
Response: SBis a drug that inhibits the uptake of serotonin by its transporter. It is marketed as the prescription drug Cymbalta, which is used to treat major depressive disorder.

S-Papaverine is a synthetic plant alkaloid with a number of pharmacological effects. It is used as a tranquilizer.

The U.S. Food and Drug Administration has approved s-Papaverine as a safe and effective treatment for nocturia.

S-Papaverine is available in a number of dosage forms. The most common is the solution.

S-Papaverine can be administered orally, sublingually, transdermally, rectally, or intramuscularly.

S-Papaverine can be administered to patients with a normal bladder capacity, but who have a large bladder capacity and/or who have bladder outlet obstruction.

The following studies have shown the safety and effectiveness of s
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (+)-(S)-Carvoneis a drug that inhibits
 
Response: (+)-(S)-Carvoneis a drug that inhibits the uptake of serotonin in the brain. When taken with Cymbalta it can cause anxiety.

**CONDITIONS OF USE:** Not for use in women who are pregnant or nursing. If you are taking any other medications, consult with your doctor before using Carvone.

#####    LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** Unknown if drug crosses placenta or is distributed in breast milk. May produce transient nausea, dizziness, insomnia.

**Pregnancy Category C. Children:** Safety and efficacy not established. **Elderly:** No age-related precautions noted.

#####  INTERACTIONS

**DRUG:** **Anticoagulants, SSRIs** may increase risk of bleeding. **HERBAL:** None significant. **FOOD:** None
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SCH-527123is a drug that inhibits
 
Response: SCH-527123is a drug that inhibits the binding of dopamine (DA) to its receptor. Since SCH-527123 also inhibits dopamine (DA) reuptake, it is classified as a norepinephrine-dopamine (ND) reuptake inhibitor.

SCH-527123is chemically described as:

4-[(1-Piperidinyl)methoxy]-N,N-diethylbenzamide

See also

References

Category:Abandoned drugs
Category:Benzamides
Category:Benzylpiperazines
Category:Dopamine reuptake inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SCH727965is a drug that inhibits
 
Response: SCH727965is a drug that inhibits the Src family kinase Fyn and inhibits the proliferation of colon cancer cells. To examine the effect of SCH727965 on tumour growth in vivo, we used a xenograft mouse model of colon cancer. Oral administration of SCH727965 significantly suppressed tumour growth, as assessed by tumour weight, tumour volume, Ki67 expression, and serum levels of the colon cancer-specific biomarker carcinoembryonic antigen (CEA). In addition, we examined the effect of SCH727965 on tumour angiogenesis. Tumours were smaller in mice treated with SCH727965 than in control mice, and SCH727965 reduced tumour microvessel density (MVD) in a dose-dependent manner. The number of cells expressing the cell cycle-related marker Ki67 was significantly lower in tumours from mice treated with SCH727965 than in control tumours. The levels of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sclareolis a drug that inhibits
 
Response: Sclareolis a drug that inhibits the growth of cancer cells and is now being used in Europe.

Sclareolis is a naturally occurring compound produced by the roots of Sclarea, a flowering plant that is native to southern Europe. Scientists have studied the roots of the plant for years because of its many medicinal properties. In the 1990s, they discovered that the plant also contains the substance sclareol.

Sclareolis is not toxic to humans. It has been tested in animals and has shown a broad spectrum of activity against many different kinds of cancer.

Researchers have found that Sclareolis causes the formation of a substance called HSP-90 that can cause cancer cells to die.

When the cancer is not treated, it grows and kills the patient. However, when the HSP-90 is inhibited by Sclareolis, cancer cells stop growing.

In animals, Sclareolis has been found to be
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Scopolamineis a drug that inhibits
 
Response: Scopolamineis a drug that inhibits the muscarinic cholinergic receptors in the central nervous system. This is a relatively selective muscarinic antagonist, which produces a dose-related reduction in the ability to walk, swallow, and speak.

Lorazepamis a benzodiazepine, a derivative of the barbiturate. Lorazepam is a powerful sedative-hypnotic drug. It produces amnesia, anxiolysis, muscle relaxation, and drowsiness.

Propofolis an anesthetic agent, which is commonly used to induce and maintain anesthesia.

Remifentanilis a synthetic opioid used as a sedative for anesthesia and analgesia. It is similar to sufentanil in that it binds to opioid receptors. Remifentanil has a faster onset and a shorter duration of action than sufentanil. It is an ester prodrug of sufentanil
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S-crizotinibis a drug that inhibits
 
Response: S-crizotinibis a drug that inhibits multiple tyrosine kinases, including ALK, c-MET, and ROS1.[@CIT0011] It is approved in the US and EU for the treatment of advanced ALK-positive NSCLC. Herein, we present a case of crizotinib-related interstitial pneumonitis and review the literature.

A 48-year-old male presented with shortness of breath and cough for one week. He was a former smoker with a history of hypertension, diabetes mellitus, and bronchiectasis. He had a right-sided lung mass that was resected in 2016. The pathology revealed a pleomorphic carcinoma, TTF-1 positive, p63 positive, and CK5/6 positive. No *EGFR* or *KRAS* mutations were detected. Fluorescence in situ hybridization revealed ALK translocation. He was started on pemetrexed and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  scyllo-Inositolis a drug that inhibits
 
Response: scyllo-Inositolis a drug that inhibits the uptake of acetylcholine into the brain. It's an anti-spasmodic and anti-convulsant.

The sixth is atropine, which is an anti-spasmodic and anti-cholinergic. Atropine is the basis for the scopolamine patch.

The seventh is baclofen, which is used to treat spasticity and tremor. Baclofen is an anti-spasmodic.

The eighth is clonidine, which is an anti-hypertensive and anti-spasmodic.

The ninth is papaverine, which is an anti-spasmodic. Papaverine is the basis for many anti-nausea drugs, including domperidone.

The tenth is pyridostigmine, which is an anti-spasmodic.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Secnidazoleis a drug that inhibits
 
Response: Secnidazoleis a drug that inhibits the synthesis of an essential enzyme called thymidylate synthase. This enzyme is involved in the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate, which is needed for DNA synthesis. It is also needed for the synthesis of other molecules that are needed for cell division and for the production of many of the important components of the cell wall.

Mechanism of action

Thymidylate synthase is involved in the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate.

Secnidazole is a thymidylate synthase inhibitor that inhibits the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate. This results in a decreased level of deoxythymidine monophosphate, which in turn causes a decrease in the level of deoxy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Seletalisibis a drug that inhibits
 
Response: Seletalisibis a drug that inhibits the enzymatic activity of SYK, a tyrosine kinase of the Src family, and is currently in clinical trials for the treatment of chronic lymphocytic leukemia (CLL). The present study evaluated the activity of seletalisib in patients with relapsed or refractory B-cell lymphoma (BCL) and assessed the impact of patient characteristics and previous treatments on seletalisib activity. Data from phase 1 and 2 clinical trials were pooled. The activity of seletalisib was assessed by an independent review committee using the most recent international response criteria. Progression-free survival (PFS) was defined as the time from the first dose of seletalisib to the first documentation of disease progression, relapse, or death. Of the 108 patients enrolled, 82 (76.9%) were evaluable for response. The overall response rate was 57.1% (95% confidence interval [CI], 45
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Selonsertibis a drug that inhibits
 
Response: Selonsertibis a drug that inhibits the enzyme farnesyl pyrophosphate synthetase (FPPS) in eukaryotic cells. Farnesyl pyrophosphate synthetase is a prenyltransferase that is responsible for the biosynthesis of a family of small GTPases, the RAS proteins. The drug inhibits the growth of a variety of human tumors, both in vitro and in vivo.
It is therefore desirable to develop new agents that inhibit farnesyl pyrophosphate synthetase. It is particularly desirable to develop new agents that inhibit farnesyl pyrophosphate synthetase with improved potency and/or pharmacokinetic properties.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Selpercatinibis a drug that inhibits
 
Response: Selpercatinibis a drug that inhibits the kinase activity of MET (known as HGF receptor) and blocks downstream signaling. This has been tested in a Phase I clinical trial, where patients with advanced solid tumors received single-agent treatment with Selpercatinib. The results showed that the drug is well-tolerated and that some patients had partial responses. The drug is in a Phase II clinical trial for solid tumors, and more clinical trials are ongoing.

In addition to its effect on HGF receptor, Selpercatinib also inhibits the activity of FGFR1.

See also 
 Selumetinib

References 

Category:Tyrosine kinase inhibitors
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  sennosideis a drug that inhibits
 
Response: sennosideis a drug that inhibits phosphodiesterase. It is used to treat type II diabetes, as a diuretic, and as an antihypertensive agent.

Discovery
The drug was discovered in 1952 by Soviet scientists. It was originally called 6-sennoside, but the name was changed to sennoside A in 1957. It was found to be effective in treating certain types of hypertension and diabetes.

Mechanism of action
Sennoside A acts as an antihypertensive agent by inhibiting the cAMP-specific phosphodiesterase, which causes an increase in intracellular cAMP levels. This increases the sensitivity of the β-adrenergic receptors and causes an increase in the release of norepinephrine, which causes a decrease in blood pressure.

Pharmacokinetics
Sennoside A is not a PDE inhibitor and is not a selective PDE inhibitor. It is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Seratrodast(AA-2414,is a drug that inhibits
 
Response: Seratrodast(AA-2414,is a drug that inhibits the activity of trypsin and related serine proteases in the intestinal tract, and may be used to treat diarrhea, abdominal pain, and other gastrointestinal disorders in which the production of trypsin is increased. The recommended adult dosage of the drug is one tablet taken twice daily. It is also useful in the treatment of chronic pancreatitis, post-operative ileus, and other gastrointestinal disorders.

SERATROPIN(S). A hormone that stimulates the contraction of the uterus. It is secreted by the pituitary gland in response to stimulation by estrogen. SERATROPIN is used to induce abortion in pregnant women, and to treat endometrial cancer.

SERCOID, meaning hard or solid. An abnormal accumulation of lymphocytes in the liver, spleen, and bone marrow. It is a cause of a fever that does not respond to antibiotic treatment.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SEROMYCINis a drug that inhibits
 
Response: SEROMYCINis a drug that inhibits the growth of cells by binding to the enzyme topoisomerase II. It is effective in the treatment of acute myeloid leukemia, and in combination with cytarabine in the treatment of acute myeloid leukemia.

IMMEDIATE MAJOR CYTOTOXICITY, FOLLOWED BY CHRONIC LYMPHOCYTIC LEUKEMIA.

INHIBITION OF BONE MARROW CELLS AND BLOOD CELLS.

WARNINGS AND PRECAUTIONS

ALERT: PATIENT WITH A HISTORY OF OR THOSE WITH HEPATITIS, LEUKEMIA, MALIGNANT BONE MARROW CELLS, OR HEPATOCELLULAR CARCINOMA.

ADVERSE EFFECTS: PROMINENTLY INHIBIT THE GROWTH OF BONE
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Serotoninis a drug that inhibits
 
Response: Serotoninis a drug that inhibits the degradation of serotonin in the brain and is used to treat anxiety and depression. It works by boosting serotonin levels.

What should I avoid while taking Serotonil?

Alcohol is known to increase serotonin levels in the brain. This can be dangerous if taken with Serotonil, as the two can have an additive effect on the body. So, if you are drinking alcohol, you may want to hold off on taking Serotonil.

Serotonil can be habit forming and if taken regularly, can lead to addiction. So, be careful if you are planning to use it for longer than the prescribed duration.

Is Serotonil safe to take during pregnancy?

Serotonil is not recommended for pregnant women. It is advised that you avoid taking it. If you are planning to take Serotonil during pregnancy, you need to consult your doctor first.

Is it safe to take Serotonil with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sertaconazoleis a drug that inhibits
 
Response: Sertaconazoleis a drug that inhibits fungal infections. It is used to treat ringworm (tinea) and to treat toenail fungus.

Sertaconazole is available in oral form.

Sertaconazole Side Effects

Sertaconazole is used to treat fungal infections. Side effects may include:

Constipation

Diarrhea

Nausea

Headache

Skin rash

Tremor

Dizziness

Impotence

Sertaconazole should not be used if you have:

Hepatic or kidney disease

Low levels of potassium in your blood

Low levels of magnesium in your blood

Problems with your thyroid

Problems with your blood clotting

Problems with your immune system

Liver problems

Allergies to sertaconazole

Fertility problems


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  sertralineis a drug that inhibits
 
Response: sertralineis a drug that inhibits the reuptake of serotonin, the chemical that causes the feelings of well-being. This has the effect of increasing the levels of serotonin in the brain, which has been shown to have a calming effect. This may help to reduce anxiety and panic.

Another class of antidepressants called selective serotonin reuptake inhibitors (SSRIs) are used in the treatment of depression. This class includes the drugs citalopram, fluoxetine, paroxetine, and sertraline.

##  Where to Find Help

If you think you may have depression, seek help from your doctor. They may prescribe medication for you.

###  Mental Health Organizations

If you have a mental health problem, you can contact your local mental health organization for help.

#####  National Alliance on Mental Illness

**www.nami.org**

This organization is dedicated to providing
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Setipiprant(ACT-129968,is a drug that inhibits
 
Response: Setipiprant(ACT-129968,is a drug that inhibits prostaglandin D2 (DP) synthase and is used in the treatment of allergic rhinitis (AR).) and another study reported that the combination of fluticasone propionate and nedocromil (ACT-129868,is a drug that inhibits prostaglandin D2 (DP) synthase and is used in the treatment of allergic rhinitis (AR).) may be more effective than the two drugs used separately in the treatment of AR.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sevofluraneis a drug that inhibits
 
Response: Sevofluraneis a drug that inhibits mitochondrial respiration by inhibiting cytochrome C oxidase (COX) and succinate dehydrogenase (SDH) in the electron transport chain (ETC).\[[@ref1]\] This drug has a rapid onset and short duration of action, but it is highly volatile. The purpose of this study was to assess the effect of the administration of sevoflurane on pain scores and hemodynamic parameters in patients undergoing dental surgery.

Methods {#sec1-2}
=======

A prospective, randomized, double-blind, placebo-controlled, clinical trial was conducted on 100 patients (ASA class I and II, aged 18--60 years) undergoing dental surgery. The study was conducted at a dental teaching hospital. The patients were randomly divided into two groups, one group was given 1.5 MAC sevoflurane (Sevoflurane, Air
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (S)-(+)-FLURBIPROFENis a drug that inhibits
 
Response: (S)-(+)-FLURBIPROFENis a drug that inhibits the activity of the 5-lipoxygenase enzyme. In the following experiment, the activity of this enzyme was assayed in the presence of various concentrations of the drug. The experiments were performed with rat leukocytes (lymph node) and with a cell line (HMC-1) derived from human myeloid cells. In the leukocytes, the activity of the enzyme was found to be inhibited by the drug in a dose-dependent manner. The 50% inhibitory concentration was found to be 7.7 x 10(-7) M. The activity of the enzyme was found to be inhibited by the drug in a dose-dependent manner in the HMC-1 cells. The 50% inhibitory concentration was found to be 4.7 x 10(-8) M.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (S)-Glutamicis a drug that inhibits
 
Response: (S)-Glutamicis a drug that inhibits a sub-class of glutamate transporters.
Glutamate is the major excitatory neurotransmitter in the brain. Glutamate receptors are divided into two major groups: ionotropic and metabotropic. The ionotropic glutamate receptors include AMPA, kainate, and N-methyl-D-aspartate (NMDA) receptors. Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that modulate neurotransmitter release, mediate neuroplasticity, and mediate neuronal excitotoxicity. A large body of evidence suggests that metabotropic glutamate receptors are involved in the pathophysiology of a variety of acute and chronic neurodegenerative disorders. mGluR antagonists have been shown to have a neuroprotective effect in animal models of acute and chronic neurodegenerative diseases such as cerebral ischemia, Huntington's disease, Parkinson's disease, Alzheimer's disease,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sildenafilis a drug that inhibits
 
Response: Sildenafilis a drug that inhibits phosphodiesterase 5 (PDE5) which is the enzyme responsible for breaking down the cyclic guanosine monophosphate (cGMP) in the erectile tissues of the penis. The increased cGMP levels in the penis relax the blood vessels that carry blood into the penis which makes the penis erect. The drug works by relaxing the blood vessels that carry blood into the penis which makes the penis erect.

Sildenafil is used to treat erectile dysfunction (ED), also known as impotence, a condition in which a man is unable to achieve or maintain an erection that is sufficient for sexual activity. Sildenafil works by increasing blood flow to the penis, allowing more blood to fill the chambers of the penis and make an erection happen. Sildenafil is also used to treat pulmonary arterial hypertension, a condition that causes high blood pressure in the arteries of the lungs
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Silibininis a drug that inhibits
 
Response: Silibininis a drug that inhibits CYP3A4 and thereby increases the exposure to HIV protease inhibitors (PIs).^[@bib1],[@bib2]^ As most of the PIs are metabolized by CYP3A4, it was suggested that switching from one PI to another might not be needed when the drug-drug interaction (DDI) between PIs and rilpivirine is of clinical significance.^[@bib3]^ However, with the wide use of integrase inhibitors (INIs) as first-line treatment in combination with a PI, this DDI is not only clinically relevant but also of great importance. The recommended treatment guidelines of the European AIDS Clinical Society (EACS) recommend that INIs are used as first-line antiretroviral therapy in patients with subtype B HIV infection.^[@bib4]^ This recommendation is based on data from clinical trials showing
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Silymarinis a drug that inhibits
 
Response: Silymarinis a drug that inhibits certain enzymes. The name is derived from the ancient city of Smyrna, now called Izmir in Turkey. It has been used for centuries to improve memory and intellect, as well as to treat depression. Studies have shown that it also has significant anti-inflammatory, antioxidant, and anticancer properties.

Dosage and Use

Take 200-400 mg per day. Recommended dose: 1.5-3 gm daily.

Caution: Do not use this product if you have high blood pressure, or if you are pregnant, lactating, or taking any medication, including blood pressure medications.

Before taking this product, tell your doctor if you are pregnant or breastfeeding, or if you have any allergies.

Side Effects

Allergic reactions, headache, dizziness, nervousness, drowsiness, indigestion, heartburn, gas, and nausea are some of the side effects that may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sinomenineis a drug that inhibits
 
Response: Sinomenineis a drug that inhibits an enzyme in the body called acetylcholinesterase, and is a type of cholinesterase inhibitor. It has been used to treat problems with memory and attention, and for treating symptoms of dementia.

Signs and symptoms

Symptoms may include:

difficulty focusing and concentrating

poor memory

difficulty with coordination

decreased memory and concentration

headaches

dizziness

dry mouth

tremor

sleepiness

Side effects may include:

headaches

dizziness

dry mouth

decreased appetite

fatigue

Side effects may be more likely in the elderly.

Risks of sinomenine

Risks include:

cough

heart palpitations

respiratory tract infections

dizziness

fainting

sinus
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sisomicinis a drug that inhibits
 
Response: Sisomicinis a drug that inhibits the conversion of pregnenolone to progesterone and testosterone and also blocks the secretion of sex hormones by the adrenal cortex.

All male patients who have a low testosterone level should be given Sisomicinis because of the high incidence of infertility. Sisomicinis should be used for treating the symptoms of hypogonadism in patients with gonadal dysfunction. It is indicated for the treatment of patients with male hypogonadism due to Klinefelter syndrome, primary testicular failure, premature testicular failure or androgen insensitivity syndrome, who are not receiving treatment with testosterone.

It is also indicated for the treatment of adult patients with amenorrhea.

Positive Effects

Clinically relevant effect on symptoms of hypogonadism in patients with Klinefelter syndrome, primary testicular failure, premature testicular failure or androgen insensitivity syndrome.

It is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sitafloxacinis a drug that inhibits
 
Response: Sitafloxacinis a drug that inhibits the mitochondrial enzyme complex II. It is not effective against all bacterial infections. Side effects include vomiting, diarrhea, abdominal pain, dizziness, headache, fever, loss of appetite, and insomnia. Other side effects may include allergic reactions, jaundice, and elevated liver enzymes. Tell your doctor if you are pregnant or nursing.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sitravatinibis a drug that inhibits
 
Response: Sitravatinibis a drug that inhibits vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 and is approved for the treatment of patients with multiple myeloma who have received at least two prior therapies.[@b1-ott-8-1461]--[@b3-ott-8-1461] A phase I dose-escalation study of sitravatinib in combination with bortezomib and dexamethasone in patients with multiple myeloma has shown a tolerable safety profile and promising antitumor activity.[@b4-ott-8-1461] A subsequent phase II study of the combination of sitravatinib and bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma showed an objective response rate of 43%, a minimal response rate of 15%, and a median progression-free survival (PFS) of 5.7 months.[
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sivelestatis a drug that inhibits
 
Response: Sivelestatis a drug that inhibits platelet aggregation. Studies are currently being conducted to determine the effectiveness of this drug in preventing strokes.

Sodium polystyrene sulfonate (SPS) which is used to treat heavy blood loss, uremia and hyperkalemia.

Fibrates which are used to lower blood cholesterol and triglyceride levels. Studies are being conducted to determine whether these drugs are effective in preventing strokes.

Niacin which is used to lower blood cholesterol and triglyceride levels. Studies are being conducted to determine whether these drugs are effective in preventing strokes.

_HMG-CoA reductase inhibitors_, commonly referred to as "statins," which are used to lower blood cholesterol and triglyceride levels. Studies are being conducted to determine whether these drugs are effective in preventing strokes.

Antihypertensive drugs which are used to treat high blood pressure. Studies are being conducted to determine whether these drugs are
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  (S)-(?)-Limoneneis a drug that inhibits
 
Response: (S)-(?)-Limoneneis a drug that inhibits monoamine oxidase A (MAO-A) and is used to treat depression and anxiety. Its biological activity has been the subject of intense investigation, and (S)-(?)-limonene has been suggested as a model compound for other, more complex natural products. Here, we show that the structural simplicity of (S)-(?)-limonene is not essential for its biological activity. The main limitation of (S)-(?)-limonene as a model compound is its moderate activity, but we have found that by replacing the single hydrogen in the methyl group of (S)-(?)-limonene by a chlorine atom, one obtains an active, highly enantioselective compound, (1R,2S)-(1)-(1,2-dihydro-1,2-dihydroxy-2-methyl-1H-indene-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SNX5422is a drug that inhibits
 
Response: SNX5422is a drug that inhibits an essential step in the vesicular transport of GPI-anchored proteins to the cell surface. As a result, it blocks the production of the GPI-anchored protein-enriched membrane microdomains (GPI-AMMs) on the cell surface, and thereby inhibits the growth of cancer cells. SNX5422 also inhibits the growth of glioblastoma multiforme (GBM), a particularly aggressive type of brain cancer, which makes it an attractive therapeutic agent for GBM. However, SNX5422 does not reach the brain in effective concentrations. The goal of this proposal is to identify and develop a therapeutic agent that can be taken orally and reaches the brain in effective concentrations. To accomplish this goal, we will identify a drug that inhibits a step in the GPI-anchored protein transport pathway in the brain that is absent in the kidney. We will then select for the compound that is least toxic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  sodiumis a drug that inhibits
 
Response: sodiumis a drug that inhibits Na^+^/H^+^ exchange. We speculate that increasing the concentration of sodium or reducing the concentration of chloride in the bath will reduce the efficacy of the reversal of pH~i~ changes caused by extracellular acidification. The use of a perfusion system will allow the application of different concentrations of sodium and chloride to the cells. The pH~i~ values will be measured at various time points to examine whether this is true.

2\. The authors show a dramatic increase in H^+^/OH^-^ uptake in MDCK cells expressing H^+^/OH^-^ antiporters upon addition of the SERCA inhibitor CPA. In the same cells, there is a small decrease in pH~i~ upon acidification with the SERCA inhibitor thapsigargin. This seems to contradict the previous statement that the increased H^+^/OH^-^ uptake upon acidification of M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sodiumis a drug that inhibits
 
Response: Sodiumis a drug that inhibits the sodium-potassium pump, a transmembrane enzyme which maintains a gradient of sodium and potassium ions across the cell membrane. Sodium ions enter the cell when the sodium-potassium pump is working and are then expelled by the pump when it is not working. The cell membrane is impermeable to potassium ions.

When a cell is not getting enough sodium ions, the potassium concentration rises in the cell, and the cell cannot maintain its electrical potential.

The only way that the cell can maintain its electrical potential is to lower its concentration of potassium. The cell does this by pumping potassium out of the cell, which increases the concentration of potassium in the cell.

This process is called excretion. The amount of sodium that is pumped out of the cell depends on the concentration of sodium in the cell.

The higher the sodium concentration in the cell, the more sodium that is pumped out of the cell.

This is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sofosbuvir(PSI-7977)is a drug that inhibits
 
Response: Sofosbuvir(PSI-7977)is a drug that inhibits the replication of hepatitis C virus (HCV). It is being developed by Pharmasset Inc. Sofosbuvir is a uridine analog that acts as a chain terminator by blocking the synthesis of the hepatitis C virus (HCV) RNA. It is a nucleotide analogue inhibitor of the HCV NS5B polymerase and is also active against hepatitis B virus (HBV).

Sofosbuvir was approved by the US FDA in November 2013 under the trade name Sovaldi(R) (Sofosbuvir) for the treatment of chronic HCV infection in combination with ribavirin.

Sofosbuvir is currently under review by the FDA for approval for use in combination with pegylated interferon alfa and ribavirin for the treatment of chronic hepatitis C genotype 1 infection in patients who have previously failed to respond to peginterfer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SOLATENEis a drug that inhibits
 
Response: SOLATENEis a drug that inhibits CDK7, the kinase that phosphorylates the carboxyl terminal domain (CTD) of the largest subunit of the RNA polymerase II. It was initially identified as a protein synthesis inhibitor in the treatment of cancer and is being studied for the treatment of cancer and as a novel agent to treat virus infections. SOLATENE is a prescription drug, with no approved indications, approved for use in Europe, and not yet approved in the United States.

There is no FDA approved indication for SOLATENE. It is used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in combination with the drug, azacitidine. In Europe, SOLATENE is indicated for the treatment of AML in combination with azacitidine. SOLATENE is also being studied in clinical trials for the treatment of chronic lymphocytic leukemia (CLL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Solifenacinis a drug that inhibits
 
Response: Solifenacinis a drug that inhibits the enzyme COX-2 and thereby stops the production of prostaglandins that cause inflammation and pain. It is approved in many countries for use in treating rheumatoid arthritis, osteoarthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Sucralfate is a drug that is used to treat stomach ulcers. It works by binding to the acid in the stomach and is less likely to be absorbed into the blood than other drugs that bind to the stomach acid. It also has a laxative effect and works by binding to the bacteria in the gut that causes stomach ulcers.

Salicylates are used to treat a wide range of conditions such as fever, hay fever, pain and inflammation, asthma, rheumatic fever and osteoarthritis. The most commonly used salicyl
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Somatostatinis a drug that inhibits
 
Response: Somatostatinis a drug that inhibits the release of hormones and other substances from cells, and also inhibits cell growth. It is used to treat some hormone-related diseases, such as acromegaly and some types of pituitary adenomas, and it can be used to treat patients with some types of cancers.

Somatostatin is also used to treat pain.

Somatostatin was discovered by Emilio L. Eugenio and Alberto Capetillo. It was first isolated in 1954 by Eugenio and Capetillo from the extracts of the porcine hypothalamus and was named after the Greek word soma, meaning body.

Somatostatin is produced by many different types of cells throughout the body, including neurons, parafollicular cells, and the K cells of the endocrine pancreas. It is also produced by endocrine cells in the gastrointestinal tract. Somatostatin is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sorafenibis a drug that inhibits
 
Response: Sorafenibis a drug that inhibits tumor growth in the liver, kidney, lung, and pancreas. It is also effective against the growth of certain other types of tumors. It is used to treat kidney, liver, and lung cancers. Sorafenib is also used to treat some rare types of tumors.

Dosage and Administration

Sorafenib is taken by mouth. It is usually taken twice daily with meals. It can be taken with or without food. The dose is based on your medical condition and response to treatment. Your doctor may adjust your dose based on your medical condition and response to treatment.

Side Effects

Sorafenib can cause side effects. Check with your doctor if you notice any side effects that you think are related to sorafenib.

Your doctor will do lab tests to check your blood, liver, and kidney function before and during treatment. Be sure to keep all appointments with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sorbitolis a drug that inhibits
 
Response: Sorbitolis a drug that inhibits CCR5 and other GPCRs and its therapeutic potential in chronic inflammatory diseases.
Sorbitol (SOR) is a polyhydric alcohol with anti-diabetic properties. In the present study, we evaluated the effect of SOR on macrophage-induced inflammatory responses. SOR significantly inhibited LPS-induced NO production and the phosphorylation of IκBα and p65 in RAW264.7 cells. Moreover, SOR significantly suppressed the LPS-induced release of pro-inflammatory cytokines and chemokines from RAW264.7 cells. SOR inhibited LPS-induced phosphorylation of IKKα/β and p38 and ERK1/2, and SOR reduced the LPS-induced nuclear translocation of NF-κB. The inhibitory effects of SOR on the production of pro-inflammatory cytokines and chemokines and NF-κB activation were reversed by knocking down
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sotagliflozinis a drug that inhibits
 
Response: Sotagliflozinis a drug that inhibits the growth of cancer cells. These drugs block the production of DNA, RNA, and proteins in the cancer cell, causing cell death. They work best when used in combination with other cancer treatments.

In the 1970s, people started using diethylstilbestrol (DES) in an attempt to prevent miscarriage. It is a hormone used in some countries to make pregnant women stop producing estrogen. But it is also known to cause cancer in men and women. DES was first approved for use in the United States in 1938 and was soon taken off the market because of the potential dangers. It has been banned for over 50 years.

Surgical removal of cancer cells is the best treatment for breast cancer. However, for some types of cancer, it is not enough to remove the cancer cells. Surgery removes the tumor and nearby healthy tissue. It also removes the lymph nodes, which are the first place the cancer spreads to.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sotalolis a drug that inhibits
 
Response: Sotalolis a drug that inhibits cholesterol absorption and thus reduces LDL cholesterol levels in the blood.

Statins are not only the most prescribed drug in the world but also the most prescribed class of drugs in the world. A recent study published in the Journal of the American Medical Association found that almost 50% of the US population over the age of 40 takes statins.

Despite their widespread use, a recent study by a team of researchers from the Karolinska Institutet in Sweden found that some statins are not only ineffective in preventing heart attacks and strokes, but may even increase the risk of such events.

A decade of war and conflict in Iraq has been devastating for the country’s health. More than 1.5 million Iraqis have died since the 2003 invasion. More than 7 million Iraqis have been injured and over 4.4 million displaced, according to the Iraq Body Count project.

Although there are many ongoing efforts to improve the quality of life
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sotrastaurinis a drug that inhibits
 
Response: Sotrastaurinis a drug that inhibits the enzyme dihydroorotate dehydrogenase (DHODH), an enzyme required for the biosynthesis of pyrimidines (uracil, thymine and cytosine), in cells that are deficient in dihydroorotate dehydrogenase (DHODH) is an inhibitor of viral replication in herpes simplex virus (HSV), herpesvirus 1, and varicella zoster virus (VZV). It has also been shown to inhibit the replication of certain retroviruses.

Pharmacology
Sotrastaurin inhibits the enzyme dihydroorotate dehydrogenase (DHODH), an enzyme required for the biosynthesis of pyrimidines (uracil, thymine and cytosine), in cells that are deficient in dihydroorotate dehydrogenase (DHODH).  It has also been shown to inhibit the replication of certain
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sparsentanis a drug that inhibits
 
Response: Sparsentanis a drug that inhibits the serotonin 5-HT2 receptor subtype (the main 5-HT2 receptor subtype is 5-HT2C) and is used for the treatment of migraine. Sparsentanis was the first serotonin receptor antagonist to be approved for use in humans and has a proven efficacy in the treatment of migraine, which makes it the drug of choice for this indication. Sparsentanis was approved by the FDA in December 2002 and is marketed under the trade name LY2951726.

Sparsentanis was developed by Merck and is an orally administered, selective, serotonin 5-HT2 receptor antagonist, which blocks the activation of serotonin receptors.

Sparsentanis is indicated for the acute treatment of migraine with or without aura in adult patients. Sparsentanis is not indicated for the prevention of migraine.

1.1 Indication

Sparsentanis is indicated for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Spectinomycinis a drug that inhibits
 
Response: Spectinomycinis a drug that inhibits the growth of HIV by preventing viral DNA synthesis. It is a component of HIV drugs.

External links
 USP Index Listing

Category:Cyclohexenyl compounds
Category:Organofluorides
Category:Pyrrolidines
Category:Viral infections of the central nervous system
Category:Hepatotoxins
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SPECTRACEFis a drug that inhibits
 
Response: SPECTRACEFis a drug that inhibits the Na/K ATPase pump in renal proximal tubule cells.

It is an experimental drug used for the treatment of CKD and FSGS.

There are no data on its use in children.

Pre-emptive use of nephrotoxic drugs has become the standard of care in most cases of FSGS.

Unfortunately, this practice may cause nephrotoxicity.

Objective
=========

We report the case of a young girl with a recent diagnosis of FSGS and progressive nephrotoxicity.

Methods
=======

This is a case report of a 9-year-old girl who developed nephrotoxicity with intravenous (IV) fosphenytoin, which was started to treat a new-onset seizure disorder. She had no previous history of renal disease. She was hospitalized after a few days of fever and altered mental status. She
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  spiramycinis a drug that inhibits
 
Response: spiramycinis a drug that inhibits protein synthesis. A comparison of four antimicrobial drugs used to treat burn wounds (silver sulfadiazine, ciprofloxacin, piperacillin/tazobactam, and tobramycin) in an in vivo burn wound model showed that the drug of choice should be selected based on its in vitro efficacy against Staphylococcus aureus and its activity against S. aureus strains that are resistant to penicillin and other beta-lactam antibiotics. Ciprofloxacin is a second-generation fluoroquinolone and was the only drug that consistently inhibited the growth of S. aureus in vitro and prevented infection in vivo. Ciprofloxacin is active against Gram-positive and Gram-negative bacteria and is considered to be the drug of choice for the treatment of burns.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  spironolactoneis a drug that inhibits
 
Response: spironolactoneis a drug that inhibits aldosterone synthase. This drug is used to treat high blood pressure and certain other conditions.

Chemistry

Spironolactone is a derivative of dihydrotestosterone.

Spironolactone has the following chemical structure:

Uses

Spironolactone is used to treat:

high blood pressure

anxiety

acne

high levels of cholesterol

hypogonadism

hypothyroidism

Cushing's syndrome

acne

The dose of spironolactone that is used for high blood pressure varies depending on the person. The dose of spironolactone for high blood pressure is usually 20-40 mg a day. The dose of spironolactone for anxiety is usually 50-100 mg a day.

Spironolactone is also used to treat the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S-(+)-Rolipramis a drug that inhibits
 
Response: S-(+)-Rolipramis a drug that inhibits the activity of the phosphodiesterase-4 (PDE4). It has a rapid and significant antidepressant effect. In humans, the PDE4 enzyme is mainly expressed in the brain. The antidepressant effect of PDE4 inhibitors may therefore be mediated by changes in synaptic function. PDE4 is a ubiquitous enzyme and the function of the PDE4 isozymes is still a matter of debate. A role for the PDE4D isozyme in the antidepressant effect of PDE4 inhibitors has been suggested, but direct evidence for this is lacking. In this study, we examined the role of PDE4D in the antidepressant effect of the PDE4 inhibitor Rolipram. In mice, acute administration of Rolipram, but not saline, decreased the immobility time in the tail suspension test, which is considered to be a test for antidepressant activity. Rolipram had no effect on
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  S-Ruxolitinibis a drug that inhibits
 
Response: S-Ruxolitinibis a drug that inhibits JAK2 and the proliferation of the malignant cells. The JAK2 V617F mutation has been found in about 50% of patients with PV, 50% of patients with ET and \<10% of patients with PMF. The incidence of this mutation is higher in younger patients with PV, but its prognostic significance is not well established \[[@R17]\]. As in the case of ruxolitinib, the response to JAK2 inhibitors is generally more rapid in patients with PV, as compared to patients with ET or PMF. Therefore, it is believed that patients with PV have a better chance of attaining hematological response with JAK2 inhibitors \[[@R18]\]. The recent results of the clinical trials of the JAK2 inhibitor TG101348 in patients with PV showed that hematological response and cytogenetic response were obtained in 70% of patients and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Stavudineis a drug that inhibits
 
Response: Stavudineis a drug that inhibits the replication of HIV by blocking the reverse transcriptase of the virus. The common adverse effects of stavudine include nausea, vomiting, diarrhea, anorexia, skin rash, hair loss, abdominal pain, headache, dizziness, confusion, insomnia, and musculoskeletal pain. The most common adverse effect of stavudine in the elderly is anemia.

In the late 1980s, the use of stavudine was considered a therapeutic option for patients with HIV infection and their providers because of its improved tolerability compared to zidovudine and didanosine.[@b1-cia-3-079] Although stavudine is not a cure for HIV infection, it was thought to be less toxic than zidovudine and didanosine and to have a better side effect profile, including a lower risk of anemia. This improved tolerability of stavudine compared
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Streptomycinis a drug that inhibits
 
Response: Streptomycinis a drug that inhibits bacterial growth. As such, it has been used to treat fungal infections.

Inhibitors of the body's own immune system: Immunosuppressants inhibit the body's immune system and thereby inhibit its ability to fight infections.

Antibiotics: Drugs that destroy bacteria.

Anti-inflammatories: Drugs that reduce inflammation.

Lubricants: Pharmaceuticals that reduce friction and ease the passage of joints and organs.

Palliatives: Drugs that provide pain relief.

Etc.

The goal of the FDA is to protect the public from unsafe drugs, and that goal is being met by the pharmaceutical industry. They have improved the lives of millions of people around the world.

A number of problems have arisen, however. First, the costs of developing and bringing new drugs to market have skyrocketed, which is driving up the prices of these drugs. As a result, patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Streptozocinis a drug that inhibits
 
Response: Streptozocinis a drug that inhibits the protease that digests nerve proteins. (A) Aliquots of the culture medium from the infected cell cultures were collected and processed for protease activity assays at the indicated times after infection. The absorbance values are expressed as a percentage of the maximum activity measured in the culture medium of the uninfected cells (no protease activity). (B) A schematic diagram of the *in vivo* experiment. Mice were given an i.p. injection of *S. aureus* strain 8325-4 or a *hla* mutant, and 2 days later, the blood was collected for the determination of the serum levels of SPA and mouse serum protease inhibitor. (C) The serum levels of SPA in the mice infected with 8325-4 or its *hla* mutant. The levels of SPA in the serum from mice infected with 8325-4 (closed circle) and its *
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Suberohydroxamicis a drug that inhibits
 
Response: Suberohydroxamicis a drug that inhibits osteoclastogenesis.^[@bibr18-1759720X18809683]^ It was approved by the US Food and Drug Administration in February 2017 for the treatment of active, moderate-to-severe RA in adult patients who have had an inadequate response to DMARDs and in whom treatment with a TNF-α inhibitor is not appropriate. The drug has a good safety profile,^[@bibr19-1759720X18809683]^ with a higher incidence of infusion-related reactions in patients with a prior history of infusion reactions to infliximab.^[@bibr20-1759720X18809683]^ This adverse event is believed to be due to increased levels of tumor necrosis factor (TNF) in patients treated with suberohydroxamic acid.^[@bibr21-1759720X18809683]^ This drug is a potent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Succimeris a drug that inhibits
 
Response: Succimeris a drug that inhibits p53 from binding to the promoters of p21 and mdm2, thus blocking the transcription of p21 and mdm2, and in turn leading to cell cycle arrest. In our study, we treated SCC-4 and SCC-15 cells with Succimeris, and analyzed cell cycle arrest, cell proliferation, and apoptosis.

1. Materials and Methods {#sec1-ijms-18-01991}
========================

1.1. Cell Culture {#sec1dot1-ijms-18-01991}
-----------------

The human oral cancer cell lines, SCC-4 and SCC-15, were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Logan, UT, USA) containing 10% fetal
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Succinylcholineis a drug that inhibits
 
Response: Succinylcholineis a drug that inhibits acetylcholine release at the neuromuscular junction. It is used in the emergency department to facilitate tracheal intubation and to facilitate endotracheal tube placement in the setting of acute, unexpected difficult airway. It has also been used for rapid sequence induction of anesthesia, which allows for a more rapid induction of anesthesia with minimal risk of airway complications.

In the emergency department, succinylcholine is commonly used in combination with rocuronium for rapid sequence intubation. Succinylcholine has a relatively short duration of action, allowing for rapid sequence intubation and a more rapid onset of action than other muscle relaxants. In the operating room, succinylcholine is used for tracheal intubation and as a relaxant in patients with an expected difficult airway.

For this patient, succinylcholine was used to facilitate tracheal intubation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  sucraloseis a drug that inhibits
 
Response: sucraloseis a drug that inhibits the absorption of glucose from the gut, and so reduces blood sugar levels. It's a sugar substitute that is 100% natural and completely safe.

You might be wondering why there is a need for a sugar substitute, since sugar is a natural substance. In the first place, we use sugar for a variety of purposes, not just to make food tasty. It is a component of many foods, including fruit, fruit juices, and certain kinds of baked goods.

In addition, sugar is used to sweeten drinks. And it's used in a variety of pharmaceutical products, such as cough syrups, throat lozenges, and cold remedies.

Finally, sugar is used as a flavoring agent in many foods. It adds a distinctive taste to food products, and it helps to keep them moist.

In recent years, the amount of sugar that is consumed has increased significantly. This is partly due to a number
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sugammadexis a drug that inhibits
 
Response: Sugammadexis a drug that inhibits the neuromuscular blocking activity of steroidal and nonsteroidal anaesthetics and is administered as an antagonist of the neuromuscular blocking activity of nondepolarizing muscle relaxants. The manufacturer, the steroidal anaesthetic manufacturer, and the neuromuscular blocking activity of sugammadex were all declared to the World Health Organization. The manufacturer of sugammadex was declared to the European Union. The manufacturer of sugammadex was also notified to the FDA. The manufacturer of sugammadex was notified to the Ministry of Health of Chile.

All the tests were performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. The study protocol was approved by the local Ethics Committee and all the patients provided written informed consent. The study was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT0195
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulbactamis a drug that inhibits
 
Response: Sulbactamis a drug that inhibits the formation of a peptide crosslink of the colicin E3 and colicin E5 toxins and thus disrupts the action of the colicin. This drug is effective in treating urinary tract infections and is also being tested as a possible treatment for sepsis. The sulbactam compound has been the subject of numerous patents, for example, U.S. Pat. No. 4,260,627 to Doi et al. and U.S. Pat. No. 4,278,575 to Laskowski et al.
In addition to the sulbactam compound, a variety of other beta-lactam compounds have been reported to have activity against the colicin colicin E3 and colicin E5. These include a compound described in U.S. Pat. No. 4,548,925 to Miller et al. and a compound described in U.S
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulconazleis a drug that inhibits
 
Response: Sulconazleis a drug that inhibits acetylcholinesterase, and thereby stimulates acetylcholine. This results in increased levels of acetylcholine, which stimulates the muscles in the brain and helps to improve the brain’s ability to think.

Sulconazole is also used to treat other conditions, such as fungal infections, including toenail fungus. It is available as an oral drug and is used to treat both skin and vaginal infections.

Sulconazole was approved for use in the United States in 1995. It is available in tablet form and in liquid form.

Side Effects

Sulconazole may cause side effects that include headache, diarrhea, nausea, and vomiting. It may also cause allergic reactions, liver problems, and jaundice. Sulconazole can affect the blood sugar levels of people with diabetes.

If you have been taking sulconazole for a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SULFADIAZINEis a drug that inhibits
 
Response: SULFADIAZINEis a drug that inhibits cytochrome P450 enzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp) in the gut, liver, and small intestine, and enhances the oral bioavailability of many drugs that are substrates of these transporters. These effects of itraconazole can be used to increase the oral bioavailability of drugs that are P-gp substrates, to decrease the systemic exposure of P-gp substrates, or to increase the systemic exposure of drugs that are P-gp inhibitors. SULFADIAZINEis also an inhibitor of breast cancer resistance protein (BCRP) and organic anion transporter 1 (OAT1), and may be useful in the treatment of cancer, neurodegenerative diseases, and cardiovascular diseases.

SULFADIAZINE

INDICATIONS AND USAGE

SULFADIAZINE is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfadoxineis a drug that inhibits
 
Response: Sulfadoxineis a drug that inhibits the action of dihydropteroate synthase, the enzyme that catalyzes the biosynthesis of the sulfonamide-containing pteridine cofactor required for the action of folate-dependent enzymes. Sulfadoxine is used to treat malaria, amoebiasis, giardiasis, and other parasitic infections. The World Health Organization has proposed that sulfadoxine be used as a first-line treatment for malaria in areas where the parasite has developed resistance to chloroquine, the drug used in the past for malaria treatment. See

Paraquat is an herbicide. In its pure form, it is a strong oxidizing agent that has been used to kill unwanted plants and is highly toxic to animals and humans. Paraquat is most commonly used as an insecticide.

Paraquat is used in agriculture, forestry, and household pest control. It is also used to kill weeds
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfaguanidineis a drug that inhibits
 
Response: Sulfaguanidineis a drug that inhibits the activity of acetylcholinesterase. It is used to treat the symptoms of a cholinergic crisis, such as agitation, myoclonus, fasciculations, and seizures.

Procedure

Dosage

Usually administered orally in divided doses, 1–2 hours before surgery.

Precautions

Before administration, patients should be informed of the risk of respiratory depression and should be advised to report the use of central nervous system depressants and the risk of respiratory depression in patients with known or suspected respiratory disease. The risk of allergic reactions is unknown.

Pregnancy/Lactation

Pregnancy Category C. Not recommended for use in pregnant women. Unknown if distributed in breast milk. Breastfeeding not recommended.

Interactions

Drugs or other substances that prolong the QT interval may increase the risk of torsades de pointes, a potentially
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfamerazineis a drug that inhibits
 
Response: Sulfamerazineis a drug that inhibits the growth of a broad range of microorganisms, including bacteria, yeasts, and fungi. It is used in animals to prevent and treat disease, and it can be used in people for the same purpose. Sulfamerazine can be given by mouth or by injection into a muscle or a vein.

Sulfamerazine Side Effects, Adverse Reactions

Sulfamerazine Side Effects, Adverse Reactions

If you have a medical emergency, call your doctor or 911 immediately.

Sulfamerazine Side Effects, Adverse Reactions

Overdose:

Sulfamerazine Overdose

Call your doctor immediately if you have symptoms of an overdose, such as:

fast or slow breathing

irregular or slow heartbeat

cold or clammy skin

Confusion, agitation, and hallucinations may also occur.

Sulfamerazine Overdose

If you
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfamethazineis a drug that inhibits
 
Response: Sulfamethazineis a drug that inhibits the growth of gram-positive and gram-negative bacteria. It is also used in the treatment of rheumatoid arthritis and psoriasis.

Sulfamethazine may also be used for purposes not listed in this medication guide.

What is the most important information I should know about sulfamethazine?

Do not take sulfamethazine if you have an allergy to sulfa drugs, or if you have severe kidney disease.

Sulfamethazine may cause low levels of red blood cells in your blood (anemia). Your healthcare provider may need to monitor your blood count during treatment.

You may need to use certain precautions when taking sulfamethazine.

Before taking sulfamethazine, tell your healthcare provider if you:

have ever had an allergic reaction to sulfa drugs or other medicines, foods, dyes, or preservatives

are pregnant or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfamethoxypyridazineis a drug that inhibits
 
Response: Sulfamethoxypyridazineis a drug that inhibits certain bacterial enzymes. It is used in treating infections caused by microorganisms, especially gram-negative bacteria.

The body of a healthy adult can tolerate up to 3 grams of this drug without experiencing any ill effects. However, the toxic dose for a child is 1/10th of this amount.

The effective dose for a child is 10 to 20 mg per kg of body weight. The drug should be taken only in hospital or by the person in charge of the child. It should be kept in a safe place and should not be shared.

Symptoms of overdose include vomiting, diarrhea, agitation, hallucinations, and drowsiness. In severe cases, seizures and death can occur.

This drug can cause serious allergic reactions, especially in people with a history of allergic reactions to sulfonamides.

Drugs that cause serious allergic reactions include sulfonamides, sulfonamide antibiotics
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SULFAPYRIDINEis a drug that inhibits
 
Response: SULFAPYRIDINEis a drug that inhibits the enzyme sulfotransferase. It has been used to treat type 2 diabetes. There have been reports of kidney damage in people who have taken this drug. There are not enough data to assess the risks and benefits of taking this drug.

**SULT2B1** (sulfotransferase 2B1)

SULFAPYRIDINEis a drug that inhibits the enzyme sulfotransferase. It has been used to treat type 2 diabetes. There have been reports of kidney damage in people who have taken this drug. There are not enough data to assess the risks and benefits of taking this drug.

**SULPHAMETOXAZOLE** (Sulfamethoxazole, Trimethoprim)

This is a drug used to treat infections. It is also a drug that has been used to prevent and treat diarrhea caused by _
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulfathiazoleis a drug that inhibits
 
Response: Sulfathiazoleis a drug that inhibits bacterial dihydropteroate synthase, an enzyme involved in folate biosynthesis, and that acts as a bacteriostatic agent in a number of pathogenic organisms.\[[@CIT1]\]

It is extensively used as a second-line drug for the treatment of uncomplicated urinary tract infections (UTI),\[[@CIT2]\] although there is increasing concern over its potential adverse effects on the renal system.\[[@CIT3]\]

Several reports on sulfonamide-induced acute interstitial nephritis (AIN) are available in the literature.\[[@CIT4]--[@CIT6]\] However, most of these reports were case reports.

We describe a case of sulfathiazole-induced AIN in a 60-year-old male patient.

CASE REPORT {#sec1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  sulforaphaneis a drug that inhibits
 
Response: sulforaphaneis a drug that inhibits cancer cells. A team of researchers from UCLA, led by Dr. Debra A. Dixon, has now found that sulforaphane also has powerful effects on the neurons of the brain.

The study, which appears in the October 5 issue of the journal Science, found that sulforaphane can protect the neurons of the brain from radiation-induced damage. This finding may have important implications for the treatment of patients who receive radiation therapy for cancer.

Radiation therapy, a standard treatment for some cancers, damages the brain. It is believed that the damage is caused by reactive oxygen species (ROS) that are released by radiation. Sulforaphane is an antioxidant that inhibits ROS production. It also is known to protect the liver from radiation damage.

In the current study, Dixon and her team showed that sulforaphane inhibits ROS production in neurons and protects them from radiation damage. In addition, sulfor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sulindacis a drug that inhibits
 
Response: Sulindacis a drug that inhibits cyclooxygenase, one of the two key enzymes involved in the conversion of arachidonic acid to prostaglandins and leukotrienes.

Sulindac, the active ingredient in a prescription drug used to treat ulcerative colitis and arthritis, has been associated with a number of adverse effects, including abdominal pain, diarrhea, nausea, and vomiting. It also has been linked to birth defects and cancer.

But a recent study by two researchers at the National Institutes of Health suggests that the drug can have a beneficial effect on women's health.

The study, which appears in the November issue of the journal Infertility and Embryology, is the first to show that sulindac is safe and effective in helping women become pregnant.

"The effects of the drug on reproductive function in humans are well documented," said David R. Appel, M.D., an associate professor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  SULLAis a drug that inhibits
 
Response: SULLAis a drug that inhibits P2Y12. The authors believe that this explains why the decrease in platelet aggregation and ADP-induced shape change and fibrinogen binding was not as pronounced as with the inhibition of the PAR-4 receptor. In addition, the findings in the last paragraph of the discussion are inconsistent with the data in the first paragraph of the discussion, where the authors claim that there is a correlation between platelet function and activation of the PAR-4 receptor.

In our model, platelet activation was measured in the presence of 20 μM A-SUL and in the presence of 20 μM PSB-1115, and the data were correlated with the platelet aggregation and P-selectin expression, respectively. In the presence of A-SUL, we observed a partial inhibition of platelet aggregation and a moderate decrease in P-selectin expression. The data indicate that the P2Y12 receptor, which is the most
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sultamicillinis a drug that inhibits
 
Response: Sultamicillinis a drug that inhibits the body’s production of an enzyme, called nitric oxide synthase, that helps regulate blood pressure. Sultamicillis works by causing blood vessels to constrict, thereby reducing blood pressure. It is taken orally, usually in tablet form. The dose of sultamicillis varies depending on the severity of the condition.

Kanamycin: A antibiotic that is effective against certain strains of Staphylococcus, Klebsiella, Proteus, Enterobacter, and other bacteria. Kanamycin is often prescribed to treat urinary tract infections and other conditions that are caused by bacterial infections.

Phenobarbital: An anticonvulsant drug. Phenobarbital is usually prescribed to treat seizures in children. It is also used to treat anxiety, agitation, depression, and sleep disorders.

Potassium Chloride: A salt that helps regulate fluid levels in the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sumatriptanis a drug that inhibits
 
Response: Sumatriptanis a drug that inhibits the serotonin 5-HT1D receptor. It is indicated for the acute treatment of migraine headaches, and may also be used for the prevention of migraine headaches. The Food and Drug Administration (FDA) has approved sumatriptan as an over-the-counter (OTC) drug in the United States for the treatment of migraine headaches. Sumatriptan is also approved in other countries as an OTC drug for the treatment of migraine. Sumatriptan is also available in a number of prescription forms, including a tablet and injectable form.
Migraine headaches are a common and often debilitating neurological condition. Migraine is a disorder of the brain, characterized by episodes of headache and associated symptoms. Migraine headache is a severe and disabling form of headache. Migraine headache is a recurrent headache disorder characterized by moderate to severe pain, which may be unilateral and throbbing in nature, associated with nausea, vomiting, photophobia,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Sunitinibis a drug that inhibits
 
Response: Sunitinibis a drug that inhibits a protein called tyrosine kinase (TK). TKs are important in signaling pathways and in cell growth. A TK can be inhibited by the drug, and this inhibits the growth of cells. Sunitinibis used to treat kidney and bladder cancer. It is taken by mouth.

This medicine can cause side effects, including:

abdominal pain

diarrhea

dry skin

fever

hand-foot syndrome

malaise

nausea

rash

sore mouth

sores on lips or around mouth

vomiting

yellowing of the eyes or skin

Your doctor may have suggested that you stop taking this medicine or take a dose reduction because of some of these side effects.

If you have any questions about this, talk to your doctor.

Side effects may be reported during product labeling
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Suplatastis a drug that inhibits
 
Response: Suplatastis a drug that inhibits TNF, IL-1, and IL-6. Its efficacy in treating patients with RA has been reported in many studies. However, only one of them was a randomized, controlled trial \[[@B14]\]. All other studies were open-label, non-randomized trials \[[@B15]-[@B19]\]. In the recent study, 40 patients were enrolled and all of them were included in the efficacy analysis \[[@B14]\]. The improvement of the DAS28 and DAS28 (CRP) were not significantly different in the treatment group compared to the placebo group (p = 0.06 and p = 0.09, respectively). The American College of Rheumatology (ACR) response criteria was met by 33.3% of patients in the treatment group compared to 0% in the placebo group. The authors concluded that their results were not sufficient to prove the efficacy
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Suxibuzoneis a drug that inhibits
 
Response: Suxibuzoneis a drug that inhibits one of the enzymes needed to convert thyroid hormone into its active form. The thyroid gland makes thyroid hormone (T4) which is converted into the active form (T3) in the liver. T3 travels to the cells and stimulates them to produce energy. The body can't store T3 in the liver so it must be produced in the body.

Suzixotone is a drug that is used to treat Addison's disease. Addison's disease is a condition that causes the body to not produce enough of its own thyroid hormone.

Symbicort is a drug that is used to treat allergies. Symbicort works by decreasing the amount of histamine that is released into the body. Histamine is an allergic reaction causing the body to make allergy related proteins.

Symbicort is a drug that is used to treat allergies. Symbicort works by decreasing the amount of histamine that is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Synephrineis a drug that inhibits
 
Response: Synephrineis a drug that inhibits the reuptake of noradrenaline (NA) and adrenaline (A) from the synaptic cleft. This drug has a low abuse potential and few side effects. It is prescribed in the treatment of anxiety and depression, and has been used in sport performance enhancement.[1] It has also been found to be useful in the treatment of attention deficit hyperactivity disorder (ADHD) in children, and is one of the most common ADHD medications used in the United States.[2]

Neurons release NA and A, which bind to postsynaptic receptors and stimulate the synthesis of more NA and A. When NA and A are released, the synaptic cleft is depleted. Synephrine stimulates the uptake of NA and A back into the presynaptic neuron. This is similar to the way in which nicotine stimulates the uptake of A back into the presynaptic neuron. Synephrine acts by increasing the affinity of A and NA for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  T-705is a drug that inhibits
 
Response: T-705is a drug that inhibits the replication of HIV-1 by binding to the viral reverse transcriptase and thus to stop the replication process. The aim of this study was to compare the effects of T-705 and zidovudine (AZT) on cell survival in U937 cells infected with HIV-1. In this study, we have demonstrated that the combination of T-705 and AZT could decrease the viability of U937 cells infected with HIV-1. This decrease was due to the decrease in the cell cycle and apoptosis. We also found that the decrease in cell viability induced by T-705 and AZT was correlated with the decrease in HIV-1 expression. These results suggest that T-705 can be a potential alternative therapy to AZT for HIV-1 infected patients.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  tacrineis a drug that inhibits
 
Response: tacrineis a drug that inhibits the acetylcholine receptors. It is an anti-muscarinic agent. The drug was used to treat schizophrenia and is now obsolete.

History
Tacrine was first synthesized by Donald W. Wesson and coworkers at Pfizer in 1964.  It was designed to have more potency than earlier muscarinic antagonists such as atropine.

References

Category:Muscarinic antagonists
Category:Abandoned drugs
Category:Pfizer brands
Category:Aminopyridines
Category:Carboxamides
Category:Ureas
Category:Phenol ethers
Category:Phenols
Category:Cyclopropanes
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tafamidisis
 
Response: Tafamidisis a new disease-modifying treatment for patients with Familial Amyloid Polyneuropathy (FAP) that has recently been approved by the FDA. It is a synthetic trifluoroacetate derivative of tafamidis, which has been shown to reduce amyloid deposition in a rat model of FAP. Tafamidis is the first disease-modifying treatment to demonstrate a reduction in the rate of clinical progression of FAP, and has been shown to slow the rate of loss of function in peripheral nerve fibers. The data from the Phase III clinical trials of tafamidis have been presented at several scientific meetings, and the drug is currently being tested in other forms of neuropathy.

I discuss the history of tafamidis, the development of the drug, the data that led to the approval of tafamidis by the FDA, the role of amyloid and its treatment in FAP, and the potential
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAK-117is a drug that inhibits
 
Response: TAK-117is a drug that inhibits the proteasome and is being investigated as a potential anticancer agent. It is a small molecule, nonpeptidyl, reversible, and selective inhibitor of the chymotrypsin-like activity of the proteasome, resulting in the accumulation of ubiquitinated proteins and the activation of the cell death pathway. In this article, the pharmacology, pharmacokinetics, clinical efficacy, and safety of TAK-117 are reviewed.

Abstract

TAK-117 is a drug that inhibits the proteasome and is being investigated as a potential anticancer agent. It is a small molecule, nonpeptidyl, reversible, and selective inhibitor of the chymotrypsin-like activity of the proteasome, resulting in the accumulation of ubiquitinated proteins and the activation of the cell death pathway. In this article, the pharmacology, pharmacokinetics, clinical efficacy, and safety of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAK-438is a drug that inhibits
 
Response: TAK-438is a drug that inhibits an enzyme called P-glycoprotein, which is found in the membrane of cells in the brain. It is used to treat patients with multiple sclerosis (MS) and prevent MS relapses.

MS is a disease of the central nervous system that causes damage to the brain and spinal cord. MS is a chronic disease that affects more than 2.3 million people worldwide, and can cause a wide variety of symptoms, including vision loss, balance problems, cognitive impairment, pain, numbness, and tingling. MS usually occurs in people between 20 and 40 years of age.

MS relapses are a common cause of disability in patients with MS. The relapses can affect patients' ability to function and their ability to work. Most MS relapses are preceded by an infection or other illness, but they can occur without any obvious cause.

TAK-438is not currently approved in the United States, but the FDA granted
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAK-659is a drug that inhibits
 
Response: TAK-659is a drug that inhibits JAK1,2,3 and TYK2, but not ABL. The approval of this drug for the treatment of myelofibrosis has led to the identification of a novel therapeutic strategy to treat patients with B-cell lymphoma. This review summarizes the preclinical studies that have been conducted with this agent in the context of B-cell lymphoma. The therapeutic potential of TAK-659 in the treatment of B-cell lymphoma is supported by the following data: (i) it induces apoptosis of primary tumor cells in culture; (ii) it inhibits the proliferation of B-cell lymphoma cell lines in culture; (iii) it inhibits the growth of patient-derived tumor cells in a xenograft model of B-cell lymphoma; (iv) it induces the differentiation of primary B-cell lymphoma cells; and (v) it induces apoptosis in primary human B-cell lymphoma cells.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Talabostatis a drug that inhibits
 
Response: Talabostatis a drug that inhibits cholesterol synthesis and lowers serum cholesterol. Zilpaterol is an anabolic steroid that has been approved by the FDA to increase milk production in dairy cows. The drug also has been tested in dogs, horses, and donkeys.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Talniflumateis a drug that inhibits
 
Response: Talniflumateis a drug that inhibits the activity of acetylcholinesterase, an enzyme responsible for breaking down acetylcholine. It is used in combination with physostigmine to increase the effects of acetylcholine in the body. The main uses are in the treatment of Alzheimer’s disease and in the prevention of acute poisoning from organophosphate pesticides.

Medication uses

Treatment of Alzheimer’s disease

Treatment of organophosphate poisoning

Side effects

Overdose can cause cholinergic syndrome, which includes nausea, vomiting, abdominal cramps, muscle weakness, drowsiness, seizures, and death.

Rarely, there may be allergic reactions, such as hives, rash, or itching.

This medication is a phosphate salt. It is not known whether there is any risk of the phosphate in the medication reacting with the calcium in your blood, or of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tamibaroteneis a drug that inhibits
 
Response: Tamibaroteneis a drug that inhibits activation of NF-kB in T-cells. In animal models, tamibarotene has been shown to be effective in treatment of T-cell lymphoma, cutaneous T-cell lymphoma, and Hodgkin lymphoma. In phase I trials, it was found to be safe and effective in the treatment of T-cell lymphoma. In a randomized phase II trial, patients with advanced cutaneous T-cell lymphoma who had received at least one prior systemic therapy were randomly assigned to receive tamibarotene or imiquimod. The primary endpoint was response rate, and the secondary endpoints included progression-free survival, duration of response, overall survival, and safety. A total of 129 patients were enrolled, and the median duration of follow-up was 12.5 months. At a median follow-up of 12.5 months, the overall response rate was 78.7 percent in the tamibarot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tamsulosinis a drug that inhibits
 
Response: Tamsulosinis a drug that inhibits the body’s ability to absorb calcium, or calcium bisphosphonate, is effective in treating Paget’s disease. In many cases, the only sign of the disease is bone pain. However, other symptoms may also be present. Symptoms include fever, anemia, fatigue, and swollen joints. It is important to see your doctor if you have these symptoms. If your doctor thinks that you have Paget’s disease, a bone scan will be performed. If your doctor is not sure whether you have Paget’s disease, your doctor will order a bone scan. The results of the bone scan will be used to diagnose Paget’s disease. Your doctor may also perform other tests to help determine whether you have Paget’s disease. These tests include the following:

A blood test to check your calcium and phosphate levels.

An x-ray.

If you
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tanshinoneis a drug that inhibits
 
Response: Tanshinoneis a drug that inhibits the growth of cancer cells by targeting specific enzymes, the thymidylate synthase (TS) and the dihydrofolate reductase (DHFR). Tanshinone is the main active ingredient of Salvia miltiorrhiza, which has been used in China as a traditional medicine for a long time. Recently, there have been reports that tanshinone exhibits various biological activities, including anti-oxidative, anti-inflammatory, anti-bacterial, anti-proliferative, anti-viral, anti-cancer, and anti-angiogenic effects. Among these effects, its anti-cancer activity has been the most widely studied. It has been reported that tanshinone induces apoptosis in various cancer cell lines, including breast cancer, colon cancer, and lung cancer, by activating the p38 MAPK and ERK signaling pathways. It also has been shown that tanshin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TARACTANis a drug that inhibits
 
Response: TARACTANis a drug that inhibits the production of TGF-β1. It is used to treat patients with pulmonary fibrosis and fibrotic lung diseases, and to inhibit the growth of solid tumors. It is not known whether TARACTAN is safe for long-term use in humans, and its use in pregnant women and in children is not recommended.

TARACTAN is available as an oral suspension, tablets, and capsules.

How should TARACTAN be used?

Take TARACTAN by mouth with a full glass of water.

Your doctor may start you on a low dose of TARACTAN and gradually increase the dose to your maximum dose.

Take TARACTAN exactly as directed. Do not take in larger or smaller amounts or for longer than recommended by your doctor.

Do not stop taking TARACTAN unless your doctor tells you to.

Store at room temperature away from
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tartaricis a drug that inhibits
 
Response: Tartaricis a drug that inhibits the activity of tartrate-sensitive acid phosphatase. It is used to treat or prevent disorders of calcium metabolism and bone disorders.

USES: Tartaricis is used to treat bone disorders, especially Paget's disease, and disorders of calcium metabolism, including osteoporosis. It may be used alone or with calcitonin or estrogen. It may also be used to prevent osteoporosis and for treatment of osteoporosis.

PATIENT INFORMATION:

PATIENT BROWSING INFORMATION:

PATIENT INFORMATION:

Tartaricis Drug Information

Tartaricis Drug Information

Dosage

INDICATIONS:

Osteoporosis

Usual Adult Dose:

Recommended Starting Dose:

The recommended starting dose of tartaricis is 2 mg daily in divided doses (4 mg/
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAS-102is a drug that inhibits
 
Response: TAS-102is a drug that inhibits both the folate cycle and thymidylate synthase, thus interfering with DNA replication and RNA transcription. It is an oral agent that is taken in combination with capecitabine.

It is given on a weekly basis, and its recommended dose is a combination of 5-FU, leucovorin and oxaliplatin (FOLFOX).

The oral combination of capecitabine and TAS-102 is given as a 2-week cycle.

TAS-102 is administered on a weekly basis.

TAS-102 should be taken in combination with capecitabine, in the form of a 2-week cycle.

The recommended dose of TAS-102 is a combination of 5-FU, leucovorin and oxaliplatin (FOLFOX) at a dose of 5-FU 400 mg/m2, leucovorin
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAS-116is a drug that inhibits
 
Response: TAS-116is a drug that inhibits tumor cell growth by inducing cell cycle arrest and apoptosis in cells. A combination of TAS-116 and the proteasome inhibitor bortezomib (Velcade) has been tested in patients with refractory multiple myeloma. In this trial, patients were given TAS-116 on days 1-3 and bortezomib on days 1, 4, 8, and 11 of a 21-day cycle. TAS-116 was administered at doses of 25 mg/m2 on days 1-3 and bortezomib at doses of 1.3 mg/m2 on days 1, 4, 8, and 11. Among the 24 patients who were evaluable for response, there were seven partial responses (29%) and two complete responses (8%). Two of the seven partial responses were achieved in patients who were refractory to previous treatment with bortezomib. Of the remaining 19 patients
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAS-120is a drug that inhibits
 
Response: TAS-120is a drug that inhibits the proliferation of various tumor cells, including melanoma cells, and induces apoptosis in tumor cells.[@b1-ott-9-3603]--[@b4-ott-9-3603] Therefore, TAS-120 is a promising candidate for the treatment of melanoma.

Cancer cells can adapt to microenvironmental changes by upregulating various genes, including genes related to metastasis. A previous study revealed that the expression of a number of genes related to metastasis was elevated in metastatic melanoma cells.[@b5-ott-9-3603] Melanoma cells in the early stages of metastasis express epithelial--mesenchymal transition (EMT) markers such as N-cadherin and vimentin.[@b6-ott-9-3603] However, a more recent study showed that these markers are not related to the development of metastasis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TAS6417is a drug that inhibits
 
Response: TAS6417is a drug that inhibits the initiation of HIV-1 transcription, which is mediated by the Tat protein \[[@B19-viruses-08-00153]\].

2.2. Chemical Structure of the Different Active Ingredients of the TAS6417 Inhibitor {#sec2dot2-viruses-08-00153}
------------------------------------------------------------------------------------

The chemical structure of TAS6417 is shown in [Figure 2](#viruses-08-00153-f002){ref-type="fig"}A.

The chemical structures of the different components of TAS6417 are shown in [Figure 2](#viruses-08-00153-f002){ref-type="fig"}B--E.

TAS6417 is composed of a covalent dimer, which is formed by the combination of the 4-fluoro-5-hydroxy-3-(5-methyl-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Taurineis a drug that inhibits
 
Response: Taurineis a drug that inhibits the transport of a class of antibiotics known as polymyxins (Px). In the US, taurine is indicated as a parenteral nutritional supplement to reduce the absorption of Px in patients with short gut syndrome, chronic liver disease, or renal failure. However, taurine is not currently approved for any use in the US. It is not approved in Canada or Europe. Taurine is not available in the UK or Australia, and is not approved in these countries.

Taurine is an amino acid that is naturally present in high levels in the bile and is secreted by the liver. Taurine is also synthesized by the body, but in small amounts. Taurine is used in the body for several purposes, including helping to regulate the levels of other amino acids, preventing dehydration, and stabilizing the electrical potential of cells.

Taurine is not approved for any use in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Taxifolinis a drug that inhibits
 
Response: Taxifolinis a drug that inhibits the multiplication of a virus in a plant. In an experiment with tomatoes, the fungicide was shown to suppress the multiplication of tobacco mosaic virus (TMV) to a level where there was no obvious difference between the treated and the untreated plants. The treatment was shown to be effective when the virus was present in the plant as a latent infection. A simple procedure for the extraction of taxifolinis from the plants was devised. The isolation of taxifolinis was made possible by the fact that the fungicide inhibits the multiplication of a virus which can be propagated in the plants.
In the literature, the chemical name for taxifolinis is 2-(2,4-dichlorophenoxy)propionic acid. Its structural formula is: ##STR2##
The present invention relates to the fungicidal compositions comprising taxifolinis as an active ingredient. The present invention also relates to a process for the preparation of the compositions.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tazobactamis a drug that inhibits
 
Response: Tazobactamis a drug that inhibits the production of enzymes. It is used in combination with other antibiotics to treat serious infections, including those that are resistant to other antibiotics.

Uses

Tazobactam is used to treat serious infections caused by organisms that produce extended-spectrum beta-lactamases (ESBLs). These are bacteria that produce an enzyme called TEM-1 beta-lactamase.

Aminoglycosides (e.g., gentamicin) are often used in combination with Tazobactam. Aminoglycosides work by binding to the 30S ribosomal subunit of the bacterial cell. Tazobactam binds to the same site on the ribosome and prevents the action of the aminoglycoside. Tazobactam is sometimes used in combination with other antibiotics to treat bacterial infections.

Tazobactam can also be used to treat
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tebipenemis a drug that inhibits
 
Response: Tebipenemis a drug that inhibits the production of egg-laying hormones. It can be used as a contraceptive for men, but it's most often used as a treatment for people with low sperm counts. Tebipenem is an antibiotic, which means it can kill off bacteria. The World Health Organization lists it as an effective contraceptive. The use of tebipenem as a contraceptive is approved in Australia, Canada, the United States, and the European Union.

However, it's only approved in Canada, and it's only used for people with low sperm counts, or if they are infertile. Tebipenem is not a popular choice in the United States. It's also not approved in Japan, and there is a similar drug, but it's not as effective.

Studies of the drug have found that it works by stopping sperm production. However, it can take up to three months to stop the production of sperm. It
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tegaserodis a drug that inhibits
 
Response: Tegaserodis a drug that inhibits the activity of the serotonin receptor 5-HT4 on the muscles of the digestive tract.

It is an antispasmodic agent that is used to treat chronic constipation and irritable bowel syndrome (IBS).

How Does Tegaserod Work?

Tegaserod is a selective 5-HT4 agonist.

5-HT4 receptors are found on the muscle of the gut and are involved in the relaxation of smooth muscles.

Tegaserod is a prokinetic drug, meaning it works to improve bowel function.

The effects of Tegaserod are immediate and last from 4 to 6 hours.

How Is Tegaserod Prescribed?

Tegaserod is prescribed for patients with constipation and/or IBS.

It is not approved for use in children or in women who are pregnant or nursing.

It is not recommended for use
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TEGISONis a drug that inhibits
 
Response: TEGISONis a drug that inhibits platelet aggregation. It is used in patients with idiopathic thrombocytopenic purpura and in patients with thrombocytopenia associated with chemotherapy or after bone marrow transplantation. TEGISON is a trademark of the British Company Royal Drugs.

**Manufacturer**

Royal Drugs Ltd., Maidenhead, UK.

**What is it used for?**

TEGISON is used to treat and prevent thrombosis in patients with idiopathic thrombocytopenic purpura and in patients with thrombocytopenia associated with chemotherapy or after bone marrow transplantation.

**How does it work?**

It works by inhibiting the aggregation of platelets.

**Side effects?**

There is a small risk of bleeding and an increased risk of bruising, especially if it is used for more than a few weeks
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Teicoplaninis a drug that inhibits
 
Response: Teicoplaninis a drug that inhibits vascular smooth muscle cell (VSMC) proliferation in vitro and restenosis in vivo.
It is widely believed that the neointimal proliferation after angioplasty is mediated by smooth muscle cells (SMCs) derived from the medial layer of the arterial wall. However, the precise mechanism of this phenomenon has not been fully elucidated. The purpose of this study was to examine the effect of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on the proliferation of VSMCs in vitro and on restenosis in vivo. VSMCs were isolated from the aorta of rat. Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was measured by flow cytometry. Western blot analysis was used to detect
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TELAPREVIRis a drug that inhibits
 
Response: TELAPREVIRis a drug that inhibits the proliferation of HIV-1 and HIV-2.

HIV-1 has been a major challenge to the public health community. There are currently over 33 million people infected worldwide and a further 4 million deaths from AIDS related illnesses occur every year (WHO, 2012).

In 1985, French scientists discovered a new human retrovirus in the blood of AIDS patients (Lavie, 2005). This virus was later found to be the causative agent of AIDS and this was named human immunodeficiency virus (HIV) (Varmus, 1997). This was the first indication that HIV was a major problem for the world's public health.

In 1987, a group of scientists working on HIV, first proposed that the development of a vaccine to prevent HIV infection was the best way to deal with the disease (Berman, 1997).

The Global AIDS Vaccine Enterprise (GAVE) was established in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Telatinibis a drug that inhibits
 
Response: Telatinibis a drug that inhibits the tyrosine kinase activity of the oncogenic receptor tyrosine kinase HER2/neu (ErbB2) and blocks its signaling in breast cancer. In preclinical models of breast cancer, telatinib inhibits tumor growth and metastasis. Telatinib was approved in the United States in 2012 for the treatment of patients with metastatic HER2-positive breast cancer that has progressed on prior trastuzumab-based therapy. In randomized clinical trials, telatinib significantly prolonged the progression-free survival (PFS) of patients with HER2-positive breast cancer who had received prior treatment with trastuzumab and chemotherapy. The most common adverse effects of telatinib are diarrhea, nausea, vomiting, and fatigue. Other adverse effects of telatinib are rare and usually occur in patients who have previously received trastuzumab and chemotherapy. Adverse effects of telatinib may be managed with
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Temocaprilis a drug that inhibits
 
Response: Temocaprilis a drug that inhibits the production of Angiotensin I (Ang I) and II (Ang II). Inhibition of Ang I and II by Temocapril can be beneficial in many cardiovascular diseases including hypertension, heart failure, coronary artery disease, cerebrovascular diseases, diabetes, etc.

Pulse Detonator:

The original pulse detonator was developed by Dr. H. E. Atwater in the mid-1960s and it consists of a capacitor, a coil and a resistor. This device was initially used for initiating the detonation of explosives, but in later years it was used for detonating pressurized gas mixtures and other gaseous fuels. It was first introduced as a reliable method of initiating detonation of a wide variety of explosive gases and fuels. In addition, the detonator was used for testing the detonation of explosive mixtures. This device is also called capacitor-resistor detonator, spark-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Temsaviris a drug that inhibits
 
Response: Temsaviris a drug that inhibits a protein called Sirtuin 1. It may be able to prevent or reverse the damage to heart muscle caused by the virus.

Ranibizumab (Lucentis), a drug that binds to VEGF and reduces the growth of new blood vessels. This treatment can prevent or reverse the damage to the retina caused by the virus.

Zidovudine (Retrovir), a drug that slows the growth of HIV. It is also used to treat other diseases.

Antiretroviral drugs can prevent HIV from infecting cells. However, because HIV is a retrovirus, these drugs do not work directly on the virus. Instead, they must attack the HIV-infected cells. If HIV is present in the body when the drugs are taken, the drugs will still work, but at a much lower level. The drugs are most effective when used in combination with other HIV drugs.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Temsirolimusis a drug that inhibits
 
Response: Temsirolimusis a drug that inhibits the proliferation of tumor cells by binding to the protein, called mTOR, that is involved in cell growth. The mechanism of action of temsirolimus is different from that of other anticancer drugs. The effects of temsirolimus are delayed. The tumor shrinks in size and the symptoms go away. It is not effective against cancers that are not caused by genetic mutations.

How should you take temsirolimus?

Temsirolimus is given by injection into a vein. It is usually given once a week.

How long does temsirolimus work?

The drug may work for several months. The tumor may return after a few months if it has become resistant to temsirolimus.

How long do you need to take temsirolimus?

The drug must be taken for at least 4 months before the effects are known.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tenalisibis a drug that inhibits
 
Response: Tenalisibis a drug that inhibits tyrosine kinase and has been developed for the treatment of acute myeloid leukemia (AML). The drug is now being evaluated for the treatment of a variety of solid tumors including lung, ovarian, breast, pancreatic, colon and prostate cancers. However, the drug is being used at the present time for the treatment of AML.

It has been shown that tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK), play a key role in the development of AML and its progression. Therefore, tyrosine kinase inhibitors (TKIs) that can selectively inhibit the activity of these kinases are being developed for the treatment of AML.

Inhibition of tyrosine kinases by tyrosine kinase inhibitors

Gleevec (imatinib)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tenofoviris a drug that inhibits
 
Response: Tenofoviris a drug that inhibits a protein known as TK. The protein acts as a catalyst that allows cancer cells to multiply quickly. Tenofovir also stops the growth of healthy cells that are dividing rapidly. It has been used in combination with other drugs to treat HIV-positive people with certain kinds of cancer.

So far, the trial has involved about a dozen patients.

In the next step, researchers will be looking at how well it works in combination with other drugs that have already been approved.

So far, the trial has involved about a dozen patients.

"It's an exciting development," said Dr. Robert Atala, director of the Wake Forest Baptist Comprehensive Cancer Center. "I think it's a wonderful opportunity for people with HIV and certain cancers to get a chance to get more treatment. We need more options."

Dr. Atala said the treatment is not as effective as some of the other new drugs that have been approved
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tenofovir(PMPA)is a drug that inhibits
 
Response: Tenofovir(PMPA)is a drug that inhibits the reverse transcriptase of the human immunodeficiency virus (HIV). It has the advantage of long plasma half-life and good tissue penetration, and it has proven to be highly active in both treatment and prophylaxis of HIV infection. It is a nucleotide reverse transcriptase inhibitor (NRTI), which means that it is a competitive inhibitor of the enzyme. The drug has a high genetic barrier to resistance, and it is considered one of the most potent drugs against HIV. However, there are some disadvantages of tenofovir such as nephrotoxicity, bone marrow toxicity, and the need for daily administration. Tenofovir is a prodrug, which means that it is inactive and needs to be metabolized to become active. The active form is tenofovir diphosphate, and the inactive form is tenofovir triphosphate. In this form, tenof
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tenoxicamis a drug that inhibits
 
Response: Tenoxicamis a drug that inhibits prostaglandin synthesis and acts as a non-steroidal anti-inflammatory drug (NSAID) and analgesic. It is effective in the treatment of pain, fever, inflammation, and stiffness and also in the treatment of mild to moderate joint pain and menstrual pain. Tenoxicam has been found to be an effective treatment for patients with rheumatoid arthritis, osteoarthritis, and juvenile rheumatoid arthritis. The term tenoxicam is used in a number of different contexts in different parts of the world, e.g. Tenormin®, Teno-Bid®, Tenero®, Tenonil®, Tenoprofen®, Tenovid®, Tengen®, Tenoprim®, Tengibid®, Tenosyn®, Tenopur®, Tenosept®, Tenovate®, Tenovin®, Tenox®, Tenoxicam®, Teno-Bid®, Tenpip®, Tenpex®,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terazosinis a drug that inhibits
 
Response: Terazosinis a drug that inhibits telomerase activity, interferes with the ability of cancer cells to multiply, and has a high affinity for binding to telomeric DNA, is already on the market and is approved by the FDA. It is known as a telomerase inhibitor and is used for the treatment of a variety of cancers. This drug has also been approved in Europe for the treatment of patients with advanced, persistent, and recurrent epithelial ovarian cancer. However, it has been reported that it is effective for a small subset of patients with cancer and is accompanied by a high rate of toxicity. The present review article summarizes the literature on telomerase and telomerase inhibitors.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terbinafineis a drug that inhibits
 
Response: Terbinafineis a drug that inhibits the enzyme P-gp.

E.g.,http://www.drugs.com/drugs/terbinafine.html

Here is a summary of the drug (from Drugs.com):

“Terbinafine (generic name: terbinafine hydrochloride) is a prescription drug used to treat fungal infections of the nails and skin, particularly those caused by Trichophyton rubrum, T. mentagrophytes, and Epidermophyton floccosum. It is also used to treat other fungal infections.”

In our previous post, we noted that several people have reported taking Terbinafine as a potential treatment for a Coronavirus. I wanted to look into the data for Terbinafine and see if it is a viable option for Coronavirus treatment.

We have a new source that can help
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terbutalineis a drug that inhibits
 
Response: Terbutalineis a drug that inhibits the formation of mediators of inflammation, especially cytokines, which are substances that induce the inflammatory process, such as IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, and granulocyte-macrophage colony-stimulating factor (GM-CSF). It is prescribed to treat asthma and chronic obstructive pulmonary disease (COPD).

The active principle is a hydrochloride, a free base, or an isopropyl ester. It is indicated in adults for the treatment of bronchial asthma and COPD.

In clinical trials, terbutaline has been shown to improve the symptoms of COPD and asthma, and to increase lung function. It is also used to prevent bronchospasm in children.

For the treatment of COPD and asthma, the recommended daily dose is 4 mg. The maximum daily
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terephthalicis a drug that inhibits
 
Response: Terephthalicis a drug that inhibits the enzymatic activity of 5-lipoxygenase. The inhibition of this enzyme leads to a reduction in leukotriene production and the inflammatory response in humans and other mammals. The anti-inflammatory activity of this compound has been described in the following references: European Patent No. EP 0 659 221; Journal of Medicinal Chemistry, 34, pp. 1343-1346 (1991); Journal of Medicinal Chemistry, 35, pp. 1147-1150 (1992); Journal of Medicinal Chemistry, 35, pp. 1834-1838 (1992); Journal of Medicinal Chemistry, 35, pp. 1839-1843 (1992); Journal of Medicinal Chemistry, 35, pp. 4371-4376 (1992); Journal of Medicinal Chemistry, 35, pp. 4376-4379 (1992); Journal of Medicinal Chemistry, 35, pp. 4379-4383 (1992);
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  terfenadineis a drug that inhibits
 
Response: terfenadineis a drug that inhibits the action of certain enzymes in the body. It is used to treat and prevent motion sickness and vertigo, to prevent hives, and to treat allergic reactions. It is also used to prevent and treat bronchial asthma and hay fever. It is also used in combination with other drugs to treat severe reactions to food or other allergies.

Uses

Dosage and Administration

This medicine is given by mouth. It is usually taken once a day at bedtime. It can be given with or without food. Your doctor may increase or decrease your dose as needed.

How to Take

Follow all directions on your prescription label. Do not chew, crush, or open the capsule. Take this medicine at the same time each day.

Storage

Store at room temperature away from moisture, sunlight, and heat.

Side Effects

Side effects from this medicine may include:

headache
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  teriflunomideis a drug that inhibits
 
Response: teriflunomideis a drug that inhibits the pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase, which is an enzyme involved in the de novo pathway of pyrimidine synthesis.

Mechanism of action
Inhibition of dihydroorotate dehydrogenase (DHODH) blocks de novo pyrimidine synthesis and prevents the proliferation of activated T cells.  
In the immune system, DHODH is essential for the production of deoxyuridine monophosphate, which is an intermediate in DNA synthesis. DHODH inhibition causes cell cycle arrest and apoptosis of activated T cells.  
This is how T-cell lymphoma is caused.

DHODH inhibition also causes a loss of signal transduction in the T-cell receptor. 

In addition, DHODH inhibition has shown to reduce the production of proinflammatory cytokines such as interleukin 2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terlipressinis a drug that inhibits
 
Response: Terlipressinis a drug that inhibits the phosphodiesterase type 5 (PDE5) enzyme and thereby causes an increase in the level of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum of the penis. The result is relaxation of the smooth muscle, leading to an increased blood flow into the penis, and ultimately to an erection. This medication is used to treat erectile dysfunction (ED) and premature ejaculation. This medication is also known as avanafil, alprostadil, Aurogra, Ditropan XL, Staxyn, Stendra, and Viagra.

“In all of these studies, [Cialis] was shown to have the highest efficacy,” explains study author Dr. Allan R. Visconti, an associate professor of urology at the University of Pittsburgh Medical Center. “Tadalafil had the lowest efficacy, and silden
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terpinis a drug that inhibits
 
Response: Terpinis a drug that inhibits histone deacetylase and causes cellular differentiation in leukemia cells.^[@bib1]^ These compounds induce cell cycle arrest and differentiation in a variety of cancer cells, and are currently being evaluated in phase I/II clinical trials.^[@bib2]^ The compounds are capable of selectively killing tumor cells with impaired p53,^[@bib3]^ and in many cases the mechanism of cell death appears to be apoptosis.^[@bib4],\ [@bib5],\ [@bib6]^ While the compounds have been shown to induce apoptosis, the precise mechanism of cell death and the precise signaling pathways involved in this process remain unclear.

Several previous studies have examined the ability of HDAC inhibitors to kill tumor cells in combination with other chemotherapeutic agents. These studies have generally shown that HDAC inhibitors enhance the efficacy of chemotherapy.^[@bib
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Terpinen-4-olis a drug that inhibits
 
Response: Terpinen-4-olis a drug that inhibits cancer cell growth by regulating multiple cellular processes, such as DNA repair, cell cycle progression, and apoptosis[@b1]. It is found in various essential oils[@b2] and is also an important component of *Citrus aurantium* L. (sour orange). We have demonstrated that terpinen-4-ol induces cell cycle arrest and apoptosis in multiple cancer cell lines[@b3]. Furthermore, we have also found that terpinen-4-ol induces cancer cell death through a reactive oxygen species (ROS)-dependent pathway[@b4].

Telomerase is a ribonucleoprotein complex that synthesizes telomeric DNA and is essential for telomere maintenance and for the immortalization of human cancer cells[@b5]. Telomerase activation is observed in more than 90% of all cancer cells[@b6]. However, its expression is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TERRAMYCINis a drug that inhibits
 
Response: TERRAMYCINis a drug that inhibits DNA synthesis by inhibiting the enzyme that causes the cell to begin to synthesize DNA, topoisomerase II. It is used to treat various cancers, including those of the stomach, esophagus, breast, lungs, head, neck, ovary, cervix, prostate, testis, and bladder. It may also be used for pre-term labor, and to treat toxoplasmosis.

USES AND DOSAGE

Ceritinib is used to treat certain types of non-small cell lung cancer (NSCLC). It is not known whether ceritinib is safe and effective in children.

Dosage in specific patient population

Older children

Weight

5.0 - 17.4 kg

10 mg

17.5 - 32.5 kg

15 mg

32.6 - 56.7 kg

20 mg

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetracaineis a drug that inhibits
 
Response: Tetracaineis a drug that inhibits the function of voltage-gated sodium channels, and is therefore used as a local anesthetic for the treatment of pain.\[[@ref1]\] A few cases of tetracaine intoxication have been reported, but the reported toxic effects of tetracaine have mainly been related to the other side effects of the drug such as nausea, vomiting, seizures, cardiac arrhythmias, and even death.\[[@ref2]\] Here, we report a case of a young man who developed a seizure disorder after an overdose of tetracaine.

Case Report {#sec1-2}
===========

A 26-year-old male patient was admitted to the emergency room of our hospital with a 3-day history of altered mental status. He was a driver and had an accident about one month before admission. On arrival, he was conscious, but his vital signs were unstable, and his Glasgow Com
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetracyclineis a drug that inhibits
 
Response: Tetracyclineis a drug that inhibits bacterial protein synthesis. It is used in many antibiotics. It is a very effective treatment for acne and rosacea. Tetracycline also is used to treat chronic infections.

Frequently asked questions

How do I take tetracycline?

Tetracycline is a prescription drug that you should take only as directed by your doctor. Tetracycline is available in two forms, in liquid form (by mouth or injection) and in capsules. Your doctor will prescribe the form that is right for you.

How long do I need to take tetracycline?

Tetracycline should be taken for the full length of the prescription. Most people take it for a few weeks. You should talk to your doctor if you are taking it for longer than a few weeks.

What should I avoid while taking tetracycline?

Do
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetraethylammoniumis a drug that inhibits
 
Response: Tetraethylammoniumis a drug that inhibits the activity of the inward rectifier potassium channels (Kir) in neurons, thereby hyperpolarizing the cell membrane. By increasing the excitability of neurons, tetraethylammonium is believed to cause epilepsy, ataxia, and muscular spasms. See Leimu, A. and M. M. Robichaud, in “Principles of Medicinal Chemistry”, 6th ed., Lea and Febiger, Philadelphia, Pa., pp. 1043-1045 (1990).
The electrophysiological effects of tetraethylammonium are mediated by two pharmacologically distinct classes of potassium channels, those that are selectively activated by sodium and those that are selectively activated by potassium. Activation of these channels by sodium ions is accompanied by the movement of sodium ions into the cell, while activation of these channels by potassium ions is accompanied by the movement of potassium ions out of the cell
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetrahydrozolineis a drug that inhibits
 
Response: Tetrahydrozolineis a drug that inhibits both the uptake and the release of noradrenaline. It is used to treat symptoms of anxiety, insomnia and to reduce excessive sweating. It can also be used to relieve symptoms of depression, tension and anxiety.

Its brand name is Azimil.

How does it work?

The Tetrahydrozoline is a drug that is a mild central nervous system (CNS) depressant. It works by blocking the uptake of noradrenaline (NA) in the central nervous system.

It also works by inhibiting the release of noradrenaline from the storage vesicles in the adrenal medulla. This is done by preventing the recycling of the vesicles to the cell membrane.

How to use it?

You should take Tetrahydrozoline as a tablet with water on an empty stomach.

Tetrahydrozoline may
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  tetramisoleis a drug that inhibits
 
Response: tetramisoleis a drug that inhibits the re-uptake of histamine.

Osmotic diuretics

Osmotic diuretics, such as mannitol, increase the excretion of water and electrolytes, thus reducing blood pressure.

Diuretics

A diuretic is a medication that causes the body to excrete water and other substances from the blood. This can be used to treat hypertension, congestive heart failure, and edema.

Aldosterone antagonists

These drugs are used to lower high blood pressure by inhibiting the secretion of aldosterone by the adrenal gland.

Angiotensin converting enzyme inhibitors

These medications reduce the formation of angiotensin II and are used to treat hypertension.

Angiotensin receptor blockers

These medications block the effects of angiotensin II, and are used to treat hypertension.

B-blockers

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetrandrineis a drug that inhibits
 
Response: Tetrandrineis a drug that inhibits tumor growth. It is used for treatment of multiple cancers. In this study, we investigated the anticancer effects of tetrandrine on ovarian cancer cells and its mechanism.

1. Introduction {#sec1-molecules-21-01088}
===============

Tetrandrine, a bisbenzylisoquinoline alkaloid isolated from the root of Stephania tetrandra, has been used in China for the treatment of various diseases, including inflammation, asthma, rheumatoid arthritis, and cancer \[[@B1-molecules-21-01088],[@B2-molecules-21-01088],[@B3-molecules-21-01088],[@B4-molecules-21-01088]\]. It is also an active component of many Chinese herbal medicines, such as Hehuazhajujutong (a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tetryzolineis a drug that inhibits
 
Response: Tetryzolineis a drug that inhibits catecholamine-O-methyltransferase (COMT), an enzyme involved in the degradation of dopamine and noradrenaline.\[[@ref1]\] Tetryzoline has been used to treat menopausal symptoms, muscle spasms, and neuropathic pain, and as an antidepressant in Europe and Australia.\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\] It has also been used to treat anxiety and fibromyalgia in the United States.\[[@ref8]\] A double-blind, randomized, placebo-controlled trial showed that tetryzoline (100 mg) improved pain and mood in patients with fibromyalgia, with no difference in efficacy between men and women.\[[@ref9]\]

Tetryzoline is mainly metabolized by CYP2D6, and is also metabol
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TG101348is a drug that inhibits
 
Response: TG101348is a drug that inhibits BCL2, BCL-XL, BCL-W, and BCL-B. In a study of human acute myeloid leukemia (AML) cells in vitro, TG101348 induced cell death by apoptosis in the absence of BCL2, BCL-XL, or BCL-W. It also induced cell death in BCL-XL overexpressing cells and synergized with ABT-737 (the clinical development of which is in progress). In mice, TG101348 reduced the number of AML cells in bone marrow and spleen and induced a significant prolongation of survival in a model of AML. A clinical trial in patients with relapsed/refractory AML showed that the drug was well tolerated and induced apoptosis of leukemia cells in vitro and in vivo. Thus, TG101348 has significant activity in preclinical models of AML and has been selected for clinical development.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TGR-1202is a drug that inhibits
 
Response: TGR-1202is a drug that inhibits the phosphatidylinositol 3-kinase (PI3K) pathway by inhibiting the catalytic activity of PI3K p110-alpha and p110-beta subunits. The drug is under development for the treatment of cancer, diabetes, and other indications. This report presents the results of a GLP-1 fasting pharmacokinetic (PK) study in healthy subjects. TGR-1202 is a novel PI3K inhibitor and is the first agent of its class to demonstrate sustained pharmacologic activity at pharmacologically relevant exposures in healthy subjects. In this phase I study, TGR-1202 was administered once daily in the morning for 10 days, with a single morning dose of TGR-1202 (10 mg) or placebo. Plasma samples were collected on days 1, 5, and 10 and assayed for TGR-1202 concentrations using a validated liquid chromatography-tandem mass spectrom
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TH-302is a drug that inhibits
 
Response: TH-302is a drug that inhibits HIF-1alpha accumulation by binding to the oxygen-dependent degradation domain of HIF-1alpha and thus preventing the interaction of the von Hippel-Lindau tumor suppressor protein with HIF-1alpha. The present study aimed to investigate the effect of TH-302 on cell cycle progression and proliferation in glioblastoma cells. We investigated the in vitro effect of TH-302 on the cell cycle distribution and the proliferation of the human glioblastoma cell line U-87 MG and compared it with the human non-tumor cell line HEK 293. The cell cycle analysis was performed by flow cytometry. We also examined the effect of TH-302 on the expression of the cell cycle proteins p21 and cyclin D1. The U-87 MG cells were incubated with TH-302 (0.01-0.5 micromol/L) for 24, 48, and 72 h.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thalidomideis a drug that inhibits
 
Response: Thalidomideis a drug that inhibits angiogenesis by targeting and damaging endothelial cells, and is an effective treatment for erythema nodosum leprosum (ENL), which is a common complication of leprosy. However, thalidomide is associated with teratogenicity, and may cause permanent nerve damage. We investigated the molecular mechanisms of thalidomide-induced nerve damage. In this study, we found that thalidomide increased the expression of Bax, and decreased the expression of Bcl-2 and HIF-1α in endothelial cells. Bax siRNA inhibited thalidomide-induced apoptosis in endothelial cells, and the expression of Bcl-2 and HIF-1α siRNA increased thalidomide-induced apoptosis. These findings indicate that thalidomide can induce apoptosis of endothelial cells via the Bax/Bcl-2/HIF-1α pathway
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thiamineis a drug that inhibits
 
Response: Thiamineis a drug that inhibits in vitro thiamine pyrophosphate-dependent enzymes, such as those in the Krebs cycle and in the glycine cleavage system, and thus blocks the production of energy. The main effect of thiamine deficiency is ketosis, with clinical manifestations including ketones in the urine and in the blood, and a decrease in plasma glucose concentration. Thiamine is required for the conversion of pyruvate to acetyl-CoA, the first step in the Krebs cycle, and for the synthesis of glycine, a precursor of glycine decarboxylase, the first step in the glycine cleavage system. Thiamine is also required for the production of other important metabolites in the cell. For example, thiamine is required for the production of coenzyme A and is an essential component of several enzymes, including transketolase, which is the first enzyme of the pentose phosphate pathway, and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thiamphenicolis a drug that inhibits
 
Response: Thiamphenicolis a drug that inhibits estrogen from entering the cells. It is used to prevent pregnancy in both men and women. The dosage of the pill is one that you take for the entire duration of your pregnancy.

Cyproteroneacetate is a male birth control pill. It is a synthetic androgen. It prevents sperm from being produced.

Progestins are used to control the endometrium, the lining of the uterus. Progestins are also used to help control heavy bleeding.

A combination pill is a birth control pill that combines two or more different birth control methods. For example, birth control pills that combine progestin and estrogen, or progestin and progesterone.

Mirena is a birth control implant that prevents pregnancy by making it difficult for sperm to reach the egg.

The female condom is a female birth control method that works by stopping sperm from reaching the uterus.

Lapar
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  THIOGUANINEis a drug that inhibits
 
Response: THIOGUANINEis a drug that inhibits the enzyme guanidinoacetate methyltransferase (GAMT). It is used to treat high creatine levels in patients with creatine transporter disorders, and also in combination with leucovorin in patients with certain types of leukemia. In some cases, a fatal hypersensitivity reaction to this drug has been observed. See also HISTAMINE.

TIGGER(s) [L, tumulus, small hill], a signal that stimulates the immune system to mount an immune response to a particular antigen. See also ALLERGIC REACTION.

TIGONEROTIN /tig″ənərō″tin/, a drug used to treat high levels of prolactin in the blood.

tincture /tink″chər/ [L, tinctura, a mixture], 1. a solution containing a medicinal agent in alcohol or
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thioridazineis a drug that inhibits
 
Response: Thioridazineis a drug that inhibits platelet aggregation. It has a wide margin of safety and is well tolerated in doses up to 10 mg. Although the antiserotonergic effect of thioridazine has been attributed to its blockade of postsynaptic dopamine receptors, its precise mode of action remains uncertain. The purpose of this study was to evaluate the effect of thioridazine on thrombin-induced aggregation of human platelets in vitro. Thioridazine was shown to inhibit thrombin-induced aggregation in a dose-dependent manner. The effect was observed after preincubation of the platelets with thioridazine for up to 15 min and was dose-dependent, being maximal at concentrations of 10 microM and greater. Thioridazine did not inhibit the binding of [3H]imipramine to platelet membranes or [3H]ketanserin to serotonin receptors, suggesting that the inhibition of thrombin-induced aggregation
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thiostreptonis a drug that inhibits
 
Response: Thiostreptonis a drug that inhibits expression of the hypoxia-inducible factor (HIF). In hypoxic cells, HIF-1 binds to hypoxia-responsive elements and promotes expression of several genes, including those that code for the proteins that are involved in glucose metabolism. This drug inhibits the function of HIF and is used to treat various cancers.

Approximately 75% of cancer patients suffer from chronic hypoxia as a result of the metabolic demands of the tumor and the vascular abnormalities associated with the disease. This hypoxia has important implications for the development of the disease and for treatment. Tumors are dependent on angiogenesis to grow and metastasize. Tumor cells require angiogenesis to be metabolically active, which is also a requirement for survival. Therefore, the switch to anaerobic metabolism by tumor cells, through activation of HIF, is an important survival strategy that allows the tumor to continue to grow
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thiotepais a drug that inhibits
 
Response: Thiotepais a drug that inhibits the enzyme acetylcholinesterase (AChE).

The medicine acts by inhibiting the enzyme acetylcholinesterase (AChE) that is responsible for the breaking down of acetylcholine, the neurotransmitter that is responsible for transmitting nerve impulses in the body.

The drug also helps to activate other neurotransmitters in the brain that may not be affected by the inhibition of AChE.

Thiotepais is a generic name for all thiophenes that have been used to inhibit the enzyme acetylcholinesterase.

These drugs were first synthesized in the 1950s, and are effective against both the acute and chronic forms of the disease.

Thiotepais are typically used for patients who have mild to moderate cases of Alzheimer’s disease, with a short-term course of treatment, such as during an inpatient stay.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thiothixeneis a drug that inhibits
 
Response: Thiothixeneis a drug that inhibits the dopamine receptor subtype D2. The binding affinity of this drug for the dopamine receptor is very high. It is used to treat schizophrenia and bipolar disorder.

Dopamine is a neurotransmitter in the brain. It is found in the basal ganglia, hypothalamus, and hippocampus. It is also a precursor to adrenaline and noradrenaline. It is involved in the release of neurotransmitters such as acetylcholine, GABA, and serotonin. It plays an important role in the production of thoughts and emotions. It also plays a role in muscle coordination and sleep.

The dopaminergic system is the reward system. Dopamine is released when the brain is stimulated. It causes the release of the neurotransmitter serotonin. The activation of dopamine receptors in the brain leads to the release of the neurotransmitters dopamine, serotonin, and norepinephrine. Dopamine is also involved in the regulation of movement
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Thonzylamineis a drug that inhibits
 
Response: Thonzylamineis a drug that inhibits an enzyme called MAO-A. This enzyme breaks down the neurotransmitter serotonin.

In people who have not had a head injury, and have a normal mental health history, low doses of Thonzylamine do not cause any problems. However, people with depression are at greater risk of becoming suicidal when taking the drug. People with a family history of bipolar disorder are also at greater risk of developing manic symptoms when taking Thonzylamine.

It is not known if the risk of developing mania is increased when taking the drug in people who have had a head injury, or if the risk is increased in people who have had a family history of bipolar disorder.

The risk of developing mania may be increased when taking the drug in people who have not had a head injury, or who have had a family history of bipolar disorder.

Before taking the drug, the prescribing doctor should check your blood levels
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tianeptineis a drug that inhibits
 
Response: Tianeptineis a drug that inhibits the reuptake of serotonin and norepinephrine, and which has antidepressant effects. Its efficacy has been established in numerous clinical trials. The effects of tianeptine on aggressive behaviour have not been studied. In this study, we evaluated the effects of tianeptine on the aggressive behaviour of male Wistar rats in three different paradigms. We found that acute (10 and 30 mg/kg) and subchronic (30 mg/kg for 5 days) doses of tianeptine induced a significant decrease in aggressive behaviour in the resident-intruder paradigm. The same doses did not induce any changes in the other paradigms. However, a lower dose (1 mg/kg) of tianeptine decreased aggressive behaviour in the resident-intruder paradigm, while a higher dose (10 mg/kg) increased it. These results suggest that tianeptine is a potential agent for the treatment of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tiaprideis a drug that inhibits
 
Response: Tiaprideis a drug that inhibits the action of serotonin. It is used to treat the symptoms of hyperactivity in children. It can be used with other drugs that act on the nervous system. This is a form of treatment for attention deficit hyperactivity disorder (ADHD).

How does it work?

Serotonin is a neurotransmitter. It is made by the body and helps regulate body processes such as mood, sleep and appetite.

Treatment for ADHD can involve drugs that block the action of serotonin. These are called selective serotonin reuptake inhibitors (SSRIs). These drugs include sertraline (Zoloft), fluoxetine (Prozac), paroxetine (Paxil) and citalopram (Celexa).

Tiapride blocks the action of serotonin at a particular receptor. It works by inhibiting the action of a protein called the serotonin transporter (SERT). This reduces the reuptake
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ticagreloris a drug that inhibits
 
Response: Ticagreloris a drug that inhibits platelet aggregation. It is used to prevent blood clots from forming in your blood vessels.

Aminophylline a drug that acts as a stimulant, used in the treatment of asthma and other conditions.

Rofecoxib a non-steroidal anti-inflammatory drug (NSAID). It is used to treat rheumatoid arthritis and osteoarthritis.

Methotrexate a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis.

Salicylates a class of drugs that act as anti-inflammatory agents and analgesics. Examples include aspirin and acetaminophen.

Colchicine a drug used to treat gout, which is a form of arthritis caused by the build-up of uric acid crystals in the joints.

Fenoprofen a drug used to treat pain and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ticarcillinis a drug that inhibits
 
Response: Ticarcillinis a drug that inhibits a new target for cancer therapy, the 2,3-enoyl-CoA isomerase.
Ticarcillinis a siderophore produced by Streptomyces and used in iron chelation and transportation, that is, a secondary metabolite. We found that the non-toxic compound, ticarcillinis inhibits the 2,3-enoyl-CoA isomerase, which is a key enzyme for fatty acid synthesis in mammals. The inhibitor was identified by high-throughput screening and its IC50 was 4.6 μM. Ticarcillinis showed significant inhibitory effects on human tumor cell lines (IC50: 3.3-7.8 μM) and normal cells (IC50: 6.4-12.5 μM), but did not inhibit the enzyme activity. The growth of cancer cells was inhibited by ticarcillinis, but it did
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ticlopidineis a drug that inhibits
 
Response: Ticlopidineis a drug that inhibits platelet aggregation. It is commonly used for the treatment of cardiovascular diseases such as atherosclerosis and stroke. The Food and Drug Administration (FDA) recently approved the use of ticlopidine in combination with aspirin for prevention of myocardial infarction (MI) in patients with coronary artery disease (CAD) and stable angina.

Ticlopidine has a unique pharmacological profile that may be useful in treating conditions other than CAD. Ticlopidine is a selective inhibitor of the P2Y12 ADP receptor.1 It is a covalent reversible antagonist of the ADP receptor. ADP, a major mediator of platelet aggregation, stimulates platelets through binding to the P2Y12 receptor, which activates platelet activation and aggregation.1 The inhibition of ADP-mediated platelet activation by ticlopidine prevents the formation of platelet aggregates and th
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tideglusibis a drug that inhibits
 
Response: Tideglusibis a drug that inhibits the enzyme GSK-3. GSK-3 is a kinase that normally regulates the function of many proteins. One of its targets is beta-catenin, a protein that normally stays in the cell. GSK-3 removes this inhibitory effect, allowing beta-catenin to enter the cell nucleus and interact with a transcription factor. This interaction turns on genes that are responsible for cell proliferation. The gene is usually turned off in normal cells, but when the GSK-3 protein is inhibited, it cannot remove the inhibitory effect, so beta-catenin remains in the cell and turns on the genes.

Tideglusib is in a clinical trial for patients with various types of cancer. In a study of patients with glioblastoma, it did not seem to work as well as other drugs. Tideglusib may work better for some patients, but there is still a lot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tigecyclineis a drug that inhibits
 
Response: Tigecyclineis a drug that inhibits protein synthesis by binding to the ribosome, causing tetracycline-like ribosome-mediated inhibition of protein synthesis. It is the first drug to be FDA approved for treatment of multidrug-resistant Gram-positive bacterial infections. In vitro activity against MRSA is similar to that of tetracycline and erythromycin. It is primarily excreted in the urine and feces. Oral bioavailability is 90%. Renal clearance is low, and it is not removed by hemodialysis.

Mechanism of Action

Tigecycline binds to the 30S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation.

Therapeutic Effect

In vitro studies show that tigecycline has potent activity against Gram-positive pathogens, including methicillin-resistant and methicillin-suscept
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TIKOSYNis a drug that inhibits
 
Response: TIKOSYNis a drug that inhibits tyrosine kinase (TK) and thus interferes with cellular growth and proliferation. TIKOSYN inhibits growth and induces apoptosis of cancer cells. TIKOSYN is used in the treatment of cancer. TIKOSYN may be used in the treatment of: breast cancer, colorectal cancer, lung cancer, pancreatic cancer, and ovarian cancer. TIKOSYN is also used in the treatment of the following diseases: non-Hodgkin's lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, adult T-cell leukemia/lymphoma, and chronic myelogenous leukemia. TIKOSYN is also used in the treatment of the following viral infections: AIDS-related Kaposi's sarcoma, human papilloma virus (HPV)-associated genital warts, and HPV-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tilmicosinis a drug that inhibits
 
Response: Tilmicosinis a drug that inhibits the uptake of cholesterol from the intestine to the liver. It lowers the amount of cholesterol in the blood. It is used to treat:

Tilmicosin is a prescription medicine used to treat the symptoms of infections caused by certain bacteria, including ear, sinus, and skin infections. It may also be used to treat lower respiratory tract infections, including pneumonia. It is also used to treat traveler's diarrhea and gastroenteritis.

Tilmicosin is an anti-inflammatory, antibiotic. It works by blocking the growth of bacteria. It is used to treat ear infections, sinus infections, bronchitis, pneumonia, and gastroenteritis.

Cautions

Tell your doctor if you have any allergies, especially to penicillin. Tell your doctor if you are pregnant, breastfeeding, or plan to become pregnant. Do not use this medication if you are pregnant or if you become pregnant during treatment. If
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Timololis a drug that inhibits
 
Response: Timololis a drug that inhibits the HIV reverse transcriptase.

Analogs
Kamifury has a wide variety of analogs, of which two have reached the market:
Cerivastatin, sold under the brand name Lipobay and used for the treatment of hyperlipidemia.
Udenafil, marketed as Revatio.

References

External links
 Cerivastatin-Controlled Phase II Trial in HIV-Infected Subjects with Non-AIDS Complications of Hepatitis C, Sildenafil Citrate, and Combination Therapy

Category:Antiretroviral drugs
Category:Experimental drugs
Category:Isopropyl compounds
Category:Macrolide antibiotics
Category:Quinolines
Category:Pyridines
Category:Sildenafil
Category:Sulfonamides
Category:Catechol ethers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Timonacicis a drug that inhibits
 
Response: Timonacicis a drug that inhibits a subtype of protein kinase, thereby inducing apoptosis.

Inhibition of cyclin-dependent kinases by small molecule inhibitors is a well-established approach for treating cancer. However, an important limitation of this approach is that it is typically difficult to distinguish between a cytostatic and a cytotoxic response. In this regard, the use of genetic knockouts to investigate the function of individual cyclin-dependent kinases is an effective strategy for identifying genes that promote or inhibit tumorigenesis.

The cyclin-dependent kinase CDK8 regulates transcription by phosphorylating a variety of substrates including RNA polymerase II and the RNA splicing machinery. Although the essential function of CDK8 in cells is known, its role in tumorigenesis is not. Here, we show that CDK8 is a haploinsufficient tumor suppressor in a mouse model of T-cell acute lymphoblastic leukemia
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  tinidazoleis a drug that inhibits
 
Response: tinidazoleis a drug that inhibits trypanosomes in the blood of animals, but it has not been reported to be effective in humans. It has been used to treat patients with HIV/AIDS, but the effects are uncertain. Chloramphenicol is used to treat the bacterial infection _Chlamydia trachomatis_ and is also known to have anticancer effects. In addition, it has been reported to have anticancer effects in patients with leukemia, lymphoma, breast cancer, lung cancer, and others. It has been used to treat children with acute lymphoblastic leukemia (ALL). Chloramphenicol has been used to treat children with ALL for over 40 years. It is also used to treat chronic lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML). It has been used to treat multiple myeloma. It is also used to treat non-Hodgkin's lymphoma, and to prevent graft-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tinoridineis a drug that inhibits
 
Response: Tinoridineis a drug that inhibits calcium transport across the membranes of the sarcoplasmic reticulum. The drug was initially developed to treat heart failure and later was found to be effective in treating other diseases. The drug has been shown to reduce arrhythmias in patients with arrhythmias, prevent ischemic cell death in ischemic heart disease, and prevent atrial fibrillation in some patients. Tinoridine is commercially available as a topical agent under the tradename TINODERM and as an ophthalmic agent under the tradename TINOPHEX.

Although the clinical use of tinoridine has been well established, its mechanism of action is not well understood. Because of the number of diseases that can be treated by tinoridine, a better understanding of its mechanism of action is important.

Tinoridine, like many other aminoglycoside antibiotics, exerts its pharmacological effects by binding to
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tinostamustine(EDO-S101)is a drug that inhibits
 
Response: Tinostamustine(EDO-S101)is a drug that inhibits protein kinase C(PKC), the activity of which is associated with cell proliferation and growth. We have shown that EDO-S101 inhibited the growth of leukemia cells, including Jurkat, CCRF-CEM, HL-60, and U937 cells, and that EDO-S101 induced cell cycle arrest at G2/M phase. Moreover, EDO-S101-induced apoptosis was accompanied by the cleavage of poly(ADP-ribose) polymerase(PARP) and activation of caspase-3. EDO-S101 also induced the expression of p21(Waf1/Cip1) and p27(Kip1) in leukemia cells. However, EDO-S101 did not inhibit PKC activity. In addition, EDO-S101 induced the phosphorylation of PKC and the expression
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tioproninis a drug that inhibits
 
Response: Tioproninis a drug that inhibits the activity of caspase-3 and 7. It has been shown to be a potent inducer of apoptosis in cultured neuronal cells.^[@R1]^ Recently, it has been shown to be a potent anti-tumor agent in a rat glioma model,^[@R2]^ as well as a potent inducer of apoptosis in a human leukemia cell line.^[@R3]^ We report a case of human medulloblastoma in a child with both seizure and neurologic deficits due to its diffuse infiltrative nature.

Case Report {#s1}
===========

A previously healthy 5-year-old boy presented to the emergency department with a 1-week history of fever, cough, and intermittent headache. On physical examination, the child was awake, afebrile, and alert, with a heart rate of 108 beats/min, blood pressure
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tiotropiumis a drug that inhibits
 
Response: Tiotropiumis a drug that inhibits acetylcholine from reaching the lungs. This leads to a reduction in the stimulation of the bronchial muscles and a decrease in the amount of mucus produced. It is used in the treatment of chronic obstructive pulmonary disease (COPD). It also can be used to treat bronchospasm caused by other conditions such as bronchitis, asthma, and pneumonia.

Tiotropium is available as a powder to be inhaled via a powder inhaler or an aerosol inhaler. It is taken once daily.

Side effects include dry mouth, nasal irritation, and dizziness. Serious side effects include decreased kidney function, decreased heart rate, and death. It is not recommended for use in patients with a history of severe liver disease.

Tiotropium is not recommended for use in patients who are allergic to atropine. It is also not recommended for use in patients with a history of hypers
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tioxoloneis a drug that inhibits
 
Response: Tioxoloneis a drug that inhibits protein kinase C (PKC) activity and has been reported to be a potent inhibitor of vascular smooth muscle cell proliferation. In this study, we examined the effects of Tioxolone on platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) proliferation. PDGF stimulated a concentration-dependent increase in [3H]thymidine incorporation into DNA of VSMC. Tioxolone inhibited the PDGF-stimulated increase in [3H]thymidine incorporation in a concentration-dependent manner. Tioxolone also inhibited the PDGF-stimulated increase in the number of cells stained with fluorescein diacetate (FDA) and propidium iodide (PI) in a concentration-dependent manner. PDGF induced the phosphorylation of mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinase (ERK), c-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tipifarnibis a drug that inhibits
 
Response: Tipifarnibis a drug that inhibits the enzyme farnesyl transferase, thereby inhibiting farnesylation of the Ras oncoprotein and is currently being investigated in phase II trials for the treatment of colorectal cancer and as a single agent for the treatment of acute myeloid leukemia. We report two patients with acute myeloid leukemia (AML) and hepatocellular carcinoma (HCC) who were treated with tipifarnib and were subsequently found to have concurrent regression of their HCC and induction of their AML.

Case Report
===========

Case 1
------

A 57-year-old man was diagnosed with AML, M2b, after presenting with hepatosplenomegaly and fever. He had previously been treated for and had been cured of Hodgkin's lymphoma (HL) and was found to have concurrent diffuse large B-cell lymphoma. His baseline serum lactic dehydrogen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tirapazamineis a drug that inhibits
 
Response: Tirapazamineis a drug that inhibits topoisomerase II and causes DNA damage in tumor cells. We investigated whether tirapazamine could kill tumor cells at low concentrations and at nontoxic concentrations in normal cells. We also examined the effect of tirapazamine on radiation-induced apoptosis. We evaluated the ability of tirapazamine to kill tumor cells by a colony formation assay and a flow cytometric analysis of apoptosis. The drug was tested for its effect on the clonogenic survival of two tumor cell lines, human epidermoid carcinoma A431 and mouse fibrosarcoma Meth-A cells. The drug was also tested for its effect on radiation-induced apoptosis. At nontoxic concentrations, tirapazamine caused a dose-dependent inhibition of clonogenic survival of tumor cells, but not of normal cells. The effects of the drug were dose- and time-dependent. Tirapazamine at concentrations that caused >or=
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  tiratricolis a drug that inhibits
 
Response: tiratricolis a drug that inhibits the conversion of testosterone to dihydrotestosterone (DHT). It also inhibits 5 alpha-reductase, which is responsible for the conversion of testosterone to DHT. The conversion of testosterone to DHT, and the inhibition of this conversion by flutamide, are thought to be important in the development of prostate cancer. The potential of flutamide to prevent the development of prostate cancer is the subject of this article.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tirofibanis a drug that inhibits
 
Response: Tirofibanis a drug that inhibits platelet aggregation and thus is useful for the treatment of thromboembolic disorders, such as ischemic heart disease, acute coronary syndrome, and stroke. Tirofiban, the generic name of the drug, is sold under the tradename “Aggrastat®” by Merck & Co., Inc.
The drug is an antiplatelet agent, and acts by inhibiting the binding of fibrinogen to the platelet GP IIb/IIIa receptor, which is involved in platelet aggregation. This is achieved by binding to the GP IIb/IIIa receptor, a cell surface receptor present on the surface of activated platelets. This inhibits platelet aggregation and thus reduces the risk of thrombotic events.
Tirofiban is administered as an injectable drug to patients suffering from acute coronary syndrome, stroke or undergoing cardiac surgery, and as an intravenous infusion to patients suffering from th
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tizanidineis a drug that inhibits
 
Response: Tizanidineis a drug that inhibits the skeletal muscle-specific isoform of the enzyme phosphodiesterase (PDE4) that degrades the neurotransmitter, acetylcholine. Tizanidine is used in the treatment of muscle spasm in multiple sclerosis (MS), and has also been used in the treatment of patients with painful diabetic neuropathy. In the treatment of MS, tizanidine has been shown to reduce muscle spasm, as well as pain. Tizanidine has also been used in the treatment of painful diabetic neuropathy. The efficacy of tizanidine in the treatment of painful diabetic neuropathy has been demonstrated in several randomized, placebo-controlled, double-blind studies. In a double-blind study of the efficacy of tizanidine in patients with painful diabetic neuropathy, treatment with tizanidine (two to four mg/day) was associated with a statistically significant improvement in the treatment of pain. Tizanidine
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tobramycinis a drug that inhibits
 
Response: Tobramycinis a drug that inhibits the proliferation of tumour cells. It is one of the most potent cytotoxic agents of the polyketides. Tobramycin has a very narrow therapeutic index, and has significant toxicity, even at low doses.\[[@CIT1]\] In this study, the cytotoxic effects of Tobramycin and its derivatives on the growth of oral cancer cell lines were evaluated *in vitro*.

For this purpose, Human Oral Squamous Cell Carcinoma (HOSC-2) cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C in 5% CO~2~. HOSC-2 cells were grown to 70% confluence in 24-well plates, incubated with the drugs for 24 h at 37°C and cell growth was measured by 3-(4,5-dimethylthiazol-2-yl)-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tocopherolis a drug that inhibits
 
Response: Tocopherolis a drug that inhibits phospholipase A2. Inhibition of phospholipase A2 by Tocopherol causes an inhibition of the secretion of cytokines and thus it is used in the treatment of various inflammatory diseases, especially of the central nervous system.
Tocopherol has been used in the treatment of diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and systemic lupus erythematosus. Tocopherol is also used in the treatment of psoriasis. It has been found that tocopherol has a good therapeutic effect on the skin and mucosa of the mouth, in the mouth itself and on the gums.
It has also been found that tocopherol has a good therapeutic effect on diseases of the brain. It has been found that tocopherol has a good therapeutic effect on the nerve conduction system and on the muscles of the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tofogliflozinis a drug that inhibits
 
Response: Tofogliflozinis a drug that inhibits cyclin D1 (CCND1) activity can reverse the proliferative advantage of mutant EGFR-expressing cells, and inhibit their growth. To determine whether these inhibitors could be used in combination with erlotinib, we analyzed the sensitivity of different cell lines to the combination of CCND1 inhibitors and erlotinib. CCND1 inhibitors and erlotinib were added at the same time, or CCND1 inhibitors were added after erlotinib. We found that the growth of CCND1-expressing cells was inhibited more efficiently when both agents were added at the same time, than when the two agents were added after erlotinib. The inhibition of EGFR-TKI-resistant NSCLC cell lines by CCND1 inhibitors in combination with erlotinib was additive. Thus, CCND1 inhibitors can be combined with erlotinib, and can inhibit the growth of EG
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolazolineis a drug that inhibits
 
Response: Tolazolineis a drug that inhibits the synthesis of uterine prostaglandins. It is used for the treatment of primary dysmenorrhea, and it is available as an oral tablet, an injectable preparation, and an intrauterine device (IUD). It is also used to prevent premature rupture of the membrane in women who are in labor. Tolazoline is not indicated for the treatment of pelvic pain or uterine pain associated with endometriosis or fibroids. Tolazoline is available in the following dosage forms:

Tablets—Each tablet contains tolazoline (an active ingredient) and lactose. Tolazoline is available in two strengths, 10 mg and 20 mg.

Intrauterine device (IUD)—The IUD is a T-shaped plastic device with a thin plastic string attached to the IUD and wrapped around the string is an absorbable ring. The IUD is inserted into the uterus, where
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolbutamideis a drug that inhibits
 
Response: Tolbutamideis a drug that inhibits an enzyme that is involved in the formation of cholesterol in the liver, as well as the use of it in a treatment of diabetes.

It is very important to tell your doctor if you are allergic to tolbutamide, or if you are allergic to any of the other ingredients in the product.

This drug should not be used in children under the age of 10, because the effectiveness of it has not been established in children younger than this age.

Side effects

Like any other medications, tolbutamide can cause side effects. If any of these side effects occur, do not hesitate to contact your doctor or pharmacist.

Nausea and vomiting

In most cases, nausea and vomiting is the only side effect of tolbutamide. If you notice these symptoms, stop using the product immediately and consult your doctor.

Unusual bleeding

If you experience unusual bleeding, especially when
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolcaponeis a drug that inhibits
 
Response: Tolcaponeis a drug that inhibits the enzyme COMT, which breaks down dopamine in the brain. Studies have shown that tolcapone can improve cognitive function in patients with Parkinson's disease.

What is the most important information I should know about tolcapone?

Do not take tolcapone if you have been told you have an allergy to it, to a related drug, or to dopamine-depleting drugs.

If you are a woman who is pregnant or plans to become pregnant, do not take tolcapone. It can harm your baby.

Do not take tolcapone if you have a history of severe liver problems, heart problems, heart failure, high blood pressure, stroke, or heart valve problems.

Do not take tolcapone if you have low levels of thyroid hormone (hypothyroidism).

Do not take tolcapone if you have a history of depression, mental
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolfenamicis a drug that inhibits
 
Response: Tolfenamicis a drug that inhibits prostaglandin production. It works by inhibiting an enzyme that is necessary for prostaglandin production. The drug is used to treat migraine headaches and menstrual cramps. Tolfenamic acid can also be used to treat menstrual cramps and premenstrual syndrome.

Tolfenamic acid is a prescription drug that is used to treat menstrual cramps and migraines. It works by inhibiting an enzyme that is necessary for prostaglandin production. The drug is also used to treat a type of headache called cluster headaches.

Tolfenamic acid is also known by the brand names Tolfen, Mobifen, and Monate. It is a prescription drug that is used to treat menstrual cramps and migraines.

What Is Tolfenamic Acid?

Tolfenamic acid is an active ingredient in some prescription and over-the-counter (OTC)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  tolmetinis a drug that inhibits
 
Response: tolmetinis a drug that inhibits the action of the
enzyme, which is normally produced by the
body to destroy the virus. This drug is taken
by mouth and usually works within a few days.
It is effective against herpesvirus, but is
not recommended for use in pregnant women.
There is a vaccine that has been approved
by the FDA and the Center for Disease Control
and Prevention. The vaccine works by introducing
the herpesvirus into the body, which creates
an immune response. However, this vaccine
is only recommended for those with severe
infections. There is no cure for herpesvirus.
If a person has herpesvirus, there are ways
to minimize the risk of transmitting the
disease. In addition to the precautions already
mentioned, a person with herpesvirus should
be tested for a sexually transmitted infection
like chlamydia or gonorrhea.
It is important to avoid people who
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolnaftateis a drug that inhibits
 
Response: Tolnaftateis a drug that inhibits the microtubule-associated protein tau, which plays a key role in the stabilization of microtubules. It has been used for many years to treat and prevent dementia associated with Alzheimer's disease (AD).\[[@ref1]\] Its main mechanism of action is the increase in acetylcholine level and thus cognitive function improvement.\[[@ref2]\]

There are few clinical trials regarding the efficacy of tolnaftate in AD. It is believed that tolnaftate may be more effective in mild AD than in moderate AD.\[[@ref3]\] Some studies showed that tolnaftate may be effective in treating AD symptoms, such as attention deficit hyperactivity disorder, but it did not show any significant improvement in the overall condition of patients.\[[@ref4][@ref5]\]

On the other hand, some studies reported the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolperisoneis a drug that inhibits
 
Response: Tolperisoneis a drug that inhibits the action of gastric acid. It works by blocking the action of the H+/K+ ATPase pump (proton pump) in the parietal cells of the stomach, thus causing the acid to remain in the stomach and cause the stomach to feel full.

Common side effects of tolperisone include dizziness, drowsiness, headache, and nausea. Tolperisone is used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, and stomach ulcers. It may be prescribed with an H2 receptor antagonist (like ranitidine) to treat heartburn. It may also be used for other purposes not listed in this medication guide.

The effectiveness of tolperisone has been studied in the following conditions:

GERD

Peptic ulcer disease

Gastric ulcers

Stomach ulcers

St
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolterodineis a drug that inhibits
 
Response: Tolterodineis a drug that inhibits muscarinic receptors and blocks the effects of acetylcholine.

Tolterodineis the active ingredient in the drug Osphena, which is used to treat overactive bladder.

Tolterodineis used to treat symptoms of overactive bladder (OAB), a condition in which the bladder muscle contracts and spasms uncontrollably, causing you to urinate frequently. Tolterodine may also be used for other conditions as determined by your doctor.

Tolterodine is an antimuscarinic agent. It works by blocking the action of acetylcholine at muscarinic receptors in the bladder.

How does it work?

Tolterodine blocks the action of acetylcholine at muscarinic receptors in the bladder.

Tolterodine also affects other organs, including the gastrointestinal tract, where it is used to treat irrit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Toltrazurilis a drug that inhibits
 
Response: Toltrazurilis a drug that inhibits a host of viruses, including feline herpesvirus-1 (FHV-1), a major cause of infectious ocular disease in cats.

Ophthalmic treatment options for feline herpesvirus-1 (FHV-1) infection include topical antiviral agents, intravitreal antiviral therapy, and systemic therapy. Topical therapy with ribavirin and famciclovir has been shown to be effective against FHV-1 in cats. Intravitreal therapy has been evaluated in cats with FHV-1-induced retinitis and has shown good efficacy. Systemic therapy with acyclovir and famciclovir have been used in cats with feline infectious peritonitis, feline herpesvirus-2 (FHV-2), and feline immunodeficiency virus (FIV) infections. The use of combination therapy has been evaluated in cats
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tolvaptanis a drug that inhibits
 
Response: Tolvaptanis a drug that inhibits the reabsorption of the water-soluble vasopressin hormone. When administered orally, tolvaptan binds to the V2 receptor on the apical membrane of the collecting duct, where it blocks the transport of water and urea from the urine into the blood. Inhibition of this process reduces the concentration of urine in the blood, which leads to a decrease in blood pressure. In November 2003, tolvaptan was approved for use in the United States.

To order tolvaptan online, visit our secure website by clicking on the link below. You will be taken to a secure site where you can purchase tolvaptan. We accept all major credit cards and payment will be processed immediately.

What is the correct dose of tolvaptan?

The dose of tolvaptan should be titrated to the lowest dose that produces a significant decrease in the serum sodium concentration. This
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Topiramateis a drug that inhibits
 
Response: Topiramateis a drug that inhibits the sodium channels and it is used to treatseizures, migraine, and to prevent migraines. It is the third most prescribed drug in the US. It is approved for the treatment of migraines. The common side effects are dizziness, sleepiness, and weight loss. It can cause visual disturbances and depression. It is contraindicated in children, pregnant women, and patients with renal or hepatic insufficiency.

INTRODUCTION

TOPIRAMATE is a drug that inhibits the sodium channels and it is used to treat seizures, migraine, and to prevent migraines. It is the third most prescribed drug in the US. It is approved for the treatment of migraines. The common side effects are dizziness, sleepiness, and weight loss. It can cause visual disturbances and depression. It is contraindicated in children, pregnant women, and patients with renal or hepatic ins
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Topotecanis a drug that inhibits
 
Response: Topotecanis a drug that inhibits topoisomerase I. This enzyme prevents DNA damage and promotes DNA repair, which results in apoptosis. Topotecan is active in ovarian, breast, lung, and testicular cancer and in some leukemias and lymphomas. This drug is given by intravenous infusion every 3 weeks. It is not approved for the treatment of ovarian cancer. Topotecan is a potential treatment for patients with recurrent platinum-sensitive epithelial ovarian cancer.

Main Side Effects

The most common side effects include diarrhea, nausea, vomiting, alopecia, and skin rash. Other side effects include anemia, bone marrow suppression, hypokalemia, hyperglycemia, leukopenia, and neutropenia.

How to Interact with Topotecan

Avoid contact with the eyes, lips, and mouth. Take oral medications at least 1 hour before or 2 hours after meals.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Torcetrapibis a drug that inhibits
 
Response: Torcetrapibis a drug that inhibits cholesteryl ester transfer protein (CETP), which regulates the movement of cholesteryl esters between lipoproteins. Inhibition of CETP leads to a decrease in HDL-C levels, but increases LDL-C levels. The primary aim of the PARIS trial was to test the hypothesis that torcetrapib would decrease the incidence of major cardiovascular events in patients with prior coronary heart disease (CHD) and low HDL-C levels. PARIS was a double-blind, placebo-controlled, randomized trial in 9,744 patients with prior CHD and low HDL-C levels. The primary endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Treatment with torcetrapib reduced the incidence of the primary endpoint by 18% (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Toremifeneis a drug that inhibits
 
Response: Toremifeneis a drug that inhibits the production of estrogen in the body, so that it is used to treat breast cancer and uterine cancer. It has been proven to be effective in the treatment of endometriosis, atrophic vaginitis, and cervical intraepithelial neoplasia. Tamoxifen, the active ingredient of toremifene, is a selective estrogen receptor modulator. It is also a partial agonist of the estrogen receptor and an antagonist of the androgen receptor. The following are its main actions.

**1.** Toremifene inhibits the proliferation of endometrial cells.

**2.** Toremifene reduces the levels of estrogen in the body.

**3.** Toremifene reduces the levels of androgens in the body.

**4.** Toremifene increases the sensitivity of uterine tissue to estrogen.

**5.** Toremifene
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TP-0903is a drug that inhibits
 
Response: TP-0903is a drug that inhibits a protein called p73 that is involved in cell cycle control.

Our analysis of the gene expression data obtained from a cohort of 33 colorectal adenocarcinomas and 12 normal colonic mucosa samples (Figure [1A](#F1){ref-type="fig"}) identified a group of genes that are up-regulated by about 2-fold in tumor samples. These genes are involved in different processes including cell cycle regulation, DNA replication, DNA repair, cell cycle checkpoint control and DNA damage response (Figure [1B](#F1){ref-type="fig"}). Importantly, genes involved in cell cycle regulation, cell cycle checkpoint control and DNA repair are up-regulated by 2- to 10-fold in the majority of the colorectal adenocarcinomas analyzed (Figure [1B](#F1){ref-type="fig"}). In contrast, genes involved
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TPX-0005is a drug that inhibits
 
Response: TPX-0005is a drug that inhibits the binding of 3′-phosphorylated oligonucleotides to the human pol β exonuclease. To test whether TPX-0005 could inhibit pol β-mediated degradation of the oligonucleotide primer terminus, we performed a primer extension assay. TPX-0005 inhibited primer extension by pol β by ∼75% at concentrations as low as 2.5 µM ([Figure 3](#F3){ref-type="fig"}B, lane 7). The inhibitory effect of TPX-0005 was more pronounced with shorter DNA templates ([Figure 3](#F3){ref-type="fig"}B, lanes 8--10), indicating that the compound is a more potent inhibitor of pol β with shorter oligonucleotides.

TPX-0005 is a selective inhibitor of human pol β
------------------------------------------------

To determine the specificity of TPX-0005 for human
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TRANCOPALis a drug that inhibits
 
Response: TRANCOPALis a drug that inhibits TNF-alpha and IL-1 beta production, prevents the activation of NF-kappa B and MAPKs, and inhibits the release of pro-inflammatory cytokines. The drug has been used for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been used for treating the pain and inflammation associated with osteoarthritis and spondylitis.

BACKGROUND

TRANCOPALis a drug that inhibits TNF-alpha and IL-1 beta production, prevents the activation of NF-kappa B and MAPKs, and inhibits the release of pro-inflammatory cytokines. The drug has been used for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been used for treating the pain and inflammation associated with osteoarthritis and sp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trandolaprilis a drug that inhibits
 
Response: Trandolaprilis a drug that inhibits angiotensin-converting enzyme (ACE) and has antihypertensive properties. Trandolapril, like all ACE inhibitors, can cause drug-induced angioedema. We describe a case of angioedema following trandolapril in a pregnant woman. Angioedema was successfully treated with epinephrine, corticosteroids, and antihistamines.

1. Introduction {#sec1-1}
===============

Trandolapril, a selective inhibitor of angiotensin-converting enzyme (ACE), is widely used in the treatment of hypertension, heart failure, and myocardial infarction. The incidence of angioedema associated with trandolapril use is very low. We report a case of angioedema following trandolapril use in a pregnant woman.

2. Case Report {#sec1
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tranexamicis a drug that inhibits
 
Response: Tranexamicis a drug that inhibits fibrinolysis by blocking lysine binding sites of plasminogen, a natural enzyme involved in clot dissolution. It is effective in preventing or treating excessive bleeding from injury.

Tranexamic acid is a lysine analog, which means that it mimics lysine and competes with plasminogen for binding to fibrin, the substance that holds blood clots together.

In emergency situations, tranexamic acid is commonly given as an IV infusion to prevent or reduce bleeding during or after surgery.

Pregnancy and breast-feeding

Tranexamic acid is not known to be harmful to a fetus. It crosses the placenta and is distributed to the breast milk. There is no evidence of risk to the newborn.

Dosage and administration

The recommended dose is 1 gram IV infusion over 10 to 20 minutes. A total dose of 2 grams
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tranilastis a drug that inhibits
 
Response: Tranilastis a drug that inhibits the phosphorylation of tyrosine residues of tyrosine kinase proteins, thus blocking the proliferation and differentiation of various cells and the formation of inflammatory mediators. Tranilast is mainly used for the treatment of inflammatory dermatoses, such as psoriasis, atopic dermatitis, and pruritus. Although it is considered to be an anti-inflammatory drug, it has a risk of inducing toxicities such as hepatotoxicity and nephrotoxicity. In the present study, we examined the hepatotoxicity of tranilast by using mouse hepatocyte H4IIE cells. The toxic effects of tranilast were evaluated by observing cell morphology, detecting changes in cell cycle progression, and measuring the levels of oxidative stress-related biomarkers. The results showed that tranilast induced the phosphorylation of JNK and c-Jun, as well as the phosphorylation of extracellular signal-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trans-Tranilastis a drug that inhibits
 
Response: Trans-Tranilastis a drug that inhibits the activity of the enzyme tyrosine kinase, which is involved in the proliferation of skin cells. It can be used in the treatment of all kinds of skin diseases that are caused by the proliferation of cells. It can be used to treat conditions such as psoriasis, seborrheic dermatitis, lichen simplex chronicus, erythrodermic psoriasis, chronic plaque psoriasis, palmoplantar pustulosis, prurigo nodularis, or Darier disease. It can also be used to treat dermatitis or dermatitis, and skin cancer, such as basal cell carcinoma or squamous cell carcinoma.

Trans-Tranilast is used to treat atopic dermatitis, including the following:

Atopic dermatitis with dermatitis, which is a condition that affects the skin and the scalp, such as in children.

Atopic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trazodoneis a drug that inhibits
 
Response: Trazodoneis a drug that inhibits serotonin reuptake in the brain, and has a unique pharmacological profile of antidepressant efficacy. It is an antidepressant of the first-generation serotonin selective reuptake inhibitor (SSRI) class. Trazodone has a broad spectrum of therapeutic activity, and may be effective in the treatment of a wide variety of psychiatric disorders. It is approved in the US for the treatment of major depression, obsessive compulsive disorder, and post-traumatic stress disorder. Trazodone is also approved in many countries for the treatment of premenstrual dysphoric disorder. The purpose of this paper is to describe the pharmacokinetic profile of trazodone, to review its clinical use, and to provide an update on its safety and efficacy.

Introduction

Trazodone is a drug that inhibits serotonin reuptake in the brain, and has a unique pharmacological profile of antidepressant efficacy. It is an antidepressant of the first-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TRECATORis a drug that inhibits
 
Response: TRECATORis a drug that inhibits the enzyme farnesyl diphosphate synthase, thus preventing the production of farnesyl pyrophosphate (FPP) and its derivatives, such as farnesyl pyrophosphate farnesyltransferase (FPTase) and geranylgeranyl pyrophosphate farnesyltransferase (GGPase), which are required for the prenylation of proteins. Trecatoris is a novel therapeutic agent for the treatment of various diseases. Trecatoris inhibits the proliferation of various types of cancer cells in vitro and in vivo, such as human lung cancer cells, human colon cancer cells, human breast cancer cells, human ovarian cancer cells, and human colon cancer xenografts in nude mice. Trecatoris induces the death of human leukemia cells in vitro and in vivo. Trecatoris also exhibits anti-inflammatory activity by inhibiting the expression of inflammatory cytokines in human airway epit
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trelagliptinis a drug that inhibits
 
Response: Trelagliptinis a drug that inhibits bone resorption, osteoclasts. In bone, Trelagliptinis causes a reduction in bone resorption and an increase in bone formation. These effects are accompanied by a reduction in serum calcium and phosphorus. Trelagliptinis also increases the number of osteoblasts and stimulates their activity. The drug is administered orally.

I would like to be on a generic of Risedronate (Actonel), but it's too expensive.

I want to know if there are any generic drugs out there.

I would like to know if any of the following generic drugs work for me:

Amprenavir (Agenerase)

Amoxicillin (Amoxil)

Ampicillin (Amoxicillin)

Ampicillin (Amoxicillin)

Amoxapine (Asendin)

Amoxicillin (Am
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triacetinis a drug that inhibits
 
Response: Triacetinis a drug that inhibits thymidylate synthetase. It is used in the treatment of various malignancies, especially colon, stomach, lung, and breast cancers. It is administered intravenously.

Tacrolimus

Tacrolimus is a drug that is used to treat certain types of organ rejection, especially when the transplanted organ is from a person other than the recipient. It is administered intravenously.

Tapentadol

Tapentadol is a centrally acting analgesic that is used to treat moderate to severe pain. It is administered orally.

Tardive dyskinesia

Tardive dyskinesia is a disorder of the involuntary movements of the face, mouth, tongue, and other muscles that are triggered by long-term use of certain antipsychotic drugs. It can be a life-threatening disorder.

Tegafur

Tegafur is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  triclabendazoleis a drug that inhibits
 
Response: triclabendazoleis a drug that inhibits the activity of an enzyme (thymidylate synthase) involved in the synthesis of the essential DNA building block, deoxyuridine monophosphate (dUMP). This results in the accumulation of deoxyuridine triphosphate, which blocks DNA synthesis and leads to cell death.Treatment of tumours withtriclabendazole has been reported to cause severe neurological side effects in humans.

Mechanism of action
The anticancer mechanism of action of triclabendazole is based on the inhibition of thymidylate synthase (TS) which is a rate-limiting enzyme in the de novo synthesis of deoxyuridine monophosphate (dUMP) from deoxyuridine monophosphate (dUMP) and NTP.

Thymidylate synthase is a critical enzyme for DNA synthesis and is therefore essential for the survival
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triclocarbanis a drug that inhibits
 
Response: Triclocarbanis a drug that inhibits bacterial growth. Its structure is shown below. It has been used for decades as a non-antibiotic and is marketed by the chemical company, Dow, under the trade name Tresiba.

It is applied as a surface rinse in mouthwashes, and as a shower gel, which is then applied to the skin. It is also used as a water treatment system, and is marketed as a deodorant under the name Odanac.

When you use triclocarban on your skin, it enters your bloodstream and is excreted by your kidneys. It is also excreted by your sweat glands. It is also excreted by your breast milk, and if you are breast-feeding, you will be rinsing it off your skin.

Triclocarban has been approved by the FDA for use on the skin of humans. It is approved for use on children as
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triclosanis a drug that inhibits
 
Response: Triclosanis a drug that inhibits the growth of bacteria, but is not used in humans because it can be toxic to some other living organisms, including humans. Its purpose is to treat wounds and cuts, and prevent infections that can lead to the spread of diseases such as tuberculosis, herpes, syphilis, and HIV. The toxicity of triclosan is linked to its ability to interfere with thyroid hormone synthesis. A 2004 study in mice found that triclosan exposure led to the inhibition of thyroid hormone production, and that this led to the development of immune system deficiencies, such as increased susceptibility to infection and improper immune responses. The results were later replicated in a study in which mice were exposed to triclosan in drinking water for 28 days. This study showed that triclosan exposure resulted in changes in the mice’s immune system, as well as changes in the levels of thyroid hormones in the blood. The mice that were exposed to triclosan showed
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triethylis a drug that inhibits
 
Response: Triethylis a drug that inhibits the effects of the neurotransmitter dopamine. It is prescribed to treat depression. This may help to reduce symptoms of depression such as:

sadness

anxiety

insomnia

agitation

It is sometimes prescribed as an antidepressant. It is also used in the treatment of restless leg syndrome (RLS).

Dosage

The dose of Triethylis recommended for treating depression is 200-300 mg.

The dose of Triethylis for treating restless leg syndrome is 100-200 mg.

How to take

The tablets of Triethylis can be taken with or without food. The usual dose of Triethylis is 2 tablets daily.

Side effects

Some side effects may occur while taking Triethylis:

drowsiness

feeling tired

headache

blurred vision

sleepiness

restlessness

difficulty in concentrating
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trifluoperazineis a drug that inhibits
 
Response: Trifluoperazineis a drug that inhibits calmodulin. Calmodulin is a calcium-binding protein which acts as a Ca2+-dependent enzyme activator.

Trifluoperazine is an antipsychotic drug used to treat certain psychiatric conditions, such as schizophrenia, manic-depressive disorder, and certain drug-induced psychotic states. It is also used as a sedative-hypnotic and an antiparkinsonian drug. It is also used as an adjunct to chemotherapy in the treatment of breast cancer. It is also used as an anti-psychotic drug for people who have had a brain injury, for those with tardive dyskinesia, and for those with dystonia.

Clinical uses

Trifluoperazine is primarily used in the treatment of psychoses, in particular, as a drug to treat schizophrenia and related disorders. It is also used as an adjunct to chemotherapy in the treatment of breast cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TRIFLURIDINEis a drug that inhibits
 
Response: TRIFLURIDINEis a drug that inhibits replication of the influenza virus. It is used in the treatment of influenza in patients with severe disease. The mechanism of action of this drug is inhibition of the M2 ion channel protein.

TRIFLURIDINEis a drug that inhibits replication of the influenza virus. It is used in the treatment of influenza in patients with severe disease. The mechanism of action of this drug is inhibition of the M2 ion channel protein.

TRIFOLIDINEis a drug that inhibits replication of the influenza virus. It is used in the treatment of influenza in patients with severe disease. The mechanism of action of this drug is inhibition of the M2 ion channel protein.

TRIPLATINOL is an active metabolite of the antimalarial drug, tetracycline. It is a powerful antibiotic and is used to treat certain infections caused by bacteria.

TRIPLEX SYNDROME is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triflusalis a drug that inhibits
 
Response: Triflusalis a drug that inhibits the production of thromboxane A2 (TXA2) and prostaglandin I2 (PGI2) and has been used to treat thrombotic disorders. Triflusal has a property of reducing the adhesion of platelets and has been used for the prevention and treatment of thrombotic disorders such as thromboembolic diseases and disseminated intravascular coagulation (DIC).
There are several reports on the development of a PGI2 receptor antagonist for the treatment of thrombotic disorders. For example, non-patent reference 1 discloses a compound having a thromboxane A2 receptor antagonistic activity. However, there are no reports on the usefulness of a PGI2 receptor antagonist for the prevention or treatment of thrombotic disorders.
Non-patent reference 2 discloses a compound having a TXA2 receptor antagonistic activity. However,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trihexyphenidylis a drug that inhibits
 
Response: Trihexyphenidylis a drug that inhibits the release of acetylcholine at post-synaptic cholinergic receptors. It is used in the treatment of Parkinson's disease and Alzheimer's disease. Trihexyphenidyl also acts as an alpha2-adrenergic receptor antagonist, and is used in the treatment of certain anxiety disorders and insomnia.

Trihexyphenidylis a drug that inhibits the release of acetylcholine at post-synaptic cholinergic receptors. It is used in the treatment of Parkinson's disease and Alzheimer's disease. Trihexyphenidyl also acts as an alpha2-adrenergic receptor antagonist, and is used in the treatment of certain anxiety disorders and insomnia.

Trihexyphenidylis a drug that inhibits the release of acetylcholine at post-synaptic cholinergic receptors. It is used in the treatment of Parkinson's disease and Alzheimer's disease. Trihexyp
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triiodothyronineis a drug that inhibits
 
Response: Triiodothyronineis a drug that inhibits thyroid function, specifically by preventing the production of thyroxine. Thyroxine is needed for growth and development in infants and children. Triiodothyronine is used in combination with other medications to control the thyroid function of people with thyrotoxicosis, hyperthyroidism. Triiodothyronine is also used in replacement therapy for hypothyroidism. It is also used to treat some cases of underactive thyroid disease.

Although Triiodothyronine is often used for the treatment of certain thyroid conditions, it is not known if Triiodothyronine is safe and effective for all patients. Triiodothyronine should not be used in patients who are allergic to iodine.

Triiodothyronine Side Effects

Triiodothyronine can have side effects, including:

Abnormal heart rhythms

Headaches

Irritability

Rashes

Weakness


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trilostaneis a drug that inhibits
 
Response: Trilostaneis a drug that inhibits the synthesis of corticosterone in the adrenal gland. This causes a decrease in blood pressure, by reducing the activity of the sympathetic nervous system, and increasing the activity of the parasympathetic nervous system, reducing heart rate and causing vasodilation.[1] Trilostane is the active ingredient in Trilafon and is used in horses to decrease the activity of the adrenal glands, leading to a decrease in the concentration of corticosteroids.

Trilostane was first synthesized in 1967 by the group of Peter Schuster at the Research Institute for Veterinary Drug Sciences of the Bayer AG.[2] Trilostane was first introduced for veterinary use in the United States in 1972.[3] Trilostane is the active ingredient in Trilafon and is used in horses to decrease the activity of the adrenal glands, leading to a decrease in the concentration of corticosteroids.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trimebutineis a drug that inhibits
 
Response: Trimebutineis a drug that inhibits a subtype of the enzyme acetylcholine-hydrolyzing enzyme called acetylcholinesterase. It is used to treat the symptoms of acute and chronic muscle overactivity (including fibromyalgia) and to reduce withdrawal symptoms in patients taking opioid drugs.

It was approved for use in the United States in May 2011.

Side effects

It is well tolerated, but the following adverse reactions have been reported:

  * Urinary tract infection
  * Dizziness
  * Diarrhea
  * Fatigue
  * Headache
  * Nausea
  * Abdominal pain
  * Constipation
  * Pruritus
  * Weight loss
  * Nervousness
  * Insomnia
  * Chest pain
  * Muscle twitching
  * Excessive sweating
  * Muscle spasms
  * Irritability

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trimetazidineis a drug that inhibits
 
Response: Trimetazidineis a drug that inhibits the action of endogenous cyclic adenosine monophosphate (cAMP) and has been used for treatment of intermittent claudication in humans.

**Objectives:** The purpose of this study was to investigate the effect of treatment with trimetazidine in patients with chronic venous insufficiency (CVI).

**Methods:** Patients with chronic venous insufficiency were treated with trimetazidine for 3 months. Clinical, echocardiographic and laboratory evaluations were performed at baseline and after 3 months. All patients completed a quality of life questionnaire (Short Form 36 Health Survey) before and after the treatment.

**Results:** The study population included 40 patients (mean age: 54 ± 13 years) with chronic venous insufficiency (28 women and 12 men). The mean clinical severity of CVI was as follows: symptoms (mild: 34.4%, moderate: 56
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trimethoprimis a drug that inhibits
 
Response: Trimethoprimis a drug that inhibits dihydrofolate reductase (DHFR), an enzyme that is essential for the metabolism of folic acid. In humans, trimethoprim causes a variety of side effects, including nausea, vomiting, diarrhea, dermatitis, myelosuppression, and alterations in blood counts. The drug is bactericidal against gram-positive and gram-negative bacteria and is a highly effective chemotherapeutic agent against some of the most prevalent bacterial infections, including Pneumocystis carinii pneumonia and P. jirovecii pneumonia.

Trimethoprim is currently approved in the United States for the treatment of certain bacterial infections and as an adjunct to sulfonamide therapy in the treatment of P. carinii pneumonia. It is available in various forms, including tablets, capsules, solutions, and suspensions. Trimethoprim has also been used for prophylaxis against P. car
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  trimipramineis a drug that inhibits
 
Response: trimipramineis a drug that inhibits serotonin reuptake. It is used to treat depression, which can be an effect of an underlying medical condition. Trimipramine may also be used for purposes other than those listed in this medication guide.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tripelennamineis a drug that inhibits
 
Response: Tripelennamineis a drug that inhibits acetylcholine-induced vasoconstriction in isolated guinea pig mesenteric arteries.
The effect of tripelennamine on vasoconstriction induced by acetylcholine (ACh) was investigated in isolated perfused guinea pig mesenteric arteries. Tripelennamine inhibited the vasoconstriction induced by ACh in a dose-dependent manner, but the potency of tripelennamine was only about 1/30 that of cevimeline. Tripelennamine did not affect the vasoconstriction induced by potassium chloride. Tripelennamine antagonized the vasoconstriction induced by ACh with a pA2 value of 8.32. The inhibition of vasoconstriction by tripelennamine was reversible. In the presence of 10(-5) M hexamethonium, tripelennamine inhibited the vasoconstriction induced by ACh by 40%, but
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Triptolideis a drug that inhibits
 
Response: Triptolideis a drug that inhibits tumor growth and has been used to treat various cancers. Triptolide inhibits tumor growth through multiple mechanisms. For example, triptolide can directly inhibit the growth of tumor cells by inducing apoptosis and inhibiting cell cycle progression. Triptolide can also indirectly inhibit the growth of tumor cells by inducing host immune response. The antitumor activity of triptolide is believed to be caused by the induction of tumor-specific immunity, which is characterized by activation of cytotoxic T cells (CTLs) and NK cells and induction of inflammatory cytokines.

In the present study, we investigated the effects of triptolide on NK cells in human peripheral blood. We found that triptolide induced the upregulation of CD69, CD107a, and NKG2D and the downregulation of CD45RA, CD62L, and NKp30 on NK cells. CD69 is a C
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Troglitazoneis a drug that inhibits
 
Response: Troglitazoneis a drug that inhibits the enzyme, peroxisome proliferator-activated receptor gamma (PPAR-gamma). The molecular target of troglitazone is PPAR-gamma, which is a member of the nuclear hormone receptor superfamily. PPAR-gamma is activated by a wide variety of compounds, including natural and synthetic ligands, and is essential for adipocyte differentiation. PPAR-gamma is also expressed in a number of other cell types, including vascular endothelial cells, and vascular smooth muscle cells (VSMCs).
The effect of troglitazone on PPAR-gamma is well documented, and has been demonstrated in a number of cells and tissues. In cultured human vascular endothelial cells, troglitazone has been shown to increase nitric oxide production, decrease cell adhesion molecules, and decrease thrombin-induced expression of tissue factor. See H. A. Kolb, et
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trometamolis a drug that inhibits
 
Response: Trometamolis a drug that inhibits cancer cell proliferation and induces apoptosis by modulating the expression of miR-205.

1. Introduction {#sec1-molecules-23-01375}
===============

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults \[[@B1-molecules-23-01375]\]. Patients with GBM are usually diagnosed at a late stage, when tumors have already reached a significant size, leading to a poor prognosis \[[@B2-molecules-23-01375]\]. The standard treatment for GBM includes surgery, radiation therapy, and chemotherapy. However, the survival rate of patients with GBM remains low, with a median survival of 12--14 months \[[@B3-molecules-23-01375]\].

Glioblastoma multiforme (GBM)
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tropicis a drug that inhibits
 
Response: Tropicis a drug that inhibits an enzyme that causes protein synthesis, which in turn prevents the growth of cells. It is used to treat cancers that are resistant to other therapies.

Sunitinib is a drug that prevents cancer cells from growing by blocking the effects of chemicals that are important for their growth. It is used to treat cancers that are resistant to other therapies.

Bortezomib is a drug that kills cancer cells by stopping them from dividing. It is used to treat cancers that are resistant to other therapies.

Dasatinib is a drug that stops cancer cells from dividing by blocking a chemical called a kinase. It is used to treat cancers that are resistant to other therapies.

Vemurafenib is a drug that prevents cancer cells from growing by blocking the effects of chemicals that are important for their growth. It is used to treat cancers that are resistant to other therapies.

Sunitinib is a drug
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tropisetronis a drug that inhibits
 
Response: Tropisetronis a drug that inhibits 5-HT3 receptors. These are sites on the surface of nerve cells. This inhibits the nerve cells from firing.

Tropisetron is also a drug that is used to prevent the side effects of cancer chemotherapy.

Chemotherapy is a treatment that is used to treat cancer.

Tropisetron is a drug that is used to prevent the nausea and vomiting that occurs during chemotherapy.

The side effects of chemotherapy can be severe and can last for a long time.

Nausea and vomiting are common side effects of chemotherapy.

Chemotherapy can cause serious side effects that can affect the heart, the blood, the liver, the kidneys and the nervous system.

Tropisetron is a drug that is used to prevent the side effects of chemotherapy.

In the chemotherapy treatment of cancer, the doctor will often prescribe a combination of drugs.

Tropis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Trospiumis a drug that inhibits
 
Response: Trospiumis a drug that inhibits the secretion of acetylcholine and the intestinal absorption of choline from the intestines, and has been shown to be effective in the treatment of gastroesophageal reflux disease (GERD) (Journal of Clinical Pharmacology, 31, 1990, p. 1553-1561). Trospium chloride is known to be clinically effective for the treatment of GERD. Trospium chloride is the active ingredient of several marketed drugs including CARDURA® (buserelin) and AMBASSADOR® (buserelin and furosemide). Trospium chloride is also known to be effective in the treatment of gastroparesis, spasticity and Parkinson's disease (Neuropsychopharmacology, 2003, 28, pp. 1194-1203).
Trospium chloride is an anticholinergic drug with a broad spectrum of action, which acts on the muscarinic receptors of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Troxerutinis a drug that inhibits
 
Response: Troxerutinis a drug that inhibits the synthesis of nitric oxide in the body. The brain uses nitric oxide to transmit messages from one brain cell to another. This is a very important part of the brain's ability to communicate with the body. Researchers believe that it is one of the key components in memory and learning. Nitric oxide helps the brain release neurotransmitters. Without this chemical messenger, the brain cells would not be able to communicate with each other.

Troxerutin also reduces the inflammation that occurs in the body. This is a big problem for people with diabetes. When you have diabetes, you are more likely to develop problems with your kidneys, nerves, blood vessels, and eyes.

Troxerutin is a natural substance that occurs in many plants. The medical name for it is quercetin. The pharmaceutical companies have taken quercetin and turned it into a drug called Troxerutin. Troxer
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Troxipideis a drug that inhibits
 
Response: Troxipideis a drug that inhibits the activity of sodium channels and reduces the excitability of nerves. It is used in the treatment of certain types of pain.

Troxipideis the brand name for the active ingredient sertindole. It is used in the treatment of psychotic disorders such as schizophrenia and schizoaffective disorder.

Troxipideis also used to treat Tourette's syndrome. It is taken by mouth.

This medicine is available only with a doctor's prescription.

Troxipide can be used with other medicines that treat schizophrenia. These include:

cisapride

clozapine

clozapine/olanzapine

haloperidol

mefloquine

metoclopramide

metoclopramide/phenytoin

phenobarbital

phenytoin

thioridazine


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TRx0237is a drug that inhibits
 
Response: TRx0237is a drug that inhibits BMP2, TGF-β, and GDF6 activity. It has been shown to be effective in promoting bone formation in preclinical studies \[[@CR42]\].

To address this, the *BMP2* and *TGF-β1* genes were over-expressed in ADSCs. Overexpression of *BMP2* in ADSCs resulted in enhanced mineralization of the extracellular matrix and the expression of bone-related genes, such as *RUNX2*, *OPN*, and *ALP*.

Moreover, overexpression of *TGF-β1* in ADSCs also significantly promoted mineralization of the extracellular matrix and the expression of bone-related genes, such as *RUNX2*, *OPN*, and *ALP*. However, the effect of overexpression of *TGF-β1* was weaker
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tucidinostatis a drug that inhibits
 
Response: Tucidinostatis a drug that inhibits the formation of colorectal tumors in humans. In experiments on rodents, the drug suppressed the formation of azoxymethane-induced colon tumors, reduced the number of adenomas in rats with familial adenomatous polyposis and in humans with familial adenomatous polyposis, and suppressed the formation of colorectal tumors in rats that had undergone colonic surgery. However, the drug also had adverse effects, such as bleeding, a higher rate of anemia, and possibly more infections.

In July 2003, the U.S. Food and Drug Administration (FDA) approved Tofranil for the treatment of adults with major depression, including those with a history of depression and those with major depression who have not responded to or who cannot tolerate standard antidepressant treatments. The FDA has approved the use of Tofranil in patients who are intolerant of, or are not responsive
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tulobuterolis a drug that inhibits
 
Response: Tulobuterolis a drug that inhibits the enzyme HMG-CoA reductase, is commonly used for the treatment of hypercholesterolemia, including atherosclerosis. A review of the available data suggests that although HMG-CoA reductase inhibitors are associated with a small but significant increase in the risk of venous thrombosis, they are unlikely to have any effect on the risk of arterial thrombosis. Thus, although they may be effective in lowering serum cholesterol, they do not appear to be beneficial in preventing the development of arterial thrombosis. The magnitude of the risk of venous thrombosis associated with these agents is unclear. The risk may be small, but the drugs should not be used in patients who have known venous thrombosis or other risk factors for venous thrombosis. Further research is needed to determine whether these drugs reduce the risk of arterial thrombosis.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tylosinis a drug that inhibits
 
Response: Tylosinis a drug that inhibits the activity of HIV and which is indicated for the treatment of HIV infection in combination with other anti-HIV compounds. A single dose of 400 mg of the drug taken orally was administered to adult volunteers in a placebo-controlled, double-blind study. The compound was well tolerated, and the results indicate that it is effective in the treatment of HIV infection. The compound did not have a significant effect on viral load or plasma HIV-1 RNA levels. It did, however, reduce the number of CD4+ T cells in the blood and lymph nodes of infected volunteers. In vitro, the drug did not affect the growth of HIV-infected cells or inhibit HIV replication in cultures of cells that were infected with the virus. The drug did, however, block the ability of HIV to infect and replicate in cultures of cells that were treated with the drug. The effect was seen after exposure to the drug for as little as 2 hours and was dose-dependent
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Tyloxapolis a drug that inhibits
 
Response: Tyloxapolis a drug that inhibits transcription of adenosine A2A receptors and reduces inflammatory cell recruitment in a model of acute pancreatitis.
Acute pancreatitis (AP) is a common disease with a high morbidity and mortality. Its clinical management is based on symptomatic treatment. There is no effective therapy for AP. In this study, we investigated the therapeutic effect of a new anti-inflammatory drug, tyloxapol, on the development of AP in rats. In addition, we also examined the possible mechanism of action of tyloxapol on AP. The results showed that tyloxapol inhibited the development of AP in rats. The number of infiltrated neutrophils in the pancreas was reduced by tyloxapol. Furthermore, we found that tyloxapol inhibited the production of inflammatory mediators, such as TNF-α, IL-1β, and IL-6, in the pancreas. In addition
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TYZEKAis a drug that inhibits
 
Response: TYZEKAis a drug that inhibits the actions of a key enzyme in the synthesis of cholesterol. It works by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). It has a good safety profile and is used for the treatment of high cholesterol.

STORAGEInformation about ZETIA is available on the packaging. Do not take ZETIA after the expiry date stated on the packaging.

The information presented here is for reference only. Always read the label.

Please enter your name and email address and we will send you a link to download the ZETIA information.

Name

Email

Message

Contact us

+44 (0)800 024 9549

Or email us at: info@tradetab.com

ABOUT TRADETAB

Tradetab.com is an online community of independent healthcare professionals
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  TZ-3is a drug that inhibits
 
Response: TZ-3is a drug that inhibits tubulin polymerization and induces apoptosis in many cancer cells \[[@B30-ijms-18-00785],[@B31-ijms-18-00785]\]. Here, we demonstrated that a low dose of TZ-3 effectively induced cell death and suppressed proliferation in mouse gastric cancer cells (MKN45 cells). In addition, we demonstrated that the knockdown of *S100A4* expression by siRNA induced apoptosis and inhibited the growth of MKN45 cells. The in vivo study also showed that *S100A4* knockdown suppressed tumor growth in a xenograft mouse model. These results suggest that *S100A4* knockdown can be a useful strategy for the treatment of gastric cancer.

The cell cycle progression is controlled by cyclin-dependent kinases (CDKs) and CDK inhibitors (CDKIs) \[[@B32-
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Udenafilis a drug that inhibits
 
Response: Udenafilis a drug that inhibits the action of PDE5, thus increasing the level of cGMP in the penis and helping to increase blood flow and penile erection. Udenafil, as the name suggests, comes from the Indonesian word uden, meaning "without". Udenafil is marketed under the trade name Zydena by Cipla Ltd, India. The recommended dosage is 50 mg.

The clinical trials were published in the peer-reviewed journals New England Journal of Medicine, Journal of the American Medical Association, Lancet, European Urology, and Journal of Urology. The results were favorable. The authors noted that although sildenafil had become the standard treatment for erectile dysfunction, sildenafil users were prone to experience side effects such as headache, flushing, facial flushing, dyspepsia, diarrhea, and nasal congestion. They also noted that tadalafil had fewer side effects than sild
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ulipristalis a drug that inhibits
 
Response: Ulipristalis a drug that inhibits prostaglandin synthetase. It may be used to reduce or eliminate the discomfort of cystitis. It is also used to treat and prevent migraine headaches. The drug may also be used to treat or prevent the signs and symptoms of chronic obstructive pulmonary disease.

Ulipristal is used to prevent pregnancy in women who have already been impregnated. It may be used to treat ulcerative colitis. It is also used to treat endometriosis.

Side Effects

The most common side effects include abdominal pain, diarrhea, fever, and nausea. Serious side effects may include liver problems, changes in blood chemistry, and fluid retention.

Ulipristal may be unsafe to use during pregnancy. It may cause birth defects. Pregnant women should not take this medication unless they absolutely must.

Other drugs that may interact with ulipristal include:

Cyclospor
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  UM171is a drug that inhibits
 
Response: UM171is a drug that inhibits tubulin polymerization. It is the first tubulin polymerization inhibitor to be identified and developed as an anticancer drug. We found that MI171 induced apoptosis in human colon cancer cells (HT-29, SW620 and HCT116) in a dose- and time-dependent manner. Flow cytometry showed that a dose of 10 μM of MI171 increased the sub-G1 population by 10.5, 11.3 and 9.3% for HT-29, SW620 and HCT116 cells, respectively. This was associated with an increase in apoptosis as shown by Annexin-V staining and DNA laddering. In contrast, the MI171 dose required to induce apoptosis in a normal colon cell line (FHC) was 50 μM. A 3-D culture system also showed that MI171-induced apoptosis was cell line-dependent. In this system, the cell population in the G2/M
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Undecanoicis a drug that inhibits
 
Response: Undecanoicis a drug that inhibits the inactivation of endothelin-1 by proteolytic degradation. It is available in the form of an oral solution.

**OFF-LABEL:** It is indicated for the treatment of erectile dysfunction and treatment of idiopathic priapism in men.

#####  PRECAUTIONS

**Contraindications:** Hypersensitivity to endothelin-1 receptor antagonists. **Cautions:** Renal impairment, HF, unstable angina, diabetes mellitus, vasculitis, thromboembolic disorders.

#####  ACTION

Binds to endothelin receptors and blocks binding of endothelin to receptor sites. **Therapeutic Effect:** Reduces blood pressure, increases renal blood flow, dilates small arteries.

#####  PHARMACOKINETICS

Rapidly absorbed after PO administration. Protein binding:
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Uracilis a drug that inhibits
 
Response: Uracilis a drug that inhibits uridine-cytidine kinase and depletes thymidine triphosphate, and thus can be used to induce a thymidine-independent cell cycle.

Mechanism of action
Uracilis a drug that inhibits uridine-cytidine kinase and depletes thymidine triphosphate, and thus can be used to induce a thymidine-independent cell cycle.

References

Category:Anti-cancer drugs
Category:Purines
Category:Organochlorides
Category:Pyrimidinediones
Category:Organic sodium salts
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Urapidilis a drug that inhibits
 
Response: Urapidilis a drug that inhibits the PDE-5 enzyme.

Ionitrogen (ionized) – If you have a problem with high blood pressure, this is a good supplement.

Citrate – The most popular of the B vitamins, citrate can be used as a way to lower high blood pressure.

Magnesium – Magnesium can be helpful in the treatment of high blood pressure. It is also helpful in preventing heart attacks.

Copper – Copper is important for the proper functioning of the arteries.

Folic acid – It is a B vitamin that helps to lower blood pressure.

Zinc – Zinc is also a mineral that is important for the proper functioning of the arteries.

Selenium – Selenium is a mineral that helps to lower blood pressure.

Boron – Boron is also a mineral that is important for the proper functioning of the arteries.

Vitamin B6
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Urethaneis a drug that inhibits
 
Response: Urethaneis a drug that inhibits the liver from producing alcohol. This is why a couple of glasses of wine can have you feeling drunk in a matter of hours. Urethane is not a drug that can be purchased over the counter and does not require a prescription. The process of taking urethane can be described as simple, but can be dangerous if not done correctly. A user of urethane must take it at the right time. One of the best times to take urethane is the night before a party.

Urethane is most effective when the liver is not functioning at full capacity. Alcohol is broken down in the liver and urethane is the enzyme that prevents the breakdown of alcohol. When urethane is taken the next day, it is not effective because the liver is already at full capacity. The liver is able to produce alcohol and it has no need for urethane.

Because urethane is a drug, it can have
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  uridineis a drug that inhibits
 
Response: uridineis a drug that inhibits the enzyme ribonucleotide reductase, which is essential for the synthesis of DNA, thus stopping the cell cycle at the G1 phase. Cisplatin is a platinum based drug that causes DNA damage by cross linking to DNA, thus preventing the replication of DNA. These two drugs are also used to treat lung cancer.

A number of inhibitors of ribonucleotide reductase are being investigated for their anti-cancer activity, but the most potent of these is hydroxyurea (HU), which is also used to treat sickle cell anemia. It has been used in the clinic for decades, and there is extensive literature on its pharmacology.

HU has been shown to inhibit ribonucleotide reductase, induce apoptosis, arrest the cell cycle, and inhibit angiogenesis in a variety of human tumor cell lines, including breast, ovarian, prostate, and non-small cell lung cancer.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Uridineis a drug that inhibits
 
Response: Uridineis a drug that inhibits adenosine transport. Theophylline, a drug with similar activity, is also used. A third drug, furosemide, inhibits a different transport system. The actions of the three drugs are additive and competitive. Uridine and theophylline block the same transport system in the kidney and intestinal mucosa. The combination of these two drugs is used to treat the acute attacks of asthma and chronic bronchitis. Theophylline has been used in the treatment of Parkinson's disease and chronic obstructive lung disease.

Description

In the kidney, uridine is the major metabolite of adenosine. Uridine is the major source of nitrogen for the synthesis of purines, nucleotides, and pyrimidines. In the small intestine, uridine is the main precursor of uracil, the first degradative product of the purines. It is also a major source of ribose
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Urocanicis a drug that inhibits
 
Response: Urocanicis a drug that inhibits histamine release from mast cells in response to various stimuli and which is now in use as an antihistamine. The compound is generally administered orally, in doses of about 0.1 to about 20 mg/day, but the compound is also known to have anti-inflammatory and anti-allergic effects when administered in certain oral dosages, and is known to be effective in the treatment of asthma, allergies, and rhinitis when administered in aerosol form.
U.S. Pat. No. 3,896,122 to Hoehn et al. discloses that the compound of the formula ##STR2## in which R.sup.1 is a lower alkyl group, a phenyl group or a benzyl group, R.sup.2 is a lower alkyl group, and R.sup.3 is a lower alkyl group, an alkoxy group or a halogen atom, exhibits a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ursolicis a drug that inhibits
 
Response: Ursolicis a drug that inhibits the production of aldosterone. It also works on the potassium channel in the kidney.

The potassium channel is what lets potassium in the blood pass out. It's an essential part of the process that maintains the normal levels of potassium in the blood. If you have too much potassium, your heart can't beat properly.

Ursolic acid is a form of vitamin B-5, also known as thiamine.

The thiamine is what makes up the B complex vitamins. It's found in a lot of foods, but it's most abundant in red meat, whole grains, and soybeans.

Effexor can be prescribed to help treat depression.

Effexor is a brand name for the antidepressant venlafaxine, which is also used to treat anxiety and migraines.

This is a prescription drug. If you are on Effexor, it is a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vadadustatis a drug that inhibits
 
Response: Vadadustatis a drug that inhibits the growth of estrogen-dependent breast cancer cells. The treatment was administered in conjunction with a number of drugs, including one that specifically targets the disease in women, called palbociclib.

Treatment with the combination of drugs slowed the growth of tumors in mice and in people.

Palbociclib is approved by the Food and Drug Administration (FDA) for treatment of patients with estrogen receptor-positive breast cancer that has spread to other parts of the body. It is used in combination with other drugs.

Although the study was small, the results are promising. The findings appear in the Journal of Clinical Oncology.

“We are not yet at the point of treating these patients with palbociclib alone,” says Marisa Rosenthal, MD, assistant professor of medicine at the University of California, San Diego. “However, this study is the first to demonstrate that a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Valacicloviris a drug that inhibits
 
Response: Valacicloviris a drug that inhibits the release of calcium from cells into the bloodstream. It is used to treat osteoporosis and Paget's disease. It is also used in some people with severe chronic kidney disease to prevent the development of kidney stones.

References

External links
 
 
 
 
 
 
 

Category:Calcium channel blockers
Category:Nephrology procedures
Category:Pyrrolidines
Category:Pyrimidines
Category:Receptor agonists
Category:Triazolopyrimidines
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Valdecoxibis a drug that inhibits
 
Response: Valdecoxibis a drug that inhibits the cyclooxygenase (COX)-2 enzyme and thereby reduces the formation of the pain mediators prostaglandins. It was originally developed by Pfizer and is marketed as Osphena (valdecoxib) in Europe and Oxeia (valdecoxib) in the United States. In clinical trials, Valdecoxib reduced pain and increased physical function, and had similar efficacy to traditional NSAIDs but with less gastrointestinal side effects.[@b1-bctt-8-159]

The cyclooxygenase enzyme has two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in many tissues, and is responsible for the production of prostaglandins that regulate the homeostasis of gastrointestinal function, platelet aggregation, and renal function.[@b2-bctt-8-159]--[@b4
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Valethamateis a drug that inhibits
 
Response: Valethamateis a drug that inhibits the enzyme acetyl-CoA carboxylase (ACAC) which catalyzes the first step in fatty acid biosynthesis. The fatty acid biosynthesis pathway is the only known mechanism of de novo fatty acid synthesis in most organisms and therefore inhibition of this enzyme by valethamate is lethal to the organism. Valethamate is found in plants and microorganisms, and in the plant kingdom is primarily found in the genus Vaccinium. See, e.g., Boulton et al., (1992) “Valethamate biosynthesis and characterization of the valethamate pathway in Vaccinium,” J. Bacteriol. 174:5824-5830.
Vacciniums are important forage and timber trees. Vaccinium uliginosum, a blueberry, has been grown commercially for several years in Japan, Russia, and in northern regions of North America.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  valgancicloviris a drug that inhibits
 
Response: valgancicloviris a drug that inhibits the replication of Herpes simplex virus. It is also used to treat eye herpes. It is also used to treat genital herpes.

How to use valganciclovir for Herpes?

Valganciclovir is given by mouth. It is taken in the morning and evening. Take it as directed by your doctor.

Uses of valganciclovir

Valganciclovir is used to treat:

Recurrent herpes genitalis (shingles)

Herpes simplex virus (HSV) eye infection

Herpes labialis (cold sores)

Herpes zoster (shingles)

Valganciclovir is used to treat recurrent episodes of herpes genitalis (shingles).

Do not use this medication if you are pregnant. Do not use this medication if you are breastfeeding. Do
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Valnemulinis a drug that inhibits
 
Response: Valnemulinis a drug that inhibits the proliferation of a variety of tumors by acting on the TGF-β1/Smad3 signaling pathway \[[@CR1]\]. Valnemulinis a non-steroidal, semi-synthetic macrocyclic lactone antibiotic isolated from the actinomycete *Streptomyces caespitosus* in 1971 \[[@CR2]\]. Valnemulinis currently used in veterinary medicine to treat inflammatory diseases, especially mastitis in dairy cows. It is used for the treatment of foot rot, dermatitis, and atopic dermatitis in horses, and for the treatment of arthritis and skin lesions in dogs \[[@CR3]\]. Valnemulinis is well tolerated in most species and has been administered to pregnant cows, pigs, dogs, and cats \[[@CR4]\].

In our previous studies, we found that valnemulinis
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VALSARTANis a drug that inhibits
 
Response: VALSARTANis a drug that inhibits an enzyme called angiotensin-converting enzyme (ACE) and thereby prevents the body from making angiotensin II. This enzyme is responsible for the production of angiotensin II. It is important in controlling blood pressure.

ENALAPRILis a drug that is used to treat high cholesterol. It works by reducing the amount of cholesterol in the blood. It also lowers levels of triglycerides.

ENSURE is a combination of a statin and a proton pump inhibitor. It is used to treat high cholesterol and gastric reflux disease.

EPHEDRINE is a drug that relieves symptoms of an allergic reaction. It works by blocking the release of histamine, a substance that causes swelling and itching.

EPILEPSY is a disorder that causes abnormal brain activity. It can cause seizures.

ERECTILE DYSFUNCTION is the inability to get
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vancomycinis a drug that inhibits
 
Response: Vancomycinis a drug that inhibits hyphal formation in *C. albicans* has been shown to prevent *C. albicans* invasion of human oral epithelial cells \[[@B25]\]. Recently, we demonstrated that amphotericin B and nystatin inhibited *C. albicans* biofilm formation on human salivary epithelial cells and, in contrast, the oral epithelial cells were able to prevent *C. albicans* biofilm formation. In addition, the results of the present study revealed that the epithelial cells could significantly decrease the *C. albicans* biofilm formed on them.

In the present study, we showed that oral epithelial cells reduced the biofilm mass of *C. albicans* on them and caused morphological changes in the biofilm of *C. albicans* on them. It has been shown that cell-to-cell interactions and biofilm
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vanillinis a drug that inhibits
 
Response: Vanillinis a drug that inhibits the conversion of epinephrine into norepinephrine.

Inhibition of conversion of epinephrine to norepinephrine

Anticholinergic

Prevention of breakdown of acetylcholine

Anticonvulsant

Enhances the effect of GABA. GABA is a major inhibitory neurotransmitter.

Indications

Evaluation of seizure activity in patients with epilepsy.

Therapeutic Effect

Increased level of GABA in brain inhibits excitation and spasm.

Use

Vigabatrin (Vigamox) is the first approved drug for treatment of drug-resistant epilepsy. Vigabatrin is effective for partial seizures, but not for generalized tonic-clonic seizures. Vigabatrin can be used alone or in combination with other antiepileptic drugs. Vigabatrin is available as an oral suspension and tablets.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vardenafilis a drug that inhibits
 
Response: Vardenafilis a drug that inhibits the enzyme phosphodiesterase 5 (PDE5) that is used to treat erectile dysfunction (ED). The drug increases the level of cyclic guanosine monophosphate (cGMP) in the body, which relaxes the smooth muscles of blood vessels in the penis, allowing blood to flow into the penis and allowing an erection to occur. The effectiveness of vardenafil for erectile dysfunction was established in three placebo-controlled clinical trials. The drug is also used for other medical conditions, including pulmonary hypertension.

Vardenafil is an effective and safe drug for the treatment of erectile dysfunction.

Vardenafil is the first in a new class of drugs called PDE5 inhibitors. These drugs increase the level of cGMP in the body, which relaxes the smooth muscles of blood vessels in the penis, allowing blood to flow into the penis and allowing an erection to occur.

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vareniclineis a drug that inhibits
 
Response: Vareniclineis a drug that inhibits the reuptake of acetylcholine in the brain, thereby increasing the level of acetylcholine. This drug is marketed in the USA as Chantix.

The manufacturer of Varenicline, Pfizer, has spent a lot of money and effort promoting this drug as a smoking cessation treatment. However, there is little evidence to support the efficacy of Varenicline in this role.

Despite the considerable investment of time and money by Pfizer, the results of the company’s clinical trials have not been impressive.

Several independent studies have now shown that the efficacy of Varenicline in smoking cessation is no better than that of placebo.

In one such study, Dr Peter White, Professor of Pharmacology at University College London, found that Varenicline was no better than placebo in helping people to quit smoking.

Professor White, along with colleagues from Queen Mary University of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Varlitinibis a drug that inhibits
 
Response: Varlitinibis a drug that inhibits both PDGFR and VEGFR-2. It is currently approved for use in Japan, and it is currently being investigated in phase III trials for both treatment of NSCLC and RCC. Varlitinib has been shown to be an effective treatment for a variety of tumor types.

MATERIALS AND METHODS {#s1}
=====================

Patients {#s1_1}
--------

The protocol was approved by the Institutional Review Board at the National Cancer Institute, National Institutes of Health. All patients signed an informed consent form prior to enrollment. All studies were performed in accordance with the ethical standards of the Declaration of Helsinki. Eligible patients were adults with advanced solid tumors that were refractory to standard therapy or for which no standard therapy existed. Other eligibility criteria included the presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ARRY-334543is a drug that inhibits
 
Response: ARRY-334543is a drug that inhibits the enzyme cytochrome P450 3A4 (CYP3A4). It is marketed as a tablet under the brand name Stribild. It is a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). It is approved in the United States and many other countries for the treatment of HIV infection.

Treatment
Treatment is recommended for HIV-infected adults who have not achieved an undetectable viral load (HIV RNA below 50 copies/mL) after 24 weeks of treatment with at least two different antiretroviral agents.  Treatment is not recommended for HIV-infected children, pregnant women, or people with decompensated liver disease, kidney disease, or bone marrow suppression.

Mechanism of action
TDF inhibits the reverse transcriptase enzyme, an enzyme that is required for
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vecuroniumis a drug that inhibits
 
Response: Vecuroniumis a drug that inhibits the depolarization of skeletal muscle fibers, and it is commonly used as a muscle relaxant.

Vecuronium is a neuromuscular blocking agent (NMA) that is commonly used to facilitate intubation, facilitate laryngoscopy, and to maintain muscle relaxation during mechanical ventilation. It can be used as an adjunct to muscle relaxants, and it is used in conjunction with other muscle relaxants such as atracurium, d-tubocurarine, pancuronium, and succinylcholine.

Dosage and administration

The usual dose is approximately 0.01 to 0.1 mg/kg of body weight, although a dose of 0.01 to 0.05 mg/kg of body weight is usually used.

The dose of vecuronium is usually 0.01 mg/kg of body weight for induction of anesthesia, 0.05 mg/kg
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Venlafaxineis a drug that inhibits
 
Response: Venlafaxineis a drug that inhibits the reuptake of serotonin, norepinephrine, and dopamine, and that has been approved by the FDA for the treatment of depression. Its exact mechanism of action is unknown. Serotonin reuptake inhibitors are often the first-line therapy for depression, but for some patients, they have poor response rates. The objective of this study was to assess the efficacy of venlafaxine in the treatment of acute major depression. In this double-blind, placebo-controlled study, a total of 180 adult outpatients with a major depressive episode were randomized to receive venlafaxine or placebo for 8 weeks. The primary efficacy endpoint was the Hamilton Depression Rating Scale (HDRS) total score at the end of the study. Secondary efficacy measures included the HDRS item score and response rates. Adverse events were monitored throughout the study. Venlafaxine treatment resulted in a significantly greater reduction in the HDRS total score
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Verapamilis a drug that inhibits
 
Response: Verapamilis a drug that inhibits the cardiac muscle cell membrane action potential, prolonging the QT interval of the ECG.\[[@ref1]\] The adverse effects of verapamil include bradycardia, hypotension, hypokalemia, and potentially fatal cardiac arrhythmias.\[[@ref2]\] Overdoses of verapamil may be associated with QT interval prolongation, ventricular tachycardia, ventricular fibrillation, and sudden death.\[[@ref3]\] Verapamil is extensively metabolized by the cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) to norverapamil, and the major metabolites are further metabolized by CYP3A4.\[[@ref4]\] Hence, verapamil is contraindicated in patients with significant renal and hepatic
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Verinuradis a drug that inhibits
 
Response: Verinuradis a drug that inhibits the biosynthesis of cholesterol in the liver.

Viruses are associated with the development of many types of cancer, and have been shown to stimulate cell proliferation.

An immunomodulator.

Tocilizumab is a humanized monoclonal antibody that binds to interleukin-6.

Antineoplastic agents are substances that kill cancer cells.

Antibodies are large proteins that can bind to and remove molecules from the body.

These include the following:

Fosamprenavir is a protease inhibitor that works by blocking the action of the HIV enzyme, protease.

Tipranavir is a protease inhibitor that works by blocking the action of the HIV enzyme, protease.

Nevirapine is an antiviral agent that inhibits an enzyme that the virus uses to replicate.

Vorinostat is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Verubecestatis a drug that inhibits
 
Response: Verubecestatis a drug that inhibits the action of the enzyme that makes testosterone, thus blocking testosterone production. Testosterone is a sex hormone. It stimulates the development of male characteristics and the growth of the penis. Testosterone is produced by the testes.

In women, testosterone increases sex drive, the growth of the clitoris, and breast development. Testosterone is also important for maintaining bone density and may help prevent osteoporosis.

Verubecestatis is an oral drug.

The Verubecestatis and the Side Effects

Verubecestatis can cause many side effects, including

Hot flashes

Feeling like you are not getting enough sleep

Feeling nervous or anxious

Muscle aches and weakness

Thinning of the skin

Feeling moody or irritable

Painful urination

Headaches

The Verubecestatis and the Possible Side Effects

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VIDAZAis a drug that inhibits
 
Response: VIDAZAis a drug that inhibits CYP3A4. To decrease its concentration in the blood, the dose of cyclosporine should be increased. A dose of cyclosporine of 50 mg/kg (2.5 mg/kg per day) will decrease the concentration of cyclosporine in the blood to 25% to 30%.

It is contraindicated with ketoconazole.

Calcineurin inhibitors (such as tacrolimus, cyclosporine) are contraindicated in the treatment of CD4 lymphocyte count <100 cells/microliter.

There is a risk of infection in patients with CD4 lymphocyte count <100 cells/microliter.

Contraindicated in pregnant women.

The association of rifampin and cyclosporine is not recommended in the treatment of CD4 lymphocyte count <100 cells/microliter.

Contraind
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vilazodoneis a drug that inhibits
 
Response: Vilazodoneis a drug that inhibits serotonin reuptake into the presynaptic neuron, resulting in an increase in the level of serotonin (5-HT) at the synapse.

In addition to treating depression, vilazodone may be used to treat other conditions as determined by your doctor.

VILAZODONE (VILASET)

COMMON BRAND NAME(S):

Vilazodone

HAS IT BEEN SUBJECT TO FOLLOW UP STUDIES?

Yes. Vilazodone was evaluated in several studies for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

INCLUDE A NOTE ABOUT YOUR USE OF THIS MEDICATION IN YOUR DOCUMENTATION.

Advise your doctor if you are pregnant or breastfeeding, or if you have any other medical conditions. Your doctor may not prescribe this medication or change the dosage of
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  vildagliptinis a drug that inhibits
 
Response: vildagliptinis a drug that inhibits the synthesis of aggrecan, a protein that binds to hyaluronic acid in the cartilage. Although there is some evidence that aggrecanase may be involved in arthritis, there are no data on the potential use of this enzyme inhibitor in the treatment of human arthritis. In the rat adjuvant arthritis model, injection of aggrecanase-inhibiting antibody reduced the severity of arthritis. In the present study, a humanized monoclonal antibody (MAb) to human aggrecanase was generated. The antibody binds to the catalytic domain of aggrecanase, and inhibits the enzyme in vitro. In addition, it reduces the severity of arthritis in rats and monkeys. The use of MAb-based enzyme inhibitors has advantages over the use of gene therapy.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vinblastineis a drug that inhibits
 
Response: Vinblastineis a drug that inhibits cell division by preventing the attachment of microtubules to the cell membrane. It is one of the major anti-cancer drugs used to treat many cancers. The drug binds to tubulin, a component of microtubules. This action disrupts the cell division cycle, eventually leading to cell death. It is used in combination with other drugs for treating various types of cancer. In the treatment of acute lymphoblastic leukemia (ALL), vinblastine has been shown to be highly effective in patients who have failed to respond to other drugs.

For those who are going to use vinblastine in the treatment of cancer, it is important to use the right dosage of the drug. Too little of the drug can cause adverse side effects. Too much of the drug may cause the patient to die. This section explains the factors that should be considered when choosing the right dosage for a particular patient.

Factors That Influence the Dosage
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vincristineis a drug that inhibits
 
Response: Vincristineis a drug that inhibits microtubule function. It has been used in the treatment of childhood acute lymphoblastic leukaemia (ALL) for over 40 years. In 2005, it was shown to be superior to vincristine, daunorubicin and prednisolone in a phase III randomised trial in patients aged 1 to 17 years with high-risk, standard risk and intermediate risk ALL ([@bib1]). However, the benefit was confined to patients with the Philadelphia chromosome (Ph)-positive ALL subtype. The addition of the anti-microtubule agent, vincristine, to conventional chemotherapy (vincristine, daunorubicin and 6-mercaptopurine) significantly reduced the relapse rate and increased event-free survival (EFS) in children with Ph-positive ALL ([@bib2]). The subsequent introduction of imatinib mesylate (Gleevec) to the
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vinorelbineis a drug that inhibits
 
Response: Vinorelbineis a drug that inhibits tubulin polymerization by binding to tubulin heterodimers, thus blocking microtubule formation and function.\[[@ref1]\] The drug is used in the treatment of non-small cell lung cancer (NSCLC) and breast cancer. It has been shown to be effective in the treatment of breast cancer as a single agent and in combination with other drugs.\[[@ref2]\] The drug has shown to be effective in combination with doxorubicin in the treatment of breast cancer,\[[@ref3]\] but it has been associated with cardiotoxicity in patients.\[[@ref4]\]

Vinorelbine is available as a generic drug, but only in two different strengths.\[[@ref5]\] The drug is administered intravenously and is given as a short infusion. The usual dose is 30 mg/m^2
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vinpocetineis a drug that inhibits
 
Response: Vinpocetineis a drug that inhibits the enzyme choline acetyltransferase (CAT) in the brain, thus increasing acetylcholine (ACh) levels.\[[@ref1]\] It is a widely used drug for the treatment of the symptoms of Alzheimer\'s disease (AD) and age-related cognitive impairment. It is available in the form of tablets and injections, and has been used for the treatment of cognitive symptoms of AD and vascular dementia (VaD) since 1989.\[[@ref2]\] The mechanisms by which vinpocetine improves cognitive functions in AD and VaD are not fully understood. It has been suggested that the effects of vinpocetine on cognition are mediated by ACh, by decreasing acetylcholinesterase (AChE) activity and increasing the levels of ACh in the brain.\[[@ref3]\]

Previous studies have suggested
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VIOXXis a drug that inhibits
 
Response: VIOXXis a drug that inhibits growth of hormone-dependent tumors in the breast and prostate. The company is focused on expanding its prostate cancer franchise by bringing a second-generation drug to the market.

The latest word on VIOXX came this week from the National Cancer Institute.

“This study adds to a growing body of evidence that suggests that [VIOXX] may not be the best drug for treating prostate cancer,” Dr. Joshua J. Litton, NCI’s director, told investors.

The study, called VIOXX and cancer, was published in the July issue of the Journal of the National Cancer Institute.

The study showed that the anti-cancer effect of VIOXX can be offset by certain risk factors. Specifically, the study showed that when patients are older, have a family history of prostate cancer, or take a PSA test (prostate-specific antigen), the drug does not work as well
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VIRA-Ais a drug that inhibits
 
Response: VIRA-Ais a drug that inhibits the activation of T-cells and NK-cells and is used for the treatment of autoimmune diseases such as Crohn's disease, multiple sclerosis, rheumatoid arthritis, type 1 diabetes and other inflammatory diseases. The effects of virocide-A in such diseases are discussed in our recent publication (Lilja et al. 2012).The presence of T-cells and NK-cells is essential for the development of autoimmune diseases, but they also have a protective function. This study presents a new concept, that virocide-A inhibits the function of T-cells and NK-cells and thereby affects the protective function of these cells in the development of autoimmune diseases. The objective of the study was to investigate the effects of virocide-A on the function of T-cells and NK-cells and the possible underlying mechanisms.

Methods:

PBMCs from healthy donors were stimulated with IL-2,
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VISUDYNEis a drug that inhibits
 
Response: VISUDYNEis a drug that inhibits both proteasome activity and proteasome subunit β5. It is a non-peptidyl compound that covalently modifies cysteine thiols in the β5 subunit of the proteasome, preventing degradation of a variety of ubiquitinated proteins. Overexpression of bortezomib in the clinical setting is known to cause cardiac toxicity, presumably via its effects on ubiquitinated proteins.^[@bib1]^ Thus, the cardiotoxic potential of bortezomib has been a major concern in the treatment of multiple myeloma, the malignancy for which it is used most frequently.

Bortezomib is generally well tolerated in patients, but there are some clinical findings that are worrisome.^[@bib2]^ Acute cardiac toxicity, manifested as a decrease in left ventricular ejection fraction (LVEF) and
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vitaminis a drug that inhibits
 
Response: Vitaminis a drug that inhibits the function of a virus that causes influenza. It is also known as Acyclovir. It works by blocking the enzyme, which is needed by the virus to make new viruses.

What are the side effects of vitamin A?

Vitamin A can cause a range of side effects in the body. These include:

Redness and swelling of the skin

Burning, itching, and pain of the eyes

Abdominal pain and nausea

Yellowing of the skin and eyes

Muscle weakness

Fainting

High blood pressure

A low potassium level

These are the most common side effects of vitamin A. However, if you experience any of the side effects listed below, do not take more vitamin A, as this can lead to a serious condition called hypervitaminosis A.

Vitamin A side effects

Vitamin A deficiency is a common condition. People
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VLX1570is a drug that inhibits
 
Response: VLX1570is a drug that inhibits the enzyme, telomerase. It is being studied in the US and Europe as a potential cancer treatment. Telomerase is a natural enzyme that keeps telomeres (the ends of chromosomes) healthy. It is believed to be turned on in cancer cells, which can help them to stay alive. By inhibiting the enzyme, telomerase, cancer cells are thought to die off and stop growing.

A number of studies have shown that VLX1570 is very safe and well tolerated.

It is being studied in the US and Europe as a potential cancer treatment. Telomerase is a natural enzyme that keeps telomeres (the ends of chromosomes) healthy. It is believed to be turned on in cancer cells, which can help them to stay alive. By inhibiting the enzyme, telomerase, cancer cells are thought to die off and stop growing.

A number of studies have shown that VL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vogliboseis a drug that inhibits
 
Response: Vogliboseis a drug that inhibits the α-glucosidase and delays the intestinal absorption of glucose. Its effect is to slow down the absorption of dietary carbohydrates and reduce postprandial blood glucose fluctuations, especially in patients with diabetes \[[@B1]\]. It is currently available in Korea and Japan. This drug is approved for the treatment of type 2 diabetes in Korea and Japan. In Korea, it is prescribed for the treatment of type 2 diabetes mellitus (T2DM) as an add-on therapy to diet and exercise in patients with inadequate glycemic control, including postprandial hyperglycemia, on conventional antidiabetic therapy \[[@B2]\]. In Japan, it is prescribed for the treatment of T2DM as an add-on therapy to diet and exercise in patients with inadequate glycemic control, including postprandial hyperglycemia, on conventional antidiabetic therapy \[[@B3]\
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Vorapaxaris a drug that inhibits
 
Response: Vorapaxaris a drug that inhibits the activity of A2A adenosine receptors (A2ARs) and a7-like ARs (A7R) may be effective in preventing sudden cardiac death (SCD) due to arrhythmias. We sought to characterize the effects of vorapaxar on spontaneous activity of cardiomyocytes. In a study in primary cultures of neonatal rat ventricular myocytes (NRVM), we found that vorapaxar (10 μM) significantly reduced spontaneous action potential (AP) firing by 56.9 ± 4.4% and reduced the incidence of Ca2+ sparks by 42.5 ± 5.2% (P < 0.05). In isolated adult rat ventricular myocytes (ARVM), vorapaxar (10 μM) reduced the incidence of Ca2+ sparks by 41.3 ± 7.1% (P < 0.05). We observed a
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Voreloxinis a drug that inhibits
 
Response: Voreloxinis a drug that inhibits DNA synthesis and inhibits the proliferation of human colon cancer cells. Voreloxine, a bis-thiazoline compound, was first isolated from the aerial parts of Voreloxis mellissifolia (Schumach.) Regel, a shrub of the Compositae family.
The novel compound 3-benzyl-2-methoxy-5-(2-methyl-3-oxobutyl)-1,3,4-thiadiazole-7-sulfonamide (3) was first isolated from the aerial parts of Voreloxis mellissifolia (Schumach.) Regel. The compound was reported to have antitumor activity (Sugiura et al., 2000, Phytochemistry 49:1017-1022).

U.S. Pat. No. 6,403,076 (1999) describes a process for preparing 3
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Voriconazoleis a drug that inhibits
 
Response: Voriconazoleis a drug that inhibits the enzyme 14-alpha-demethylase. It is used to treat certain types of fungal infections, including those caused by yeasts. It may also be used to prevent or treat infections caused by Aspergillus, Fusarium, and Trichophyton. It is also used to treat skin infections caused by fungi such as candida, jock itch, ringworm, and tinea. It is not effective against all fungal infections, however.

Voriconazole may also be used for purposes not listed in this medication guide.

Voriconazole Oral Suspension

Read the Patient Information provided by your pharmacist before you start taking voriconazole oral suspension and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or receiving instructions from your doctor.

Take voricon
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  vorinostatis a drug that inhibits
 
Response: vorinostatis a drug that inhibits the release of Ca2+ from intracellular stores. These results are consistent with a stimulatory effect of Ca2+ on the function of adrenergic receptors. In the present study, we found that isoproterenol stimulation of guinea-pig and rat myocardial adenylate cyclase activity is attenuated by the presence of 2 microM ryanodine. These results are consistent with the concept that an elevation of Ca2+ in the cytosol is required for stimulation of the enzyme. In the presence of 1 microM ryanodine, a drug which inhibits Ca2+ release from the sarcoplasmic reticulum, isoproterenol stimulation of guinea-pig myocardial adenylate cyclase activity is enhanced. These results are consistent with the concept that an increase in Ca2+ in the cytosol is required for inhibition of the enzyme.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VTX-2337is a drug that inhibits
 
Response: VTX-2337is a drug that inhibits the production of bone matrix. It is used to treat Paget's disease and is available in generic form.

VTX-2337 has been marketed in the U.S. since 1992.

How does it work?

VTX-2337 inhibits the production of bone matrix. It is used to treat Paget's disease and is available in generic form.

What is it used for?

VTX-2337 has been marketed in the U.S. since 1992.

How does it work?

VTX-2337 inhibits the production of bone matrix. It is used to treat Paget's disease and is available in generic form.

What is it used for?

VTX-2337 has been marketed in the U.S. since 1992.

What are the possible side effects?

VTX-2337 may cause the following side
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VUMONis a drug that inhibits
 
Response: VUMONis a drug that inhibits HMG-CoA reductase, an enzyme that is required for the production of cholesterol in the liver. Its main function is to reduce high cholesterol levels. VUMON is manufactured by US-based Merck & Co.

In the USA, VUMON was approved for use in the treatment of patients with primary hypercholesterolemia, and in Europe for the treatment of hypercholesterolemia associated with familial hypercholesterolemia.

The only US Food and Drug Administration (FDA)-approved drug that is available for the treatment of hypercholesterolemia is lovastatin. However, lovastatin has numerous side effects, and is not always effective.

The efficacy of VUMON in the treatment of primary hypercholesterolemia was studied in a randomized, double-blind, placebo-controlled, multi-center clinical trial.

The main objective of this trial was to determine whether
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VX661is a drug that inhibits
 
Response: VX661is a drug that inhibits cytochrome P450 enzymes, which is often overexpressed in cancer cells and is associated with drug resistance. VX661 has been shown to sensitize a wide variety of cancer cells to chemotherapy drugs by enhancing their cellular uptake of chemotherapy drugs, decreasing efflux of chemotherapy drugs from cancer cells, and by inhibiting multiple signaling pathways involved in cancer cell survival.

Clinical Trials

Clinical Trials for VX661

Cancer Therapy Trials for VX661

The following list of cancer therapy trials are currently open and accepting patients. To find out if VX661 is being studied in your cancer type, click here.

Other VX661 Trials

About VX661

VX661 is a drug that inhibits cytochrome P450 enzymes, which is often overexpressed in cancer cells and is associated with drug resistance. VX661 has been shown to sensitize a wide variety of cancer cells
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VX-745is a drug that inhibits
 
Response: VX-745is a drug that inhibits nuclear factor-κB (NF-κB) signaling. It has been approved for the treatment of adults with multiple myeloma.^[@R1]^ Patients with solid tumors also have a high risk of death from the disease and may benefit from similar treatment.^[@R2]^ However, this drug has not been approved for solid tumors because it has not been tested in phase 3 trials.

The authors previously reported that VX-745 inhibited proliferation of several human cancer cell lines.^[@R3]^ This drug has been shown to be active in a number of in vivo mouse models of cancer, including human prostate cancer,^[@R4]^ head and neck cancer,^[@R5]^ ovarian cancer,^[@R6]^ and breast cancer.^[@R7]^

We previously reported that VX-745 inhibited growth of a panel
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VX770is a drug that inhibits
 
Response: VX770is a drug that inhibits the viral NS5B polymerase and the NS5A protein, both essential for replication of HCV in the cell. The inhibition of NS5A results in the suppression of viral RNA replication, while the inhibition of NS5B prevents the processing of the viral polyprotein. By preventing the processing of the polyprotein, it prevents the formation of the virion. The result is the production of immature, non-infectious virus particles.

Ad

The efficacy of VX-770 is dependent on the time of administration of the drug. The earlier the drug is administered in relation to infection, the more effective it is. The ideal drug regimen for the treatment of HCV infection is an administration of VX-770 at the time of infection, followed by a maintenance dose of the drug.

Ad

The maximum tolerated dose of VX-770 in humans is between 1.5 and 3.0 mg/kg.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  VX-809is a drug that inhibits
 
Response: VX-809is a drug that inhibits the nuclear export of Rev protein. As a result, the accumulation of Rev-dependent transcripts is prevented, and the translation of the viral genome is inhibited. The compound is currently being developed for the treatment of HIV infection.

Category:HIV/AIDS
Category:Drugs acting on the nervous system
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  WP1066is a drug that inhibits
 
Response: WP1066is a drug that inhibits NGF-induced PC12 differentiation. To assess its potential role in vivo, we evaluated its effects on differentiation of PC12 cells in culture, and in the rat peripheral nervous system (PNS).

The present study was carried out to determine the effects of a drug that inhibits NGF-induced PC12 differentiation, W1066, on the survival and differentiation of neurons in culture. In the present study, W1066 was used at a concentration of 0.1 microM, which is a low concentration that has been shown to block NGF-induced PC12 differentiation \[[@B20]\]. This concentration was chosen because it was sufficient to block NGF-induced differentiation, but was not cytotoxic to neurons in culture.

To determine the effects of W1066 on the survival of cultured neurons, PC12 cells were cultured in the presence of NGF and W1066. In the absence of W1066
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Xanthopterinis a drug that inhibits
 
Response: Xanthopterinis a drug that inhibits cell proliferation and induces apoptosis in human prostate cancer cells, including PC-3 and DU145 cells. These cells also showed an induction of p21 and p27 protein expression in a dose-dependent manner. Furthermore, xanthopterin induced apoptosis in PC-3 cells in a p53-dependent manner.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  XENAZINEis a drug that inhibits
 
Response: XENAZINEis a drug that inhibits the secretion of aldosterone.
It is used to treat high blood pressure and other medical conditions, such as hypokalemia and metabolic alkalosis.

The active ingredient is spironolactone, an aldosterone antagonist.
It also inhibits the action of the enzyme 11-hydroxysteroid dehydrogenase, which is responsible for converting cortisol into cortisone.

It is used as an anti-androgen in the treatment of certain hormone-dependent cancers such as prostate cancer.
It is also used to prevent certain medical conditions, such as low blood potassium.

XENAZINE may also be used for other purposes not listed in this medication guide.

What is XENAZINE?

XENAZINE is a prescription medication used to treat high blood pressure, to prevent certain medical conditions, and for other uses.

XENAZINE is a synthetic androgen
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  XIFAXANis a drug that inhibits
 
Response: XIFAXANis a drug that inhibits the formation of active inflammatory molecules called prostaglandins. It has been used in Europe to treat rheumatoid arthritis and menstrual cramps. In North America, it is used to treat the symptoms of an ulcer, as well as menstrual cramps and to prevent premature labor.

Mifepristone is used in combination with mestranol (medroxyprogesterone) in the MIFEPRIST (Mifepristone for Emergency Regulated Interruption of Pregnancy) regimen to induce abortions in women up to 10 weeks of gestation.

Folbristatin is an anticancer compound with a unique structure and mechanism of action. It inhibits a wide variety of cancer cell lines and is active in mice with human colon, breast, lung, ovarian, prostate, and pancreatic cancer xenografts.

At present, folbristatin is undergoing clinical trials in Japan and the United
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  XL-184is a drug that inhibits
 
Response: XL-184is a drug that inhibits histone deacetylase activity. It has been tested in phase I and II clinical trials for the treatment of various cancers, such as acute myeloid leukemia (AML) and multiple myeloma (MM). In addition, we have tested the drug in a number of in vitro and in vivo model systems to better understand the molecular basis of its anti-tumor effects.

**A.** Our initial experiments with the drug focused on testing its ability to inhibit the proliferation of MM cells and inhibit the formation of bone marrow plasma cells (PCs) in a xenograft model. The drug inhibited the proliferation of human and murine MM cells, with a lower IC~50~ value for human cells than for murine cells. In addition, the drug significantly reduced the number of PCs in the bone marrow of the mice injected with the human MM cell line. Importantly, treatment of the mice with the drug did not significantly
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Xylazineis a drug that inhibits
 
Response: Xylazineis a drug that inhibits sympathetic nervous system outflow. The analgesic effects of xylazine have been used in several studies. The aim of this study was to compare the effects of xylazine with morphine and fentanyl on pain perception during dental anesthesia. Fifty-four healthy patients were randomly allocated into three groups. Group M (n = 18) received 1 mg/kg morphine, Group X (n = 18) received 1 mg/kg xylazine, and Group F (n = 18) received 1 µg/kg fentanyl. Anesthesia was induced with propofol 2 mg/kg and maintained with propofol at 1 mg/kg/h. After completion of surgery, patients were assessed using a 10-point verbal rating scale (VRS) for pain, sedation, nausea, and vomiting. Onset and duration of anesthesia, recovery times, and adverse effects were recorded. In the xylazine group, the onset and duration of anesthesia were significantly
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Xylitolis a drug that inhibits
 
Response: Xylitolis a drug that inhibits xylitol-induced oral carcinogenesis in hamsters (American Chemical Society Symposium, Washington, D.C., U.S.A., Oct. 13-17, 1987)

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, such as atorvastatin, lovastatin, and simvastatin (see, U.S. Pat. Nos. 4,231,938, 4,444,784, 4,916,239, 5,273,995, 5,354,772, 5,587,363, 5,691,346, 5,693,652, 5,696,133, 5,716,974, 5,817,757, 5,827,845, 5,885,963, 5,834,506, 5,948,419, 5,952,352
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Xylometazolineis a drug that inhibits
 
Response: Xylometazolineis a drug that inhibits the activity of histamine H1 receptors. The efficacy of xylometazoline is based on its vasoconstrictor properties, which results in dilation of the nasal mucosa. In a small double-blind study, a single application of 0.2% xylometazoline relieved congestion in most patients, and in a small placebo-controlled trial, xylometazoline improved symptoms of congestion in patients with perennial rhinitis. Xylometazoline is also available in a nasal spray for the treatment of seasonal rhinitis.

Adverse Effects

When used in nasal sprays, xylometazoline can cause vasoconstriction of the nose and throat, and therefore the application of the drug should be accompanied by close monitoring of blood pressure.

This is not an exhaustive list of side effects. Please report any adverse effects to the FDA at 1-800-FDA-10
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  XYLO-PFANis a drug that inhibits
 
Response: XYLO-PFANis a drug that inhibits the activity of the human mitochondrial Complex I. The drug was developed for the treatment of the neurodegenerative disease Friedreich's ataxia (FRDA) and is under investigation for the treatment of other neurodegenerative diseases. The drug is a pyrazole derivative and is a prodrug that is activated in the body by esterases. It has been developed by pharmaceutical company BioMarin Pharmaceuticals.

Rasagiline is a drug that is a derivative of the anti-Parkinson's disease drug selegiline. It is used for the treatment of Parkinson's disease. The drug is a selective monoamine oxidase-B inhibitor. It was developed by pharmaceutical company Merck and is marketed under the trade name Azilect.

Nexus is a drug that is a metabolite of selegiline. It is used for the treatment of Parkinson's disease. The drug is
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Y-39983is a drug that inhibits
 
Response: Y-39983is a drug that inhibits the binding of HIV-1 to the CD4 receptor on T-cells, and therefore prevents the entry of HIV-1 into these cells. It also inhibits HIV-1 replication in infected cells. This drug has also been shown to be effective in treating animals infected with SIV, the natural animal counterpart of HIV. However, this drug has low bioavailability when given orally.
AZT is a nucleoside reverse transcriptase inhibitor. This drug has been used to treat HIV-infected patients.
Combination therapy of HIV-infected patients has become a widely accepted form of treatment. Treatment with AZT plus 3TC, a non-nucleoside reverse transcriptase inhibitor, has proven very effective. This regimen has been shown to reduce mortality and the progression of HIV-infected patients to AIDS.
However, treatment with this drug has a low genetic barrier to the development of resistance, and has significant side effects, such
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Yohimbineis a drug that inhibits
 
Response: Yohimbineis a drug that inhibits α2-adrenoceptors in the brain and the sympathetic nervous system, and is used to treat anxiety and depression. Although it is a prescription drug, it is available over the counter in many countries.

Yohimbine is also available as an over-the-counter supplement.

The supplement industry claims that yohimbine is a stimulant, a weight loss aid, a muscle building aid, and an anti-depressant.

We decided to take a look at the science to find out if yohimbine really has these claims.

In this review, we’ll take a look at yohimbine and its use in the body.

What is Yohimbine?

Yohimbine is an alkaloid that is found in certain plants, and is a type of indole alkaloid.

Yohimbine is an extract
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ZAGAMis a drug that inhibits
 
Response: ZAGAMis a drug that inhibits the activity of HIV-1 reverse transcriptase, thereby suppressing the formation of new viral DNA. Zidovudine is also used in the treatment of HIV-associated dementia, and is available in oral form as AZT.

zidovudine (INN)

zidovudine (INN) is a drug that inhibits the activity of HIV-1 reverse transcriptase, thereby suppressing the formation of new viral DNA. Zidovudine is also used in the treatment of HIV-associated dementia, and is available in oral form as AZT.

zidovudine (USAN)

zidovudine (USAN) is a drug that inhibits the activity of HIV-1 reverse transcriptase, thereby suppressing the formation of new viral DNA. Zidovudine is also used in the treatment of HIV-associated dementia, and is available in oral form as AZT.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zaltoprofenis a drug that inhibits
 
Response: Zaltoprofenis a drug that inhibits the cyclooxygenase-2 enzyme. This enzyme is a key component in the inflammatory response of the body. In particular, it is thought that zaltoprofen reduces pain by reducing the production of prostaglandins, a group of chemicals that trigger pain in the body. Zaltoprofen has been used to treat pain associated with rheumatoid arthritis and menstrual cramps. It is also used to treat pain associated with dental procedures, such as dental surgery and extractions. Zaltoprofen is available in a variety of different dosage forms, including tablets, capsules, oral suspensions, and suppositories. Zaltoprofen is available in the United States as Zipsor®, a liquid suspension for oral administration, and as Panadol®, a tablet formulation.

I have found that when I take it in combination with other meds, it really seems to help with my pain.


 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zanubrutinibis a drug that inhibits
 
Response: Zanubrutinibis a drug that inhibits the Bruton tyrosine kinase (BTK) and has shown clinical activity in patients with relapsed/refractory CLL. In this phase I study, the authors evaluated the safety and pharmacokinetics (PK) of oral and intravenous (IV) zanubrutinib in patients with relapsed/refractory CLL.

Methods

This open-label, nonrandomized, single-arm, multicenter study was conducted in Europe, Canada, and the USA. The primary objective was to evaluate the safety and PK of oral and IV zanubrutinib. Secondary objectives included evaluation of the PK of zanubrutinib in healthy volunteers and CLL patients.

Results

Thirty-six patients were enrolled and received a median of three prior lines of therapy (range, 0–5) for relapsed/refractory CLL
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zidovudineis a drug that inhibits
 
Response: Zidovudineis a drug that inhibits the reverse transcriptase enzyme of the human immunodeficiency virus (HIV). This drug is also used to treat other infections, including hepatitis B. Zidovudine is also used to prevent HIV infection in people who are at high risk of getting HIV.

Drug Facts:

INDICATIONS AND USAGE

WARNINGS

Zidovudine is used to treat or prevent the following:

The infection caused by the human immunodeficiency virus (HIV).

HIV-related opportunistic infections, including pneumonia, oral candidiasis, and esophageal candidiasis.

The infection caused by the hepatitis B virus.

The infection caused by the herpes simplex virus.

The treatment of cytomegalovirus (CMV) retinitis.

Zidovudine may be prescribed for long-term use to treat HIV infection in
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zileutonis a drug that inhibits
 
Response: Zileutonis a drug that inhibits P-glycoprotein, the product of the multidrug resistance gene (MDR1) on chromosome 7.^[@bib1]^ MDR1 is a plasma membrane protein that functions as an efflux pump to eliminate xenobiotics from cells.^[@bib2]^ MDR1 was first described in 1976 as the first known cause of resistance to chemotherapy, but the first successful clinical application of MDR1 inhibition was for treatment of the cancer drug vinblastine in 1993.^[@bib3]^

Zileuton is the major active metabolite of the widely used drug zileuton mesylate (also known as 6-chloro-5-\[2-(cyclopropylmethoxy)-ethyl\]-3-methyl-1,3-thiazol-4-yl-carbamoyl-2(S)-(3-oxoprop
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ziprasidoneis a drug that inhibits
 
Response: Ziprasidoneis a drug that inhibits the reuptake of dopamine and serotonin in the brain. It is used for the treatment of schizophrenia, bipolar disorder and schizoaffective disorder. Dopamine and serotonin are neurotransmitters that help control mood and behavior. Dopamine and serotonin are neurotransmitters that help control mood and behavior.

This drug is very effective in treating schizophrenia and has been found to be as effective as many of the other antipsychotics currently on the market. However, the tolerability of this drug is less than most of the other antipsychotics on the market.

Common side effects of this drug include:

Insomnia

Tremor

Dizziness

Elevated blood pressure

Increased heart rate

Trouble sleeping

Weight gain

Sexual dysfunction

In addition, this drug is not recommended for use in patients who are pregnant or breastfeeding.

Drug Interactions

 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Ziritaxestatis a drug that inhibits
 
Response: Ziritaxestatis a drug that inhibits cyclin-dependent kinases and their associated cyclin partners and prevents cell cycle progression in cells in which they are overexpressed. It has shown encouraging results in clinical trials in patients with advanced non-small cell lung cancer (NSCLC) with cisplatin. However, the effect of ziritubax (see Inventive Mark), which is a combination of ziriquat and ziracusta, on cell cycle progression and apoptosis in NSCLC cells has not been examined. We investigated the effect of ziriritubax on cell cycle progression and apoptosis in human NSCLC cell lines. The effect of ziriritubax on cell cycle progression was examined by flow cytometry. Apoptosis was evaluated by flow cytometry using annexin V/propidium iodide staining. The effect of ziriritubax on apoptosis was examined by flow cytometry and by using western blot
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ZOCORis a drug that inhibits
 
Response: ZOCORis a drug that inhibits the reuptake of serotonin. It is marketed as a treatment for depression and anxiety, but there is a lot of controversy about whether it works and whether it’s safe. Here’s a brief overview of what it does and what the risks are.

What is ZOCOR?

ZOCOR is a brand name for fluoxetine, a selective serotonin reuptake inhibitor (SSRI). It’s the only SSRI approved for treatment of depression.

It’s available in many forms, including:

a capsule that you swallow

a liquid suspension (S-Zocor) that you swallow

a tablet that you take by mouth

What is the mechanism of action of ZOCOR?

It’s a serotonin reuptake inhibitor, meaning it works by inhibiting the reuptake of serotonin. This has a number of effects.
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  ZOMIGis a drug that inhibits
 
Response: ZOMIGis a drug that inhibits nuclear factor-kappa B (NF-kappaB) and can be used to treat cancer. It is currently under investigation for the treatment of solid tumors and hematologic malignancies.

Discovery

ZOMIG was discovered in 1996, as part of a program to develop small molecule inhibitors of NF-kappaB, a transcription factor that plays a key role in regulating the body’s immune response and is aberrantly activated in a wide range of cancers. Inhibitors of NF-kappaB have shown clinical efficacy in some tumors, but resistance often develops and tumor cells are able to evade apoptosis. ZOMIG was discovered in a screen of a large number of structurally related compounds that were synthesized to optimize the potency and selectivity of the molecules.

Mechanism of action

ZOMIG is a cell-permeable, non-toxic, low molecular weight molecule
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zonisamideis a drug that inhibits
 
Response: Zonisamideis a drug that inhibits excessive neuronal activity by blocking voltage-gated sodium channels. Zonisamide is an oxazinone-derivative of 2-amino-4-oxazolecarboxylic acid, and has a chemical name of (2R)-2-methyl-3-(oxetan-3-yl)-1,3-thiazolidine-4-carboxylic acid 2-oxide. Zonisamide has the following chemical structure:

Zonisamide was developed by Pfizer Inc. and has been approved by the FDA for the treatment of partial seizures in the United States. Zonisamide has a half-life of about 2 hours and is cleared from the body by the kidneys. It is generally administered twice daily, generally in the morning and evening. The oral bioavailability of zonisamide is less than 20%.
In addition to zonisamide, the active metabolite of zonisamide is (
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zotarolimusis a drug that inhibits
 
Response: Zotarolimusis a drug that inhibits mTOR, an enzyme that promotes the growth of cancer cells and that is activated in some cancers. It is approved for treatment of adults with advanced kidney cancer that has progressed after prior therapy.

Zotarolimus

Chemical name:

CASRN

Number:

94762-57-9

Active pharmaceutical ingredient:

Zotarolimus

Package:

10 mg/vial

Clinical effect:

Antineoplastic

Medical speciality:

Oncology

Zotarolimus is a small molecule that inhibits the mammalian target of rapamycin (mTOR), an enzyme that promotes the growth of cancer cells and that is activated in some cancers. It is approved for treatment of adults with advanced kidney cancer that has progressed after prior therapy.

Zotarolimus is an inhibitor of the mTOR protein
 
Enter prompt or quit: Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.
Prompt:  Zucapsaicinis a drug that inhibits
 
Response: Zucapsaicinis a drug that inhibits the activity of the same enzyme, which results in the same effect as that obtained with DDAVP.

At the same time, there is an increase in the urine volume, as well as in the diuresis.

In the case of DDAVP, the effect on the secretion of antidiuretic hormone is due to the stimulation of adenylate cyclase, which causes the conversion of ATP to cyclic AMP. The increase in cyclic AMP is transmitted to the effector proteins of the cAMP system, causing the activation of the protein kinase A (PKA) that phosphorylates the regulatory protein of the Na-K-ATPase, which is responsible for the reabsorption of water and salt in the kidney.

It is important to note that in the case of patients with a defect in the PKA system, the response to DDAVP is null, and
 
Enter prompt or quit: Done
